PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Bhat, A; Kolibaba, K; Oda, T; OhnoJones, S; Heaney, C; Druker, BJ				Bhat, A; Kolibaba, K; Oda, T; OhnoJones, S; Heaney, C; Druker, BJ			Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE-PHOSPHORYLATED PROTEIN; COLONY-STIMULATING FACTOR; C-CBL; PHILADELPHIA-CHROMOSOME; HEMATOPOIETIC-CELLS; SH2 DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; PROTOONCOGENE PRODUCT; ADAPTER PROTEIN	The Philadelphia chromosome, detected in virtually all cases of chronic myelogenous leukemia (CML), is formed by a reciprocal translocation between chromosomes 9 and 22 that fuses BCR-encoded sequences upstream of exon 2 of c-ABL, The BCR-ABL fusion creates a gene whose protein product, p210BCR-ABL, has been implicated as the cause of the disease, Although ABL kinase activity has been shown to be required for the transforming abilities of BCR-ABL and numerous substrates of the BCR-ABL tyrosine kinase have been identified, the requirement of most of these substrates for the transforming function of BCR-ABL is unknown, In this study we mapped a direct binding site of the c-CBL proto-oncogene to the SH2 domain of BCR-ABL. This interaction only occurs under conditions where c-CBL is tyrosine-phosphorylated. Despite the direct interaction of c-CBL with the SH2 domain of BCR-ABL, deletion of the SH2 domain of BCR-ABL did not result in an alteration in the complex formation of BCR-ABL and c-CBL, suggesting that another site of direct interaction between c-CBL and BCR-ABL exists or that another protein mediates an indirect interaction of c-CBL and BCR-ABL, Since CRKL, an SH2, SH3 domain-containing adapter protein is known to bind directly to BCR-ABL and also binds to tyrosine-phosphorylated c-CBL, the ability of CRKL to mediate a complex between c-CBL and BCR-ABL was examined.	OREGON HLTH SCI UNIV,DIV HEMATOL & MED ONCOL,DEPT DEV & CELL BIOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT MOL MICROBIOL & IMMUNOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOL BIOL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University			Oda, Tsukasa/ABI-1855-2020	Druker, Brian/0000-0001-8331-8206; Oda, Tsukasa/0000-0002-8941-161X	NATIONAL CANCER INSTITUTE [R37CA065823, R01CA065823] Funding Source: NIH RePORTER; NCI NIH HHS [CA65823] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P32; DAVIS RL, 1985, MOL CELL BIOL, V5, P204, DOI 10.1128/MCB.5.1.204; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DRUKER B, 1992, BLOOD, V79, P2215; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; ERNST TJ, 1994, J BIOL CHEM, V269, P5764; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20402; GREENBERGER JS, 1983, P NATL ACAD SCI USA, V80, P2391; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Heaney C, 1997, BLOOD, V89, P297, DOI 10.1182/blood.V89.1.297.297_297_306; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; ILARIA RL, 1995, BLOOD, V86, P3897, DOI 10.1182/blood.V86.10.3897.bloodjournal86103897; KANAKURA Y, 1990, BLOOD, V76, P706; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; LANEUVILLE P, 1991, ONCOGENE, V6, P275; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LU D, 1993, BLOOD, V82, P1257; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; NOWELL PC, 1960, SCIENCE, V132, P1497; ODA T, 1994, J BIOL CHEM, V269, P22925; ODA T, 1995, LEUKEMIA, V9, P295; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Ribon V, 1996, MOL CELL BIOL, V16, P45; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SALGIA R, 1995, ONCOGENE, V11, P1149; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sattler M, 1996, ONCOGENE, V12, P839; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; TENHOEVE J, 1994, CANCER RES, V54, P2563; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079	54	64	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16170	16175		10.1074/jbc.272.26.16170	http://dx.doi.org/10.1074/jbc.272.26.16170			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195915	hybrid			2022-12-27	WOS:A1997XG01900019
J	Ko, BCB; Ruepp, B; Bohren, KM; Gabbay, KH; Chung, SSM				Ko, BCB; Ruepp, B; Bohren, KM; Gabbay, KH; Chung, SSM			Identification and characterization of multiple osmotic response sequences in the human aldose reductase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPEROSMOTIC STRESS; ORGANIC OSMOLYTES; HYPERTONIC STRESS; CELLS; KIDNEY; EXPRESSION; ACCUMULATION; PURIFICATION; INDUCTION; CLONING	Aldose reductase (AR) has been implicated in osmoregulation in the kidney because it reduces glucose to sorbitol, which can serve as an osmolite. Under hyperosmotic stress, transcription of this gene is induced to increase the enzyme level. This mode of osmotic regulation of AR, gene expression has been observed in a number of nonrenal cells as well, suggesting that this is a common response to hyperosmotic stress. We have identified a 132-base pair sequence similar to 1 kilobase pairs upstream of the transcription start site of the AR gene that enhances the transcription activity of the AR promoter as well as that of the SV40 promoter when the cells are under hyperosmotic stress. Within this 132-base pair sequence, there are three sequences that resemble TonE, the tonicity response element of the canine betaine transporter gene, and the osmotic response element of the rabbit AR gene, suggesting that the mechanism of osmotic regulation of gene expression in these animals is similar. However, our data indicate that cooperative interaction among the three TonE-like sequence's in the human AR may be necessary for their enhancer function.	UNIV HONG KONG,INST MOL BIOL,POKFULAM,HONG KONG; BAYLOR COLL MED,DEPT PEDIAT,MOL DIABET & METAB SECT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	University of Hong Kong; Baylor College of Medicine; Baylor College of Medicine			Ko, Chi-bun/ACH-7514-2022	Ko, Ben Chi Bun/0000-0003-2027-5899; Bohren, Kurt/0000-0002-3183-4118	NATIONAL EYE INSTITUTE [R01EY011018] Funding Source: NIH RePORTER; NEI NIH HHS [EY11018] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AUSUBEL FM, 1996, CURRENT PROTOCOLS MO, V1; BAGNASCO S, 1986, J BIOL CHEM, V261, P5872; BURG MB, 1988, KIDNEY INT, V33, P635, DOI 10.1038/ki.1988.46; BURG MB, 1995, AM J PHYSIOL-RENAL, V268, pF983, DOI 10.1152/ajprenal.1995.268.6.F983; CAIRNEY J, 1985, J BACTERIOL, V164, P1224, DOI 10.1128/JB.164.3.1224-1232.1985; CHUNG S, 1989, J BIOL CHEM, V264, P14775; COHEN DM, 1991, AM J PHYSIOL, V261, pC594, DOI 10.1152/ajpcell.1991.261.4.C594; COWLEY BD, 1990, AM J PHYSIOL, V258, pF154, DOI 10.1152/ajprenal.1990.258.1.F154; DAS B, 1985, ARCH BIOCHEM BIOPHYS, V238, P670, DOI 10.1016/0003-9861(85)90213-9; FERRARETTO A, 1993, BIOCHIM BIOPHYS ACTA, V1175, P283, DOI 10.1016/0167-4889(93)90218-E; FERRARIS JD, 1994, P NATL ACAD SCI USA, V91, P10742, DOI 10.1073/pnas.91.22.10742; Ferraris JD, 1996, J BIOL CHEM, V271, P18318, DOI 10.1074/jbc.271.31.18318; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GARCIAPEREZ A, 1989, J BIOL CHEM, V264, P16815; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; GRAHAM A, 1991, J BIOL CHEM, V266, P6872; GREENE DA, 1985, DIABETES CARE, V8, P290, DOI 10.2337/diacare.8.3.290; GULLANS SR, 1988, AM J PHYSIOL, V255, pF626, DOI 10.1152/ajprenal.1988.255.4.F626; ITOH T, 1994, J CLIN INVEST, V93, P2387, DOI 10.1172/JCI117245; KADOR PF, 1985, AM J MED, V79, P8, DOI 10.1016/0002-9343(85)90504-2; KANEKO M, 1990, EXP CELL RES, V188, P135, DOI 10.1016/0014-4827(90)90288-L; KING TE, 1959, PROC R SOC SER B-BIO, V151, P226, DOI 10.1098/rspb.1959.0061; KO BCB, 1995, DIABETES, V44, P727, DOI 10.2337/diabetes.44.7.727; LEE AYW, 1995, P NATL ACAD SCI USA, V92, P2780, DOI 10.1073/pnas.92.7.2780; OHTA M, 1991, BIOCHIM BIOPHYS ACTA, V1078, P395, DOI 10.1016/0167-4838(91)90162-S; PETRASH JM, 1992, BIOCHEM BIOPH RES CO, V187, P201, DOI 10.1016/S0006-291X(05)81479-2; PETRASH JM, 1982, BIOCHIM BIOPHYS ACTA, V707, P105, DOI 10.1016/0167-4838(82)90402-2; Ruepp B, 1996, P NATL ACAD SCI USA, V93, P8624, DOI 10.1073/pnas.93.16.8624; RUSSELL P, 1990, ARCH BIOCHEM BIOPHYS, V276, P259, DOI 10.1016/0003-9861(90)90036-X; SIEVENS MJ, 1993, AM J PHYSIOL, V265, pE428; SMARDO FL, 1992, AM J PHYSIOL, V262, pC776, DOI 10.1152/ajpcell.1992.262.3.C776; SRIVASTAVA SK, 1984, LENS RES, V2, P309; TAKENAKA M, 1994, J BIOL CHEM, V269, P29379; TERADA Y, 1994, J BIOL CHEM, V269, P31296; UCHIDA S, 1989, AM J PHYSIOL, V256, pC614, DOI 10.1152/ajpcell.1989.256.3.C614; UEGUCHI C, 1993, EMBO J, V12, P1039, DOI 10.1002/j.1460-2075.1993.tb05745.x; WANG K, 1993, J BIOL CHEM, V268, P16052; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	39	176	181	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16431	16437		10.1074/jbc.272.26.16431	http://dx.doi.org/10.1074/jbc.272.26.16431			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195951	hybrid			2022-12-27	WOS:A1997XG01900055
J	Mortensen, ER; Marks, PA; Shiotani, A; Merchant, JL				Mortensen, ER; Marks, PA; Shiotani, A; Merchant, JL			Epidermal growth factor and okadaic acid stimulate Sp1 proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PITUITARY-CELLS; TRANSCRIPTION FACTOR SP1; NF-KAPPA-B; SP1-MEDIATED TRANSCRIPTION; GASTRIN PROMOTER; C-FOS; PROTEIN; EXPRESSION; INHIBITION; BINDING	Sp1 nuclear levels have been shown to directly correlate with the proliferative state of the cell. We therefore studied changes in the abundance of Sp1 in a rat pituitary cell line GH(4) whose growth rate is regulated by epidermal growth factor (EGF). Nuclear extracts from GH, cells treated with 10 nM EGF for at least 16 h showed a 50% decrease in Sp1 binding to a GC-rich element present in the gastrin promoter. The decrease in binding correlated with a decrease in cell proliferation, a loss of nuclear Sp1 protein and a 50-60% decrease in Sp1-mediated transactivation through an Sp1 enhancer element in transfection assays. Okadaic acid, a phosphatase inhibitor, was synergistic with the effect of EGF on Sp1 protein levels suggesting that the loss of Sp1 was mediated by phosphorylation events. This result was confirmed by showing a 2-fold increase in orthophosphate-labeled Sp1 with EGF and okadaic acid, Cycloheximide prevented the expected loss of Sp1 mediated by EGF and okadaic acid suggesting that the synthesis of a protease may mediate these events. This hypothesis was tested directly by showing that the cysteine protease inhibitor leupeptin prevented Sp1 degradation. Using the PEST-FIND computer program, the computed PEST score for human and rat Sp1 is 10.4 and 13.7, respectively, indicating that Sp1 has a domain with a high concentration of proline, glutamic acid, serine, and threonine residues as reported for a number of proteins with inducible rates of degradation. Collectively, these results indicate that sustained stimulation of GH(4) cells by EGF initiates a cascade of phosphorylation events that promotes Sp1 proteolysis, decreased Sp1 nuclear levels and decreased cellular proliferation.	UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PHYSIOL,ANN ARBOR,MI 48109; HOWARD HUGHES MED INST,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute			Merchant, Juanita/AAF-8277-2019	Merchant, Juanita/0000-0002-6559-8184	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK045729, R01DK045729] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR-00042] Funding Source: Medline; NIDDK NIH HHS [DK-45729] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, P743; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FISCH TM, 1989, MOL CELL BIOL, V9, P1327, DOI 10.1128/MCB.9.3.1327; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; JACKSON S, 1993, ADV SEC MESS PHOSPH, V28, P279; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JOHNSON LK, 1980, P NATL ACAD SCI-BIOL, V77, P394, DOI 10.1073/pnas.77.1.394; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KITADAI Y, 1992, BIOCHEM BIOPH RES CO, V189, P1342, DOI 10.1016/0006-291X(92)90221-6; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; MERCHANT JL, 1995, J BIOL CHEM, V270, P6314, DOI 10.1074/jbc.270.11.6314; MERCHANT JL, 1991, MOL CELL BIOL, V11, P2686, DOI 10.1128/MCB.11.5.2686; NEHLS MC, 1992, DNA CELL BIOL, V11, P443, DOI 10.1089/dna.1992.11.443; OSBORNE R, 1981, ENDOCRINOLOGY, V108, P1164, DOI 10.1210/endo-108-4-1164; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; PARK K, 1992, J BIOL CHEM, V267, P10810; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; Scholtz B, 1996, DEV BIOL, V173, P420, DOI 10.1006/dbio.1996.0037; SCHONBRUNN A, 1980, J CELL BIOL, V85, P786, DOI 10.1083/jcb.85.3.786; SCHONTHAL A, 1992, NEW BIOL, V4, P16; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Tashjian A H Jr, 1979, Methods Enzymol, V58, P527; THEVENIN C, 1991, J BIOL CHEM, V266, P9363; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TSUBUKI S, 1993, BIOCHEM BIOPH RES CO, V196, P1195, DOI 10.1006/bbrc.1993.2378; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; VANDOLAH FM, 1992, J CELL PHYSIOL, V152, P190, DOI 10.1002/jcp.1041520124; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8	45	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16540	16547		10.1074/jbc.272.26.16540	http://dx.doi.org/10.1074/jbc.272.26.16540			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195964	hybrid			2022-12-27	WOS:A1997XG01900068
J	Uesono, Y; Tohe, A; Kikuchi, Y				Uesono, Y; Tohe, A; Kikuchi, Y			Ssd1p of Saccharomyces cerevisiae associates with RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE FUNCTIONS; COLI RIBONUCLEASE-II; BINDING-PROTEIN; NEUROSPORA MITOCHONDRIA; CELL-GROWTH; CYCLIC-AMP; KINASE-C; YEAST; GENE; EXORIBONUCLEASE	The SSD1 gene has been isolated as a single copy suppressor of many mutants, such as sit4, slk1/bck1, pde2, and rpc31, in the yeast Saccharomyces cerevisiae. Ssd1p has domains showing weak but significant homology with RNase II-related proteins, Cyt4p, Dss1p, VacB, and RNase II, which are involved in the modification of RNA. We found that Ssd1p had the ability to bind RNA, preferably poly(rA), as well as single-stranded DNA, Interestingly, the most conserved domain among the RNase II-related proteins was not necessary for interaction with RNA. Indirect immunofluorescence staining with anti-Ssd1p antibody revealed that Ssd1p was detected mainly in the cytoplasm. Furthermore, sucrose gradient sedimentation analysis demonstrated that Ssd1p was not cofractionated with polyribosomes, suggesting that Ssd1p is not particularly bound to a translationally active subpopulation of mRNA in the cytoplasm.	UNIV TOKYO, DEPT BIOL SCI, GRAD SCH SCI, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo								ANDERSON JT, 1993, MOL CELL BIOL, V13, P6102, DOI 10.1128/MCB.13.10.6102; ATWATER JA, 1990, ANNU REV GENET, V24, P519; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; Beelman CA, 1996, NATURE, V382, P642, DOI 10.1038/382642a0; BEUF L, 1995, PLANT MOL BIOL, V27, P779, DOI 10.1007/BF00020230; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CARUCCIO N, 1994, J BIOL CHEM, V269, P31814; CHERRY JR, 1989, CELL, V56, P409, DOI 10.1016/0092-8674(89)90244-4; COSTIGAN C, 1992, MOL CELL BIOL, V12, P1162, DOI 10.1128/MCB.12.3.1162; CVRCKOVA F, 1993, EMBO J, V12, P5277, DOI 10.1002/j.1460-2075.1993.tb06223.x; DMOCHOWSKA A, 1995, CURR GENET, V28, P108, DOI 10.1007/BF00315775; FERNANDEZSARABIA MJ, 1992, GENE DEV, V6, P2417, DOI 10.1101/gad.6.12a.2417; GARRIGA G, 1984, CELL, V36, P623, DOI 10.1016/0092-8674(84)90342-8; HARGROVE JL, 1991, BIOESSAYS, V13, P667, DOI 10.1002/bies.950131209; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; KENNA M, 1993, MOL CELL BIOL, V13, P341, DOI 10.1128/MCB.13.1.341; KINOSHITA N, 1991, MOL CELL BIOL, V11, P5839, DOI 10.1128/MCB.11.12.5839; KRAIG E, 1980, J BACTERIOL, V144, P1098, DOI 10.1128/JB.144.3.1098-1112.1980; LARIMER FW, 1990, GENE, V95, P85, DOI 10.1016/0378-1119(90)90417-P; LEE FJS, 1993, J BIOL CHEM, V268, P15080; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; Liang S, 1996, MOL CELL BIOL, V16, P5139; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; Margossian SP, 1996, CELL, V84, P199, DOI 10.1016/S0092-8674(00)80975-7; MASISON DC, 1995, MOL CELL BIOL, V15, P2763; MATSUURA A, 1990, EMBO J, V9, P3225, DOI 10.1002/j.1460-2075.1990.tb07521.x; MATUNIS MJ, 1993, MOL CELL BIOL, V13, P6114, DOI 10.1128/MCB.13.10.6114; MIN JJ, 1993, J BACTERIOL, V175, P6245, DOI 10.1128/JB.175.19.6245-6253.1993; MIN JJ, 1993, J BIOL CHEM, V268, P7350; MUHLRAD D, 1994, NATURE, V370, P578, DOI 10.1038/370578a0; Noguchi E, 1996, EMBO J, V15, P5595, DOI 10.1002/j.1460-2075.1996.tb00944.x; PIEDADE J, 1995, FEMS MICROBIOL LETT, V127, P187; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; Rose MD., 1990, METHODS YEAST GENETI; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; STETTLER S, 1993, MOL GEN GENET, V239, P169, DOI 10.1007/BF00281615; STEVENS A, 1980, J BIOL CHEM, V255, P3080; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; TANAKA K, 1988, EMBO J, V7, P495, DOI 10.1002/j.1460-2075.1988.tb02837.x; TOBE T, 1992, J BACTERIOL, V174, P6359, DOI 10.1128/JB.174.20.6359-6367.1992; TURCQ B, 1992, P NATL ACAD SCI USA, V89, P1676, DOI 10.1073/pnas.89.5.1676; UESONO Y, 1994, GENE, V143, P135; WATANABE Y, 1995, MOL CELL BIOL, V15, P5740; WILSON RB, 1991, MOL CELL BIOL, V11, P3369, DOI 10.1128/MCB.11.6.3369; ZILHAO R, 1993, MOL MICROBIOL, V8, P43, DOI 10.1111/j.1365-2958.1993.tb01201.x	46	87	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16103	16109		10.1074/jbc.272.26.16103	http://dx.doi.org/10.1074/jbc.272.26.16103			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195905	hybrid			2022-12-27	WOS:A1997XG01900009
J	Zhu, CX; Roche, CJ; TseDinh, YC				Zhu, CX; Roche, CJ; TseDinh, YC			Effect of Mg(II) binding on the structure and activity of Escherichia coli DNA topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL FRAGMENT; PROTEIN-OMEGA; COMPLEX	Escherichia coli DNA topoisomerase I requires Mg(II) as a cofactor for the relaxation of negatively supercoiled DNA. Mg(II) binding to the enzyme was shown by fluorescence spectroscopy to affect the tertiary structure of the enzyme. Addition of 2 mM MgCl2 resulted in a 30% decrease in the maximum emission of tryptophan fluorescence of the enzyme. These Mg(II)-induced changes in fluorescence properties were reversible by the addition of EDTA and not obtained with other divalent cations. After incubation with Mg(II) and dialysis, inductively coupled plasma (ICP) analysis showed that each enzyme molecule could form a complex with 1-2 Mg(II) bound to each enzyme molecule. Such Mg(II) enzyme complexes were found to be active in the relaxation of negatively supercoiled DNA in the absence of additional Mg(II). Results from ICP analysis after equilibrium dialysis and relaxation assays with limiting Mg(II) concentrations indicated that both Mg(ZI) binding sites had to be occupied for the enzyme to catalyze relaxation of negatively supercoiled DNA.	NEW YORK MED COLL,DEPT BIOCHEM & MOL BIOL,VALHALLA,NY 10595	New York Medical College					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054226] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54226] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BERANSTEED RK, 1989, PROTEINS, V6, P249, DOI 10.1002/prot.340060307; DEPEW RE, 1978, J BIOL CHEM, V253, P511; DOMANICO PL, 1991, J INORG BIOCHEM, V42, P87, DOI 10.1016/0162-0134(91)80035-G; DOMANICO PL, 1988, BIOCHEMISTRY-US, V27, P6365, DOI 10.1021/bi00417a026; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; Tse-Dinh Y C, 1994, Adv Pharmacol, V29A, P21; TSEDINH YC, 1988, J BIOL CHEM, V263, P15857; TSEDINH YC, 1986, J BIOL CHEM, V261, P931; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; ZHU CX, 1995, BIOCHEM MOL BIOL INT, V35, P375	15	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16206	16210		10.1074/jbc.272.26.16206	http://dx.doi.org/10.1074/jbc.272.26.16206			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195920	hybrid			2022-12-27	WOS:A1997XG01900024
J	Bigg, HF; Shi, YE; Liu, YLE; Steffensen, B; Overall, CM				Bigg, HF; Shi, YE; Liu, YLE; Steffensen, B; Overall, CM			Specific, high affinity binding of tissue inhibitor of metalloproteinases-4 (TIMP4) to the COOH-terminal hemopexin-like domain of human gelatinase A - TIMP-4 binds progelatinase A and the COOH-terminal domain in a similar manner to TIMP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN 72-KDA GELATINASE; FIBROBLAST COLLAGENASE INHIBITOR; 72 KDA PROGELATINASE; IV COLLAGENASE; MATRIX METALLOPROTEINASES; BONE METALLOPROTEINASE; COMPLEX-FORMATION; ACTIVATION; PURIFICATION; IDENTIFICATION	The binding properties of the newly described tissue inhibitor of metalloproteinases-4 (TIMP-4) to progelatinase A and to the COOH-terminal hemopexin-like domain (C domain) of the enzyme were examined. We present evidence for the first time of a specific, high affinity interaction between TIMP-4 and the C domain of human gelatinase A and show that TIMP-4 binds both progelatinase A and the C domain in a similar manner to that of TIMP-2. Saturable binding of recombinant C domain to TIMP-4 and to TIMP-2 but not to TIMP-1 was demonstrated using a microwell protein binding assay, The recombinant collagen binding domain of gelatinase A, comprised of the three fibronectin type II-like repeats, did not bind to TIMP-4, indicating that binding is mediated selectively by the C domain. Binding to TIMP-4 was of high affinity with an apparent K-d of 1.7 x 10(-7) M but slightly weaker than that to TIMP-2 (apparent K-d of 0.66 x 10(-7) M). Affinity chromatography confirmed the TIMP-4-C domain interaction and also showed that the complex could not be disrupted by 1 M NaCl or 10% dimethyl sulfoxide, thereby further demonstrating the tight binding, To verify the biological significance of this interaction, binding of full-length progelatinase A to TIMP-4 was investigated. TIMP-4 and TIMP-2 but not TIMP-1 bound specifically to purified TIMP-2-free human recombinant full-length progelatinase A and to full-length Pat proenzyme from the conditioned culture medium of BOS 17/2.8 cells. Preincubation of the C domain with TIMP-2 was found to reduce subsequent binding to TIMP-4 in a concentration-dependent manner. Competition between TIMP-2 and TIMP-4 for a common or overlapping binding sites on the gelatinase A C domain may occur; alternatively TIMP-2 may prevent the binding of TIMP-4 by steric hindrance or induction of a conformational change in the C domain, We propose that the binding of progelatinase A to TIMP-4 represents a third TIMP-progelatinase interaction in addition to that of progelatinase A with TIMP-8 and progelatinase B with TIMP-1 described previously. This new phenomenon may be of important physiological significance in modulating the cell surface activation of progelatinase A.	UNIV BRITISH COLUMBIA, DEPT BIOCHEM & MOL BIOL, FAC MED, VANCOUVER, BC V6T 1Z3, CANADA; UNIV BRITISH COLUMBIA, FAC DENT, VANCOUVER, BC V6T 1Z3, CANADA; LONG ISL JEWISH MED CTR, ALBERT EINSTEIN COLL MED, DEPT PEDIAT, NEW HYDE PK, NY 11042 USA	University of British Columbia; University of British Columbia; Northwell Health; Yeshiva University								APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; BANYAI L, 1991, FEBS LETT, V282, P23, DOI 10.1016/0014-5793(91)80436-7; BANYAI L, 1994, BIOCHEM J, V298, P403, DOI 10.1042/bj2980403; BROWN PD, 1990, CANCER RES, V50, P6184; CARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407, DOI 10.1073/pnas.83.8.2407; CAWSTON TE, 1983, BIOCHEM J, V211, P313, DOI 10.1042/bj2110313; CAWSTON TE, 1981, BIOCHEM J, V195, P159, DOI 10.1042/bj1950159; COLLIER IE, 1992, J BIOL CHEM, V267, P6776; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; DECLERCK YA, 1989, J BIOL CHEM, V264, P17445; DOCHERTY AJP, 1990, ANN RHEUM DIS, P469; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; FUJIMOTO N, 1993, CLIN CHIM ACTA, V220, P31, DOI 10.1016/0009-8981(93)90004-N; Fujimoto N, 1996, BIOCHEM J, V313, P827, DOI 10.1042/bj3130827; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leco KJ, 1997, FEBS LETT, V401, P213, DOI 10.1016/S0014-5793(96)01474-3; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MACKAY AR, 1990, J BIOL CHEM, V265, P21929; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1991, British Journal of Rheumatology, V30, P25; MURPHY G, 1985, BIOCHIM BIOPHYS ACTA, V831, P49, DOI 10.1016/0167-4838(85)90148-7; NAGASE H, 1991, BIOCHEM SOC T, V19, P715, DOI 10.1042/bst0190715; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OVERALL CM, 1988, BIOCHEM J, V256, P965, DOI 10.1042/bj2560965; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; OVERALL CM, 1997, IN PRESS INHIBITORS; OVERALL CM, 1991, TRENDS GLYCOSCI GLYC, V3, P384; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SHI YE, 1993, CANCER RES, V53, P1409; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; STRICKLIN GP, 1983, J BIOL CHEM, V258, P2252; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; YANG TT, 1992, P NATL ACAD SCI USA, V89, P10676, DOI 10.1073/pnas.89.22.10676	50	130	136	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15496	15500		10.1074/jbc.272.24.15496	http://dx.doi.org/10.1074/jbc.272.24.15496			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182583	hybrid			2022-12-27	WOS:A1997XE03400066
J	Das, KC; White, CW				Das, KC; White, CW			Activation of NF-kappa B by antineoplastic agents - Role of protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; TAXOL; ADRIAMYCIN; CELLS; MICROTUBULES; MACROPHAGES; TRANSCRIPTION; EXPRESSION; MECHANISM; INHIBITOR	Paclitaxel can induce tumor necrosis factor (TNF) and interleukin-1 gene expression, similar to lipopolysaccharides, Since lipopolysaccharide-induced expression of TNF is related to activation of NF-kappa B, we determined whether NP-kappa B could be activated by paclitaxel. In the human lung adenocarcinoma cell line A549, paclitaxel activated NF-kappa B in a dose-dependent manner with maximal activation after 2-4 h, Since paclitaxel could upregulate TNF and interleukin-1 secretion and subsequent NF-kappa B activation could be caused by these cytokines, the effect of two other groups of anticancer drugs including vinca alkaloids (vinblastine and vincristine) and anthracyclines (daunomycin and doxorubicin), neither of which induce TNF or interleukin-1 gene expression, were examined, Like paclitaxel, vinblastine, vincristine, daunomycin, and doxorubicin each caused activation of NF-kappa B. Therefore, it is unlikely that activation of NF-kappa B caused by these agents or by paclitaxel is mediated via cytokine up-regulation. Furthermore, actinomycin D and cycloheximide, inhibitors of transcription and translation, respectively, did not inhibit paclitaxel-induced NF-kappa B activation, Several other transcription factors such as AP-1, AP-2, CREB, SP-1, or TFIID were not activated by antineoplastic agents demonstrating specificity of NF-kappa B activation, The involvement of both subunits in the NF-kappa B DNA binding complex was demonstrated by its abrogation by anti-p65 and by supershift by anti-p50 antibodies. Since protein phosphorylation is implicated in the activation of NF-kappa B, the effect of anticancer drugs on protein kinase C activity was measured, Vincristine, daunomycin, and paclitaxel significantly increased protein kinase C activity, and vinblastine and doxorubicin caused similar trends, Following treatment with antineoplastics (1-4 h), cytoplasmic I kappa B alpha degradation occurred concomitantly with translocation of p65 to the nucleus, Specific protein kinase C inhibitors (bisindolylmaleimide (GF109203X) and calphostin C) blocked the activation of NF-kappa B by each compound. Hence, protein kinase C activation may contribute to NF-kappa B activation by antineoplastic agents.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DENVER,CO 80206	National Jewish Health					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052732, P50HL046481] Funding Source: NIH RePORTER; NHLBI NIH HHS [1RO1 HL 52732, HL 46481] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BOGDAN C, 1992, J LEUKOCYTE BIOL, V52, P119, DOI 10.1002/jlb.52.1.119; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DING AH, 1990, SCIENCE, V248, P370, DOI 10.1126/science.1970196; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; IDO M, 1986, LEUKEMIA RES, V10, P1063, DOI 10.1016/0145-2126(86)90050-0; KUMAR N, 1981, J BIOL CHEM, V256, P435; MANTHEY CL, 1992, J IMMUNOL, V149, P2459; Martelly I, 1989, CURR OPIN CELL BIOL, V1, P206, DOI 10.1016/0955-0674(89)90088-4; MUROI M, 1993, CELL SIGNAL, V5, P289, DOI 10.1016/0898-6568(93)90019-I; MURPHREE SA, 1981, BIOCHIM BIOPHYS ACTA, V649, P317, DOI 10.1016/0005-2736(81)90421-1; PIGRAM WJ, 1972, NATURE-NEW BIOL, V235, P17, DOI 10.1038/newbio235017a0; ROSETTE C, 1995, J CELL BIOL, V128, P1111, DOI 10.1083/jcb.128.6.1111; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SIEGFRIED JA, 1983, J BIOL CHEM, V258, P339; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRITTON TR, 1982, SCIENCE, V217, P248, DOI 10.1126/science.7089561; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; WATANABE K, 1982, FED PROC, V41, P2292; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z	26	256	269	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14914	14920		10.1074/jbc.272.23.14914	http://dx.doi.org/10.1074/jbc.272.23.14914			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169462	hybrid			2022-12-27	WOS:A1997XC32700059
J	Ohmori, Y; Schreiber, RD; Hamilton, TA				Ohmori, Y; Schreiber, RD; Hamilton, TA			Synergy between interferon-gamma and tumor necrosis factor-alpha in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; TATA-BINDING PROTEIN; IFN-GAMMA; RESPONSE ELEMENT; INFLAMMATORY CYTOKINES; GENE PROMOTER; FUNCTIONAL-ANALYSIS; ENDOTHELIAL-CELLS; CHEMOKINE RANTES; MAMMALIAN-CELLS	Interferon-gamma (IFN gamma) and tumor necrosis factor-alpha (TNF alpha) cooperate to induce the expression of many gene products during inflammation, The present report demonstrates that a portion of this cooperativity is mediated by synergism between two distinct transcription factors: signal transducer and activator of transcription 1 (STAT1) and nuclear factor kappa B (NF-kappa B). IFN gamma and TNF alpha synergistically induce expression of mRNAs encoding interferon regulatory factor-1 (IRF-1), intercellular adhesion molecule-1, Mig (monokine induced by gamma-interferon), and RANTES (regulated on activation normal T cell expressed and secreted) in normal but not STAT1-deficient mouse fibroblasts, indicating a requirement for STAT1, Transient transfection assays in fibroblasts using site-directed mutants of a 1.3-kilobase pair sequence of the IRF-1 gene promoter revealed that the synergy was dependent upon two sequence elements; a STAT binding element and a kappa B motif. Artificial constructs containing a single copy of both a STAT binding element and a kappa B motif linked to the herpes virus thymidine kinase promoter were able to mediate synergistic response to IFN gamma and TNF alpha; such response varied with both the relative spacing and the specific sequence of the regions between these two sites, Cooperatively responsive sequence constructs bound both STAT1 alpha and NF-kappa B in nuclear extracts prepared from IFN gamma- and/or TNF alpha-stimulated fibroblasts, although binding of individual factors was not cooperative, Thus, the frequently observed synergy between IFN gamma and TNF alpha in promoting inflammatory response depends in part upon cooperation between STAT1 alpha and NF-kappa B, which is most likely mediated by their independent interaction with one or more components of the basal transcription complex.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,CTR IMMUNOL,ST LOUIS,MO 63110	Washington University (WUSTL)	Ohmori, Y (corresponding author), CLEVELAND CLIN FDN,DEPT IMMUNOL,9500 EUCLID AVE,NN10,CLEVELAND,OH 44195, USA.		Schreiber, Robert D/A-1276-2013; Schreiber, Robert/Q-7550-2019; Hamilton, Thomas A/A-7756-2009	Schreiber, Robert D/0000-0001-6311-0432; Hamilton, Thomas/0000-0002-9817-242X; Schreiber, Robert/0000-0003-1590-2341; Ohmori, Yoshihiro/0000-0002-6069-357X	NCI NIH HHS [CA62220] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALLANTYNE CM, 1989, NUCLEIC ACIDS RES, V17, P5853, DOI 10.1093/nar/17.14.5853; BARKER JNWN, 1990, J CLIN INVEST, V85, P605, DOI 10.1172/JCI114481; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANOFF TM, 1994, J IMMUNOL, V152, P1182; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; Deng WL, 1996, CELL IMMUNOL, V170, P20, DOI 10.1006/cimm.1996.0129; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; FARBER JM, 1990, P NATL ACAD SCI USA, V87, P5238, DOI 10.1073/pnas.87.14.5238; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; GAROUFALIS E, 1994, J VIROL, V68, P4707, DOI 10.1128/JVI.68.8.4707-4715.1994; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRILLI M, 1993, INT REV CYTOL, V143, P1; GUYER NB, 1995, J IMMUNOL, V155, P3472; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; JOHNSON DR, 1994, MOL CELL BIOL, V14, P1322, DOI 10.1128/MCB.14.2.1322; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; LARNER AC, 1995, BBA-MOL CELL RES, V1266, P278, DOI 10.1016/0167-4889(95)00015-K; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; LOOK DC, 1994, J BIOL CHEM, V269, P8952; MARFAINGKOKA A, 1995, J IMMUNOL, V154, P1870; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; OHMORI Y, 1995, J IMMUNOL, V154, P5235; OHMORI Y, 1990, BIOCHEM BIOPH RES CO, V168, P1261, DOI 10.1016/0006-291X(90)91164-N; OHMORI Y, 1994, J BIOL CHEM, V269, P17684; OHMORI Y, 1993, J BIOL CHEM, V268, P6677; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; RATHANASWAMI P, 1993, J BIOL CHEM, V268, P5834; REIN T, 1994, NUCLEIC ACIDS RES, V22, P3033, DOI 10.1093/nar/22.15.3033; REIN T, 1996, NUCLEIC ACIDS RES, V170, P20; RILLEY JL, 1995, IMMUNITY, V2, P533; Sambrook J., 2002, MOL CLONING LAB MANU; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHALL TJ, 1992, EUR J IMMUNOL, V22, P1477, DOI 10.1002/eji.1830220621; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHIN HS, 1994, MOL CELL BIOL, V14, P2914, DOI 10.1128/MCB.14.5.2914; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STELLATO C, 1995, J IMMUNOL, V155, P410; Stewart RJ, 1996, J IMMUNOL, V156, P1221; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WONG P, 1994, MOL CELL BIOL, V14, P914, DOI 10.1128/MCB.14.2.914; WRIGHT TM, 1991, J EXP MED, V173, P417, DOI 10.1084/jem.173.2.417; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; YAMAMOTO K, 1992, J BIOL CHEM, V267, P22506	69	359	373	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14899	14907		10.1074/jbc.272.23.14899	http://dx.doi.org/10.1074/jbc.272.23.14899			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169460	hybrid			2022-12-27	WOS:A1997XC32700057
J	Wang, SP; Shuman, S				Wang, SP; Shuman, S			Structure-function analysis of the mRNA cap methyltransferase of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYLMETHIONINE-DEPENDENT METHYLTRANSFERASES; SEQUENCE MOTIFS; RNA; PROTEIN	The Saccharomyces cerevisiae mRNA cap methylating enzyme is a 436-amino acid protein encoded by the essential ABD1 gene. To identify structural features of ABD1 required for enzyme function, we introduced alanine mutations at 19 positions within a 205-amino acid region of similarity to the methyltransferase domain of the vaccinia capping enzyme. Three new recessive lethal. mutations, E170A, D194A and R206A, were identified. Structure-function relationships were clarified by introducing conservative substitutions at Glu-170, Asp-194, and Arg-206, and at Tyr-254 (an essential residue identified previously). Alleles E170D and D194E were viable, whereas E170Q and D194N were lethal; hence, acidic side chains were critical at both positions. R206K was viable, suggesting that a basic residue sufficed. Y254S was lethal, whereas Y254F was viable, albeit slow growing; thus, an aromatic side chain was important. The ABD1 mutations that were deleterious in vivo elicited catalytic defects in vitro. By studying the effects of amino- and carboxyl-terminal deletions, we defined a fully active catalytic domain of ABD1 from residues 130 to 426. Residues 110-129 were dispensable for methyltransferase activity in vitro, but essential for function in vivo. This analysis allowed us to delineate a subfamily of ABD1-like proteins within the superfamily of AdoMet-dependent methyltransferases. In addition, we identify a candidate Caenorhabditis elegans gene encoding a putative cap methyltransferase. All residues essential for ABD1 activity are conserved in the C. elegans homologue.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center								INGROSSO D, 1989, J BIOL CHEM, V264, P20131; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; KOONIN EV, 1995, P NATL ACAD SCI USA, V92, P11921, DOI 10.1073/pnas.92.25.11921; Mao XD, 1996, BIOCHEMISTRY-US, V35, P6900, DOI 10.1021/bi960221a; MAO XD, 1995, MOL CELL BIOL, V15, P4167; Mao XD, 1996, MOL CELL BIOL, V16, P475; SHUMAN S, 1995, PROG NUCLEIC ACID RE, V50, P101, DOI 10.1016/S0079-6603(08)60812-0	7	52	54	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14683	14689		10.1074/jbc.272.23.14683	http://dx.doi.org/10.1074/jbc.272.23.14683			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169431	hybrid			2022-12-27	WOS:A1997XC32700028
J	Falls, LA; Farrell, DH				Falls, LA; Farrell, DH			Resistance of gamma A/gamma' fibrin clots to fibrinolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CHAIN; HUMAN-PLASMA; FACTOR-XIII; CROSS-LINKING; PLATELETS; ACTIVATION; IDENTIFICATION; INCREASES; BINDING; DISEASE	Elevated plasma fibrinogen levels are a major risk factor for thrombosis, This report shows two mechanisms by which fibrinogen can affect the fibrinolysis rate in vitro and thus may lead to thrombosis, First, the lysis rate of fibrin decreases as the initial concentration of fibrinogen increases. Second, a minor variant form of fibrinogen decreases the rate of fibrinolysis. This variant, gamma A/gamma' fibrinogen, has one altered gamma chain and is known to bind to factor XIII zymogen, In a fibrinolysis assay containing purified thrombin, fibrinogen, tissue-type plasminogen activator, and plasminogen, clots from gamma A/gamma A and gamma A/gamma' fibrinogen lysed at similar rates, However, when factor XIII was added, slower lysis was seen in gamma A/gamma' fibrin clots when compared with gamma A/gamma A fibrin clots. A D-dimer agglutination assay showed that the gamma A/gamma' clots were more highly cross-linked than the gamma A/gamma A clots, The lysis rates of gamma A/gamma' clots were similar to gamma A/gamma A clots in the presence of N-ethylmaleimide, a specific inhibitor of factor XIIIa, The gamma A/gamma' fibrin clots made in the presence of factor XIII showed increased proteolytic resistance to both plasmin and trypsin, Clots made from afibrinogenemic plasma reconstituted with gamma A/gamma' fibrinogen also showed significant resistance to lysis compared with gamma A/gamma A fibrinogen. These data demonstrate gamma A/gamma' fibrin is resistant to fibrinolysis, possibly as a result of concentrating factor XIII on the clot, The total fibrinogen concentration and the amount of gamma A/gamma' fibrinogen increase clot stability in vitro and thus may contribute independently to the risk of thrombosis in humans.	PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT BIOCHEM & MOL BIOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health								BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; Blomback B, 1996, THROMB RES, V83, P1, DOI 10.1016/0049-3848(96)00111-9; CHEN R, 1969, P NATL ACAD SCI USA, V63, P420, DOI 10.1073/pnas.63.2.420; CHOOI CC, 1989, THROMB RES, V53, P493, DOI 10.1016/0049-3848(89)90204-1; CHUNG DW, 1984, BIOCHEMISTRY-US, V23, P4232, DOI 10.1021/bi00313a033; COOK NS, 1990, TRENDS PHARMACOL SCI, V11, P444, DOI 10.1016/0165-6147(90)90125-R; ERNST E, 1994, ANN MED, V26, P15, DOI 10.3109/07853899409147322; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FARRELL DH, 1994, J BIOL CHEM, V269, P226; FINLAYSON JS, 1960, J CLIN INVEST, V39, P1837, DOI 10.1172/JCI104207; FORNACE AJ, 1984, J BIOL CHEM, V259, P2826; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FRANCIS CW, 1980, J BIOL CHEM, V255, P5599; GAFFNEY PJ, 1979, THROMB RES, V14, P85, DOI 10.1016/0049-3848(79)90027-6; GUREWICH V, 1976, THROMB HAEMOSTASIS, V36, P605; HAIDARIS PJ, 1992, BLOOD, V79, P1218; JONES AJS, 1990, THROMB HAEMOSTASIS, V64, P455; KUDRYK BJ, 1974, J BIOL CHEM, V249, P3322; LAWRENCE SO, 1993, BLOOD, V82, P2406; LEWIS ML, 1991, THROMB RES, V64, P223, DOI 10.1016/0049-3848(91)90121-C; LORAND L, 1972, ANN NY ACAD SCI, V202, P6, DOI 10.1111/j.1749-6632.1972.tb16319.x; LORAND L, 1993, METHOD ENZYMOL, V222, P22; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MOSESSON MW, 1972, J BIOL CHEM, V247, P5223; NASKI MC, 1991, J BIOL CHEM, V266, P13003; PEERSCHKE EIB, 1986, BLOOD, V67, P385; REED GL, 1992, THROMB HAEMOSTASIS, V68, P315; SCHWARTZ ML, 1973, J BIOL CHEM, V248, P1395; SIEBENLIST KR, 1994, J BIOL CHEM, V269, P28414; Siebenlist KR, 1996, BIOCHEMISTRY-US, V35, P10448, DOI 10.1021/bi9606206; THOMPSON WD, 1989, J PATHOL, V159, P97, DOI 10.1002/path.1711590203; VANPELTVERKUIL E, 1989, THROMB HAEMOSTASIS, V61, P246; WOLFENSTEINTODEL C, 1980, P NATL ACAD SCI-BIOL, V77, P5069, DOI 10.1073/pnas.77.9.5069; WUN TC, 1985, J BIOL CHEM, V260, P5061; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836	35	65	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14251	14256		10.1074/jbc.272.22.14251	http://dx.doi.org/10.1074/jbc.272.22.14251			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162058	hybrid			2022-12-27	WOS:A1997XB49200045
J	Huflejt, ME; Jordan, ET; Gitt, MA; Barondes, SH; Leffler, H				Huflejt, ME; Jordan, ET; Gitt, MA; Barondes, SH; Leffler, H			Strikingly different localization of galectin-3 and galectin-4 in human colon adenocarcinoma T84 cells - Galectin-4 is localized at sites of cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE BINDING PROTEIN-35; ADHERENS JUNCTION PROTEIN; LACTOSE-BINDING; ELECTROLYTE TRANSPORT; EXTRACELLULAR-MATRIX; NUCLEAR-LOCALIZATION; INITIAL BINDING; LECTIN; MAC-2; KIDNEY	Two beta-galactoside-binding proteins were found to be prominently expressed in the human colon adenocarcinoma T84 cell line. Cloning and sequencing of one, a 36-kDa protein, identified it as the human homolog of galectin-4, a protein containing two carbohydrate binding domains and previously found only in the epithelial cells of the rat and porcine alimentary tract, The other, a 29-kDa protein, is galectin-3, containing a single carbohydrate binding domain, previously found in a number of different cell types including human intestinal epithelium. Despite the marked similarities in the carbohydrate binding domains of these two galectins, their cellular distribution patterns are strikingly different and vary with cellular conditions, In confluent T84 cells, galectin-4 is mostly cytosolic and concentrated at the basal membrane, whereas galectin-3 tends to be concentrated in large granular inclusions mostly at the apical membrane. In subconfluent T84 cells, each galectin is distributed to specific domains of lamellipodia, with galectin-4 concentrated in the leading edge and galectin-3 more proximally. Such different localization of galectins-4 and -3 within T84 cells implies different targeting mechanisms, ligands, and functions, The localization of galectin-4 suggests a role in cell adhesion which is also supported by the ability of immobilized recombinant galectin-4 to stimulate adhesion of T84 cells.	UNIV CALIF SAN FRANCISCO, CTR NEUROBIOL & PSYCHIAT, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco			Leffler, Hakon/A-2416-2019	Huflejt, Malgorzata/0000-0002-2016-8367; Leffler, Hakon/0000-0003-4482-8945	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE007244, R37DE007244] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 07244] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BROWN WJ, 1987, METHOD CELL BIOL, V31, P553; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; CHIU ML, 1992, J CELL BIOL, V119, P1689, DOI 10.1083/jcb.119.6.1689; CHIU ML, 1994, J BIOL CHEM, V269, P31770; COLGAN SP, 1995, J BIOL CHEM, V270, P10531, DOI 10.1074/jbc.270.18.10531; COLGAN SP, 1993, J CELL BIOL, V120, P785, DOI 10.1083/jcb.120.3.785; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; DAMSKY CH, 1992, J CLIN INVEST, V89, P210, DOI 10.1172/JCI115565; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, pG204, DOI 10.1152/ajpgi.1984.246.2.G204; DHARMSATHAPHORN K, 1990, METHOD ENZYMOL, V192, P354; FODDY L, 1990, J CELL SCI, V97, P139; GITT MA, 1995, J BIOL CHEM, V270, P5032, DOI 10.1074/jbc.270.10.5032; GU MJ, 1994, J CELL SCI, V107, P175; HO MK, 1982, J IMMUNOL, V128, P1221; HUFLEJT ME, 1993, J BIOL CHEM, V268, P26712; HUFLEJT ME, 1995, J CELL BIOCH B, V19, P20; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; Kuwabara I, 1996, J IMMUNOL, V156, P3939; LEFFLER H, 1986, J BIOL CHEM, V261, P119; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LINDSTEDT R, 1993, J BIOL CHEM, V268, P11750; LOTZ MM, 1989, J CELL BIOL, V109, P1795, DOI 10.1083/jcb.109.4.1795; LOTZ MM, 1993, P NATL ACAD SCI USA, V90, P3466, DOI 10.1073/pnas.90.8.3466; MCCLAY DR, 1981, P NATL ACAD SCI-BIOL, V78, P4975, DOI 10.1073/pnas.78.8.4975; MOORE R, 1989, LAB INVEST, V60, P237; MOUTSATSOS IK, 1987, P NATL ACAD SCI USA, V84, P6452, DOI 10.1073/pnas.84.18.6452; NUSRAT A, 1992, J CLIN INVEST, V89, P1501, DOI 10.1172/JCI115741; ODA Y, 1993, J BIOL CHEM, V268, P5929; OZEKI Y, 1995, GLYCOBIOLOGY, V5, P255, DOI 10.1093/glycob/5.2.255; RUTTEN MJ, 1983, AM J PHYSIOL, V244, pG171, DOI 10.1152/ajpgi.1983.244.2.G171; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SATO S, 1994, J BIOL CHEM, V269, P4424; SATO S, 1993, EXP CELL RES, V207, P8, DOI 10.1006/excr.1993.1157; SEVE AP, 1994, EXP CELL RES, V213, P191, DOI 10.1006/excr.1994.1190; TARDY F, 1995, FEBS LETT, V359, P169, DOI 10.1016/0014-5793(95)00025-5; WANG JL, 1992, BIOCHEM SOC T, V20, P269, DOI 10.1042/bst0200269; WASANO K, 1995, CELL TISSUE RES, V281, P77, DOI 10.1007/BF00307960; WOO HJ, 1990, J BIOL CHEM, V265, P7097; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737	41	82	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14294	14303		10.1074/jbc.272.22.14294	http://dx.doi.org/10.1074/jbc.272.22.14294			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162064	hybrid			2022-12-27	WOS:A1997XB49200051
J	Stephens, DJ; Crump, CM; Clarke, AR; Banting, G				Stephens, DJ; Crump, CM; Clarke, AR; Banting, G			Serine 331 and tyrosine 333 are both involved in the interaction between the cytosolic domain of TGN38 and the mu 2 subunit of the AP2 clathrin adaptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; CYTOPLASMIC DOMAIN; MEMBRANE-PROTEIN; BINDING; RECEPTOR; IDENTIFICATION; LOCALIZATION; SEQUENCE; SIGNALS; MOTIF	TGN38 is a type I integral membrane protein that cycles between the trans-Golgi network and the plasma membrane, Internalization at the cell surface and targeting back to the trans-Golgi network is dependent on a hexapeptide motif, SDYQRL, in the cytosolic tail of the protein, It was recently demonstrated that this motif specifically interacts with the mu 2 subunit of the AP2 adaptor complex, We have studied the interaction between the entire cytosolic domain of TGN38 and mu 2 using the yeast two hybrid system, in vitro binding of recombinant fusion proteins and IAsys optical biosensor technology, A specific interaction has been demonstrated in each of the systems we have employed, We have shown an absolute requirement for Tyr-333 of TGN38 in binding to mu 2. In addition we found that mutation of Ser-331 to alanine reduces the affinity of the interaction, By measuring tryptophan fluorescence at equilibrium, we have also determined the dissociation constant for the interaction between the entire cytosolic tail of TGN38 and mu 2 as 58 nM. In contrast to previously published work, our data suggest that not only Tyr-333 but also its context is important in determining the specificity of binding of TGN38 to mu 2.	UNIV BRISTOL,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND	University of Bristol				Banting, George/0000-0001-8249-1621; Crump, Colin/0000-0001-9918-9998; Stephens, David/0000-0001-5297-3240				AHLE S, 1989, J BIOL CHEM, V264, P20089; Banting G, 1997, BBA-MOL CELL RES, V1355, P209, DOI 10.1016/S0167-4889(96)00146-2; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; BOLL W, 1995, CURR BIOL, V5, P1168, DOI 10.1016/S0960-9822(95)00233-8; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JI X, 1992, BIOCHEMISTRY-US, V267, P4296; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; REAVES B, 1993, MOL BIOL CELL, V4, P93, DOI 10.1091/mbc.4.1.93; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Sambrook J., 2002, MOL CLONING LAB MANU; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SOSA MA, 1993, J BIOL CHEM, V268, P12537; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WILDE A, 1994, J BIOL CHEM, V269, P7131; WONG SH, 1993, J BIOL CHEM, V268, P22853	28	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14104	14109		10.1074/jbc.272.22.14104	http://dx.doi.org/10.1074/jbc.272.22.14104			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162036	hybrid			2022-12-27	WOS:A1997XB49200023
J	Hashimoto, O; Nakamura, T; Shoji, H; Shimasaki, S; Hayashi, Y; Sugino, H				Hashimoto, O; Nakamura, T; Shoji, H; Shimasaki, S; Hayashi, Y; Sugino, H			A novel role of follistatin, an activin-binding protein, in the inhibition of activin action in rat pituitary cells - Endocytotic degradation of actin and its acceleration by follistatin associated with cell-surface heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID-DIFFERENTIATION FACTOR; FOLLICULAR GRANULOSA-CELLS; SEQUENCE-ANALYSIS; OVARIAN INHIBINS; SERINE KINASE; FLUID; EXPRESSION; RECEPTOR; CLONING; SUBUNITS	There are two types of the activin-binding protein follistatin (BS), B8-288 and FS-315. These result from alternative splicing of mRNA. FS-288 exhibits high affinity for cell-surface heparan sulfate proteoglycans, whereas FS-315 shows low affinity. To understand the physiological role of cell associated FS, we investigated the binding of activin to cell-associated FS and its behavior on the cell surface using primary cultured rat pituitary cells. Affinity cross-linking experiments using I-I25-activin A demonstrated that activin bound to rat pituitary cells via PS as well as to their receptors on the cell surface. FS-288 promoted the binding of activin A to the cell surface more markedly than FS-315, When the cells were incubated with I-125-activin A in the presence of B8-288, significant degradation of activin A was observed, and this was dependent on the FS-288 concentration. This activin degradation was abolished by heparan sulfate, chloroquine, and several lysosomal enzyme inhibitors. Moreover, FS-288 stimulated cellular uptake of activin A, whereas chloroquine suppressed lysosomal degradation following internalization, as demonstrated by microscopic autoradiography. These results suggest that cell-associated FS-288 accelerates the uptake of activin A into pituitary cells, leading to increased degradation by lysosomal enzymes, and thus plays a role in the activin clearance system.	UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN; UNIV TOKYO,FAC AGR,DEPT VET ANAT,BUNKYO KU,TOKYO 113,JAPAN; UNIV CALIF SAN DIEGO,SCH MED,DEPT REPROD MED,LA JOLLA,CA 92093	Tokushima University; University of Tokyo; University of California System; University of California San Diego								ASASHIMA M, 1991, P NATL ACAD SCI USA, V88, P6511, DOI 10.1073/pnas.88.15.6511; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; Dalkin AC, 1996, ENDOCRINOLOGY, V137, P548, DOI 10.1210/en.137.2.548; deWinter JP, 1996, MOL CELL ENDOCRINOL, V116, P105, DOI 10.1016/0303-7207(95)03705-5; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; ESCH FS, 1987, MOL ENDOCRINOL, V1, P388, DOI 10.1210/mend-1-5-388; FORAGE RG, 1986, P NATL ACAD SCI USA, V83, P3091, DOI 10.1073/pnas.83.10.3091; HASEGAWA Y, 1986, ENDOCRINOL JAPON, V33, P645; HASHIMOTO M, 1992, J BIOL CHEM, V267, P7203; INOUYE S, 1991, ENDOCRINOLOGY, V129, P815, DOI 10.1210/endo-129-2-815; KOGAWA K, 1991, ENDOCRINOLOGY, V128, P1434, DOI 10.1210/endo-128-3-1434; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; LING N, 1985, P NATL ACAD SCI USA, V82, P7217, DOI 10.1073/pnas.82.21.7217; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MANSON AJ, 1985, NATURE, V318, P659; MASON AJ, 1986, BIOCHEM BIOPH RES CO, V135, P957, DOI 10.1016/0006-291X(86)91021-1; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MEUNIER H, 1988, P NATL ACAD SCI USA, V85, P247, DOI 10.1073/pnas.85.1.247; MIYAMOTO K, 1985, BIOCHEM BIOPH RES CO, V129, P396, DOI 10.1016/0006-291X(85)90164-0; NAKAMURA T, 1992, BIOCHIM BIOPHYS ACTA, V1135, P103, DOI 10.1016/0167-4889(92)90173-9; NAKAMURA T, 1992, J BIOL CHEM, V267, P16385; NAKAMURA T, 1991, J BIOL CHEM, V266, P19432; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; RIVER J, 1985, BIOCHEM BIOPH RES CO, V133, P120; ROBERTSON DM, 1987, BIOCHEM BIOPH RES CO, V149, P744, DOI 10.1016/0006-291X(87)90430-X; ROBERTSON DM, 1985, BIOCHEM BIOPH RES CO, V126, P220, DOI 10.1016/0006-291X(85)90594-7; SHIMASAKI S, 1989, MOL ENDOCRINOL, V3, P651, DOI 10.1210/mend-3-4-651; SHIMASAKI S, 1988, P NATL ACAD SCI USA, V85, P4218, DOI 10.1073/pnas.85.12.4218; SHIOZAKI M, 1992, P NATL ACAD SCI USA, V89, P1553, DOI 10.1073/pnas.89.5.1553; SUGINO K, 1993, J BIOL CHEM, V268, P15579; TAKABE Y, 1988, MOL CELL BIOL, V8, P466; UENO N, 1987, P NATL ACAD SCI USA, V84, P8282, DOI 10.1073/pnas.84.23.8282; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	35	164	167	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13835	13842		10.1074/jbc.272.21.13835	http://dx.doi.org/10.1074/jbc.272.21.13835			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153241	hybrid			2022-12-27	WOS:A1997XA06200056
J	Blakesley, VA; BeitnerJohnson, D; VanBrocklyn, JR; Rani, S; ShenOrr, Z; Stannard, BS; Spiegel, S; LeRoith, D				Blakesley, VA; BeitnerJohnson, D; VanBrocklyn, JR; Rani, S; ShenOrr, Z; Stannard, BS; Spiegel, S; LeRoith, D			Sphingosine 1-phosphate stimulates tyrosine phosphorylation of Crk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NUCLEOTIDE EXCHANGE FACTOR; PHOSPHATIDIC-ACID LEVELS; SRC HOMOLOGY-3 DOMAIN; 2ND MESSENGER; PC12 CELLS; C-CRK; V-CRK; CERAMIDE; PATHWAY	The proto-oncogene molecule c-Crk plays a role in growth factor-induced activation of Pas. Sphingosine 1-phosphate (SPP), a metabolite of cellular sphingolipids, has previously been shown to play a role in growth factor receptor signaling (Olivera, A., and Spiegel, S. (1993) Nature 365, 557-560), SPP was found to strongly induce tyrosine phosphorylation of Crk, but not She, in NIH-3T3 parental, insulin-like growth factor-I receptor-overexpressing and Crk-overexpressing (3T3-Crk) fibroblasts. Sphingosine, a metabolic precursor of SPP, also produced a slight increase in tyrosine phosphorylation of Crk. In contrast, other sphingolipid metabolites including ceramide did not alter Crk tyrosine phosphorylation. Furthermore, Crk enhanced SPP-induced mitogenesis, as measured by SPP-stimulated [H-3]thymidine incorporation in a manner proportional to the level of Crk expression in 3T3-Crk cells. This stimulation appears to be Ras dependent, whereas SPP stimulation of MAP kinase activity is Ras independent. These data indicate that SPP activates a tyrosine kinase that phosphorylates Crk and that Crk is a positive effector of SPP-induced mitogenesis.	NIDDK,DIABET BRANCH,NATL INST HLTH,BETHESDA,MD 20892; GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOL BIOL,WASHINGTON,DC 20007	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Georgetown University			Van Brocklyn, Jim/A-9733-2010		NATIONAL CANCER INSTITUTE [R01CA061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043880, R01GM043880] Funding Source: NIH RePORTER; NCI NIH HHS [CA61774] Funding Source: Medline; NIGMS NIH HHS [GM43880] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BeitnerJohnson D, 1996, J BIOL CHEM, V271, P9287, DOI 10.1074/jbc.271.16.9287; BLAKESLEY VA, 1995, J BIOL CHEM, V270, P2764, DOI 10.1074/jbc.270.6.2764; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHAO CP, 1994, J BIOL CHEM, V269, P5849; DESAI NN, 1992, J BIOL CHEM, V267, P23122; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; GOODEMOTE KA, 1995, J BIOL CHEM, V270, P10272, DOI 10.1074/jbc.270.17.10272; Greulich H, 1996, CELL GROWTH DIFFER, V7, P1443; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HAUSER JML, 1994, J BIOL CHEM, V269, P6803; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LAVIE Y, 1990, BIOCHEM BIOPH RES CO, V167, P607; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAINES MA, 1993, J BIOL CHEM, V268, P14572; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VENABLE ME, 1994, J BIOL CHEM, V269, P26040; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; ZHANG H, 1990, J BIOL CHEM, V265, P21309	39	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16211	16215		10.1074/jbc.272.26.16211	http://dx.doi.org/10.1074/jbc.272.26.16211			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195921	hybrid			2022-12-27	WOS:A1997XG01900025
J	Lackmann, M; Mann, RJ; Kravets, L; Smith, FM; Bucci, TA; Maxwell, KF; Howlett, GJ; Olsson, JE; Bos, TV; Cerretti, DP; Boyd, AW				Lackmann, M; Mann, RJ; Kravets, L; Smith, FM; Bucci, TA; Maxwell, KF; Howlett, GJ; Olsson, JE; Bos, TV; Cerretti, DP; Boyd, AW			Ligand for EPH-related kinase (LERK) 7 is the preferred high affinity ligand for the HEK receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SURFACE-PLASMON RESONANCE; BINDING CONSTANTS; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; KINETIC-ANALYSIS; GROWTH-FACTOR; CELL LINES; FAMILY; EXPRESSION	HEK is a member of the EPH-like receptor tyrosine kinase family, which appear to have roles in development and oncogenesis. Recently, we purified a soluble HEK ligand which is also a ligand (AL1) for the HEK-related receptor EHK1. Promiscuity appears to be a characteristic feature of interactions between the EPH-like receptors and their ligands, termed ligands for EPH-related kinases (LERKs). This prompted us to analyze the interactions between the HER exodomain and fusion proteins comprising candidate LERKs and the Fc portion of human IgG(1) (Fc) or a FLAG(TM)-peptide tag by surface plasmon resonance, size exclusion high performance liquid chromatography, sedimentation equilibrium, and transphosphorylation. Our results indicate that AL1/LERK7 is the preferred high-affinity ligand for HEK, forming a stable 1:1 complex with a dissociation constant of 12 nM. As expected the apparent affinities of bivalent fusion proteins of LERKs and the Fc portion of human IgG(1) had significantly reduced dissociation rates compared with their monovalent, FLAG(TM)-tagged derivatives. High-avidity binding of monovalent ligands can be achieved by antibody-mediated cross-linking of monovalent ligands and with LERK7 results in specific phosphorylation of the receptor. By extrapolation, our findings indicate that some of the reported LERK-receptor interactions are a consequence of the use of bivalent ligand or receptor constructs and may be functionally irrelevant.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,LUDWIG INST CANC RES,MELBOURNE BRANCH,MELBOURNE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,LIONS CANC RES LAB,MELBOURNE,VIC 3050,AUSTRALIA; UNIV MELBOURNE,RUSSELL GRIMWADE SCH BIOCHEM & MOL BIOL,PARKVILLE,VIC 3052,AUSTRALIA; IMMUNEX RES & DEV CORP,SEATTLE,WA 98101; ROYAL BRISBANE HOSP,BANCROFT CTR,QUEENSLAND INST MED RES,HERSTON,QLD 4029,AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Melbourne; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital	Lackmann, M (corresponding author), ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,COOPERAT RES CTR CELLULAR GROWTH FACTORS,MELBOURNE,VIC 3050,AUSTRALIA.		Boyd, Andrew/G-2083-2010					ALTSCHUH D, 1992, BIOCHEMISTRY-US, V31, P6298, DOI 10.1021/bi00142a019; ANDRES AC, 1994, ONCOGENE, V9, P1461; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BIOSENSOR P, 1995, BIATECHNOLOGY HDB; Bohme B, 1996, J BIOL CHEM, V271, P24747, DOI 10.1074/jbc.271.40.24747; BOYD AW, 1992, J BIOL CHEM, V267, P3262; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; Cerretti DP, 1996, GENOMICS, V35, P376, DOI 10.1006/geno.1996.0371; Cerretti DP, 1995, MOL IMMUNOL, V32, P1197, DOI 10.1016/0161-5890(95)00108-5; Chatellier J, 1996, J MOL RECOGNIT, V9, P39, DOI 10.1002/(SICI)1099-1352(199601)9:1<39::AID-JMR239>3.0.CO;2-V; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; EASTY DJ, 1995, CANCER RES, V55, P2528; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOGG PJ, 1987, BIOCHEMISTRY-US, V26, P1867, DOI 10.1021/bi00381a012; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KARLSSON R, 1992, STRUCTURE ANTIGENS; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; Lackmann M, 1996, P NATL ACAD SCI USA, V93, P2523, DOI 10.1073/pnas.93.6.2523; MARU Y, 1990, ONCOGENE, V5, P445; Nicola NA, 1996, GROWTH FACTORS, V13, P141, DOI 10.3109/08977199609034574; Nieba L, 1996, ANAL BIOCHEM, V234, P155, DOI 10.1006/abio.1996.0067; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; PELLEQUER JL, 1993, J IMMUNOL METHODS, V166, P133, DOI 10.1016/0022-1759(93)90337-7; POSNER RG, 1991, BIOCHEMISTRY-US, V30, P2348, DOI 10.1021/bi00223a008; SALVARIS E, 1992, LEUKEMIA RES, V16, P655, DOI 10.1016/0145-2126(92)90016-Z; SHAO HN, 1995, J BIOL CHEM, V270, P5636, DOI 10.1074/jbc.270.10.5636; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SHAO HN, 1995, J BIOL CHEM, V270, P3467, DOI 10.1074/jbc.270.8.3467; SIMPSON RJ, 1986, EUR J BIOCHEM, V157, P497, DOI 10.1111/j.1432-1033.1986.tb09694.x; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANDERMERWE PA, 1993, EMBO J, V12, P4945, DOI 10.1002/j.1460-2075.1993.tb06188.x; Ward LD, 1996, J BIOL CHEM, V271, P20138, DOI 10.1074/jbc.271.33.20138; WARD LD, 1995, BIOCHEMISTRY-US, V34, P2901, DOI 10.1021/bi00009a021; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6	49	63	65	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16521	16530		10.1074/jbc.272.26.16521	http://dx.doi.org/10.1074/jbc.272.26.16521			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195962	hybrid			2022-12-27	WOS:A1997XG01900066
J	Matsuo, N; Ogawa, S; Takagi, T; Wanaka, A; Mori, T; Matsuyama, T; Pinsky, DJ; Stern, DM; Tohyama, M				Matsuo, N; Ogawa, S; Takagi, T; Wanaka, A; Mori, T; Matsuyama, T; Pinsky, DJ; Stern, DM; Tohyama, M			Cloning of a putative vesicle transport-related protein, RA410, from cultured rat astrocytes and its expression in ischemic rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; MEDIATED INDUCTION; FREE-RADICALS; GENE; SURVIVAL; HYPOXIA/REOXYGENATION; INTERLEUKIN-6; ENDOTHELIUM; METABOLISM; MECHANISM	To elucidate the role of astrocytes in the stress response of the central nervous system to ischemia, early gene expression was evaluated in cultured rat astrocytes subjected to hypoxia/reoxygenation. Using differential display, a novel putative vesicle transport-related factor (RA410) was cloned from reoxygenated astrocytes. Analysis of the deduced amino acid sequence showed RA410 to be composed of domains common to vesicle transport-related proteins of the Sec1/Unc18 family, including Sly1p and Sec1p (yeast), Rop (Drosophila), Unc18 (Caenorhabditis elegans), and Munc18 (mammalian), suggesting its possible role in vesicular transport. Northern analysis of normal rat tissues showed the highest expression of RA410 transcripts in testis. When astrocyte cultures were subjected to a period of hypoxia followed by reoxygenation, induction of RA410 mRNA was observed within 15 min of reoxygenation, reaching a maximum by 60 min. At the start of reoxygenation, the addition of diphenyl iodonium, an NADPH oxidase inhibitor, blocked in parallel astrocyte generation of reactive oxygen intermediates and expression of RA410 message. In contrast, cycloheximide did not affect RA410 mRNA levels, indicating that RA410 is an immediate-early gene in the setting of reoxygenation. Using polyclonal antibody raised against an RA410-derived synthetic peptide, Western blotting of lysates from reoxygenated astrocytes displayed an immunoreactive band of approximate to 70 kDa, the expression of which followed induction of the mRNA. Fractionation of astrocyte lysates on sucrose gradients showed RA410 antigen to be predominantly in the plasma membrane. Immunoelectron microscopic analysis demonstrated RA410 in large vesicles associated with the Golgi, but not in the Golgi apparatus itself, consistent with its participation in post-Golgi transport. Consistent with these in vitro data, RA410 expression was observed in rat brain astrocytes following transient occlusion of the middle cerebral artery. These data provide insight into a new protein (RA410) that participates in the ischemia-related stress response in astrocytes.	OSAKA UNIV, SCH MED, DEPT ANAT & NEUROSCI, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT MOL NEUROBIOL TANABE, SUITA, OSAKA 565, JAPAN; FUKUSHIMA MED COLL, DEPT CELL SCI, INST BIOMED SCI, FUKUSHIMA 96012, JAPAN; HYOGO MED UNIV, DEPT MED 5, NISHINOMIYA, HYOGO 663, JAPAN; DAINIPPON PHARMACEUT CO LTD, SUITA, OSAKA 564, JAPAN; COLUMBIA UNIV COLL PHYS & SURG, DEPT PHYSIOL & CELLULAR BIOPHYS & SURG, NEW YORK, NY 10032 USA	Osaka University; Osaka University; Fukushima Medical University; Hyogo College of Medicine; University of Hyogo; Dainippon Sumitomo Pharmaceutical Company; Columbia University			Wanaka, Akio/AAC-9754-2019; Wanaka, Akio/ABE-4671-2020; Wanaka, Akio/GPW-8926-2022	Wanaka, Akio/0000-0001-9951-9862; 	NHLBI NIH HHS [HL50629, HL42507] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042507, R01HL050629] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALATO MK, 1991, YEAST, V7, P643; ARTHUR FE, 1987, DEV BRAIN RES, V36, P155, DOI 10.1016/0165-3806(87)90075-7; BANTA LM, 1990, MOL CELL BIOL, V10, P4638, DOI 10.1128/MCB.10.9.4638; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COWLES CR, 1994, J CELL SCI, V107, P3449; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREI K, 1989, EUR J IMMUNOL, V19, P689, DOI 10.1002/eji.1830190418; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HEIN J, 1990, METHOD ENZYMOL, V183, P626; HENN FA, 1972, BRAIN RES, V43, P435; HORI O, 1994, J NEUROCHEM, V62, P1489; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Hori O, 1996, J NEUROCHEM, V66, P973; HOSONO R, 1992, J NEUROCHEM, V58, P1517, DOI 10.1111/j.1471-4159.1992.tb11373.x; JANECZKO K, 1991, BRAIN RES, V564, P86, DOI 10.1016/0006-8993(91)91355-5; KITAGAWA K, 1991, BRAIN RES, V561, P203, DOI 10.1016/0006-8993(91)91596-S; KUBOTA Y, 1987, BRAIN RES, V413, P179, DOI 10.1016/0006-8993(87)90167-3; Kuwabara K, 1996, J BIOL CHEM, V271, P5025; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MAEDA Y, 1994, J EXP MED, V180, P2297, DOI 10.1084/jem.180.6.2297; MATSUO N, 1995, J BIOL CHEM, V270, P28216, DOI 10.1074/jbc.270.47.28216; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; NAGASAWA H, 1989, STROKE, V20, P1037, DOI 10.1161/01.STR.20.8.1037; OGAWA S, 1990, J CLIN INVEST, V85, P1090, DOI 10.1172/JCI114540; PECHAN PA, 1992, NEUROREPORT, V3, P469, DOI 10.1097/00001756-199206000-00003; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; SALZBERG A, 1993, DEVELOPMENT, V117, P1309; SCHOUSBOE A, 1977, NEUROCHEM RES, V2, P217, DOI 10.1007/BF00964098; SHRECK R, 1991, EMBO J, V10, P2247; SIESJO BK, 1988, CRIT CARE MED, V16, P954, DOI 10.1097/00003246-198810000-00006; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SORGER PK, 1987, EMBO J, V6, P993, DOI 10.1002/j.1460-2075.1987.tb04850.x; SWANSON RA, 1993, J CEREBR BLOOD F MET, V13, P162, DOI 10.1038/jcbfm.1993.19; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VACA K, 1992, EXP NEUROL, V118, P62, DOI 10.1016/0014-4886(92)90023-J; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8	42	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16438	16444		10.1074/jbc.272.26.16438	http://dx.doi.org/10.1074/jbc.272.26.16438			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195952	Green Published, hybrid			2022-12-27	WOS:A1997XG01900056
J	Manie, SN; Astier, A; Haghayeghi, N; Canty, T; Druker, BJ; Hirai, H; Freedman, AS				Manie, SN; Astier, A; Haghayeghi, N; Canty, T; Druker, BJ; Hirai, H; Freedman, AS			Regulation of integrin-mediated p130(Cas) tyrosine phosphorylation in human B cells - A role for p59(Fyn) and SHP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; IN-VIVO; CRK; PP125(FAK); SRC; IDENTIFICATION; ACTIVATION; PROTEINS; BINDING; VLA-4	Engagement of beta 1 integrins in terminally differentiated human B cell lines, such as ARH-77, leads to prominent tyrosine phosphorylation of the p130 Crk-associated substrate (Cas), Cas regulates the assembly of several SH2 and SH3 domain-containing proteins into signaling complexes, which are potentially involved in the propagation of downstream signals. Ne demonstrate here that immunoprecipitated Cas from beta 1 integrin-stimulated ARH-77 cells was associated sith tyrosine kinase and phosphatase activities and that integrin ligation led to the recruitment of at least p59(Fyn) tyrosine kinase and SHP2 tyrosine phosphatase in Cas immune complexes, Cotransfection studies in COS-7 cells further indicated that Fyn/Cas physical interaction and Fyn-mediated Cas phosphorylation required amino acids 638-889 in the C-terminal region of Gas. This sequence contains both c-Src SH2 and SNS domain-binding motifs. In vitro binding studies using glutathione S-transferase fusion proteins derived from the SK2 or SH3 domains of Fyn suggested that both Fyn domains can participate in Fyn/Cas interaction. These data implicate Fyn and SHP2 as potential modulators of Cas signaling complexes in B cells.	DANA FARBER CANC INST, DIV HEMATOL MALIGNANCES, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; OREGON HLTH SCI UNIV, DIV HEMATOL & MED ONCOL, PORTLAND, OR 97201 USA; UNIV TOKYO, DEPT INTERNAL MED 3, TOKYO 113, JAPAN	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Oregon Health & Science University; University of Tokyo			Astier, Anne L/A-1641-2008; Manie, Serge/ABC-8331-2021	Astier, Anne L/0000-0002-0144-3431; manie, serge/0000-0002-9168-1977; Druker, Brian/0000-0001-8331-8206	NATIONAL CANCER INSTITUTE [P01CA066996, R01CA055207] Funding Source: NIH RePORTER; NCI NIH HHS [CA66996, CA55207] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Astier A, 1997, J BIOL CHEM, V272, P228; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Burnham MR, 1996, ONCOGENE, V12, P2467; daSilva AJ, 1997, J IMMUNOL, V158, P2007; FELLER SM, 1995, ONCOGENE, V10, P1465; FREEDMAN AS, 1990, SCIENCE, V249, P1030, DOI 10.1126/science.1697696; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ishino M, 1995, ONCOGENE, V11, P2331; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KOOPMAN G, 1991, J EXP MED, V173, P1297, DOI 10.1084/jem.173.6.1297; KOOPMAN G, 1994, J IMMUNOL, V152, P3760; Law SF, 1996, MOL CELL BIOL, V16, P3327; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Manie SN, 1996, BLOOD, V87, P1855; Manie SN, 1997, EXP HEMATOL, V25, P45; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; PATCH LA, 1995, J CELL SCI, V108, P1371; Petruzzelli L, 1996, J BIOL CHEM, V271, P7796, DOI 10.1074/jbc.271.13.7796; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; PULIDO R, 1994, J EXP MED, V179, P1035, DOI 10.1084/jem.179.3.1035; RYAN DH, 1991, J CLIN INVEST, V88, P995, DOI 10.1172/JCI115403; RYAN DH, 1992, J IMMUNOL, V149, P3759; RYAN DH, 1990, J IMMUNOL, V145, P477; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259	52	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15636	15641		10.1074/jbc.272.25.15636	http://dx.doi.org/10.1074/jbc.272.25.15636			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188452	hybrid			2022-12-27	WOS:A1997XF32900012
J	Overvoorde, PJ; Chao, WS; Grimes, HD				Overvoorde, PJ; Chao, WS; Grimes, HD			A plasma membrane sucrose-binding protein that mediates sucrose uptake shares structural and sequence similarity with seed storage proteins but remains functionally distinct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPING SOYBEAN COTYLEDONS; BEAN CANAVALIA-ENSIFORMIS; DEVELOPING PEA COTYLEDONS; PHASEOLUS-VULGARIS; 3-DIMENSIONAL STRUCTURE; ENDOPLASMIC-RETICULUM; GLYCINE-MAX; EXPRESSION; TRANSPORT; VICILIN	Photoaffinity labeling of a soybean cotyledon membrane fraction identified a sucrose-binding protein (SEP). Subsequent studies have shown that the SBP is a unique plasma membrane protein that mediates the linear uptake of sucrose in the presence of up to 30 mM external sucrose when ectopically expressed in yeast, Analysis of the SEP-deduced amino acid sequence indicates it lacks sequence similarity with other known transport proteins, Data presented here, however, indicate that the SEP shares significant sequence and structural homology with the vicilin-like seed storage proteins that organize into homotrimers. These similarities include a repeated sequence that forms the basis of the reiterated domain structure characteristic of the vicilin-like protein family, In addition, analytical ultracentrifugation and nonreducing SDS-polyacrylamide gel electrophoresis demonstrate that the SEP appears to be organized into oligomeric complexes with a M-r indicative of the existence of SEP homotrimers and homodimers, The structural similarity shared by the SEP and vicilin-like proteins provides st novel framework to explore the mechanistic basis of SEP-mediated sucrose uptake, Expression of the maize Glb protein (a vicilin-like protein closely related to the SEP) in yeast demonstrates that a closely related vicilin-like protein is unable to mediate sucrose uptake, Thus, despite sequence and structural similarities shared by the SEP and the vicilin-like protein family, the SEP is functionally divergent from other members of this group.	WASHINGTON STATE UNIV,DEPT CELL BIOL & BOT,PULLMAN,WA 99164	Washington State University	Overvoorde, PJ (corresponding author), WASHINGTON STATE UNIV,DEPT GENET,PULLMAN,WA 99164, USA.		Grimes, Howard D/C-6490-2017	Grimes, Howard D/0000-0002-8956-8609				ARGOS P, 1985, EMBO J, V4, P1111, DOI 10.1002/j.1460-2075.1985.tb03747.x; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Baumlein H, 1995, J MOL EVOL, V41, P1070, DOI 10.1007/BF00173188; BLAGROVE RJ, 1984, INT J BIOL MACROMOL, V6, P137, DOI 10.1016/0141-8130(84)90054-0; BORROTO K, 1987, PLANT MOL BIOL, V8, P113, DOI 10.1007/BF00025323; Braun H, 1996, PLANT MOL BIOL, V31, P35, DOI 10.1007/BF00020604; CHRISPEELS MJ, 1982, J CELL BIOL, V93, P5, DOI 10.1083/jcb.93.1.5; CHRISPEELS MJ, 1982, J CELL BIOL, V93, P306, DOI 10.1083/jcb.93.2.306; DERBYSHIRE E, 1976, PHYTOCHEMISTRY, V15, P3, DOI 10.1016/S0031-9422(00)89046-9; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DICKINSON CD, 1987, P NATL ACAD SCI USA, V84, P5525, DOI 10.1073/pnas.84.16.5525; DOYLE JJ, 1986, J BIOL CHEM, V261, P9228; Dure L 3rd, 1990, New Biol, V2, P487; FELSENSTEIN J, 1995, PHYLIP PHYLOGENY INF; GIBBS PEM, 1989, MOL BIOL EVOL, V6, P614; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Grimes HD, 1996, J EXP BOT, V47, P1217, DOI 10.1093/jxb/47.Special_Issue.1217; GRIMES HD, 1992, PLANT CELL, V4, P1561, DOI 10.1105/tpc.4.12.1561; GRIMES HD, 1986, BIOCHIM BIOPHYS ACTA, V862, P165, DOI 10.1016/0005-2736(86)90480-3; HECK GR, 1993, MOL GEN GENET, V239, P209, DOI 10.1007/BF00281620; HIGGINS TJV, 1984, ANNU REV PLANT PHYS, V35, P191, DOI 10.1146/annurev.pp.35.060184.001203; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; KJELLBOM P, 1984, PHYSIOL PLANTARUM, V62, P501, DOI 10.1111/j.1399-3054.1984.tb02791.x; KO TP, 1993, PLANT PHYSIOL, V101, P729, DOI 10.1104/pp.101.3.729; KRIZ AL, 1989, BIOCHEM GENET, V27, P239, DOI 10.1007/BF02401804; KRIZ AR, 1990, PLANT PHYSIOL, V92, P538, DOI 10.1104/pp.92.2.538; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE BG, 1991, J BIOL CHEM, V266, P10461; LAWRENCE MC, 1990, EMBO J, V9, P9, DOI 10.1002/j.1460-2075.1990.tb08074.x; LAWRENCE MC, 1994, J MOL BIOL, V238, P748, DOI 10.1006/jmbi.1994.1333; LELIEVRE JM, 1992, PLANT MOL BIOL, V18, P259, DOI 10.1007/BF00034954; LICHTNER FT, 1981, PLANT PHYSIOL, V67, P869, DOI 10.1104/pp.67.4.869; LIN W, 1984, PLANT PHYSIOL, V75, P936, DOI 10.1104/pp.75.4.936; MAYNARD JW, 1982, PLANT PHYSIOL, V69, P734, DOI 10.1104/pp.69.3.734; MCHENRY L, 1992, PLANT MOL BIOL, V18, P1173, DOI 10.1007/BF00047720; MEINKE DW, 1981, PLANTA, V153, P130, DOI 10.1007/BF00384094; MILLERD A, 1975, ANNU REV PLANT PHYS, V26, P53, DOI 10.1146/annurev.pp.26.060175.000413; NEWTON CH, 1992, PLANT MOL BIOL, V20, P315, DOI 10.1007/BF00014500; NG JD, 1993, PLANT PHYSIOL, V101, P713, DOI 10.1104/pp.101.3.713; NIELSEN SS, 1984, PLANT PHYSIOL, V74, P494, DOI 10.1104/pp.74.3.494; OVERVOORDE PJ, 1994, J BIOL CHEM, V269, P15154; Overvoorde PJ, 1996, PLANT CELL, V8, P271, DOI 10.1105/tpc.8.2.271; PEDROSA C, 1994, BIOCHEMISTRY-US, V33, P4046, DOI 10.1021/bi00179a033; RICHARDSON JS, 1978, P NATL ACAD SCI USA, V75, P2574, DOI 10.1073/pnas.75.6.2574; RIESMEIER JW, 1992, EMBO J, V11, P4705, DOI 10.1002/j.1460-2075.1992.tb05575.x; RIPP KG, 1988, PLANT PHYSIOL, V88, P1435, DOI 10.1104/pp.88.4.1435; RUSH DR, 1993, ANN REV PLANT PHYSL, V44, P513; SANDELIUS AS, 1986, PLANT SCI, V48, P1; SCHULER MA, 1983, PLANT MOL BIOL, V2, P119, DOI 10.1007/BF01578512; Shutov AD, 1995, J MOL EVOL, V41, P1057, DOI 10.1007/BF00173187; SVEDBERG T., 1937, Nature, V139, P1051, DOI 10.1038/1391051a0; THORNE JH, 1980, PLANT PHYSIOL, V65, P975, DOI 10.1104/pp.65.5.975; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	53	30	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15898	15904		10.1074/jbc.272.25.15898	http://dx.doi.org/10.1074/jbc.272.25.15898			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188489	hybrid			2022-12-27	WOS:A1997XF32900049
J	Joyal, JL; Annan, RS; Ho, YD; Huddleston, ME; Carr, SA; Hart, MJ; Sacks, DB				Joyal, JL; Annan, RS; Ho, YD; Huddleston, ME; Carr, SA; Hart, MJ; Sacks, DB			Calmodulin modulates the interaction between IQGAP1 and Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; CALCIUM; PROTEIN; IDENTIFICATION; ANTIBODIES; DOMAIN; MYOSIN; RAS	Calmodulin regulates numerous fundamental metabolic pathways by binding to and modulating diverse target proteins. In this study, calmodulin-binding proteins were isolated from normal (Hs578Bst) and malignant (MCF-7) human breast cell lines with calmodulin-Sepharose and analyzed by SDS-polyacrylamide gel electrophoresis. A protein that migrated at approximately 190 kDa bound to calmodulin in the presence of Ca2+ and was the only calmodulin-binding protein detected in the absence of Ca2+. This 190-kDa protein was identified as IQGAP1 by nanoelectrospray mass spectrometry and collision-induced dissociation tandem mass spectrometry. IQGAP1 coimmunoprecipitated with calmodulin from lysates of MCF-7 cells. Moreover, overlay with I-125-calmodulin confirmed that IQGAP1 binds directly to calmodulin. Analysis of the functional effects of the interaction revealed that Ca2+/calmodulin disrupted the binding of purified IQGAP1 to the Ras-related protein Cdc42 in a concentration-dependent manner. These data clearly identify IQGAP1 as the predominant calmodulin-binding protein in Ca2+-free breast cell lysates and reveal that calmodulin modulates the interaction between IQGAP1 and Cdc42.	BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; SMITHKLINE BEECHAM PHARMACEUT,DEPT PHYS & STRUCT CHEM,KING OF PRUSSIA,PA 19406; ONYX PHARMACEUT,RICHMOND,CA 94806	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; GlaxoSmithKline			Carr, Steven A./AAH-8366-2019	Sacks, David/0000-0003-3100-0735; Hart, Matthew/0000-0002-2683-480X				ANNAN RS, 1996, P 44 ASMS C MASS SPE, P702; BAHLER M, 1994, J CELL BIOL, V126, P375, DOI 10.1083/jcb.126.2.375; BAUDIER J, 1989, J BIOL CHEM, V264, P1824; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUELT MK, 1994, J BIOL CHEM, V269, P29367; CARR DW, 1992, TRENDS BIOCHEM SCI, V17, P246, DOI 10.1016/0968-0004(92)90402-U; Carr SA, 1996, ANAL BIOCHEM, V239, P180, DOI 10.1006/abio.1996.0313; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; Cohen P, 1988, CALMODULIN; DASH D, 1995, FEBS LETT, V363, P231, DOI 10.1016/0014-5793(95)00320-9; ERIKSON JW, 1996, J BIOL CHEM, V271, P26850; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; GRATZER WB, 1988, CALMODULIN, P329; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; HOUDUSSE A, 1995, P NATL ACAD SCI USA, V92, P10644, DOI 10.1073/pnas.92.23.10644; HOUDUSSE A, 1996, CURR BIOL, V4, P1475; IKURA M, 1983, BIOCHEMISTRY-US, V22, P2573, DOI 10.1021/bi00279a039; JOYAL JL, 1994, J BIOL CHEM, V269, P30039; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KURODA A, 1996, J BIOL CHEM, V271, P23363; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; Munshi HG, 1996, BIOCHEMISTRY-US, V35, P15883, DOI 10.1021/bi962107y; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; RASMUSSEN CD, 1992, CELL MOTIL CYTOSKEL, V21, P45, DOI 10.1002/cm.970210106; REDDY GPV, 1992, BIOCHEMISTRY-US, V31, P10426, DOI 10.1021/bi00158a002; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SACKS DB, 1991, ANAL BIOCHEM, V194, P369, DOI 10.1016/0003-2697(91)90243-M; SINGER AL, 1976, CANCER RES, V36, P60; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; VANELDIK LJ, 1983, J BIOL CHEM, V258, P4539; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; WEST D W, 1981, Biochemical Society Transactions, V9, P77; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; WILM MS, 1994, INT J MASS SPECTROM, V136, P167, DOI 10.1016/0168-1176(94)04024-9; WOLENSKI JS, 1995, TRENDS CELL BIOL, V5, P310, DOI 10.1016/S0962-8924(00)89053-4	39	124	125	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15419	15425		10.1074/jbc.272.24.15419	http://dx.doi.org/10.1074/jbc.272.24.15419			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182573	hybrid			2022-12-27	WOS:A1997XE03400056
J	Silva-Filho, MC; Wieers, MC; Flugge, UI; Chaumont, F; Boutry, M				Silva-Filho, MC; Wieers, MC; Flugge, UI; Chaumont, F; Boutry, M			Different in vitro and in vivo targeting properties of the transit peptide of a chloroplast envelope inner membrane protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE TRANSLOCATOR; PLANT-MITOCHONDRIA; IMPORT; TRANSPORT; PRECURSOR; SUBUNIT; EXPRESSION; SEQUENCE; TOBACCO	The triose phosphate 5-phosphoglycerate phosphate translocator (TPT) is a chloroplast envelope inner membrane protein whose transit peptide has structural properties typical of a mitochondrial presequence. To study the TPT transit peptide in more detail, we constructed two chimeric genes encompassing the TPT transit peptide and either 5 or 23 amino-terminal residues of the mature TPT, both linked to the reporter chloramphenicol acetyltransferase (cat) gene, The precursors were synthesized in vitro and translocated to and processed in purified plant mitochondria, However, this import was not specific since both precursors were also imported into isolated chloroplasts, To extend this analysis in vivo, the chimeric genes were introduced into tobacco by genetic transformation. Analysis of CAT distribution in subcellular fractions of transgenic plants did not confirm the data obtained in vitro. With the construct retaining only 5 residues of the mature TPT, CAT was found in the cytosolic fraction. Extension of the TPT transit peptide to 23 residues of the mature TPT allowed specific import and processing of CAT into chloroplasts, These results indicate that, despite its unusual structure, the TPT transit peptide is able to target a passenger protein specifically into chloroplasts, provided that NH2-terminal residues of the mature TPT are still present. The discrepancy between the in vitro and in vivo data suggests that the translocation machinery is more stringent in the latter case and that sorting of proteins might not be addressed adequately by in vitro experiments.	UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM; UNIV COLOGNE, INST BOT, D-50931 COLOGNE, GERMANY	Universite Catholique Louvain; University of Cologne			Chaumont, Francois/A-5006-2010; Silva-Filho, Marcio/F-2639-2012	Silva-Filho, Marcio/0000-0003-2129-0388; Boutry, Marc/0000-0002-2315-6900				ARCHER EK, 1990, J BIOENERG BIOMEMBR, V22, P789; BARTLETT SG, 1982, METHODS CHLOROPLAST, P1081; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; BOUTRY M, 1987, NATURE, V328, P340, DOI 10.1038/328340a0; BRINK S, 1995, J BIOL CHEM, V270, P20808, DOI 10.1074/jbc.270.35.20808; BRINKS S, 1994, J BIOL CHEM, V269, P16478; Bruce B.D., 1994, PLANT MOL BIOL MANUA, VJ1, P1; CHAUMONT F, 1994, PLANT MOL BIOL, V24, P631, DOI 10.1007/BF00023559; CHAUMONT F, 1990, J BIOL CHEM, V265, P16856; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; FISCHER K, 1994, PLANT J, V5, P215, DOI 10.1046/j.1365-313X.1994.05020215.x; FLUGGE UI, 1989, EMBO J, V8, P39, DOI 10.1002/j.1460-2075.1989.tb03346.x; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; KAVANAGH TA, 1988, MOL GEN GENET, V215, P38, DOI 10.1007/BF00331300; KNIGHT JS, 1994, MOL GEN GENET, V242, P586, DOI 10.1007/BF00285282; KNIGHT JS, 1995, PLANT CELL, V7, P1421, DOI 10.1105/tpc.7.9.1421; Komiya T, 1996, EMBO J, V15, P399, DOI 10.1002/j.1460-2075.1996.tb00370.x; LITHGOW T, 1993, FEBS LETT, V329, P1, DOI 10.1016/0014-5793(93)80179-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOORE AL, 1994, ANNU REV PLANT PHYS, V45, P545, DOI 10.1146/annurev.pp.45.060194.002553; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; ROGERS SG, 1986, METHOD ENZYMOL, V118, P627; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMIDT GW, 1979, J CELL BIOL, V83, P615, DOI 10.1083/jcb.83.3.615; SCHMITZ UK, 1989, PLANT CELL, V1, P783, DOI 10.1105/tpc.1.8.783; Silva-Filho MC, 1996, PLANT MOL BIOL, V30, P769, DOI 10.1007/BF00019010; TURNER SR, 1992, J BIOL CHEM, V267, P7745; VONHEIJNE G, 1991, FEBS LETT, V278, P1, DOI 10.1016/0014-5793(91)80069-F; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WHELAN J, 1990, PLANT MOL BIOL, V14, P977, DOI 10.1007/BF00019394; ZHOU JZ, 1995, J BIOL CHEM, V270, P16689, DOI 10.1074/jbc.270.28.16689	31	42	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15264	15269		10.1074/jbc.272.24.15264	http://dx.doi.org/10.1074/jbc.272.24.15264			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182551	hybrid			2022-12-27	WOS:A1997XE03400034
J	Baba, M; Imai, T; Nishimura, M; Kakizaki, M; Takagi, S; Hieshima, K; Nomiyama, H; Yoshie, O				Baba, M; Imai, T; Nishimura, M; Kakizaki, M; Takagi, S; Hieshima, K; Nomiyama, H; Yoshie, O			Identification of CCR6, the specific receptor for a novel lymphocyte-directed CC chemokine LARC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-3; HUMAN INTERLEUKIN-8 RECEPTOR; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; CHROMOSOMAL LOCALIZATION; CHEMOTACTIC CYTOKINES; COUPLED RECEPTOR; LIGAND; GENE; RANTES	Liver and activation-regulated chemokine (LARC) is a recently identified CC chemokine that is expressed mainly in the liver. LARC functions as a selective chemoattractant for lymphocytes that express a class of receptors specifically binding to LARC with high affinity. To identify the receptor for LARC, we examined LARC-induced calcium mobilization in cells stably expressing five CC chemokine receptors (CCR1-CCR5) and five orphan seven-transmembrane receptors. LARC specifically induced calcium flux in K562 cells as well as 293/EBNA-1 cells stably expressing an orphan receptor GPR-CY4. LARC induced migration in 293/EBNA-1 cells stably expressing GPR-CY4 with a bi-modal dose-response curve. LARC fused with secreted alkaline phosphatase (LARC-SEAP) bound specifically to Raji cells stably expressing GPR-CY4 with a K-d of 0.9 nM. Only LARC but not five other CC chemokines (MCP-1, RANTES, MIP-1 alpha, MIP-1 beta, and TARC) competed with LARC-SEAP for binding to GPR-CY4. By Northern blot analysis, GPR-CY4 mRNA was expressed mainly in speen, lymph nodes, appendix, and fetal liver among various human tissues. Among various leukocyte subsets, GPR-CY4 mRNA was detected in lymphocytes (CD4(+) and CD8(+) T cells and B cells) but not in natural killer cells, monocytes, or granulocytes. Expression of GPR-CY4 mRNA in CD4(+) and CD8(+) T cells was strongly up-regulated by IL-2. Taken together, GPR-CY4 is the specific receptor for LARC expressed selectively on lymphocytes, and LARC is a unique functional ligand for GPR-CY4. We propose GPR-CY4 to be designated as CCR6.	SHIONOGI INST MED SCI,SETTSU,OSAKA 566,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT BIOCHEM,HONJO,KUMAMOTO 860,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT INTERNAL MED,HONJO,KUMAMOTO 860,JAPAN	Shionogi & Company Limited; Kumamoto University; Kumamoto University			Hieshima, Kunio/AAF-7040-2019; Nomiyama, Hisayuki/F-2840-2013	Hieshima, Kunio/0000-0002-7786-4646; Nomiyama, Hisayuki/0000-0002-2716-4043; Yoshie, Osamu/0000-0003-4353-5809				Anderson JA, 1996, J CLIN INVEST, V97, P1952, DOI 10.1172/JCI118627; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BENBARUCH A, 1995, J BIOL CHEM, V270, P11703, DOI 10.1074/jbc.270.20.11703; BENBARUCH A, 1995, J BIOL CHEM, V270, P22123, DOI 10.1074/jbc.270.38.22123; BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; COMBADIERE C, 1995, DNA CELL BIOL, V14, P673, DOI 10.1089/dna.1995.14.673; COMBADIERE C, 1995, J BIOL CHEM, V270, P29671; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; DOBNER T, 1992, EUR J IMMUNOL, V22, P2795, DOI 10.1002/eji.1830221107; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; FRANCI C, 1995, J IMMUNOL, V154, P6511; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GarciaZepeda EA, 1996, J IMMUNOL, V157, P5613; GEISER T, 1993, J BIOL CHEM, V268, P15419; Hieshima K, 1997, J BIOL CHEM, V272, P5846, DOI 10.1074/jbc.272.9.5846; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; Imai T, 1996, J BIOL CHEM, V271, P21514, DOI 10.1074/jbc.271.35.21514; IMAI T, 1997, IN PRESS J BIOL CHEM, V272; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; LEE J, 1992, J BIOL CHEM, V267, P16283; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Nomiyama H, 1997, GENOMICS, V40, P211, DOI 10.1006/geno.1996.4552; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; RAPORT CJ, 1995, GENE, V163, P295, DOI 10.1016/0378-1119(95)00336-5; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Uguccioni M, 1996, J EXP MED, V183, P2379, DOI 10.1084/jem.183.5.2379; Yoshida T, 1996, FEBS LETT, V395, P82, DOI 10.1016/0014-5793(96)01004-6; YOSHIDA T, 1995, FEBS LETT, V360, P155, DOI 10.1016/0014-5793(95)00093-O; ZAHALLOS A, 1996, BIOCH BIPOHYS RES CO, V227, P846	46	331	385	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14893	14898		10.1074/jbc.272.23.14893	http://dx.doi.org/10.1074/jbc.272.23.14893			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169459	hybrid			2022-12-27	WOS:A1997XC32700056
J	Li, XO; Yu, H; Graves, LM; Earp, HS				Li, XO; Yu, H; Graves, LM; Earp, HS			Protein kinase C and protein kinase A inhibit calcium-dependent but not stress-dependent c-Jun N-terminal kinase activation in rat liver epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; ANGIOTENSIN-II; SIGNALING PATHWAY; COUPLED RECEPTORS; T-LYMPHOCYTES; JNK; PROLIFERATION; SUBFAMILY; INDUCTION; APOPTOSIS	In rat liver epithelial cells (GN4), angiotensin II (Ang II) and thapsigargin stimulate a novel calcium-dependent tyrosine kinase (CADTK) also known as PYK2, CAK beta, or RAFTK. Activation of CADTK by a thapsigargin-dependent increase in intracellular calcium failed to stimulate the extracellular signal-regulated protein kinase pathway but was well correlated with a 30-50-fold activation of c-Jun N-terminal kinase (JNK). In contrast, Ang II, which increased both protein kinase C (PKC) activity and intracellular calcium, stimulated extracellular signal-regulated protein kinase but produced a smaller, less sustained, JNK activation than thapsigargin. 12-O-Tetradecanoylphorbol 13-acetate (TPA), which slowly activated CADTK, did not stimulate JNK. These findings suggest either that CADTK is not involved in JNK activation or PKC activation inhibits the CADTK to JNK pathway. A 1-min TPA pretreatment of GN4 cells inhibited thapsigargin-dependent JNK activation by 80-90%. In contrast, TPA did not inhibit the >50-fold JNK activation effected by anisomycin or UV. The consequence of PKC-dependent JNK inhibition was reflected in c-Jun and c-Fos mRNA induction following treatment with thapsigargin and Ang II. Thapsigargin, which only minimally induced c-Fos, produced a much greater and more prolonged c-Jun response than Ang II. Elevation of another intracellular second messenger, cAMP, for 5-15 min also inhibited calcium-dependent JNK activation by similar to 80-90% but likewise had no effect on the stress-dependent JNK pathway. In summary, two pathways stimulate JNK in cells expressing CADTK, a calcium-dependent pathway modifiable by PKC and cAMP-dependent protein kinase and a stress-activated pathway independent of CADTK, PKC, and cAMP-dependent protein kinase; the inhibition by PKC can ultimately alter gene expression initiated by a calcium signal.	UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Graves, Lee/AAG-5470-2021					ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Astier A, 1997, J BIOL CHEM, V272, P228; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coso OA, 1996, J BIOL CHEM, V271, P3963; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; EARP HS, 1995, J BIOL CHEM, V270, P28440; Graves LM, 1997, J BIOL CHEM, V272, P1920, DOI 10.1074/jbc.272.3.1920; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HEPLER JR, 1988, J BIOL CHEM, V263, P7610; HSUEH YP, 1995, J BIOL CHEM, V270, P18094, DOI 10.1074/jbc.270.30.18094; Huckle William R., 1994, Progress in Growth Factor Research, V5, P177, DOI 10.1016/0955-2235(94)90004-3; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Post GR, 1996, FASEB J, V10, P741, DOI 10.1096/fasebj.10.7.8635691; Rao GN, 1996, J BIOL CHEM, V271, P20805, DOI 10.1074/jbc.271.34.20805; ROCHE E, 1994, CELL CALCIUM, V16, P331, DOI 10.1016/0143-4160(94)90097-3; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Shapiro PS, 1996, J BIOL CHEM, V271, P5750, DOI 10.1074/jbc.271.10.5750; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	57	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14996	15002		10.1074/jbc.272.23.14996	http://dx.doi.org/10.1074/jbc.272.23.14996			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169474	hybrid			2022-12-27	WOS:A1997XC32700071
J	Meyboom, A; Maretzki, D; Stevens, PA; Hofmann, KP				Meyboom, A; Maretzki, D; Stevens, PA; Hofmann, KP			Reversible calcium-dependent interaction of liposomes with pulmonary surfactant protein A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A SP-A; II CELLS; PHOSPHOLIPID-VESICLES; SECRETION; BINDING; LIPIDS; AGGREGATION; RHODOPSIN; RECEPTOR; DOMAINS	Surfactant protein A (SP-A) is crucial for lung function, including tubular myelin formation and lipid uptake by type II pneumocytes, Known properties of SP-A in vitro are its Ca2+-dependent interaction with phospholipids and its role in the aggregation of liposomes. To dissect and to analyze these processes, we have immobilized SP-A and measured binding of liposomes by the resonant mirror technique. Liposome aggregation was followed separately by kinetic light scattering in suspensions. It was found that SP-A-mediated binding and aggregation of liposomes have a common K-0.5 of 20 mu M for free Ca2+, independent of the species (sheep, rat, or cow) and of the phospholipid composition, and that both reactions exhibit the same high cooperativity (Hill coefficients of 6-9) for Ca2+ ions, However, binding of liposomes to SP-A is >10-fold faster than aggregation. Both processes are completely reversed by low Ca2+ concentrations, but liposomes dissociate from SP-A in <0.3 s, whereas disaggregation of the liposomes takes similar to 30 s. At equilibrium, the level of aggregation depends on the concentration of free SP-A. We interpret these results to be a rapid and reversible sequence of three reactions: (i) a cooperative Ca2+-dependent conformational change in SP-A, (ii) binding of Ca2+-bound SP-A to liposomes, and (iii) aggregation of the Ca2+/SP-A-bound liposomes.	HUMBOLDT UNIV BERLIN,UNIV KLINIKUM CHARITE,INST MED PHYS & BIOPHYS,D-10098 BERLIN,GERMANY; HUMBOLDT UNIV BERLIN,UNIV KLINIKUM CHARITE,ABT NEONATOL,D-10098 BERLIN,GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin								DOBBS LG, 1987, P NATL ACAD SCI USA, V84, P1010, DOI 10.1073/pnas.84.4.1010; EFRATI H, 1987, BIOCHEMISTRY-US, V26, P7986, DOI 10.1021/bi00398a066; ERNST OP, 1995, J BIOL CHEM, V270, P10580, DOI 10.1074/jbc.270.18.10580; HAAGSMAN HP, 1991, BIOCHEM J, V275, P273, DOI 10.1042/bj2750273; HAAGSMAN HP, 1990, BIOCHEMISTRY-US, V29, P8894, DOI 10.1021/bi00490a003; Haddad IY, 1996, AM J PHYSIOL-LUNG C, V270, pL281, DOI 10.1152/ajplung.1996.270.2.L281; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; KAHLERT M, 1990, NATURE, V345, P537, DOI 10.1038/345537a0; KING RJ, 1984, EXP LUNG RES, V6, P237, DOI 10.3109/01902148409109251; KING RJ, 1973, AM J PHYSIOL, V224, P788, DOI 10.1152/ajplegacy.1973.224.4.788; KUROKI Y, 1994, J BIOL CHEM, V269, P29793; KUROKI Y, 1988, J BIOL CHEM, V263, P3388; KUROKI Y, 1994, J BIOL CHEM, V269, P25943; KUROKI Y, 1991, J BIOL CHEM, V266, P3068; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MCCORMACK FX, 1994, J BIOL CHEM, V269, P29801; NIELSON DW, 1988, PEDIATR RES, V24, P322, DOI 10.1203/00006450-198809000-00009; OOSTING RS, 1991, AM J PHYSIOL, V261, pL77, DOI 10.1152/ajplung.1991.261.2.L77; ROSS GF, 1991, BIOCHEMISTRY-US, V30, P858, DOI 10.1021/bi00217a040; ROSS GF, 1986, J BIOL CHEM, V261, P14283; Ruano MLF, 1996, BIOCHEM J, V313, P683, DOI 10.1042/bj3130683; SCHLEICHER A, 1987, J MEMBRANE BIOL, V95, P271, DOI 10.1007/BF01869489; SCHURCH S, 1992, AM J PHYSIOL, V263, pL210, DOI 10.1152/ajplung.1992.263.2.L210; SOHMA H, 1992, BIOCHIM BIOPHYS ACTA, V1159, P150, DOI 10.1016/0167-4838(92)90019-A; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0; WRIGHT JR, 1991, ANNU REV PHYSIOL, V53, P395, DOI 10.1146/annurev.physiol.53.1.395; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888; YINGST DR, 1983, ANAL BIOCHEM, V132, P431, DOI 10.1016/0003-2697(83)90031-3	32	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14600	14605		10.1074/jbc.272.23.14600	http://dx.doi.org/10.1074/jbc.272.23.14600			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169419	hybrid			2022-12-27	WOS:A1997XC32700016
J	Rink, R; Fennema, M; Smids, M; Dehmel, U; Janssen, DB				Rink, R; Fennema, M; Smids, M; Dehmel, U; Janssen, DB			Primary structure and catalytic mechanism of the epoxide hydrolase from Agrobacterium radiobacter AD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; XANTHOBACTER-AUTOTROPHICUS GJ10; SITE-DIRECTED MUTAGENESIS; HALOALKANE DEHALOGENASE; CIRCULAR-DICHROISM; ESCHERICHIA-COLI; NEURAL-NETWORK; EXPRESSION; CLONING; GENE	The epoxide hydrolase gene from Agrobacterium radiobacter AD1, a bacterium that is able to grow on epichlorohydrin as the sole carbon source, was cloned by means of the polymerase chain reaction with two degenerate primers based on the N-terminal and C-terminal sequences of the enzyme, The epoxide hydrolase gene coded for a protein of 294 amino acids with a molecular mass of 34 kDa, An identical epoxide hydrolase gene was cloned from chromosomal DNA of the closely related strain A, radiobacter CFZ11, The recombinant epoxide hydrolase was expressed up to 40% of the total cellular protein content in Escherichia coli BL21(DE3) and the purified enzyme had a k(cat) of 21 s(-1) with epichlorohydrin, Amino acid sequence similarity of the epoxide hydrolase with eukaryotic epoxide hydrolases, haloalkane dehalogenase from Xanthobacter autotrophicus GJ10, and bromoperoxidase A2 from Streptomyces aureofaciens indicated that it belonged to the alpha/beta-hydrolase fold family, This conclusion was supported by secondary structure predictions and analysis of the secondary structure with circular dichroism spectroscopy. The catalytic triad residues of epoxide hydrolase are proposed to be Asp(107), His(275), and Asp(246). Replacement of these residues to Ala/Glu, Arg/Gln, and Ala, respectively, resulted in a dramatic loss of activity for epichlorohydrin, The reaction mechanism of epoxide hydrolase proceeds via a covalently bound ester intermediate, as was shown by single turnover experiments with the His(275) --> Arg mutant of epoxide hydrolase in which the ester intermediate could be trapped.	UNIV GRONINGEN, DEPT BIOCHEM, GRONINGEN BIOMOL SCI & BIOTECHNOL INST, NL-9747 AG GRONINGEN, NETHERLANDS	University of Groningen								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; ARAND M, 1994, FEBS LETT, V338, P251, DOI 10.1016/0014-5793(94)80278-5; Arand M, 1996, J BIOL CHEM, V271, P4223; ARMSTRONG KM, 1993, J MOL BIOL, V230, P284, DOI 10.1006/jmbi.1993.1142; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BEETHAM JK, 1995, DNA CELL BIOL, V14, P61, DOI 10.1089/dna.1995.14.61; BEETHAM JK, 1993, ARCH BIOCHEM BIOPHYS, V305, P197, DOI 10.1006/abbi.1993.1411; BELL PA, 1993, J BIOL CHEM, V268, P14011; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; DIAZ E, 1995, J BIOL CHEM, V270, P6403, DOI 10.1074/jbc.270.11.6403; FALANY CN, 1987, J BIOL CHEM, V262, P5924; FUJIO Y, 1994, BIOSCI BIOTECH BIOCH, V58, P1451; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; GRANT DF, 1993, J BIOL CHEM, V268, P17628; HASSETT C, 1989, ARCH BIOCHEM BIOPHYS, V271, P380, DOI 10.1016/0003-9861(89)90287-7; HECHT HJ, 1994, NAT STRUCT BIOL, V1, P532, DOI 10.1038/nsb0894-532; HEIDELBACH M, 1993, J BACTERIOL, V175, P7479, DOI 10.1128/JB.175.22.7479-7482.1993; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; ITZHAKI RF, 1964, ANAL BIOCHEM, V9, P401, DOI 10.1016/0003-2697(64)90200-3; JACOBS MHJ, 1991, EUR J BIOCHEM, V202, P1217, DOI 10.1111/j.1432-1033.1991.tb16493.x; JANSSEN DB, 1985, APPL ENVIRON MICROB, V49, P673, DOI 10.1128/AEM.49.3.673-677.1985; JANSSEN DB, 1989, J BACTERIOL, V171, P6791, DOI 10.1128/jb.171.12.6791-6799.1989; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KAWASAKI H, 1992, J GEN MICROBIOL, V138, P1317, DOI 10.1099/00221287-138-7-1317; KIYOSUE T, 1994, PLANT J, V6, P259, DOI 10.1046/j.1365-313X.1994.6020259.x; KNEHR M, 1993, J BIOL CHEM, V268, P17623; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LACOURCIERE GM, 1994, CHEM RES TOXICOL, V7, P121, DOI 10.1021/tx00038a001; LOEWENTHAL R, 1992, J MOL BIOL, V224, P759, DOI 10.1016/0022-2836(92)90560-7; MEHTA PK, 1995, PROTEIN SCI, V4, P2517, DOI 10.1002/pro.5560041208; MILLER RE, 1982, BIOCHEMISTRY-US, V21, P1090, DOI 10.1021/bi00534a041; NOBLE MEM, 1993, FEBS LETT, V331, P123, DOI 10.1016/0014-5793(93)80310-Q; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; PRIES F, 1994, BIOCHEMISTRY-US, V33, P1242, DOI 10.1021/bi00171a026; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; REESE MG, 1994, THESIS GERMAN CANC R; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHANSTRA JP, 1993, PROTEIN EXPRES PURIF, V4, P479, DOI 10.1006/prep.1993.1063; SKODA RC, 1988, J BIOL CHEM, V263, P1549; SOLOV'EV V V, 1991, Molekulyarnaya Biologiya (Moscow), V25, P810; SREERAMA N, 1994, J MOL BIOL, V242, P497, DOI 10.1006/jmbi.1994.1597; STAPLETON A, 1994, PLANT J, V6, P251, DOI 10.1046/j.1365-313X.1994.6020251.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMAS KA, 1982, P NATL ACAD SCI-BIOL, V79, P4843, DOI 10.1073/pnas.79.16.4843; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANDENWIJNGAARD AJ, 1989, J GEN MICROBIOL, V135, P2199; VERSCHUEREN KHG, 1993, J MOL BIOL, V232, P856, DOI 10.1006/jmbi.1993.1436; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; Wojtasek H, 1996, BIOCHEM BIOPH RES CO, V220, P323, DOI 10.1006/bbrc.1996.0404; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	56	145	159	3	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14650	14657		10.1074/jbc.272.23.14650	http://dx.doi.org/10.1074/jbc.272.23.14650			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169427	Green Published, hybrid			2022-12-27	WOS:A1997XC32700024
J	Lu, TT; Barreuther, M; Davis, S; Madri, JA				Lu, TT; Barreuther, M; Davis, S; Madri, JA			Platelet endothelial cell adhesion molecule-1 is phosphorylatable by c-Src, binds Src-Src homology 2 domain, and exhibits immunoreceptor tyrosine-based activation motif-like properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; CYTOPLASMIC DOMAIN; PECAM-1; PROTEIN; MIGRATION; CLONING; KINASES; IDENTIFICATION; SUPERFAMILY	Platelet endothelial cell adhesion molecule-1 (PECAM-1) is 180-kDa member of the immunoglobulin gene superfamily that localizes to cell-cell borders of confluent endothelial cells and has been shown to play a role in the control of endothelial sheet migration and leukocyte transmigration through the endothelium. The cytoplasmic tail plays an important role in the modulation of PECAM-1 function, Mutation of tyrosine 663 or 686 in the cytoplasmic tail reduces phosphorylation and mutation of 686 is associated with a reduction in PECAM-1-mediated inhibition of cell migration (1), We have previously noted that these two tyrosine residues are surrounded by consensus sequences for Src homology 2 (SH2) domain binding (1, 2), and the experiments presented explore the potential for PECAM-1 Src and PECAM-1-SH2 domain interactions, PECAM-1 is more highly phosphorylated in endothelial cells overexpressing c-Src, and in in vitro kinase assays, c-Src can phosphorylate a glutathione S-transferase (GST)-PECAM cytoplasmic tail fusion protein. The phosphorylated fusion protein associates with the bead-bound c-Src. This association appears to be mediated by Src-SH2 domain, because PECAM-1 can be precipitated by a GST-Src-SH2 affinity matrix, The binding to the GST-Src-SH2 affinity matrix correlates directly with the level of PECAM-1 phosphorylation, because more PECAM-1 is precipitated from c-Src overexpressors and from wild-type rather than Tyr(663) --> Phe and Tyr(686) --> Phe mutant PECAM-1 expressors, Yet unidentified phosphoproteins can also be coimmunoprecipitated with wild-type but not mutant PECAM-1. Finally, me note the similarity of the PECAM-1 cytoplasmic domain sequence to the immunoreceptor tyrosine-based activation motif, Our data begin to delineate how tyrosines 663 and 686 may play a role in mediating PECAM-1 signal transduction.	YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06510 USA; YALE UNIV, DEPT BIOL, NEW HAVEN, CT 06510 USA	Yale University; Yale University				Lu, Theresa/0000-0002-5707-8744	NHLBI NIH HHS [R01-HL-28373, R01-HL-51018] Funding Source: Medline; PHS HHS [P01-KD-38979] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028373, R01HL051018] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELL L, 1992, J CLIN INVEST, V89, P315, DOI 10.1172/JCI115578; Berman ME, 1996, J IMMUNOL, V156, P1515; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; COLONNA M, 1995, SCIENCE, V268, P405, DOI 10.1126/science.7716543; DELISSER HM, 1994, J CELL BIOL, V124, P195, DOI 10.1083/jcb.124.1.195; FLASWINKEL H, 1994, EMBO J, V13, P83, DOI 10.1002/j.1460-2075.1994.tb06237.x; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KIRSCHBAUM NE, 1994, BLOOD, V84, P4028, DOI 10.1182/blood.V84.12.4028.bloodjournal84124028; LEAVESLEY DI, 1994, J IMMUNOL, V22, P4073; Lu TT, 1996, P NATL ACAD SCI USA, V93, P11808, DOI 10.1073/pnas.93.21.11808; MADRI JA, 1988, AM J PATHOL, V132, P18; Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; OSMAN N, 1995, EUR J IMMUNOL, V25, P2863, DOI 10.1002/eji.1830251023; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PINTER E, 1997, IN PRESS AM J PATHOL; SCHIMMENTI LA, 1992, J CELL PHYSIOL, V153, P417, DOI 10.1002/jcp.1041530222; TANAKA Y, 1992, J EXP MED, V176, P245, DOI 10.1084/jem.176.1.245; VANDENHERIKOUDIJK IE, 1995, BLOOD, V85, P2202, DOI 10.1182/blood.V85.8.2202.bloodjournal8582202; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; XIE Y, 1993, P NATL ACAD SCI USA, V90, P5569, DOI 10.1073/pnas.90.12.5569; YAN HC, 1995, J BIOL CHEM, V270, P23672, DOI 10.1074/jbc.270.40.23672; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	27	89	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14442	14446		10.1074/jbc.272.22.14442	http://dx.doi.org/10.1074/jbc.272.22.14442			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162084	hybrid			2022-12-27	WOS:A1997XB49200071
J	Socolovsky, M; DusanterFourt, I; Lodish, HF				Socolovsky, M; DusanterFourt, I; Lodish, HF			The prolactin receptor and severely truncated erythropoietin receptors support differentiation of erythroid progenitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; CYTOPLASMIC REGION; CYTOKINE RECEPTORS; LYMPHOID-CELLS; SIGNAL-TRANSDUCTION; RETROVIRAL VECTORS; ACTIVATION; EXPRESSION; GENE; COMMITMENT	Activation of the erythropoietin receptor is essential for the survival, proliferation, and differentiation of erythroid progenitors, To understand the role of erythropoietin receptor (EpoR) activation in erythroid differentiation, we infected primary erythroid progenitors with high-titer retrovirus encoding the non-hematopoietic prolactin receptor, The infected progenitors responded to prolactin in the absence of Epo by generating fully differentiated erythroid colonies, Therefore, differentiation of erythroid progenitors does not require an intracellular signal generated uniquely by the EpoR; the EpoR does not have an instructive role in erythroid differentiation. We also infected primary erythroid progenitors with retrovirus encoding chimeric receptors containing the extracellular domain of PrlR and the intracellular domain of either the wildtype or truncated EpoRs, A chimeric receptor containing only the membrane-proximal 136 amino acids of the EpoR cytoplasmic domain efficiently supported prolactin-dependent differentiation of erythroid progenitors, Substitution of the single cytoplasmic domain tyrosine in this receptor with phenylalanine (Y343F) eliminated its ability to support differentiation. The minimal EpoR cytoplasmic domain required for erythroid differentiation is therefore the same as that previously reported to be sufficient to support cell proliferation (D'Andrea, A. D., Yoshimura, A., Youssoufian, H., Zon, L. I., Koo, J. W., and Lodish, H. F, (1991) Mol. Cell, Biol, 11, 1980-1987; Miura, O., D'Andrea, A. D., Kabat, D., and Ihle, J. N. (1991) Mel. Cell, Biol, 11, 4895-4902; Re, T.-C., Jiang, N., Zhuang, H., Quelle, D. E., and Wojchowski, D. M. (1994) J, Biol, Chem, 269, 18291-18294).	WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; HOP COCHIN,LAB ONCOL CELLULAIRE & MOL,F-75014 PARIS,FRANCE; MIT,DEPT BIOL,CAMBRIDGE,MA 02138	Massachusetts Institute of Technology (MIT); Whitehead Institute; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Massachusetts Institute of Technology (MIT)			Dusanter-Fourt, Isabelle/P-4558-2017	Dusanter-Fourt, Isabelle/0000-0002-9286-1021; Socolovsky, Merav/0000-0001-6747-7960	NHLBI NIH HHS [HL32262] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BORZILLO GV, 1990, MOL CELL BIOL, V10, P2703, DOI 10.1128/MCB.10.6.2703; BOYER SH, 1992, BLOOD, V80, P2503; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; CHIBA T, 1993, NATURE, V362, P646, DOI 10.1038/362646a0; CORREA PN, 1991, BLOOD, V78, P2823; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DEXTER TM, 1987, ANNU REV CELL BIOL, V3, P423; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FUH G, 1993, J BIOL CHEM, V268, P5376; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HAWLEY RG, 1994, GENE THER, V1, P136; HE TC, 1994, J BIOL CHEM, V269, P18291; IHLE JN, 1994, BAILLIERE CLIN HAEM, V7, P17, DOI 10.1016/S0950-3536(05)80005-8; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; JUBINSKY PT, 1993, BLOOD, V81, P587; JUST U, 1991, CELL, V64, P1163, DOI 10.1016/0092-8674(91)90271-Y; KATOH M, 1985, J BIOL CHEM, V260, P1422; Kieran MW, 1996, P NATL ACAD SCI USA, V93, P9126, DOI 10.1073/pnas.93.17.9126; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; KORN A P, 1973, Experimental Hematology (Charlottesville), V1, P362; LIBOI E, 1993, P NATL ACAD SCI USA, V90, P11351, DOI 10.1073/pnas.90.23.11351; MCCARTHUR GA, 1994, BLOOD, V83, P972; METCALF D, 1991, P NATL ACAD SCI USA, V88, P11310, DOI 10.1073/pnas.88.24.11310; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NAKAHATA T, 1982, J CELL PHYSIOL, V113, P455, DOI 10.1002/jcp.1041130314; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; PHARR PN, 1993, P NATL ACAD SCI USA, V90, P938, DOI 10.1073/pnas.90.3.938; PHARR PN, 1994, P NATL ACAD SCI USA, V91, P7482, DOI 10.1073/pnas.91.16.7482; Porteu F, 1996, MOL CELL BIOL, V16, P2473; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; STARK GR, 1996, SCIENCE, V273, P750; SUDA T, 1984, P NATL ACAD SCI-BIOL, V81, P2520, DOI 10.1073/pnas.81.8.2520; TILL JE, 1964, P NATL ACAD SCI USA, V51, P29, DOI 10.1073/pnas.51.1.29; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Watowich SS, 1996, ANNU REV CELL DEV BI, V12, P91, DOI 10.1146/annurev.cellbio.12.1.91; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0	46	82	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14009	14012		10.1074/jbc.272.22.14009	http://dx.doi.org/10.1074/jbc.272.22.14009			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162017	hybrid			2022-12-27	WOS:A1997XB49200004
J	Tang, XW; Downes, CP				Tang, XW; Downes, CP			Purification and characterization of G beta gamma-responsive phosphoinositide 3-kinases from pig platelet cytosol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN PHOSPHATIDYLINOSITOL 3-KINASE; THROMBIN-STIMULATED PLATELETS; RECEPTOR TYROSINE KINASES; PHOSPHOLIPASE-C; SIGNAL-TRANSDUCTION; ACTIVATION; BINDING; 3,4,5-TRISPHOSPHATE; CLONING	A G-protein beta gamma subunit (G beta gamma)-responsive phosphoinositide 3-kinase (PI 3-kinase) was purified approximately 5000-fold from pig platelet cytosol, The enzyme was purified by polyethylene glycol precipitation of the cytosol followed by column chromatography on Q-Sepharose fast flow, gel filtration, heparin-Sepharose, and hydroxyapatite. The major G beta gamma-responsive PI 3-kinase is distinct from p85 containing PI 3-kinase as the activities can be distinguished chromatographically and immunologically and is related to p110 gamma as it crossreacts with anti-p110 gamma-specific antibodies. The p110 gamma-related PI 3-kinase cannot be activated by G-protein alpha(i/o) subunits, and it has an apparent native molecular mass of 210 kDa, The p110 gamma-related PI 3-kinase phosphorylates phosphatidylinositol (PtdIns), phosphatidylinositol 4-phosphate (PtdIns4P), and phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2). The apparent K-m values for ATP were found to be 25 mu M with PtdIns, 44 mu M with PtdIns4P, and 37 mu M with PtdIns(4,5)P-2 as the substrate, G beta gamma subunits did not alter the K-m of the enzyme for ATP; however, V-max increased 2-fold with PtdIns as substrate, 3.5-fold with PtdIns4P, and 10-fold with PtdIns(4,5)P-2. Under basal conditions the apparent K-m values for lipid substrates were 64, 10, and 15 mu M for PtdIns, PtdIns4P, and PtdIns(4,5)P-2, respectively, In the presence of G beta gamma subunits the dependence of PI 3-kinase activity on the concentrations of lipid substrates became complex with the highest level of stimulation occurring at high substrate concentration, suggesting that the binding of G beta gamma and lipid substrate (particularly PtdIns(4,5)P-2) may be mutually cooperative, Wortmannin and LY294002 inhibit the G beta gamma-responsive PI 3-kinase activity with IC50 values of 10 nM and 2 mu M, respectively, Unlike the p85 containing PI 3-kinase in platelets, the p110 gamma-related PI 3-kinase is not associated with a PtdIns(3,4,5)P-3 specific 5-phosphatase. The p85-associated PI 3-kinase was not activated by G beta gamma alone but could be synergistically activated by G beta gamma and phosphotyrosyl platelet-derived growth factor receptor peptides, This may represent a form of coincidence detection through which the effects of tyrosine kinase and G-protein-linked receptors might be coordinated.	UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND	University of Dundee				tang, xiuwen/0000-0002-6601-1234				Abrams CS, 1996, J BIOL CHEM, V271, P25192, DOI 10.1074/jbc.271.41.25192; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTER AN, 1994, BIOCHEM J, V301, P415, DOI 10.1042/bj3010415; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; DIETRICH A, 1994, EUR J BIOCHEM, V219, P171, DOI 10.1111/j.1432-1033.1994.tb19927.x; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; JACKSON SP, 1995, EMBO J, V14, P4490, DOI 10.1002/j.1460-2075.1995.tb00128.x; JAMES SR, 1994, BIOCHEM J, V298, P499, DOI 10.1042/bj2980499; JAMES SR, 1995, J BIOL CHEM, V270, P11872, DOI 10.1074/jbc.270.20.11872; KASHISHIAN A, 1992, EMBO J, V11, P3469; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Okada T, 1996, BIOCHEM J, V317, P475, DOI 10.1042/bj3170475; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; SINGH SS, 1993, BIOCHEM BIOPH RES CO, V195, P104, DOI 10.1006/bbrc.1993.2016; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SORISKY A, 1992, BIOCHEM J, V286, P581, DOI 10.1042/bj2860581; STEPHENS L, 1994, CURR BIOL, V4, P203, DOI 10.1016/S0960-9822(00)00049-X; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; TOKER A, 1994, J BIOL CHEM, V269, P32358; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YANO H, 1995, BIOCHEM J, V312, P145, DOI 10.1042/bj3120145; ZHANG J, 1995, J BIOL CHEM, V270, P6589, DOI 10.1074/jbc.270.12.6589	40	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14193	14199		10.1074/jbc.272.22.14193	http://dx.doi.org/10.1074/jbc.272.22.14193			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162050	hybrid			2022-12-27	WOS:A1997XB49200037
J	Lenarcic, B; Ritonja, A; Strukelj, B; Turk, B; Turk, V				Lenarcic, B; Ritonja, A; Strukelj, B; Turk, B; Turk, V			Equistatin, a new inhibitor of cysteine proteinases from Actinia equina, is structurally related to thyroglobulin type-1 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANEMONE STICHODACTYLA-HELIANTHUS; AMINO-ACID SEQUENCE; SEA-ANEMONE; CATHEPSIN-B; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; PAPAYA-LATEX; BINDING; IV; IDENTIFICATION	It is well known that the activities of the lysosomal cysteine proteinases are tightly regulated by their endogenous inhibitors, cystatins, Here we report a new inhibitor of cysteine proteinases isolated from sea anemone Actinia equina, The inhibitor, equistatin, is an acidic protein with pi 4.7 and molecular weight of 14,129., It binds tightly and rapidly to cathepsin L (k(a) = 5.7 x 10(7) M-1 s(-1), K-i = 0.051 nM) and papain (k(a) = 1.2 x 10(7) M-1 s(-1), K-i = 0.57 nM). The lower affinity for cathepsin B (K-i = 1.4 nM) was shown to be due mainly to a lower second order association rate constant (k(a) = 0.04 x 10(6) M-1 s(-1)), The inhibitor is composed of 128 amino acids forming two repeated domains with 48% identity, Neither of the domains shows any sequence homology to cystatins, but they do show a significant homology to thyroglobulin type-1 domains, A highly conserved consensus sequence motif of Cys-Trp-Cys-Val together with conserved Cys, Pro, and Gly residues is present in major histocompatibility complex class II-associated p41 invariant chain, nidogen, insulin-like growth factor proteins, saxiphilin domain a, pancreatic carcinoma marker proteins (GA733), and chum salmon egg cysteine proteinase inhibitor, In each of the domains of the equistatin, the three residues are similarly conserved, and the sequences Val-Trp-Cys-Val and Cys Trp-Cys-Val are present in domains a and b, respectively, We suggest that equistatin belongs to a new superfamily of protein inhibitors of cysteine proteinases named thyroglobulin type-1 domain inhibitors, This superfamily currently includes equistatin, major histocompatibility complex class II- associated p41 invariant chain fragment, and chum salmon egg cysteine proteinase inhibitor.			Lenarcic, B (corresponding author), JOZEF STEFAN INST,DEPT BIOCHEM & MOL BIOL,JAMOVA 39,LJUBLJANA 1000,SLOVENIA.			Turk, Boris/0000-0002-9007-5764; Lenarcic, Brigita/0000-0002-2508-3776				ALLANDER SV, 1994, J BIOL CHEM, V269, P10891; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANTUCH W, 1993, EUR J BIOCHEM, V212, P675, DOI 10.1111/j.1432-1033.1993.tb17705.x; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2247, DOI 10.1093/nar/19.suppl.2247; BARRETT AJ, 1986, BIOCHEM J, V236, P312, DOI 10.1042/bj2360312; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; Bevec T, 1996, J EXP MED, V183, P1331, DOI 10.1084/jem.183.4.1331; BIETH JG, 1984, BIOCHEM MED METAB B, V32, P387, DOI 10.1016/0006-2944(84)90046-2; BLUMBERG S, 1970, EUR J BIOCHEM, V15, P97, DOI 10.1111/j.1432-1033.1970.tb00981.x; BOUDIER C, 1992, J BIOL CHEM, V267, P4370; BROCKLEHURST K, 1973, BIOCHEM J, V133, P573, DOI 10.1042/bj1330573; BUTTLE DJ, 1990, FEBS LETT, V260, P195, DOI 10.1016/0014-5793(90)80100-W; BUTTLE DJ, 1989, BIOCHEM J, V261, P469, DOI 10.1042/bj2610469; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; FRITZ H, 1972, H-S Z PHYSIOL CHEM, V353, P19, DOI 10.1515/bchm2.1972.353.1.19; GIBSON D, 1969, NATURE, V222, P753, DOI 10.1038/222753a0; HENSCHEN A, 1986, ADV METHODS PROTEIN, P244; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; KEM WR, 1989, BIOCHEMISTRY-US, V28, P3483, DOI 10.1021/bi00434a050; KOLKENBROCK H, 1987, BIOL CHEM H-S, V368, P93, DOI 10.1515/bchm3.1987.368.1.93; KUHELJ R, 1995, EUR J BIOCHEM, V229, P533, DOI 10.1111/j.1432-1033.1995.0533k.x; Lenarcic B, 1996, FEBS LETT, V395, P113, DOI 10.1016/0014-5793(96)00984-2; LENARCIC B, 1986, CYSTEINE PROTEINASES, P609; Lenarcic B., 1986, CYSTEINE PROTEINASES, P473; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALTHIERY Y, 1987, EUR J BIOCHEM, V165, P491, DOI 10.1111/j.1432-1033.1987.tb11466.x; MANN K, 1989, EMBO J, V8, P65, DOI 10.1002/j.1460-2075.1989.tb03349.x; MANOLERAS N, 1994, BIOCHEMISTRY-US, V33, P11051, DOI 10.1021/bi00203a001; MASON RW, 1986, BIOCHEM J, V240, P285, DOI 10.1042/bj2400285; MEBS D, 1980, TOXICON, V18, P97, DOI 10.1016/0041-0101(80)90035-5; MORABITO MA, 1994, P NATL ACAD SCI USA, V91, P2478, DOI 10.1073/pnas.91.7.2478; MORABITO MA, 1995, P NATL ACAD SCI USA, V92, P6651, DOI 10.1073/pnas.92.14.6651; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; NAKAE H, 1993, EUR J BIOCHEM, V213, P11, DOI 10.1111/j.1432-1033.1993.tb17729.x; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; SALVESEN G, 1986, BIOCHEM J, V234, P429, DOI 10.1042/bj2340429; SCHMUTZLER C, 1992, J BIOL CHEM, V267, P22534; STRUBIN M, 1986, EMBO J, V5, P3483, DOI 10.1002/j.1460-2075.1986.tb04673.x; SZALA S, 1990, P NATL ACAD SCI USA, V87, P3542, DOI 10.1073/pnas.87.9.3542; TSCHESCHE H, 1987, BIOL CHEM HOPPESEYLE, V386, P1297; TURK B, 1993, BIOCHEMISTRY-US, V32, P375, DOI 10.1021/bi00052a046; TURK B, 1993, J BIOL CHEM, V268, P7323; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; VANDELOCHT A, 1995, EMBO J, V14, P5149, DOI 10.1002/j.1460-2075.1995.tb00199.x; Wunderer G., 1976, Methods Enzymol, V45, P881; YAMASHITA M, 1991, J BIOCHEM, V110, P762, DOI 10.1093/oxfordjournals.jbchem.a123655; Yamashita M, 1996, J BIOL CHEM, V271, P1282, DOI 10.1074/jbc.271.3.1282; ZUCKER S, 1985, BIOCHIM BIOPHYS ACTA, V828, P196, DOI 10.1016/0167-4838(85)90057-3	50	93	100	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13899	13903						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153250				2022-12-27	WOS:A1997XA06200065
J	Matsumura, K; Chiba, A; Yamada, H; FukutaOhi, H; Fujita, S; Endo, T; Kobata, A; Anderson, LVB; Kanazawa, I; Campbell, KP; Shimizu, T				Matsumura, K; Chiba, A; Yamada, H; FukutaOhi, H; Fujita, S; Endo, T; Kobata, A; Anderson, LVB; Kanazawa, I; Campbell, KP; Shimizu, T			A role of dystroglycan in schwannoma cell adhesion to laminin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-ASSOCIATED PROTEINS; CONGENITAL MUSCULAR-DYSTROPHY; GLYCOPROTEIN-COMPLEX; PERIPHERAL-NERVE; AGRIN RECEPTOR; MEMBRANE ORGANIZATION; EXTRACELLULAR-MATRIX; ALPHA-DYSTROGLYCAN; BETA-DYSTROGLYCAN; BASEMENT-MEMBRANE	Dystroglycan is encoded by a single gene and cleaved into two proteins alpha- and beta-dystroglycan by posttranslational processing. Recently, alpha-dystroglycan was demonstrated to be an extracellular laminin-binding protein anchored to the cell membrane by a transmembrane protein beta-dystroglycan in striated muscle and Schwann cells. However, the biological functions of the dystroglycan-laminin interaction remain obscure, and in particular, it is still unclear if dystroglycan plays a role in cell adhesion. In the present study, we characterized the role of dystroglycan in the adhesion of schwannoma cells to laminin-l. Immunochemical analysis demonstrated that the dystroglycan complex, comprised of alpha- and beta-dystroglycan, was a major laminin-binding protein complex in the surface membrane of rat schwannoma cell line RT4. It also demonstrated the presence of alpha-dystroglycan, but not beta-dystroglycan, in the culture medium, suggesting secretion of alpha-dystroglycan by RT4 cells. RT4 cells cultured on dishes coated with laminin-1 became spindle in shape and adhered to the bottom surface tightly. Monoclonal antibody IIH6 against alpha-dystroglycan was shown previously to inhibit the binding of laminin-l to alpha-dystroglycan. In the presence of IIH6, but not several other control antibodies in the culture medium, RT4 cells remained round in shape and did not adhere to the bottom surface. The adhesion of RT4 cells to dishes coated with fibronectin was not affected by IIH6. The known inhibitors of the interaction of a dystroglycan with laminin-l, including EDTA, sulfatide, fucoidan, dextran sulfate, heparin, and sialic acid, also perturbed the adhesion of RT4 cells to laminin-l, whereas the reagents which do not inhibit the interaction, including dextran, chondroitin sulfate, dermatan sulfate, and GlcNAc, did not. Altogether, these results support a role for dystroglycan as a major cell adhesion molecule in the surface membrane of RT4 cells.	TEIKYO UNIV,SCH MED,DEPT NEUROL & NEUROSCI,TOKYO 173,JAPAN; TOKYO METROPOLITAN INST GERONTOL,DEPT GLYCOBIOL,TOKYO 173,JAPAN; UNIV NEWCASTLE UPON TYNE,NEWCASTLE GEN HOSP,REG NEUROSCI CTR,SCH NEUROSCI,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,NEWCASTLE GEN HOSP,REG NEUROSCI CTR,MUSCULAR DYSTROPHY GRP LABS,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND; UNIV TOKYO,FAC MED,BRAIN RES INST,DEPT NEUROL,TOKYO 113,JAPAN; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Teikyo University; Tokyo Metropolitan Institute of Gerontology; Newcastle General Hospital; Newcastle University - UK; Newcastle General Hospital; Newcastle University - UK; University of Tokyo; Howard Hughes Medical Institute; University of Iowa; University of Iowa				Campbell, Kevin/0000-0003-2066-5889				ARAHATA K, 1993, P JPN ACAD B-PHYS, V69, P259, DOI 10.2183/pjab.69.259; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; Campanelli JT, 1996, DEVELOPMENT, V122, P1663; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CARBONETTO S, 1995, CURR OPIN NEUROBIOL, V5, P596, DOI 10.1016/0959-4388(95)80064-6; CODY RL, 1986, EXP CELL RES, V165, P107, DOI 10.1016/0014-4827(86)90536-7; CULLEN MJ, 1994, ACTA NEUROPATHOL, V87, P349; DEYST KA, 1995, J BIOL CHEM, V270, P25956, DOI 10.1074/jbc.270.43.25956; DURBEEJ M, 1995, J CELL BIOL, V130, P79, DOI 10.1083/jcb.130.1.79; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FALLON JR, 1994, TRENDS NEUROSCI, V17, P469, DOI 10.1016/0166-2236(94)90135-X; FREEMAN MR, 1987, P NATL ACAD SCI USA, V84, P5808, DOI 10.1073/pnas.84.16.5808; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; GEE SH, 1993, J BIOL CHEM, V268, P14972; Gesemann M, 1996, NEURON, V16, P755, DOI 10.1016/S0896-6273(00)80096-3; GESEMANN M, 1995, J CELL BIOL, V128, P625, DOI 10.1083/jcb.128.4.625; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; Hopf C, 1996, J BIOL CHEM, V271, P5231; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; MATSUMURA K, 1993, FEBS LETT, V334, P281, DOI 10.1016/0014-5793(93)80695-Q; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; Meier T, 1996, EMBO J, V15, P2625, DOI 10.1002/j.1460-2075.1996.tb00622.x; OToole JJ, 1996, P NATL ACAD SCI USA, V93, P7369, DOI 10.1073/pnas.93.14.7369; OZAWA E, 1995, HUM MOL GENET, V4, P1711, DOI 10.1093/hmg/4.suppl_1.1711; Pall EA, 1996, J BIOL CHEM, V271, P3817; SHORER Z, 1995, J CHILD NEUROL, V10, P472, DOI 10.1177/088307389501000610; SMALHEISER NR, 1995, J BIOL CHEM, V270, P15425, DOI 10.1074/jbc.270.25.15425; SMALHEISER NR, 1993, J NEUROSCI RES, V36, P528, DOI 10.1002/jnr.490360505; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; SUNADA Y, 1995, HUM MOL GENET, V4, P1055, DOI 10.1093/hmg/4.6.1055; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; SUZUKI A, 1994, EUR J BIOCHEM, V220, P283, DOI 10.1111/j.1432-1033.1994.tb18624.x; TOME FMS, 1994, CR ACAD SCI III-VIE, V317, P351; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; XU H, 1994, P NATL ACAD SCI USA, V91, P5572, DOI 10.1073/pnas.91.12.5572; Yamada H, 1996, J NEUROCHEM, V66, P1518; YAMADA H, 1994, FEBS LETT, V352, P49, DOI 10.1016/0014-5793(94)00917-1; Yamada H, 1996, J BIOL CHEM, V271, P23418, DOI 10.1074/jbc.271.38.23418; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711	44	83	83	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13904	13910		10.1074/jbc.272.21.13904	http://dx.doi.org/10.1074/jbc.272.21.13904			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153251	hybrid			2022-12-27	WOS:A1997XA06200066
J	Gibson, RM; JiBuechler, Y; Taylor, SS				Gibson, RM; JiBuechler, Y; Taylor, SS			Interaction of the regulatory and catalytic subunits of cAMP-dependent protein kinase - Electrostatic sites on the type I alpha regulatory subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; HEAT-STABLE INHIBITOR; ESCHERICHIA-COLI; HOLOENZYME FORMATION; RABBIT SKELETAL; BINDING; EXPRESSION; MUTATIONS; DELETION; DOMAINS	Since a basic surface on the catalytic (C) subunit of cAMP-dependent protein kinase is important for binding to the regulatory (R) subunit, acidic residues in R were sought that might contribute to R-C interaction. Using differential labeling by a water-soluble carbodiimide (Buechler, T. A., and Taylor, S. S. (1990) Biochemistry 29, 1937-1943), seven specific carboxylates in RI alpha were identified that were protected from chemical modification in the holoenzyme; each was then replaced with Ala. Of these, rRI(E15A/E106A/D107A)), rRI(E105A), rRI(D140A), rRI(E143A), and rRI(D258A) all were defective in holoenzyme formation and define negative electrostatic surfaces on RI alpha. An additional conserved car boxylate, Glu(101) in RI alpha and the equivalent, Glu(99) in RII alpha were mutated to Ala. Replacement of Glu(101) had no effect while rRII(E99A) was very defective. RI alpha and RII alpha thus differ in the molecular details of how they recognize C. Unlike wild-type RI, two additional mutants, rRI(D170A) and rRI(K242A), inhibited C-subunit stoichiometrically in the presence of cAMP and show increases in both on- and off-rates. Asp(170), which contributes directly to the hydrogen bonding network in cAMP-binding site A, thus contributes also to holoenzyme stability.	UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego			Gibson, Robin/A-6841-2009		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034921] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA0952223-08] Funding Source: Medline; NIGMS NIH HHS [GM34921] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUBIS J, 1988, J BIOL CHEM, V263, P9668; BUECHLER JA, 1990, BIOCHEMISTRY-US, V29, P1937, DOI 10.1021/bi00459a039; BUECHLER YJ, 1993, J BIOL CHEM, V268, P16495; BUILDER SE, 1980, J BIOL CHEM, V255, P2350; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; GLASS DB, 1989, J BIOL CHEM, V264, P8802; Herberg FW, 1996, BIOCHEMISTRY-US, V35, P2934, DOI 10.1021/bi951647c; HERBERG FW, 1993, PROTEIN ENG, V6, P771, DOI 10.1093/protein/6.7.771; HERBERG FW, 1993, BIOCHEMISTRY-US, V32, P14015, DOI 10.1021/bi00213a035; HERBERG FW, 1994, BIOCHEMISTRY-US, V33, P7485, DOI 10.1021/bi00189a057; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; HOFMANN F, 1980, J BIOL CHEM, V255, P1559; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEON DA, 1991, BIOCHEMISTRY-US, V30, P3035, DOI 10.1021/bi00226a008; LEVIN LR, 1990, MOL CELL BIOL, V10, P1066, DOI 10.1128/MCB.10.3.1066; OGREID D, 1989, EUR J BIOCHEM, V181, P19; ORELLANA SA, 1993, J BIOL CHEM, V268, P6843; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; RINGHEIM GE, 1988, J BIOL CHEM, V263, P18247; RINGHEIM GE, 1990, J BIOL CHEM, V265, P19472; SARASWAT LD, 1988, J BIOL CHEM, V263, P18241; SARASWAT LD, 1986, J BIOL CHEM, V261, P1091; SARASWAT LD, 1988, METHOD ENZYMOL, V159, P325; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P5732, DOI 10.1073/pnas.82.17.5732; SLICE LW, 1989, J BIOL CHEM, V264, P20940; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; SYMCOX MM, 1994, J BIOL CHEM, V269, P23025; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4200, DOI 10.1021/bi00313a029; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; WALSH DA, 1990, CRC CRIT REV BIOCH, P43; WANG YH, 1991, P NATL ACAD SCI USA, V88, P2446, DOI 10.1073/pnas.88.6.2446; WELDON SL, 1985, J BIOL CHEM, V260, P4203; Zetterqvist O.Z., 1990, PEPTIDES PROTEIN PHO, P171	38	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16343	16350		10.1074/jbc.272.26.16343	http://dx.doi.org/10.1074/jbc.272.26.16343			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195940	hybrid			2022-12-27	WOS:A1997XG01900044
J	Chung, JK; Sekiya, F; Kang, HS; Lee, CH; Han, JS; Kim, SR; Bae, YS; Morris, AJ; Rhee, SG				Chung, JK; Sekiya, F; Kang, HS; Lee, CH; Han, JS; Kim, SR; Bae, YS; Morris, AJ; Rhee, SG			Synaptojanin inhibition of phospholipase D activity by hydrolysis of phosphatidylinositol 4,5-bisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PROTEIN; BRAIN; 5-PHOSPHATASE; GRANULOCYTES; AMPHIPHYSIN; MUTATIONS; RVS161; GOLGI; ACID	A 150-kDa protein that inhibits phospholipase D (PLD) activity stimulated by ADP-ribosylation factor and phosphatidylinositol 4,5-bisphosphate (PI(4,5)P-2) was previously purified from rat brain. The sequences of peptides derived from the purified PLD inhibitor now identify it as synaptojanin, a nerve terminal protein that has been implicated in the endocytosis of fused synaptic vesicles and shown to be a member of the inositol polyphosphate 5-phosphatase family, Further characterization of the enzymatic properties of synaptojanin now shows that it hydrolyzes only the 5-phosphate from inositol 1,4,5-trisphosphate (I(1,4,5)P-3) and that it does not catalyze the dephosphorylation of either I(1,3,4)P-3 or inositol 1,4-bisphosphate. However, synaptojanin hydrolyzes both the 4- and 5-phosphates of PI(4,5)P-2 and the 4-phosphate of phosphatidylinositol 4-phosphate, converting both compounds to phosphatidylinositol. Magnesium is required for the hydrolysis of I(1,4,5)P-3, but not for that of phosphoinositides, by synaptojanin. The inhibition of PLD by synaptojanin is attributable to its ability to hydrolyze PI(4,5)P-2. Synaptojanin did not inhibit PLD in the absence of PI(4,5)P-2, and the extent of PLD inhibition was related to the extent of PI(4,5)P-2 hydrolysis in substrate Vesicles. It has been proposed that the biosynthesis of PI(4,5)P-2 and the activation of PLD by ADP-ribosylation factor constitute a positive loop to increase rapidly the concentrations of PI(4,5)P-2 and phosphatidic acid (PA) during membrane vesiculation. The PA thus produced, probably together with PI(4,5)P-2, facilitates vesicle coat assembly. The hydrolysis of PI(4,5)P-2, and consequent inhibition of PLD, by synaptojanin might therefore constitute a mechanism to halt the positive loop connecting PI(4,5)P-2 and PA during the endocytotic cycle of synaptic vesicles and serve as a signal for uncoating.	NHLBI,LAB CELL SIGNALING,NIH,BETHESDA,MD 20892; SUNY STONY BROOK,DEPT PHARMACOL SCI,STONY BROOK,NY 11794	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Morris, Andrew/B-7869-2010; Han, Joong-Soo/P-2072-2015	Han, Joong-Soo/0000-0002-0875-6158				ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Han JS, 1996, J BIOL CHEM, V271, P11163, DOI 10.1074/jbc.271.19.11163; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HOPE HMR, 1994, J BIOL CHEM, V269, P23648; Hwang SC, 1996, J BIOL CHEM, V271, P18342, DOI 10.1074/jbc.271.31.18342; JEFFERSON AB, 1995, J BIOL CHEM, V270, P9370, DOI 10.1074/jbc.270.16.9370; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; Lee CH, 1997, J BIOL CHEM, V272, P15986, DOI 10.1074/jbc.272.25.15986; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; Majerus PW, 1996, GENE DEV, V10, P1051, DOI 10.1101/gad.10.9.1051; MATZARIS M, 1994, J BIOL CHEM, V269, P3397; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; OLIVOSGLANDER IM, 1995, AM J HUM GENET, V57, P817; PAI JK, 1988, J BIOL CHEM, V263, P12472; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; SIVADON P, 1995, MOL GEN GENET, V246, P485, DOI 10.1007/BF00290452; TERUI T, 1994, J BIOL CHEM, V269, P28130	32	109	112	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15980	15985		10.1074/jbc.272.25.15980	http://dx.doi.org/10.1074/jbc.272.25.15980			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188500	hybrid			2022-12-27	WOS:A1997XF32900060
J	Marchetti, D; Liu, SC; Spohn, WC; Carson, DD				Marchetti, D; Liu, SC; Spohn, WC; Carson, DD			Heparanase and a synthetic peptide of heparan sulfate-interacting protein recognize common sites on cell surface and extracellular matrix heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED ENDOTHELIAL-CELLS; PARACRINE GROWTH-FACTORS; TUMOR-METASTASIS; HUMAN-MELANOMA; LINE RL95; PROTEOGLYCANS; GLYCOSAMINOGLYCANS; BINDING; DEGRADATION; ENZYMES	Heparanase is an endo-P-D-glucuronidase that de grades the glycosaminoglycan chains of heparan sulfate (HS) proteoglycans at specific sites, Elevated levels of heparanase are associated with the metastatic potential of melanoma and other types of tumor cells, We previously reported heparanase degradation of cell surface HS subpopulations of the human adenocarcinoma cell line RL95, In the present study, heparanase activity was examined on RL95 cell surface HS subpopulations in the presence of a synthetic peptide (CRPKAKAKAKAKDQTK) of heparin/heparan sulfate-interacting protein (HIP; Liu, S., Smith, S, E,, Julian, J,, Rohde, L, H., Karin, N. J., and Carson, D, D, (1996) J, Biol, Chem, 271, 11817-11823), Heparanase digestion generated HS fragments from cell surface- or extracellular matrix-derived HS of approximately 25 and 9 kDa, respectively, In contrast, HS of various size classes isolated from proteoglycans secreted or released by RL95 and endothelial cells in culture were not susceptible to heparanase digestion, Incubation of heparanase-containing melanoma cellular extracts or partially purified heparanase preparations with cell! surface- or ECM-derived HS and HIP peptide, but not a scrambled sequence of this peptide or other HS-binding proteins present in ECM, completely inhibited heparanase action, Conversely, predigestion of cell surface HS with either heparanase-containing cellular extracts or with secreted or partially purified heparanase destroyed binding to HIP peptide, Preincubation of HS with HIP peptide prevented subsequent heparanase digestion. Collectively, these data demonstrate that HIP peptide and heparanase recognize specific, common motifs within HS chains at cell surfaces and in ECM add may mutually modulate HS-dependent activities.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BIOCHEM & MOL BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	Marchetti, D (corresponding author), UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030, USA.				NCI NIH HHS [CA64178, R29-CA64178] Funding Source: Medline; NICHD NIH HHS [HD25235] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD025235, R01HD025235] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R29CA064178] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; CASTELLOT JJ, 1981, J CELL BIOL, V90, P372, DOI 10.1083/jcb.90.2.372; CHENG CF, 1981, J BIOL CHEM, V256, P2893; COHEN IR, 1994, CANCER RES, V54, P5771; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; FRANSSON LA, 1981, J BIOL CHEM, V256, P3039; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; GAMSE G, 1978, BIOCHIM BIOPHYS ACTA, V544, P514, DOI 10.1016/0304-4165(78)90326-4; GJALMARSSON K, 1980, P NATL ACAD SCI USA, V77, P6662; Gorio A, 1996, J NEUROSCI RES, V46, P572, DOI 10.1002/(SICI)1097-4547(19961201)46:5<572::AID-JNR6>3.3.CO;2-J; HEDMAN K, 1982, CELL, V28, P663, DOI 10.1016/0092-8674(82)90221-5; HOOGEWERF AJ, 1995, J BIOL CHEM, V270, P3268, DOI 10.1074/jbc.270.7.3268; HOOK M, 1984, ANNU REV BIOCHEM, V53, P847; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; ISHIKAWA M, 1988, CANCER RES, V48, P4897; JALKANEN M, 1987, MED BIOL, V65, P41; JIN L, 1990, INT J CANCER, V45, P1088, DOI 10.1002/ijc.2910450618; Lesma E, 1996, J NEUROSCI RES, V46, P565, DOI 10.1002/(SICI)1097-4547(19961201)46:5<565::AID-JNR5>3.0.CO;2-H; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Liu SC, 1996, J BIOL CHEM, V271, P11817, DOI 10.1074/jbc.271.20.11817; Liu SC, 1997, P NATL ACAD SCI USA, V94, P1739, DOI 10.1073/pnas.94.5.1739; LOHSE DL, 1992, J BIOL CHEM, V267, P24347; Marchetti D, 1996, CANCER RES, V56, P2856; MARCHETTI D, 1993, INT J CANCER, V55, P692, DOI 10.1002/ijc.2910550430; MARCHETTI D, 1997, IN PRESS J CELL PHYS; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; MCQUILLAN DJ, 1991, BIOCHEM J, V277, P199, DOI 10.1042/bj2770199; NAKAJIMA M, 1991, J BIOL CHEM, V266, P9661; NAKAJIMA M, 1984, J BIOL CHEM, V259, P2283; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; NAKAJIMA M, 1986, ANAL BIOCHEM, V157, P162, DOI 10.1016/0003-2697(86)90209-5; NELSON RM, 1993, BLOOD, V82, P3253; Nicolson GL, 1989, CURR OPIN CELL BIOL, V1, P1009, DOI 10.1016/0955-0674(89)90073-2; NICOLSON GL, 1994, CRIT REV ONCOGENESIS, V5, P451, DOI 10.1615/CritRevOncog.v5.i5.20; NICOLSON GL, 1994, J NEURO-ONCOL, V18, P139, DOI 10.1007/BF01050420; RABOUDI N, 1992, J BIOL CHEM, V267, P11930; REDINI F, 1988, BIOCHEM J, V252, P515, DOI 10.1042/bj2520515; ROHDE LH, 1993, J CELL PHYSIOL, V155, P185, DOI 10.1002/jcp.1041550124; Rohde LH, 1996, J BIOL CHEM, V271, P11824, DOI 10.1074/jbc.271.20.11824; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SJOBERG I, 1980, BIOCHEM J, V191, P103; STIPP CS, 1994, J CELL BIOL, V124, P149, DOI 10.1083/jcb.124.1.149; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; VLODAVSKY I, 1990, CANCER METAST REV, V9, P203, DOI 10.1007/BF00046361; VLODAVSKY I, 1983, CANCER RES, V43, P2704; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; WAY DL, 1983, IN VITRO CELL DEV B, V19, P147; YANAGASHITA M, 1986, ANN REV BIOCH, V55, P539; YURCHENCO PD, 1986, J HISTOCHEM CYTOCHEM, V34, P93, DOI 10.1177/34.1.3510247	52	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15891	15897		10.1074/jbc.272.25.15891	http://dx.doi.org/10.1074/jbc.272.25.15891			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188488	hybrid			2022-12-27	WOS:A1997XF32900048
J	Ohnishi, H; Ernst, SA; Yule, DI; Baker, CW; Williams, JA				Ohnishi, H; Ernst, SA; Yule, DI; Baker, CW; Williams, JA			Heterotrimeric G-protein G(q/11) localized on pancreatic zymogen granules is involved in calcium-regulated amylase secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; ADRENAL CHROMAFFIN CELLS; GUANINE-NUCLEOTIDES; ALPHA-SUBUNITS; RAB PROTEINS; EXOCYTOSIS; MASTOPARAN; MEMBRANES; RECEPTOR; MECHANISM	The heterotrimeric G-protein G(q/11) was identified on pancreatic acinar zymogen granules and its function ill calcium-regulated exocytosis was examined, Western blotting showed alpha(q/11), but not alpha(s) or alpha(o), to be localized to the zymogen granule membrane along with G-protein beta-subunit; all three alpha subunits were present in a plasma membrane fraction and the alpha(q/11) signal was 30-fold more enriched in the plasma membrane as compared with granule membrane. Neither CCK receptors nor ru subunits of the sodium pump, both plasma membrane markers were present on granule membranes, Immunohistochemistry of pancreatic lobules showed that alpha(q/11) localized to the zymogen granule-rich apical region of acinar cells together with a mush stronger signal at the basolateral plasma membrane. When the substance-P-related peptide GPAnt-2a, an antagonist of G(q/11), was introduced into streptolysin-O permeabilized acini to bypass the plasma membrane, the amylase release induced by 10 mu M free calcium was potentiated in a concentration-dependent manner. By contrast, another substance-P-related peptide, GPAnt-1, an antagonist of G(o) and G(i), showed no effect on calcium-induced amylase release from permeabilized acini, GPAnt-2a peptide also exerted an inhibitory effect on the total. GTPase activity of the purified zymogen granules and a larger inhibitory effect on the GTPase activity of the G(q/11) protein immunopurified from zymogen granules, GPAnt-1, however, did not inhibit GTPase activity of either zymogen granules or immunopurified G(q)/(11). These results suggest that GPAnt-2a peptide augmented calcium-induced amylase release from permeabilized acini by inhibiting GTPase activity of the G(q/11) protein on zymogen granules. We conclude that G(q/11) protein on zymogen granules plays a tonic inhibitory role in calcium-regulated amylase secretion from pancreatic acini.	UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT ANAT & CELL BIOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Williams, John/0000-0002-6063-7615	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020572, R01DK045722, P30DK034933, P60DK020572] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-34933, DK-45722, DK-20572] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHNERTHILGER G, 1994, EUR J CELL BIOL, V65, P26; BADER MF, 1989, J BIOL CHEM, V264, P16426; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BARROWMAN MM, 1986, NATURE, V319, P504, DOI 10.1038/319504a0; BARTHEL LK, 1990, J HISTOCHEM CYTOCHEM, V38, P383; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BLEVINS GT, 1994, AM J PHYSIOL-GASTR L, V267, pG866, DOI 10.1152/ajpgi.1994.267.5.G866; BURNHAM DB, 1985, BIOCHEM J, V227, P743, DOI 10.1042/bj2270743; BURNHAM DB, 1982, J BIOL CHEM, V257, P523; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; Denker SP, 1996, J CELL BIOL, V133, P1027, DOI 10.1083/jcb.133.5.1027; ERNST SA, 1994, AM J PHYSIOL-CELL PH, V267, pC990, DOI 10.1152/ajpcell.1994.267.4.C990; GOKE B, 1992, AM J PHYSIOL, V262, pC493, DOI 10.1152/ajpcell.1992.262.2.C493; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIEBER V, 1989, J NEUROSCI RES, V23, P9, DOI 10.1002/jnr.490230103; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; HOWELL TW, 1987, J CELL BIOL, V105, P191, DOI 10.1083/jcb.105.1.191; IBARRONDO J, 1995, P NATL ACAD SCI USA, V92, P8413, DOI 10.1073/pnas.92.18.8413; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; KOMATSU M, 1993, J BIOL CHEM, V268, P23297; KONRAD RJ, 1995, J BIOL CHEM, V270, P12869, DOI 10.1074/jbc.270.21.12869; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; MUKAI H, 1992, J BIOL CHEM, V267, P16237; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; OHARAIMAIZUMI M, 1992, J NEUROCHEM, V58, P2275, DOI 10.1111/j.1471-4159.1992.tb10974.x; Ohnishi H, 1996, AM J PHYSIOL-GASTR L, V271, pG531, DOI 10.1152/ajpgi.1996.271.3.G531; OZAKI Y, 1990, BIOCHEM BIOPH RES CO, V170, P779, DOI 10.1016/0006-291X(90)92159-W; PADFIELD PJ, 1991, BIOCHEM BIOPH RES CO, V174, P600, DOI 10.1016/0006-291X(91)91459-P; SCHNEFEL S, 1992, Cellular Physiology and Biochemistry, V2, P77, DOI 10.1159/000154628; SCRIMACHI M, 1988, JPN J PHYSL, V38, P227; SCRIMACHI M, 1987, BIOMED RES, V8, P205; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SONTAG JM, 1991, BIOCHEM J, V274, P339, DOI 10.1042/bj2740339; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUKUMAR M, 1992, J BIOL CHEM, V267, P21421; Tang LH, 1996, GASTROENTEROLOGY, V110, P809, DOI 10.1053/gast.1996.v110.pm8608891; TSUNODA Y, 1995, BIOCHEM BIOPH RES CO, V211, P648, DOI 10.1006/bbrc.1995.1861; Valentijn JA, 1996, EUR J CELL BIOL, V70, P33; VALLAR L, 1987, J BIOL CHEM, V262, P5049; VITALE ML, 1991, J CELL BIOL, V113, P1057, DOI 10.1083/jcb.113.5.1057; VITALE N, 1994, J BIOL CHEM, V269, P30293; VITALE N, 1993, J BIOL CHEM, V268, P14715; VONMOLLARD GF, 1994, TRENDS BIOCHEM SCI, V19, P164, DOI 10.1016/0968-0004(94)90278-X; WAGNER ACC, 1994, DIGESTION, V55, P191, DOI 10.1159/000201147; WAGNER ACC, 1994, J BIOL CHEM, V269, P9099; WAGNER ACC, 1994, BIOCHEM BIOPH RES CO, V200, P542, DOI 10.1006/bbrc.1994.1482; WATSON EL, 1992, BIOCHEM J, V285, P441, DOI 10.1042/bj2850441; WHEELERJONES CPD, 1992, BIOCHEM J, V281, P465, DOI 10.1042/bj2810465; WILSON BS, 1994, ENDOCRINOLOGY, V134, P233, DOI 10.1210/en.134.1.233; Yule DI, 1997, J BIOL CHEM, V272, P9093	57	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					16056	16061		10.1074/jbc.272.25.16056	http://dx.doi.org/10.1074/jbc.272.25.16056			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188511	hybrid			2022-12-27	WOS:A1997XF32900071
J	Abedi, H; Zachary, I				Abedi, H; Zachary, I			Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; SWISS 3T3 CELLS; ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION; PERMEABILITY FACTOR; PHOSPHOINOSITIDE 3-KINASE; BETA-CATENIN; FACTOR VEGF; MAP KINASE; CROSS-TALK	Vascular endothelial growth factor (VEGF) stimulated the tyrosine phosphorylation of multiple components in confluent human umbilical vein endothelial cells (HUVECs) including bands of ill, 205,000, corresponding to the VEGF receptors Flt-1 and KDR, and M-r, 145,000, 120,000, 97,000, and 65,000-70,000. VEGF caused a striking and transient increase in mitogen-activated protein (MAP) kinase activity and stimulated phospholipase C-gamma tyrosine phosphorylation, but it had no effect on phosphatidylinositol 3'-kinase activity. VEGF caused a marked increase in tyrosine phosphorylation of p125 focal adhesion kinase (p125(FAK)), which was bath rapid and concentration-dependent. VEGF produced similar effects on p125(FAK) in the endothelial cell line ECV.304. VEGF stimulated tyrosine phosphorylation of the 68-kDa focal adhesion-associated component, paxillin, with similar kinetics and concentration dependence to that for p125(FAK), Thrombin and the phorbol ester, phorbol 12-myristate 13-acetate, also increased p125(FAK) tyrosine phosphorylation in HUVECs, The effect of VEGF on p125(FAK) tyrosine phosphorylation was completely inhibited by the actin filament-disrupting agent cytochalasin D and was partially inhibited by the protein kinase C inhibitor GF109203X. inhibition of the MAP kinase pathway using a specific inhibitor of MAP kinase kinase had no effect on p125(FAK) tyrosine phosphorylation. VEGF stimulated migration and actin stress fiber formation in confluent HUVEC, and VEGF-induced p125(FAK)/paxillin tyrosine phosphorylation was accompanied by increased immunofluorescent staining of p125(FAK), paxillin, and phosphotyrosine in focal adhesions in confluent cultures of HUVECs, These findings identify p125(FAK) and paxillin as components in a VEGF stimulated signaling pathway and suggest a novel mechanism for VEGF regulation of endothelial cell functions.	UNIV LONDON UNIV COLL,CRUCIFORM PROJECT,LONDON WC1E 6JJ,ENGLAND; UNIV LONDON UNIV COLL,DEPT MED,LONDON WC1E 6JJ,ENGLAND	University of London; University College London; University of London; University College London								ABEDI H, 1995, CARDIOVASC RES, V30, P544, DOI 10.1016/0008-6363(95)00092-5; ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; ANDRE E, 1993, BIOCHEM BIOPH RES CO, V190, P140, DOI 10.1006/bbrc.1993.1022; ASAHARA T, 1995, CIRCULATION, V91, P2793, DOI 10.1161/01.CIR.91.11.2793; Bacon KB, 1996, J EXP MED, V184, P873, DOI 10.1084/jem.184.3.873; BANAI S, 1994, CARDIOVASC RES, V28, P1176, DOI 10.1093/cvr/28.8.1176; BARGER AC, 1984, NEW ENGL J MED, V310, P175, DOI 10.1056/NEJM198401193100307; BAUTERS C, 1995, CIRCULATION, V91, P2802, DOI 10.1161/01.CIR.91.11.2802; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BIKFALVI A, 1991, J CELL PHYSIOL, V149, P50, DOI 10.1002/jcp.1041490108; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Choudhury GG, 1996, AM J PHYSIOL-RENAL, V270, pF295, DOI 10.1152/ajprenal.1996.270.2.F295; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ENOMOTO T, 1994, BIOCHEM BIOPH RES CO, V202, P1716, DOI 10.1006/bbrc.1994.2133; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; GARCIA JGN, 1995, BLOOD COAGUL FIBRIN, V6, P609, DOI 10.1097/00001721-199510000-00001; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HALL CL, 1994, J CELL BIOL, V126, P575, DOI 10.1083/jcb.126.2.575; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; HUDLICKA O, 1992, PHYSIOL REV, V72, P369, DOI 10.1152/physrev.1992.72.2.369; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Isner JM, 1996, LANCET, V348, P370, DOI 10.1016/S0140-6736(96)03361-2; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; KARNOVASKY MORRIS J., 1967, J CELL BIOL, V35, P213, DOI 10.1083/jcb.35.1.213; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LUM H, 1993, J CELL BIOL, V120, P1491, DOI 10.1083/jcb.120.6.1491; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; OBRIEN ER, 1994, AM J PATHOL, V145, P883; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RANKIN S, 1994, J BIOL CHEM, V269, P704; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHLAEPFER DD, 1994, NATURE, V372, P786; SEETHARAM L, 1995, ONCOGENE, V10, P135; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; STAVRI G, 1995, CIRCULATION, V92, P5; STAVRI GT, 1995, FEBS LETT, V358, P311, DOI 10.1016/0014-5793(94)01458-D; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; TAKAHASHI K, 1990, IN VITRO CELL DEV, V25, P265; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1991, J BIOL CHEM, V266, P11947; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TURNER CE, 1995, J CELL SCI, V108, P333; TURNER CE, 1993, J CELL SCI, V105, P637; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WENNSTROM S, 1994, ONCOGENE, V9, P651; WheelerJones CPD, 1996, FEBS LETT, V388, P180, DOI 10.1016/0014-5793(96)00547-9; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	92	403	410	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15442	15451		10.1074/jbc.272.24.15442	http://dx.doi.org/10.1074/jbc.272.24.15442			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182576	hybrid			2022-12-27	WOS:A1997XE03400059
J	Leppa, S; Pirkkala, L; Saarento, H; Sarge, KD; Sistonen, L				Leppa, S; Pirkkala, L; Saarento, H; Sarge, KD; Sistonen, L			Overexpression of HSF2-beta inhibits hemin-induced heat shock gene expression and erythroid differentiation in K562 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; TRANSCRIPTIONAL ACTIVATION; HSP70 GENE; NEGATIVE REGULATOR; CELLULAR FACTOR; MESSENGER-RNAS; BETA-ACTIN; FACTOR-I; PROTEINS; NUCLEAR	Acquisition of heat shock factor 2 (HSF2) DNA binding activity is accompanied by induced transcription of heat shock genes in hemin-treated K562 cells undergoing erythroid differentiation. Previous studies revealed that HSF2 consists of two alternatively spliced isoforms, HSF2-alpha and HSF2-beta, whose relative abundance is developmentally regulated and varies between different tissues. To investigate whether the molar ratio of HSF2-alpha and HSF2-beta isoforms is crucial for the activation of HSF2 and whether the HSF2 isoforms play functionally distinct roles during the hemin-mediated erythroid differentiation, we generated cell clones expressing different levels of HSF2-alpha and HSF2-beta. We show that in parental K562 cells, the HSF2-alpha isoform is predominantly expressed and HSF2 can be activated upon hemin treatment. In contrast, when HSF2-beta is expressed at levels exceeding those of endogenous HSF2-alpha, the hemin-induced DNA binding activity and transcription of heat shock genes are repressed, whereas overexpression of HSF2-alpha results in an enhanced hemin response. Furthermore, the hemin-induced accumulation of globin, known as a marker of erythroid differentiation, is decreased in cells overexpressing HSF2-beta. We suggest that HSF2-beta acts as a negative regulator of HSF2 activity during hemin-mediated erythroid differentiation of K562 cells.	UNIV TURKU, ABO AKAD UNIV, TURKU CTR BIOTECHNOL, FIN-20521 TURKU, FINLAND; ABO AKAD UNIV, DEPT BIOL, FIN-20520 TURKU, FINLAND; UNIV KENTUCKY, ALBERT B CHANDLER MED CTR, DEPT BIOCHEM, LEXINGTON, KY 40536 USA	Abo Akademi University; University of Turku; Abo Akademi University; University of Kentucky				Sistonen, Lea/0000-0003-1341-2867; Leppa, Sirpa/0000-0002-8265-511X				AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; BANERJI SS, 1984, MOL CELL BIOL, V4, P2437, DOI 10.1128/MCB.4.11.2437; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; DEAN A, 1981, SCIENCE, V212, P459, DOI 10.1126/science.6163216; FIORENZA MT, 1995, NUCLEIC ACIDS RES, V23, P467, DOI 10.1093/nar/23.3.467; FYTLOVICH S, 1993, EMBO J, V12, P1209, DOI 10.1002/j.1460-2075.1993.tb05762.x; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GOODSON ML, 1995, MOL CELL BIOL, V15, P5288; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HALDEMAN MT, 1995, J BIOL CHEM, V270, P9507, DOI 10.1074/jbc.270.16.9507; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; KROEGER PE, 1993, MOL CELL BIOL, V13, P3370, DOI 10.1128/MCB.13.6.3370; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEZGER V, 1994, DEV BIOL, V166, P819, DOI 10.1006/dbio.1994.1361; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; MURPHY SP, 1994, MOL CELL BIOL, V14, P5309, DOI 10.1128/MCB.14.8.5309; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; PADMANABAN G, 1989, TRENDS BIOCHEM SCI, V14, P492, DOI 10.1016/0968-0004(89)90182-5; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1994, BIOL REPROD, V50, P1334, DOI 10.1095/biolreprod50.6.1334; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SINGH MK, 1984, NATURE, V309, P631, DOI 10.1038/309631a0; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; THEODORAKIS NG, 1989, MOL CELL BIOL, V9, P3166, DOI 10.1128/MCB.9.8.3166; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; ZHANG L, 1995, EMBO J, V14, P313, DOI 10.1002/j.1460-2075.1995.tb07005.x; ZHANG L, 1994, J BIOL CHEM, V269, P14643; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557	43	39	41	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15293	15298		10.1074/jbc.272.24.15293	http://dx.doi.org/10.1074/jbc.272.24.15293			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182556	hybrid			2022-12-27	WOS:A1997XE03400039
J	Lytle, C				Lytle, C			Activation of the avian erythrocyte Na-K-Cl cotransport protein by cell shrinkage, cAMP, fluoride, and calyculin-A involves phosphorylation at common sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCK RED-CELLS; CO-TRANSPORT; KINASE INHIBITORS; ION-TRANSPORT; OKADAIC ACID; MEMBRANE; KINETICS; BINDING; VOLUME; GLAND	Na-K-Cl cotransport activity in duck erythrocytes increases similar to 10 fold in response to osmotic cell shrinkage, norepinephrine, fluoride, or calyculin-A (an inhibitor of type-1 and -2a phosphatases), To assess whether all four stimuli promote phosphorylation of the cotransport protein and whether this phosphorylation is catalyzed by the same kinase, the cotransporter was isolated from erythrocytes by immunoprecipitation and its pattern of phosphorylation was evaluated, Each stimulus evoked proportionate increases in cotransporter activity and phosphorylation, No two stimuli in combination evoked greater activation and phosphorylation than did the more potent of the two stimuli acting alone. Phosphoamino acid analysis of the cotransport protein indicated that phosphorylation occurs at serine and threonine residues, Phosphopeptide mapping revealed a distinctive pattern of 8 major tryptic phosphopeptides, none of which were significantly phosphorylated in the unstimulated state, Maps of cotransporters activated by the four different stimuli were indistinguishable. Measurements of phosphorylation stoichiometry indicated that each cotransporter acquires similar to 5 phosphates on going from an inactive state in swollen cells to an active state in shrunken cells, Staurosporine, a kinase inhibitor with broad selectivity, inhibited each stimulus equipotently (IC50 similar to 0.7 mu M) Staurosporine promptly reversed cotransporter activity and phosphorylation when added to shrinkage-stimulated but not to calyculin-stimulated cells, indicating that it enters the cell rapidly and blocks phosphorylation. These results suggest that cell shrinkage, cAMP, fluoride, and calyculin-A promote the phosphorylation of the Na-K-Cl cotransport protein at a similar constellation of serine and threo nine residues, It is proposed that all modes of stimulation ultimately involve the same protein kinase.			Lytle, C (corresponding author), UNIV CALIF RIVERSIDE, DIV BIOMED SCI, RIVERSIDE, CA 92521 USA.		Lytle, Christian/X-2836-2019	Lytle, Christian/0000-0001-5442-1546				ALPER SL, 1980, J BIOL CHEM, V255, P4864; ALTAMIRANO AA, 1988, AM J PHYSIOL, V254, pC582, DOI 10.1152/ajpcell.1988.254.4.C582; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; CASHEL M, 1969, J CHROMATOGR, V40, P103, DOI 10.1016/S0021-9673(01)96624-5; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DAndrea L, 1996, J BIOL CHEM, V271, P28969, DOI 10.1074/jbc.271.46.28969; DUNHAM PB, 1993, J GEN PHYSIOL, V101, P733, DOI 10.1085/jgp.101.5.733; FORBUSH B, 1994, B MT DESERT IS BIOL, V33, P72; GECK P, 1980, BIOCHIM BIOPHYS ACTA, V600, P432, DOI 10.1016/0005-2736(80)90446-0; HAAS M, 1986, J BIOL CHEM, V261, P8434; HAAS M, 1982, J GEN PHYSIOL, V80, P125, DOI 10.1085/jgp.80.1.125; HAAS M, 1995, J BIOL CHEM, V270, P28955, DOI 10.1074/jbc.270.48.28955; Hidaka H, 1994, ESSAYS BIOCHEM, V28, P73; JENNINGS ML, 1990, J GEN PHYSIOL, V95, P1021, DOI 10.1085/jgp.95.6.1021; JESSEN F, 1992, BIOCHIM BIOPHYS ACTA, V1110, P199, DOI 10.1016/0005-2736(92)90359-T; KLEIN JD, 1995, AM J PHYSIOL, V269, pC154; LISCHWE MA, 1982, ANAL BIOCHEM, V127, P453, DOI 10.1016/0003-2697(82)90203-2; LYTLE C, 1992, J BIOL CHEM, V267, P25438; Lytle C, 1996, AM J PHYSIOL-CELL PH, V270, pC437, DOI 10.1152/ajpcell.1996.270.2.C437; Lytle C, 1995, AM J PHYSIOL-CELL PH, V269, pC1496, DOI 10.1152/ajpcell.1995.269.6.C1496; Lytle C, 1996, FASEB J, V10, P472; LYTLE CY, 1988, THESIS DUKE U DURHAM; MATTHEWS JB, 1992, J CLIN INVEST, V90, P1608, DOI 10.1172/JCI116030; MAYER SE, 1970, J BIOL CHEM, V245, P3153; MILLS JW, 1994, FASEB J, V8, P1161, DOI 10.1096/fasebj.8.14.7958622; ODonnell ME, 1995, AM J PHYSIOL-CELL PH, V269, pC1513, DOI 10.1152/ajpcell.1995.269.6.C1513; OGRADY SM, 1988, AM J PHYSIOL, V254, pC115, DOI 10.1152/ajpcell.1988.254.1.C115; Palfrey H C, 1981, Ann N Y Acad Sci, V372, P291, DOI 10.1111/j.1749-6632.1981.tb15482.x; Palfrey H. Clive, 1992, Cellular Physiology and Biochemistry, V2, P293; PALFREY HC, 1980, J EXP BIOL, V89, P103; PALFREY HC, 1983, J EXP BIOL, V106, P43; PALFREY HC, 1993, PFLUG ARCH EUR J PHY, V425, P321, DOI 10.1007/BF00374182; Palfrey HC, 1994, CELLULAR MOL PHYSL C, P201; PAULAIS M, 1992, J BIOL CHEM, V267, P21558; PAYNE JA, 1995, CURR OPIN CELL BIOL, V7, P493, DOI 10.1016/0955-0674(95)80005-0; PEWITT EB, 1990, J BIOL CHEM, V265, P20747; Russell J M, 1980, Ann N Y Acad Sci, V341, P510, DOI 10.1111/j.1749-6632.1980.tb47195.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT WF, 1977, J GEN PHYSIOL, V70, P59, DOI 10.1085/jgp.70.1.59; STARKE LC, 1989, THESIS DUKE U DURHAM; TAKEDA M, 1993, AM J PHYSIOL, V264, pF421, DOI 10.1152/ajprenal.1993.264.3.F421; TANIMURA A, 1995, J BIOL CHEM, V270, P25252, DOI 10.1074/jbc.270.42.25252; TORCHIA J, 1992, J BIOL CHEM, V267, P25444; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201	44	108	111	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15069	15077		10.1074/jbc.272.24.15069	http://dx.doi.org/10.1074/jbc.272.24.15069			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182525	hybrid			2022-12-27	WOS:A1997XE03400008
J	Park, YS; Gee, P; Sanker, S; Schurter, EJ; Zuiderweg, ERP; Kent, C				Park, YS; Gee, P; Sanker, S; Schurter, EJ; Zuiderweg, ERP; Kent, C			Identification of functional conserved residues of CTP:glycerol-3-phosphate cytidylyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; RAT-LIVER CTP; ESCHERICHIA-COLI; PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; BACILLUS-SUBTILIS; TEICHOIC-ACID; PROTEINS; EXPRESSION; MUTANT; PURIFICATION	The CTP:glycerol-3-phosphate cytidylyltransferase (GCT) of Bacillus subtilis has been shown to be similar in primary structure to the CTP:phosphocholine cytidylyltransferases of several organisms, To identify the residues of this cytidylyltransferase family that function in catalysis, the conserved hydrophilic amino acid residues plus a conserved tryptophan of the GCT were mutated to alanine, The most dramatic losses in activity occurred with H14A and H17A; these histidine residues are part of an HXGH sequence similar to that found in class I aminoacyl-tRNA synthetases, The k(cat) values for H14A and H17A were decreased by factors of 5 x 10(-5) and 4 x 10(-4), respectively, with no significant change in K-m values, Asp-11, which is found near the HXGH sequence in the cytidylyltransferases but not aminoacyl-tRNA synthetases, was also important for activity, with the D11A mutation decreasing activity by a factor of 2 x 10(-3), Several residues found in the sequence RTEGISTT, a signature sequence for this cytidylyltransferase family, as well as other isolated residues were also shown to be important for activity, with k(cat) values decreasing by factors of 0.14-4 x 10(-4), The K-m values of three mutant enzymes, D38A, W74A, and D94A, for both CTP and glycerol-3-phosphate were 6-130-fold higher than that of the wild-type enzyme, Mutant enzymes were analyzed by two-dimensional NMR to determine if the overall structures of the enzymes were intact, One of the mutant enzymes, D66A, was defective in overall structure, but several of the others, including H14A and H17A, were not, These results indicate that His-14 and His-17 play a role in catalysis and suggest that their role is similar to the role of the His residues in the HXGH sequence in class I aminoacyl-tRNA synthetases, i.e. to stabilize a pentacoordinate transition state.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,DIV BIOPHYS RES,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Park, Young-Seo/AAB-9366-2019	Park, Young-Seo/0000-0002-9930-4201	NATIONAL CANCER INSTITUTE [R01CA064159] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NCI NIH HHS [CA64159] Funding Source: Medline; NCRR NIH HHS [M01-RR0042] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BORK P, 1995, PROTEINS, V22, P259, DOI 10.1002/prot.340220306; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; BUJARD H, 1987, METHOD ENZYMOL, V155, P416; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; DELARUE M, 1993, BIOESSAYS, V15, P675, DOI 10.1002/bies.950151007; ESKO JD, 1980, P NATL ACAD SCI-BIOL, V77, P5192, DOI 10.1073/pnas.77.9.5192; ESKO JD, 1981, J BIOL CHEM, V256, P7388; Gibson T. J., 1984, THESIS CAMBRIDGE U C; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HURD RE, 1991, J MAGN RESON, V91, P648, DOI 10.1016/0022-2364(91)90395-A; JANIN J, 1979, NATURE, V277, P491, DOI 10.1038/277491a0; JONES MD, 1986, BIOCHEMISTRY-US, V25, P1887, DOI 10.1021/bi00356a008; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERBARROW RJ, 1985, P NATL ACAD SCI USA, V82, P7840, DOI 10.1073/pnas.82.23.7840; MAUEL C, 1991, J GEN MICROBIOL, V137, P929, DOI 10.1099/00221287-137-4-929; NUREKI O, 1995, SCIENCE, V267, P1958, DOI 10.1126/science.7701318; PARK YS, 1993, J BIOL CHEM, V268, P16648; PERONA JJ, 1993, BIOCHEMISTRY-US, V32, P8758, DOI 10.1021/bi00085a006; POOLE HM, 1991, J GEN MICROBIOL, V137, P921, DOI 10.1099/00221287-137-4-921; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYERS JR, 1992, BIOTECHNIQUES, V13, P592; SWEITZER TD, 1994, ARCH BIOCHEM BIOPHYS, V311, P107, DOI 10.1006/abbi.1994.1215; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P33; Veitch DP, 1996, BIOCHEMISTRY-US, V35, P10743, DOI 10.1021/bi960402c; VILLAREJO MR, 1974, J BACTERIOL, V120, P466, DOI 10.1128/JB.120.1.466-474.1974; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104	31	59	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15161	15166		10.1074/jbc.272.24.15161	http://dx.doi.org/10.1074/jbc.272.24.15161			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182537	hybrid			2022-12-27	WOS:A1997XE03400020
J	Veaute, X; Sarasin, A				Veaute, X; Sarasin, A			Differential replication of a single N-2-acetylaminofluorene lesion in the leading or lagging strand DNA in a human cell extract	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SFII RESTRICTION-ENDONUCLEASE; UV-INDUCED MUTATIONS; SIMIAN VIRUS-40 DNA; TRANSLESION SYNTHESIS; REPAIR-PROFICIENT; PYRIMIDINE DIMERS; ESCHERICHIA-COLI; IRRADIATED DNA; SPECIFICITY; SITE	DNA replication in eucaryotic cells is a complex process involving a variety of proteins that synthesize the leading and lagging strand in an asymmetric, coordinated manner. To investigate the effect of this asymmetry on the translesion synthesis of bulky lesions, we have constructed SV40 origin-containing plasmids with site-specific N-2-acetylaminofluorene adduct on either leading or lagging strand templates. These plasmids have been incubated with DNA replication competent extracts made from human HeLa cells, Two dimensional agarose gel electrophoresis analyses reveal a strong blockage of fork progression only when the N-2-acetylaminofluorene adduct is located on the leading strand template. Morever, the analysis revealed that replication with HeLa cell extracts of SV40 origin-de pendent plasmids functions in both directions from the origin with equal efficiency but, probably due to an important asynchrony at the formation of the two forks, proceeds unidirectionally for a large number of individual molecules. The validity of the in vitro replication approach to study the fidelity of both leading- and lagging strand synthesis is discussed with regard to these new data.	INST RECH SCI CANC,CNRS,IFC 1,GENET MOL LAB,F-94801 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS)								ARMIER J, 1988, CARCINOGENESIS, V9, P789, DOI 10.1093/carcin/9.5.789; BERGER CA, 1986, MOL CELL BIOL, V6, P3443, DOI 10.1128/MCB.6.10.3443; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; CARTY MP, 1993, MOL CELL BIOL, V13, P533, DOI 10.1128/MCB.13.1.533; Carty MP, 1996, J BIOL CHEM, V271, P9637, DOI 10.1074/jbc.271.16.9637; CLARK JM, 1984, MUTAT RES, V132, P1, DOI 10.1016/0167-8817(84)90061-0; Deshpande AM, 1996, SCIENCE, V272, P1030, DOI 10.1126/science.272.5264.1030; DHAR V, 1991, MOL CELL BIOL, V11, P6268, DOI 10.1128/MCB.11.12.6268; EDENBERG HJ, 1983, VIROLOGY, V16, P298; Friedman KL, 1995, METHOD ENZYMOL, V262, P613; FUCHS RPP, 1981, NATURE, V294, P657, DOI 10.1038/294657a0; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KOFFELSCHWARTZ N, 1984, J MOL BIOL, V177, P33, DOI 10.1016/0022-2836(84)90056-1; Kornberg A., 1991, DNA REPLICATION; LI JJ, 1985, MOL CELL BIOL, V5, P1238, DOI 10.1128/MCB.5.6.1238; MARTINPARRAS L, 1992, J BIOL CHEM, V267, P22496; MARTINPARRAS L, 1991, J MOL BIOL, V220, P843, DOI 10.1016/0022-2836(91)90357-C; MCGREGOR WG, 1991, MOL CELL BIOL, V11, P1927, DOI 10.1128/MCB.11.4.1927; MENEGHINI R, 1976, BIOCHIM BIOPHYS ACTA, V425, P428, DOI 10.1016/0005-2787(76)90007-1; MENICHINI P, 1991, MUTAT RES, V251, P143, DOI 10.1016/0027-5107(91)90224-C; NOBBS TJ, 1995, J MOL BIOL, V252, P399, DOI 10.1006/jmbi.1995.0506; ROBERTS JD, 1993, METHODS MOL GENET, V2, P295; SARASIN AR, 1980, J MOL BIOL, V138, P299, DOI 10.1016/0022-2836(80)90288-0; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; Svoboda DL, 1995, P NATL ACAD SCI USA, V92, P11975, DOI 10.1073/pnas.92.26.11975; THOMAS DC, 1995, J BIOL CHEM, V270, P21226, DOI 10.1074/jbc.270.36.21226; THOMAS DC, 1994, P NATL ACAD SCI USA, V91, P7752, DOI 10.1073/pnas.91.16.7752; THOMAS DC, 1993, P NATL ACAD SCI USA, V90, P7744, DOI 10.1073/pnas.90.16.7744; THOMAS DC, 1993, BIOCHEMISTRY-US, V32, P11476, DOI 10.1021/bi00094a002; Thomas DC, 1996, MOL CELL BIOL, V16, P2537; VEAUTE X, 1993, SCIENCE, V261, P598, DOI 10.1126/science.8342022; VRIELING H, 1989, MOL CELL BIOL, V9, P1277, DOI 10.1128/MCB.9.3.1277; VRIELING H, 1991, NUCLEIC ACIDS RES, V19, P2411, DOI 10.1093/nar/19.9.2411; WENTZELL LM, 1995, J MOL BIOL, V248, P581, DOI 10.1006/jmbi.1995.0244; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710	36	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15351	15357		10.1074/jbc.272.24.15351	http://dx.doi.org/10.1074/jbc.272.24.15351			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182564	hybrid			2022-12-27	WOS:A1997XE03400047
J	Woo, WM; LinChao, S				Woo, WM; LinChao, S			Processing of the rne transcript by an RNase E-independent amino acid-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; AMS GENE; RIBONUCLEIC-ACID; PRODUCT; PURIFICATION; DEGRADATION; STABILITY; MUTATION; ENCODES	RNase E is encoded by the I ne (also known as ams or hmp) gene and is the principal enzyme that controls the chemical decay of bulk mRNA in Escherichia coli. Earlier work has shown that, RNase E degrades its own mRNA, autoregulating production of the RNase E protein, Here we show that in cells lacking RNase E activity, the 3,6-kilobase nae gene transcript is cleaved site specifically at two locations near its center by a novel endonuclease whose activity is modulated by the presence or absence of amino acids in the culture medium. These cleavages produce a 2-kilobase RNase E-sensitive RNA fragment corresponding to the 3' half of the transcript, Using primer extension and RNase protection analysis, we mapped RNase E-independent cleavages to sites 1558 and 1576 nucleotides from the 5' end of the me transcript (coordinates 1738 and 1747 of the me gene). Our results indicate the existence of a previously unknown RNase E-independent mechanism for degradation of me transcripts and further demonstrate that this mechanism responds to changes in cell growth conditions.	ACAD SINICA,INST MOL BIOL,TAIPEI 115,TAIWAN; NATL YANG MING UNIV,INST BIOCHEM,TAIPEI 112,TAIWAN	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University			Woo, Wei Meng/H-6594-2015; Lin-Chao, Sue/AAZ-8246-2021; Lin-Chao, Sue/AGI-2030-2022; Woo, Wei Meng/M-5856-2013	Lin-Chao, Sue/0000-0002-8415-9304; Lin-Chao, Sue/0000-0002-8415-9304; 				ALIFANO P, 1994, GENE DEV, V8, P3021, DOI 10.1101/gad.8.24.3021; APIRION D, 1978, GENETICS, V90, P659; APIRION D, 1978, J BIOL CHEM, V253, P1738; CASAREGOLA S, 1992, J MOL BIOL, V228, P30, DOI 10.1016/0022-2836(92)90489-7; CASAREGOLA S, 1994, J MOL BIOL, V238, P867, DOI 10.1006/jmbi.1994.1344; CHAUHAN AK, 1991, MOL GEN GENET, V228, P49, DOI 10.1007/BF00282446; CLAVERIEMARTIN F, 1991, J BIOL CHEM, V266, P2843; Cohen SN, 1997, MOL MICROBIOL, V23, P1099, DOI 10.1111/j.1365-2958.1997.tb02593.x; CORMACK RS, 1993, P NATL ACAD SCI USA, V90, P9006, DOI 10.1073/pnas.90.19.9006; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GEORGELLIS D, 1992, J BACTERIOL, V174, P5382, DOI 10.1128/JB.174.16.5382-5390.1992; GOLDBLUM K, 1981, J BACTERIOL, V146, P128, DOI 10.1128/JB.146.1.128-132.1981; HILLMAN JD, 1975, J BACTERIOL, V122, P1175, DOI 10.1128/JB.122.3.1175-1179.1975; JAIN C, 1995, GENE DEV, V9, P84, DOI 10.1101/gad.9.1.84; KUWANO M, 1977, MOL GEN GENET, V154, P279, DOI 10.1007/BF00571283; Lin-Chao S, 1992, MOL MICROBIOL, V6, P3385, DOI 10.1111/j.1365-2958.1992.tb02206.x; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; MCDOWALL KJ, 1993, J BACTERIOL, V175, P4245, DOI 10.1128/JB.175.13.4245-4249.1993; McDowall KJ, 1996, J MOL BIOL, V255, P349, DOI 10.1006/jmbi.1996.0027; MELEFORS O, 1993, CONTROL MESSENGER RN, P53; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; MUDD EA, 1993, MOL MICROBIOL, V9, P557, DOI 10.1111/j.1365-2958.1993.tb01716.x; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; ROTH JR, 1970, METHODS ENZYMOL    A, V17, P3; Sambrook J., 2002, MOL CLONING LAB MANU; TARASEVICIENE L, 1994, J BIOL CHEM, V269, P12167; TARASEVICIENE L, 1995, J BIOL CHEM, V270, P26391, DOI 10.1074/jbc.270.44.26391	29	7	7	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15516	15520		10.1074/jbc.272.24.15516	http://dx.doi.org/10.1074/jbc.272.24.15516			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182586	hybrid			2022-12-27	WOS:A1997XE03400069
J	Burke, PV; Raitt, DC; Allen, LA; Kellogg, EA; Poyton, RO				Burke, PV; Raitt, DC; Allen, LA; Kellogg, EA; Poyton, RO			Effects of oxygen concentration on the expression of cytochrome c and cytochrome c oxidase genes in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SUBUNIT-V; ESCHERICHIA-COLI; DIFFERENTIAL REGULATION; ANAEROBIC RESPIRATION; KINASE-ACTIVITY; HEME PROTEIN; TRANSCRIPTION; COX6; FIXL	Oxygen is an important environmental regulator for the transcription of several genes in Saccharomyces cerevisiae, but it is not yet clear how this yeast or other eukaryotes actually sense oxygen. To begin to address this we have examined the effects of oxygen concentration on the expression of several nuclear genes (CYC1, CYC7, COX4, COX5a, COX5b, COX6, COX7, COX8, and COX9) for proteins of the terminal portion of the respiratory chain. COX5b and CYC7 are hypoxic genes; the rest are aerobic genes. We have found that the level of expression of these genes is determined by oxygen concentration per se and not merely the presence or absence of oxygen and that each of these genes has a low oxygen threshold (0.5-1 mu M O-2) for expression. For some aerobic genes (COX4, COX5a, COX7, COX8, and COX9) there is a gradual decline in expression between 200 mu M O-2 (air) and their oxygen threshold. Below this threshold expression drops precipitously. For others (COX5a and CYC1) the level of expression is nearly constant between 200 mu M O-2 and their threshold and then drops off. The hypoxic genes COX5b and CYC7 are not expressed until the oxygen concentration is below 0.5 mu M O-2. These studies have also revealed that COX5a and CYC1, the genes for the aerobic isoforms of cytochrome c oxidase subunit V and cytochrome c, and COX5b and CYC7, the genes for the hypoxic isoforms of cytochrome c oxidase subunit V and cytochrome c, are coexpressed at a variety of oxygen concentrations and switch on or off at extremely low oxygen concentrations. By shifting cells from one oxygen concentration to another we have found that aerobic genes are induced faster than hypoxic genes and that transcripts from both types of gene are turned over quickly. These findings have important implications for cytochrome c oxidase function and biogenesis and far models of oxygen sensing in yeast.	UNIV COLORADO, DEPT MOL CELLULAR & DEV BIOL, BOULDER, CO 80309 USA	University of Colorado System; University of Colorado Boulder			Kellogg, Elizabeth/M-2845-2013	Kellogg, Elizabeth/0000-0003-1671-7447	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030228, R01GM039324] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 39324, GM 30228] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN LA, 1995, J BIOL CHEM, V270, P110, DOI 10.1074/jbc.270.1.110; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; CHEN J, 1985, BIOTECHNOL BIOENG, V27, P151, DOI 10.1002/bit.260270208; CRIDDLE RS, 1969, BIOCHEMISTRY-US, V8, P322, DOI 10.1021/bi00829a045; CUMSKY MG, 1985, P NATL ACAD SCI USA, V82, P2235, DOI 10.1073/pnas.82.8.2235; CUMSKY MG, 1987, MOL CELL BIOL, V7, P3511, DOI 10.1128/MCB.7.10.3511; DECKERT J, 1995, GENETICS, V139, P1149; DEWINDE JH, 1993, PROG NUCLEIC ACID RE, V46, P51, DOI 10.1016/S0079-6603(08)61018-1; ELDER RT, 1983, P NATL ACAD SCI-BIOL, V80, P2432, DOI 10.1073/pnas.80.9.2432; GILLESGONZALEZ MA, 1994, BIOCHEMISTRY-US, V33, P8067, DOI 10.1021/bi00192a011; GILLESGONZALEZ MA, 1995, BIOCHEMISTRY-US, V34, P232, DOI 10.1021/bi00001a027; GILLESGONZALEZ MA, 1993, J BIOL CHEM, V268, P16293; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HIDALGO E, 1995, J BIOL CHEM, V270, P20908, DOI 10.1074/jbc.270.36.20908; HODGE MR, 1989, MOL CELL BIOL, V9, P1958, DOI 10.1128/MCB.9.5.1958; KENG T, 1992, MOL CELL BIOL, V12, P2616, DOI 10.1128/MCB.12.6.2616; Labbe-Bois R, 1990, BIOSYNTHESIS HEME CH, P235; LAZ TM, 1984, P NATL ACAD SCI-BIOL, V81, P4475, DOI 10.1073/pnas.81.14.4475; PADMANABAN G, 1989, TRENDS BIOCHEM SCI, V14, P492, DOI 10.1016/0968-0004(89)90182-5; PINKHAM JL, 1992, METAL IONS FUNGI, P451; Poyton RO, 1995, METHOD ENZYMOL, V260, P97, DOI 10.1016/0076-6879(95)60133-3; POYTON RO, 1988, ANN NY ACAD SCI, V550, P289, DOI 10.1111/j.1749-6632.1988.tb35344.x; POYTON RO, 1992, BIOCHIM BIOPHYS ACTA, V1101, P252, DOI 10.1016/S0005-2728(05)80033-7; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; ROGERS PJ, 1973, J GEN MICROBIOL, V79, P205, DOI 10.1099/00221287-79-2-205; ROGERS PJ, 1973, J BACTERIOL, V115, P88, DOI 10.1128/JB.115.1.88-97.1973; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; SULKOWSKI E, 1964, NATURE, V202, P36, DOI 10.1038/202036a0; TRAGESER M, 1989, MOL MICROBIOL, V3, P593, DOI 10.1111/j.1365-2958.1989.tb00206.x; TRAWICK JD, 1989, MOL CELL BIOL, V9, P5350, DOI 10.1128/MCB.9.12.5350; TRAWICK JD, 1989, J BIOL CHEM, V264, P7005; TRUEBLOOD CE, 1987, MOL CELL BIOL, V7, P3520, DOI 10.1128/MCB.7.10.3520; TRUEBLOOD CE, 1988, MOL CELL BIOL, V8, P4537, DOI 10.1128/MCB.8.10.4537; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; UNDEN G, 1991, ANTON LEEUW INT J G, V59, P65, DOI 10.1007/BF00445650; WATERLAND RA, 1991, J BIOL CHEM, V266, P4180; Wikstrom M, 1981, CYTOCHROME C OXIDASE; WRIGHT RM, 1995, BIOCHEM BIOPH RES CO, V216, P676, DOI 10.1006/bbrc.1995.2675; WU J, 1995, J BIOL CHEM, V270, P10323, DOI 10.1074/jbc.270.17.10323; ZHANG L, 1994, J BIOL CHEM, V269, P14643; ZITOMER RS, 1992, MICROBIOL REV, V56, P1	41	103	106	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14705	14712		10.1074/jbc.272.23.14705	http://dx.doi.org/10.1074/jbc.272.23.14705			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169434	hybrid			2022-12-27	WOS:A1997XC32700031
J	Chung, J; Gao, AG; Frazier, WA				Chung, J; Gao, AG; Frazier, WA			Thrombospondin acts via integrin-associated protein to activate the platelet integrin alpha(IIb)beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODY; LIGAND-BINDING; RECEPTOR; KINASE; AGGREGATION; FAMILY; PP125(FAK); THROMBIN	Integrin-associated protein (IAP or CD47) is a receptor for the cell/platelet-binding domain (CBD) of thrombospondin-1 (TS1), the most abundant protein of platelet alpha granules. Although it associates with alpha IIb beta 3, IAP has no known function in platelets. TS1, the CBD, and an IAP agonist peptide (4N1K) from the CBD of TS1 activate the platelet integrin alpha IIb beta 3, resulting in platelet spreading on immobilized fibrinogen, stimulation of platelet aggregation, and enhanced tyrosine phosphorylation of focal adhesion kinase. Furthermore, 4N1K peptide selectively stimulates the phosphorylation of LYN and SYK and their association with FAK. The phosphorylation of SYK is blocked by pertussis toxin, implicating a G(i)-like heterotrimeric G protein. IAP solublized from membranes of unstimulated platelets binds specifically to an affinity column of 4N1K peptide. Both alpha IIb and beta 3 integrin subunits and c-Src bind along with IAP. This complex of proteins is also detected with immunoprecipitation. Activation of platelets with the agonist peptide 4N1K results in the association of FAK with the IAP-alpha IIb beta 3 complex. Thus an important function of TS1 in platelets is that of a secreted costimulator of alpha IIb beta 3. whose unique properties result in its localization to the platelet surface and the fibrin clot.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL)								AIKEN ML, 1990, BLOOD, V76, P2501; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; BAENZIGE.NL, 1971, P NATL ACAD SCI USA, V68, P240, DOI 10.1073/pnas.68.1.240; BALE MD, 1985, J BIOL CHEM, V260, P7502; Blystone SD, 1996, J BIOL CHEM, V271, P31458, DOI 10.1074/jbc.271.49.31458; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CLARK EA, 1994, J BIOL CHEM, V269, P28859; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; DIXIT VM, 1985, P NATL ACAD SCI USA, V82, P3472, DOI 10.1073/pnas.82.10.3472; Dorahy DJ, 1997, J BIOL CHEM, V272, P1323, DOI 10.1074/jbc.272.2.1323; FUJIMOTO T, 1995, BLOOD, V86, P2174, DOI 10.1182/blood.V86.6.2174.bloodjournal8662174; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Gao AG, 1996, J CELL BIOL, V135, P533, DOI 10.1083/jcb.135.2.533; GARTNER TK, 1981, NATURE, V289, P688, DOI 10.1038/289688a0; GARTNER TK, 1984, BIOCHEM BIOPH RES CO, V15, P290; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; Haimovich B, 1996, J BIOL CHEM, V271, P16332, DOI 10.1074/jbc.271.27.16332; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; Keely PJ, 1996, J BIOL CHEM, V271, P26668, DOI 10.1074/jbc.271.43.26668; KEFALAS P, 1995, INT J BIOCHEM CELL B, V27, P551, DOI 10.1016/1357-2725(95)00024-J; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; LAWLER J, 1989, BLOOD, V74, P2022; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LEUNG LLK, 1984, J CLIN INVEST, V74, P1764, DOI 10.1172/JCI111595; Lindberg FP, 1996, SCIENCE, V274, P795, DOI 10.1126/science.274.5288.795; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MCGREGOR JL, 1993, THROMBOSPONDIN, P111; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; ROBERTS DD, 1993, THROMBOSPONDIN, P73; ROSALES C, 1992, J IMMUNOL, V149, P2759; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SCHWARTZ MA, 1993, J BIOL CHEM, V268, P19931; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; TSAO PW, 1995, J BIOL CHEM, V270, P23747, DOI 10.1074/jbc.270.40.23747; TUSZYNSKI GP, 1988, BLOOD, V72, P109; WALZ DA, 1993, THROMBOSPONDIN, P149; Wymann MP, 1996, MOL CELL BIOL, V16, P1722	48	164	170	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14740	14746		10.1074/jbc.272.23.14740	http://dx.doi.org/10.1074/jbc.272.23.14740			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169439	hybrid			2022-12-27	WOS:A1997XC32700036
J	Cuthbert, C; Wang, ZW; Zhang, X; Tam, SP				Cuthbert, C; Wang, ZW; Zhang, X; Tam, SP			Regulation of human apolipoprotein A-I gene expression by gramoxone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; ANTIOXIDANT RESPONSIVE ELEMENT; HDL CHOLESTEROL; MESSENGER-RNA; CELL-LINE; APOA-I; ATHEROSCLEROSIS; IDENTIFICATION; PROTEIN; FAT	To induce oxidative stress, HepG2 cells were exposed to a compound known as gramoxone. This compound undergoes a one-electron reduction to form a stable free radical which is capable of generating reactive oxygen species. We demonstrated that exposure of HepG2 cells to gramoxone (0.1 mu M) resulted in a 2-fold decrease in apoA-I mRNA with no significant change in apoB and apoE mRNA levels. To examine if increased rates of mRNA degradation were responsible for the reduction in apoA-I mRNA levels, mRNA half-lives were measured in the presence of actinomycin D with and without gramoxone treatment, These studies revealed a 4-fold increase in the rate of apoA-I mRNA degradation in cells exposed to gramoxone, In similarly treated cells, nuclear run-off assays indicated that the transcription rate of the apoA-I gene was also increased 2-fold, Consistent with nuclear run-off assays, transient transfection experiments using a series of pGL2-derived luciferase reporter plasmids containing the human apoAI proximal promoter demonstrated that gramoxone treatment increased apoA-I promoter activity 2-fold. We have identified a potential ''antioxidant response element'' (ARE) in the apoA-I promoter region that may be responsible fdr the increase in apoA-I transcriptional activity by gramoxone, Gel mobility shift assays with an ARE oligonucleotide revealed increased levels of a specific protein-DNA complex that formed with nuclear extracts from gramoxone-treated cells, UV cross-linking experiments with the ARE and nuclear extracts from either untreated or gramoxone-treated cells detected proteins of approximately 100 and 115 kDa. When a single copy of the ARE was inserted upstream of the SV40 promoter in a luciferase reporter plasmid, a significant 2-fold induction in luciferase activity was observed in HepG2 cells in the presence of gramoxone, In contrast, a plasmid containing a mutant apoAI-ARE did not confer responsiveness to gramoxone. Furthermore, pGL2 (apoAI-250 mutant ARE), in which point mutations eliminated the ARE in the apoAI promoter, showed no increase in luciferase activity in response to gramoxone, Taken together, the data suggest that gramoxone affects apoA-I mRNA levels by both transcriptional and post-transcriptional mechanisms.	QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA	Queens University - Canada			Zhang, Xia/B-8152-2008	Zhang, Xia/0000-0002-9040-1486				ASSMANN G, 1984, J CLIN CHEM CLIN BIO, V22, P397; AZROLAN N, 1995, J BIOL CHEM, V270, P19833, DOI 10.1074/jbc.270.34.19833; BARTALENA L, 1992, MOL ENDOCRINOL, V6, P935, DOI 10.1210/me.6.6.935; BUS JS, 1984, ENVIRON HEALTH PERSP, V55, P37, DOI 10.2307/3429690; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COWAN DB, 1993, J BIOL CHEM, V268, P26904; DEGRAY JA, 1991, ARCH BIOCHEM BIOPHYS, V129, P145; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; GO MF, 1988, J CLIN INVEST, V81, P1615, DOI 10.1172/JCI113496; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAFFNER SM, 1985, ARTERIOSCLEROSIS, V5, P169, DOI 10.1161/01.ATV.5.2.169; HAYEK T, 1993, J CLIN INVEST, V91, P1665, DOI 10.1172/JCI116375; KLIMOV A N, 1989, Biokhimiya, V54, P118; KLIMOV AN, 1993, ATHEROSCLEROSIS, V100, P13, DOI 10.1016/0021-9150(93)90063-Z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINLEE YC, 1993, J LIPID RES, V24, P249; MACKNESS MI, 1991, FEBS LETT, V286, P152, DOI 10.1016/0014-5793(91)80962-3; MACKNESS MI, 1991, FEBS LETT, V292, P307; MAITRE B, 1993, AM J PHYSIOL, V265, pL635; Michaelis L, 1933, J GEN PHYSIOL, V16, P859, DOI 10.1085/jgp.16.6.859; Michaelis L, 1933, J AM CHEM SOC, V55, P1481, DOI 10.1021/ja01331a027; MORRISON HG, 1993, BIOTECHNIQUES, V14, P454; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; PARTHASARATHY S, 1992, PROG LIPID RES, V31, P127, DOI 10.1016/0163-7827(92)90006-5; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; *PROM CORP, 1991, PLASM TECHN MAN; PRYOR WA, 1983, ENVIRON HEALTH PERSP, V47, P345, DOI 10.1289/ehp.8347345; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SORCITHOMAS M, 1988, J BIOL CHEM, V263, P5183; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; SRIVASTAVA RAK, 1992, BIOCHIM BIOPHYS ACTA, V1125, P251, DOI 10.1016/0005-2760(92)90053-X; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STROBL W, 1990, J CLIN INVEST, V85, P659, DOI 10.1172/JCI114489; TAM SP, 1991, ATHEROSCLEROSIS, V91, P51, DOI 10.1016/0021-9150(91)90186-7; TAM SP, 1985, J BIOL CHEM, V260, P1670; TAM SP, 1994, ATHEROSCLEROSIS, V105, P235, DOI 10.1016/0021-9150(94)90054-X; VANHINSBERGH VWM, 1986, BIOCHIM BIOPHYS ACTA, V878, P49, DOI 10.1016/0005-2760(86)90343-7; WATERS D, 1991, AM J MED, V91, pS10, DOI 10.1016/0002-9343(91)90051-X; WILHELMSSON C, 1975, Lancet, V1, P415; WISSLER RW, 1991, AM J MED, V91, pS3, DOI 10.1016/0002-9343(91)90050-8; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975; Zhang X, 1996, J BIOL CHEM, V271, P27152, DOI 10.1074/jbc.271.43.27152	44	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14954	14960		10.1074/jbc.272.23.14954	http://dx.doi.org/10.1074/jbc.272.23.14954			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169468	hybrid			2022-12-27	WOS:A1997XC32700065
J	Fiete, D; Baenziger, JU				Fiete, D; Baenziger, JU			Isolation of the SO4-4-GalNAc beta 1,4GlcNAc beta 1,2Man alpha-specific receptor from rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; CARBOHYDRATE-RECOGNITION DOMAINS; PITUITARY GLYCOPROTEIN HORMONES; MACROPHAGE MANNOSE RECEPTOR; CIRCULATORY HALF-LIFE; N-ACETYLGLUCOSAMINE; SIALYLATED OLIGOSACCHARIDES; CHORIONIC-GONADOTROPIN; HUMAN THYROTROPIN; SULFATED OLIGOSACCHARIDES	Glycoproteins, such as the glycoprotein hormone lutropin (LH), bear oligosaccharides terminating with the sequence SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha (S4GGnM) and are rapidly removed from the circulation by a receptor present in hepatic endothelial cells and Kupffer cells, Rapid removal from the circulation is essential for attaining maximal hormone activity in vivo. We have isolated a protein from rat liver which has the properties expected for the S4GGnM-specific receptor (S4GGnM-R). The S4GGnM-R is closely related to the macrophage mannose receptor (Man-R) both antigenically and structurally. At least 12 peptides prepared from the S4GGnM-R have amino acid sequences that are identical to those of the Man-R, Nonetheless, the ligand binding properties of the S4GGnM-R and the Man-R differ in a number of respects, The S4GGnM-R binds to immobilized LH but not to immobilized mannose, whereas the Man-R binds to immobilized mannose but not to immobilized LH, When analyzed using a binding assay that precipitates receptor ligand complexes with polyethylene glycol, the S4GGnM-R is able to bind S4GGnM-bovine serum albumin (S4GGnM-BSA) conjugates gates whereas the Man-R is not, In contrast both the S4GGnM-R and the Man-R are able to bind Man-BSA. Monosaccharides that inhibit binding of Man-BSA by the Man-R enhance binding by the S4GGnM-R. Oligosaccharides terminating with S4GGnM and those terminating with Man are bound at independent sites on the S4GGnM-R, The S4GGnM-R present in hepatic endothelial cells may account for clearance of glycoproteins bearing oligosaccharides terminating with S4GGnM and glycoproteins bearing oligosaccharides terminating with either mannose, fucose, or N-acetylglucosamine.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Baenziger, Jacques U/E-9430-2012		NATIONAL CANCER INSTITUTE [R01CA021923] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA21923] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; Baenziger JU, 1996, ENDOCRINOLOGY, V137, P1520, DOI 10.1210/en.137.5.1520; BAENZIGER JU, 1980, CELL, V22, P611, DOI 10.1016/0092-8674(80)90371-2; BAENZIGER JU, 1991, BIOL CARBOHYDRATES, V3, P1; BLUM JS, 1991, CARBOHYD RES, V213, P145, DOI 10.1016/S0008-6215(00)90605-0; DHARMESH SM, 1993, P NATL ACAD SCI USA, V90, P11127, DOI 10.1073/pnas.90.23.11127; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; ENDO Y, 1979, J BIOCHEM-TOKYO, V85, P669; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; GREEN ED, 1988, J BIOL CHEM, V263, P25; GREEN ED, 1988, J BIOL CHEM, V263, P36; GROSSMANN M, 1995, J BIOL CHEM, V270, P29378, DOI 10.1074/jbc.270.49.29378; HALTIWANGER RS, 1986, J BIOL CHEM, V261, P7433; HALTIWANGER RS, 1986, J BIOL CHEM, V261, P7440; HARRIS N, 1992, BLOOD, V80, P2363; HARTREE AS, 1992, BIOCHEM J, V287, P665, DOI 10.1042/bj2870665; II M, 1988, J BIOCHEM-TOKYO, V104, P587; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; KERY V, 1992, ARCH BIOCHEM BIOPHYS, V298, P49, DOI 10.1016/0003-9861(92)90092-B; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LEITOLF H, 1995, HORM METAB RES, V27, P173, DOI 10.1055/s-2007-979933; LENNARTZ MR, 1987, J BIOL CHEM, V262, P9942; LENNARTZ MR, 1987, BIOCHEM J, V245, P705, DOI 10.1042/bj2450705; Manzella SM, 1996, J BIOL CHEM, V271, P12117, DOI 10.1074/jbc.271.21.12117; MANZELLA SM, 1995, J BIOL CHEM, V270, P21665, DOI 10.1074/jbc.270.37.21665; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAYNARD Y, 1981, J BIOL CHEM, V256, P8063; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; SCHLESINGER PH, 1978, BIOCHEM J, V176, P103, DOI 10.1042/bj1760103; SCHLESINGER PH, 1980, BIOCHEM J, V192, P597, DOI 10.1042/bj1920597; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SHEPHERD VL, 1981, P NATL ACAD SCI-BIOL, V78, P1019, DOI 10.1073/pnas.78.2.1019; SMITH PL, 1993, J BIOL CHEM, V268, P795; SMITH PL, 1990, J BIOL CHEM, V265, P874; SUMMERFIELD JA, 1982, J CLIN INVEST, V69, P1337, DOI 10.1172/JCI110573; SZKUDLINSKI MW, 1995, ENDOCRINOLOGY, V136, P3325, DOI 10.1210/en.136.8.3325; SZKUDLINSKI MW, 1995, P NATL ACAD SCI USA, V92, P9062, DOI 10.1073/pnas.92.20.9062; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; Wu K, 1996, J BIOL CHEM, V271, P21323, DOI 10.1074/jbc.271.35.21323	43	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14629	14637		10.1074/jbc.272.23.14629	http://dx.doi.org/10.1074/jbc.272.23.14629			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169424	hybrid			2022-12-27	WOS:A1997XC32700021
J	Wei, SH; Lai, K; Patel, S; Piantedosi, R; Shen, H; Colantuoni, V; Kraemer, FB; Blaner, WS				Wei, SH; Lai, K; Patel, S; Piantedosi, R; Shen, H; Colantuoni, V; Kraemer, FB; Blaner, WS			Retinyl ester hydrolysis and retinol efflux from BFC-1 beta adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; BINDING-PROTEIN; RAT-LIVER; ADIPOSE-TISSUE; CELLS; EXPRESSION; DIFFERENTIATION; PHOSPHORYLATION; ESTERIFICATION; LOCALIZATION	Adipose tissue is an important storage depot for retinol, but there are no data regarding retinol mobilization from adipose stores. To address this, dibutyryl cAMP was provided to murine BFC-1 beta adipocytes and its effects on retinol efflux assessed. High performance liquid chromatography analysis of retinol and retinyl esters in adipocytes and media indicated that cAMP stimulated, in a time- and dose-dependent manner, retinol accumulation in the culture media and decreased cellular retinyl ester concentrations. Study of adipocyte retinol-binding protein synthesis and secretion indicated that cAMP-stimulated retinol efflux into the media did not result from increased retinol-retinol-binding protein secretion but was dependent on the presence of fetal bovine serum in the culture media. Since our data suggested that retinyl esters can be hydrolyzed by a cAMP-dependent enzyme like hormone-sensitive lipase (HSL), in separate studies, we purified a HSL-containing fraction from BFC-1 beta adipocytes and demonstrated that it catalyzed retinyl palmitate hydrolysis. Homogenates of Chinese hamster ovary cells overexpressing HSL catalyzed retinyl palmitate hydrolysis in a time-, protein-, and substrate-dependent manner, with an apparent K-m for retinyl palmitate of 161 mu M, whereas homogenates from control Chinese hamster ovary cells did not.	COLUMBIA UNIV,DEPT MED,NEW YORK,NY 10032; COLUMBIA UNIV,INST HUMAN NUTR,NEW YORK,NY 10032; STANFORD UNIV,SCH MED,DEPT VET AFFAIRS,PALO ALTO,CA 94305; STANFORD UNIV,SCH MED,DEPT MED,PALO ALTO,CA 94305; UNIV NAPLES,DIPARTIMENTO BIOCHIM & BIOTECNOL MED,I-80131 NAPLES,ITALY	Columbia University; Columbia University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; University of Naples Federico II			Kraemer, Fredric/AAC-3633-2019	Kraemer, Fredric/0000-0003-2468-7807	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047389, R01DK049705, R01DK046942] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 49705, DK 47389, DK 46942] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUMRAD NA, 1991, P NATL ACAD SCI USA, V88, P6008, DOI 10.1073/pnas.88.14.6008; BECKETT GJ, 1977, EUR J BIOCHEM, V72, P223, DOI 10.1111/j.1432-1033.1977.tb11243.x; BELFRAGE P, 1984, LIPASES, P366; Blaner William S., 1994, P229; Blaner William S., 1994, P529; BLANER WS, 1990, METHOD ENZYMOL, V189, P270; BLANER WS, 1985, J LIPID RES, V26, P1241; BLANER WS, 1994, J BIOL CHEM, V269, P1655; BRIDGES CDB, 1981, METHOD ENZYMOL, V81, P463; BROUWER A, 1988, CHEM-BIOL INTERACT, V68, P203, DOI 10.1016/0009-2797(88)90017-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK KG, 1981, FEBS LETT, V132, P10, DOI 10.1016/0014-5793(81)80416-4; DAS SR, 1992, BIOCHEM J, V285, P907, DOI 10.1042/bj2850907; FLOOD MT, 1983, INVEST OPHTH VIS SCI, V24, P1227; FOREST C, 1987, EXP CELL RES, V168, P218, DOI 10.1016/0014-4827(87)90430-7; FOREST C, 1987, EXP CELL RES, V168, P233, DOI 10.1016/0014-4827(87)90431-9; FREDRIKSON G, 1981, J BIOL CHEM, V256, P6311; HOLST LS, 1994, FEBS LETT, V355, P125, DOI 10.1016/0014-5793(94)01185-0; KRAEMER FB, 1993, J LIPID RES, V34, P663; LINSCHEER WG, 1994, MODERN NUTR HLTH DIS, P47; MAKOVER A, 1989, J LIPID RES, V30, P171; Maniatis T., 1982, MOL CLONING; MORIWAKI H, 1988, J LIPID RES, V29, P1523; NOY N, 1991, BIOCHEMISTRY-US, V30, P6380, DOI 10.1021/bi00240a005; ONG DE, 1988, J BIOL CHEM, V263, P5789; POSCH KC, 1991, BIOCHEMISTRY-US, V30, P6224, DOI 10.1021/bi00239a021; Snedecor G.W., 1967, STAT METHODS; Soprano Dianne Robert, 1994, P257; SOPRANO DR, 1988, J BIOL CHEM, V263, P2934; STRALFORS P, 1984, P NATL ACAD SCI-BIOL, V81, P3317, DOI 10.1073/pnas.81.11.3317; STRALFORS P, 1987, ENZYMES B, V18, P147; SZTALRYD C, 1995, J CLIN INVEST, V95, P2652, DOI 10.1172/JCI117967; TSUTSUMI C, 1992, J BIOL CHEM, V267, P1805; VAUGHAN M, 1964, J BIOL CHEM, V239, P401; WEI SH, 1995, J BIOL CHEM, V270, P866, DOI 10.1074/jbc.270.2.866; YEAMAN SJ, 1990, BIOCHIM BIOPHYS ACTA, V1052, P128, DOI 10.1016/0167-4889(90)90067-N; YOST RW, 1988, J BIOL CHEM, V263, P18693; ZOVICH DC, 1992, J BIOL CHEM, V267, P13884	38	87	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14159	14165		10.1074/jbc.272.22.14159	http://dx.doi.org/10.1074/jbc.272.22.14159			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162045	hybrid			2022-12-27	WOS:A1997XB49200032
J	Zhu, SH; Romano, PR; Wek, RC				Zhu, SH; Romano, PR; Wek, RC			Ribosome targeting of PKR is mediated by two double-stranded RNA-binding domains and facilitates in vivo phosphorylation of eukaryotic initiation factor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; NF-KAPPA-B; SACCHAROMYCES-CEREVISIAE; INTERFERON ACTION; MALIGNANT TRANSFORMATION; TRANSLATION INITIATION; IN-VIVO; INTERMOLECULAR AUTOPHOSPHORYLATION; TERMINAL REGION; P68 KINASE	Protein kinase PKR is activated in mammalian cells during viral infection, leading to phosphorylation of the alpha subunit of eukaryotic initiation factor-2 (eIF-2 alpha) and inhibition of protein synthesis. This antiviral response is thought to be mediated by association of double-stranded RNA (ds-RNA), a by-product of viral replication, with two ds-RNA-binding domains (DRBDs) located in the amino terminus of PKR, Recent studies have observed that expression of mammalian PKR in yeast leads to a slow growth phenotype due to hyperphosphorylation of eIF-2 alpha. In this report, we observed that while DRBD sequences are required for PKR to function in the yeast model system, these sequences are not required for in vitro phosphorylation of eIF-2 alpha. To explain this apparent contradiction, we proposed that these sequences are required to target the kinase to the translation machinery, Using sucrose gradient sedimentation, we found that wild-type PKR was associated with ribosomes, specifically with 40 S particles, Deletions or residue substitutions in the DRBD sequences blocked kinase interaction with ribosomes. These results indicate that in addition to mediating ds-RNA control of PKR, the DRBD sequences facilitate PKR association with ribosomes, Targeting to ribosomes may enhance in vivo phosphorylation of eIF-2 alpha, by providing PKR access to its substrate.	INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOL BIOL, INDIANAPOLIS, IN 46202 USA; NICHHD, LAB EUKARYOT GENE EXPRESS, NIH, BETHESDA, MD 20892 USA	Indiana University System; Indiana University-Purdue University Indianapolis; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)					NIGMS NIH HHS [GM49164] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM049164, R01GM049164] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBER GN, 1993, P NATL ACAD SCI USA, V90, P4621, DOI 10.1073/pnas.90.10.4621; BARBER GN, 1995, MOL CELL BIOL, V15, P3138; BARBER GN, 1995, J BIOL CHEM, V270, P17423, DOI 10.1074/jbc.270.29.17423; BERRY MJ, 1985, J BIOL CHEM, V260, P1120; BISCHOFF JR, 1985, J BIOL CHEM, V260, P8237; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BYCROFT M, 1995, FEBS LETT, V362, P333, DOI 10.1016/0014-5793(95)00181-8; BYCROFT M, 1995, EMBO J, V14, P3563, DOI 10.1002/j.1460-2075.1995.tb07362.x; Cesareni G, 1987, GENETIC ENG PRINCIPL, V9, P135, DOI DOI 10.1007/978-1-4684-5377-5_9; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COSENTINO GP, 1995, P NATL ACAD SCI USA, V92, P9445, DOI 10.1073/pnas.92.21.9445; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; FENG L, 1994, MOL CELL BIOL, V14, P5139, DOI 10.1128/MCB.14.8.5139; GALABRU J, 1989, EUR J BIOCHEM, V178, P581, DOI 10.1111/j.1432-1033.1989.tb14485.x; GRAACK HR, 1988, FEBS LETT, V242, P4, DOI 10.1016/0014-5793(88)80975-X; GRAACK HR, 1992, EUR J BIOCHEM, V206, P373, DOI 10.1111/j.1432-1033.1992.tb16937.x; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; GREEN SR, 1995, MOL CELL BIOL, V15, P358, DOI 10.1128/MCB.15.1.358; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Hinnebusch Alan G., 1994, Seminars in Cell Biology, V5, P417, DOI 10.1006/scel.1994.1049; HOVANESSIAN AG, 1987, EUR J BIOCHEM, V167, P467, DOI 10.1111/j.1432-1033.1987.tb13360.x; HOVANESSIAN AG, 1987, VIROLOGY, V159, P126, DOI 10.1016/0042-6822(87)90355-2; Jackson RJ, 1991, TRANSLATION EUKARYOT, P193; JEFFREY IW, 1995, EXP CELL RES, V218, P17, DOI 10.1006/excr.1995.1126; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LEE SB, 1994, P NATL ACAD SCI USA, V91, P10551, DOI 10.1073/pnas.91.22.10551; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MATHEWS MB, 1993, SEMIN VIROL, V4, P247, DOI 10.1006/smvy.1993.1021; MCCORMACK SJ, 1994, VIROLOGY, V198, P92, DOI 10.1006/viro.1994.1011; MCCORMACK SJ, 1992, VIROLOGY, V188, P47, DOI 10.1016/0042-6822(92)90733-6; MCMILLAN NAJ, 1995, J BIOL CHEM, V270, P2601, DOI 10.1074/jbc.270.6.2601; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; PATEL RC, 1992, J BIOL CHEM, V267, P7671; PATEL RC, 1994, J BIOL CHEM, V269, P18593; PATEL RC, 1995, P NATL ACAD SCI USA, V92, P8283, DOI 10.1073/pnas.92.18.8283; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P217; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; SAMUEL CE, 1986, METHOD ENZYMOL, V119, P499; SCHWEMMLE M, 1992, P NATL ACAD SCI USA, V89, P10292, DOI 10.1073/pnas.89.21.10292; Sherman F., 1974, METHODS YEAST GENETI; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; SZYSZKA R, 1989, J BIOL CHEM, V264, P3827; Taylor DR, 1996, MOL CELL BIOL, V16, P6295; THOMIS DC, 1992, P NATL ACAD SCI USA, V89, P10837, DOI 10.1073/pnas.89.22.10837; THOMIS DC, 1995, J VIROL, V69, P5195, DOI 10.1128/JVI.69.8.5195-5198.1995; THOMIS DC, 1993, J VIROL, V67, P7695, DOI 10.1128/JVI.67.12.7695-7700.1993; VANDENHEUVEL J, 1995, BBA-GENE STRUCT EXPR, V1261, P337, DOI 10.1016/0167-4781(95)00026-D; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291; Wu SY, 1996, J BIOL CHEM, V271, P1756, DOI 10.1074/jbc.271.3.1756; YOON H, 1992, MOL MICROBIOL, V6, P1413, DOI 10.1111/j.1365-2958.1992.tb00861.x; Zhu SH, 1996, J BIOL CHEM, V271, P24989, DOI 10.1074/jbc.271.40.24989; ZINKER S, 1976, J BIOL CHEM, V251, P1799	69	70	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14434	14441		10.1074/jbc.272.22.14434	http://dx.doi.org/10.1074/jbc.272.22.14434			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162083	hybrid			2022-12-27	WOS:A1997XB49200070
J	Hsu, YT; Youle, RJ				Hsu, YT; Youle, RJ			Nonionic detergents induce dimerization among members of the Bcl-2 family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD PHOTORECEPTOR CELLS; GATED CHANNEL; PROTEIN; DEATH; BAX; BCL-X(L); CLONING; HETERODIMERIZATION; TRANSLOCATION; MITOCHONDRIA	Members of the Bcl-2 family (including Bcl-2, Bcl-X-L, and Bax) play key roles in the regulation of apoptosis. These proteins are believed to be membrane-associated and have been proposed to regulate apoptosis through both homodimerization and heterodimerization. We have found that whereas Bcl-2 is predominantly membrane-associated as previously reported, significant amounts of Bcl-X-L and most of the Bax proteins are not membrane-associated and thus appear in the cytosolic fraction of thymocyte and splenocyte extracts, This finding allows the study of the dimerization properties and conformation of these proteins in the absence of detergent perturbation. For this analysis, we have produced monoclonal antibodies that are specific for known epitopes of Bax, Bcl-2, and Bcl-X-L. An antibody to an N-terminal epitope (alpha uBax 6A7) between amino acids 12 and 24 fails to bind the soluble cytosolic form of Bax, indicating that this epitope is normally buried. Nonionic detergents alter the fax conformation to expose this epitope. In the presence of nonionic detergent, the 6A7 antibody avidly binds the monomeric form of fax, but not Bax complexed with either Bcl-X, or Bcl-2. In contrast, a monoclonal antibody to an adjacent epitope of Bax (alpha mBax 5B7) within amino acids 3-16 binds the soluble and detergent-altered forms of fax and also binds the Bax.Bcl-X-L or the Bax.Bcl-2 complex. Surprisingly, in the absence of detergent Bax fails to form homodimers or heterodimers with Bcl-X-L. These results demonstrate a novel conformational state of members of the Bcl-2 family under a physiological condition that is distinct from the detergent-altered state that forms dimers and is currently believed to regulate apoptosis.	NINCDS, BIOCHEM SECT, SURG NEUROL BRANCH, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)								BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Decker LA., 1977, WORTHINGTON ENZYME M, DOI [10.1002/tox.20212, DOI 10.1002/TOX.20212]; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HSU YT, 1994, J BIOL CHEM, V269, P29765; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADDEN EA, 1987, ANAL BIOCHEM, V163, P350, DOI 10.1016/0003-2697(87)90235-1; MOLDAY LL, 1990, J BIOL CHEM, V265, P18690; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1995, HEMATOL ONCOL CLIN N, V9, P451, DOI 10.1016/S0889-8588(18)30104-7; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; TSUJIMOTO Y, 1987, ONCOGENE, V2, P3; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	30	502	523	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13829	13834		10.1074/jbc.272.21.13829	http://dx.doi.org/10.1074/jbc.272.21.13829			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153240	hybrid			2022-12-27	WOS:A1997XA06200055
J	Overdier, DG; Ye, HG; Peterson, RS; Clevidence, DE; Costa, RH				Overdier, DG; Ye, HG; Peterson, RS; Clevidence, DE; Costa, RH			The winged helix transcriptional activator HFH-3 is expressed in the distal tubules of embryonic and adult mouse kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE NUCLEAR FACTOR-3-ALPHA; GENE FORK-HEAD; DNA-BINDING; MESSENGER-RNAS; DIFFERENTIAL EXPRESSION; DEFINITIVE ENDODERM; DOMAIN FAMILY; RAT-KIDNEY; E-CADHERIN; PROTEIN	The hepatocyte nuclear factor-3 (HNF-3)/fork head homolog (HFH) proteins are an extensive family of transcription factors, which share homology in the winged helix DNA binding domain. Members of the HFH/winged helix family have been implicated in cell fate determination during pattern formation, in organogenesis, and in cell-type-specific gene expression. In this study we isolated a full-length HFH-3 cDNA clone from a human kidney library which encoded a 351-amino acid protein containing a centrally located winged helix DNA binding domain. We demonstrate that HFH-3 is a potent transcriptional activator requiring 138 C-terminal residues for activity. We used in situ hybridization to demonstrate that HFH-3 expression is restricted to the epithelium of the renal distal convoluted tubules. We determined the HFH-3 DNA binding consensus sequence by in vitro DNA binding site selection using recombinant HFH-3 protein and used this consensus sequence to identify putative HFH-3 target genes expressed there. These putative HFH-3 target genes include the Na/K-ATPase, Na/H and anion exchangers, E-cadherin, and mineralocorticoid receptor genes as well as genes for the transcription factors HNF-1, vHNP-1, and HNF-4.	UNIV ILLINOIS,COLL MED,DEPT BIOCHEM MC 536,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043241] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM43241-07] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN KY, 1993, AM J PHYSIOL, V265, pF792, DOI 10.1152/ajprenal.1993.265.6.F792; ANG SL, 1993, DEVELOPMENT, V119, P1301; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BINGLE CD, 1995, BIOCHEM J, V308, P197, DOI 10.1042/bj3080197; CEREGHINI S, 1992, DEVELOPMENT, V116, P783; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLEVIDENCE DE, 1994, DEV BIOL, V166, P195, DOI 10.1006/dbio.1994.1307; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; COSTA RH, 1994, LIVER GENE TRANSCRIP, P183; DEMAUREX N, 1995, J GEN PHYSIOL, V106, P85, DOI 10.1085/jgp.106.1.85; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; DUNCAN SA, 1994, P NATL ACAD SCI USA, V91, P7598, DOI 10.1073/pnas.91.16.7598; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; HACKETT BP, 1995, P NATL ACAD SCI USA, V92, P4249, DOI 10.1073/pnas.92.10.4249; HATINI V, 1994, J NEUROBIOL, V25, P1293, DOI 10.1002/neu.480251010; Hatini V, 1996, GENE DEV, V10, P1467, DOI 10.1101/gad.10.12.1467; HROMAS R, 1995, CRIT REV ONCOL HEMAT, V20, P129, DOI 10.1016/1040-8428(94)00151-I; Kaestner KH, 1996, DEVELOPMENT, V122, P1751; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LAZZARO D, 1992, DEVELOPMENT, V114, P469; LI J, 1995, CANCER RES, V55, P5540; LI J, 1993, P NATL ACAD SCI USA, V90, P4490, DOI 10.1073/pnas.90.10.4490; LOMBES M, 1990, P NATL ACAD SCI USA, V87, P1086, DOI 10.1073/pnas.87.3.1086; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIURA N, 1993, FEBS LETT, V326, P171, DOI 10.1016/0014-5793(93)81785-X; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; Nehls M, 1996, SCIENCE, V272, P886, DOI 10.1126/science.272.5263.886; OBERLEITHNER H, 1987, P NATL ACAD SCI USA, V84, P1464, DOI 10.1073/pnas.84.5.1464; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; ORLOWSKI J, 1988, J BIOL CHEM, V263, P10436; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; Peterson RS, 1997, CELL GROWTH DIFFER, V8, P69; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Power SC, 1996, MOL CELL BIOL, V16, P778; QIAN XB, 1995, NUCLEIC ACIDS RES, V23, P1184, DOI 10.1093/nar/23.7.1184; QIAN XB, 1995, MOL CELL BIOL, V15, P1364; ROLAND BL, 1995, MOL CELL ENDOCRINOL, V111, pR1, DOI 10.1016/0303-7207(95)03559-P; SAHR KE, 1994, GENOMICS, V24, P491, DOI 10.1006/geno.1994.1658; SASAKI H, 1993, DEVELOPMENT, V118, P47; SHORE EM, 1991, J BIOL CHEM, V266, P19672; STANTON BA, 1986, J CLIN INVEST, V78, P1612, DOI 10.1172/JCI112754; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; TARAVIRAS S, 1994, MECH DEVELOP, V48, P67, DOI 10.1016/0925-4773(94)90017-5; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WU JC, 1993, BIOCHEM BIOPH RES CO, V195, P1329, DOI 10.1006/bbrc.1993.2189; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	52	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13725	13730		10.1074/jbc.272.21.13725	http://dx.doi.org/10.1074/jbc.272.21.13725			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153225	hybrid			2022-12-27	WOS:A1997XA06200040
J	Jorgensen, S; Vorgias, CE; Antranikian, G				Jorgensen, S; Vorgias, CE; Antranikian, G			Cloning, sequencing, characterization, and expression of an extracellular alpha-amylase from the hyperthermophilic archaeon Pyrococcus furiosus in Escherichia coli and Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCES; NUCLEOTIDE-SEQUENCE; AMYLOLYTIC ENZYME; SP-NOV; ARCHAEBACTERIUM; GENE; DNA; STRAINS; WOESEI	A gene encoding a highly thermostable extracellular alpha-amylase from the hyperthermophilic archaeon Pyrococcus furiosus was identified, The gene was cloned, sequenced, and expressed in Escherichia coli and Bacillus subtilis. The gene is 1383 base pairs long and encodes a protein of 461 amino acids, The open reading frame of the gene was Verified by microsequencing of the recombinant purified enzyme. The deduced amino acid sequence is 25 amino acids longer at the N terminus than that determined by sequencing of the purified protein, suggesting that a leader sequence is removed during transport of the enzyme across the membrane. The recombinant alpha-amylase was biochemically characterized and shows an activity optimum at pH 4.5, whereas the optimun temperature for enzymatic activity is close to 100 degrees C. alpha-Amylase shows sequence homology to the other known alpha-amylases and belongs to family 13 of glycosyl hydrolases. This extracellular alpha-amylase is not homologous to the subcellular alpha-amylase previously isolated from the same organism.	TECH UNIV HAMBURG,INST BIOTECHNOL,DEPT TECH MICROBIOL,D-21071 HAMBURG,GERMANY; NOVO NORDISK AS,DK-2880 BAGSVAERD,DENMARK; UNIV ATHENS,DEPT BIOL,DIV BIOCHEM & MOL BIOL,ATHENS 15071,GREECE	Hamburg University of Technology; Novo Nordisk; National & Kapodistrian University of Athens								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; [Anonymous], 1983, METHODS ENZYMATIC AN; ANTRANIKIAN G, 1990, FEMS MICROBIOL LETT, V75, P201, DOI 10.1111/j.1574-6968.1990.tb04095.x; BROWN SH, 1990, APPL ENVIRON MICROB, V56, P1985, DOI 10.1128/AEM.56.7.1985-1991.1990; DIDERICHSEN B, 1990, J BACTERIOL, V172, P4315, DOI 10.1128/jb.172.8.4315-4321.1990; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; Fritsch EF, 1986, MOL CLONING LAB MANU, V2nd; FUJITA M, 1989, J BACTERIOL, V171, P1333, DOI 10.1128/jb.171.3.1333-1339.1989; FUKUSUMI S, 1988, EUR J BIOCHEM, V174, P15, DOI 10.1111/j.1432-1033.1988.tb14056.x; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HUANG N, 1990, PLANT MOL BIOL, V14, P655, DOI 10.1007/BF00016499; KIESER T, 1984, PLASMID, V12, P19, DOI 10.1016/0147-619X(84)90063-5; KOCH R, 1990, FEMS MICROBIOL LETT, V71, P21, DOI 10.1111/j.1574-6968.1990.tb03792.x; LADERMAN KA, 1993, J BIOL CHEM, V268, P24402; LADERMAN KA, 1993, J BIOL CHEM, V268, P24394; LEUSCHNER C, 1995, WORLD J MICROB BIOT, V11, P95, DOI 10.1007/BF00339139; NAKAJIMA R, 1986, APPL MICROBIOL BIOT, V23, P355; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PITCHER DG, 1989, LETT APPL MICROBIOL, V8, P151, DOI 10.1111/j.1472-765X.1989.tb00262.x; RAHA M, 1992, J BACTERIOL, V174, P6644, DOI 10.1128/JB.174.20.6644-6652.1992; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YASBIN RE, 1975, J BACTERIOL, V121, P296, DOI 10.1128/JB.121.1.296-304.1975; YUUKI T, 1985, J BIOCHEM-TOKYO, V98, P1147, DOI 10.1093/oxfordjournals.jbchem.a135381; ZILLIG W, 1987, SYST APPL MICROBIOL, V9, P62, DOI 10.1016/S0723-2020(87)80057-7; ZWICKL P, 1990, J BACTERIOL, V172, P4329, DOI 10.1128/jb.172.8.4329-4338.1990	27	96	113	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16335	16342		10.1074/jbc.272.26.16335	http://dx.doi.org/10.1074/jbc.272.26.16335			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195939	hybrid			2022-12-27	WOS:A1997XG01900043
J	Stranick, KS; Zambas, DN; Uss, AS; Egan, RW; Billah, MM; Umland, SP				Stranick, KS; Zambas, DN; Uss, AS; Egan, RW; Billah, MM; Umland, SP			Identification of transcription factor binding sites important in the regulation of the human interleukin-5 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE PROMOTER ELEMENTS; CELL RECEPTOR STIMULATION; LYMPHOCYTE-T ACTIVATION; NUCLEAR FACTOR; DIFFERENTIAL REGULATION; INDUCIBLE ENHANCER; MOLECULAR-CLONING; NF-Y; EXPRESSION; PROTEINS	This study identifies three regions of the human interleukin (IL)-5 promoter involved in binding nuclear factors from activated T cells. DNase I footprinting and mobility shift assays with nuclear proteins from the human T cell clone, SP-B21, demonstrated protein interactions with each of these response elements (REs), located between positions -79 and -45 (RE-I), -123 and -92 (RE-II), and -170 and -130 (RE-III). Two of these regions, RE-II and RE-III, have not previously been described to regulate IL-5 expression in T cells. The RE-II site was shown to be critical for inducible IL-5 promoter activity in transient transfection assays in D10.G4.1 T cells, while the RE-III site functions as a negative regulatory element. The activity of the RE-II site was specifically inhibited by cyclosporin A, and transfection assays with IL-5 constructs containing mutations in the RE-II site showed greatly reduced reporter gene activity. We have defined the sequence involved in stimulation-dependent transcription and have identified constitutive as well as inducible DNA-binding protein complexes that bind to RE-II. Antibodies against at least two members of the nuclear factor of activated T cells (NFAT) family of transcription factors are capable of binding to the IL-5 RE-II complexes, although they can be distinguished from previously identified NFAT-specific complexes by several characteristics.			Stranick, KS (corresponding author), SCHERING PLOUGH CORP,RES INST,DEPT ALLERGY,2015 GALLOPING HILL RD,KENILWORTH,NJ 07033, USA.							Ausubel FM., 2006, ENZYMATIC MANIPULATI; BOHJANEN PR, 1990, P NATL ACAD SCI USA, V87, P5283, DOI 10.1073/pnas.87.14.5283; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BOURKE PF, 1995, BLOOD, V85, P2069, DOI 10.1182/blood.V85.8.2069.bloodjournal8582069; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL HD, 1987, P NATL ACAD SCI USA, V84, P6629, DOI 10.1073/pnas.84.19.6629; CHAND N, 1992, EUR J PHARMACOL, V211, P121, DOI 10.1016/0014-2999(92)90273-7; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DAVYDOV IV, 1995, J IMMUNOL, V155, P5273; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GRUARTGOUILLEUX V, 1995, EUR J IMMUNOL, V25, P1431, DOI 10.1002/eji.1830250544; GULBENKIAN AR, 1992, AM REV RESPIR DIS, V146, P263, DOI 10.1164/ajrccm/146.1.263; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; JENKINS F, 1995, J IMMUNOL, V155, P1240; KAMOGAWA Y, 1993, CELL, V75, P985, DOI 10.1016/0092-8674(93)90542-X; KITA H, 1992, J IMMUNOL, V149, P629; LEE HJ, 1995, J BIOL CHEM, V270, P17541, DOI 10.1074/jbc.270.29.17196; LEE HJ, 1993, J IMMUNOL, V151, P6135; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MAUSER PJ, 1993, AM REV RESPIR DIS, V148, P1623, DOI 10.1164/ajrccm/148.6_Pt_1.1623; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; Mori A, 1996, J IMMUNOL, V156, P2400; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Nagai Hiroichi, 1993, Life Sciences, V53, P243; NAORA H, 1995, EXP HEMATOL, V23, P597; NAORA H, 1994, J IMMUNOL, V152, P5691; NIMER S, 1990, MOL CELL BIOL, V10, P6084, DOI 10.1128/MCB.10.11.6084; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; PARK JH, 1993, J BIOL CHEM, V268, P6299; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; PRIESCHL EE, 1995, J IMMUNOL, V154, P6112; RAO A, 1995, J LEUKOCYTE BIOL, V57, P536, DOI 10.1002/jlb.57.4.536; ROMAGNANI S, 1995, J CLIN IMMUNOL, V15, P121, DOI 10.1007/BF01543103; RONCAROLO MG, 1988, J EXP MED, V168, P2139, DOI 10.1084/jem.168.6.2139; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; Sambrook J., 2002, MOL CLONING LAB MANU; SERFLING E, 1995, BBA-GENE STRUCT EXPR, V1263, P181, DOI 10.1016/0167-4781(95)00112-T; SHANNON MF, 1988, P NATL ACAD SCI USA, V85, P674, DOI 10.1073/pnas.85.3.674; SHEPHERD NS, 1994, P NATL ACAD SCI USA, V91, P2629, DOI 10.1073/pnas.91.7.2629; STRANICK KS, 1995, J BIOL CHEM, V270, P20575, DOI 10.1074/jbc.270.35.20575; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; TODD MD, 1993, J EXP MED, V177, P1663, DOI 10.1084/jem.177.6.1663; Tsuruta L, 1995, J ALLERGY CLIN IMMUN, V96, P1126, DOI 10.1016/S0091-6749(95)70197-4; VANDERPOUWKRAAN T, 1992, EUR J IMMUNOL, V22, P1237, DOI 10.1002/eji.1830220519; WARREN DJ, 1988, J IMMUNOL, V140, P94; WATANABE S, 1994, INT IMMUNOL, V6, P523, DOI 10.1093/intimm/6.4.523; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; WOLFF CHJ, 1993, J IMMUNOL, V151, P1337; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YAMAGATA T, 1995, MOL CELL BIOL, V15, P3830; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737; YSSEL H, 1984, J IMMUNOL METHODS, V72, P219, DOI 10.1016/0022-1759(84)90450-2	62	46	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16453	16465		10.1074/jbc.272.26.16453	http://dx.doi.org/10.1074/jbc.272.26.16453			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195954	hybrid			2022-12-27	WOS:A1997XG01900058
J	Chaudhry, MA; Weinfeld, M				Chaudhry, MA; Weinfeld, M			Reactivity of human apurinic/apyrimidinic endonuclease and Escherichia coli exonuclease III with bistranded abasic sites in DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; APURINIC APYRIMIDINIC ENDONUCLEASES; MULTIPLY DAMAGED SITES; MAMMALIAN-CELLS; REPAIR; NEOCARZINOSTATIN; MUTAGENESIS; INDUCTION; CLEAVAGE; GLYCOSYLASE	Several oxidative DNA-damaging agents, including ionizing radiation, can generate multiply damaged sites in DNA, Among the postulated lesions are those with abasic sites located in close proximity on opposite strands, The repair of all abasic site requires strand scission by a repair endonuclease such as human apurinic/apyrimidinic endonuclease (Ape) or exonuclease LII in Escherichia coli, Therefore, a potential consequence of the ''repair'' of bistranded abasic sites is the formation of double-strand breaks, To test this possibility and to investigate the influence of the relative distance between the two abasic sites and their orientation to each other, we prepared a series of oligonucleotide duplexes containing abasic sites at defined positions either directly opposite each other or separated by 1, 3, or 5 base pairs in the 5'- or 3'-direction. Analysis following Ape and exonuclease III treatment of these substrates indicated a variety of responses, In general, cleavage at abasic sites was slower in duplexes with paired lesions than in control duplexes with single lesions, Double-strand breaks were, however, readily generated. in duplexes with abasic sites positioned 3' to each other. With the duplex containing abasic sites set 1 base pair apart, 5' to each other, both Ape and exonuclease III slowly cleaved the abasic sits an one strand only and were unable to incise the other strand, With the duplex containing abasic sites set 3 base pairs apart, 5' to each other, Ape protein was unable to cleave either strand, These data suggest that closely positioned abasic sites could have several deleterious consequences in the cell, In addition, this approach has allowed us to map bases that make significant contact with the enzymes when acting an an abasic site on the opposite strand.	CROSS CANC INST, RADIOBIOL PRGRAM, EDMONTON, AB T6G 1Z2, CANADA	University of Alberta								AHNSTROM G, 1982, INT J RADIAT BIOL, V41, P671, DOI 10.1080/09553008214550761; ASAHARA H, 1989, BIOCHEMISTRY-US, V28, P4444, DOI 10.1021/bi00436a048; BONURA T, 1975, P NATL ACAD SCI USA, V72, P4265, DOI 10.1073/pnas.72.11.4265; BRENNER DJ, 1992, INT J RADIAT BIOL, V61, P737, DOI 10.1080/09553009214551591; CHAUDHRY MA, 1995, NUCLEIC ACIDS RES, V23, P3805, DOI 10.1093/nar/23.19.3805; CHAUDHRY MA, 1995, J MOL BIOL, V249, P914; CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DEVCHAND PR, 1993, NUCLEIC ACIDS RES, V21, P3437, DOI 10.1093/nar/21.15.3437; DUGLE DL, 1976, P NATL ACAD SCI USA, V73, P809, DOI 10.1073/pnas.73.3.809; EFTEDAL I, 1993, NUCLEIC ACIDS RES, V21, P2095, DOI 10.1093/nar/21.9.2095; Gelfand CA, 1996, BIOPOLYMERS, V38, P439; GOODHEAD DT, 1994, INT J RADIAT BIOL, V65, P7, DOI 10.1080/09553009414550021; ILLIAKIS G, 1991, BIOESSAYS, V13, P641; KAPPEN LS, 1989, BIOCHEMISTRY-US, V28, P1027, DOI 10.1021/bi00429a016; LEVIN JD, 1991, J BIOL CHEM, V266, P22893; LEVIN JD, 1990, NUCLEIC ACIDS RES, V18, P5069, DOI 10.1093/nar/18.17.5069; LINN S, 1985, NUCLEASES, P59; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; MESCHWITZ SM, 1992, BIOCHEMISTRY-US, V31, P9117, DOI 10.1021/bi00153a001; MILLIGAN JR, 1995, RADIAT RES, V143, P273, DOI 10.2307/3579213; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; POVIRK LF, 1988, J BIOL CHEM, V263, P19263; POVIRK LF, 1985, P NATL ACAD SCI USA, V82, P3182, DOI 10.1073/pnas.82.10.3182; POVIRK LF, 1988, BIOCHEMISTRY-US, V27, P3850, DOI 10.1021/bi00410a049; PRISE KM, 1993, RADIAT RES, V134, P102, DOI 10.2307/3578507; PRISE KM, 1994, INT J RADIAT BIOL, V65, P43, DOI 10.1080/09553009414550061; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; Rogers S G, 1980, Methods Enzymol, V65, P201; Sambrook J., 2002, MOL CLONING LAB MANU; Shida T, 1996, NUCLEIC ACIDS RES, V24, P4572, DOI 10.1093/nar/24.22.4572; STEIGHNER RJ, 1990, P NATL ACAD SCI USA, V87, P8350, DOI 10.1073/pnas.87.21.8350; TAKESHITA M, 1994, NUCLEIC ACIDS RES, V22, P1897, DOI 10.1093/nar/22.10.1897; TAKEUCHI M, 1994, J BIOL CHEM, V269, P21907; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Wilson DM, 1997, NUCLEIC ACIDS RES, V25, P933, DOI 10.1093/nar/25.5.933	38	133	148	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15650	15655		10.1074/jbc.272.25.15650	http://dx.doi.org/10.1074/jbc.272.25.15650			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188454	hybrid			2022-12-27	WOS:A1997XF32900014
J	Exton, JH				Exton, JH			New developments in phospholipase D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ADP-RIBOSYLATION-FACTOR; PROTEIN-KINASE-C; GTP-BINDING PROTEIN; CELL-FREE ACTIVATION; PHOSPHATIDIC-ACID; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PARTIAL-PURIFICATION; HUMAN NEUTROPHILS; NADPH OXIDASE; HL-60 CELLS		VANDERBILT UNIV,DEPT PHYSIOL & MOL BIOPHYS,SCH MED,NASHVILLE,TN 37232	Vanderbilt University	Exton, JH (corresponding author), VANDERBILT UNIV,HOWARD HUGHES MED INST,SCH MED,221 KIRKLAND HALL,NASHVILLE,TN 37232, USA.							Abousalham A, 1997, J BIOL CHEM, V272, P1069, DOI 10.1074/jbc.272.2.1069; BALBOA MA, 1995, J BIOL CHEM, V270, P29843; BOARDER MR, 1994, TRENDS PHARMACOL SCI, V15, P57, DOI 10.1016/0165-6147(94)90111-2; BOURGOIN S, 1995, J BIOL CHEM, V270, P3172, DOI 10.1074/jbc.270.7.3172; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Bunemann M, 1996, EMBO J, V15, P5527, DOI 10.1002/j.1460-2075.1996.tb00937.x; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; Cockcroft S, 1996, CHEM PHYS LIPIDS, V80, P59, DOI 10.1016/0009-3084(96)02546-7; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; CONRICODE KM, 1994, FEBS LETT, V342, P149, DOI 10.1016/0014-5793(94)80490-7; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; EXTON JH, 1997, IN PRESS PHYSL REV; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; GENY B, 1995, EUR J BIOCHEM, V231, P31, DOI 10.1111/j.1432-1033.1995.tb20666.x; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; HA KS, 1993, J BIOL CHEM, V268, P10534; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Han JS, 1996, J BIOL CHEM, V271, P11163, DOI 10.1074/jbc.271.19.11163; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HOULE MG, 1995, J BIOL CHEM, V270, P22795, DOI 10.1074/jbc.270.39.22795; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; Kanfer JN, 1996, FEBS LETT, V383, P6, DOI 10.1016/0014-5793(96)00205-0; Kim JH, 1996, J BIOL CHEM, V271, P25213, DOI 10.1074/jbc.271.41.25213; KLEIN J, 1995, J NEUROCHEM, V65, P1445; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; KWAK JY, 1995, J BIOL CHEM, V270, P27093, DOI 10.1074/jbc.270.45.27093; LAMBETH JD, 1995, J BIOL CHEM, V270, P2431, DOI 10.1074/jbc.270.6.2431; Liscovitch M, 1996, CHEM PHYS LIPIDS, V80, P37, DOI 10.1016/0009-3084(96)02544-3; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LOPEZ I, 1995, J BIOL CHEM, V270, P19465, DOI 10.1074/jbc.270.33.19465; Lukowski S, 1996, J BIOL CHEM, V271, P24164, DOI 10.1074/jbc.271.39.24164; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MCPHAIL LC, 1995, P NATL ACAD SCI USA, V92, P7931, DOI 10.1073/pnas.92.17.7931; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; Morris AJ, 1996, TRENDS PHARMACOL SCI, V17, P182, DOI 10.1016/0165-6147(96)10016-X; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Nakamura SI, 1996, P NATL ACAD SCI USA, V93, P4300, DOI 10.1073/pnas.93.9.4300; Nakamura Y, 1996, J IMMUNOL, V156, P256; Ohguchi K, 1996, J BIOL CHEM, V271, P4366; OJIO K, 1996, BIOCHEM BIOPH RES CO, V234, P591; OKAHUMA SI, 1994, J BIOL CHEM, V269, P31207; Olson SC, 1996, CHEM PHYS LIPIDS, V80, P3, DOI 10.1016/0009-3084(96)02541-8; PAUL A, 1994, TRENDS PHARMACOL SCI, V15, P174, DOI 10.1016/0165-6147(94)90140-6; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; Ponting CP, 1996, PROTEIN SCI, V5, P914; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; Provost JJ, 1996, BIOCHEM J, V319, P285, DOI 10.1042/bj3190285; QUALLIOTINEMANN D, 1993, J BIOL CHEM, V268, P23843; Ribbes G, 1996, BIOCHEM BIOPH RES CO, V224, P206, DOI 10.1006/bbrc.1996.1008; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Rose K, 1995, P NATL ACAD SCI USA, V92, P12151, DOI 10.1073/pnas.92.26.12151; RUMENAPP U, 1995, EUR J BIOCHEM, V234, P240, DOI 10.1111/j.1432-1033.1995.240_c.x; Schmidt M, 1996, J BIOL CHEM, V271, P2422, DOI 10.1074/jbc.271.5.2422; Schmidt M, 1996, EUR J BIOCHEM, V240, P707, DOI 10.1111/j.1432-1033.1996.0707h.x; Shimooku K, 1996, FEBS LETT, V387, P141, DOI 10.1016/0014-5793(96)00483-8; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; Singer WD, 1996, J BIOL CHEM, V271, P4504; Spiegel S, 1996, CHEM PHYS LIPIDS, V80, P27, DOI 10.1016/0009-3084(96)02543-1; Steed PM, 1996, BIOCHEMISTRY-US, V35, P5229, DOI 10.1021/bi952370j; Takahashi K, 1996, J IMMUNOL, V156, P1229; Venable ME, 1996, J BIOL CHEM, V271, P24800, DOI 10.1074/jbc.271.40.24800; Whatmore J, 1996, BIOCHEM J, V320, P785, DOI 10.1042/bj3200785; Yoshimura S, 1996, BIOCHEM BIOPH RES CO, V225, P494, DOI 10.1006/bbrc.1996.1201	77	285	289	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15579	15582		10.1074/jbc.272.25.15579	http://dx.doi.org/10.1074/jbc.272.25.15579			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188441	hybrid			2022-12-27	WOS:A1997XF32900001
J	Jeannin, P; Delneste, Y; LecoanetHenchoz, S; Gauchat, JF; Ellis, J; Bonnefoy, JY				Jeannin, P; Delneste, Y; LecoanetHenchoz, S; Gauchat, JF; Ellis, J; Bonnefoy, JY			CD86 (B7-2) on human B cells - A functional role in proliferation and selective differentiation into IgE- and IgG4-producing cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-CD40 MONOCLONAL-ANTIBODIES; T-CELLS; STIMULATION PROVIDES; MESSENGER-RNA; SOLUBLE FORM; 2ND LIGAND; CTLA-4; ACTIVATION; CD28; EXPRESSION	Immunoglobulin (Ig) E production by B cells requires two primary signals provided by T cells, interleukin (IL)-4 or IL-13 and CD40 ligand (CD40L), In addition, costimulatory signals, such as CD23-CD21 interaction, contribute further ensuring a selective control over this production. Recently, CD28, expressed on T cells, has been reported to be involved in this process, The CD28 ligands, CD80 (B7-1) and CD86 (B7-2), are expressed on human tonsillar B cells, and their expression is up-regulated by IL-4, IL-13, and/or an anti-CD40 monoclonal antibody (mAb), We have investigated whether signaling via the B7 molecules affects IgE synthesis, Human B cells were stimulated by IL-4 plus anti CD40 mAb in the presence of different anti-B7 mAbs. Cross-linking of CD86 with IT2.2 potentiated IgE and IgG4 production and E transcripts expression, The production of the other isotypes was not modulated, Conversely, the anti-CD80 and the other anti-CD86 mAbs tested had no effect, The increase of IgE and IgG4 production induced by IT2.2 was accompanied by an increase in proliferation, in cell surface density of CD23, and in CD23 binding to CD21-expressing B cells, In contrast, the expression of other B cell surface molecules such as CD11a, CD30, and CD58 remained unaffected, Since IT2.2 favors CD23-CD21 pairing, we tested whether blocking this interaction affected IT2.2-increased IgE production, The neutralizing anti-CD23 mAb, Mab 25, caused a dose-dependent inhibition of the effect of IT2.2 on IgE synthesis, Finally, IT2.2 potentiation on B cell proliferation and IgE production required the two primary signals, IL-4 and anti-CD40 mAb, since IT2.2 alone or in combination with only one of these stimuli did not show any effect on B cells, This study is the first demonstration of a signaling role for CD86, Together with IL-4 or IL-13 and CD40L, CD86 favors CD23-CD21 pairing and consequently functions as a selective and potent costimulus for human IgE and IgG4 synthesis.	GLAXO WELLCOME RES & DEV LTD,GENEVA BIOMED RES INST,DEPT IMMUNOL,CH-1228 PLAN LES OUATES,GENEVA,SWITZERLAND; GLAXOWELLCOME MED RES CTR,IMMUNOPATHOL UNIT,STEVENAGE SG1 2NY,HERTS,ENGLAND	GlaxoSmithKline; GlaxoSmithKline			Delneste, Yves/O-3956-2016; DELNESTE, Yves/K-7367-2015; JEANNIN, Pascale/K-8656-2015	DELNESTE, Yves/0000-0002-2142-596X; JEANNIN, Pascale/0000-0002-3666-3856				AUBRY JP, 1994, J IMMUNOL, V152, P5806; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; AZUMA M, 1993, NATURE, V366, P76, DOI 10.1038/366076a0; BONNEFOY JY, 1990, EUR J IMMUNOL, V20, P139, DOI 10.1002/eji.1830200120; BOUSSIOTIS VA, 1993, P NATL ACAD SCI USA, V90, P11059, DOI 10.1073/pnas.90.23.11059; CAUX C, 1994, J EXP MED, V180, P1841, DOI 10.1084/jem.180.5.1841; CLARK EA, 1989, J IMMUNOL, V143, P3873; DEBOER M, 1993, EUR J IMMUNOL, V23, P3120, DOI 10.1002/eji.1830231212; DEFRANCE T, 1987, J EXP MED, V165, P1459, DOI 10.1084/jem.165.6.1459; DIAZSANCHEZ D, 1994, J IMMUNOL, V153, P10; ELLIS JH, 1996, J IMMUNOL, V56, P2700; ENGEL P, 1994, BLOOD, V84, P1402, DOI 10.1182/blood.V84.5.1402.bloodjournal8451402; FREEMAN GJ, 1989, J IMMUNOL, V143, P2714; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; FREEMAN GJ, 1995, IMMUNITY, V2, P523, DOI 10.1016/1074-7613(95)90032-2; FREEMAN GJ, 1992, J IMMUNOL, V149, P3795; GASCAN H, 1991, J IMMUNOL, V147, P8; GAUCHAT JF, 1993, FEBS LETT, V315, P259, DOI 10.1016/0014-5793(93)81175-Y; GAUCHAT JF, 1992, INT IMMUNOL, V4, P397, DOI 10.1093/intimm/4.3.397; GAUCHAT JF, 1990, J EXP MED, V172, P468; GRIBBEN JG, 1995, P NATL ACAD SCI USA, V92, P811, DOI 10.1073/pnas.92.3.811; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; Hathcock KS, 1996, ADV IMMUNOL, V62, P131, DOI 10.1016/S0065-2776(08)60429-0; HenchozLecoanet S, 1996, IMMUNOLOGY, V88, P35, DOI 10.1046/j.1365-2567.1996.d01-651.x; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; KLAUS SJ, 1994, J IMMUNOL, V152, P5643; KOZBOR D, 1987, J IMMUNOL, V138, P4128; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; KUIPER HM, 1995, J IMMUNOL, V155, P1776; LEBMAN DA, 1988, J EXP MED, V168, P853, DOI 10.1084/jem.168.3.853; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LIFE P, 1995, EUR J IMMUNOL, V25, P333, DOI 10.1002/eji.1830250205; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; LUNDGREN M, 1989, EUR J IMMUNOL, V19, P1311, DOI 10.1002/eji.1830190724; Natesan M, 1996, J IMMUNOL, V156, P2783; POCHON S, 1992, J EXP MED, V176, P389, DOI 10.1084/jem.176.2.389; PUNNONEN J, 1994, ALLERGY, V49, P576, DOI 10.1111/j.1398-9995.1994.tb00122.x; RONCHESE F, 1994, J EXP MED, V179, P809, DOI 10.1084/jem.179.3.809; ROY M, 1995, EUR J IMMUNOL, V25, P596, DOI 10.1002/eji.1830250243; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; STACK RM, 1994, J IMMUNOL, V152, P5723; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Yang YP, 1996, SCIENCE, V273, P1862, DOI 10.1126/science.273.5283.1862; YOKOCHI T, 1982, J IMMUNOL, V128, P823; YOSHINORI K, 1996, EUR J IMMUNOL, V26, P192; ZHANG K, 1991, J IMMUNOL, V146, P1836	49	100	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15613	15619		10.1074/jbc.272.25.15613	http://dx.doi.org/10.1074/jbc.272.25.15613			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188449	hybrid			2022-12-27	WOS:A1997XF32900009
J	Kurosaki, T; Kurosaki, M				Kurosaki, T; Kurosaki, M			Transphosphorylation of Bruton's tyrosine kinase on tyrosine 551 is critical for B cell antigen receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; LYMPHOCYTES	Bruton's tyrosine kinase (Btk) is required for B cell development and B cell antigen receptor (BCR) function. Cross-linking of BCR induces phosphorylation of Btk at Tyr(551) and Tyr(223). However, the functional requirement of these phosphorylation for BCR signaling remains unclear. We demonstrate here that mutation of Tyr(551), not Tyr(223), abrogates the BCR-induced calcium mobilization. Not only Lyn, but also Syk was required for tyrosine phosphorylation of Btk in BCR signaling. These results suggest that transphosphorylation of Btk on Tyr(551) is essential for BCR function and that this phosphorylation is mediated through the concerted actions of Lyn and Syk.			Kurosaki, T (corresponding author), KANSAI MED UNIV,DEPT MOL GENET,INST LIVER RES,MORIGUCHI,OSAKA 570,JAPAN.		Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X				Afar DEH, 1996, MOL CELL BIOL, V16, P3465; Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HINSHELWOOD S, 1995, EUR J IMMUNOL, V25, P1113, DOI 10.1002/eji.1830250439; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; KUROSAKI T, 1997, IN PRESS CURR OPIN I; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31	17	113	114	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15595	15598		10.1074/jbc.272.25.15595	http://dx.doi.org/10.1074/jbc.272.25.15595			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188445	hybrid			2022-12-27	WOS:A1997XF32900005
J	Smith, GK; Banks, S; Blumenkopf, TA; Cory, M; Humphreys, J; Laethem, RM; Miller, J; Moxham, CP; Mullin, R; Ray, PH; Walton, LM; Wolfe, LA				Smith, GK; Banks, S; Blumenkopf, TA; Cory, M; Humphreys, J; Laethem, RM; Miller, J; Moxham, CP; Mullin, R; Ray, PH; Walton, LM; Wolfe, LA			Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G AMIDASE CONJUGATE; MONOCLONAL-ANTIBODIES; CYTOSINE DEAMINASE; SEQUENCE-ANALYSIS; TARGETED ENZYMES; IMMUNE-RESPONSE; CANCER-THERAPY; CDNA CLONING; ACTIVATION; DOXORUBICIN	Antibody-directed enzyme prodrug therapy (ADEPT) has the potential of greatly enhancing antitumor selectivity of cancer therapy by synthesizing chemotherapeutic agents selectively at tumor sites, This therapy is based upon targeting a prodrug-activating enzyme to a tumor by attaching the enzyme to st tumor-selective antibody and dosing the enzyme-antibody conjugate systemically, After the enzyme-antibody conjugate is localized to the tumor the prodrug is then also dosed systemically, and the previously targeted enzyme converts it to the active drug selectively at the tumor, Unfortunately, most enzymes capable of this specific, tumor site generation of drugs are foreign to the human body and as such are expected to raise an immune response when injected, which will limit their repeated administration, Ne reasoned that with the power of crystallography, molecular modeling and site-directed mutagenesis, this problem could be addressed through the development of a human enzyme that is capable of catalyzing a reaction that is otherwise not carried out in the human body, This would then allow use of prodrugs that are otherwise stable in vivo but that are substrates for a tumor-targeted mutant human enzyme, We report here the first test of this concept using the human enzyme carboxypeptidase A1 (hCPA1) and prodrugs of methotrexate (MTX), Based upon a computer model of the human enzyme built from the well known crystal structure of bovine carboxypeptidase A, we have designed and synthesized novel bulky phenylalanine- and tyrosine-based prodrugs of MTX: that are metabolically stable in vivo and are not substrates for wild type human carboxypeptidases A, Two of these analogs are MTX-alpha-3-cyclobutylphenylalanine and MTX-alpha-3-cyclopentyltyrosine, Also based upon the computer model, we have designed and produced a mutant of human carboxypeptidase A1, changed at position 268 from the wild type threonine to a glycine (hCPA1-T268G), This novel enzyme is capable of using the in vivo stable prodrugs, which are not substrates for the wild type hCPA1, as efficiently as the wild type hCPA1 uses its best substrates (i.e. MTX-alpha-phenylalanine). Thus, the k(cat)/K-m value for the wild type hCPA1 with MTX-alpha-phenylalanine is 0.44 mu M-1 s(-1) and k(cat)/K-m values for hCPA1-T286G with MTX-alpha-3-cyclobutylphenylalanine and MTX-alpha-3-cyclopentyltyrosine are 1.8 and 0.16 mu M-1 s(-1) respectively, The cytotoxic efficiency of hCPA1-268G was tested in an in vitro ADEPT model, For this experiment, hCPA1-T268G was chemically conjugated to ING-1, an antibody that binds to the tumor antigen Ep-Cam, or to Campath-1H, an antibody that binds to the T and B cell antigen CDw52, These conjugates mere then incubated with HT-29 human colon adenocarcinoma cells (which express Ep-Cam but not the Campath. 1H antigen) followed by incubation of the cells with the in vivo stable prodrugs. The results showed that the targeted ING-1:hCPA1-T268G conjugate produced excellent activation of the MTX prodrugs to kill HT-29 cells as efficiently as MTX itself, By contrast, the enzyme-Campath 1H conjugate was without effect, These data strongly support the feasibility of ADEPT using a mutated human enzyme with a single amino acid change.			Smith, GK (corresponding author), GLAXO WELLCOME INC,RES & DEV,DEPT MOL BIOCHEM,5 MOORE DR,RES TRIANGLE PK,NC 27709, USA.							BAGSHAWE KD, 1988, BRIT J CANCER, V58, P700, DOI 10.1038/bjc.1988.293; BAGSHAWE KD, 1989, BRIT J CANCER, V60, P275, DOI 10.1038/bjc.1989.270; BIGNAMI GS, 1992, CANCER RES, V52, P5759; Blakey DC, 1996, CANCER RES, V56, P3287; BOSSLET K, 1994, CANCER RES, V54, P2151; CATASUS L, 1992, BIOCHEM J, V287, P299, DOI 10.1042/bj2870299; CATASUS L, 1995, J BIOL CHEM, V270, P6651, DOI 10.1074/jbc.270.12.6651; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; DUCH DS, 1993, CANCER RES, V53, P810; ECCLES SA, 1994, CANCER RES, V54, P5171; ENSMINGER WD, 1984, FOLATE ANTAGONISTS T, V2, P133; FOLK JE, 1963, J BIOL CHEM, V238, P3884; GARDELL SJ, 1985, NATURE, V317, P551, DOI 10.1038/317551a0; GARDELL SJ, 1988, J BIOL CHEM, V263, P17828; HAENSELER E, 1992, BIOCHEMISTRY-US, V31, P891, DOI 10.1021/bi00118a035; HAISMA HJ, 1992, BRIT J CANCER, V66, P474, DOI 10.1038/bjc.1992.298; HUENNEKENS FM, 1994, TRENDS BIOTECHNOL, V12, P234, DOI 10.1016/0167-7799(94)90122-8; JUNGHEIM LN, 1994, CHEM REV, V94, P1553, DOI 10.1021/cr00030a004; KERR DE, 1995, CANCER RES, V55, P3558; KERR DE, 1993, BIOCONJUGATE CHEM, V4, P353, DOI 10.1021/bc00023a008; KUEFNER U, 1989, BIOCHEMISTRY-US, V28, P2288, DOI 10.1021/bi00431a047; Laethem R. M., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P467; Laethem RM, 1996, ARCH BIOCHEM BIOPHYS, V332, P8, DOI 10.1006/abbi.1996.0310; LEDERMANN JA, 1991, INT J CANCER, V47, P659, DOI 10.1002/ijc.2910470505; Liao S K, 1990, Hum Antibodies Hybridomas, V1, P66; LINDMO T, 1984, J IMMUNOL METHODS, V72, P77, DOI 10.1016/0022-1759(84)90435-6; Melton RG, 1996, JNCI-J NATL CANCER I, V88, P153, DOI 10.1093/jnci/88.3-4.153; MEYER DL, 1995, BIOCONJUGATE CHEM, V6, P440, DOI 10.1021/bc00034a014; MEYER DL, 1993, CANCER RES, V53, P3956; PAGE MJ, 1991, BIO-TECHNOL, V9, P64, DOI 10.1038/nbt0191-64; PETERSON LM, 1976, BIOCHEMISTRY-US, V15, P2501, DOI 10.1021/bi00657a001; PHILLIPS MA, 1990, J BIOL CHEM, V265, P20692; QUINTO C, 1982, P NATL ACAD SCI-BIOL, V79, P31, DOI 10.1073/pnas.79.1.31; REICHMANN L, 1988, NATURE, V332, P323; SELL S, 1985, MONOCLONAL ANTIBODIE; SENTER PD, 1990, FASEB J, V4, P188, DOI 10.1096/fasebj.4.2.2404820; SENTER PD, 1989, CANCER RES, V49, P5789; SENTER PD, 1991, BIOCONJUGATE CHEM, V2, P447, DOI 10.1021/bc00012a012; SENTER PD, 1993, BIOCONJUGATE CHEM, V4, P3, DOI 10.1021/bc00019a001; SHARMA SK, 1992, CELL BIOPHYS, V21, P109, DOI 10.1007/BF02789482; SMITH GK, 1995, Patent No. 9513095; SMITH GK, 1995, Patent No. 9402483; Springer C J, 1993, Cell Biophys, V22, P9; SVENSSON HP, 1995, CANCER RES, V55, P2357; TATTERSALL MHN, 1984, FOLATE ANTAGONISTS T, V2, P166; VITOLS KS, 1995, CANCER RES, V55, P478; VRUDHULA VM, 1993, J MED CHEM, V36, P919, DOI 10.1021/jm00059a018; WALLACE PM, 1991, BIOCONJUGATE CHEM, V2, P349, DOI 10.1021/bc00011a010; WANG SM, 1992, CANCER RES, V52, P4484; Wolfe L.a., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P467	50	55	57	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15804	15816		10.1074/jbc.272.25.15804	http://dx.doi.org/10.1074/jbc.272.25.15804			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188478	hybrid			2022-12-27	WOS:A1997XF32900038
J	Kaludov, NK; PabonPena, L; Seavy, M; Robinson, G; Hurt, MM				Kaludov, NK; PabonPena, L; Seavy, M; Robinson, G; Hurt, MM			A mouse histone H1 variant, H1b, binds preferentially to a regulatory sequence within a mouse H3.2 replication-dependent histone gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; IN-VIVO; LINKER HISTONE; TRANSCRIPTION; EXPRESSION; CHROMATIN; DNA; REGION; PROMOTER; STATES	H1 histones, found in all multicellular eukaryotes, associate with Linker DNA between adjacent nucleosomes, presumably to keep the chromatin in a compact, helical state, The identification of multiple histone H1 subtypes in vertebrates suggests these proteins have specialized roles in chromatin organization and thus influence the regulation of gene expression in the multicellular organism, The mechanism by which the association of H1. with nucleosomal DNA is regulated Is not completely understood, but affinity far different DNA sequences may play a role, Here we report that a specific H1 subtype in the mouse, namely H1b, selectively binds to a regulatory element within the protein-encoding sequence of a replication dependent mouse H3.2 gene. We have previously shown that this coding region element, Omega, is the target of very specific interactions in vitro with another nuclear factor called the Omega factor, This element is required for normal gene expression in stably transfected rodent cells. The mouse H1b protein interacts poorly (100-fold lower affinity) with She comparable ''Omega'' sequence of a replication-independent mouse H3.3 gene, This H3.3 sequence differs at only 4 out of 22 nucleotide positions from the H3.2 sequence, Our findings raise the possibility that this H1b protein plays a specific role in regulation of expression of the replication-dependent histone gene family.	FLORIDA STATE UNIV, DEPT SCI BIOL, TALLAHASSEE, FL 32306 USA	State University System of Florida; Florida State University					NIGMS NIH HHS [R01-GM46768] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046768] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AJIRO K, 1990, J BIOL CHEM, V265, P6494; AJIRO K, 1981, BIOCHEMISTRY-US, V20, P1445, DOI 10.1021/bi00509a007; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; BERENT SL, 1984, BIOCHEMISTRY-US, V23, P2977, DOI 10.1021/bi00308a020; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; Bowman TL, 1996, GENE, V176, P1, DOI 10.1016/0378-1119(96)00198-9; BOWMAN TL, 1995, NUCLEIC ACIDS RES, V23, P3083, DOI 10.1093/nar/23.16.3083; BRENEMAN JW, 1993, EXP CELL RES, V206, P16, DOI 10.1006/excr.1993.1115; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; BROWN DT, 1993, J BIOL CHEM, V268, P713; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; COLE RD, 1989, METHOD ENZYMOL, V170, P524; DIEZCABALLERO T, 1981, NUCLEIC ACIDS RES, V9, P1383, DOI 10.1093/nar/9.6.1383; DRABENT B, 1995, MAMM GENOME, V6, P505, DOI 10.1007/BF00356166; ERICSSON C, 1990, CELL, V60, P73, DOI 10.1016/0092-8674(90)90717-S; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HEINTZ N, 1991, BIOCHIM BIOPHYS ACTA, V1088, P327, DOI 10.1016/0167-4781(91)90122-3; HRABARENEVEY S, 1989, NUCLEIC ACIDS RES, V17, P2449, DOI 10.1093/nar/17.7.2449; HURT MM, 1989, P NATL ACAD SCI USA, V86, P4450, DOI 10.1073/pnas.86.12.4450; HURT MM, 1991, MOL CELL BIOL, V11, P2929, DOI 10.1128/MCB.11.6.2929; KADONAGA RD, 1992, ANN REV CELL BIOL, V8, P563; Kaludov NK, 1996, NUCLEIC ACIDS RES, V24, P523, DOI 10.1093/nar/24.3.523; Kaludov NK, 1996, P NATL ACAD SCI USA, V93, P4465, DOI 10.1073/pnas.93.9.4465; KANDOLF H, 1994, P NATL ACAD SCI USA, V91, P7257, DOI 10.1073/pnas.91.15.7257; KISTLER WS, 1975, BIOCHEM BIOPH RES CO, V63, P378, DOI 10.1016/0006-291X(75)90699-3; KRIMER DB, 1993, NUCLEIC ACIDS RES, V21, P2873, DOI 10.1093/nar/21.12.2873; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LEE HL, 1994, MOL CELL BIOL, V14, P32, DOI 10.1128/MCB.14.1.32; LENNOX RW, 1989, METHOD ENZYMOL, V170, P532; LENNOX RW, 1982, J BIOL CHEM, V257, P5183; LENNOX RW, 1983, J BIOL CHEM, V258, P262; LENNOX RW, 1984, J BIOL CHEM, V259, P669; LENNOX RW, 1984, HISTONE GENES STRUCT, P373; LENORMAND JL, 1993, NUCLEIC ACIDS RES, V21, P695, DOI 10.1093/nar/21.3.695; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MENDELSON E, 1986, EUR J BIOCHEM, V160, P253, DOI 10.1111/j.1432-1033.1986.tb09964.x; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.biochem.60.1.827; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; PARSEGHIAN MH, 1994, PROTEIN SCI, V3, P575; PAULI U, 1989, J CELL PHYSIOL, V139, P320, DOI 10.1002/jcp.1041390214; RISTINIEMI J, 1989, J BIOL CHEM, V264, P2164; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; SIROTKIN AM, 1995, P NATL ACAD SCI USA, V92, P6434, DOI 10.1073/pnas.92.14.6434; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; van Holde KE., 1989, SPRINGER SERIES MOL; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WELLMAN SE, 1987, GENE, V59, P29, DOI 10.1016/0378-1119(87)90263-0; Wolffe A., 1995, CHROMATIN STRUCTURE; Wolffe A P, 1991, Trends Cell Biol, V1, P61, DOI 10.1016/0962-8924(91)90091-M; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; WOLFFE AP, 1987, CELL, V51, P732, DOI 10.1016/0092-8674(87)90096-1; WU RS, 1981, CELL, V27, P321, DOI 10.1016/0092-8674(81)90415-3; YANEVA J, 1995, P NATL ACAD SCI USA, V92, P7060, DOI 10.1073/pnas.92.15.7060; ZLATANOVA J, 1991, MOL BIOL REP, V15, P53, DOI 10.1007/BF00369901; ZLATANOVA J, 1990, TRENDS BIOCHEM SCI, V15, P273, DOI 10.1016/0968-0004(90)90053-E; Zweidler A, 1984, HISTONE GENES STRUCT, P339	59	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15120	15127		10.1074/jbc.272.24.15120	http://dx.doi.org/10.1074/jbc.272.24.15120			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182532	hybrid			2022-12-27	WOS:A1997XE03400015
J	Niidome, T; Ohmori, N; Ichinose, A; Wada, A; Mihara, H; Hirayama, T; Aoyagi, H				Niidome, T; Ohmori, N; Ichinose, A; Wada, A; Mihara, H; Hirayama, T; Aoyagi, H			Binding of cationic alpha-helical peptides to plasmid DNA and their gene transfer abilities into cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; MAMMALIAN-CELLS; HEPATOMA-CELLS; CARRIER SYSTEM; LIPOSOMES; EXPRESSION; EFFICIENT; DELIVERY; VIRUSES; LIGAND	Polycationic reagents such as cationic lipids and poly-L-lysine are widely used for gene transfer into cells in vitro and show promise as vectors for in vivo gene therapy applications as nonviral gene transfer techniques, We have developed a novel transfection method using cationic amphiphilic alpha-helical oligopeptides with repeated sequences, Oligopeptide has the advantages of being easily designed and modified because of its simple structure, In this study, we synthesized five kinds of peptides of which the total chain length and the width of the hydrophobic region were changed. The binding of the peptides to plasmid DNA was evaluated by agarose gel electrophoresis, It was found that the long and/or hydrophobic peptides can strongly bind to the DNA, The formation of large aggregates with a 0.5-5-mu m diameter, which consisted of the long peptides and the DNA, was observed by electron microscopy. The transfection abilities of the peptides were determined by the expression of luciferase from its cDNA in COS-7 cells, The long peptides showed high transfection abilities. As: a result, it could be said that the transfection ability of these peptides was parallel to their ability to form aggregates with DNA, Furthermore, the transfection ability was increased by the addition of chloroquine in the transfection procedure, This result indicated that aggregates would be mediated by the endocytosis pathway.	NAGASAKI UNIV,DEPT APPL CHEM,FAC ENGN,NAGASAKI 852,JAPAN; NAGASAKI UNIV,INST TROP MED,CENT LAB,NAGASAKI 852,JAPAN; NAGASAKI UNIV,INST TROP MED,DEPT BACTERIOL,NAGASAKI 852,JAPAN	Nagasaki University; Nagasaki University; Nagasaki University			Mihara, Hisakazu/B-9993-2015; Niidome, Takuro/F-1508-2010	Mihara, Hisakazu/0000-0003-3549-2036; Niidome, Takuro/0000-0002-8070-8708				AGAWA Y, 1991, J BIOL CHEM, V266, P20218; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; CORNETTA K, 1991, HUM GENE THER, V2, P5, DOI 10.1089/hum.1991.2.1-5; DEGRADO WF, 1980, J ORG CHEM, V45, P1295, DOI 10.1021/jo01295a026; FARHOOD H, 1992, BIOCHIM BIOPHYS ACTA, V1111, P239, DOI 10.1016/0005-2736(92)90316-E; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HUCKETT B, 1990, BIOCHEM PHARMACOL, V40, P253, DOI 10.1016/0006-2952(90)90686-F; ITO A, 1990, BIOCHEM INT, V22, P235; KAISER ET, 1989, SCIENCE, V243, P187, DOI 10.1126/science.2492114; LEE S, 1993, BIOCHIM BIOPHYS ACTA, V1151, P76, DOI 10.1016/0005-2736(93)90073-9; LEGENDRE JY, 1992, PHARMACEUT RES, V9, P1235, DOI 10.1023/A:1015836829670; MIDOUX P, 1993, NUCLEIC ACIDS RES, V21, P871, DOI 10.1093/nar/21.4.871; MIHARA H, 1995, J CHEM SOC P1, V2, P1133; MILLER AD, 1990, BLOOD, V76, P271; MOOLTEN FL, 1992, HUM GENE THER, V3, P479, DOI 10.1089/hum.1992.3.5-479; MUZYCZKA N, 1992, CURR TOP MICROBIOL, V158, P97; PLANK C, 1994, J BIOL CHEM, V269, P12918; PLANK C, 1992, BIOCONJUGATE CHEM, V3, P533, DOI 10.1021/bc00018a012; REMY JS, 1995, P NATL ACAD SCI USA, V92, P1744, DOI 10.1073/pnas.92.5.1744; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; SAMULSKI RJ, 1989, J VIROL, V63, P3822, DOI 10.1128/JVI.63.9.3822-3828.1989; SMITH JG, 1993, BIOCHIM BIOPHYS ACTA, V1154, P327, DOI 10.1016/0304-4157(93)90004-8; SUENAGA M, 1989, BIOCHIM BIOPHYS ACTA, V981, P143, DOI 10.1016/0005-2736(89)90092-8; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; WU GY, 1987, J BIOL CHEM, V262, P4429; WU GY, 1994, J BIOL CHEM, V269, P11542; YOSHIMURA T, 1992, BIOCHEMISTRY-US, V31, P6119, DOI 10.1021/bi00141a023	30	145	156	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15307	15312		10.1074/jbc.272.24.15307	http://dx.doi.org/10.1074/jbc.272.24.15307			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182558	hybrid			2022-12-27	WOS:A1997XE03400041
J	Imai, T; Baba, M; Nishimura, M; Kakizaki, M; Takagi, S; Yoshie, O				Imai, T; Baba, M; Nishimura, M; Kakizaki, M; Takagi, S; Yoshie, O			The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-3; MOLECULAR-CLONING; FUNCTIONAL EXPRESSION; MESSENGER-RNA; COUPLED RECEPTOR; LYMPHOCYTES; GENE; CDNA; MIP-1-ALPHA; MIP-1-BETA	Thymus and activation-regulated chemokine (TARC) is a recently identified CC chemokine that is expressed constitutively in thymus and transiently in stimulated peripheral blood mononuclear cells. TARC functions as a selective chemoattractant for T cells that express a class of receptors binding TARC with high affinity and specificity. To identify the receptor for TARC, we produced TARC as a fusion protein with secreted alkaline phosphatase (SEAP) and used it for specific binding. By stably transfecting five orphan receptors and five known CC chemokine receptors (CCR1 to -5) into K562 cells, we found that TARC-SEAP bound selectively to cells expressing CCR4. TARC-SEAP also bound to K562 cells stably expressing CCR4 with a high affinity (K-d = 0.5 nM). Only TARC and not five other CC chemokines (MCP-1 (monocyte chemoattractant protein-1), RANTES (regulated upon activation, normal T cells expressed and secreted), MIP-1 alpha (macrophage inflammatory protein-1 alpha), MIP-1 beta, and LARC (liver and activation-regulated chemokine)) competed with TARC-SEAP for binding to CCR4. TARC but not RANTES or MIP-1 alpha induced migration and calcium mobilization in 293/EBNA-1 cells stably expressing CCR4. K562 cells stably expressing CCR4 also responded to TARC in a calcium mobilization assay. Northern blot analysis revealed that CCR4 mRNA was expressed strongly in human T cell lines and peripheral blood T cells but not in B cells, natural killer cells, monocytes, or granulocytes. Taken together, TARC is a specific functional ligand for CCR4, and CCR4 is the specific receptor for TARC selectively expressed on T cells.			Imai, T (corresponding author), SHIONOGI INST MED SCI,2-5-1 MISHIMA,SETTSU,OSAKA 566,JAPAN.			Yoshie, Osamu/0000-0003-4353-5809				BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; BENBARUCH A, 1995, J BIOL CHEM, V270, P11703, DOI 10.1074/jbc.270.20.11703; BENBARUCH A, 1995, J BIOL CHEM, V270, P22123, DOI 10.1074/jbc.270.38.22123; BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; Chang H C, 1989, Int Immunol, V1, P388, DOI 10.1093/intimm/1.4.388; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COMBADIERE C, 1995, J BIOL CHEM, V270, P29671; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; DOBNER T, 1992, EUR J IMMUNOL, V22, P2795, DOI 10.1002/eji.1830221107; DSouza MP, 1996, NAT MED, V2, P1293, DOI 10.1038/nm1296-1293; FRANCI C, 1995, J IMMUNOL, V154, P6511; FURUTANI Y, 1989, BIOCHEM BIOPH RES CO, V159, P249, DOI 10.1016/0006-291X(89)92430-3; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GRAHAM GJ, 1994, J BIOL CHEM, V269, P4974; Hieshima K, 1997, J BIOL CHEM, V272, P5846, DOI 10.1074/jbc.272.9.5846; Hoogewerf AJ, 1996, BIOCHEM BIOPH RES CO, V218, P337, DOI 10.1006/bbrc.1996.0059; Imai T, 1996, J BIOL CHEM, V271, P21514, DOI 10.1074/jbc.271.35.21514; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; LIPES MA, 1988, P NATL ACAD SCI USA, V85, P9704, DOI 10.1073/pnas.85.24.9704; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; LOETSCHER P, 1994, FASEB J, V8, P1055, DOI 10.1096/fasebj.8.13.7926371; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MILLER MD, 1989, J IMMUNOL, V143, P2907; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Naruse K, 1996, GENOMICS, V34, P236, DOI 10.1006/geno.1996.0274; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Nomiyama H, 1997, GENOMICS, V40, P211, DOI 10.1006/geno.1996.4552; OBARU K, 1986, J BIOCHEM-TOKYO, V99, P885, DOI 10.1093/oxfordjournals.jbchem.a135549; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; OPDENAKKER G, 1993, BIOCHEM BIOPH RES CO, V191, P535, DOI 10.1006/bbrc.1993.1251; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; POWER CA, 1995, CYTOKINE, V7, P479, DOI 10.1006/cyto.1995.0065; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; RAPORT CJ, 1995, GENE, V163, P295, DOI 10.1016/0378-1119(95)00336-5; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SCHALL TJ, 1993, J EXP MED, V177, P1821, DOI 10.1084/jem.177.6.1821; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; SchulzKnappe P, 1996, J EXP MED, V183, P295, DOI 10.1084/jem.183.1.295; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809; TAUB DD, 1995, J CLIN INVEST, V95, P1370, DOI 10.1172/JCI117788; Uguccioni M, 1996, J EXP MED, V183, P2379, DOI 10.1084/jem.183.5.2379; VanSnick J, 1996, J IMMUNOL, V157, P2570; Yoshida T, 1996, FEBS LETT, V395, P82, DOI 10.1016/0014-5793(96)01004-6; YOSHIDA T, 1995, FEBS LETT, V360, P155, DOI 10.1016/0014-5793(95)00093-O; YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3	66	451	475	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					15036	15042		10.1074/jbc.272.23.15036	http://dx.doi.org/10.1074/jbc.272.23.15036			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169480	hybrid			2022-12-27	WOS:A1997XC32700077
J	Yamasaki, S; Tachibana, M; Shinohara, N; Iwashima, M				Yamasaki, S; Tachibana, M; Shinohara, N; Iwashima, M			Lck-independent triggering of T-cell antigen receptor signal transduction by staphylococcal enterotoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; CD45 PHOSPHOTYROSINE PHOSPHATASE; ZETA-CHAIN; MICE LACKING; ACTIVATION; PHOSPHORYLATION; ZAP-70; P59(FYN); STIMULATION; P56(LCK)	Superantigens (SAgs) activate T-cells in a manner specific to the V beta region of the T-cell antigen receptor. Stimulations by SAgs provoke drastic T-cell activation that leads to programmed cell death or the anergic state of responding cells. To characterize the signal transduction pathway initiated by SAgs, mutant lines derived from the human leukemic T-cell line Jurkat were tested for their reactivities against prototypic SAgs, staphylococcal enterotoxins. The J.CaM1.6 cell line, which lacks Lck expression and lost reactivity against T-cell antigen receptor-mediated stimulation, was activated by staphylococcal enterotoxins in a manner indistinguishable from the Jurkat cell line. In contrast, the J.45.01 cell line, which lacks expression of functional CD45, showed severely impaired reactivity. The role of Lck appears to be replaced by another Src family protein-tyrosine kinase, Fyn. In J.CaM1.6 cells, Fyn was rapidly phosphorylated and activated after staphylococcal enterotoxin treatment. The kinase-inactive mutant of Fyn significantly suppressed the reactivity against staphylococcal enterotoxin E in J.CaM1.6 cells, and the expression of the active form of Fyn reconstituted reactivity against staphylococcal enterotoxin E in J.45.01 cells. These results demonstrate that SAgs activate T-cells in an Lck-independent pathway and that Fyn plays a critical role in the process.	MITSUBISHI KASEI INST LIFE SCI,TOKYO 194,JAPAN; JAPAN SCI & TECHNOL CORP,DIV CELL & INFORMAT,TOKYO 194,JAPAN; MITSUBISHI CHEM CORP,YOKOHAMA RES CTR,PHARMACEUT LAB 2,YOKOHAMA,KANAGAWA 227,JAPAN	Japan Science & Technology Agency (JST); Mitsubishi Chemical Holdings Corporation; Mitsubishi Chemical								ALEXANDER D, 1992, IMMUNOL TODAY, V13, P477, DOI 10.1016/0167-5699(92)90021-X; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BIFFEN M, 1994, EMBO J, V13, P1920, DOI 10.1002/j.1460-2075.1994.tb06461.x; BURNS CM, 1994, J BIOL CHEM, V269, P13594; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CONRAD B, 1994, NATURE, V371, P351, DOI 10.1038/371351a0; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; Fields BA, 1996, NATURE, V384, P188, DOI 10.1038/384188a0; FUSAKI N, 1994, INT IMMUNOL, V6, P1245, DOI 10.1093/intimm/6.8.1245; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; GOLDSMITH MA, 1987, P NATL ACAD SCI USA, V84, P6879, DOI 10.1073/pnas.84.19.6879; Groves T, 1996, IMMUNITY, V5, P417, DOI 10.1016/S1074-7613(00)80498-7; HAMEL ME, 1995, INT IMMUNOL, V7, P1065, DOI 10.1093/intimm/7.7.1065; Hashimoto K, 1996, J EXP MED, V184, P931, DOI 10.1084/jem.184.3.931; HERMAN A, 1990, J EXP MED, V172, P709, DOI 10.1084/jem.172.3.709; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; MIGITA K, 1995, IMMUNOLOGY, V85, P550; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OGURA A, 1990, NEUROSCI RES, V9, P103, DOI 10.1016/0168-0102(90)90026-B; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PENNINGER JM, 1993, IMMUNOL REV, V135, P183, DOI 10.1111/j.1600-065X.1993.tb00649.x; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; Yamasaki S, 1996, MOL CELL BIOL, V16, P7151	44	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14787	14791		10.1074/jbc.272.23.14787	http://dx.doi.org/10.1074/jbc.272.23.14787			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169445	hybrid			2022-12-27	WOS:A1997XC32700042
J	PalsRylaarsdam, R; Hosey, MM				PalsRylaarsdam, R; Hosey, MM			Two homologous phosphorylation domains differentially contribute to desensitization and internalization of the m2 muscarinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED PHOSPHORYLATION; CHOLINERGIC RECEPTORS; BOMBESIN RECEPTOR; ADENYLYL CYCLASE; BOVINE RHODOPSIN; BETA-ARRESTIN; PROTEIN; KINASE; CELLS; SITES	Short term exposure of m2 muscarinic acetylcholine receptors (m2 mAChRs) to agonist causes a rapid phosphorylation of the activated receptors, followed by a profound loss in the ability of the m2 mAChR to activate its signaling pathways, We have used site-directed mutagenesis to identify two clusters of Ser/Thr residues in the third intracellular loop of the m2 mAChR that can serve as redundant targets for agonist-dependent phosphorylation, Mutation of both clusters of Ser/Thr residues to alanines abolished agonist-dependent phosphorylation, while wild-type levels of m2 mAChR phosphorylation were observed in mutant receptors with only one or the other cluster mutated, However, the functional effects of phosphorylation of these two ''redundant'' clusters were not equivalent, No receptor desensitization was observed in an m2 mAChR with residues Thr(307)-Ser(311) mutated to alanine residues, In contrast, mutation of the other Ser/Thr cluster. residues Ser(286)-Ser(290), to alanines produced a receptor that continued to desensitize, Internalization of the m2 mAChR was promoted by phosphorylation of either cluster, suggesting that distinct mechanisms with unique structural requirements act downstream of m2 mAChR phosphorylation to mediate receptor desensitization and receptor internalization.	NORTHWESTERN UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, CHICAGO, IL 60611 USA	Northwestern University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R43HL050201] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 50201] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGUILAR JS, 1995, BIOCHEM J, V307, P729, DOI 10.1042/bj3070729; BATTEY JF, 1993, METHODS NEUROSCI, V12, P85; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; FATHI Z, 1993, J BIOL CHEM, V268, P5979; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P3; KOENIG JA, 1994, J BIOL CHEM, V269, P17174; KWATRA MM, 1987, J BIOL CHEM, V262, P16314; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LEVEY AI, 1995, J COMP NEUROL, V351, P339, DOI 10.1002/cne.903510303; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; MCDOWELL JH, 1993, BIOCHEMISTRY-US, V32, P4968, DOI 10.1021/bi00069a036; MORO O, 1993, J BIOL CHEM, V268, P6862; NAWATA H, 1995, STEROIDS, V60, P28, DOI 10.1016/0039-128X(94)00022-5; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PAPAC DI, 1993, BIOCHEMISTRY-US, V32, P5930, DOI 10.1021/bi00074a002; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PULLEN N, 1994, BIOCHEMISTRY-US, V33, P14536, DOI 10.1021/bi00252a021; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; TSUGA H, 1994, J BIOL CHEM, V269, P32522; WADA E, 1991, NEURON, V6, P421, DOI 10.1016/0896-6273(91)90250-4; WEINSHANK RL, 1992, P NATL ACAD SCI USA, V89, P3630, DOI 10.1073/pnas.89.8.3630; ZANG WJ, 1993, J PHYSIOL-LONDON, V464, P649, DOI 10.1113/jphysiol.1993.sp019656	32	98	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14152	14158		10.1074/jbc.272.22.14152	http://dx.doi.org/10.1074/jbc.272.22.14152			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162044	hybrid			2022-12-27	WOS:A1997XB49200031
J	Weigert, R; Colanzi, A; Mironov, A; Buccione, R; Cericola, C; Sciulli, MG; Santini, G; Flati, S; Fusella, A; Donaldson, JG; DiGirolamo, M; Corda, D; DeMatteis, MA; Luini, A				Weigert, R; Colanzi, A; Mironov, A; Buccione, R; Cericola, C; Sciulli, MG; Santini, G; Flati, S; Fusella, A; Donaldson, JG; DiGirolamo, M; Corda, D; DeMatteis, MA; Luini, A			Characterization of chemical inhibitors of brefeldin A-activated mono-ADP-ribosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL MEMBRANE-PROTEIN; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; GOLGI MEMBRANES; RAT-LIVER; ORGANELLE STRUCTURE; GUANINE-NUCLEOTIDE; NITRIC-OXIDE; CELLS; ENDOSOMES; COMPLEX	Brefeldin A, a toxin inhibitor of vesicular traffic, induces the selective mono-ADP-ribosylation of two cytosolic proteins, glyceraldehyde 3-phosphate dehydrogenase and the novel GTP-binding protein BARS-50, Here, we have used a new quantitative assay for the characterization of this reaction and the development of specific pharmacological inhibitors, Mono-ADP-ribosylation is activated by brefeldin A with an EC50 of 17.0 +/- 3.1 mu g/ml, but not by biologically inactive analogs including a brefeldin A stereoisomer, Brefeldin A acts by increasing the V-max of the reaction, whereas it does not influence the K-m of the enzyme for NAD(+) (154 +/- 13 mu M). The enzyme is an integral membrane protein present in most tissues and is modulated by Zn2+, Cu2+, ATP (but not by other nucleotides), pH, temperature, and ionic strength, To identify inhibitors of the reaction, a large number of drugs previously tested as blockers of bacterial ADP-ribosyltransferases were screened, Two classes of molecules, one belonging to the coumarin group (dicumarol, coumermycin A(1), and novobiocin) and the other to the quinone group (ilimaquinone, benzoquinone, and naphthoquinone), rather potently and specifically inhibited brefeldin A dependent mono-ADP-ribosylation. When tested in living cells, these molecules antagonized the tubular reticular redistribution of the Golgi complex caused by brefeldin A at concentrations similar to those active in the mono-ADP-ribosylation assay in vitro, suggesting a role for mono-ADP-ribosylation in the cellular actions of brefeldin A.	NHLBI, CELL BIOL LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Weigert, R (corresponding author), CONSORZIO MARIO NEGRI SUD, IST RIC FARMACOL MARIO NEGRI, DEPT CELL BIOL & ONCOL, VIA NAZL, I-66030 SANTA MARIA IMBARO, CHIETI, ITALY.		Colanzi, Antonino/D-6821-2012; Corda, Daniela/K-6385-2016; Luini, Alberto/L-1372-2013; De Matteis, Maria Antonietta/AHE-5161-2022	Colanzi, Antonino/0000-0002-5643-0216; Corda, Daniela/0000-0002-3614-751X; Luini, Alberto/0000-0002-8729-2549; De Matteis, Maria Antonietta/0000-0003-0053-3061; Buccione, Roberto/0000-0001-9210-5261				ACHARYA U, 1995, J CELL BIOL, V129, P577, DOI 10.1083/jcb.129.3.577; ALCALDE J, 1992, J CELL BIOL, V116, P69, DOI 10.1083/jcb.116.1.69; BANASIK M, 1992, J BIOL CHEM, V267, P1569; BECK KA, 1994, J CELL BIOL, V127, P707, DOI 10.1083/jcb.127.3.707; BEREITERHAHN J, 1989, INT REV CYTOL, V122, P1; BORGESE N, 1980, J CELL BIOL, V85, P501, DOI 10.1083/jcb.85.3.501; Buccione R, 1996, J BIOL CHEM, V271, P3523; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; COREY EJ, 1976, TETRAHEDRON LETT, P4701; DEMATTEIS MA, 1994, P NATL ACAD SCI USA, V91, P1114, DOI 10.1073/pnas.91.3.1114; DEMATTEIS MA, 1991, J BIOL CHEM, V266, P10452; DIGIROLAMO M, 1995, P NATL ACAD SCI USA, V92, P7065, DOI 10.1073/pnas.92.15.7065; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; Ernster, 1967, METHOD ENZYMOL, V10, P309, DOI [DOI 10.1016/0076-6879(67)10059-1, 10.1016/0076-6879(67)10059-1]; HARRI E, 1963, HELV CHIM ACTA, V46, P1235, DOI 10.1002/hlca.19630460419; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HUITOREL P, 1985, EUR J BIOCHEM, V150, P265, DOI 10.1111/j.1432-1033.1985.tb09016.x; KIM KC, 1990, BIOCHEMISTRY-US, V29, P9281, DOI 10.1021/bi00491a025; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KochNolte F, 1996, J BIOL CHEM, V271, P7686, DOI 10.1074/jbc.271.13.7686; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDRIAN C, 1982, J AM CHEM SOC, V104, P5473, DOI 10.1021/ja00384a038; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MA Q, 1992, J BIOL CHEM, V267, P22298; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; MIRONOV A, 1995, EUR J CELL BIOL S, V5, P155; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; NARULA N, 1992, J CELL BIOL, V117, P27, DOI 10.1083/jcb.117.1.27; OKAZAKI IJ, 1996, BLOOD S, V86, P324; ORCI L, 1991, CELL, V64, P1183; PAVELKA M, 1993, J HISTOCHEM CYTOCHEM, V41, P1031, DOI 10.1177/41.7.8515046; PODOS SD, 1994, J CELL BIOL, V127, P679, DOI 10.1083/jcb.127.3.679; RANKIN PW, 1989, J BIOL CHEM, V264, P4312; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; RUSINOL AE, 1994, J BIOL CHEM, V269, P27494; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; TAKIZAWA PA, 1993, CELL, V73, P1079, DOI 10.1016/0092-8674(93)90638-7; TOOZE J, 1992, J CELL BIOL, V118, P813, DOI 10.1083/jcb.118.4.813; TSUCHIYA M, 1994, J BIOL CHEM, V269, P27451; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; VEIT B, 1993, J CELL BIOL, V122, P1197, DOI 10.1083/jcb.122.6.1197; VINALS AEL, 1987, BIOCHEM BIOPH RES CO, V143, P403, DOI 10.1016/0006-291X(87)90680-2; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; WOOD SA, 1992, J CELL BIOL, V119, P273, DOI 10.1083/jcb.119.2.273; ZHANG J, 1992, P NATL ACAD SCI USA, V89, P9382, DOI 10.1073/pnas.89.20.9382	51	32	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14200	14207		10.1074/jbc.272.22.14200	http://dx.doi.org/10.1074/jbc.272.22.14200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162051	hybrid			2022-12-27	WOS:A1997XB49200038
J	Iratni, R; Diederich, L; Harrak, H; Bligny, M; LerbsMache, S				Iratni, R; Diederich, L; Harrak, H; Bligny, M; LerbsMache, S			Organ-specific transcription of the rrn operon in spinach plastids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA GENE; PSBA MESSENGER-RNA; INVITRO TRANSCRIPTION; CHLOROPLAST GENOME; TANDEM PROMOTERS; ZEA-MAYS; POLYMERASE; PLANT; INITIATION; REGION	The spinach rrn operon is used as a model system to study transcriptional regulation in higher plant photosynthetic and non-photosynthetic plastids. We performed capping experiments to determine whether P1, PC, or P2 promoters are employed for rrn transcription start sites in cotyledon and root tissues. By using a new method of analysis of capped RNA we demonstrate for the first time that 1) in both organs the rrn operon is expressed in a constitutive manner by cotranscription with the preceding tRNA(GAC)(Val) gene, and 2) the PC transcription start site is used only in cotyledons and leaves, i.e. we demonstrate the organ specific usage of a plastid promoter. Both start sites, PC and that of the tRNA(GAC)(Val) cotranscript, lack Escherichia coli-like consensus sequences. The cotranscript is initiated 457 base pairs upstream of the tRNA(GAC)(Val) gene. The PC specific DNA-binding factor, CDF2, is not detectable in root tissues confirming its regulatory role in PC-initiated rnn expression and the organ specificity of PC expression. Furthermore, our results show that rrn operon expression patterns differ in spinach and tobacco indicating species-specific transcriptional regulation of plant plastid gene expression.	UNIV GRENOBLE 1,PLANT MOL GENET LAB,F-38041 GRENOBLE,FRANCE; CNRS,F-38041 GRENOBLE,FRANCE	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS)			Iratni, Rabah/M-5224-2016					ADAMS CC, 1990, NUCLEIC ACIDS RES, V18, P6003, DOI 10.1093/nar/18.20.6003; Allison LA, 1996, EMBO J, V15, P2802, DOI 10.1002/j.1460-2075.1996.tb00640.x; BAEZA L, 1991, NUCLEIC ACIDS RES, V19, P3577, DOI 10.1093/nar/19.13.3577; BAUMGARTNER BJ, 1993, PLANT PHYSIOL, V101, P781, DOI 10.1104/pp.101.3.781; BRIAT JF, 1982, NUCLEIC ACIDS RES, V10, P6865, DOI 10.1093/nar/10.21.6865; CONDON C, 1995, MICROBIOL REV, V59, P623, DOI 10.1128/MMBR.59.4.623-645.1995; DENG XW, 1988, EMBO J, V7, P3301, DOI 10.1002/j.1460-2075.1988.tb03200.x; DEPAMPHILIS CW, 1990, NATURE, V348, P337, DOI 10.1038/348337a0; DORMANNPRZYBYL D, 1986, PLANT MOL BIOL, V7, P419, DOI 10.1007/BF00020326; EISERMANN A, 1990, EMBO J, V9, P3981, DOI 10.1002/j.1460-2075.1990.tb07619.x; GRUISSEM W, 1985, EMBO J, V4, P3375, DOI 10.1002/j.1460-2075.1985.tb04093.x; GRUISSEM W, 1985, EMBO J, V4, P1637, DOI 10.1002/j.1460-2075.1985.tb03831.x; HESS WR, 1993, EMBO J, V12, P563, DOI 10.1002/j.1460-2075.1993.tb05688.x; HU J, 1991, NUCLEIC ACIDS RES, V19, P3431, DOI 10.1093/nar/19.12.3431; HU J, 1990, P NATL ACAD SCI USA, V87, P1531, DOI 10.1073/pnas.87.4.1531; IRATNI R, 1994, GENE DEV, V8, P2928, DOI 10.1101/gad.8.23.2928; LERBS S, 1988, MOL GEN GENET, V211, P459, DOI 10.1007/BF00425701; LERBS S, 1985, EMBO J, V7, P1661; LERBSMACHE S, 1993, P NATL ACAD SCI USA, V90, P5509, DOI 10.1073/pnas.90.12.5509; LERBSMACHE S, 1996, PHOTOSYNTHESIS LIGHT, V3, P557; LESCURE AM, 1985, NUCLEIC ACIDS RES, V13, P8787, DOI 10.1093/nar/13.24.8787; MORDEN CW, 1991, EMBO J, V10, P3281, DOI 10.1002/j.1460-2075.1991.tb04892.x; MULLET JE, 1987, EMBO J, V6, P1571, DOI 10.1002/j.1460-2075.1987.tb02402.x; MULLET JE, 1985, PLANT MOL BIOL, V4, P39, DOI 10.1007/BF02498714; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; SIJBENMULLER G, 1986, NUCLEIC ACIDS RES, V14, P1029, DOI 10.1093/nar/14.2.1029; STRITTMATTER G, 1984, NUCLEIC ACIDS RES, V12, P7633, DOI 10.1093/nar/12.20.7633; STRITTMATTER G, 1985, EMBO J, V4, P599, DOI 10.1002/j.1460-2075.1985.tb03672.x; Sugita M, 1996, PLANT MOL BIOL, V32, P315, DOI 10.1007/BF00039388; SUN E, 1989, MOL CELL BIOL, V9, P5650, DOI 10.1128/MCB.9.12.5650; VERA A, 1993, FEBS LETT, V327, P29, DOI 10.1016/0014-5793(93)81032-U; Vera A, 1996, MOL GEN GENET, V251, P518, DOI 10.1007/s004380050197; VERA A, 1995, CURR GENET, V27, P280, DOI 10.1007/BF00326161	33	32	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13676	13682		10.1074/jbc.272.21.13676	http://dx.doi.org/10.1074/jbc.272.21.13676			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153218	hybrid			2022-12-27	WOS:A1997XA06200033
J	Kolev, K; Tenekedjiev, K; Komorowicz, E; Machovich, R				Kolev, K; Tenekedjiev, K; Komorowicz, E; Machovich, R			Functional evaluation of the structural features of proteases and their substrate in fibrin surface degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMIC DEGRADATION; LEUKOCYTE ELASTASE; FACTOR-XIII; CLOT LYSIS; PERMEATION; KINETICS; DIFFUSION; CROSSLINKING; PURIFICATION; ACTIVATION	A new model has been introduced to characterize the action of a fluid phase enzyme on a solid phase substrate. This approach is applied to evaluate the kinetics of fibrin dissolution with several proteases. The model predicts the rate constants for the formation and dissociation of the protease-fibrin complex, the apparent order of the association reaction between the enzyme and the substrate, as well as a global catalytic constant (k(cat)) for the dissolution process. These kinetic parameters show a strong dependence on the nature of the applied protease and on the structure of the polymerized substrate. The kinetic data for trypsin, PMN elastase, and three plasminogen derived proteases with identical catalytic domain, but with a varied N-terminal structure, are compared. The absence of kringle(5) in des-kringle(1-5)-plasmin (microplasmin) is related to a markedly lower k(cat) (0.008 s(-1)) compared with plasmin and des-kringle(1-4)-plasmin (miniplasmin) (0.039 s(-1)). The essentially identical kinetic parameters for miniplasmin and plasmin with the exception of k(diss), which is higher for miniplas min (81.8 s(-1) versus 57.6 s(-1)), suggest that the first four kringle domains are needed to retain the enzyme in the enzyme-fibrin complex. Trypsin, a protease of similar primary specificity to plasmin, but with a different catalytic domain, shows basically the same k(cat) as plasmin, but its affinity to fibrin is markedly lower compared with plasmin and even microplasmin. The latter suggests that in addition to the kringle domains, the structure of the catalytic domain in plasmin also contributes to its specificity for fibrin. The thinner and extensively branched fibers of fibrin are more efficiently dissolved than the fibers with greater diameter and lower number of branching points. When the polymer is stabilized through covalent cross-linking, the k(cat) for plasmin and miniplasmin is 2-4-fold higher than on non-cross-linked fibrin, but the decrease in the association rate constant for the formation of enzyme-substrate complex explains the relative proteolytic resistance of the cross-linked fibrin. Thus, the functional evaluation of the discrete steps of the fibrinolytic process reveals new aspects of the interactions between proteases and their polymer substrate.	SEMMELWEIS UNIV MED,DEPT BIOCHEM MED,H-1088 BUDAPEST,HUNGARY	Semmelweis University			Kolev, Krasimir/A-3517-2008; Tenekedjiev, Kiril/D-8141-2012; Kolev, Krasimir/J-7648-2019	Kolev, Krasimir/0000-0002-5612-004X; Tenekedjiev, Kiril/0000-0003-3549-0671; Kolev, Krasimir/0000-0002-5612-004X				ALKJAERSIG N, 1959, J CLIN INVEST, V38, P1086, DOI 10.1172/JCI103885; ANAND S, 1995, BIOTECHNOL BIOENG, V48, P89, DOI 10.1002/bit.260480203; AXELROD D, 1994, BIOPHYS J, V66, P588, DOI 10.1016/S0006-3495(94)80834-3; Bachmann F., 1994, HEMOSTASIS THROMBOSI, V3rd, P1592; BARADET TC, 1995, BIOPHYS J, V68, P1551, DOI 10.1016/S0006-3495(95)80327-9; Blinc A, 1996, THROMB HAEMOSTASIS, V76, P481; BLOMBACK B, 1989, BIOCHIM BIOPHYS ACTA, V997, P96, DOI 10.1016/0167-4838(89)90140-4; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CARMASSI F, 1990, FIBRINOLYSIS, V3, P45; CARR ME, 1977, BIOPOLYMERS, V16, P1, DOI 10.1002/bip.1977.360160102; CARR ME, 1986, BIOCHEM J, V239, P513, DOI 10.1042/bj2390513; CHASE T, 1970, METHOD ENZYMOL, V19, P20; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DIAMOND SL, 1993, BIOPHYS J, V65, P2622, DOI 10.1016/S0006-3495(93)81314-6; FRANCIS CW, 1986, J LAB CLIN MED, V107, P342; FRANCIS CW, 1988, BLOOD, V71, P1361; GASPERS PB, 1995, J COLLOID INTERF SCI, V172, P518, DOI 10.1006/jcis.1995.1283; HANTGAN RR, 1994, HEMOSTASIS THROMBOSI, P277; HENIS YI, 1988, BIOPOLYMERS, V27, P123, DOI 10.1002/bip.360270110; KOLEV K, 1994, J BIOL CHEM, V269, P17030; Kolev K, 1996, THROMB HAEMOSTASIS, V75, P140; LOIKE JD, 1991, P NATL ACAD SCI USA, V88, P1044, DOI 10.1073/pnas.88.3.1044; LORAND L, 1966, NATURE, V210, P1273; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACHOVICH R, 1989, BIOCHEMISTRY-US, V28, P4517, DOI 10.1021/bi00436a059; Machovich R, 1990, Blood Coagul Fibrinolysis, V1, P79, DOI 10.1097/00001721-199003000-00011; MATVEYEV MY, 1992, BIOPHYS J, V63, P862, DOI 10.1016/S0006-3495(92)81656-9; MCDONAGH RP, 1971, BRIT J HAEMATOL, V21, P323, DOI 10.1111/j.1365-2141.1971.tb03444.x; MORRIS JP, 1981, BIOCHEMISTRY-US, V20, P4811, DOI 10.1021/bi00520a001; MORRIS JP, 1983, BIOCHIM BIOPHYS ACTA, V744, P99, DOI 10.1016/0167-4838(83)90345-X; Muszbek L, 1984, THROMBIN, P83; NIEWIAROWSKI S, 1972, ANN NY ACAD SCI, V201, P72, DOI 10.1111/j.1749-6632.1972.tb16288.x; PLOW EF, 1982, J CLIN INVEST, V69, P564, DOI 10.1172/JCI110482; PLOW EF, 1983, J LAB CLIN MED, V102, P858; PLOW EF, 1980, BIOCHIM BIOPHYS ACTA, V630, P47, DOI 10.1016/0304-4165(80)90136-1; RIDDLE JM, 1964, AM J PATHOL, V45, P805; SAKHAROV DV, 1995, CIRCULATION, V92, P1883, DOI 10.1161/01.CIR.92.7.1883; Sakharov DV, 1996, J BIOL CHEM, V271, P2133, DOI 10.1074/jbc.271.4.2133; SCHWARTZ ML, 1973, J BIOL CHEM, V248, P1395; SHI GY, 1988, J BIOL CHEM, V263, P17071; TEASDALE RD, 1985, J THEOR BIOL, V114, P375, DOI 10.1016/S0022-5193(85)80172-7; TINKER DO, 1980, CAN J BIOCHEM CELL B, V58, P898, DOI 10.1139/o80-124; Vindigni A, 1996, BIOCHEMISTRY-US, V35, P4417, DOI 10.1021/bi952834d; WANG D, 1992, BIOPHYS CHEM, V43, P117, DOI 10.1016/0301-4622(92)80027-3; WU HL, 1987, P NATL ACAD SCI USA, V84, P8292, DOI 10.1073/pnas.84.23.8292; WU JH, 1994, THROMB HAEMOSTASIS, V72, P105; ZAHN FW, 1875, VIRCHOWS ARCH PATHOL, V62, P82	47	43	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13666	13675		10.1074/jbc.272.21.13666	http://dx.doi.org/10.1074/jbc.272.21.13666			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153217	hybrid			2022-12-27	WOS:A1997XA06200032
J	Wang, YX; Farr, CL; Kaguni, LS				Wang, YX; Farr, CL; Kaguni, LS			Accessory subunit of mitochondrial DNA polymerase from Drosophila embryos - Cloning, molecular analysis, and association in the native enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; 3'->5' EXONUCLEASE; CATALYTIC SUBUNIT; XENOPUS-LAEVIS; GAMMA; EXPRESSION; NUCLEAR; GENE; MELANOGASTER; PURIFICATION	A full-length cDNA of the accessory (beta) subunit of mitochondrial DNA polymerase from Drosophila embryos has been obtained, and its nucleotide sequence was determined. The cDNA clone encodes a polypeptide with a deduced amino acid sequence of 361 residues and a predicted molecular mass of 41 kDa. The gene encoding the beta subunit lies within 4 kilobase pairs of that for the catalytic subunit in the Drosophila genome, on the left arm of chromosome 2. The two genes have similar structural features and share several common DNA sequence elements in their upstream regions, suggesting the possibility of coordinate regulation. A human cDNA homolog of the accessory subunit was identified, and its nucleotide sequence was determined. The human sequence encodes a polypeptide with a predicted molecular mass of 43 kDa that shows a high degree of amino acid sequence similarity to the Drosophila beta subunit. Subunit-specific rabbit antisera, directed against the recombinant catalytic and accessory subunit polypeptides overexpressed and purified from Escherichia coli, recognize specifically and immunoprecipitate the native enzyme from Drosophila embryos. Demonstration of the physical association of the two subunits in the Drosophila enzyme and identification of a human accessory subunit homolog provide evidence for a common heterodimeric structure for animal mitochondrial DNA polymerases.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University					NIGMS NIH HHS [GM45295] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045295] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bedford E, 1997, P NATL ACAD SCI USA, V94, P479, DOI 10.1073/pnas.94.2.479; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BERTAZZONI U, 1977, EUR J BIOCHEM, V81, P237, DOI 10.1111/j.1432-1033.1977.tb11945.x; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; CHERBAS L, 1993, INSECT BIOCHEM MOLEC, V23, P81, DOI 10.1016/0965-1748(93)90085-7; CHIANG CS, 1993, P NATL ACAD SCI USA, V90, P9105, DOI 10.1073/pnas.90.19.9105; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; FOURY F, 1992, EMBO J, V11, P2717, DOI 10.1002/j.1460-2075.1992.tb05337.x; FOURY F, 1989, J BIOL CHEM, V264, P20552; GOULIAN M, 1990, J BIOL CHEM, V265, P16402; GRAY H, 1992, J BIOL CHEM, V267, P5835; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HERNANDEZ TR, 1990, J BIOL CHEM, V265, P11227; Hirose F, 1996, J BIOL CHEM, V271, P3930; HIROSE F, 1993, J BIOL CHEM, V268, P2092; INSDORF NF, 1989, J BIOL CHEM, V264, P21498; INSDORF NF, 1989, J BIOL CHEM, V264, P21491; KAGUNI LS, 1989, P NATL ACAD SCI USA, V86, P6469, DOI 10.1073/pnas.86.17.6469; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANTZ V, 1992, DEVELOPMENT, V115, P75; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; Lewis DL, 1996, J BIOL CHEM, V271, P23389, DOI 10.1074/jbc.271.38.23389; LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417; LONGLEY MJ, 1991, J BIOL CHEM, V266, P24702; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MURPHY GJP, 1991, FEBS LETT, V289, P4, DOI 10.1016/0014-5793(91)80895-A; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; Nakamura A, 1996, SCIENCE, V274, P2075, DOI 10.1126/science.274.5295.2075; Ohno K, 1996, NUCLEIC ACIDS RES, V24, P3942, DOI 10.1093/nar/24.20.3942; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; OLSON MW, 1995, J BIOL CHEM, V270, P28932, DOI 10.1074/jbc.270.48.28932; Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490; ROPP PA, 1995, GENE, V165, P103, DOI 10.1016/0378-1119(95)00412-Y; SUOMALAINEN A, 1995, NAT GENET, V9, P146, DOI 10.1038/ng0295-146; TAN CK, 1986, J BIOL CHEM, V261, P2310; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WERNETTE CM, 1988, BIOCHEMISTRY-US, V27, P6046, DOI 10.1021/bi00416a033; WERNETTE CM, 1986, J BIOL CHEM, V261, P4764; WILLIAMS AJ, 1993, J BIOL CHEM, V268, P24855; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P15808, DOI 10.1074/jbc.270.26.15808; Ye F, 1996, NUCLEIC ACIDS RES, V24, P1481, DOI 10.1093/nar/24.8.1481; Zhou JQ, 1996, J BIOL CHEM, V271, P29740, DOI 10.1074/jbc.271.47.29740; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1	49	57	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13640	13646		10.1074/jbc.272.21.13640	http://dx.doi.org/10.1074/jbc.272.21.13640			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153213	hybrid			2022-12-27	WOS:A1997XA06200028
J	Romey, G; Attali, B; Chouabe, C; Abitbol, I; Guillemare, E; Barhanin, J; Lazdunski, M				Romey, G; Attali, B; Chouabe, C; Abitbol, I; Guillemare, E; Barhanin, J; Lazdunski, M			Molecular mechanism and functional significance of the MinK control of the KvLQT1 channel activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFIER K+-CURRENT; XENOPUS-OOCYTES; POTASSIUM CURRENT; ACTION-POTENTIALS; MEMBRANE PATCHES; MESSENGER-RNA; EXPRESSION; CLONING; PROTEIN; BLOCK	The very slowly activating delayed rectifier K+ channel I-Ks is essential for controlling the repolarization phase of cardiac action potentials and K+ homeostasis in the inner ear. The I-Ks channel is formed via the assembly of two transmembrane proteins, KvLQT1 and MinK. Mutations in KvLQT1 are associated with a long QT syndrome that causes syncope and sudden death and also with deafness. Here, we show a new mode of association between ion channel forming subunits in that the cytoplasmic C-terminal end of MinK interacts directly with the pore region of KvLQT1. This interaction reduces KvLQT1 channel conductance from 7.6 to 0.58 picosiemens. However, because MinK also reveals a large number of previously silent KvLQT1 channels (x 60), the overall effect is a large increase (x 4) in the macroscopic K+ current. Conformational changes associated with the KvLQT1/MinK association create very slow and complex activation kinetics without much alteration in the deactivation process. Changes induced by MinK have an essential regulatory role in the development of this K+ channel activity upon repetitive electrical stimulation with a particular interest in tachycardia.	CNRS,INST PHARMACOL MOL & CELLULAIRE,F-06560 VALBONNE,FRANCE; WEIZMANN INST SCI,DEPT NEUROBIOL,IL-76100 REHOVOT,ISRAEL	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Weizmann Institute of Science								ATTALI B, 1993, NATURE, V365, P850, DOI 10.1038/365850a0; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; BLUMENTHAL EM, 1994, J NEUROSCI, V14, P3097; CUI J, 1994, J GEN PHYSIOL, V104, P87, DOI 10.1085/jgp.104.1.87; Drici MD, 1996, CIRCULATION, V94, P1471, DOI 10.1161/01.CIR.94.6.1471; Fink M, 1996, J BIOL CHEM, V271, P26341, DOI 10.1074/jbc.271.42.26341; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAUSWIRTH O, 1972, J PHYSIOL-LONDON, V222, P27, DOI 10.1113/jphysiol.1972.sp009786; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HONORE E, 1991, EMBO J, V10, P2805, DOI 10.1002/j.1460-2075.1991.tb07829.x; JURKIEWICZ NK, 1993, CIRC RES, V72, P75, DOI 10.1161/01.RES.72.1.75; LESAGE F, 1993, RECEPTOR CHANNEL, V1, P143; MARCUS DC, 1994, AM J PHYSIOL, V267, pC857, DOI 10.1152/ajpcell.1994.267.3.C857; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; PONGS O, 1995, SEMIN NEUROSCI, V7, P137, DOI 10.1006/smns.1995.0015; PRAGNELL M, 1990, NEURON, V4, P807, DOI 10.1016/0896-6273(90)90207-V; Roden DM, 1996, CIRCULATION, V94, P1996, DOI 10.1161/01.CIR.94.8.1996; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; TOHSE N, 1990, AM J PHYSIOL, V258, pH1200, DOI 10.1152/ajpheart.1990.258.4.H1200; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; WALSH KB, 1991, AM J PHYSIOL, V260, pH1390, DOI 10.1152/ajpheart.1991.260.4.H1390; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; YEH JZ, 1978, NATURE, V273, P387, DOI 10.1038/273387a0; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8	28	115	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16713	16716		10.1074/jbc.272.27.16713	http://dx.doi.org/10.1074/jbc.272.27.16713			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201970	hybrid			2022-12-27	WOS:A1997XH44600002
J	Ho, YS; Magnenat, JL; Bronson, RT; Cao, J; Gargano, M; Sugawara, M; Funk, CD				Ho, YS; Magnenat, JL; Bronson, RT; Cao, J; Gargano, M; Sugawara, M; Funk, CD			Mice deficient in cellular glutathione peroxidase develop normally and show no increased sensitivity to hyperoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENIUM DEFICIENCY; NUCLEOTIDE-SEQUENCE; HYDROGEN-PEROXIDE; LIPID-PEROXIDATION; BOVINE LYMPHOCYTES; SELENOPROTEIN-P; MESSENGER-RNA; HUMAN-PLASMA; ACTIVE-SITE; GSHPX-GI	Glutathione peroxidase, a selenium-containing enzyme, is believed to protect cells from the toxicity of hydroperoxides. The physiological role of this enzyme has previously been implicated mainly using animals fed with a selenium-deficient diet. Although selenium deficiency also affects the activity of several other cellular selenium-containing enzymes, a dramatic decrease of glutathione peroxidase activity has been postulated to play a role in the pathogenesis of a number of diseases, particularly those whose progression is associated with an overproduction of reactive oxygen species, found in selenium-deficient animals. To further clarify the physiological relevance of this enzyme, a model of mice deficient in cellular glutathione peroxidase (GSHPx-1), the major isoform of glutathione peroxidase ubiquitously expressed In all types of cells, was generated by gene-targeting technology. Mice deficient in this enzyme were apparently healthy and fertile and showed no increased sensitivity to hyperoxia. Their tissues exhibited neither a retarded rate in consuming extracellular hydrogen peroxide nor an increased content of protein carbonyl groups and lipid peroxidation compared with those of wild-type mice. However, platelets from GSHPx-1-deficient mice incubated with arachidonic acid generated less 12-hydroxyeicosatetraenoic acid and more polar products relative to control platelets at a higher concentration of arachidonic acid, presumably reflecting a decreased ability to reduce the 12-hydroperoxyeicosatetraenoic acid intermediate. These results suggest that the contribution of GSHPx-1 to the cellular antioxidant mechanism under normal animal development and physiological conditions and to the pulmonary defense against hyperoxic insult is very limited. Nevertheless, the potential antioxidant role of this enzyme in protecting cells and animals against the pathogenic effect of reactive oxygen species in other disorders remains to be defined. The knockout mouse model described in this report will also provide a new tool for future study to distinguish the physiological role of this enzyme from other selenium-containing proteins in mammals under normal and disease states.	WAYNE STATE UNIV, DEPT BIOCHEM, DETROIT, MI 48201 USA; TUFTS UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02111 USA; UNIV PENN, CTR EXPT THERAPEUT, PHILADELPHIA, PA 19104 USA	Wayne State University; Tufts University; University of Pennsylvania	Ho, YS (corresponding author), WAYNE STATE UNIV, INST CHEM TOXICOL, 2727 2ND AVE, RM 4000, DETROIT, MI 48201 USA.		Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056421, R01HL053558] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AEBI H, 1984, METHOD ENZYMOL, V105, P121; Arthur John R., 1993, American Journal of Clinical Nutrition, V57, p236S, DOI 10.1093/ajcn/57.2.236S; BEDWAL RS, 1994, EXPERIENTIA, V50, P626, DOI 10.1007/BF01952862; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; Borg D. C., 1993, OXYGEN FREE RADICALS, P12; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRYANT RW, 1980, BIOCHEM BIOPH RES CO, V92, P268, DOI 10.1016/0006-291X(80)91548-X; BURK RF, 1994, J NUTR, V124, P1891, DOI 10.1093/jn/124.10.1891; BURK RF, 1980, J CLIN INVEST, V65, P1024, DOI 10.1172/JCI109754; CAO YZ, 1992, J NUTR, V122, P2121, DOI 10.1093/jn/122.11.2121; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chiu D, 1982, FREE RADICAL BIO MED, V5, P115; CHU FF, 1993, J BIOL CHEM, V268, P2571; CHU FF, 1995, ARCH BIOCHEM BIOPHYS, V323, P288, DOI 10.1006/abbi.1995.9962; COHEN G, 1963, BIOCHEMISTRY-US, V2, P1420, DOI 10.1021/bi00906a038; Crapo J D, 1978, Methods Enzymol, V53, P382; CRAPO JD, 1980, AM REV RESPIR DIS, V122, P123; David M., 1965, METHOD ENZYMAT AN, P875; EPP O, 1983, EUR J BIOCHEM, V133, P51, DOI 10.1111/j.1432-1033.1983.tb07429.x; ESKEW ML, 1993, PROSTAG OTH LIPID M, V46, P319, DOI 10.1016/0090-6980(93)90097-Q; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; Flohe L., 1982, FREE RADICAL BIO MED, V5, P223; Forman H.J., 1982, OXYGEN LIVING PROCES, P235; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRAMPTON J, 1987, NUCLEIC ACIDS RES, V15, P3671, DOI 10.1093/nar/15.9.3671; FREEMAN BA, 1984, ENVIRON HEALTH PERSP, V56, P51; FREEMAN BA, 1982, LAB INVEST, V47, P412; GAETANI G F, 1989, Blood, V73, P334; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; HAWKER FH, 1993, EUR RESPIR J, V6, P1317; HILL KE, 1991, J BIOL CHEM, V266, P10050; HO YS, 1988, NUCLEIC ACIDS RES, V16, P5207, DOI 10.1093/nar/16.11.5207; HONG Y, 1989, J BIOL CHEM, V264, P13793; HYSLOP PA, 1984, ANAL BIOCHEM, V141, P280, DOI 10.1016/0003-2697(84)90457-3; ISHIDA K, 1987, NUCLEIC ACIDS RES, V15, P10051, DOI 10.1093/nar/15.23.10051; JONES DP, 1981, ARCH BIOCHEM BIOPHYS, V210, P505, DOI 10.1016/0003-9861(81)90215-0; KIM CH, 1988, NUTR RES, V8, P767, DOI 10.1016/S0271-5317(88)80157-X; LEE BJ, 1989, J BIOL CHEM, V264, P9724; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LOHR GW, 1974, METHOD ENZYMAT AN, P636; MADDIPATI KR, 1987, ARCH BIOCHEM BIOPHYS, V254, P9, DOI 10.1016/0003-9861(87)90075-0; MADDOX JF, 1991, BIOCHEM BIOPH RES CO, V181, P389, DOI 10.1016/S0006-291X(05)81431-7; MAKINO N, 1994, J BIOL CHEM, V269, P1020; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MIRAULT ME, 1991, J BIOL CHEM, V266, P20752; MIROCHNITCHENKO O, 1995, P NATL ACAD SCI USA, V92, P8120, DOI 10.1073/pnas.92.18.8120; MULLENBACH GT, 1987, NUCLEIC ACIDS RES, V15, P5484, DOI 10.1093/nar/15.13.5484; MULLENBACH GT, 1988, PROTEIN ENG, V2, P239, DOI 10.1093/protein/2.3.239; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NEVE J, 1985, CLIN ENDOCRINOL META, V14, P629, DOI 10.1016/S0300-595X(85)80010-4; NICHOLLS P, 1972, BIOCHIM BIOPHYS ACTA, V279, P306, DOI 10.1016/0304-4165(72)90147-X; OCHI H, 1992, ARCH BIOCHEM BIOPHYS, V294, P407, DOI 10.1016/0003-9861(92)90704-Z; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; REDDY AP, 1988, NUCLEIC ACIDS RES, V16, P5557, DOI 10.1093/nar/16.12.5557; SANDSTROM PA, 1994, J BIOL CHEM, V269, P798; SUKENAGA Y, 1987, NUCLEIC ACIDS RES, V15, P7178, DOI 10.1093/nar/15.17.7178; Sun DX, 1996, J BIOL CHEM, V271, P24055, DOI 10.1074/jbc.271.39.24055; TAKAHASHI K, 1987, ARCH BIOCHEM BIOPHYS, V256, P677, DOI 10.1016/0003-9861(87)90624-2; TAPPEL AL, 1984, CURR TOP CELL REGUL, V24, P87; THOMAS JP, 1990, J BIOL CHEM, V265, P454; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TIMCENKOYOUSSEF L, 1985, J BIOL CHEM, V260, P3355; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; URSINI F, 1982, BIOCHIM BIOPHYS ACTA, V710, P197, DOI 10.1016/0005-2760(82)90150-3; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; WENDEL A, 1980, ENZYMATIC BASIS DETO, P333, DOI DOI 10.1016/B978-0-12-380001-5.50022-0; Yoshida T, 1996, J MOL CELL CARDIOL, V28, P1759, DOI 10.1006/jmcc.1996.0165; YOSHIMURA S, 1988, BIOCHEM BIOPH RES CO, V154, P1024, DOI 10.1016/0006-291X(88)90242-2; ZAROWSKI J, 1978, BIOCHIM BIOPHYS ACTA, V526, P65	70	465	479	1	17	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16644	16651		10.1074/jbc.272.26.16644	http://dx.doi.org/10.1074/jbc.272.26.16644			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195979	hybrid			2022-12-27	WOS:A1997XG01900083
J	Ogilvie, I; Aggeler, R; Capaldi, RA				Ogilvie, I; Aggeler, R; Capaldi, RA			Cross-linking of the delta subunit to one of the three alpha subunits has no effect on functioning, as expected if delta is a part of the stator that links the F-1 and F-0 parts of the Escherichia coli ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F1 ADENOSINE-TRIPHOSPHATASE; EPSILON-SUBUNIT; CRYOELECTRON MICROSCOPY; PROTON-ATPASE; H+-ATPASE; F1-ATPASE; BINDING; NUCLEOTIDE; MEMBRANE; COMPLEX	A mutant of the Escherichia coli F1F0-ATPase has been generated (alpha Q2C) in which the glutamine at position 2 of the alpha subunit has been replaced with a cysteine residue. Cu2+ treatment of ECF1 from this mutant crosslinked an alpha subunit to the delta subunit in high yield. Two different sites of disulfide bond formation were involved, i.e. between Cys(90) (or the closely spaced Cys(47)) of alpha with Cys(140) of delta, and between Cys(2) of alpha and Cys140 of delta. Small amounts of other cross-linked products, including alpha-alpha, delta internal, and alpha-alpha-delta were obtained. In ECF1F0, there was no cross-linking between the intrinsic Cys of alpha and Cys140. Instead, the product generated between Cys(2) of alpha and Cys140 of delta was obtained at near 90% yield. Small amounts of alpha-alpha and delta internal were present, and under high Cu2+ concentrations, alpha-alpha-delta was also formed. The ATPase activity of ECF1 and ECF1F0 was not significantly affected by the presence of these cross-links, When Cys(140) of delta was first modified with N-ethylmaleimide in ECF1F0, an alpha-delta cross-link was still produced, although in lower yield, between Cys(64) of delta and Cys(2) of alpha. ATP hydrolysis-linked proton pumping of inner membranes from the mutant alpha B2C was only marginally affected by cross-linking of the alpha to the delta subunit. These results indicate that Cys(140) and Cys(64) of the delta subunit and Cys(2) of the alpha subunit are in close proximity. This places the delta subunit near the top of the alpha-beta hexagon and not in the stalk region. As fixing the delta to the alpha by cross-linking does not greatly impair either the ATPase function of the enzyme, or coupled proton translocation, we argue that the delta subunit forms a portion of the stator linking F-1 to F-0.	UNIV OREGON,INST MOL BIOL,EUGENE,OR 97403	University of Oregon					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 24526] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; AGGELER R, 1995, BBA-BIOENERGETICS, V1230, P62, DOI 10.1016/0005-2728(95)00040-P; AGGELER R, 1987, BIOCHEMISTRY-US, V26, P7107, DOI 10.1021/bi00396a036; BECKERS G, 1992, BIOCHIM BIOPHYS ACTA, V1101, P97, DOI 10.1016/0167-4838(92)90473-Q; BELOGRUDOV GI, 1995, J BIOL CHEM, V270, P2053, DOI 10.1074/jbc.270.5.2053; BRAGG PD, 1986, BIOCHIM BIOPHYS ACTA, V851, P385, DOI 10.1016/0005-2728(86)90075-7; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DAVIES LG, 1986, BASIC METHODS MOL BI; DOWNER NW, 1976, BIOCHEMISTRY-US, V15, P2930, DOI 10.1021/bi00658a036; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNN SD, 1980, J BIOL CHEM, V255, P6891; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; GOGOL EP, 1987, FEBS LETT, V219, P276; HUNDAL T, 1983, FEBS LETT, V162, P5, DOI 10.1016/0014-5793(83)81038-2; Joshi S, 1996, BIOCHEMISTRY-US, V35, P12094, DOI 10.1021/bi9612327; JOUNOUCHI M, 1992, ARCH BIOCHEM BIOPHYS, V292, P376, DOI 10.1016/0003-9861(92)90005-H; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, BIOCHEMISTRY-US, V9, P4620; Lill H, 1996, J BIOL CHEM, V271, P32737, DOI 10.1074/jbc.271.51.32737; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; MAGGIO MB, 1988, J BIOL CHEM, V263, P4619; Maniatis T., 1982, MOL CLONING; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MENDELHARTVIG J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P115, DOI 10.1016/S0005-2728(05)80126-4; Pedersen PL, 1996, J BIOENERG BIOMEMBR, V28, P389, DOI 10.1007/BF02113979; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SENIOR AE, 1990, ANN REV BIOPHYS, V19, P17; SKAKOON EN, 1993, ARCH BIOCHEM BIOPHYS, V302, P272, DOI 10.1006/abbi.1993.1210; STANLOTTER H, 1986, FEBS LETT, V197, P121, DOI 10.1016/0014-5793(86)80310-6; STERNWEIS PC, 1977, BIOCHEMISTRY-US, V16, P4020, DOI 10.1021/bi00637a013; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; TOZER RG, 1986, EUR J BIOCHEM, V161, P513, DOI 10.1111/j.1432-1033.1986.tb10472.x; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WATTS SD, 1995, FEBS LETT, V368, P235, DOI 10.1016/0014-5793(95)00658-V; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; WILKENS S, 1997, IN PRESS BIOPHYS CHE; WISE JG, 1981, J BIOL CHEM, V256, P383; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609; ZIEGLER M, 1994, J BIOL CHEM, V269, P4233	49	137	139	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16652	16656		10.1074/jbc.272.26.16652	http://dx.doi.org/10.1074/jbc.272.26.16652			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195980	hybrid			2022-12-27	WOS:A1997XG01900084
J	Zhang, L; Dresser, MJ; Chun, JK; Babbitt, PC; Giacomini, KM				Zhang, L; Dresser, MJ; Chun, JK; Babbitt, PC; Giacomini, KM			Cloning and functional characterization of a rat renal organic cation transporter isoform (rOCT1A)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; BASOLATERAL MEMBRANE; CIMETIDINE TRANSPORT; MOLECULAR-CLONING; MESSENGER-RNAS; VESICLES; KIDNEY; PROTEIN; MECHANISMS; EXPRESSION	Polyspecific organic cation transporters in the renal proximal tubule mediate the secretion of many clinically used drugs as well as endogenous metabolites. Recently, two organic cation transporters (rOCT1 and rOCT2) were cloned from rat kidney. In this study, we report the cloning and functional expression of an rOCT1 isoform, rOCT1A, from rat kidney. Genomic DNA cloning and sequencing demonstrated that rOCT1A is an alternatively spliced variant of rOCT1 with a deletion of 104 base pairs near the 5'-end. The uptake of [C-14]tetraethylammonium (TEA) in oocytes injected with the cRNA-encoding rOCT1A was increased 10-fold over that in water-injected oocytes (29 +/- 2.8 pmol/oocyte/h versus 1.8 +/- 0.13 pmol/oocyte/h, mean +/- S.E., p < 0.05). [C-14]TEA uptake in the cRNA-injected oocytes was saturable (K-m = 42 +/- 11 mu M) and was inhibited significantly by organic cations, including cimetidine and N-1-methylnicotinamide. The amino acid sequence was deduced from the cDNA after examination of all three reading frames. Two overlapping open reading frames were found. Studies with synthetic constructs suggest that a functional organic cation transporter is encoded by the larger open reading frame. The larger open reading frame encodes a 430-amino acid protein (termed rOCT1A) that is 92% identical to rOCT1 and 57% identical to rOCT2. From hydropathy analysis, rOCT1A is predicted to have 10 transmembrane domains with both amino and carboxyl termini intracellular. RNase protection assays demonstrate the presence of rOCT1A mRNA transcripts in rat kidney cortex, medulla, and intestine. These studies demonstrate the presence of a functional, alternatively spliced organic cation transporter (rOCT1A) in rat kidney.	UNIV CALIF SAN FRANCISCO,DEPT BIOPHARMACEUT SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Giacomini, Kathleen/AEF-2452-2022		NIGMS NIH HHS [GM 36780, GM 26691] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM026691, R01GM036780] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; CACINI W, 1982, J PHARMACOL EXP THER, V221, P342; Canton H, 1996, MOL PHARMACOL, V50, P799; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; DANTZLER WH, 1989, AM J PHYSIOL, V256, pF290, DOI 10.1152/ajprenal.1989.256.2.F290; GIACOMINI KM, 1994, PFLUG ARCH EUR J PHY, V427, P381, DOI 10.1007/BF00374549; GISCLON L, 1987, AM J PHYSIOL, V253, pF141, DOI 10.1152/ajprenal.1987.253.1.F141; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HILFIKER H, 1994, J BIOL CHEM, V269, P26178; HOLOHAN PD, 1981, J PHARMACOL EXP THER, V216, P294; HOLOHAN PD, 1980, J PHARMACOL EXP THER, V215, P191; HSYU PH, 1988, AM J PHYSIOL, V254, pF56, DOI 10.1152/ajprenal.1988.254.1.F56; HSYU PH, 1987, J BIOL CHEM, V262, P3964; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KATSURA T, 1993, BIOCHIM BIOPHYS ACTA, V1146, P197, DOI 10.1016/0005-2736(93)90356-5; Koehler MR, 1996, MAMM GENOME, V7, P247, DOI 10.1007/s003359900074; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MCKINNEY TD, 1987, AM J PHYSIOL, V252, pF525, DOI 10.1152/ajprenal.1987.252.3.F525; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; Okuda M, 1996, BIOCHEM BIOPH RES CO, V224, P500, DOI 10.1006/bbrc.1996.1056; OTT RJ, 1991, AM J PHYSIOL, V261, pF443, DOI 10.1152/ajprenal.1991.261.3.F443; PEABODY DS, 1986, MOL CELL BIOL, V6, P2695, DOI 10.1128/MCB.6.7.2695; Preiano BS, 1996, BIOCHEMISTRY-US, V35, P7946; PRITCHARD JB, 1993, PHYSIOL REV, V73, P765, DOI 10.1152/physrev.1993.73.4.765; Roch-Ramel F., 1992, HDB PHYSL 8, P2189; SHIRE D, 1995, J BIOL CHEM, V270, P3726, DOI 10.1074/jbc.270.8.3726; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SIEBERT PD, 1995, NUCLEIC ACIDS RES, V23, P1087, DOI 10.1093/nar/23.6.1087; SOKOL PP, 1985, J PHARMACOL EXP THER, V233, P694; STAUFFER TP, 1993, J BIOL CHEM, V268, P25993; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; TAKANO M, 1984, BIOCHIM BIOPHYS ACTA, V773, P113, DOI 10.1016/0005-2736(84)90556-X; TAKANO M, 1985, LIFE SCI, V37, P1579, DOI 10.1016/0024-3205(85)90476-X; ULLRICH KJ, 1994, BBA-REV BIOMEMBRANES, V1197, P45, DOI 10.1016/0304-4157(94)90018-3; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1995, BIOESSAYS, V17, P25, DOI 10.1002/bies.950170107; WRIGHT SH, 1987, AM J PHYSIOL, V253, pF1040, DOI 10.1152/ajprenal.1987.253.5.F1040; ZHANG L, 1997, IN PRESS MOL PHARM	40	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16548	16554		10.1074/jbc.272.26.16548	http://dx.doi.org/10.1074/jbc.272.26.16548			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195965	hybrid			2022-12-27	WOS:A1997XG01900069
J	Ebihara, S; Sasaki, T; Hida, W; Kikuchi, Y; Oshiro, T; Shimura, S; Takasawa, S; Okamoto, H; Nishiyama, A; Akaike, N; Shirato, K				Ebihara, S; Sasaki, T; Hida, W; Kikuchi, Y; Oshiro, T; Shimura, S; Takasawa, S; Okamoto, H; Nishiyama, A; Akaike, N; Shirato, K			Role of cyclic ADP-ribose in ATP-activated potassium currents in alveolar macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE PERITONEAL-MACROPHAGES; SEA-URCHIN EGGS; EXTRACELLULAR ATP; INTRACELLULAR CA2+; SKELETAL-MUSCLE; INOSITOL TRISPHOSPHATE; RYANODINE RECEPTOR; CALCIUM STORES; RAT; CHANNELS	There is growing evidence that extracellular ATP causes a dramatic change in the membrane conductance of a variety of inflammatory cells. In the present study, using the nystatin perforated patch recording configuration, we found that ATP (0.3-30 mu M) induced a transient outward current in a concentration-dependent manner and that the reversal potential of the ATP-induced outward current was close to the K+ equilibrium potential, indicating that the membrane behaves like a K+ electrode in the presence of ATP. The first application of ATP to alveolar macrophages perfused with Ca2+-free external solution could induce the outward current, but the response to ATP was diminished with successive applications. Intracellular perfusion with a Ca2+ chelator. 1,2-bis(2-aminophenoxy)ethane N,N,N', N'-tetraacetic acid, also diminished the response. When cyclic ADP-ribose (cADPR) was applied to the macrophage cytoplasm, a transient outward current was elicited. Thereafter, the successive outward current was inhibited, suggesting the involvement of cADPR in the response. Intracellular perfusion with inositol 1,4,5-trisphosphate also induced a transient outward current, but the successive current was not inhibited. The ATP-induced outward current was abolished when 8-amino-cADPR (as a blocker of cADPR, 10(-6)-10(-5) M) was introduced into the cytoplasm. Homogenates of alveolar macrophages showed both ADP-ribosyl cyclase and cADPR hydrolase activities, and CD38 (ADP-ribosyl cyclase/cADPR hydrolase) expression was confirmed by reverse transcriptase-polymerase chain reaction and Western blot analyses. These results indicate that ATP activates K+ currents by releasing Ca2+ from cADPR-sensitive internal Ca2+ stores.	TOHOKU UNIV,SCH MED,DEPT INTERNAL MED 1,AOBA KU,SENDAI,MIYAGI 98077,JAPAN; TOHOKU UNIV,SCH MED,DEPT BIOCHEM,SENDAI,MIYAGI 98077,JAPAN; TOHOKU UNIV,SCH MED,DEPT PHYSIOL 1,SENDAI,MIYAGI 98077,JAPAN; KYUSHU UNIV,FAC MED,DEPT PHYSIOL,FUKUOKA 81282,JAPAN	Tohoku University; Tohoku University; Tohoku University; Kyushu University			Ebihara, Satoru/GYD-3723-2022	Ebihara, Satoru/0000-0002-3574-649X; Kikuchi, Yoshihiro/0000-0002-3262-3881				AKAIKE N, 1994, JPN J PHYSIOL, V44, P433, DOI 10.2170/jjphysiol.44.433; ALBUQUERQUE C, 1993, AM J PHYSIOL, V265, pC1663, DOI 10.1152/ajpcell.1993.265.6.C1663; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLATZ AL, 1986, NATURE, V323, P718, DOI 10.1038/323718a0; BUISMAN HP, 1988, P NATL ACAD SCI USA, V85, P7988, DOI 10.1073/pnas.85.21.7988; CASTLE NA, 1989, TRENDS NEUROSCI, V12, P59, DOI 10.1016/0166-2236(89)90137-9; CRYSTAL RG, 1991, LUNG SCI FDN, P527; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; EHRLICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145, DOI 10.1016/0165-6147(94)90074-4; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FURUYA Y, 1995, GENE, V165, P329, DOI 10.1016/0378-1119(95)00540-M; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GALIONE A, 1993, SCIENCE, V259, P325, DOI 10.1126/science.8380506; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GROMADA J, 1995, PFLUG ARCH EUR J PHY, V429, P751, DOI 10.1007/BF00374798; HAGENLOCKER BE, 1990, J IMMUNOL, V144, P3898; HARA N, 1990, COMP BIOCH PHYSL A, V98, P417; HIGASHIDA H, 1995, J PHYSIOL-LONDON, V482, P317, DOI 10.1113/jphysiol.1995.sp020520; HIRATA Y, 1994, FEBS LETT, V356, P244, DOI 10.1016/0014-5793(94)01279-2; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; KOGUMA T, 1994, BBA-MOL CELL RES, V1223, P160, DOI 10.1016/0167-4889(94)90087-6; LEE HC, 1995, BIOCHIMIE, V77, P345, DOI 10.1016/0300-9084(96)88145-4; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; MCKINNEY LC, 1992, J MEMBRANE BIOL, V130, P265; MURASE K, 1990, BRAIN RES, V525, P84, DOI 10.1016/0006-8993(90)91323-9; MYRVIK QN, 1961, J IMMUNOL, V86, P128; Noguchi N, 1997, J BIOL CHEM, V272, P3133, DOI 10.1074/jbc.272.6.3133; Okamoto H, 1997, METHOD ENZYMOL, V280, P306; OKAMOTO H, 1995, BIOCHIMIE, V77, P356, DOI 10.1016/0300-9084(96)88146-6; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PFEILSCHIFTER J, 1989, EUR J BIOCHEM, V186, P509, DOI 10.1111/j.1432-1033.1989.tb15236.x; PRPIC V, 1988, J CELL BIOL, V107, P363, DOI 10.1083/jcb.107.1.363; PRPIC V, 1987, J IMMUNOL, V139, P526; RANDRIAMAMPITA C, 1987, J CELL BIOL, V105, P761, DOI 10.1083/jcb.105.2.761; RANDRIAMAMPITA C, 1991, PFLUG ARCH EUR J PHY, V417, P633, DOI 10.1007/BF00372962; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SASAKI T, 1993, AM REV RESPIR DIS, V147, P936; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; YOUNG JDE, 1985, J CELL BIOCHEM, V29, P289, DOI 10.1002/jcb.240290403; YPEY DL, 1984, P NATL ACAD SCI-BIOL, V81, P3083, DOI 10.1073/pnas.81.10.3083	46	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					16023	16029		10.1074/jbc.272.25.16023	http://dx.doi.org/10.1074/jbc.272.25.16023			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188506	hybrid			2022-12-27	WOS:A1997XF32900066
J	Labbe, S; Zhu, ZW; Thiele, DJ				Labbe, S; Zhu, ZW; Thiele, DJ			Copper-specific transcriptional repression of yeast genes encoding critical components in the copper transport pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MOLECULAR CHARACTERIZATION; METALLOTHIONEIN GENE; IRON UPTAKE; PROTEIN; EXPRESSION; CONFORMATION; RESISTANCE; DISEASE; FUSION	Copper is an essential micronutrient that is toxic in excess, To maintain an adequate yet non-toxic concentration of copper, cells possess several modes of control, One involves copper uptake mediated by genes encoding proteins that play key roles in high affinity copper transport, These include the FRE1-encoded Cu2+/Fe3+ reductase and the CTR1 and CTR3-encoded membrane-associated copper transport proteins, Each of these genes is transcriptionally regulated as a function of copper availability: repressed when cells are grown in the presence of copper and highly activated during copper starvation. Our data demonstrate that repression of CTR3 transcription is exquisitely copper-sensitive and specific, Although copper represses CTR3 gene expression at picomolar metal concentrations, cadmium and mercury down-regulate CTR3 expression only at concentrations 3 orders magnitude greater, Furthermore, copper-starvation rapidly and potently induces CTR3 gene expression, We demonstrate that the CTR1, CTR3, and FRE1 genes involved in high affinity copper uptake share a common promoter element, TTTGCTC, which is necessary for booth copper repression and copper starvation activation of gene expression, Furthermore, the Maclp is essential for down- or up-regulation of the copper-transport genes, In vivo footprinting studies reveal that the cis-acting element, termed CuRE (copper-response element), is occupied under copper-starvation and accessible to DNA modifying agents in response to copper repression, and that this regulated occupancy requires a functional MAC1 gene, Therefore, yeast cells coordinately express genes involved in high affinity copper transport through the action of a common signaling pathway.	UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan				Labbe, Simon/0000-0002-4947-523X	NIGMS NIH HHS [R01 GM41840] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041840] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Askwith CC, 1996, MOL MICROBIOL, V20, P27, DOI 10.1111/j.1365-2958.1996.tb02485.x; BULL PC, 1994, TRENDS GENET, V10, P246, DOI 10.1016/0168-9525(94)90172-4; BUTT TR, 1984, P NATL ACAD SCI-BIOL, V81, P3332, DOI 10.1073/pnas.81.11.3332; CULOTTA VC, 1994, J BIOL CHEM, V269, P25295; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1994, J BIOL CHEM, V269, P25660; FOGEL S, 1982, P NATL ACAD SCI-BIOL, V79, P5342, DOI 10.1073/pnas.79.17.5342; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; Graden JA, 1996, BIOCHEMISTRY-US, V35, P14583, DOI 10.1021/bi961642v; GRALLA EB, 1991, P NATL ACAD SCI USA, V88, P8558, DOI 10.1073/pnas.88.19.8558; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HAMER DH, 1985, SCIENCE, V228, P685, DOI 10.1126/science.3887570; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; Kaplan J, 1996, SCIENCE, V271, P1510, DOI 10.1126/science.271.5255.1510; KLAUSNER RD, 1994, FEBS LETT, V355, P109, DOI 10.1016/0014-5793(94)01111-7; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Koch KA, 1996, MOL CELL BIOL, V16, P724; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; LI HH, 1995, J BIOL CHEM, V270, P23504, DOI 10.1074/jbc.270.40.23504; Linder Maria C., 1996, American Journal of Clinical Nutrition, V63, p797S; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; PREDKI PF, 1992, J BIOL CHEM, V267, P5842; RYCHLIK W, 1990, NUCLEIC ACIDS RES, V18, P6409, DOI 10.1093/nar/18.21.6409; RYMOND BC, 1983, GENE, V25, P249, DOI 10.1016/0378-1119(83)90229-9; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANTORO N, 1997, YEAST STRESS RESPONS, P165; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; THIELE DJ, 1992, NUCLEIC ACIDS RES, V20, P1183, DOI 10.1093/nar/20.6.1183; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; VULPE CD, 1995, ANNU REV NUTR, V15, P293, DOI 10.1146/annurev.nu.15.070195.001453; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; ZHOU PB, 1991, P NATL ACAD SCI USA, V88, P6112, DOI 10.1073/pnas.88.14.6112; Zhu ZW, 1996, CELL, V87, P459, DOI 10.1016/S0092-8674(00)81366-5	40	200	212	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15951	15958		10.1074/jbc.272.25.15951	http://dx.doi.org/10.1074/jbc.272.25.15951			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188496	hybrid			2022-12-27	WOS:A1997XF32900056
J	Landini, P; Gaal, T; Ross, W; Volkert, MR				Landini, P; Gaal, T; Ross, W; Volkert, MR			The RNA polymerase alpha subunit carboxyl-terminal domain is required for both basal and activated transcription from the alkA promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI ADA; ALKYLATING-AGENTS; ADAPTIVE RESPONSE; PROTEIN ACTS; DNA-REPAIR; EXPRESSION; BINDING; GENE; RECOGNITION; INDUCTION	Expression of the Escherichia coli adaptive response genes (ada, aidB, and alkA) is regulated by the transcriptional activator, Ada, However, the interactions of RNA polymerase and Ada with these promoters differ. In this report we characterize the interactions of Ada, methylated Ada ((me)Ada), and RNA polymerase at the alkA promoter and contrast these interactions with those characterized previously for the ada and aidB promoters, At the alkA promoter, we do not detect the RNA polymerase alpha subunit-mediated binary complex detected at the uda and aidB promoters, In the presence of either of these two activators, RNA polymerase protects the alkA core promoter, including the elements at -35 and -10, and is more efficient in transcription initiation in vitro, RNA polymerase holoenzyme containing the alpha subunit mutation R265A is severely impaired in Ada-independent basal alkA transcription, shows no activation by Ada or (me)Ada, and fails to bind the alkA promoter in vitro. Binding of the purified wild type alpha subunit to alkA was not detected, but a complex of promoter DNA, Ada or (me)Ada, and alpha was observed in gel shift assays, These observations suggest that both forms of Ada protein activate alkA transcription by enhancing RNA polymerase holoenzyme and alpha subunit binding.	UNIV MASSACHUSETTS, SCH MED, DEPT MOL GENET & MICROBIOL, WORCESTER, MA 01655 USA; UNIV WISCONSIN, DEPT BACTERIOL, MADISON, WI 53706 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Wisconsin System; University of Wisconsin Madison			Landini, Paolo/B-7859-2017	Landini, Paolo/0000-0003-0999-426X; Volkert, Michael/0000-0002-0045-0912	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037048, R01GM037048, R01GM037052] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37052, GM37048] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIMARU H, 1990, J MOL BIOL, V216, P261, DOI 10.1016/S0022-2836(05)80318-3; ATTEY A, 1994, NUCLEIC ACIDS RES, V22, P4375, DOI 10.1093/nar/22.21.4375; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; DEMPLE B, 1982, NUCLEIC ACIDS RES, V10, P3781, DOI 10.1093/nar/10.12.3781; FURUICHI M, 1992, MOL GEN GENET, V236, P25, DOI 10.1007/BF00279639; Gaal T, 1996, GENE DEV, V10, P16, DOI 10.1101/gad.10.1.16; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; JEGGO P, 1979, J BACTERIOL, V139, P783, DOI 10.1128/JB.139.3.783-791.1979; LANDINI P, 1995, EMBO J, V14, P4329, DOI 10.1002/j.1460-2075.1995.tb00107.x; LANDINI P, 1995, J BIOL CHEM, V270, P8285, DOI 10.1074/jbc.270.14.8285; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; MCCARTHY TV, 1985, NUCLEIC ACIDS RES, V13, P2683, DOI 10.1093/nar/13.8.2683; MELANCON P, 1982, BIOCHEMISTRY-US, V21, P4318, DOI 10.1021/bi00261a022; NAKABEPPU Y, 1984, J BIOL CHEM, V259, P3730; NAKABEPPU Y, 1986, P NATL ACAD SCI USA, V83, P6297, DOI 10.1073/pnas.83.17.6297; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; SAGET BM, 1994, P NATL ACAD SCI USA, V91, P9730, DOI 10.1073/pnas.91.21.9730; SAGET BM, 1995, J BACTERIOL, V177, P1268, DOI 10.1128/jb.177.5.1268-1274.1995; SAKUMI K, 1989, J MOL BIOL, V205, P373, DOI 10.1016/0022-2836(89)90348-3; SAKUMI K, 1993, J BACTERIOL, V175, P2455, DOI 10.1128/JB.175.8.2455-2457.1993; SAMSON L, 1977, NATURE, V267, P281, DOI 10.1038/267281a0; SHEVELL DE, 1991, P NATL ACAD SCI USA, V88, P9001, DOI 10.1073/pnas.88.20.9001; TEO I, 1986, CELL, V45, P315, DOI 10.1016/0092-8674(86)90396-X; VOLKERT MR, 1989, MUTAT RES, V217, P109, DOI 10.1016/0921-8777(89)90062-1	24	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15914	15919		10.1074/jbc.272.25.15914	http://dx.doi.org/10.1074/jbc.272.25.15914			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188491	hybrid			2022-12-27	WOS:A1997XF32900051
J	Roos, W; Schulze, R; Steighardt, J				Roos, W; Schulze, R; Steighardt, J			Dynamic compartmentation of vacuolar amino acids in Penicillium cyclopium - Cytosolic adenylates act as a control signal for efflux into the cytosol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NEUROSPORA-CRASSA; MEMBRANE-VESICLES; PLASMA-MEMBRANE; TRANSPORT SYSTEMS; ARGININE; TONOPLAST; MOBILIZATION; CHANNELS; ATPASE	The regulation of amino acid transport from the vacuolar reservoir into the cytoplasm has been studied in hyphal cells of Penicillium cyclopium. To avoid artifacts caused by the isolation of vacuoles, efflux was examined ''in situ,'' i.e. in cells whose plasma membranes were permeabilized for micromolecules by a treatment with nystatin, The ATP-dependent proton gradient and amino acid transport activities at the vacuolar membrane remained intact under these conditions, Accumu lation of amino acids in the vacuole proved to be the result of a dynamic equilibrium of active, ATP-dependent uptake and energy-independent efflux, The latter was strongly accelerated after the vacuolar amino acid content had surpassed a threshold level, Efflux of vacuolar amino acids was specifically controlled by extravacuolar adenylates: ATP, 5'-adenylyl imidodiphosphate (an ATPase-resistant ATP-analogue), ADP, or AMP caused a strong inhibition in the concentration range around 200 mu mol/liter, whereas both lower and higher concentrations allowed significant efflux rates, Estimates; of the cytosolic adenylates (which consisted mainly of ATP) were close to 2 mmol/liter in glucose-metabolizing cells, which concentration allowed maximum rates of both vacuolar uptake and efflux, During 24 h of carl,on and nitrogen starvation, the adenylate level decreased toward the efflux-inhibiting region around 200 mu mol/liter, whereas 3-4 d of carbon and nitrogen starvation caused a further decline of the adenylate content, leading again to efflux-permitting concentrations, Thus, the cytosolic adenylate pool appears to effectively control the availability of vacuolar amino acids for the cellular metabolism.			Roos, W (corresponding author), UNIV HALLE WITTENBERG,COLL PHARM,INST PHARMACEUT BIOL,DEPT CELL PHYSIOL,KURT MOTHES STR 3,D-06120 HALLE,GERMANY.							ANRAKU Y, 1989, J BIOENERG BIOMEMBR, V21, P589, DOI 10.1007/BF00808115; BALL WJ, 1975, J BACTERIOL, V121, P975, DOI 10.1128/JB.121.3.975-982.1975; BERTL A, 1990, P NATL ACAD SCI USA, V87, P7824, DOI 10.1073/pnas.87.20.7824; BOLLER T, 1975, EUR J BIOCHEM, V54, P81, DOI 10.1111/j.1432-1033.1975.tb04116.x; BOLLER T, 1986, ANNU REV PLANT PHYS, V37, P137, DOI 10.1146/annurev.pp.37.060186.001033; CARROLL AD, 1992, PLANT PHYSIOL, V100, P1808, DOI 10.1104/pp.100.4.1808; COLOMBO R, 1994, BIOCHEM BIOPH RES CO, V200, P1150, DOI 10.1006/bbrc.1994.1571; Cooper T., 1982, MOL BIOL YEAST SACCH, P399; DAVIS RH, 1978, J SUPRAMOL STR CELL, V9, P473, DOI 10.1002/jss.400090403; DIETZ KJ, 1990, PLANT PHYSIOL, V92, P123, DOI 10.1104/pp.92.1.123; DIETZ KJ, 1989, BIOCHIM BIOPHYS ACTA, V984, P57, DOI 10.1016/0005-2736(89)90342-8; DRAINAS C, 1982, J BACTERIOL, V150, P779, DOI 10.1128/JB.150.2.779-784.1982; DRAINAS C, 1982, J BACTERIOL, V150, P770, DOI 10.1128/JB.150.2.770-778.1982; DURR M, 1975, ARCH MICROBIOL, V105, P319, DOI 10.1007/BF00447152; EINARSSON S, 1987, ANAL CHEM, V59, P1191, DOI 10.1021/ac00135a025; Gale E.F., 1981, MOL BASIS ANTIBIOTIC, Vsecond; Hampp R, 1985, METHOD ENZYMAT AN, VVII, P370; HERNANDEZ A, 1994, BBA-BIOMEMBRANES, V1195, P103, DOI 10.1016/0005-2736(94)90015-9; HOMEYER U, 1989, PLANT PHYSIOL, V89, P1388, DOI 10.1104/pp.89.4.1388; HORAK J, 1986, BIOCHIM BIOPHYS ACTA, V864, P223, DOI 10.1016/0304-4157(86)90001-8; HUBERWALCHLI V, 1979, ARCH MICROBIOL, V120, P141, DOI 10.1007/BF00409100; KATSUHARA M, 1987, PROTOPLASMA, V138, P190, DOI 10.1007/BF01281029; KINSKY SC, 1961, J BACTERIOL, V82, P889, DOI 10.1128/JB.82.6.889-897.1961; KITAMOTO K, 1988, J BACTERIOL, V170, P2683, DOI 10.1128/jb.170.6.2683-2686.1988; KRINGSTAD R, 1980, PLANT PHYSIOL, V66, P379, DOI 10.1104/pp.66.3.379; LEGERTON TL, 1984, J BIOL CHEM, V259, P8875; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTINOIA E, 1991, PLANT PHYSIOL, V97, P644, DOI 10.1104/pp.97.2.644; MARTINOIA E, 1992, BOT ACTA, V105, P232, DOI 10.1111/j.1438-8677.1992.tb00293.x; OHSUMI Y, 1988, J BACTERIOL, V170, P2676, DOI 10.1128/jb.170.6.2676-2682.1988; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; PAEK YL, 1989, J BIOL CHEM, V264, P7285; PONITZ J, 1994, J BACTERIOL, V176, P5429; PUGIN A, 1986, PLANT SCI, V47, P165, DOI 10.1016/0168-9452(86)90174-3; REA PA, 1987, PHYSIOL PLANTARUM, V71, P131, DOI 10.1111/j.1399-3054.1987.tb04630.x; ROOS W, 1989, BIOCHIM BIOPHYS ACTA, V978, P119, DOI 10.1016/0005-2736(89)90507-5; Roos W., 1990, ALKALOIDS, V39, P63; SAKANO K, 1984, PLANT CELL PHYSIOL, V25, P1477, DOI 10.1093/oxfordjournals.pcp.a076860; SATO T, 1984, J BIOL CHEM, V259, P1505; SCHLEGEL R, 1982, STUD BIOPHYS, V92, P135; SZE H, 1992, J BIOENERG BIOMEMBR, V24, P371, DOI 10.1007/BF00762530; WEISER T, 1993, NONSELECTIVE CATION, P305	42	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15849	15855		10.1074/jbc.272.25.15849	http://dx.doi.org/10.1074/jbc.272.25.15849			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188483	hybrid			2022-12-27	WOS:A1997XF32900043
J	Lencer, WI; Constable, C; Moe, S; Rufo, PA; Wolf, A; Jobling, MG; Ruston, SP; Madara, JL; Holmes, RK; Hirst, TR				Lencer, WI; Constable, C; Moe, S; Rufo, PA; Wolf, A; Jobling, MG; Ruston, SP; Madara, JL; Holmes, RK; Hirst, TR			Proteolytic activation of cholera toxin and Escherichia coli labile toxin by entry into host epithelial cells - Signal transduction by a protease-resistant toxin variant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; ENTEROTOXIN; MECHANISM; GENERATION; KALLIKREIN; SITE	Cholera and Escherichia coli heat-labile toxins (CT and LT) require proteolysis of a peptide loop connecting two major domains of their enzymatic A subunits for maximal activity (termed ''nicking''). To test whether host intestinal epithelial cells may supply the necessary protease, recombinant rCT and rLT and a protease-resistant mutant CTR192H were prepared, Toxin action was assessed as a Cl- secretory response (Isc)elicited from monolayers of polarized human epithelial T84 cells, When applied to apical cell surfaces, wild type toxins elicited a brisk increase in Isc (80 mu A/cm(2)). Ise was reduced a-fold, however, when toxins were applied to basolateral membranes, Pretreatment of wild typo toxins with trypsin in vitro restored the ''basolateral'' secretory responses to ''apical'' levels. Toxin entry into T84 cells via apical but not basolateral membranes led to nicking of the A subunit by a serine-type protease; T84 cells, however, did not nick CTR192H, and the secretory response elicited by CTR192H remained attenuated even when applied to apical membranes. Thus, T84 cells express a serine-type protease(s) fully sufficient, for activating the A subunits of CT and LT, The protease, however, is only accessible for activation when the toxin enters the cell via the apical membrane.	HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD DIGEST DIS CTR, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; UNIV COLORADO, HLTH SCI CTR, DEPT MICROBIOL, DENVER, CO 80262 USA; UNIV BRISTOL, SCH MED SCI, DEPT PATHOL & MICROBIOL, BRISTOL BS8 1TD, AVON, ENGLAND	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Bristol	Lencer, WI (corresponding author), CHILDRENS HOSP, COMBINED PROGRAM PEDIAT GASTROENTEROL & NUTR, 300 LONGWOOD AVE, ENDERS 1220, BOSTON, MA 02115 USA.		Jobling, Michael G/AAJ-3814-2021; Rufo, Paul/F-6458-2019	Jobling, Michael/0000-0001-7689-3093; Lencer, Wayne/0000-0001-7346-2730	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031940] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK033506, R01DK035932, R01DK048106, R37DK048106, R37DK035932] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI031940] Funding Source: Medline; NIDDK NIH HHS [DK48106, DK35932, DK33506] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome TrustEuropean Commission)		BAIRD AW, 1991, AM J PHYSIOL, V261, pC822, DOI 10.1152/ajpcell.1991.261.5.C822; BARRETT AJ, 1994, METHOD ENZYMOL, V274, P1; Bastiaens PIH, 1996, EMBO J, V15, P4246, DOI 10.1002/j.1460-2075.1996.tb00799.x; BOOTH BA, 1984, INFECT IMMUN, V45, P558, DOI 10.1128/IAI.45.3.558-560.1984; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CASSEL D, 1977, P NATL ACAD SCI USA, V74, P3307, DOI 10.1073/pnas.74.8.3307; CHAI KX, 1993, J BIOL CHEM, V268, P24498; CHEN LM, 1995, BIOCHEM J, V307, P481, DOI 10.1042/bj3070481; DHARMSATHAPHORN K, 1990, METHOD ENZYMOL, V192, P354; DICKINSON BL, 1995, INFECT IMMUN, V63, P1617, DOI 10.1128/IAI.63.5.1617-1623.1995; DONOWITZ M, 1987, PHYSL GASTROINTESTIN, V2, P1351; FIELD M, 1993, ANNU REV PHYSIOL, V55, P631, DOI 10.1146/annurev.ph.55.030193.003215; GORDON VM, 1994, INFECT IMMUN, V62, P333, DOI 10.1128/IAI.62.2.333-340.1994; GRANT CCR, 1994, INFECT IMMUN, V62, P4270, DOI 10.1128/IAI.62.10.4270-4278.1994; HALM DR, 1990, TXB SECRETORY DIARRH, P47; HIRST TR, 1995, HDB NATURAL TOXINS, V8, P123; KASSIS S, 1982, J BIOL CHEM, V257, P2148; Kaufman Melissa R., 1994, P187; KIMBERG DV, 1971, J CLIN INVEST, V50, P1218, DOI 10.1172/JCI106599; LEE CM, 1991, J CLIN INVEST, V87, P1780, DOI 10.1172/JCI115197; LENCER WI, 1993, J CLIN INVEST, V92, P2941, DOI 10.1172/JCI116917; LENCER WI, 1992, J CELL BIOL, V117, P1197, DOI 10.1083/jcb.117.6.1197; LENCER WI, 1995, P NATL ACAD SCI USA, V92, P10094, DOI 10.1073/pnas.92.22.10094; LENCER WI, 1995, AM J PHYSIOL-GASTR L, V269, pG548, DOI 10.1152/ajpgi.1995.269.4.G548; LENCER WI, 1995, J CELL BIOL, V131, P951, DOI 10.1083/jcb.131.4.951; Madara JL, 1992, J TISS CULT METHODS, V14, P209; Majoul IV, 1996, J CELL BIOL, V133, P777, DOI 10.1083/jcb.133.4.777; MEKALANOS JJ, 1979, J BIOL CHEM, V254, P5855; MEKALANOS JJ, 1988, METHOD ENZYMOL, V165, P169; MERRITT EA, 1994, PROTEIN SCI, V3, P166; MOSS J, 1993, J BIOL CHEM, V268, P6383; Ottemann Karen M., 1994, P177; PELHAM H R B, 1992, Trends in Cell Biology, V2, P183, DOI 10.1016/0962-8924(92)90230-K; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SPANGLER BD, 1992, MICROBIOL REV, V56, P622, DOI 10.1128/MMBR.56.4.622-647.1992; UESAKA Y, 1994, MICROB PATHOGENESIS, V16, P71, DOI 10.1006/mpat.1994.1007; YU J, 1993, J BIOL CHEM, V268, P4326; [No title captured]	39	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15562	15568		10.1074/jbc.272.24.15562	http://dx.doi.org/10.1074/jbc.272.24.15562			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182593	hybrid			2022-12-27	WOS:A1997XE03400076
J	Brown, D; Brown, J; Kang, CH; Gold, L; Allen, P				Brown, D; Brown, J; Kang, CH; Gold, L; Allen, P			Single-stranded RNA recognition by the bacteriophage T4 translational repressor, RegA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-44 MESSENGER-RNA; DNA-POLYMERASE; PROTEIN BINDS; IDENTIFICATION; REGION; SITE	The T4 protein, RegA, is a translational repressor that blocks ribosome binding to multiple T4 messages by interacting with the mRNAs near their respective AUG start codons. Other than the AUG, there are no obvious similarities between the affected mRNAs, High affinity RNA ligands to RegA were isolated using SELEX (Systematic evolution of ligands by exponential enrichment). The selected RNAs exhibited the consensus sequence 5'-AAAAUUGUUAUGUAA-3'. The AUG was invariant, suggesting that it is the primary effector of binding specificity. The UU immediately 5' to the AUG and the upstream poly(A) tract were highly conserved among the selected RNAs. Boundary and footprinting experiments are consistent with the consensus sequence defining the RegA-binding site. Interestingly, chemical modification and nuclease digestion data indicate that the RNA-binding site is single-stranded, as if RegA discriminates between targets based on their primary sequence, not their secondary structure. Minor variations from the consensus at positions other than the universally conserved AUG have little effect on RegA binding, but accumulation of mutations has a profound effect on the interaction. Comparison of the in vivo targets for RegA to the SELEX-generated consensus suggests a repression pattern whereby the translation of individual messages is sequentially halted until the least similarly affected message, the regA gene itself, is repressed.	UNIV COLORADO, DEPT MOL CELLULAR & DEV BIOL, BOULDER, CO 80309 USA; NEXSTAR PHARMACEUT INC, BOULDER, CO 80301 USA; WASHINGTON STATE UNIV, DEPT BIOCHEM & BIOPHYS, PULLMAN, WA 99164 USA	University of Colorado System; University of Colorado Boulder; Washington State University					NIAID NIH HHS [AI39186] Funding Source: Medline; NIGMS NIH HHS [GM19963, GM53651] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019963, R37GM019963, R29GM053651] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BINKLEY J, 1995, NUCLEIC ACIDS RES, V23, P3198, DOI 10.1093/nar/23.16.3198; BROWN D, 1995, BIOCHEMISTRY-US, V34, P14765, DOI 10.1021/bi00045a018; CAMPBELL K, 1982, INTERACTION TRANSLAT, P69; CAMPBELL KM, 1983, GENE FUNCTION PROKAR, P185; CARDILLO TS, 1979, J VIROL, V32, P905, DOI 10.1128/JVI.32.3.905-916.1979; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHEN H, 1997, IN PRESS METHODS ENZ, V275; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; KANG CH, 1995, SCIENCE, V268, P1170, DOI 10.1126/science.7761833; KARAM J, 1981, P NATL ACAD SCI-BIOL, V78, P4669, DOI 10.1073/pnas.78.8.4669; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; MACDONALD PM, 1984, EMBO J, V3, P2863, DOI 10.1002/j.1460-2075.1984.tb02221.x; Maniatis T., 1982, MOL CLONING; MCCARTHY JEG, 1990, TRENDS GENET, V6, P78, DOI 10.1016/0168-9525(90)90098-Q; MILLER ES, 1987, J MOL BIOL, V194, P397, DOI 10.1016/0022-2836(87)90670-X; MILLER ES, 1994, MOL BIOL BACTERIOP T, V4, P193; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; OMALLEY SM, 1995, J BIOL CHEM, V270, P5107, DOI 10.1074/jbc.270.10.5107; STANDART N, 1994, BIOCHIMIE, V76, P867, DOI 10.1016/0300-9084(94)90189-9; STERN S, 1988, METHOD ENZYMOL, V164, P481; SZEWCZAK AA, 1991, J BIOL CHEM, V266, P17832; TRIMBLE RB, 1976, J VIROL, V17, P538, DOI 10.1128/JVI.17.2.538-549.1976; TUERK C, 1990, J MOL BIOL, V213, P749, DOI 10.1016/S0022-2836(05)80261-X; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; UNNITHAN S, 1990, NUCLEIC ACIDS RES, V18, P7083, DOI 10.1093/nar/18.23.7083; WEBSTER KR, 1992, J BIOL CHEM, V267, P26097; WEBSTER KR, 1989, NUCLEIC ACIDS RES, V17, P10047, DOI 10.1093/nar/17.23.10047; WEBSTER KR, 1990, J BIOL CHEM, V265, P19007; Wiberg J. S., 1983, BACTERIOPHAGE T4, P193; WINTER RB, 1987, P NATL ACAD SCI USA, V84, P7822, DOI 10.1073/pnas.84.22.7822	30	22	23	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14969	14974		10.1074/jbc.272.23.14969	http://dx.doi.org/10.1074/jbc.272.23.14969			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169470	hybrid			2022-12-27	WOS:A1997XC32700067
J	Marciset, O; JeronimusStratingh, MC; Mollet, B; Poolman, B				Marciset, O; JeronimusStratingh, MC; Mollet, B; Poolman, B			Thermophilin 13, a nontypical antilisterial poration complex bacteriocin, that functions without a receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; LACTIC-ACID BACTERIA; 2 PEPTIDES; LACTOCOCCAL BACTERIOCIN; COMPLEMENTARY ACTION; ESCHERICHIA-COLI; ACTIVITY DEPENDS; PURIFICATION; PROTEIN; RECONSTITUTION	A novel broad host range antimicrobial substance, Thermophilin 13, has been isolated and purified from the growth medium of Streptococcus thermophilus. Thermophilin 13 is composed of the antibacterial peptide ThmA (M-r of 5776) and the enhancing factor ThmB (M-r of 3910); the latter peptide increased the activity of ThmA similar to 40 x, Both peptides are encoded by a single operon, and an equimolar ratio was optimal for Thermophilin 13 activity, Despite the antilisterial activity of Thermophilin 13, neither ThmA nor ThmB contain the YGNGV-C consensus sequence of Listeria active peptides, and post-translational modifications comparable to that in the lantibiotics are also absent, Mass spectrometry did reveal the apparent oxidation of methionines in ThmA, which resulted in a peptide that could not be enhanced any longer by ThmB, whereas the intrinsic bactericidal activity was normal, Thermophilin 13 dissipated the membrane potential and the pH gradient in liposomes, and this activity was independent of membrane components from a sensitive strain (e.g. lipid or proteinaceous receptor), Models of possible poration complexes formed are proposed on the basis of sequence comparisons, structure predictions, and the functional analysis of Thermophilin 13.	UNIV GRONINGEN, DEPT MICROBIOL, GRONINGEN BIOMOL SCI & BIOTECHNOL INST, NL-9751 NN HAREN, NETHERLANDS; NESTEC LTD, NESTLE RES CTR, CH-1000 LAUSANNE 26, SWITZERLAND; UNIV GRONINGEN, CTR PHARM, NL-9713 AW GRONINGEN, NETHERLANDS	University of Groningen; Nestle SA; University of Groningen								ABEE T, 1995, FEMS MICROBIOL LETT, V129, P1, DOI 10.1016/0378-1097(95)00137-T; ALLISON GE, 1994, J BACTERIOL, V176, P2235, DOI 10.1128/JB.176.8.2235-2241.1994; BRUNO MEC, 1993, APPL ENVIRON MICROB, V59, P3003, DOI 10.1128/AEM.59.9.3003-3010.1993; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CONZALES B, 1994, APPL ENVIRON MICROB, V60, P2158; CONZALES B, 1996, APPL ENVIRON MICROB, V62, P2701; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; DAMIANO E, 1984, FEBS LETT, V166, P120, DOI 10.1016/0014-5793(84)80056-3; DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X; Diep DB, 1996, J BACTERIOL, V178, P4472, DOI 10.1128/jb.178.15.4472-4483.1996; DRIESSEN AJM, 1993, METHOD ENZYMOL, V221, P394, DOI 10.1016/0076-6879(93)21032-4; FOUCAUD C, 1992, J BIOL CHEM, V267, P22087; GAO FH, 1991, APPL ENVIRON MICROB, V57, P2164, DOI 10.1128/AEM.57.8.2164-2170.1991; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GARVER KI, 1994, APPL ENVIRON MICROB, V60, P2191, DOI 10.1128/AEM.60.6.2191-2195.1994; HUCHO F, 1994, TRENDS BIOCHEM SCI, V19, P383, DOI 10.1016/0968-0004(94)90116-3; JACK RW, 1995, MICROBIOL REV, V59, P171, DOI 10.1128/MMBR.59.2.171-200.1995; JIMENEZDIAZ R, 1995, APPL ENVIRON MICROB, V61, P4459; KLAENHAMMER TR, 1993, FEMS MICROBIOL REV, V12, P39, DOI 10.1111/j.1574-6976.1993.tb00012.x; KONINGS WN, 1989, CRC CR REV MICROBIOL, V16, P419, DOI 10.3109/10408418909104474; LOLKEMA JS, 1982, BIOCHIM BIOPHYS ACTA, V681, P85, DOI 10.1016/0005-2728(82)90281-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALOY WL, 1995, BIOPOLYMERS, V37, P105, DOI 10.1002/bip.360370206; MARCISET O, 1994, BIOTECHNOL BIOENG, V43, P490, DOI 10.1002/bit.260430609; MELLOR IR, 1988, BIOCHIM BIOPHYS ACTA, V942, P280, DOI 10.1016/0005-2736(88)90030-2; Moll G, 1996, J BACTERIOL, V178, P600, DOI 10.1128/jb.178.3.600-605.1996; NISSENMEYER J, 1993, J GEN MICROBIOL, V139, P1973, DOI 10.1099/00221287-139-9-1973; NISSENMEYER J, 1992, J BACTERIOL, V174, P5686, DOI 10.1128/JB.174.17.5686-5692.1992; OLEARY WN, 1988, MICROBIAL LIPIDS, P179; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; SAHL HG, 1995, EUR J BIOCHEM, V230, P827, DOI 10.1111/j.1432-1033.1995.tb20627.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VANBELKUM MJ, 1991, APPL ENVIRON MICROB, V57, P492, DOI 10.1128/AEM.57.2.492-498.1991; VIITANEN P, 1986, METHOD ENZYMOL, V125, P429; ZUBER P, 1992, BACILLUS SUBTILIS OT, P897	36	110	114	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14277	14284		10.1074/jbc.272.22.14277	http://dx.doi.org/10.1074/jbc.272.22.14277			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162062	Green Published, hybrid			2022-12-27	WOS:A1997XB49200049
J	Olshevskaya, EV; Hughes, RE; Hurley, JB; Dizhoor, AM				Olshevskaya, EV; Hughes, RE; Hurley, JB; Dizhoor, AM			Calcium binding, but not a calcium-myristoyl switch, controls the ability of guanylyl cyclase-activating protein GCAP-2 to regulate photoreceptor guanylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; AMINO TERMINUS; MEMBRANE; VERTEBRATE; RECOVERIN; PHOTOTRANSDUCTION; PHOSPHODIESTERASE; EXPRESSION; RECEPTORS; RETGC	Guanylyl cyclase-activating protein 2 (GCAP-2) is a recoverin-like calcium binding protein that regulates photoreceptor guanylyl cyclase (RetGC) (Dizhoor, A, M., and Hurley, J. B. (1996) J. Biol. Chem. 271, 19346-19350), It was reported that myristoylation of a related protein, GCAP-1, was critical for its affinity for RetGC (Frins, S,, Bonigk W,, Muller, F,, Kellner, R,, and Koch, K,-W, (1996) J, Biol. Chem, 271, 8022-8027), We demonstrate that the N terminus of GCAP-2, like those of other members of the recoverin family of Ca2+-binding proteins, is fatty acylated. However, unlike other proteins of this family, more GCAP-2 is present in the membrane fraction at low Ca2+ than at high Ca2+ concentrations. We investigated the role of the N-terminal fatty acyl residue in the ability of GCAP-2 to regulate RetGCs, Myristoylated or nonacylated GCAP-2 forms were expressed in Escherichia coli, Wild-type GCAP-2 and the Gly(2) --> Ala(2) GCAP-2 mutant, which is unable to undergo N-terminal myristoylation, were also expressed in mammalian HEK293 cells, We found that compartmentalization of GCAP-2 in photoreceptor outer segment membranes is Ca2+- and ionic strength-sensitive, but it does not require the presence of the fatty acyl group and does not necessarily directly reflect GCAP-2 interaction with RetGC, The lack of myristoylation does not significantly affect the ability of GCAP-2 to stimulate RetGC, Nor does it affect the ability of the Ca2+-loaded form of GCAP-2 to compete with the GCAP-2 mutant that constitutively activates RetGC, We conclude that while Ca2+ binding plays a major regulatory role in GCAP-2 function, it does not operate through a calcium-myristoyl switch similar to the one found in recoverin.	UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA; UNIV WASHINGTON, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle				Dizhoor, Alexander/0000-0001-6770-9186	NATIONAL EYE INSTITUTE [R01EY011522] Funding Source: NIH RePORTER; NEI NIH HHS [EY11522] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ames JB, 1995, J BIOL CHEM, V270, P30909, DOI 10.1074/jbc.270.52.30909; Ames JB, 1996, CURR OPIN STRUC BIOL, V6, P432, DOI 10.1016/S0959-440X(96)80106-0; Aparicio JG, 1996, J BIOL CHEM, V271, P27083, DOI 10.1074/jbc.271.43.27083; Baylor D, 1996, P NATL ACAD SCI USA, V93, P560, DOI 10.1073/pnas.93.2.560; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; Dizhoor AM, 1996, J BIOL CHEM, V271, P19346, DOI 10.1074/jbc.271.32.19346; Duda T, 1996, BIOCHEMISTRY-US, V35, P8478, DOI 10.1021/bi960752z; Frins S, 1996, J BIOL CHEM, V271, P8022, DOI 10.1074/jbc.271.14.8022; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GORACZNIAK RM, 1994, BIOCHEM J, V302, P455, DOI 10.1042/bj3020455; GORCZYCA WA, 1995, J BIOL CHEM, V270, P22029, DOI 10.1074/jbc.270.37.22029; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P1014; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; Hallett MA, 1996, J CELL SCI, V109, P1803; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4746, DOI 10.1073/pnas.88.11.4746; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; HUGHES RE, 1995, BIOCHEMISTRY-US, V34, P11410, DOI 10.1021/bi00036a013; JOHNSON RS, 1994, J BIOL CHEM, V269, P21067; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KOBAYASHI M, 1993, J BIOL CHEM, V268, P18898; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOCH KW, 1991, J BIOL CHEM, V266, P8634; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; LADANT D, 1995, J BIOL CHEM, V270, P3179; Laura RP, 1996, J BIOL CHEM, V271, P11646, DOI 10.1074/jbc.271.20.11646; LIU XR, 1994, EXP EYE RES, V59, P761, DOI 10.1006/exer.1994.1162; LOLLEY RN, 1982, VISION RES, V22, P1481, DOI 10.1016/0042-6989(82)90213-9; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; McDowell J. H., 1993, PHOTORECEPTOR CELLS, V15, P123; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; POZDNYAKOV N, 1995, BIOCHEMISTRY-US, V34, P14279, DOI 10.1021/bi00044a002; ROCQUE WJ, 1993, J BIOL CHEM, V268, P9964; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; SITARAMAYYA A, 1995, MOL CELL BIOCHEM, V148, P139, DOI 10.1007/BF00928151; SUBBARAYA I, 1994, J BIOL CHEM, V269, P31080; Surgucheva Irina, 1996, Investigative Ophthalmology and Visual Science, V37, pS215; Surguchov A, 1997, GENOMICS, V39, P312, DOI 10.1006/geno.1996.4513; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; Wolbring G, 1996, BIOCHEMISTRY-US, V35, P11013, DOI 10.1021/bi960699e; YANG RB, 1995, P NATL ACAD SCI USA, V92, P602, DOI 10.1073/pnas.92.2.602; YARFITZ S, 1994, J BIOL CHEM, V269, P14329; YUEN PST, 1992, ANNU REV NEUROSCI, V15, P193; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	48	118	119	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14327	14333		10.1074/jbc.272.22.14327	http://dx.doi.org/10.1074/jbc.272.22.14327			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162068	hybrid			2022-12-27	WOS:A1997XB49200055
J	Sakharov, DV; Plow, EF; Rijken, DC				Sakharov, DV; Plow, EF; Rijken, DC			On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; PLASMINOGEN-ACTIVATOR; CLOT LYSIS; HUMAN-SERUM; FIBRINOLYSIS; THROMBOMODULIN; SYSTEM; PURIFICATION; INHIBITOR; THROMBIN	The precursor of plasma carboxypeptidase B (pCPB) also known as thrombin-activable fibrinolysis inhibitor can be converted by thrombin to an active enzyme capable of eliminating C-terminal Lys- and Arg-residues from proteins. The activation is about 1000-fold more efficient in the presence of thrombomodulin (TM), We investigated the antifibrinolytic potency of maximally activated pCPB in plasma and explored the antifibrinolytic mechanism of pCPB, During clotting of plasma in the presence of 3.3 NIH units/ml thrombin and 1 mu g/ml soluble TM, more than 80% pro-pCPB was converted into the active form causing an increase of plasma carboxypeptidase activity from 100 units/liter (constitutive activity ascribed to plasma carboxypeptidase N) to 430 units/liter as measured with furoylacroleyl-alanyl-arginine substrate, Under these conditions, lysis of a plasma clot induced by a range of tissue-type plasminogen activator (t-PA) concentrations (0.2-2 mu g/ml) was retarded more than 4-fold. A considerable retardation of fibrinolysis was observed upon addition of as little as 12 ng/ml soluble TM, a concentration comparable with physiological concentrations of soluble TM in human plasma, The presence of Ca2+ appeared to be a critical requirement for effective activation of pro-pCPB by thrombin-TM in plasma, Plasminogen-binding sites (C-terminal lysines) on the surface of a plasmin-treated fibrin clot were eliminated within 1-3 min by plasma with maximally activated pCPB, as studied in a recently described model involving fluorescence microscopy, Confocal fluorescence microscopy showed that in the absence of TM plasminogen strongly accumulated on fibrin fibers during t-PA-induced lysis of a plasma clot. In the presence of TM (and a concomitant pro-pCPB activation), lysis was slow and was not accompanied by accumulation of plasminogen on the fibers, In conclusion, generation of active pCPB during clotting of plasma in the presence of Ca2+ and TM leads to a retardation of plasma clot lysis in a wide range of t-PA concentrations, from low to therapeutic, and to a fast elimination of plasminogen-binding sites on partially degraded fibrin, This is a likely mechanism for the antifibrinolytic effect of active pCPB.	CLEVELAND CLIN FDN,DEPT MOL CARDIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation	Sakharov, DV (corresponding author), TNO PREVENT & HLTH,GAUBIUS LAB,POB 2215,NL-2301 CE LEIDEN,NETHERLANDS.							AMIRAL J, 1994, HYBRIDOMA, V13, P205, DOI 10.1089/hyb.1994.13.205; Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; Bajzar L, 1996, J BIOL CHEM, V271, P22949, DOI 10.1074/jbc.271.38.22949; BAJZAR L, 1993, J BIOL CHEM, V268, P8608; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Bajzar L, 1996, BLOOD, V88, P2093, DOI 10.1182/blood.V88.6.2093.bloodjournal8862093; BAJZAR L, 1990, J BIOL CHEM, V265, P16948; Broze GJ, 1996, BLOOD, V88, P3815, DOI 10.1182/blood.V88.10.3815.bloodjournal88103815; COLLEN D, 1989, DRUGS, V38, P346, DOI 10.2165/00003495-198938030-00003; DEFOUW NJ, 1986, BLOOD, V67, P1189; DEFOUW NJ, 1993, BLOOD COAGUL FIBRIN, V4, P201, DOI 10.1097/00001721-199304000-00001; DEFOUW NJ, 1988, THESIS U LEIDEN NETH; EATON DL, 1991, J BIOL CHEM, V266, P21833; ESMON CT, 1989, J BIOL CHEM, V264, P4743; FLEURY V, 1993, J BIOL CHEM, V268, P18554; HENDRIKS D, 1990, BIOCHIM BIOPHYS ACTA, V1034, P86, DOI 10.1016/0304-4165(90)90157-R; HENDRIKS D, 1989, J CLIN CHEM CLIN BIO, V27, P277; KAWAKAMI M, 1992, J RHEUMATOL, V19, P1704; LIU JN, 1992, BIOCHEMISTRY-US, V31, P6311, DOI 10.1021/bi00142a021; NORRMAN B, 1985, EUR J BIOCHEM, V149, P193, DOI 10.1111/j.1432-1033.1985.tb08911.x; REDLITZ A, 1995, J CLIN INVEST, V96, P2534, DOI 10.1172/JCI118315; Redlitz A, 1996, CIRCULATION, V93, P1328, DOI 10.1161/01.CIR.93.7.1328; SAKHAROV DV, 1995, CIRCULATION, V92, P1883, DOI 10.1161/01.CIR.92.7.1883; Sakharov DV, 1996, J BIOL CHEM, V271, P2133, DOI 10.1074/jbc.271.4.2133; Sakharov DV, 1996, J BIOL CHEM, V271, P27912, DOI 10.1074/jbc.271.44.27912; SAKHAROV DV, 1994, FIBRINOLYSIS, V8, P116, DOI 10.1016/0268-9499(94)90268-2; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; TANAKA A, 1991, CLIN CHEM, V37, P269; TANSWELL P, 1992, J AM COLL CARDIOL, V19, P1071, DOI 10.1016/0735-1097(92)90297-Z; Von Dem Borne P. A. K., 1996, Fibrinolysis, V10, P81; VONDEMBORNE PAK, 1995, BLOOD, V86, P3035; WANG W, 1994, J BIOL CHEM, V269, P15937; Wang W., 1996, Fibrinolysis, V10, P124; WIMAN B, 1978, NATURE, V272, P549, DOI 10.1038/272549a0	35	187	190	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14477	14482		10.1074/jbc.272.22.14477	http://dx.doi.org/10.1074/jbc.272.22.14477			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162090	Green Published, hybrid			2022-12-27	WOS:A1997XB49200077
J	Zaia, J; Boynton, RE; McIntosh, A; Marshak, DR; Olsson, H; Heinegard, D; Barry, FP				Zaia, J; Boynton, RE; McIntosh, A; Marshak, DR; Olsson, H; Heinegard, D; Barry, FP			Post-translational modifications in cartilage oligomeric matrix protein - Characterization of the N-linked oligosaccharides by matrix-assisted laser desorption ionization time-of-flight mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMP; PSEUDOACHONDROPLASIA; MUTATIONS	Analysis of the carboxymethylated subunit of human cartilage oligomeric matrix protein (COMP) by matrix-assisted laser desorption time-of-flight mass spectrometry indicated a protonated molecular mass of 86949 +/- 149 Da, compared with 83547.0 Da calculated from the sequence, Treatment with N-glycanase caused a reduction in mass of 3571 +/- 219 Da, but there was no loss of mass after treatment with O-glycanase or neuraminidase, Peptides containing two putative sites of N-glycosylation were purified and characterized, Analysis of the masses of these after N-glycanase treatment indicated that one was substituted at Asn-101 with an oligosaccharide of mass 1847.2 +/- 6.6 Da, and the other was unsubstituted at Asn-124, The remaining site of attachment, at Asn-721, was, therefore, also substituted with an oligosaccharide of mass 1724 +/- 226 Da. Analysis of the total monosaccharide content by chemical methods indicated that there were no additional oligosaccharide substituents, The MALDI-TOF mass spectra of COMP from bovine fetal and adult cartilage were compared, indicating a more heterogeneous pattern of substitution at Asn-101 in the fetal form, Since COMP is distributed throughout the pericellular and territorial environments in developing cartilage but occupies the interterritorial zone in mature cartilage, these changes in glycosylation may allow for different intermolecular interactions.	OSIRIS THERAPEUT INC,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,BALTIMORE,MD 21205; LUND UNIV,DEPT CELL & MOL BIOL,S-22100 LUND,SWEDEN	Osiris Therapeutics; Johns Hopkins University; Johns Hopkins University; Lund University			Barry, Frank P/K-5960-2013; Zaia, Joseph/U-7850-2019	Zaia, Joseph/0000-0001-9497-8701; Olsson, Henric/0000-0002-5101-8871				ALLEN G, 1989, SEQUENCING PROTEINS; BARRY FP, 1995, J BIOL CHEM, V270, P20516, DOI 10.1074/jbc.270.35.20516; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; DICESARE P, 1994, FEBS LETT, V354, P237, DOI 10.1016/0014-5793(94)01134-6; FRANZEN A, 1987, DIFFERENTIATION, V36, P199, DOI 10.1111/j.1432-0436.1987.tb00194.x; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Malashkevich VN, 1996, SCIENCE, V274, P761, DOI 10.1126/science.274.5288.761; MORGELIN M, 1992, J BIOL CHEM, V267, P6137; NEWTON G, 1994, GENOMICS, V24, P435, DOI 10.1006/geno.1994.1649; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; SHEN Z, 1994, MATRIX BIOL, V14, P773; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; WANG WC, 1988, J BIOL CHEM, V263, P4576	17	30	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14120	14126		10.1074/jbc.272.22.14120	http://dx.doi.org/10.1074/jbc.272.22.14120			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162039	hybrid			2022-12-27	WOS:A1997XB49200026
J	Hung, CH; Huang, HR; Huang, CJ; Huang, FL; Chang, GD				Hung, CH; Huang, HR; Huang, CJ; Huang, FL; Chang, GD			Purification and cloning of carp nephrosin, a secreted zinc endopeptidase of the astacin family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BOUND METALLOENDOPEPTIDASE; 2 CONSTITUENT PROTEASES; SODIUM DODECYL-SULFATE; EXTRACELLULAR-MATRIX; CYPRINUS-CARPIO; MESSENGER-RNAS; HATCHING ENZYME; ORYZIAS-LATIPES; TELEOST FISH; HEAD KIDNEY	We have purified a secreted proteinase of 23 kDa from carp head kidney by sequential column chromatography on a Reactive Blue 72-agarose dye affinity column and an FPLC Mono-P column. The secretion of this proteinase from carp head kidney can be stimulated by high concentrations of potassium. Since the carp proteinase is present mainly in the head kidney, kidney, and spleen (all of which are lymphohematopoietic organs), it is named nephrosin. The carp nephrosin is most sensitive to metal chelators, but not to inhibitors specific for other classes of proteinases. A cDNA clone has been isolated from a carp head kidney cDNA library by immunoscreening with a polyclonal antiserum raised against purified nephrosin. The cloned cDNA is 1086 base pairs in length and has an open reading frame encoding a protein of 273 amino acids, including a 19-amino acid signal peptide and 56-amino acid propeptide. The deduced amino acid sequence shows moderate levels of identity to medaka HCE1 (52.5%), medaka LCE (50.7%), crayfish astacin (33.2%), murine meprin-alpha (34%), and murine meprin-beta (33.5%), all members of the astacin family of zinc endopeptidases. Nephrosin is the first member of the astacin family found in lymphohematopoietic tissues.	NATL TAIWAN UNIV,GRAD INST BIOCHEM SCI,TAIPEI 10098,TAIWAN; NATL TAIWAN UNIV,DEPT ZOOL,TAIPEI 10098,TAIWAN; ACAD SINICA,INST BIOL CHEM,TAIPEI 115,TAIWAN	National Taiwan University; National Taiwan University; Academia Sinica - Taiwan								BALM PHM, 1989, GEN COMP ENDOCR, V76, P53, DOI 10.1016/0016-6480(89)90032-4; BARNES K, 1989, BIOCHEM J, V264, P335, DOI 10.1042/bj2640335; BENGTEN E, 1991, EUR J IMMUNOL, V21, P3027, DOI 10.1002/eji.1830211219; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER PE, 1987, BIOCHEM J, V241, P229, DOI 10.1042/bj2410229; CORBEIL D, 1993, FEBS LETT, V335, P361, DOI 10.1016/0014-5793(93)80420-Y; GALLO VP, 1993, GEN COMP ENDOCR, V92, P133, DOI 10.1006/gcen.1993.1150; GORBEA CM, 1993, J BIOL CHEM, V268, P21035; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HASPAL J, 1983, ANAL BIOCHEM, V132, P288; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HUANG CJ, 1995, J NEUROCHEM, V64, P1715; HUANG FL, 1983, ARCH BIOCHEM BIOPHYS, V225, P512, DOI 10.1016/0003-9861(83)90061-9; IMAGAWA T, 1990, J FISH BIOL, V37, P357, DOI 10.1111/j.1095-8649.1990.tb05866.x; Imagawa T., 1991, Fish & Shellfish Immunology, V1, P173, DOI 10.1016/S1050-4648(10)80003-8; IMAGAWA T, 1996, ANATOMY, V188, P149; JOHNSON GD, 1992, J BIOL CHEM, V267, P13505; JOHNSON GD, 1993, J BIOL CHEM, V268, P17647; KAUSHAL GP, 1994, J CELL BIOL, V126, P1319, DOI 10.1083/jcb.126.5.1319; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOUMANSVANDIEPEN JCE, 1995, DEV COMP IMMUNOL, V19, P97, DOI 10.1016/0145-305X(94)00061-J; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEE KS, 1994, FEBS LETT, V339, P281, DOI 10.1016/0014-5793(94)80431-1; LEPAGE T, 1992, DEVELOPMENT, V114, P147; Levine J E, 1986, Methods Enzymol, V124, P466; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REYNOLDS SD, 1992, DEVELOPMENT, V114, P769; Sambrook J., 2002, MOL CLONING LAB MANU; SANGALANG GB, 1994, GEN COMP ENDOCR, V95, P273, DOI 10.1006/gcen.1994.1124; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHIMELL MJ, 1991, CELL, V67, P479; SHIMIZU Y, 1991, FASEB J, V5, P2292, DOI 10.1096/fasebj.5.9.1860621; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TITANI K, 1987, BIOCHEMISTRY-US, V26, P222, DOI 10.1021/bi00375a029; Tsai YJ, 1996, COMP BIOCHEM PHYS B, V113, P573, DOI 10.1016/0305-0491(95)02070-5; VERBURGVANKEMENADE BML, 1994, J EXP BIOL, V187, P143; VOGT G, 1989, HISTOCHEMISTRY, V91, P373, DOI 10.1007/BF00493824; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YAMAGUCHI T, 1993, J BIOCHEM-TOKYO, V113, P299, DOI 10.1093/oxfordjournals.jbchem.a124042; YAN L, 1995, DEVELOPMENT, V121, P1591; YASUMASU S, 1992, DEV BIOL, V149, P349, DOI 10.1016/0012-1606(92)90290-W; YASUMASU S, 1992, DEV BIOL, V153, P250, DOI 10.1016/0012-1606(92)90110-3; ZAPATA A, 1979, DEV COMP IMMUNOL, V3, P55, DOI 10.1016/S0145-305X(79)80006-3	50	25	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13772	13778		10.1074/jbc.272.21.13772	http://dx.doi.org/10.1074/jbc.272.21.13772			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153232	hybrid, Green Published			2022-12-27	WOS:A1997XA06200047
J	Kimura, M; Kotani, S; Hattori, T; Sumi, N; Yoshioka, T; Todokoro, K; Okano, Y				Kimura, M; Kotani, S; Hattori, T; Sumi, N; Yoshioka, T; Todokoro, K; Okano, Y			Cell cycle-dependent expression and spindle pole localization of a novel human protein kinase, aik, related to aurora of Drosophila and yeast Ipl1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CENTROSOMES; MITOSIS; PLK; EXTRACTS; TYROSINE; ENCODES; HOMOLOG; CLONING; MUTANT	Mutations in Aurora of Drosophila and related Saccharomyces cerevisiae Ipl1 kinase are known to cause abnormal chromosome segregation. We have isolated a cDNA encoding a novel human protein kinase of 402 amino acids with a predicted molecular mass of 45.9 kDa, which shares high amino acid identities with the Aurora/Ipl1 protein kinase family; hence the cDNA is designated as Aik (aurora/IPL1-related kinase). Amino acid sequence of C-terminal kinase domain of Aik shares 86, 86, 72, 59, and 49% identity with those of Xenopus XLP46APK and XLP46BPK, mouse STK-1, Aurora of Drosophila, and yeast Ipl1, respectively, whereas N-terminal domain of Aik shares high homology only with those of XLP46APK and XLP46BPK, Northern and Western blotting analyses revealed that Aik is expressed highly in testis and various proliferating cells including HeLa cells. In HeLa cells, the endogenous levels of aik mRNA and protein contents are tightly regulated during cell cycle progression. Both of these levels are low in G(1)/S, accumulate during G(2)/M, and reduce rapidly after mitosis. Its protein kinase activity is also enhanced at mitosis as inferred by exogenous casein phosphorylation. Immunofluorescence studies using a specific antibody have shown that Aik is localized to the spindle pole during mitosis, especially from prophase through anaphase. These results strongly suggest that Aik is a novel member of a protein kinase family possibly involved in a centrosome function(s) such as chromosome segregation or spindle formation.	GIFU UNIV,SCH MED,DEPT MOL PATHOBIOCHEM,GIFU 500,JAPAN; RIKEN,INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,TSUKUBA,IBARAKI 305,JAPAN	Gifu University; RIKEN								AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; BUENDIA B, 1992, J CELL BIOL, V116, P1431, DOI 10.1083/jcb.116.6.1431; CENTONZE VE, 1990, J CELL SCI, V95, P405; CHAN CSM, 1993, GENETICS, V135, P677; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; DAVIDPFEUTY T, 1993, J CELL SCI, V105, P613; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; KELLOGG DR, 1995, MOL BIOL CELL, V6, P1673, DOI 10.1091/mbc.6.12.1673; KIMURA M, 1991, J BIOCHEM, V109, P399, DOI 10.1093/oxfordjournals.jbchem.a123393; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; KURIYAMA R, 1992, EXP CELL RES, V202, P345, DOI 10.1016/0014-4827(92)90084-L; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; LEE KS, 1995, MOL CELL BIOL, V15, P7143; LEY SC, 1994, J CELL BIOL, V125, P639, DOI 10.1083/jcb.125.3.639; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; MAITY M, 1996, ONCOGENE, V13, P1647; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; Niwa H, 1996, GENE, V169, P197, DOI 10.1016/0378-1119(95)00809-8; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; STEIN GS, 1972, J CELL BIOL, V52, P292, DOI 10.1083/jcb.52.2.292; TAAGEPERA S, 1995, EXP CELL RES, V221, P249, DOI 10.1006/excr.1995.1373; VANDRE DD, 1984, P NATL ACAD SCI-BIOL, V81, P4439, DOI 10.1073/pnas.81.14.4439; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177	34	239	270	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13766	13771		10.1074/jbc.272.21.13766	http://dx.doi.org/10.1074/jbc.272.21.13766			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153231	hybrid			2022-12-27	WOS:A1997XA06200046
J	Herr, AB; Ornitz, DM; Sasisekharan, R; Venkataraman, G; Waksman, G				Herr, AB; Ornitz, DM; Sasisekharan, R; Venkataraman, G; Waksman, G			Heparin-induced self-association of fibroblast growth factor-alpha - Evidence for two oligomerization processes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; CRYSTAL-STRUCTURE; BINDING DOMAIN; CELL-SURFACE; ACTIVATION; SULFATE; DIMERIZATION; MOLECULES; MECHANISM; PRODUCE	Fibroblast growth factor-2 (FGF-2), a potent angiogenic factor, requires heparin for dimerization and activation of the FGF receptor tyrosine kinase. The binding of multiple fibroblast growth factors by heparin may be necessary for dimerization of the FGF receptor, Analytical ultracentrifugation of FGF-2 in the presence of heparin-derived saccharides shows that both an active heparin octasaccharide and an inactive heparin-like disaccharide induce fibroblast growth factor-2 self-association, Analysis of the data indicates that the heparin octasaccharide induces a monomer-dimer-tetramer assembly of FGF-2 while the disaccharide induces a monomer-dimer equilibrium. Evidence is presented indicating that the dimer conformation induced by the heparin octasaccharide is a side by side dimer with the FGF-2 molecules cis to the heparin, while the disaccharide-induced dimer is a head to head dimer in which FGF-2 molecules are trans to the ligand. These results, combined with previous studies, support the model that formation of a specific side by side heparin-induced FGF-2 dimer is required for activation of the FGF receptor.	WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOL BIOPHYS, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOL BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; MIT, HARVARD MIT DIV HLTH SCI & TECHNOL, CAMBRIDGE, MA 02139 USA	Washington University (WUSTL); Washington University (WUSTL); Harvard University; Massachusetts Institute of Technology (MIT)			Herr, Andrew/R-3049-2019	Herr, Andrew/0000-0002-3598-3399; Ornitz, David/0000-0003-1592-7629	NATIONAL CANCER INSTITUTE [R01CA060673] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R43DK051207, R44DK051207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008492] Funding Source: NIH RePORTER; NCI NIH HHS [CA60673] Funding Source: Medline; NIDDK NIH HHS [DK51207] Funding Source: Medline; NIGMS NIH HHS [5 T32 GM08492-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKAWA T, 1993, J PROTEIN CHEM, V12, P689, DOI 10.1007/BF01024927; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; Burz DS, 1996, BIOCHEMISTRY-US, V35, P3341, DOI 10.1021/bi952055x; Delehedde M, 1996, EXP CELL RES, V229, P398, DOI 10.1006/excr.1996.0385; ERIKSSON AE, 1993, PROTEIN SCI, V2, P1274, DOI 10.1002/pro.5560020810; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; GALLAGHER JT, 1992, GLYCOBIOLOGY, V2, P523, DOI 10.1093/glycob/2.6.523; Horan T, 1996, BIOCHEMISTRY-US, V35, P4886, DOI 10.1021/bi9525841; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; Lemmon MA, 1997, J BIOL CHEM, V272, P6311, DOI 10.1074/jbc.272.10.6311; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; Schlessinger J., 1979, PHYSICAL CHEM ASPECT, P89; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; Venkataraman G, 1996, P NATL ACAD SCI USA, V93, P845, DOI 10.1073/pnas.93.2.845; VLODAVSKY I, 1987, J CELL PHYSIOL, V131, P402, DOI 10.1002/jcp.1041310312; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHU XT, 1993, STRUCTURE, V1, P27, DOI 10.1016/0969-2126(93)90006-3	41	100	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16382	16389		10.1074/jbc.272.26.16382	http://dx.doi.org/10.1074/jbc.272.26.16382			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195945	hybrid			2022-12-27	WOS:A1997XG01900049
J	Paxton, LLL; Li, LJ; Secor, V; Duff, JL; Naik, SM; Shibagaki, N; Caughman, SW				Paxton, LLL; Li, LJ; Secor, V; Duff, JL; Naik, SM; Shibagaki, N; Caughman, SW			Flanking sequences for the human intercellular adhesion molecule-1 NF-kappa B response element are necessary for tumor necrosis factor alpha-induced gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL-CELLS; STIMULATING FACTOR GENE; TRANSCRIPTIONAL REGULATION; INFLAMMATORY CYTOKINES; INTERFERON-GAMMA; GLUCOCORTICOID RECEPTOR; GEL-ELECTROPHORESIS; FUNCTIONAL-ANALYSIS; BINDING-PROTEINS; ESCHERICHIA-COLI	The regulated expression of intercellular adhesion molecule-1 (ICAM-1) by cytokines such as tumor necrosis factor alpha (TNF-alpha) plays an important role in inflammation and immune responses, Induction of ICAM-1 gene transcription by TNF-alpha has previously been shown to be dependent upon a region of the ICAM-1 5'-flanking sequences that contains a modified kappa B site. We demonstrate here that this modified kappa B site alone is insufficient. for induction of transcription by TNF-alpha, Site-directed mutagenesis of both the kappa B site and specific flanking nucleotides demonstrates that both the specific 5'- and 3'-flanking sequences and the modified kappa B site are necessary for TNF-alpha induction. Further, site-directed mutagenesis of this modified kappa B site to a consensus kappa B site allows it to mediate transcriptional activation in response to TNF-alpha, even in the absence of specific flanking sequences. Transcription through this minimal ICAM-1 TNF-alpha-responsive region can be driven by coexpression of p65, and the minimal response element interacts with p65 and p50 in supershift mobility shift assays. However, when in vitro transcription/translation products for the Rel proteins ape used in an electrophoretic mobility shift assay, only p65 is capable of binding the minimal response element while both p50 and p65 bind a consensus kappa B oligonucleotide, Additionally, in the absence of the specific flanking nucleotides, the ICAM-1 kappa B site is incapable of DNA-protein complex formation in bath electrophoretic mobility shift assay and UV cross-linking/SDS -polyacrylamide gel electrophoresis analysis. These results demonstrate the requirement for specific flanking sequences surrounding a kappa B binding site for functional transcription factor binding and transactivation and TNF-alpha-mediated induction of ICAM-1.	EMORY UNIV, SCH MED, DEPT DERMATOL, EMORY SKIN DIS RES CORE CTR, ATLANTA, GA 30322 USA; EMORY UNIV, GRAD DIV BIOL & BIOMED SCI, ATLANTA, GA 30322 USA; UNIV PENN, SCH MED, DEPT DERMATOL, PHILADELPHIA, PA 19104 USA; INST CANC, CHEMOTHERAPY CTR, TOSHIMA KU, TOKAI, IBARAKI 170, JAPAN	Emory University; Emory University; University of Pennsylvania					NIAMS NIH HHS [T32 AR 07587, AR 41206, AR 42687] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007587, P30AR042687] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AHMAD M, 1995, J BIOL CHEM, V270, P8976, DOI 10.1074/jbc.270.15.8976; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; DEGITZ K, 1991, J BIOL CHEM, V266, P14024; DUSTIN ML, 1988, J EXP MED, V167, P1323, DOI 10.1084/jem.167.4.1323; DUSTIN ML, 1986, J IMMUNOL, V137, P245; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HANSEN SK, 1994, J BIOL CHEM, V269, P22230; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HOU JZ, 1994, P NATL ACAD SCI USA, V91, P11641, DOI 10.1073/pnas.91.24.11641; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; IYER RR, 1991, GENE, V105, P97, DOI 10.1016/0378-1119(91)90518-G; JAHNKE A, 1994, FEBS LETT, V354, P220, DOI 10.1016/0014-5793(94)01130-3; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; LAWLEY TJ, 1989, J INVEST DERMATOL, V93, pS59, DOI 10.1111/1523-1747.ep12581070; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LOOK DC, 1994, J BIOL CHEM, V269, P8952; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MOFFAT GJ, 1992, BIOCHEMISTRY-US, V31, P12376, DOI 10.1021/bi00164a012; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; MULLER S, 1995, J INVEST DERMATOL, V104, P970, DOI 10.1111/1523-1747.ep12606225; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; NELSH AS, 1995, MOL CELL BIOL, V15, P2558; NISHIZAWA M, 1990, MOL CELL BIOL, V10, P2002, DOI 10.1128/MCB.10.5.2002; PARRY GCN, 1994, J BIOL CHEM, V269, P20823; POBER JS, 1986, J IMMUNOL, V137, P1893; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; ROTHLEIN R, 1988, J IMMUNOL, V141, P1665; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; SCHRECK R, 1990, MOL CELL BIOL, V10, P1281, DOI 10.1128/MCB.10.3.1281; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; VANHUIJSDUIJNEN RH, 1992, J BIOL CHEM, V267, P22385; WERTHEIMER SJ, 1992, J BIOL CHEM, V267, P12030; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	57	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15928	15935		10.1074/jbc.272.25.15928	http://dx.doi.org/10.1074/jbc.272.25.15928			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188493	hybrid			2022-12-27	WOS:A1997XF32900053
J	Qu, BH; Strickland, EH; Thomas, PJ				Qu, BH; Strickland, EH; Thomas, PJ			Localization and suppression of a kinetic defect in cystic fibrosis transmembrane conductance regulator folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; NUCLEOTIDE-BINDING; SYNTHETIC PEPTIDE; MOLECULAR-BASIS; MUTATIONS; GENE; IDENTIFICATION; TRANSPORT; DISEASE	A growing body of evidence indicates that the most common cystic fibrosis-causing mutation, Delta F508, alters the ability of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to fold and transit to the plasma membrane, Here we present evidence that the Delta F508 mutation affects a step on the folding pathway prior to formation of the ATP binding site in the nucleotide binding domain (NBD), Notably, stabilization of the native state with 4 mM ATP does not alter the temperature-dependent folding yield of the mutant Delta F508 NBD1 in vitro. In contrast, glycerol, which promotes Delta F508-CFTR maturation in vivo, increases the folding yield of NBD1 Delta F and reduces the off pathway rate in vitro, although it does not significantly alter the free energy of stability, Likewise a second site mutation, R553M, which corrects the maturation defect in vivo, is a superfolder which counters the effects of Delta F508 on the temperature-dependent folding yield in vitro, but does not significantly alter the free energy of stability, A disease-causing mutation, G551D, which does not alter the maturation of CFTR in vivo but rather its function as a chloride channel, and the S549R maturation mutation have no discernible effect on the folding of the domain, These results demonstrate that Delta F508 is a kinetic folding mutation that affects a step early in the process, and that there is a significant energy barrier between the native state and the step affected by the mutation precluding the use of native state ligands to promote folding, The implications for protein folding in general are that the primary sequence may not necessarily simply define the most stable native structure, but rather a stable structure that is kinetically accessible.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Thomas, Philip J/F-7115-2012		NIDDK NIH HHS [DK49835] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK049835, R01DK049835] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DORK T, 1991, HUM GENET, V87, P441; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; KO YH, 1995, J BIOL CHEM, V270, P22093, DOI 10.1074/jbc.270.38.22093; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Miroy GJ, 1996, P NATL ACAD SCI USA, V93, P15051, DOI 10.1073/pnas.93.26.15051; Qu BH, 1996, J BIOL CHEM, V271, P7261, DOI 10.1074/jbc.271.13.7261; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RIORDAN JR, 1989, SCIENCE, V245, P1066; Sambrook J., 2002, MOL CLONING LAB MANU; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TEEM JL, 1993, CELL, V73, P335, DOI 10.1016/0092-8674(93)90233-G; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; THOMAS PJ, 1992, FEBS LETT, V312, P7, DOI 10.1016/0014-5793(92)81399-7; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J	23	109	110	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15739	15744		10.1074/jbc.272.25.15739	http://dx.doi.org/10.1074/jbc.272.25.15739			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188468	hybrid			2022-12-27	WOS:A1997XF32900028
J	BoschiMuller, S; Azza, S; Pollastro, D; Corbier, C; Branlant, G				BoschiMuller, S; Azza, S; Pollastro, D; Corbier, C; Branlant, G			Comparative enzymatic properties of GapB-encoded erythrose-4-phosphate dehydrogenase of Escherichia coli and phosphorylating glyceraldehyde-3-phosphate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; BACILLUS-STEAROTHERMOPHILUS; HOLO-GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; D-GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; COENZYME SPECIFICITY; CRYSTAL-STRUCTURE; SEQUENCE; GENE; RESOLUTION; RESIDUE	GapB-encoded protein of Escherichia coli and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) share more than 40% amino acid identity. Most of the amino acids involved in the binding of cofactor and substrates to GAP;DR are conserved in GapB-encoded protein, This enzyme shows an efficient non-phosphorylating erythrose-4-phosphate dehydrogenase activity (Zhao, G., Pease, A, J., Bharani, N., and Winkler, M. E. (1995) J. Bacteriol: 177, 2804-2812) but a low phosphorylating glyceraldehyde-3-phosphate dehydrogenase activity, whereas GAPDN shows a high efficient phosphorylating glyceraldehyde-8-phosphate dehydrogenase activity and a low phosphorylating erythrose-4-phosphate dehydrogenase activity, To identify the structural factors responsible for these differences, comparative kinetic and binding studies have been carried out on both GapB-encoded protein of Escherichia coli and GAPDH of Bacillus stearothermophilus. The K-D constant of GapB-encoded protein for NAD is 800-fold higher than that of GAPDH. The chemical mechanism of erythrose 4-phosphate oxidation by GapB-encoded protein is shown to proceed through a two-step mechanism involving covalent intermediates with Cys-149, with rates associated to the acylation and deacylation processes of 280 s(-1) and 20 s(-1), respectively. No isotopic solvent effect is observed suggesting that the rate-limiting step is not hydrolysis. The rate of oxidation of glyceraldehyde 3-phosphate is 0.12 s(-1) and is hydride transfer limiting, at least 2000-fold less efficient compared with that of erythrose 4-phosphate. Thus, it can be concluded that it is only the structure of the substrates that prevails in forming a ternary complex enzyme-NAD-thiohemiacetal productive (or not) for hydride transfer in the acylation step, This conclusion is reinforced by the fact that the rats of oxidation for erythrose 4-phosphate by GAPDH is 0.1 s(-1) and is limited by the acylation. step, whereas glyceraldehyde 3-phosphate acylation is efficient and is not rate-determining (greater than or equal to 800 s(-1)), Substituting Asn for His-176 on GapB-encoded protein, a residue postulated to facilitate hydride transfer as a base catalyst, decreases 40-fold the k(cat) of glyceraldehyde 8-phosphate oxidation. This suggests that the non-efficient positioning of the C-1 atom of glyceraldehyde 3-phosphate relative to the pyridinium of the cofactor within the ternary complex is responsible for the low catalytic efficiency, No phosphorylating activity on erythrose 4-phosphate with GapB-encoded protein is observed although the Pi site is operative as proven by the oxidative phosphorylation of glyceraldehyde 3-phosphate. Thus the binding of inorganic phosphate to the ki site likely is not productive for attacking efficiently the thioacyl intermediate formed with erythrose 4-phosphate, whereas a water molecule is an efficient nucleophile for the hydrolysis of the thioacyl intermediate, Compared with glyceraldehyde-3-phosphate dehydrogenase activity, this corresponds to an activation of the deacylation step by greater than or equal to 4.5 Kcal.mol(-1). Altogether these results suggest subtle structural differences between the active sites of GAPDH and GapB-encode protein that could be revealed and/or modulated by the structure of the substrate bound. This also indicates that a protein engineering approach could be used to convert a phosphorylating aldehyde dehydrogenase into an efficient non-phosphorylating one and vice versa.	UNIV NANCY 1, URA CNRS 457, LAB ENZYMOL & GENIE GENET, F-54506 VANDOEUVRE LES NANCY, FRANCE	Universite de Lorraine				Boschi, Sandrine/0000-0001-8962-4749				ALEFOUNDER PR, 1989, MOL MICROBIOL, V3, P723, DOI 10.1111/j.1365-2958.1989.tb00221.x; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BIESECKER G, 1977, NATURE, V266, P328, DOI 10.1038/266328a0; BRANLANT G, 1985, EUR J BIOCHEM, V150, P61, DOI 10.1111/j.1432-1033.1985.tb08988.x; CANELLAS PF, 1991, BIOCHEMISTRY-US, V30, P8871, DOI 10.1021/bi00100a021; CHARPENTIER B, 1994, J BACTERIOL, V176, P830, DOI 10.1128/jb.176.3.830-839.1994; CLERMONT S, 1993, BIOCHEMISTRY-US, V32, P10178, DOI 10.1021/bi00089a038; CORBIER C, 1994, BIOCHEMISTRY-US, V33, P3260, DOI 10.1021/bi00177a017; CORBIER C, 1990, BIOCHIMIE, V72, P545, DOI 10.1016/0300-9084(90)90119-2; CORBIER C, 1990, BIOCHEMISTRY-US, V29, P7101, DOI 10.1021/bi00482a022; CORBIER C, 1992, BIOCHEMISTRY-US, V31, P12532, DOI 10.1021/bi00164a033; DOOLITTLE RF, 1990, J MOL EVOL, V31, P383, DOI 10.1007/BF02106053; Duee E, 1996, J MOL BIOL, V257, P814, DOI 10.1006/jmbi.1996.0204; Eyschen J, 1996, BIOCHEMISTRY-US, V35, P6064, DOI 10.1021/bi952579x; FERDINAND W, 1964, BIOCHEM J, V92, P578, DOI 10.1042/bj0920578; HARRIS JI, 1976, ENZYMES, V12, P1; HILLMAN JD, 1975, J BACTERIOL, V122, P1175, DOI 10.1128/JB.122.3.1175-1179.1975; KIM HD, 1995, BIOCHEMISTRY-US, V34, P14975, DOI 10.1021/bi00046a004; KORNDORFER I, 1995, J MOL BIOL, V246, P511, DOI 10.1006/jmbi.1994.0103; KRIMSKY I, 1952, J BIOL CHEM, V198, P721; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN W, 1986, EUR J BIOCHEM, V159, P323, DOI 10.1111/j.1432-1033.1986.tb09871.x; MARTIN W, 1993, P NATL ACAD SCI USA, V90, P8692, DOI 10.1073/pnas.90.18.8692; Michels S, 1996, EUR J BIOCHEM, V235, P641, DOI 10.1111/j.1432-1033.1996.00641.x; MORAS D, 1975, J BIOL CHEM, V250, P9137; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; SKARZYNSKI T, 1987, J MOL BIOL, V193, P171, DOI 10.1016/0022-2836(87)90635-8; SOUKRI A, 1989, BIOCHEMISTRY-US, V28, P2586, DOI 10.1021/bi00432a036; Tanner JJ, 1996, BIOCHEMISTRY-US, V35, P2597, DOI 10.1021/bi951988q; TONOMURA B, 1978, ANAL BIOCHEM, V84, P370, DOI 10.1016/0003-2697(78)90054-4; ZHAO GS, 1995, J BACTERIOL, V177, P2804, DOI 10.1128/jb.177.10.2804-2812.1995	32	32	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15106	15112		10.1074/jbc.272.24.15106	http://dx.doi.org/10.1074/jbc.272.24.15106			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182530	hybrid			2022-12-27	WOS:A1997XE03400013
J	Haverstick, DM; Dicus, M; Resnick, MS; Sando, JJ; Gray, LS				Haverstick, DM; Dicus, M; Resnick, MS; Sando, JJ; Gray, LS			A role for protein kinase C beta I in the regulation of Ca2+ entry in Jurkat T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL TRISPHOSPHATE; CHEMOTACTIC PEPTIDE; HUMAN NEUTROPHILS; PLASMA-MEMBRANE; TUMOR PROMOTER; CALCIUM INFLUX; LYMPHOCYTES-T; CA-2+ INFLUX; INHIBITION; ACTIVATION	T cell activation leading to cytokine production and cellular proliferation involves a regulated increase and subsequent decrease in the intracellular concentration of Ca2+ ([Ca2+](i)). While much is understood about agonist-induced increases in [Ca2+](i), less is known about down-regulation of this pathway. Understanding the mechanism of this down-regulation is critical to the prevention of cell death that can be the consequence of a sustained elevation in [Ca2+](i). Protein kinase C (PKC), activated by the diacylglycerol produced as a consequence of T cell receptor engagement, has long been presumed to be involved in this down-regulation, although the precise mechanism is not wholly clear. In this report we demonstrate that activation of PHC by phorbol esters slightly decreases the rate of Ca2+ efflux from the cytosol of Jurkat T cells following stimulation through the T cell receptor or stimulation in a receptor-independent manner by thapsigargin. On the other hand, phorbol ester treatment dramatically reduces the rate of Ca2+ influx following stimulation. Phorbol ester treatment is without an effect on Ca2+ influx in a different T cell line, HSB. Down-regulation of PKC beta I expression by IS-h phorbol ester treatment is associated with a loss of the response to acute phorbol ester treatment in Jurkat cells, suggesting that PKC beta I may be the isozyme responsible for the effects on Ca2+ influx, Electroporation of an anti-PXC beta I antibody, but not antibodies against PKC alpha or PKC gamma, led to an increase in the rate of Ca2+ influx following stimulation. Taken together, these data suggest that PKC beta I may be a component of the down-regulation of increases in [Ca2+](i) associated with Jurkat T cell activation.	UNIV VIRGINIA,SCH MED,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908	University of Virginia	Haverstick, DM (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,SCH MED,BOX 214,CHARLOTTESVILLE,VA 22908, USA.				NIGMS NIH HHS [GM31184] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031184] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM RT, 1988, MOL CELL BIOL, V8, P5448, DOI 10.1128/MCB.8.12.5448; BALASUBRAMANYAM M, 1995, CELL CALCIUM, V18, P526, DOI 10.1016/0143-4160(95)90015-2; BALASUBRAMANYAM M, 1993, AM J PHYSIOL, V265, pC321, DOI 10.1152/ajpcell.1993.265.2.C321; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CANTRELL DA, 1989, J IMMUNOL, V143, P3653; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; CONRAD R, 1994, J BIOL CHEM, V269, P32051; Densmore JJ, 1996, AM J PHYSIOL-CELL PH, V271, pC1494, DOI 10.1152/ajpcell.1996.271.5.C1494; DIVIRGILIO F, 1986, J BIOL CHEM, V261, P32; DONNADIEU E, 1992, J BIOL CHEM, V267, P25864; DUTZ JP, 1993, J IMMUNOL, V150, P2591; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; GRAY LS, 1987, J IMMUNOL, V138, P63; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAVERSTICK DM, 1993, MOL BIOL CELL, V4, P173, DOI 10.1091/mbc.4.2.173; HAVERSTICK DM, 1991, J IMMUNOL, V146, P3306; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; LU KP, 1993, ENDOCR REV, V14, P40, DOI 10.1210/er.14.1.40; LUCAS S, 1990, FEBS LETT, V260, P53, DOI 10.1016/0014-5793(90)80064-P; LUKAS J, 1994, J IMMUNOL METHODS, V170, P255, DOI 10.1016/0022-1759(94)90400-6; MCCONKEY DJ, 1994, BIOCHEM SOC T, V22, P606, DOI 10.1042/bst0220606; Melner MH, 1996, BIOCHEM PHARMACOL, V51, P869, DOI 10.1016/0006-2952(95)02196-5; MONTERO M, 1993, J BIOL CHEM, V268, P26911; MONTERO M, 1993, J BIOL CHEM, V268, P13055; MONTERO M, 1994, J BIOL CHEM, V269, P3963; NAGASAWA K, 1981, J CELL PHYSIOL, V109, P181, DOI 10.1002/jcp.1041090120; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; PETERSEN CCH, 1994, J BIOL CHEM, V269, P32246; SCANLON M, 1987, J BIOL CHEM, V262, P6308; SHIVNAN E, 1995, J IMMUNOL, V154, P1146; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; STOOLMAN LM, 1993, J CELL PHYSIOL, V154, P593, DOI 10.1002/jcp.1041540318; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TORDAI A, 1989, IMMUNOL LETT, V20, P47, DOI 10.1016/0165-2478(89)90067-9; TSUTSUMI A, 1993, J IMMUNOL, V150, P1746	39	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15426	15433		10.1074/jbc.272.24.15426	http://dx.doi.org/10.1074/jbc.272.24.15426			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182574	hybrid			2022-12-27	WOS:A1997XE03400057
J	Kang, DC; Miyako, K; Kai, Y; Irie, T; Takeshige, K				Kang, DC; Miyako, K; Kai, Y; Irie, T; Takeshige, K			In vivo determination of replication origins of human mitochondrial DNA by ligation-mediated polymerase chain reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION; LOCALIZATION; INITIATION; MECHANISM; SEQUENCE; STRANDS; CELLS; PCR	A large part of replication is aborted in human mitochondria, the result being a D-loop. As few attempts have been made to distinguish free 5' ends of true replicate from those of abortive ones, we examined the 5' ends of true replicate of human mitochondrial DNA at one nucleotide resolution in vivo by making use of ligation-mediated polymerase chain reaction. The distribution and relative amounts of origins of the true replicate are exactly the same as those of total newly synthesized heavy strands, which means that the abortion of replication is independent of 5' ends. Treatment of DNA with RNase H frees 5' ends on both heavy and light strands. This is the first in vivo evidence for covalently attached primer RNA to nascent strand in human mitochondrial DNA.	KYUSHU UNIV,SCH MED,DEPT BIOCHEM,FUKUOKA 81282,JAPAN	Kyushu University								ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BOGENHAGEN D, 1978, J MOL BIOL, V119, P49, DOI 10.1016/0022-2836(78)90269-3; CHANG DD, 1985, P NATL ACAD SCI USA, V82, P351, DOI 10.1073/pnas.82.2.351; CHANG DD, 1985, EMBO J, V4, P1559, DOI 10.1002/j.1460-2075.1985.tb03817.x; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; DODA JN, 1981, P NATL ACAD SCI-BIOL, V78, P6116, DOI 10.1073/pnas.78.10.6116; KANG D, 1995, J BIOL CHEM, V270, P14659, DOI 10.1074/jbc.270.24.14659; KOIKE K, 1974, BIOCHIM BIOPHYS ACTA, V361, P144, DOI 10.1016/0005-2787(74)90342-6; KOIKE K, 1973, BIOCHIM BIOPHYS ACTA, V324, P452, DOI 10.1016/0005-2787(73)90204-9; Maxam A M, 1980, Methods Enzymol, V65, P499; MIYAKO K, 1997, J BIOL CHEM, P9605; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MUELLER PR, 1992, CURRENT PROTOCOLS MO; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; TAPPER DP, 1981, J BIOL CHEM, V256, P5109; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WONG TW, 1985, CELL, V42, P951, DOI 10.1016/0092-8674(85)90291-0; XU BJ, 1995, MOL CELL BIOL, V15, P580, DOI 10.1128/MCB.15.1.580; Xu BJ, 1996, EMBO J, V15, P3135, DOI 10.1002/j.1460-2075.1996.tb00676.x	20	87	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15275	15279		10.1074/jbc.272.24.15275	http://dx.doi.org/10.1074/jbc.272.24.15275			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182553	hybrid			2022-12-27	WOS:A1997XE03400036
J	Lussier, M; Sdicu, AM; Bussereau, F; Jacquet, M; Bussey, H				Lussier, M; Sdicu, AM; Bussereau, F; Jacquet, M; Bussey, H			The Ktr1p, Ktr3p, and Kre2p/Mnt1p mannosyltransferases participate in the elaboration of yeast O- and N-linked carbohydrate chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GLYCOPROTEIN-BIOSYNTHESIS; OUTER CHAIN; GENE FAMILY; GLYCOSYLATION; PROTEIN; ENCODES; ALPHA-1,2-MANNOSYLTRANSFERASE; OLIGOSACCHARIDES; LOCALIZATION	We have determined a role for Ktr1p and Ktr3p as mannosyltransferases in the synthesis of the carbohydrate chains attached to Saccharomyces cerevisiae O- and N-modified proteins. KTR1 and KTR3 encode related proteins that are highly similar to the Kre2p/Mnt1p Golgi alpha 1,2-mannosyltransferase (Lussier, M., Camirand, A., Sdicu, A.-M,, and Bussey, H, (1993) Yeast 9, 1057-1063; Mallet, L,, Bussereau, F,, and Jacquet, M. (1994) Yeast 10, 819-831), Examination of the electrophoretic mobility of a specifically O linked protein from mutants and an analysis of their total O-linked mannosyl chains demonstrates that Ktr1p, Ktr3p, and Kre2p/Mnt1p have overlapping roles and collectively add most of the second and the third alpha 1,2-linked mannose residues on O-linked oligosaccharides. Determination of the mobility of the specifically N-linked glycoprotein invertase in different null strains indicates that Ktr1p, Ktr3p, and Kre2p are also jointly involved in N-linked glycosylation, possibly in establishing some of the outer chain alpha 1,2-linkages.	MCGILL UNIV, DEPT BIOL, MONTREAL, PQ H3A 1B1, CANADA; UNIV PARIS 11, INST MICROBIOL & GENET, ORSAY, FRANCE	McGill University; UDICE-French Research Universities; Universite Paris Saclay								BALLOU CE, 1990, METHOD ENZYMOL, V185, P441; BROWN JL, 1993, MOL CELL BIOL, V13, P6346, DOI 10.1128/MCB.13.10.6346; BROWN JL, 1994, MOL GENETICS YEAST P, P217; COOPER A, 1992, J CELL BIOL, V119, P1459, DOI 10.1083/jcb.119.6.1459; GENTZSCH M, 1995, GLYCOBIOLOGY, V5, P77, DOI 10.1093/glycob/5.1.77; Gentzsch M, 1996, EMBO J, V15, P5752, DOI 10.1002/j.1460-2075.1996.tb00961.x; GRAHAM TR, 1994, J CELL BIOL, V127, P667, DOI 10.1083/jcb.127.3.667; HAUSLER A, 1992, P NATL ACAD SCI USA, V89, P6846, DOI 10.1073/pnas.89.15.6846; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HILL K, 1992, GENETICS, V130, P273; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; LEHLE L, 1995, GLYCOPROTEINS, P1; Lussier M, 1997, YEAST, V13, P267, DOI 10.1002/(SICI)1097-0061(19970315)13:3<267::AID-YEA72>3.0.CO;2-K; Lussier M, 1996, J BIOL CHEM, V271, P11001, DOI 10.1074/jbc.271.18.11001; LUSSIER M, 1993, YEAST, V9, P1057, DOI 10.1002/yea.320091004; LUSSIER M, 1995, J BIOL CHEM, V270, P2770, DOI 10.1074/jbc.270.6.2770; LUSSIER M, 1995, J CELL BIOL, V131, P913, DOI 10.1083/jcb.131.4.913; MALLET L, 1994, YEAST, V10, P819, DOI 10.1002/yea.320100612; NAKANISHISHINDO Y, 1993, J BIOL CHEM, V268, P26338; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; ORLEAN P, 1991, METHOD ENZYMOL, V194, P682; Romero PA, 1997, BIOCHEM J, V321, P289, DOI 10.1042/bj3210289; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; STRAHLBOLSINGER S, 1991, EUR J BIOCHEM, V196, P185, DOI 10.1111/j.1432-1033.1991.tb15802.x; YIP CL, 1994, P NATL ACAD SCI USA, V91, P2723, DOI 10.1073/pnas.91.7.2723; ZIEGLER FD, 1988, J BIOL CHEM, V263, P6986	28	77	81	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15527	15531		10.1074/jbc.272.24.15527	http://dx.doi.org/10.1074/jbc.272.24.15527			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182588	hybrid			2022-12-27	WOS:A1997XE03400071
J	Poland, BW; Bruns, C; Fromm, HJ; Honzatko, RB				Poland, BW; Bruns, C; Fromm, HJ; Honzatko, RB			Entrapment of 6-thiophosphoryl-IMP in the active site of crystalline adenylosuccinate synthetase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOTOPE EXCHANGE; LYASE; SPECIFICITY	Crystal structures of adenylosuccinate synthetase from Escherichia coli complexed with Mg2+, 6-thiophosphoryl-IMP, GDP, and hadacidin at 298 and 100 K have been refined to R-factors of 0.171 and 0.206 against data to 2.8 and 2.5 Angstrom resolution, respectively. interactions of GDP, Mg2+ and hadacidin are similar to those observed. for the same ligands in the complex of IMP, GDP, NO3-, Mg2+ and hadacidin (Poland, B, W., Fromm, H. J. & Honzatko, R. B. (1996), J. Mol. Biol. 264, 1013-1027). Although crystals were grown from solutions containing 6-mercapto-IMP and GTP, the Electron density at the active site is consistent with 6-thiophosphoryl-IMP and GDP. Asp-13 and Gln-224 probably work in concert to stabilize the 6-thioanion of 6-mercapto-IMP, which in turn is the nucleophile in the displacement of GDP from the gamma-phosphate of GTP. Once formed, 6-thiophosphoryl-IMP is stable in the active site of the enzyme under the conditions of the structural investigation. The direct observation of 6-thiophosphoryl-IMP in the active site is consistent with the putative generation of 6-phosphoryl-IMP along the reaction pathway of the synthetase.	IOWA STATE UNIV,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011	Iowa State University								BASS MB, 1987, ARCH BIOCHEM BIOPHYS, V256, P335, DOI 10.1016/0003-9861(87)90454-1; BASS MB, 1984, J BIOL CHEM, V259, P2330; BERNARDINELLI G, 1991, Z KRISTALLOGR, V195, P135, DOI 10.1524/zkri.1991.195.1-2.135; BRUNGER AT, 1992, XPLOR VERSION 3 1; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; CLARK SW, 1976, BIOCHIM BIOPHYS ACTA, V437, P87, DOI 10.1016/0304-4165(76)90349-4; COOPER BF, 1986, BIOCHEMISTRY-US, V25, P7323, DOI 10.1021/bi00371a013; DEABREU RA, 1995, PURINE PYRIMIDINE ME, V8, P195; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FROMM HJ, 1958, BIOCHIM BIOPHYS ACTA, V29, P255, DOI 10.1016/0006-3002(58)90182-3; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; KACZKA EA, 1962, BIOCHEMISTRY-US, V1, P340, DOI 10.1021/bi00908a022; Kang CH, 1997, J BIOL CHEM, V272, P11881, DOI 10.1074/jbc.272.18.11881; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIEBERMAN I, 1956, J BIOL CHEM, V223, P327; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MARKHAM DG, 1977, ARCH BIOCHEM BIOPHYS, V184, P24; MARKHAM GD, 1978, J BIOL CHEM, V253, P6184; MILLER RW, 1962, J BIOL CHEM, V237, P485; Poland BW, 1996, J MOL BIOL, V264, P1013, DOI 10.1006/jmbi.1996.0693; POLAND BW, 1993, J BIOL CHEM, V268, P25334; Poland BW, 1996, J BIOL CHEM, V271, P15407, DOI 10.1074/jbc.271.26.15407; Poland BW, 1996, BIOCHEMISTRY-US, V35, P15753, DOI 10.1021/bi961758r; PORTER DJT, 1983, ARCH BIOCHEM BIOPHYS, V225, P157, DOI 10.1016/0003-9861(83)90019-X; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; RUDOLPH FB, 1969, J BIOL CHEM, V244, P3832; SHIGEURA HT, 1967, ANTIBIOTICS, P451; SILVA MM, 1995, J MOL BIOL, V254, P431, DOI 10.1006/jmbi.1995.0629; SPECTOR T, 1979, J BIOL CHEM, V254, P8422; SPECTOR T, 1982, BIOCHEM PHARMACOL, V31, P225, DOI 10.1016/0006-2952(82)90215-5; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103	31	27	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15200	15205		10.1074/jbc.272.24.15200	http://dx.doi.org/10.1074/jbc.272.24.15200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182542	hybrid			2022-12-27	WOS:A1997XE03400025
J	Chen, Q; Galleano, M; Cederbaum, AI				Chen, Q; Galleano, M; Cederbaum, AI			Cytotoxicity and apoptosis produced by arachidonic acid in hep G2 cells overexpressing human cytochrome P4502E1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; CHRONIC ETHANOL-CONSUMPTION; LIPID-PEROXIDATION; LIVER-MICROSOMES; DEPENDENT PRODUCTION; ANTIOXIDANT PATHWAY; CHEMI-LUMINESCENCE; DNA FRAGMENTATION; RAT HEPATOCYTES; HEPATOMA-CELLS	The goal of the current study was to evaluate the effects of arachidonic acid, as a representative polyunsaturated fatty acid, on the viability of a Hep G2 cell line, which has been transduced to express human cytochrome P4502E1 (CYP2E1). Arachidonic acid produced a concentration- and time-dependent toxicity to Hep G2-MV2E1-9 cells, which express CYP2E1, but little or no toxicity was found with control Hep G2-MV-5 cells, which were infected with retrovirus lacking human CYP2E1 cDNA. In contrast to arachidonic acid, oleic acid was not toxic to the Hep G2-MV2E1-9 cells. The cytotoxicity of arachidonic acid appeared to involve a lipid peroxidation type of mechanism since toxicity was enhanced after depletion of cellular glutathione; formation of malondialdehyde and 4-hydroxy-2-nonenal was markedly elevated in the cells expressing CYP2E1, and toxicity was prevented by antioxidants such as alpha-tocopherol phosphate, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (trolox), propylgallate, ascorbate, and diphenylphenylenediamine, and the iron chelator desferrioxamine. Transfection of the Hep G2-MV2E1-9 cells with plasmid containing CYP2E1 in the sense orientation enhanced the arachidonic acid toxicity, whereas transfection with plasmid containing CYP2E1 in the antisense orientation decreased toxicity. The CYP2E1-dependent arachidonic acid toxicity appeared to involve apoptosis, as demonstrated by terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling and DNA laddering experiments. Trolox, which prevented toxicity of arachidonic acid, also prevented the apoptosis. Transfection with a plasmid containing bcl-2 resulted in complete protection against the CYP2E1-dependent arachidonic acid toxicity. It is proposed that elevated production of reactive oxygen intermediates by cells expressing CYP2E1 can cause lipid peroxidation, which subsequently promotes apoptosis and cell toxicity when the cells are enriched with polyunsaturated fatty acids such as arachidonic acid. The Hep G2-MV2E1-9 cells appear to be a valuable model to study interaction between CYP2E1, polyunsaturated fatty acids, reactive radicals, and the consequence of these interactions on cell viability and to reproduce several of the key features associated with ethanol hepatotoxicity in the intragastric infusion model of ethanol treatment.	CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029; UNIV BUENOS AIRES,SCH PHARM & BIOCHEM,RA-1113 BUENOS AIRES,DF,ARGENTINA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Buenos Aires					NIAAA NIH HHS [AA06610, AA03312] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA003312, R37AA006610, R56AA003312, R01AA006610] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALBANO E, 1991, BIOCHEM PHARMACOL, V41, P1895, DOI 10.1016/0006-2952(91)90129-S; AMSTRONG RC, 1996, J BIOL CHEM, V271, P16850; AUST S D, 1985, Journal of Free Radicals in Biology and Medicine, V1, P3, DOI 10.1016/0748-5514(85)90025-X; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BOVERIS A, 1983, ARCH BIOCHEM BIOPHYS, V227, P534, DOI 10.1016/0003-9861(83)90482-4; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; CANUTO RA, 1991, CANCER RES, V51, P4603; CANUTO RA, 1995, FREE RADICAL BIO MED, V18, P287, DOI 10.1016/0891-5849(94)E0137-8; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; CARONLESLIE LAM, 1991, MOL ENDOCRINOL, V5, P1169, DOI 10.1210/mend-5-8-1169; CASTILLO T, 1992, HEPATOLOGY, V16, P992, DOI 10.1002/hep.1840160423; CASTLE PJ, 1995, DRUG METAB DISPOS, V23, P1037; COMPTON MM, 1992, CANCER METAST REV, V11, P105, DOI 10.1007/BF00048058; DAI Y, 1995, J PHARMACOL EXP THER, V273, P1497; DAI Y, 1993, BIOCHEMISTRY-US, V32, P6926; DICKER E, 1988, FASEB J, V2, P2901, DOI 10.1096/fasebj.2.13.3169467; DIRVEN HAAM, 1991, BIOCHEM PHARMACOL, V42, P1841; EKSTROM G, 1989, BIOCHEM PHARMACOL, V38, P1313, DOI 10.1016/0006-2952(89)90338-9; EKSTROM G, 1986, BIOCHEM J, V233, P755, DOI 10.1042/bj2330755; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; FEIERMAN DE, 1986, BIOCHEM J, V239, P671, DOI 10.1042/bj2390671; FRENCH SW, 1993, EXP MOL PATHOL, V58, P61, DOI 10.1006/exmp.1993.1006; FRENCH SW, 1992, CRIT REV CL LAB SCI, V29, P83, DOI 10.3109/10408369209114597; FUKUDA T, 1994, J BIOCHEM-TOKYO, V115, P338, DOI 10.1093/oxfordjournals.jbchem.a124339; Furuno K, 1996, J TOXICOL ENV HEALTH, V48, P121, DOI 10.1080/009841096161375; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GORSKY LD, 1984, J BIOL CHEM, V259, P6812; Guengerich F. Peter, 1995, P473; HARMON JM, 1979, J CELL PHYSIOL, V98, P267, DOI 10.1002/jcp.1040980203; HAWLEYNELSON P, 1993, FOCUS, V15, P3; Hockenbery D M, 1992, Semin Immunol, V4, P413; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; KORSMEYER SJ, 1995, BBA-MOL BASIS DIS, V1271, P63, DOI 10.1016/0925-4439(95)00011-R; KUKIELKA E, 1994, BIOCHEM J, V302, P773, DOI 10.1042/bj3020773; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAETHEM RM, 1993, J BIOL CHEM, V268, P12912; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MEISTER A, 1994, J BIOL CHEM, V269, P9397; MEMON SA, 1995, J IMMUNOL, V155, P4644; MERINO R, 1994, EMBO J, V13, P683, DOI 10.1002/j.1460-2075.1994.tb06307.x; MIKKELSEN L, 1994, LIPIDS, V29, P369, DOI 10.1007/BF02537192; MIKKELSEN L, 1993, BIOCHIM BIOPHYS ACTA, V1166, P99, DOI 10.1016/0005-2760(93)90289-L; MONKS TJ, 1989, REV BIOCHEM TOXICOL, V10, P41; MOROMOTO M, 1993, ALCOHOL, V10, P459; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NANJI AA, 1993, ALCOHOL CLIN EXP RES, V17, P598, DOI 10.1111/j.1530-0277.1993.tb00806.x; NANJI AA, 1985, LANCET, V1, P681; NANJI AA, 1986, ALCOHOL CLIN EXP RES, V10, P271, DOI 10.1111/j.1530-0277.1986.tb05088.x; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; NOBEL CSI, 1995, J BIOL CHEM, V270, P26202, DOI 10.1074/jbc.270.44.26202; NORDMANN R, 1992, FREE RADICAL BIO MED, V12, P219, DOI 10.1016/0891-5849(92)90030-K; Okazawa H, 1996, J CELL BIOL, V132, P955, DOI 10.1083/jcb.132.5.955; PELEDKAMAR M, 1995, EMBO J, V14, P4985, DOI 10.1002/j.1460-2075.1995.tb00181.x; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; PUNTARULO S, 1988, ARCH BIOCHEM BIOPHYS, V266, P435, DOI 10.1016/0003-9861(88)90275-5; PUNTARULO S, 1988, ARCH BIOCHEM BIOPHYS, V254, P482; RASHBASTEP J, 1993, ARCH BIOCHEM BIOPHYS, V300, P401, DOI 10.1006/abbi.1993.1054; REAP EA, 1995, J IMMUNOL, V155, P5455; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REINKE LA, 1987, P NATL ACAD SCI USA, V84, P9223, DOI 10.1073/pnas.84.24.9223; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SHARMA R, 1988, BIOCHEM PHARMACOL, V37, P1193, DOI 10.1016/0006-2952(88)90770-8; SINICROPE FA, 1995, CANCER RES, V55, P237; SUGIHARA N, 1994, TOXICOL APPL PHARM, V126, P124, DOI 10.1006/taap.1994.1098; TAKAHASHI H, 1992, PHARMACOL TOXICOL, V70, P347, DOI 10.1111/j.1600-0773.1992.tb00485.x; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; THURMAN RG, 1973, MOL PHARMACOL, V9, P670; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUKAMOTO H, 1986, HEPATOLOGY, V6, P814, DOI 10.1002/hep.1840060503; TSUKAMOTO H, 1995, J CLIN INVEST, V96, P620, DOI 10.1172/JCI118077; TSUKAMOTO H, 1993, ALCOHOL, V10, P439, DOI 10.1016/0741-8329(93)90061-R; VEDECKIS WV, 1983, MOL CELL ENDOCRINOL, V30, P215, DOI 10.1016/0303-7207(83)90049-7; Weltin D, 1996, BIOCHEM PHARMACOL, V51, P1123, DOI 10.1016/0006-2952(96)83389-2; Wu DF, 1996, J BIOL CHEM, V271, P23914, DOI 10.1074/jbc.271.39.23914	78	159	165	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14532	14541		10.1074/jbc.272.23.14532	http://dx.doi.org/10.1074/jbc.272.23.14532			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169410	hybrid			2022-12-27	WOS:A1997XC32700007
J	Shibata, H; Omata, W; Kojima, I				Shibata, H; Omata, W; Kojima, I			Insulin stimulates guanine nucleotide exchange on Rab4 via a wortmannin-sensitive signaling pathway in rat adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT4 GLUCOSE-TRANSPORTER; PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR; GTP-BINDING PROTEINS; 3T3-L1 ADIPOCYTES; TRANSFERRIN RECEPTORS; PHOSPHOINOSITIDE 3-KINASE; SUBCELLULAR TRAFFICKING; PLASMA-MEMBRANE; SKELETAL-MUSCLE; ADIPOSE-CELLS	Rab4, a member of the Rab family of Ras-related small GTP-binding proteins, has been shown to be associated with GLUT4-containing vesicles and implicated in the insulin action on glucose transport in rat adipocytes. In the present study, we investigated the insulin effects on the guanine nucleotide exchange on Rab4. In electrically permeabilized rat adipocytes, the amount of [S-35]guanosine 5'-O-(3-thiotrisphosphate) (GTP gamma S) bound to Rab4 increased in a time-dependent manner during 45 min of the incubation period. Addition of insulin resulted in about a 2-fold stimulation of the binding of [S-35]GTP gamma S to Rab4, indicating that insulin stimulated the guanine nucleotide exchange on the GTPase. Pretreatment of the cells with wortmannin, a specific inhibitor of phosphatidylinositol 3-kinase, completely abolished the stimulatory effect of insulin on [S-35]GTP gamma S binding to Rab4. Wortmannin also attenuated the nucleotide binding to Rab4 in the basal cells, Suggesting that phosphatidylinositol 3-kinase activity may be essential for regulation of guanine nucleotide exchange on the GTPase and insulin may up-regulate the exchange activity by stimulating the lipid kinase. Insulin-induced subcellular redistribution of Rab4 from the microsomal fraction to the soluble fraction was also inhibited by wortmannin. These results suggest that insulin stimulates the guanine nucleotide exchange on Rab4 via a phosphatidylinositol 3-kinase-dependent signaling pathway and that Rab4 is one of possible targets of insulin action on intracellular vesicle traffic in rat adipocytes.			Shibata, H (corresponding author), GUNMA UNIV,INST MOL & CELLULAR REGULAT,DEPT CELL BIOL,MAEBASHI,GUMMA 371,JAPAN.							BALDINI G, 1995, P NATL ACAD SCI USA, V92, P4284, DOI 10.1073/pnas.92.10.4284; BALDINI G, 1991, J BIOL CHEM, V266, P4037; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; Bortoluzzi MN, 1996, DIABETOLOGIA, V39, P899, DOI 10.1007/BF00403908; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CORMONT M, 1993, J BIOL CHEM, V268, P19491; DAVIS RJ, 1986, J BIOL CHEM, V261, P8708; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; HELMS JB, 1995, FEBS LETT, V369, P84, DOI 10.1016/0014-5793(95)00620-O; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; James David E., 1994, Trends in Cell Biology, V4, P120, DOI 10.1016/0962-8924(94)90066-3; KALIMAN P, 1995, BIOCHEM J, V312, P471, DOI 10.1042/bj3120471; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KLUMPERMAN J, 1993, J CELL BIOL, V121, P997, DOI 10.1083/jcb.121.5.997; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMARCHANDBRUSTEL Y, 1995, ENDOCRINOLOGY, V136, P3564, DOI 10.1210/en.136.8.3564; LIU JP, 1995, ENDOCR REV, V16, P590, DOI 10.1210/er.16.5.590; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; OKADA T, 1994, J BIOL CHEM, V269, P3568; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; RICORT JM, 1994, FEBS LETT, V347, P42, DOI 10.1016/0014-5793(94)00510-9; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; RODBELL M, 1964, J BIOL CHEM, V239, P375; SHEPHERD PR, 1995, BIOCHEM BIOPH RES CO, V211, P535, DOI 10.1006/bbrc.1995.1846; Sherman LA, 1996, ENDOCRINOLOGY, V137, P266, DOI 10.1210/en.137.1.266; SHIBATA H, 1995, J BIOL CHEM, V270, P11489, DOI 10.1074/jbc.270.19.11489; SHIBATA H, 1991, ARCH BIOCHEM BIOPHYS, V285, P97, DOI 10.1016/0003-9861(91)90333-E; Shibata H, 1996, J BIOL CHEM, V271, P9704, DOI 10.1074/jbc.271.16.9704; SUZUKI Y, 1992, BIOCHEM BIOPH RES CO, V189, P572, DOI 10.1016/0006-291X(92)91596-I; TANNER LI, 1987, J BIOL CHEM, V262, P8975; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233; YANG J, 1993, J BIOL CHEM, V268, P4600; YANO Y, 1993, BIOCHIM BIOPHYS ACTA, V1176, P327, DOI 10.1016/0167-4889(93)90062-T	44	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14542	14546		10.1074/jbc.272.23.14542	http://dx.doi.org/10.1074/jbc.272.23.14542			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169411	hybrid			2022-12-27	WOS:A1997XC32700008
J	Takaki, S; Watts, JD; Forbush, KA; Nguyen, NT; Hayashi, J; AlberolaIla, J; Aebersold, R; Perlmutter, RM				Takaki, S; Watts, JD; Forbush, KA; Nguyen, NT; Hayashi, J; AlberolaIla, J; Aebersold, R; Perlmutter, RM			Characterization of Lnk - An adaptor protein expressed in lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ANTIGEN RECEPTOR; NITRIC-OXIDE SYNTHASE; TYROSINE-PHOSPHORYLATED PROTEIN; JURKAT T-CELLS; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-1; PHOSPHATIDYLINOSITOL 3-KINASE; KINASE ZAP-70; HS1 PROTEIN; ZETA-CHAIN	Stimulation of the T cell antigen receptor (TCR) activates a set of non-receptor protein tyrosine kinases that assist in delivering signals to the cell interior. Among the presumed substrates for these kinases, adaptor proteins, which juxtapose effector enzyme systems with the antigen receptor complex, figure prominently. Previous studies suggested that Lnk, a 38-kDa protein consisting of a single SH2 domain and a region containing potential tyrosine phosphorylation sites, might serve to join Grb2, phospholipase C-gamma 1, and phosphatidylinositol 3-kinase to the TCR. To elucidate the physiologicalroles of Lnk in T cell signal transduction, we isolated the mouse Lnk cDNA, characterized the structure of the mouse Lnk gene, and generated transgenic mice that overproduce Lnk in thymocytes. Here we report that although Lnk becomes phosphoryIated during T cell activation, it plays no limiting role in the TCR signaling process. Moreover, we have distinguished p38(Lnk) from the more prominent 36-kDa tyrosine phosphoproteins that appear in activated T cells. Together these studies suggest that Lnk participates in signaling from receptors other than antigen receptors in lymphocytes.	UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98195; UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MOL BIOTECHNOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED MED GENET,SEATTLE,WA 98195; UNIV MARYLAND,DEPT PHARMACEUT SCI,BALTIMORE,MD 21201	University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University System of Maryland; University of Maryland Baltimore				alberola-ila, Jose/0000-0003-2439-553X				ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BOLLAG RJ, 1994, NAT GENET, V7, P383, DOI 10.1038/ng0794-383; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGERTON M, 1992, J IMMUNOL, V149, P1847; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; FUKAZAWA T, 1995, J BIOL CHEM, V270, P20177, DOI 10.1074/jbc.270.34.20177; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; GROSS JA, 1995, J EXP MED, V181, P463, DOI 10.1084/jem.181.2.463; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HEBERT J, 1994, CANCER GENET CYTOGEN, V73, P65, DOI 10.1016/0165-4608(94)90184-8; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; HUBERT P, 1993, J EXP MED, V178, P1587, DOI 10.1084/jem.178.5.1587; Isakov N, 1996, J BIOL CHEM, V271, P15753, DOI 10.1074/jbc.271.26.15753; ISAKOV N, 1994, J LEUKOCYTE BIOL, V55, P265, DOI 10.1002/jlb.55.2.265; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; JULIUSSON G, 1990, CANCER GENET CYTOGEN, V45, P143, DOI 10.1016/0165-4608(90)90079-P; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEE CGL, 1995, MAMM GENOME, V6, P56, DOI 10.1007/BF00350898; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Motto DG, 1996, MOL CELL BIOL, V16, P2823; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; Northrop JP, 1996, MOL CELL BIOL, V16, P2255; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; OSMAN N, 1995, J BIOL CHEM, V270, P13981, DOI 10.1074/jbc.270.23.13981; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5450; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; QIAN DP, 1993, J BIOL CHEM, V268, P4488; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Ribon V, 1996, MOL CELL BIOL, V16, P45; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; TAKEMOTO Y, 1995, EMBO J, V14, P3403, DOI 10.1002/j.1460-2075.1995.tb07346.x; TANIUCHI I, 1995, EMBO J, V14, P3664, DOI 10.1002/j.1460-2075.1995.tb00036.x; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WATTS JD, 1994, J BIOL CHEM, V269, P29520; WATTS JD, 1992, J BIOL CHEM, V267, P901; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WLODARSKA I, 1992, GENE CHROMOSOME CANC, V4, P302, DOI 10.1002/gcc.2870040405; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; XU WM, 1993, CYTOGENET CELL GENET, V64, P62, DOI 10.1159/000133562; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631	65	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14562	14570		10.1074/jbc.272.23.14562	http://dx.doi.org/10.1074/jbc.272.23.14562			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169414	hybrid			2022-12-27	WOS:A1997XC32700011
J	Georgatsou, E; Mavrogiannis, LA; Fragiadakis, GS; Alexandraki, D				Georgatsou, E; Mavrogiannis, LA; Fragiadakis, GS; Alexandraki, D			The yeast Fre1p/Fre2p cupric reductases facilitate copper uptake and are regulated by the copper-modulated Mac1p activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; IRON UPTAKE; MOLECULAR CHARACTERIZATION; TRANSCRIPTIONAL CONTROL; TRANSPORT PROTEIN; FET3 GENE; REDUCTION; REPRESSOR; COMPLEX	Fre1p and Fre2p are ferric reductases which account for the total plasma membrane associated activity, a prerequisite for iron uptake, in Saccharomyces cerevisiae. The two genes are transcriptionally induced by iron depletion. In this communication, we provide evidence that Fre2p has also cupric reductase activity, as has been previously shown for Fre1p (Hassett, R., and Kosman, D.J. (1995) J. Biol. Chem. 270, 128-134). Both Fre1p and Fre2p enzymes are functionally significant for copper uptake, as monitored by the accumulation of the copper-regulated CUP1 and CTR1 mRNAs in fre1 Delta, fre2 Delta, and fre1 Delta fre2 Delta mutant strains. However, only Fre1p activity is induced by copper depletion, even in the presence ofiron. This differential copper-dependent regulation of Fre1p and Fre2p is exerted at the transcriptional level of the two genes. We have shown that Mac1p, known to affect the basal levels of FRE1 gene expression (Jungmann, J., Reins, H.-A., Lee, J., Romeo, A., Hassett, R., Kosman, D., and Jentsch, S. (1993) EMBO J. 12, 5051-5056), accounts for both the copper-dependent induction of FRE1 and down-regulation of FRE2 gene. Finally, Mac1p transcriptional activation function is itself modulated by the availability of copper.	FDN RES & TECHNOL HELLAS,INST MOL BIOL & BIOTECHNOL,IRAKLION 71110,CRETE,GREECE; UNIV CRETE,DEPT BIOL,IRAKLION 71110,CRETE,GREECE	Foundation for Research & Technology - Hellas (FORTH); University of Crete				Mavrogiannis, Lampros/0000-0002-2869-2067				ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BRENT R, 1984, NATURE, V312, P612, DOI 10.1038/312612a0; CHANG A, 1994, CURR BIOL, V4, P532, DOI 10.1016/S0960-9822(00)00116-0; CRICHTON RR, 1987, EUR J BIOCHEM, V164, P485, DOI 10.1111/j.1432-1033.1987.tb11155.x; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; EIDE D, 1992, J BIOL CHEM, V267, P20774; EVANS KM, 1992, PLANT MOL BIOL, V20, P1019, DOI 10.1007/BF00028889; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; Guthrie C, 1991, METHODS ENZYMOLOGY, V194; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; Kaplan J, 1996, SCIENCE, V271, P1510, DOI 10.1126/science.271.5255.1510; KARIN M, 1984, P NATL ACAD SCI-BIOL, V81, P337, DOI 10.1073/pnas.81.2.337; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; LANDERS JW, 1958, AM J CLIN PATHOL, V29, P590; LESUISSE E, 1992, PLANT PHYSIOL, V100, P769, DOI 10.1104/pp.100.2.769; STREARMAN R, 1996, SCIENCE, V271, P1552; SZCZYPKA MS, 1989, MOL CELL BIOL, V9, P421, DOI 10.1128/MCB.9.2.421; Theil E.C., 1994, BIOINORG CHEM, P1; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; WELCH RM, 1993, PLANTA, V190, P555, DOI 10.1007/BF00224795; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; YAN DS, 1995, P NATL ACAD SCI USA, V92, P2632	31	210	220	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13786	13792		10.1074/jbc.272.21.13786	http://dx.doi.org/10.1074/jbc.272.21.13786			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153234	hybrid			2022-12-27	WOS:A1997XA06200049
J	Bhunia, AK; Han, H; Snowden, A; Chatterjee, S				Bhunia, AK; Han, H; Snowden, A; Chatterjee, S			Redox-regulated signaling by lactosylceramide in the proliferation of human aortic smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; FREE-RADICALS; TYROSINE PHOSPHORYLATION; PROTEIN KINASE; GROWTH; GLUTATHIONE; EXPRESSION; ACTIVATION; SUPEROXIDE; FOS	Previously, our laboratory reported that lactosylcer-amide (LacCer) stimulated human aortic smooth muscle cell proliferation via specific activation of p44 mitogen-activated protein kinase (MAPK) in the p21(ras)/Raf-1/MEK2 pathway and induced expression of the transcription factor c-fos downstream to the p44 MAPK signaling cascade (Bhunia A, R., Han, H., Snowden, A., and Chatterjee S. (1906) J. Biol. Chem. 271, 10660-10666). In the present study, we explored the role of free oxygen radicals in LacCer-mediated induction of cell proliferation. Superoxide levels were measured by the lucigenin chemiluminescence method, MAPK activity was measured by immunocomplex kinase assays, and Western blot analysis and c-fos expression were measured by Northern blot assay, We found that LacCer (10 mu M) stimulates endogenous superoxide production tl-fold compared with control) in human aortic smooth muscle cells specifically by activating membrane-associated NADPH oxidase, but not NADH or xanthine oxidase. This process was inhibited by an inhibitor of NADPH oxidase, diphenylene iodonium (DPI), and by antioxidants, N acetyl-L-cysteine (NAC or pyrrolidine dithiocarbamate. NAC and DPI both abrogated individual steps in the signaling pathway leading to cell proliferation. For example, the p21(ras.)GTP loading, p44 MAPK activity, and induction of transcription factor c-fos all were inhibited by NAC and DPI as well as an antioxidant pyrrolidine dithiocarbamate or reduced glutathione (GSH), In contrast, depletion of GSH by L-buthionine (S,R)-sulfoximine up-regulated the above described signaling cascade. In sum, LacCer, by virtue of activating NADPH oxidase, produces superoxide (a redox stress signaling molecule), which mediates cell proliferation via activation of the kinase cascade, Our findings may er;plain She potential role of LacCer in the pathogenesis of atherosclerosis involving the proliferation of aortic smooth muscle cells.	JOHNS HOPKINS UNIV, SCH MED, LIPID RES ATHEROSCLEROSIS UNIT, DEPT PEDIAT, BALTIMORE, MD 21287 USA	Johns Hopkins University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL047212] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031722] Funding Source: NIH RePORTER; NHLBI NIH HHS [1-P50 HL47212] Funding Source: Medline; NIDDK NIH HHS [R01-DK31722] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Bhunia AK, 1996, J BIOL CHEM, V271, P10660, DOI 10.1074/jbc.271.18.10660; Bhunia AK, 1996, J EUKARYOT MICROBIOL, V43, P373, DOI 10.1111/j.1550-7408.1996.tb05046.x; BREMER EG, 1986, J BIOL CHEM, V261, P2434; CHATTERJEE S, 1983, P NATL ACAD SCI-BIOL, V80, P1313, DOI 10.1073/pnas.80.5.1313; CHATTERJEE S, 1991, BIOCHEM BIOPH RES CO, V181, P554, DOI 10.1016/0006-291X(91)91225-2; Chatterjee S, 1996, J LIPID RES, V37, P1334; CHATTERJEE S, 1982, J LIPID RES, V23, P513; Chatterjee SB, 1997, GLYCOBIOLOGY, V7, P57, DOI 10.1093/glycob/7.1.57; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022-1759(88)90310-9; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FRIEDL HP, 1989, FASEB J, V3, P2512, DOI 10.1096/fasebj.3.13.2806779; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; GUYTON KZ, 1993, BRIT MED BULL, V49, P523, DOI 10.1093/oxfordjournals.bmb.a072628; GYLLENHAMMAR H, 1987, J IMMUNOL METHODS, V97, P209, DOI 10.1016/0022-1759(87)90461-3; Hakomori SI, 1983, SPINGOLIPID CHEM, P52; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; KALEBIC T, 1991, P NATL ACAD SCI USA, V88, P986, DOI 10.1073/pnas.88.3.986; KEHRER JP, 1993, CRIT REV TOXICOL, V23, P21, DOI 10.3109/10408449309104073; LAINE RA, 1973, BIOCHEM BIOPH RES CO, V54, P1039, DOI 10.1016/0006-291X(73)90798-5; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LARSSON R, 1988, J BIOL CHEM, V263, P17452; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAKADATE T, 1988, BIOCHEM PHARMACOL, V37, P1541, DOI 10.1016/0006-2952(88)90016-0; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; PURI PL, 1995, J BIOL CHEM, V270, P22129, DOI 10.1074/jbc.270.38.22129; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHIBANUMA M, 1988, J CELL PHYSIOL, V136, P379, DOI 10.1002/jcp.1041360224; STAAL FJT, 1994, P NATL ACAD SCI USA, V91, P3619, DOI 10.1073/pnas.91.9.3619; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TIKU ML, 1990, J IMMUNOL, V145, P690	45	174	180	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15642	15649		10.1074/jbc.272.25.15642	http://dx.doi.org/10.1074/jbc.272.25.15642			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188453	hybrid			2022-12-27	WOS:A1997XF32900013
J	Biswas, MG; Russell, DW				Biswas, MG; Russell, DW			Expression cloning and characterization of oxidative 17 beta- and 3 alpha-hydroxysteroid dehydrogenases from rat and human prostate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; 5-ALPHA-REDUCTASE; HYPERPLASIA; ANDROGENS; TISSUES; ENZYME; TYPE-2	Intracellular levels of active steroid hormones are determined by their relative rates of synthesis and breakdown. In the case of the potent androgen dihydrotestosterone, synthesis from the precursor testosterone is mediated by steroid 5 alpha-reductase, whereas breakdown to the inactive androgens 5 alpha-androstane-3 alpha,17 beta-diol (3 alpha-adiol), and androsterone is mediated by reductive 3 alpha-hydroxysteroid dehydrogenases (3 alpha-HSD) and oxidative 17 beta-hydroxysteroid dehydrogenases (17 beta-HSD), respectively. We report the isolation by expression cloning of a cDNA encoding a 17 beta-HSD6 isozyme that oxidizes 3 alpha-adiol to androsterone. 17 beta-HSD6 is a member of the short chain dehydrogenase/reductase family and shares 65% sequence identity with retinol dehydrogenase 1 (RoDH1), which catalyzes the oxidation of retinol to ret inal. Expression of rat and human RoDH cDNAs in mammalian cells is associated with the oxidative conversion of 3 alpha-adiol to dihydrotestosterone. Thus, 17 beta-HSD6 and RoDH play opposing roles in androgen action; 17 beta-HSD6 inactivates 3 alpha-adiol by conversion to androsterone and RoDH activates 3 alpha-adiol by conversion to dihydrotestosterone. The synthesis of an active steroid hormone by back conversion of an inactive metabolite represents a potentially important mechanism by which the steady state level of a transcriptional effector can be regulated.	UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Russell, David/0000-0002-0277-403X	NIDDK NIH HHS [DK 47657] Funding Source: Medline; NIGMS NIH HHS [GM08014] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK047657] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andersson S, 1996, TRENDS ENDOCRIN MET, V7, P121, DOI 10.1016/1043-2760(96)00034-3; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Baker ME, 1996, BIOESSAYS, V18, P63, DOI 10.1002/bies.950180112; BAULIEU EE, 1968, NATURE, V219, P1155, DOI 10.1038/2191155a0; Beaulieu M, 1996, J BIOL CHEM, V271, P22855, DOI 10.1074/jbc.271.37.22855; BRENDLER CB, 1985, J UROLOGY, V133, P495, DOI 10.1016/S0022-5347(17)49040-9; BRUCHOVSKY N, 1971, ENDOCRINOLOGY, V89, P1212, DOI 10.1210/endo-89-5-1212; CASEY ML, 1994, J CLIN INVEST, V94, P2135, DOI 10.1172/JCI117569; Chai XY, 1996, GENE, V169, P219, DOI 10.1016/0378-1119(95)00833-0; CHAI XY, 1995, J BIOL CHEM, V270, P3900, DOI 10.1074/jbc.270.8.3900; CHAI XY, 1995, J BIOL CHEM, V270, P28408, DOI 10.1074/jbc.270.47.28408; Duester G, 1996, BIOCHEMISTRY-US, V35, P12221, DOI 10.1021/bi961176+; Elo JP, 1996, INT J CANCER, V66, P37, DOI 10.1002/(SICI)1097-0215(19960328)66:1<37::AID-IJC7>3.0.CO;2-#; FIESER LF, 1959, STEROIDS, P503; GEISSLER WM, 1994, NAT GENET, V7, P34, DOI 10.1038/ng0594-34; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Labrie F, 1997, STEROIDS, V62, P148, DOI 10.1016/S0039-128X(96)00174-2; Mahendroo MS, 1996, MOL ENDOCRINOL, V10, P380, DOI 10.1210/me.10.4.380; MARTEL C, 1992, J STEROID BIOCHEM, V41, P597, DOI 10.1016/0960-0760(92)90390-5; MCCONNELL JD, 1992, J CLIN ENDOCR METAB, V74, P505, DOI 10.1210/jc.74.3.505; MOORE RJ, 1973, ENDOCRINOLOGY, V93, P581, DOI 10.1210/endo-93-3-581; NAPOLI JL, 1992, BIOCHIM BIOPHYS ACTA, V1120, P183, DOI 10.1016/0167-4838(92)90267-H; Pasquali D, 1996, J CLIN ENDOCR METAB, V81, P2186, DOI 10.1210/jc.81.6.2186; PENNING TM, 1997, IN PRESS ENDOCR REV; RUSSELL DW, 1994, ANNU REV BIOCHEM, V63, P25, DOI 10.1146/annurev.bi.63.070194.000325; Sambrook J., 2002, MOL CLONING LAB MANU; SANDFORD NL, 1984, PATHOLOGY, V16, P406, DOI 10.3109/00313028409084731; SCHNEIDER RJ, 1987, ANNU REV BIOCHEM, V56, P317, DOI 10.1146/annurev.biochem.56.1.317; SCHULTZ FM, 1974, ENDOCRINOLOGY, V94, P979; SILVER RI, 1994, J UROLOGY, V152, P433, DOI 10.1016/S0022-5347(17)32757-X; WALSH PC, 1976, J CLIN INVEST, V57, P1093, DOI 10.1172/JCI108353; WILSON JD, 1993, ENDOCR REV, V14, P577, DOI 10.1210/er.14.5.577; WILSON JD, 1980, AM J MED, V68, P745, DOI 10.1016/0002-9343(80)90267-3; WU L, 1993, J BIOL CHEM, V268, P12964	35	202	210	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15959	15966		10.1074/jbc.272.25.15959	http://dx.doi.org/10.1074/jbc.272.25.15959			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188497	hybrid			2022-12-27	WOS:A1997XF32900057
J	Chong, SR; Xu, MQ				Chong, SR; Xu, MQ			Protein splicing of the Saccharomyces cerevisiae VMA intein without the endonuclease motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARCHAEA DNA-POLYMERASE; BRANCHED INTERMEDIATE; INTERVENING SEQUENCES; INTRONS; GENE	The protein splicing element (intein) of the vacuolar ATPase subunit (VMA) of Saccharomyces cerevisiae catalyzes both protein splicing and site-specific DNA cleavage. It has been demonstrated that the conserved splice junction residues are directly involved in protein splicing and the central dodecapeptide motifs are required for DNA cleavage. To examine whether the splicing activity of the intein can be structurally separated from the endonuclease motifs, we made large in-frame deletions at the central region of the intein. We demonstrate for the first time that protein splicing can proceed efficiently after the removal of the central region of the intein including the endonuclease motifs. Our results suggest that the N- and C-terminal regions of the See VMA intein may form a separate domain that is not only catalytically sufficient for protein splicing but also structurally independent from the endonuclease domain.	NEW ENGLAND BIOLABS INC,BEVERLY,MA 01915				Wood, David W/B-2992-2012	Chong, shaorong/0000-0002-6525-3389				CHONG S, 1997, IN PRESS GENE AMST; Chong SR, 1996, J BIOL CHEM, V271, P22159, DOI 10.1074/jbc.271.36.22159; COOPER AA, 1993, EMBO J, V12, P2575, DOI 10.1002/j.1460-2075.1993.tb05913.x; DAVIS EO, 1994, EMBO J, V13, P699, DOI 10.1002/j.1460-2075.1994.tb06309.x; DAVIS EO, 1992, CELL, V71, P201, DOI 10.1016/0092-8674(92)90349-H; GIMBLE FS, 1995, J BIOL CHEM, V270, P5849, DOI 10.1074/jbc.270.11.5849; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; GIMBLE FS, 1993, J BIOL CHEM, V268, P21844; HIRATA R, 1992, BIOCHEM BIOPH RES CO, V188, P40, DOI 10.1016/0006-291X(92)92347-Z; HODGES RA, 1992, NUCLEIC ACIDS RES, V20, P6153, DOI 10.1093/nar/20.23.6153; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; PERLER FB, 1994, NUCLEIC ACIDS RES, V22, P1125, DOI 10.1093/nar/22.7.1125; Perler FB, 1997, NUCLEIC ACIDS RES, V25, P1087, DOI 10.1093/nar/25.6.1087; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; PIETROKOVSKI S, 1994, PROTEIN SCI, V3, P2340, DOI 10.1002/pro.5560031218; Shao Y, 1996, BIOCHEMISTRY-US, V35, P3810, DOI 10.1021/bi952592h; SHAO Y, 1995, BIOCHEMISTRY-US, V34, P10844, DOI 10.1021/bi00034a017; SHUB DA, 1992, CELL, V71, P183, DOI 10.1016/0092-8674(92)90345-D; XU MQ, 1993, CELL, V75, P1371, DOI 10.1016/0092-8674(93)90623-X; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x	21	92	104	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15587	15590		10.1074/jbc.272.25.15587	http://dx.doi.org/10.1074/jbc.272.25.15587			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188443	hybrid			2022-12-27	WOS:A1997XF32900003
J	Pillarisetti, S; Paka, L; Sasaki, A; VanniReyes, T; Yin, BY; Parthasarathy, N; Wagner, WD; Goldberg, IJ				Pillarisetti, S; Paka, L; Sasaki, A; VanniReyes, T; Yin, BY; Parthasarathy, N; Wagner, WD; Goldberg, IJ			Endothelial cell heparanase modulation of lipoprotein lipase activity - Evidence that heparan sulfate oligosaccharide is an extracellular chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; HUMAN ADIPOSE-TISSUE; BINDING-PROTEIN; HEPATIC LIPASE; PROTEOGLYCANS; ADIPOCYTES; DEGRADATION; AFFINITY; RELEASE; IDENTIFICATION	A unique feature of lipoprotein lipase (LpL), the ratelimiting enzyme in the hydrolysis of circulating triglycerides, is its movement from its cell of synthesis, adipocyte or myocyte, to its site of action, the luminal endothelial surface. This involves processes that allow LpL to be released from the adipocyte cell surface and transferred against the flow of interstitial fluid to the luminal surface of endothelial cells, LpL, an unstable enzyme, must retain its activity during this process, Whether a chaperone-like molecule is involved in LpL stabilization and transport is unclear. In the present study, we tested the hypothesis that endothelial cells secrete factors that release LpL and promote its transfer to the luminal endothelial surface. Incubation of adipocytes with endothelial cell conditioned medium (ECCM) led to release of about a-fold more LpL activity than control medium. Medium from endothelial cells exposed to lysophosphatidylcholine (lyso-ECCM), a product of LpL lipolysis of lipoproteins, released ap proximately 3-fold more LpL than ECCM. Concomitant with the release of LpL, adipocyte cell surface heparan sulfate (HS) proteoglycans were degraded suggesting that lyso ECCM contained a heparanase-like activity. More heparanase was found in media from the basolateral than the apical side of lysolecithin-stimulated polarized endothelial cells. In coculture experiments, lipolysis and lysolecithin stimulation of endothelial cells increased LpL release from adipocytes. LpL released by lyso-ECCM remained stable and did mot lose enzymatic activity at 37 degrees C for 1 h. LPL activity was also stabilized, by heparanase-digested fragments of HS (HS oligosaccharide) and by purified LPL binding decasaccharide. Moreover, LpL HS oligosaccharide complexes crossed endothelial cell monolayers and bound to the apical side of the cells. Thus, an endothelial heparanase may play a critical role in releasing subendothelial HS bound proteins, and specific HS oligosaccharides produced by this enzyme may serve as extracellular chaperones.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT COMPARAT MED, WINSTON SALEM, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center	Pillarisetti, S (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, DIV PREVENT MED, 630 W 168TH ST, NEW YORK, NY 10032 USA.				NHLBI NIH HHS [HL 45095, HL 45848] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL045095, R01HL045848, R01HL045095] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BENGTSSONOLIVECRONA G, 1991, METHOD ENZYMOL, V197, P345; BERRYMAN DE, 1993, J BIOL CHEM, V268, P3272; BERRYMAN DE, 1995, J BIOL CHEM, V270, P24525, DOI 10.1074/jbc.270.41.24525; BUSCH C, 1982, J CLIN INVEST, V69, P726, DOI 10.1172/JCI110502; CAMPS L, 1990, AM J PHYSIOL, V258, pC673, DOI 10.1152/ajpcell.1990.258.4.C673; CISAR LA, 1989, J BIOL CHEM, V264, P1767; CUNNINGHAM DD, 1992, ADV EXP MED BIOL, V313, P297; CUPP M, 1987, J BIOL CHEM, V262, P6383; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DAVIS RC, 1992, J BIOL CHEM, V267, P21499; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P4570; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; FRIED SK, 1993, J CLIN INVEST, V92, P2191, DOI 10.1172/JCI116821; GALLAGHER JT, 1990, BIOCHEM SOC T, V18, P207, DOI 10.1042/bst0180207; Goldberg IJ, 1996, J LIPID RES, V37, P693; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HEDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349; JONASSON L, 1984, ATHEROSCLEROSIS, V51, P313, DOI 10.1016/0021-9150(84)90179-5; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LARNKJAER A, 1995, BIOCHEM J, V307, P205, DOI 10.1042/bj3070205; LORTAT-JACOB H, 1991, CELL MOL BIOL, V37, P253; LYON M, 1994, J BIOL CHEM, V269, P11216; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MAIMONE MM, 1988, BIOCHEM BIOPH RES CO, V152, P1056, DOI 10.1016/S0006-291X(88)80391-7; MARCUM JA, 1987, SEMIN THROMB HEMOST, V13, P464, DOI 10.1055/s-2007-1003523; Nelson RM, 1995, ANNU REV CELL DEV BI, V11, P601, DOI 10.1146/annurev.cellbio.11.1.601; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; Olivecrona Thomas, 1993, Current Opinion in Lipidology, V4, P187, DOI 10.1097/00041433-199306000-00003; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; Parthasarathy N, 1996, FASEB J, V10, P1726; ROVELLI G, 1992, BIOCHEMISTRY-US, V31, P3542, DOI 10.1021/bi00128a031; SASAKI A, 1992, J BIOL CHEM, V267, P15198; SASAKI A, 1993, AM J PHYSIOL, V265, pE880, DOI 10.1152/ajpendo.1993.265.6.E880; SAXENA U, 1990, ARTERIOSCLEROSIS, V10, P470, DOI 10.1161/01.ATV.10.3.470; SAXENA U, 1989, J BIOL CHEM, V264, P4349; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SEMB H, 1989, BIOCHEM J, V262, P505, DOI 10.1042/bj2620505; SIMSOLO RB, 1992, J LIPID RES, V33, P89; SIVARAM P, 1995, J BIOL CHEM, V270, P29760; Sivaram P, 1996, J BIOL CHEM, V271, P15261, DOI 10.1074/jbc.271.25.15261; SIVARAM P, 1994, J BIOL CHEM, V269, P9409; SIVARAM P, 1992, J BIOL CHEM, V267, P16517; SOCORRO L, 1985, PREP BIOCHEM, V15, P133, DOI 10.1080/10826068508062267; STINS MF, 1992, ARTERIOSCLER THROMB, V12, P1437, DOI 10.1161/01.ATV.12.12.1437; TAVANGAR K, 1992, J CLIN INVEST, V90, P1672, DOI 10.1172/JCI116039; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; VLODAVSKY I, 1995, THROMB HAEMOSTASIS, V74, P534; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I	52	72	78	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15753	15759		10.1074/jbc.272.25.15753	http://dx.doi.org/10.1074/jbc.272.25.15753			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188470	hybrid			2022-12-27	WOS:A1997XF32900030
J	Chen, Q; Lin, RY; Rubin, CS				Chen, Q; Lin, RY; Rubin, CS			Organelle-specific targeting of protein kinase AII (PKAII) - Molecular and in situ characterization of murine a kinase anchor proteins that recruit regulatory subunits of PKAII to the cytoplasmic surface of mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY BINDING-PROTEIN; II-BETA; A-KINASE; CAENORHABDITIS-ELEGANS; MESSENGER-RNAS; EXPRESSION; LOCALIZATION; SPERM; GENE; CLONING	Experiments were designed to test the idea that A kinase anchor proteins (AKAPs) tether regulatory subunits (RII) of protein kinase All (PKAII) isoforms to surfaces of organelles that are bounded by phospholipid bilayers. S-AKAP84, one of three RII binding proteins encoded by a single-copy murine gene, was studied as a prototypic organelle-associated AKAP. When S-AKAP84 was expressed in HEK293 cells, the anchor protein was targeted to mitochondria and excluded from other cell compartments. The RII tethering site is located in the cytoplasm adjacent to the mitochondrial surface. Endogenous RII subunits are not associated with mitochondria isolated from control cells. Expression of S-AKAP84 in transfected HEK293 cells triggered a redistribution of 15% of total RII to mitochondria. Thus, the tethering region of the organelle-inserted anchor protein is properly oriented and avidly binds RII (PKAII) isoforms in intact cells. Two critical domains in S-AKAP84 were mapped. Residues 1 to 30 govern insertion of the polypeptide into the outer mitochondrial membrane; amino acids 306-325 constitute the RII-binding site. Properties established for S-AKAP84 in vitro and in situ strongly suggest that a physiological function of this protein is to concentrate and immobilize RII (PKAII) isoforms at the cytoplasmic face of a phospholipid bilayer.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOL PHARMACOL,ATRAN LABS,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NIGMS NIH HHS [GM22792] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022792] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS B, 1994, MOL BIOL CELL, P369; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEASLEY EM, 1993, EMBO J, V12, P2303, DOI 10.1002/j.1460-2075.1993.tb05884.x; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; BROKAW CJ, 1987, J CELL BIOCHEM, V35, P175, DOI 10.1002/jcb.240350302; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1991, J BIOL CHEM, V266, P14188; CARRERA A, 1994, DEV BIOL, V165, P272, DOI 10.1006/dbio.1994.1252; Clermont Y., 1993, FRONT ENDOCRINOL, P332; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; HANNE K, 1994, CELL, V79, P829; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; HU ED, 1990, J BIOL CHEM, V265, P5072; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAND M, 1994, J BIOL CHEM, V269, P9234; LAND M, 1994, J BIOL CHEM, V269, P14820; LANDMARK BF, 1993, J REPROD FERTIL, V99, P323, DOI 10.1530/jrf.0.0990323; Lester LB, 1996, J BIOL CHEM, V271, P9460, DOI 10.1074/jbc.271.16.9460; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; Li Y, 1996, J BIOL CHEM, V271, P16862, DOI 10.1074/jbc.271.28.16862; LI Y, 1993, EXP CELL RES, V208, P170; LIEBERMAN SJ, 1988, J CELL BIOL, V107, P1809, DOI 10.1083/jcb.107.5.1809; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; LONNERBERG P, 1992, BIOL REPROD, V46, P1057, DOI 10.1095/biolreprod46.6.1057; Musco G, 1996, CELL, V85, P237, DOI 10.1016/S0092-8674(00)81100-9; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; TASH JS, 1982, BIOL REPROD, V26, P745, DOI 10.1095/biolreprod26.4.745; Trendelenburg G, 1996, BIOCHEM BIOPH RES CO, V225, P313, DOI 10.1006/bbrc.1996.1172; Wharton DC., 1967, METHOD ENZYMOL, P245	39	128	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15247	15257		10.1074/jbc.272.24.15247	http://dx.doi.org/10.1074/jbc.272.24.15247			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182549	hybrid			2022-12-27	WOS:A1997XE03400032
J	Sun, JR; Ooms, L; Bird, CH; Sutton, VR; Trapani, JA; Bird, PI				Sun, JR; Ooms, L; Bird, CH; Sutton, VR; Trapani, JA; Bird, PI			A new family of 10 murine ovalbumin serpins includes two homologs of proteinase inhibitor 8 and two homologs of the granzyme B inhibitor (proteinase inhibitor 9)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL CARCINOMA ANTIGEN; MONOCYTE/NEUTROPHIL ELASTASE INHIBITOR; MOLECULAR CHARACTERIZATION; CLONING; GENE; EXPRESSION; PURIFICATION; SPECIFICITY; SECRETION; SUBSTRATE	Serine proteinase inhibitors (serpins) are classically regulators of extracellular proteolysis, however, recent evidence suggests that some function intracellularly, Such ''ovalbumin'' serpins include the human proteinase inhibitors 6 (PI-6), 8 (PI-8), and 9 (PI 9), plasminogen activator inhibitor 2, and the monocyte/neutrophil elastase inhibitor, PI-9 is a potent granzyme B (graB) inhibitor that has an unusual P-1 Glu and is present primarily in lymphocytes. In a search for the murine equivalent of PI-9 we screened cDNA libraries, and performed reverse transcriptase-polymerase chain reaction on RNA isolated from leukocyte cell lines and from lymph nodes and spleens of allo-immunized mice. We identified 10 new ovalbumin serpin sequences: two resemble PI-8, two resemble PI-9, and the remaining six have no obvious human counterparts. Ey RNA analysis only one of the two sequences resembling PI-9 (designated SPI6) is present in mouse lymphocytes while the other (a partial clone designated mBM2A) is predominantly in testis, SPI6 comprises a 1.8-kilobase cDNA encoding a 374-amino acid polypeptide that is 68% identical to PI-9. mBM2A is 65% identical to PI-9 and over 80% identical to SPI6. Although the reactive loops of SPI6 and mBM2A differ from PI-9, both contain a Glu in a region likely to contain the P-1-P-1' bond. SPI6 produced in vitro using a coupled transcription/translation system formed an SDS-stable complex with human graB and did not interact with trypsin, chymotrypsin, leukocyte elastase, pancreatic elastase, thrombin, or cathepsin G. Recombinant SPI6 produced in a yeast expression system was used to examine the interaction with human, graB in more detail. The second-order rate constant for the interaction was estimated as 8 x 10(4) M-1 s(-1), and inhibition depended on the Glu in the SPI6 reactive center, The SPI6 gene was mapped to the same region on mouse chromosome 13 as Spi3, which encodes the murine homolog of PI-6. We conclude that even though their reactive centers are not highly conserved, SPI6 is a functional homolog of PI-9, and that the regulation of graB in the mouse may involve a second serpin encoded by mBM2A. Our identification of multiple sequence homologs of PI-S and PI-9, and six new ovalbumin serpins, is consonant with the idea that the larger set of granule and other proteinases known to exist in the mouse (compared with human) is balanced by a larger array of serpins.	MONASH UNIV SCH MED,BOX HILL HOSP,DEPT MED,CLIVE WARD CTR,BOX HILL,VIC 3128,AUSTRALIA; AUSTIN RES INST,CELLULAR CYTOTOX LAB,HEIDELBERG,VIC 3084,AUSTRALIA	Box Hill Hospital; Monash University; Austin Research Institute			Ooms, Lisa/AGZ-7420-2022	Ooms, Lisa Michelle/0000-0002-8918-9932; Bird, Phillip/0000-0002-6695-606X; Trapani, Joseph/0000-0003-0983-1532				Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BELIN D, 1993, THROMB HAEMOSTASIS, V70, P144; BORRIELLO F, 1991, P NATL ACAD SCI USA, V88, P9417, DOI 10.1073/pnas.88.21.9417; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; COUGHLIN P, 1993, P NATL ACAD SCI USA, V90, P9417, DOI 10.1073/pnas.90.20.9417; COUGHLIN P, 1995, GENOMICS, V26, P431, DOI 10.1016/0888-7543(95)80240-M; COUGHLIN PB, 1993, J BIOL CHEM, V268, P9541; EVANS E, 1995, GENOMICS, V28, P235, DOI 10.1006/geno.1995.1136; Eyre HJ, 1996, GENOMICS, V37, P406, DOI 10.1006/geno.1996.0580; HAMES BD., 1981, GEL ELECTROPHORESIS, P1; HOPKINS PCR, 1994, SCIENCE, V265, P1893; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; INGLIS JD, 1991, EMBO J, V10, P255, DOI 10.1002/j.1460-2075.1991.tb07945.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADISON EL, 1992, GENE, V121, P179, DOI 10.1016/0378-1119(92)90179-S; MANLY KF, 1993, MAMM GENOME, V4, P303, DOI 10.1007/BF00357089; MORGENSTERN KA, 1993, J BIOL CHEM, V268, P21560; OOMS L, 1995, CHROMOSOME RES, V3, P447, DOI 10.1007/BF00713898; PALLADINO MA, 1983, CANCER RES, V43, P572; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; POE M, 1991, J BIOL CHEM, V266, P98; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; QUAN LT, 1995, J BIOL CHEM, V270, P10377, DOI 10.1074/jbc.270.18.10377; REMOLDODONNELL E, 1992, P NATL ACAD SCI USA, V89, P5635, DOI 10.1073/pnas.89.12.5635; REMOLDODONNELL E, 1993, FEBS LETT, V315, P105, DOI 10.1016/0014-5793(93)81143-N; RIEWALD M, 1995, J BIOL CHEM, V270, P26754, DOI 10.1074/jbc.270.45.26754; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER SS, 1995, P NATL ACAD SCI USA, V92, P3147, DOI 10.1073/pnas.92.8.3147; SMYTH MJ, 1995, IMMUNOL TODAY, V16, P202, DOI 10.1016/0167-5699(95)80122-7; SPRECHER CA, 1995, J BIOL CHEM, V270, P29854; SUGIMORI T, 1995, AM J RESP CELL MOL, V13, P314, DOI 10.1165/ajrcmb.13.3.7654387; SUMINAMI Y, 1991, BIOCHEM BIOPH RES CO, V181, P51, DOI 10.1016/S0006-291X(05)81380-4; SUN JR, 1995, BBA-PROTEIN STRUCT M, V1252, P28, DOI 10.1016/0167-4838(95)00108-7; Sun JR, 1996, J BIOL CHEM, V271, P27802, DOI 10.1074/jbc.271.44.27802; SUN JR, 1995, J BIOL CHEM, V270, P16089, DOI 10.1074/jbc.270.27.16089; SUTTON VR, 1997, IN PRESS J IMMUNOL; TAKEDA A, 1995, FEBS LETT, V359, P78, DOI 10.1016/0014-5793(94)01456-B; THOMPSON EA, 1988, THROMB HAEMOSTASIS, V59, P415; TRAPANI JA, 1993, BIOCHEM BIOPH RES CO, V195, P910, DOI 10.1006/bbrc.1993.2131; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; YE RD, 1987, J BIOL CHEM, V262, P3718; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	45	98	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15434	15441		10.1074/jbc.272.24.15434	http://dx.doi.org/10.1074/jbc.272.24.15434			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182575	hybrid			2022-12-27	WOS:A1997XE03400058
J	Bowman, EJ; ONeill, FJ; Bowman, BJ				Bowman, EJ; ONeill, FJ; Bowman, BJ			Mutations of pma-1, the gene encoding the plasma membrane H+-ATPase of Neurospora crassa, suppress inhibition of growth by concanamycin A, a specific inhibitor of vacuolar ATPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SARCOPLASMIC-RETICULUM; ELECTRON-MICROSCOPY; PROTON TRANSPORT; CELL-DEATH; YEAST; MUTANTS; PROTEIN; BAFILOMYCIN-A1; ACIDIFICATION	Concanamycin A (CCA), a specific inhibitor of vacuolar ATPases, inhibited growth of Neurospora crassa in medium adjusted to pH 7 or above. Mutant strains were elected for growth on medium containing 1.0 mu M CCA. Sixty-four (of 66) mutations mapped in the region of the pma1 locus, which encodes the plasma membrane H+- ATPase. Analysis of V-ATPase activity in isolated vacuolar membranes from the mutant strains showed wildtype activity and sensitivity to CCA. In contrast, plasma membrane H+-ATPase activity in isolated plasma membranes from the mutants was reduced as compared with wild-type, and in four strains the activity showed increased resistance to vanadate. The most interesting change in the plasma membrane H+-ATPase was in kinetic behavior. The wild-type enzyme showed sigmoid dependence on MgATP concentration with a Hill number of 2.0, while the seven mutants tested exhibited hyperbolic kinetics with a Hill number of 1.0. One interpretation of these data was that the enzyme had changed from a functional dimer to a functional monomer. Mutation of the plasma membrane H+-ATPase did not confer resistance by preventing uptake of CCA. In the presence of CCA both wild-type and mutant strains were unable to accumulate arginine, failed to concentrate chloroquine in acidic vesicles, and exhibited gross alterations in hyphal morphology, indicating that the CCA had entered the cells and inactivated the V-ATPase. Instead, we hypothesize that the mutations conferred resistance because the altered plasma membrane H+- ATPase could more efficiently rid the cell of toxic levels of Ca2+ or protons or other ions accumulated in the cytoplasm following inactivation of the V-ATPase by CCA.	UNIV CALIF SANTA CRUZ, SINSHEIMER LABS, DEPT BIOL, SANTA CRUZ, CA 95064 USA	University of California System; University of California Santa Cruz					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028703] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-28703, GM-08123] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDISON R, 1986, J BIOL CHEM, V261, P4896; ANRAKU Y, 1996, HDB BIOL PHYS, V2, P93; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; BOWMAN BJ, 1979, J BIOL CHEM, V254, P2928; BOWMAN BJ, 1985, J BIOL CHEM, V260, P8726; BOWMAN BJ, 1983, J BIOL CHEM, V258, P3002; BOWMAN BJ, 1992, J EXP BIOL, V172, P57; BOWMAN EJ, 1988, METHOD ENZYMOL, V157, P562; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BOWMAN J, 1996, MYCOTA, V3, P57; CRAIG WS, 1982, BIOCHEMISTRY-US, V21, P5707, DOI 10.1021/bi00265a049; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; Davis R.H., 1970, METHODS ENZYMOL, V17, P79, DOI [10.1016/0076-6879(71)17168-6, DOI 10.1016/0076-6879(71)17168-6]; DAVIS RH, 1986, MICROBIOL REV, V50, P280, DOI 10.1128/MMBR.50.3.280-313.1986; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; DSCHIDA WJ, 1992, J BIOL CHEM, V267, P18783; Ferea TL, 1996, GENETICS, V143, P147; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GOORMAGHTIGH E, 1986, J BIOL CHEM, V261, P7466; GOTTLIEB RA, 1995, P NATL ACAD SCI USA, V92, P5965, DOI 10.1073/pnas.92.13.5965; GUINEA R, 1995, J VIROL, V69, P2306, DOI 10.1128/JVI.69.4.2306-2312.1995; HAASS C, 1995, J BIOL CHEM, V270, P6186, DOI 10.1074/jbc.270.11.6186; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; HEMING TA, 1995, J EXP BIOL, V198, P1711; JACKSON SL, 1993, MICROBIOL REV, V57, P367, DOI 10.1128/MMBR.57.2.367-382.1993; KITAMOTO K, 1988, J BACTERIOL, V170, P2683, DOI 10.1128/jb.170.6.2683-2686.1988; KITAMOTO K, 1988, J BACTERIOL, V170, P2687, DOI 10.1128/jb.170.6.2687-2691.1988; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KOLAND JG, 1986, J BIOL CHEM, V261, P5936; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; MCGILLVIRAY AM, 1987, J GEN MICROBIOL, V133, P2875; METZENBERG RL, 1992, FUNGAL GENET NEWSLET, V39, P50; MILLER AJ, 1990, P NATL ACAD SCI USA, V87, P9348, DOI 10.1073/pnas.87.23.9348; MOLLER JV, 1980, J BIOL CHEM, V255, P1912; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; NAO SQ, 1995, J BIOL CHEM, V270, P6815, DOI 10.1074/jbc.270.12.6815; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NISHIHARA T, 1995, BIOCHEM BIOPH RES CO, V212, P255, DOI 10.1006/bbrc.1995.1964; OHYA Y, 1991, J BIOL CHEM, V266, P13971; PALOKANGAS H, 1994, J BIOL CHEM, V269, P17577; PERKINS DD, 1982, MICROBIOL REV, V46, P426, DOI 10.1128/MMBR.46.4.426-570.1982; PERLIN DS, 1988, J BIOL CHEM, V263, P18118; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RAO R, 1996, MYCOTA, V3, P29; Sackett DL, 1996, J BIOL CHEM, V271, P9987, DOI 10.1074/jbc.271.17.9987; SANDERS D, 1982, J GEN PHYSIOL, V80, P377, DOI 10.1085/jgp.80.3.377; SEBALD W, 1981, CURR TOP BIOENERG, V12, P1; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SLAYMAN CL, 1973, J BACTERIOL, V114, P752, DOI 10.1128/JB.114.2.752-766.1973; Staben C, 1989, FUNGAL GENET NEWSL, V36, P79, DOI DOI 10.4148/1941-4765.1519; SUNDQUIST K, 1990, BIOCHEM BIOPH RES CO, V168, P309, DOI 10.1016/0006-291X(90)91709-2; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; Temesvari LA, 1996, J CELL SCI, V109, P1479; ULASZEWSKI S, 1983, EUR J BIOCHEM, V130, P235, DOI 10.1111/j.1432-1033.1983.tb07141.x; ULASZEWSKI S, 1986, CURR GENET, V10, P359, DOI 10.1007/BF00418407; UMATA T, 1990, J BIOL CHEM, V265, P21940; VANPILSUM JF, 1956, J BIOL CHEM, V222, P225; VOGEL HJ, 1964, AM NAT, V98, P435, DOI 10.1086/282338; WOO JT, 1992, EUR J BIOCHEM, V207, P383, DOI 10.1111/j.1432-1033.1992.tb17061.x; YILLA M, 1993, J BIOL CHEM, V268, P19092; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; ZEREZ CR, 1986, J BIOL CHEM, V261, P8877; ZHANG JM, 1994, J BIOL CHEM, V269, P23518	64	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14776	14786		10.1074/jbc.272.23.14776	http://dx.doi.org/10.1074/jbc.272.23.14776			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169444	hybrid			2022-12-27	WOS:A1997XC32700041
J	Francis, SE; Banerjee, R; Goldberg, DE				Francis, SE; Banerjee, R; Goldberg, DE			Biosynthesis and maturation of the malaria aspartic hemoglobinases plasmepsins I and II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARASITE PLASMODIUM-FALCIPARUM; MULTICATALYTIC PROTEINASE COMPLEX; UBIQUITIN-PROTEASOME PATHWAY; LYSOSOMAL ACID-PHOSPHATASE; NF-KAPPA-B; MEMBRANE-PROTEIN; CHARGED RESIDUES; BREFELDIN-A; DEGRADATION; CELLS	During the intraerythrocytic stage of infection, the malaria parasite Plasmodium falciparum digests most of the host cell hemoglobin. Hemoglobin degradation occurs in the acidic digestive vacuole and is essential for the survival of the parasite. Two aspartic proteases, plasmepsins I and II, have been isolated from the vacuole and shown to make the initial cleavages in the hemoglobin molecule. We have studied the biosynthesis of these two enzymes. Plasmepsin I is synthesized and processed to the mature form soon after the parasite invades the red blood cell, while plasmepsin II synthesis is delayed until later in development. Otherwise, biosynthesis of the plasmepsins is identical. The proplasmepsins are type II integral membrane proteins that are transported through the secretory pathway before cleavage to the soluble form. They are not glycosylated in vivo, despite the presence of several potential glycosylation sites. Proplasmepsin maturation appears to require acidic conditions and is reversibly inhibited by the tripeptide aldehydes N-acetyl-L-leucyl-L-leucyl-norleucinal and N-acetyl-L-leucyl-L-leucyl-methional. These compounds are known to inhibit cysteine proteases and the chymotryptic activity of proteasomes but not aspartic proteases. However, proplasmepsin processing is not blocked by other cysteine protease inhibitors, nor by the proteasome inhibitor lactacystin. Processing is also not blocked by aspartic protease inhibitors. This inhibitor profile suggests that unlike most other aspartic proteases, proplasmepsin maturation may not be autocatalytic in vivo, but instead could require the action of an unusual processing enzyme. Compounds that block processing are expected to be potent antimalarials.	WASHINGTON UNIV,SCH MED,DEPT MOL MICROBIOL,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)					NIAID NIH HHS [AI31615] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI031615] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ASH J, 1995, J BIOL CHEM, V270, P20847, DOI 10.1074/jbc.270.35.20847; BALL EG, 1948, J BIOL CHEM, V175, P547; BANTING G, 1995, TRENDS CELL BIOL, V5, P340, DOI 10.1016/S0962-8924(00)89060-1; BELTZER JP, 1991, J BIOL CHEM, V266, P973; BLUNDELL TL, 1990, J MOL BIOL, V211, P919, DOI 10.1016/0022-2836(90)90084-Y; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CRARY JL, 1992, MOL BIOCHEM PARASIT, V53, P185, DOI 10.1016/0166-6851(92)90020-K; DAME JB, 1994, MOL BIOCHEM PARASIT, V64, P177, DOI 10.1016/0166-6851(94)90024-8; DIECKMANNSCHUPPERT A, 1992, EUR J BIOCHEM, V205, P815, DOI 10.1111/j.1432-1033.1992.tb16846.x; ELMENDORF HG, 1993, PARASITOL TODAY, V9, P98, DOI 10.1016/0169-4758(93)90216-3; ELMENDORF HG, 1992, MOL BIOCHEM PARASIT, V52, P215, DOI 10.1016/0166-6851(92)90054-N; ELMENDORF HG, 1993, EMBO J, V12, P4763, DOI 10.1002/j.1460-2075.1993.tb06165.x; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FRANCIS SE, 1994, EMBO J, V13, P306, DOI 10.1002/j.1460-2075.1994.tb06263.x; Francis SE, 1996, MOL BIOCHEM PARASIT, V83, P189, DOI 10.1016/S0166-6851(96)02772-7; GINSBURG H, 1989, BIOCHEM PHARMACOL, V38, P2645, DOI 10.1016/0006-2952(89)90550-9; GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961; GOTTSCHALK S, 1989, EMBO J, V8, P3215, DOI 10.1002/j.1460-2075.1989.tb08480.x; GUNTHER K, 1991, MOL BIOCHEM PARASIT, V46, P149, DOI 10.1016/0166-6851(91)90208-N; Haldar Kasturi, 1993, Seminars in Cell Biology, V4, P345, DOI 10.1006/scel.1993.1041; HASLIK S, 1978, EUR J BIOCHEM, V85, P599; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HILL J, 1994, FEBS LETT, V352, P155, DOI 10.1016/0014-5793(94)00940-6; Howard R.J., 1987, NATO ASI Series Series H Cell Biology, V11, P281; Howard R. J., 1988, The biology of parasitism. A molecular and immunological approach., P111; HUI GSN, 1984, T ROY SOC TROP MED H, V78, P625, DOI 10.1016/0035-9203(84)90222-0; INOMATA M, 1993, BIOCHIM BIOPHYS ACTA, V1178, P207, DOI 10.1016/0167-4889(93)90011-D; Kimura EA, 1996, J BIOL CHEM, V271, P14452, DOI 10.1074/jbc.271.24.14452; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P10752, DOI 10.1073/pnas.92.23.10752; KROGSTAD DJ, 1985, J CELL BIOL, V101, P2302, DOI 10.1083/jcb.101.6.2302; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LINGELBACH KR, 1993, EXP PARASITOL, V76, P318, DOI 10.1006/expr.1993.1039; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LUJAN HD, 1995, J BIOL CHEM, V270, P4612, DOI 10.1074/jbc.270.9.4612; Luker KE, 1996, MOL BIOCHEM PARASIT, V79, P71, DOI 10.1016/0166-6851(96)02651-5; MCINTYRE GF, 1991, J BIOL CHEM, V266, P15438; MORRISON DEMPSIE B., 1948, JOUR NATION MALARIA SOC, V7, P259; MURACHI T, 1983, TRENDS BIOCHEM SCI, V8, P167, DOI 10.1016/0968-0004(83)90165-2; OLLIARO PL, 1995, PARASITOL TODAY, V11, P294, DOI 10.1016/0169-4758(95)80042-5; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P4862; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROSENTHAL PJ, 1989, MOL BIOCHEM PARASIT, V35, P177, DOI 10.1016/0166-6851(89)90120-5; ROSENTHAL PJ, 1993, J CLIN INVEST, V91, P1052, DOI 10.1172/JCI116262; Sadoul R, 1996, EMBO J, V15, P3845, DOI 10.1002/j.1460-2075.1996.tb00758.x; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SCHERBAUM WA, 1988, J AUTOIMMUN, V1, P219, DOI 10.1016/0896-8411(88)90028-5; STURCHLER D, 1989, PARASITOL TODAY, V5, P39, DOI 10.1016/0169-4758(89)90188-9; TANG J, 1987, J CELL BIOCHEM, V33, P53, DOI 10.1002/jcb.240330106; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TSUBUKI S, 1993, BIOCHEM BIOPH RES CO, V196, P1195, DOI 10.1006/bbrc.1993.2378; VANDERJAGT DL, 1992, BIOCHIM BIOPHYS ACTA, V1122, P256, DOI 10.1016/0167-4838(92)90401-X; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x; WELLEMS TE, 1991, PARASITOL TODAY, V7, P110, DOI 10.1016/0169-4758(91)90168-N; WILK S, 1993, ENZYME PROTEIN, V47, P306, DOI 10.1159/000468688; WOOD PA, 1993, AM J TROP MED HYG, V48, P465, DOI 10.4269/ajtmh.1993.48.465; YAYON A, 1984, EMBO J, V3, P2695, DOI 10.1002/j.1460-2075.1984.tb02195.x; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707	66	99	102	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14961	14968		10.1074/jbc.272.23.14961	http://dx.doi.org/10.1074/jbc.272.23.14961			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169469	hybrid			2022-12-27	WOS:A1997XC32700066
J	Nagaich, AK; Zhurkin, VB; Sakamoto, H; Gorin, AA; Clore, GM; Gronenborn, AM; Appella, E; Harrington, RE				Nagaich, AK; Zhurkin, VB; Sakamoto, H; Gorin, AA; Clore, GM; Gronenborn, AM; Appella, E; Harrington, RE			Architectural accommodation in the complex of four p53 DNA binding domain peptides with the p21/waf1/cip1 DNA response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; MUTANT P53; CURVED DNA; WILD-TYPE; SEQUENCE; PROTEIN; SUPPRESSOR; RESOLUTION; ACTIVATION; CURVATURE	High resolution chemical footprinting and cross-linking experiments have provided a basis for elucidating the overall architecture of the complex between the core DNA binding domain of p53 (p53DBD, amino acids 98-309) and the p21/waf1/cip1 DNA response element implicated in the G(1)/S phase cell cycle checkpoint. These studies complement both a crystal structure and earlier biophysical studies and provide the first direct experimental evidence that four subunits of p53DBD bind to the response element in a regular staggered array having pseudodyad symmetry, The invariant guanosines in the highly conserved C(A/T)\(T/A)G parts of the consensus half-sites are critical to the p53DBD-DNA binding. Molecular modeling of the complex using the observed peptide-DNA contacts shows that when four subunits of p53DBD bind the response element, the DNA has to bend similar to 50 degrees to relieve steric clashes among different subunits, consistent with recent DNA cyclization studies. The overall lateral arrangement of the four p53 subunits with respect to the DNA loop comprises a novel nucleoprotein assembly that has not been reported previously in other complexes. We suggest that this kind of nucleoprotein superstructure may be important for p53 binding to response elements packed in chromatin and for subsequent transactivation of p53-mediated genes.	UNIV NEVADA,SCH MED,DEPT BIOCHEM 330,RENO,NV 89557; RUTGERS STATE UNIV,DEPT CHEM,PISCATAWAY,NJ 08855; NCI,LAB EXPT & COMPUTAT BIOL,NIH,BETHESDA,MD 20892; NCI,CELL BIOL LAB,NIH,BETHESDA,MD 20892; NIDDK,PHYS CHEM LAB,NIH,BETHESDA,MD 20892	Nevada System of Higher Education (NSHE); University of Nevada Reno; Rutgers State University New Brunswick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Sakamoto, Hiroshi/A-3181-2011; Clore, G. Marius/A-3511-2008; Clore, G Marius/L-2546-2018; Gorin, Andrey A/B-1545-2014	Clore, G. Marius/0000-0003-3809-1027; Clore, G Marius/0000-0003-3809-1027; Gronenborn, Angela M/0000-0001-9072-3525	NATIONAL CANCER INSTITUTE [R01CA070274] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R55HG000656] Funding Source: NIH RePORTER; NCI NIH HHS [CA70274] Funding Source: Medline; NHGRI NIH HHS [HG00656] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARBER AM, 1990, J BIOMOL STRUCT DYN, V8, P213, DOI 10.1080/07391102.1990.10507803; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BOLSHOY A, 1991, P NATL ACAD SCI USA, V88, P2312, DOI 10.1073/pnas.88.6.2312; BRUKNER I, 1994, J MOL BIOL, V236, P26, DOI 10.1006/jmbi.1994.1115; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DIXON WJ, 1991, METHOD ENZYMOL, V208, P380; DLAKIC M, 1995, J BIOL CHEM, V270, P29945; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRATINI AV, 1982, J BIOL CHEM, V257, P4686; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GOODSELL DS, 1993, P NATL ACAD SCI USA, V90, P2930, DOI 10.1073/pnas.90.7.2930; GORIN AA, 1995, J MOL BIOL, V247, P34, DOI 10.1006/jmbi.1994.0120; HARRINGTON RE, 1994, PROG NUCLEIC ACID RE, V47, P195, DOI 10.1016/S0079-6603(08)60253-6; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HAYES JJ, 1989, BIOCHEMISTRY-US, V28, P9521, DOI 10.1021/bi00450a041; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARX J, 1994, SCIENCE, V266, P1321, DOI 10.1126/science.7973719; Maxam A M, 1980, Methods Enzymol, V65, P499; MCNAMARA PT, 1990, J BIOMOL STRUCT DYN, V8, P529, DOI 10.1080/07391102.1990.10507827; NAGAICH AK, 1994, J BIOL CHEM, V269, P7824; Nagaich AK, 1997, J BIOL CHEM, V272, P14842, DOI 10.1074/jbc.272.23.14842; NAMBA H, 1995, CANCER RES, V55, P2075; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; Sambrook J., 2002, MOL CLONING LAB MANU; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SELIVANOVA G, 1995, ADV CANCER RES, V66, P143, DOI 10.1016/S0065-230X(08)60253-5; SHPIGELMAN ES, 1993, COMPUT APPL BIOSCI, V9, P435; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; TAO X, 1995, P NATL ACAD SCI USA, V92, P6803, DOI 10.1073/pnas.92.15.6803; THUKRAL SK, 1995, MOL CELL BIOL, V15, P5196; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; Urpi L, 1996, NAT STRUCT BIOL, V3, P325, DOI 10.1038/nsb0496-325; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; WISSMANN A, 1991, METHOD ENZYMOL, V208, P365; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; ZHURKIN VB, 1991, P NATL ACAD SCI USA, V88, P7046, DOI 10.1073/pnas.88.16.7046	64	61	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14830	14841		10.1074/jbc.272.23.14830	http://dx.doi.org/10.1074/jbc.272.23.14830			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169452	hybrid			2022-12-27	WOS:A1997XC32700049
J	Otero, AD				Otero, AD			Copurification of vimentin, energy metabolism enzymes, and a MER5 homolog with nucleoside diphosphate kinase - Identification of tissue-specific interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT PROTEINS; DEVELOPMENTAL EXPRESSION; XENOPUS-LAEVIS; NM23 GENE; PURIFICATION; CELLS; CREATINE; FAMILY; DESMIN; PHOSPHORYLATION	Chromatography on immobilized antibodies specific to nucleoside diphosphate (NDP) kinase was utilized for affinity purification of this enzyme from detergent extracts of frog heart post-mitochondrial fractions. SDS-polyacrylamide gel electrophoresis analysis of eluates from these. supports shows that five polypeptides copurify with nucleoside diphosphate (NDP) kinase. Tryptic digests of each band were analyzed by mass spectrometric microsequencing. Data base searches by peptide mass matching and sequence homology led to the identification of these proteins as glyceraldehyde-3-phosphate dehydrogenase (40 kDa), creatine kinase (45 kDa), vimentin (55 kDa), pyruvate kinase (60 kDa), and a putative member of the antioxidant protein family (28 kDa). Distinct protein compositions were found in eluates of lung and liver extracts processed in a like manner. The 28-kDa band and vimentin were associated with NDP kinase from all tissues, but co-purification of pyruvate kinase was seen only in liver, while creatine kinase and glyceraldehyde-3-phosphate dehydrogenase were absent from eluates from lung and liver. The results suggest that while NDP kinase is associated with vimentin intermediate filaments and an antioxidant protein in most tissues, it interacts with energy metabolism enzymes in a tissue-specific manner.			Otero, AD (corresponding author), UNIV VIRGINIA,SCH MED,DEPT MOL PHYSIOL & BIOL PHYS,POB 10011,CHARLOTTESVILLE,VA 22906, USA.				NHLBI NIH HHS [HL 48726] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048726] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; Chang CL, 1996, ONCOGENE, V12, P659; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; DOHERTY FJ, 1987, BIOCHEM J, V241, P793, DOI 10.1042/bj2410793; ECKERT BS, 1980, J CELL BIOL, V86, P1, DOI 10.1083/jcb.86.1.1; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; FUKUCHI T, 1994, BBA-PROTEIN STRUCT M, V1205, P113, DOI 10.1016/0167-4838(94)90099-X; GEISLER N, 1980, EUR J BIOCHEM, V111, P425, DOI 10.1111/j.1432-1033.1980.tb04957.x; HERRMANN H, 1989, DEVELOPMENT, V105, P279; HOWLETT AR, 1994, J NATL CANCER I, V86, P1838, DOI 10.1093/jnci/86.24.1838; ISOBE Y, 1994, HISTOCHEMISTRY, V101, P155, DOI 10.1007/BF00269541; KANTOR JD, 1993, CANCER RES, V53, P1971; KORETSKY AP, 1990, P NATL ACAD SCI USA, V87, P3112, DOI 10.1073/pnas.87.8.3112; MACLEOD AR, 1981, EUR J BIOCHEM, V119, P353, DOI 10.1111/j.1432-1033.1981.tb05615.x; MARTIN F, 1995, J MOL BIOL, V247, P49, DOI 10.1006/jmbi.1994.0121; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; Milon L, 1997, HUM GENET, V99, P550, DOI 10.1007/s004390050405; NELSON WJ, 1982, J BIOL CHEM, V257, P5544; Osborn Mary, 1993, P169; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; ROBERT J, 1991, GENET RES, V58, P35, DOI 10.1017/S001667230002958X; ROGERS KR, 1991, BIOCHEM J, V275, P789, DOI 10.1042/bj2750789; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SHI YB, 1994, FEBS LETT, V355, P61, DOI 10.1016/0014-5793(94)01173-7; STAHL JA, 1991, CANCER RES, V51, P445; Sundin GW, 1996, MOL MICROBIOL, V20, P965, DOI 10.1111/j.1365-2958.1996.tb02538.x; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; TRASK RV, 1990, BIOCHIM BIOPHYS ACTA, V1049, P182, DOI 10.1016/0167-4781(90)90039-5; TROLL H, 1993, J BIOL CHEM, V268, P25469; Tsutsumi H, 1988, GENOMICS, V2, P86, DOI 10.1016/0888-7543(88)90112-7; VASSY J, 1990, J MICROSC, V152, P91; VENTURELLI D, 1995, P NATL ACAD SCI USA, V92, P7435, DOI 10.1073/pnas.92.16.7435; WAGNER PD, 1995, J BIOL CHEM, V270, P21758, DOI 10.1074/jbc.270.37.21758; Xu L, 1996, J BIOL CHEM, V271, P21120, DOI 10.1074/jbc.271.35.21120; YAMAMOTO T, 1989, GENE, V80, P337; Yi XB, 1996, BBA-MOL CELL RES, V1310, P334, DOI 10.1016/0167-4889(95)00164-6	38	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14690	14694		10.1074/jbc.272.23.14690	http://dx.doi.org/10.1074/jbc.272.23.14690			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169432	hybrid			2022-12-27	WOS:A1997XC32700029
J	Chen, YX; Rosen, BP				Chen, YX; Rosen, BP			Metalloregulatory properties of the ArsD repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARSENICAL RESISTANCE OPERON; ACTING REGULATORY PROTEIN; EXPRESSION; IDENTIFICATION; CONSTRUCTION; TOPOLOGY; ATPASE; GENES	The plasmid-encoded arsenical resistance (ars) operon of plasmid R773 produces resistance to trivalent and pentavalent salts of the metalloids arsenic and antimony in cells of Escherichia coli, The first two genes in the operon, arsR and arsD, were previously shown to encode trans-acting repressor proteins, ArsR controls the basal level of expression of the operon, while ArsD controls maximal expression. Thus, action of the two repressors form a homeostatic regulatory circuit that maintains the level of ars expression within a narrow range. In this study, we demonstrate that ArsD binds to the same site on the ars promoter element as ArsR but with 2 orders of magnitude lower affinity, The results of gel shift assays demonstrate that ArsD is released from the ars DNA promoter by phenylarsine oxide, sodium arsenite, and potassium antimonyl tartrate (in order of effectiveness), the same inducers to which ArsR responds, Using the quenching of intrinsic tryptophan fluorescence to measure the affinity of the repressor for inducers, apparent K-d values for Sb(III) and As(III) of 2 and 60 mu M, respectively, were obtained, These results demonstrate that the arsR-arsD pair provide a sensitive mechanism for sensing a wide range of environmental heavy metals.	WAYNE STATE UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,DETROIT,MI 48201	Wayne State University				Rosen, Barry P./0000-0002-5230-4271	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019793] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19793] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bhattacharjee H, 1996, J BIOL CHEM, V271, P24465, DOI 10.1074/jbc.271.40.24465; BHATTACHARJEE H, 1995, J BIOL CHEM, V270, P11245, DOI 10.1074/jbc.270.19.11245; BROOMESMITH JK, 1986, GENE, V49, P341, DOI 10.1016/0378-1119(86)90370-7; Bruhn DF, 1996, FEMS MICROBIOL LETT, V139, P149, DOI 10.1016/0378-1097(96)00134-6; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHEN CM, 1986, J BIOL CHEM, V261, P5030; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Miller J.H., 1972, EXPT MOL GENETICS; Rosen BP, 1996, J BIOL INORG CHEM, V1, P273, DOI 10.1007/s007750050053; Sambrook J., 2002, MOL CLONING LAB MANU; SANFRANCISCO MJD, 1990, NUCLEIC ACIDS RES, V18, P619; SHI WP, 1994, J BIOL CHEM, V269, P19826; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WU J, 1991, MOL MICROBIOL, V5, P1331, DOI 10.1111/j.1365-2958.1991.tb00779.x; WU JH, 1993, J BIOL CHEM, V268, P52; WU JH, 1993, MOL MICROBIOL, V8, P615, DOI 10.1111/j.1365-2958.1993.tb01605.x; WU JH, 1992, J BIOL CHEM, V267, P12570; XU C, 1996, J BIOL CHEM, V271, P24227; YU HR, 1994, J BIOL CHEM, V269, P15697	20	62	65	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14257	14262		10.1074/jbc.272.22.14257	http://dx.doi.org/10.1074/jbc.272.22.14257			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162059	hybrid			2022-12-27	WOS:A1997XB49200046
J	Lin, ECK; Ratnikov, BI; Tsai, PR; Gonzalez, ER; McDonald, S; Pelletier, AJ; Smith, JW				Lin, ECK; Ratnikov, BI; Tsai, PR; Gonzalez, ER; McDonald, S; Pelletier, AJ; Smith, JW			Evidence that the integrin beta 3 and beta 5 subunits contain a metal ion-dependent adhesion site-like motif but lack an I domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; ALPHA(V) INTEGRINS; CRYSTAL-STRUCTURE; CATION-BINDING; CELL-ADHESION; A-DOMAIN; DIVALENT; PERSPECTIVES; ATTACHMENT; CD11B/CD18	The amino-terminal domain of each integrin beta subunit is hypothesized to contain an ion binding site that is key to cell adhesion, A new hypothesis regarding the structure of this site is suggested by the crystallization of the I domains of the integrin alpha(L) and alpha(M) subunits (Lee, J.-O., Rieu, P., Arnaout, M. A., and Liddington, R. (1995) Cell 80, 631-638; Qu, A., and Leahy, D. J. (1995) Proc. Natl, Acad, Sci, U.S.A. 92, 10277-10281), In those proteins, an essential metal ion is bound by a metal ion-dependent adhesion site (MIDAS), The MIDAS is presented at the apex of a larger protein module called an I domain, The metal ligands in the MIDAS can be separated into three distantly spaced clusters of oxygenated residues, These three coordination sites also appear to exist in the integrin beta 3 and beta 5 subunits, Here, we examined the putative metal binding site within beta 3 and beta 5 using site-directed mutagenesis and ligand binding studies, We also investigated the fold of the domain containing the putative metal binding site using the PHD structural algorithm. The results of the study point to the similarity between the integrin beta subunits and the MIDAS motif at two of three key coordination points, Importantly though, the study failed to identify a residue in either beta subunit that corresponds to the second metal coordination group in the MIDAS, Moreover, structural algorithms indicate that the fold of the beta subunits is considerably different than the I domains, Thus, the integrin beta subunits appear to present a MIDAS-like motif in the context of a protein module that is structurally distinct from known I domains.	LA JOLLA CANC RES CTR, BURNHAM INST, PROGRAM CELL ADHES & EXTRACELLULAR MATRIX, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute; Scripps Research Institute					NATIONAL CANCER INSTITUTE [R01CA056483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053489] Funding Source: NIH RePORTER; NCI NIH HHS [CA 56483] Funding Source: Medline; NIAMS NIH HHS [AR 42750] Funding Source: Medline; NIGMS NIH HHS [GM 53489] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBAS CF, 1993, P NATL ACAD SCI USA, V90, P10003, DOI 10.1073/pnas.90.21.10003; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CHARO IF, 1991, BIOCHIM BIOPHYS ACTA, V1119, P312; COOK JJ, 1992, BIOCHIM BIOPHYS ACTA, V1119, P312, DOI 10.1016/0167-4838(92)90219-4; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GRZESIAK JJ, 1992, J CELL BIOL, V117, P1109, DOI 10.1083/jcb.117.5.1109; HORTON MA, 1989, J BONE MINER RES, V4, P803; Hu DD, 1996, J BIOL CHEM, V271, P21745, DOI 10.1074/jbc.271.36.21745; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Nemerow Glen R., 1994, Trends in Cell Biology, V4, P52, DOI 10.1016/0962-8924(94)90010-8; Pelletier AJ, 1996, J BIOL CHEM, V271, P1364, DOI 10.1074/jbc.271.3.1364; PERSECHINI A, 1989, TRENDS NEUROSCI, V12, P462, DOI 10.1016/0166-2236(89)90097-0; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RECHLER MM, 1977, J BIOL CHEM, V252, P3898; ROSS FP, 1993, J BIOL CHEM, V268, P9901; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rost B, 1996, METHOD ENZYMOL, V266, P525; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SMITH JW, 1994, J BIOL CHEM, V269, P32788; SMITH JW, 1994, J BIOL CHEM, V269, P960; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; Stuiver I, 1996, J CELL PHYSIOL, V168, P521, DOI 10.1002/(SICI)1097-4652(199609)168:3<521::AID-JCP4>3.0.CO;2-R; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	34	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14236	14243		10.1074/jbc.272.22.14236	http://dx.doi.org/10.1074/jbc.272.22.14236			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162056	hybrid			2022-12-27	WOS:A1997XB49200043
J	Ono, T; Inokuchi, K; Ogura, A; Ikawa, Y; Kudo, Y; Kawashima, S				Ono, T; Inokuchi, K; Ogura, A; Ikawa, Y; Kudo, Y; Kawashima, S			Activity-dependent expression of parathyroid hormone-related protein (PTHrP) in rat cerebellar granule neurons - Requirement of PTHrP for the activity-dependent survival of granule neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOWN-REGULATION; GENE-EXPRESSION; MESSENGER-RNAS; SMOOTH-MUSCLE; SNAIL NEURONS; PEPTIDE GENE; CELLS; RECEPTOR; CALCIUM; ACTIVATION	To identify genes whose expression is neuronal activity-dependent, we used an mRNA differential display technique and discovered that parathyroid hormone-related protein (PTHrP) is expressed in an activity-dependent manner in primary cultures of rat cerebellar granule neurons. PTHrP mRNA was expressed as early as 1 h by the addition of KCl to a final concentration of 25 mM to the culture medium. This expression was induced by Ca2+ influx through voltage-dependent L-type Ca2+ channels and regulated at the transcriptional step. PTHrP mRNA was persistently expressed before and after the time of commitment of granule neurons to apoptosis when they are cultured in the presence of 25 mM KCl or both 150 mu M N-methyl-D-aspartic acid and 15 mM KCl, both of which promote the survival of these neurons, PTHrP was rapidly secreted into the culture medium in a depolarization-dependent manner. Parathyroid hormone/PTHrP receptor mRNA was also expressed in the primary cultures, and its expression was up-regulated by KCl and/or N-methyl-D-aspartic acid. The addition of anti-PTHrP antiserum to the culture medium resulted in a reduction of the activity-dependent survival of the granule neurons, These results suggest that PTHrP is involved in an autocrine loop and required for the survival of granule neurons.	MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN; OSAKA UNIV,FAC SCI,DEPT BIOL,TOYONAKA,OSAKA 560,JAPAN; TOKYO MED & DENT UNIV,DIV MED RES,DEPT RETROVIRAL REGULAT,BUNKYO KU,TOKYO 113,JAPAN; TOKYO UNIV PHARM & LIFE SCI,SCH LIFE SCI,LAB CELLULAR NEUROBIOL,HACHIOJI,TOKYO 19203,JAPAN	Osaka University; Tokyo Medical & Dental University (TMDU); Tokyo University of Pharmacy & Life Sciences	Ono, T (corresponding author), TOKYO METROPOLITAN INST MED SCI,DEPT MOL BIOL,BUNKYO KU,3-18-22 HONKOMAGOME,TOKYO 113,JAPAN.		Inokuchi, Kaoru/AAI-9693-2020	Inokuchi, Kaoru/0000-0002-5393-3133; Kudo, Yoshihisa/0000-0002-5978-8264				ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ABOUSAMRA AB, 1994, ENDOCRINOLOGY, V135, P2588, DOI 10.1210/en.135.6.2588; BALAZS R, 1988, NEUROSCIENCE, V27, P437, DOI 10.1016/0306-4522(88)90279-5; BALAZS R, 1990, NEUROSCIENCE, V37, P251, DOI 10.1016/0306-4522(90)90211-L; BAMBRICK LL, 1995, P NATL ACAD SCI USA, V92, P9692, DOI 10.1073/pnas.92.21.9692; BIRCH MA, 1995, BRIT J CANCER, V72, P90, DOI 10.1038/bjc.1995.282; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNEMAN DE, 1990, DEV BRAIN RES, V51, P63, DOI 10.1016/0165-3806(90)90258-Z; CHILCO PJ, 1993, MOL CELL ENDOCRINOL, V94, P1, DOI 10.1016/0303-7207(93)90045-L; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAIFOTIS AG, 1992, J BIOL CHEM, V267, P23455; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; FUKAYAMA S, 1995, P NATL ACAD SCI USA, V92, P10182, DOI 10.1073/pnas.92.22.10182; FUKAYAMA S, 1994, ENDOCRINOLOGY, V134, P1851, DOI 10.1210/en.134.4.1851; GAICH G, 1993, ENDOCRINOLOGY, V132, P1402, DOI 10.1210/en.132.3.1402; GALLO V, 1987, J NEUROSCI, V7, P2203; GILLESPIE MT, 1994, MOL CELL ENDOCRINOL, V100, P143, DOI 10.1016/0303-7207(94)90293-3; GRAHAM ME, 1994, EUR J PHARM-MOLEC PH, V288, P115, DOI 10.1016/0922-4106(94)90016-7; HARVEY S, 1993, J ENDOCRINOL, V139, P353, DOI 10.1677/joe.0.1390353; HAYASHI I, 1976, NATURE, V259, P132, DOI 10.1038/259132a0; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; IKEDA K, 1993, J BIOL CHEM, V268, P1174; Inokuchi K, 1996, FEBS LETT, V382, P48, DOI 10.1016/0014-5793(96)00135-4; ISHIKAWA M, 1994, EUR J PHARM-MOLEC PH, V269, P311, DOI 10.1016/0922-4106(94)90038-8; KAISER SM, 1992, J BIOL CHEM, V267, P13623; KOSTYUK PG, 1992, PFLUG ARCH EUR J PHY, V420, P146, DOI 10.1007/BF00374983; Levi G., 1989, DISSECTION TISSUE CU, P211; LI X, 1994, J BIOL CHEM, V269, P6263; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MISRA RP, 1994, J BIOL CHEM, V269, P25483; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PANG PKT, 1990, P NATL ACAD SCI USA, V87, P623, DOI 10.1073/pnas.87.2.623; Philbrick WM, 1996, PHYSIOL REV, V76, P127, DOI 10.1152/physrev.1996.76.1.127; PLAWNER LL, 1995, J BIOL CHEM, V270, P14078, DOI 10.1074/jbc.270.23.14078; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SMOGORZEWSKI M, 1995, KIDNEY INT, V47, P1182, DOI 10.1038/ki.1995.168; STOLPE A, 1993, J CELL BIOL, V120, P235; URENA P, 1993, ENDOCRINOLOGY, V133, P617, DOI 10.1210/en.133.2.617; VITRY F, 1983, EMBO J, V2, P199; WANG R, 1993, CAN J PHYSIOL PHARM, V71, P582, DOI 10.1139/y93-082; WEAVER DR, 1995, MOL BRAIN RES, V28, P296, DOI 10.1016/0169-328X(94)00222-Z; WEIR EC, 1990, P NATL ACAD SCI USA, V87, P108, DOI 10.1073/pnas.87.1.108; YAMAMOTO M, 1992, P NATL ACAD SCI USA, V89, P5326, DOI 10.1073/pnas.89.12.5326; YAN GM, 1995, MOL PHARMACOL, V47, P248; YASUDA T, 1989, MOL ENDOCRINOL, V3, P518, DOI 10.1210/mend-3-3-518; Yuzaki M, 1996, J NEUROSCI, V16, P4651	51	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14404	14411		10.1074/jbc.272.22.14404	http://dx.doi.org/10.1074/jbc.272.22.14404			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162079	hybrid			2022-12-27	WOS:A1997XB49200066
J	Ramirez, MT; Sah, VP; Zhao, XL; Hunter, JJ; Chien, KR; Brown, JH				Ramirez, MT; Sah, VP; Zhao, XL; Hunter, JJ; Chien, KR; Brown, JH			The MEKK-JNK pathway is stimulated by alpha(1)-adrenergic receptor and Ras activation and is associated with in vitro and in vivo cardiac hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE CELL HYPERTROPHY; PROTEIN-KINASE KINASE; MYOSIN LIGHT CHAIN-2; ATRIAL-NATRIURETIC-FACTOR; GENE-EXPRESSION; C-JUN; SIGNALING PATHWAY; VENTRICULAR CARDIOMYOCYTES; ADRENERGIC STIMULATION; PHOSPHORYLATION	In neonatal rat ventricular myocytes, stimulation of the alpha(1)-adrenergic receptor (alpha(1)-AdrR) activates a program of genetic and morphological changes characterized by transcriptional activation of the atrial natriuretic factor (ANF) gene and enlargement (hypertrophy) of the cells. The low molecular weight GTPase Ras has been established as an important regulator of hypertrophy both in vitro and in vivo. Ras activates a kinase cascade involving Raf, the mitogen-activated protein kinase kinase (MEK), and the extracellular signal-regulated protein kinase (ERK), However, the extent of involvement of this pathway in regulating hypertrophic responses is controversial. We demonstrate here that both alpha(1)-AdrR stimulation and Ras can also activate the c-Jun NH2-terminal kinase (JNK) in cardiomyocytes. The alpha(1)-AdrR effect on JNK occurs through a pathway requiring Ras and MEK kinase (MEKK). A constitutively activated mutant of MEKK that preferentially activates JNK, stimulates ANF reporter gene expression, while a dominant negative MEKK mutant inhibits ANF expression induced by PE. Furthermore, JNK activity is increased in the ventricles of mice overexpressing oncogenic Ras, whereas ERK activity is not, These results suggest that the alpha(1)-AdrR mediates ANF gene expression through a Ras-MEKK-JNK pathway and that activation of this pathway is associated with in vitro and in vivo hypertrophy.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046345, R01HL028143, R37HL028143] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28143, HL 46345] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adler V, 1996, J BIOL CHEM, V271, P23304, DOI 10.1074/jbc.271.38.23304; Bogoyevitch MA, 1996, BIOCHEM J, V314, P115, DOI 10.1042/bj3140115; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coso OA, 1996, J BIOL CHEM, V271, P3963; GILLESPIEBROWN J, 1995, J BIOL CHEM, V270, P28092; Glennon PE, 1996, CIRC RES, V78, P954, DOI 10.1161/01.RES.78.6.954; GOTTSHALL KR, 1996, J CARD FAIL, V2, pS29; HENDERSON SA, 1989, J BIOL CHEM, V264, P18142; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; IWAKI K, 1990, J BIOL CHEM, V265, P13809; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Sadoshima J, 1996, EMBO J, V15, P5535, DOI 10.1002/j.1460-2075.1996.tb00938.x; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; THORBURN A, 1994, BIOCHEM BIOPH RES CO, V205, P1417, DOI 10.1006/bbrc.1994.2823; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1994, BIOCHEM BIOPH RES CO, V202, P1586, DOI 10.1006/bbrc.1994.2113; THORBURN J, 1995, MOL BIOL CELL, V6, P1479, DOI 10.1091/mbc.6.11.1479; THORBURN J, 1994, J BIOL CHEM, V269, P30580; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; YAN MH, 1994, NATURE, V372, P798; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	44	206	212	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14057	14061		10.1074/jbc.272.22.14057	http://dx.doi.org/10.1074/jbc.272.22.14057			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162028	hybrid			2022-12-27	WOS:A1997XB49200015
J	Ravel, P; Craescu, CT; Arous, N; Rosa, J; Garel, MC				Ravel, P; Craescu, CT; Arous, N; Rosa, J; Garel, MC			Critical role of human bisphosphoglycerate mutase Cys(22) in the phosphatase activator binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; PHOSPHOGLYCERATE MUTASE; DIPHOSPHOGLYCERATE MUTASE; HUMAN ERYTHROCYTES; 2,3-DIPHOSPHOGLYCERATE PHOSPHATASE; MOLECULAR-CLONING; ESCHERICHIA-COLI; 2,3-BISPHOSPHOGLYCERATE; CDNA; PURIFICATION	The enzymatic activities catalysed by bisphosphoglycerate mutase (BPGM, EC 5.4.2.4) have been shown to occur at a unique active site, with distinct binding sites for diphosphoglycerates and monophosphoglycerates. The physiological phosphatase activator (2-phosphoglycolate) binds to BPGM, at an undetermined site. BPGM variants were constructed by site-directed mutagenesis of three amino acid residues in the active site to identify residues specifically involved in the binding of the monophosphoglycerates and 2-phosphoglycolate. Substitution of Cys(22) by functionally conservative residues, Thr or Ser, caused a great decrease in 2-phosphoglycolate-stimulated phosphatase activity and in the K-a value of the activator, whereas it caused no change in other catalytic activities or in the K-m values of 2,3-diphosphoglycerate (2,3-DPG) and glycerate 3-phosphate (3-PG, EC 1.1.1.12), indicating that Cys(22) is specifically involved either directly or indirectly in 2-phosphoglycolate binding. Kinetic experiments showed that the K-a of the cofactor and the K-m of 3-PG were affected by the substitution of Ser(23) indicating that this residue is necessary for the fixation of both 3-PG and 2-phosphoglycolate. The R89K variant has previously been shown to have a modified K-m value for monophosphoglycerates, however, its affinity for 2-phosphogiycolate is unaltered, suggesting that Arg(89) is specifically involved in monophosphoglycerates binding. CD spectroscopic studies of substrates and cofactor binding showed that 2,3-DPG; induced structural modifications of normal and mutated enzymes which could be due to protein phosphorylation. Addition of 2-phosphoglycolate to phosphorylated proteins with normal affinity for the cofactor produced spectra with the same characteristics as unphosphorylated species. In summary, monophosphoglycerates and 2-phosphoglycolate have partially distinct binding sites in human BPGM, The specific implication of the Cys(22) residue in 2-phosphoglycolate binding is of great significance in the design of analogs of therapeutic benefit.	HOP HENRI MONDOR, INSERM U91, F-94010 CRETEIL, FRANCE; CTR UNIV ORSAY, INST CURIE, INSERM U350, F-91405 ORSAY, FRANCE	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay								BLOUQUIT Y, 1988, J BIOL CHEM, V263, P16906; CALVIN MC, 1990, BIOCHIMIE, V72, P337, DOI 10.1016/0300-9084(90)90029-G; CHERFILS J, 1991, J MOL BIOL, V218, P269, DOI 10.1016/0022-2836(91)90710-N; Chiba H, 1978, Curr Top Cell Regul, V14, P75; CRAESCU CT, 1992, BIOCHIMIE, V74, P519, DOI 10.1016/0300-9084(92)90149-9; DIEDERICH D, 1970, BIOCHIM BIOPHYS ACTA, V212, P441, DOI 10.1016/0005-2744(70)90250-0; FOTHERGILLGILMORE LA, 1989, ADV ENZYMOL RAMB, V62, P227; GAREL MC, 1994, P NATL ACAD SCI USA, V91, P3593, DOI 10.1073/pnas.91.9.3593; GAREL MC, 1989, J BIOL CHEM, V264, P18966; GAREL MC, 1993, EUR J BIOCHEM, V213, P493, DOI 10.1111/j.1432-1033.1993.tb17786.x; HAGGARTY NW, 1983, EMBO J, V2, P1213, DOI 10.1002/j.1460-2075.1983.tb01569.x; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; JOULIN V, 1986, EMBO J, V5, P2275, DOI 10.1002/j.1460-2075.1986.tb04495.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBOULCH P, 1988, BIOCHEM BIOPH RES CO, V156, P874, DOI 10.1016/S0006-291X(88)80925-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MAY A, 1975, BRIT J HAEMATOL, V30, P317, DOI 10.1111/j.1365-2141.1975.tb00548.x; POILLON WN, 1995, BLOOD, V85, P3289, DOI 10.1182/blood.V85.11.3289.bloodjournal85113289; POILLON WN, 1990, BLOOD, V76, P1028; RAPOPORT S, 1950, J BIOL CHEM, V183, P507; Ravel P, 1997, CR ACAD SCI III-VIE, V320, P27, DOI 10.1016/S0764-4469(99)80083-3; ROSA R, 1988, BIOCHEM BIOPH RES CO, V153, P945, DOI 10.1016/S0006-291X(88)81319-6; ROSA R, 1983, BIOCHIM BIOPHYS ACTA, V742, P243, DOI 10.1016/0167-4838(83)90382-5; ROSA R, 1984, J CHROMATOGR, V285, P203, DOI 10.1016/S0021-9673(01)87753-0; ROSA R, 1973, BIOCHEM BIOPH RES CO, V51, P536, DOI 10.1016/0006-291X(73)91347-8; ROSA R, 1978, J CLIN INVEST, V62, P907, DOI 10.1172/JCI109218; ROSA R, 1989, J BIOL CHEM, V264, P7837; Rose Z B, 1980, Adv Enzymol Relat Areas Mol Biol, V51, P211; ROSE ZB, 1970, J BIOL CHEM, V245, P3232; ROSE ZB, 1968, J BIOL CHEM, V243, P4810; ROSE ZB, 1973, J BIOL CHEM, V248, P1513; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI R, 1975, EUR J BIOCHEM, V50, P581, DOI 10.1111/j.1432-1033.1975.tb09899.x; SHANSKE S, 1987, J BIOL CHEM, V262, P14612; TAULER A, 1983, COMP BIOCHEM PHYS B, V76, P789, DOI 10.1016/0305-0491(83)90394-2; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; WHITE MF, 1988, FEBS LETT, V229, P383, DOI 10.1016/0014-5793(88)81161-X; WHITE MF, 1993, BIOCHEM J, V291, P479, DOI 10.1042/bj2910479; WINN SI, 1981, PHILOS T ROY SOC B, V293, P121, DOI 10.1098/rstb.1981.0066; YANAGAWA S, 1986, GENE, V44, P185, DOI 10.1016/0378-1119(86)90181-2	41	7	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14045	14050		10.1074/jbc.272.22.14045	http://dx.doi.org/10.1074/jbc.272.22.14045			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162026	hybrid			2022-12-27	WOS:A1997XB49200013
J	Tsugeno, Y; Ito, A				Tsugeno, Y; Ito, A			A key amino acid responsible for substrate selectivity of monoamine oxidase A and B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE SEQUENCES; LIVER; CDNA; CLONING; PARKINSONISM; BRAIN; FORMS; CELLS; MPTP	Monoamine oxidase (MAO) oxidizes biologically important amines including neurotransmitters and plays a central role in the regulation of intracellular level of these amines. Two distinct forms of MAO (MAO A and MAO B) were defined based on differences in substrate and inhibitor specificities, We earlier reported that the region between about residues 120 and 220 of rat MAO is responsible for determination of the substrate selectivity of MAO A and B (Tsugeno, Y. Hirashiki, I., Ogata, F., and Ito, A. (1995) J. Biochem, (Tokyo) 118, 974-980), To determine the essential amino acids in this region that participate in substrate recognition, a series of mutant enzymes in which amino acid residues that are conserved among various species but are different between the two forms of the enzyme were replaced with the corresponding amino acids of the counterpart and were engineered from the cDNAs of rat liver MAO A and B, and affinities for several substrates were examined, A single mutation in which Phe-208 in MAO A was substituted by the corresponding residue of He in MAO B was sufficient to convert the A-type substrate selectivity, and the reverse was exactly the case. Phe at this position was replaceable with Tyr for the A-type specificity and lie was replaceable with Val and Ala for the B-type. Thus, aromatic and aliphatic residues seem to contribute to render substrate selectivity of MAO A and MAO B, respectively.	KYUSHU UNIV,FAC SCI,DEPT CHEM,FUKUOKA 81281,JAPAN	Kyushu University								BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; BOND PA, 1977, CLIN CHIM ACTA, V80, P317, DOI 10.1016/0009-8981(77)90039-0; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; Chen K, 1996, J NEUROCHEM, V66, P797; CHEN K, 1994, MOL PHARMACOL, V46, P1226; CHIBA K, 1984, BIOCHEM BIOPH RES CO, V120, P574, DOI 10.1016/0006-291X(84)91293-2; DONNELLY CH, 1977, BIOCHEM PHARMACOL, V26, P853, DOI 10.1016/0006-2952(77)90398-7; EGASHIRA T, 1976, JPN J PHARMACOL, V26, P493, DOI 10.1254/jjp.26.493; FOWLER CJ, 1982, BIOCHEM PHARMACOL, V31, P3553; Fowler JS, 1996, NATURE, V379, P733, DOI 10.1038/379733a0; GOTTOWIK J, 1995, EUR J BIOCHEM, V230, P934, DOI 10.1111/j.1432-1033.1995.tb20639.x; Grimsby J, 1996, LIFE SCI, V58, P777, DOI 10.1016/0024-3205(95)02356-9; HSU YPP, 1988, J NEUROCHEM, V51, P1321, DOI 10.1111/j.1471-4159.1988.tb03105.x; ITO A, 1988, BIOCHEM BIOPH RES CO, V157, P970, DOI 10.1016/S0006-291X(88)80969-0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUWAHARA T, 1990, AGR BIOL CHEM TOKYO, V54, P253, DOI 10.1080/00021369.1990.10869903; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; POWELL JF, 1989, BIOCHEM J, V259, P407, DOI 10.1042/bj2590407; SALACH JI, 1984, BIOCHEM BIOPH RES CO, V125, P831, DOI 10.1016/0006-291X(84)90614-4; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SINGER TP, 1987, J NEURAL TRANSM-SUPP, V23, P1; Tipton K F, 1987, J Neural Transm Suppl, V23, P25; TIPTON KF, 1994, BIOCHEM SOC T, V22, P764, DOI 10.1042/bst0220764; TSUGENO Y, 1995, J BIOCHEM-TOKYO, V118, P974, DOI 10.1093/jb/118.5.974; WHITE HL, 1977, J NEUROCHEM, V29, P987, DOI 10.1111/j.1471-4159.1977.tb06502.x; WURTMAN RJ, 1963, BIOCHEM PHARMACOL, V12, P1439, DOI 10.1016/0006-2952(63)90215-6; YOUDIM MBH, 1984, SCIENCE, V224, P619, DOI 10.1126/science.6424235; YU PH, 1989, J PHARM PHARMACOL, V41, P205, DOI 10.1111/j.2042-7158.1989.tb06433.x	30	85	88	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14033	14036		10.1074/jbc.272.22.14033	http://dx.doi.org/10.1074/jbc.272.22.14033			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162023	hybrid			2022-12-27	WOS:A1997XB49200010
J	Kobayashi, M; Habuchi, H; Yoneda, M; Habuchi, O; Kimata, K				Kobayashi, M; Habuchi, H; Yoneda, M; Habuchi, O; Kimata, K			Molecular cloning and expression of Chinese hamster ovary cell heparan-sulfate 2-sulfotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; DEACETYLASE N-SULFOTRANSFERASE; INSITU PROTEASE DIGESTION; BINDING SEQUENCE; HIGH-AFFINITY; BIOSYNTHESIS; PROTEINS; RECEPTOR; PURIFICATION; 6-SULFOTRANSFERASE	Heparan-sulfate a-sulfotransferase (HS2ST), which catalyzes the transfer of sulfate from 3'-phosphoadenosine 5'-phosphosulfate to L-iduronic acid at position 2 in heparan sulfate, was purified from cultured Chinese hamster ovary (CHO) cells to apparent homogeneity (Kobayashi, M., Habuchi, H., Habuchi, O., Saito, M,, and Kimata, K, (1996) J, Biol. Chem, 271, 7645-7653), The internal amino acid sequences were obtained from the peptides after digestion of the purified protein with a combination of endoproteinases, Mixed oligonucleotides based on the peptide sequences were used as primers to obtain a probe fragment by reverse transcriptase-polymerase chain reaction using CHO cell poly(A)(+) RNA as template. The clone obtained from a CHO cDNA library by screening with the probe is 2.2 kilobases in size and contains an open reading frame of 1068 bases encoding a new protein composed of 356 amino acid residues, The protein predicts a type II transmembrane topology similar to other Gels membrane proteins, Messages of 5.0 and 3.0 kilobases were observed in Northern analysis, Evidence that the cDNA clone corresponds to the purified HS2ST protein is as follows, (a) The predicted amino acid sequence contains all five peptides obtained after endoproteinase digestion of the purified protein; (b) the characteristics of the predicted protein fit those of the purified protein in terms of molecular mass, membrane localization, and N-glycosylation; and (c) when the cDNA containing the entire coding sequence of the enzyme in a eukaryotic expression vector was transfected into COS-7 cells, the HS2ST activity increased 2.6-fold over controls, and the FLAG-HS2ST fusion protein purified by affinity chromatography showed the HS2ST activity alone.	AICHI UNIV EDUC, DEPT LIFE SCI, KARIYA, AICHI 448, JAPAN	Aichi University Education	Kobayashi, M (corresponding author), AICHI MED UNIV, INST MOL SCI MED, NAGAKUTE, AICHI 48011, JAPAN.							AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ARUFFO A, 1991, CURRENT PROTOCOLS MO, V14; ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; BARZU T, 1989, J CELL PHYSIOL, V140, P538, DOI 10.1002/jcp.1041400320; BRANDAN E, 1988, J BIOL CHEM, V263, P2417; DIXON J, 1995, GENOMICS, V26, P239, DOI 10.1016/0888-7543(95)80206-2; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Kobayashi M, 1996, J BIOL CHEM, V271, P7645, DOI 10.1074/jbc.271.13.7645; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBARON RG, 1989, J BIOL CHEM, V264, P7950; LEBARON RG, 1988, J CELL BIOL, V106, P945, DOI 10.1083/jcb.106.3.945; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LINDAHL U, 1989, ANN NY ACAD SCI, V556, P36; LUPA MT, 1990, DEV BIOL, V142, P31, DOI 10.1016/0012-1606(90)90148-C; LuuThe V, 1996, ANN NY ACAD SCI, V784, P137, DOI 10.1111/j.1749-6632.1996.tb16233.x; LYON M, 1994, J BIOL CHEM, V269, P11216; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; Nader H. B., 1989, HEPARIN CHEM BIOL PR, P81; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; POWERS PA, 1991, GENETICS, V129, P133; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TYRRELL DJ, 1993, J BIOL CHEM, V268, P4684; WLAD H, 1994, J BIOL CHEM, V269, P24538; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; YANAGISHITA M, 1984, J BIOL CHEM, V259, P270; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHENG YQ, 1994, J BIOL CHEM, V269, P30313	43	118	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13980	13985		10.1074/jbc.272.21.13980	http://dx.doi.org/10.1074/jbc.272.21.13980			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153262	hybrid			2022-12-27	WOS:A1997XA06200077
J	Lam, BK; Penrose, JF; Xu, KY; Baldasaro, MH; Austen, KF				Lam, BK; Penrose, JF; Xu, KY; Baldasaro, MH; Austen, KF			Site-directed mutagenesis of human leukotriene C-4 synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; EXPRESSION CLONING; ARACHIDONIC-ACID; 5-LIPOXYGENASE; BIOSYNTHESIS; PROTEIN; LEUKOCYTES; LUNG; IDENTIFICATION; TRANSLOCATION	The functional characteristics of leukotriene C-4 synthase (LTC4S), which specifically conjugates leukotriene A(4) with GSH, were assessed by mutagenic analysis. Human LTC4S and the 5-lipoxygenase-activating protein share substantial amino acid identity and predicted secondary structure. The mutation of Arg-51 of LTC4S to Thr or lie abolishes the enzyme function, whereas the mutation of Arg-51 to His or Lys provides a fully active recombinant protein. The mutations Y59F, Y97F, Y93F, N55A, V49F, and A52S increase the K-m of the recombinant microsomal enzyme for GSH. The mutation Y93F also markedly reduces enzyme function and increases the optimum for pH-dependent activity. The deletion of the third hydrophobic domain with the carboxyl terminus abolishes the enzyme activity, and function is restored by the substitution of the third hydrophobic domain and carboxyl terminus of 5-lipoxygenase-activating protein for that of LTC4S. Mutations of C56S and C82V alone or together and the deletion of Lys-a and Asp-3 of LTC4S do not alter enzyme function. The direct linkage of two LTC4S monomers by a 12-amino acid bridge provides an active dimer, and the same bridging of inactive R51I with a wild-type monomer creates an active pseudo-dimer with function similar to that of the wild-type enzyme. These results suggest that in the catalytic function of LTC4S, Arg-51 probably opens the epoxide ring and Tyr-93 provides the thiolate anion of GSH. Furthermore, the monomer has independent conjugation activity, and dimerization of LTC4S maintains the proper protein structure.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV RHEUMATOL ALLERGY & IMMUNOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital					NIAID NIH HHS [AI22531, AI31599] Funding Source: Medline; NIAMS NIH HHS [AR36308] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022531, R01AI022531, U01AI031599, U19AI031599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABRAMOVITZ M, 1993, EUR J BIOCHEM, V215, P105, DOI 10.1111/j.1432-1033.1993.tb18012.x; ANDERSON ME, 1982, P NATL ACAD SCI-BIOL, V79, P1088, DOI 10.1073/pnas.79.4.1088; BROCK TG, 1994, J BIOL CHEM, V269, P22059; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; DAHLEN SE, 1983, P NATL ACAD SCI-BIOL, V80, P1712, DOI 10.1073/pnas.80.6.1712; GILLARD J, 1989, CAN J PHYSIOL PHARM, V67, P456, DOI 10.1139/y89-073; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; Jakobsson PJ, 1996, J BIOL CHEM, V271, P22203, DOI 10.1074/jbc.271.36.22203; JOHNSON WW, 1993, J BIOL CHEM, V268, P11508; LAM BK, 1989, J BIOL CHEM, V264, P12885; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; LAM BK, 1992, P NATL ACAD SCI USA, V89, P11598, DOI 10.1073/pnas.89.23.11598; Lam BK, 1996, EUR J BIOCHEM, V238, P606, DOI 10.1111/j.1432-1033.1996.0606w.x; LAM BK, 1995, ADV PROSTAG THROMB L, V23, P35; LEE CW, 1983, IMMUNOLOGY, V48, P27; LEWIS RA, 1984, J CLIN INVEST, V73, P889, DOI 10.1172/JCI111312; MAKKER HK, 1993, AM REV RESPIR DIS, V147, P1413, DOI 10.1164/ajrccm/147.6_Pt_1.1413; NICHOLSON DW, 1993, P NATL ACAD SCI USA, V90, P2015, DOI 10.1073/pnas.90.5.2015; PENROSE JF, 1995, AM J RESP CRIT CARE, V152, P283, DOI 10.1164/ajrccm.152.1.7599836; ROKACH J, 1981, TETRAHEDRON LETT, V22, P2759, DOI 10.1016/S0040-4039(01)90545-3; ROUZER CA, 1986, P NATL ACAD SCI USA, V83, P857, DOI 10.1073/pnas.83.4.857; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; VICKERS PJ, 1992, MOL PHARMACOL, V42, P94; WANG RW, 1992, J BIOL CHEM, V267, P19866; WELSCH DJ, 1994, P NATL ACAD SCI USA, V91, P9745, DOI 10.1073/pnas.91.21.9745; YOSHIMOTO T, 1988, J CLIN INVEST, V81, P866, DOI 10.1172/JCI113396	31	61	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13923	13928		10.1074/jbc.272.21.13923	http://dx.doi.org/10.1074/jbc.272.21.13923			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153254	hybrid			2022-12-27	WOS:A1997XA06200069
J	Yang, RB; Garbers, DL				Yang, RB; Garbers, DL			Two eye guanylyl cyclases are expressed in the same photoreceptor cells and form homomers in preference to heteromers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN BETA-SUBUNIT; CONE PHOTORECEPTORS; CATALYTIC ACTIVITY; OUTER SEGMENTS; RETINAL RODS; RECEPTOR; IDENTIFICATION; CLONING; PHOSPHODIESTERASE; LOCALIZATION	We recently described two eye guanylyl cyclases (GC-E and GC-F) that contain an apparent extracellular domain potentially capable of binding ligands (Yang, R.-B., Foster, D, C., Garbers, D. L., and Fulle, H.-J, (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 602-606). Here, Northern and Western analyses showed that both cyclases are expressed in the retina and enriched in photoreceptor outer segments. By the use of specific GC-E and GC-F antibodies coupled to different sized gold particles both cyclases were colocalized within the same photoreceptor cells raising the possibility of homomeric and/or heteromeric interactions. A point mutant of GC-E (D878A) was constructed and expressed; it contained no detectable cyclase activity but acted in a dominant negative fashion to abolish the activity of native GC-E and GC-F in coexpression studies. These results suggested that GC-E and GC-F could form either homomers or heteromers, at least when overexpressed in COS-7 cells. Immunoprecipitation with GC-E and GC-F antibody followed by Western analysis confirmed that both homomers and heteromers could be formed. However, similar experiments using retina or outer segments revealed that a vast majority of GC-E and GC-F were precipitated as homomers in the eye. Therefore, like other members of the membrane guanylyl cyclase subfamily, GC-E and GC-F appear to preferentially form homomers.	UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Yang, Ruey-Bing/O-1494-2018	Yang, Ruey-Bing/0000-0003-3017-3714				APARICIO JG, 1995, PROTEIN EXPRES PURIF, V6, P501, DOI 10.1006/prep.1995.1067; BOZZOLA JJ, 1991, AM J ANAT, V192, P129, DOI 10.1002/aja.1001920204; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; CHINKERS M, 1992, J BIOL CHEM, V267, P18589; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cooper N, 1995, J MOL NEUROSCI, V6, P211, DOI 10.1007/BF02736766; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Detwiler PB, 1996, CURR OPIN NEUROBIOL, V6, P440, DOI 10.1016/S0959-4388(96)80047-X; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; DOMINO SE, 1991, METHOD ENZYMOL, V195, P345; FULLE HJ, 1995, P NATL ACAD SCI USA, V92, P3571, DOI 10.1073/pnas.92.8.3571; GORACZNIAK RM, 1994, BIOCHEM J, V302, P455, DOI 10.1042/bj3020455; GORCZYCA WA, 1995, J BIOL CHEM, V270, P22029, DOI 10.1074/jbc.270.37.22029; Hallett MA, 1996, J CELL SCI, V109, P1803; HAMILTON SE, 1990, J BIOL CHEM, V265, P11259; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4746, DOI 10.1073/pnas.88.11.4746; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HURWITZ RL, 1985, J BIOL CHEM, V260, P568; JACKSON T, 1991, PHARMACOL THERAPEUT, V50, P425, DOI 10.1016/0163-7258(91)90052-N; KOCH KW, 1995, CELL CALCIUM, V18, P314, DOI 10.1016/0143-4160(95)90027-6; LEE RH, 1992, J BIOL CHEM, V267, P24776; LEREA CL, 1986, SCIENCE, V234, P77, DOI 10.1126/science.3529395; LIU XR, 1994, EXP EYE RES, V59, P761, DOI 10.1006/exer.1994.1162; LOWE DG, 1992, BIOCHEMISTRY-US, V31, P10421, DOI 10.1021/bi00158a001; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; MCDOWELL JH, 1993, PHOTORECEPTOR CELLS, P123; PENG YW, 1992, P NATL ACAD SCI USA, V89, P10882, DOI 10.1073/pnas.89.22.10882; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; THOMPSON DK, 1995, J BIOL CHEM, V270, P425, DOI 10.1074/jbc.270.1.425; VAANDRAGER AB, 1994, J BIOL CHEM, V269, P16409; WEDEL B, 1995, J BIOL CHEM, V270, P24871, DOI 10.1074/jbc.270.42.24871; Yang RB, 1996, GENOMICS, V31, P367, DOI 10.1006/geno.1996.0060; YANG RB, 1995, P NATL ACAD SCI USA, V92, P602, DOI 10.1073/pnas.92.2.602	35	114	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13738	13742		10.1074/jbc.272.21.13738	http://dx.doi.org/10.1074/jbc.272.21.13738			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153227	hybrid			2022-12-27	WOS:A1997XA06200042
J	Bianchi, V; Borella, S; Rampazzo, C; Ferraro, P; Calderazzo, F; Bianchi, LC; Skog, S; Reichard, P				Bianchi, V; Borella, S; Rampazzo, C; Ferraro, P; Calderazzo, F; Bianchi, LC; Skog, S; Reichard, P			Cell cycle-dependent metabolism of pyrimidine deoxynucleoside triphosphates in CEM cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-SYNTHESIS; DEOXYRIBONUCLEOSIDE TRIPHOSPHATES; RIBONUCLEOTIDE REDUCTASE; MOUSE FIBROBLASTS; THYMIDINE KINASE; MAMMALIAN-CELLS; POOLS; DEOXYCYTIDINE; REPLICATION; DYNAMICS	We incorporated H-3-labeled thymidine, deoxycytidine, or cytidine into dNTPs and DNA of exponentially growing CEM cells. G(1) and S phase cells were separated by centrifugal elutriation, and the size and specific activity of dNTP pools were determined to study the cell cycle-dependent regulation of specific dNTP synthesizing enzymes in their metabolic context. With [H-3]thymidine, we confirm the earlier demonstrated S phase specificity of thymidine kinase. Incorporation of radioactivity from [5-H-3]deoxycytidine into dCTP occurred almost exclusively in G(1) cells, During S phase, de novo synthesis by ribonucleotide reductase was switched on, resulting in a 70-fold dilution of [H-3]dCTP, confirming that ribonucleotide reductase is an S phase-specific enzyme, whereas deoxycytidine kinase is not, [5-H-3]Cytidine appeared in dCTP almost to the same extent in G(1) as in S phase, despite the S phase specificity of ribonucleotide reductase, During S phase, DNA replication greatly increased the turnover of dCTP, requiring a corresponding increase in ribonucleotide reductase activity. During G(1), the enzyme maintained activity to provide dNTPs for DNA repair and mitochondrial DNA synthesis, The poor incorporation of isotope from deoxycytidine into DNA earlier led to the suggestion that the nucleoside is used only for DNA repair (Xu, Y-Z., Peng, H., and Plunkett, W. (1995) J. Biol. Chem. 270, 631-637). The poor phosphorylation of deoxycytidine in S phase provides a better explanation.	UNIV PADUA,DEPT BIOL,I-35121 PADUA,ITALY; DEPT ONCOL & SURG SERV,ONCOL SECT,I-35128 PADUA,ITALY; KAROLINSKA INST,DEPT MED RADIOBIOL,S-17177 STOCKHOLM,SWEDEN; KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,MED NOBEL INST,S-17177 STOCKHOLM,SWEDEN	University of Padua; Karolinska Institutet; Karolinska Institutet								ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9; BIANCHI V, 1986, J BIOL CHEM, V261, P6037; BIANCHI V, 1992, EXP CELL RES, V199, P120, DOI 10.1016/0014-4827(92)90469-O; BIANCHI V, 1987, MOL CELL BIOL, V7, P4218, DOI 10.1128/MCB.7.12.4218; BIANCHI V, 1994, J BIOL CHEM, V269, P16677; BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; FERRARO P, 1992, EXP CELL RES, V199, P349, DOI 10.1016/0014-4827(92)90444-D; HELLGREN D, 1979, BIOCHEM BIOPH RES CO, V88, P16, DOI 10.1016/0006-291X(79)91690-5; JOHANSSON E, 1995, J BIOL CHEM, V270, P30162, DOI 10.1074/jbc.270.50.30162; KAUFFMAN MG, 1991, MOL CELL BIOL, V11, P2538, DOI 10.1128/MCB.11.5.2538; KAUFFMAN MG, 1990, ANAL BIOCHEM, V191, P41, DOI 10.1016/0003-2697(90)90384-L; LEEDS JM, 1987, MOL CELL BIOL, V7, P532, DOI 10.1128/MCB.7.1.532; LEEDS JM, 1985, MOL CELL BIOL, V5, P3442; Mikulits W, 1996, J BIOL CHEM, V271, P853, DOI 10.1074/jbc.271.2.853; NICANDER B, 1985, J BIOL CHEM, V260, P5376; NICANDER B, 1983, P NATL ACAD SCI-BIOL, V80, P1347, DOI 10.1073/pnas.80.5.1347; PLUCINSKI TM, 1990, MOL PHARMACOL, V38, P114; REDDY GPV, 1980, P NATL ACAD SCI-BIOL, V77, P3312; REDDY GPV, 1983, NATURE, V303, P86; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; REICHARD P, 1951, J BIOL CHEM, V188, P839; RODE W, 1980, J BIOL CHEM, V255, P1305; Sanderson R J, 1977, Methods Cell Biol, V15, P1, DOI 10.1016/S0091-679X(08)60206-X; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; SPASOKUKOTSKAJA T, 1988, BIOCHEM BIOPH RES CO, V155, P923, DOI 10.1016/S0006-291X(88)80584-9; SPYROU G, 1988, MUTAT RES, V200, P37, DOI 10.1016/0027-5107(88)90069-3; SPYROU G, 1989, J BIOL CHEM, V264, P960; TANAKA K, 1984, ANAL BIOCHEM, V139, P35, DOI 10.1016/0003-2697(84)90386-5; XU YZ, 1995, J BIOL CHEM, V270, P631, DOI 10.1074/jbc.270.2.631	31	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16118	16124		10.1074/jbc.272.26.16118	http://dx.doi.org/10.1074/jbc.272.26.16118			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195907	hybrid			2022-12-27	WOS:A1997XG01900011
J	Ryden, M; Hempstead, B; Ibanez, CF				Ryden, M; Hempstead, B; Ibanez, CF			Differential modulation of neuron survival during development by nerve growth factor binding to the p75 neurotrophin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY NGF RECEPTOR; TRK PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; SYMPATHETIC NEURONS; PC12 CELLS; EXPRESSION; BRAIN; DEATH; RAT; COEXPRESSION	Nerve growth factor (NGF) supports the survival and differentiation of distinct populations of peripheral and central neurons, NGF binds to two classes of cell-surface receptors, the protein tyrosine kinase TrkA and the smaller p75 receptor lacking intrinsic catalytic activity. It has been suggested that both receptors are required for NGF high affinity binding, although TrkA appears to be sufficient for transducing most of the biological effects of NGF. Some evidence suggests that p75 could play a modulatory role on TrkA activation by an as yet unknown mechanism, In this study, we have investigated functional roles of p75 using a purified triple mutant NGF (triNGF) deficient in p75 binding but retaining significant TrkA binding and activation, The mutant was found to be as potent as wild type NGF at promoting survival of serum-deprived TrkA-expressing fibroblasts, On developing chick sensory neurons, survival responses to mutant and native NGF were indistinguishable when assayed at nanomolar concentrations, However, triNGF was 3- to 4-fold less potent than wild type NGF at lower concentrations (i.e. 10(-11)M). Interestingly, in PC12 cells coexpressing TrkA and p75, no high affinity binding sites for triNGF could be detected, The reduced responsiveness to triNGF in sensory neurons was increasingly evident at later developmental stages; late embryonic neurons did not respond at all to concentrations of triNGF that were saturating at earlier developmental stages, Likewise, although no difference could be seen between wild type and mutant NGF on the survival responses of embryonic rat superior cervical ganglion sympathetic neurons, the mutant was much less potent than native NGF on postnatal sympathetic neurons, In sensory neurons, the decrease in responsiveness to triNGF correlated with a developmental reduction in the expression of both p75 and TrkA. Thus, NGF binding to p75 enhances responsiveness to ligand, particularly when this is present at limiting concentrations, During development, p75 modulates responsiveness to NGF so that binding to p75 becomes increasingly important in neurons undergoing a down-regulation of NGF receptors. These results support a ligand-dependent modulatory role for p75 in NGF-mediated neuron survival consistent with p75 functioning as a TrkA regulator and/or signaling receptor.	KAROLINSKA INST,MOL NEUROBIOL LAB,DIV MOL NEUROBIOL,DEPT NEUROSCI,S-17177 STOCKHOLM,SWEDEN; CORNELL UNIV,COLL MED,DEPT MED,DIV HEMATOL ONCOL,NEW YORK,NY 10021	Karolinska Institutet; Cornell University					NINDS NIH HHS [NS 3081] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BARRETT GL, 1994, P NATL ACAD SCI USA, V91, P6501, DOI 10.1073/pnas.91.14.6501; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; CLARY DO, 1994, P NATL ACAD SCI USA, V91, P11133, DOI 10.1073/pnas.91.23.11133; DAVIES AM, 1993, NEURON, V11, P565, DOI 10.1016/0896-6273(93)90069-4; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; ERNFORS P, 1988, NEURON, V1, P983, DOI 10.1016/0896-6273(88)90155-9; Frade JM, 1996, NATURE, V383, P166; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HUBER LJ, 1995, J NEUROSCI RES, V40, P557, DOI 10.1002/jnr.490400415; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IBANEZ CF, 1995, TRENDS BIOTECHNOL, V13, P217, DOI 10.1016/S0167-7799(00)88949-0; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON EM, 1987, J NEUROSCI, V7, P923; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEE KF, 1994, DEVELOPMENT, V120, P1027; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MEAKIN SO, 1992, P NATL ACAD SCI USA, V89, P2374, DOI 10.1073/pnas.89.6.2374; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; Ross AH, 1996, J CELL BIOL, V132, P945, DOI 10.1083/jcb.132.5.945; RYDEN M, 1995, EMBO J, V14, P1979, DOI 10.1002/j.1460-2075.1995.tb07190.x; Ryden M, 1996, J BIOL CHEM, V271, P5623, DOI 10.1074/jbc.271.10.5623; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SUTTER A, 1979, J BIOL CHEM, V254, P5972; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VanderZee CEEM, 1996, SCIENCE, V274, P1729, DOI 10.1126/science.274.5293.1729; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; WRIGHT LL, 1983, J NEUROCYTOL, V12, P727, DOI 10.1007/BF01258147; WYATT S, 1995, J CELL BIOL, V130, P1435, DOI 10.1083/jcb.130.6.1435	51	84	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16322	16328		10.1074/jbc.272.26.16322	http://dx.doi.org/10.1074/jbc.272.26.16322			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195937	hybrid			2022-12-27	WOS:A1997XG01900041
J	Silverstein, AM; Galigniana, MD; Chen, MS; OwensGrillo, JK; Chinkers, M; Pratt, WB				Silverstein, AM; Galigniana, MD; Chen, MS; OwensGrillo, JK; Chinkers, M; Pratt, WB			Protein phosphatase 5 is a major component of glucocorticoid receptor hsp90 complexes with properties of an FK506-binding immunophilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; TETRATRICOPEPTIDE REPEAT DOMAIN; HAMSTER OVARY CELLS; STEROID-RECEPTOR; PROGESTERONE-RECEPTOR; ESTROGEN-RECEPTOR; CYCLOSPORINE-A; SERINE/THREONINE PHOSPHATASE; POLYCLONAL ANTIBODY; MOLECULAR-CLONING	Steroid receptors are recovered from hormone-free cells in multiprotein complexes containing hsp90, p23, an immunophilin, and often some hsp70, The immunophilin, which can be of the FK506- or cyclosporin A-binding class, binds to hsp90 via its tetratricopeptide repeat (TPR) domain, and different receptor heterocomplexes exist depending upon which immunophilin occupies the TPR-binding region of hsp90, We have recently reported that a protein serine/threonine phosphatase that is designated PP5 and contains four TPRs binds to hsp90 and is co-purified with the glucocorticoid receptor (GR) (Chen, M.-S., Silverstein, A. M., Pratt, W. B., and Chinkers, M. (1996) J. Biol. Chem. 271, 32315-32320). In this work, we show that PP5 is recovered with both GR that is nuclear and GR that is cytoplasmic in hormone-free cells. Approximately one-half of the GR hsp90 heterocomplexes in L cell cytosol contains an immunophilin with high affinity FK506 binding activity, such as FKBP51 or FKBP52, and similar to 35% contains PP5. Only a small (but undetermined) fraction of the native GR hsp90 heterocomplexes contain the cyclosporin A-binding immunophilin CyP-40. PP5, FKBP52, and CyP-40 exist in separate heterocomplexes with hsp90, and competition binding experiments with the PP5 TPR domain suggest that the three proteins occupy a common binding site on hsp90. A 55-residue connecting region between the N-terminal TPR domain of human PP5 and its C-terminal phosphatase domain has 50% amino acid homology and 22% identity with the central portion of the peptidylprolyl isomerase domain of human FKBP52, Of the 9 residues in this portion of FKBP52 involved in high affinity interactions with FK506, 3 residues are retained and 4 have homologous substitutions in PP5, Although immunoadsorbed PP5 did not bind [H-3]FK506, we found that both rabbit PP5 in reticulocyte lysate and purified rat PP5 were specifically retained by an FK506 affinity matrix. Thus, we propose that PP5 possesses properties of an immunophilin with low affinity FK506 binding activity and that it determines a major portion of the native GR heterocomplexes in L cell cytosol.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109; OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	University of Michigan System; University of Michigan; Oregon Health & Science University				GALIGNIANA, MARIO/0000-0002-9130-8574	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD030236] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA028010] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047063] Funding Source: NIH RePORTER; NCI NIH HHS [CA28010] Funding Source: Medline; NHLBI NIH HHS [HL47063] Funding Source: Medline; NICHD NIH HHS [HD30236] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BECKER W, 1994, J BIOL CHEM, V269, P22586; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CALLEBAUT I, 1992, P NATL ACAD SCI USA, V89, P6270, DOI 10.1073/pnas.89.14.6270; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; CZAR MJ, 1994, J BIOL CHEM, V269, P11155; CZAR MJ, 1995, MOL ENDOCRINOL, V9, P1549, DOI 10.1210/me.9.11.1549; CZAR MJ, 1994, MOL ENDOCRINOL, V8, P1731, DOI 10.1210/me.8.12.1731; DEFRANCO DB, 1991, MOL ENDOCRINOL, V5, P1215, DOI 10.1210/mend-5-9-1215; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; Duina AA, 1996, SCIENCE, V274, P1713, DOI 10.1126/science.274.5293.1713; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; GEHRING U, 1995, GLUCOCORTICOID RECEP, P35; HIRST MA, 1990, MOL ENDOCRINOL, V4, P162, DOI 10.1210/mend-4-1-162; HOFFMANN K, 1995, BIOCHEM J, V307, P5, DOI 10.1042/bj3070005; HONORE B, 1992, J BIOL CHEM, V267, P8485; HUTCHISON KA, 1993, BIOCHEMISTRY-US, V32, P3953, DOI 10.1021/bi00066a015; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; KIEFFER LJ, 1993, J BIOL CHEM, V268, P12303; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; MARTINS VR, 1991, MOL ENDOCRINOL, V5, P217, DOI 10.1210/mend-5-2-217; MASSOL N, 1992, BIOCHEM BIOPH RES CO, V187, P1330, DOI 10.1016/0006-291X(92)90448-T; MCGOWAN CH, 1987, EUR J BIOCHEM, V166, P713, DOI 10.1111/j.1432-1033.1987.tb13570.x; MINAMI Y, 1994, MOL CELL BIOL, V14, P1459, DOI 10.1128/MCB.14.2.1459; Nair SC, 1997, MOL CELL BIOL, V17, P594, DOI 10.1128/MCB.17.2.594; NAKAO K, 1985, CAN J BIOCHEM CELL B, V63, P33, DOI 10.1139/o85-005; OwensGrillo JK, 1996, BIOCHEMISTRY-US, V35, P15249, DOI 10.1021/bi9615349; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P20479, DOI 10.1074/jbc.270.35.20479; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PRATT WB, 1993, J STEROID BIOCHEM, V46, P269, DOI 10.1016/0960-0760(93)90216-J; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; RATAJCZAK T, 1990, J STEROID BIOCHEM, V35, P543, DOI 10.1016/0022-4731(90)90197-Z; REHBERGER P, 1992, P NATL ACAD SCI USA, V89, P8001, DOI 10.1073/pnas.89.17.8001; RENOIR JM, 1995, P NATL ACAD SCI USA, V92, P4977, DOI 10.1073/pnas.92.11.4977; REXIN M, 1991, J BIOL CHEM, V266, P24601; RUFF VA, 1992, J BIOL CHEM, V267, P21285; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; SEGNITZ B, 1995, P NATL ACAD SCI USA, V92, P2179, DOI 10.1073/pnas.92.6.2179; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1993, J BIOL CHEM, V268, P24270; SMITH DF, 1993, J BIOL CHEM, V268, P18365; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WALSH CT, 1992, J BIOL CHEM, V267, P13115; YEM AW, 1992, J BIOL CHEM, V267, P2868	62	205	222	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16224	16230		10.1074/jbc.272.26.16224	http://dx.doi.org/10.1074/jbc.272.26.16224			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195923	hybrid			2022-12-27	WOS:A1997XG01900027
J	Kashiwada, K; Nishida, W; Hayashi, K; Ozawa, K; Yamanaka, Y; Saga, H; Yamashita, T; Tohyama, M; Shimada, S; Sato, K; Sobue, K				Kashiwada, K; Nishida, W; Hayashi, K; Ozawa, K; Yamanaka, Y; Saga, H; Yamashita, T; Tohyama, M; Shimada, S; Sato, K; Sobue, K			Coordinate expression of alpha-tropomyosin and caldesmon isoforms in association with phenotypic modulation of smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN-EMBRYO FIBROBLASTS; CALMODULIN-BINDING PROTEIN; MESSENGER-RNA EXPRESSION; EXCLUSIVE EXON SELECTION; TRANSFORMED-CELLS; TRANSCRIPTIONAL CONTROL; REGULATED EXPRESSION; EXTRACELLULAR-MATRIX; PROMOTER ELEMENTS; CULTURED-CELLS	Isoform diversity of tropomyosin is generated from the limited genes by a combination of differential transcription and alternative splicing. In the case of the alpha-tropomyosin (alpha-TM) gene, exon 2a rather than exon 2b is specifically spliced in alpha-TM-SM mRNA, which is one of the major tropomyosin isoforms in smooth muscle cells. Here we demonstrate that expressions of cr-tropomyosin and caldesmon isoforms are coordinately regulated in association with phenotypic modulation of smooth muscle cells. Molecular cloning and Western and Northern blottings have revealed that in addition to the downregulation of beta-TM-SM, alpha-TM-SM converted to alpha-TM-F1 and alpha-TM-F2 by a selectional change from exon 2a to exon 2b during dedifferentiation of smooth muscle cells in culture. Simultaneously, a change of caldesmon isoforms from high M-r type to low M-r type was also observed by alternative selection between exons 3b and 4 in the caldesmon gene during this process. In contrast, cultured smooth muscle cells maintaining a differentiated phenotype continued to express alpha-TM-SM, beta-TM-SM, and high M-r caldesmon. In situ hybridization revealed specific coexpression of alpha-TM-SM and high M-r caldesmon in smooth muscle in developing embryos. These results suggest a common splicing mechanism for phenotype-dependent expression of tropomyosin and caldesmon isoforms in both visceral and vascular smooth muscle cells.	OSAKA UNIV,SCH MED,DEPT NEUROCHEM & NEUROPHARMACOL,CTR BIOMED RES,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT ANAT & NEUROSCI,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT MOL NEUROBIOL TANABE,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University; Osaka University				Yamashita, Toshihide/0000-0003-4559-7018				BERGSMA DJ, 1986, MOL CELL BIOL, V6, P2462, DOI 10.1128/MCB.6.7.2462; DINGUS J, 1986, J CELL BIOL, V102, P1748, DOI 10.1083/jcb.102.5.1748; DRAEGER A, 1991, FEBS LETT, V291, P24, DOI 10.1016/0014-5793(91)81095-P; FORRYSCHAUDIES S, 1991, J BIOL CHEM, V266, P13821; FOSTER DN, 1992, J BIOL CHEM, V267, P11995; FRID MG, 1992, DEV BIOL, V153, P185, DOI 10.1016/0012-1606(92)90104-O; GIMONA M, 1990, FEBS LETT, V274, P159, DOI 10.1016/0014-5793(90)81353-P; GIMONA M, 1995, P NATL ACAD SCI USA, V92, P9776, DOI 10.1073/pnas.92.21.9776; GLUKHOVA M, 1993, DEV BIOL, V157, P437, DOI 10.1006/dbio.1993.1147; GLUKHOVA MA, 1988, P NATL ACAD SCI USA, V85, P9542, DOI 10.1073/pnas.85.24.9542; GOODING C, 1994, EMBO J, V13, P3861, DOI 10.1002/j.1460-2075.1994.tb06697.x; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; HARUNA M, 1993, BIOCHEM BIOPH RES CO, V197, P145, DOI 10.1006/bbrc.1993.2453; HAYASHI K, 1992, P NATL ACAD SCI USA, V89, P12122, DOI 10.1073/pnas.89.24.12122; HEDIN U, 1987, DIFFERENTIATION, V33, P239, DOI 10.1111/j.1432-0436.1987.tb01563.x; HELFMAN DM, 1984, J BIOL CHEM, V259, P4136; HELFMAN DM, 1986, MOL CELL BIOL, V6, P3582, DOI 10.1128/MCB.6.11.3582; HENDRICKS M, 1984, MOL CELL BIOL, V4, P1823, DOI 10.1128/MCB.4.9.1823; HUBER PAJ, 1995, BIOCHEM J, V312, P617, DOI 10.1042/bj3120617; HUMPHREY MB, 1995, MOL CELL BIOL, V15, P3979; INOUE A, 1989, EUR J BIOCHEM, V183, P645, DOI 10.1111/j.1432-1033.1989.tb21094.x; ISHIKAWA R, 1989, J BIOL CHEM, V264, P7490; KATOH Y, 1994, J BIOL CHEM, V269, P30538; KOCHER O, 1987, DIFFERENTIATION, V34, P201, DOI 10.1111/j.1432-0436.1987.tb00067.x; KOTELIANSKY VE, 1992, EUR J BIOCHEM, V204, P767, DOI 10.1111/j.1432-1033.1992.tb16692.x; KUROO M, 1989, J BIOL CHEM, V264, P18272; LEMONNIER M, 1991, GENE, V107, P229, DOI 10.1016/0378-1119(91)90323-4; LIBRI D, 1989, J BIOL CHEM, V264, P2935; LIN JJC, 1985, J CELL BIOL, V100, P692, DOI 10.1083/jcb.100.3.692; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; Matsumura F, 1993, CURR OPIN CELL BIOL, V5, P70, DOI 10.1016/S0955-0674(05)80010-9; MILLS AE, 1991, AM J DERMATOPATH, V13, P429, DOI 10.1097/00000372-199108000-00019; MULLEN MP, 1991, GENE DEV, V5, P642, DOI 10.1101/gad.5.4.642; MUTHUCHAMY M, 1993, MOL CELL BIOL, V13, P3311, DOI 10.1128/MCB.13.6.3311; NAKANO Y, 1991, GENE, V99, P285; NISHIDA W, 1993, GENE, V130, P297, DOI 10.1016/0378-1119(93)90435-6; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OWADA MK, 1984, P NATL ACAD SCI-BIOL, V81, P3133, DOI 10.1073/pnas.81.10.3133; OWENS GK, 1986, J CELL BIOL, V102, P343, DOI 10.1083/jcb.102.2.343; RISAU W, 1988, DEV BIOL, V125, P441, DOI 10.1016/0012-1606(88)90225-4; ROVNER AS, 1986, J BIOL CHEM, V261, P4740; Samaha FF, 1996, J BIOL CHEM, V271, P395, DOI 10.1074/jbc.271.1.395; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOBUE K, 1985, P NATL ACAD SCI USA, V82, P5025, DOI 10.1073/pnas.82.15.5025; SOLWAY J, 1995, J BIOL CHEM, V270, P13460, DOI 10.1074/jbc.270.22.13460; STREULI CH, 1995, J BIOL CHEM, V270, P21639, DOI 10.1074/jbc.270.37.21639; TANAKA J, 1993, J CELL SCI, V104, P595; TOUTANT M, 1994, NUCLEIC ACIDS RES, V22, P1838, DOI 10.1093/nar/22.10.1838; UEKI N, 1987, P NATL ACAD SCI USA, V84, P9049, DOI 10.1073/pnas.84.24.9049; VOLBERG T, 1986, DIFFERENTIATION, V32, P34, DOI 10.1111/j.1432-0436.1986.tb00553.x; WARREN KS, 1995, J CELL BIOL, V129, P697, DOI 10.1083/jcb.129.3.697; WARREN KS, 1994, J CELL BIOL, V125, P359, DOI 10.1083/jcb.125.2.359; WIECZOREK DF, 1988, MOL CELL BIOL, V8, P679, DOI 10.1128/MCB.8.2.679; YANO H, 1995, J BIOL CHEM, V270, P23661, DOI 10.1074/jbc.270.40.23661	55	57	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15396	15404		10.1074/jbc.272.24.15396	http://dx.doi.org/10.1074/jbc.272.24.15396			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182570	hybrid			2022-12-27	WOS:A1997XE03400053
J	Kuropatwinski, KK; DeImus, C; Gearing, D; Baumann, H; Mosley, B				Kuropatwinski, KK; DeImus, C; Gearing, D; Baumann, H; Mosley, B			Influence of subunit combinations on signaling by receptors for oncostatin M, leukemia inhibitory factor, and interleukin-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; STIMULATING FACTOR-RECEPTOR; CILIARY NEUROTROPHIC FACTOR; BINDING-PROTEIN; HEMATOPOIETIN RECEPTORS; CYTOKINE RECEPTORS; CYTOPLASMIC DOMAIN; HEPATOMA-CELLS; DNA-BINDING; GP130	Oncostatin M (OSM), leukemia inhibitory factor (LIF), and interleukin-6 (IL-6) induce expression of a similar set of acute phase plasma protein genes in hepatic cells, The redundant action of these cytokines has been ascribed to the involvement of the common signal-transducing receptor subunit, gp130, in combination with cytokine-specific, ligand-binding subunits, To define the specificity of the signal transduction by the LIF/OSM receptor (a heterodimer of gp130 and LIF receptor (LIFR)) and the OSM-specific receptor (a heterodimer of gp130 and OSM receptor (OSMR)), we reconstituted the receptor function by transfection into receptor-negative Hep3B hepatoma cells, Both receptors activate DNA binding activity of STAT1, -3, and -5B and induce gene transcription through IL-6-responsive elements, The signaling competent cytoplasmic domain regions of OSMR and LIFR were defined by the analysis of progressive carboxyl-terminal deletion constructs, The 36 residue carboxyl-terminal region containing the distal box 3 sequence motif of OSMR is required for signal transduction by the OSM-specific receptor. In contrast, signaling by LIFR did not display the same requirement for receptor domains and was not strictly dependent on the box 3 elements, The signaling by endogenous LIF and OSM receptors differed from that by IL-6R by the prominent activation of STATE as shown in the mouse hepatoma cell line, Hepa-1. The data suggest that the signaling specificity of the receptors for the three cytokines is determined by the composition of the cytoplasmic domains associated in the signal-competent receptor complex and that the signaling is not identical among these cytokine receptors.	ROSWELL PK CANC INST,DEPT MOL & CELLULAR BIOL,BUFFALO,NY 14263; IMMUNEX CORP,SEATTLE,WA 98101; MILLENNIUM PHARMACEUT INC,CAMBRIDGE,MA 02139	Roswell Park Cancer Institute; Immunex Corporation; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals					NCI NIH HHS [CA26122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BAUMANN H, 1992, CIBA F SYMP, V167, P100; BERNHARD HP, 1973, DEV BIOL, V35, P83, DOI 10.1016/0012-1606(73)90008-0; BRECHNER T, 1991, MOL BIOL MED, V8, P267; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Chevalier S, 1996, J BIOL CHEM, V271, P14764, DOI 10.1074/jbc.271.25.14764; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Guillet C, 1995, ANN NY ACAD SCI, V762, P407; Han YL, 1996, J BIOL CHEM, V271, P5947, DOI 10.1074/jbc.271.10.5947; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HIRANO T, 1994, STEM CELLS, V12, P262, DOI 10.1002/stem.5530120303; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; Kordula T, 1996, J BIOL CHEM, V271, P6752, DOI 10.1074/jbc.271.12.6752; Lai CF, 1996, J BIOL CHEM, V271, P13968, DOI 10.1074/jbc.271.24.13968; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; Lai CF, 1995, ANN NY ACAD SCI, V762, P189; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LECAM A, 1995, EUR J BIOCHEM, V231, P620; LIU JW, 1992, J BIOL CHEM, V267, P16763; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MORELLA KK, 1995, J BIOL CHEM, V270, P8298, DOI 10.1074/jbc.270.14.8298; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; PROWSE KR, 1988, MOL CELL BIOL, V8, P42, DOI 10.1128/MCB.8.1.42; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; RICHARDS CD, 1992, J IMMUNOL, V148, P1731; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; THOMA B, 1994, J BIOL CHEM, V269, P6215; THOMPSON EB, 1966, P NATL ACAD SCI USA, V56, P296, DOI 10.1073/pnas.56.1.296; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; WARD LD, 1994, J BIOL CHEM, V269, P23286; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; ZIEGLER SF, 1993, MOL CELL BIOL, V13, P2384, DOI 10.1128/MCB.13.4.2384	55	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15135	15144		10.1074/jbc.272.24.15135	http://dx.doi.org/10.1074/jbc.272.24.15135			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182534	hybrid			2022-12-27	WOS:A1997XE03400017
J	McDonald, TP; Walmsley, AR; Henderson, PJF				McDonald, TP; Walmsley, AR; Henderson, PJF			Asparagine 394 in putative helix 11 of the galactose-H+ symport protein (GalP) from Escherichia coli is associated with the internal binding site for cytochalasin B and sugar	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE GLUCOSE TRANSPORTER; CONFORMATIONAL-CHANGES; SUBSTRATE RECOGNITION; FACILITATED DIFFUSION; HEXOSE TRANSPORTER; LIGAND-BINDING; KINETICS; SYSTEM; ARABINOSE; FORSKOLIN	The galactose-H+ symport protein (Ga1P) of Escherichia coli is very similar to the human glucose transport protein, GLUT1, and both contain a highly conserved Asn residue in predicted helix 11 that is different in a cytochalasin B-resistant member of this sugar transport family (XylE). The role of the Asn(394) residue (which is predicted to be in putative trans-membrane alpha-helix 11) in the structure/activity relationship of the D-galactose-H+ symporter (GalP) was therefore assessed by measuring the interaction of sugar substrates and the inhibitory antibiotics, cytochalasin B, and forskolin with the wild-type and Asn(394) --> Gin mutant proteins, Steady-state fluorescence quenching experiments show that the mutant protein binds cytochalasin B with a K-d 37-53-fold higher than the wild type, This low affinity binding was not detected with equilibrium binding or photolabeling experiments, In contrast, the mutant protein binds forskolin with a K-d similar to that of the wild type and is photolabeled by 3-I-125-4-azido-phenethylamido -7-O-succinyl-desacetyl-forskolin. The mutant protein displays an increased amount of steady-state fluorescence quenching with the binding of forskolin, suggesting that the substitution of the Asn residue has altered the environment of a tryptophan, probably Trp(395), in a conformationally active region of the protein, Time-resolved fluorescence measurements on the mutant protein provided association and dissociation rate constants (k(2) and k(-2),), describing the initial interaction of cytochalasin B to the inward-facing binding site (T-i), that are decreased (9-fold) and increased (4.9-fold) compared with the wild type, This yielded a dissociation constant (K-2) for cytochalasin B to the inward-facing binding site 44-fold higher than that of the wild type, The binding of forskolin gave values for k(2) and k(-2) 3.9- and 3.6-fold lower, respectively, yielding a K-2 value for T-i similar to that of the wild type, The low overall affinity (high K-d) of the mutant protein for cytochalasin B is due mainly to a disruption in binding to the T-i conformation. It is proposed that Asn(394) forms either a direct binding interaction with cytochalasin B or is part of the immediate environment of the binding site and that Asn(394) is in the immediate environment, but not part, of the forskolin binding site, The ability of the mutant protein to catalyze energized transport is only mildly impaired with 4.8- and 2.1-fold reduction in V-max/K-m values for D-galactose and D-glucose, respectively, In stark contrast, the overall K-d describing binding of D-galactose and D-glucose to the inward-facing conformation of the mutant and their subsequent trans location across the membrane is substantially increased (64-fold for D-galactose and 163.3-fold for D-glucose), These data indicate that Asn(394) is associated with both the cytochalasin B and internal sugar binding sites, This conclusion is also supported by data showing that the sugar specificity of the mutant protein has been altered for D-xylose, This work powerfully illustrates how comparisons of the aligned amino acid sequences of homologous membrane proteins of unknown structure and characterization of their phenotypes can be used to map substrate and ligand binding sites.	UNIV LEEDS, DEPT BIOCHEM & MOL BIOL, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND; UNIV SHEFFIELD, KREBS INST BIOMOLEC RES, DEPT MOL BIOL & BIOTECHNOL, KREBS INST BIOMOLEC RES, SHEFFIELD S10 2UH, S YORKSHIRE, ENGLAND	University of Leeds; University of Sheffield			Henderson, Peter JF/Q-1907-2018	McDonald, Terence/0000-0002-0807-558X; Henderson, Peter/0000-0002-9187-0938	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BALDWIN JM, 1980, BIOCHIM BIOPHYS ACTA, V599, P699, DOI 10.1016/0005-2736(80)90211-4; BALDWIN SA, 1981, TRENDS BIOCHEM SCI, V6, P208, DOI 10.1016/0968-0004(81)90076-1; BALDWIN SA, 1989, ANNU REV PHYSIOL, V51, P459, DOI 10.1146/annurev.physiol.51.1.459; BARNETT JEG, 1973, BIOCHEM J, V131, P211, DOI 10.1042/bj1310211; BARNETT JEG, 1975, BIOCHEM J, V145, P417, DOI 10.1042/bj1450417a; BURANT CF, 1992, BIOCHEMISTRY-US, V31, P10414, DOI 10.1021/bi00157a032; BURANT CF, 1992, J BIOL CHEM, V267, P14523; CAIRNS MT, 1991, J BIOL CHEM, V266, P8176; CAIRNS MT, 1987, BIOCHIM BIOPHYS ACTA, V905, P295, DOI 10.1016/0005-2736(87)90458-5; CAIRNS MT, 1984, BIOCHEM J, V221, P179, DOI 10.1042/bj2210179; CARRUTHERS A, 1986, BIOCHEMISTRY-US, V25, P3592, DOI 10.1021/bi00360a018; CARRUTHERS A, 1991, BIOCHEMISTRY-US, V30, P3907, DOI 10.1021/bi00230a015; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; CARTERSU C, 1982, J BIOL CHEM, V257, P5419; CHIN JJ, 1992, BIOCHEMISTRY-US, V31, P1945, DOI 10.1021/bi00122a007; CLELAND WW, 1967, ADV ENZYMOL RAMB, V29, P1; COLVILLE CA, 1993, BIOCHEM J, V290, P701, DOI 10.1042/bj2900701; DENT HC, 1993, THESIS U CAMBRIDGE C; DEVES R, 1978, BIOCHIM BIOPHYS ACTA, V510, P339, DOI 10.1016/0005-2736(78)90034-2; FUTAI M, 1978, BACTERIAL TRANSPORT, P7; GORGA FR, 1981, BIOCHEMISTRY-US, V20, P5108, DOI 10.1021/bi00521a003; GORGA L, 1982, J BIOL CHEM, V247, P2542; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; HELGERSON AL, 1987, J BIOL CHEM, V262, P5464; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; HENDERSON PJF, 1992, INT REV CYTOL, V137A, P149; HENDERSON PJF, 1977, BIOCHEM J, V162, P309, DOI 10.1042/bj1620309; HENDERSON PJF, 1990, J BIOENERG BIOMEMBR, V22, P525, DOI 10.1007/BF00762961; HENDERSON PJF, 1990, PHILOS T ROY SOC B, V326, P391, DOI 10.1098/rstb.1990.0020; HENDERSON PJF, 1986, METHOD ENZYMOL, V125, P387; HOLMAN GD, 1986, BIOCHIM BIOPHYS ACTA, V855, P115, DOI 10.1016/0005-2736(86)90195-1; HOLMAN GD, 1987, BIOCHIM BIOPHYS ACTA, V897, P395, DOI 10.1016/0005-2736(87)90437-8; INUKAI K, 1994, BIOCHEM J, V302, P355, DOI 10.1042/bj3020355; ISHIHARA H, 1991, BIOCHEM BIOPH RES CO, V176, P922, DOI 10.1016/S0006-291X(05)80274-8; KARIM AR, 1987, BIOCHIM BIOPHYS ACTA, V902, P402, DOI 10.1016/0005-2736(87)90208-2; KING APJ, 1991, BIOCHEMISTRY-US, V30, P11546, DOI 10.1021/bi00113a009; LEIVE L, 1965, BIOCHEM BIOPH RES CO, V21, P290, DOI 10.1016/0006-291X(65)90191-9; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; MAIDEN MCJ, 1988, J BIOL CHEM, V263, P8003; MARTIN GEM, 1995, BIOCHEM J, V308, P261, DOI 10.1042/bj3080261; MARTIN GEM, 1994, J BIOL CHEM, V269, P24870; McDonald TP, 1995, J BIOL CHEM, V270, P30359, DOI 10.1074/jbc.270.51.30359; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; PAWAGI AB, 1990, BIOCHEMISTRY-US, V29, P950, DOI 10.1021/bi00456a015; REES WD, 1981, BIOCHIM BIOPHYS ACTA, V646, P251, DOI 10.1016/0005-2736(81)90331-X; ROBERTS PE, 1992, GALACTOSE H PLUS SYM; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHANAHAN MF, 1982, J BIOL CHEM, V257, P7290; WADDELL ID, 1992, BIOCHEM J, V286, P173, DOI 10.1042/bj2860173; WADZINSKI BE, 1990, BIOCHEM J, V272, P151, DOI 10.1042/bj2720151; WALMSLEY AR, 1988, TRENDS BIOCHEM SCI, V13, P226, DOI 10.1016/0968-0004(88)90089-8; WALMSLEY AR, 1993, EUR J BIOCHEM, V215, P43, DOI 10.1111/j.1432-1033.1993.tb18005.x; WALMSLEY AR, 1994, EUR J BIOCHEM, V221, P513, DOI 10.1111/j.1432-1033.1994.tb18763.x; WALMSLEY AR, 1994, J BIOL CHEM, V269, P17009; WEST I, 1972, J BIOENERG, V3, P445, DOI 10.1007/BF01516082; WEST IC, 1970, BIOCHEM BIOPH RES CO, V41, P655, DOI 10.1016/0006-291X(70)90063-X	57	30	35	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15189	15199		10.1074/jbc.272.24.15189	http://dx.doi.org/10.1074/jbc.272.24.15189			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182541	hybrid			2022-12-27	WOS:A1997XE03400024
J	Vaughan, RA; Huff, RA; Uhl, GR; Kuhar, MJ				Vaughan, RA; Huff, RA; Uhl, GR; Kuhar, MJ			Protein kinase C-mediated phosphorylation and functional regulation of dopamine transporters in striatal synaptosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COCAINE; RECEPTORS; CLONING; EXPRESSION; ACTIVATION; CELLS; MODULATION; PROGRESS; BRAIN; CDNA	Dopamine transporters (DATs) are members of a family of Na+- and Cl--dependent neurotransmitter transporters responsible for the rapid clearance of dopamine from synaptic clefts, The predicted primary sequence of DAT contains numerous consensus phosphorylation sites, In this report we demonstrate that DATs undergo endogenous phosphorylation in striatal synaptosomes that is regulated by activators of protein kinase C. Rat striatal synaptosomes were metabolically labeled with [P-32]orthophosphate, and solubilized homogenates were subjected to immunoprecipitation with am antiserum specific for DAT, Basal phosphorylation occurred in the absence of exogenous treatments, and the phosphorylation level was rapidly increased when synaptosomes were treated with the phosphatase inhibitors okadaic acid or calyculin, Treatment of synaptosomes with the protein kinase C activator phorbol 12-myristate 13-acetate (PMA) also increased the level of phosphate incorporation. This occurred within 10 min and was dose-dependent between 0.1 and 1 mu M PMA, DAT phosphorylation was also significantly increased by two other protein kinase C activators, (-)-indolactam V and 1-oleoyl-2-acetyl sn glycerol. The inactive phorbol ester 4 alpha-phorbol 12,13-didecanoate at 10 mu M was without effect, and PMA-induced phosphorylation was blocked by treatment of synaptosomes with the protein kinase C inhibitors staurosporine and bisindoylmaleimide. These results indicate that DATs undergo rapid in vivo phosphorylation in response to protein kinase C activation and that a robust mechanism exists in synaptosomes for DAT dephosphorylation, Dopamine transport activity in synaptosomes was reduced by all treatments that promoted DAT phosphorylation, with comparable dose, time, and inhibitor characteristics. The change in transport activity was produced by a reduction in V-max with no significant effect on the K-m for dopamine, These results suggest that synaptosomal dopamine transport activity is regulated by phosphorylation of DAT and present a potential mechanism for local neuronal control of synaptic neurotransmitter levels and consequent downstream neural activity.	EMORY UNIV,YERKES REG PRIMATE RES CTR,DIV NEUROSCI,ATLANTA,GA 30322; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205	Emory University; Johns Hopkins University; Johns Hopkins University	Vaughan, RA (corresponding author), NIDA,IRP,MOL NEUROBIOL BRANCH,POB 5180,BALTIMORE,MD 21224, USA.				NCRR NIH HHS [RR00165] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000165] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; BERGMAN J, 1989, J PHARMACOL EXP THER, V251, P150; CASADO M, 1993, J BIOL CHEM, V268, P27313; Copeland BJ, 1996, J PHARMACOL EXP THER, V277, P1527; COREY JL, 1994, J BIOL CHEM, V269, P14759; GIAMBALVO CT, 1994, J NEUROCHEM, V63, P169; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GIROS B, 1991, FEBS LETT, V295, P149, DOI 10.1016/0014-5793(91)81406-X; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; GRIGORIADIS DE, 1989, J NEUROSCI, V9, P2664; HORN AS, 1990, PROG NEUROBIOL, V34, P387, DOI 10.1016/0301-0082(90)90033-D; Huff RA, 1997, J NEUROCHEM, V68, P225; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JAYANTHI LD, 1994, J BIOL CHEM, V269, P14424; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KITAYAMA S, 1992, ANN NEUROL, V32, P109, DOI 10.1002/ana.410320120; KITAYAMA S, 1994, EUR J PHARM-MOLEC PH, V268, P115, DOI 10.1016/0922-4106(94)90180-5; MEIERGERD SM, 1993, J NEUROCHEM, V61, P764; MILLER KJ, 1994, J BIOL CHEM, V269, P27351; Nirenberg MJ, 1996, J NEUROSCI, V16, P436; PIFL C, 1993, J NEUROSCI, V13, P4246, DOI 10.1523/jneurosci.13-10-04246.1993; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; Qian Y., 1995, Society for Neuroscience Abstracts, V21, P865; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; SATO K, 1995, J NEUROCHEM, V65, P1967; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHWARTZ JC, 1992, NEUROSCIENCES, V4, P99; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; UCHIKAWA T, 1995, J NEUROCHEM, V65, P2065; UHL GR, 1992, TRENDS PHARMACOL SCI, V13, P421, DOI 10.1016/0165-6147(92)90133-Q; UNDIE AS, 1994, J NEUROCHEM, V62, P2045; USDIN TB, 1991, P NATL ACAD SCI USA, V88, P11168, DOI 10.1073/pnas.88.24.11168; VALLAR L, 1990, J BIOL CHEM, V265, P10320; VANDENBERGH DJ, 1992, MOL BRAIN RES, V15, P161, DOI 10.1016/0169-328X(92)90165-8; VAUGHAN RA, 1995, MOL PHARMACOL, V47, P956; Vrindavanam NS, 1996, NEUROSCI LETT, V216, P133; Zhang L, 1996, EUR J PHARMACOL, V315, P345, DOI 10.1016/S0014-2999(96)00646-2; Zhang L, 1997, BIOCHEM PHARMACOL, V53, P677, DOI 10.1016/S0006-2952(96)00898-2	38	208	210	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15541	15546		10.1074/jbc.272.24.15541	http://dx.doi.org/10.1074/jbc.272.24.15541			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182590	hybrid			2022-12-27	WOS:A1997XE03400073
J	Zhou, G; Kuo, MT				Zhou, G; Kuo, MT			NF-kappa B-mediated induction of mdr1b expression by insulin in rat hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE GENE; P-GLYCOPROTEIN GENE; BACTERIAL TRANSPORT PROTEINS; TRANSCRIPTION FACTOR; VIRUS INDUCTION; MAMMALIAN-CELLS; REQUIRES RAF-1; GROWTH-FACTORS; ACTIVATION; LIVER	The expression of P-glycoproteins encoded by the mdr gene family is associated, with the emergence of multidrug resistance phenotype in animal cells. However the mechanisms controlling the expression of these genes have not been well elucidated. Here, we report that the expression of rat mdr1b gene in cultured H-4-II-E hepatoma cells call be induced by insulin. Transient transfection assays using reporter gene constructs containing various 5' mdr1b sequences showed that the sequence located between base pairs -243 and -163 is important far insulin's induction of mdr1b promoter activity, Further analyses revealed that a NF-kappa B-binding site (located between base pairs -167 and -158) is required for insulin-induced promoter activity, Gel mobility shift assay demonstrated that insulin stimulates the binding of nuclear p50/p65 subunits to the mdr1b NF-kappa B sequence, Cotransfection of plasmids expressing either the p50/p65 NF-kappa B subunits or Raf-1 kinase or both resulted in increased expression of the gene containing wild-type but not NF-kappa B site-mutated mdr1b promoter. Finally, expression of either the antisense p65 subunit of NF-kappa B or dominant negative Raf-1 kinase blocked insulin's induction of the mdr1b promoter activity. Taken together, our results suggest that the insulin-induced mdr1b expression is mediated by transcription factor NF-kappa B via the Raf-1 kinase signaling pathway.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA16672, CA56846, CA72404] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA072404, R01CA056846] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BERTRAND F, 1995, J BIOL CHEM, V270, P24435, DOI 10.1074/jbc.270.41.24435; BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHAUDHARY PM, 1992, ONCOL RES, V4, P281; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHIN KV, 1990, J BIOL CHEM, V265, P221; CHIN KV, 1990, CELL GROWTH DIFFER, V1, P361; CORNWELL MM, 1993, J BIOL CHEM, V268, P15347; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DIGMAN JD, 1983, NUCLEIC ACIDS RES, V11, P1475; FARDEL O, 1992, EUR J BIOCHEM, V205, P847, DOI 10.1111/j.1432-1033.1992.tb16849.x; FARDEL O, 1993, FEBS LETT, V327, P189, DOI 10.1016/0014-5793(93)80167-S; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; GANT TW, 1991, MOL CARCINOGEN, V4, P499, DOI 10.1002/mc.2940040614; GANT TW, 1992, NUCLEIC ACIDS RES, V20, P2841, DOI 10.1093/nar/20.11.2841; GEIER A, 1995, CANCER INVEST, V13, P480, DOI 10.3109/07357909509024911; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; HANKINSON O, 1979, P NATL ACAD SCI USA, V76, P373, DOI 10.1073/pnas.76.1.373; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HIRSCHERNST KI, 1995, BIOCHEM BIOPH RES CO, V215, P179, DOI 10.1006/bbrc.1995.2450; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; KASZUBAKA W, MOL CELL BIOL, V13, P7180; KNHNO K, 1989, BIOCHEM BIOPH RES CO, V164, P1415; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; MARINO PA, 1990, CELL GROWTH DIFFER, V1, P57; MCCOY C, 1995, MOL CELL BIOL, V15, P6100; McKnight S.L., 1992, TRANSCRIPTIONAL REGU; MICKLEY LA, 1989, J BIOL CHEM, V264, P18031; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PIEKARZ RL, 1993, J BIOL CHEM, V268, P7613; POWIS G, 1995, PHARMACOL THERAPEUT, V68, P149, DOI 10.1016/0163-7258(95)02004-7; RUETZ S, 1995, J BIOL CHEM, V270, P25388, DOI 10.1074/jbc.270.43.25388; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1996, MOL CELL BIOL, V15, P4052; SCHUETZ JD, 1993, CELL GROWTH DIFFER, V4, P32; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Sharma HW, 1996, ANTICANCER RES, V16, P589; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SILVERMAN JA, 1995, MOL CARCINOGEN, V13, P50, DOI 10.1002/mc.2940130109; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; Tanaka S, 1996, J BIOL CHEM, V271, P14610, DOI 10.1074/jbc.271.24.14610; TANIMURA H, 1992, BIOCHEM BIOPH RES CO, V183, P917, DOI 10.1016/0006-291X(92)90571-2; Taub R, 1996, FASEB J, V10, P413, DOI 10.1096/fasebj.10.4.8647340; TEETER LD, 1993, MOL CARCINOGEN, V8, P67, DOI 10.1002/mc.2940080202; TEETER LD, 1990, MOL CELL BIOL, V10, P5728, DOI 10.1128/MCB.10.11.5728; TEETER LD, 1991, CELL GROWTH DIFFER, V2, P429; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; THORGEIRSSON SS, 1987, SCIENCE, V236, P1120, DOI 10.1126/science.3576227; TIJIAN R, 1994, CELL, V77, P5; UCHIUMI T, 1993, CELL GROWTH DIFFER, V4, P147; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; Zhou G, 1996, CELL GROWTH DIFFER, V7, P1369	80	166	175	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15174	15183		10.1074/jbc.272.24.15174	http://dx.doi.org/10.1074/jbc.272.24.15174			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182539	hybrid			2022-12-27	WOS:A1997XE03400022
J	Clark, JA				Clark, JA			Analysis of the transmembrane topology and membrane assembly of the GAT-1 gamma-aminobutyric acid transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; HUMAN NOREPINEPHRINE TRANSPORTER; NEUROTRANSMITTER TRANSPORTERS; ENDOPLASMIC-RETICULUM; GLYCINE TRANSPORTER; EXPRESSION CLONING; GLUTAMATE-RECEPTOR; SPANNING REGIONS; N-GLYCOSYLATION; SIGNAL SEQUENCE	The transmembrane topology of the Na+- and Cl--dependent gamma-aminobutyric acid transporter GAT-1 has been studied using protein chimeras in Xenopus oocytes. A series of COOH-terminal truncations was generated to which a prolactin epitope was fused. Following expression of transporter-prolactin chimeras in Xenopus oocytes, the transmembrane orientation of each chimera was determined by testing for protease sensitivity in an oocyte membrane preparation. Data from protease protection assays with GAT-1-prolactin chimeras has shown that residues in the loops connecting hydrophobic domain (HD)3 and HD4 and HD7 and HD8 are accessible to protease in the cytoplasm and suggest the presence of pore loop structures which extend into the membrane from the extracellular face. Such pore loop structures may be involved in the formation of the substrate binding pocket. Studies presented herein confirm that the NH, and COOH termini are cytosolic and hydrophobic domains span the membrane in a manner con sistent with the predicted hydropathy model for Na+- and Cl- dependent transporters. These data also provide insight into GAT-1 transmembrane assembly and suggest that a complex series of topogenic sequences directs this process. A potential pause-transfer sequence has been identified and may be responsible for the translocational pausing observed in this study.			Clark, JA (corresponding author), NIMH,CELL BIOL LAB,BETHESDA,MD 20892, USA.		Clark, Janet/P-4896-2018					AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P5783, DOI 10.1073/pnas.84.16.5783; Bennett ER, 1997, J BIOL CHEM, V272, P1203, DOI 10.1074/jbc.272.2.1203; BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; BLAKELY RD, 1991, J NEUROCHEM, V56, P860, DOI 10.1111/j.1471-4159.1991.tb02002.x; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BRUSS M, 1995, J BIOL CHEM, V270, P9197; CHANG XB, 1994, J BIOL CHEM, V269, P18572; CHAVEZ RA, 1992, J CELL BIOL, V116, P385, DOI 10.1083/jcb.116.2.385; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CLARK JA, 1993, BIOESSAYS, V15, P323, DOI 10.1002/bies.950150506; COREY JL, 1994, J BIOL CHEM, V269, P14759; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GRAMINSKI GF, 1993, J BIOL CHEM, V268, P5957; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HENNESSEY ES, 1993, CURR OPIN STRUC BIOL, V3, P524, DOI 10.1016/0959-440X(93)90078-Y; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; KATZ FN, 1977, P NATL ACAD SCI USA, V74, P3278, DOI 10.1073/pnas.74.8.3278; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINGAPPA VR, 1979, NATURE, V281, P117, DOI 10.1038/281117a0; LIU QR, 1993, FEBS LETT, V315, P114, DOI 10.1016/0014-5793(93)81145-P; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; MELIKIAN HE, 1994, J BIOL CHEM, V269, P12290; Melikian HE, 1996, MOL PHARMACOL, V50, P266; MESTIKAWY SE, 1994, J NEUROCHEM, V62, P445; NAKAHARA DH, 1994, J BIOL CHEM, V269, P7617; OLIVARES L, 1995, J BIOL CHEM, V270, P9437, DOI 10.1074/jbc.270.16.9437; OLIVARES L, 1994, J BIOL CHEM, V269, P28400; Olivares L, 1997, J BIOL CHEM, V272, P1211, DOI 10.1074/jbc.272.2.1211; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; SKACH WR, 1994, CANCER RES, V54, P3202; SKACH WR, 1993, J BIOL CHEM, V268, P23552; SKACH WR, 1993, J BIOL CHEM, V268, P6903; TAMURA S, 1995, J BIOL CHEM, V270, P28712, DOI 10.1074/jbc.270.48.28712; TATE CG, 1994, J BIOL CHEM, V269, P26303; Turk E, 1996, J BIOL CHEM, V271, P1925, DOI 10.1074/jbc.271.4.1925; UHL GR, 1992, MOL BRAIN RES, V16, P353, DOI 10.1016/0169-328X(92)90246-8; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; ZAFRA F, 1995, J NEUROSCI, V15, P3952	43	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14695	14704		10.1074/jbc.272.23.14695	http://dx.doi.org/10.1074/jbc.272.23.14695			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169433	hybrid			2022-12-27	WOS:A1997XC32700030
J	Subramanian, SV; Fitzgerald, ML; Bernfield, M				Subramanian, SV; Fitzgerald, ML; Bernfield, M			Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; CELL-SURFACE PROTEOGLYCAN; MAMMARY EPITHELIAL-CELLS; FACTOR-ALPHA PRECURSOR; WOUND FLUID; MOLECULAR-CLONING; ENDOTHELIAL-CELLS; FINE-STRUCTURE; IL-6 RECEPTOR; CLEAVAGE SITE	The syndecan family of transmembrane heparan sulfate proteoglycans is abundant on the surface of all adherent mammalian cells. Syndecans bind and modify the action of various growth factors/cytokines, proteases/antiproteases, cell adhesion molecules, and extracellular matrix components. Syndecan expression is highly regulated during wound repair, a process orchestrated by many of these effecters. Each syndecan ectodomain is shed constitutively by cultured cells, but the mechanism and significance of this shedding are not understood. Therefore, we examined (i) whether physiological agents active during wound repair influence syndecan shedding, and (ii) whether wound fluids contain shed syndecan ectodomains. Using SVEC4-10 endothelial cells we find that certain proteases and growth factors accelerate shedding of the syndecan-1 and -4 ectodomains. Protease-accelerated shedding is completely inhibited by serum-containing media. Thrombin activity is duplicated by the 14-amino acid thrombin receptor agonist peptide that directly activates the thrombin receptor and is not inhibited by serum. Epidermal growth factor family members accelerate shedding but FGF-S, platelet-derived growth factor-AB, transforming growth factor-beta, tumor necrosis factor-cu, and vascular endothelial cell growth factor 165 do not. Shed ectodomains are soluble, stable in the conditioned medium, have the same size core proteins regardless whether shed at a basal rate, or accelerated by thrombin or epidermal growth factor-family members and are found in acute human dermal wound fluids. Thus, shedding is accelerated by activation of at least two distinct receptor classes, Gr protein-coupled (thrombin) and protein tyrosine kinase (epidermal growth factor). Proteases and growth factors active during wound repair can accelerate syndecan shedding from cell surfaces. Regulated shedding of syndecans suggests physiological roles for the soluble proteoglycan ectodomains.	HARVARD UNIV,SCH MED,JOINT PROGRAM NEONATOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NCI NIH HHS [CA28735] Funding Source: Medline; NICHD NIH HHS [HD07466] Funding Source: Medline; NINDS NIH HHS [5T32NS07264-13] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007264] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BERNFIELD M, 1993, DEVELOPMENT, P205; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Bosenberg MW, 1993, CURR OPIN CELL BIOL, V5, P832, DOI 10.1016/0955-0674(93)90032-L; BOSENBERG MW, 1993, J CELL BIOL, V122, P95, DOI 10.1083/jcb.122.1.95; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; BRAKEBUSCH C, 1994, J BIOL CHEM, V269, P32488; Cabrera N, 1996, J CELL BIOL, V132, P427, DOI 10.1083/jcb.132.3.427; Clark R. A. F, 1996, MOL CELLULAR BIOL WO; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; Deng P, 1996, J BIOL CHEM, V271, P16338, DOI 10.1074/jbc.271.27.16338; DENNINGTON PM, 1994, CLIN EXP PHARMACOL P, V21, P349, DOI 10.1111/j.1440-1681.1994.tb02527.x; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; FERNANDEZBOTRAN R, 1991, FASEB J, V5, P2567, DOI 10.1096/fasebj.5.11.1868981; Fitzgerald M. L., 1994, Molecular Biology of the Cell, V5, p312A; Gallo R, 1996, J INVEST DERMATOL, V107, P676, DOI 10.1111/1523-1747.ep12365571; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; GALLO RL, 1995, MOL CELLULAR BIOL WO, P475; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; GRINNELL F, 1992, J INVEST DERMATOL, V98, P410, DOI 10.1111/1523-1747.ep12499839; Inki P, 1996, ANN MED, V28, P63, DOI 10.3109/07853899608999076; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; JALKANEN M, 1991, BIOL EXTRACELLULAR M, V7, P1; KAHN J, 1994, J CELL BIOL, V125, P461, DOI 10.1083/jcb.125.2.461; KATO M, 1994, J BIOL CHEM, V269, P18881; KATO M, 1995, MOL BIOL CELL, V6, P559, DOI 10.1091/mbc.6.5.559; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECA G, 1995, J IMMUNOL, V154, P1069; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; LEPPA S, 1991, CELL REGUL, V2, P1; Levine SJ, 1996, AM J RESP CELL MOL, V14, P254, DOI 10.1165/ajrcmb.14.3.8845176; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MULLBERG J, 1994, J IMMUNOL, V152, P4958; MULLBERG J, 1995, J IMMUNOL, V155, P5198; OCONNELL KA, 1990, J IMMUNOL, V144, P521; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; PIGOTT R, 1992, BIOCHEM BIOPH RES CO, V187, P584, DOI 10.1016/0006-291X(92)91234-H; RAPRAEGER A, 1985, J BIOL CHEM, V260, P4103; RAPRAEGER A, 1987, BIOL EXTRACELLULAR M, V2, P129; ROARK EF, 1992, DEVELOPMENT, V114, P973; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; SANDERSON RD, 1988, P NATL ACAD SCI USA, V85, P9562, DOI 10.1073/pnas.85.24.9562; SANDERSON RD, 1992, J INVEST DERMATOL, V99, P1; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SPRING J, 1994, P NATL ACAD SCI USA, V91, P3334, DOI 10.1073/pnas.91.8.3334; STEIN J, 1991, ONCOGENE, V6, P601; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; TROYER D, 1992, J BIOL CHEM, V267, P20126; VAINIO S, 1991, DEV BIOL, V147, P322, DOI 10.1016/0012-1606(91)90290-J; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; WYSOCKI AB, 1993, J INVEST DERMATOL, V101, P64, DOI 10.1111/1523-1747.ep12359590; YEAMAN C, 1993, J CELL BIOL, V122, P941, DOI 10.1083/jcb.122.4.941	69	304	313	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14713	14720		10.1074/jbc.272.23.14713	http://dx.doi.org/10.1074/jbc.272.23.14713			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169435	hybrid			2022-12-27	WOS:A1997XC32700032
J	Tarasova, NI; Stauber, RH; Choi, JK; Hudson, EA; Czerwinski, G; Miller, JL; Pavlakis, GN; Michejda, CJ; Wank, SA				Tarasova, NI; Stauber, RH; Choi, JK; Hudson, EA; Czerwinski, G; Miller, JL; Pavlakis, GN; Michejda, CJ; Wank, SA			Visualization of G protein-coupled receptor trafficking with the aid of the green fluorescent protein - Endocytosis and recycling of cholecystokinin receptor type A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR-CELLS; TEMPERATURE-DEPENDENCE; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; INTERNALIZATION; BINDING; LIGAND; CCK; COLOCALIZATION; LOCALIZATION	A chimeric protein consisting of the cholecystokinin receptor type A (CCKAR) and the green fluorescent protein (GFP) was used for studying receptor localization, internalization, and recycling in live cells in real time in four different cell lines. Fusion of the C terminus of the CCKAR to the N terminus of the GFP did not alter receptor ligand binding affinity, signal transduction, or the pattern of receptor surface expression and receptor-mediated cholecystokinin (CCK) internalization. The use of a new GFP mutant with increased fluorescence allowed the continuous observation of CCKAR-GFP in stably expressing cell lines. Newly obtained biologically active fluorescent derivatives of CCK were used for simultaneous observation of receptor and ligand trafficking in CHO, NIH/3T3, and HeLa cells stably expressing the fluorescent CCKAR and in transiently transfected COS-1 cells. Receptor internalization was predominantly ligand dependent in HeLa, COS-1, and CHO cells, but was mostly constitutive in NIH/3T3 cells, suggesting the existence of cell-specific regulation of receptor internalization. The CCKAR antagonists, L-364,718 and CCK 27-32 amide potently inhibited spontaneous internalization of the receptor. The average sorting time of CCK and the receptor in the endosomes was about 25 min. The receptor recycled back to the cell membrane with an average time of 60 min. While the ligands sorted to lysosomes, no receptor molecules could be detected there, and no receptor degradation was observed during recycling. These results demonstrate the usefulness of GFP tagging for real time imaging of G protein-coupled receptor trafficking in living cells and suggest that this technique may be successfully applied to the study of the regulation and trafficking mechanisms of other receptors.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MOL ASPECTS DRUG DESIGN SECT,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,HUMAN RETROVIRUS SECT,FREDERICK,MD 21702; NIDDK,DIGEST DIS BRANCH,CHEM BIOL BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Stauber, Roland/0000-0002-1341-4523; Tarasova, Nadya/0000-0002-4949-0069				ASHWORTH R, 1995, P NATL ACAD SCI USA, V92, P512, DOI 10.1073/pnas.92.2.512; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; CRAWLEY JN, 1994, PEPTIDES, V15, P731, DOI 10.1016/0196-9781(94)90104-X; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Czerwinski Grzegorz, 1995, Letters in Peptide Science, V1, P235, DOI 10.1007/BF00127270; FEGUSON SSG, 1996, SCIENCE, V271, P363; GHINEA N, 1992, J CELL BIOL, V118, P1347, DOI 10.1083/jcb.118.6.1347; GRADY EF, 1995, J BIOL CHEM, V270, P4603, DOI 10.1074/jbc.270.9.4603; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; IZZO RS, 1988, AM J PHYSIOL, V255, pG738, DOI 10.1152/ajpgi.1988.255.6.G738; KAIN SR, 1995, BIOTECHNIQUES, V19, P650; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; MENOZZI D, 1991, J BIOL CHEM, V266, P10385; MOORE RH, 1995, J CELL SCI, V108, P2983; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKATA T, 1995, J CELL BIOL, V131, P1039, DOI 10.1083/jcb.131.4.1039; NarayFejesToth A, 1996, J BIOL CHEM, V271, P15436, DOI 10.1074/jbc.271.26.15436; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; Ozcelebi F, 1996, J BIOL CHEM, V271, P3750; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; POHL M, 1997, IN PRESS J BIOL CHEM; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; ROETTGER BF, 1995, J CELL BIOL, V130, P579, DOI 10.1083/jcb.130.3.579; SCHWARTZ AL, 1995, PEDIATR RES, V38, P835, DOI 10.1203/00006450-199512000-00003; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; Siderovski DP, 1996, CURR BIOL, V6, P211, DOI 10.1016/S0960-9822(02)00454-2; STAUBER R, 1995, VIROLOGY, V213, P439, DOI 10.1006/viro.1995.0016; SVOBODA M, 1990, BIOCHIM BIOPHYS ACTA, V1055, P207, DOI 10.1016/0167-4889(90)90034-B; Tarasova NI, 1997, CELL TISSUE RES, V287, P325, DOI 10.1007/s004410050757; TERASAKI M, 1992, J CELL SCI, V101, P315; TSUNODA Y, 1995, AM J PHYSIOL-GASTR L, V269, pG435, DOI 10.1152/ajpgi.1995.269.3.G435; WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/pnas.89.7.3125; WANK SA, 1995, AM J PHYSIOL-GASTR L, V269, pG628, DOI 10.1152/ajpgi.1995.269.5.G628; WILLIAMS JA, 1988, AM J PHYSIOL, V254, pG513, DOI 10.1152/ajpgi.1988.254.4.G513; YULE DI, 1993, AM J PHYSIOL, V265, pG999, DOI 10.1152/ajpgi.1993.265.5.G999; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	43	162	168	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14817	14824		10.1074/jbc.272.23.14817	http://dx.doi.org/10.1074/jbc.272.23.14817			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169450	hybrid			2022-12-27	WOS:A1997XC32700047
J	Linton, MF; Raabe, M; Pierotti, V; Young, SG				Linton, MF; Raabe, M; Pierotti, V; Young, SG			Reading-frame restoration by transcriptional slippage at long stretches of adenine residues in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; APOLIPOPROTEIN-B GENE; FAMILIAL HYPOBETALIPOPROTEINEMIA; PLASMA-CONCENTRATIONS; ESCHERICHIA-COLI; GAMMA-SUBUNIT; DNA; EXPRESSION; DENSITY; B100	We previously characterized a mutant apoB allele (the apoB86 allele) that produces both a truncated apoB (apoB86) and a full length apoB100, The mutant allele contained a deletion of a single cytosine in exon 26, creating a stretch of eight consecutive adenines in the -1 reading frame. The altered reading-frame allele was restored, with similar to 10% efficiency, by the transcriptional insertion of an extra adenine into the stretch of eight consecutive adenines, thereby accounting for the synthesis of the full-length apoB100, Here, we demonstrate that this reading-frame restoration does not occur when the long stretch of adenines is interrupted by a cytosine, To assess whether reading-frame restoration is unique to a single site in the apoB gene, the same mutation (eight consecutive adenines in the -1 reading frame) was inserted into another site within the apoB gene, Reading-frame restoration occurred at the second site and was abrogated when the stretch of adenines was interrupted by another base, Of note, a computerized analysis of human cDNA sequences revealed that long stretches of adenines in protein-coding sequences occur at a lower than predicted frequency, suggesting that evolution has selected against these sequences.	VANDERBILT UNIV,SCH MED,DEPT MED,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37232; UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141	Vanderbilt University; Vanderbilt University; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Young, Stephen/0000-0001-7270-3176	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002925, P01HL041633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-02925, HL41633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATKINS JF, 1990, CELL, V62, P413, DOI 10.1016/0092-8674(90)90007-2; CHAMBERLIN M, 1962, P NATL ACAD SCI USA, V48, P81, DOI 10.1073/pnas.48.1.81; CHAMORRO M, 1992, P NATL ACAD SCI USA, V89, P713, DOI 10.1073/pnas.89.2.713; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; Glantz SA., 2012, PRIMER BIOSTATISTICS, V7; JACKS T, 1987, P NATL ACAD SCI USA, V84, P4298, DOI 10.1073/pnas.84.12.4298; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; LINTON MF, 1992, P NATL ACAD SCI USA, V89, P11431, DOI 10.1073/pnas.89.23.11431; Nakamura Y, 1996, NUCLEIC ACIDS RES, V24, P214, DOI 10.1093/nar/24.1.214; PEASE RJ, 1990, J BIOL CHEM, V265, P553; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; SEKINE Y, 1989, P NATL ACAD SCI USA, V86, P4609, DOI 10.1073/pnas.86.12.4609; STEINBERG D, 1979, J CLIN INVEST, V64, P292, DOI 10.1172/JCI109451; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; WAGNER LA, 1990, NUCLEIC ACIDS RES, V18, P3529, DOI 10.1093/nar/18.12.3529; WEISS R B, 1989, New Biologist, V1, P159; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YAO ZM, 1992, J BIOL CHEM, V267, P1175; YOUNG SG, 1987, J BIOL CHEM, V262, P16604; YOUNG SG, 1987, J CLIN INVEST, V79, P1831, DOI 10.1172/JCI113025; YOUNG SG, 1987, J CLIN INVEST, V79, P1842, DOI 10.1172/JCI113026; YOUNG SG, 1988, SCIENCE, V241, P591, DOI 10.1126/science.3399894	24	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14127	14132		10.1074/jbc.272.22.14127	http://dx.doi.org/10.1074/jbc.272.22.14127			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162040	hybrid			2022-12-27	WOS:A1997XB49200027
J	Burke, SA; Krzycki, JA				Burke, SA; Krzycki, JA			Reconstitution of monomethylamine:Coenzyme M methyl transfer with a corrinoid protein and two methyltransferases purified from Methanosarcina barkeri	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE DEHYDROGENASE; IRON-SULFUR PROTEIN; CO DEHYDROGENASE; CLOSTRIDIUM-THERMOACETICUM; METHIONINE SYNTHASE; ENZYME COMPLEX; ACETYL-COA; METHANOGENESIS; CENTERS; TRIMETHYLAMINE	Methanogenesis from methylamines requires the intermediate methylation of 2-mercaptoethanesulfonate (CoM). In vitro reconstitution of CoM methylation with monomethylamine was achieved with three purified proteins: a monomethylamine corrinoid protein (MMCP), the ''A'' isozyme of methylcobamide:CoM methyltransferase (MTS-A), and a newly isolated protein termed monomethylamine methyltransferase (MMAMT). MMAMT is a 170-kDa protein with 52-kDa subunits. The MMAMT polypeptide was rate-limiting for methyl transfer until at a 2-fold molar excess over MMCP. MMAMT is a monomethylamine:MMCP methyltransferase, since methylation of MMCP required MMAMT but not MTS-A. MMCP and MMAMT formed a complex detectable by size exclusion high pressure liquid chromatography. Methyl group transfer from methyl-MMCP to CoM was mediated by MTS-A since methyl iodide:CoM methyl transfer by MMCP and MTS-A did not require MMAMT. MTS-M, an isozyme of MTS-A, was inactive in MMCP-dependent methyl transfer. Immunodepletion of MMCP from the extract inhibited CoM methylation with monomethylamine but mot dimethylamine. Purified MMCP reconstituted activity in immunodepleted extracts. These results show that MMCP is the major corrinoid protein for methanogenesis from monomethylamine detectable in extracts and that it interacts with two methyltransferases. MMAMT functions as a MMA: MMCP methyltransferase, while MTS-A functions as a methyl-MMCP:CoM methyltransferase.	OHIO STATE UNIV,DEPT MICROBIOL,COLUMBUS,OH 43210	University System of Ohio; Ohio State University								BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P1129, DOI 10.1021/bi00457a005; Blaut Michael, 1993, P171; Boone David R., 1993, P35; BURKE SA, 1995, J BACTERIOL, V177, P4410, DOI 10.1128/jb.177.15.4410-4416.1995; CAO XJ, 1991, J BACTERIOL, V173, P5439, DOI 10.1128/jb.173.17.5439-5448.1991; Daas PJH, 1996, J BIOL CHEM, V271, P22346, DOI 10.1074/jbc.271.37.22346; DAAS PJH, 1993, J BACTERIOL, V175, P1278, DOI 10.1128/JB.175.5.1278-1283.1993; Daas PJH, 1996, J BIOL CHEM, V271, P22339, DOI 10.1074/jbc.271.37.22339; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6; Ferguson DJ, 1997, J BACTERIOL, V179, P846, DOI 10.1128/jb.179.3.846-852.1997; Ferguson DJ, 1996, J BIOL CHEM, V271, P5189; FERRY JG, 1992, CRIT REV BIOCHEM MOL, V27, P473, DOI 10.3109/10409239209082570; GRAHAME DA, 1993, BIOCHEMISTRY-US, V32, P10786, DOI 10.1021/bi00091a033; GRAHAME DA, 1989, J BIOL CHEM, V264, P12890; HARDER SR, 1989, BIOCHEMISTRY-US, V28, P9080, DOI 10.1021/bi00449a019; Harlow E, 1988, ANTIBODIES LAB MANUA, P564; Harms U, 1996, EUR J BIOCHEM, V235, P653, DOI 10.1111/j.1432-1033.1996.00653.x; HIPPE H, 1979, P NATL ACAD SCI USA, V76, P494, DOI 10.1073/pnas.76.1.494; JABLONSKI PE, 1993, J BIOL CHEM, V268, P325; KREMER JD, 1993, J BACTERIOL, V175, P4824, DOI 10.1128/JB.175.15.4824-4833.1993; KRZYCKI JA, 1989, J BIOL CHEM, V264, P7217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LeClerc GM, 1996, J BIOL CHEM, V271, P18725, DOI 10.1074/jbc.271.31.18725; LU WP, 1990, J BIOL CHEM, V265, P3124; LU WP, 1995, J BACTERIOL, V177, P2245, DOI 10.1128/jb.177.9.2245-2250.1995; MCLACHLAN KL, 1990, J ELECTROANAL CHEM, V295, P113, DOI 10.1016/0022-0728(90)85009-T; NAUMANN E, 1984, ARCH MICROBIOL, V138, P79, DOI 10.1007/BF00425412; Paul L, 1996, J BACTERIOL, V178, P6599, DOI 10.1128/jb.178.22.6599-6607.1996; POL A, 1982, BIOCHEM BIOPH RES CO, V108, P731, DOI 10.1016/0006-291X(82)90890-7; POL A, 1984, BIOCHIM BIOPHYS ACTA, V797, P83, DOI 10.1016/0304-4165(84)90385-4; RAYBUCK SA, 1991, J BACTERIOL, V173, P929, DOI 10.1128/jb.173.2.929-932.1991; Sauer K, 1997, EUR J BIOCHEM, V243, P670, DOI 10.1111/j.1432-1033.1997.t01-1-00670.x; SEEFELDT LC, 1994, ANAL BIOCHEM, V221, P379, DOI 10.1006/abio.1994.1429; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Tallant TC, 1996, J BACTERIOL, V178, P1295, DOI 10.1128/jb.178.5.1295-1301.1996; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERMEIJDEN P, 1984, J BACTERIOL, V160, P629, DOI 10.1128/JB.160.2.629-635.1984; VANDERMEIJDEN P, 1983, ARCH MICROBIOL, V134, P238, DOI 10.1007/BF00407765; Wassenaar RW, 1996, J BACTERIOL, V178, P6937, DOI 10.1128/jb.178.23.6937-6944.1996; WEISS DS, 1993, CELL, V72, P819, DOI 10.1016/0092-8674(93)90570-G; Wolfe Ralph S., 1993, P1; YELISEEV A, 1993, ARCH MICROBIOL, V159, P530, DOI 10.1007/BF00249031; ZINDER SH, 1993, METHANOGENESIS ECOLO, P129	44	77	84	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16570	16577		10.1074/jbc.272.26.16570	http://dx.doi.org/10.1074/jbc.272.26.16570			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195968	hybrid			2022-12-27	WOS:A1997XG01900072
J	Ma, WL; Lehner, PJ; Cresswell, P; Pober, JS; Johnson, DR				Ma, WL; Lehner, PJ; Cresswell, P; Pober, JS; Johnson, DR			Interferon-gamma rapidly increases peptide transporter (TAP) subunit expression and peptide transport capacity in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HLA-CLASS-I; MAJOR HISTOCOMPATIBILITY COMPLEX; MHC CLASS-I; TUMOR-NECROSIS-FACTOR; ANTIGEN PRESENTATION; ENDOPLASMIC-RETICULUM; PROTEASOME SUBUNITS; T-CELLS; UP-REGULATION; MUTANT MICE	Human cytotoxic T lymphocytes (CTL) recognize specific complexes of HLA class I molecules and peptides, which assemble when nascent class I molecules bind peptides transported from the cytoplasm into the endoplasmic reticulum by the heterodimeric transporter associated with antigen processing (TAP). Increased class I molecule expression on the cell surface increases the efficiency of CTL lysis. The kinetics of interferon (IFN)-gamma induction of TAP, peptide transport capacity, and HLA class I molecule expression was determined in endothelial cells, which are targets of CTL following transplantation or viral infection, TAP mRNAs are induced rapidly, increasing 20-fold (TAP1) or 10-fold (TAP2) by 12 h, whereas HLA class I mRNA is induced more slowly, increasing 10-fold in 24 h. TAP1 and TAP2 proteins are also induced rapidly, increasing 10-fold in 24 h, whereas HLA class I heavy chain proteins and surface expression increase more slowly. Peptide transport capacity in endothelial and HeLa cells increases within 6 h of IFN-gamma treatment, suggesting that the IFN-gamma-induced TAP heterodimers are functional. Therefore, the IFN-gamma-induced increase in TAP proteins is accompanied by an increased peptide transport capacity, which may be important in supporting the subsequent rise in HLA class I protein expression.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,MOL CARDIOBIOL PROGRAM,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University; Howard Hughes Medical Institute; Yale University				Lehner, Paul Joseph/0000-0001-9383-1054	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI035099] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37-HL36003] Funding Source: Medline; NIAID NIH HHS [R29-AI35099] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIYAMA KY, 1994, SCIENCE, V265, P1231, DOI 10.1126/science.8066462; ALBELDA SM, 1994, FASEB J, V8, P504, DOI 10.1096/fasebj.8.8.8181668; ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; BAHRAM S, 1991, P NATL ACAD SCI USA, V88, P10094, DOI 10.1073/pnas.88.22.10094; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BENJAMIN RJ, 1991, NATURE, V351, P74, DOI 10.1038/351074a0; COX JH, 1990, SCIENCE, V247, P715, DOI 10.1126/science.2137259; DELASALLE H, 1994, SCIENCE, V265, P237, DOI 10.1126/science.7517574; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; EPPERSON DE, 1994, J IMMUNOL, V153, P5402; EPPERSON DE, 1992, J IMMUNOL, V149, P3297; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FRUH K, 1994, EMBO J, V13, P3236, DOI 10.1002/j.1460-2075.1994.tb06625.x; FRUH K, 1995, NATURE, V375, P415, DOI 10.1038/375415a0; GABATHULER R, 1994, J EXP MED, V180, P1415, DOI 10.1084/jem.180.4.1415; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; HILL A, 1995, NATURE, V375, P411, DOI 10.1038/375411a0; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JOHNSON DR, 1994, MOL CELL BIOL, V14, P1322, DOI 10.1128/MCB.14.2.1322; JOHNSON DR, 1990, P NATL ACAD SCI USA, V87, P5183, DOI 10.1073/pnas.87.13.5183; Kagi D, 1996, ANNU REV IMMUNOL, V14, P207, DOI 10.1146/annurev.immunol.14.1.207; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; KOENIG S, 1990, J IMMUNOL, V145, P127; Lehner PJ, 1996, CURR OPIN IMMUNOL, V8, P59, DOI 10.1016/S0952-7915(96)80106-3; LEVY F, 1991, CELL, V67, P265, DOI 10.1016/0092-8674(91)90178-2; LUTZ PM, 1987, IMMUNOGENETICS, V25, P228, DOI 10.1007/BF00404692; MASHESHWARI R, 1980, NATURE, V287, P454; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; Min W, 1996, J IMMUNOL, V156, P3174; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; MULLBACHER A, 1995, IMMUNITY, V3, P207, DOI 10.1016/1074-7613(95)90090-X; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; OLDEN K, 1982, NATURE, V300, P290, DOI 10.1038/300290a0; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; Ozato Keiko, 1995, P80, DOI 10.1017/CBO9780511525339.005; PARHAM P, 1995, IMMUNOL REV, V143, P141, DOI 10.1111/j.1600-065X.1995.tb00674.x; POBER JS, 1987, J IMMUNOL, V138, P3319; REALINI C, 1994, J BIOL CHEM, V269, P20727; ROSENBERG AS, 1986, NATURE, V322, P829, DOI 10.1038/322829a0; ROWE M, 1995, EUR J IMMUNOL, V25, P1374, DOI 10.1002/eji.1830250536; RUSS G, 1995, J BIOL CHEM, V270, P21312, DOI 10.1074/jbc.270.36.21312; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TARLETON RL, 1992, NATURE, V356, P338, DOI 10.1038/356338a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; WRIGHT KL, 1995, J EXP MED, V181, P1459, DOI 10.1084/jem.181.4.1459; YANG B, 1995, J IMMUNOL, V155, P3889; YEWDELL J, 1994, J IMMUNOL, V152, P1163; York IA, 1996, ANNU REV IMMUNOL, V14, P369, DOI 10.1146/annurev.immunol.14.1.369; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	62	64	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16585	16590		10.1074/jbc.272.26.16585	http://dx.doi.org/10.1074/jbc.272.26.16585			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195970	hybrid			2022-12-27	WOS:A1997XG01900074
J	MarieCardine, A; Bruyns, E; Eckerskorn, C; Kirchgessner, H; Meuer, SC; Schraven, B				MarieCardine, A; Bruyns, E; Eckerskorn, C; Kirchgessner, H; Meuer, SC; Schraven, B			Molecular cloning of SKAP55, a novel protein that associates with the protein tyrosine kinase p59(fyn) in human T-lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; CROSS-LINKING; ACTIVATION; P59(FYN); BINDING; DOMAIN; DISTINCT; P59FYN; CELLS; TCR	In human T-lymphocytes the Src family protein tyrosine kinase p59(fyn) associates with three phosphoproteins of 43, 55, and 85 kDa (pp43, pp55, and pp85), Employing a GST-Fyn-Src homology 2 (SH2) domain fusion protein pp55 was purified from lysates of Jurkat T-cells, Molecular cloning of the pp55 cDNA reveals that the pp55 gene codes for a so far nondescribed polypeptide of 359 amino acids that comprises a pleckstrin homology domain, a C-terminal SH3 domain, as well as several potential tyrosine phosphorylation sites, among which one fulfills the criteria to bind Src-like SH2 domains with high affinity, Consistent with this observation, pp55 selectively binds to isolated SH2 domains of Lck, Lyn, Src, and Fyn but not to the SH2 domains of ZAP70, Syk, Shc, SLP-76, Grb2, phosphatidylinositol 3-kinase, and c-abl in vitro, Based on these properties the protein was termed SKAP55 (src kinase-associated phosphoprotein of 55 kDa). Northern blot analysis shows that SKAP55 mRNA is preferentially expressed in lymphatic tissues, SKAP55 is detected in resting human T-lymphocytes as a constitutively tyrosine phosphorylated protein that selectively interacts with p59(fyn). These data suggest that SKAP55 represents a novel adaptor protein likely involved in Fyn-mediated signaling in human T-lymphocytes.	MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	Max Planck Society	MarieCardine, A (corresponding author), UNIV HEIDELBERG, INST IMMUNOL, NEUENHEIMER FELD 305, D-69120 HEIDELBERG, GERMANY.							APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; ARNI S, 1993, ONCOGENE, V8, P2485; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DANIELIAN S, 1992, EUR J IMMUNOL, V22, P2915, DOI 10.1002/eji.1830221124; DASILVA AJ, 1993, J EXP MED, V178, P2107, DOI 10.1084/jem.178.6.2107; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; ECKERSKORN C, 1988, EUR J BIOCHEM, V176, P509, DOI 10.1111/j.1432-1033.1988.tb14308.x; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; Fusaki N, 1996, J IMMUNOL, V156, P1369; GASSMANN M, 1992, EUR J IMMUNOL, V22, P283, DOI 10.1002/eji.1830220142; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LEE SK, 1994, INT IMMUNOL, V6, P1621, DOI 10.1093/intimm/6.10.1621; LEY SC, 1994, J CELL BIOL, V125, P639, DOI 10.1083/jcb.125.3.639; MarieCardine A, 1995, EUR J IMMUNOL, V25, P3290, DOI 10.1002/eji.1830251214; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; RIGLEY K, 1995, J IMMUNOL, V154, P1136; SAROSI GA, 1992, INT IMMUNOL, V4, P1211, DOI 10.1093/intimm/4.11.1211; SCHRAVEN B, 1994, J BIOL CHEM, V269, P29102; SCHRAVEN B, 1990, NATURE, V345, P71, DOI 10.1038/345071a0; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; TSYGANKOV AY, 1994, J BIOL CHEM, V269, P7792; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	28	87	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16077	16080		10.1074/jbc.272.26.16077	http://dx.doi.org/10.1074/jbc.272.26.16077			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195899	hybrid			2022-12-27	WOS:A1997XG01900003
J	Miyoshi, H; Inoue, M; Okamoto, S; Ohshima, M; Sakamoto, K; Iwamura, H				Miyoshi, H; Inoue, M; Okamoto, S; Ohshima, M; Sakamoto, K; Iwamura, H			Probing the ubiquinone reduction site of mitochondrial complex I using novel cationic inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE DINUCLEOTIDE DEHYDROGENASE; ENERGY-COUPLING SITE-1; 1-METHYL-4-PHENYLPYRIDINIUM MPP+; OXIDATIVE-PHOSPHORYLATION; ELECTRON-TRANSPORT; PIERICIDIN-A; NADH; OXIDOREDUCTASE; ANALOGS; ACCUMULATION	A wide variety of N-methylpyridinium and quinolinium cationic inhibitors of mitochondrial complex I was synthesized to develop potent and specific inhibitors acting selectively at one of the two proposed ubiquinone binding sites of this enzyme (Gluck, M. R., Krueger, M. J., Ramsay, R. R., Sablin, S. O., Singer, T. P., and Nicklas, W. J. (1994) J. Biol. Chem. 269, 3167-3174). N-Methyl-2-n-dodecyl-3-methylquinolinium (MQ18) inhibited electron transfer of complex I at under mu M order regardless of whether exogenous or endogenous ubiquinone was used as an electron acceptor, The presence of tetraphenylboron (TPB-) potentiated the inhibition by MQ18 in a different way depending upon the molar ratio of TPB- to MQ18, In the presence of a catalytic amount of TPB-, the inhibitory potency of MQ18 was remarkably enhanced, and the extent of inhibition was almost complete, The presence of equimolar TPB- partially reactivated the enzyme activity, and the inhibition was saturated at an incomplete level (similar to 50%), These results are explained by the proposed dual binding sites model for ubiquinone (cited above), The inhibition behavior of MQ18 for proton pumping activity was similar to that for electron transfer activity, The good correlation of the inhibition behavior for the two activities indicates that both ubiquinone binding sites contribute to redox-driven proton pumping, On the other hand, N-methyl-4-[2-methyl-3-(p-tert-butylphenyl)]propylpyridinium (MP6) without TPB- brought about approximately 50% inhibition at 5 mu M, but the inhibition reached a plateau at this level over a wide range of concentrations, Almost complete inhibition was readily obtained at low concentrations of MP6 in the presence of TPB-. Thus MP6 appears to be a selective inhibitor of one of the two ubiquinone binding sites, with a combined use of MP6 and 2,3-diethoxy-5-methyl-6-geranyl-1,4-benzoquinone, we also provided kinetic evidence for the existence of two ubiquinone binding sites.			Miyoshi, H (corresponding author), KYOTO UNIV, DEPT AGR CHEM, SAKYO KU, KYOTO 606, JAPAN.		Sakamoto, Kimitoshi/G-4539-2014					AKIBA K, 1984, B CHEM SOC JPN, V57, P1994, DOI 10.1246/bcsj.57.1994; DEJONG AMP, 1994, EUR J BIOCHEM, V222, P975; Esposti MD, 1996, BIOCHEM J, V313, P327, DOI 10.1042/bj3130327; Fato R, 1996, BIOCHEMISTRY-US, V35, P2705, DOI 10.1021/bi9516034; FRIEDRICH T, 1994, EUR J BIOCHEM, V219, P691, DOI 10.1111/j.1432-1033.1994.tb19985.x; GLUCK MR, 1994, J BIOL CHEM, V269, P3167; GUTMAN M, 1970, J BIOL CHEM, V245, P1992; GUTMAN M, 1970, BIOCHEMISTRY-US, V9, P2678, DOI 10.1021/bi00815a016; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015; HE DY, 1994, BIOCHEMISTRY-US, V33, P880, DOI 10.1021/bi00170a005; HOFHAUS G, 1991, J MOL BIOL, V221, P1027, DOI 10.1016/0022-2836(91)80190-6; HOFSTEE BHJ, 1952, SCIENCE, V116, P329, DOI 10.1126/science.116.3013.329; KAISER EM, 1975, SYNTHESIS-STUTTGART, P705; KANO K, 1978, BIOCHIM BIOPHYS ACTA, V509, P289, DOI 10.1016/0005-2736(78)90048-2; KEAN EA, 1971, J BIOL CHEM, V246, P2346; LANDINI D, 1975, SYNTHESIS-STUTTGART, P430; MAJANDER A, 1994, J BIOL CHEM, V269, P21037; MATSUNOYAGI A, 1985, J BIOL CHEM, V260, P4424; MURPHY MP, 1995, BIOCHEM J, V306, P359, DOI 10.1042/bj3060359; RAMSAY RR, 1992, BIOCHEM BIOPH RES CO, V189, P47, DOI 10.1016/0006-291X(92)91523-S; RAMSAY RR, 1989, P NATL ACAD SCI USA, V86, P9168, DOI 10.1073/pnas.86.23.9168; RAMSAY RR, 1991, BIOCHEM J, V273, P481, DOI 10.1042/bj2730481; Sakamoto K, 1996, EUR J BIOCHEM, V237, P128, DOI 10.1111/j.1432-1033.1996.0128n.x; Sakamoto K, 1996, J BIOL CHEM, V271, P29897, DOI 10.1074/jbc.271.47.29897; Satoh T, 1996, BBA-BIOENERGETICS, V1273, P21, DOI 10.1016/0005-2728(95)00131-X; SAYRE LM, 1990, ARCH BIOCHEM BIOPHYS, V280, P274, DOI 10.1016/0003-9861(90)90330-2; UENO H, 1994, EUR J BIOCHEM, V225, P411, DOI 10.1111/j.1432-1033.1994.00411.x; VINOGRADOV AD, 1995, FEBS LETT, V370, P83, DOI 10.1016/0014-5793(95)00803-H; VINOGRADOV AD, 1993, J BIOENERG BIOMEMBR, V25, P367, DOI 10.1007/BF00762462; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; YAGI T, 1990, ARCH BIOCHEM BIOPHYS, V281, P305, DOI 10.1016/0003-9861(90)90448-8; YAGI T, 1987, BIOCHEMISTRY-US, V26, P2822, DOI 10.1021/bi00384a025; YAGI T, 1988, J BIOL CHEM, V263, P16150	33	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16176	16183		10.1074/jbc.272.26.16176	http://dx.doi.org/10.1074/jbc.272.26.16176			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195916	hybrid			2022-12-27	WOS:A1997XG01900020
J	Ramjaun, AR; Micheva, KD; Bouchelet, I; McPherson, PS				Ramjaun, AR; Micheva, KD; Bouchelet, I; McPherson, PS			Identification and characterization of a nerve terminal-enriched amphiphysin isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-COATED VESICLES; SYNAPTIC VESICLES; DYNAMIN; PROTEIN; GENE; ENDOCYTOSIS; DROSOPHILA; VIABILITY; SHIBIRE; CLONING	Amphiphysin is a nerve terminal-enriched protein thought to function in synaptic vesicle endocytosis, in part through Src homology 3 (SH3) domain-mediated interactions with dynamin and synaptojanin. Here, we report the characterization of a novel amphiphysin isoform (termed amphiphysin II) that was identified through a homology search of the data base of expressed sequence tags. Antibodies specific to amphiphysin II recognize a 90-kDa protein on Western blot that is brain-specific and highly enriched in nerve terminals. Like amphiphysin (now referred to as amphiphysin I), amphiphysin II binds to dynamin and synaptojanin through its SH3 domain. Further, both proteins bind directly to clathrin in an SH3 domain-independent manner. Taken together, these data suggest that amphiphysin II may participate with amphiphysin I in the regulation of synaptic vesicle endocytosis.	MCGILL UNIV,MONTREAL NEUROL INST,DEPT NEUROL & NEUROSURG,MONTREAL,PQ H3A 2B4,CANADA	McGill University			Micheva, Kristina/ABH-6913-2020	Micheva, Kristina/0000-0003-1138-3732				BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; Bouchelet I, 1996, MOL PHARMACOL, V50, P219; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CROUZET M, 1991, YEAST, V7, P727, DOI 10.1002/yea.320070708; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; Estes PS, 1996, J NEUROSCI, V16, P5443; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Haffner C, 1996, MOL BIOL CELL, V7, P455; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; Lin HC, 1996, J BIOL CHEM, V271, P27979, DOI 10.1074/jbc.271.45.27979; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MCPHERSON PS, 1994, SEMIN NEUROSCI, V6, P137; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; STONE J, 1987, MOL CELL BIOL, V7, P1679; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002	38	150	156	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16700	16706		10.1074/jbc.272.26.16700	http://dx.doi.org/10.1074/jbc.272.26.16700			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195986	hybrid			2022-12-27	WOS:A1997XG01900090
J	WildBode, C; Yamazaki, T; Capell, A; Leimer, U; Steiner, H; Ihara, Y; Haass, C				WildBode, C; Yamazaki, T; Capell, A; Leimer, U; Steiner, H; Ihara, Y; Haass, C			Intracellular generation and accumulation of amyloid beta-peptide terminating at amino acid 42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PROTEIN-PRECURSOR; METABOLISM; PATHWAY; CELLS	Amyloid beta-peptide (A beta) is known to accumulate in senile plaques of Alzheimer's disease (AD) patients and is now widely believed to play a major role in the disease. Two populations of peptides occur terminating either at amino acid 40 or at amino acid 42 (A beta 1-40 and A beta 1-42). Alternative N-terminal cleavages produce additional heterogeneity (A beta x-40 and A beta x-42), Peptides terminating at amino acid 42 are believed to be the major player in sporadic AD as well as familial AD (FAD). Whereas the cellular mechanism for the generation of AP terminating at amino acid 40 is well understood, very little is known about the cleavage of A beta after amino acid 42, By using two independent methods we demonstrate intracellular A beta 1-42 as well as A beta x-42 but less A beta x-40 and A beta 1-40 in kidney 293 cells stably transfected with wild type beta-amyloid precursor protein (beta APP) or the FAD-associated Val/Gly mutation, Moreover, retention of beta APP within the endoplasmic reticulum (ER) by treatment with brefeldin A does not block the cleavage at amino acid 42 but results in an increased production of all species of A beta terminating at amino acid 42. This indicates that the cleavage after amino acid 42 can occur within the ER. Treatment of cells with monensin, which blocks transport of (beta APP) within the Golgi causes a marked accumulation of intracellular A beta x-42 and A beta x-40. Therefore these experiments indicate that the gamma-secretase cleavage of A beta after amino acid 42 can occur within the ER and later within the secretory pathway within the Golgi. Moreover inhibition of reinternalization by cytoplasmic deletions of beta APP as well as inhibition of intracellular acidification by NH4Cl does not block intracellular A beta 1-42 or A beta x-42 production.	CENT INST MENTAL HLTH,DEPT MOL BIOL,D-68159 MANNHEIM,GERMANY; UNIV TOKYO,DEPT NEUROPATHOL,INST BRAIN RES,FAC MED,TOKYO 113,JAPAN	Central Institute of Mental Health; University of Tokyo								BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; Capell A, 1996, AMYLOID, V3, P150, DOI 10.3109/13506129609045514; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; Cotman Carl W., 1994, P305; CUMMINGS BJ, 1995, LANCET, V346, P1524, DOI 10.1016/S0140-6736(95)92053-6; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; GABUZDA D, 1994, J BIOL CHEM, V269, P13623; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; HAASS C, 1995, J BIOL CHEM, V270, P6186, DOI 10.1074/jbc.270.11.6186; HAASS C, 1994, J BIOL CHEM, V269, P17741; Klafki HW, 1996, J BIOL CHEM, V271, P28655, DOI 10.1074/jbc.271.45.28655; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Leimer U, 1996, EXP CELL RES, V224, P88, DOI 10.1006/excr.1996.0114; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; Mann DMA, 1996, ANN NEUROL, V40, P149, DOI 10.1002/ana.410400205; Masliah E, 1996, J NEUROSCI, V16, P5795; PIKE CJ, 1995, J BIOL CHEM, V270, P23895, DOI 10.1074/jbc.270.41.23895; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SHINKAI Y, 1995, ANN NEUROL, V38, P421, DOI 10.1002/ana.410380312; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016; Tischer E, 1996, J BIOL CHEM, V271, P21914, DOI 10.1074/jbc.271.36.21914; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349; YOUNKIN SG, 1995, ANN NEUROL, V37, P287, DOI 10.1002/ana.410370303	33	281	291	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16085	16088		10.1074/jbc.272.26.16085	http://dx.doi.org/10.1074/jbc.272.26.16085			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195901	hybrid			2022-12-27	WOS:A1997XG01900005
J	Andersen, B; Hariri, A; Pittelkow, MR; Rosenfeld, MG				Andersen, B; Hariri, A; Pittelkow, MR; Rosenfeld, MG			Characterization of Skn-1a/i POU domain factors and sinkage to papillomavirus gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCTAMER-BINDING-PROTEINS; LONG CONTROL REGION; TRANSCRIPTION FACTOR; DNA-BINDING; ANTERIOR-PITUITARY; ACTIVATION DOMAINS; REGULATORY ELEMENT; SKIN DEVELOPMENT; ACID RECEPTOR; CELL-TYPE	Tissue-restricted POU domain transcription factors, which bind octamer or octamer-like gene sequences, play roles in cellular differentiation and the development of several organs, We have previously identified a POU domain gene, Skn-1a/i, expressed primarily in epidermis, that encodes at least two products through alternative splicing. One of these, Skn-1a, acts as a transcriptional activator, and the other, Skn-1i, contains an inhibitory domain in the NH2 terminus, which prevents DNA-binding in vitro and transcriptional activation in vivo. We now demonstrate that when Skn-1i is expressed in eukaryotic cells it can bind to an octamer site, suggesting that in vivo cellular factors modulate the activity of the inhibitory domain to permit DNA-binding. Yet the inhibitory domain does not allow transactivation by Skn-1i or by a heterologous transactivator containing this domain in cis. Furthermore, we demonstrate that Skn-1a, Tst-1, and Oct-1 are the major octamer binding proteins in epidermis. Since Skn-1a is primarily expressed in suprabasal cells of the epidermis, we have tested its possible role in the regulation of epidermal papillomaviruses. In transient transfection assays, Skn-1a and Tst-1 can activate the long control region of the epidermis-specific human papillomavirus 1A (HPV-1A), Consistent with these in vivo transcription data, in. vitro DNA binding studies identify three octamer-like sites, which are capable of binding Skn-1a, in the HPV-1A long control region, Mutations of all three octamer-like sites prevent transactivation by Skn-1a in transient transfection assays. Taken together, these re suits provide evidence that Skn-1a and Tst-1 may provide a molecular link between HPV gene expression and epidermal differentiation.	UNIV CALIF SAN DIEGO,SCH & DEPT MED,HOWARD HUGHES MED INST,LA JOLLA,CA 92037; UNIV CALIF SAN DIEGO,SCH & DEPT MED,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92037; MAYO CLIN & MAYO FDN,DEPT DERMATOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; Mayo Clinic; Mayo Clinic					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002411] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK02411] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; ANDERSEN B, 1993, J BIOL CHEM, V268, P23390; Bermingham JR, 1996, GENE DEV, V10, P1751, DOI 10.1101/gad.10.14.1751; BRENOWITZ M, 1993, CURRENT PROTOCOLS MO, V2; BYRNE C, 1994, DEVELOPMENT, V120, P2369; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; CUTHILL S, 1993, MOL CARCINOGEN, V8, P96, DOI 10.1002/mc.2940080206; DANOS O, 1980, EUR J BIOCHEM, V109, P457, DOI 10.1111/j.1432-1033.1980.tb04815.x; DAS G, 1993, J BIOL CHEM, V268, P25026; DENT CL, 1991, NUCLEIC ACIDS RES, V19, P4531, DOI 10.1093/nar/19.16.4531; DOLLARD SC, 1993, J VIROL, V67, P1721, DOI 10.1128/JVI.67.3.1721-1726.1993; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; FAUS I, 1994, MOL CELL BIOL, V14, P3263, DOI 10.1128/MCB.14.5.3263; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; Fuchs E, 1995, ANNU REV CELL DEV BI, V11, P123, DOI 10.1146/annurev.cb.11.110195.001011; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; GAUTHIER JM, 1991, NEW BIOL, V3, P498; GOLDSBOROUGH AS, 1993, NUCLEIC ACIDS RES, V21, P127, DOI 10.1093/nar/21.1.127; Hagmann M, 1995, NUCLEIC ACIDS RES, V23, P4978, DOI 10.1093/nar/23.24.4978; HALL PA, 1989, DEVELOPMENT, V106, P619; HE X, 1991, MOL CELL BIOL, V11, P1739, DOI 10.1128/MCB.11.3.1739; HEILMAN CA, 1980, J VIROL, V36, P395, DOI 10.1128/JVI.36.2.395-407.1980; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HOWLEY PM, 1991, CANCER RES, V51, pS5019; HUFF CA, 1993, J BIOL CHEM, V268, P377; IMAKADO S, 1995, GENE DEV, V9, P317, DOI 10.1101/gad.9.3.317; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; LICHTSTEINER S, 1995, EMBO J, V14, P3937, DOI 10.1002/j.1460-2075.1995.tb00065.x; LILLYCROP KA, 1995, BIOCHEM J, V307, P581, DOI 10.1042/bj3070581; LILLYCROP KA, 1995, MOL BIOL REP, V21, P87, DOI 10.1007/BF00986498; LILLYCROP KA, 1991, NEURON, V7, P381, DOI 10.1016/0896-6273(91)90290-G; Lymboussaki A, 1996, BRIT J CANCER, V73, P1347, DOI 10.1038/bjc.1996.257; MEYERS C, 1992, SCIENCE, V257, P971, DOI 10.1126/science.1323879; Mittal V, 1996, MOL CELL BIOL, V16, P1955; MORRIS PJ, 1993, NUCLEIC ACIDS RES, V21, P4506, DOI 10.1093/nar/21.19.4506; MOSER M, 1995, DEVELOPMENT, V121, P2779; OCONNOR M, 1995, VIROLOGY, V207, P77, DOI 10.1006/viro.1995.1053; Rosenfeld MG, 1996, RECENT PROG HORM RES, V51, P217; RUTHBERG SE, 1996, ONCOGENE, V13, P167; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT GA, 1993, J INVEST DERMATOL, V101, P3, DOI 10.1111/1523-1747.ep12358258; SIBBET GJ, 1995, J VIROL, V69, P4006, DOI 10.1128/JVI.69.7.4006-4011.1995; SPALHOLZ BA, 1985, CELL, V42, P183, DOI 10.1016/S0092-8674(85)80114-8; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; TANAKA M, 1994, MOL CELL BIOL, V14, P6046, DOI 10.1128/MCB.14.9.6046; TARAVIRAS S, 1994, MECH DEVELOP, V48, P67, DOI 10.1016/0925-4773(94)90017-5; TSENG H, 1994, J CELL BIOL, V126, P495, DOI 10.1083/jcb.126.2.495; TSENG H, 1992, P NATL ACAD SCI USA, V89, P10311, DOI 10.1073/pnas.89.21.10311; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; VERRIJZER CP, 1992, NUCLEIC ACIDS RES, V20, P6369, DOI 10.1093/nar/20.23.6369; WEGNER M, 1993, P NATL ACAD SCI USA, V90, P4743, DOI 10.1073/pnas.90.10.4743; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; Welter JF, 1996, J BIOL CHEM, V271, P14727, DOI 10.1074/jbc.271.25.14727; Welter JF, 1995, ONCOGENE, V11, P2681; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0; YUKAWA K, 1993, GENE, V133, P163; Yukawa K, 1996, J VIROL, V70, P10, DOI 10.1128/JVI.70.1.10-16.1996; ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700	66	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15905	15913		10.1074/jbc.272.25.15905	http://dx.doi.org/10.1074/jbc.272.25.15905			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188490	hybrid			2022-12-27	WOS:A1997XF32900050
J	Dustin, ML				Dustin, ML			Adhesive bond dynamics in contacts between T lymphocytes and glass-supported planar bilayers reconstituted with the immunoglobulin-related adhesion molecule CD58	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-3; FLUORESCENCE PHOTOBLEACHING RECOVERY; CELL-ADHESION; CYTOPLASMIC DOMAIN; LATERAL MOBILITY; MONOCLONAL-ANTIBODY; DISSOCIATION RATE; LIGAND AVIDITY; COATED PITS; CD2	The interaction of the IT cell glycoprotein CD2 and its ligand CD58 is important for T cell interaction with antigen-presenting and target cells, The binding interaction is of low affinity and has a fast off-rate (>5 s(-1)) ill solution, However, solution measurements may not accurately predict the behavior of molecules in an adhesive contact area, Interaction between T cells that express CD2 and glass-supported planar bilayers containing purified and fluorescently labeled CD58 leads to accumulation of CD58 (fluorescence) in the cell/ bilayer contact area, CD58 molecules accumulated within the contact area in excess of the CD58 density in the bilayer outside the contact area call be considered as bound by cell surface CD2. Here, this phenomena and fluorescence photobleaching recovery were utilized to determine whether CD2-CD58 bonds are transient in contact areas, Fluorescent CD58 molecules accumulated in the T cell-bilayer inter face were completely bleached, The bleached CD58 molecules accumulated in the contact area were rapidly replaced by fluorescent CD58 that diffused into the contact area from adjacent bilayer regions outside the contact area, Rapid recovery of the accumulated fluorescence directly demonstrates that the CD2-CD58 bonds are dissociating and that the dissociation leads to partner exchange, rather than rebinding of the same CD2-CD58 pairs, This suggests that the solution off-rate provides an accurate description of CDB-CD58 interaction in contact areas, Accumulated fluorescent IgG in contacts between K562 cells expressing low affinity Fe receptors and planar bilayers with fluorescent IgG bound to hapten-derivitized phospholipids displayed slower recovery than CD58 by a factor of 10, This suggests that the Fc receptor-IgG interaction has a longer life-time than the CD2-CD58 interaction, These findings have implications for the mechanism of signaling by CD2 and the mechanism of cell detachment from large numbers of transient interactions.	WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	Dustin, ML (corresponding author), WASHINGTON UNIV, SCH MED, CTR IMMUNOL, BOX 8118, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA.		Dustin, Michael/AAM-4611-2020	Dustin, Michael/0000-0003-4983-6389				AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; Bell GM, 1996, J EXP MED, V183, P169, DOI 10.1084/jem.183.1.169; BERNARD A, 1986, HUM IMMUNOL, V17, P388, DOI 10.1016/0198-8859(86)90299-5; BOCKENSTEDT LK, 1988, J IMMUNOL, V141, P1904; BRIAN AA, 1984, P NATL ACAD SCI-BIOL, V81, P6159, DOI 10.1073/pnas.81.19.6159; CHAN PY, 1991, J CELL BIOL, V115, P245, DOI 10.1083/jcb.115.1.245; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; Davis SJ, 1996, IMMUNOL TODAY, V17, P177, DOI 10.1016/0167-5699(96)80617-7; DIMINNO G, 1983, BLOOD, V61, P140; DUBAND JL, 1988, J CELL BIOL, V107, P1385, DOI 10.1083/jcb.107.4.1385; DUSTIN ML, 1987, J EXP MED, V165, P677, DOI 10.1084/jem.165.3.677; Dustin ML, 1996, J CELL BIOL, V132, P465, DOI 10.1083/jcb.132.3.465; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; DUSTIN ML, 1989, J EXP MED, V169, P503, DOI 10.1084/jem.169.2.503; ELSON EL, 1989, METHOD CELL BIOL, V30, P307; FIRE E, 1991, J CELL BIOL, V115, P1585, DOI 10.1083/jcb.115.6.1585; HAHN WC, 1993, J EXP MED, V178, P1831, DOI 10.1084/jem.178.5.1831; HAHN WC, 1992, P NATL ACAD SCI USA, V89, P7179, DOI 10.1073/pnas.89.15.7179; HE Q, 1988, CELL, V54, P979, DOI 10.1016/0092-8674(88)90112-2; HSIEH HV, 1995, BIOCHEMISTRY-US, V34, P12481, DOI 10.1021/bi00038a047; IZZARD CS, 1976, J CELL SCI, V21, P129; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; KAPITZA HG, 1985, P NATL ACAD SCI USA, V82, P4122, DOI 10.1073/pnas.82.12.4122; KATZIR Z, 1994, J BIOL CHEM, V269, P21568; LIU SJ, 1995, BIOPHYS J, V68, P459, DOI 10.1016/S0006-3495(95)80207-9; MATSUI K, 1994, P NATL ACAD SCI USA, V91, P12862, DOI 10.1073/pnas.91.26.12862; MCKEITHAN TW, 1995, P NATL ACAD SCI USA, V92, P5042, DOI 10.1073/pnas.92.11.5042; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MOINGEON PE, 1991, EUR J IMMUNOL, V21, P605, DOI 10.1002/eji.1830210311; ORLANDO RA, 1991, J BIOL CHEM, V266, P19543; Pierres A, 1996, P NATL ACAD SCI USA, V93, P15114, DOI 10.1073/pnas.93.26.15114; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SANCHEZMATEOS P, 1995, BLOOD, V86, P2228, DOI 10.1182/blood.V86.6.2228.bloodjournal8662228; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; TOZEREN A, 1992, J CELL BIOL, V116, P997, DOI 10.1083/jcb.116.4.997; UNANUE ER, 1984, ANNU REV IMMUNOL, V2, P395, DOI 10.1146/annurev.iy.02.040184.002143; VANDERMERWE PA, 1994, BIOCHEMISTRY-US, V33, P10149, DOI 10.1021/bi00199a043; YECHIEL E, 1987, J CELL BIOL, V105, P755, DOI 10.1083/jcb.105.2.755; ZINKERNA.RM, 1974, NATURE, V251, P547, DOI 10.1038/251547a0	43	65	66	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15782	15788		10.1074/jbc.272.25.15782	http://dx.doi.org/10.1074/jbc.272.25.15782			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188475	hybrid			2022-12-27	WOS:A1997XF32900035
J	Grossmann, M; Szkudlinski, MW; Wong, R; Dias, JA; Ji, TH; Weintraub, BD				Grossmann, M; Szkudlinski, MW; Wong, R; Dias, JA; Ji, TH; Weintraub, BD			Substitution of the seat-belt region of the thyroid-stimulating hormone (TSH) beta-subunit with the corresponding regions of choriogonadotropin or follitropin confers luteotropic but not follitropic activity to chimeric TSH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; SITE-DIRECTED MUTAGENESIS; RECEPTOR-BINDING REGION; GLYCOPROTEIN HORMONES; BIOLOGICAL-ACTIVITY; ALPHA-SUBUNIT; SIGNAL-TRANSDUCTION; HUMAN THYROTROPIN; LUTROPIN; EXPRESSION	The region between the 10th and 12th cysteine (Cys(88)-Cys(105) in human thyroid-stimulating hormone beta-subunit (hTSH beta)) of the glycoprotein hormone beta-subunits corresponds to the disulfide-linked seat-belt region. It wraps around the common alpha-subunit and has been implicated in regulating specificity between human choriogonado-tropin (hCG) and human follicle-stimulating hormone (hFSH), but determinants of hTSH specificity are unknown, To characterize the role of this region for hTSH, we constructed hTSH chimeras in which the entire seatbelt region Cys(88)-Cys(105) or individual intercysteine segments Cys(88)-Cys(95) and Cys(95)-Cys(105) were replaced with the corresponding sequences of hCG and hFSH or alanine cassettes. Alanine cassette mutagenesis of hTSH showed that the Cys(95)-Cys(105) segment of the seat-belt was more important for TSI-I receptor binding and signal transduction than the Cys(88)-Cys(95) determinant loop region. Replacing the entire seat-belt of hTSH beta with the hCG sequence conferred full hCG receptor binding and activation to the hTSH chimera, whereas TSI-I receptor binding and activation were abolished. Conversely, introduction of the hTSH beta seat-belt sequence into hCG beta generated an hCG chimera that bound to and activated the TSH receptor but not the CG/lutropin (LH) receptor. In contrast, an hTSH chimera bearing hFSH seat-belt residues did not possess any follitropic activity, and its thyrotropic activity was only slightly reduced. This may in part be due to the fact that the net charge of the seat-belt is similar in hTSH and hFSH but different from hCG. However, exchanging other regions of charge heterogeneity between hTSH beta and hFSH beta did not confer follitropic activity to hTSH. Thus, exchanging the seatbelt region between hTSH and hCG; switches hormonal specificity in a mutually exclusive fashion, In contrast, the seat-belt appears not to discriminate between the TSH and the FSH receptors, indicating for the first time that domains outside the seat-belt region contribute to glycoprotein hormone specificity.	UNIV MARYLAND,SCH MED,DEPT MED,MOL ENDOCRINOL LAB,BALTIMORE,MD 21201; NIDDK,MOL & CELLULAR ENDOCRINOL BRANCH,NIH,BETHESDA,MD 20892; NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,ALBANY,NY 12201; UNIV WYOMING,DEPT MOL BIOL,LARAMIE,WY 82071	University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); State University of New York (SUNY) System; Wadsworth Center; University of Wyoming	Grossmann, M (corresponding author), CTR MED BIOTECHNOL,INST HUMAN VIROL,MOL ENDOCRINOL LAB,725 W LOMBARD ST,N457,BALTIMORE,MD 21201, USA.			Dias, James A/0000-0002-9792-5469				ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; Baenziger J.U., 1994, GLYCOPROTEIN HORMONE, P167; BIELINSKA M, 1995, GLYCOPROTEINS, P565; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; CHEN F, 1991, J BIOL CHEM, V266, P19357; CHEN F, 1991, J BIOL CHEM, V266, P6904; COLOMA TAS, 1990, J BIOL CHEM, V265, P5037; COMBARNOUS Y, 1992, ENDOCR REV, V13, P670, DOI 10.1210/edrv-13-4-670; COSTAGLIOLA S, 1992, J CLIN ENDOCR METAB, V75, P1540, DOI 10.1210/jc.75.6.1540; DIAS JA, 1994, J BIOL CHEM, V269, P25289; FIDDES JC, 1984, RECENT PROG HORM RES, V40, P43; GROSSMANN M, 1995, J BIOL CHEM, V270, P29378, DOI 10.1074/jbc.270.49.29378; Grossmann M, 1996, MOL ENDOCRINOL, V10, P769, DOI 10.1210/me.10.6.769; GROSSMANN M, 1995, MOL ENDOCRINOL, V9, P948, DOI 10.1210/me.9.8.948; IBANEZ CF, 1994, J NEUROBIOL, V25, P1349, DOI 10.1002/neu.480251104; JEEVANRAM R, 1990, GLYCOPROTEIN HORMONE, P395; JI IH, 1993, J BIOL CHEM, V268, P22971; KEUTMANN HT, 1987, P NATL ACAD SCI USA, V84, P2038, DOI 10.1073/pnas.84.7.2038; KEUTMANN HT, 1989, MOL ENDOCRINOL, V3, P526, DOI 10.1210/mend-3-3-526; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LIU C, 1993, J BIOL CHEM, V268, P21613; MATZUK MM, 1989, J BIOL CHEM, V264, P2409; MedeirosNeto G, 1996, J CLIN INVEST, V97, P1250, DOI 10.1172/JCI118540; MOORE WT, 1980, CHORIONIC GONADOTROP, P89; MORRIS JC, 1990, J BIOL CHEM, V265, P1881; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; SAIRAM MR, 1990, BIOCHEM CELL BIOL, V68, P889, DOI 10.1139/o90-131; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; Szkudlinski MW, 1996, NAT BIOTECHNOL, V14, P1257, DOI 10.1038/nbt1096-1257; SZKUDLINSKI MW, 1996, TRENDS ENDOCRIN MET, V7, P11; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; YOO JK, 1993, J BIOL CHEM, V268, P13034; YOSHIMURA M, 1995, THYROID, V5, P425, DOI 10.1089/thy.1995.5.425	36	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15532	15540		10.1074/jbc.272.24.15532	http://dx.doi.org/10.1074/jbc.272.24.15532			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182589	hybrid			2022-12-27	WOS:A1997XE03400072
J	Tsujimoto, M; Tsuruoka, N; Ishida, N; Kurihara, T; Iwasa, F; Yamashiro, K; Rogi, T; Kodama, S; Katsuragi, N; Adachi, M; Katayama, T; Nakao, M; Yamaichi, K; Hashino, J; Haruyama, M; Miura, K; Nakanishi, T; Nakazato, H; Teramura, M; Mizoguchi, H; Yamaguchi, N				Tsujimoto, M; Tsuruoka, N; Ishida, N; Kurihara, T; Iwasa, F; Yamashiro, K; Rogi, T; Kodama, S; Katsuragi, N; Adachi, M; Katayama, T; Nakao, M; Yamaichi, K; Hashino, J; Haruyama, M; Miura, K; Nakanishi, T; Nakazato, H; Teramura, M; Mizoguchi, H; Yamaguchi, N			Purification, cDNA cloning, and characterization of a new serpin with megakaryocyte maturation activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINE; COLONY FORMATION; MPL LIGAND; SERUM-FREE; PROLIFERATION; STIMULATION; CYTOKINE; GROWTH; THROMBOPOIETIN; INTERLEUKIN-3	A new member of the serine protease inhibitor (serpin) superfamily with megakaryocyte maturation activity was purified, and its cDNA was cloned and characterized, The predicted amino acid sequence consisting of 380 residues was unique and was 38% identical to the serpin plasminogen activator inhibitor type 2 (PAI-2). The recombinant factor expressed in Chinese hamster ovary cells showed species-specific activity on the induction of megakaryocyte maturation in vitro. When injected into mice, the factor indeed elicited an increase in the number of platelets in plasma. The sequence alignment indicated that the factor possessed a lysine residue at the P-1 position, suggesting that it might function as an inhibitor of Lys-specific proteases. Although we could not show any inhibitory activities toward several known Lys specific proteases, we detected the activity toward protease activity present in the culture supernatant of COLO 201 cells. These results suggested that the protein might influence the maturation of megakaryocytes via action as a serpin.	SUNTORY INST BIOMED RES,SHIMAMOTO,OSAKA 618,JAPAN; TOKYO WOMENS MED COLL,DIV HEMATOL,DEPT MED,TOKYO 162,JAPAN; KYOTO PREFECTURAL UNIV MED,RES INST NEUROL DIS & GERIATR,DEPT CELL BIOL,KYOTO 602,JAPAN	Suntory Holdings Ltd; Tokyo Women's Medical University; Kyoto Prefectural University of Medicine								BARTLEY TD, 1994, CELL, V77, P1117, DOI 10.1016/0092-8674(94)90450-2; BRACH MA, 1990, BLOOD, V76, P1972; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; GINSBURG D, 1986, J CLIN INVEST, V78, P1673, DOI 10.1172/JCI112761; GORDON MS, 1992, BLOOD, V80, P302; GURNEY AL, 1994, SCIENCE, V265, P1445, DOI 10.1126/science.8073287; HENDRIE PC, 1991, EXP HEMATOL, V19, P1031; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; IKEBUCHI K, 1987, P NATL ACAD SCI USA, V84, P9035, DOI 10.1073/pnas.84.24.9035; ISHIBASHI T, 1989, P NATL ACAD SCI USA, V86, P5953, DOI 10.1073/pnas.86.15.5953; JACOBS K, 1985, NATURE, V313, P806, DOI 10.1038/313806a0; KATO T, 1995, J BIOCHEM-TOKYO, V118, P229, DOI 10.1093/oxfordjournals.jbchem.a124883; KAUSHANSKY K, 1995, P NATL ACAD SCI USA, V92, P3234, DOI 10.1073/pnas.92.8.3234; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; METCALF D, 1992, TRENDS BIOCHEM SCI, V17, P286, DOI 10.1016/0968-0004(92)90436-D; METCALF D, 1991, BLOOD, V77, P2150; OGAWA M, 1993, BLOOD, V81, P2844; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; QUESENBERRY PJ, 1985, BLOOD, V65, P214; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; ROBINSON BE, 1987, J CLIN INVEST, V79, P1648, DOI 10.1172/JCI113002; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEUNING WD, 1987, MOL CELL BIOL, V7, P4564, DOI 10.1128/MCB.7.12.4564; STEELE FR, 1992, P NATL ACAD SCI USA, V90, P1526; SUMINAMI Y, 1991, BIOCHEM BIOPH RES CO, V181, P51, DOI 10.1016/S0006-291X(05)81380-4; TERAMURA M, 1992, BLOOD, V79, P327; TERAMURA M, 1988, EXP HEMATOL, V16, P843; TSUJIMOTO M, 1989, J BIOCHEM-TOKYO, V106, P23, DOI 10.1093/oxfordjournals.jbchem.a122812; WILLIAMS N, 1982, J CELL PHYSIOL, V110, P101, DOI 10.1002/jcp.1041100116; YAMAGUCHI N, 1994, J BIOL CHEM, V269, P805; YAMAGUCHI N, 1986, CANCER RES, V46, P5353; YAMAGUCHI N, 1990, CANCER RES, V50, P658; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	36	15	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15373	15380		10.1074/jbc.272.24.15373	http://dx.doi.org/10.1074/jbc.272.24.15373			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182567	hybrid			2022-12-27	WOS:A1997XE03400050
J	Hoffmann, KF; Strand, M				Hoffmann, KF; Strand, M			Molecular characterization of a 20.8-kDa Schistosoma mansoni antigen - Sequence similarity to tegumental associated antigens and dynein light chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-ARM DYNEIN; CYTOPLASMIC DYNEIN; CLONING; MICE; IDENTIFICATION; GLYCOPROTEINS; ANTIBODIES; CALNEXIN; SMIRV1; MOTOR	Survival of Schistosoma mansoni within the infected host requires the parasite to actively maintain its protective tegument. The components responsible for this maintenance are therefore attractive targets for immunoprophylaxis or chemotherapy. Here we report the molecular characterization of a 20.8-kDa tegumental antigen with sequence similarity to dynein light chains and tegumental associated antigens. A cDNA encoding the 20.8-kDa polypeptide contains an open reading frame of 181 amino acids and predicts an isoelectric point of 7.27, Expression of the 20.8-kDa antigen is developmentally regulated, with the highest concentration found in cercariae, Our data show that the 20.8-kDa polypeptide specifically interacts with a S. mansoni 10.4-kDa dynein light chain that we have previously;described (Hoffmann, K. F., and Strand, M. (1996) J. Biol. Chem. 271, 26117-26123), Velocity sedimentation analysis oi a parasite extract demonstrated that this 10.4-kDa dynein light chain and the 20.8-kDa polypeptide were present in a complex that sedimented at 4.4 Svedberg units. We have also shown by antibody cross-reactivity that a 20.8-kDa homolog of the S. mansoni antigen is present in Schistosoma japonicum, but not in Schistosoma hematobium or Fasciola hepatica, Because the 20.8-kDa polypeptide displays ideal characteristics of a potential vaccine candidate, including (i) expression in the tegument, (ii) significant divergence from mammalian brain cytoplasmic dynein, and (iii) a conserved homolog in S. japonicum, we are currently evaluating its immunoprophylactic efficacy.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOL SCI,CTR MONOCLONAL STUDIES,BALTIMORE,MD 21205	Johns Hopkins University				Hoffmann, Karl/0000-0002-3932-5502	NIAID NIH HHS [AI-55270, AI-19217] Funding Source: Medline; NIGMS NIH HHS [5732GM07626] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI019217, R37AI019217] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007626] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRESEN K, 1991, J BIOL CHEM, V266, P15085; BERQUIST NR, 1995, PARASITOL TODAY, V11, P191; BLOOM G S, 1992, Current Opinion in Cell Biology, V4, P66, DOI 10.1016/0955-0674(92)90060-P; CIANFRIGLIA M, 1983, HYBRIDOMA, V2, P451, DOI 10.1089/hyb.1983.2.451; DALTON JP, 1986, J IMMUNOL, V136, P4689; Dick T, 1996, MOL CELL BIOL, V16, P1966; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; FRANCIS P, 1992, MOL BIOCHEM PARASIT, V50, P215, DOI 10.1016/0166-6851(92)90218-9; Harlow E., 1989, ANTIBODIES LAB MANUA; HAWN TR, 1993, J BIOL CHEM, V268, P7692; HAWN TR, 1994, J BIOL CHEM, V269, P20083; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; HOCKLEY D J, 1973, International Journal for Parasitology, V3, P13, DOI 10.1016/0020-7519(73)90004-0; Hoffmann KF, 1996, J BIOL CHEM, V271, P26117, DOI 10.1074/jbc.271.42.26117; Holzbaur Erika L. F., 1994, V13, P251; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; JEFFS SA, 1991, MOL BIOCHEM PARASIT, V46, P159, DOI 10.1016/0166-6851(91)90209-O; KING SM, 1995, J CELL SCI, V108, P3757; KING SM, 1990, CELL MOTIL CYTOSKEL, V16, P266, DOI 10.1002/cm.970160406; King SM, 1996, J BIOL CHEM, V271, P19358, DOI 10.1074/jbc.271.32.19358; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEWIS SA, 1988, THESIS J HOPKINS U; NORDEN AP, 1985, AM J TROP MED HYG, V34, P495, DOI 10.4269/ajtmh.1985.34.495; OAKS JA, 1981, J PARASITOL, V67, P761, DOI 10.2307/3280697; PASCHAL BM, 1992, J CELL BIOL, V118, P1133, DOI 10.1083/jcb.118.5.1133; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; SOISSON LMA, 1992, J IMMUNOL, V149, P3612; STEIN LD, 1986, MOL BIOCHEM PARASIT, V20, P253, DOI 10.1016/0166-6851(86)90106-4; VALLEE R, 1993, P NATL ACAD SCI USA, V90, P8769, DOI 10.1073/pnas.90.19.8769; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; WAINE GJ, 1994, GENE, V142, P259, DOI 10.1016/0378-1119(94)90271-2; Webster M, 1996, INFECT IMMUN, V64, P4042, DOI 10.1128/IAI.64.10.4042-4046.1996	34	39	39	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14509	14515		10.1074/jbc.272.23.14509	http://dx.doi.org/10.1074/jbc.272.23.14509			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169407	hybrid			2022-12-27	WOS:A1997XC32700004
J	Feder, JN; Tsuchihashi, Z; Irrinki, A; Lee, VK; Mapa, FA; Morikang, E; Prass, CE; Starnes, SM; Wolff, RK; Parkkila, S; Sly, WS; Schatzman, RC				Feder, JN; Tsuchihashi, Z; Irrinki, A; Lee, VK; Mapa, FA; Morikang, E; Prass, CE; Starnes, SM; Wolff, RK; Parkkila, S; Sly, WS; Schatzman, RC			The hemochromatosis founder mutation in HLA-H disrupts beta(2)-microglobulin interaction and cell surface expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B ANTIGENS INVIVO; INTRACELLULAR-TRANSPORT; MOLECULES; GENE	We recently reported the positional cloning of a candidate gene for hereditary hemochromatosis (HH), called HLA-H, which is a novel member of the major histocompatibility complex class I family, A mutation in this gene, cysteine 282 --> tyrosine (C282Y), was found to be present in 83% of HH patient DNAs, while a second variant, histidine 63 --> aspartate (H63D), was enriched in patients heterozygous for C282Y, The functional relevance of either mutation has not been described. Co-immunoprecipitation studies of cell lysates from human embryonic kidney cells transfected with wild-type or mutant HLA-H cDNA demonstrate that wild-type HLA-H binds beta(2)-microglobulin and that the C282Y mutation, but not the H63D mutation, completely abrogates this interaction, Immunofluorescence labelling and subcellular fractionations demonstrate that while the wild-type and H63D HLA-H proteins are expressed on the cell surface, the C282Y mutant protein is localized exclusively intracellularly. This report describes the first functional significance of the C282Y mutation by suggesting that an abnormality in protein trafficking and/or cell-surface expression of HLA-H leads to HH disease.	MERCATOR GENET INC,MENLO PK,CA 94025; ST LOUIS UNIV,SCH MED,EDWARD A DOISY DEPT BIOCHEM & MOL BIOL,ST LOUIS,MO 63104	Saint Louis University				Parkkila, Seppo/0000-0001-7323-8536				ARCEGOMEZ B, 1978, TISSUE ANTIGENS, V11, P96, DOI 10.1111/j.1399-0039.1978.tb01233.x; Beutler Ernest, 1996, Blood Cells Molecules and Diseases, V22, P187, DOI 10.1006/bcmd.1996.0027; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; DADONE MM, 1982, AM J CLIN PATHOL, V78, P196, DOI 10.1093/ajcp/78.2.196; DESOUSA M, 1994, IMMUNOL LETT, V39, P105, DOI 10.1016/0165-2478(94)90094-9; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Ford C F, 1991, Protein Expr Purif, V2, P95, DOI 10.1016/1046-5928(91)90057-P; HANSEN TH, 1988, J IMMUNOL, V140, P3522; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; JASWINSKA EC, 1996, NAT GEN, V14, P250; Jouanolle AM, 1996, NAT GENET, V14, P251, DOI 10.1038/ng1196-251; KRANGEL MS, 1979, CELL, V18, P979, DOI 10.1016/0092-8674(79)90210-1; MIYAZAKI JI, 1986, P NATL ACAD SCI USA, V83, P757, DOI 10.1073/pnas.83.3.757; OWEN MJ, 1980, J BIOL CHEM, V255, P9678; PLOEGH HL, 1979, P NATL ACAD SCI USA, V76, P2273, DOI 10.1073/pnas.76.5.2273; PRIVALSKY ML, 1984, VIROLOGY, V135, P356, DOI 10.1016/0042-6822(84)90192-2; Rothenberg BE, 1996, P NATL ACAD SCI USA, V93, P1529, DOI 10.1073/pnas.93.4.1529; SALTER RD, 1994, IMMUNOGENETICS, V39, P266; Santos M, 1996, J EXP MED, V184, P1975, DOI 10.1084/jem.184.5.1975; SEONG RH, 1988, J EXP MED, V167, P288, DOI 10.1084/jem.167.2.288; WILLIAMS DB, 1995, CURR OPIN IMMUNOL, V7, P77, DOI 10.1016/0952-7915(95)80032-8	22	421	434	3	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14025	14028		10.1074/jbc.272.22.14025	http://dx.doi.org/10.1074/jbc.272.22.14025			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162021	hybrid			2022-12-27	WOS:A1997XB49200008
J	Wang, DY; Shin, TH; Kudlow, JE				Wang, DY; Shin, TH; Kudlow, JE			Transcription factor AP-2 controls transcription of the human transforming growth factor-alpha gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTERIOR-PITUITARY GLAND; TRANSGENIC MICE; PHORBOL ESTER; TGF-ALPHA; INDUCIBLE ENHANCER; DISPERSED CELLS; FACTOR RECEPTOR; MESSENGER-RNAS; EXPRESSION; PROMOTER	The epidermal growth factor receptor is vital for normal development and plays a role in oncogenesis, The level of activation of this receptor by transforming growth factor-alpha (TGF-alpha) is controlled, in part, by the rate of transcription of the TGF-alpha gene, In the characterization of the proximal TGF-alpha promoter by DNase I footprinting, a 43-base pair element (-88 to -130 relative to the transcription start site), designated T alpha RE I, was found that was specifically protected by nuclear proteins from human mammary carcinoma MDA468 cells, T alpha RE I was essential for the maximal expression of the TGF-alpha gene as indicated by deletion and mutagenesis analyses, T alpha RE I consists of two cis-acting elements, a proximal regulatory element (PRE, -89 to -103) and a distal regulatory element (DRE, -121 to -128), Both elements were able to form specific complexes with protein from MDA468 cell nuclear extracts and are necessary for the full activity of the entire 1.1-kilobase pair TGF-alpha promoter, Competition and antibody studies determined that the DRE contains a binding site for the transcription factor AP 2, while the protein that binds to the PRE has yet to be identified, When linked upstream to the heterologous herpes simplex thymidine kinase promoter, the T alpha RE I enhanced transcription up to 11-fold in MDA468 cells, Cotransfection of an AP-2 expression vector was able to activate transcription from the T alpha REI-TK construct in a DRE-dependent manner. These results further our understanding of how TGF-alpha transcription is regulated.	UNIV ALABAMA,DEPT MED,DIV ENDOCRINOL & METAB,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT CELL BIOL,DIV ENDOCRINOL & METAB,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043652] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43652] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANZANO MA, 1983, P NATL ACAD SCI-BIOL, V80, P6264, DOI 10.1073/pnas.80.20.6264; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BJORGE JD, 1989, J BIOL CHEM, V264, P4021; BJORGE JD, 1987, J BIOL CHEM, V262, P6615; BLASBAND AJ, 1990, MOL CELL BIOL, V10, P2111, DOI 10.1128/MCB.10.5.2111; BUICK RN, 1987, EXP CELL RES, V170, P300, DOI 10.1016/0014-4827(87)90308-9; CHEN XR, 1992, ONCOGENE, V7, P1805; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; DERYNCK R, 1987, CANCER RES, V47, P707; DYCK JRB, 1995, J BIOL CHEM, V270, P1375, DOI 10.1074/jbc.270.3.1375; HASLINGER A, 1985, P NATL ACAD SCI USA, V82, P8572, DOI 10.1073/pnas.82.24.8572; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JU WD, 1991, NEW BIOL, V3, P380; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; KOBRIN MS, 1987, ENDOCRINOLOGY, V121, P1412, DOI 10.1210/endo-121-4-1412; KUDLOW JE, 1989, J BIOL CHEM, V264, P3880; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LOBB DK, 1989, BIOL REPROD, V40, P1087, DOI 10.1095/biolreprod40.5.1087; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MCANDREW J, 1995, ENDOCRINOLOGY, V136, P4479, DOI 10.1210/en.136.10.4479; MCCLAIN DA, 1992, P NATL ACAD SCI USA, V89, P8150, DOI 10.1073/pnas.89.17.8150; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MUELLER SG, 1989, MOL ENDOCRINOL, V3, P976, DOI 10.1210/mend-3-6-976; MUELLER SG, 1990, MOL CELL BIOL, V10, P4596, DOI 10.1128/MCB.10.9.4596; NISTER M, 1988, CANCER RES, V48, P3910; RAJA RH, 1991, MOL ENDOCRINOL, V5, P514, DOI 10.1210/mend-5-4-514; REISS M, 1991, CANCER RES, V51, P6254; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SAEKI T, 1991, MOL ENDOCRINOL, V5, P1955, DOI 10.1210/mend-5-12-1955; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SHIN TH, 1994, MOL ENDOCRINOL, V8, P704, DOI 10.1210/me.8.6.704; SHIN TH, 1992, MOL CELL BIOL, V12, P3998, DOI 10.1128/MCB.12.9.3998; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; WATANABE S, 1987, P NATL ACAD SCI USA, V84, P1258, DOI 10.1073/pnas.84.5.1258; WILCOX JN, 1988, J NEUROSCI, V8, P1910; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557	51	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14244	14250		10.1074/jbc.272.22.14244	http://dx.doi.org/10.1074/jbc.272.22.14244			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162057	hybrid			2022-12-27	WOS:A1997XB49200044
J	Huang, C; Ni, YS; Wang, T; Gao, YM; Haudenschild, CC; Zhan, X				Huang, C; Ni, YS; Wang, T; Gao, YM; Haudenschild, CC; Zhan, X			Down-regulation of the filamentous actin cross-linking activity of cortactin by src-mediated tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-SRC; F-ACTIN; PH; IDENTIFICATION; CYTOSKELETON; SUBSTRATE; PROTEINS; BINDING; CELLS; ASSOCIATION	Cortactin, a prominent substrate for pp60(c-src), is a filamentous actin (F-actin) binding protein. We show here that cortactin can promote sedimentation of F-actin at centrifugation forces under which F-actin is otherwise not able to be precipitated. Electron microscopic analysis after negative staining further revealed that actin filaments in the presence of cortactin are cross-linked into bundles of various degrees of thickness. Hence, cortactin is also an F-actin cross-linking protein. We also demonstrate that the optimal F-actin cross-linking activity of cortactin requires a physiological pH in a range of 7.3-7.5. Furthermore, pp60(c-src) phosphorylates cortactin in vitro, resulting in a dramatic reduction of its F-actin cross-linking activity in a manner depending on levels of tyrosine phosphorylation, In addition, pp60(c-src) moderately inhibits the F-actin binding activity of cortactin. This study presents the first evidence that pp60(c-src) can directly regulate the activity of its substrate toward the cytoskeleton and implies a role of cortactin as an F-actin modulator in tyrosine kinase-regulated cytoskeleton reorganization.	AMER RED CROSS,JEROME H HOLLAND LAB,DEPT EXPT PATHOL,ROCKVILLE,MD 20855; GLAXO INC,RES INST,DIV BIOL,RES TRIANGLE PK,NC 27709; GEORGE WASHINGTON UNIV,DEPT PATHOL,WASHINGTON,DC 20037; GEORGE WASHINGTON UNIV,DEPT ANAT & CELL BIOL,WASHINGTON,DC 20037	American Red Cross; GlaxoSmithKline; George Washington University; George Washington University			Christian, Haudenschild C/D-1602-2009		NHLBI NIH HHS [R29 HL52753] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL052753] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; Bringuier PP, 1996, ONCOGENE, V12, P1747; BROTSCHI EA, 1978, J BIOL CHEM, V253, P8988; CONDEELIS J, 1982, J CELL BIOL, V94, P466, DOI 10.1083/jcb.94.2.466; DEHIO C, 1995, EMBO J, V14, P2471, DOI 10.1002/j.1460-2075.1995.tb07244.x; DUIJN BV, 1991, P NATL ACAD SCI USA, V88, P4951; EDMONDS BT, 1995, J BIOL CHEM, V270, P15222, DOI 10.1074/jbc.270.25.15222; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu MY, 1996, J BIOL CHEM, V271, P7066, DOI 10.1074/jbc.271.12.7066; MAA MC, 1992, ONCOGENE, V7, P2429; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; NADA S, 1994, ONCOGENE, V9, P3571; OHSATO Y, 1994, JPN J CANCER RES, V85, P1023, DOI 10.1111/j.1349-7006.1994.tb02900.x; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; RICHERT ND, 1982, J BIOL CHEM, V257, P7143; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SIMCHOWITZ L, 1986, J BIOL CHEM, V261, P6492; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Vexler ZS, 1996, J BIOL CHEM, V271, P22281, DOI 10.1074/jbc.271.37.22281; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WONG S, 1992, ONCOGENE, V7, P2407; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1414; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1993, J BIOL CHEM, V268, P9611; ZHAN X, 1994, J BIOL CHEM, V269, P20221; Zhang JW, 1996, BIOCHEM BIOPH RES CO, V218, P530, DOI 10.1006/bbrc.1996.0095	30	216	219	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13911	13915		10.1074/jbc.272.21.13911	http://dx.doi.org/10.1074/jbc.272.21.13911			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153252	hybrid			2022-12-27	WOS:A1997XA06200067
J	Finn, JP; Edwards, RH				Finn, JP; Edwards, RH			Individual residues contribute to multiple differences in ligand recognition between vesicular monoamine transporters 1 and 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMAFFIN GRANULES; RESERPINE BINDING; AMINE TRANSPORTER; NEUROTRANSMITTER TRANSPORTERS; DIHYDROTETRABENAZINE BINDING; LOCALIZATION; EXPRESSION; INHIBITORS; CLONING; CDNA	Molecular cloning has identified two vesicular monoamine transporters (VMATs), one expressed in non-neural cells of the periphery (VMAT1) and the other by multiple monoamine cell populations in the brain (VMAT2), Functional analysis has previously shown that VMAT2 has a higher affinity than VMAT1 for monoamine neurotransmitters as well as the inhibitor tetrabenazine, The analysis of chimeric transporters has also identified two major regions required for the high affinity interactions of VMAT2 with these ligands, We have now used site-directed mutagenesis to identify the individual residues responsible for these differences, Focusing on the region that spans transmembrane domains 9 through 12, we have replaced VMAT2 residues with the corresponding residues from VMAT1, Many residues in this region had no effect on the recognition of these ligands, but substitution of Tyr-434 with Phe and Asp-461 with Asn reduced the affinity for tetrabenazine, histamine, and serotonin, Although the ability to affect recognition of multiple ligands suggests a general structural role for these residues, the mutations did not affect dopamine recognition, indicating a more specific role, possibly in recognition of the ring nitrogen that occurs in tetrabenazine, histamine, and serotonin but not dopamine, The mutation K446Q reduced the affinity of VMATB for tetrabenazine and serotonin but not histamine, whereas F464Y reduced serotonin affinity and perhaps histamine recognition but not tetrabenazine sensitivity, providing more evidence for specificity, Interestingly, the V-max of both VMATs for dopamine exceeded that for serotonin by 3-5-fold, indicating a difference in the speed of packaging of these two neurotransmitters, We also found that VMAT1 has a higher affinity for tryptamine than VMAT2, This mutually exclusive interaction with serotonin and tryptamine also suggests a physiological rationale for the existence of two VMATs, Surprisingly, the residue responsible for this difference, Tyr-434, also accounts for the higher affinity interaction of VMAT2 with tetrabenazine, histamine, and serotonin, Interestingly, replacement of Tyr-434 with alanine increases the affinity of VMATB for both serotonin and dopamine and reduces the rate of dopamine transport.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT NEUROL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MICROBIOL & IMMUNOL, LOS ANGELES, CA 90024 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; COHEN G, 1990, J NEUR TR S, P229; DARCHEN F, 1989, BIOCHEMISTRY-US, V28, P1692, DOI 10.1021/bi00430a040; Edwards R H, 1992, Curr Opin Neurobiol, V2, P586, DOI 10.1016/0959-4388(92)90023-E; Erickson JD, 1996, P NATL ACAD SCI USA, V93, P5166, DOI 10.1073/pnas.93.10.5166; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; HOWELL M, 1994, FEBS LETT, V338, P16, DOI 10.1016/0014-5793(94)80108-8; JOHNSON RG, 1988, PHYSIOL REV, V68, P232, DOI 10.1152/physrev.1988.68.1.232; KANNER BI, 1994, J EXP BIOL, V196, P237; KNOTH J, 1981, BIOCHEMISTRY-US, V20, P6625, DOI 10.1021/bi00526a016; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LIU Y, 1992, P NATL ACAD SCI USA, V89, P9074, DOI 10.1073/pnas.89.19.9074; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; MERICKEL A, 1995, NEUROPHARMACOLOGY, V34, P1543, DOI 10.1016/0028-3908(95)00148-Y; Peter D, 1996, J BIOL CHEM, V271, P2979, DOI 10.1074/jbc.271.6.2979; PETER D, 1993, GENOMICS, V18, P720, DOI 10.1016/S0888-7543(05)80383-0; PETER D, 1994, J BIOL CHEM, V269, P7231; PETER D, 1995, J NEUROSCI, V15, P6179; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERMAN D, 1986, J NEUROCHEM, V47, P331; SCHERMAN D, 1984, MOL PHARMACOL, V25, P113; SCHULDINER S, 1993, J BIOL CHEM, V268, P29; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; SURRATT CK, 1993, FEBS LETT, V318, P325, DOI 10.1016/0014-5793(93)80539-7; WEAVER JA, 1982, EUR J PHARMACOL, V80, P437, DOI 10.1016/0014-2999(82)90093-0; WEIHE E, 1994, J MOL NEUROSCI, V5, P149, DOI 10.1007/BF02736730	26	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16301	16307		10.1074/jbc.272.26.16301	http://dx.doi.org/10.1074/jbc.272.26.16301			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195934	hybrid			2022-12-27	WOS:A1997XG01900038
J	Orita, S; Naito, A; Sakaguchi, G; Maeda, M; Igarashi, H; Sasaki, T; Takai, Y				Orita, S; Naito, A; Sakaguchi, G; Maeda, M; Igarashi, H; Sasaki, T; Takai, Y			Physical and functional interactions of Doc2 and Munc13 in Ca2+-dependent exocytotic machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN GROWTH-HORMONE; CAENORHABDITIS-ELEGANS; UNC-13 GENE; BINDING; EXPRESSION; COMPLEX; REGION	Doc2 has two C2 domains that interact with Ca2+ and phospholipid. Munc13 has two C2 domains and one C1 domain that interacts with phorbol ester or diacylglycerol (DAG) and phospholipid. Both Doca and Munc13 are implicated in Ca2+-dependent neurotransmitter release, but their modes of action still remain unclear. We show here that Doc2 interacts with Munc13 both in a cell-free system and in intact PC12 cells during the high K+-induced Ca2+-dependent exocytosis. The Doc2-Munc13 interactions are stimulated by phorbol ester through the C1 domain of Munc13. Overexpression of the Doc2-interacting domain of Munc13 reduces the Ca2+-dependent exocytosis from PC12 cells, and co expression with Doc2 suppresses this reduction. These results, together with the earlier findings that secretagogues produce DAG and elevate cytoplasmic Ca2+, suggest that the DAG-induced Doc2-Munc13 interactions play an important role in Ca2+-dependent exocytotic machinery.	OSAKA UNIV,SCH MED,DEPT MOL BIOL & BIOCHEM,SUITA,OSAKA 565,JAPAN; SHIONOGI INST MED SCI,SETTSU 566,JAPAN	Osaka University; Shionogi & Company Limited								Betz A, 1997, J BIOL CHEM, V272, P2520; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; Gillis KD, 1996, NEURON, V16, P1209, DOI 10.1016/S0896-6273(00)80147-6; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HOSONO R, 1991, NEUROSCI LETT, V128, P243, DOI 10.1016/0304-3940(91)90270-4; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P10777, DOI 10.1074/jbc.270.18.10777; Komuro R, 1996, GENES CELLS, V1, P943, DOI 10.1046/j.1365-2443.1996.760276.x; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; Miller J.H., 1972, EXPT MOL GENETICS; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Naito A, 1997, MOL BRAIN RES, V44, P198, DOI 10.1016/S0169-328X(96)00198-2; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; ORITA S, 1995, BIOCHEM BIOPH RES CO, V206, P439, DOI 10.1006/bbrc.1995.1062; Orita S, 1996, J BIOL CHEM, V271, P7257, DOI 10.1074/jbc.271.13.7257; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SAKAGUCHI G, 1995, BIOCHEM BIOPH RES CO, V217, P1253; SCHWEITZER ES, 1985, J CELL BIOL, V101, P667, DOI 10.1083/jcb.101.2.667; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAKADE TD, 1991, J BIOL CHEM, V266, P6424; WICK PF, 1993, J BIOL CHEM, V268, P10983	27	115	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16081	16084		10.1074/jbc.272.26.16081	http://dx.doi.org/10.1074/jbc.272.26.16081			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195900	hybrid			2022-12-27	WOS:A1997XG01900004
J	Sethi, JK; Empson, RM; Bailey, VC; Potter, BVL; Galione, A				Sethi, JK; Empson, RM; Bailey, VC; Potter, BVL; Galione, A			7-deaza-8-bromo-cyclic ADP-ribose, the first membrane-permeant, hydrolysis-resistant cyclic ADP-ribose antagonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; INDUCED CA2+ RELEASE; SEA-URCHIN EGGS; RYANODINE RECEPTOR; CALCIUM-RELEASE; FERTILIZATION; METABOLITE; TUBERCIDIN; TISSUES; CELLS	Cyclic ADP-ribose (cADPR) is a putative second messenger that has been demonstrated to mobilize Ca2+ in many cell types. Its postulated role as the endogenous regulator of ryanodine-sensitive Ca2+ release channels has been greatly supported by the advent and use of specific cADPR receptor antagonists such as 8-NH2-cADPR (Walseth, T. F., and Lee, H. C. (1993) Biochim. Biophys. Acta 1178, 235-242), However, investigations of the role of cADPR in physiological responses, such as fertilization, stimulus-secretion coupling, and excitation-contraction coupling, have been hindered by the susceptibility of cADPR receptor antagonists to hydrolysis and the need to introduce these molecules into cells by microinjection or patch clamp techniques. We have recently reported on the discovery of a poorly hydrolyzable analogue of cADPR, 7-deaza-cADPR (Bailey, V. C., Sethi, J. K., Fortt, S. M., Galione, A., and Potter, B. V. L. (1997) Chem. Biol. 4, 41-51) but this, like cADPR, is an agonist of ryanodine-sensitive Ca2+ release channels. We therefore explored the possibility of combining antagonistic activity with that of hydrolytic resistance and now report on the biological properties of the first hydrolysis-resistant cADPR receptor antagonist, 7-deaza-8-bromo-cADPR. In addition this compound has the advantage of being membrane-permeable. Together these properties make this hybrid molecule the most powerful tool to date for studying cADPR-mediated Ca2+ signaling in intact cells.	UNIV OXFORD,DEPT PHARMACOL,OXFORD OX1 3QT,ENGLAND; UNIV BATH,SCH PHARM & PHARMACOL,DEPT MED CHEM,BATH BA2 7AY,AVON,ENGLAND	University of Oxford; University of Bath			Potter, Barry VL/A-1845-2012; Potter, Barry/AAX-4781-2020; Sethi, Jaswinder K./B-1413-2008	Sethi, Jaswinder K./0000-0003-4157-0475; Galione, Antony/0000-0002-4132-7646; Empson, Ruth/0000-0002-0415-6083	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLEN GJ, 1995, SCIENCE, V268, P735, DOI 10.1126/science.7732384; ASHAMU GA, 1995, J CHEM SOC CHEM COMM, P1359, DOI 10.1039/c39950001359; BAILEY VC, 1997, J CHEM SOC CHEM COMM, V7, P695; BAILEY VC, 1997, CHEM BIOL, V4, P41; BERGSTROM DE, 1980, NUCLEIC ACIDS RES, V8, P6213, DOI 10.1093/nar/8.24.6213; BUTT E, 1992, BIOCHEM PHARMACOL, V43, P2591, DOI 10.1016/0006-2952(92)90148-C; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; Clementi E, 1996, J BIOL CHEM, V271, P17739, DOI 10.1074/jbc.271.30.17739; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GALIONE A, 1996, RYANODINE RECEPTORS, P51; Galione A, 1996, BIOCH SMOOTH MUSCLE; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; GUSE AH, 1995, J IMMUNOL, V155, P3353; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; JI LN, 1991, J CHEM SOC DALTON, P1367, DOI 10.1039/dt9910001367; KIM H, 1993, BIOCHEM BIOPH RES CO, V194, P1143, DOI 10.1006/bbrc.1993.1941; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LINDEN DJ, 1995, J NEUROSCI, V15, P5098; MAHANTY NK, 1995, SOC NEUR ABSTR, V21, P1806; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; PIKE JE, 1964, J HETEROCYCLIC CHEM, V1, P159; Rakovic S, 1996, CURR BIOL, V6, P989, DOI 10.1016/S0960-9822(02)00643-7; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; SARDET C, 1987, CELL DIFFER DEV, V21, P1, DOI 10.1016/0045-6039(87)90443-X; SASAKI H, 1984, DEV BIOL, V101, P125, DOI 10.1016/0012-1606(84)90123-4; Sethi JK, 1996, BIOCHEM J, V319, P613, DOI 10.1042/bj3190613; SITSAPESAN R, 1995, TRENDS PHARMACOL SCI, V16, P386, DOI 10.1016/S0165-6147(00)89080-X; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WALSETH TF, 1993, J BIOL CHEM, V268, P26686; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; Willmott N, 1996, J BIOL CHEM, V271, P3699; WILLMOTT NJ, 1995, CELL CALCIUM, V18, P411, DOI 10.1016/0143-4160(95)90056-X; YOSHIKAWA M, 1969, B CHEM SOC JPN, V42, P3505, DOI 10.1246/bcsj.42.3505	36	71	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16358	16363		10.1074/jbc.272.26.16358	http://dx.doi.org/10.1074/jbc.272.26.16358			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195942	hybrid			2022-12-27	WOS:A1997XG01900046
J	Nakamura, N; Inoue, N; Watanabe, R; Takahaski, M; Takeda, J; Stevens, VL; Kinoshita, T				Nakamura, N; Inoue, N; Watanabe, R; Takahaski, M; Takeda, J; Stevens, VL; Kinoshita, T			Expression cloning of PIG-L, a candidate N-acetylglucosaminylphosphatidylinositol deacetylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHOR BIOSYNTHESIS; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; DECAY-ACCELERATING FACTOR; HAMSTER OVARY CELLS; GPI-ANCHOR; ENDOPLASMIC-RETICULUM; MOLECULAR-CLONING; MAMMALIAN-CELLS; CLASS-H; PHOSPHATIDYLINOSITOL	Many eukaryotic cell surface proteins are bound to the cell membrane by a glycosylphosphatidylinositol (GPT) anchor. Several genes involved in GPT anchor biosynthesis have been cloned using complementation of mutant mammalian cell lines and yeasts that are defective in its biosynthesis pathway. However, the gene involved in the second step of this pathway, in which N-acetylglucosaminyl-phosphatidylinositol (GlcNAc-PI) is N-deacetylated to form glucosaminyl (GlcN)-PI, has not been cloned, In this study, we established a GPI anchor-deficient mutant of Chinese hamster ovary (CHO) cells defective in the second step. Complementation analysis with the known GPI anchor mutant cells demonstrated that it belonged to the same complementation group as the CHO cell mutant G9PLAP.85. Using the new mutant, me cloned a rat gene termed PIG-L (for phosphatidylinositol glycan class (L) under bar) that is involved in this step, PIG-L encodes a 252-amino acid, endoplasmic reticulum membrane protein, most of which is ill the cytoplasmic side. This orientation of PIG-L protein is consistent with the notion that the second step of GPI anchor biosynthesis occurs on the cytoplasmic side of the endoplasmic reticulum.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT IMMUNOREGULAT,SUITA,OSAKA 565,JAPAN; EMORY UNIV,SCH MED,DEPT RADIAT ONCOL,DIV CANC BIOL,ATLANTA,GA 30335; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30335	Osaka University; Emory University; Emory University			Takahashi, Minoru/G-4748-2011; Kinoshita, Taroh/C-7353-2009	Watanabe, Reika/0000-0002-7427-7702	NIGMS NIH HHS [GM51419] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051419] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BENGHEZAL M, 1995, J CELL BIOL, V130, P1333, DOI 10.1083/jcb.130.6.1333; BLATTNER FR, 1993, NUCLEIC ACIDS RES, V21, P5408; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; BOYEN A, 1992, GENE, V116, P1, DOI 10.1016/0378-1119(92)90621-U; CAMP LA, 1993, J BIOL CHEM, V268, P6721; CARAS IW, 1987, NATURE, V325, P545, DOI 10.1038/325545a0; Chen R, 1996, P NATL ACAD SCI USA, V93, P2280, DOI 10.1073/pnas.93.6.2280; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; DEGASPERI R, 1990, SCIENCE, V250, P988, DOI 10.1126/science.1978413; DELUCA AW, 1994, GLYCOBIOLOGY, V4, P909, DOI 10.1093/glycob/4.6.909; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; FINNEGAN PM, 1991, CURR GENET, V20, P53, DOI 10.1007/BF00312765; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; HAMBURGER D, 1995, J CELL BIOL, V129, P629, DOI 10.1083/jcb.129.3.629; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HYMAN R, 1988, TRENDS GENET, V4, P5, DOI 10.1016/0168-9525(88)90120-5; INOUE N, 1993, J BIOL CHEM, V268, P6882; Inoue N, 1996, BIOCHEM BIOPH RES CO, V226, P193, DOI 10.1006/bbrc.1996.1332; JAT P, 1982, MOL CELL BIOL, V2, P737, DOI 10.1128/MCB.2.7.737; KAMITANI T, 1993, J BIOL CHEM, V268, P20733; Kawagoe K, 1996, BLOOD, V87, P3600, DOI 10.1182/blood.V87.9.3600.bloodjournal8793600; KINOSHITA T, 1995, METHOD ENZYMOL, V250, P547; KINOSHITA T, 1985, J EXP MED, V162, P75, DOI 10.1084/jem.162.1.75; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEHRMAN MA, 1989, J BIOL CHEM, V264, P1584; MAXWELL SE, 1995, J BIOL CHEM, V270, P19576, DOI 10.1074/jbc.270.33.19576; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MEINNEL T, 1992, J BACTERIOL, V174, P2323, DOI 10.1128/JB.174.7.2323-2331.1992; MENON AK, 1992, J BIOL CHEM, V267, P15277; MENON AK, 1993, EMBO J, V12, P1907, DOI 10.1002/j.1460-2075.1993.tb05839.x; MILNE KG, 1994, J BIOL CHEM, V269, P16403; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; MOHNEY RP, 1994, J BIOL CHEM, V269, P6536; OHISHI N, 1996, GENOMICS, V34, P340; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PLUMBRIDGE JA, 1989, MOL MICROBIOL, V3, P505, DOI 10.1111/j.1365-2958.1989.tb00197.x; PUOTI A, 1993, J BIOL CHEM, V268, P7215; PUOTI A, 1991, J BIOL CHEM, V266, P21051; Smith TK, 1996, J BIOL CHEM, V271, P6476, DOI 10.1074/jbc.271.11.6476; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; STEVENS VL, 1993, J BIOL CHEM, V268, P9718; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; STEVENS VL, 1995, BIOCHEM J, V310, P361, DOI 10.1042/bj3100361; Stevens VL, 1996, BIOCHEM J, V313, P253, DOI 10.1042/bj3130253; SUGITA Y, 1989, J BIOCHEM-TOKYO, V106, P555, DOI 10.1093/oxfordjournals.jbchem.a122893; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; TAJKABASHI M, 1996, EMBO J, V15, P4254; TAKAHASHI M, 1993, J EXP MED, V177, P517, DOI 10.1084/jem.177.2.517; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; URAKAZE M, 1992, J BIOL CHEM, V267, P6459; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987; VIDUGIRIENE J, 1994, J CELL BIOL, V127, P333, DOI 10.1083/jcb.127.2.333; Watanabe R, 1996, J BIOL CHEM, V271, P26868, DOI 10.1074/jbc.271.43.26868; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	58	122	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15834	15840		10.1074/jbc.272.25.15834	http://dx.doi.org/10.1074/jbc.272.25.15834			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188481	hybrid			2022-12-27	WOS:A1997XF32900041
J	Bennett, BJ; Mohandas, N; Coppel, RL				Bennett, BJ; Mohandas, N; Coppel, RL			Defining the minimal domain of the Plasmodium falciparum protein MESA involved in the interaction with the red cell membrane skeletal protein 4.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE SURFACE-ANTIGEN; INFECTED ERYTHROCYTES; BLOOD-CELL; MALARIA PARASITES; BINDING DOMAIN; SPECTRIN; CYTOADHERENCE; ASSOCIATION; MODULATION; BAND-4.1	During part of its life cycle, the protozoan parasite Plasmodium falciparum lives within the human red blood cell and modifies both the structural and functional properties of the red cell. It does this by synthesizing a number of polypeptides that it transports into the red cell cytoplasm and to the red cell membrane. One of these transported proteins, MESA (mature parasite-infected erythrocyte Surface antigen), is anchored to the red cell membrane by noncovalent interaction with erythrocyte protein 4.1. We have utilized a combination of in vitro transcription and translation and a membrane binding assay to identify the protein sequence involved in anchoring MESA to the membrane. Labeled fragments of different regions of the MESA protein were evaluated for their ability to bind to inside-out vesicle membrane preparations of human red cells. Binding was dependent on the presence of red cell membrane proteins and was abolished either by trypsin treatment or by selective depletion of membrane proteins. Binding was specific and could be inhibited by the addition of competing protein, with an IC,, of (6.3 +/- 1.2) x 10(-7) M, indicative of a moderate affinity interaction. Fractionation studies demonstrated that binding fragments interacted most efficiently with membrane protein fractions that had been enriched in protein 4.1. Binding inhibition experiments using synthetic peptides identified the binding domain of MESA for protein 4.1 as a 19-residue sequence near the amino terminus of MESA, a region capable of forming an amphipathic helix.	MONASH UNIV,DEPT MICROBIOL,CLAYTON,VIC 3168,AUSTRALIA; WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA; UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV LIFE SCI,BERKELEY,CA 94720; MONASH UNIV,DEPT MICROBIOL,CLAYTON,VIC 3168,AUSTRALIA	Monash University; Walter & Eliza Hall Institute; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Monash University			Coppel, Ross L/A-6626-2008	Coppel, Ross L/0000-0002-4476-9124	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK032094] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32094-10] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIKAWA M, 1977, J PARASITOL, V63, P152, DOI 10.2307/3280126; AIKAWA M, 1983, CIBA F SYMP, V94, P45; ANCELIN ML, 1991, BIOCHEM J, V273, P701, DOI 10.1042/bj2730701; ANDERS RF, 1988, PROG ALLERGY, V41, P148; BENNETT V, 1985, ANNU REV BIOCHEM, V54, P273, DOI 10.1146/annurev.biochem.54.1.273; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; CABANTCHIK ZI, 1989, BLOOD, V74, P1464; CARR DW, 1992, J BIOL CHEM, V267, P13376; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; CHASIS JA, 1992, BLOOD, V80, P1869; CONBOY JG, 1993, SEMIN HEMATOL, V30, P58; COOKE BM, 1995, PARASITOL TODAY, V11, P282, DOI 10.1016/0169-4758(95)80040-9; COPPEL RL, 1986, MOL BIOCHEM PARASIT, V20, P265, DOI 10.1016/0166-6851(86)90107-6; COPPEL RL, 1988, MOL BIOCHEM PARASIT, V31, P223, DOI 10.1016/0166-6851(88)90152-1; COPPEL RL, 1992, MOL BIOCHEM PARASIT, V50, P335, DOI 10.1016/0166-6851(92)90231-8; DAVID PH, 1983, P NATL ACAD SCI-BIOL, V80, P5075, DOI 10.1073/pnas.80.16.5075; FOLEY M, 1994, EXP PARASITOL, V79, P340, DOI 10.1006/expr.1994.1096; FOLEY M, 1995, PARASITOL TODAY, V11, P436, DOI 10.1016/0169-4758(95)80032-8; Gardner K, 1989, RED BLOOD CELL MEMBR, P1; GERO AM, 1991, ADV EXP MED BIOL, V309, P169; GERO AM, 1994, PARASITOL TODAY, V10, P395, DOI 10.1016/0169-4758(94)90231-3; GRUENBERG J, 1983, J CELL BIOL, V97, P795, DOI 10.1083/jcb.97.3.795; HALDAR K, 1994, PARASITOL TODAY, V10, P393, DOI 10.1016/0169-4758(94)90230-5; HERRERA S, 1993, EMBO J, V12, P1607, DOI 10.1002/j.1460-2075.1993.tb05805.x; HOLLINGDALE MR, 1984, J IMMUNOL, V132, P909; HOMMEL M, 1983, J EXP MED, V157, P1137, DOI 10.1084/jem.157.4.1137; HOWARD RF, 1988, GENE, V64, P65, DOI 10.1016/0378-1119(88)90481-7; HOWARD RJ, 1988, PROG ALLERGY, V41, P98; HOWARD RJ, 1988, MOL BIOCHEM PARASIT, V27, P207, DOI 10.1016/0166-6851(88)90040-0; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KEMP DJ, 1987, ANNU REV MICROBIOL, V41, P181, DOI 10.1146/annurev.mi.41.100187.001145; KILEJIAN A, 1991, MOL BIOCHEM PARASIT, V44, P175, DOI 10.1016/0166-6851(91)90003-O; LING E, 1988, J BIOL CHEM, V263, P2209; LUSTIGMAN S, 1990, MOL BIOCHEM PARASIT, V38, P261, DOI 10.1016/0166-6851(90)90029-L; MAGOWAN C, 1995, BLOOD, V86, P3196; MANNO S, 1995, J BIOL CHEM, V270, P5659, DOI 10.1074/jbc.270.10.5659; MARCHESI VT, 1985, ANNU REV CELL BIOL, V1, P531, DOI 10.1146/annurev.cellbio.1.1.531; MOHANDAS N, 1993, SEMIN HEMATOL, V30, P171; MOHANDAS N, 1992, BIOCHEM SOC T, V20, P776, DOI 10.1042/bst0200776; MOHANDAS N, 1984, BLOOD, V63, P1385; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; PASLOSKE BL, 1994, ANNU REV MED, V45, P283; PETERSEN C, 1989, MOL BIOCHEM PARASIT, V36, P61, DOI 10.1016/0166-6851(89)90200-4; PODGORSKI A, 1985, BIOCHEMISTRY-US, V24, P7871, DOI 10.1021/bi00348a004; POLLACK S, 1984, BRIT J HAEMATOL, V58, P289, DOI 10.1111/j.1365-2141.1984.tb06087.x; ROBERTS DJ, 1993, PARASITOL TODAY, V9, P281, DOI 10.1016/0169-4758(93)90121-U; SCHOFIELD L, 1991, PARASITOL TODAY, V7, P99, DOI 10.1016/0169-4758(91)90166-L; SCHULMAN S, 1990, P NATL ACAD SCI USA, V87, P7339, DOI 10.1073/pnas.87.18.7339; SEGREST JP, 1992, J LIPID RES, V33, P141; SHERMAN IW, 1985, PARASITOLOGY, V91, P609, DOI 10.1017/S0031182000062843; SHERMAN IW, 1992, BIOL CELL, V74, P161, DOI 10.1016/0248-4900(92)90022-S; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VIAL HJ, 1990, BLOOD CELLS, V16, P559; VUISTER GW, 1994, NAT STRUCT BIOL, V1, P605, DOI 10.1038/nsb0994-605	54	49	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15299	15306		10.1074/jbc.272.24.15299	http://dx.doi.org/10.1074/jbc.272.24.15299			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182557	hybrid			2022-12-27	WOS:A1997XE03400040
J	Chan, SN; Harris, L; Bolt, EL; Whitby, MC; Lloyd, RG				Chan, SN; Harris, L; Bolt, EL; Whitby, MC; Lloyd, RG			Sequence specificity and biochemical characterization of the RusA Holliday junction resolvase of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA BRANCH MIGRATION; ENDONUCLEASE-VII; RUVC PROTEIN; SACCHAROMYCES-CEREVISIAE; IN-VITRO; GENETIC-RECOMBINATION; CLEAVAGE SPECIFICITY; GENE-3 ENDONUCLEASE; RECG PROTEIN; RESOLUTION	The RusA protein of Escherichia coli is an endonuclease that resolves Holliday intermediates in recombination and DNA repair. Analysis of its subunit structure revealed that the native protein is a dimer. Its resolution activity was investigated using synthetic X-junctions with homologous cores. Resolution occurs by dual strand incision predominantly 5' of CC dinucleotides located symmetrically. A junction lacking homology is not resolved. The efficiency of resolution is related inversely to the number of base pairs in the homologous core, which suggests that branch migration is rate-limiting. Inhibition of resolution at high ratios of protein to DNA suggests that binding of RusA may immobilize the junction point at non-cleavable sites. Resolution is stimulated by alkaline pH and by Mn2+. The protein is unstable in the absence of substrate DNA and loses similar to 80% of its activity within 1 min under standard reaction conditions. DNA binding stabilizes the activity. Junction resolution is inhibited in the presence of RuvA. This observation probably explains why RusA is unable to promote efficient recombination and DNA repair in ruvA(+) strains unless it is expressed at a high level.	UNIV NOTTINGHAM,DEPT GENET,QUEENS MED CTR,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham				Whitby, Matthew/0000-0003-0951-3374; Bolt, Edward/0000-0002-5656-7706				ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; Bennett RJ, 1996, P NATL ACAD SCI USA, V93, P12217, DOI 10.1073/pnas.93.22.12217; BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; BENNETT RJ, 1995, P NATL ACAD SCI USA, V92, P5635, DOI 10.1073/pnas.92.12.5635; BENNETT RJ, 1995, J MOL BIOL, V252, P213, DOI 10.1006/jmbi.1995.0489; BENSON FE, 1994, J BIOL CHEM, V269, P5195; CHURCHILL MEA, 1988, P NATL ACAD SCI USA, V85, P4653, DOI 10.1073/pnas.85.13.4653; CONNOLLY B, 1991, P NATL ACAD SCI USA, V88, P6063, DOI 10.1073/pnas.88.14.6063; DEMASSY B, 1987, J MOL BIOL, V193, P359, DOI 10.1016/0022-2836(87)90224-5; DEMASSY B, 1984, COLD SPRING HARB SYM, V49, P715, DOI 10.1101/SQB.1984.049.01.081; DUCKETT DR, 1990, EMBO J, V9, P583, DOI 10.1002/j.1460-2075.1990.tb08146.x; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; DUNDERDALE HJ, 1994, J BIOL CHEM, V269, P5187; ELBOROUGH KM, 1990, EMBO J, V9, P2931, DOI 10.1002/j.1460-2075.1990.tb07484.x; HYDE H, 1994, J BIOL CHEM, V269, P5202; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; JENSCH F, 1986, EMBO J, V5, P181, DOI 10.1002/j.1460-2075.1986.tb04194.x; KEMPER B, 1981, EUR J BIOCHEM, V115, P123; KEMPER B, 1990, STRUCTURE METHODS, V1, P215; KLEFF S, 1988, EMBO J, V7, P1527, DOI 10.1002/j.1460-2075.1988.tb02972.x; LILLEY DMJ, 1984, CELL, V36, P413, DOI 10.1016/0092-8674(84)90234-4; LILLEY DMJ, 1993, ANNU REV BIOPH BIOM, V22, P299, DOI 10.1146/annurev.bb.22.060193.001503; LLOYD RG, 1993, EMBO J, V12, P17, DOI 10.1002/j.1460-2075.1993.tb05627.x; Mahdi AA, 1996, J MOL BIOL, V257, P561, DOI 10.1006/jmbi.1996.0185; MANDAL TN, 1993, J BACTERIOL, V175, P4325, DOI 10.1128/JB.175.14.4325-4334.1993; MIZUUCHI K, 1982, CELL, V29, P357, DOI 10.1016/0092-8674(82)90152-0; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; PANYUTIN IG, 1995, EMBO J, V14, P1819, DOI 10.1002/j.1460-2075.1995.tb07170.x; PARSONS CA, 1990, J BIOL CHEM, V265, P9285; PARSONS CA, 1995, NATURE, V374, P375, DOI 10.1038/374375a0; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; PICKSLEY SM, 1990, J MOL BIOL, V212, P723, DOI 10.1016/0022-2836(90)90233-C; Pohler JRG, 1996, J MOL BIOL, V260, P678; Rafferty JB, 1996, SCIENCE, V274, P415, DOI 10.1126/science.274.5286.415; SAITO A, 1995, P NATL ACAD SCI USA, V92, P7470, DOI 10.1073/pnas.92.16.7470; Sambrook J., 2002, MOL CLONING LAB MANU; SEEMAN NC, 1994, ANNU REV BIOPH BIOM, V23, P53, DOI 10.1146/annurev.bb.23.060194.000413; SHAH R, 1994, NUCLEIC ACIDS RES, V22, P2490, DOI 10.1093/nar/22.13.2490; Shah R, 1997, EMBO J, V16, P1464, DOI 10.1093/emboj/16.6.1464; SHAH R, 1994, CELL, V79, P853, DOI 10.1016/0092-8674(94)90074-4; SHARPLES GJ, 1994, EMBO J, V13, P6133, DOI 10.1002/j.1460-2075.1994.tb06960.x; Shida T, 1996, J BIOL CHEM, V271, P26105, DOI 10.1074/jbc.271.42.26105; SOLARO PC, 1993, J MOL BIOL, V230, P868, DOI 10.1006/jmbi.1993.1207; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SYMINGTON LS, 1985, P NATL ACAD SCI USA, V82, P7247, DOI 10.1073/pnas.82.21.7247; TAKAHAGI M, 1994, J BIOL CHEM, V269, P15132; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; West SC, 1996, J BACTERIOL, V178, P1237, DOI 10.1128/jb.178.5.1237-1241.1996; WEST SC, 1987, J BIOL CHEM, V262, P12752; WEST SC, 1985, P NATL ACAD SCI USA, V82, P6445, DOI 10.1073/pnas.82.19.6445; WHITBY MC, 1993, CELL, V75, P341, DOI 10.1016/0092-8674(93)80075-P; Whitby MC, 1996, J MOL BIOL, V264, P878, DOI 10.1006/jmbi.1996.0684; White MF, 1996, J MOL BIOL, V257, P330, DOI 10.1006/jmbi.1996.0166; Yu X, 1997, J MOL BIOL, V266, P217, DOI 10.1006/jmbi.1996.0799	56	59	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14873	14882		10.1074/jbc.272.23.14873	http://dx.doi.org/10.1074/jbc.272.23.14873			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169457	hybrid			2022-12-27	WOS:A1997XC32700054
J	Hartmann, H; Busciglio, J; Baumann, KH; Staufenbiel, M; Yankner, BA				Hartmann, H; Busciglio, J; Baumann, KH; Staufenbiel, M; Yankner, BA			Developmental regulation of presenilin-1 processing in the brain suggests a role in neuronal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; GENE	Most cases of early-onset familial Alzheimer's disease are caused by mutations in the presenilin genes. Presenilin-1 (PS1) is subject to proteolytic cleavage resulting in the accumulation of N- and C-terminal fragments. In this report, we show that the proteolytic cleavage of PS1 is developmentally regulated in the brain, Low levels of full-length PS1 and higher levels of 30-kDa N-terminal and 20-kDa C-terminal fragments are identified at all developmental stages in the rat brain, However, in the adult brain, additional 36-kDa N-terminal and 14-kDa C-terminal fragments appear and become major PS1 species, Alternative N-terminal PS1 fragments also appear in the adult human brain, but are more heterogenous than in the rat brain, The alternative PS1 fragments are not detected at significant levels in rat or human peripheral tissues that express PS1. The alternative cleavage of PS1 is also detected in primary cultures of rat hippocampal neurons, but not in astrocytes, and is induced by neuronal differentiation. Furthermore, alternative PS1 cleavage is detected in rat PC12 cells and human neuroblastoma SH-SY5Y cells following induction of neuronal differentiation. These results suggest that an alternative pathway of PS1 proteolytic processing is induced in the brain by neuronal differentiation. PS1 may therefore play an important role in brain development and neuronal function, which may relate to the brain-specific pathological effects of PS1 mutations.	CHILDRENS HOSP, DIV NEUROSCI, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA; SANDOZ PHARMA LTD, PRECLIN RES, CH-4002 BASEL, SWITZERLAND	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Novartis; Sandoz					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033325, R01NS030352] Funding Source: NIH RePORTER; NINDS NIH HHS [NS33325, NS30352] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; BUSCIGLIO J, 1997, IN PRESS J NEUROSCI; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; HARLOW E, 1988, ANTIBODIES LABORATOR, P90; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Selkoe D. J., 1996, Society for Neuroscience Abstracts, V22, P278; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Takahashi H, 1996, NEUROSCI LETT, V206, P113, DOI 10.1016/S0304-3940(96)12449-6; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	16	62	62	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14505	14508		10.1074/jbc.272.23.14505	http://dx.doi.org/10.1074/jbc.272.23.14505			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169406	hybrid			2022-12-27	WOS:A1997XC32700003
J	Kanzaki, M; Lindorfer, MA; Garrison, JC; Kojima, I				Kanzaki, M; Lindorfer, MA; Garrison, JC; Kojima, I			Activation of the calcium-permeable cation channel CD20 by alpha subunits of the G(i) protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; BALB/C 3T3 CELLS; BACULOVIRUS EXPRESSION SYSTEM; BETA-GAMMA-SUBUNITS; INSULIN-RECEPTOR; PHOSPHOLIPASE-C; RAT HEPATOCYTES; TOXIN; PURIFICATION; LYMPHOCYTES	When the calcium-permeable cation channel CD20 is expressed in Balb/c 3T3 cells, it is activated by insulin-like growth factor-I (IGF-I) via the IGF-I receptor (Kanzaki, M., Nie, L., Shibata, H., and Kojima, I. (1997) J. Biol. Chem. 272, 4964-4969). The present study was conducted to investigate the role of G proteins in the regulation of the CD20 channel. In the excised patch clamp mode, activation of the CD20 channel by IGF-I required GTP, Mg2+, and ATP in the bath solution, and removal of either GTP or ATP attenuated the activation. Non-hydrolyzable ATP could substitute for ATP, and guanyl-5'-yl thiophosphate blocked the activation of the channel by IGF-I. The CD20 channel was also activated by guanosine 5'-3-O-(thio)triphosphate, and ATP was not required for the activation. Addition of a preparation of G(i)/G(o) holoprotein purified from bovine brain activated the CD20, and the beta-adrenergic receptor kinase peptide did not affect the number of channel openings induced by the G protein. The CD20 channel was stimulated by the GTP-bound form of recombinant G(i2) alpha subunit purified from Sf9 cells. The G(i1) alpha subunit was less effective, and the G(i1) alpha subunit had no effect. Purified recombinant beta(1) gamma(2) subunits did not affect the activity of the channel. Finally, IGF-I-induced activation of CD20 was inhibited by an antibody against G(i2) alpha subunit. These findings indicate that the CD20 channel expressed in Balb/c 3T3 cells is activated by the IGF-I receptor via the alpha subunits of heterotrimeric G proteins.	GUNMA UNIV, INST MOL & CELLULAR REGULAT, DEPT CELL BIOL, MAEBASHI, GUMMA 371, JAPAN; UNIV VIRGINIA, HLTH SCI CTR, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA	Gunma University; University of Virginia			Kanzaki, Makoto/H-6680-2017	Kanzaki, Makoto/0000-0002-6884-2955	NIDDK NIH HHS [DK-19952] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019952] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOYER JL, 1994, J BIOL CHEM, V269, P2814; BUBIEN JK, 1993, J CELL BIOL, V121, P1121, DOI 10.1083/jcb.121.5.1121; CLAPHAM DE, 1994, ANNU REV NEUROSCI, V17, P441; DEANS JP, 1995, J BIOL CHEM, V270, P22632, DOI 10.1074/jbc.270.38.22632; DIVERSEPIERLUISSI M, 1995, NEURON, V14, P191, DOI 10.1016/0896-6273(95)90254-6; EINFELD DA, 1988, EMBO J, V7, P711, DOI 10.1002/j.1460-2075.1988.tb02867.x; GRABER SG, 1994, METHOD ENZYMOL, V237, P212; GRABER SG, 1992, J BIOL CHEM, V267, P1271; GRABER SG, 1996, METH NEUROSCI, V29, P207; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; KANZAKI M, 1995, J BIOL CHEM, V270, P13099, DOI 10.1074/jbc.270.22.13099; Kanzaki M, 1997, J BIOL CHEM, V272, P4964, DOI 10.1074/jbc.272.8.4964; KATADA T, 1994, METHOD ENZYMOL, V237, P131; KOJIMA I, 1989, FEBS LETT, V258, P150, DOI 10.1016/0014-5793(89)81637-0; KOJIMA I, 1993, J BIOL CHEM, V268, P10003; KOJIMA I, 1988, J BIOL CHEM, V263, P16561; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LIANG M, 1992, MOL PHARMACOL, V42, P743; LIANG M, 1991, J BIOL CHEM, V266, P13342; LUTTRELL L, 1990, J BIOL CHEM, V265, P16873; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MADDUX BA, 1991, J BIOL CHEM, V266, P6731; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Miller BA, 1996, J CLIN INVEST, V98, P1728, DOI 10.1172/JCI118971; NADLER LM, 1984, J CLIN INVEST, V74, P332, DOI 10.1172/JCI111428; NAIR BG, 1990, J BIOL CHEM, V265, P21317; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NISHIMOTO I, 1987, BIOCHEM BIOPH RES CO, V148, P403, DOI 10.1016/0006-291X(87)91125-9; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; OKAMOTO T, 1991, J BIOL CHEM, V266, P1085; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PLEDGER WJ, 1978, P NATL ACAD SCI USA, V75, P2839, DOI 10.1073/pnas.75.6.2839; ROSENTHAL P, 1983, J IMMUNOL, V131, P232; STASHENKO P, 1980, J IMMUNOL, V125, P1678; STERNWEIS PC, 1993, RECEPTOR EFFECTOR CO, P1; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; TEDDER TF, 1988, P NATL ACAD SCI USA, V85, P208, DOI 10.1073/pnas.85.1.208; TEDDER TF, 1986, EUR J IMMUNOL, V16, P881, DOI 10.1002/eji.1830160802; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; Yasuda H, 1996, J BIOL CHEM, V271, P18588, DOI 10.1074/jbc.271.31.18588	46	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14733	14739		10.1074/jbc.272.23.14733	http://dx.doi.org/10.1074/jbc.272.23.14733			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169438	hybrid			2022-12-27	WOS:A1997XC32700035
J	Litt, MD; Hansen, RS; Hornstra, IK; Gartler, SM; Yang, TP				Litt, MD; Hansen, RS; Hornstra, IK; Gartler, SM; Yang, TP			5-Azadeoxycytidine-induced chromatin remodeling of the inactive X-linked HPRT gene promoter occurs prior to transcription factor binding and gene reactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE GENE; RESOLUTION METHYLATION ANALYSIS; LIGATION-MEDIATED PCR; SOMATIC-CELL HYBRID; CHROMOSOME INACTIVATION; 5' REGION; DNA METHYLATION; CPG ISLAND; PHOSPHOGLYCERATE KINASE; NUCLEASE SENSITIVITY	During the process of 5-aza-2'-deoxycytidine (5aCdr)-induced reactivation of the X-linked human hypoxanthine phosphoribosyltransferase (HPRT) gene on the inactive X chromosome, acquisition of a nuclease-sensitive chromatin conformation in the 5' region occurs before the appearance of HPRT mRNA, In vivo footprinting experiments reported here show that the 5aCdr-induced change in HPRT chromatin structure precedes the appearance of three footprints in the immediate 5' nanking region that are characteristic of the active HPRT allele, These and other data suggest the following sequence of events that lead to the reactivation of the HPRT gene after 5aCdr treatment: (a) hemi-demethylation of the promoter, (b) an ''opening'' of chromatin structure detectable as increased nuclease sensitivity, (c) transcription factor binding to the promoter, (d) assembly of the transcription complex, and (e) synthesis of HPRT RNA, This sequence of events supports the view that inactive X-linked genes are silenced by a repressive chromatin structure that prevents the binding of transcriptional activators to the promoter.	UNIV FLORIDA, COLL MED, DEPT BIOCHEM & MOL BIOL, GAINESVILLE, FL 32610 USA; UNIV FLORIDA, COLL MED, CTR MAMMALIAN GENET, GAINESVILLE, FL 32610 USA; UNIV FLORIDA, COLL MED, DIV PEDIAT GENET, GAINESVILLE, FL 32610 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT GENET, SEATTLE, WA 98195 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016659, R37HD016659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044286] Funding Source: NIH RePORTER; NICHD NIH HHS [HD16659] Funding Source: Medline; NIGMS NIH HHS [GM44286] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALBAS MAM, 1995, CELL, V83, P29; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; COOPER GE, 1993, SOMAT CELL MOLEC GEN, V19, P221, DOI 10.1007/BF01233070; DRACOPOLI NC, 1985, AM J HUM GENET, V37, P199; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; ELLIS N, 1987, SOMAT CELL MOLEC GEN, V13, P191, DOI 10.1007/BF01535202; GARTLER SM, 1983, ANNU REV GENET, V17, P155, DOI 10.1146/annurev.ge.17.120183.001103; GRAVES JAM, 1986, SOMAT CELL MOLEC GEN, V12, P275, DOI 10.1007/BF01570786; HANSEN RS, 1990, P NATL ACAD SCI USA, V87, P4174, DOI 10.1073/pnas.87.11.4174; HANSEN RS, 1988, MOL CELL BIOL, V8, P4692, DOI 10.1128/MCB.8.11.4692; HORNSTRA IK, 1993, ANAL BIOCHEM, V213, P179, DOI 10.1006/abio.1993.1407; HORNSTRA IK, 1994, MOL CELL BIOL, V14, P1419, DOI 10.1128/MCB.14.2.1419; HORNSTRA IK, 1993, HUM MOL GENET, V2, P1659; HORNSTRA IK, 1992, MOL CELL BIOL, V12, P5345, DOI 10.1128/MCB.12.12.5345; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; KEITH DH, 1986, MOL CELL BIOL, V6, P4122, DOI 10.1128/MCB.6.11.4122; KEREM BS, 1983, NATURE, V304, P88, DOI 10.1038/304088a0; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; LEE MS, 1992, P NATL ACAD SCI USA, V89, P9166, DOI 10.1073/pnas.89.19.9166; LEVINE A, 1992, P NATL ACAD SCI USA, V89, P10119, DOI 10.1073/pnas.89.21.10119; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LIN D, 1988, SOMAT CELL MOLEC GEN, V14, P261, DOI 10.1007/BF01534587; LISKAY RM, 1980, P NATL ACAD SCI-BIOL, V77, P4895, DOI 10.1073/pnas.77.8.4895; Litt MD, 1996, MOL CELL BIOL, V16, P6190; LOCK LF, 1987, CELL, V48, P39, DOI 10.1016/0092-8674(87)90353-9; MCBURNEY MW, 1988, BIOESSAYS, V9, P85, DOI 10.1002/bies.950090211; MOHANDAS T, 1981, SCIENCE, V211, P393, DOI 10.1126/science.6164095; NUSSBAUM RL, 1983, HUM GENET, V64, P148, DOI 10.1007/BF00327113; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; SASAKI T, 1992, MOL CELL BIOL, V12, P3819, DOI 10.1128/MCB.12.9.3819; TOMMASI S, 1993, SOMAT CELL MOLEC GEN, V19, P529, DOI 10.1007/BF01233380; TONIOLO D, 1988, EMBO J, V7, P401, DOI 10.1002/j.1460-2075.1988.tb02827.x; VENOLIA L, 1983, NATURE, V302, P82, DOI 10.1038/302082a0; VENOLIA L, 1982, P NATL ACAD SCI-BIOL, V79, P2352, DOI 10.1073/pnas.79.7.2352; WOLF SF, 1984, P NATL ACAD SCI-BIOL, V81, P2806, DOI 10.1073/pnas.81.9.2806; WOLF SF, 1985, NATURE, V314, P467, DOI 10.1038/314467a0; YANG TP, 1987, MOL CELL BIOL, V7, P2994, DOI 10.1128/MCB.7.8.2994	40	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14921	14926		10.1074/jbc.272.23.14921	http://dx.doi.org/10.1074/jbc.272.23.14921			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169463	hybrid			2022-12-27	WOS:A1997XC32700060
J	Takenaka, S; Murakami, S; Shinke, R; Hatakeyama, K; Yukawa, H; Aoki, K				Takenaka, S; Murakami, S; Shinke, R; Hatakeyama, K; Yukawa, H; Aoki, K			Novel genes encoding 2-aminophenol 1,6-dioxygenase from Pseudomonas species AP-3 growing on 2-aminophenol and catalytic properties of the purified enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; PROTOCATECHUATE 4,5-DIOXYGENASE; GENTISATE 1,2-DIOXYGENASE; MICROBIAL-METABOLISM; AROMATIC-AMINES; PURIFICATION; CLONING; 2,3-DIOXYGENASE; PAUCIMOBILIS	2-Aminophenol 1,6-dioxygenase was purified from the cell extracts of Pseudomonas sp. AP-3 grown on 2-aminophenol. The product from 2-aminophenol by catalysis of the purified enzyme was identified as 2-aminomuconic 6-semialdehyde by gas chromatographic and mass spectrometric analyses. The molecular mass of the native enzyme was 140 kDa based on gel filtration. It was dissociated into molecular mass subunits of 32 (alpha-subunit) and 40 kDa (beta subunit) by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, indicating that the dioxygenase was a heterotetramer of alpha(2) beta(2). The genes coding for the alpha- and beta-subunits of the enzyme were cloned and sequenced. Open reading frames of the genes (amnA and amnB) were 816 and 918 base pairs in length, respectively. The amino acid sequences predicted from the open reading frames of amnA and amnB corresponded to the NH2-terminal amino acid sequences of the alpha-subunit (AmnA) and beta-subunit (AmnB), respectively. The deduced amino acid sequences of AmnB showed identities to some extent with HpaD (25.4%) and HpcB (24.4%) that are homoprotocatechuate 2,8-dioxygenases from Escherichia coli W and C, respectively, belonging to class III in the extradiol dioxygenases. On the other hand, AmnA had identity (23.3%) with only AmnB among the enzymes examined.	KOBE UNIV, FAC AGR, DEPT BIOFUNCT CHEM, KOBE, KOBE 657, JAPAN; KOBE UNIV, FAC AGR, GRAD SCH SCI & TECHNOL, DIV SCI & BIOL RESOURCES, KOBE, KOBE 657, JAPAN; MITSUBISHI CHEM, TSUKUBA RES CTR, TSUKUBA, IBARAKI 30003, JAPAN	Kobe University; Kobe University				Takenaka, Shinji/0000-0002-7189-5927				AOKI K, 1984, AGR BIOL CHEM TOKYO, V48, P2087, DOI 10.1080/00021369.1984.10866453; AOKI K, 1997, MICROBIOL RES, V152, P1; ARCIERO DM, 1983, J BIOL CHEM, V258, P4981; ASTURIAS JA, 1994, J BIOL CHEM, V269, P7807; CRAWFORD RL, 1975, J BACTERIOL, V121, P794, DOI 10.1128/JB.121.3.794-799.1975; DARBY JM, 1987, J GEN MICROBIOL, V133, P2137; DILELLA AG, 1987, METHOD ENZYMOL, V152, P199; FUJISAWA H, 1968, J BIOL CHEM, V243, P2673; GYLLENHAAL O, 1980, J CHROMATOGR, V190, P347, DOI 10.1016/S0021-9673(00)88239-4; HARPEL MR, 1990, J BIOL CHEM, V265, P6301; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; HOSHIKA Y, 1978, J CHROMATOGR, V152, P224, DOI 10.1016/S0021-9673(00)85355-8; KABISCH M, 1990, NUCLEIC ACIDS RES, V18, P3405, DOI 10.1093/nar/18.11.3405; KURODA R, 1990, ANAL CHEM, P252; LARWAY P, 1965, BIOCHEM J, V95, pP52; Lendenmann U, 1996, J BACTERIOL, V178, P6227, DOI 10.1128/jb.178.21.6227-6232.1996; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NAKAI C, 1983, J BIOL CHEM, V258, P2923; NAKANISHI Y, 1991, AGR BIOL CHEM TOKYO, V55, P1281, DOI 10.1080/00021369.1991.10870759; NISHINO SF, 1993, APPL ENVIRON MICROB, V59, P2520, DOI 10.1128/AEM.59.8.2520-2525.1993; NODA Y, 1990, J BACTERIOL, V172, P2704, DOI 10.1128/jb.172.5.2704-2709.1990; NOZAKI M, 1970, METHODS ENZYMOLOGY A, V17, P522; Prieto MA, 1996, J BACTERIOL, V178, P111, DOI 10.1128/jb.178.1.111-120.1996; ROPER DI, 1990, FEBS LETT, V275, P53, DOI 10.1016/0014-5793(90)81437-S; Sambook J, 1989, MOL CLONING LAB MANU; SPAIN JC, 1991, APPL ENVIRON MICROB, V57, P812, DOI 10.1128/AEM.57.3.812-819.1991; Spence EL, 1996, J BACTERIOL, V178, P5249, DOI 10.1128/jb.178.17.5249-5256.1996; TAIRA K, 1988, BIOCHEMISTRY-US, V27, P3990, DOI 10.1021/bi00411a015; WEBER K, 1969, J BIOL CHEM, V244, P4406	30	66	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14727	14732		10.1074/jbc.272.23.14727	http://dx.doi.org/10.1074/jbc.272.23.14727			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169437	hybrid			2022-12-27	WOS:A1997XC32700034
J	Reif, K; Burgering, BMT; Cantrell, DA				Reif, K; Burgering, BMT; Cantrell, DA			Phosphatidylinositol 3-kinase links the interleukin-2 receptor to protein kinase B and p70 S6 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL LINE; TRANSCRIPTIONAL ACTIVATION DOMAIN; BETA-CHAIN; CYTOPLASMIC DOMAINS; IN-VIVO; C-AKT; ASSOCIATION; PHOSPHORYLATION; PATHWAY; 3'-KINASE	Phosphatidylinositol 3-kinase (PI 3-kinase) is activated by the cytokine interleukin-2 (IL-2), We have used a constitutively active PI 3-kinase to identify IL-2-mediated signal transduction pathways directly regulated by PI 3-kinase in lymphoid cells, The serine/threonine protein kinase B (PKB)/Akt can act as a powerful oncogene in T cells, but its positioning in normal T cell responses has not been explored, Herein, we demonstrate that PKB is activated by IL-2 in a PI 3-kinase-dependent fashion, Importantly, PI 3-kinase signals are sufficient for PKB activation in IL-2-dependent T cells, and PKB is a target for PI 3-kinase signals in IL-2 activation pathways, The present study establishes also that PI 3-kinase signals or PKB signals are sufficient for activation of p70 S6 kinase in T cells, PI 3-kinase can contribute to, but is not sufficient for, activation of extracellular signal-regulated kinases (Erks) and Erk effector pathways, Therefore, PI 3-kinase is a selective regulator of serine/threonine kinase signal transduction pathways in T lymphocytes, and this enzyme provides a crucial link between the interleukin-2 receptor, the protooncogene PKB, and p70 S6 kinase.	UNIV UTRECHT, PHYSIOL CHEM LAB, NL-3584 CG UTRECHT, NETHERLANDS	Utrecht University	Reif, K (corresponding author), IMPERIAL CANC RES FUND, LYMPHOCYTE ACTIVAT LAB, 44 LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.		Reif, Karin/AAD-4692-2020	Reif, Karin/0000-0001-5490-8389				Abraham RT, 1996, CURR OPIN IMMUNOL, V8, P412, DOI 10.1016/S0952-7915(96)80132-4; AHMED NN, 1993, ONCOGENE, V8, P1957; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Corcoran AE, 1996, EMBO J, V15, P1924, DOI 10.1002/j.1460-2075.1996.tb00543.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; GOLD MR, 1994, J BIOL CHEM, V269, P5403; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORI T, 1987, BLOOD, V70, P1069; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IZQUIERDO M, 1992, EUR J IMMUNOL, V22, P817, DOI 10.1002/eji.1830220328; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; KARNITZ LM, 1994, J EXP MED, V179, P1799, DOI 10.1084/jem.179.6.1799; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Mills G B, 1993, Semin Immunol, V5, P345, DOI 10.1006/smim.1993.1041; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; MYERS MG, 1994, J BIOL CHEM, V269, P28783; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; REIF K, 1993, J BIOL CHEM, V268, P10780; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; STAAL SP, 1988, J EXP MED, V167, P1259, DOI 10.1084/jem.167.3.1259; TAICHMAN R, 1993, J BIOL CHEM, V268, P20031; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TOKER A, 1994, J BIOL CHEM, V269, P32358; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TRUITT KE, 1994, J BIOL CHEM, V269, P5937; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; VENKITARAMAN AR, 1994, EUR J IMMUNOL, V24, P2168, DOI 10.1002/eji.1830240935; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; Williamson P, 1993, Semin Immunol, V5, P337, DOI 10.1006/smim.1993.1040; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	69	160	163	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14426	14433		10.1074/jbc.272.22.14426	http://dx.doi.org/10.1074/jbc.272.22.14426			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162082	hybrid			2022-12-27	WOS:A1997XB49200069
J	White, DM; Takeda, T; DeGroot, LJ; Stefansson, K; Arnason, BGW				White, DM; Takeda, T; DeGroot, LJ; Stefansson, K; Arnason, BGW			beta-trace gene expression is regulated by a core promoter and a distal thyroid hormone response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CEREBROSPINAL-FLUID; PROSTAGLANDIN-D SYNTHASE; RETINOL-BINDING-PROTEIN; MAMMALIAN-CELLS; RECEPTOR BETA-1; CHOROID-PLEXUS; MESSENGER-RNAS; INSULIN GENE; X RECEPTORS; IDENTIFICATION	We isolated and characterized the human P-Trace protein (beta TP) gene promoter. beta TP, also known as prostaglandin D-2 synthase, is a lipocalin secreted from the choroid plexus and meninges into cerebrospinal fluid. Basal transcription of the beta TP gene is directed from a core promoter found within the first 325 bases of the 5'-flanking sequence. The beta TP gene promoter is responsive to thyroid hormone (3,3',5 triiodothyronine, T-3) and efficiently repressed by unliganded human thyroid hormone receptor beta (TR beta, Functional analysis of the beta TP promoter in TE671 cells revealed that responsiveness to T-3 occurs in sequences 2.5 kilobase pairs 5' of the start site, Within the hormone-responsive region we identified a thyroid hormone response element (TRE) located from -2576 to -2562 base pairs relative to the transcription start site. The beta TP TRE is composed of two directly repeated consensus half-sites separated by a 3-base pair space (DR3). The beta TP TRE forms specific complexes with TR beta, We have shown that a gene active in the choroid plexus and meninges is responsive to T-3. T-3 may play a role in the regulated transport of substances into the cerebrospinal fluid and ultimately the brain.	UNIV CHICAGO,BRAIN RES INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,THYROID STUDY UNIT,CHICAGO,IL 60637; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115	University of Chicago; University of Chicago; Harvard University; Harvard Medical School	White, DM (corresponding author), UNIV CHICAGO,DEPT NEUROL,5841 S MARYLAND AVE,MC2030,CHICAGO,IL 60637, USA.		Stefansson, Kari/AAE-7187-2019		NIDDK NIH HHS [DK-27384] Funding Source: Medline; NINDS NIH HHS [P01 NS 24565] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027384] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALDRED AR, 1995, COMP BIOCHEM PHYS B, V111, P1, DOI 10.1016/0305-0491(94)00229-N; ALI S, 1988, J MOL BIOL, V199, P415, DOI 10.1016/0022-2836(88)90614-6; BRADLEY DJ, 1992, J NEUROSCI, V12, P2288; CARR FE, 1994, J BIOL CHEM, V269, P4175; CASSARDDOULCIER AM, 1994, J BIOL CHEM, V269, P24335; CHEN TR, 1989, NATURE, V340, P106, DOI 10.1038/340106b0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK AR, 1995, BIOCHEM J, V309, P863, DOI 10.1042/bj3090863; CLAUSEN J, 1961, P SOC EXP BIOL MED, V107, P170; COHEN O, 1995, J BIOL CHEM, V270, P13899, DOI 10.1074/jbc.270.23.13899; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DEPAGTERHOLTHUIZEN P, 1988, BIOCHIM BIOPHYS ACTA, V950, P282, DOI 10.1016/0167-4781(88)90124-8; EASTMAN A, 1987, BIOTECHNIQUES, V5, P731; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FALCONE M, 1992, ENDOCRINOLOGY, V131, P2419, DOI 10.1210/en.131.5.2419; FARSETTI A, 1992, J BIOL CHEM, V267, P15784; FRIDOVICHKEIL JL, 1991, BIOTECHNIQUES, V11, P572; GARCIAFERNANDEZ LF, 1993, BIOCHEM BIOPH RES CO, V196, P396, DOI 10.1006/bbrc.1993.2262; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAYAISHI O, 1991, FASEB J, V5, P2575, DOI 10.1096/fasebj.5.11.1907936; HOCHWALD GM, 1967, P SOC EXP BIOL MED, V124, P961; HOFFMANN A, 1993, J NEUROCHEM, V61, P451; Hoffmann A, 1996, DEV DYNAM, V207, P332, DOI 10.1002/(SICI)1097-0177(199611)207:3<332::AID-AJA10>3.0.CO;2-6; JAMESON JL, 1986, DNA-J MOLEC CELL BIO, V5, P227, DOI 10.1089/dna.1986.5.227; JANNINI EA, 1994, MOL ENDOCRINOL, V8, P89, DOI 10.1210/me.8.1.89; KATZ RW, 1995, J BIOL CHEM, V270, P5238, DOI 10.1074/jbc.270.10.5238; KEOWN WA, 1990, METHOD ENZYMOL, V185, P527, DOI 10.1016/0076-6879(90)85043-N; LINDVALLAXELSSON M, 1985, ACTA PHYSIOL SCAND, V125, P627, DOI 10.1111/j.1748-1716.1985.tb07764.x; LINK H, 1967, ACTA NEUROL SCAN S28, V43, P1; LIU HC, 1994, MOL ENDOCRINOL, V8, P1021, DOI 10.1210/me.8.8.1021; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MADER S, 1993, J BIOL CHEM, V268, P591; MADISON LD, 1993, MOL CELL ENDOCRINOL, V94, P129, DOI 10.1016/0303-7207(93)90060-W; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; MIYAMOTO T, 1994, MOL CELL ENDOCRINOL, V102, P111, DOI 10.1016/0303-7207(94)90104-X; NAGATA A, 1991, P NATL ACAD SCI USA, V88, P4020, DOI 10.1073/pnas.88.9.4020; NAKAI A, 1990, MOL CELL ENDOCRINOL, V72, P143, DOI 10.1016/0303-7207(90)90138-X; NILSSON C, 1992, BRAIN RES REV, V17, P109, DOI 10.1016/0165-0173(92)90011-A; Ohe Y, 1996, J NEUROCHEM, V67, P964; OHLSSON R, 1994, DEVELOPMENT, V120, P361; OLSSON JE, 1973, J NEUROCHEM, V21, P625, DOI 10.1111/j.1471-4159.1973.tb06007.x; OLSSON JE, 1975, NEUROBIOLOGY, V5, P270; ONOE H, 1988, P NATL ACAD SCI USA, V85, P4082, DOI 10.1073/pnas.85.11.4082; PERVAIZ S, 1985, SCIENCE, V228, P335, DOI 10.1126/science.2580349; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; RABELO R, 1995, ENDOCRINOLOGY, V136, P1003, DOI 10.1210/en.136.3.1003; SAKURAI A, 1995, MOL CELL ENDOCRINOL, V110, P103, DOI 10.1016/0303-7207(95)03522-9; SALIER JP, 1992, GENOMICS, V14, P83, DOI 10.1016/S0888-7543(05)80287-3; SAMBROOK J, 1989, MOL CLONING LAB MAN, V3; SEGAL MB, 1993, J INHERIT METAB DIS, V16, P617, DOI 10.1007/BF00711896; STRATTON MR, 1989, CARCINOGENESIS, V10, P899, DOI 10.1093/carcin/10.5.899; SUZUKI S, 1994, MOL ENDOCRINOL, V8, P305, DOI 10.1210/me.8.3.305; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; URADE Y, 1985, J BIOL CHEM, V260, P2410; WESTCOTT JY, 1987, PROSTAGLANDINS, V34, P877, DOI 10.1016/0090-6980(87)90068-2; WHITE DM, 1992, J BIOL CHEM, V267, P23202; ZAHN M, 1993, NEUROSCI LETT, V154, P93, DOI 10.1016/0304-3940(93)90179-O	60	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14387	14393		10.1074/jbc.272.22.14387	http://dx.doi.org/10.1074/jbc.272.22.14387			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162076	hybrid			2022-12-27	WOS:A1997XB49200063
J	Iwama, T; Homma, M; Kawagishi, I				Iwama, T; Homma, M; Kawagishi, I			Uncoupling of ligand-binding affinity of the bacterial serine chemoreceptor from methylation- and temperature-modulated signaling states	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI TSR; ASPARTATE RECEPTOR; COVALENT MODIFICATION; SENSORY RECEPTOR; CROSS-LINKING; IN-VIVO; CHEMOTAXIS; TRANSDUCTION; DOMAIN; SITE	The Escherichia coli chemoreceptor Tsr mediates tactic responses to serine, repellents, and changes in temperature. We have previously shown that the serine sensing ability of Tsr-T156C, which has a unique cysteine in place of threonine at residue 156, is specifically inactivated by thiol-modifying reagents and that L-serine protects the receptor from modification. In this study, we demonstrated the correlation between protective effects of various attractants and their potencies to elicit attractant responses. This indirect binding assay was used to monitor the affinity of the receptor for L-serine under various conditions. It has been demonstrated by in vitro assays that the ligand-binding affinities of Tsr and the related chemoreceptor Tar are unaffected by changes in the methylation state of the receptor. Using the serine protection assay, we re-examined this issue both in vitro and in vitro. The methylation levels of Tsr-T156C did not affect its ligand-binding affinity. We also showed both in vitro and in vivo that the ligand-binding affinity was unaffected by temperature. These results suggest that the structure of the periplasmic domain of the receptor is uncoupled from the signaling states of the cytoplasmic domain. This ligand-binding assay system should be applicable to other receptors.	NAGOYA UNIV, GRAD SCH SCI, DIV BIOL SCI, CHIKUSA KU, NAGOYA, AICHI 46401, JAPAN; GIFU UNIV, FAC AGR, DEPT BIOTECHNOL, DIV UTILIZAT BIOL RESOURCE, GIFU 50111, JAPAN	Nagoya University; Gifu University								BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BURROWS GG, 1989, J BIOL CHEM, V264, P17309; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; CLARKE S, 1979, J BIOL CHEM, V254, P9695; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; DUNTEN P, 1991, J BIOL CHEM, V266, P1491; FOSTER DL, 1985, J BIOL CHEM, V260, P1706; Gardina PJ, 1996, SCIENCE, V274, P425, DOI 10.1126/science.274.5286.425; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; HAZELBAUER GL, 1990, SOC GENERAL MICROBIO, V46, P107; Imae Y., 1985, SENSING RESPONSE MIC, P73; IWAMA T, 1995, J BACTERIOL, V177, P2218, DOI 10.1128/jb.177.8.2218-2221.1995; JEFFERY CJ, 1994, BIOCHEMISTRY-US, V33, P3457, DOI 10.1021/bi00178a001; KAHRY MR, 1983, P NATL SCI US, V80, P3599; KEHRY MR, 1982, CELL, V29, P761, DOI 10.1016/0092-8674(82)90438-X; LEE GF, 1995, P NATL ACAD SCI USA, V92, P3391, DOI 10.1073/pnas.92.8.3391; LEE L, 1988, J BACTERIOL, V170, P4769, DOI 10.1128/jb.170.10.4769-4774.1988; LIN LN, 1994, BIOCHEMISTRY-US, V33, P6564, DOI 10.1021/bi00187a025; LONG DG, 1992, BIOCHEMISTRY-US, V31, P9904, DOI 10.1021/bi00156a007; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; MAEDA K, 1979, P NATL ACAD SCI USA, V76, P91, DOI 10.1073/pnas.76.1.91; MAEDA K, 1976, J BACTERIOL, V127, P1039, DOI 10.1128/JB.127.3.1039-1046.1976; MANSON MD, 1992, ADV MICROB PHYSIOL, V33, P277, DOI 10.1016/S0065-2911(08)60219-2; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; NARA T, 1991, J BACTERIOL, V173, P1120, DOI 10.1128/jb.173.3.1120-1124.1991; Nara T, 1996, J BIOL CHEM, V271, P17932, DOI 10.1074/jbc.271.30.17932; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; RICE MS, 1991, J BIOL CHEM, V266, P9746; SCOTT WG, 1993, J MOL BIOL, V232, P555, DOI 10.1006/jmbi.1993.1411; SCRUTTON MC, 1965, J BIOL CHEM, V240, P3714; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; Stock JB, 1996, ESCHERICHIA COLI SAL, P1103; TATSUNO I, 1994, MOL MICROBIOL, V14, P755, DOI 10.1111/j.1365-2958.1994.tb01312.x; Tatsuno I, 1996, SCIENCE, V274, P423, DOI 10.1126/science.274.5286.423; WOLFE AJ, 1987, J BACTERIOL, V169, P1676; YEH JI, 1993, J BIOL CHEM, V268, P9787; YONEKAWA H, 1986, FEBS LETT, V198, P21, DOI 10.1016/0014-5793(86)81176-0	40	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13810	13815		10.1074/jbc.272.21.13810	http://dx.doi.org/10.1074/jbc.272.21.13810			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153237	hybrid, Green Submitted			2022-12-27	WOS:A1997XA06200052
J	Salih, E; Ashkar, S; Gerstenfeld, LC; Glimcher, MJ				Salih, E; Ashkar, S; Gerstenfeld, LC; Glimcher, MJ			Identification of the phosphorylated sites of metabolically P-32-labeled osteopontin from cultured chicken osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; NON-COLLAGENOUS PROTEINS; O-PHOSPHOSERINE; BONE PHOSPHOPROTEIN; CONTAINING PEPTIDES; BOVINE OSTEOPONTIN; ORGANIC MATRIX; MESSENGER-RNA; EXPRESSION; PHOSPHOTHREONINE	Osteopontin (OPN) is one of the major secretory phosphoproteins in both calcifying and non-calcifying tissues. Evidence has accumulated for the biological importance of the phosphoproteins and, in particular, the phosphate groups in bone formation, resorption, and calcification. The precise locations of the phosphate groups in the OPN molecule were determined by metabolically labeling OPN with P-32 in cultured chicken osteoblasts, followed by purification to homogeneity. N-terminal sequencing showed a single sequence of WPVSKRQHAISA, consistent with that deduced from both cDNA, and previous amino acid sequencing of the protein isolated from chicken bone, Three P-32-labeled peptides were isolated by reverse-phase high performance liquid chromatography of thrombin-digested, P-32-labeled OPN. The N-terminal sequencing of each of these thrombin fragments gave single sequences as follows: WPVSKSRQHAIS, SHHTHRYHQDHVD, and ASKLRKAARKL, with approximate molecular masses of 5, 30, and 20 kDa. These data demonstrate that P-32 was incorporated throughout the N- to C-terminal sequence of the protein. Thrombin specifically cleaved chicken OPN at two sites: between Arg 22 and Ser-23, which generated the 5-kda N-terminal end fragment, and another between Lys-138 and Ale-139, which generated the 30- and 20-kDa fragments. To further define the exact locations of the phosphorylated amino acids and the surrounding amino acid sequences, OPN was digested with trypsin, which generated seven major P-32-labeled peptides whose amino acid sequences were determined. The phosphorylated peptide regions of osteopontin were identified as amino acids 8-18 (QHAIS*AS*S*EEK), 39-54 (LASQQTHYS*S*EENAD), 150-171 (LIEDDAT*AEVGDSQLAGLWLPK), 179-191 (ELAQHQSVENDSR), 194-205 (FDS*PEVGGDSK), 214-219 (ES*LASR), and 239-248 (HSIENNEVTR). The phosphorylated amino acid sites are followed by an asterisk (*). Of the seven identified phosphorylated peptide regions, three were localized on the N-terminal end of the osteopontin molecule (with five phosphorylated serines) and contained the sequence motifs that were phosphorylated by casein kinase II type(s), whereas the remaining four peptides are concentrated toward the C-terminal half of the molecule (with five phosphorylated residues) and contained recognition motifs for other kinases as well as casein kinase II.	HARVARD UNIV, SCH MED, DEPT ORTHOPAED SURG, LAB STUDY SKELETAL DISORDERS & REHABIL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	Salih, E (corresponding author), CHILDRENS HOSP, LAB STUDY SKELETAL DISORDERS & REHABIL, 300 LONGWOOD AVE, BOSTON, MA 02115 USA.			/0000-0002-0477-1211; Salih, Erdjan/0000-0003-3322-2323	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR034078] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR34078] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ASHKAR S, 1993, BIOCHEM BIOPH RES CO, V191, P126, DOI 10.1006/bbrc.1993.1193; ASHKAR S, 1995, ANN N Y ACAD SCI T, V60, P296; BOSKEY AL, 1993, BONE MINER, V22, P147, DOI 10.1016/S0169-6009(08)80225-5; CARR C, 1987, BIOCHEMISTRY-US, V26, P7090, DOI 10.1021/bi00396a034; COHENSOLAL L, 1979, BIOCHEM J, V177, P81, DOI 10.1042/bj1770081; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; ENDO A, 1989, CONNECT TISSUE RES, V21, P509, DOI 10.3109/03008208909050008; GERSTENFELD LC, 1989, CONNECT TISSUE RES, V21, P545; GERSTENFELD LC, 1990, ANAT RECORD, V228, P93, DOI 10.1002/ar.1092280113; GIACHELLI CM, 1993, J CLIN INVEST, V92, P1686, DOI 10.1172/JCI116755; Glimcher M. J., 1968, TREATISE COLLAGEN  B, VII, P68; GLIMCHER MJ, 1964, BIOCHIM BIOPHYS ACTA, V90, P477, DOI 10.1016/0304-4165(64)90227-2; GLIMCHER MJ, 1981, CALCIFIED TISSUE INT, V33, P185, DOI 10.1007/BF02409434; GLIMCHER MJ, 1979, CALCIFIED TISSUE INT, V27, P281, DOI 10.1007/BF02441198; GLIMCHER MJ, 1979, CALCIFIED TISSUE INT, V27, P187, DOI 10.1007/BF02441183; GLIMCHER MJ, 1984, PHILOS T R SOC B, V304, P479, DOI 10.1098/rstb.1984.0041; GLIMCHER MJ, 1979, CALCIFIED TISSUE INT, V28, P83, DOI 10.1007/BF02441222; GLIMCHER MJ, 1989, ANAT REC, V224, P139, DOI 10.1002/ar.1092240205; GLIMCHER MJ, 1985, CALCIUM BIOL SYSTEMS, P607; Goldberg HA, 1996, CONNECT TISSUE RES, V35, P385, DOI 10.3109/03008209609029216; GOTOH Y, 1990, EUR J BIOCHEM, V187, P49, DOI 10.1111/j.1432-1033.1990.tb15276.x; GOTOH Y, 1990, BIOCHEM BIOPH RES CO, V173, P471, DOI 10.1016/S0006-291X(05)81082-4; HUNTER GK, 1993, P NATL ACAD SCI USA, V90, P8562, DOI 10.1073/pnas.90.18.8562; IKEDA T, 1993, J CLIN INVEST, V92, P2814, DOI 10.1172/JCI116901; KEMP BE, 1991, PEPTIDES PROTEIN PHO, P43; KERR JM, 1991, GENE, V108, P237, DOI 10.1016/0378-1119(91)90439-I; KOHRI K, 1993, J BIOL CHEM, V268, P15180; KRANE SM, 1965, BIOCHIM BIOPHYS ACTA, V97, P77, DOI 10.1016/0304-4165(65)90271-0; Krebs EG, 1986, ENZYMES, V17, P3, DOI 10.1016/S1874-6047(08)60426-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDIS WJ, 1984, J CELL BIOL, V98, P986, DOI 10.1083/jcb.98.3.986; MARK MP, 1988, CELL TISSUE RES, V251, P23, DOI 10.1007/BF00215443; MCKEE MD, 1990, ANAT REC, V228, P77, DOI 10.1002/ar.1092280112; MCKEE MD, 1992, ANAT REC, V234, P479, DOI 10.1002/ar.1092340404; McKee MD, 1996, ANAT RECORD, V245, P293, DOI 10.1002/(SICI)1097-0185(199606)245:2<293::AID-AR13>3.0.CO;2-K; McKee MD, 1996, ANAT RECORD, V245, P394, DOI 10.1002/(SICI)1097-0185(199606)245:2<394::AID-AR19>3.0.CO;2-K; MIKUNITAKAGAKI Y, 1990, BIOCHEM J, V268, P585, DOI 10.1042/bj2680585; MOORE MA, 1991, BIOCHEMISTRY-US, V30, P2501, DOI 10.1021/bi00223a029; NOMURA S, 1988, J CELL BIOL, V106, P441, DOI 10.1083/jcb.106.2.441; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; Salih E, 1996, J BIOL CHEM, V271, P16897, DOI 10.1074/jbc.271.28.16897; Salih E, 1996, J BONE MINER RES, V11, P1461; Salih E, 1996, CONNECT TISSUE RES, V35, P207, DOI 10.3109/03008209609029193; SENGER DR, 1989, BIOCHIM BIOPHYS ACTA, V996, P43, DOI 10.1016/0167-4838(89)90092-7; SENGER DR, 1994, MOL BIOL CELL, V5, P565, DOI 10.1091/mbc.5.5.565; SEYER JM, 1971, BIOCHIM BIOPHYS ACTA, V236, P279, DOI 10.1016/0005-2795(71)90177-2; SFEIR C, 1995, J BONE MINER RES, V10, P607; SHANAHAN CM, 1994, J CLIN INVEST, V93, P2393, DOI 10.1172/JCI117246; SOMERMAN MJ, 1987, J BONE MINER RES, V2, P259; SORENSEN ES, 1995, PROTEIN SCI, V4, P2040, DOI 10.1002/pro.5560041009; SPECTOR AR, 1973, BIOCHIM BIOPHYS ACTA, V303, P360, DOI 10.1016/0005-2795(73)90367-X; Stubbs JT, 1996, CONNECT TISSUE RES, V35, P393, DOI 10.3109/03008209609029217; UCHIYAMA A, 1988, BIOCHEMISTRY-US, V24, P6363; Veis A, 1983, BIOMINERALIZATION BI, V240, p[273, 35]; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; WETTENHALL REH, 1991, METHOD ENZYMOL, V201, P186; WU CB, 1992, J BIOL CHEM, V267, P16588; WU CB, 1995, CALCIFIED TISSUE INT, V57, P285, DOI 10.1007/BF00298884	59	45	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13966	13973		10.1074/jbc.272.21.13966	http://dx.doi.org/10.1074/jbc.272.21.13966			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153260	hybrid			2022-12-27	WOS:A1997XA06200075
J	Cong, YS; Yao, YL; Yang, WM; Kuzhandaivelu, N; Seto, E				Cong, YS; Yao, YL; Yang, WM; Kuzhandaivelu, N; Seto, E			The hepatitis B virus X-associated protein, XAP3, is a protein kinase C-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; IMMEDIATE EARLY PROTEIN; LONG TERMINAL REPEAT; TRANSCRIPTION FACTOR; REGULATORY PROTEIN; CELLULAR PROTEINS; TRANS-ACTIVATION; MAMMALIAN-CELLS; HBX PROTEIN; DNA	The hepatitis B virus X protein induces transcriptional activation of a wide variety of viral and cellular genes. In addition to its ability to interact directly with many nuclear transcription factors, several reports indicate that the X protein stimulates different cytoplasmic kinase signal cascades. Using the yeast two-hybrid screen, we have isolated a clone designated X-associated protein 3 (XAP3) that encodes a human homolog of the rat protein kinase C-binding protein. One of the activation domains of X (amino acids 90-122) is required for binding to XAP3, while the NH2-terminal part of XAP3 is necessary for binding to X. Both X and XAP3 bound specifically to the eta PKC isoenzyme synthesized in rabbit reticulocyte lysates. Overexpression of XAP3 enhanced X transactivation activity. These results support earlier findings that one of the mechanisms of transactivation by X is through involvement with the cellular protein kinase C pathway.	UNIV S FLORIDA, COLL MED, DEPT MED MICROBIOL & IMMUNOL, MOL ONCOL PROGRAM, TAMPA, FL 33612 USA	State University System of Florida; University of South Florida				Yang, Wen-Ming/0000-0002-5871-5979	NCI NIH HHS [R01-CA61257] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061257] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABMAYR SM, 1985, CELL, V43, P821, DOI 10.1016/0092-8674(85)90255-7; ABMAYR SM, 1988, GENE DEV, V2, P542, DOI 10.1101/gad.2.5.542; ARII M, 1992, ONCOGENE, V7, P397; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALSANO C, 1991, BIOCHEM BIOPH RES CO, V176, P985, DOI 10.1016/0006-291X(91)90379-L; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; CHATTERJEE PK, 1988, EMBO J, V7, P835, DOI 10.1002/j.1460-2075.1988.tb02882.x; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; DONG LQ, 1995, J BIOL CHEM, V270, P25534, DOI 10.1074/jbc.270.43.25534; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FABER SW, 1986, NUCLEIC ACIDS RES, V14, P6067, DOI 10.1093/nar/14.15.6067; FAKTOR O, 1990, ONCOGENE, V5, P867; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FRIEDMAN M, 1986, CONTEMP POLICY ISSUE, V4, P1, DOI 10.1111/j.1465-7287.1986.tb00827.x; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GLAZER RI, 1994, PROTEIN KINASE C, P171; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Harlow E., 1988, ANTIBODIES LAB MANUA; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; Jaken S, 1990, CURR OPIN CELL BIOL, V2, P192, DOI 10.1016/0955-0674(90)90006-Z; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Koike K, 1995, INTERVIROLOGY, V38, P134, DOI 10.1159/000150424; KRISTIE TM, 1984, P NATL ACAD SCI-BIOL, V81, P4065, DOI 10.1073/pnas.81.13.4065; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; Kumar V, 1996, P NATL ACAD SCI USA, V93, P5647, DOI 10.1073/pnas.93.11.5647; Kuzhandaivelu N, 1996, NUCLEIC ACIDS RES, V24, P4741, DOI 10.1093/nar/24.23.4741; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; LEVRERO M, 1990, J VIROL, V64, P3082, DOI 10.1128/JVI.64.6.3082-3086.1990; Lindholm PF, 1996, J VIROL, V70, P2525, DOI 10.1128/JVI.70.4.2525-2532.1996; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MAHONEY CW, 1994, PROTEIN KINASE C, P16; MCKNIGHT JLC, 1987, P NATL ACAD SCI USA, V84, P7061, DOI 10.1073/pnas.84.20.7061; MICHAEL N, 1988, SCIENCE, V239, P1531, DOI 10.1126/science.2832940; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; OHARE P, 1988, EMBO J, V7, P4231, DOI 10.1002/j.1460-2075.1988.tb03320.x; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; PARKER PJ, 1994, PROTEIN KINASE C, P3; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; RITTER SE, 1991, VIROLOGY, V182, P841, DOI 10.1016/0042-6822(91)90626-M; RON D, 1992, BIOTECHNIQUES, V13, P866; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5468; Schaefer S, 1995, INTERVIROLOGY, V38, P143, DOI 10.1159/000150425; SCHEK N, 1991, ONCOGENE, V6, P1735; SETO E, 1989, VIROLOGY, V173, P764, DOI 10.1016/0042-6822(89)90594-1; SETO E, 1988, P NATL ACAD SCI USA, V85, P8286, DOI 10.1073/pnas.85.21.8286; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SPALHOLZ BA, 1988, J VIROL, V62, P3143, DOI 10.1128/JVI.62.9.3143-3150.1988; STABEL S, 1994, SEMIN CANCER BIOL, V5, P277; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; TAKADA S, 1994, VIROLOGY, V205, P503, DOI 10.1006/viro.1994.1671; TAKADA S, 1994, ONCOGENE, V9, P341; UNGER T, 1990, EMBO J, V9, P1889, DOI 10.1002/j.1460-2075.1990.tb08315.x; VALENZUELA P, 1980, ANIMAL VIRUS GENETIC, P57; WANG HD, 1995, MOL CELL BIOL, V15, P6720; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; WOLF M, 1986, J BIOL CHEM, V261, P3327; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845	89	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16482	16489		10.1074/jbc.272.26.16482	http://dx.doi.org/10.1074/jbc.272.26.16482			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195957	hybrid			2022-12-27	WOS:A1997XG01900061
J	Funato, K; Beron, W; Yang, CZ; Mukhopadhyay, A; Stahl, PD				Funato, K; Beron, W; Yang, CZ; Mukhopadhyay, A; Stahl, PD			Reconstitution of phagosome-lysosome fusion in streptolysin O-permeabilized cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; GTP-BINDING-PROTEINS; VESICULAR TRANSPORT; MEMBRANE-FUSION; ENDOSOME FUSION; VESICLE FUSION; FREE SYSTEM; COMPARTMENTS; INVITRO; RAB5	We have reconstituted fusion between phagosomes and lysosomes in streptolysin O-permeabilized J774-E macrophages. Fusion was assessed by measuring the delivery of avidin-conjugated horseradish peroxidase pre-internalized into lysosomes to phagosomes containing biotinylated beta-glucuronidase-conjugated paramagnetic beads (1-2 mu m). Fusion was dependent on energy and exogenously supplied cytosol. Phagosome-lysosome fusion was greatly inhibited when microtubules were depolymerized by nocodazole treatment, suggesting that fusion occurs via microtubule-dependent transport. Furthermore, fusion was inhibited by GTP gamma S and Rab GDP dissociation inhibitor. These results suggest that rab proteins are involved in the regulation of fusion. Lastly, anti-NEM-sensitive factor (NSF) antibodies inhibited fusion, and addition of recombinant NSF wild type partially restored the fusogenic activity, indicating that NSF is required for fusion between phagosomes and lysosomes.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; RIKEN,INST PHYS & CHEM RES,ANIM & CELLULAR SYST LAB,WAKO,SAITAMA 35101,JAPAN; UNIV NACL CUYO,FAC CIENCIAS MED,INST HISTOL & EMBIOL,RA-5500 MENDOZA,ARGENTINA; NATL INST IMMUNOL,CELL BIOL LAB,NEW DELHI 110067,INDIA	Washington University (WUSTL); RIKEN; University Nacional Cuyo Mendoza; Department of Biotechnology (DBT) India; National Institute of Immunology (NII)			Mukhopadhyay, Asok/C-4051-2009; Stahl, Philip/D-6315-2012					AlvarezDominguez C, 1996, J BIOL CHEM, V271, P13834, DOI 10.1074/jbc.271.23.13834; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; BARBIERI MA, 1994, J BIOL CHEM, V269, P18720; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BERON W, 1995, TRENDS CELL BIOL, V5, P100, DOI 10.1016/S0962-8924(00)88958-8; BERON W, 1995, ARCH BIOCHEM BIOPHYS, V317, P337, DOI 10.1006/abbi.1995.1172; BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167; Blocker A, 1996, J BIOL CHEM, V271, P3803; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Colombo MI, 1996, J BIOL CHEM, V271, P18810, DOI 10.1074/jbc.271.31.18810; DESJARDINS M, 1995, TRENDS CELL BIOL, V5, P183, DOI 10.1016/S0962-8924(00)88989-8; DESJARDINS M, 1994, J BIOL CHEM, V269, P32194; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; DIAZ R, 1991, EUR J CELL BIOL, V56, P223; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; GARCIADELPORTILLO F, 1995, TRENDS MICROBIOL, V3, P373, DOI 10.1016/S0966-842X(00)88982-9; GODA Y, 1991, J CELL BIOL, V112, P823, DOI 10.1083/jcb.112.5.823; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GREENBERG S, 1995, TRENDS CELL BIOL, V5, P93, DOI 10.1016/S0962-8924(00)88957-6; Hackam DJ, 1996, J IMMUNOL, V156, P4377; HELMS JB, 1995, FEBS LETT, V369, P84, DOI 10.1016/0014-5793(95)00620-O; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MAYORGA LS, 1991, J BIOL CHEM, V266, P6511; MELLMAN I, 1995, CELL, V82, P869, DOI 10.1016/0092-8674(95)90018-7; Mukhopadhyay A, 1997, J CELL BIOL, V136, P1227, DOI 10.1083/jcb.136.6.1227; MULLOCK BM, 1994, J CELL BIOL, V126, P1173, DOI 10.1083/jcb.126.5.1173; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; RABINOWITZ S, 1992, J CELL BIOL, V116, P95, DOI 10.1083/jcb.116.1.95; Rickard JE, 1996, TRENDS CELL BIOL, V6, P178, DOI 10.1016/0962-8924(96)10017-9; RODRIGUEZ L, 1994, MOL BIOL CELL, V5, P773, DOI 10.1091/mbc.5.7.773; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SCHIMMOLLER F, 1993, J CELL SCI, V106, P823; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Tjelle TE, 1996, J CELL SCI, V109, P2905; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5	39	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16147	16151		10.1074/jbc.272.26.16147	http://dx.doi.org/10.1074/jbc.272.26.16147			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195911	hybrid			2022-12-27	WOS:A1997XG01900015
J	Ke, SH; Coombs, GS; Tachias, K; Navre, M; Corey, DR; Madison, EL				Ke, SH; Coombs, GS; Tachias, K; Navre, M; Corey, DR; Madison, EL			Distinguishing the specificities of closely related proteases - Role of P3 in substrate and inhibitor discrimination between tissue-type plasminogen activator and urokinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; HUMAN ALPHA-THROMBIN; DIRECTED MUTAGENESIS; SERINE PROTEINASES; CRYSTAL-STRUCTURE; TRYPSIN; IDENTIFICATION; SELECTION; PEPTIDES; RESIDUES	Elucidating subtle specificity differences between closely related enzymes is a fundamental challenge for both enzymology and drug design, We have addressed this issue for two intimately related serine proteases, tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA), by modifying the technique of substrate phage display to create substrate subtraction libraries. Characterization of individual members of the substrate subtraction library accomplished the rapid, direct identification of small, highly selective substrates for t-PA. Comparison of the amino acid sequences of these selective substrates with the consensus sequence for optimal substrates for t-PA, derived using standard substrate phage display protocols, suggested that the P3 and P4 residues are the primary determinants of the ability of a substrate to discriminate between t-PA and u-PA. Mutagenesis of the P3 and P4 residues of plasminogen activator inhibitor type 1, the primary physiological inhibitor of both t-PA and u-PA, confirmed this prediction and indicated a predominant role for the P3 residue. Appropriate replacement of both the P3 and P4 residues enhanced the t-PA specificity of plasminogen activator inhibitor type 1 by a factor of 600, and mutation of the P3 residue alone increased this selectivity by a factor of 170. These results demonstrate that the combination of substrate phage display and substrate subtraction methods can be used to discover specificity differences between very closely related enzymes and that this information can be utilized to create highly selective inhibitors.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; AFFYMAX RES INST, SANTA CLARA, CA 95051 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Scripps Research Institute				Coombs, Gary/0000-0002-0711-185X	NHLBI NIH HHS [R01 HL52475, P01 HL31950] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950, R01HL052475] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALPERT AJ, 1990, J CHROMATOGR, V499, P177, DOI 10.1016/S0021-9673(00)96972-3; BAGGIO R, 1996, BIOCHEMISTRY-US, V35, P3551; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BODE W, 1990, EUR J BIOCHEM, V193, P175, DOI 10.1111/j.1432-1033.1990.tb19320.x; BODE W, 1992, PROTEIN SCI, V1, P426; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; COLLEN D, 1991, BLOOD, V78, P3114; Coombs GS, 1996, J BIOL CHEM, V271, P4461; Crooke ST, 1996, NAT BIOTECHNOL, V14, P238, DOI 10.1038/nbt0396-238b; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DING L, 1995, P NATL ACAD SCI USA, V92, P7627, DOI 10.1073/pnas.92.17.7627; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; GANU VS, 1982, INT J PEPT PROT RES, V20, P421; HOLMES WE, 1987, BIOCHEMISTRY-US, V26, P5133, DOI 10.1021/bi00390a036; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMBA B, 1996, J MOL BIOL, V258, P117; MADISON EL, 1993, METHOD ENZYMOL, V223, P249; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MADISON EL, 1994, FIBRINOLYSIS, V8, P221, DOI 10.1016/0268-9499(94)90720-X; MADISON EL, 1995, J BIOL CHEM, V270, P7558, DOI 10.1074/jbc.270.13.7558; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; Min HY, 1996, CANCER RES, V56, P2428; NI F, 1989, BIOCHEMISTRY-US, V28, P3094, DOI 10.1021/bi00433a053; OLSON ST, 1995, J BIOL CHEM, V270, P30007; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; PERONA JJ, 1995, PROTEIN SCI, V4, P337; SANCHO E, 1994, EUR J BIOCHEM, V224, P125, DOI 10.1111/j.1432-1033.1994.tb20003.x; SEEDS NW, 1995, SCIENCE, V270, P1992, DOI 10.1126/science.270.5244.1992; Shapiro RL, 1996, CANCER RES, V56, P3597; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; SPRAGGON G, 1995, STRUCTURE, V3, P681, DOI 10.1016/S0969-2126(01)00203-9; Taylor J. R., 1982, INTRO ERROR ANAL STU; TEIXEIRA AV, 1994, BBA-GENE STRUCT EXPR, V1217, P23, DOI 10.1016/0167-4781(94)90120-1; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; TUCKER HM, 1995, NAT STRUCT BIOL, V2, P442, DOI 10.1038/nsb0695-442; URANO T, 1988, BIOCHEM BIOPH RES CO, V150, P45, DOI 10.1016/0006-291X(88)90484-6; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	39	51	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16603	16609		10.1074/jbc.272.26.16603	http://dx.doi.org/10.1074/jbc.272.26.16603			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195973	hybrid			2022-12-27	WOS:A1997XG01900077
J	Lai, TS; Bielawska, A; Peoples, KA; Hannun, YA; Greenburg, CS				Lai, TS; Bielawska, A; Peoples, KA; Hannun, YA; Greenburg, CS			Sphingosylphosphocholine reduces the calcium ion requirement for activating tissue transglutaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING ENZYMES; PROTEIN-KINASE; CERAMIDE; BINDING; GTP; IDENTIFICATION; SPHINGOMYELIN; MECHANISM; APOPTOSIS; CYCLE	Tissue transglutaminase (DTG) catalyzes a Ca2+-dependent transglutaminase reaction resulting in the formation of gamma-glutamyl-epsilon-lysine bonds and is activated during apoptosis to catalyze the formation of apoptotic body, We investigate whether lipids that are membrane components and involved in cell signaling could modify the Ca2+-dependent activation of tTG. We found that sphingosylphosphocholine (lyso-SM) was the only lipid to activate transglutaminase at low Ca2+ concentrations. In the presence of lyso-SM (125 mu M), transglutaminase was detectable at 10 mu M Ca2+, whereas in the absence of lyso-SM, similar activity was obtained at 160 mu M Ca2+. Furthermore, in the presence of lipid vesicles lyso-SM retained the ability to enhance the Ca2+-dependent activation of tTG. Lyso-SM did not significantly change the K-m for the glutamyl and primary amine substrates, However, the K-act, for Ca2+ was reduced from 300 mu M to 90 mu M. Structure-function studies of lyso-SM analogs indicate that phosphocholine group on C1, the free amino group at C2 and a C4-C5 double bond are critical for the activation of transglutaminase activity. This is the first demonstration that a specific sphingolipid could enhance the activity of tTG and could play a role in vivo in activation of the tTG at physiologic Ca2+ levels.	DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT PATHOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, SPECIALIZED CTR BREAST CANC, DURHAM, NC 27710 USA	Duke University; Duke University; Duke University; Duke University				, Thung-Shen/0000-0002-8791-9698	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038245] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039162] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38391, HL 38245] Funding Source: Medline; NIAMS NIH HHS [AR 39162] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; BELL RM, 1993, SPHINGOLIPIDS B; BERGAMINI CM, 1988, FEBS LETT, V239, P255, DOI 10.1016/0014-5793(88)80928-1; BERGER A, 1995, P NATL ACAD SCI USA, V92, P5885, DOI 10.1073/pnas.92.13.5885; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BIRCKBICHLER PJ, 1985, HYBRIDOMA, V4, P179, DOI 10.1089/hyb.1985.4.179; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bunemann M, 1996, EMBO J, V15, P5527, DOI 10.1002/j.1460-2075.1996.tb00937.x; CREDO RB, 1978, P NATL ACAD SCI USA, V75, P4234, DOI 10.1073/pnas.75.9.4234; EISENTHAL R, 1993, ENZYME ASSAYS; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; FESUS L, 1983, FEBS LETT, V155, P1, DOI 10.1016/0014-5793(83)80196-3; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FESUS L, 1995, J CELL BIOCHEM, P151; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1993, ADV LIPID RES, V25, P43; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HARSFALVI J, 1987, BIOCHIM BIOPHYS ACTA, V923, P42, DOI 10.1016/0304-4165(87)90123-1; HEROLD P, 1988, HELV CHIM ACTA, V71, P354, DOI 10.1002/hlca.19880710208; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; ITO M, 1995, J BIOL CHEM, V270, P24370, DOI 10.1074/jbc.270.41.24370; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; KORNER G, 1989, BIOCHEM J, V262, P633, DOI 10.1042/bj2620633; LAI TS, 1994, J BIOL CHEM, V269, P24596; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MIRAGLIA CC, 1985, ANAL BIOCHEM, V144, P165, DOI 10.1016/0003-2697(85)90099-5; Murata Y, 1996, J INVEST DERMATOL, V106, P1242, DOI 10.1111/1523-1747.ep12348937; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nemes Z, 1996, EUR J CELL BIOL, V70, P125; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; SEIJO L, 1994, LIPIDS, V29, P359, DOI 10.1007/BF02537190; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; Singh US, 1996, J BIOL CHEM, V271, P27292, DOI 10.1074/jbc.271.44.27292; SINGH US, 1995, BIOCHEMISTRY-US, V34, P15863, DOI 10.1021/bi00048a032; SLAUGHTER TF, 1992, ANAL BIOCHEM, V205, P166, DOI 10.1016/0003-2697(92)90594-W; Smethurst PA, 1996, BIOCHEM J, V313, P803, DOI 10.1042/bj3130803; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; VANVELDHOVEN PP, 1989, J LIPID RES, V30, P611	42	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16295	16300		10.1074/jbc.272.26.16295	http://dx.doi.org/10.1074/jbc.272.26.16295			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195933	hybrid			2022-12-27	WOS:A1997XG01900037
J	Baude, EJ; Arora, VK; Yu, S; Garbers, DL; Wedel, BJ				Baude, EJ; Arora, VK; Yu, S; Garbers, DL; Wedel, BJ			The cloning of a Caenorhabditis elegans guanylyl cyclase and the construction of a ligand-sensitive mammalian/nematode chimeric receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATRIURETIC-PEPTIDE RECEPTOR; PROTEIN-KINASE; ACTIVATION; DEPHOSPHORYLATION; DESENSITIZATION; IDENTIFICATION; EXPRESSION; SEQUENCES; CNP	Substantial guanylyl cyclase activity was detected in membrane fractions prepared from Caenorhabditis elegans (100 pmol cGMP/min/mg at 20 degrees C or 500 pmol cGMP/min/mg art 37 degrees C), suggesting the potential existence of orphan cyclase receptors in the nematode, Using degenerate primers, a cDNA clone encoding a putative membrane form of the enzyme (GCY-X-1) was obtained, The apparent cyclase was most closely related to the mammalian natriuretic peptide receptor family, and retained cysteine residues conserved within the extracellular domain of the mammalian receptors, Expression of the cDNA in COS-7 cells resulted in low, but detectable guanylyl cyclase activity (about 2-fold above vector alone), The extracellular and protein kinase homology domain of the mammalian receptor (GC-B) for C-type natriuretic peptide (CNP) was fused to the catalytic domain of GCY-X, and expressed in COS-7 cells to determine whether ligand dependent regulation would now be obtained. The resulting chimeric protein (GC-BX1) was active, and CNP elevated cGMP in a concentration-dependent manner, Subsequently, a search of the genome data base demonstrated the existence of at least 29 different genes From C. elegans that align closely with the catalytic domain of GCY-X-1, and thus an equally large number of different regulatory ligands may exist.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Bin Sidney Yu, Siu/R-4936-2018	Bin Sidney Yu, Siu/0000-0001-9643-2729				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHRISMAN TD, 1975, J BIOL CHEM, V250, P374; Coburn CM, 1996, NEURON, V17, P695, DOI 10.1016/S0896-6273(00)80201-9; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DOMINO SE, 1991, METHOD ENZYMOL, V195, P345; DURBIN R, 1993, ACEDB AC ELEGANS DAT; FULLE HJ, 1995, P NATL ACAD SCI USA, V92, P3571, DOI 10.1073/pnas.92.8.3571; GARBERS DL, 1974, BIOCHEMISTRY-US, V13, P4166, DOI 10.1021/bi00717a015; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GARBERS DL, 1992, CELL, V71, P1; GILKES AF, 1994, BIOCHEM BIOPH RES CO, V204, P1318, DOI 10.1006/bbrc.1994.2607; HUANG XY, 1989, P NATL ACAD SCI USA, V86, P3640; KOLLER KJ, 1992, MOL CELL BIOL, V12, P2581, DOI 10.1128/MCB.12.6.2581; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIU WC, 1995, J BIOL CHEM, V270, P12418, DOI 10.1074/jbc.270.21.12418; MCNEIL L, 1995, J BIOL CHEM, V270, P7189, DOI 10.1074/jbc.270.13.7189; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; POTTER LR, 1992, J BIOL CHEM, V267, P14531; POTTER LR, 1994, J BIOL CHEM, V269, P14636; Schackwitz WS, 1996, NEURON, V17, P719, DOI 10.1016/S0896-6273(00)80203-2; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SINGH S, 1988, NATURE, V334, P708, DOI 10.1038/334708a0; TANG WJ, 1991, J BIOL CHEM, V266, P8595; THALHOFER HP, 1989, ARCH BIOCHEM BIOPHYS, V273, P535, DOI 10.1016/0003-9861(89)90513-4; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; WILLETT JD, 1978, COMP BIOCHEM PHYS B, V61, P243, DOI 10.1016/0305-0491(78)90169-4; WILSON EM, 1995, BIOCHEMISTRY-US, V34, P4696, DOI 10.1021/bi00014a025; Wood WB, 1988, NEMATODE CAENORHABDI	33	23	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					16035	16039		10.1074/jbc.272.25.16035	http://dx.doi.org/10.1074/jbc.272.25.16035			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188508	hybrid			2022-12-27	WOS:A1997XF32900068
J	DiJulio, DH; Watson, EL; Pessah, IN; Jacobson, KL; Ott, SM; Buck, ED; Singh, JC				DiJulio, DH; Watson, EL; Pessah, IN; Jacobson, KL; Ott, SM; Buck, ED; Singh, JC			Ryanodine receptor type III (Ry(3)R) identification in mouse parotid acini - Properties and modulation of [H-3]ryanodine-binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; MUSCLE SARCOPLASMIC-RETICULUM; CA2+-INDUCED CA2+ RELEASE; FK-506 BINDING-PROTEIN; RABBIT SKELETAL-MUSCLE; H-3 RYANODINE; RAT-BRAIN; INOSITOL 1,4,5-TRISPHOSPHATE; TERMINAL CISTERNAE; CAFFEINE	Immunoblot analysis and [H-3]ryanodine binding were used to characterize and identify ryanodine receptors (RyRs) in nonexcitable mouse parotid acini. Western analysis revealed ryanodine receptor type III (Ry(3)R) to be the only detectable isoform in parotid microsomal membranes. Binding of [H-3]ryanodine to microsomal fractions was dependent on Ca2+, salt, pH, and temperature. At 23 degrees C, and in the presence of 0.5 M KCl and 100 mu M Ca2+, [H-3]ryanodine bound specifically to membranes with high affinity (K-d = 6 nM); maximum binding capacity (B-max) was 275 fmol/mg protein. Mg2+ and ruthenium red inhibited [H-3]ryanodine binding: (IC50 = 1.4 mM and 0.5 mu M, respectively), 4-Chloro-3-ethylphenol enhanced the binding of [H-3]ryanodine 2.5-fold; whereas ATP and caffeine were much less efficacious toward activating Ry(3)R (56% and 18% maximal enhancement, respectively), Bastadin, a novel modulator of the 12-kDa FK506 binding protein RyR complex, increased [H-3]ryanodine binding 3-4-fold by enhancing K-d. The immunosuppressant FK506 enhanced [H-3]ryanodine receptor occupancy at >100 mu M and antagonized the action of bastadin, suggesting that an immunophilin modulates Ry(3)R in parotid acini, These results suggest that Ry(3)R may play an important role in Ca2+ homeostasis in mouse parotid acini.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195; UNIV CALIF DAVIS,DEPT MOL BIOSCI,DAVIS,CA 95616	University of Washington; University of Washington Seattle; University of California System; University of California Davis	DiJulio, DH (corresponding author), UNIV WASHINGTON,DEPT ORAL BIOL,SEATTLE,WA 98195, USA.		Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X	NIDCR NIH HHS [DE05249] Funding Source: Medline; NIEHS NIH HHS [ES05002] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES005002, R01ES005002] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AIREY JA, 1993, BIOCHEMISTRY-US, V32, P5739, DOI 10.1021/bi00073a003; BAUM BJ, 1990, METHOD ENZYMOL, V192, P26; Bennett DL, 1996, J BIOL CHEM, V271, P6356, DOI 10.1074/jbc.271.11.6356; BERRIDGE MJ, 1993, NATURE, V365, P388, DOI 10.1038/365388a0; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; BUCK E, 1992, J BIOL CHEM, V267, P23560; BULL R, 1989, BIOPHYS J, V56, P749, DOI 10.1016/S0006-3495(89)82722-5; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; CARROLL S, 1991, ARCH BIOCHEM BIOPHYS, V290, P239, DOI 10.1016/0003-9861(91)90615-P; CHU A, 1990, MOL PHARMACOL, V37, P735; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; DAMIANI E, 1994, J MUSCLE RES CELL M, V15, P86, DOI 10.1007/BF00130421; FEHER JJ, 1991, J MOL CELL CARDIOL, V23, P249, DOI 10.1016/0022-2828(91)90061-P; FENG L, 1992, CELL CALCIUM, V13, P79, DOI 10.1016/0143-4160(92)90001-9; FLEISCHER S, 1985, P NATL ACAD SCI USA, V82, P7256, DOI 10.1073/pnas.82.21.7256; FOSKETT JK, 1991, J BIOL CHEM, V266, P14535; FURUICHI T, 1994, J NEUROSCI, V14, P4794; GALAT A, 1995, PROG BIOPHYS MOL BIO, V63, P67, DOI 10.1016/0079-6107(94)00009-X; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; GIANNINI G, 1995, MED RES REV, V15, P313, DOI 10.1002/med.2610150405; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; GUSE AH, 1993, BIOCHEM J, V291, P447, DOI 10.1042/bj2910447; HAKAMATA Y, 1994, FEBS LETT, V352, P206, DOI 10.1016/0014-5793(94)00955-4; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HerrmannFrank A, 1996, BBA-GEN SUBJECTS, V1289, P31, DOI 10.1016/0304-4165(95)00131-X; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; Kay JE, 1996, BIOCHEM J, V314, P361, DOI 10.1042/bj3140361; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM E, 1995, J BIOL CHEM, V270, P26511, DOI 10.1074/jbc.270.44.26511; LARINI F, 1995, MOL PHARMACOL, V47, P21; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACK MM, 1994, J BIOL CHEM, V269, P23236; MANGOS JA, 1975, AM J PHYSIOL, V229, P553, DOI 10.1152/ajplegacy.1975.229.3.553; Marengo JJ, 1996, FEBS LETT, V383, P59, DOI 10.1016/0014-5793(96)00222-0; MAYRLEITNER M, 1994, CELL CALCIUM, V15, P99, DOI 10.1016/0143-4160(94)90048-5; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MCPHERSON PS, 1990, J BIOL CHEM, V265, P18454; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MESZAROS LG, 1991, AM J PHYSIOL, V261, pC1048, DOI 10.1152/ajpcell.1991.261.6.C1048; MICHALAK M, 1988, BIOCHIM BIOPHYS ACTA, V939, P587, DOI 10.1016/0005-2736(88)90106-X; Murayama T, 1996, J BIOL CHEM, V271, P5079; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; NELSON PA, 1991, GENE, V109, P255, DOI 10.1016/0378-1119(91)90617-K; OGAWA Y, 1990, J BIOCHEM-TOKYO, V107, P887, DOI 10.1093/oxfordjournals.jbchem.a123143; OGAWA Y, 1990, J BIOCHEM-TOKYO, V107, P894, DOI 10.1093/oxfordjournals.jbchem.a123144; PADUA RA, 1991, BRAIN RES, V542, P135, DOI 10.1016/0006-8993(91)91007-N; PADUA RA, 1994, J NEUROCHEM, V62, P2340; PESSAH IN, 1985, BIOCHEM BIOPH RES CO, V128, P449, DOI 10.1016/0006-291X(85)91699-7; PESSAH IN, 1986, J BIOL CHEM, V261, P8643; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; PETERSEN OH, 1991, CELL CALCIUM, V12, P135, DOI 10.1016/0143-4160(91)90015-7; RUSKO J, 1995, BRIT J PHARMACOL, V115, P133, DOI 10.1111/j.1476-5381.1995.tb16330.x; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SCOTT J, 1991, ARCH ORAL BIOL, V36, P855, DOI 10.1016/0003-9969(91)90035-S; SHOSHANBARMATZ V, 1992, BIOCHEM J, V285, P61, DOI 10.1042/bj2850061; SHOSHANBARMATZ V, 1991, BIOCHEM J, V276, P41, DOI 10.1042/bj2760041; SOCCI R, 1993, COMP BIOCHEM PHYS B, V106, P793, DOI 10.1016/0305-0491(93)90032-Z; SORRENTINO V, 1993, GENOMICS, V18, P163, DOI 10.1006/geno.1993.1446; TAKESHIMA H, 1995, EMBO J, V14, P2999, DOI 10.1002/j.1460-2075.1995.tb07302.x; Takeshima H, 1996, J BIOL CHEM, V271, P19649, DOI 10.1074/jbc.271.33.19649; TIMERMAN AP, 1994, BIOCHEM BIOPH RES CO, V198, P701, DOI 10.1006/bbrc.1994.1101; VALDIVIA HH, 1990, BIOPHYS J, V58, P471, DOI 10.1016/S0006-3495(90)82392-4; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; WATSON EL, 1993, AM J PHYSIOL, V265, pC1061; WATSON EL, 1981, AM J PHYSIOL, V240, pC189, DOI 10.1152/ajpcell.1981.240.5.C189; ZHANG ZD, 1993, BIOCHEM J, V290, P259, DOI 10.1042/bj2900259; ZIMANYI I, 1991, J PHARMACOL EXP THER, V256, P938; ZIMANYI I, 1991, BRAIN RES, V561, P181, DOI 10.1016/0006-8993(91)91594-Q; ZORZATO F, 1993, MOL PHARMACOL, V44, P1192	71	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15687	15696		10.1074/jbc.272.25.15687	http://dx.doi.org/10.1074/jbc.272.25.15687			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188460	hybrid			2022-12-27	WOS:A1997XF32900020
J	LeGros, HL; Geller, AM; Kotb, M				LeGros, HL; Geller, AM; Kotb, M			Differential regulation of methionine adenosyltransferase in superantigen and mitogen stimulated human T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE SYNTHETASE; RAT-LIVER; ISOENZYME PATTERNS; MOLECULAR-CLONING; CELL ACTIVATION; PURIFICATION; ISOZYMES; RECEPTOR; FRACTIONATION; INHIBITION	Superantigens interact with the T tell receptor for antigen (TCR) and are, therefore, more physiological stimulators of T lymphocytes than nonspecific polyclonal T cell mitogens. The effects of these two classes of T cell stimulators on methionine adenosyltransferase (MAT) and S-adenosylmethionine (AdoMet) levels were investigated, Activation of resting human peripheral blood T lymphocytes by the mitogen phytohemagglutinin (PHA) or the superantigen staphylococcal enterotoxin B (SEE) caused a 3- to 6-fold increase in MAT II specific activity. Although the proliferative response was higher in cultures stimulated with PHA compared with SEE, MAT II activity was comparable in both cultures. Both stimuli caused down-regulation of the MAT 68-kDa lambda subunit expression and induced a comparable increase in the expression of the catalytic alpha 2/alpha 2' subunit mRNA and protein. However, in superantigen-stimulated cells, the expression of the noncatalytic beta subunit was down-regulated and virtually disappeared by 72 h post-stimulation; whereas, no change in the expression of this subunit was noted in PHA-stimulated cells. Thus, at 72 h following stimulation, PHA-stimulated cells expressed MAT II alpha 2/alpha 2' and beta subunits while SEB-stimulated cells expressed the alpha 2/alpha 2' subunits only; the beta subunit was no longer expressed in superantigen-stimulated cells. Kinetic analysis of MAT II in extracts of PHA- and SEE-stimulated cells using reciprocal kinetic plots revealed that in the absence of the beta subunit the K-m of the enzyme for L-methionine (L-Met) was S-fold higher than in the presence of the beta subunit. Furthermore, AdoMet levels were 5-fold higher in cell extracts lacking the beta subunit (SEB-stimulated cell extracts) compared with extracts containing MAT II alpha 2/alpha 2' and beta subunits. We propose that the increased levels of AdoMet in superantigen-stimulated cells may be attributed to the absence of the beta subunit, which seems to have rendered MAT II less sensitive to product feedback inhibition by (-)AdoMet. The data suggest that the beta subunit of MAT II, which has no catalytic activity, may be a regulatory subunit that imparts a lower K-m for L-Met but increases the sensitivity to feedback inhibition by AdoMet, The down-regulation of the beta subunit, which occurred when T cells were stimulated via the TCR, may be an important mechanism to regulate AdoMet levels at different stages of T cell differentiation under physiological conditions.	UNIV TENNESSEE,CTR HLTH SCI,DEPT BIOCHEM,MEMPHIS,TN 38163; UNIV TENNESSEE,CTR HLTH SCI,DEPT MICROBIOL & IMMUNOL,MEMPHIS,TN 38163; UNIV TENNESSEE,CTR HLTH SCI,DEPT SURG,MEMPHIS,TN 38163; VET ADM MED CTR,MEMPHIS,TN 38104	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054892] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-54892-07] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ L, 1994, BIOCHEM J, V301, P557, DOI 10.1042/bj3010557; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTRON K, 1956, BIOCHEM J, V62, P315; CABRERO C, 1988, BIOCHIM BIOPHYS ACTA, V952, P277, DOI 10.1016/0167-4838(88)90127-6; CABRERO C, 1987, EUR J BIOCHEM, V170, P299, DOI 10.1111/j.1432-1033.1987.tb13699.x; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CARBONE AM, 1988, SCIENCE, V242, P1174, DOI 10.1126/science.2460926; Clarke S, 1993, CURR OPIN CELL BIOL, V5, P977, DOI 10.1016/0955-0674(93)90080-A; CORRALES F, 1991, HEPATOLOGY, V14, P528, DOI 10.1002/hep.1840140320; CORRALES F, 1990, HEPATOLOGY, V11, P216, DOI 10.1002/hep.1840110210; DELAROSA J, 1992, J BIOL CHEM, V267, P10699; DELAROSA J, 1995, J BIOL CHEM, V270, P21860; DELAROSA J, 1992, CANCER RES, V52, P3361; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GELLER AM, 1986, EXP EYE RES, V43, P997, DOI 10.1016/0014-4835(86)90077-1; GERMAN DC, 1983, J BIOL CHEM, V258, P997; HOFFMAN JL, 1983, METHOD ENZYMOL, V94, P223; HORIKAWA S, 1990, J BIOL CHEM, V265, P13683; HORIKAWA S, 1992, FEBS LETT, V312, P37, DOI 10.1016/0014-5793(92)81405-B; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; KLOTZ IM, 1946, ARCH BIOCHEM, V9, P109; KOTB M, 1995, CLIN MICROBIOL REV, V8, P411, DOI 10.1128/CMR.8.3.411; KOTB M, 1985, J BIOL CHEM, V260, P3923; KOTB M, 1990, BIOCHIM BIOPHYS ACTA, V1039, P253, DOI 10.1016/0167-4838(90)90193-J; KOTB M, 1990, BIOCHIM BIOPHYS ACTA, V1040, P137, DOI 10.1016/0167-4838(90)90068-Q; KOTB M, 1993, PHARMACOL THERAPEUT, V59, P125, DOI 10.1016/0163-7258(93)90042-C; KOTB M, 1987, J IMMUNOL, V139, P202; KOTB M, 1993, IMMUNOMETHODS, V2, P33; KOTB M, 1996, TRENDS GENET, V13, P51; LIAU MC, 1979, CANCER RES, V39, P162; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; MAJUMDAR G, 1991, CELL SIGNAL, V2, P521; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MATO JM, 1994, ADV EXP MED BIOL, V368, P113; MITSUI KI, 1988, J BIOL CHEM, V263, P11211; MUDD SH, 1973, ENZYMES, V3, P121; ODEN KL, 1983, BIOCHEMISTRY-US, V22, P2978, DOI 10.1021/bi00281a030; OHNISHI H, 1995, J IMMUNOL, V154, P3180; OKADA G, 1981, BIOCHEMISTRY-US, V20, P934, DOI 10.1021/bi00507a045; PAJARES MA, 1992, FEBS LETT, V309, P1, DOI 10.1016/0014-5793(92)80726-W; SEGEL IH, 1975, ENZYME KINETICS, P64; SULLIVAN DM, 1983, BIOCHEMISTRY-US, V22, P1636, DOI 10.1021/bi00276a017; SUMA Y, 1986, J BIOCHEM, V100, P67, DOI 10.1093/oxfordjournals.jbchem.a121707; TABOR CW, 1984, ADV ENZYMOL RAMB, V56, P251; TSUKADA K, 1980, BIOCHEM BIOPH RES CO, V94, P1078, DOI 10.1016/0006-291X(80)90529-X	46	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					16040	16047		10.1074/jbc.272.25.16040	http://dx.doi.org/10.1074/jbc.272.25.16040			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188509	hybrid			2022-12-27	WOS:A1997XF32900069
J	Raziuddin, A; Court, D; Sarkar, FH; Liu, YL; Kung, HF; Raziuddin, R				Raziuddin, A; Court, D; Sarkar, FH; Liu, YL; Kung, HF; Raziuddin, R			A c-erbB-2 promoter-specific nuclear matrix protein from human breast tumor tissues mediates NF-kappa B DNA binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATTACHMENT REGIONS; MOLECULAR-CLONING; TOPOISOMERASE-II; CANCER CELLS; GENE; TRANSCRIPTION; SCAFFOLD; ENHANCER; SITES; IDENTIFICATION	The c-erbB-2 gene overexpression plays a major role in the pathogenesis of breast cancer. Binding studies detected a nuclear matrix protein (NMP) in human breast tumor tissues that recognizes a matrix attachment re gion (MAR) in the immediate vicinity of the c-erbB-2 gene promoter. This NMP is expressed in breast tumor tissues and cell lines along with c-erbB-2, but is not found in corresponding normal tissues. Furthermore, when NMP purified from the breast tumors by its affinity to the MAR sequence is added to nuclear extracts of breast cancer cells, it selectively stimulates the binding of the NF-kappa B transcription factor to DNA. A model is suggested in which the association of the MAR like sequence with the nuclear matrix raises the local concentration of the specific NMP, which in turn interacts with the nuclear factor NF-kappa B to increase its local level. Such a complex could explain at a molecular level the ''increase in NF-kappa B DNA binding activity'' often observed in c-erbB-2- and BRCA1-positive human breast tumors. The increased NF-kappa B activity could thereby contribute to breast cancer progression.	NCI,FREDERICK CANC RES & DEV CTR,IRSP,SAIC,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,LAB BIOCHEM PHYSIOL,FREDERICK,MD 21702; WAYNE STATE UNIV,SCH MED,DEPT PATHOL,DETROIT,MI 48201	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Wayne State University								ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; BELGRADER P, 1991, J BIOL CHEM, V266, P9893; BIDWELL JP, 1993, P NATL ACAD SCI USA, V90, P3162, DOI 10.1073/pnas.90.8.3162; BRANCOLINI C, 1991, P NATL ACAD SCI USA, V88, P6936, DOI 10.1073/pnas.88.16.6936; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; DEJARDIN E, 1995, ONCOGENE, V11, P1835; DICKINSON LA, 1995, MOL CELL BIOL, V15, P456, DOI 10.1128/MCB.15.1.456; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; DWORETZKY SI, 1990, P NATL ACAD SCI USA, V87, P4605, DOI 10.1073/pnas.87.12.4605; DWORETZKY SI, 1992, P NATL ACAD SCI USA, V89, P4178, DOI 10.1073/pnas.89.9.4178; FEUERSTEIN N, 1988, J BIOL CHEM, V263, P10608; FEY EG, 1988, P NATL ACAD SCI USA, V85, P121, DOI 10.1073/pnas.85.1.121; FORRESTER WC, 1994, SCIENCE, V265, P1221, DOI 10.1126/science.8066460; GETZENBERG RH, 1990, MOL ENDOCRINOL, V4, P1336, DOI 10.1210/mend-4-9-1336; GORDON JN, 1993, CANCER RES, V53, P4971; HAKES DJ, 1991, P NATL ACAD SCI USA, V88, P6186, DOI 10.1073/pnas.88.14.6186; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; IBARAKI K, 1993, GENE, V130, P225, DOI 10.1016/0378-1119(93)90423-Z; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; KAS E, 1989, J MOL BIOL, V210, P587, DOI 10.1016/0022-2836(89)90134-4; KHANUJA PS, 1993, CANCER RES, V53, P3394; Kim MK, 1996, MOL CELL BIOL, V16, P4366; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; MIRKOVITCH J, 1984, CELL, V39, P2223; MIZUGUCHI G, 1994, FEBS LETT, V348, P80, DOI 10.1016/0014-5793(94)00578-8; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; PARTIN AW, 1993, CANCER RES, V53, P744; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; RAZIUDDIN J A M, 1991, Proceedings of the National Academy of Sciences of the United States of America, V88, P9426; SARKAR FH, 1994, J BIOL CHEM, V269, P12285; SCHAACK J, 1990, GENE DEV, V4, P1197, DOI 10.1101/gad.4.7.1197; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TSUTSUI K, 1988, J BIOL CHEM, V263, P7235; VANWIJNEN AJ, 1993, BIOCHEMISTRY-US, V32, P8397, DOI 10.1021/bi00084a003; VONKRIES JP, 1991, CELL, V64, P123, DOI 10.1016/0092-8674(91)90214-J; WEST M, 1992, J BIOL CHEM, V267, P24948; Yanagisawa J, 1996, CANCER RES, V56, P457; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179; ZENK DW, 1990, BIOCHEMISTRY-US, V29, P5221, DOI 10.1021/bi00474a001	45	22	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15715	15720		10.1074/jbc.272.25.15715	http://dx.doi.org/10.1074/jbc.272.25.15715			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188464	hybrid			2022-12-27	WOS:A1997XF32900024
J	Chatterjee, TK; Eapen, AK; Fisher, RA				Chatterjee, TK; Eapen, AK; Fisher, RA			A truncated form of RGS3 negatively regulates G protein-coupled receptor stimulation of adenylyl cyclase and phosphoinositide phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA; SACCHAROMYCES-CEREVISIAE; HUMAN GENE; PHOSPHOPROTEIN; ACTIVATION; SUBUNITS; KINASE	Identification of a new family of proteins (RGS proteins) that function as negative regulators of (G) under bar protein Signaling has sparked new understanding of desensitization of this signaling process, Recent studies with several mammalian RGS proteins has delineated their ability to interact with and function as GTPase activating proteins specifically for G proteins in the G(i) family, Here, we investigated the functional activity of RGS3 and a truncated form of RGS3 on G protein-coupled receptor-mediated activation of adenylyl cyclase, phosphoinositide phospholipase C, and mitogen-activated protein kinase in intact cells, Polymerase chain reaction and 5'-rapid amplification of cDNA ends analyses revealed the tissue specific expression of a short form of the RGS3 transcript that encodes the approximate carboxyl terminal half of RGS3. This truncated form of RGS3 (RGS3T) was shown recently to function as a negative regulator of pheromone signaling in yeast (Druey, K, M,, Blumer, K, J,, Rang, V, R,, and Kehrl, J, H, (1996) Nature 379, 742-746), Baby hamster kidney cells transiently transfected with RGS3T cDNA exhibited a pronounced impairment in platelet-activating factor receptor-stimulated inositol phosphate production, a pertussis toxin insensitive response, Similarly, calcitonin gene-related peptide receptor-stimulated increases in intracellular cAMP and pituitary adenylate-cyclase activating polypeptide receptor stimulated increases in both cAMP and inositol phosphates were reduced significantly in RGS3T transfectants compared with vector-transfected control cells, In contrast, baby hamster kidney cells transfected with the full length RGS3 cDNA showed no impairment in cAMP and inositol phosphate production mediated by these G; protein-coupled receptors, However, lysophosphatidic acid receptor-stimulated phosphorylation of endogenous ERK1 and ERK2 was impaired markedly in both RGS3 and RGS3T transfectants, demonstrating the functional ability of both RGS forms to modulate G(i)-mediated signaling, These results provide the first evidence for regulatory effects of an RGS protein on G(s)- and G(q)-mediated signaling in intact cells and document that the carboxyl-terminal region of RGS3 comprises the structural domain for this activity.	UNIV IOWA,COLL MED,DEPT PHARMACOL,IOWA CITY,IA 52242	University of Iowa			Chatterjee, Rima/J-8066-2017	Fisher, Rory/0000-0003-3108-4836	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL041071, R01HL041071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41071] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; Carlson SA, 1996, J BIOL CHEM, V271, P23146, DOI 10.1074/jbc.271.38.23146; Chatterjee TK, 1996, J BIOL CHEM, V271, P32226, DOI 10.1074/jbc.271.50.32226; CHATTERJEE TK, 1995, METH NEUROSCI, V26, P29; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; Damaj BB, 1996, J BIOL CHEM, V271, P12783, DOI 10.1074/jbc.271.22.12783; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; NAKAFUKU M, 1987, P NATL ACAD SCI USA, V84, P2140, DOI 10.1073/pnas.84.8.2140; NEWTON JS, 1993, BIOCHIM BIOPHYS ACTA, V1216, P314, DOI 10.1016/0167-4781(93)90163-8; SIDEROVSKI DP, 1994, DNA CELL BIOL, V13, P125, DOI 10.1089/dna.1994.13.125; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0	22	110	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15481	15487		10.1074/jbc.272.24.15481	http://dx.doi.org/10.1074/jbc.272.24.15481			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182581	hybrid			2022-12-27	WOS:A1997XE03400064
J	DellAngelica, EC; Ooi, CE; Bonifacino, JS				DellAngelica, EC; Ooi, CE; Bonifacino, JS			beta 3A-adaptin, a subunit of the adaptor-like complex AP-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-COATED VESICLES; PLASMA-MEMBRANE; PROTEIN COMPLEX; ALPHA-ADAPTIN; BINDING; RECEPTOR; PITS; SIGNALS; DOMAIN; PHOSPHORYLATION	Recent studies have described a widely expressed adaptor-like complex, named AP-3, which is likely involved in protein sorting in exocytic/endocytic pathways. The AP-3 complex is composed of four distinct subunits. Here, we report the identification of one of the subunits of this complex, which we call beta 3A-adaptin. The predicted amino acid sequence of beta 3A-adaptin reveals that the protein is closely related to the neuron-specific protein beta-NAP (61% overall identity) and more distantly related to the beta 1- and beta 2-adaptin subunits of the clathrin-associated adaptor complexes AP-1 and AP-2, respectively. Sequence comparisons also suggest that: beta 3A-adaptin has a domain organization similar to beta-NAP and to beta 1- and beta 2-adaptins, beta 3A-adaptin is expressed in all tissues and cells examined. Go-purification and co-precipitation analysesdemonstrate that beta 3A-adaptin corresponds to the similar to 140-kDa subunit of the ubiquitous AP-3 complex, the other subunits being delta-adaptin, p47A (now called mu 3A) and sigma 3 (A or 8). beta 3A-adaptin is phosphorylated on serine residues in vivo while the other subunits of the complex are not detectably phosphorylated, beta 3A-adaptin is not present in significant amounts in clathrin-coated vesicles, The characteristics of beta 3A-adaptin reported here lend support to the idea that AP-3 is a structural and functional homolog of the clathrin-associated adaptors AP-1 and AP-2.	NICHHD, CBMB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Bonifacino, Juan S./0000-0002-5673-6370				AHLE S, 1989, J BIOL CHEM, V264, P20089; BARZVI D, 1988, J BIOL CHEM, V263, P4408; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; BOLL W, 1995, CURR BIOL, V5, P1168, DOI 10.1016/S0960-9822(95)00233-8; CHANG MP, 1993, EMBO J, V12, P2169, DOI 10.1002/j.1460-2075.1993.tb05865.x; Cosson P, 1996, EMBO J, V15, P1792, DOI 10.1002/j.1460-2075.1996.tb00528.x; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; Faulstich D, 1996, J CELL BIOL, V135, P53, DOI 10.1083/jcb.135.1.53; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; GILBOA L, 1995, J BIOL CHEM, V270, P7061, DOI 10.1074/jbc.270.13.7061; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; HARDIE G, 1995, PROTEIN KINASE FACTS, P240; HARLOW E, 1988, ANTIBODIES; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; HEUSER JE, 1988, J CELL BIOL, V107, P877, DOI 10.1083/jcb.107.3.877; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; KEEN JH, 1986, J CELL BIOL, V102, P1325, DOI 10.1083/jcb.102.4.1325; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; KIRCHHAUSEN T, 1993, CURR OPIN STRUC BIOL, V3, P182, DOI 10.1016/S0959-440X(05)80150-2; KUGE O, 1993, J CELL BIOL, V123, P1727, DOI 10.1083/jcb.123.6.1727; KUSSEL P, 1995, J CELL BIOL, V129, P1491, DOI 10.1083/jcb.129.6.1491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORRIS SA, 1990, J BIOL CHEM, V265, P3354; NEWMAN LS, 1995, CELL, V82, P773, DOI 10.1016/0092-8674(95)90474-3; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PAGE LJ, 1995, J CELL BIOL, V131, P619, DOI 10.1083/jcb.131.3.619; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PEVSNER J, 1994, GENE, V146, P279, DOI 10.1016/0378-1119(94)90306-9; PONNAMBALAM S, 1990, J BIOL CHEM, V265, P4814; ROBINSON MS, 1993, J CELL BIOL, V123, P67, DOI 10.1083/jcb.123.1.67; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHRODER S, 1991, J BIOL CHEM, V266, P7910; Sheff D, 1996, J BIOL CHEM, V271, P7230, DOI 10.1074/jbc.271.12.7230; Shih W, 1995, J BIOL CHEM, V270, P31083, DOI 10.1074/jbc.270.52.31083; SIEGEL JN, 1992, CURRENT PROTOCOLS IM; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SOSA MA, 1993, J BIOL CHEM, V268, P12537; Traub LM, 1997, TRENDS CELL BIOL, V7, P43, DOI 10.1016/S0962-8924(96)20042-X; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Watanabe TK, 1996, CYTOGENET CELL GENET, V73, P214, DOI 10.1159/000134341; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; [No title captured]	52	114	116	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15078	15084		10.1074/jbc.272.24.15078	http://dx.doi.org/10.1074/jbc.272.24.15078			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182526	hybrid			2022-12-27	WOS:A1997XE03400009
J	Erhardt, P; Tomaselli, KJ; Cooper, GM				Erhardt, P; Tomaselli, KJ; Cooper, GM			Identification of the MDM2 oncoprotein as a substrate for CPP32-like apoptotic proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; PROTEIN; GENE	Programmed cell death is mediated by members of the interleukin 1-beta convertase family of proteases, which are activated in response to diverse cell death stimuli. However, the key substrates of these proteases that are responsible for apoptotic cell death have not been identified. Here we report that the MDM2 oncoprotein is cleaved by members of the CPP32 subfamily of interleukin l-p convertase proteases both in vitro and in vivo, resulting in the disappearance of MDM2 from apoptotic cells. Because MDM2 functions as a negative regulator of the p53 tumor suppressor and because p53 induces apoptosis in response to a variety of stimuli, this cleavage of MDM2 by CPP32-like proteases may result in deregulation of p53 and contribute directly to the process of apoptotic cell death.	DANA FARBER CANC INST,DIV MOL GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; IDUN PHARMACEUT INC,LA JOLLA,CA 92037	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA018689] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA18689] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; CASCIOLAROSEN L, 1996, J EXP MED, V183, P1947; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; GOTTLIEB MT, 1996, BIOCHIM BIOPHYS ACTA, V1287, P77; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MOMAND J, 1992, CELL, V69, P1127; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	28	83	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15049	15052		10.1074/jbc.272.24.15049	http://dx.doi.org/10.1074/jbc.272.24.15049			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182520	hybrid			2022-12-27	WOS:A1997XE03400003
J	Dennery, PA; Sridhar, KJ; Lee, CS; Wong, HE; Shokoohi, V; Rodgers, PA; Spitz, DR				Dennery, PA; Sridhar, KJ; Lee, CS; Wong, HE; Shokoohi, V; Rodgers, PA; Spitz, DR			Heme oxygenase-mediated resistance to oxygen toxicity in hamster fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; OXIDANT DAMAGE; RAT-LIVER; IRON; FERRITIN; EXPRESSION; SUPEROXIDE; BILIRUBIN	The role of heme oxygenase (HO)-1 was evaluated in the oxygen-resistant hamster fibroblast cell line, O(2)R95, which moderately overexpress HO when compared with the parental cell line, HA-1. To suppress HO-1 expression, O(2)R95 were transfected with HO-1 antisense oligonucleotide or treated with tin-mesoporphyrin (SnMP), To increase HO-1 expression, cells were transfected with HO-1 cDNA in a pRC/cytomegalovirus (CMV) vector, All cells were challenged with a 48-h exposure to 95% O-2 (hyperoxia). When HO activity was suppressed, O(2)R95 cells had significantly decreased Cell viability, increased susceptibility to lipid peroxidation, and increased protein oxidation in hyperoxia. In contrast, further overexpression of HO-1 did not improve resistance to oxygen toxicity. Antisense-transfected cells and SnMP-treated cells with lowered HO activity showed increased levels of cellular heme compared with controls, In the HO-1 cDNA-transfected O(2)R95 cells, cellular heme was lowered compared with controls; however, cellular redox active iron levels were increased, We conclude that HO mediates cytoprotection to oxygen toxicity within a narrow range of expression, We speculate that this protective effect may be mediated in part through increased metabolism of the pro-oxidant heme but that higher levels of HO activity obviate protection by increased redox active iron release.	WASHINGTON UNIV, DEPT RADIOL, CANC BIOL SECT, ST LOUIS, MO 63108 USA	Washington University (WUSTL)	Dennery, PA (corresponding author), STANFORD UNIV, SCH MED, DEPT PEDIAT, 750 WELCH RD, 315, PALO ALTO, CA 94304 USA.		Dennery, Phyllis/GQG-9113-2022	Dennery, Phyllis/0000-0001-5745-1855; Spitz, Douglas/0000-0002-1254-8765	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL052701, R01HL051469] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; AEBI H, 1984, METHOD ENZYMOL, V105, P121; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; AUST SD, 1990, METHOD ENZYMOL, V186, P457; BALLA G, 1990, J LAB CLIN MED, V116, P546; BALLA G, 1992, J BIOL CHEM, V267, P18148; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; BEERS RF, 1952, J BIOL CHEM, V195, P133; BONFILS C, 1995, ANAL BIOCHEM, V226, P302, DOI 10.1006/abio.1995.1229; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER P, 1971, ANAL BIOCHEM, V40, P450, DOI 10.1016/0003-2697(71)90405-2; CHRISTENSEN T, 1983, BRIT J CANCER, V48, P35, DOI 10.1038/bjc.1983.154; COCCIA EM, 1994, J BIOL REG HOMEOS AG, V8, P81; Dennery PA, 1996, AM J PHYSIOL-LUNG C, V271, pL672, DOI 10.1152/ajplung.1996.271.4.L672; Dennery PA, 1996, J INVEST MED, V44, pA114; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; LLESUY SF, 1994, BBA-MOL CELL RES, V1223, P9, DOI 10.1016/0167-4889(94)90067-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MINOTTI G, 1992, LIPIDS, V27, P219, DOI 10.1007/BF02536182; MONYER H, 1989, BRAIN RES, V483, P347, DOI 10.1016/0006-8993(89)90179-0; NELSON SK, 1994, FREE RADICAL BIO MED, V16, P195, DOI 10.1016/0891-5849(94)90143-0; NY L, 1995, BRIT J PHARMACOL, V115, P186, DOI 10.1111/j.1476-5381.1995.tb16337.x; Rodgers PA, 1996, PEDIATR RES, V39, P1041, DOI 10.1203/00006450-199606000-00018; SHACTER E, 1994, FREE RADICAL BIO MED, V17, P429, DOI 10.1016/0891-5849(94)90169-4; SIMONS PC, 1977, ANAL BIOCHEM, V82, P334, DOI 10.1016/0003-2697(77)90169-5; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; SULLIVAN SJ, 1992, AM J PHYSIOL, V262, pL748, DOI 10.1152/ajplung.1992.262.6.L748; VALAES T, 1994, PEDIATRICS, V93, P1; VERCELLOTTI GM, 1994, ARTIF CELL BLOOD SUB, V22, P207, DOI 10.3109/10731199409117415; VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607; VILE GF, 1993, J BIOL CHEM, V268, P14678; VREMAN HJ, 1988, ANAL BIOCHEM, V168, P31, DOI 10.1016/0003-2697(88)90006-1; WILKS A, 1993, J BIOL CHEM, V268, P22357; WRIGHT JR, 1981, ARCH BIOCHEM BIOPHYS, V206, P296, DOI 10.1016/0003-9861(81)90095-3	36	121	122	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14937	14942		10.1074/jbc.272.23.14937	http://dx.doi.org/10.1074/jbc.272.23.14937			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169465	hybrid			2022-12-27	WOS:A1997XC32700062
J	Landis, CA; Bobkova, A; Homsher, E; Tobacman, LS				Landis, CA; Bobkova, A; Homsher, E; Tobacman, LS			The active state of the thin filament is destabilized by an internal deletion in tropomyosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; TROPONIN-TROPOMYOSIN; ALPHA-TROPOMYOSIN; MYOSIN SUBFRAGMENT-1; F-ACTIN; COOPERATIVE BINDING; ESCHERICHIA-COLI; HEAVY-MEROMYOSIN; CALCIUM-BINDING; COMPLEX	The function of three of tropomyosin's sequential quasiequivalent regions was studied by deletion from skeletal muscle alpha-tropomyosin of internal residues 49-167, This deletion mutant tropomyosin spans four instead of the normal seven actins, and most of the tropomyosin region believed to interact with troponin is retained and uninterrupted in the mutant. The mutant tropomyosin was compared with a full-length control molecule that was modified to functionally resemble muscle tropomyosin (Monteiro, P. B., Lataro, R. C., Ferro, J. A., and Reinach, F. C. (1994) J. Biol. Chem. 269, 10461-10466). The tropomyosin deletion suppressed the actin-myosin subfragment 1 MgATPase rate and the in vitro sliding of thin filaments over a heavy meromyosin-coated surface, This inhibition was not reversed by troponin plus Ca2+. Comparable tropomyosin affinities for actin, regardless of the deletion, suggest that the deleted region has little interaction with actin in the absence of other proteins, Similarly, the deletion did not weaken binding of the troponin-tropomyosin complex to actin. Furthermore, Ca2+ had a 2-fold effect on troponin-tropomyosin's affinity for actin, regardless of the deletion, Notably, the deletion greatly weakened tropomyosin binding to myosin subfragment 1-decorated actin, with the full-length tropomyosin having a 100-fold greater affinity, The inhibitory properties resulting from the deletion are attributed to defective stabilization of the myosin-induced active state of the thin filament.	UNIV IOWA,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242; UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,LOS ANGELES,CA 90024	University of Iowa; University of Iowa; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								BREMEL RD, 1972, NATURE-NEW BIOL, V238, P97, DOI 10.1038/newbio238097a0; BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; BUTTERS CA, 1997, IN PRESS J BIOL CHEM, V272; CANTINO ME, 1993, BIOPHYS J, V64, P211, DOI 10.1016/S0006-3495(93)81358-4; Cassell M, 1996, J BIOL CHEM, V271, P12867, DOI 10.1074/jbc.271.22.12867; EATON BL, 1976, SCIENCE, V192, P1337, DOI 10.1126/science.131972; FISHER D, 1995, J BIOL CHEM, V270, P25455, DOI 10.1074/jbc.270.43.25455; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GREENE LE, 1980, P NATL ACAD SCI-BIOL, V77, P2616, DOI 10.1073/pnas.77.5.2616; GUTH K, 1987, J BIOL CHEM, V262, P13627; HEALD RW, 1988, J BIOL CHEM, V263, P5254; HEELEY DH, 1987, J BIOL CHEM, V262, P9971; HILL LE, 1992, J BIOL CHEM, V267, P16106; HitchcockDeGregori SE, 1996, J BIOL CHEM, V271, P3600; HITCHCOCKDEGREGORI SE, 1990, J MOL BIOL, V214, P885, DOI 10.1016/0022-2836(90)90343-K; HITCHCOCKDEGREGORI SE, 1987, J BIOL CHEM, V262, P9730; HOFFMAN PA, 1987, AM J PHYSIOL, V253, pC541; HOLMES KC, 1995, BIOPHYS J, V68, pS2; Homsher E, 1996, BIOPHYS J, V70, P1881, DOI 10.1016/S0006-3495(96)79753-9; HOMSHER E, 1992, AM J PHYSIOL, V262, pC714, DOI 10.1152/ajpcell.1992.262.3.C714; Huynh Q, 1996, BIOPHYS J, V70, P1447, DOI 10.1016/S0006-3495(96)79704-7; LAMKIN M, 1983, BIOCHEMISTRY-US, V22, P3053, DOI 10.1021/bi00282a005; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; LEHMAN W, 1995, J MOL BIOL, V251, P191, DOI 10.1006/jmbi.1995.0425; LEHMAN W, 1996, BIOPHYS J, V70, P15; LEHRER SS, 1982, J BIOL CHEM, V257, P8073; LORENZ M, 1995, J MOL BIOL, V246, P108, DOI 10.1006/jmbi.1994.0070; Mabuchi K, 1996, J STRUCT BIOL, V116, P278, DOI 10.1006/jsbi.1996.0043; MAK AS, 1981, J MOL BIOL, V149, P541, DOI 10.1016/0022-2836(81)90486-1; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; Metzger JM, 1996, BIOPHYS J, V70, P409, DOI 10.1016/S0006-3495(96)79584-X; MILLAR NC, 1990, J BIOL CHEM, V265, P20234; MONTEIRO PB, 1994, J BIOL CHEM, V269, P10461; MORRIS EP, 1984, BIOCHEMISTRY-US, V23, P2214, DOI 10.1021/bi00305a018; MURRAY JM, 1982, BIOCHEMISTRY-US, V21, P906, DOI 10.1021/bi00534a015; MURRAY JM, 1975, CALCIUM TRANSPORT CO, P489; PAN BS, 1987, J BIOL CHEM, V262, P7839; PEARLSTONE JR, 1983, J BIOL CHEM, V258, P2534; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; POOLE KJV, 1994, BIOPHYS J, V68, P348; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Regnier M, 1995, AM J PHYSIOL-CELL PH, V269, pC1532, DOI 10.1152/ajpcell.1995.269.6.C1532; ROSENFELD SS, 1985, J BIOL CHEM, V260, P252; SMILLIE LB, 1980, J MOL BIOL, V136, P199, DOI 10.1016/0022-2836(80)90314-9; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SZCZESNA D, 1989, BIOL CHEM H-S, V370, P399, DOI 10.1515/bchm3.1989.370.1.399; TANOKURA M, 1983, J BIOCHEM, V93, P331, DOI 10.1093/oxfordjournals.jbchem.a134185; TAO T, 1986, BIOCHEMISTRY-US, V25, P7633, DOI 10.1021/bi00371a054; TOBACMAN LS, 1986, BIOCHEMISTRY-US, V25, P798, DOI 10.1021/bi00352a010; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; TRYBUS KM, 1980, P NATL ACAD SCI-BIOL, V77, P7209, DOI 10.1073/pnas.77.12.7209; URBANCIKOVA M, 1994, J BIOL CHEM, V269, P24310; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; VIBERT P, 1996, BIOPHYS J, V70, P15; WALKER JW, 1992, J BIOL CHEM, V267, P2459; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; WILLADSEN KA, 1992, J BIOL CHEM, V267, P23746; WILLIAMS DL, 1988, BIOCHEMISTRY-US, V27, P6987, DOI 10.1021/bi00418a048; Zhao Y, 1996, BIOPHYS J, V71, P2759, DOI 10.1016/S0006-3495(96)79469-9; [No title captured]	64	52	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14051	14056		10.1074/jbc.272.22.14051	http://dx.doi.org/10.1074/jbc.272.22.14051			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162027	hybrid			2022-12-27	WOS:A1997XB49200014
J	Lei, ZM; Rao, CV				Lei, ZM; Rao, CV			cis-acting elements and trans-acting proteins in the transcriptional inhibition of gonadotropin-releasing hormone gene by human chorionic gonadotropin in immortalized hypothalamic GT1-7 neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GNRH NEURONS; RAT-BRAIN; EXPRESSION; PROMOTER; REPRESSION; RECEPTORS; ENHANCER; MEDIATE; SYSTEM; CELLS	We investigated the cis-acting elements and trans-acting proteins required for the transcriptional inhibition of the gonadotropin releasing horomone (GnRH) gene by human chorionic gonadotropin (hCG) in GT1-7 neurons. Transient transfection of GT1-7 neurons with the 5'-flanking region of the rat GnRH gene-luciferase fusion constructs revealed that a 53-base pair (bp) sequence between -126 and -73 bp is required for the hCG inhibition. Nuclear extracts from GT1-7 neurons contained 110- and 95-MDa proteins that formed two complexes with the 53-bp sequence, These proteins are not related to Fos, cAMP response element-binding protein; Oct-1, or progesterone receptors, and hCG treatment selectively increased the 95-kDa protein, DNase I footprinting with GT1-7 cell nuclear extracts protected the -99 to -79-bp region, which contained a so-called imperfect AP-1 site (-99 to -94 bp) and two AT-rich palindromic sequences (-91 to -87 bp and -85 to -81 bp), The mutagenesis of the AT-rich regions, but not the AP-1 site, resulted in a loss of DNA binding of the 95-kDa protein and the inhibitory effect of hCG, In summary, our results are consistent with hCG inducing a 95-kDa trans-acting protein, which binds to -91- to -81-bp AT-rich sequences in the 5'-flanking region to inhibit the transcription of the GnRH gene.	UNIV LOUISVILLE, HLTH SCI CTR, DEPT OBSTET & GYNECOL, LAB MOL REPROD BIOL & MED, LOUISVILLE, KY 40292 USA	University of Louisville								BLACKLOW SC, 1991, DIRECTED MUTAGENESIS, P177; BRUDER JM, 1994, MOL CELL ENDOCRINOL, V99, P177, DOI 10.1016/0303-7207(94)90006-X; BURDER JM, 1996, MOL ENDOCRINOL, V10, P35; CLARK ME, 1995, MOL CELL BIOL, V15, P6169; DAVID MA, 1966, ENDOCRINOLOGY, V78, P55, DOI 10.1210/endo-78-1-55; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERALY SA, 1995, MOL ENDOCRINOL, V9, P848, DOI 10.1210/me.9.7.848; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; Jackson S. P., 1993, Gene transcription: a practical approach., P189; KALRA SP, 1983, ENDOCR REV, V4, P311, DOI 10.1210/edrv-4-4-311; KEPA JK, 1992, NUCLEIC ACIDS RES, V20, P1393, DOI 10.1093/nar/20.6.1393; Kepa JK, 1996, MOL CELL ENDOCRINOL, V117, P27, DOI 10.1016/0303-7207(95)03723-3; Kordon Claude, 1994, P1621; LEI ZM, 1994, MOL ENDOCRINOL, V8, P1111, DOI 10.1210/me.8.8.1111; LEI ZM, 1995, MOL CELL ENDOCRINOL, V109, P151, DOI 10.1016/0303-7207(95)03497-U; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; Li X, 1996, ENDOCRINOLOGY, V137, P899, DOI 10.1210/en.137.3.899; LIPOSITS Z, 1984, NEUROSCIENCE, V13, P513, DOI 10.1016/0306-4522(84)90245-8; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; MELLON PL, 1991, RECENT PROG HORM RES, V47, P69; MERCHENTHALER I, 1984, CELL TISSUE RES, V237, P15; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Mores N, 1996, ENDOCRINOLOGY, V137, P5731, DOI 10.1210/en.137.12.5731; PFAFF DW, 1986, J NEUROSCI RES, V16, P109, DOI 10.1002/jnr.490160111; POHL CR, 1982, ANNU REV PHYSIOL, V44, P583, DOI 10.1146/annurev.ph.44.030182.003055; QUINN PG, 1993, J BIOL CHEM, V268, P16999; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SEEBURG PH, 1987, RECENT PROG HORM RES, V43, P69; Steel R.G.D., 1960, PRINCIPLES PROCEDURE, P99; WHYTE DB, 1995, MOL ENDOCRINOL, V9, P465	33	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14365	14371		10.1074/jbc.272.22.14365	http://dx.doi.org/10.1074/jbc.272.22.14365			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162073	hybrid			2022-12-27	WOS:A1997XB49200060
J	Scherr, M; Grez, R; Ganser, A; Engels, JW				Scherr, M; Grez, R; Ganser, A; Engels, JW			Specific hammerhead ribozyme-mediated cleavage of mutant N-ras mRNA in vitro and ex vivo - Oligoribonucleotides as therapeutic agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; CATALYTIC ACTIVITY; GENE-EXPRESSION; MESSENGER-RNA; MAMMALIAN-CELLS; IN-VIVO; INVIVO; DNA; ENZYMES; OLIGONUCLEOTIDES	Two hammerhead ribozymes targeted to point mutations in codon 13 of the N-ras oncogene were synthesized and their catalytic activity and substrate specificity evaluated in vitro and ex vivo. In vitro studies showed that these ribozymes were specific for the oncogenic form of N-ras, since cleavage was observed only in a 849-nucleotide-long transcript containing mutant but not wild-type N-ras sequences. For the ex vivo studies, the ribozymes were 2'-modified to protect them against degradation by nucleases. 2'-Fluoro-2'-deoxyuridine/cytidine-substituted ribozymes were nearly as active as their unmodified counterparts, but had a prolonged stability in cell culture supernatant containing fetal calf serum. The stability of the modified ribozymes increased by introduction of terminal phosphorothioates groups without significant influence in their catalytic efficiency. A sensitive assay based on the use of N-ras/luciferase fusion genes as a reporter system was established to detect ribozyme-mediated cleavage in HeLa cells. A reduction of nearly 60% in luciferase activity was observed in cells expressing mutant but not wild type N-ras/luciferase fusion transcripts. Moreover, cleavage of N-ras transcripts in HeLa cells was directly confirmed by a semi-quantitative RT-PCR assay.	UNIV FRANKFURT, INST ORGAN CHEM, D-60439 FRANKFURT, GERMANY; GEORG SPEYER HAUS, ABT MOL VIROL 3, D-60596 FRANKFURT, GERMANY; HANNOVER MED SCH, ABT HAMATOL & ONKOL, D-30625 HANNOVER, GERMANY	Goethe University Frankfurt; Octapharma; Hannover Medical School			Engels, Joachim W/A-9224-2012					ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; ALTMAN S, 1989, ADV ENZYMOL RAMB, V62, P1; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Beck J, 1995, NUCLEIC ACIDS RES, V23, P4954, DOI 10.1093/nar/23.24.4954; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOS JL, 1989, CANCER RES, V49, P4682; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMERON FH, 1989, P NATL ACAD SCI USA, V86, P9139, DOI 10.1073/pnas.86.23.9139; CECH TR, 1990, ANGEW CHEM INT EDIT, V29, P759, DOI 10.1002/anie.199007591; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLLINS S, 1992, TRENDS BIOCHEM SCI, V17, P37, DOI 10.1016/0968-0004(92)90425-9; COTTEN M, 1989, EMBO J, V8, P3861, DOI 10.1002/j.1460-2075.1989.tb08564.x; COTTEN M, 1989, MOL CELL BIOL, V9, P4479, DOI 10.1128/MCB.9.10.4479; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EDGINGTON SM, 1992, BIO-TECHNOL, V10, P152; FEDOR MJ, 1992, BIOCHEMISTRY-US, V31, P12042, DOI 10.1021/bi00163a012; Flory CM, 1996, P NATL ACAD SCI USA, V93, P754, DOI 10.1073/pnas.93.2.754; GOODCHILD J, 1992, NUCLEIC ACIDS RES, V20, P4607, DOI 10.1093/nar/20.17.4607; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HEIDENREICH O, 1994, J BIOL CHEM, V269, P2131; Heidenreich O, 1996, ANTISENSE NUCLEIC A, V6, P141, DOI 10.1089/oli.1.1996.6.141; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; HIRAI H, 1987, NATURE, V327, P430, DOI 10.1038/327430a0; Kashani-Sabet M, 1992, Antisense Res Dev, V2, P3; KHORANA HG, 1979, SCIENCE, V203, P614, DOI 10.1126/science.366749; KIEHNTOPF M, 1994, EMBO J, V13, P4645, DOI 10.1002/j.1460-2075.1994.tb06787.x; KOIZUMI M, 1989, NUCLEIC ACIDS RES, V17, P7059, DOI 10.1093/nar/17.17.7059; KOIZUMI M, 1992, GENE, V117, P179, DOI 10.1016/0378-1119(92)90727-7; Leonetti JP, 1990, BIOCONJUGATE CHEM, V1, P149, DOI 10.1021/bc00002a010; LETSINGER RL, 1989, P NATL ACAD SCI USA, V86, P6553, DOI 10.1073/pnas.86.17.6553; LYNGSTADAAS SP, 1995, EMBO J, V14, P5224, DOI 10.1002/j.1460-2075.1995.tb00207.x; MACKELLAR C, 1992, NUCLEIC ACIDS RES, V20, P3411, DOI 10.1093/nar/20.13.3411; PAOLELLA G, 1992, EMBO J, V11, P1913, DOI 10.1002/j.1460-2075.1992.tb05244.x; PERREAULT JP, 1990, NATURE, V344, P565, DOI 10.1038/344565a0; PORTIER M, 1992, ONCOGENE, V7, P2539; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SAXENA SK, 1990, J BIOL CHEM, V265, P17106; SCANLON KJ, 1991, P NATL ACAD SCI USA, V88, P10591, DOI 10.1073/pnas.88.23.10591; SHIBAHARA S, 1989, NUCLEIC ACIDS RES, V17, P239, DOI 10.1093/nar/17.1.239; SHORE SK, 1993, ONCOGENE, V8, P3183; STEINECKE P, 1992, EMBO J, V11, P1525, DOI 10.1002/j.1460-2075.1992.tb05197.x; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; TAYLOR NR, 1992, NUCLEIC ACIDS RES, V20, P4559, DOI 10.1093/nar/20.17.4559; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; YANG JH, 1992, BIOCHEMISTRY-US, V31, P5005, DOI 10.1021/bi00136a013	48	52	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14304	14313		10.1074/jbc.272.22.14304	http://dx.doi.org/10.1074/jbc.272.22.14304			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162065	hybrid			2022-12-27	WOS:A1997XB49200052
J	Presley, JF; Mayor, S; McGraw, TE; Dunn, KW; Maxfield, FR				Presley, JF; Mayor, S; McGraw, TE; Dunn, KW; Maxfield, FR			Bafilomycin A(1) treatment retards transferrin receptor recycling more than bulk membrane recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MEDIATED ENDOCYTOSIS; ASIALOGLYCOPROTEIN RECEPTOR; INTERNALIZATION MOTIF; RAPID ACIDIFICATION; CYTOPLASMIC DOMAIN; LATE ENDOSOMES; CELLS; COMPARTMENT; TRAFFICKING	Treatment of Chinese hamster ovary cells with the vacuolar proton pump inhibitor bafilomycin A(1) causes a 2-fold retardation in the rate of recycling of transfected human transferrin receptors back to the cell surface as measured using biochemical assays (Johnson, L. S., Dunn, K. W., Pytowski, B., and McGraw, T. E. (1993) Mol. Biol. Cell 4, 1251-1266). We have used quantitative fluorescence microscopy to determine which step(s) in the endocytic recycling pathway are affected. We show that removal of transferrin from sorting endosomes and accumulation in the peri-centriolar endocytic recycling compartment takes place normally in bafilomycin A(1)-treated cells. However, the rate constant for exit of transferrin receptors from recycling endosomes (k(e)) is reduced from 0.063 min(-1) in untreated cells to 0.034 min(-1) in the presence of bafilomycin A(1). This retardation appears to be dependent on the presence of internalization motifs in the cytoplasmic domain since modified receptors lacking these oligopeptide motifs do not show as large a decrease in recycling rate in the presence of bafilomycin A(1). Bulk membrane recycling (measured by efflux of an internalized fluorescent lipid analog, 6-[N-[7-nitrobenzo-2-oxa-1,3-diazol-4-yl]-amino]hexoyl-sphingosylphosphorylcholine) is slowed from an exit rate constant of 0.060 min(-1) without drug to 0.046 min(-1) in the presence of bafilomycin A(1). We conclude that bafilomycin A(1) slows bulk membrane flow, but it causes additional inhibition of receptor recycling in a manner that is dependent on a peptide motif on the cytoplasmic domain.	CORNELL UNIV,COLL MED,DEPT BIOCHEM,NEW YORK,NY 10021; COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032	Cornell University; Columbia University			Maxfield, Fred/A-1718-2011; Maxfield, Fred/M-6747-2019	Maxfield, Fred/0000-0003-4396-8866	NIDDK NIH HHS [DK27083] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK027083, R01DK027083] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAUTRYVARSAT A, 1983, P NATL ACAD SCI USA, V80, P2253; DUNN KW, 1992, J CELL BIOL, V117, P301, DOI 10.1083/jcb.117.2.301; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; DUNN KW, 1994, J BIOL CHEM, V269, P5336; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GHOSH RN, 1994, J CELL SCI, V107, P2177; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; JOHNSON LS, 1994, J CELL PHYSIOL, V158, P29, DOI 10.1002/jcp.1041580105; JOHNSON LS, 1993, MOL BIOL CELL, V4, P1251, DOI 10.1091/mbc.4.12.1251; KLAUSNER RD, 1984, J CELL BIOL, V98, P1098, DOI 10.1083/jcb.98.3.1098; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; MARSH EW, 1995, J CELL BIOL, V129, P1509, DOI 10.1083/jcb.129.6.1509; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; PRESLEY JF, 1993, J CELL BIOL, V122, P1231, DOI 10.1083/jcb.122.6.1231; PYTOWSKI B, 1995, J BIOL CHEM, V270, P9067, DOI 10.1074/jbc.270.16.9067; SALZMAN NH, 1989, J CELL BIOL, V109, P2097, DOI 10.1083/jcb.109.5.2097; SCHWARTZ AL, 1984, J CELL BIOL, V98, P732, DOI 10.1083/jcb.98.2.732; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TIETZE C, 1980, BIOCHEM BIOPH RES CO, V93, P1, DOI 10.1016/S0006-291X(80)80237-3; TYCKO B, 1983, J CELL BIOL, V97, P1762, DOI 10.1083/jcb.97.6.1762; TYCKO B, 1982, CELL, V28, P643, DOI 10.1016/0092-8674(82)90219-7; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; YAMASHIRO DJ, 1984, J CELL BIOCHEM, V26, P231, DOI 10.1002/jcb.240260404; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8	31	137	137	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13929	13936		10.1074/jbc.272.21.13929	http://dx.doi.org/10.1074/jbc.272.21.13929			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153255	hybrid			2022-12-27	WOS:A1997XA06200070
J	Gu, HH; Griffin, JD; Neel, BG				Gu, HH; Griffin, JD; Neel, BG			Characterization of two SHP-2-associated binding proteins and potential substrates in hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE PHOSPHATASE SYP; COLONY-STIMULATING FACTOR; TYROSINE-PHOSPHATASE; SIGNAL-TRANSDUCTION; MAP KINASE; PHOSPHORYLATION; INSULIN; SH-PTP2; SHPTP2; IDENTIFICATION	Multiple studies have demonstrated an important role for the Src homology 2-containing tyrosine phosphatase 2 (SHP-2) in receptor tyrosine kinase-regulated cell proliferation and differentiation. Recent studies have identified potential SHP-2 substrates which mediate these effects. SHP-2 also is implicated in several cytokine receptor signaling pathways and in Bcr-Abl transformation. However, its precise role and targets in normal and abnormal hematopoietic cells remain to be determined. We identified two novel tyrosyl-phosphorylated proteins associated with SHP-2 in hematopoietic cells. The first, a 97-kDa cytosolic protein (p97), associates inducibly with SHP-2 upon cytokine stimulation and constitutively in Bcr-Abl-transformed cells. In contrast, p135, a 135-kDa transmembrane glycoprotein, forms a distinct complex with SHP-2, independent of cytokine stimulation or Bcr-Abl transformation. Far Western analysis reveals that SHP-2, via its Src homology 2 domains, can interact directly with either protein. In vitro dephosphorylation experiments, as well as transient transfection studies using wild type and mutant SHP-2 constructs, suggest that p97 and p135 also are SHP-2 substrates. Our results indicate that SHP-2 forms at least two separate complexes in hematopoietic cells and point to new potential SHP-2 targets.	HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV HEMATOL MALIGNANCIES, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Gu, HH (corresponding author), BETH ISRAEL HOSP, DEPT MED,DIV HEMATOL ONCOL,CANC BIOL PROGRAM, HIM 1043, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.				NCI NIH HHS [R01 CA 49152, CA 36167] Funding Source: Medline; NIDDK NIH HHS [P01-DK50654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049152, R37CA036167, R01CA036167] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi M, 1996, CELL, V85, P15; Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; Allard JD, 1996, DEVELOPMENT, V122, P1137; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BIGNON JS, 1994, CLIN IMMUNOL IMMUNOP, V73, P168, DOI 10.1006/clin.1994.1185; BLISKA JB, 1992, J EXP MED, V176, P1625, DOI 10.1084/jem.176.6.1625; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Cleghon V, 1996, GENE DEV, V10, P566, DOI 10.1101/gad.10.5.566; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; Cossette LJ, 1996, EXP CELL RES, V223, P459, DOI 10.1006/excr.1996.0102; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; HARLOW E, 1988, ANTIBODIES LABORATOR, P309; HAUSDORFF SF, 1995, J BIOL CHEM, V270, P12965, DOI 10.1074/jbc.270.22.12965; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MIYAJIMA A, 1993, BLOOD, V82, P1960; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; Noguchi T, 1996, J BIOL CHEM, V271, P27652, DOI 10.1074/jbc.271.44.27652; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; Perkins LA, 1996, DEV BIOL, V180, P63, DOI 10.1006/dbio.1996.0285; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Sattler M, 1996, ONCOGENE, V12, P839; SAWADA T, 1995, BIOCHEM BIOPH RES CO, V214, P737, DOI 10.1006/bbrc.1995.2347; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Van Etten R A, 1992, Cancer Treat Res, V63, P167; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, J BIOL CHEM, V270, P14871, DOI 10.1074/jbc.270.25.14871; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	53	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16421	16430		10.1074/jbc.272.26.16421	http://dx.doi.org/10.1074/jbc.272.26.16421			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195950	hybrid			2022-12-27	WOS:A1997XG01900054
J	Li, M; DeBlas, AL				Li, M; DeBlas, AL			Coexistence of two beta subunit isoforms in the same gamma-aminobutyric acid type A receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA(A) RECEPTOR; RAT-BRAIN; A RECEPTORS; MONOCLONAL-ANTIBODIES; MESSENGER-RNAS; BENZODIAZEPINE RECEPTOR; FUNCTIONAL EXPRESSION; HETEROGENEITY; GABA(A)-RECEPTOR; SUBPOPULATIONS	Three novel subunit-specific antisera to the beta(1), beta(2), and beta(3) subunits of rat gamma-aminobutyric acid type A (GABA(A)) receptors have been used to study the native receptor in the rat brain. Affinity-purified anti-beta(1), anti-beta(2), and anti-beta(2) antibodies recognized in immunoblots protein bands of 57, 55, and 57 kDa, respectively. Quantitative immunoprecipitation of solubilized GABA(A) receptors from various rat brain regions showed that the beta(3), subunit was the most abundant isoform in cerebellum (in 96% of the GABA(A) receptors) and cerebral cortex (64%) but that it was the least abundant isoform in hippocampus (44%). The beta(3) subunit was found most abundant in hippocampus (64%) followed by cerebral cortex (48%) and cerebellum (33%). The beta(1) subunit was present in a very small proportion of the cerebellar GABA(A) receptors (3%), but it was present in a high proportion of the GABA(A) receptors from the hippocampus (49%) and cerebral cortex (32%). Quantitative receptor immunoprecipitation or immunopurification followed by immunoblotting experiments have revealed the existence of colocalization of two different beta subunit isoforms in a significant proportion of the brain GABA(A) receptors. Thus, in the rat cerebral cortex 33% of the GABA(A) receptors have both beta(2) and beta(3) subunits, and 19% of the receptors have both beta(2) and beta(3) subunits. The extent of colocalization of beta subunit isoforms varied among brain regions, being highest in hippocampus and lowest in cerebellum. These and other results taken together suggest that the number of alpha, beta, and gamma subunits (stoichiometry) in the brain GABA(A) receptor pentamers might not be unique. It might vary depending on receptor type.	UNIV MISSOURI,SCH BIOL SCI,DIV MOL BIOL & BIOCHEM,KANSAS CITY,MO 64110	University of Missouri System; University of Missouri Kansas City					NINDS NIH HHS [NS17708] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017708] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; ANGELOTTI TP, 1993, J NEUROSCI, V13, P1429; BACKUS KH, 1993, NEUROREPORT, V5, P285, DOI 10.1097/00001756-199312000-00026; BENKE D, 1994, J BIOL CHEM, V269, P27100; BENKE D, 1991, J BIOL CHEM, V266, P4478; BUCHSTALLER A, 1991, FEBS LETT, V287, P27, DOI 10.1016/0014-5793(91)80008-Q; Chang YC, 1996, J NEUROSCI, V16, P5415; DEBLAS AL, 1984, BRAIN RES, V322, P277, DOI 10.1016/0006-8993(84)90118-5; DeBlas AL, 1996, MOL NEUROBIOL, V12, P55, DOI 10.1007/BF02740747; DEBLAS AL, 1983, ANAL BIOCHEM, V133, P214, DOI 10.1016/0003-2697(83)90245-2; DUGGAN MJ, 1991, J BIOL CHEM, V266, P24778; DUGGAN MJ, 1992, J NEUROCHEM, V58, P72, DOI 10.1111/j.1471-4159.1992.tb09278.x; EBERT B, 1994, MOL PHARMACOL, V46, P957; FERNANDO LP, 1995, MOL BRAIN RES, V28, P94, DOI 10.1016/0169-328X(94)00188-K; FRITSCHY JM, 1995, J COMP NEUROL, V359, P154, DOI 10.1002/cne.903590111; HADINGHAM KL, 1993, MOL PHARMACOL, V44, P1211; HUH KH, 1995, MOL PHARMACOL, V48, P666; HUH KH, 1996, EUR J PHARMACOL, V301, P225; IM WB, 1995, J BIOL CHEM, V270, P26063, DOI 10.1074/jbc.270.44.26063; KHAN ZU, 1994, J NEUROCHEM, V63, P1466; KHAN ZU, 1994, J NEUROCHEM, V63, P371; Khan ZU, 1996, J NEUROCHEM, V66, P685; KHAN ZU, 1993, J NEUROCHEM, V60, P961, DOI 10.1111/j.1471-4159.1993.tb03243.x; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MACHU TK, 1993, J NEUROCHEM, V61, P2034, DOI 10.1111/j.1471-4159.1993.tb07439.x; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; MERTENS S, 1993, J BIOL CHEM, V268, P5965; MORENO JI, 1994, J COMP NEUROL, V350, P260, DOI 10.1002/cne.903500209; NAYEEM N, 1994, J NEUROCHEM, V62, P815; PERSOHN E, 1992, J COMP NEUROL, V326, P193, DOI 10.1002/cne.903260204; POLLARD S, 1993, J BIOL CHEM, V268, P3753; POLLARD S, 1991, FEBS LETT, V295, P81, DOI 10.1016/0014-5793(91)81390-T; PRICHETT DB, 1989, SCIENCE, V245, P1389; QUIRK K, 1994, MOL PHARMACOL, V45, P1061; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SMITH GB, 1990, MOL PHARMACOL, V37, P497; STEPHENSON FA, 1995, BIOCHEM J, V310, P1; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; VITORICA J, 1988, J NEUROSCI, V8, P615; WAFFORD KA, 1994, NEURON, V12, P775, DOI 10.1016/0896-6273(94)90330-1; WISDEN W, 1992, J NEUROSCI, V12, P1040; YMER S, 1989, EMBO J, V8, P1665, DOI 10.1002/j.1460-2075.1989.tb03557.x; ZHANG JH, 1991, J COMP NEUROL, V303, P637, DOI 10.1002/cne.903030409	45	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16564	16569		10.1074/jbc.272.26.16564	http://dx.doi.org/10.1074/jbc.272.26.16564			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195967	hybrid			2022-12-27	WOS:A1997XG01900071
J	Imamura, T; Potempa, J; Tanase, S; Travis, J				Imamura, T; Potempa, J; Tanase, S; Travis, J			Activation of blood coagulation factor X by arginine-specific cysteine proteinases (gingipain-Rs) from Porphyromonas gingivalis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREVICULAR FLUID; TISSUE-FACTOR; BACTEROIDES-GINGIVALIS; PERIODONTAL-DISEASE; VIPER VENOM; EXOENZYME-S; THROMBIN; PATHOGENESIS; ENZYME; INTERLEUKIN-1-BETA	The effect of two arginine-specific cysteine proteinases (gingipain Rs) from Porphyromonas gingivalis, a causative bacterium of adult periodontitis, on human blood coagulation was investigated, Activated partial thromboplastin time and prothrombin time were shortened by these proteinases, with a 95-kDa gingipain R containing adhesin domains being B-fold more efficient in comparison to a 50-kDa gingipain R containing the catalytic domain alone, The 50-kDa enzyme reduced each coagulation time in several plasmas deficient in various coagulation factors, while it was ineffective in factor X-deficient plasma unless reconstituted with this protein. Each proteinase activated factor X in a dose- and time-dependent manner, with Michaelis constants (K-m) being found to be lower than the normal plasma factor X concentration, strongly suggesting that factor X activation by gingipain Rs, especially the 95-kDa form which is strongly activated by phospholipids, could occur in plasma. This is the first report of factor X activation by bacterial proteinases and indicates that the gingipain Rs could be responsible for the production of thrombin and, indirectly, with the generation of prostaglandins, interleukin-1, etc., which have been found to be associated with the development of periodontitis induced by P. gingivalis infections. Furthermore, the data support the hypothesis that induction of blood coagulation by bacterial proteinases may be a causative agent in the pathogenesis of disseminated intravascular coagulation in sepsis.	UNIV GEORGIA, DEPT BIOCHEM, ATHENS, GA 30602 USA; KUMAMOTO UNIV, GRAD SCH MED SCI, DEPT NEUROSCI & IMMUNOL, DIV MOL PATHOL, KUMAMOTO 860, JAPAN; JAGIELLONIAN UNIV, INST MOL BIOL, DEPT IMMUNOL & MICROBIOL, PL-31120 KRAKOW, POLAND	University System of Georgia; University of Georgia; Kumamoto University; Jagiellonian University					NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE009761] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 09761] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALTIERI DC, 1994, CELL IMMUNOL, V155, P372, DOI 10.1006/cimm.1994.1130; [Anonymous], HOST PARASITE INTERA; BAKER NR, 1991, INFECT IMMUN, V59, P2859, DOI 10.1128/IAI.59.9.2859-2863.1991; BIZIOS R, 1986, J CELL PHYSIOL, V128, P485, DOI 10.1002/jcp.1041280318; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; CHEN ZX, 1992, J BIOL CHEM, V267, P18896; COCHRANE CG, 1973, J EXP MED, V138, P1564, DOI 10.1084/jem.138.6.1564; COCHRANE CG, 1982, ADV IMMUNOL, V33, P241, DOI 10.1016/S0065-2776(08)60837-8; COLMAN RW, 1987, HEMOSTASIS THROMBOSI, P3; CONKLING PR, 1988, BLOOD, V72, P128; CURRIE WJR, 1993, BRIT J ORAL MAX SURG, V31, P296, DOI 10.1016/0266-4356(93)90063-3; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; DUFFY EJ, 1992, J BIOL CHEM, V267, P7821; FARID T, 1993, TOXICON, V31, P1007, DOI 10.1016/0041-0101(93)90260-P; FENTON JW, 1986, ANN NY ACAD SCI, V485, P5, DOI 10.1111/j.1749-6632.1986.tb34563.x; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GAJDUSEK C, 1986, J CELL BIOL, V103, P419, DOI 10.1083/jcb.103.2.419; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; GRENIER D, 1987, J CLIN MICROBIOL, V25, P738, DOI 10.1128/JCM.25.4.738-740.1987; Halkier T., 1991, MECH BLOOD COAGULATI; HEMKER HC, 1975, BIOCHIM BIOPHYS ACTA, V379, P180, DOI 10.1016/0005-2795(75)90020-3; HOFFMANN O, 1986, PROSTAGLANDINS, V31, P601, DOI 10.1016/0090-6980(86)90168-1; HOLT SC, 1988, SCIENCE, V239, P55, DOI 10.1126/science.3336774; HONIG J, 1989, J PERIODONTAL RES, V24, P362, DOI 10.1111/j.1600-0765.1989.tb00883.x; IMAMURA T, 1995, INFECT IMMUN, V63, P4877, DOI 10.1128/IAI.63.12.4877-4882.1995; IMAMURA T, 1994, J CLIN INVEST, V94, P361, DOI 10.1172/JCI117330; JONES A, 1990, IMMUNOLOGY, V71, P236; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNER UH, 1988, BIOCHIM BIOPHYS ACTA, V964, P309, DOI 10.1016/0304-4165(88)90031-1; LEVI M, 1993, JAMA-J AM MED ASSOC, V270, P975, DOI 10.1001/jama.270.8.975; LEYTUS SP, 1984, P NATL ACAD SCI-BIOL, V81, P3699, DOI 10.1073/pnas.81.12.3699; LINGWOOD CA, 1992, INFECT IMMUN, V60, P2470, DOI 10.1128/IAI.60.6.2470-2474.1992; Mann K.G.R., 1987, HEMOSTASIS THROMBOSI, P148; MARSH PD, 1989, FEMS MICROBIOL LETT, V59, P181; MASADA MP, 1990, J PERIODONTAL RES, V25, P156, DOI 10.1111/j.1600-0765.1990.tb01038.x; NEMERSON Y, 1988, BLOOD, V71, P1; OFFENBACHER S, 1986, J PERIODONTAL RES, V21, P101, DOI 10.1111/j.1600-0765.1986.tb01443.x; PARTRIDGE NC, 1985, PROSTAGLANDINS, V30, P527; PAVLOFF N, 1995, J BIOL CHEM, V270, P1007, DOI 10.1074/jbc.270.3.1007; PIKE R, 1994, J BIOL CHEM, V269, P406; Pike RN, 1996, J BACTERIOL, V178, P2876, DOI 10.1128/jb.178.10.2876-2882.1996; RIVERS RPA, 1975, BRIT J HAEMATOL, V30, P311, DOI 10.1111/j.1365-2141.1975.tb00547.x; SAKODA M, 1976, J BIOCHEM-TOKYO, V80, P547, DOI 10.1093/oxfordjournals.jbchem.a131310; SENIOR RM, 1986, J CLIN INVEST, V77, P1014, DOI 10.1172/JCI112353; SHAW JH, 1987, NEW ENGL J MED, V317, P996, DOI 10.1056/NEJM198710153171605; SMALLEY JW, 1989, ORAL MICROBIOL IMMUN, V4, P178, DOI 10.1111/j.1399-302X.1989.tb00249.x; Sylvester FA, 1996, INFECT IMMUN, V64, P1420, DOI 10.1128/IAI.64.4.1420-1425.1996; TUBB M, 1990, ARCH ORAL BIOL, V35, P529, DOI 10.1016/0003-9969(90)90083-M; WILLIAMS DM, 1992, PATHOLOGY PERIODONTA, P90; WILLIAMS RC, 1990, NEW ENGL J MED, V322, P373, DOI 10.1056/NEJM199002083220606; ZAMBON JJ, 1990, CONT PERIODONTICS, P147	53	85	89	0	10	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					16062	16067		10.1074/jbc.272.25.16062	http://dx.doi.org/10.1074/jbc.272.25.16062			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188512	hybrid			2022-12-27	WOS:A1997XF32900072
J	Karvonen, U; Kallio, PJ; Janne, OA; Palvimo, JJ				Karvonen, U; Kallio, PJ; Janne, OA; Palvimo, JJ			Interaction of androgen receptors with androgen response element in intact cells - Roles of amino- and carboxyl-terminal regions and the ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-INDEPENDENT TRANSACTIVATION; DNA-BINDING; STEROID-BINDING; TRANSCRIPTIONAL ACTIVATION; ESTROGEN-RECEPTOR; INSECT CELLS; DOMAIN; PHOSPHORYLATION; PROTEINS	Promoter interference assay was employed to examine in intact cells the roles of the functional domains of androgen receptor (AR) and the ligand for specific DNA interactions using a cytomegalovirus-(androgen response element)-chloramphenicol acetyltransferase reporter (pCMV-ARE(2)-CAT). Native rat and human ARs interfered with pCMV-ARE(2)-CAT expression in a hormone-dependent fashion, Low steroid-independent interference see:med to occur because of the ligand binding domain (LED), which was transcriptionally inhibitory also in a heterologous context, AR devoid of LED (rAR Delta 641-902) decreased pCMV-ARE(2)-CAT activity by 50%, The rAR Delta 46-408 mutant devoid of the NH2-terminal transcription activation region exhibited ligand-dependent promoter interference of a similar magnitude, Ligand and DNA binding-deficient mutants (hARM807R and rARC562G, respectively) did not influence pCMV-ARE(2)-CAT expression, although hARM807R binds to ARE in vitro, Non-steroidal anti-androgens casodex and hydroxyflutamide antagonized agonist-dependent promoter interference, whereas cyproterone acetate, RU 56187, RU 57073, and RU 59063 were partial agonists/antagonists, Collectively, interaction of ARs with ARE in intact cells does not require the presence of the COOH-terminal or NH2-terminal domain and/or their interaction. In the context of native AR, however, the androgen-induced conformational change in LED is mandatory for generation of a transcriptionally competent receptor that binds to DNA in intact cells.	UNIV HELSINKI, INST BIOMED, DEPT PHYSIOL, FIN-00014 HELSINKI, FINLAND; UNIV HELSINKI, DEPT CLIN CHEM, FIN-00014 HELSINKI, FINLAND	University of Helsinki; University of Helsinki				Palvimo, Jorma/0000-0003-2373-0578				ADEYEMO O, 1993, HUM MOL GENET, V2, P1809, DOI 10.1093/hmg/2.11.1809; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; DEVOS P, 1991, J BIOL CHEM, V266, P3439; EASTMAN A, 1987, BIOTECHNIQUES, V5, P730; GASS L, 1996, 10 INT C END SAN FRA; HU MCT, 1987, CELL, V48, P555, DOI 10.1016/0092-8674(87)90234-0; IKONEN T, 1994, ENDOCRINOLOGY, V135, P1359, DOI 10.1210/en.135.4.1359; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; JENSTER G, 1993, BIOCHEM J, V293, P761, DOI 10.1042/bj2930761; KALLIO PJ, 1995, MOL ENDOCRINOL, V9, P1017, DOI 10.1210/me.9.8.1017; KALLIO PJ, 1994, J BIOL CHEM, V269, P11514; KALLIO PJ, 1994, ENDOCRINOLOGY, V134, P998, DOI 10.1210/en.134.2.998; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; Kuil CW, 1996, ENDOCRINOLOGY, V137, P1870, DOI 10.1210/en.137.5.1870; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; PALVIMO JJ, 1993, MOL ENDOCRINOL, V7, P1399, DOI 10.1210/me.7.11.1399; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; REESE JC, 1992, MOL CELL BIOL, V12, P4531, DOI 10.1128/MCB.12.10.4531; Reinikainen P, 1996, ENDOCRINOLOGY, V137, P4351, DOI 10.1210/en.137.10.4351; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; RUNDLETT SE, 1990, MOL ENDOCRINOL, V4, P708, DOI 10.1210/mend-4-5-708; SCARLETT CO, 1995, MOL ENDOCRINOL, V9, P413, DOI 10.1210/me.9.4.413; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; TEUTSCH G, 1994, J STEROID BIOCHEM, V48, P111, DOI 10.1016/0960-0760(94)90257-7; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P742, DOI 10.1021/bi00147a029; WONG CI, 1993, J BIOL CHEM, V268, P19004; XIE YB, 1992, J BIOL CHEM, V267, P4939; XING H, 1993, J BIOL CHEM, V268, P23227; Xu JM, 1996, P NATL ACAD SCI USA, V93, P12195, DOI 10.1073/pnas.93.22.12195	33	64	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15973	15979		10.1074/jbc.272.25.15973	http://dx.doi.org/10.1074/jbc.272.25.15973			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188499	hybrid			2022-12-27	WOS:A1997XF32900059
J	Prinz, WA; Aslund, F; Holmgren, A; Beckwith, J				Prinz, WA; Aslund, F; Holmgren, A; Beckwith, J			The role of the thioredoxin and glutaredoxin pathways in reducing protein disulfide bonds in the Escherichia coli cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEOTIDE REDUCTASE; ALKALINE-PHOSPHATASE; HYDROGEN DONOR; SIGNAL SEQUENCE; BETA-LACTAMASE; GLUTATHIONE; MUTANT; CONSTRUCTION; MECHANISM; SECRETION	In Escherichia coli, two pathways use NADPH to reduce disulfide bonds that form in some cytoplasmic enzymes during catalysis: the thioredoxin system, which consists of thioredoxin reductase and thioredoxin, and the glutaredoxin system, composed of glutathione reductase, glutathione, and three glutaredoxins. These systems may also reduce disulfide bonds which form spontaneously in cytoplasmic proteins when E. coli is grown aerobically. We have investigated the role of both systems in determining the thiol-disulfide balance in the cytoplasm by determining the ability of protein disulfide bonds to form in mutants missing components of these systems, We find that both the thioredoxin and glutaredoxin systems contribute to reducing disulfide bonds in cytoplasmic proteins. In addition, these systems can partially substitute for each other in, vivo since double mutants missing parts of both systems generally allow substantially more disulfide bond formation than mutants missing components of just one system, Some of these double mutants were found to require the addition of a disulfide reductant to the medium to grow well aerobically, Thus, E. coli requires either a functional thioredoxin or glutaredoxin system to reduce disulfide bonds which appear after each catalytic cycle in the essential enzyme ribonucleotide reductase and perhaps to reduce non-native disulfide bonds in cytoplasmic proteins, Our results suggest the existence of a novel thioredoxin in E. coli.	HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOL GENET, BOSTON, MA 02115 USA; KAROLINSKA INST, DEPT MED BIOCHEM & BIOPHYS, MED NOBEL INST BIOCHEM, S-17177 STOCKHOLM, SWEDEN	Harvard University; Harvard Medical School; Karolinska Institutet								Aslund F, 1996, J BIOL CHEM, V271, P6736, DOI 10.1074/jbc.271.12.6736; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; CHANG YY, 1995, J BIOL CHEM, V270, P7896, DOI 10.1074/jbc.270.14.7896; CREIGHTON TE, 1992, PROTEIN FOLDING; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; DOIG AJ, 1991, J MOL BIOL, V217, P389, DOI 10.1016/0022-2836(91)90551-G; FELLAY R, 1987, GENE, V52, P147, DOI 10.1016/0378-1119(87)90041-2; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GLEASON FK, 1988, FEMS MICROBIOL LETT, V54, P271, DOI 10.1111/j.1574-6968.1988.tb02747.x; GREENBERG JT, 1986, J BACTERIOL, V168, P1026, DOI 10.1128/jb.168.2.1026-1029.1986; HIBBERD KA, 1978, J BACTERIOL, V133, P1150, DOI 10.1128/JB.133.3.1150-1155.1978; HOLMGREN A, 1984, METHOD ENZYMOL, V107, P295; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KIM EE, 1990, CLIN CHIM ACTA, V186, P175, DOI 10.1016/0009-8981(90)90035-Q; Kosower N S, 1978, Int Rev Cytol, V54, P109, DOI 10.1016/S0074-7696(08)60166-7; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; KREN B, 1988, J BACTERIOL, V170, P308, DOI 10.1128/jb.170.1.308-315.1988; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MirandaVizuete A, 1996, J BIOL CHEM, V271, P19099, DOI 10.1074/jbc.271.32.19099; MIRANDAVIZUETE A, 1994, J BIOL CHEM, V269, P16631; MULLIEZ E, 1995, P NATL ACAD SCI USA, V92, P8759, DOI 10.1073/pnas.92.19.8759; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; NILSSON B, 1991, J BIOL CHEM, V266, P2970; POLLITT S, 1983, J BACTERIOL, V153, P27, DOI 10.1128/JB.153.1.27-32.1983; RANDALL LL, 1995, TRENDS BIOCHEM SCI, V20, P65, DOI 10.1016/S0968-0004(00)88959-8; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; RUSSEL M, 1988, P NATL ACAD SCI USA, V85, P990, DOI 10.1073/pnas.85.4.990; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; RUSSEL M, 1990, J BACTERIOL, V172, P1923, DOI 10.1128/jb.172.4.1923-1929.1990; RUSSEL M, 1986, THIOREDOXIN GLUTARED, P331; RUSSELL CB, 1989, J BACTERIOL, V171, P2609, DOI 10.1128/jb.171.5.2609-2613.1989; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; Schulz G. E., 1979, PRINCIPLES PROTEIN S; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; TUGGLE CK, 1985, J BACTERIOL, V162, P448, DOI 10.1128/JB.162.1.448-450.1985; WALKER KW, 1994, J BIOL CHEM, V269, P28487; Wax R, 1970, J BACTERIOL, V101, P1092, DOI 10.1128/JB.101.3.1092-1093.1970; ZIEGLER DM, 1977, TRENDS BIOCHEM SCI, V2, P79, DOI 10.1016/0968-0004(77)90042-1	49	517	557	2	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15661	15667		10.1074/jbc.272.25.15661	http://dx.doi.org/10.1074/jbc.272.25.15661			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188456	hybrid			2022-12-27	WOS:A1997XF32900016
J	Sakurai, H; Ohishi, T; Fukasawa, T				Sakurai, H; Ohishi, T; Fukasawa, T			Promoter structure-dependent functioning of the general transcription factor IIE in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; START SITE SELECTION; BASAL TRANSCRIPTION; TERMINAL DOMAIN; REGULATORY GENE; YEAST; DNA; INITIATION; TFIIH	General transcription factor (TF) IIE is an essential component of the basal transcription complex for protein-encoding genes, which is widely conserved in eukaryotes. Here we analyzed requirement for TFIIE for transcription in vivo by using yeast Saccharomyces cerevisiae cells harboring mutations in the TFA1 gene encoding the larger one of the two subunits of TFIIE. Deletion analysis indicated that the N-terminal half of Tfa1 protein has all essential function to support the cell growth. In a temperature-sensitive tfa1 mutant cell, the steady-state level of bulk poly(A)(+) RNA decreased rapidly at the restrictive temperature, Surprisingly, levels of several mRNAs, whose transcription is directed by the promoters lacking the typical TATA sequence, were not affected in the mutant cells at that temperature, This promoter-specific functioning of TFIIE was reproduced in a cell-free system composed of TFIIE-depleted nuclear extracts, These results strongly suggest that requirement for TFIIE varies In each gene depending on the promoter structures in vivo.	KEIO UNIV,SCH MED,MOL GENET LAB,SHINJUKU KU,TOKYO 160,JAPAN; KAZUSA DNA RES INST,KISARAZU,CHIBA 292,JAPAN	Keio University; Kazusa DNA Research Institute	Sakurai, H (corresponding author), KANAZAWA UNIV,FAC MED,SCH HLTH SCI,5-11-80 KODATSUNO,KANAZAWA,ISHIKAWA 920,JAPAN.							BENNETZEN JL, 1982, J BIOL CHEM, V257, P3018; BJORKLUND S, 1996, TRENDS BIOCHEM SCI, V21, P327; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DRAPKIN R, 1994, TRENDS BIOCHEM SCI, V19, P504, DOI 10.1016/0968-0004(94)90139-2; FEAVER WJ, 1994, J BIOL CHEM, V269, P27549; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GRIGGS DW, 1993, MOL CELL BIOL, V13, P4999, DOI 10.1128/MCB.13.8.4999; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; INOKUCHI K, 1987, MOL CELL BIOL, V7, P3185, DOI 10.1128/MCB.7.9.3185; IYER V, 1995, MOL CELL BIOL, V15, P7059; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; Leuther KK, 1996, CELL, V85, P773, DOI 10.1016/S0092-8674(00)81242-8; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MAHADEVAN S, 1990, MOL CELL BIOL, V10, P4447, DOI 10.1128/MCB.10.9.4447; Martin ML, 1996, MOL CELL BIOL, V16, P2110; MARTINEZ E, 1995, P NATL ACAD SCI USA, V92, P11864, DOI 10.1073/pnas.92.25.11864; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; Merli C, 1996, GENE DEV, V10, P1260, DOI 10.1101/gad.10.10.1260; MOYE WS, 1985, J BIOL CHEM, V260, P4718; MUNHOLLAND JM, 1990, NUCLEIC ACIDS RES, V18, P6061, DOI 10.1093/nar/18.20.6061; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; OHKUMA Y, 1995, MOL CELL BIOL, V15, P4856; PAN GH, 1994, J BIOL CHEM, V269, P30101; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; QIU HF, 1993, GENE DEV, V7, P2161, DOI 10.1101/gad.7.11.2161; Robert F, 1996, J BIOL CHEM, V271, P8517, DOI 10.1074/jbc.271.15.8517; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SAKURAI H, 1994, MOL CELL BIOL, V14, P6819, DOI 10.1128/MCB.14.10.6819; Sakurai H, 1996, P NATL ACAD SCI USA, V93, P9488, DOI 10.1073/pnas.93.18.9488; SAKURAI H, 1994, FEBS LETT, V351, P176, DOI 10.1016/0014-5793(94)80098-7; SAKURAI H, 1996, FEBS LETT, V393, P113; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; SAYRE MH, 1992, J BIOL CHEM, V267, P23383; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SCHWINDINGER WF, 1987, J BIOL CHEM, V262, P5690; SERIZAWA H, 1994, J BIOL CHEM, V269, P20750; SIKORSKI RS, 1989, GENETICS, V122, P19; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; SUN ZW, 1995, P NATL ACAD SCI USA, V92, P3127, DOI 10.1073/pnas.92.8.3127; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TAJIMA M, 1986, MOL CELL BIOL, V6, P246, DOI 10.1128/MCB.6.1.246; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; TONG X, 1995, MOL CELL BIOL, V15, P4725; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	60	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15936	15942		10.1074/jbc.272.25.15936	http://dx.doi.org/10.1074/jbc.272.25.15936			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188494	hybrid			2022-12-27	WOS:A1997XF32900054
J	Kirken, RA; Malabarba, MG; Xu, J; DaSilva, L; Erwin, RA; Liu, XW; Hennighausen, L; Rui, H; Farrar, WL				Kirken, RA; Malabarba, MG; Xu, J; DaSilva, L; Erwin, RA; Liu, XW; Hennighausen, L; Rui, H; Farrar, WL			Two discrete regions of interleukin-2 (IL2) receptor beta independently mediate IL2 activation of a PD98059/Rapamycin/Wortmannin-insensitive Stat5a/b serine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CHAIN; FUNCTIONAL COMPONENT; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; TERMINAL REGION; TYROSINE; ASSOCIATION; EXPRESSION; IL-2	Many cytokines, hormones, and growth factors activate Janus kinases to tyrosine phosphorylate select members of the Stat transcription factors, For full transcriptional activation, Stat1 and Stat3 also require phosphorylation of a conserved serine residue within a mitogen-activated protein kinase phosphorylation consensus site. On the other hand, two recently identified and highly homologous Stat5a and Stat5b proteins lack this putative mitogen-activated protein kinase phosphorylation site, The present study set out to establish whether Stat5a and Stat5b are under the control of an interleukin-2 (IL2)-activated Stat5 serine kinase, We now report that IL2 stimulated marked phosphorylation of serine and tyrosine residues of both Stat5a and Stat5b in human T lymphocytes and in several IL2-responsive lymphocytic cell lines, No Stat5a/b phosphothreonine was detected. Phosphoamino acid analysis also revealed that Stat5a/b phosphotyrosine levels were maximized within 1-5 min of IL2 stimulation, whereas serine phosphorylation kinetics were slower, Interestingly, IL2-induced serine phosphorylation of Stat5a differed quantitatively and temporally from that of Stat5b with Stat5a serine phosphorylation leveling off after 10 min and the more pronounced Stat5b response continuing to rise for at least 60 min of IL2 stimulation, Furthermore, we identified two discrete domains of IL2 receptor beta (IL2R beta) that could independently restore the ability of a truncated IL2R beta mutant to mediate Stat5a/b phosphorylation and DNA binding to the gamma-activated site of the beta-casein gene promoter, These observations demonstrated that there is no strict requirement for one particular IL2R beta region for Stat5 phosphorylation. Finally, we established that the IL2-activated Stat5a/b serine kinase is insensitive to several selective inhibitors of known IL2-stimulated kinases including MEK1/MEK2 (PD98059), mTOR (rapamycin), and phosphatidylinositol 3 kinase (wortmannin) as determined by phosphoamino acid and DNA binding analysis, thus suggesting that a yet-to-be-identified serine kinase mediates Stat5a/b activation.	SCI APPLICAT INT CORP,INTRAMURAL RES SUPPORT PROGRAM,FREDERICK,MD 21702; NIDDK,NIH,BIOCHEM & METAB LAB,BETHESDA,MD 20892	Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Kirken, RA (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,DIV BASIC SCI,LAB MOL IMMUNOREGULAT,FREDERICK,MD 21702, USA.		Malabarba, Maria Grazia/L-4805-2015	Malabarba, Maria Grazia/0000-0002-9457-2047; Hennighausen, Lothar/0000-0001-8319-9841				Abraham RT, 1996, CURR OPIN IMMUNOL, V8, P412, DOI 10.1016/S0952-7915(96)80132-4; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DaSilva L, 1996, MOL CELL ENDOCRINOL, V117, P131, DOI 10.1016/0303-7207(95)03738-1; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; EVANS GA, 1995, J BIOL CHEM, V270, P28858, DOI 10.1074/jbc.270.48.28858; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; Gaffen SL, 1996, J BIOL CHEM, V271, P21381, DOI 10.1074/jbc.271.35.21381; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; HOWARD OMZ, 1995, BIOCHEM J, V306, P217, DOI 10.1042/bj3060217; Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; KIRKEN RA, 1995, CYTOKINE, V7, P689, DOI 10.1006/cyto.1995.0081; KIRKEN RA, 1994, J BIOL CHEM, V269, P19136; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KONING JP, 1996, BLOOD, V87, P1335; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LIU XL, 1995, MOL ENDOCRINOL, V10, P1496; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; MERIDA I, 1991, J IMMUNOL, V147, P2202; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; Rolling C, 1996, FEBS LETT, V393, P53, DOI 10.1016/0014-5793(96)00835-6; RUI H, 1994, J BIOL CHEM, V269, P5364; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; WAHL LM, 1984, CELL IMMUNOL, V85, P373, DOI 10.1016/0008-8749(84)90251-X; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964; Winston LA, 1996, CURR BIOL, V6, P668, DOI 10.1016/S0960-9822(09)00445-X; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	48	59	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15459	15465		10.1074/jbc.272.24.15459	http://dx.doi.org/10.1074/jbc.272.24.15459			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182578	hybrid			2022-12-27	WOS:A1997XE03400061
J	Wahl, RC; Costigan, VJ; Batac, JP; Chen, K; Cam, L; Courchesne, PL; Patterson, SD; Zhang, K; Pacifici, RE				Wahl, RC; Costigan, VJ; Batac, JP; Chen, K; Cam, L; Courchesne, PL; Patterson, SD; Zhang, K; Pacifici, RE			Mutation of Cys(672) allows recombinant expression of activatible macrophage-stimulating protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE; GENE-PRODUCT; RECEPTOR; IDENTIFICATION; HGF1/MSP; CLONING; FAMILY; HGF/SF; RON	We readily produced recombinant pro-macrophage stimulating protein in a mammalian expression system, but it was only weakly active after proteolytic activation. Active macrophage stimulating protein is a disulfide-bonded heterodimer, but in our hands, the subunits of recombinant macrophage stimulating protein were mostly not disulfide bonded, Molecular modeling of the serine proteinase domain of macrophage stimulating protein based on homology to human trypsin suggested that macrophage stimulating protein, but not plasminogen or hepatocyte growth factor, has a Cys residue (672) in close proximity to the Cys residue (578) that forms the intersubunit disulfide link with the other subunit. We hypothesized that Cys(672) might interfere with intersubunit disulfide formation by forming an intrasubunit disulfide with Cys(578) and therefore mutated Cys(672) to Ala. After kallikrein activation, the subunits of Cys(672) --> Ala macrophage stimulating protein were fully disulfide linked, and the mutant macrophage stimulating protein had 10-20 fold higher specific activity than the wild type recombinant macrophage stimulating protein.			Wahl, RC (corresponding author), AMGEN INC,MS 14-2-D,1840 DEHAVILLAND DR,THOUSAND OAKS,CA 91320, USA.		Patterson, Scott/A-7404-2009					BEZERRA JA, 1993, PROTEIN SCI, V2, P666; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; DONATE LE, 1994, PROTEIN SCI, V3, P2378, DOI 10.1002/pro.5560031222; GABORIAUD C, 1996, J BIOL CHEM, V259, P9950; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; OHSHIRO K, 1996, BIOCHEM BIOPH RES CO, V226, P273; THERY C, 1995, DEV GENET, V17, P90, DOI 10.1002/dvg.1020170110; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; WANG MH, 1995, P NATL ACAD SCI USA, V92, P3933, DOI 10.1073/pnas.92.9.3933; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WANG MH, 1994, J BIOL CHEM, V269, P13806; WANG MH, 1994, J BIOL CHEM, V269, P3436; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461; Zhang K, 1996, J BIOL CHEM, V271, P3884	19	8	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15053	15056		10.1074/jbc.272.24.15053	http://dx.doi.org/10.1074/jbc.272.24.15053			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182521	hybrid			2022-12-27	WOS:A1997XE03400004
J	OBrien, CA; Manolagas, SC				OBrien, CA; Manolagas, SC			Isolation and characterization of the human gp130 promoter - Regulation by STATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCER GP130; PHASE RESPONSE FACTOR; EPIDERMAL GROWTH-FACTOR; IL-6 RECEPTOR; INTERLEUKIN-6 RECEPTOR; TYROSINE PHOSPHORYLATION; MOLECULAR-CLONING; DNA-BINDING; GENE; EXPRESSION	Glycoprotein 130 (gp130), a shared component of all the receptors for the interleukin-6 cytokine family, transduces cytokine signals in part by activating latent cytoplasmic signal transducers and activators of transcription (STATs), STATs subsequently translocate into the nucleus and stimulate gene expression. In the studies reported here, the 5'-flanking region of the human gp130 gene was isolated and the transcription initiation sites were mapped. To demonstrate that the isolated DNA fragment contained a functional promoter, a plasmid construct containing 2433 base pairs of the gp130 5'-flanking region, inserted upstream from the firefly luciferase gene, was transiently transfected into HepG2 hepatoma cells. The construct exhibited constitutive promoter activity. In addition, a 5-h treatment with interleukin-6 or oncostatin M stimulated the activity of this promoter severalfold. Localization of the cytokine response element by 5'-deletion analysis and site-directed mutagenesis revealed a cis-acting binding site for activated STAT complexes. Furthermore, DNA binding analysis demonstrated that this element binds activated STAT1 and STAT3 homo and heterodimers. This STAT-binding element was sufficient to confer cytokine stimulation to a minimal herpesvirus thymidine kinase promoter. These results establish that the DNA fragment we have isolated contains the human gp130 promoter and that interleukin-6 type cytokines may influence the activity of this promoter via activated STATs.	UNIV ARKANSAS MED SCI HOSP,VET ADM MED CTR,GRECC,LITTLE ROCK,AR 72205	Geriatric Research Education & Clinical Center; University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA)	OBrien, CA (corresponding author), UNIV ARKANSAS MED SCI HOSP,DIV ENDOCRINOL,CTR OSTEOPOROSIS & METAB BONE DIS,4301 W MARKHAM ST,LITTLE ROCK,AR 72205, USA.		O'Brien, Charles A./AAL-5078-2020		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG013918] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR43003] Funding Source: Medline; NIA NIH HHS [P01 AG13918-01] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bellido T, 1996, J CLIN INVEST, V97, P431, DOI 10.1172/JCI118432; BELLIDO T, 1994, J BONE MINER RES, V9, pS123; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DITTRICH E, 1994, J BIOL CHEM, V269, P19014; GERHARTZ C, 1994, EUR J BIOCHEM, V223, P265, DOI 10.1111/j.1432-1033.1994.tb18991.x; GIRASOLE G, 1994, J CLIN INVEST, V93, P1516, DOI 10.1172/JCI117130; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KIDD VJ, 1992, SOMAT CELL MOLEC GEN, V18, P477, DOI 10.1007/BF01233087; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; Kordula T, 1996, J BIOL CHEM, V271, P6752, DOI 10.1074/jbc.271.12.6752; Kotanides H, 1996, J BIOL CHEM, V271, P25555, DOI 10.1074/jbc.271.41.25555; KRAUSE E, 1992, BIOL CHEM H-S, V373, P509, DOI 10.1515/bchm3.1992.373.2.509; KUNZ D, 1989, NUCLEIC ACIDS RES, V17, P1121, DOI 10.1093/nar/17.3.1121; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; LAMB P, 1995, NUCLEIC ACIDS RES, V23, P3283, DOI 10.1093/nar/23.16.3283; LASFAR A, 1994, EUR J IMMUNOL, V24, P124, DOI 10.1002/eji.1830240119; LIN SC, 1996, J BONE MINER RES, V11, pS161; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MANN EA, 1991, J BIOL CHEM, V266, P16931; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MURAKAMIMORI K, 1995, J CLIN INVEST, V96, P1319, DOI 10.1172/JCI118167; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; OGATA A, 1994, BLOOD, V84, P3040; RAZ R, 1994, J BIOL CHEM, V269, P24391; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; RODRIGUEZ C, 1995, CYTOGENET CELL GENET, V70, P64, DOI 10.1159/000133993; Romas E, 1996, J EXP MED, V183, P2581, DOI 10.1084/jem.183.6.2581; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SAITO M, 1992, J IMMUNOL, V148, P4066; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOESTER M, 1994, FEBS LETT, V345, P131, DOI 10.1016/0014-5793(94)00416-1; SCHOOLTINK H, 1992, FEBS LETT, V297, P263, DOI 10.1016/0014-5793(92)80552-R; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; Sehgal PB, 1995, ANN NY ACAD SCI, V762, P1; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SETO Y, 1992, J IMMUNOL, V148, P259; SNYERS L, 1992, BIOCHEM BIOPH RES CO, V185, P902, DOI 10.1016/0006-291X(92)91712-Y; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WANG Y, 1994, MOL BIOL CELL, V5, P819, DOI 10.1091/mbc.5.7.819; WANG Y, 1995, J CELL BIOCHEM, V57, P610, DOI 10.1002/jcb.240570405; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHANG ZX, 1995, J BIOL CHEM, V270, P24287, DOI 10.1074/jbc.270.41.24287; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	54	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					15003	15010		10.1074/jbc.272.23.15003	http://dx.doi.org/10.1074/jbc.272.23.15003			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169475	hybrid			2022-12-27	WOS:A1997XC32700072
J	Sharma, K; Wang, LW; Zhu, YQ; Bokkala, S; Joseph, SK				Sharma, K; Wang, LW; Zhu, YQ; Bokkala, S; Joseph, SK			Transforming growth factor-beta 1 inhibits type I inositol 1,4,5-trisphosphate receptor expression and enhances its phosphorylation in mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; TRISPHOSPHATE RECEPTOR; CA2+ MOBILIZATION; DIABETIC RATS; GROWTH-FACTOR-BETA-1; GLOMERULI; PROTEIN; CALCIUM; BETA; PROLIFERATION	A potentially important cross-talk characteristic of transforming growth factor-beta (TGF-beta) is to inhibit platelet-derived growth factor-induced intracellular calcium rise (Baffy, G., Sharma, K., Shi, W., Ziyadeh, F. N., and Williamson, J. R. (1995) Biochem. Biophys. Res. Commun. 210, 378-383) in murine mesangial cells. The present study examined the possible basis for this effect by evaluating the regulation of the type I inositol 1,4,5-trisphosphate receptor (IP3R) by TGF-beta. TGF-beta 1 down-regulates IP3R protein expression by >90% with maximal and half-maximal effects after 8 and 2 h, respectively. TGF-beta 1 also decreased IP3R mRNA expression by 59% after 1 h. Phosphorylation of the IP3R was also demonstrated as early as 15 min after TGF-beta 1 exposure, Back phosphorylation assays of IP3R from TGF-beta 1-treated mesangial cells with protein kinase A (PKA), indicated that TGF-beta 1-induced phosphorylation of the IP3R occurs at similar sites as for PKA. In vitro kinase assays using the known IP3R peptide substrates for PKA, RPS-GRRESLTSFGNP and ARRDSVLAAS, demonstrated that TGF-beta 1 induces phosphorylation of both peptides (158 and 123% of control values, respectively), TGF-beta 1-induced phosphorylation was prevented by the addition of the PKA inhibitor peptide in the in vitro kinase assay. It is proposed that TGF-beta-mediated effects on the IP3R may be an important characteristic of its ability to modulate the response of cells to factors that employ IP3R-mediated calcium release.	THOMAS JEFFERSON UNIV, SCH MED, DEPT ANAT PATHOL & CELL BIOL, PHILADELPHIA, PA 19107 USA	Jefferson University	Sharma, K (corresponding author), THOMAS JEFFERSON UNIV, SCH MED,DEPT MED,DIV NEPHROL,SUITE 353, JAH, 1020 LUCUST ST, PHILADELPHIA, PA 19107 USA.				NIAAA NIH HHS [R01-AA10971, T32-AA07463] Funding Source: Medline; NIDDK NIH HHS [KO8 DK02308] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010971, T32AA007463] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BAFFY G, 1995, BIOCHEM BIOPH RES CO, V210, P378, DOI 10.1006/bbrc.1995.1672; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; FONTENAY M, 1992, J CELL PHYSIOL, V152, P507, DOI 10.1002/jcp.1041520310; FUKUI M, 1993, J LAB CLIN MED, V122, P149; FURUICHI T, 1989, NUCLEIC ACIDS RES, V17, P5385, DOI 10.1093/nar/17.13.5385; FURUICHI T, 1990, FEBS LETT, V267, P85, DOI 10.1016/0014-5793(90)80294-S; IIZUKA K, 1994, J MOL CELL CARDIOL, V26, P435, DOI 10.1006/jmcc.1994.1054; IIZUKA K, 1995, JPN HEART J, V36, P101; JAFFER F, 1989, AM J PATHOL, V135, P261; Joseph SK, 1996, CELL SIGNAL, V8, P1, DOI 10.1016/0898-6568(95)02012-8; JOSEPH SK, 1994, J BIOL CHEM, V269, P5673; JOSEPH SK, 1993, J BIOL CHEM, V268, P23059; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; NAKAMURA T, 1993, DIABETES, V42, P450, DOI 10.2337/diabetes.42.3.450; NAKAMURA T, 1993, CLIN IMMUNOL IMMUNOP, V66, P33, DOI 10.1006/clin.1993.1005; Nakanishi S, 1996, CELL TISSUE RES, V285, P235, DOI 10.1007/s004410050641; SHARMA K, 1994, AM J PHYSIOL-RENAL, V267, pF1094, DOI 10.1152/ajprenal.1994.267.6.F1094; Sharma K, 1996, DIABETES, V45, P522, DOI 10.2337/diabetes.45.4.522; SHARMA K, 1994, AM J PHYSIOL, V266, pF829, DOI 10.1152/ajprenal.1994.266.6.F829; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; WOJCIKIEWICZ RJH, 1991, J BIOL CHEM, V266, P22234; WOLF G, 1992, KIDNEY INT, V42, P647, DOI 10.1038/ki.1992.330; WOLF G, 1992, AM J PATHOL, V140, P95; Wymore RS, 1996, J BIOL CHEM, V271, P15629, DOI 10.1074/jbc.271.26.15629; YANG TX, 1995, AM J PHYSIOL-RENAL, V268, pF1046, DOI 10.1152/ajprenal.1995.268.6.F1046; Zhu D., 1992, Journal of the American Society of Nephrology, V3, P770; ZHU Z, 1995, EUR J CLIN INVEST, V25, P317, DOI 10.1111/j.1365-2362.1995.tb01708.x	35	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14617	14623		10.1074/jbc.272.23.14617	http://dx.doi.org/10.1074/jbc.272.23.14617			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169422	hybrid			2022-12-27	WOS:A1997XC32700019
J	Li, X; Earp, HS				Li, X; Earp, HS			Paxillin is tyrosine-phosphorylated by and preferentially associates with the calcium-dependent tyrosine kinase in rat liver epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; SWISS 3T3 CELLS; SMOOTH-MUSCLE CELLS; SIGNAL-TRANSDUCTION; ANGIOTENSIN-II; GROWTH-FACTOR; EXTRACELLULAR-MATRIX; PROTEIN PAXILLIN; CROSS-TALK; V-CRK	We and others have recently cloned a non-receptor, calcium-dependent tyrosine kinase (CADTK; also known as PYK2, CAK beta, and RAFTK) that shares both overall domain structure and 45% amino acid identity with p125(FAK), We have studied the signaling, activation, and potential function of these related enzymes in GN4 rat liver epithelial cells that express CADTK and p125(FAK) at roughly similar levels, p125(FAK) is nearly fully tyrosine-phosphorylated in resting GN4 cells, In contrast, while CADTK is not tyrosine-autophosphorylated in untreated cells, angiotensin II increases CADTK Tyr(P) by 5-10-fold, With regard to signaling, CADTK activation is correlated with stimulation of c-Jun N-terminal kinase and p70(S6K) pathways but not with the stimulation of mitogen-activated protein kinase or p90(RSK), In this report we assessed the contribution of CADTK and p125(FAK) to tyrosine phosphorylation of focal contact proteins, In adherent GN4 cells, the constitutive activity of p125(FAK) was correlated with basal paxillin, tensin, and p130(CAS) tyrosine phosphorylation, A rapid increase in the tyrosine phosphorylation of each protein was detected after treatment with angiotensin II or other agonists that stimulate CADTK; the prolonged 3-4-fold increase in paxillin tyrosine phosphorylation was the most substantial change, In the WE cell line that expresses 3-fold less CADTK than GN4 cell line agonist-dependent paxillin tyrosine phosphorylation is similarly reduced. Immunoprecipitation of CADTK from GN4 cells revealed CADTK paxillin complexes that persisted in 500 mM NaCl but not in 0.1% SDS cell lysis buffer, The complexes were largely independent of the tyrosine phosphorylation state of either protein, Surprisingly, we did not detect pl25(FAK) paxillin complexes in immunoprecipitates using either of two p125(FAK) antibodies, When CADTK and p125(FAK) were transiently overexpressed in 293(T) cells, both enzymes associated with paxillin, but the avidity of CADTK appeared to be greater, In addition, in transfected 293(T) cells, complexes between CADTK and another potential substrate, p130(CAS), were detected, In summary, in GN4 rat liver epithelial cells stimulation of CADTK was highly correlated with paxillin tyrosine phosphorylation; in addition, CADTK but not p125(FAK) was complexed to paxillin at detectable levels, This suggests that agonist-dependent cytoskeletal changes in epithelial cells might proceed, in part, by CADTK-dependent mechanisms.	UNIV N CAROLINA, DEPT MED & PHARMACOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill								AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COBB BS, 1994, MOL CELL BIOL, V15, P2819; EARP HS, 1995, J BIOL CHEM, V270, P28440; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; Graves LM, 1997, J BIOL CHEM, V272, P1920, DOI 10.1074/jbc.272.3.1920; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; ILLC D, 1995, NATURE, V377, P539; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LEDUC I, 1995, J BIOL CHEM, V270, P4401, DOI 10.1074/jbc.270.9.4401; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MCCUNE BK, 1989, J BIOL CHEM, V264, P15501; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; PATCH LA, 1995, J CELL SCI, V108, P1371; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; RANKIN S, 1994, J BIOL CHEM, V269, P704; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SECKL MJ, 1995, J BIOL CHEM, V270, P6984, DOI 10.1074/jbc.270.12.6984; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TURNER CE, 1995, J CELL SCI, V108, P333; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	64	110	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14341	14348		10.1074/jbc.272.22.14341	http://dx.doi.org/10.1074/jbc.272.22.14341			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162070	Green Published, hybrid			2022-12-27	WOS:A1997XB49200057
J	deCaestecker, MP; Hemmati, P; LarischBloch, S; Ajmera, R; Roberts, AB; Lechleider, RJ				deCaestecker, MP; Hemmati, P; LarischBloch, S; Ajmera, R; Roberts, AB; Lechleider, RJ			Characterization of functional domains within Smad4/DPC4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; RECEPTOR; GENE; DROSOPHILA	Smad proteins are a family of highly conserved, intracellular proteins that signal cellular responses downstream of transforming growth factor-beta (TGF-beta) family serine/threonine kinase receptors. One of these molecules, Smad4, originally identified as the candidate tumor suppressor gene dpc-4, reconstitutes TGF-beta- and activin-dependent transcriptional responses in Smad4 null cell lines and interacts in a ligand-dependent manner with other Smad family members in both TGF-beta, activin, and bone morphogenetic protein-2/-4 pathways. Here, we used an assay based on the restoration of ligand-dependent transcriptional responses in a Smad4 null cell line to characterize functional domain structures within Smad4. We showed that restoration of TGF-beta-induced transcriptional responses by Smad4 was inhibited by co-transfection with a kinase dead TGF-beta type II receptor and that constitutive activation was blocked with TGF-beta neutralizing antibodies, confirming the essential role of Smad4 in TGF-beta signaling. Using a series of Smad4 mutation, deletion, and Smad1/Smad4 chimera constructs we identified a 47-amino acid deletion within the middle-linker region of Smad4 that is essential for the mediation of signaling responses. In addition, we showed that the NH2-terminal domain of Smad4 augments ligand-dependent activation associated with the middle-linker region, indicating that there is a distinct ligand-response domain within the N terminus of this molecule.			deCaestecker, MP (corresponding author), NCI,CHEMOPREVENT LAB,NIH,BLDG 41,RM C629,41 LIB DR,MSC 5055,BETHESDA,MD 20892, USA.							Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BRAND T, 1995, J BIOL CHEM, V270, P8274, DOI 10.1074/jbc.270.14.8274; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79, DOI 10.1002/jcp.1041380112; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GELBART WM, 1989, DEVELOPMENT, V107, P65; GLICK AB, 1990, MOL ENDOCRINOL, V4, P46, DOI 10.1210/mend-4-1-46; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Newfeld SJ, 1996, DEVELOPMENT, V122, P2099; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; Schutte M, 1996, CANCER RES, V56, P2527; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	25	127	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13690	13696		10.1074/jbc.272.21.13690	http://dx.doi.org/10.1074/jbc.272.21.13690			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153220	hybrid			2022-12-27	WOS:A1997XA06200035
J	Elliott, JG; Oliver, JD; High, S				Elliott, JG; Oliver, JD; High, S			The thiol-dependent reductase ERp57 interacts specifically with N-glycosylated integral membrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-ALPHA; ENDOPLASMIC-RETICULUM PROTEIN; DISULFIDE-ISOMERASE; MOLECULAR-CLONING; GLYCOPROTEIN GLUCOSYLTRANSFERASE; THIOREDOXIN SUPERFAMILY; REGULATED PROTEIN; QUALITY-CONTROL; CDNA SEQUENCE; UDP-GLC	The lumen of the endoplasmic reticulum contains a number of distinct molecular chaperones and folding factors, which modulate the folding and assembly of newly synthesized proteins and protein complexes. A subset of these luminal components are specific for glycoproteins, and, like calnexin and calreticulin, the thiol-dependent reductase ERp57 has been shown to interact specifically with soluble secretory proteins bearing N-linked carbohydrate. Calnexin and calreticulin also interact with glycosylated integral membrane proteins, and in this study we have examined the interaction of ERp57 with these substrates. As with soluble proteins, the binding of ERp57 to an integral membrane protein is dependent upon the protein bearing an N-glycan that has undergone glucose trimming. Furthermore, ERp57 binds to newly synthesized glycoproteins in combination with either calnexin or calreticulin. We propose that ERp57 acts in concert with calnexin and calreticulin to modulate glycoprotein folding and enforce the glycoprotein specific quality control mechanism operating in the endoplasmic reticulum.	UNIV MANCHESTER,SCH BIOL SCI,MANCHESTER M13 9PT,LANCS,ENGLAND	University of Manchester				High, Stephen/0000-0002-4532-8152	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENNETT CF, 1988, NATURE, V334, P268, DOI 10.1038/334268a0; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOURDI M, 1995, ARCH BIOCHEM BIOPHYS, V323, P397, DOI 10.1006/abbi.1995.0060; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HIGH S, 1987, BIOCHEM J, V243, P277, DOI 10.1042/bj2430277; HIGH S, 1992, Current Opinion in Cell Biology, V4, P581, DOI 10.1016/0955-0674(92)90075-N; HIRANO N, 1994, BIOCHEM BIOPH RES CO, V204, P375, DOI 10.1006/bbrc.1994.2469; HIRANO N, 1995, EUR J BIOCHEM, V234, P336, DOI 10.1111/j.1432-1033.1995.336_c.x; Kim PS, 1996, J CELL BIOL, V133, P517, DOI 10.1083/jcb.133.3.517; KUZNETSOV G, 1994, J BIOL CHEM, V269, P22990; LABRIOLA C, 1995, J CELL BIOL, V130, P771, DOI 10.1083/jcb.130.4.771; Laird V, 1997, J BIOL CHEM, V272, P1983, DOI 10.1074/jbc.272.3.1983; LEE AS, 1981, J CELL PHYSIOL, V106, P119, DOI 10.1002/jcp.1041060113; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LEWIS MJ, 1986, ARCH BIOCHEM BIOPHYS, V245, P389, DOI 10.1016/0003-9861(86)90230-4; MARTIN JL, 1991, BIOCHEM BIOPH RES CO, V178, P679, DOI 10.1016/0006-291X(91)90161-Y; MAZZARELLA RA, 1994, ARCH BIOCHEM BIOPHYS, V308, P454, DOI 10.1006/abbi.1994.1064; MOBBS CV, 1990, SCIENCE, V247, P1477, DOI 10.1126/science.2181662; MURTHY MSR, 1994, BIOCHEM J, V304, P31, DOI 10.1042/bj3040031; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; Oliver JD, 1996, J BIOL CHEM, V271, P13691, DOI 10.1074/jbc.271.23.13691; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; ORA A, 1995, J BIOL CHEM, V270, P26060, DOI 10.1074/jbc.270.44.26060; OTSU M, 1995, J BIOL CHEM, V270, P14958, DOI 10.1074/jbc.270.25.14958; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; PUIG A, 1994, J BIOL CHEM, V269, P7764; PUIG A, 1994, J BIOL CHEM, V269, P19128; Rodan AR, 1996, EMBO J, V15, P6921, DOI 10.1002/j.1460-2075.1996.tb01084.x; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; SRIVASTAVA SP, 1991, J BIOL CHEM, V266, P20337; SRIVASTAVA SP, 1993, BIOCHEM BIOPH RES CO, V193, P971, DOI 10.1006/bbrc.1993.1720; STEUBER D, 1984, EMBO J, V3, P3143; URADE R, 1992, J BIOL CHEM, V267, P15152; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697	45	112	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13849	13855		10.1074/jbc.272.21.13849	http://dx.doi.org/10.1074/jbc.272.21.13849			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153243	hybrid			2022-12-27	WOS:A1997XA06200058
J	Esteban, JA; Banerjee, AR; Burke, JM				Esteban, JA; Banerjee, AR; Burke, JM			Kinetic mechanism of the hairpin ribozyme - Identification and characterization of two nonexchangeable conformations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOBACCO RINGSPOT VIRUS; HELIX-COIL TRANSITION; GROUP-II INTRON; CATALYZED CLEAVAGE; RNA; COMPLEMENTARY; SEQUENCES; BINDING; OLIGONUCLEOTIDES; THERMODYNAMICS	To investigate the relationship between RNA folding and ribozyme catalysis, we have carried out a detailed kinetic analysis of four structural derivatives of the hairpin ribozyme. Optimal and suboptimal (wild-type) substrate sequences were studied in conjunction with stabilization of helix 4, which supports formation of the catalytic core. Pre-steady-state and steady-state kinetic studies strongly support a model in which each of the ribozyme variants partitions between two major conformations leading to active and inactive ribozyme substrate complexes. Reaction rates for cleavage, ligation, and substrate binding to both ribozyme conformations were determined. Ligation rates (3, min(-1)) were typically 15-fold greater than cleavage rates (0.2 min(-1)), demonstrating that the hairpin ribozyme is an efficient RNA ligase. On the other hand, substrate binding is very rapid (k(on) = 4 x 10(8) M-1 min(-1)), and the ribozyme substrate complex is very stable (K-D < 25 pm; k(off) < 0.01 min(-1)). Stabilization of helix 4 increases the proportion of RNA molecules folded into the active conformation, and enhances substrate association and ligation rates. These effects can be explained by stabilization of the catalytic core of the ribozyme, Rigorous consideration of conformational isomers and their intrinsic kinetic properties was necessary for development of a kinetic scheme for the ribozyme-catalyzed reaction.	UNIV VERMONT, DEPT MICROBIOL & MOL GENET, MARKEY CTR MOL GENET, BURLINGTON, VT 05405 USA	University of Vermont			Esteban, Jose/L-4944-2014; , John/AAB-5945-2021	Esteban, Jose/0000-0002-3759-3300; 				Amiri KMA, 1996, J MOL BIOL, V261, P125, DOI 10.1006/jmbi.1996.0446; Beebe JA, 1996, BIOCHEMISTRY-US, V35, P10493, DOI 10.1021/bi960870m; BEEBE JA, 1994, BIOCHEMISTRY-US, V33, P10294, DOI 10.1021/bi00200a009; BERZALHERRANZ A, 1992, GENE DEV, V6, P129, DOI 10.1101/gad.6.1.129; BERZALHERRANZ A, 1993, EMBO J, V12, P2567, DOI 10.1002/j.1460-2075.1993.tb05912.x; Bevilacqua PC, 1996, BIOCHEMISTRY-US, V35, P648, DOI 10.1021/bi951962z; BEVILACQUA PC, 1992, SCIENCE, V258, P1355, DOI 10.1126/science.1455230; BRESLAUER KJ, 1977, BIOPHYS CHEM, V7, P211, DOI 10.1016/0301-4622(77)87024-5; BURKE JM, 1994, NUCL ACIDS MOL BIOL, V8, P105; BURKE JM, 1996, NUCL ACIDS MOL BIOL, V10, P129; BUTCHER SE, 1994, BIOCHEMISTRY-US, V33, P992, DOI 10.1021/bi00170a018; BUTCHER SE, 1994, J MOL BIOL, V244, P52, DOI 10.1006/jmbi.1994.1703; BUTCHER SE, 1995, J BIOL CHEM, V270, P29648; CECH TR, 1981, CELL, V27, P487, DOI 10.1016/0092-8674(81)90390-1; CHOWRIRA BM, 1991, BIOCHEMISTRY-US, V30, P8518, DOI 10.1021/bi00099a003; CRAIG ME, 1971, J MOL BIOL, V62, P383, DOI 10.1016/0022-2836(71)90434-7; Daniels DL, 1996, J MOL BIOL, V256, P31, DOI 10.1006/jmbi.1996.0066; Emerick VL, 1996, BIOCHEMISTRY-US, V35, P13469, DOI 10.1021/bi960865i; FELDSTEIN PA, 1989, GENE, V82, P53, DOI 10.1016/0378-1119(89)90029-2; GAST FU, 1994, BIOCHEMISTRY-US, V33, P1788, DOI 10.1021/bi00173a023; Golden BL, 1996, BIOCHEMISTRY-US, V35, P3754, DOI 10.1021/bi952599z; GRALLA J, 1973, J MOL BIOL, V73, P497, DOI 10.1016/0022-2836(73)90096-X; HAMPEL A, 1989, BIOCHEMISTRY-US, V28, P4929, DOI 10.1021/bi00438a002; HASELOFF J, 1989, GENE, V82, P43, DOI 10.1016/0378-1119(89)90028-0; HEGG LA, 1995, BIOCHEMISTRY-US, V34, P15813, DOI 10.1021/bi00048a027; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERTEL KJ, 1995, BIOCHEMISTRY-US, V34, P1744, DOI 10.1021/bi00005a031; HERTEL KJ, 1994, BIOCHEMISTRY-US, V33, P3374, DOI 10.1021/bi00177a031; Komatsu Y, 1996, BIOCHEMISTRY-US, V35, P9815, DOI 10.1021/bi960627n; Lee CB, 1996, BIOCHEMISTRY-US, V35, P12303, DOI 10.1021/bi961219m; Mei R, 1996, BIOCHEMISTRY-US, V35, P5796, DOI 10.1021/bi9527653; MICHELS WJ, 1995, BIOCHEMISTRY-US, V34, P2965, DOI 10.1021/bi00009a028; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; NELSON JW, 1982, BIOCHEMISTRY-US, V21, P5289, DOI 10.1021/bi00264a026; PORSCHKE D, 1973, BIOPOLYMERS, V12, P1313, DOI 10.1002/bip.1973.360120609; PORSCHKE D, 1971, J MOL BIOL, V62, P361, DOI 10.1016/0022-2836(71)90433-5; PYLE AM, 1994, BIOCHEMISTRY-US, V33, P2716, DOI 10.1021/bi00175a047; RAVETCH J, 1974, NUCLEIC ACIDS RES, V1, P109, DOI 10.1093/nar/1.1.109; SARGUEIL B, 1995, BIOCHEMISTRY-US, V34, P7739, DOI 10.1021/bi00023a021; THILL G, 1993, BIOCHEMISTRY-US, V32, P4254, DOI 10.1021/bi00067a013; UHLENBECK OC, 1995, RNA, V1, P4; Walter NG, 1997, RNA, V3, P392	42	89	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13629	13639		10.1074/jbc.272.21.13629	http://dx.doi.org/10.1074/jbc.272.21.13629			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153212	Green Published, hybrid			2022-12-27	WOS:A1997XA06200027
J	Hipkin, RW; Friedman, J; Clark, RB; Eppler, CM; Schonbrunn, A				Hipkin, RW; Friedman, J; Clark, RB; Eppler, CM; Schonbrunn, A			Agonist-induced desensitization, internalization, and phosphorylation of the sst2A somatostatin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PITUITARY-TUMOR-CELLS; BETA-ADRENERGIC-RECEPTOR; INTRACELLULAR FREE CALCIUM; AMP-INDEPENDENT ACTIONS; EPIDERMAL GROWTH-FACTOR; ADENYLATE-CYCLASE; PROTEIN-KINASE; PHOSPHATASE-ACTIVITY; PROLACTIN SECRETION; ANALOG SMS-201-995	Cellular responsiveness to the inhibitory peptide somatostatin (SRIP) or its clinically used analogs can desensitize with agonist exposure. While desensitization of other seven-transmembrane domain receptors is mediated by receptor phosphorylation and/or internalization, the mechanisms mediating SRIF receptor (sst) desensitization are unknown. Therefore, we investigated the susceptibility of the sst2A receptor isotype to ligand-induced desensitization, internalization, and phosphorylation in GH-R2 cells, a clone of pituitary tumor cells overexpressing this receptor. A 30-min exposure of cells to either SRIF or the analog SMS 201-995 (SMS) reduced both the potency and efficacy of agonist inhibition of adenylyl cyclase. Internalization of receptor-bound ligand was rapid (t(1/2) = 4 min) and temperature-dependent. SRIF and SMS increased the phosphorylation of the 71-kDa sst2A protein 25-fold within 15 min. Receptor phosphorylation was dependent on both the concentration and time of agonist exposure and was not affected by pertussis toxin pretreatment, indicating that receptor occupancy rather than second messenger formation was required. Receptor phosphorylation was also stimulated by phorbol 12-myristate 13-acetate activation of protein kinase C. Both ligand-stimulated and phorbol 12-myristate 13-acetate-stimulated receptor phosphorylation occurred primarily on serine. These studies are the first demonstration of agonist-dependent desensitization, internalization, and phosphorylation of the sst2A receptor and suggest that phosphorylation may mediate the homologous and heterologous regulation of this receptor.	UNIV TEXAS,SCH MED,DEPT PHARMACOL,HOUSTON,TX 77225; AMER CYANAMID CO,AGR RES CTR,PRINCETON,NJ 08543	University of Texas System; American Cyanamid Company					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032234, R56DK032234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031208] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32234] Funding Source: Medline; NIGMS NIH HHS [GM31208] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMHERDT M, 1989, J CLIN INVEST, V84, P412, DOI 10.1172/JCI114181; BITO H, 1994, J BIOL CHEM, V269, P12722; Bradford M. M., 1976, ANAL BIOCHEM, V53, P304; BROWN PJ, 1990, J BIOL CHEM, V265, P17995; CARRICK TA, 1995, ENDOCRINOLOGY, V136, P4701, DOI 10.1210/en.136.10.4701; COLAS B, 1992, EUR J BIOCHEM, V207, P1017, DOI 10.1111/j.1432-1033.1992.tb17138.x; DORFLINGER LJ, 1985, ENDOCRINOLOGY, V117, P2330, DOI 10.1210/endo-117-6-2330; Dournaud P, 1996, J NEUROSCI, V16, P4468; DUCASSE MCR, 1987, J CLIN ENDOCR METAB, V65, P1042, DOI 10.1210/jcem-65-5-1042; Duerson K, 1996, NEUROPHARMACOLOGY, V35, P949, DOI 10.1016/0028-3908(96)00131-1; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; FLORIO T, 1994, MOL ENDOCRINOL, V8, P1289, DOI 10.1210/me.8.10.1289; GORDELADZE JO, 1989, EUR J BIOCHEM, V183, P397, DOI 10.1111/j.1432-1033.1989.tb14941.x; Gu YZ, 1995, MOL PHARMACOL, V48, P1004; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HIPKIN RW, 1993, MOL ENDOCRINOL, V7, P823, DOI 10.1210/me.7.7.823; HOFLAND LJ, 1995, ENDOCRINOLOGY, V136, P3698, DOI 10.1210/en.136.9.3698; HOU CF, 1994, J BIOL CHEM, V269, P10357; HOYER D, 1995, TRENDS PHARMACOL SCI, V16, P86, DOI 10.1016/S0165-6147(00)88988-9; Hukovic N, 1996, ENDOCRINOLOGY, V137, P4046, DOI 10.1210/en.137.9.4046; KEHIJMAN M, 1990, J CLIN ENDOCR METAB, V71, P157; KENNELLY PJ, 1991, J BIOL CHEM, V266, P1555; KOCH BD, 1988, J BIOL CHEM, V263, P216; KOCH BD, 1985, J BIOL CHEM, V260, P3138; KOPER JW, 1990, CANCER RES, V50, P6238; KUBOTA A, 1994, J CLIN INVEST, V93, P1321, DOI 10.1172/JCI117090; Lamberts SWJ, 1996, NEW ENGL J MED, V334, P246, DOI 10.1056/NEJM199601253340408; MAHY N, 1988, J PHARMACOL EXP THER, V247, P390; MATOZAKI T, 1986, J BIOL CHEM, V261, P1414; MAYOR F, 1987, J BIOL CHEM, V262, P6468; MOREL G, 1986, ENDOCRINOLOGY, V119, P1972, DOI 10.1210/endo-119-5-1972; ONALI P, 1983, MOL PHARMACOL, V24, P189; OSBORNE R, 1982, CANCER RES, V42, P4375; PRESKY DH, 1988, J BIOL CHEM, V263, P714; PRESKY DH, 1988, MOL PHARMACOL, V34, P651; PRESKY DH, 1986, J CELL BIOL, V102, P878, DOI 10.1083/jcb.102.3.878; REISINE T, 1988, J PHARMACOL EXP THER, V245, P225; REISINE T, 1984, J PHARMACOL EXP THER, V229, P14; REISINE T, 1995, ENDOCR REV, V16, P427, DOI 10.1210/er.16.4.427; RENSDOMIANO S, 1992, MOL PHARMACOL, V42, P28; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; SCHONBRUNN A, 1978, J BIOL CHEM, V253, P6473; SCHONBRUNN A, 1995, CIBA F SYMP, V190, P204; SMITH MA, 1984, MOL CELL ENDOCRINOL, V37, P311, DOI 10.1016/0303-7207(84)90101-1; SRIKANT CB, 1985, ENDOCRINOLOGY, V117, P271, DOI 10.1210/endo-117-1-271; SULLIVAN SJ, 1986, J BIOL CHEM, V261, P3571; TOMURA H, 1994, BIOCHEM BIOPH RES CO, V200, P986, DOI 10.1006/bbrc.1994.1547; TSUGA H, 1994, J BIOL CHEM, V269, P32522; VANETTI M, 1993, FEBS LETT, V331, P260, DOI 10.1016/0014-5793(93)80349-Y; VIGUERIE N, 1987, AM J PHYSIOL, V252, pG535, DOI 10.1152/ajpgi.1987.252.4.G535; WELSH JB, 1988, ENDOCRINOLOGY, V123, P2230, DOI 10.1210/endo-123-5-2230; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; Williams BY, 1996, MOL PHARMACOL, V50, P716; YATANI A, 1987, MOL ENDOCRINOL, V1, P283, DOI 10.1210/mend-1-4-283; YUAN NY, 1994, J BIOL CHEM, V269, P23032	55	139	140	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13869	13876		10.1074/jbc.272.21.13869	http://dx.doi.org/10.1074/jbc.272.21.13869			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153246	hybrid			2022-12-27	WOS:A1997XA06200061
J	Kimura, T; Sakamoto, H; Appella, E; Siraganian, RP				Kimura, T; Sakamoto, H; Appella, E; Siraganian, RP			The negative signaling molecule SH2 domain-containing inositol-polyphosphate 5-phosphatase (SHIP) binds to the tyrosine-phosphorylated beta subunit of the high affinity IgE receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; BASOPHILIC LEUKEMIA-CELLS; FC-GAMMA-RIIB; T-CELL; HISTAMINE-RELEASE; MAST-CELLS; ZETA-CHAIN; PROTEIN; ACTIVATION; TRANSDUCTION	The SH2 domain-containing inositol-polyphosphate 5-phosphatase, SHIP, associates with Fc gamma RIIB and negatively regulates both B-cell and mast cell function, We report here that SHIP was tyrosine phosphorylated after high affinity IgE receptor (Fc epsilon RI) aggregation in rat basophilic leukemia RBL-2H3 cells, The ty rosine phosphorylation of SHIP was an early event after receptor aggregation and was present in cells deficient in the protein-tyrosine kinase Syk, Furthermore it was not secondary to the increase of intracellular calcium or the activation of protein kinase C. SHIP was precipitated by immobilized phosphorylated synthetic peptides based on the immunoreceptor tyrosine-based activation motif (ITAM) of the beta but not the gamma subunit of the high affinity IgE receptor. Tyrosine phosphorylation of SHIP and its association with the tyrosine-phosphorylated beta subunit of Fc epsilon RI could play an important role in down-regulating receptor-mediated signal transduction in mast cells, Thus, whereas the activation molecule Syk associates with the gamma subunit ITAM, the beta subunit ITAM binds the negative signaling molecule SHIP. Therefore, unlike B cells where the antigen receptor and coreceptors such as Fc gamma RIIB or CD22 each recruits molecules with opposite effects, the Fc epsilon RI contains subunits which recruit molecules that activate and inhibit signal transduction.	NCI,CELL BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kimura, T (corresponding author), NIDR,IMMUNOL LAB,NIH,BLDG 10,RM 1N106,BETHESDA,MD 20892, USA.		Sakamoto, Hiroshi/A-3181-2011					ALBER G, 1991, J BIOL CHEM, V266, P22613; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; Busse WW, 1993, ALLERGY PRINCIPLES P, P105; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; Chacko GW, 1996, J IMMUNOL, V157, P2234; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; Crowley MT, 1996, J BIOL CHEM, V271, P1145, DOI 10.1074/jbc.271.2.1145; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DEFRANCO AL, 1995, SCIENCE, V268, P263, DOI 10.1126/science.7716518; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; HAMAWY MM, 1995, CELL SIGNAL, V7, P535, DOI 10.1016/0898-6568(95)00024-J; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HIRASAWA N, 1995, J IMMUNOL, V154, P5391; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Kimura T, 1996, J BIOL CHEM, V271, P27962, DOI 10.1074/jbc.271.44.27962; Kimura T, 1996, MOL CELL BIOL, V16, P1471; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; MEYER S, 1994, MOL CELL BIOL, V14, P3253, DOI 10.1128/MCB.14.5.3253; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; OFFERMANNS S, 1994, J IMMUNOL, V152, P250; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Rider LG, 1996, J IMMUNOL, V157, P2374; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; STEPHAN V, 1992, J BIOL CHEM, V267, P5434; THOMAS ML, 1995, J EXP MED, V181, P1953, DOI 10.1084/jem.181.6.1953; TURNER H, 1995, J BIOL CHEM, V270, P9500, DOI 10.1074/jbc.270.16.9500; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71	45	119	120	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13991	13996		10.1074/jbc.272.21.13991	http://dx.doi.org/10.1074/jbc.272.21.13991			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153264	hybrid			2022-12-27	WOS:A1997XA06200079
J	Bromann, PA; Boetticher, EE; Lomasney, JW				Bromann, PA; Boetticher, EE; Lomasney, JW			A single amino acid substitution in the pleckstrin homology domain of phospholipase C delta 1 enhances the rate of substrate hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MONOLAYER SURFACE PRESSURE; INTERFACIAL CATALYSIS; HIGH-AFFINITY; INOSITOL TRISPHOSPHATE; KINETIC-ANALYSIS; BINDING; C-DELTA-1; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLSERINE	The pleckstrin homology (PH) domain has been postulated to serve as an anchor for enzymes that operate at a lipid/water interface. To understand further the relationship between the PH domain and enzyme activity, a phospholipase C (PLC) delta 1/PH domain enhancement-of-activity mutant was generated. A lysine residue was substituted for glutamic acid in the PH domain of PLC delta 1 at position 54 (E54K). Purified native and mutant enzymes were characterized using a phosphatidylinositol 4,5-bisphosphate (PI(4,5)P-2)/dodecyl maltoside mixed micelle assay and kinetics measured according to the dual phospholipid model of Dennis and co-workers (Hendrickson, H. S., and Dennis, E. A. (1984) J. Biol. Chem. 259, 5734-5739; Carmen, G. M., Deems, R. A., and Dennis, E. A. (1995) J. Biol; Chem. 270, 18711-18714). Our results show that both PLC delta 1 and E54K bind phosphatidylinositol bisphosphate cooperatively (Hill coefficients, n = 2.2 +/- 0.2 and 2.0 +/- 0.1, respectively). However, E54K shows a dramatically increased rate of (PI(4,5)P-2)-stimulated PI(4,5)P-2 hydrolysis (interfacial V-max for PLC delta 1 = 4.9 +/- 0.3 mu mol/min/mg and for E54K = 31 +/- 3 mu mol/min/mg) as well as PI hydrolysis (V-max for PLC delta 1 = 27 +/- 3.4 nmol/min/mg and for E54K = 95 +/- 12 nmol/min/mg). In the absence of PI(4,5)P-2 both native and mutant enzyme hydrolyze PI at similar rates. E54K also has a higher affinity for micellar substrate (equilibrium dissociation constant, K-s = 85 +/- 36 mu M for E54R and 210 +/- 48 mu M for PLC delta 1). Centrifugation binding assays using large unilamelar phospholipid vesicles confirm that E54K binds PI(4,5)P-2 with higher affinity than native enzyme. E54K is more active even though the interfacial Michaelis constant (K-m) for E54K (0.034 +/- 0.01 mol fraction PI(4,5)P-2) is higher than the K-m for native enzyme (0.012 +/- 0.002 mol fraction PI(4,5)P-2). D-Inositol trisphosphate is less potent at inhibiting E54K PI(4,5)P-2 hydrolysis compared with native enzyme. These results demonstrate that a single amino acid substitution in the PH domain of PLC delta 1 can dramatically enhance enzyme activity. Additionally, the marked increase in V-max for E54R argues for a direct role of PH domains in regulating catalysis by allosteric modulation of enzyme structure.	NORTHWESTERN UNIV,SCH MED,FEINBERG CARDIOVASC RES INST,DEPT PATHOL,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,FEINBERG CARDIOVASC RES INST,DEPT PHARMACOL,CHICAGO,IL 60611; NORTHWESTERN UNIV,INST NEUROSCI,CHICAGO,IL 60611	Northwestern University; Northwestern University; Northwestern University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL055591, R01HL055591] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55591] Funding Source: Medline; NIMH NIH HHS [MH11219] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BERG OG, 1991, BIOCHEMISTRY-US, V30, P7283, DOI 10.1021/bi00243a034; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIANCO ID, 1995, BBA-PROTEIN STRUCT M, V1250, P197, DOI 10.1016/0167-4838(95)00051-U; BOGUSLAVSKY V, 1994, BIOCHEMISTRY-US, V33, P3032, DOI 10.1021/bi00176a036; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CHENG HF, 1995, J BIOL CHEM, V270, P5495, DOI 10.1074/jbc.270.10.5495; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; CIFUENTES ME, 1994, J BIOL CHEM, V269, P1945; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; HENDRICKSON HS, 1992, BIOCHEMISTRY-US, V31, P12169, DOI 10.1021/bi00163a028; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5740; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P7330, DOI 10.1021/bi00243a038; JAMES SR, 1995, J BIOL CHEM, V270, P11872, DOI 10.1074/jbc.270.20.11872; JONES GA, 1993, J BIOL CHEM, V268, P20845; KATO H, 1992, J BIOL CHEM, V267, P6483; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; Lomasney JW, 1996, J BIOL CHEM, V271, P25316, DOI 10.1074/jbc.271.41.25316; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12748, DOI 10.1021/bi00166a006; Romoser V, 1996, J BIOL CHEM, V271, P25071, DOI 10.1074/jbc.271.41.25071; SHIMOHAMA S, 1995, BRAIN RES, V669, P217, DOI 10.1016/0006-8993(94)01239-E; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; WAHL MI, 1992, J BIOL CHEM, V267, P10447; YAGISAWA H, 1991, J HYPERTENS, V9, P997, DOI 10.1097/00004872-199111000-00004; YU FX, 1992, J BIOL CHEM, V267, P14616	39	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16240	16246		10.1074/jbc.272.26.16240	http://dx.doi.org/10.1074/jbc.272.26.16240			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195925	hybrid			2022-12-27	WOS:A1997XG01900029
J	Mizukami, Y; Yoshioka, K; Morimoto, S; Yoshida, K				Mizukami, Y; Yoshioka, K; Morimoto, S; Yoshida, K			A novel mechanism of JNK1 activation - Nuclear translocation and activation of JNK1 during ischemia and reperfusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENES; NECROSIS-FACTOR-ALPHA; C-FOS EXPRESSION; PROTEIN-KINASE; CARDIAC MYOCYTES; AP-1 ACTIVITY; HA-RAS; HUMAN-PLATELETS; MAP KINASES; JUN	Cytokines and various cellular stresses are known to activate c-Jun NH2-terminal kinase (JNK), which plays a role in conveying signals from the cytosol to the nucleus. Here we investigate the translocation and activation of JNK1 during ischemia and reperfusion in perfused rat heart. Ischemia induces the translocation of JNK1 from the cytosol fraction to the nuclear fraction in a time-dependent manner. Immunohistochemical observation also shows that JNK1 staining in the nucleus is enhanced after ischemia. During reperfusion after ischemia, further nuclear translocation of JNK1 is apparently inhibited. In contrast, JNK1 activity in the nuclear fraction does not increased during ischemia but increases significantly during reperfusion with a peak at 10 min of reperfusion. The activation of JNK1 is confirmed by the phosphorylation of endogenous c-Jun (Ser-73) with similar kinetics. The level of c-jun mRNA also increases during reperfusion but not during ischemia. Based on fractionation and immunohistochemical analyses, an upstream kinase for JNK1, SAPK/ERK kinase 1 (SEK1), is constantly present in both the nucleus and cytoplasm throughout ischemia and reperfusion, whereas an upstream kinase for mitogen-activated protein kinase, MAPK/ERK kinase 1, remains in the cytosol. Furthermore, phosphorylation at Thr-223 of SEK1, necessary for its activation, rapidly increases in the nuclear fraction during postischemic reperfusion. These findings demonstrate that JNK1 translocates to the nucleus during ischemia without activation and is then activated during reperfusion, probably by SEK1 in the nucleus.	KANAZAWA UNIV,CANC RES INST,DEPT MOL PATHOL,KANAZAWA,ISHIKAWA 920,JAPAN; KYUSHU UNIV,SCH MED,DEPT CLIN PHARM,FUKUOKA 812,JAPAN	Kanazawa University; Kyushu University	Mizukami, Y (corresponding author), YAMAGUCHI UNIV,SCH MED,DEPT LEGAL MED,1144 KOGUSHI,UBE,YAMAGUCHI 755,JAPAN.			Morimoto, Sachio/0000-0001-9171-3636				ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; BAK MI, 1994, J CLIN INVEST, V93, P40, DOI 10.1172/JCI116974; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BISHOPRIC NH, 1992, J BIOL CHEM, V267, P25535; BOHMANN D, 1994, CELL, V78, P973, DOI 10.1016/0092-8674(94)90273-9; BRAND T, 1992, CIRC RES, V71, P1351, DOI 10.1161/01.RES.71.6.1351; BUSAM KJ, 1992, J BIOL CHEM, V267, P19971; Canman CE, 1996, NATURE, V384, P213, DOI 10.1038/384213a0; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHEN B, 1992, J CLIN INVEST, V90, P1778, DOI 10.1172/JCI116052; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLESPIEBROWN J, 1995, J BIOL CHEM, V270, P28092; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KIM MY, 1991, J BIOL CHEM, V266, P484; Knight RJ, 1996, BIOCHEM BIOPH RES CO, V218, P83, DOI 10.1006/bbrc.1996.0016; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Mizukami Y, 1997, BIOCHEM J, V323, P785, DOI 10.1042/bj3230785; MIZUKAMI Y, 1994, EUR J BIOCHEM, V224, P959, DOI 10.1111/j.1432-1033.1994.00959.x; Mizukami Y, 1997, FEBS LETT, V401, P247, DOI 10.1016/S0014-5793(96)01481-0; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OUELLETTE AJ, 1990, J CLIN INVEST, V85, P766, DOI 10.1172/JCI114502; POMBO CM, 1994, J BIOL CHEM, V269, P26546; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RofflerTarlov S, 1996, DEVELOPMENT, V122, P1; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; ROTHMAN A, 1994, J BIOL CHEM, V269, P6399; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Takasawa S, 1995, J BIOL CHEM, V270, P30257, DOI 10.1074/jbc.270.51.30257; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; WEBSTER KA, 1994, CIRC RES, V74, P679, DOI 10.1161/01.RES.74.4.679; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WHITELAW PF, 1992, BIOCHEM J, V281, P143, DOI 10.1042/bj2810143; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; YANG HQ, 1994, J BIOL CHEM, V269, P18977; YOSHIDA K, 1988, BIOCHEM J, V249, P487, DOI 10.1042/bj2490487; YOSHIDA K, 1993, BIOCHIM BIOPHYS ACTA, V1182, P215, DOI 10.1016/0925-4439(93)90143-O; YOSHIDA K, 1995, CIRC RES, V77, P603, DOI 10.1161/01.RES.77.3.603; Yoshida K, 1996, BBA-MOL BASIS DIS, V1317, P36, DOI 10.1016/0925-4439(96)00035-X; YOSHIDA K, 1987, J BIOL CHEM, V262, P16048; YOSHIOKA K, 1990, EMBO J, V9, P535, DOI 10.1002/j.1460-2075.1990.tb08140.x; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; ZHENG CF, 1994, J BIOL CHEM, V269, P19947	66	160	162	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16657	16662		10.1074/jbc.272.26.16657	http://dx.doi.org/10.1074/jbc.272.26.16657			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195981	hybrid			2022-12-27	WOS:A1997XG01900085
J	Toribara, NW; Ho, SB; Gum, JR; Lau, P; Kim, YS				Toribara, NW; Ho, SB; Gum, JR; Lau, P; Kim, YS			The carboxyl-terminal sequence of the human secretory mucin, MUC6 - Analysis of the primary amino acid sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND FACTOR; HUMAN GASTRIC MUCIN; GENE LOCUS PUM; MOLECULAR-CLONING; INTESTINAL MUCIN; VONWILLEBRAND-FACTOR; HELICOBACTER-PYLORI; EXPRESSION CLONING; EPITHELIAL MUCINS; CDNA SEQUENCES	The distribution of MUC6 suggests that its primary function is protection of vulnerable epithelial surfaces from damaging effects of constant exposure to a wide range of endogenous caustic or proteolytic agents. A combination of genomic, cDNA. and 3' rapid amplification of cDNA ends techniques was used to isolate the carboxyl-terminal end of MUC6. The 3' nontandem repeat region contained 1083 base pairs of coding sequence (361 amino acids) followed by 632 base pairs of 3'-untranslated region. The coding sequence consists of two distinct regions; region 1 contained the initial 270 amino acids (62% Ser-Thr-Pro with no Cys residues), and region 2 contained the COOH-terminal 91 amino acids (22% Ser-Thr-Pro with 12% Cys). Although region 1 had no homology to any sequences in GenBank, region 2 had approximately 25% amino acid homology to the COOH-terminal regions of human mucins MUC2, -5, and -5B and von Willebrand factor. The shortness of region 2 would leave little of the peptide backbone exposed to a potentially hostile environment. Antibody studies suggest that MUC6 in its native form exists as a disulfide-bonded multimer, The conservation of the 11 cysteine positions in region 2 suggests the importance of this short region to mucin polymerization.	UNIV CALIF SAN FRANCISCO, DIV GASTROENTEROL, SAN FRANCISCO, CA 94121 USA; UNIV MINNESOTA, DEPT MED, MINNEAPOLIS, MN 55417 USA; DEPT VET AFFAIRS MED CTR, MINNEAPOLIS, MN 55417 USA	University of California System; University of California San Francisco; University of Minnesota System; University of Minnesota Twin Cities	Toribara, NW (corresponding author), DEPT VET AFFAIRS MED CTR, GASTROINTESTINAL RES LAB 151M2, 4150 CLEMENT ST, SAN FRANCISCO, CA 94121 USA.							AUBERT JP, 1991, AM J RESP CELL MOL, V5, P178, DOI 10.1165/ajrcmb/5.2.178; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; BYRD JC, 1989, BIOCHEM J, V261, P617, DOI 10.1042/bj2610617; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONG NV, 1990, HUM GENET, V86, P167; DEBOLOS C, 1995, GASTROENTEROLOGY, V109, P723, DOI 10.1016/0016-5085(95)90379-8; DEKKER J, 1990, J BIOL CHEM, V265, P18116; Forstner Janet F., 1994, P1255; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GERARD C, 1990, J CLIN INVEST, V86, P1921, DOI 10.1172/JCI114925; Gipson IK, 1997, BIOL REPROD, V56, P999, DOI 10.1095/biolreprod56.4.999; GRIFFITHS B, 1990, ANN HUM GENET, V54, P277, DOI 10.1111/j.1469-1809.1990.tb00383.x; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1992, J BIOL CHEM, V267, P21375; GUM JR, 1994, J BIOL CHEM, V269, P2440; HO SB, 1995, GASTROENTEROLOGY, V109, P735, DOI 10.1016/0016-5085(95)90380-1; HO SB, 1995, CANCER RES, V55, P2681; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; JANY BH, 1991, J CLIN INVEST, V87, P77, DOI 10.1172/JCI115004; Keates AC, 1997, BIOCHEM J, V324, P295, DOI 10.1042/bj3240295; Kitamura H, 1996, EUR J CANCER, V32A, P1788, DOI 10.1016/0959-8049(96)00168-2; KLOMP LWJ, 1994, BIOCHEM J, V304, P693, DOI 10.1042/bj3040693; LESUFFLEUR T, 1995, J BIOL CHEM, V270, P13665, DOI 10.1074/jbc.270.23.13665; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MEERZAMAN D, 1994, J BIOL CHEM, V269, P12932; Meier PB, 1996, GASTROENTEROLOGY, V110, pA417; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; SADLER JE, 1985, P NATL ACAD SCI USA, V82, P6394, DOI 10.1073/pnas.82.19.6394; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; SLOMIANY BL, 1992, BIOCHEM BIOPH RES CO, V183, P506, DOI 10.1016/0006-291X(92)90511-I; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; SWALLOW DM, 1987, ANN HUM GENET, V51, P289, DOI 10.1111/j.1469-1809.1987.tb01063.x; SWALLOW DM, 1987, NATURE, V328, P82, DOI 10.1038/328082a0; TORIBARA NW, 1991, J CLIN INVEST, V88, P1005, DOI 10.1172/JCI115360; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x; YOUNAN F, 1982, GASTROENTEROLOGY, V82, P827	45	88	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16398	16403		10.1074/jbc.272.26.16398	http://dx.doi.org/10.1074/jbc.272.26.16398			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195947	hybrid			2022-12-27	WOS:A1997XG01900051
J	Yamaguchi, I; Harmon, SK; Todd, RD; OMalley, KL				Yamaguchi, I; Harmon, SK; Todd, RD; OMalley, KL			The rat D-4 dopamine receptor couples to cone transducin (G alpha(t2)) to inhibit forskolin-stimulated cAMP accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; ALPHA-SUBUNIT; EXPRESSION; TRANSDUCIN; CELLS; GENE; SEQUENCE; PHOTORECEPTORS; AFFINITY	Based on its expression pattern and pharmacology, the D-4 dopamine receptor may play a role in schizophrenia. Thus it is of interest to know what signaling pathways are utilized by this receptor. Previously, we showed that activation of D-4 receptors in a mouse mesencephalic neuronal cell line (MN9D) inhibited forskolin-stimulated cAMP accumulation in a pertussis toxin-sensitive (Ptx-sensitive) fashion. Of the known Ptx-sensitive G-protein alpha subunits, MN9D expressed G alpha(i2), G alpha(oA), and G alpha(oB); however, none of these coupled td the D-4 receptor. Using a low stringency polymerase chain reaction cloning method, we found an additional Ptx-sensitive G-protein cone transducin (G alpha(t2)) expressed in the MN9D cells. We also found that G alpha(t2) mRNA is highly expressed in rat mesencephalic tissue. To test the hypothesis that the D-4 receptor couples to G alpha(t2) we cotransfected MNSD cells with the D-4 receptor and a mutagenized Ptx-resistant G alpha(t2) subunit (mG alpha(t2)). Application of the dopaminergic agonist quinpirole to cotransfected cells inhibited forskolin-stimulated cAMP accumulation in the presence or absence of Ptx. To our knowledge, this is the first report demonstrating that the D-4 dopamine receptor functionally couples to a specific G-protein and that a non-opsin-like receptor can couple with a transducin subunit.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Todd, Robert/GWM-4486-2022		NIDA NIH HHS [DA08818] Funding Source: Medline; NIMH NIH HHS [MH31302] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH031302, P50MH031302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA008818] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CHABERT C, 1994, J NEUROCHEM, V63, P62; CHAN YL, 1984, J BIOL CHEM, V259, P224; CHIO CL, 1994, J BIOL CHEM, V269, P11813; CHOI HK, 1992, P NATL ACAD SCI USA, V89, P8943, DOI 10.1073/pnas.89.19.8943; CHOI HK, 1991, BRAIN RES, V552, P67, DOI 10.1016/0006-8993(91)90661-E; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN AI, 1992, P NATL ACAD SCI USA, V89, P12093, DOI 10.1073/pnas.89.24.12093; COLOMA MJ, 1992, J IMMUNOL METHODS, V152, P89, DOI 10.1016/0022-1759(92)90092-8; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; KOLESNIKOV SS, 1995, NATURE, V376, P85, DOI 10.1038/376085a0; KUBO M, 1991, FEBS LETT, V291, P245, DOI 10.1016/0014-5793(91)81294-I; LEREA CL, 1986, SCIENCE, V234, P77, DOI 10.1126/science.3529395; MCHALE M, 1994, FEBS LETT, V345, P147, DOI 10.1016/0014-5793(94)00423-4; MILLS A, 1993, FEBS LETT, V320, P130, DOI 10.1016/0014-5793(93)80077-8; Mrzljak L, 1996, NATURE, V381, P245, DOI 10.1038/381245a0; OHara CM, 1996, J PHARMACOL EXP THER, V278, P354; OMALLEY KL, 1992, NEW BIOL, V4, P137; RUIZAVILA L, 1995, NATURE, V376, P80, DOI 10.1038/376080a0; SCHOOTS O, 1995, EUR J PHARM-MOLEC PH, V289, P67, DOI 10.1016/0922-4106(95)90169-8; SEEMAN P, 1993, NATURE, V365, P441, DOI 10.1038/365441a0; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; STRYER L, 1991, J BIOL CHEM, V266, P10711; Sun D, 1996, AM J PHYSIOL-RENAL, V271, pF391, DOI 10.1152/ajprenal.1996.271.2.F391; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; TANG L, 1994, J PHARMACOL EXP THER, V268, P495; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1992, NEURON, V8, P799, DOI 10.1016/0896-6273(92)90100-R; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0; ZIGMAN JM, 1994, ENDOCRINOLOGY, V135, P31, DOI 10.1210/en.135.1.31	36	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16599	16602		10.1074/jbc.272.26.16599	http://dx.doi.org/10.1074/jbc.272.26.16599			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195972	hybrid			2022-12-27	WOS:A1997XG01900076
J	Yang, BX; Verkman, AS				Yang, BX; Verkman, AS			Water and glycerol permeabilities of aquaporins 1-5 and MIP determined quantitatively by expression of epitope-tagged constructs in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY COLLECTING TUBULE; MOLECULAR-CLONING; INTRINSIC PROTEIN; RAT-KIDNEY; CHANNEL; CHIP28; CELLS; MEMBRANE; DUCT; TISSUES	The goal of this study was to compare single channel water and glycerol permeabilities of mammalian aqua-porins (AQP) 1-5 and the major intrinsic protein of lens fiber (MIP). Each of the six cloned cDNAs from rat was left untagged or was epitope-tagged with c-Myc or FLAG at either the N or C terminus so that results would not depend on epitope identity or location. The constructs were expressed in Xenopus oocytes for measurement of osmotic water permeability (P-f), [H-3]glycerol uptake, and protein expression. Each of the 30 epitope-tagged constructs was expressed strongly at the oocyte plasma membrane. The 10-min uptake of [H-3]glycerol was increased significantly (range of 4.5-8-fold over control) in oocytes expressing untagged AQP3 (GLIP) and each of the four tagged AQP3 constructs; [H-3]glycerol uptake was not increased in oocytes expressing AQP1, AQP2, AQP4, AQP5, or MIP. In oocytes microinjected with 5 ng of cRNA, average P-f values (in cm/s x 10(-3)) were 0.67 +/- 0.06 (control), 19 +/- 2 (AQP1), 10 +/- 1 (AQP2), 8 +/- 2 (AQP3), 29 +/- 1 (AQP4), 10 +/- 1 (AQP5), and 1.3 +/- 0.2 (MIP), and they were relatively insensitive to the presence, identity, or location of the epitope tag. P-f values were not affected by protein kinase A or C activation. After normalization for plasma membrane expression by immunoprecipitation of microdissected plasma membranes, single channel water permeabilities (p(f), referenced to the AQP1 p(f) of 6 x 10(-14) cm(3)/s) were (in cm(3)/s x 10(-14)) 3.3 +/- 0.2 (AQP2), 2.1 +/- 0.3 (AQP3), 24 +/- 0.6 (AQP4), 5.0 +/- 0.4 (AQP5), and 0.25 +/- 0.05 (MIP); p(f) values were insensitive to epitope identity and location. These results indicate very different intrinsic water permeabilities for the mammalian aquaporin homologs, with the p(f) value for AQP4 remarkably higher than those for the others. The p(f) values establish limits on aquaporin tissue densities required for physiological function and suggest significant structural and functional differences among the aquaporins.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035124, R01DK035124] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42368] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMI L, 1994, BBA-BIOMEMBRANES, V1192, P147, DOI 10.1016/0005-2736(94)90155-4; ABRAMI L, 1995, PFLUG ARCH EUR J PHY, V430, P447, DOI 10.1007/BF00373921; AGRE P, 1995, KIDNEY INT, V24, P1057; CHENG A, 1997, IN PRESS NATURE; CHRISPEELS MJ, 1994, TRENDS BIOCHEM SCI, V19, P421, DOI 10.1016/0968-0004(94)90091-4; Chubet RG, 1996, BIOTECHNIQUES, V20, P136; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; Echevarria M, 1996, J BIOL CHEM, V271, P25079, DOI 10.1074/jbc.271.41.25079; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FISCHBARG J, 1990, P NATL ACAD SCI USA, V87, P3244, DOI 10.1073/pnas.87.8.3244; FRIGERI A, 1995, P NATL ACAD SCI USA, V92, P4328, DOI 10.1073/pnas.92.10.4328; FRIGERI A, 1995, J CELL SCI, V108, P2993; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; Fushimi Kiyohide, 1996, Journal of the American Society of Nephrology, V7, P1267; HASEGAWA H, 1992, SCIENCE, V258, P1477, DOI 10.1126/science.1279809; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; KATSURA T, 1995, P NATL ACAD SCI USA, V92, P7212, DOI 10.1073/pnas.92.16.7212; Katsura Toshiya, 1996, Journal of the American Society of Nephrology, V7, P1268; Kishore BK, 1996, AM J PHYSIOL-RENAL, V271, pF62, DOI 10.1152/ajprenal.1996.271.1.F62; KNEPPER MA, 1994, P NATL ACAD SCI USA, V91, P6255, DOI 10.1073/pnas.91.14.6255; KUWAHARA M, 1995, J BIOL CHEM, V270, P10384, DOI 10.1074/jbc.270.18.10384; Lande MB, 1996, J BIOL CHEM, V271, P5552, DOI 10.1074/jbc.271.10.5552; Loo DDF, 1996, P NATL ACAD SCI USA, V93, P13367, DOI 10.1073/pnas.93.23.13367; MA T, 1997, IN PRESS J CLIN INVE; Ma TH, 1996, GENOMICS, V35, P543, DOI 10.1006/geno.1996.0396; MA TH, 1993, J BIOL CHEM, V268, P22756; MA TH, 1994, J BIOL CHEM, V269, P21845; MA TH, 1994, AM J PHYSIOL, V266, pC189, DOI 10.1152/ajpcell.1994.266.1.C189; Ma TH, 1996, AM J PHYSIOL-CELL PH, V271, pC1699, DOI 10.1152/ajpcell.1996.271.5.C1699; MAUREL C, 1995, EMBO J, V14, P3028, DOI 10.1002/j.1460-2075.1995.tb07305.x; MAUREL C, 1994, J BIOL CHEM, V269, P11869; MULDERS SM, 1995, J BIOL CHEM, V270, P9010, DOI 10.1074/jbc.270.15.9010; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; RAINA S, 1995, J BIOL CHEM, V270, P1908, DOI 10.1074/jbc.270.4.1908; SHI LB, 1994, J BIOL CHEM, V269, P10417; SKACH WR, 1994, J CELL BIOL, V125, P803, DOI 10.1083/jcb.125.4.803; STRANGE K, 1987, J MEMBRANE BIOL, V96, P27, DOI 10.1007/BF01869332; VANHOEK AN, 1993, BIOCHEMISTRY-US, V32, P11847, DOI 10.1021/bi00095a013; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; VANOS CH, 1994, BBA-REV BIOMEMBRANES, V1197, P291; VERBAVATZ JM, 1993, J CELL BIOL, V123, P605, DOI 10.1083/jcb.123.3.605; VERKMAN AS, 1988, NATURE, V333, P268, DOI 10.1038/333268a0; Verkman AS, 1997, SCIENCE, V275, P1491; Verkman AS, 1996, AM J PHYSIOL-CELL PH, V270, pC12, DOI 10.1152/ajpcell.1996.270.1.C12; WALZ T, 1995, NAT STRUCT BIOL, V2, P730, DOI 10.1038/nsb0995-730; Yang BX, 1996, J BIOL CHEM, V271, P4577; YANG BX, 1995, J BIOL CHEM, V270, P22907, DOI 10.1074/jbc.270.39.22907; Yool AJ, 1996, SCIENCE, V273, P1216, DOI 10.1126/science.273.5279.1216; ZAMPIGHI GA, 1989, J CELL BIOL, V108, P2255, DOI 10.1083/jcb.108.6.2255; ZAMPIGHI GA, 1995, J MEMBRANE BIOL, V148, P65; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZHANG R, 1990, J BIOL CHEM, V265, P15375; ZHANG RB, 1993, J CELL BIOL, V120, P359, DOI 10.1083/jcb.120.2.359	55	322	330	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16140	16146		10.1074/jbc.272.26.16140	http://dx.doi.org/10.1074/jbc.272.26.16140			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195910	hybrid			2022-12-27	WOS:A1997XG01900014
J	Bondarenko, VA; Desai, M; Dua, S; Yamazaki, M; Amin, RH; Yousif, KK; Kinumi, T; Ohashi, M; Komori, N; Matsumoto, H; Jackson, KW; Hayashi, F; Usukura, J; Lipkin, VM; Yamazaki, A				Bondarenko, VA; Desai, M; Dua, S; Yamazaki, M; Amin, RH; Yousif, KK; Kinumi, T; Ohashi, M; Komori, N; Matsumoto, H; Jackson, KW; Hayashi, F; Usukura, J; Lipkin, VM; Yamazaki, A			Residues within the polycationic region of cGMP phosphodiesterase gamma subunit crucial for the interaction with transducin alpha subunit - Identification by endogenous ADP-ribosylation and site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; CYCLIC-GMP PHOSPHODIESTERASE; GTP-BINDING PROTEIN; RABBIT SKELETAL-MUSCLE; INHIBITORY SUBUNIT; ACTIVATION MECHANISM; SYNTHETIC PEPTIDES; CATALYTIC SUBUNITS; PHOTORECEPTORS; HYDROLYSIS	Interaction between the gamma subunit (P gamma) of cGMP phosphodiesterase and the alpha subunit (T alpha) of transducin is a key step for the regulation of cGMP phosphodiesterase in retinal rod outer segments. Here we have utilized a combination of specific modification by an endogenous enzyme and site-directed mutagenesis of the P gamma polycationic region to identify residues required for the interaction with T alpha, P gamma, free or complexed with the alpha beta subunit (P alpha beta) or cGMP phosphodiesterase, was specifically radiolabeled by prewashed rod membranes in the presence of [adenylate-P-32]NAD. Identification of ADP-ribose in the radiolabeled P gamma and radiolabeling or arginine-replaced mutant forms of P gamma indicate that both arginine 33 and arginine 36 are similarly ADP-ribosylated by endogenous ADP-ribosyltransferase, but only one arginine is modified at a time. P gamma complexed with T alpha (both GTP- and GDP-bound forms) was not ADP-ribosylated; however, agmatine, which cannot interact with T alpha, was ADP-ribosylated int he presence of T alpha, suggesting that a P gamma domain containing these arginines is masked by T alpha. A P gamma mutant (R33,36K), as well as wild type P gamma, inhibited both GTP hydrolysis of T alpha and GTP binding to T alpha. Moreover, GTP-bound T alpha activated P alpha beta that had been inhibited by R33,36K. However, another P gamma mutant (R33,36L) could not inhibit these T alpha functions. In addition, GTP-bound T alpha could not activate P alpha beta that had been inhibited by R33,36L. These results indicate that a P gamma domain containing these arginines is required for its interaction with T alpha, but not with P alpha beta, and that positive charges in these arginines are crucial for the interaction.	WAYNE STATE UNIV, SCH MED, DEPT OPHTHALMOL, DETROIT, MI 48201 USA; WAYNE STATE UNIV, SCH MED, DEPT PHARMACOL, DETROIT, MI 48201 USA; UNIV ELECTROCOMMUN, DEPT APPL PHYS & CHEM, CHOFU, TOKYO 182, JAPAN; UNIV OKLAHOMA, HLTH SCI CTR, DEPT MED, OKLAHOMA CITY, OK 73190 USA; UNIV OKLAHOMA, HLTH SCI CTR, WILLIAM K WARREN MED RES INST, OKLAHOMA CITY, OK 73190 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT BIOCHEM & MOL BIOL, OKLAHOMA CITY, OK 73190 USA; KOBE UNIV, FAC SCI, DEPT BIOL, KOBE, HYOGO 657, JAPAN; NAGOYA UNIV, SCH MED, DEPT ANAT, NAGOYA, AICHI 466, JAPAN; RUSSIAN ACAD SCI, SHEMYAKIN INST BIOORGAN CHEM, PUSHCHINO 142292, RUSSIA	Wayne State University; Wayne State University; University of Electro-Communications - Japan; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Kobe University; Nagoya University; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences	Bondarenko, VA (corresponding author), WAYNE STATE UNIV, SCH MED, KRESGE EYE INST, 4717 ST ANTOINE ST, DETROIT, MI 48201 USA.		Bondarenko, Vladimir/AFY-8370-2022; Kinumi, Tomoya/M-1707-2018	Kinumi, Tomoya/0000-0002-2432-2763; Usukura, Jiro/0000-0003-2286-5403	NATIONAL EYE INSTITUTE [R01EY007546, R01EY009631] Funding Source: NIH RePORTER; NEI NIH HHS [EY07546, EY06595, EY09631] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARTEMYEV NO, 1992, J BIOL CHEM, V267, P25067; ARTEMYEV NO, 1993, J BIOL CHEM, V268, P23611; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; COTE RH, 1993, J BIOL CHEM, V268, P17190; COTE RH, 1994, P NATL ACAD SCI USA, V91, P4845, DOI 10.1073/pnas.91.11.4845; EHRETHILBERER S, 1992, FEBS LETT, V309, P394, DOI 10.1016/0014-5793(92)80814-W; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; HARA N, 1987, BIOCHEM BIOPH RES CO, V144, P856, DOI 10.1016/S0006-291X(87)80043-8; HARGRAVE PA, 1992, INT REV CYTOL, V137B, P49; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; HURLEY JB, 1987, ANNU REV PHYSIOL, V49, P793; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; LIPKIN VM, 1993, BIOCHIM BIOPHYS ACTA, V1176, P250, DOI 10.1016/0167-4889(93)90052-Q; MIKI N, 1975, J BIOL CHEM, V250, P6320; MILLER WH, 1990, INVEST OPHTH VIS SCI, V31, P1664; MORRISON DF, 1989, J BIOL CHEM, V264, P11671; MORRISON DF, 1987, FEBS LETT, V222, P266, DOI 10.1016/0014-5793(87)80383-6; OBARA S, 1991, EUR J BIOCHEM, V200, P75, DOI 10.1111/j.1432-1033.1991.tb21050.x; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; POZDNYAKOV N, 1993, BIOCHEM BIOPH RES CO, V192, P610, DOI 10.1006/bbrc.1993.1459; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SKIBA NP, 1995, J BIOL CHEM, V270, P13210, DOI 10.1074/jbc.270.22.13210; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TSUBOI S, 1994, J BIOL CHEM, V269, P15024; TSUBOI S, 1994, J BIOL CHEM, V269, P15016; VANDOP C, 1984, J BIOL CHEM, V259, P23; WEST RE, 1985, J BIOL CHEM, V260, P4428; YAMAZAKI A, 1982, P NATL ACAD SCI-BIOL, V79, P3702, DOI 10.1073/pnas.79.12.3702; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; YAMAZAKI A, 1993, J BIOL CHEM, V268, P8899; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9316; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619; Yamazaki A, 1996, J BIOL CHEM, V271, P32495, DOI 10.1074/jbc.271.51.32495; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9324; Yamazaki A, 1996, BIOCHEM BIOPH RES CO, V222, P488, DOI 10.1006/bbrc.1996.0771; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445; ZOLKIEWSKA A, 1993, J BIOL CHEM, V268, P25273; ZOLKIEWSKA A, 1992, P NATL ACAD SCI USA, V89, P11352, DOI 10.1073/pnas.89.23.11352	44	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15856	15864		10.1074/jbc.272.25.15856	http://dx.doi.org/10.1074/jbc.272.25.15856			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188484	hybrid			2022-12-27	WOS:A1997XF32900044
J	Wakasugi, M; Reardon, JT; Sancar, A				Wakasugi, M; Reardon, JT; Sancar, A			The non-catalytic function of XPG protein human nucleotide excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; (A)BC EXCINUCLEASE; ACTIVE-SITE; 5' INCISION; DNA; TFIIH; NUCLEASE	XPG is a member of the FEN-1 structure-specific endonuclease family, It has 3'-junction cutting activity on bubble substrates and makes the 3'-incision in the human dual incision (excision nuclease) repair system, To investigate the precise role of XPG in nucleotide excision repair, we mutagenized two amino acid residues thought to he involved in DNA binding and catalysis, overproduced the mutant proteins using a baculovirus/insect cell system, and purified and characterized the mutant proteins. The mutation D77A had a modest effect on junction cutting and excision activity and gave rise to uncoupled 5'-incision by mammalian cell-free extracts, The D812A mutation completely abolished the junction cutting and 3'-incision activities of XPG, but the excision nuclease reconstituted with XPG (D812A) carried out normal 5'-incision at the 23rd-24th phosphodiester bonds 5' to a (6-4) photoproduct without producing any 5'-incision, It is concluded that Asp-812 is an active site residue of XPG and that in addition to making the 3'-incision, the physical presence of XPG in the protein-DNA complex is required non-catalytically for subsequent 5'-incision by XPF-ERCC1.	UNIV N CAROLINA, DEPT BIOCHEM & BIOPHYS, SCH MED, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Wakasugi, Mitsuo/D-8417-2015	Wakasugi, Mitsuo/0000-0001-9593-0566	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32833] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barnes CJ, 1996, J BIOL CHEM, V271, P29624, DOI 10.1074/jbc.271.47.29624; BESHO T, 1997, J BIOL CHEM, V272, P3833; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2749; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; FRIEDBERG EC, 1995, DNA REPAIR; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; LIN JJ, 1992, J BIOL CHEM, V267, P17693; LIN JJ, 1992, J BIOL CHEM, V267, P17688; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; Matsunaga T, 1996, J BIOL CHEM, V271, P11047, DOI 10.1074/jbc.271.19.11047; Moolenaar GF, 1995, J BIOL CHEM, V270, P30508, DOI 10.1074/jbc.270.51.30508; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PARK CH, 1995, J BIOL CHEM, V270, P4896, DOI 10.1074/jbc.270.9.4896; Reardon JT, 1996, J BIOL CHEM, V271, P19451, DOI 10.1074/jbc.271.32.19451; REARDON JT, 1993, COLD SPRING HARB SYM, V58, P605, DOI 10.1101/SQB.1993.058.01.067; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; THOMPSON LH, 1997, IN PRESS DNA DAMAGE; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031	25	133	136	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					16030	16034		10.1074/jbc.272.25.16030	http://dx.doi.org/10.1074/jbc.272.25.16030			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188507	hybrid			2022-12-27	WOS:A1997XF32900067
J	Lenouvel, F; Nikolaev, I; Felenbok, B				Lenouvel, F; Nikolaev, I; Felenbok, B			In vitro recognition of specific DNA targets by AlcR, a zinc binuclear cluster activator different from the other proteins of this class	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPERGILLUS-NIDULANS; ESCHERICHIA-COLI; ETHANOL REGULON; BINDING-SITES; TRANSCRIPTIONAL ACTIVATOR; REGULATORY GENE; SEQUENCE; DOMAIN; GAL4; GALACTOSIDASE	AlcR is the transactivator mediating transcriptional induction of the ale gene cluster in Aspergillus nidulans. The AlcR DNA-binding domain consists of a zinc binuclear cluster different from the other members of the Zn(2)Cys(6) family by several features, In particular, it is able to bind to symmetric and asymmetric sites with the same affinity, with both sites being functional in A, nidulans. Here, we show that unlike the other proteins of the Zn(2)Cys(6) binuclear cluster family, AlcR, binds most probably as a monomer to its cognate targets, Two molecules of the AlcR protein can simultaneously bind in a noncooperative manner to inverted repeats, The consensus core has been determined precisely (5'-CCGCN-3'), and the AlcR-binding site in the aldA promoter has been localized, The sequence downstream of the zinc cluster is necessary for high affinity binding, Furthermore, our data show that the use of the carrier protein glutathione S-transferase in AlcR binding experiments introduces an important bias in the recognition of DMA sites due to its tertiary dimeric structure.	UNIV PARIS 11,URA CNRS D 2225,INST MICROBIOL & GENET,CTR UNIV ORSAY,F-91405 ORSAY,FRANCE	UDICE-French Research Universities; Universite Paris Saclay								ALEX R, 1992, NUCLEIC ACIDS RES, V20, P2257, DOI 10.1093/nar/20.9.2257; BRAZAS R, 1993, MOL CELL BIOL, V13, P5424; BURGER G, 1991, MOL CELL BIOL, V11, P5746, DOI 10.1128/MCB.11.11.5746; CAZELLE B, 1993, THESIS U PARIS SUD O; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; FELENBOK B, 1988, GENE, V73, P385, DOI 10.1016/0378-1119(88)90503-3; FELENBOK B, 1991, J BIOTECHNOL, V17, P11, DOI 10.1016/0168-1656(91)90023-O; Felenbok B, 1994, Prog Ind Microbiol, V29, P141; Fillinger S, 1996, MOL MICROBIOL, V20, P475, DOI 10.1046/j.1365-2958.1996.5301061.x; GOLDBERG ME, 1969, J MOL BIOL, V46, P441, DOI 10.1016/0022-2836(69)90187-9; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; KULMBURG P, 1992, J BIOL CHEM, V267, P21146; KULMBURG P, 1991, FEBS LETT, V280, P11, DOI 10.1016/0014-5793(91)80193-7; KULMBURG P, 1992, MOL CELL BIOL, V12, P1932, DOI 10.1128/MCB.12.5.1932; KULMBURG P, 1993, MOL MICROBIOL, V7, P847, DOI 10.1111/j.1365-2958.1993.tb01175.x; LIM K, 1994, PROTEIN SCI, V3, P2233, DOI 10.1002/pro.5560031209; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MARMORSTEIN R, 1994, GENE DEV, V8, P2504, DOI 10.1101/gad.8.20.2504; Maxam A M, 1980, Methods Enzymol, V65, P499; PICKETT M, 1987, GENE, V51, P217, DOI 10.1016/0378-1119(87)90310-6; PUNT PJ, 1995, MOL CELL BIOL, V15, P5688; REECE RJ, 1993, SCIENCE, V261, P909, DOI 10.1126/science.8346441; SCARABEL M, 1995, GENE, V153, P9, DOI 10.1016/0378-1119(94)00660-K; SEQUEVAL D, 1994, MOL GEN GENET, V242, P33, DOI 10.1007/BF00277345; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUAREZ T, 1995, EMBO J, V14, P1453, DOI 10.1002/j.1460-2075.1995.tb07132.x; Timmerman J, 1996, J MOL BIOL, V259, P792, DOI 10.1006/jmbi.1996.0358; XU HE, 1995, P NATL ACAD SCI USA, V92, P7677, DOI 10.1073/pnas.92.17.7677; Zhang L, 1996, EMBO J, V15, P4676, DOI 10.1002/j.1460-2075.1996.tb00844.x; ZHANG L, 1994, GENE DEV, V8, P2110, DOI 10.1101/gad.8.17.2110	32	37	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15521	15526		10.1074/jbc.272.24.15521	http://dx.doi.org/10.1074/jbc.272.24.15521			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182587	hybrid			2022-12-27	WOS:A1997XE03400070
J	Prescott, SM				Prescott, SM			Minireview prologue - A thematic series on phospholipases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material											Prescott, SM (corresponding author), UNIV UTAH,ECCLES INST HUMAN GENET,SALT LAKE CITY,UT 84112, USA.								0	17	19	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15043	15043		10.1074/jbc.272.24.15043	http://dx.doi.org/10.1074/jbc.272.24.15043			1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182518	hybrid			2022-12-27	WOS:A1997XE03400001
J	Tao, WK; Kurschner, C; Morgan, JI				Tao, WK; Kurschner, C; Morgan, JI			Modulation of cell death in yeast by the Bcl-2 family of proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FOLLICULAR LYMPHOMA; CONSERVED DOMAINS; DEFICIENT MICE; GENE; BAX; APOPTOSIS; IDENTIFICATION; ENCODES; HOMOLOG; SYSTEM	Bcl-2 family members are regulators of cell death. The precise biochemical properties of these proteins are unclear although intrafamily protein protein association is thought to be involved. To elucidate structure-activity relationships among Bcl-2 proteins and identify the pathways in which they act, an inducible death suppressor assay was developed in yeast. Only Bax and Bak killed yeast via a process that did not require interleukin-1 beta converting enzyme-like proteases. Bax/Bak lethality was suppressed by coexpression of Bcl-2 family members that are anti-apoptotic in vertebrates, namely Bcl-xL, Bcl-2, Mcl-1, and A1. Furthermore, Bcl-xL and Bcl-2 suppressed Bax toxicity by distinct mechanisms in yeast, Bad, Bcl-xS, and Ced-9 lacked suppressor activity. These inactive proteins bound to anti-apoptotic members of the Bcl-2 family but not to Bax or Bak. In contrast, most Bcl-2 family proteins that attenuated death bound to Bax and Bak. However, two mutants of Bcl-xL suppressed Bax-induced cell death while having no Bax binding activity. Therefore, Bcl-xL functions independently of Bax binding, perhaps by interacting with a common target or promoting a pathway that antagonizes Bax. Thus, the pathways downstream of Bax and Bcl-xL may be conserved between vertebrates and yeast. This suppressor assay could be used to isolate components of these pathways.	ST JUDE CHILDRENS RES HOSP, DEPT DEV NEUROBIOL, MEMPHIS, TN 38105 USA; UNIV MED & DENT NEW JERSEY, GRAD SCH BIOMED SCI, DEPT BIOCHEM & MOL BIOL, NEWARK, NJ 07103 USA	St Jude Children's Research Hospital; Rutgers State University New Brunswick; Rutgers State University Medical Center			Morgan, James/GRO-2905-2022; tao, wei/GXN-4445-2022; Morgan, James/N-8104-2018	Morgan, James/0000-0002-8920-1065; 	NCI NIH HHS [P30 CA21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; GALLAGHER SR, 1993, CURRENT PROTOCOLS MO; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; Greenhalf W, 1996, FEBS LETT, V380, P169, DOI 10.1016/0014-5793(96)00044-0; HAIE AJ, 1996, EUR J BIOCHEM, V236, P1; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KURSCHNER C, 1995, MOL CELL BIOL, V15, P246, DOI 10.1128/MCB.15.1.246; Kurschner C, 1996, MOL BRAIN RES, V37, P249, DOI 10.1016/0169-328X(95)00323-K; Miura M, 1996, CURR TOP DEV BIOL, V32, P139, DOI 10.1016/S0070-2153(08)60427-5; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Sambrook J., 2002, MOL CLONING LAB MANU; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Tuscano JM, 1996, BLOOD, V88, P1359, DOI 10.1182/blood.V88.4.1359.bloodjournal8841359; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha HB, 1996, MOL CELL BIOL, V16, P6494	35	96	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15547	15552		10.1074/jbc.272.24.15547	http://dx.doi.org/10.1074/jbc.272.24.15547			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182591	hybrid			2022-12-27	WOS:A1997XE03400074
J	JinsiParimoo, A; Deth, RC				JinsiParimoo, A; Deth, RC			Reconstitution of alpha(2D)-adrenergic receptor coupling to phospholipase D in a PC12 cell lysate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEIN; BETA-GAMMA-SUBUNITS; SYNERGISTIC ACTIVATION; HL-60 GRANULOCYTES; TYROSINE-KINASE; FREE SYSTEM; V-SRC; MEMBRANE; FIBROBLASTS	We have previously shown that alpha(2)-adrenergic receptor-mediated coupling to phospholipase D (PLD) in vascular tissues requires a tyrosine kinase activity (Jinsi, A., Paradise, J., and Deth, R. C. (1996) fur. J. Pharmacol. 302, 183-190). To further clarify this mode of regulation we reconstituted alpha(2A/D)-adrenergic receptor-stimulated PLD activity in PC12 cells expressing the cloned receptor. [H-3]Myristic acid-labeled cells were lysed by nitrogen cavitation, and aliquots of subnuclear fraction were utilized in the PLD assay. Agonist-stimulated PLD activity was measured in the presence of 0.4% butanol as [H-3]phosphatidylbutanol formation. Both GTP and its non-hydrolyzable analog guanosine 5'-O-(thiotriphosphate) stimulated PLD activity in a concentration- and time-dependent manner that required co-activation of protein kinase C by phorbol dibutyrate. Addition of epinephrine produced a 3-fold stimulation of PLD activity in the presence of GTP and GDP. This agonist-stimulated PLD activity was completely blocked by the alpha(2)-adrenergic receptor antagonist rauwolscine and by Clostridium botulinum toxin as well as by antibodies directed against either pp60(src), RhoA, or Ras GTPase-activating protein. These results indicate that coupling of the alpha(2A/D)-adrenergic receptor to PLD is complexly regulated by both the tyrosine kinase pp60(src) and the low molecular weight G protein RhoA.	NORTHEASTERN UNIV,DEPT PHARMACEUT SCI 312MU,BOSTON,MA 02115	Northeastern University			Deth, Richard/AFV-2608-2022		NHLBI NIH HHS [HL29847] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029847] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAM LP, 1995, CIRC RES, V76, P183, DOI 10.1161/01.RES.76.2.183; ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BIRD GS, 1993, J BIOL CHEM, V268, P21486; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOURGOIN S, 1995, J BIOL CHEM, V270, P3172, DOI 10.1074/jbc.270.7.3172; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DUZIC E, 1992, J BIOL CHEM, V267, P24045; EASON MG, 1994, MOL PHARMACOL, V45, P696; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; FAURE M, 1994, J BIOL CHEM, V269, P7851; GENY B, 1992, BIOCHEM J, V284, P531, DOI 10.1042/bj2840531; GIERSCHIK P, 1991, EUR J BIOCHEM, V197, P725, DOI 10.1111/j.1432-1033.1991.tb15964.x; HALENDA SP, 1990, BIOCHEM J, V267, P479, DOI 10.1042/bj2670479; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; JIANG H, 1994, MOL CELL BIOL, V14, P3676, DOI 10.1128/MCB.14.6.3676; JIANG H, 1995, J BIOL CHEM, V270, P6006, DOI 10.1074/jbc.270.11.6006; JINSI A, 1995, EUR J PHARMACOL, V277, P29, DOI 10.1016/0014-2999(95)00053-N; Jinsi A, 1996, EUR J PHARMACOL, V302, P183, DOI 10.1016/0014-2999(96)00049-0; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; KUSNER DJ, 1993, J BIOL CHEM, V268, P19973; LUTRELL LM, 1996, J BIOL CHEM, V271, P19443; MACNULTY EE, 1992, J BIOL CHEM, V267, P2149; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; Morris AJ, 1996, TRENDS PHARMACOL SCI, V17, P182, DOI 10.1016/0165-6147(96)10016-X; Ohguchi K, 1996, J BIOL CHEM, V271, P4366; OLSON SC, 1991, J BIOL CHEM, V266, P17236; POSTNOV YV, 1990, HYPERTENSION, V15, P332, DOI 10.1161/01.HYP.15.3.332; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SEUWEN K, 1990, CELL REGUL, V1, P445, DOI 10.1091/mbc.1.6.445; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TIAN WN, 1994, MOL PHARMACOL, V45, P524; TIGYI G, 1994, P NATL ACAD SCI USA, V91, P1908, DOI 10.1073/pnas.91.5.1908; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; UINGS IJ, 1992, BIOCHEM J, V281, P597, DOI 10.1042/bj2810597; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERMEULEN J, 1990, BIOCHEM J, V271, P693, DOI 10.1042/bj2710693; WAENSAFRANCHIK VI, 1994, PHARMACOLOGY, V48, P349, DOI 10.1159/000139200; ZHANG J, 1993, J BIOL CHEM, V268, P22251	45	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14556	14561		10.1074/jbc.272.23.14556	http://dx.doi.org/10.1074/jbc.272.23.14556			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169413	hybrid			2022-12-27	WOS:A1997XC32700010
J	Saiki, K; Mogi, T; Tsubaki, M; Hori, H; Anraku, Y				Saiki, K; Mogi, T; Tsubaki, M; Hori, H; Anraku, Y			Exploring subunit-subunit interactions in the Escherichia coli bo-type ubiquinol oxidase by extragenic suppressor mutation analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CYTOCHROME-C-OXIDASE; AEROBIC RESPIRATORY-CHAIN; COPPER BINUCLEAR CENTER; O TERMINAL OXIDASE; PARACOCCUS-DENITRIFICANS; HEME-O; COMPLEX; IDENTIFICATION; PURIFICATION	Cytochrome bo-type ubiquinol oxidase is a four-subunit heme-copper terminal oxidase and functions as a redox-coupled proton pump in the aerobic respiratory chain of Escherichia cell. On the basis of deletion and chemical cross-linking analyses on subunit IV, we proposed that subunit IV is essential for Cu-B binding to subunit I and that it is present in a cleft between subunits I and III (Saiki, K., Nakamura, H., Mogi, T., and Anraku, Y. (1996) J. Biol. Chem. 271, 15336-15340). To extend previous studies, we carried out alanine-scanning mutagenesis for selected 16-amino acid residues in subunit IV to explore subunit-subunit interac tions in bo-type ubiquinol oxidase. We found that only the replacement of Phe(83) in helix III resulted in the reduction of the catalytic activity but that this did not significantly affect the UV-visible spectroscopic properties and the copper content. This suggests that individual amino acid substitutions, including the six invariant residues, are not enough to alter such properties of the metal centers. Extragenic suppressor mutations were isolated for the Phe(83) --> Ala mutation of subunit IV and identified as missense mutations in helices VII and VIII in subunit I. These observations provide further support for specific interactions of subunit IV with helix VII and/or VIII, the Cu-B binding domain, of subunit I and suggest that subunit IV functions as a domain-specific molecular chaperon in the oxidase complex.	UNIV TOKYO,GRAD SCH SCI,DEPT BIOL SCI,BUNKYO KU,TOKYO 113,JAPAN; HIMEJI INST TECHNOL,FAC SCI,DEPT LIFE SCI,KAMIGORI,HYOGO 67812,JAPAN; OSAKA UNIV,FAC ENGN SCI,DEPT BIOPHYS ENGN,TOYONAKA,OSAKA 560,JAPAN	University of Tokyo; University of Hyogo; Osaka University			Keitarou, Saiki/AAV-6909-2020					ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; Capaldi RA, 1996, NAT STRUCT BIOL, V3, P570, DOI 10.1038/nsb0796-570; CHEPURI V, 1990, J BIOL CHEM, V265, P11185; CHEPURI V, 1990, J BIOL CHEM, V265, P12978; COWAN SW, 1994, SCIENCE, V264, P914, DOI 10.1126/science.8178151; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; GARCIAHORSMAN JA, 1994, J BACTERIOL, V176, P5587, DOI 10.1128/JB.176.18.5587-5600.1994; HALTIA T, 1991, EMBO J, V10, P2015, DOI 10.1002/j.1460-2075.1991.tb07731.x; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KITA K, 1984, J BIOL CHEM, V259, P3368; KRANZ RG, 1983, J BIOL CHEM, V258, P614; Kusano T, 1996, BBA-BIOENERGETICS, V1273, P129, DOI 10.1016/0005-2728(95)00126-3; LEMIEUX LJ, 1992, J BIOL CHEM, V267, P2105; MATSUSHITA K, 1983, P NATL ACAD SCI-BIOL, V80, P4889, DOI 10.1073/pnas.80.16.4889; MINAGAWA J, 1992, J BIOL CHEM, V267, P2096; MITCHELL DM, 1995, FEBS LETT, V368, P148, DOI 10.1016/0014-5793(95)00626-K; MOGI T, 1994, J BIOCHEM-TOKYO, V116, P471, DOI 10.1093/oxfordjournals.jbchem.a124548; MOGI T, 1994, MOL MICROBIOL, V14, P391, DOI 10.1111/j.1365-2958.1994.tb02174.x; MOGI T, 1995, FEBS LETT, V370, P259; NAKAMURA H, 1990, J BIOL CHEM, V265, P11193; PUUSTINEN A, 1989, FEBS LETT, V249, P163, DOI 10.1016/0014-5793(89)80616-7; Saiki K, 1996, J BIOL CHEM, V271, P15336, DOI 10.1074/jbc.271.26.15336; SAIKI K, 1993, J BIOL CHEM, V268, P26927; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P6065, DOI 10.1021/bi00074a018; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; WARNE A, 1995, EUR J BIOCHEM, V234, P443, DOI 10.1111/j.1432-1033.1995.443_b.x; WELTER R, 1994, J BIOL CHEM, V269, P28834	29	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14721	14726		10.1074/jbc.272.23.14721	http://dx.doi.org/10.1074/jbc.272.23.14721			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169436	hybrid			2022-12-27	WOS:A1997XC32700033
J	Ohashi, T; Erickson, HP				Ohashi, T; Erickson, HP			Two oligomeric forms of plasma ficolin have differential lectin activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; ELECTRON-MICROSCOPY; SOLUBLE-PROTEINS; DOMAINS; PURIFICATION; FIBRINOGEN; COLLECTINS	Ficolins are plasma proteins with binding activity for carbohydrates, elastin, and corticosteroids, The ficolin polypeptide has a collagen-like domain that presumably brings three subunits together in a triple helical rod, a C-terminal fibrinogen-like domain (fbg) similar to that of tenascin, which presumably has the binding activities, and a small N-terminal domain that we find to be the primary site for forming the ficolin oligomer, By sedimentation equilibrium we determined that the main plasma form, which we call big ficolin, had mass of 827,000 Da, consistent with 24 subunits, Little ficolin, about half this size, was obtained after binding to a GlcNAc affinity column, Electron microscopy of little ficolin showed a parachute-like structure, with a small globe at one end, corresponding to the 12 N-terminal domains, and the fbg domains clustered together at the ends of the collagen rods. Big ficolin was formed by the face to face fusion of the fbg domains of two little ficolins, leaving the rods and N-terminal domains projecting at opposite ends, Little ficolin maintained a high affinity for the GlcNAc column, and big ficolin had a low affinity or none, The binding sites for ligands may be obscured in this big ficolin oligomer, providing a regulation of their activity.	DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University					NCI NIH HHS [CA47056] Funding Source: Medline; NIAMS NIH HHS [AR42180] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047056, R37CA047056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042180] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSEN O, 1992, SCAND J IMMUNOL, V36, P131, DOI 10.1111/j.1365-3083.1992.tb02949.x; AUKHIL I, 1993, J BIOL CHEM, V268, P2542; CROUCH E, 1994, J BIOL CHEM, V269, P17311; EDGAR PF, 1995, FEBS LETT, V375, P159, DOI 10.1016/0014-5793(95)01205-S; ENDO Y, 1996, GENOMICS, V26, P515; ERICKSON HP, 1982, BIOPHYS J, V37, P96; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; Harlow E., 1988, ANTIBODIES LAB MANUA, P298; HARUMIYA S, 1995, J BIOCHEM-TOKYO, V117, P1029, DOI 10.1093/oxfordjournals.jbchem.a124802; Harumiya S, 1996, J BIOCHEM-TOKYO, V120, P745; HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8; HOPPE HJ, 1994, PROTEIN SCI, V3, P1143, DOI 10.1002/pro.5560030801; HORTSCH M, 1990, J BIOL CHEM, V265, P15104; ICHIJO H, 1993, J BIOL CHEM, V268, P14505; ICHIJO H, 1991, J BIOL CHEM, V266, P22459; KNOBEL HR, 1975, EUR J IMMUNOL, V5, P78, DOI 10.1002/eji.1830050119; KUROKI Y, 1994, J BIOL CHEM, V269, P25943; Lu J, 1996, IMMUNOLOGY, V89, P289, DOI 10.1046/j.1365-2567.1996.d01-732.x; Lu JH, 1996, BIOCHEM J, V313, P473, DOI 10.1042/bj3130473; LU JH, 1993, EUR J BIOCHEM, V215, P793, DOI 10.1111/j.1432-1033.1993.tb18094.x; MALHOTRA R, 1990, J EXP MED, V172, P955, DOI 10.1084/jem.172.3.955; MALHOTRA R, 1993, BIOCHEM J, V293, P15, DOI 10.1042/bj2930015; Matsushita M, 1996, J BIOL CHEM, V271, P2448, DOI 10.1074/jbc.271.5.2448; THIEL S, 1989, FEBS LETT, V250, P78, DOI 10.1016/0014-5793(89)80689-1; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; Yee VC, 1997, STRUCTURE, V5, P125, DOI 10.1016/S0969-2126(97)00171-8	26	56	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14220	14226		10.1074/jbc.272.22.14220	http://dx.doi.org/10.1074/jbc.272.22.14220			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162054	hybrid			2022-12-27	WOS:A1997XB49200041
J	Smith, CL; Htun, H; Wolford, RC; Hager, GL				Smith, CL; Htun, H; Wolford, RC; Hager, GL			Differential activity of progesterone and glucocorticoid receptors on mouse mammary tumor virus templates differing in chromatin structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; HORMONE REGULATORY ELEMENT; DNASEI HYPERSENSITIVE SITES; SOMATIC-CELL HYBRIDS; MMTV PROMOTER; RESPONSE ELEMENTS; GENE ACTIVATION; TRANSCRIPTIONAL ENHANCEMENT; MAMMALIAN-CELLS; NUCLEOSOMAL DNA	In vivo, transcription factors interact with promoters having complex nucleoprotein structures, The transiently expressed progesterone receptor (PR) efficiently activates a transfected mouse mammary tumor virus (MMTV) promoter but is a poor activator of the MMTV promoter when it acquires an ordered chromatin structure as an endogenous, replicating gene, We show that the deficiency in PR activity is not due to insufficient expression of either B or A isoforms or competition between the two types of MMTV templates, Rather, this deficiency reflects an inability to induce the chromatin remodeling event that is required for activation of the replicated MMTV template, To determine whether this characteristic is common to transiently expressed steroid receptors or specific to the PR, we examined the activity of transiently expressed glucocorticoid (GR) receptor, Unlike the PR, the transiently expressed GR is an effective activator of both MMTV templates and efficiently induces the necessary chromatin remodeling event at the replicated template, These results indicate that the GR and PR have unique requirements for activation of promoters with ordered chromatin structure, These differences may provide a mechanism for establishing target gene specificity in vivo for steroid receptors that recognize and bind to identical DNA interactions between soluble factors, and it would not be an sequences.	NCI,LAB RECEPTOR BIOL & GENE EXPRESS,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; ARCHER TK, 1989, STEROID THYROID HORM, P221; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BECKER P, 1984, EMBO J, V3, P2015, DOI 10.1002/j.1460-2075.1984.tb02084.x; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P865, DOI 10.1093/nar/20.4.865; BRESNICK EH, 1990, P NATL ACAD SCI USA, V87, P3977, DOI 10.1073/pnas.87.10.3977; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; BULLA GA, 1992, GENE DEV, V6, P316, DOI 10.1101/gad.6.2.316; BURCH JBE, 1990, NUCLEIC ACIDS RES, V18, P4157, DOI 10.1093/nar/18.14.4157; CANNON P, 1994, J VIROL, V68, P1993, DOI 10.1128/JVI.68.3.1993-1997.1994; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHAKRABORTI PK, 1991, J BIOL CHEM, V266, P22075; CHALEPAKIS G, 1988, CELL, V53, P371, DOI 10.1016/0092-8674(88)90157-2; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DARBRE P, 1986, MOL CELL BIOL, V6, P2847, DOI 10.1128/MCB.6.8.2847; ELASHRY D, 1989, MOL ENDOCRINOL, V3, P1545, DOI 10.1210/mend-3-10-1545; FRAGOSO G, 1995, GENE DEV, V9, P1933, DOI 10.1101/gad.9.15.1933; GIORDANO T, 1991, EXP CELL RES, V192, P193, DOI 10.1016/0014-4827(91)90175-T; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOWLAND PL, 1989, MOL CELL BIOL, V9, P3999, DOI 10.1128/MCB.9.9.3999; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; HECHT A, 1988, EMBO J, V7, P2063, DOI 10.1002/j.1460-2075.1988.tb03046.x; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; JANTZEN K, 1987, NUCLEIC ACIDS RES, V15, P4535, DOI 10.1093/nar/15.11.4535; KAYE JS, 1986, EMBO J, V5, P277, DOI 10.1002/j.1460-2075.1986.tb04210.x; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LEE HL, 1994, MOL CELL BIOL, V14, P32, DOI 10.1128/MCB.14.1.32; LEFEBVRE P, 1991, MOL CELL BIOL, V11, P2529, DOI 10.1128/MCB.11.5.2529; MEYER ME, 1992, J BIOL CHEM, V267, P10882; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; PADMANABHAN R, 1993, METHOD ENZYMOL, V218, P637; PENNIE WD, 1995, MOL CELL BIOL, V15, P2125; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; SMITH CL, 1993, P NATL ACAD SCI USA, V60, P11202; STRAHLE U, 1989, NATURE, V339, P629, DOI 10.1038/339629a0; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; TUNG L, 1993, MOL ENDOCRINOL, V7, P1256, DOI 10.1210/me.7.10.1256; van Holde K.E., 1988, CHROMATIN; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; WALDMANN TA, 1986, SCIENCE, V232, P727, DOI 10.1126/science.3008337; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	52	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14227	14235		10.1074/jbc.272.22.14227	http://dx.doi.org/10.1074/jbc.272.22.14227			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162055	hybrid			2022-12-27	WOS:A1997XB49200042
J	Zhang, M; Wang, MH; Singh, RK; Wells, A; Siegal, GP				Zhang, M; Wang, MH; Singh, RK; Wells, A; Siegal, GP			Epidermal growth factor induces CD44 gene expression through a novel regulatory element in mouse fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-II; 3T3 CELLS; 12-O-TETRADECANOYL PHORBOL-13-ACETATE; TYROSINE PHOSPHORYLATION; FACTOR RECEPTOR; IN-VITRO; FOS GENE; EGF; PROMOTER; PROTEIN	Growth factors coordinately regulate a variety of genes associated with pathological states including tumor invasion and metastasis, Overexpressed epidermal growth factor receptor (EGFR) on tumor cell surfaces is associated with enhanced cell attachment and migration into extracellular matrices, which promotes tumor aggressiveness, We have demonstrated that epidermal growth factor (EGF) up-regulates the cell surface adhesion molecule CD44 at both the mRNA and protein levels on mouse fibroblasts expressing full-length wild-type EGFR (NR6-WT) but not on EGFR-deficient cells (NR6-P). This increases cell attachment to hyaluronic acid. In this investigation, transcriptional regulation of CD44 by EGF was confirmed by defining an EGF-regulatory element, By employing human CD44 gene promoter-chloramphenicol acetyltransferase (CAT) constructs transfected into NR6-WT cells, EGF inducibility was observed within a 120-base pair (bp) DNA fragment located 450 bp upstream of the RNA initiation site. Differential EGF inducibility was found among different cell lines chosen, indicating a 3.2- and 1.8-fold enhancement in DU145 cells carrying exogenous wild-type EGFR and in MCF-7 cells, respectively, while minimal EGF induction was found in cervical cancer HeLa cells. Utilizing gel shift assays, a time-dependent increase of DNA-protein complex formation was found upon EGF stimulation in NR6-WT cells but not in NR6-P cells, Based upon these observations, a novel 22-bp EGF regulatory element (ERE) (5'-(-604)CCCTCTCTCCAGCTCCTCTCCC(-583)-3') was isolated from the CD44 gene promoter. This ERE conferred DNA-protein binding ability in vitro, as well as the full functional recovery of EGF inducibility of CAT activity when linked to a homologous CD44 promoter or a SV40 promoter driving a CAT reporter gene. A two-base mutation of the ERE completely eliminated its binding activity as well as its EGF inducibility of CAT expression, Our studies indicate that EGF induces CD44 gene expression through an interaction between a specific ERE and putative novel transcriptional factor so as to regulate cell attachment to extracellular matrix.	UNIV ALABAMA,DEPT PATHOL,DIV ANAT PATHOL,BIRMINGHAM,AL 35233; UNIV ALABAMA,DEPT CELL BIOL & SURG,BIRMINGHAM,AL 35233; UNIV ALABAMA,CELL ADHES & MATRIX RES CTR,BIRMINGHAM,AL 35233; UNIV ALABAMA,CTR COMPREHENS CANC,BIRMINGHAM,AL 35233; VET AFFAIRS MED CTR,BIRMINGHAM,AL 35233	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Siegal, Gene/A-8653-2009	Siegal, Gene/0000-0003-3857-3368; Wells, Alan/0000-0002-1637-8150	NATIONAL CANCER INSTITUTE [R43CA069883] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054739] Funding Source: NIH RePORTER; NCI NIH HHS [CA69883] Funding Source: Medline; NIGMS NIH HHS [GM54739] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOKI J, 1991, J CELL BIOL, V115, P1751, DOI 10.1083/jcb.115.6.1751; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; AUSUBEL FM, 1990, CURR PROTOCOLS MOL B, V2; BELLAS RE, 1991, J BIOL CHEM, V266, P12008; BURGESS AW, 1989, BRIT MED BULL, V45, P401, DOI 10.1093/oxfordjournals.bmb.a072331; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; ELSHOLTZ HP, 1986, SCIENCE, V234, P1552, DOI 10.1126/science.3491428; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FISCH TM, 1989, MOL CELL BIOL, V9, P1327, DOI 10.1128/MCB.9.3.1327; FISCH TM, 1989, SCIENCE, V234, P1552; GUO YJ, 1994, CANCER RES, V54, P1561; KUDSON W, 1984, J CELL BIOCHEM, V25, P183; LEWIS EJ, 1987, MOL CELL BIOL, V7, P3332, DOI 10.1128/MCB.7.9.3332; LICHTNER RB, 1993, CLIN EXP METASTAS, V11, P113, DOI 10.1007/BF00880072; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MATTHAY MA, 1993, J CELL SCI, V106, P869; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MERCHANT JL, 1995, J BIOL CHEM, V270, P6314, DOI 10.1074/jbc.270.11.6314; MERZAK A, 1994, CANCER RES, V54, P3988; NISHIBE S, 1989, J BIOL CHEM, V264, P10335; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; PARKER TG, 1992, J BIOL CHEM, V267, P3343; PAULI BU, 1988, HUM PATHOL, V19, P628, DOI 10.1016/S0046-8177(88)80168-0; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; QUENTIN B, 1988, NATURE, V334, P538; SHTIVELMAN E, 1991, MOL CELL BIOL, V11, P5446, DOI 10.1128/MCB.11.11.5446; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; Turner T, 1996, CLIN EXP METASTAS, V14, P409, DOI 10.1007/BF00123400; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; WELCH JB, 1991, J CELL BIOL, V114, P533; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; XIE H, 1995, CLIN EXP METASTAS, V13, P407, DOI 10.1007/BF00118180; Zhang M, 1996, CLIN EXP METASTAS, V14, P268	37	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14139	14146		10.1074/jbc.272.22.14139	http://dx.doi.org/10.1074/jbc.272.22.14139			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162042	hybrid			2022-12-27	WOS:A1997XB49200029
J	Berkhout, TA; Sarau, HM; Moores, K; White, JR; Elshourbagy, N; Appelbaum, E; Reape, TJ; Brawner, M; Makwana, J; Foley, JJ; Schmidt, DB; Imburgia, C; McNulty, D; Matthews, J; ODonnell, K; OShannessy, D; Scott, M; Groot, PHE; Macphee, C				Berkhout, TA; Sarau, HM; Moores, K; White, JR; Elshourbagy, N; Appelbaum, E; Reape, TJ; Brawner, M; Makwana, J; Foley, JJ; Schmidt, DB; Imburgia, C; McNulty, D; Matthews, J; ODonnell, K; OShannessy, D; Scott, M; Groot, PHE; Macphee, C			Cloning, in vitro expression, and functional characterization of a novel human CC chemokine of the monocyte chemotactic protein (MCP) family (MCP-4) that binds and signals through the CC chemokine receptor 2B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; CHEMOATTRACTANT PROTEIN-1; MOLECULAR-CLONING; ATHEROSCLEROTIC LESIONS; CYTOKINE FAMILY; TRANSDUCTION; CELLS; BIOLOGY; LIGAND; CDNA	Here we describe the characterization of a novel human CC chemokine, tentatively named monocyte chemotactic protein (MCP-4). This chemokine was detected by random sequencing of expressed sequence tags in cDNA libraries. The full-length cDNA revealed an open reading frame for a 98-amino acid residue protein, and a sequence alignment with known CC chemokines showed high levels of similarity (59-62%) with MCP-1, MCP-3, and eotaxin. MCP-4 cDNA was cloned into Drosophila S2 cells, and the mature protein (residues 24-98) was purified from the conditioned medium. Recombinant MCP-4 induced a potent chemotactic response (EC50 = 2.88 +/- 0.15 nM) and a transient rise in cytosolic calcium concentration in fresh human peripheral blood monocytes but not in neutrophils. Binding studies in monocytes showed that MCP-4 and MCP-3 were very potent in displacing high affinity binding of I-125-MCP-1 (IC50 for MCP-4, MCP-3, and unlabeled MCP-1 of 2.1 +/- 1.4, 0.85-1.6, and 0.7 +/- 0.2 nM respectively), suggesting that all three chemokines interact with the CC chemokine receptor-a (MCP-1 receptor). This was confirmed in binding studies with Chinese hamster ovary cells, stably transfected with the CC chemokine 2B receptor. Northern blot analysis in extracts of normal human tissues showed expression of mRNA for MCP-4 in small intestine, thymus, and colon, but the level of protein expression was too low to be detected in Western blot analysis. However, expression of MCP-4 protein was demonstrated by immunohistochemistry in human atherosclerotic lesion and found to be associated with endothelial cells and macrophages.	SMITHKLINE BEECHAM PHARMACEUT,DEPT VASC BIOL,WELWYN GARDEN CIT AL6 9AR,HERTS,ENGLAND; SMITHKLINE BEECHAM PHARMACEUT,DEPT PHARMACOL,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT BIOPHARMACEUT SCI,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline				White, John R/0000-0003-2998-1626				ANGELICHIO ML, 1991, NUCLEIC ACIDS RES, V19, P5037, DOI 10.1093/nar/19.18.5037; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Berliner Judith A., 1993, Current Opinion in Lipidology, V4, P373, DOI 10.1097/00041433-199310000-00005; BOYUM A, 1984, METHOD ENZYMOL, V108, P88; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; COMBADIERE C, 1995, DNA CELL BIOL, V14, P673, DOI 10.1089/dna.1995.14.673; COMBADIERE C, 1995, J BIOL CHEM, V270, P29671; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; DAUGHERRY DL, 1996, J EXP MED, V183, P2349; ELSHOURBAGY NA, 1993, J BIOL CHEM, V268, P3873; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; Hoogewerf AJ, 1996, BIOCHEM BIOPH RES CO, V218, P337, DOI 10.1006/bbrc.1996.0059; HORUK R, 1995, EXPERT OPIN THER PAT, V5, P1185; JOHANSON K, 1995, J BIOL CHEM, V270, P9459, DOI 10.1074/jbc.270.16.9459; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; KUMAMOTO M, 1995, HUM PATHOL, V26, P450, DOI 10.1016/0046-8177(95)90148-5; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NEWBY AC, 1993, CARDIOVASC RES, V27, P1173, DOI 10.1093/cvr/27.7.1173; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; RAMOS L, 1992, Patent No. 5247; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SOZZANI S, 1994, J IMMUNOL, V152, P3615; SOZZANI S, 1993, J IMMUNOL, V150, P1544; SOZZANI S, 1991, J IMMUNOL, V147, P2215; TAKEYA M, 1993, HUM PATHOL, V24, P534, DOI 10.1016/0046-8177(93)90166-E; Uguccioni M, 1996, J EXP MED, V183, P2379, DOI 10.1084/jem.183.5.2379; VANDERSTRATEN A, 1989, CURR METHODS MOL BIO, V1, P1; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; YAMAGAMI S, 1994, BIOCHEM BIOPH RES CO, V202, P1156, DOI 10.1006/bbrc.1994.2049; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; YOSHIMURA T, 1990, J IMMUNOL, V145, P292; YU XH, 1992, P NATL ACAD SCI USA, V89, P6953, DOI 10.1073/pnas.89.15.6953	40	87	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16404	16413		10.1074/jbc.272.26.16404	http://dx.doi.org/10.1074/jbc.272.26.16404			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195948	hybrid			2022-12-27	WOS:A1997XG01900052
J	DeAizpurua, HJ; Cram, DS; Naselli, G; Devereux, L; Dorow, DS				DeAizpurua, HJ; Cram, DS; Naselli, G; Devereux, L; Dorow, DS			Expression of mixed lineage kinase-1 in pancreatic beta-cell lines at different stages of maturation and during embryonic pancreas development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; ACTIN STRESS FIBERS; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; BINDING PROTEINS; LEUCINE ZIPPER; SMALL GTPASES; GENE; RAT; INSULIN	Events controlling differentiation to insulin-secreting beta-cells in the pancreas are not well understood, although beta-cells are thought to arise from pluripotent ductal precursor cells, To search for signaling proteins that might be involved in beta-cell maturation, we analyzed protein kinase expression in two developmentally and functionally distinct pancreatic beta-cell lines, RIN-5AH and RIN-A12, by reverse transcriptase polymerase chain reaction, A number of tyrosine and serine/threonine kinases were identified in both lines, One protein kinase, mixed lineage kinase-1 (MLK-1), was expressed at both the RNA and protein levels in RIN-5AH cells, which display an immature beta-cell phenotype, but was not detected in the more mature RIN-A12 cells, Furthermore, levels of MLK-1 mRNA and protein were increased after brief stimulation of RIN-5AH cells with either the differentiation inducer, sodium butyrate, or with serum after serum starvation. These increases in expression were independent of phenotypic markers such as insulin secretion or surface expression of major histocompatibility class I- and A2B5-reactive ganglioside, In addition, increases in MLK-1 expression in the stimulated RIN-5AH cells were accompanied by phosphorylation of MLK-1 on serine but not tyrosine, Antisense oligonucleotides to two distinct regions of MLK-1 caused RIN-5AH cells, but not RIN-A12 cells, to adopt a highly undifferentiated morphology, with a reduction in DNA synthesis and MLR-1 protein levels and elevated glucagon mRNA levels, but with no effect on insulin mRNA, In an immunohistochemical survey of embryonic mouse tissues, we found that temporal expression of MLK-1 was regulated in a tissue-specific manner, In the embryonic pancreas, MLK-1 expression was evident in ductal cells from day 13 to 16 but was not detected in late stage gestation or neonatal pancreas, These data suggest that MLK-1 is regulated in immature pancreatic beta-cells and their ductal precursors at the level of functional maturity and may therefore play a role in beta-cell development.	PETER MACCALLUM CANC INST,TRESCOWTHICK RES LABS,MELBOURNE,VIC 3000,AUSTRALIA	Peter Maccallum Cancer Center	DeAizpurua, HJ (corresponding author), ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,BURNET CLIN RES UNIT,PARKVILLE,VIC 3050,AUSTRALIA.			Devereux, Lisa/0000-0003-2435-5888				ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; ALTSHUL SF, 1990, J MOL BIOL, V215, P443; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARTHOLOMEUSZ RK, 1990, CELL DIFFER DEV, V32, P39, DOI 10.1016/0922-3371(90)90097-G; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOROW DS, 1995, EUR J BIOCHEM, V234, P492, DOI 10.1111/j.1432-1033.1995.492_b.x; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; GAZDAR AF, 1980, P NATL ACAD SCI-BIOL, V77, P3519, DOI 10.1073/pnas.77.6.3519; HARRISON LC, 1990, ADV ENDOCRINOL METAB, V1, P35; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; KEFALAS P, 1995, INT J BIOCHEM CELL B, V27, P551, DOI 10.1016/1357-2725(95)00024-J; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEDOUARIN NM, 1988, CELL, V53, P169, DOI 10.1016/0092-8674(88)90375-3; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MADSON OD, 1986, J CELL BIOL, V102, P2025; Mares J, 1992, GROWTH FACTORS, V6, P93, DOI 10.3109/08977199209011013; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NIELSEN JH, 1982, ENDOCRINOLOGY, V110, P600, DOI 10.1210/endo-110-2-600; NIELSEN JH, 1989, EXP CLIN ENDOCRINOL, V93, P277; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PHILIPPE J, 1987, MOL CELL BIOL, V7, P560, DOI 10.1128/MCB.7.1.560; PHILIPPE J, 1987, J CLIN INVEST, V79, P351, DOI 10.1172/JCI112819; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; SWENNE I, 1983, DIABETES, V32, P14, DOI 10.2337/diabetes.32.1.14; SWENNE I, 1985, DIABETES, V34, P803, DOI 10.2337/diabetes.34.8.803; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; TIETELMAN G, 1987, DEV BIOL, V121, P454; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VISVADER J, 1991, TRENDS BIOCHEM SCI, V16, P330, DOI 10.1016/0968-0004(91)90137-K; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237	58	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16364	16373		10.1074/jbc.272.26.16364	http://dx.doi.org/10.1074/jbc.272.26.16364			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195943	hybrid			2022-12-27	WOS:A1997XG01900047
J	Engelman, JA; Wykoff, CC; Yasuhara, S; Song, KS; Okamoto, T; Lisanti, MP				Engelman, JA; Wykoff, CC; Yasuhara, S; Song, KS; Okamoto, T; Lisanti, MP			Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; RICH MEMBRANE DOMAINS; COLI LAC REPRESSOR; NIH 3T3 CELLS; TYROSINE KINASES; PLASMA-MEMBRANE; SIGNAL-TRANSDUCTION; TRANSPORT VESICLES; PROTEIN-COMPONENT; RAS	Caveolae are plasma membrane-attached vesicular organelles. Caveolin-1, a 21-24-kDa integral membrane protein, is a principal component of caveolae membranes in vivo. Both caveolae and caveolin are most abundantly expressed in terminally differentiated cells: adipocytes, endothelial cells, and muscle cells. Conversely, caveolin-1 mRNA and protein expression are lost or reduced during cell transformation by activated oncogenes such as v-abl and H-ras (G12V); caveolae are absent from these cell lines. However, its remains unknown whether down-regulation of caveolin-1 protein and caveolae organelles contributes to their transformed phenotype. Here, we have expressed caveolin-1 in oncogenically transformed cells under the control of an inducible-expression system. Regulated induction of caveolin-1 expression was monitored by Western blot analysis and immunofluorescence microscopy. Our results indicate that caveolin-1 protein is expressed well using this system and correctly localizes to the plasma membrane. Induction of caveolin-1 expression in v-Abl-transformed and H-Ras (G12V)-transformed NIH 3T3 cells abrogated the anchorage-independent growth of these cells in soft agar and resulted in the de novo formation of caveolae as seen by transmission electron microscopy. Consistent with its antagonism of Ras-mediated cell transformation, caveolin-1 expression dramatically inhibited both Ras/MAPK-mediated and basal transcriptional activation of a mitogen-sensitive promoter. Using an established system to detect apoptotic cell death, it appears that the effects of caveolin-1 may, in part, be attributed to its ability to initiate apoptosis in rapidly dividing cells. In addition, we find that caveolin-1 expression levels are reversibly down-regulated by two distinct oncogenic stimuli. Taken together, our results indicate that down-regulation of caveolin-1 expression and caveolae organelles may be critical to maintaining the transformed phenotype in certain cell populations.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL PHARMACOL, BRONX, NY 10461 USA; WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; CLEVELAND CLIN FDN, DEPT NEUROSCI, CLEVELAND, OH 44195 USA	Yeshiva University; Albert Einstein College of Medicine; Massachusetts Institute of Technology (MIT); Whitehead Institute; Cleveland Clinic Foundation			Lisanti, Michael P/C-6866-2013; Lisanti, Michael/B-6131-2018	Lisanti, Michael/0000-0003-2034-1382	NIGMS NIH HHS [GM-50443, T32-GM07288] Funding Source: Medline; NIMH NIH HHS [MH-56036] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288, R29GM050443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH056036] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ENGELMAN A, 1990, J VIROL, V64, P4242, DOI 10.1128/JVI.64.9.4242-4251.1990; FAN JY, 1983, J CELL SCI, V61, P219; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; FIGGE J, 1988, CELL, V52, P713, DOI 10.1016/0092-8674(88)90409-6; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; IKEZU T, 1994, J BIOL CHEM, V269, P31955; IZUMI T, 1988, ANAT REC, V220, P225, DOI 10.1002/ar.1092200302; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lisanti Michael P., 1995, Seminars in Developmental Biology, V6, P47, DOI 10.1016/S1044-5781(06)80084-8; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PRENDERGAST GC, 1994, BIOESSAYS, V16, P187, DOI 10.1002/bies.950160309; Raffel GD, 1996, J BIOL CHEM, V271, P4640; RAPOSO G, 1987, BIOL CELL, V60, P117, DOI 10.1111/j.1768-322X.1987.tb00551.x; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; SEVERS NJ, 1988, J CELL SCI, V90, P341; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SIMIONESCU N, 1975, J CELL BIOL, V64, P586, DOI 10.1083/jcb.64.3.586; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7; WYBORSKI DL, 1991, NUCLEIC ACIDS RES, V19, P4647, DOI 10.1093/nar/19.17.4647; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349; Yamatsuji T, 1996, EMBO J, V15, P498, DOI 10.1002/j.1460-2075.1996.tb00382.x	80	338	348	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16374	16381		10.1074/jbc.272.26.16374	http://dx.doi.org/10.1074/jbc.272.26.16374			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195944	hybrid			2022-12-27	WOS:A1997XG01900048
J	Koloteva, N; Muller, PP; McCarthy, JEG				Koloteva, N; Muller, PP; McCarthy, JEG			The position dependence of translational regulation via RNA-RNA and RNA-protein interactions in the 5'-untranslated region of eukaryotic mRNA is a function of the thermodynamic competence of 40 S ribosomes in translational initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-RESPONSIVE ELEMENT; YEAST SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; SECONDARY STRUCTURE; BINDING-PROTEIN; GENE-EXPRESSION; FERRITIN; INHIBITION; DETERMINANTS; EFFICIENCY	Cap proximity is a requirement to enable secondary structures and RNA-binding proteins to repress translational initiation via the 5'-untranslated region (5'-UTR) of mammalian mRNAs. We show that in Saccharomyces cerevisiae, unlike mammalian cells, the in vitro translational repressive effect of the mammalian iron regulatory protein 1 (IRP1) is independent of the site of its target in the 5'-UTR, the iron-responsive element (IRE). In vitro studies demonstrate that the binding affinity of IRP1 is also unaffected by the position of the IRE. Using IRE loop mutants, we observe an almost complete loss of IRP1-dependent repression in yeast concomitant with a 150-fold reduction in binding affinity for the IRE target. This mirrors the natural quantitative range of iron-induced adjustment of IRE/IRP1 affinity in mammalian cells. By enhancing the stability of the IRE stem-loop, we also show that its intrinsic folding energy acts together with the binding energy of IRP1 to give an additive capacity to restrict translational initiation. An IRE-IRP1 complex in a cap-distal position in yeast blocks scanning 40 S ribosomes on the 5'-UTR, It follows that the position effect of mammalian site-specific translational repression is dictated by the competence of the mammalian preinitiation complex to destabilize inhibitory structures at different steps of the initiation process.	UNIV MANCHESTER, INST SCI & TECHNOL, DEPT BIOMOL SCI, MANCHESTER M60 1QD, LANCS, ENGLAND; GESELL BIOTECHNOL FORSCH MBH, D-38124 BRAUNSCHWEIG, GERMANY	University of Manchester; Gesellschaft fur Biotechnologische Forschung mbH			Mueller, Peter P./H-8656-2019	Mueller, Peter P./0000-0002-1209-7546				ALTMANN M, 1985, BIOCHEMISTRY-US, V24, P6085, DOI 10.1021/bi00343a009; ALTMANN M, 1995, EMBO J, V14, P3820, DOI 10.1002/j.1460-2075.1995.tb00051.x; BAIM SB, 1988, MOL CELL BIOL, V8, P1591, DOI 10.1128/MCB.8.4.1591; BARTON HA, 1990, J BIOL CHEM, V265, P7000; BETTANY AJE, 1992, J BIOL CHEM, V267, P16531; Butt J, 1996, P NATL ACAD SCI USA, V93, P4345, DOI 10.1073/pnas.93.9.4345; CIGAN AM, 1987, GENE, V59, P1; GOOSSEN B, 1992, MOL CELL BIOL, V12, P1959, DOI 10.1128/MCB.12.5.1959; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; HAILE DJ, 1989, MOL CELL BIOL, V9, P5055, DOI 10.1128/MCB.9.11.5055; Harford J, 1993, CONTROL MESSENGER ST, P239; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; JAFFREY SR, 1993, NUCLEIC ACIDS RES, V21, P4627, DOI 10.1093/nar/21.19.4627; JOBLING SA, 1988, NUCLEIC ACIDS RES, V16, P4483, DOI 10.1093/nar/16.10.4483; KIKINIS Z, 1995, NUCLEIC ACIDS RES, V23, P4190, DOI 10.1093/nar/23.20.4190; Kohler SA, 1995, J BIOL CHEM, V270, P30781, DOI 10.1074/jbc.270.51.30781; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KOZAK M, 1992, CRIT REV BIOCHEM MOL, V27, P385, DOI 10.3109/10409239209082567; KOZAK M, 1994, BIOCHIMIE, V76, P815, DOI 10.1016/0300-9084(94)90182-1; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; LASO MRV, 1993, J BIOL CHEM, V268, P6453; Linz B, 1997, J BIOL CHEM, V272, P9131; MADER S, 1995, BIOCHIMIE, V77, P40, DOI 10.1016/0300-9084(96)88102-8; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; MCCARTHY JEG, 1990, TRENDS GENET, V6, P78, DOI 10.1016/0168-9525(90)90098-Q; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; NAGAI K, 1994, RNA PROTEIN INTERACT; OLIVEIRA CC, 1993, MOL MICROBIOL, V9, P521, DOI 10.1111/j.1365-2958.1993.tb01713.x; OLIVEIRA CC, 1993, NUCLEIC ACIDS RES, V21, P5316, DOI 10.1093/nar/21.23.5316; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; SAGLIOCCO FA, 1993, J BIOL CHEM, V268, P26522; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; STANDART N, 1994, BIOCHIMIE, V76, P867, DOI 10.1016/0300-9084(94)90189-9; STRIPECKE R, 1994, MOL CELL BIOL, V14, P5898, DOI 10.1128/MCB.14.9.5898; STRIPECKE R, 1992, NUCLEIC ACIDS RES, V20, P5555, DOI 10.1093/nar/20.21.5555; Tuite M F, 1986, Yeast, V2, P35, DOI 10.1002/yea.320020103; VANZOELEN EJJ, 1992, ANAL BIOCHEM, V200, P393, DOI 10.1016/0003-2697(92)90485-P	39	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16531	16539		10.1074/jbc.272.26.16531	http://dx.doi.org/10.1074/jbc.272.26.16531			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195963	hybrid			2022-12-27	WOS:A1997XG01900067
J	Wang, P; Granados, RR				Wang, P; Granados, RR			Molecular cloning and sequencing of a novel invertebrate intestinal mucin cDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHIC EPITHELIAL MUCIN; GENETIC-POLYMORPHISM; XENOPUS-LAEVIS; EXPRESSION; PROTEIN; RICH; DOMAINS; CELLS; GLYCOPROTEIN; SECRETION	The first invertebrate intestinal mucin, termed insect intestinal mucin (IIM), was recently identified from Trichoplusia ni larvae (Wang, P., and Granados, R. R. (1997) Proc. Natl. Acad. Sci. U. S. A., in press). We report the cDNA cloning and sequencing of IIM, which is only the second completely sequenced intestinal mucin after human intestinal mucin, MUC2. To clone and sequence the cDNA for IIM, a T. ni larval midgut cDNA expression library was constructed and screened with an anti-IIM antiserum. Two full-length cDNA clones for IIM were identified and sequenced, The deduced proteins from the two cDNA clones contained 807 and 788 amino acid residues, respectively. The structural organization of IIM is similar to that of MUC2, containing a 25-amino acid signal leading sequence and two threonine/proline/alanine-rich tandem repeat domains flanked by cysteine-rich sequences. One tandem repeat domain contained two repeating units, TTTQAP and AATTP, and the other contained one repeating unit, TAAP. The cysteine-rich regions showed potential chitin binding features. By immunolocalization in tissue sections, it was determined that IIM is expressed in midgut tissues. The IIM mRNA is abundant in the midgut tissue, and Northern blot analysis indicated that IIM transcripts were not polydispersed as is found in mammalian mucin transcription.	CORNELL UNIV, DEPT ENTOMOL, ITHACA, NY 14853 USA; CORNELL UNIV, BOYCE THOMPSON INST PLANT RES, ITHACA, NY 14853 USA	Cornell University; Cornell University; Boyce Thompson Institute for Plant Research								ALLEN A, 1993, PHYSIOL REV, V73, P823, DOI 10.1152/physrev.1993.73.4.823; ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; [Anonymous], 1992, ZOOPHYSIOLOGY; BHARGAVA AK, 1990, P NATL ACAD SCI USA, V87, P6798, DOI 10.1073/pnas.87.17.6798; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MS, 1986, ADV PROTEIN CHEM, V38, P109, DOI 10.1016/S0065-3233(08)60527-6; DINOIA JM, 1995, J BIOL CHEM, V270, P24146, DOI 10.1074/jbc.270.41.24146; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; Elvin CM, 1996, J BIOL CHEM, V271, P8925, DOI 10.1074/jbc.271.15.8925; FORSTNER G, 1995, ANNU REV PHYSIOL, V57, P585, DOI 10.1146/annurev.ph.57.030195.003101; Forstner Janet F., 1994, P1255; GARFINKEL MD, 1983, J MOL BIOL, V168, P765, DOI 10.1016/S0022-2836(83)80074-6; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1992, J BIOL CHEM, V267, P21375; GUM JR, 1994, J BIOL CHEM, V269, P2440; Hansen JE, 1996, NUCLEIC ACIDS RES, V24, P248, DOI 10.1093/nar/24.1.248; HAUSER F, 1992, J BIOL CHEM, V267, P24620; HOFFMANN W, 1988, J BIOL CHEM, V263, P7686; HUBER M, 1991, P NATL ACAD SCI USA, V88, P2807, DOI 10.1073/pnas.88.7.2807; JARMAN AP, 1989, TRENDS GENET, V5, P367, DOI 10.1016/0168-9525(89)90171-6; KIMURA S, 1994, FISHERIES SCI, V60, P193, DOI 10.2331/fishsci.60.193; Kramerov AA, 1996, FEBS LETT, V378, P213, DOI 10.1016/0014-5793(95)01444-6; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANCASTER CA, 1990, BIOCHEM BIOPH RES CO, V173, P1019, DOI 10.1016/S0006-291X(05)80888-5; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; MURRAY PJ, 1991, J BIOL CHEM, V266, P24477; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; RINALDINI LM, 1954, J PHYSIOL-LONDON, V123, pP20; SHEEHAN JK, 1990, BIOCHEM J, V265, P169, DOI 10.1042/bj2650169; SMITH GR, 1987, ANNU REV GENET, V21, P179, DOI 10.1146/annurev.genet.21.1.179; SPECIAN RD, 1991, AM J PHYSIOL, V260, pC183, DOI 10.1152/ajpcell.1991.260.2.C183; Spence Kemet D., 1991, P77; SPICER AP, 1991, J BIOL CHEM, V266, P15099; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; Sugiura Y, 1995, FISHERIES SCI, V61, P1009, DOI 10.2331/fishsci.61.1009; Theopold U, 1996, J BIOL CHEM, V271, P12708, DOI 10.1074/jbc.271.22.12708; Troxler RF, 1995, BIOCHEM BIOPH RES CO, V217, P1112, DOI 10.1006/bbrc.1995.2884; VERMA M, 1993, P NATL ACAD SCI USA, V90, P7144, DOI 10.1073/pnas.90.15.7144; VERMA M, 1994, GLYCOCONJUGATE J, V11, P172, DOI 10.1007/BF00731215; WEBER K, 1969, J BIOL CHEM, V244, P4406; WU K, 1994, J BIOL CHEM, V269, P11950; YANAI K, 1992, J BACTERIOL, V174, P7398, DOI 10.1128/jb.174.22.7398-7406.1992	46	105	129	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16663	16669		10.1074/jbc.272.26.16663	http://dx.doi.org/10.1074/jbc.272.26.16663			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195982	hybrid			2022-12-27	WOS:A1997XG01900086
J	Zawada, RJX; Khosla, C				Zawada, RJX; Khosla, C			Domain analysis of the molecular recognition features of aromatic polyketide synthase subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENGINEERED BIOSYNTHESIS; STREPTOMYCES-GLAUCESCENS; ANTIBIOTIC BIOSYNTHESIS; CATALYTIC SPECIFICITY; NUCLEOTIDE-SEQUENCE; GENE; MANIPULATION; COELICOLOR; FRENOLICIN; CLUSTER	Bacterial aromatic polyketide synthases (PKSs) are a family of homologous multienzyme assemblies that catalyze the biosynthesis of numerous polyfunctional aromatic natural products, In the absence of direct insights into their structures, the use of gene fusions can be a powerful tool for understanding the structural basis for their properties. A series of truncated and hybrid proteins were constructed and analyzed within a family of PKS subunits, designated aromatases/cyclases (ARO/CYCs), When expressed alone, neither the N-terminal nor the C-terminal domain of the actinorhodin (act) or the griseusin (gris) ARO/CYC exhibited substantial aromatase activity. However, in the presence of each other, the half proteins were active. Furthermore, analysis of a set of hybrid proteins derived from the act and gris ARO/CYCs allowed us to localize the chain length dependence of this aromatase activity to their N-terminal domains. Unexpectedly, however, when the C-terminal domain of the gris ARO/CYC was expressed in a context where aromatase activity was absent, it could modulate the chain length specificity of the tetracenomycin (tcm) minimal PKS, leading to the formation of a novel 18-carbon product in addition to the expected 20-carbon one, It was-also found that monodomain ARO/CYCs such as tcmN cannot substitute for the the N-terminal domain of didomain ARO/CYCs, even though they exhibit high sequence similarity with the N-terminal domain, Together, these results illustrate the utility of protein engineering approaches for dissecting the structure-function relationships of PKS subunits and for the generation of mutant alleles with novel biosynthetic properties.	STANFORD UNIV, DEPT CHEM ENGN, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT CHEM, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT BIOCHEM, STANFORD, CA 94305 USA	Stanford University; Stanford University; Stanford University				Khosla, Chaitan/0000-0001-6529-495X				BIBB MJ, 1989, EMBO J, V8, P2727, DOI 10.1002/j.1460-2075.1989.tb08414.x; BIBB MJ, 1994, GENE, V142, P31, DOI 10.1016/0378-1119(94)90351-4; Carreras CW, 1996, J AM CHEM SOC, V118, P5158, DOI 10.1021/ja960479o; Fu H, 1994, Chem Biol, V1, P205, DOI 10.1016/1074-5521(94)90012-4; FU H, 1994, J AM CHEM SOC, V116, P4166, DOI 10.1021/ja00089a003; FU H, 1994, BIOCHEMISTRY-US, V33, P9321, DOI 10.1021/bi00197a036; FU H, 1994, J AM CHEM SOC, V116, P6443, DOI 10.1021/ja00093a058; HOPWOOD DA, 1992, CIBA F SYMP, V171, P88; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; HOPWOOD DA, 1985, GENETIC MANIPULATION, P107; HUTCHINSON CR, 1995, ANNU REV MICROBIOL, V49, P201; IWAI Y, 1978, J ANTIBIOT, V31, P959, DOI 10.7164/antibiotics.31.959; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; Kramer PJ, 1997, J AM CHEM SOC, V119, P635, DOI 10.1021/ja962888q; MACNEIL DJ, 1988, J BACTERIOL, V170, P5607, DOI 10.1128/jb.170.12.5607-5612.1988; MANIATIS T, 1982, MOL CLONING LABORATO, P55; MCDANIEL R, 1994, P NATL ACAD SCI USA, V91, P11542, DOI 10.1073/pnas.91.24.11542; MCDANIEL R, 1993, J AM CHEM SOC, V115, P11671, DOI 10.1021/ja00078a002; MCDANIEL R, 1994, J AM CHEM SOC, V116, P10855, DOI 10.1021/ja00103a001; MCDANIEL R, 1995, J AM CHEM SOC, V117, P6805, DOI 10.1021/ja00131a001; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MCDANIEL R, 1995, NATURE, V375, P549, DOI 10.1038/375549a0; OHagan D., 1991, POLYKETIDE METABOLIT; PIEPER R, 1995, NATURE, V378, P263, DOI 10.1038/378263a0; ROBINSON JA, 1991, PHILOS T ROY SOC B, V332, P107, DOI 10.1098/rstb.1991.0038; SHEN B, 1993, SCIENCE, V262, P1535, DOI 10.1126/science.8248801; SHEN B, 1995, J AM CHEM SOC, V117, P6811, DOI 10.1021/ja00131a002; SHERMAN DH, 1991, TETRAHEDRON, V47, P6029, DOI 10.1016/S0040-4020(01)86494-2; SUMMERS RG, 1992, J BACTERIOL, V174, P1810, DOI 10.1128/jb.174.6.1810-1820.1992; TSUZUKI K, 1986, J ANTIBIOT, V39, P1343, DOI 10.7164/antibiotics.39.1343; YU TW, 1995, THESIS U E ANGLIA NO; ZHANG HL, 1990, J ORG CHEM, V55, P1682, DOI 10.1021/jo00292a053	32	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16184	16188		10.1074/jbc.272.26.16184	http://dx.doi.org/10.1074/jbc.272.26.16184			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195917	hybrid			2022-12-27	WOS:A1997XG01900021
J	Takahashi, T; Kawahara, Y; Okuda, M; Ueno, H; Takeshita, A; Yokoyama, M				Takahashi, T; Kawahara, Y; Okuda, M; Ueno, H; Takeshita, A; Yokoyama, M			Angiotensin II stimulates mitogen-activated protein kinases and protein synthesis by a Ras-independent pathway in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAYS; C ACTIVATION; MAP KINASES; HYPERTROPHY; GENE; PROLIFERATION; MOBILIZATION; INHIBITION	Angiotensin II (ANG II), a potent hypertrophic factor of vascular smooth muscle cells (VSMC), induces activation of the ras protooncogene product (Ras) and mitogen-activated protein (MAP) kinases and subsequent stimulation of protein synthesis in VSMC, Tn the present study, we examined whether Pas activation is required for ANG II-induced MAP kinase activation and stimulation of protein synthesis in cultured rat VSMC. Pretreatment with tyrosine kinase inhibitors, genistein and her bimycin A, or a putative phosphatidylinositol 3-kinase inhibitor, wortmannin, completely blocked ANG II-induced nas activation, whereas neither of them had an effect on ANG II-induced MAP kinase activation, Adenovirus-mediated expression of a dominant negative mutant of Ha-Ras completely inhibited ANG II-induced Res activation but failed to inhibit MAP kinase activation and stimulation of protein synthesis by this vasoconstrictor These results indicate that ANG II stimulates MAP kinases and protein synthesis by a Ras-independent pathway in VSMC.	KOBE UNIV,SCH MED,DEPT INTERNAL MED,DIV 1,CHUO KU,KOBE,HYOGO 650,JAPAN; KYUSHU UNIV,SCH MED,MOL CARDIOL UNIT,RES INST ANGIOCARDIOL,FUKUOKA 81282,JAPAN; KYUSHU UNIV,SCH MED,CARDIOVASC CLIN,FUKUOKA 81282,JAPAN	Kobe University; Kyushu University; Kyushu University								ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BochatonPiallat ML, 1996, ARTERIOSCL THROM VAS, V16, P815, DOI 10.1161/01.ATV.16.6.815; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; DePaolo D, 1996, MOL CELL BIOL, V16, P1450; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; FEIG LA, 1994, NATURE, V370, P508, DOI 10.1038/370508a0; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GIBBONS GH, 1990, CARDIOVASC DRUG THER, V4, P237, DOI 10.1007/BF01857638; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IRANI K, 1994, BIOCHEM BIOPH RES CO, V202, P1252, DOI 10.1006/bbrc.1994.2065; ISHIDA Y, 1992, FEBS LETT, V310, P41, DOI 10.1016/0014-5793(92)81142-9; JUNG V, 1994, MOL CELL BIOL, V14, P3707, DOI 10.1128/MCB.14.6.3707; KAWAHARA Y, 1988, BIOCHEM BIOPH RES CO, V150, P52, DOI 10.1016/0006-291X(88)90485-8; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Malarkey K, 1996, CELL SIGNAL, V8, P123, DOI 10.1016/0898-6568(95)02036-5; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; NAKAYAMA I, 1994, J BIOL CHEM, V269, P11628; OKADA T, 1994, J BIOL CHEM, V269, P3563; Okuda M, 1996, AM J PHYSIOL-HEART C, V271, pH595, DOI 10.1152/ajpheart.1996.271.2.H595; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SCHELLING P, 1991, J HYPERTENS, V9, P3; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; Takahashi T, 1996, FEBS LETT, V397, P89, DOI 10.1016/S0014-5793(96)01145-3; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TSUDA T, 1992, CIRC RES, V71, P620, DOI 10.1161/01.RES.71.3.620; UENO H, 1995, ARTERIOSCL THROM VAS, V15, P2246, DOI 10.1161/01.ATV.15.12.2246; UENO H, 1997, IN PRESS ARTERIOSCLE; Yamamoto H, 1996, J BIOL CHEM, V271, P16253, DOI 10.1074/jbc.271.27.16253; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597	41	73	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					16018	16022		10.1074/jbc.272.25.16018	http://dx.doi.org/10.1074/jbc.272.25.16018			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188505	hybrid			2022-12-27	WOS:A1997XF32900065
J	Raber, J; Chen, SZ; Mucke, L; Feng, LL				Raber, J; Chen, SZ; Mucke, L; Feng, LL			Corticotropin-releasing factor and adrenocorticotrophic hormone as potential central mediators of OB effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; OBESE ZUCKER RATS; STRESS; ADRENALECTOMY; MOUSE; CORTICOSTERONE; INVOLVEMENT; ANOREXIA; AMYGDALA; PROTEIN	OB (leptin) has been identified as a factor that suppresses appetite and stimulates metabolism. Attention has focused on the hypothalamus as its potential site of action, but OB could also act on other brain regions. In addition, the paradox of high OB levels in obese humans remains unresolved. Here we show in mice that both the long and short form of the OB receptor are expressed not only in the hypothalamus but also in the amygdala and pituitary. Recombinant murine OB elicited the release of corticotropin-releasing factor from superfused brain slice preparations containing hypothalamus or amygdala. Because corticotropin-releasing factor inhibits appetite and stimulates metabolism, it may be a key mediator of central OB effects. Recombinant OB also induced pituitary release of adrenocorticotrophic hormone. Because adrenocorticotrophic hormone-induced elevation of plasma glucocorticoid levels can inhibit corticotropin-releasing factor release via negative feedback, the OB effects on pituitary adrenocorticotrophic hormone release may be pertinent to human obesity, which combines increased plasma glucocorticoid levels with elevated levels of OB. An imbalance between the effects of OB on corticotropin-releasing factor release from the hypothalamus and on adrenocorticotrophic hormone release from the pituitary could contribute to obesity.	UNIV CALIF SAN FRANCISCO, DEPT NEUROL, SAN FRANCISCO, CA 94141 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	University of California System; University of California San Francisco; Scripps Research Institute	Raber, J (corresponding author), UNIV CALIF SAN FRANCISCO, GLADSTONE MOL NEUROBIOL PROGRAM, POB 419100, SAN FRANCISCO, CA 94141 USA.			Mucke, Lennart/0000-0001-6256-9559	NIDDK NIH HHS [DK49832-01A2] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK049832] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTONI FA, 1986, ENDOCR REV, V7, P351, DOI 10.1210/edrv-7-4-351; APPEL NM, 1991, ENDOCRINOLOGY, V128, P3237, DOI 10.1210/endo-128-6-3237; ARESE K, 1988, AM J PHYSIOL, V255, pE255; Arzt E, 1996, NEUROIMMUNOMODULAT, V3, P28, DOI 10.1159/000097224; Banks WA, 1996, PEPTIDES, V17, P305, DOI 10.1016/0196-9781(96)00025-3; BEACH JE, 1989, LIFE SCI, V44, P1, DOI 10.1016/0024-3205(89)90211-7; BEAULIEU S, 1989, NEUROENDOCRINOLOGY, V49, P255, DOI 10.1159/000125125; BJORNTORP P, 1995, METABOLISM, V44, P21, DOI 10.1016/0026-0495(95)90315-1; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; CUMMINGS S, 1983, J NEUROSCI, V3, P1355; CUNNINGHAM JJ, 1986, ENDOCRINOLOGY, V118, P98, DOI 10.1210/endo-118-1-98; DUNN JD, 1986, NEUROENDOCRINOLOGY, V42, P211, DOI 10.1159/000124442; EGAWA M, 1990, AM J PHYSIOL, V259, pR799, DOI 10.1152/ajpregu.1990.259.4.R799; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; FENG LL, 1994, J BIOL CHEM, V269, P2342; FUKUSHIMA M, 1992, NEUROSCI LETT, V138, P245, DOI 10.1016/0304-3940(92)90925-W; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; GRAY TS, 1989, NEUROENDOCRINOLOGY, V50, P433, DOI 10.1159/000125260; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Heinrichs SC, 1996, P NATL ACAD SCI USA, V93, P15475, DOI 10.1073/pnas.93.26.15475; HOLT SJ, 1989, PHYSIOL BEHAV, V45, P1123, DOI 10.1016/0031-9384(89)90098-X; KOOB GF, 1993, CIBA F SYMP, V172, P277; KOPELMAN PG, 1989, OBESITY EUROPE, V88, P141; KRAHN DD, 1986, BRAIN RES BULL, V17, P285, DOI 10.1016/0361-9230(86)90233-9; LIANG KC, 1992, J NEUROSCI, V12, P2313; MARTI O, 1994, PHYSIOL BEHAV, V55, P747, DOI 10.1016/0031-9384(94)90055-8; MCCARTHY HD, 1993, AM J PHYSIOL, V264, pE638, DOI 10.1152/ajpendo.1993.264.4.E638; McGregor GP, 1996, ENDOCRINOLOGY, V137, P1501, DOI 10.1210/en.137.4.1501; MOOK DG, 1975, HORM BEHAV, V6, P65, DOI 10.1016/0018-506X(75)90024-0; NAKAISHI S, 1990, INT J OBESITY, V14, P951; PACAK K, 1995, FRONT NEUROENDOCRIN, V16, P89, DOI 10.1006/frne.1995.1004; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PLOTSKY PM, 1992, ENDOCRINOLOGY, V130, P1931, DOI 10.1210/en.130.4.1931; Raber J, 1996, VIROLOGY, V226, P362, DOI 10.1006/viro.1996.0664; Raber J, 1997, J NEUROCHEM, V68, P176; RIVEST S, 1990, BRAIN RES BULL, V25, P169, DOI 10.1016/0361-9230(90)90270-A; ROHNERJEANRENAUD F, 1989, ENDOCRINOLOGY, V124, P733, DOI 10.1210/endo-124-2-733; SAITO M, 1984, AM J PHYSIOL, V246, pR20; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; SHIBASAKI T, 1988, LIFE SCI, V43, P1103, DOI 10.1016/0024-3205(88)90468-7; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; TOKUYAMA K, 1987, AM J PHYSIOL, V252, pE202, DOI 10.1152/ajpendo.1987.252.2.E202; Woods AJ, 1996, NATURE, V381, P745, DOI 10.1038/381745a0; Xia YY, 1996, FEBS LETT, V382, P285, DOI 10.1016/0014-5793(96)00185-8; XIA YY, 1993, AM J PHYSIOL, V264, pF774, DOI 10.1152/ajprenal.1993.264.5.F774; YUKIMURA Y, 1978, ENDOCRINOLOGY, V103, P1924, DOI 10.1210/endo-103-5-1924	48	85	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15057	15060		10.1074/jbc.272.24.15057	http://dx.doi.org/10.1074/jbc.272.24.15057			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182522	hybrid			2022-12-27	WOS:A1997XE03400005
J	Fushimi, K; Sasaki, S; Marumo, F				Fushimi, K; Sasaki, S; Marumo, F			Phosphorylation of serine 256 is required for cAMP-dependent regulatory exocytosis of the aquaporin-2 water channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLECTING DUCT; ANTIDIURETIC-HORMONE; APICAL MEMBRANE; PLASMA-MEMBRANE; F-ACTIN; EPITHELIAL-CELLS; RAT-KIDNEY; EXPRESSION; TRANSPORT; VESICLES	The aquaporin-2 (AQP2) vasopressin water channel is translocated to the apical membrane upon vasopressin stimulation. Phosphorylation of serine 256 of AQP2 by cAMP-dependent protein kinase has been shown, but its relation to vasopressin-regulated translocation has not been elucidated. To address this question, wild type (WT) AQP2 and a mutant with alanine in place of serine 256 of AQP2 (S256A) were expressed in LLC-PK1 cells by electroporation. Measurements by a stopped-flow lightscattering method revealed that the osmotic water permeability (P-f) of LLC-PK1 cells transfected with WT was 69.6 +/- 6.5 mu m/s (24.8 +/- 2.2 mu m/s for mock-transfected), and stimulation by 500 mu M 8-(4-chlorophenylthio)-cAMP increased the P-f by 85 +/- 12%. When S256A AQP2 was transfected, the cAMP-dependent increase in the P-f was only 8 +/- 5%. After cAMP stimulation, the increase in surface expression of AQP2 determined by surface biotin labeling was 4 +/- 10%, significantly less than that for WT (88 +/- 5%). In addition, an in vivo [P-32]orthophosphate labeling assay demonstrated significant phosphorylation of WT AQP2 and only minimal phosphorylation of S256A AQP2 in LLC-PK1 cells. Our results indicated that serine 256 of AQP2 is necessary for regulatory exocytosis and that cAMP-responsive redistribution of AQP2 may be regulated by phosphorylation of AQP2.			Fushimi, K (corresponding author), TOKYO MED & DENT UNIV,SCH MED,DEPT INTERNAL MED 2,BUNKYO KU,1-5-45 YUSHIMA,TOKYO 113,JAPAN.							AGRE P, 1994, J CLIN INVEST, V94, P1050, DOI 10.1172/JCI117419; Bai LQ, 1996, J BIOL CHEM, V271, P5171; BRADBURY NA, 1994, AM J PHYSIOL, V267, pC1, DOI 10.1152/ajpcell.1994.267.1.C1; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; BRIGNONI M, 1995, J CELL SCI, V108, P1931; DING G, 1991, AM J PHYSIOL, V260, pC9, DOI 10.1152/ajpcell.1991.260.1.C9; FRANKI N, 1995, AM J PHYSIOL-CELL PH, V268, pC792, DOI 10.1152/ajpcell.1995.268.3.C792; FRANKI N, 1995, AM J PHYSIOL, V38, pC797; FujitaYoshigaki J, 1996, J BIOL CHEM, V271, P13130, DOI 10.1074/jbc.271.22.13130; Furuno M, 1996, AM J PHYSIOL-RENAL, V271, pF854, DOI 10.1152/ajprenal.1996.271.4.F854; FUSHIMI K, 1994, AM J PHYSIOL-RENAL, V267, pF573, DOI 10.1152/ajprenal.1994.267.4.F573; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; HANDLER JS, 1988, AM J PHYSIOL, V255, pF375, DOI 10.1152/ajprenal.1988.255.3.F375; HARRIS HW, 1991, J CLIN INVEST, V88, P1, DOI 10.1172/JCI115263; HARRIS HW, 1991, J AM SOC NEPHROL, V1, P1114; HAYASHI M, 1994, J CLIN INVEST, V94, P1778, DOI 10.1172/JCI117525; HAYS RM, 1987, KIDNEY INT, V31, P530, DOI 10.1038/ki.1987.32; HOLMGREN K, 1992, AM J PHYSIOL, V262, pC672, DOI 10.1152/ajpcell.1992.262.3.C672; Howard M, 1996, KIDNEY INT, V49, P1642, DOI 10.1038/ki.1996.239; JO IH, 1995, P NATL ACAD SCI USA, V92, P1876, DOI 10.1073/pnas.92.6.1876; KATSURA T, 1995, P NATL ACAD SCI USA, V92, P7212, DOI 10.1073/pnas.92.16.7212; KNEPPER MA, 1994, SEMIN NEPHROL, V14, P302; KUWAHARA M, 1995, J BIOL CHEM, V270, P10384, DOI 10.1074/jbc.270.18.10384; Lande MB, 1996, J BIOL CHEM, V271, P5552, DOI 10.1074/jbc.271.10.5552; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; MA TH, 1993, J BIOL CHEM, V268, P22756; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; Nishimoto G., 1996, Journal of the American Society of Nephrology, V7, P1271; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SABOLIC I, 1995, J MEMBRANE BIOL, V143, P165, DOI 10.1007/BF00233445; SASAKI S, 1994, J CLIN INVEST, V93, P1250, DOI 10.1172/JCI117079; SCHWIEBERT EM, 1994, AM J PHYSIOL, V267, pC272, DOI 10.1152/ajpcell.1994.267.1.C272; SIMON H, 1993, AM J PHYSIOL, V265, pC757, DOI 10.1152/ajpcell.1993.265.3.C757; Valenti G, 1996, J BIOL CHEM, V271, P24365, DOI 10.1074/jbc.271.40.24365; VERKMAN AS, 1992, ANNU REV PHYSIOL, V54, P97, DOI 10.1146/annurev.physiol.54.1.97; VERKMAN AS, 1989, J BIOL CHEM, V264, P20608; YAMAMOTO T, 1995, AM J PHYSIOL-CELL PH, V268, pC1546, DOI 10.1152/ajpcell.1995.268.6.C1546	38	366	371	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14800	14804		10.1074/jbc.272.23.14800	http://dx.doi.org/10.1074/jbc.272.23.14800			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169447	hybrid			2022-12-27	WOS:A1997XC32700044
J	Kamitani, T; Nguyen, HP; Yeh, ETH				Kamitani, T; Nguyen, HP; Yeh, ETH			Preferential modification of nuclear proteins by a novel ubiquitin-like molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA1 GENE-PRODUCT; SACCHAROMYCES-CEREVISIAE; GENERATION; HOMOLOGY; MIF2	Sentrin is a novel ubiquitin-like protein that protects cells against both anti-Fas and tumor necrosis factor-induced cell death. Antiserum recognizing the N terminus of sentrin revealed the presence of a 18-kDa sentrin monomer, a 90-kDa band (p90), and multiple high molecular mass bands, Because sentrin possesses the conserved Gly-Gly residues near the C terminus, it is likely that these additional bands represent conjugation of sentrin to other proteins in a manner that is similar to the ubiquitination pathway, Transient expression of hemagglutinin epitope-tagged sentrin mutants in COS cells demonstrated that the sentrin C terminus is cleaved, which allows it to be conjugated to other proteins via the conserved C-terminal Gly residue. Immunocytochemical staining and cell fractionation analysis demonstrated that sentrin monomer is localized pre dominantly to the cytosol, However, p90 and the majority of sentrinized proteins appeared to be localized to the nucleus, When the conserved Gly-Gly residues of sentrin were changed to Gly-Ala, only sentrin monomer and p90 but not the high molecular mass bands were observed, Thus, p90 generation appears to be required for the formation of high molecular mass bands in the nucleus, Taken together, sentrinization represents a novel pathway for nuclear protein modification, which is distinct from ubiquitination.	UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DIV MOL MED,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,INST MOL MED PREVENT HUMAN DIS,CARDIOVASC RES CTR,HOUSTON,TX 77030	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston			Kamitani, Tetsu/GSI-7613-2022	Kamitani, Tetsu/0000-0002-3257-9630	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045851] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45851] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMAHAJAN R, 1997, CELL, V88, P97; ATKINSON NS, 1985, MOL CELL BIOL, V5, P907, DOI 10.1128/MCB.5.5.907; Boddy MN, 1996, ONCOGENE, V13, P971; BROWN MT, 1993, J CELL BIOL, V123, P387, DOI 10.1083/jcb.123.2.387; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEGREGORI J, 1994, GENE DEV, V8, P265, DOI 10.1101/gad.8.3.265; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; HAAS AL, 1987, J BIOL CHEM, V262, P11315; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; HODGINS RRW, 1992, J BIOL CHEM, V268, P8807; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KAMITANI T, 1991, CLIN IMMUNOL IMMUNOP, V58, P217, DOI 10.1016/0090-1229(91)90138-Z; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MELCHIOR F, 1993, MOL BIOL CELL, V4, P569, DOI 10.1091/mbc.4.6.569; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; Narasimhan J, 1996, J BIOL CHEM, V271, P324, DOI 10.1074/jbc.271.1.324; Okura T, 1996, J IMMUNOL, V157, P4277; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SHNE Z, 1996, GENOMICS, V36, P271	23	150	154	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14001	14004		10.1074/jbc.272.22.14001	http://dx.doi.org/10.1074/jbc.272.22.14001			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162015	hybrid			2022-12-27	WOS:A1997XB49200002
J	Mercier, PA; Foksa, J; Ovsenek, N; Westwood, JT				Mercier, PA; Foksa, J; Ovsenek, N; Westwood, JT			Xenopus heat shock factor 1 is a nuclear protein before heat stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; DNA-BINDING; MOLECULAR-CLONING; LAEVIS OOCYTES; ACTIVATION; EXPRESSION; OLIGOMERIZATION; INVITRO; GENES; PHOSPHORYLATION	Stress-induced expression of the heat shock (hs) genes in eukaryotes is mediated by a transcription factor known as heat shock factor 1 (HSF1). HSF1 is present in a latent, monomeric form in unstressed metazoan cells and upon exposure to heat or other forms of stress is converted to an ''active'' trimeric form, which binds the promoters of hs genes and induces their transcription, The conversion of HSF1 to its active form is hypothesized to be a multistep process involving (i) oligomerization of HSF1, plus (ii) additional changes in its physical conformation, (iii) changes in its phosphorylation state, and for some species (iv) translocation from the cyto plasm to the nucleus, Oligomerization of HSF appears to be essential for high affinity DNA binding, but it remains unclear whether the other steps occur in all organisms or what their mechanistic roles are, In this study we have examined if heat-induced cytoplasmic-nuclear translocation of HSF1 occurs in Xenopus oocytes, We observed that germinal vesicles (nuclei) that were physically dissected from unshocked Xenopus laevis oocytes contain no HSF1 binding activity, Interestingly, in vitro heat shock treatments of isolated nuclei from unshocked oocytes activated HSF1 binding, indicating that HSF1 must have been present in the unshocked nuclei prior to isolation, Induction of HSF1 binding was not observed in enucleated oocytes, Western blot analysis using an affinity-purified polyclonal antibody made against X. laevis HSF1 showed that HSF1 is present in equal amounts in unshocked and shocked oocytes and isolated nuclei, HSF1 was not detected in enucleated oocytes, These results clearly demonstrate that HSF1 is a nuclear protein in oocytes prior to exposure to stress. In Xenopus oocytes, therefore, HSF1 translocation from the cytoplasm to the nucleus is not part of the multistep process of HSF1 activation, These results also imply that the signals and/or factors involved in HSF1 activation must have their effect in the nuclear compartment.	UNIV TORONTO,ERINDALE COLL,DEPT ZOOL,MISSISSAUGA,ON L5L 1C6,CANADA; UNIV SASKATCHEWAN,COLL MED,DEPT ANAT & CELL BIOL,SASKATOON,SK S7N 5E5,CANADA	University of Toronto; University Toronto Mississauga; University of Saskatchewan								ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; CHEN YQ, 1993, EMBO J, V12, P5007, DOI 10.1002/j.1460-2075.1993.tb06194.x; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; EPPIG JJ, 1976, IN VITRO CELL DEV B, V12, P173; FRYDMAN J, 1994, BIOL HEAT SHOCK PROT, P251; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GIARDINA C, 1995, MOL CELL BIOL, V15, P2737; GOODSON ML, 1995, J BIOL CHEM, V270, P2447, DOI 10.1074/jbc.270.6.2447; GOODSON ML, 1995, BIOCHEM BIOPH RES CO, V211, P943, DOI 10.1006/bbrc.1995.1903; Gordon S, 1997, DEV BIOL, V181, P47, DOI 10.1006/dbio.1996.8441; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; HOJ A, 1994, EMBO J, V13, P2617; KARN H, 1992, BIOCHEM CELL BIOL, V70, P1006, DOI 10.1139/o92-144; LANDSBERGER N, 1995, MOL CELL BIOL, V15, P6013; LARSON JS, 1995, BIOCHEMISTRY-US, V34, P1902, DOI 10.1021/bi00006a011; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; MAGER WH, 1995, MICROBIOL REV, V59, P506, DOI 10.1128/MMBR.59.3.506-531.1995; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; MEZGER V, 1994, DEV BIOL, V166, P819, DOI 10.1006/dbio.1994.1361; MIFFLIN LC, 1994, J BIOL CHEM, V269, P15710; Moore DD, 1995, GLOB MOB SURV; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT, P1; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; Orosz A, 1996, MOL CELL BIOL, V16, P7018; OVSENEK N, 1990, DEVELOPMENT, V110, P427; PAINE PL, 1992, BIOTECHNIQUES, V13, P238; Parsell D.A., 1994, BIOL HEAT SHOCK PROT, P457; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1994, BIOL REPROD, V50, P1334, DOI 10.1095/biolreprod50.6.1334; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHARF KD, 1990, EMBO J, V9, P4495, DOI 10.1002/j.1460-2075.1990.tb07900.x; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; STUMP DG, 1995, GENE, V160, P207, DOI 10.1016/0378-1119(95)00176-7; VOELLMY R, 1982, P NATL ACAD SCI-BIOL, V79, P1776, DOI 10.1073/pnas.79.6.1776; WALLACE RA, 1973, J EXP ZOOL, V184, P321, DOI 10.1002/jez.1401840305; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; Winegarden NA, 1996, J BIOL CHEM, V271, P26971, DOI 10.1074/jbc.271.43.26971; Wisniewski J, 1996, NUCLEIC ACIDS RES, V24, P367, DOI 10.1093/nar/24.2.367; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Wu C., 1994, BIOL HEAT SHOCK PROT, P395; ZIMARINO V, 1990, MOL CELL BIOL, V10, P752, DOI 10.1128/MCB.10.2.752; [No title captured]	48	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14147	14151		10.1074/jbc.272.22.14147	http://dx.doi.org/10.1074/jbc.272.22.14147			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162043	hybrid			2022-12-27	WOS:A1997XB49200030
J	Tornero, P; Conejero, V; Vera, P				Tornero, P; Conejero, V; Vera, P			Identification of a new pathogen-induced member of the subtilisin-like processing protease family from plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS; PROPROTEIN CONVERTASE; SERINE-PROTEASE; TOMATO; PROTEINS; ENDOPROTEASES; LOCALIZATION; DEGRADATION; EXPRESSION; INFECTION	By using biochemical, immunological, and molecular strategies we have identified and cloned a cDNA encoding a protease from tomato (Lycopersicon esculentum) plants (P69B) that is part of a proteolytic system activated in the plant as a result of infection with citrus exocortis viroid, This new protease is closely related, in terms of amino acid sequence and structural organization, to the previously identified pathogenesis-related subtilisin-like protease (Tornero, P,, Conejero, V,, and Vera, P, (1996) Proc, Natl, Acad, Sci, U.S.A. 93, 6332 - 6337), The 745-residue amino acid sequence of P69B begins with a cleavable signal peptide, contains a prodomain and a 631-residue mature domain which is homologous 60 the catalytic modules of bacterial subtilisins and eukaryotic Kex2-like proteases, Within the catalytic domain, the essential Asp, His, and Ser residues that conform the catalytic triad of this family of proteases are conserved in P69B, Northern blot and reverse transcriptase-polymerase chain reaction analysis demonstrated widespread induced expression of the 2.5-kilobase hybridizing mRNA in plant tissues as a consequence of viroid infection, We propose that P69B is a member of a complex gene family of plant Kex2/subtilisin-like proteases presumably involved in a number of specific proteolytic events activated during pathogenesis in plants and that takes place in the extracellular matrix.	UNIV POLITECN VALENCIA, CSIC, IBMCP, E-46022 VALENCIA, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); Universitat Politecnica de Valencia; CSIC-UPV - Instituto de Biologia Molecular y Celular de Plantas (IBMCP)			Conejero, Vicente/H-9027-2015	Conejero, Vicente/0000-0002-3516-350X; Vera, Pablo/0000-0002-7787-7519; Tornero, Pablo/0000-0001-9755-7726				Alexander CM, 1991, CELL BIOL EXTRACELLU, P255; An YQ, 1996, PLANT CELL, V8, P15, DOI 10.1105/tpc.8.1.15; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BOL JF, 1990, ANNU REV PHYTOPATHOL, V28, P113, DOI 10.1146/annurev.py.28.090190.000553; BOWLES DJ, 1990, ANNU REV BIOCHEM, V59, P873, DOI 10.1146/annurev.bi.59.070190.004301; Chen Wen-Tien, 1992, Current Opinion in Cell Biology, V4, P802; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CONEJERO V, 1990, NATO ASI SERIES H, V14, P233; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Diener T.O., 1987, VIROIDS; DIXON RA, 1990, ANNU REV PLANT PHYS, V41, P339, DOI 10.1146/annurev.pp.41.060190.002011; FRASER RSS, 1989, BIOCH VIRUS INFECTED; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GOMEZSALADIN E, 1994, CELL MOL NEUROBIOL, V14, P9, DOI 10.1007/BF02088586; Goodman R. N., 1994, HYPERSENSITIVE REACT; HATTONI M, 1987, ANAL BIOCHEM, V152, P232; HAYFLICK JS, 1992, J NEUROSCI, V12, P705; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; MATILE P, 1975, LYTIC COMPARTMENT PL; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; PAUTOT V, 1993, P NATL ACAD SCI USA, V90, P9906, DOI 10.1073/pnas.90.21.9906; RIBEIRO A, 1995, PLANT CELL, V7, P785, DOI 10.1105/tpc.7.6.785; RODRIGO I, 1989, EUR J BIOCHEM, V184, P663, DOI 10.1111/j.1432-1033.1989.tb15064.x; RODRIGO I, 1991, PLANT PHYSIOL, V95, P616, DOI 10.1104/pp.95.2.616; ROEBROEK AJM, 1992, J BIOL CHEM, V267, P17208; ROEBROEK AJM, 1993, EMBO J, V12, P1853, DOI 10.1002/j.1460-2075.1993.tb05834.x; Rogers SO, 1988, PLANT MOL BIOL MAN A, VA6, P1, DOI DOI 10.1007/978-94-017-5294-7_; Schaller A, 1996, PLANT MOL BIOL, V31, P1073, DOI 10.1007/BF00040725; SCHALLER A, 1994, P NATL ACAD SCI USA, V91, P11802, DOI 10.1073/pnas.91.25.11802; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; SEMANCIK JS, 1987, VIROID VIROID LIKE P, P72; SEMANCIK JS, 1987, VIROIDS VIROID LIKE; STEINER DF, 1992, J BIOL CHEM, V267, P23435; THACKER C, 1995, GENE DEV, V9, P956, DOI 10.1101/gad.9.8.956; Tornero P, 1996, P NATL ACAD SCI USA, V93, P6332, DOI 10.1073/pnas.93.13.6332; Tornero P, 1996, PLANT J, V10, P315, DOI 10.1046/j.1365-313X.1996.10020315.x; VERA P, 1989, PLANT PHYSIOL, V91, P119, DOI 10.1104/pp.91.1.119; VERA P, 1988, PLANT PHYSIOL, V87, P58, DOI 10.1104/pp.87.1.58; VERA P, 1993, MOL PLANT MICROBE IN, V6, P790; VERA P, 1989, PHYSIOL MOL PLANT P, V34, P323, DOI 10.1016/0885-5765(89)90029-5; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YAMAGATA H, 1994, J BIOL CHEM, V269, P32725; ZAITLIN M, 1987, ANNU REV PLANT PHYS, V38, P291, DOI 10.1146/annurev.pp.38.060187.001451; ZHOU A, 1995, J BIOL CHEM, V270, P21509, DOI 10.1074/jbc.270.37.21509	47	114	120	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14412	14419		10.1074/jbc.272.22.14412	http://dx.doi.org/10.1074/jbc.272.22.14412			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162080	hybrid			2022-12-27	WOS:A1997XB49200067
J	Krupsky, M; Kuang, PP; Goldstein, RH				Krupsky, M; Kuang, PP; Goldstein, RH			Regulation of type I collagen mRNA by amino acid deprivation in human lung fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DERMAL FIBROBLASTS; GROWTH FACTOR-BETA; GENE-EXPRESSION; MESSENGER-RNA; ASPARAGINE SYNTHETASE; RETINOIC ACID; MOLECULAR-CLONING; INTERFERON-GAMMA; INHIBITION; CELLS	The steady state levels of alpha 1(I) collagen mRNA are decreased by retinoic acid and prostaglandin E-2. These effector substances decrease the uptake of A system amino acids. We examined the effect of amino acid deprivation on the steady state levels of alpha 1(I) collagen in human lung fibroblasts, Maintenance of fibroblasts in amino acid-free medium decreased alpha 1(I) collagen mRNA levels by 29% at 24 h and 78% at 72 h. Frequent refeeding of cultures with amino acid-free medium resulted in more rapid decreases in intracellular amino acids and in alpha 1(I) collagen mRNA levels. The decrease in alpha 1(I) collagen mRNA levels was mediated by decreases in mRNA stability as assessed by a half-life determination using actinomycin D and by decreases in the rate of transcription as assessed by nuclear run on assay. Treatment of fibroblasts with medium containing amino acids resulted in rapid restoration of alpha 1(I) collagen mRNA levels. This increase in alpha 1(I) collagen mRNA expression required protein synthesis as determined by cycloheximide sensitivity and was inhibited by prostaglandin E-2. These data indicate that alpha 1(I) collagen mRNA levels are sensitive to alterations in the amount of intracellular amino acids and suggest a potential mechanism whereby alpha 1(I) collagen accumulation may be regulated independent of inflammatory mediators following lung injury.	BOSTON UNIV,SCH MED,CTR PULM,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; VET AFFAIRS MED CTR,BOSTON,MA 02118	Boston University; Boston University; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NHLBI NIH HHS [P50HL56386] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056386] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRULIS IL, 1979, J BIOL CHEM, V254, P629; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CZAJA MJ, 1987, J BIOL CHEM, V262, P13348; DHAWAN J, 1991, J BIOL CHEM, V266, P8470; ECHES B, 1993, FEBS LETT, V318, P129; FINE A, 1987, J BIOL CHEM, V262, P3897; FINE A, 1989, J BIOL CHEM, V264, P16988; FINE A, 1992, BIOCHIM BIOPHYS ACTA, V1135, P67, DOI 10.1016/0167-4889(92)90167-A; GENOVESE C, 1984, BIOCHEMISTRY-US, V23, P6210, DOI 10.1021/bi00320a049; GOLDSTEIN RH, 1989, ENDOCRINOLOGY, V124, P964, DOI 10.1210/endo-124-2-964; GOLDSTEIN RH, 1984, PROSTAGLANDINS, V28, P717, DOI 10.1016/0090-6980(84)90180-1; GOLDSTEIN RH, 1986, J BIOL CHEM, V261, P8734; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; GUIDOTTI GG, 1978, BIOCHIM BIOPHYS ACTA, V515, P329, DOI 10.1016/0304-4157(78)90009-6; HUTSON RG, 1994, BIOCHEM J, V304, P745, DOI 10.1042/bj3040745; JIMENEZ SA, 1984, J CLIN INVEST, V74, P1112, DOI 10.1172/JCI111480; JONES DT, 1987, J BIOL CHEM, V262, P14241; KILBERG MS, 1994, FASEB J, V8, P13, DOI 10.1096/fasebj.8.1.8299885; KRUPSKY M, 1994, BBA-GENE STRUCT EXPR, V1219, P335, DOI 10.1016/0167-4781(94)90057-4; KRUPSKY M, 1993, J BIOL CHEM, V268, P23283; Lucey EC, 1996, LAB INVEST, V74, P12; MOORE PA, 1977, J BIOL CHEM, V252, P7427; ONEILL L, 1991, CARDIOSCIENCE, V2, P1; REDLICH CA, 1995, AM J RESP CELL MOL, V12, P287, DOI 10.1165/ajrcmb.12.3.7873195; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; Roy R, 1996, J CELL BIOCHEM, V62, P411, DOI 10.1002/(SICI)1097-4644(199609)62:3<411::AID-JCB11>3.0.CO;2-L; SCORNIK OA, 1984, FED PROC, V43, P1283; SHAY NF, 1990, J BIOL CHEM, V265, P17844; Snedecor G.W., 1967, STAT METHODS; THISSEN JP, 1994, ENDOCRINOLOGY, V134, P1570, DOI 10.1210/en.134.3.1570; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; VARGA J, 1987, BIOCHEM BIOPH RES CO, V147, P1282, DOI 10.1016/S0006-291X(87)80209-7; VARGA J, 1995, J CLIN INVEST, V96, P475, DOI 10.1172/JCI118058; YUFIT T, 1995, J INVEST DERMATOL, V105, P388, DOI 10.1111/1523-1747.ep12320990	38	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13864	13868		10.1074/jbc.272.21.13864	http://dx.doi.org/10.1074/jbc.272.21.13864			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153245	hybrid			2022-12-27	WOS:A1997XA06200060
J	Shrode, LD; Rubie, EA; Woodgett, JR; Grinstein, S				Shrode, LD; Rubie, EA; Woodgett, JR; Grinstein, S			Cytosolic alkalinization increases stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK) activity and p38 mitogen-activated protein kinase activity by a calcium-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; CELL-VOLUME REGULATION; NA+/H+ ANTIPORTER; INTRACELLULAR PH; HEAT-SHOCK; PHOSPHORYLATION; JNK; REPERFUSION; LYMPHOCYTES; INHIBITION	Stress-activated protein kinases (SAPK) are stimulated by a variety of agents and conditions that also activate the Na+/H+ exchanger (NHE). Activation of the exchanger results in a rapid increase in intracellular pH (pH(i)), raising the possibility that cytosolic alkalinization may contribute to SAPK activation. This hypothesis was tested by manipulating the pH(i) of U937 cells using permeant weak bases. Three different bases increased pH(i) and caused a 4-12-fold increase in SAPK activity with a time course that paralleled intracellular alkalinization. p38, a related stress kinase, was also stimulated by the weak bases. Stimulation of the stress kinases was not accompanied by changes in cytosolic free calcium nor was the activation of SAPK achieved when calcium was elevated by thapsigargin or calcium ionophores. Weak bases not only alter the pH of the cytosol but also alkalinize endomembrane compartments such as endosomes and lysosomes. However, the latter do not appear to mediate the stimulation of SAPK since neither bafilomycin A(1) nor desipramine, agents that neutralize acidic endomembrane compartments, activated the kinase. Because hyperosmolarity acutely activates the NHE, we considered whether the resulting cytosolic alkalinization mediates the activation of SAPK upon cell shrinkage. The addition of amiloride or the omission of Na+, which were verified to inhibit NHE, did not prevent the osmotically induced activation of SAPK. We conclude that cytosolic alkalinization increases the activity of SAPK and p38 by a calcium-independent mechanism that does not involve acidic intracellular organelles. In addition, even though cell shrinkage is accompanied by alkalinization due to the activation of NHE, the increased pH(i) is not the main cause of the observed stimulation of SAPK upon hyperosmotic challenge.	HOSP SICK CHILDREN,DIV CELL BIOL,TORONTO,ON M5G 1X8,CANADA; PRINCESS MARGARET HOSP,ONTARIO CANC INST,TORONTO,ON M5G 2M9,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre			Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797; Shrode, Lamara/0000-0003-4737-431X				ANDIEU N, 1994, BIOCHEM J, V303, P341; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; CHAMBERLIN ME, 1989, AM J PHYSIOL, V257, pC159, DOI 10.1152/ajpcell.1989.257.2.C159; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1018; GRINSTEIN S, 1993, EMBO J, V12, P5209, DOI 10.1002/j.1460-2075.1993.tb06216.x; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; KITAMURA K, 1995, AM J PHYSIOL-CELL PH, V268, pC101, DOI 10.1152/ajpcell.1995.268.1.C101; KLEIN HH, 1995, CIRCULATION, V92, P912, DOI 10.1161/01.CIR.92.4.912; KWON HM, 1994, CELLULAR MOL PHYSL C; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1995, ANN NY ACAD SCI, V766, P303, DOI 10.1111/j.1749-6632.1995.tb26683.x; LEE YY, 1992, BLOOD, V79, P2262; LUDT J, 1993, J MEMBRANE BIOL, V134, P143; MACDOUGALL SL, 1988, CELL, V54, P229, DOI 10.1016/0092-8674(88)90555-7; MILLER RT, 1987, BIOCHIM BIOPHYS ACTA, V900, P157, DOI 10.1016/0005-2736(87)90287-2; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOROOKA H, 1995, J BIOL CHEM, V270, P30084; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; PAREDES A, 1992, AM J PHYSIOL, V263, pC1282, DOI 10.1152/ajpcell.1992.263.6.C1282; Pelech SL, 1996, CURR BIOL, V6, P551, DOI 10.1016/S0960-9822(02)00540-7; POMBO CM, 1994, J BIOL CHEM, V269, P26546; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; ROZANSKI GJ, 1994, AM J PHYSIOL-HEART C, V267, pH1361; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; YAN MH, 1994, NATURE, V372, P798; [No title captured]	41	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13653	13659		10.1074/jbc.272.21.13653	http://dx.doi.org/10.1074/jbc.272.21.13653			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153215	hybrid			2022-12-27	WOS:A1997XA06200030
J	Xie, LJ; Gross, SS				Xie, LJ; Gross, SS			Argininosuccinate synthetase overexpression in vascular smooth muscle cells potentiates immunostimulant-induced NO production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	1996 ASBMB Meeting	JUN 02-06, 1996	NEW ORLEANS, LA	ASBMB			NITRIC-OXIDE SYNTHASE; L-ARGININE; RELAXING FACTOR; MESSENGER-RNA; ENDOTHELIAL-CELLS; L-CITRULLINE; UREA CYCLE; BIOSYNTHESIS; EXPRESSION; MEMBRANE	Immunostimulants trigger vascular smooth muscle cells (VSMC) to express both the inducible isoform of NO synthase (iNOS) and argininosuccinate synthetase (AS). With constitutively expressed argininosuccinate lyase (AL), AS confers cells with an Arg/Cit cycle that can sustain NO production via continuous regeneration of the NOS substrate, L-arginine (Arg), from the NOS coproduct, L-citrulline (Cit). To assess whether NO synthesis can be rate-limited by Arg recycling, we tested whether AS-overexpressing cells have an enhanced capacity for immununostimulant-induced NO synthesis. Rat VSMC were stably transfected with human AS cDNA in a eukaryotic cell expression vector, driven by a strong viral promoter. AS activity in transfected VSMC exceeded that induced in untransfected cells treated for 24 h with a combination of bacterial lipopolysaccharide and interferon-gamma (LPS/IFN). AS activity was predominantly associated with membranes but was also found in cytosol. Recombinant AS was purified from cytosol and possessed a specific activity exceeding that reported for native AS. Western blotting verified the basal expression of AS antigen in membranes from untreated AS-transfected VSMC and from untransfected VSMC after 24 h exposure to LPS/IFN. Epifluorescence histochemistry revealed a punctate distribution of AS antigen in transfected cells, consistent with a predominant membrane localization. Remarkably, on a per cell basis, LPS/IFN-induced NO production was 3-4-fold greater in AS-transfected cells than untransfected VSMC. In untransfected VSMC, maximal NO production during 48 h required millimolar Arg; notably, Cit was needed at approximate to 3-fold higher concentrations than Arg for a comparable NO synthesis rate. In contrast, AS-transfected VSMC utilized Arg and Cit equi-effectively and at much lower concentrations; 100 mu M of either precursor supported a maximal rate of NO synthesis for 48 h. The enhanced ability of AS-transfected cells to produce NO, compared with untransfected cells, could not be ascribed to differences in iNOS protein content or LPS/IFN potency for immunoactivation. We conclude that transfection with AS provides a continuous flux of Arg which drives NO synthesis in immunoactivated VSMC. Arg regeneration by AS is rate-limiting to NO synthesis and apparently provides iNOS with a preferred cellular source of Arg. In accord with the reported ''channeling'' of substrates by urea cycle enzymes, we hypothesize that the Arg/Cit cycle sequesters a discrete pool of recyclable substrate that sustains high-output NO synthesis.	CORNELL UNIV, COLL MED, DEPT PHARMACOL, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, PROGRAM BIOCHEM & STRUCT BIOL, NEW YORK, NY 10021 USA	Cornell University; Cornell University					NHLBI NIH HHS [HL50656, HL 46403] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050656, P01HL046403] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHEUNG CW, 1989, J BIOL CHEM, V264, P4038; DEMARQUOY J, 1994, MOL CELL BIOCHEM, V136, P145, DOI 10.1007/BF00926075; FAKLER CR, 1995, ACTA PAEDIATR, V84, P460, DOI 10.1111/j.1651-2227.1995.tb13673.x; Fiske CH, 1925, J BIOL CHEM, V66, P375; FLODSTROM M, 1995, ENDOCRINOLOGY, V136, P3200, DOI 10.1210/en.136.8.3200; FREYTAG SO, 1984, MOL CELL BIOL, V4, P1978, DOI 10.1128/MCB.4.10.1978; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GROSS SS, 1990, BIOCHEM BIOPH RES CO, V170, P96, DOI 10.1016/0006-291X(90)91245-N; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HATTORI Y, 1994, J BIOL CHEM, V269, P9405; HATTORI Y, 1995, BIOCHEM BIOPH RES CO, V215, P148, DOI 10.1006/bbrc.1995.2445; HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612; HISHIKAWA K, 1992, JPN HEART J, V33, P41; KANNO K, 1992, CLIN EXP PHARMACOL P, V19, P619, DOI 10.1111/j.1440-1681.1992.tb00514.x; KILBOURN RG, 1992, J NATL CANCER I, V84, P827, DOI 10.1093/jnci/84.11.827; KIMBALL ME, 1980, BIOCHEMISTRY-US, V19, P705, DOI 10.1021/bi00545a015; MITCHELL JA, 1990, EUR J PHARMACOL, V176, P253, DOI 10.1016/0014-2999(90)90541-D; MORRIS SM, 1992, ANNU REV NUTR, V12, P81, DOI 10.1146/annurev.nu.12.070192.000501; Nagasaki A, 1996, J BIOL CHEM, V271, P2658, DOI 10.1074/jbc.271.5.2658; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NORTHRUP H, 1989, GENOMICS, V5, P442, DOI 10.1016/0888-7543(89)90007-4; NUSSLER AK, 1994, J BIOL CHEM, V269, P1257; OBRIEN WE, 1979, BIOCHEMISTRY-US, V18, P5353, DOI 10.1021/bi00591a015; Rengasamy A, 1996, J PHARMACOL EXP THER, V276, P30; RENGASAMY A, 1991, J PHARMACOL EXP THER, V259, P310; ROCHOVANSKY O, 1977, J BIOL CHEM, V252, P5287; SADRZADEH SM, 1994, CELL, V78, P915; SADRZADEH SMH, 1993, J PHARMACOL TOXICOL, V30, P103, DOI 10.1016/1056-8719(93)90013-5; SAHEKI T, 1977, J BIOCHEM, V81, P687, DOI 10.1093/oxfordjournals.jbchem.a131505; SHUTTLEWORTH CWR, 1995, NEUROSCIENCE, V68, P1295, DOI 10.1016/0306-4522(95)00193-M; SU TS, 1981, J BIOL CHEM, V256, P1826; SU YC, 1995, AM J PHYSIOL-LUNG C, V269, pL581, DOI 10.1152/ajplung.1995.269.5.L581; Takiguchi M, 1995, BIOCHEM J, V312, P649, DOI 10.1042/bj3120649; VODOVOTZ Y, 1995, J IMMUNOL, V154, P2914; WATFORD M, 1991, ESSAYS BIOCHEM, V26, P49; YU YJ, 1995, J BIOCHEM-TOKYO, V117, P952, DOI 10.1093/oxfordjournals.jbchem.a124826	37	61	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16624	16630		10.1074/jbc.272.26.16624	http://dx.doi.org/10.1074/jbc.272.26.16624			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	XG019	9195976	hybrid			2022-12-27	WOS:A1997XG01900080
J	Carlberg, K; Rohrschneider, LR				Carlberg, K; Rohrschneider, LR			Characterization of a novel tyrosine phosphorylated 100-kDa protein that binds to SHP-2 and phosphatidylinositol 3'-kinase in myeloid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; INSULIN-RECEPTOR SUBSTRATE-1; SRC HOMOLOGY-2 DOMAINS; GROWTH-FACTOR; SH2 DOMAINS; HEMATOPOIETIC-CELLS; SIGNAL-TRANSDUCTION; SYP PHOSPHATASE; KINASE-ACTIVITY	Fms is a tyrosine kinase-containing receptor for macrophage colony-stimulating factor (M-CSF) that regulates survival, growth, and differentiation of cells along the monocyte/macrophage lineage. M-CSF stimulation of murine myeloid FDC-P1 cells expressing Fms resulted in the tyrosine phosphorylation of a number of signal transduction proteins, including an unidentified 100-kDa protein. This 100-kDa protein associated with the tyrosine phosphatase SHP-2 but not with the related phosphatase SHP-1. The kinetics of tyrosine phosphorylation of p100 and SHP-2 suggest that p100 may be a direct substrate of SHP-2. p100 bound directly to the SH2 domains of both SHP-2 and the p85 subunit of phosphatidylinositol 3'-kinase. The 100-kDa protein did not appear to bind directly to Fms, Ship, Cbl, She, or Grb2, although all of these proteins were coimmunoprecipitated with p85 lifter M-CSF stimulation. Association of p100 with SHP-2 and p85 did not require the major autophosphorylation sites on Fms nor binding of p85 to Fms, A tyrosine phosphorylated protein of 100 kDa also coprecipitated with SHP-2 from several ether myeloid cell lines after M-CSF stimulation but was not seen in immunoprecipitates from Rata fibroblasts expressing Fms. Stimulation of FDC-P1 cells with additional cytokines also resulted in coprecipitation of a 100-kDa protein with SHP-2. p100 may therefore be a common component of the signaling pathways of cytokine receptors in myeloid cells.			Carlberg, K (corresponding author), FRED HUTCHINSON CANC RES CTR, DIV BASIC SCI, 1100 FAIRVIEW AVE N, B2-152, POB 19024, SEATTLE, WA 98109 USA.				NATIONAL CANCER INSTITUTE [R01CA040987, R01CA020551] Funding Source: NIH RePORTER; NCI NIH HHS [CA40987, CA20551] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Allard JD, 1996, DEVELOPMENT, V122, P1137; ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; CARLBERG K, 1994, MOL BIOL CELL, V5, P81, DOI 10.1091/mbc.5.1.81; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FUHRER DK, 1995, J BIOL CHEM, V270, P24826, DOI 10.1074/jbc.270.42.24826; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; Kanagasundaram V, 1996, BIOCHEM J, V320, P69, DOI 10.1042/bj3200069; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; KUHNE MR, 1994, J BIOL CHEM, V269, P15833; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Lorenz U, 1996, J EXP MED, V184, P1111, DOI 10.1084/jem.184.3.1111; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MU SX, 1995, BLOOD, V86, P4532, DOI 10.1182/blood.V86.12.4532.bloodjournal86124532; Noguchi T, 1996, J BIOL CHEM, V271, P27652, DOI 10.1074/jbc.271.44.27652; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Nolte RT, 1996, NAT STRUCT BIOL, V3, P364, DOI 10.1038/nsb0496-364; Novak U, 1996, ONCOGENE, V13, P2607; Paulson RF, 1996, NAT GENET, V13, P309, DOI 10.1038/ng0796-309; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; RETTENMIER CW, 1985, SCIENCE, V228, P320, DOI 10.1126/science.2580348; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; ROHRSCHNEIDER LR, 1989, ONCOGENE, V4, P1015; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; SEELY BL, 1995, J BIOL CHEM, V270, P19151, DOI 10.1074/jbc.270.32.19151; SENGUPTA A, 1988, P NATL ACAD SCI USA, V85, P8062, DOI 10.1073/pnas.85.21.8062; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TAPLEY P, 1990, MOL CELL BIOL, V10, P2528, DOI 10.1128/MCB.10.6.2528; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; TSUI FWL, 1994, IMMUNOL REV, V138, P185, DOI 10.1111/j.1600-065X.1994.tb00852.x; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; YAMAUCHI K, 1995, J BIOL CHEM, V270, P14871, DOI 10.1074/jbc.270.25.14871; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZE W, 1993, MOL CELL BIOL, V13, P5348, DOI 10.1128/MCB.13.9.5348; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	66	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15943	15950		10.1074/jbc.272.25.15943	http://dx.doi.org/10.1074/jbc.272.25.15943			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188495	hybrid			2022-12-27	WOS:A1997XF32900055
J	Fago, A; Bendixen, E; Malte, H; Weber, RE				Fago, A; Bendixen, E; Malte, H; Weber, RE			The anodic hemoglobin of Anguilla anguilla - Molecular basis for allosteric effects in a root-effect hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; FISH PAGOTHENIA-BERNACCHII; OXYGEN-BINDING PROPERTIES; LIGAND-BINDING; SINGLE HEMOGLOBIN; STEREOCHEMISTRY; AFFINITY; MACROMOLECULES; COOPERATIVITY; ACCLIMATION	The functional and structural basis for the Root effect has been investigated in the anodic hemoglobin of the European eel, Anguilla anguilla., This hemoglobin exhibits a large Bohr effect, which is accounted for by oxygen-linked binding of seven to eight protons in the presence of GTP at pH 7.5. Oxygen equilibrium curves show nonlinear lower asymptote of Hill plots, indicating the occurrence of heme-heme interactions within the T state, Analysis of the curves according to the co-operon model (Brunori, M., Coletta, M., and Di Cera, E. (1986) Biophys., Chem. 23, 215-222) reveals that T state cooperativity is positive at high pH and in the stripped hemoglobin (where the T --> R allosteric transition is operative) and. negative at low pH and in the presence of organic phosphate (where the molecule is locked in the low affinity structure), indicating site heterogeneity. The complete amino acid sequence of eel anodic hemo-globin has been established and compared with that of other fish hemoglobins. The presence of the Root effect correlates with a specific configuration of the alpha(1) beta(2) switch interface, which at low pH would stabilize subunit ligation in the T state without changing the quaternary structure, We propose that the major groups in volved in the binding of oxygen linked protons in eel anodic hemoglobin are located on the beta chain and comprise His-HC3 at the C terminus, His-FG4 at the switch interface, and Lys-EFG and the N terminus at the phosphate-binding site.	UNIV AARHUS, DEPT MOL BIOL, DK-8000 AARHUS C, DENMARK	Aarhus University	Fago, A (corresponding author), UNIV AARHUS, DEPT ZOOPHYSIOL, INST BIOL SCI, BLDG 131, DK-8000 AARHUS C, DENMARK.		Malte, Hans/J-6018-2013; Fago, Angela/J-5946-2013	Fago, Angela/0000-0001-7315-2628				ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; ALLEN G, 1981, LABORATORY TECHNIQUE, P43; ARATA Y, 1995, BBA-PROTEIN STRUCT M, V1247, P24, DOI 10.1016/0167-4838(94)00196-N; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BARRA D, 1983, BIOCHIM BIOPHYS ACTA, V742, P72, DOI 10.1016/0167-4838(83)90360-6; BELLELLI A, 1992, OXYGEN TRANSPORT BIO, P102; Bettati S, 1996, PROTEINS, V25, P425, DOI 10.1002/(SICI)1097-0134(199608)25:4<425::AID-PROT3>3.3.CO;2-A; BRUNORI M, 1986, BIOPHYS CHEM, V23, P215, DOI 10.1016/0301-4622(86)85006-2; BRUNORI M, 1978, P NATL ACAD SCI USA, V75, P4310, DOI 10.1073/pnas.75.9.4310; CAMARDELLA L, 1992, J MOL BIOL, V224, P449, DOI 10.1016/0022-2836(92)91007-C; DAUGHERTY MA, 1994, BIOCHEMISTRY-US, V33, P10345, DOI 10.1021/bi00200a015; DAVINO R, 1994, J BIOL CHEM, V269, P9675; DAVINO R, 1992, POLAR BIOL, V12, P135, DOI 10.1007/BF00239974; EDELSTEIN SJ, 1976, J BIOL CHEM, V251, P7632; FAGO A, 1992, EUR J BIOCHEM, V210, P963, DOI 10.1111/j.1432-1033.1992.tb17501.x; FAGO A, 1995, J BIOL CHEM, V270, P18897, DOI 10.1074/jbc.270.32.18897; FAGO A, 1993, EUR J BIOCHEM, V218, P829, DOI 10.1111/j.1432-1033.1993.tb18438.x; FANELLI AR, 1958, BIOCHIM BIOPHYS ACTA, V30, P608, DOI 10.1016/0006-3002(58)90108-2; Giardina B, 1981, Methods Enzymol, V76, P417; GILL SJ, 1986, BIOPHYS J, V50, P747, DOI 10.1016/S0006-3495(86)83514-7; GILLEN RG, 1977, ARCH BIOCHEM BIOPHYS, V183, P678, DOI 10.1016/0003-9861(77)90401-5; GRONENBORN AM, 1984, J MOL BIOL, V178, P731, DOI 10.1016/0022-2836(84)90249-3; HAYASHI A, 1973, BIOCHIM BIOPHYS ACTA, V310, P309, DOI 10.1016/0005-2795(73)90110-4; IKEDASAITO M, 1983, J MOL BIOL, V168, P673, DOI 10.1016/S0022-2836(83)80308-8; IMAI K, 1982, ALLOSTERIC EFFECTS H, P87; ITO N, 1995, J MOL BIOL, V250, P648, DOI 10.1006/jmbi.1995.0405; LICATA VJ, 1993, PROTEINS, V17, P279, DOI 10.1002/prot.340170306; LUISI BF, 1986, NATURE, V320, P555, DOI 10.1038/320555a0; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Mylvaganam SE, 1996, NAT STRUCT BIOL, V3, P275, DOI 10.1038/nsb0396-275; NOBLE RW, 1970, J BIOL CHEM, V245, P6628; NOBLE RW, 1986, BIOCHIM BIOPHYS ACTA, V870, P552, DOI 10.1016/0167-4838(86)90265-7; Paoli M, 1996, J MOL BIOL, V256, P775, DOI 10.1006/jmbi.1996.0124; PARKHURST LJ, 1984, BIOCHEMISTRY-US, V23, P2180, DOI 10.1021/bi00305a012; PELLEGRINI M, 1995, EUR J BIOCHEM, V234, P431, DOI 10.1111/j.1432-1033.1995.431_b.x; Pelster B., 1991, Advances in Comparative and Environmental Physiology, V8, P51; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1994, J MOL BIOL, V239, P555, DOI 10.1006/jmbi.1994.1394; PERUTZ MF, 1985, J MOL BIOL, V183, P491, DOI 10.1016/0022-2836(85)90016-6; PERUTZ MF, 1982, NATURE, V299, P421, DOI 10.1038/299421a0; RIVETTI C, 1993, BIOCHEMISTRY-US, V32, P2888, DOI 10.1021/bi00062a021; SCHOLANDER PF, 1954, BIOL BULL, V107, P247, DOI 10.2307/1538611; SOTTRUPJENSEN L, 1993, BIOCHEM MOL BIOL INT, V30, P789; TAMBURRINI M, 1992, ARCH BIOCHEM BIOPHYS, V292, P295, DOI 10.1016/0003-9861(92)90082-8; Tamburrini M, 1996, J BIOL CHEM, V271, P23780, DOI 10.1074/jbc.271.39.23780; Tame JRH, 1996, J MOL BIOL, V259, P749, DOI 10.1006/jmbi.1996.0355; TETENS V, 1984, J EXP BIOL, V109, P265; Weber R.E., 1989, LUNG BIOL HLTH DIS C, P279; WEBER RE, 1987, J COMP PHYSIOL B, V157, P145, DOI 10.1007/BF00692358; WEBER RE, 1990, COMP PHYSIOL, V6, P58; WEBER RE, 1981, NATURE, V292, P386, DOI 10.1038/292386a0; WEBER RE, 1976, J EXP BIOL, V64, P75; WEBER RE, 1993, J APPL PHYSIOL, V75, P2646, DOI 10.1152/jappl.1993.75.6.2646; WEBER RE, 1982, EXOGENOUS ENDOGENOUS, V1, P87; Weber Roy E., 1996, P75; WOOD SC, 1972, NATURE-NEW BIOL, V237, P278, DOI 10.1038/newbio237278a0; WYMAN J, 1984, Q REV BIOPHYS, V17, P453, DOI 10.1017/S0033583500004881	57	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15628	15635		10.1074/jbc.272.25.15628	http://dx.doi.org/10.1074/jbc.272.25.15628			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188451	hybrid			2022-12-27	WOS:A1997XF32900011
J	Hottenrott, S; Schumann, T; Pluckthun, A; Fischer, G; Rahfeld, JU				Hottenrott, S; Schumann, T; Pluckthun, A; Fischer, G; Rahfeld, JU			The Escherichia coli SlyD is a metal ion-regulated peptidyl-prolyl cis/trans-isomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; FK506-BINDING PROTEINS; BINDING PROTEIN; GENE; HYPB; LSP; HYDROGENASES; COMPLEX; FKBP	In Escherichia coli as many as nine different genes coding for proteins with significant homology to peptidyl-prolyl cis/trans-isomerases (PPIases) have been found, However, for three of them, the histidine-rich SlyD, the homologous gene product of ORF149, and parvulin-like SurA, it was not known whether these proteins really possess PPIase activity, To gain access to the full set of PPIases in E. coli, SlyD, the N-terminal fragment of SlyD devoid of the histidine-rich region, as well as the protein product of ORF149 of E. coli named SlpA (SlyD-like protein) were cloned, overexpressed, and purifled to apparent homogeneity. On the basis of the amino acid sequences, both proteins proved to be of the FK506-binding protein type of PPIases, Only when using trypsin instead of chymotrypsin as helper enzyme in the PPIase assay, the enzymatic activity of full length SlyD and its N-terminal fragment can be measured, For Suc-Ala-Phe-Pro-Arg-4-nitroanilide as substrate, k(cat)/K-m of 29,600 M-1 s(-1) for SlyD and 18,600 m(-1) s(-1) for the N-terminal fragment were obtained, Surprisingly, the PPIase activity of SlyD is reversibly regulated by binding of three Ni2+ ions to the histidine-rich, C-terminal region, Because the PPIase activity of SlpA could be established as well, we now know eight distinct PPIases with proven enzyme activity in E. coli.	MAX PLANCK GESELL FORDERUNG WISSENSCH EV,FORSCHUNGSSTELLE ENZYMOL PROTEINFALTUNG,D-06120 HALLE,GERMANY; UNIV HALLE WITTENBERG,INST GEOL WISSENSCH & GEISELTALMUSEUM,D-06108 HALLE,GERMANY; UNIV ZURICH,INST BIOCHEM,CH-8057 ZURICH,SWITZERLAND	Max Planck Society; Martin Luther University Halle Wittenberg; University of Zurich			Plückthun, Andreas/C-2746-2009	Plückthun, Andreas/0000-0003-4191-5306				Adair GS, 1925, J BIOL CHEM, V63, P529; BOUVIER J, 1991, NUCLEIC ACIDS RES, V19, P180, DOI 10.1093/nar/19.1.180; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; Choi JK, 1996, ANAL BIOCHEM, V236, P82, DOI 10.1006/abio.1996.0134; COMPTON LA, 1992, EUR J BIOCHEM, V206, P927, DOI 10.1111/j.1432-1033.1992.tb17002.x; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FU CL, 1995, P NATL ACAD SCI USA, V92, P2333, DOI 10.1073/pnas.92.6.2333; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HORNE SM, 1995, ARCH MICROBIOL, V163, P357, DOI 10.1007/s002030050215; ISAKI L, 1990, J BACTERIOL, V172, P469, DOI 10.1128/JB.172.1.469-472.1990; ISAKI L, 1990, J BACTERIOL, V172, P6512, DOI 10.1128/jb.172.11.6512-6517.1990; Kay JE, 1996, BIOCHEM J, V314, P361, DOI 10.1042/bj3140361; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACKIE GA, 1980, J BIOL CHEM, V255, P8928; MAIER T, 1993, J BACTERIOL, V175, P630, DOI 10.1128/JB.175.3.630-635.1993; MAIER T, 1995, EUR J BIOCHEM, V230, P133, DOI 10.1111/j.1432-1033.1995.tb20543.x; MARATEA D, 1985, GENE, V40, P39, DOI 10.1016/0378-1119(85)90022-8; MILLER KW, 1987, J BIOL CHEM, V262, P7391; Perczel A., 1996, CIRCULAR DICHROISM C, P285; Rahfeld JU, 1996, J BIOL CHEM, V271, P22130, DOI 10.1074/jbc.271.36.22130; RAHFELD JU, 1994, FEBS LETT, V343, P65, DOI 10.1016/0014-5793(94)80608-X; REINARD T, 1989, ANAL BIOCHEM, V176, P157, DOI 10.1016/0003-2697(89)90286-8; REY L, 1994, J BACTERIOL, V176, P6066, DOI 10.1128/jb.176.19.6066-6073.1994; ROCF WD, 1994, J BIOL CHEM, V269, P2902; Sambrook J., 2002, MOL CLONING LAB MANU; Stoller G, 1996, FEBS LETT, V384, P117, DOI 10.1016/0014-5793(96)00282-7; STOLLER G, 1995, EMBO J, V14, P4939, DOI 10.1002/j.1460-2075.1995.tb00177.x; TIMERMAN AP, 1995, J BIOL CHEM, V270, P2451, DOI 10.1074/jbc.270.6.2451; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WULFING C, 1994, J BIOL CHEM, V269, P2895; [No title captured]	35	126	135	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15697	15701		10.1074/jbc.272.25.15697	http://dx.doi.org/10.1074/jbc.272.25.15697			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188461	hybrid			2022-12-27	WOS:A1997XF32900021
J	Robertson, D; Mitchell, GP; Gilroy, JS; Gerrish, C; Bolwell, GP; Slabas, AR				Robertson, D; Mitchell, GP; Gilroy, JS; Gerrish, C; Bolwell, GP; Slabas, AR			Differential extraction and protein sequencing reveals major differences in patterns of primary cell wall proteins from plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-DIMENSIONAL GEL-ELECTROPHORESIS; PHENYLALANINE AMMONIA-LYASE; SUSPENSION-CULTURES; EXTENSIN; GENES; STIMULATION; SEPARATION; TOBACCO; CDNA	The proteins of the primary cell walls of suspension cultured cells of five plant species, Arabidopsis, carrot, French bean, tomato, and tobacco, have been compared, The approach that has been adopted is differential extraction followed by SDS-polyacrylamide gel electrophoresis (PAGE), rather than two-dimensional gel analysis, to facilitate protein sequencing, Whole cells were washed sequentially with the following aqueous solutions, CaCl2, CDTA (cyclohexane diaminotetraacetic acid, DTT (dithiothreitol), NaCl, and berate, SDS-PAGE analysis showed consistent differences between species, From the 233 proteins that were selected for sequencing, 63% gave N-terminal data. This analysis shows that (i) patterns of proteins revealed by SDS-PAGE are strikingly different for all five species, (ii) a large number of these proteins cannot be identified by data base searches indicating that a significant proportion of wall proteins have not been previously described, (iii) the major proteins that can be identified belong to very different classes of proteins, (iv) the majority of proteins found in the extracellular growth media are absent from their respective cell wall extracts, and (v) the results of the extraction process are indicative of higher order structure, It appears that aspects of speciation reside in the complement of extracellular wall proteins, The data represent a protein resource for cell wall studies complementary to EST (expressed sequence tag) and DNA sequencing strategies.	UNIV DURHAM,DEPT BIOL SCI,DURHAM DH1 3LE,ENGLAND; UNIV LONDON,ROYAL HOLLOWAY & BEDFORD NEW COLL,SCH BIOL SCI,DIV BIOCHEM,EGHAM TW20 0EX,SURREY,ENGLAND	Durham University; University of London; Royal Holloway University London								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAUW G, 1987, P NATL ACAD SCI USA, V84, P4806, DOI 10.1073/pnas.84.14.4806; BAUW G, 1990, ELECTROPHORESIS, V11, P528, DOI 10.1002/elps.1150110703; BOLWELL GP, 1993, INT REV CYTOL, V146, P261, DOI 10.1016/S0074-7696(08)60384-8; BOLWELL GP, 1997, MORPHOGENESIS PLANT; CARPITA NC, 1993, PLANT J, V3, P1, DOI 10.1111/j.1365-313X.1993.tb00007.x; Cooke R, 1996, PLANT J, V9, P101, DOI 10.1046/j.1365-313X.1996.09010101.x; DATTA K, 1989, PLANT CELL, V1, P945, DOI 10.1105/tpc.1.9.945; DIXON RA, 1979, BIOCHIM BIOPHYS ACTA, V586, P453, DOI 10.1016/0304-4165(79)90035-7; ELKIND Y, 1990, P NATL ACAD SCI USA, V87, P9057, DOI 10.1073/pnas.87.22.9057; FAYE L, 1989, PHYSIOL PLANTARUM, V75, P809; Fry S. C, 1988, GROWING PLANT CELL W, DOI DOI 10.1016/0031-9422(88)83079-6; FRY SC, 1995, ANNU REV PLANT PHYS, V46, P497, DOI 10.1146/annurev.pp.46.060195.002433; KAMO M, 1995, ELECTROPHORESIS, V16, P423, DOI 10.1002/elps.1150160169; KELLER B, 1993, PLANT PHYSIOL, V101, P1127, DOI 10.1104/pp.101.4.1127; KIELISZEWSKI MJ, 1994, PLANT J, V5, P157, DOI 10.1046/j.1365-313X.1994.05020157.x; KREUGER M, 1993, PLANTA, V189, P243, DOI 10.1007/BF00195083; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAY MJ, 1993, PLANT PHYSIOL, V103, P621, DOI 10.1104/pp.103.2.621; MEMELINK J, 1987, EMBO J, V6, P3579, DOI 10.1002/j.1460-2075.1987.tb02688.x; MILLER JG, 1992, PLANT CELL TISS ORG, V31, P61, DOI 10.1007/BF00043476; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; Roberts K, 1990, CURR OPIN CELL BIOL, V2, P920, DOI 10.1016/0955-0674(90)90093-T; SHOWALTER AM, 1993, PLANT CELL, V5, P9, DOI 10.1105/tpc.5.1.9; SMITH CJS, 1988, NATURE, V334, P724, DOI 10.1038/334724a0; SMITH JJ, 1984, PHYTOCHEMISTRY, V23, P1233, DOI 10.1016/S0031-9422(00)80432-X; TSUGITA A, 1994, ELECTROPHORESIS, V15, P708, DOI 10.1002/elps.1150150198	28	102	212	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15841	15848		10.1074/jbc.272.25.15841	http://dx.doi.org/10.1074/jbc.272.25.15841			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188482	hybrid			2022-12-27	WOS:A1997XF32900042
J	Wolff, EC; Folk, JE; Park, MH				Wolff, EC; Folk, JE; Park, MH			Enzyme-substrate intermediate formation at lysine 329 of human deoxyhypusine synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPUSINE-CONTAINING PROTEIN; SACCHAROMYCES-CEREVISIAE; SODIUM CYANOBOROHYDRIDE; REDUCTIVE METHYLATION; AMINO-ACID; IDENTIFICATION; INHIBITION; CELLS; PURIFICATION; SPERMIDINE	Deoxyhypusine (N-epsilon-(4-aminobutyl)lysine) is the key intermediate in the posttranslational synthesis of the unique amino acid, hypusine (N-epsilon-(4-amino-2-hydroxybutyl)lysine). Deoxyhypusine synthase catalyzes the formation of deoxyhypusine by conjugation of the butylamine moiety of spermidine to the epsilon-amino group of one specific lysine residue of the eukaryotic translation initiation factor 5A (eIF-5A) precursor protein. However, in the absence of the eIF-5A precursor, catalysis involves only the NAD-dependent cleavage of spermidine to generate 1,3-diaminopropane and a putative 4-carbon amine intermediate that gives rise to Delta(1)-pyrroline. We have obtained evidence for a covalent enzyme-substrate intermediate that accumulates in the absence of the eIF-5A precursor. Incubation of human recombinant enzyme with [1,8-H-3]spermidine and NAD, followed by reduction with NaBH3CN, resulted in specific radiolabeling of the enzyme. The radioactive component in the reduced enzyme intermediate was identified as deoxyhypusine and was shown to occur at a single locus. The fact that labeled deoxyhypusine was found after treatment with a reducing agent suggests an intermediate with the butylamine moiety derived from spermidine attached through an imine linkage to the E-amino group of a specific lysine residue of the enzyme. This residue has been identified as lysine 329. Separate experiments showing efficient transfer of labeled butylamine moiety from enzyme intermediate to eIF-5A precursor strongly support a reaction mechanism involving an imine intermediate.			Wolff, EC (corresponding author), NIDR,NIH,ORAL & PHARYNGEAL CANC BRANCH,BLDG 30,RM 211,BETHESDA,MD 20892, USA.							ABBRUZZESE A, 1989, BIOCHIM BIOPHYS ACTA, V997, P248, DOI 10.1016/0167-4838(89)90195-7; Abeles RH, 1992, BIOCHEMISTRY-US; BORCH RF, 1971, J AM CHEM SOC, V93, P2897, DOI 10.1021/ja00741a013; BYERS TL, 1992, BIOCHEM J, V287, P717, DOI 10.1042/bj2870717; BYERS TL, 1994, BIOCHEM J, V303, P363, DOI 10.1042/bj3030363; COOPER HL, 1983, P NATL ACAD SCI-BIOL, V80, P1854, DOI 10.1073/pnas.80.7.1854; FISCHER EH, 1958, J AM CHEM SOC, V80, P2906, DOI 10.1021/ja01544a082; GIDLEY MJ, 1982, BIOCHEM J, V203, P331, DOI 10.1042/bj2030331; GORMAN JJ, 1984, ANAL BIOCHEM, V136, P397, DOI 10.1016/0003-2697(84)90235-5; GRAZI E, 1962, BIOCHEM BIOPH RES CO, V7, P250, DOI 10.1016/0006-291X(62)90184-5; HELLERMAN L, 1967, J BIOL CHEM, V242, P582; HOGG JL, 1977, J AM CHEM SOC, V99, P4772, DOI 10.1021/ja00456a039; JAKUS J, 1993, J BIOL CHEM, V268, P13151; JENCKS WP, 1969, CATALYSIS CHEM ENZYM, P505; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; JOE YA, 1995, J BIOL CHEM, V270, P22386, DOI 10.1074/jbc.270.38.22386; KANG KR, 1995, J BIOL CHEM, V270, P18408, DOI 10.1074/jbc.270.31.18408; KEIL B, 1971, ENZYMES, V3, P265; KLIER H, 1995, FEBS LETT, V364, P207, DOI 10.1016/0014-5793(95)00394-O; LEE YB, 1995, J MED CHEM, V38, P3053, DOI 10.1021/jm00016a008; MAGDOLEN V, 1994, MOL GEN GENET, V224, P646; Moritz RL, 1996, ELECTROPHORESIS, V17, P907, DOI 10.1002/elps.1150170512; PARK MH, 1983, METHOD ENZYMOL, V94, P458; PARK MH, 1986, J BIOL CHEM, V261, P14108; PARK MH, 1984, J BIOL CHEM, V259, P2123; PARK MH, 1982, J BIOL CHEM, V257, P7217; PARK MH, 1994, J BIOL CHEM, V269, P27827; PARK MH, 1993, TRENDS BIOCHEM SCI, V18, P475, DOI 10.1016/0968-0004(93)90010-K; PARK MH, 1993, BIOFACTORS, V4, P95; Park MH, 1996, AMINO ACIDS, V10, P109, DOI 10.1007/BF00806584; PARK MH, 1981, P NATL ACAD SCI-BIOL, V78, P2869, DOI 10.1073/pnas.78.5.2869; PARK MH, 1984, J BIOL CHEM, V259, P4563; RECSEI PA, 1970, BIOCHEMISTRY-US, V9, P1492, DOI 10.1021/bi00809a003; Sasaki K, 1996, FEBS LETT, V384, P151, DOI 10.1016/0014-5793(96)00310-9; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; SCHWELBERGER HG, 1993, J BIOL CHEM, V268, P14018; Tabor H, 1971, METHODS ENZYMOLOGY B, V17, P829; TAO Y, 1995, J BIOL CHEM, V270, P383, DOI 10.1074/jbc.270.1.383; TAO Y, 1995, J BIOL CHEM, V270, P23984, DOI 10.1074/jbc.270.41.23984; WALSH CT, 1979, ENZYMATIC REACTION M; WARREN S, 1966, BIOCHEMISTRY-US, V5, P817, DOI 10.1021/bi00867a002; WENG SH, 1983, J AM CHEM SOC, V105, P4082, DOI 10.1021/ja00350a056; WOHL T, 1993, MOL GEN GENET, V241, P305; WOLFF EC, 1990, J BIOL CHEM, V265, P4793; WOLFF EC, 1995, J BIOL CHEM, V270, P8660, DOI 10.1074/jbc.270.15.8660; Yan YP, 1996, BIOCHEM J, V315, P429, DOI 10.1042/bj3150429	46	40	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15865	15871		10.1074/jbc.272.25.15865	http://dx.doi.org/10.1074/jbc.272.25.15865			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188485	hybrid			2022-12-27	WOS:A1997XF32900045
J	Inokuchi, Y; Kajitani, M				Inokuchi, Y; Kajitani, M			Deletion analysis of Q beta replicase - Participation of the carboxyl-terminal region of the beta-subunit protein in template recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; VIRAL-INFECTION; RNA REPLICASE; IDENTIFICATION; INTERFERENCE; MOTIF; GENE; HOST	We have analyzed one of the functional domains of Q beta replicase, an RNA-dependent RNA polymerase of RNA coliphage Q beta. Deletion mapping analysis of the carboxyl-terminal region of the beta-subunit protein revealed that the terminal 18 amino acid residues (positions 571-588) are dispensable for the replicase reaction. Subsequent deletions up to the Ala-565 residue reduced the RNA polymerizing activity of the replicase in vivo but increased it in vitro. The mutant replicases with enhanced in vitro RNA polymerizing activity were found to have relaxed template specificity for ribosomal RNAs and cellular RNAs as well as Q beta RNA. Deletions beyond the Ile-564 residue abolished both the RNA polymerizing activity and the binding ability to midivariant (MDV)-poly(+) RNA, a derivative of a natural template for Q beta replicase, MDV-1 RNA. These results suggest that the carboxyl-terminal part of the beta-subunit participates in RNA recognition of Q beta replicase.			Inokuchi, Y (corresponding author), TEIKYO UNIV,DEPT BIOSCI,1-1 TOYOSATODAI,UTSUNOMIYA,TOCHIGI 320,JAPAN.							AGROS P, 1988, NUCLEIC ACIDS RES, V16, P9909; BALL LA, 1973, J MOL BIOL, V74, P547, DOI 10.1016/0022-2836(73)90046-6; BLUMENTHAL T, 1979, ANNU REV BIOCHEM, V48, P525, DOI 10.1146/annurev.bi.48.070179.002521; Brown D, 1996, P NATL ACAD SCI USA, V93, P11558, DOI 10.1073/pnas.93.21.11558; FIERS W, 1976, NATURE, V260, P500, DOI 10.1038/260500a0; FRANZE MT, 1968, NATURE, V219, P588, DOI 10.1038/219588a0; INOKUCHI Y, 1990, J BIOCHEM-TOKYO, V108, P53, DOI 10.1093/oxfordjournals.jbchem.a123162; INOKUCHI Y, 1987, J VIROL, V61, P3946, DOI 10.1128/JVI.61.12.3946-3949.1987; INOKUCHI Y, 1988, NUCLEIC ACIDS RES, V16, P6205, DOI 10.1093/nar/16.13.6205; INOKUCHI Y, 1986, J BIOCHEM-TOKYO, V99, P1169, DOI 10.1093/oxfordjournals.jbchem.a135580; INOKUCHI Y, 1994, J BIOCHEM-TOKYO, V116, P1275, DOI 10.1093/oxfordjournals.jbchem.a124675; JABLONSKI SA, 1995, J VIROL, V69, P1532, DOI 10.1128/JVI.69.3.1532-1539.1995; KAJITANI M, 1991, NUCLEIC ACIDS RES, V19, P1063, DOI 10.1093/nar/19.5.1063; KONDO M, 1972, EUR J BIOCHEM, V24, P530, DOI 10.1111/j.1432-1033.1972.tb19715.x; LIZARDI PM, 1988, BIO-TECHNOL, V6, P1197, DOI 10.1038/nbt1088-1197; MEKLER P, 1981, THESIS U ZURICH; MILLS DR, 1988, J MOL BIOL, V205, P751; NISHIHARA T, 1983, J BIOCHEM, V93, P669, DOI 10.1093/jb/93.3.669; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TANIGUCHI T, 1978, NATURE, V274, P223, DOI 10.1038/274223a0; WERNER M, 1991, BIOCHEMISTRY-US, V30, P5832, DOI 10.1021/bi00238a004	22	5	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15339	15345		10.1074/jbc.272.24.15339	http://dx.doi.org/10.1074/jbc.272.24.15339			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182562	hybrid			2022-12-27	WOS:A1997XE03400045
J	Paleyanda, RK; Drews, R; Lee, TK; Lubon, H				Paleyanda, RK; Drews, R; Lee, TK; Lubon, H			Secretion of human furin into mouse milk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPROTEIN PROCESSING ENZYME; ENDOPROTEOLYTIC CLEAVAGE; ENDOPLASMIC-RETICULUM; VONWILLEBRAND-FACTOR; SERINE PROTEASES; TRANSGENIC MICE; MAMMARY-GLAND; PROTEIN-C; EXPRESSION; PROPEPTIDE	We have previously described the expression of the human proprotein convertase furin or paired basic amino acid-cleaving enzyme, in mice transgenic for paired basic amino acid-cleaving enzyme and human Protein C (HPC). Here me show 100-fold or higher expression of furin in the mammary gland, compared with endogenous furin, Furin and recombinant HPC were detected in the same regions of the mammary gland and regulated similar to the endogenous whey acidic protein. In addition to the expected intracellular localization, furin was secreted into the milli as an 80-kDa form lacking the transmembrane and cytoplasmic domains. Furin present at levels of up to 40,000 units/ml milk cleaved the t-butoxycarbonyl-RVRR-AMC substrate with a K-m of 32 mu M, and processed the recombinant HPC precursor at the appropriate sites. Surprisingly, the expression of an active protease was not toxic to the mammary gland. This is a rare example of all animal model secreting active truncated forms of a processing endoprotease into a bodily fluid.	AMER RED CROSS,JEROME H HOLLAND LAB,ROCKVILLE,MD 20855	American Red Cross								AYOUBI TAY, 1994, J BIOL CHEM, V269, P9298; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; BRENNAN SO, 1991, J BIOL CHEM, V266, P21504; BVRUZZANITI A, 1996, BIOCHEM J, V314, P727; Constam DB, 1996, J CELL BIOL, V134, P181, DOI 10.1083/jcb.134.1.181; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; DITULLIO P, 1992, BIO-TECHNOL, V10, P74, DOI 10.1038/nbt0192-74; DREWS R, 1995, P NATL ACAD SCI USA, V92, P10462, DOI 10.1073/pnas.92.23.10462; DROBAN W, 1994, TRANSGENIC RES, V3, P355; DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618; FAERMAN A, 1995, J HISTOCHEM CYTOCHEM, V43, P461, DOI 10.1177/43.5.7730585; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HILL RM, 1995, J NEUROCHEM, V65, P2318; LIU B, 1995, INT J CANCER, V63, P276, DOI 10.1002/ijc.2910630222; Lubon H, 1996, TRANSFUS MED REV, V10, P131, DOI 10.1016/S0887-7963(96)80089-7; MCKNIGHT RA, 1995, TRANSGENIC RES, V4, P39, DOI 10.1007/BF01976500; Meerabux J, 1996, CANCER RES, V56, P448; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MUNZER JS, 1995, J CELL BIOCH S B, V19, pB7; PALEYANDA RK, 1994, TRANSGENIC RES, V3, P335, DOI 10.1007/BF01976765; PATTON S, 1986, LIPIDS, V21, P170, DOI 10.1007/BF02534441; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; PRIETO PA, 1995, J BIOL CHEM, V270, P29515, DOI 10.1074/jbc.270.49.29515; Prunkard D, 1996, NAT BIOTECHNOL, V14, P867, DOI 10.1038/nbt0796-867; REHEMTULLA A, 1992, P NATL ACAD SCI USA, V89, P8235, DOI 10.1073/pnas.89.17.8235; REHEMTULLA A, 1992, BLOOD, V79, P2349; SARIOLA M, 1995, J CELL SCI, V108, P2465; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; SCHALKEN JA, 1987, J CLIN INVEST, V80, P1545, DOI 10.1172/JCI113240; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; VANDUIJNHOVEN HLP, 1992, HYBRIDOMA, V11, P71, DOI 10.1089/hyb.1992.11.71; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; VIDRICAIRE G, 1993, BIOCHEM BIOPH RES CO, V195, P1011, DOI 10.1006/bbrc.1993.2145; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378	37	17	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15270	15274		10.1074/jbc.272.24.15270	http://dx.doi.org/10.1074/jbc.272.24.15270			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182552	hybrid			2022-12-27	WOS:A1997XE03400035
J	Bazemore, LR; Takahashi, M; Radding, CM				Bazemore, LR; Takahashi, M; Radding, CM			Kinetic analysis of pairing and strand exchange catalyzed by RecA - Detection by fluorescence energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DNA-MOLECULES; DUPLEX DNA; ATP HYDROLYSIS; NUCLEOPROTEIN FILAMENTS; GENETIC-RECOMBINATION; RAD51 PROTEIN; COMPLEXES; HOMOLOGY; MECHANISM	RecA is a 38-kDa protein from Escherichia coli that polymerizes on single-stranded DNA, forming a nucleoprotein filament that pairs with homologous duplex DNA and carries out strand exchange in vitro. In this study, we measured RecA-catalyzed pairing and strand exchange in solution by energy transfer between fluorescent dyes on the ends of deoxyribo-oligonucleotides. By varying the position of the dyes in separate assays, we were able to detect the pairing of single-stranded RecA filament with duplex DNA as an increase in energy transfer, and strand displacement as a decrease in energy transfer. With these assays, the kinetics of pairing and strand displacement were studied by stopped-flow spectrofluorometry. The data revealed a rapid, second order, reversible pairing step that was followed by a slower, reversible, first order strand exchange step. These data indicate that an initial unstable intermediate exists which can readily return to reactants, and that a further rate-limiting step (or steps) is required to effect or complete strand exchange.	YALE UNIV, DEPT GENET, NEW HAVEN, CT 06510 USA; UNIV PARIS 11, INST CURIE, GRP ETUD MUTAGENESE & ANCEROGENESE, UNITE MIXTE RECH 216 CNRS, F-91405 ORSAY, FRANCE	Yale University; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Bazemore, LR (corresponding author), YALE UNIV, DEPT MOL BIOPHYS & BIOCHEM, POB 6666, NEW HAVEN, CT 06510 USA.				NIGMS NIH HHS [R37 GM33504-13] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033504] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZUMA K, 1992, GENE DEV, V6, P1679, DOI 10.1101/gad.6.9.1679; BALIGA R, 1995, P NATL ACAD SCI USA, V92, P10393, DOI 10.1073/pnas.92.22.10393; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BIANCHI M, 1983, CELL, V34, P931, DOI 10.1016/0092-8674(83)90550-0; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BJORNSON KP, 1994, BIOCHEMISTRY-US, V33, P14306, DOI 10.1021/bi00251a044; BRENNER SL, 1987, J BIOL CHEM, V262, P4011; BURNETT B, 1994, J MOL BIOL, V238, P540, DOI 10.1006/jmbi.1994.1313; CHIU SK, 1993, BIOCHEMISTRY-US, V32, P13146, DOI 10.1021/bi00211a025; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; CLEGG RM, 1992, BIOCHEMISTRY-US, V31, P4846, DOI 10.1021/bi00135a016; CONLEY EC, 1989, CELL, V56, P987, DOI 10.1016/0092-8674(89)90632-6; CONLEY EC, 1990, MUTATION ENV A, V340, P121; CUNNINGHAM RP, 1981, CELL, V24, P213, DOI 10.1016/0092-8674(81)90517-1; DASGUPTA C, 1980, CELL, V22, P437, DOI 10.1016/0092-8674(80)90354-2; DICAPUA E, 1982, J MOL BIOL, V157, P87, DOI 10.1016/0022-2836(82)90514-9; EGELMAN EH, 1986, J MOL BIOL, V191, P677, DOI 10.1016/0022-2836(86)90453-5; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; GONDA DK, 1986, J BIOL CHEM, V261, P3087; GONDA DK, 1983, CELL, V34, P647, DOI 10.1016/0092-8674(83)90397-5; GONDA DK, 1985, BIOCHEMISTRY-US, V24, P413, DOI 10.1021/bi00323a026; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; HONIGBERG SM, 1986, P NATL ACAD SCI USA, V83, P9586, DOI 10.1073/pnas.83.24.9586; HONIGBERG SM, 1988, CELL, V54, P525, DOI 10.1016/0092-8674(88)90074-8; HOUSTON P, 1994, P NATL ACAD SCI USA, V91, P5471, DOI 10.1073/pnas.91.12.5471; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; HSIEH P, 1992, P NATL ACAD SCI USA, V89, P6492, DOI 10.1073/pnas.89.14.6492; JaresErijman EA, 1996, J MOL BIOL, V257, P597, DOI 10.1006/jmbi.1996.0188; JULIN DA, 1986, J BIOL CHEM, V261, P1025; LEAHY MC, 1986, J BIOL CHEM, V261, P6954; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; MULLER B, 1990, J MOL BIOL, V212, P97, DOI 10.1016/0022-2836(90)90307-8; NICKEL B, 1989, J LUMIN, V44, P1, DOI 10.1016/0022-2313(89)90016-1; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PARKHURST KM, 1995, BIOCHEMISTRY-US, V34, P285, DOI 10.1021/bi00001a035; PODYMINOGIN MA, 1995, BIOCHEMISTRY-US, V34, P13098, DOI 10.1021/bi00040a022; RAO BJ, 1993, J MOL BIOL, V229, P328, DOI 10.1006/jmbi.1993.1038; REDDY G, 1995, BIOCHEMISTRY-US, V34, P10194, DOI 10.1021/bi00032a013; REDDY G, 1994, BIOCHEMISTRY-US, V33, P11486, DOI 10.1021/bi00204a010; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; REGISTER JC, 1987, J BIOL CHEM, V262, P12812; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; ROSSELLI W, 1990, J MOL BIOL, V216, P335, DOI 10.1016/S0022-2836(05)80325-0; ROULD E, 1992, J MOL BIOL, V226, P127, DOI 10.1016/0022-2836(92)90129-8; RUSCHE JR, 1985, J BIOL CHEM, V260, P949; SCHUTTE BC, 1988, BIOCHEMISTRY-US, V27, P7886, DOI 10.1021/bi00420a046; SELVIN PR, 1995, METHOD ENZYMOL, V246, P300; SHIBATA T, 1981, J BIOL CHEM, V256, P7557; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; STASIAK A, 1984, COLD SPRING HARB SYM, V49, P561, DOI 10.1101/SQB.1984.049.01.063; STRYER L, 1967, P NATL ACAD SCI USA, V58, P719, DOI 10.1073/pnas.58.2.719; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; TAKAHASHI M, 1992, EUR J BIOCHEM, V210, P87, DOI 10.1111/j.1432-1033.1992.tb17394.x; TAKAHASHI M, 1989, J MOL BIOL, V207, P783, DOI 10.1016/0022-2836(89)90244-1; TSANG SS, 1985, BIOCHEMISTRY-US, V24, P3226, DOI 10.1021/bi00334a023; WILLIAMS RC, 1986, J MOL BIOL, V187, P109, DOI 10.1016/0022-2836(86)90410-9; WU AM, 1982, CELL, V30, P37, DOI 10.1016/0092-8674(82)90009-5; YANCEYWRONA JE, 1995, CURR BIOL, V5, P1149, DOI 10.1016/S0960-9822(95)00231-4; YANG MS, 1994, BIOCHEMISTRY-US, V33, P15329, DOI 10.1021/bi00255a014	59	65	68	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14672	14682		10.1074/jbc.272.23.14672	http://dx.doi.org/10.1074/jbc.272.23.14672			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169430	hybrid			2022-12-27	WOS:A1997XC32700027
J	Chen, YY; Fischer, WH; Gill, GN				Chen, YY; Fischer, WH; Gill, GN			Regulation of the ERBB-2 promoter by RBPJ kappa and NOTCH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-BINDING-PROTEIN; BARR-VIRUS EBNA2; SPLIT COMPLEX GENES; HUMAN-BREAST-CANCER; TRANSCRIPTIONAL REPRESSION; NEU ONCOGENE; DROSOPHILA HOMOLOG; MAMMALIAN-CELLS; SUPPRESSOR; HAIRLESS	Within the human ERBB-2 gene promoter, a 100-base pair region 5' to the TATA box enhances basal transcription 200-fold. Two palindromes present within this 100-base pair region are important for transcription, The palindrome binding protein was purified to homogeneity and found to be identical to RBPJ kappa, the mammalian homolog of Drosophila Suppressor of Hairless (Su(H)), Recombinant RBPJ kappa bound the ERBB-2 promoter with affinity comparable with that seen with well characterized RBPJ kappa binding sites. RBPJ kappa activated an ERBB-2 palindrome containing promoter in 293 cells, Because in Drosophila Su(H) acts downstream of NOTCH and because NOTCH.Su(H)/RBPJ kappa stimulates transcription from target promoters, NOTCH-IC, a constitutively active form of NOTCH, was tested for effects on the ERBB-2 palindrome, NOTCH-IC further increased RBPJ kappa-mediated transcription on wild type but not mutant ERBB-2 palindrome, Thus, RBPJ kappa can activate ERBB-2 transcription and serve as an anchor to mediate NOTCH function on the ERBB-2 gene.	UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; SALK INST BIOL STUDIES, LA JOLLA, CA 92037 USA	University of California System; University of California San Diego; Salk Institute					NIDDK NIH HHS [DK13149] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013149, R37DK013149] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMAKAWA R, 1993, GENOMICS, V17, P306, DOI 10.1006/geno.1993.1326; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; BROU C, 1994, GENE DEV, V8, P2491, DOI 10.1101/gad.8.20.2491; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen YY, 1996, J BIOL CHEM, V271, P5183; CHEN YY, 1994, ONCOGENE, V9, P2269; Christensen S, 1996, DEVELOPMENT, V122, P1373; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DOU SB, 1994, MOL CELL BIOL, V14, P3310, DOI 10.1128/MCB.14.5.3310; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; ERTL AP, 1993, GENE, V136, P361, DOI 10.1016/0378-1119(93)90496-P; FISCHER WH, 1991, METHODS NEUROSCI, V6, P69; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; FURUKAWA T, 1995, JPN J GENET, V70, P505, DOI 10.1266/jjg.70.505; FURUKAWA T, 1992, CELL, V69, P1191, DOI 10.1016/0092-8674(92)90640-X; GROSSMAN SR, 1994, P NATL ACAD SCI USA, V91, P7568, DOI 10.1073/pnas.91.16.7568; HAMAGUCHI Y, 1992, J BIOCHEM-TOKYO, V112, P314, DOI 10.1093/oxfordjournals.jbchem.a123898; HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657; HSIEH JJD, 1995, SCIENCE, V268, P560, DOI 10.1126/science.7725102; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; KOKAI Y, 1987, P NATL ACAD SCI USA, V84, P8498, DOI 10.1073/pnas.84.23.8498; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAUX G, 1994, EMBO J, V13, P5624, DOI 10.1002/j.1460-2075.1994.tb06900.x; LECOURTOIS M, 1995, GENE DEV, V9, P2598, DOI 10.1101/gad.9.21.2598; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LING PD, 1994, J VIROL, V68, P5375, DOI 10.1128/JVI.68.9.5375-5383.1994; Lu FM, 1996, P NATL ACAD SCI USA, V93, P5663, DOI 10.1073/pnas.93.11.5663; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; PRESS MF, 1990, ONCOGENE, V5, P953; SARKAR FH, 1994, J BIOL CHEM, V269, P12285; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; SUEN TC, 1991, MOL CELL BIOL, V11, P354, DOI 10.1128/MCB.11.1.354; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; TUN T, 1994, NUCLEIC ACIDS RES, V22, P965, DOI 10.1093/nar/22.6.965; WALTZER L, 1994, EMBO J, V13, P5633, DOI 10.1002/j.1460-2075.1994.tb06901.x; WHITE MRA, 1992, ONCOGENE, V7, P677; YAN DH, 1991, MOL CELL BIOL, V11, P1875, DOI 10.1128/MCB.11.4.1875; YU DH, 1992, J BIOL CHEM, V267, P10203; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; ZIMBERSTROBL U, 1994, EMBO J, V13, P4973, DOI 10.1002/j.1460-2075.1994.tb06824.x	53	91	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14110	14114		10.1074/jbc.272.22.14110	http://dx.doi.org/10.1074/jbc.272.22.14110			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162037	hybrid			2022-12-27	WOS:A1997XB49200024
J	Sparrer, H; Buchner, J				Sparrer, H; Buchner, J			How GroES regulates binding of nonnative protein to GroEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CHAPERONIN GROEL; CYCLE; COOPERATIVITY; MECHANISM; RELEASE; RECONSTITUTION; POLYPEPTIDES; AGGREGATION; HYDROLYSIS	At present, it is still enigmatic how the reaction cycle by which the Escherichia coli GroE chaperones mediate protein folding in the cell is coordinated with respect to the sequential order of binding and release of GroES, nucleotide, and nonnative protein. It is generally assumed that the asymmetric GroEL.GroES complex is the acceptor state for substrate protein, Nevertheless, this species is poorly understood in its binding characteristics for nucleotide and nonnative protein, We show here that this species has a high affinity binding site for nonnative protein. In addition to this, binding of nucleotide to one GroEL ring is strongly favored by GroES binding to the other ring, However, the slow rate of release of substrate protein from the unproductive trans-position kinetically favors the binding of a second GroES, thereby forming a symmetric GroEL(14).(GroES(7))(2) complex and simultaneously ensuring that substrate protein is sequestered in a position underneath GroES. Our results demonstrate that the intrinsic binding characteristics of the trans-bullet complex determine the sequence of events during the reaction cycle.	UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,D-93040 REGENSBURG,GERMANY	University of Regensburg			Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				BANEYX F, 1992, J BIOL CHEM, V267, P11637; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Gervasoni P, 1996, P NATL ACAD SCI USA, V93, P12189, DOI 10.1073/pnas.93.22.12189; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JAENICKE R, 1993, CURR OPIN STRUC BIOL, V3, P104, DOI 10.1016/0959-440X(93)90209-4; LILIE H, 1995, P NATL ACAD SCI USA, V92, P8100, DOI 10.1073/pnas.92.18.8100; LIN ZL, 1995, J BIOL CHEM, V270, P1011, DOI 10.1074/jbc.270.3.1011; Lin ZL, 1996, P NATL ACAD SCI USA, V93, P1977, DOI 10.1073/pnas.93.5.1977; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; Murai N, 1996, J BIOL CHEM, V271, P28229, DOI 10.1074/jbc.271.45.28229; RANDALL LL, 1995, TRENDS BIOCHEM SCI, V20, P65, DOI 10.1016/S0968-0004(00)88959-8; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; SCHMIDT M, 1994, J BIOL CHEM, V269, P27964; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; Sparrer H, 1996, J MOL BIOL, V258, P74, DOI 10.1006/jmbi.1996.0235; Sparrer H, 1997, P NATL ACAD SCI USA, V94, P1096, DOI 10.1073/pnas.94.4.1096; TESCHKE CM, 1991, J BIOL CHEM, V266, P11789; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; Todd MJ, 1996, P NATL ACAD SCI USA, V93, P4030, DOI 10.1073/pnas.93.9.4030; TODD MJ, 1995, J BIOL CHEM, V270, P5388, DOI 10.1074/jbc.270.10.5388; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; YIFRACH O, 1995, BIOCHEMISTRY-US, V34, P5303, DOI 10.1021/bi00016a001; Zahn R, 1996, SCIENCE, V271, P642, DOI 10.1126/science.271.5249.642; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0; ZAHN R, 1994, J MOL BIOL, V242, P150, DOI 10.1006/jmbi.1994.1566; ZIMMERMAN SB, 1991, J MOL BIOL, V222, P599, DOI 10.1016/0022-2836(91)90499-V	41	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14080	14086		10.1074/jbc.272.22.14080	http://dx.doi.org/10.1074/jbc.272.22.14080			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162032	hybrid			2022-12-27	WOS:A1997XB49200019
J	Fraser, JD; Keller, D; Martinez, V; SantisoMere, D; Straney, R; Briggs, MR				Fraser, JD; Keller, D; Martinez, V; SantisoMere, D; Straney, R; Briggs, MR			Utilization of recombinant adenovirus and dominant negative mutants to characterize hepatocyte nuclear factor 4-regulated apolipoprotein AI and CIII expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-III GENE; I GENE; TRANSCRIPTIONAL REGULATION; THYROID-HORMONE; TRANSGENIC MICE; HEART-DISEASE; RISK-FACTORS; RECEPTOR; PROMOTER; HYPERTRIGLYCERIDEMIA	Using recombinant adenoviral vectors and a dominant negative mutant of HNF-4, we have examined the contribution of hepatocyte nuclear factor 4 (HNF-4) to endogenous apolipoprotein Al: and CIII mRNA expression. Overexpression of HNF-4 leads to a 7.4-fold increase in apolipoprotein CIII expression, while infection with the dominant negative mutant of HNF-4 reduces the level of apolipoprotein CIII mRNA by 80%, demonstrating that endogenous HNF-4 is necessary for apolipoprotein CIII expression, Experiments using the hepatoma cell lines, HepG2 and Hep3B, indicate that HNF-4 is also involved in the regulation of apolipoprotein AI expression in these lines, However, the effect of HNF-4 on apolipoprotein AI expression is much more dramatic in cell lines derived from intestinal epithelium, Infection of the intestinal-derived cell line IEC-6 with the HNF-4 adenovirus resulted in a greater than 20-fold increase in the level of apolipoprotein AI mRNA. These results indicate that HNF-4 does regulate apolipoprotein AI and CIII mRNA expression and suggest that HNF-4 is critical for intestinal apolipoprotein AI expression.			Fraser, JD (corresponding author), LIGAND PHARMACEUT INC,9393 TOWNE CTR DR,SAN DIEGO,CA 92121, USA.							AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; BIGLER J, 1992, MOL CELL BIOL, V12, P2406, DOI 10.1128/MCB.12.5.2406; BISAHA JG, 1995, J BIOL CHEM, V270, P19979, DOI 10.1074/jbc.270.34.19979; Bradford MM, 1976, ANAL BIOCHEM, V72, P234; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CARLSON LA, 1985, ACTA MED SCAND, V218, P207; CASTELLI WP, 1992, AM J CARDIOL, V70, pH3, DOI 10.1016/0002-9149(92)91083-G; CHAN J, 1993, NUCLEIC ACIDS RES, V21, P1205, DOI 10.1093/nar/21.5.1205; CHARTIER FL, 1994, GENE, V147, P269, DOI 10.1016/0378-1119(94)90079-5; DANA SL, 1994, MOL ENDOCRINOL, V8, P1193, DOI 10.1210/me.8.9.1193; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; FRASER JD, 1992, MOL CELL BIOL, V12, P4357, DOI 10.1128/MCB.12.10.4357; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FUERNKRANZ HA, 1994, NUCLEIC ACIDS RES, V22, P5665, DOI 10.1093/nar/22.25.5665; GINSBURG GS, 1995, J CLIN INVEST, V96, P528, DOI 10.1172/JCI118065; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; HATA S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P211, DOI 10.1016/0167-4781(92)90080-J; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HSU MH, 1995, MOL PHARMACOL, V48, P559; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; KARATHANASIS SK, 1983, P NATL ACAD SCI-BIOL, V80, P6147, DOI 10.1073/pnas.80.20.6147; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KOU CJ, 1992, NATURE, V355, P457; KTISTAKI E, 1994, NUCLEIC ACIDS RES, V22, P4689, DOI 10.1093/nar/22.22.4689; LINDENSTROM E, 1994, BMJ-BRIT MED J, V309, P11, DOI 10.1136/bmj.309.6946.11; MAEDA N, 1994, J BIOL CHEM, V269, P23610; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; METZGER S, 1993, J BIOL CHEM, V268, P16831; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MIQUEROL L, 1994, J BIOL CHEM, V269, P8944; SCHONFELD G, 1979, METABOLISM, V28, P1001, DOI 10.1016/0026-0495(79)90004-0; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; WALSH A, 1993, J LIPID RES, V34, P617; Wang Lee-Ho, 1991, Gene Expression, V1, P207; ZALENT A, 1991, EMBO J, V10, P71	38	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13892	13898		10.1074/jbc.272.21.13892	http://dx.doi.org/10.1074/jbc.272.21.13892			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153249	hybrid			2022-12-27	WOS:A1997XA06200064
J	Kester, HA; vanderLeede, BM; vanderSaag, PT; vanderBurg, B				Kester, HA; vanderLeede, BM; vanderSaag, PT; vanderBurg, B			Novel progesterone target genes identified by an improved differential display technique suggest that progestin-induced growth inhibition of breast cancer cells coincides with enhancement of differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACID; E-CADHERIN EXPRESSION; ANNEXIN-VI; ESTROGEN-RECEPTOR; TRANSCRIPTION ACTIVATION; DEVELOPMENTAL REGULATION; GLUCOCORTICOID RECEPTOR; ALPHA-CATENIN; 2ND LIGAND; LINES	Progesterone is an important regulator of normal and malignant breast epithelial cells. In addition to stimulating development of normal mammary epithelium, it can be used to treat hormone-dependent breast tumors. However, the mechanism of growth inhibition by progestins is poorly understood, and only a limited number of progesterone target genes are known so far. We therefore decided to clone such target genes by means of differential display polymerase chain reaction. In this paper, we describe an improved differential display strategy that eliminates false positives, along with the identification of nine positive (TSC-22, CD-9, Na+/K+ ATPase alpha 1, desmoplakin, CD-59, FKBP51, and three unknown genes) and one negative progesterone target genes (annexin-VI) from the mammary carcinoma cell line T47D, which is growth-inhibited by progestins. None of these genes have been reported before to be progesterone targets. Regulation of desmoplakin, CD-9, CD-59, Na+/K+-ATPase alpha 1, and annexin-VI by the progestin suggests that progesterone induces T47D cells to differentiate. Three of these genes were repressed by estradiol and up-regulated by the progestin. Estradiol treatment of T47D cells also leads to formation of lamellipodia and delocalization of two cell adhesion proteins, E-cadherin and alpha-catenin. All these effects were reversed by the progestin. These data suggest that estradiol dedifferentiates T47D cells, while progestins have the opposite effect. This may be linked to the capacity of progestins to inhibit tumor growth.	NETHERLANDS INST DEV BIOL,HUBRECHT LAB,NL-3584 CT UTRECHT,NETHERLANDS	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)								ALBINI A, 1986, P NATL ACAD SCI USA, V83, P8182, DOI 10.1073/pnas.83.21.8182; AMERONGEN HM, 1989, J CELL BIOL, V109, P2129, DOI 10.1083/jcb.109.5.2129; Balbin M, 1996, J BIOL CHEM, V271, P15175, DOI 10.1074/jbc.271.25.15175; BAUGHMAN G, 1995, MOL CELL BIOL, V15, P4395; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BEHRENS J, 1994, INVAS METAST, V14, P1; CHALBOS D, 1986, NUCLEIC ACIDS RES, V14, P965, DOI 10.1093/nar/14.2.965; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK DM, 1991, HISTOCHEMISTRY, V96, P405, DOI 10.1007/BF00315998; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; CZAR MJ, 1995, MOL ENDOCRINOL, V9, P1549, DOI 10.1210/me.9.11.1549; DELSAL G, 1988, NUCLEIC ACIDS RES, V16, P9878; DILORENZO D, 1993, BIOCHEM BIOPH RES CO, V192, P1066, DOI 10.1006/bbrc.1993.1525; Fujimoto J, 1995, INVAS METAST, V15, P135; Fujimoto J, 1996, TUMOR BIOL, V17, P48, DOI 10.1159/000217966; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HAHN WC, 1992, SCIENCE, V256, P1805, DOI 10.1126/science.1377404; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; HORWITZ KB, 1978, J BIOL CHEM, V253, P2223; JACKLE S, 1994, J BIOL CHEM, V269, P1026; Jay P, 1996, BIOCHEM BIOPH RES CO, V222, P821, DOI 10.1006/bbrc.1996.0825; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; KING RJB, 1993, BREAST CANCER RES TR, V27, P3, DOI 10.1007/BF00683189; KORETZ K, 1993, BRIT J CANCER, V68, P926, DOI 10.1038/bjc.1993.456; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LI FS, 1994, NUCLEIC ACIDS RES, V22, P1764, DOI 10.1093/nar/22.9.1764; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LIN HC, 1992, CELL, V70, P283, DOI 10.1016/0092-8674(92)90102-I; LOZANO JJ, 1989, J CELL PHYSIOL, V138, P503, DOI 10.1002/jcp.1041380309; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MIYAKE M, 1995, CANCER RES, V55, P4127; Miyake M, 1996, CANCER RES, V56, P1244; Moore DD, 1995, GLOB MOB SURV; MUSGROVE EA, 1991, MOL CELL BIOL, V11, P5032, DOI 10.1128/MCB.11.10.5032; ONATE SA, 1995, SCIENCE, V270, P1354; PIERCEALL WE, 1995, ONCOGENE, V11, P1319; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; READ LD, 1989, MOL ENDOCRINOL, V3, P295, DOI 10.1210/mend-3-2-295; READ LD, 1988, MOL ENDOCRINOL, V2, P263, DOI 10.1210/mend-2-3-263; RIMM DL, 1995, LAB INVEST, V72, P506; ROCHA V, 1990, BIOCHEM SOC T, V18, P1110, DOI 10.1042/bst0181110; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; Sambrook J., 2002, MOL CLONING LAB MANU; SANTEN RJ, 1990, ENDOCR REV, V11, P1; SHAW ARE, 1995, J BIOL CHEM, V270, P24092, DOI 10.1074/jbc.270.41.24092; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; SHI YE, 1994, HUM REPROD, V9, P162, DOI 10.1093/humrep/9.suppl_1.162; SHIBANUMA M, 1992, J BIOL CHEM, V267, P10219; Siitonen SM, 1996, AM J CLIN PATHOL, V105, P394; SLATER EP, 1988, MOL ENDOCRINOL, V2, P485, DOI 10.1210/mend-2-6-485; SMITH DF, 1993, J BIOL CHEM, V268, P18365; Solomon KR, 1996, P NATL ACAD SCI USA, V93, P6053, DOI 10.1073/pnas.93.12.6053; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; SOMMERS CL, 1991, CELL GROWTH DIFFER, V2, P365; SUGITA Y, 1988, J BIOCHEM-TOKYO, V104, P633, DOI 10.1093/oxfordjournals.jbchem.a122524; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; THOMPSON EW, 1988, CANCER RES, V48, P6764; Van Roy F, 1992, Trends Cell Biol, V2, P163, DOI 10.1016/0962-8924(92)90035-L; VANDENBRULE FA, 1992, INT J CANCER, V52, P653, DOI 10.1002/ijc.2910520426; VANDERBURG B, 1988, J CELL PHYSIOL, V134, P101, DOI 10.1002/jcp.1041340112; VANDERLEEDE BJM, 1993, MOL CARCINOGEN, V8, P112, DOI 10.1002/mc.2940080208; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; VogeliLange R, 1996, NUCLEIC ACIDS RES, V24, P1385, DOI 10.1093/nar/24.7.1385; WANG ZM, 1994, AM J PHYSIOL, V267, P450; WELSH J, 1992, NUCLEIC ACIDS RES, V20, P4965, DOI 10.1093/nar/20.19.4965; XU M, 1994, CELL GROWTH DIFFER, V5, P1225; YEATMAN TJ, 1995, NUCLEIC ACIDS RES, V23, P4007, DOI 10.1093/nar/23.19.4007; YEH WC, 1995, P NATL ACAD SCI USA, V92, P11081, DOI 10.1073/pnas.92.24.11081	70	116	118	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16637	16643		10.1074/jbc.272.26.16637	http://dx.doi.org/10.1074/jbc.272.26.16637			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195978	hybrid			2022-12-27	WOS:A1997XG01900082
J	Marjamaki, A; Sato, M; BouetAlard, R; Yang, Q; LimonBoulez, I; Legrand, C; Lanier, SM				Marjamaki, A; Sato, M; BouetAlard, R; Yang, Q; LimonBoulez, I; Legrand, C; Lanier, SM			Factors determining the specificity of signal transduction by guanine nucleotide-binding protein-coupled receptors - Integration of stimulatory and inhibitory input to the effector adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PHORBOL ESTER TREATMENT; ALPHA-2-ADRENERGIC RECEPTOR; CELLS; CALMODULIN; PHOSPHORYLATION; IDENTIFICATION; ACTIVATION; EXPRESSION; SUBTYPES	To define the integration of multiple signals by different types of adenylyl cyclase (AC) within the cell, we altered the population of enzymes expressed in the cell and determined the subsequent processing of stimulatory and inhibitory input. DDT1-MF2 cells expressed AC VI-IX and were stably transfected with AC II, III, or IV. Enzyme expression was confirmed by RNA blot analysis and functional assays. Basal enzyme activity was only increased in AC II transfectants (6-fold). Maximum stimulation of enzyme activity was increased in each of the AC transfectants to varying extents. alpha(2)-AR activation elicited enzyme type-specific responses. alpha(2)-AR activation inhibited the effect of isoproterenol in control transfectants, and this action was magnified in AC III transfectants. In AC II and AC IV transfectants, alpha(2)-AR activation initiated both positive (G beta gamma) and negative signals (G(i) alpha) to the G(s) alpha-stimulated enzyme, and both types of signals were blocked by cell pretreatment with pertussis toxin. The negative input to AC II from the alpha(2)-AR was blocked by protein kinase C activation in AC II transfectants, but it was the positive input to AC IV that was compromised by protein kinase C activation. These data indicate that the integration of multiple signals by adenylyl cyclases is a dynamic process depending upon the enzyme type and phosphorylation status.	MED UNIV S CAROLINA,DEPT PHARMACOL,CHARLESTON,SC 29425; UNIV PARIS 06,REPROD PHYSIOL LAB,CNRS,URA 1449,F-75252 PARIS,FRANCE	Medical University of South Carolina; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite			Limon, Isabelle/P-2750-2017; Limon, Isabelle/AAJ-6169-2020	Limon, Isabelle/0000-0002-8773-6971; Limon, Isabelle/0000-0002-8773-6971; Lanier, Stephen/0000-0002-2740-7607	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS024821, R01NS024821] Funding Source: NIH RePORTER; NINDS NIH HHS [NS24821] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; Cali JJ, 1996, J BIOL CHEM, V271, P1089, DOI 10.1074/jbc.271.2.1089; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; CHOI EJ, 1993, BIOCHEMISTRY-US, V32, P1891, DOI 10.1021/bi00059a001; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; DUZIC E, 1992, J BIOL CHEM, V267, P24045; EASON MG, 1995, J BIOL CHEM, V270, P24753, DOI 10.1074/jbc.270.42.24753; Fagan KA, 1996, J BIOL CHEM, V271, P12438, DOI 10.1074/jbc.271.21.12438; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FRINGS S, 1993, J GEN PHYSIOL, V101, P183, DOI 10.1085/jgp.101.2.183; GUSOVSKY F, 1991, MOL PHARMACOL, V39, P124; HAMAMDZIC D, 1995, AM J PHYSIOL-ENDOC M, V269, pE162, DOI 10.1152/ajpendo.1995.269.1.E162; HELLEVUO K, 1995, J BIOL CHEM, V270, P11581, DOI 10.1074/jbc.270.19.11581; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; IWAMI G, 1995, J BIOL CHEM, V270, P12481, DOI 10.1074/jbc.270.21.12481; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; KATSUSHIKA S, 1993, J BIOL CHEM, V268, P2273; KAWABE J, 1994, J BIOL CHEM, V269, P16554; KUBALAK SW, 1993, AM J PHYSIOL, V264, pH86, DOI 10.1152/ajpheart.1993.264.1.H86; LANIER SM, 1991, J BIOL CHEM, V266, P10470; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MHAOUTY S, 1995, J BIOL CHEM, V270, P11012, DOI 10.1074/jbc.270.18.11012; MHAOUTY S, 1995, THESIS U P M CURRIE; PIAN MS, 1995, J BIOL CHEM, V270, P7427, DOI 10.1074/jbc.270.13.7427; PORT JD, 1992, J BIOL CHEM, V267, P8468; Premont RT, 1996, J BIOL CHEM, V271, P13900, DOI 10.1074/jbc.271.23.13900; SATO M, 1995, J BIOL CHEM, V270, P15269, DOI 10.1074/jbc.270.25.15269; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; XIA ZG, 1995, BEHAV BRAIN SCI, V18, P429, DOI 10.1017/S0140525X00039194; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	38	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16466	16473		10.1074/jbc.272.26.16466	http://dx.doi.org/10.1074/jbc.272.26.16466			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195955	hybrid			2022-12-27	WOS:A1997XG01900059
J	Rossi, G; Salminen, A; Rice, LM; Brunger, AT; Brennwald, P				Rossi, G; Salminen, A; Rice, LM; Brunger, AT; Brennwald, P			Analysis of a yeast SNARE complex reveals remarkable similarity to the neuronal SNARE complex and a novel function for the C terminus of the SNAP-25 homolog, Sec9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION COMPLEX; BOTULINUM NEUROTOXIN-A; SECRETORY PATHWAY; SYNAPTOBREVIN; SYNTAXIN; PROTEIN; SPECIFICITY; TRANSPORT; IDENTIFICATION; EXOCYTOSIS	SNARE proteins represent a family of related proteins that are thought to have a central role in vesicle targeting and fusion in all eukaryotic cells. The binding properties of the neuronal proteins synaptobrevin 1 (VAMP1), syntaxin 1, SNAP-25, and (s) under bar oluble (N) under bar-ethylmaleimide-(s) under bar ensitive (f) under bar actor (a) under bar ttachment (p) under bar rotein (alpha-SNAP), have been extensively studied. We report here the first biochemical characterization of a nonneuronal SNARE complex using recombinant forms of the yeast exocytic SNARE proteins Snc1, Sso1, and Sec9 and the yeast alpha-SNAP homolog, Sec17. Despite the low level of sequence identity, the association properties of the yeast and neuronal complexes are remarkably similar. The most striking difference we have found between the yeast and neuronal proteins is that individually neither of the target membrane SNAREs (t-SNAREs), Sso1 nor Sec9, show any detectable binding to the synaptobrevin homolog, Snc1. However, as a hetero-oligomeric complex, Sec9 and Sso1 show strong binding to Snc1. The clear dependence on the Sso1-Sec9 complex for t-SNARE function suggests that regulating the formation of this complex may be a key step in determining the site of vesicle fusion. In addition, we have used this in vitro assay to examine the biochemical effects of several mutations in Sec9 that result in pronounced growth defects in vivo. As expected, a temperature-sensitive mutation in the region most highly conserved between Sec9 and SNAP-25 is severely diminished in its ability to bind Sso1 and Snc1 in vitro. In contrast, a temperature-sensitive mutation near the C terminus of Sec9 shows no defect in SNARE binding in vitro. Similarly, a deletion of the C-terminal 17 residues, which is lethal in vivo, also binds Sso1 and Snc1 normally in vitro. Interestingly, we find that these same two C-terminal mutants, but not mutants that show SNARE assembly defects in vitro, act as potent dominant negative alleles when expressed behind a strong regulated promoter. Taken together these results suggest that the C-terminal domain of Sec9 is specifically required for a novel interaction that is required at a step following SNARE assembly.	CORNELL UNIV,COLL MED,DEPT CELL BIOL & ANAT,NEW YORK,NY 10021; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06511; YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511	Cornell University; Howard Hughes Medical Institute; Yale University; Yale University				Brunger, Axel/0000-0001-5121-2036; Rice, Luke/0000-0001-6551-3307				AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; BENNETT MK, 1995, CURR OPIN CELL BIOL, V7, P581, DOI 10.1016/0955-0674(95)80016-6; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; GUTIERREZ LM, 1995, FEBS LETT, V372, P39, DOI 10.1016/0014-5793(95)00944-5; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OTTO H, 1995, BIOCHEM BIOPH RES CO, V212, P945, DOI 10.1006/bbrc.1995.2061; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; SCHIAVO G, 1993, J BIOL CHEM, V268, P23784; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0	22	85	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16610	16617		10.1074/jbc.272.26.16610	http://dx.doi.org/10.1074/jbc.272.26.16610			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195974	hybrid			2022-12-27	WOS:A1997XG01900078
J	Tsukamoto, T; Nigam, SK				Tsukamoto, T; Nigam, SK			Tight junction proteins form large complexes and associate with the cytoskeleton in an ATP depletion model for reversible junction assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; EPITHELIAL-CELL POLARITY; CYTOSOLIC-FREE CALCIUM; INTRACELLULAR CALCIUM; E-CADHERIN; INJURY; ZO-1; KIDNEY; LOCALIZATION; MEMBRANE	A key feature of the ischemic epithelial cell phenotype is the disruption of tight junctions (TJ). In a Manin-Darby canine kidney cell model for ischemia-reperfusion/hypoxia-reoxygenation injury which employs inhibitors of glycolysis (2-deoxy-D-glucose) and oxidative phosphorylation (antimycin A), transepithelial electrical resistance, a measure of TJ integrity, dropped rapidly, correlating well with declining ATP levels, Although immunocytochemical studies revealed only subtle changes in the distribution of the TJ proteins, zonula occludens (ZO)-1, ZO-2, and cingulin, examination of the Triton X-100 solubilities of these proteins, an indicator of cytoskeletal association, revealed a striking shift of all three TJ proteins into the insoluble pool, consistent with increased cytoskeletal interaction during ATP depletion, In addition, rate-zonal centrifugation analysis of a detergent-soluble fraction showed an increase in the amount of ZO-1 and ZO-2 in high density fractions following ATP depletion, providing further evidence for association of TJ proteins into a large complex possibly involving the cytoskeleton. Analysis of immunoprecipitation data from [S-35]methionine-labeled cells revealed that ATP depletion led to the association of a 240-kDa protein with the ZO-1-containing complex. Western blots of this protein immunoprecipitated with anti-ZO-1 antibodies confirmed its identity as fodrin, a protein believed to link membrane and other proteins to the actin-based cytoskeleton. Together, our data suggest that in the absence of major immunocytochemical changes, ATP depletion leads TJ proteins to form large insoluble complexes and associate with the cytoskeleton. We propose a model in which a key, potentially regulated, step in the generation of the ischemic epithelial cell phenotype is the interaction between TJ proteins and fodrin and/or other cytoskeletal proteins.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School								ALEJANDRO VSJ, 1995, KIDNEY INT, V48, P1308, DOI 10.1038/ki.1995.415; Anderson JM, 1993, CURR OPIN CELL BIOL, V5, P772, DOI 10.1016/0955-0674(93)90024-K; BACALLAO R, 1994, J CELL SCI, V107, P3301; Beck KA, 1996, AM J PHYSIOL-CELL PH, V270, pC1263, DOI 10.1152/ajpcell.1996.270.5.C1263; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BUSH KT, 1994, J BIOL CHEM, V269, P23694; CANFIELD PE, 1991, AM J PHYSIOL, V261, pF1038, DOI 10.1152/ajprenal.1991.261.6.F1038; CARACENI P, 1994, AM J PHYSIOL, V266, pG799, DOI 10.1152/ajpgi.1994.266.5.G799; CITI S, 1993, J CELL BIOL, V121, P485, DOI 10.1083/jcb.121.3.485; CITI S, 1988, NATURE, V333, P272, DOI 10.1038/333272a0; Denker BM, 1996, J BIOL CHEM, V271, P25750, DOI 10.1074/jbc.271.42.25750; DOCTOR RB, 1993, AM J PHYSIOL, V264, pC1003, DOI 10.1152/ajpcell.1993.264.4.C1003; DOCTOR RB, 1994, AM J PHYSIOL, V266, pC1803, DOI 10.1152/ajpcell.1994.266.6.C1803; FEY EG, 1984, J CELL BIOL, V98, P1973, DOI 10.1083/jcb.98.6.1973; FISH EM, 1994, NEW ENGL J MED, V330, P1580; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; GARZAQUINTERO R, 1993, AM J PHYSIOL, V265, pF605, DOI 10.1152/ajprenal.1993.265.5.F605; ITOH M, 1991, J CELL BIOL, V115, P1449, DOI 10.1083/jcb.115.5.1449; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; Keon BH, 1996, J CELL BIOL, V134, P1003, DOI 10.1083/jcb.134.4.1003; KRIBBEN A, 1994, J CLIN INVEST, V93, P1922, DOI 10.1172/JCI117183; KROSHIAN VM, 1994, AM J PHYSIOL, V266, pF21, DOI 10.1152/ajprenal.1994.266.1.F21; KUZNETSOV G, 1994, J BIOL CHEM, V269, P22990; Kuznetsov G, 1996, P NATL ACAD SCI USA, V93, P8584, DOI 10.1073/pnas.93.16.8584; MADARA JL, 1987, AM J PHYSIOL, V253, pC171, DOI 10.1152/ajpcell.1987.253.1.C171; MANDEL LJ, 1993, NATURE, V361, P552, DOI 10.1038/361552a0; MANDEL LJ, 1994, J CELL SCI, V107, P3315; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MOLITORIS BA, 1990, J CLIN INVEST, V85, P3, DOI 10.1172/JCI114427; Molitoris BA, 1996, AM J PHYSIOL-RENAL, V271, pF790, DOI 10.1152/ajprenal.1996.271.4.F790; MOLITORIS BA, 1993, AM J PHYSIOL, V265, pF693, DOI 10.1152/ajprenal.1993.265.5.F693; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; Nigam S K, 1992, Curr Opin Nephrol Hypertens, V1, P187, DOI 10.1097/00041552-199212000-00001; NIGAM SK, 1992, P NATL ACAD SCI USA, V89, P6162, DOI 10.1073/pnas.89.13.6162; Nurko S, 1996, AM J PHYSIOL-RENAL, V270, pF39, DOI 10.1152/ajprenal.1996.270.1.F39; Stuart RO, 1996, J BIOL CHEM, V271, P13636, DOI 10.1074/jbc.271.23.13636; STUART RO, 1994, J CELL PHYSIOL, V159, P423, DOI 10.1002/jcp.1041590306; STUART RO, 1995, P NATL ACAD SCI USA, V92, P6072, DOI 10.1073/pnas.92.13.6072; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; WEINBERG JM, 1991, J CLIN INVEST, V87, P581, DOI 10.1172/JCI115033; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; ZHONG Y, 1993, J CELL BIOL, V120, P477, DOI 10.1083/jcb.120.2.477	44	160	165	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16133	16139		10.1074/jbc.272.26.16133	http://dx.doi.org/10.1074/jbc.272.26.16133			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195909	hybrid			2022-12-27	WOS:A1997XG01900013
J	Vance, JE; LeBlanc, DA; Wingfield, P; London, RE				Vance, JE; LeBlanc, DA; Wingfield, P; London, RE			Conformational selectivity of HIV-1 protease cleavage of X-Pro peptide bonds and its implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE-CONTAINING PEPTIDES; RESONANCE ENERGY-TRANSFER; CYCLOPHILIN-A; PROTEINASE DIMER; IMMUNODEFICIENCY; VIRIONS; ASSAY; ISOMERIZATION; STABILIZATION; SPECIFICITY	Kinetic measurements on a fluorescent peptide analog of the p17/p24 cleavage site of the Gag polyprotein demonstrate the conformational selectivity of human immunodeficiency virus, type 1 protease for the trans conformation of the Tyr-Pro bond, A mean cis/trans ratio of 0.3, and a cis --> trans isomerization rate constant of 0.022 s(-1) are determined at T = 22 degrees C. This rate is in excellent agreement with that predicted by F-19 NMR studies of structurally analogous peptides containing a fluorine/hydroxyl substitution on the tyrosyl residue, Addition of recombinant human cyclophilin resulted in a significant enhancement of this rate, and it is proposed that this enzyme, which has been shown to be associated with the Gag protein, functions as an auxiliary enzyme for the protease during cleavage in the virion.	NIEHS, STRUCT BIOL LAB, RES TRIANGLE PK, NC 27709 USA; NIAMS, PROT EXPRESS LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)			London, Robert E/F-7990-2019	London, Robert E/0000-0001-9108-8463; Wingfield, Paul/0000-0002-9515-4752				ANJUERE F, 1993, BIOCHEM J, V291, P869, DOI 10.1042/bj2910869; BALDWIN ET, 1995, STRUCTURE, V3, P581, DOI 10.1016/S0969-2126(01)00192-7; Braaten D, 1996, J VIROL, V70, P3551, DOI 10.1128/JVI.70.6.3551-3560.1996; BROADHURST AV, 1991, ANAL BIOCHEM, V193, P280, DOI 10.1016/0003-2697(91)90022-L; CHARLTON PA, 1979, J CHEM SOC CHEM COMM, P922, DOI 10.1039/c39790000922; DEBOUCK C, 1990, DRUG DEVELOP RES, V21, P1, DOI 10.1002/ddr.430210102; FISCHER G, 1983, BIOCHIM BIOPHYS ACTA, V742, P452, DOI 10.1016/0167-4838(83)90261-3; FISCHER G, 1984, BIOCHIM BIOPHYS ACTA, V791, P87, DOI 10.1016/0167-4838(84)90285-1; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; GEOGHEGAN KF, 1990, FEBS LETT, V262, P119, DOI 10.1016/0014-5793(90)80168-I; HOLZMAN TF, 1991, J BIOL CHEM, V266, P19217; KING GF, 1986, BIOCHEMISTRY-US, V25, P1054, DOI 10.1021/bi00353a016; KNIGHT M, 1995, ACS SYM SER, V593, P111; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; KRAFFT GA, 1993, ACS SYM SER, V538, P183; KUZMIC P, 1993, BIOCHEM BIOPH RES CO, V194, P301, DOI 10.1006/bbrc.1993.1819; LIN LN, 1979, BIOCHEMISTRY-US, V18, P43, DOI 10.1021/bi00568a007; LIN LN, 1983, BIOCHEMISTRY-US, V22, P553, DOI 10.1021/bi00272a005; LIN LN, 1983, BIOCHEMISTRY-US, V22, P4480, DOI 10.1021/bi00288a020; LIN LN, 1979, BIOCHEMISTRY-US, V18, P5037, DOI 10.1021/bi00590a002; LONDON RE, 1990, BIOCHEMISTRY-US, V29, P10298, DOI 10.1021/bi00497a002; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161; MOORE ML, 1989, BIOCHEM BIOPH RES CO, V159, P420, DOI 10.1016/0006-291X(89)90008-9; MORRIS GA, 1978, J MAGN RESON, V29, P433, DOI 10.1016/0022-2364(78)90003-3; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; PERRIN CL, 1990, J MAGN RESON, V90, P363, DOI 10.1016/0022-2364(90)90143-W; PETTIT SC, 1994, J VIROL, V68, P8017, DOI 10.1128/JVI.68.12.8017-8027.1994; ROSE JR, 1993, J BIOL CHEM, V268, P11939; SARUBBI E, 1991, FEBS LETT, V279, P265, DOI 10.1016/0014-5793(91)80164-X; SLEE DH, 1995, J AM CHEM SOC, V117, P11867, DOI 10.1021/ja00153a008; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; TOMASSELLI AG, 1995, ADV EXP MED BIOL, V362, P387; TYAGI SC, 1994, BIOCHEM CELL BIOL, V72, P175, DOI 10.1139/o94-026; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; WANG GT, 1990, TETRAHEDRON LETT, V31, P6493, DOI 10.1016/S0040-4039(00)97099-0	37	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15603	15606		10.1074/jbc.272.25.15603	http://dx.doi.org/10.1074/jbc.272.25.15603			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188447	hybrid			2022-12-27	WOS:A1997XF32900007
J	Webb, E; Downs, D				Webb, E; Downs, D			Characterization of thiL, encoding thiamin-monophosphate kinase, in Salmonella typhimurium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE; TRANSPOSITION; TRANSDUCTION; MUTAGENESIS; RESISTANCE; OPERON; SEARCH	Thiamin pyrophosphate is an essential cofactor that is synthesized de novo by Salmonella typhimurium. In bacteria, the end product of the de novo biosynthetic pathway is thiamin monophosphate, which is then phosphorylated by thiamin-monophosphate kinase (EC 2.7.4.16) to form thiamin pyrophosphate, We have isolated anti characterized the thiL, gene of S. typhimurium and showed that thiL is a 978-base pair open reading frame encoding a 35-kDa protein with thiamin-monophosphate kinase activity. thiL, was located in the 10-centisome region of the S. typhimurium chromosome, We demonstrated that altered thiamin-monophosphate kinase activity resulted in decreased repression of transcription of thiamin pyrophosphate-regulated thiamin biosynthetic genes. In contrast to other thi loci, thiL is not transcriptionally regulated bg thiamin pyrophosphate. This result is consistent with a dual role for ThiL in de novo biosynthesis and in salvage of exogenous thiamin.	UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047296] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47296] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BACKSTROM AD, 1995, J AM CHEM SOC, V117, P2351, DOI 10.1021/ja00113a025; BEGLEY TP, 1996, NAT PROD REP, V13, P178; BENSON NR, 1992, J BACTERIOL, V174, P1673, DOI 10.1128/jb.174.5.1673-1681.1992; BORK P, 1995, PROTEIN SCI, V4, P268; CASTILHO BA, 1984, J BACTERIOL, V158, P488, DOI 10.1128/JB.158.2.488-495.1984; CHAN RK, 1972, VIROLOGY, V50, P883, DOI 10.1016/0042-6822(72)90442-4; CHEN P, 1995, J BACTERIOL, V177, P1461, DOI 10.1128/jb.177.6.1461-1469.1995; Davis R., 1980, ADV BACTERIAL GENETI; DOWNS DM, 1994, J BACTERIOL, V176, P4858, DOI 10.1128/jb.176.16.4858-4864.1994; ESCALANTESEMERENA JC, 1987, J BACTERIOL, V169, P2251, DOI 10.1128/jb.169.5.2251-2258.1987; HUGHES KT, 1988, GENETICS, V119, P9; HUGHES KT, 1985, GENETICS, V109, P263; IMAMURA N, 1982, J BACTERIOL, V151, P708, DOI 10.1128/JB.151.2.708-717.1982; KAWASAKI T, 1986, METHOD ENZYMOL, V122, P15, DOI 10.1016/0076-6879(86)22141-2; KLECKNER N, 1977, J MOL BIOL, V116, P125, DOI 10.1016/0022-2836(77)90123-1; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; Miller J.H., 1972, EXPT MOL GENETICS; NAKAYAMA H, 1972, J BACTERIOL, V112, P1118, DOI 10.1128/JB.112.3.1118-1126.1972; NOSAKA K, 1993, J BIOL CHEM, V268, P17440; NOSAKA K, 1994, J BIOL CHEM, V269, P30510; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIEGER H, 1972, MOL GEN GENET, V119, P75, DOI 10.1007/BF00270447; TABOR S, 1990, CURRENT PROTOCOLS MO; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WAY JC, 1984, GENE, V32, P369, DOI 10.1016/0378-1119(84)90012-X; Webb E, 1996, J BACTERIOL, V178, P2533, DOI 10.1128/jb.178.9.2533-2538.1996; WEBB E, 1997, IN PRESS J BACTERIOL; YOUDERIAN P, 1988, GENETICS, V118, P581	29	51	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15702	15707		10.1074/jbc.272.25.15702	http://dx.doi.org/10.1074/jbc.272.25.15702			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188462	hybrid			2022-12-27	WOS:A1997XF32900022
J	Xu, C; Rosen, BP				Xu, C; Rosen, BP			Dimerization is essential for DNA binding and repression by the ArsR metalloregulatory protein of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-HYBRID SYSTEM; IDENTIFICATION; EXPRESSION; IDENTIFY; OPERON; GENES; YEAST; P53	Arsenical resistance (ars) operons produce resistance to trivalent and pentavalent salts of the metalloids arsenic and antimony in cells of Escherichia coli. The first gene in the operon, arsR, was previously shown to encode a homodimeric trans-acting metalloregulatory repressor protein, Dimerization of ArsR was investigated using the yeast two-hybrid system in which the ArsR protein was fused to the Saccharomyces cerevisiae GAL4 DNA-binding domain and GAL4 activation domain to produce chimeric proteins, Transcriptional activation of lacZ reporter indicated that dimerization of the ArsR is stable in yeast. The results indicated that residues 1-8 and 90-117 are not required for ArsR dimerization. The genes for a series of truncated ArsR proteins containing six histidine tags were constructed and the proteins purified. The mass of each recombinant protein, as determined by size exclusion chromatography, mas consistent; with the results from two-hybrid analysis. The results of beta-galaftosidase assays in vivo and gel mobility shift assays in vitro showed that dimers retained the ability to bind to the ars promoter and to respond to inducer; whereas monomeric ArsRs did neither. These results suggest that a core sequence of about 80 residues has al of the information necessary for dimerization, repression, and metal recognition.	WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM & MOL BIOL, DETROIT, MI 48201 USA	Wayne State University				Rosen, Barry P./0000-0002-5230-4271				BARTEL P, 1993, BIOTECHNIQUES, V14, P920; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CARLIN A, 1995, J BACTERIOL, V177, P981, DOI 10.1128/jb.177.4.981-986.1995; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRITZ C C, 1992, Current Biology, V2, P403, DOI 10.1016/0960-9822(92)90315-2; GUARENTE L, 1993, P NATL ACAD SCI USA, V90, P1639, DOI 10.1073/pnas.90.5.1639; IWABUCHI K, 1993, ONCOGENE, V8, P1693; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI B, 1993, FASEB J, V7, P957, DOI 10.1096/fasebj.7.10.8344494; Miller J.H., 1992, SHORT COURSE BACTERI, P150; ROSEN BP, 1995, J BIOENERG BIOMEMBR, V27, P85, DOI 10.1007/BF02110335; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shi WP, 1996, J BIOL CHEM, V271, P9291, DOI 10.1074/jbc.271.16.9291; SHI WP, 1994, J BIOL CHEM, V269, P19826; SOFIA HJ, 1994, NUCLEIC ACIDS RES, V22, P2576, DOI 10.1093/nar/22.13.2576; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; White MA, 1996, P NATL ACAD SCI USA, V93, P10001, DOI 10.1073/pnas.93.19.10001; WU JH, 1993, J BIOL CHEM, V268, P52; Xu C, 1996, J BIOL CHEM, V271, P2427, DOI 10.1074/jbc.271.5.2427	24	38	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15734	15738		10.1074/jbc.272.25.15734	http://dx.doi.org/10.1074/jbc.272.25.15734			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188467	hybrid			2022-12-27	WOS:A1997XF32900027
J	Ortiz, DF; StPierre, MV; Abdulmessih, A; Arias, IM				Ortiz, DF; StPierre, MV; Abdulmessih, A; Arias, IM			A yeast ATP-binding cassette-type protein mediating ATP-dependent bile acid transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANALICULAR MEMBRANE-VESICLES; MULTIDRUG-RESISTANCE GENE; P-GLYCOPROTEIN GENE; RAT-LIVER; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; TAUROCHOLATE TRANSPORT; SECRETORY VESICLES; ECTO-ATPASE; VACUOLAR MEMBRANE	ATP-dependent transport of bile acids is a key determinant of bile flow in mammalian liver and is associated with cholesterol excretion, gallstone formation, and numerous inherited and acquired hepatobiliary diseases, Secretory vesicles and a vacuole enriched fraction purified from Saccharomyces cerevisiae also exhibit ATP-dependent bile acid transport. ATP-dependent transport of bile acids by the vacuolar fraction was independent of the vacuolar proton ATPase, responded to changes in the osmotically sensitive intravesicular space, and was saturable, exhibiting a K-m of 63 mu M for taurocholate, The BAT1 (bile acid transporter) gene was isolated from yeast DNA by polymerase chain reaction amplification using degenerate oligonucleotides hybridizing to conserved regions of ABC-type proteins, ATP-dependent bile acid transport was abolished when the BAT1 coding region was deleted from the genome and restored upon reintroduction of the gene. The deduced amino acid sequence predicts that Bat1p is an ABC-type protein 1661 amino acids in length, similar to mammalian cMOAT/cMRP1 and MRP1 transporters, yeast Ycf1p, and two yeast proteins of unknown function. Information obtained from the yeast BAT1 gene may aid identification of the gene encoding the mammalian bile acid transporter.			Ortiz, DF (corresponding author), TUFTS UNIV, SCH MED, DEPT PHYSIOL, 136 HARRISON AVE, BOSTON, MA 02111 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035652, R01DK035652, R03DK051005] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK51005-01, 1 P30 DK39428, DK35652] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI Y, 1991, HEPATOLOGY, V14, P655, DOI 10.1016/0270-9139(91)90053-X; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ALM RA, 1990, MOL MICROBIOL, V4, P413, DOI 10.1111/j.1365-2958.1990.tb00608.x; AWASTHI YC, 1981, BLOOD, V58, P733; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BALZI E, 1994, J BIOL CHEM, V269, P2206; BANKER GA, 1972, J BIOL CHEM, V247, P5856; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; Buchler M, 1996, J BIOL CHEM, V271, P15091; CHU S, 1993, J BACTERIOL, V175, P3105, DOI 10.1128/JB.175.10.3105-3114.1993; CHUMAKOV KM, 1988, MOLEKULARNAYA GENETI, V3, P3; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; COOPER A, 1992, J CELL BIOL, V119, P1459, DOI 10.1083/jcb.119.6.1459; DEAN M, 1994, YEAST, V10, P377, DOI 10.1002/yea.320100310; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1730; HARLOW E, 1988, ANTIBODIES LAB MANUA, P450; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HORTENSTEINER S, 1993, J BIOL CHEM, V268, P18446; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; INOUE M, 1983, J BIOL CHEM, V258, P5183; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KAST C, 1994, J BIOL CHEM, V269, P5179; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; LIN SH, 1989, J BIOL CHEM, V264, P14403; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANIVASAKAM P, 1995, NUCLEIC ACIDS RES, V23, P2799, DOI 10.1093/nar/23.14.2799; MARIN JJG, 1995, AM J PHYSIOL-GASTR L, V268, pG685, DOI 10.1152/ajpgi.1995.268.4.G685; MAYER R, 1995, J CELL BIOL, V131, P137, DOI 10.1083/jcb.131.1.137; MEIER PJ, 1987, BIOCHEM J, V242, P465, DOI 10.1042/bj2420465; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; Nies AT, 1996, J LIPID RES, V37, P1125; NISHIDA T, 1991, P NATL ACAD SCI USA, V88, P6590, DOI 10.1073/pnas.88.15.6590; NISHIDA T, 1995, HEPATOLOGY, V21, P1058, DOI 10.1016/0270-9139(95)90255-4; ORTIZ DF, 1992, EMBO J, V11, P3491, DOI 10.1002/j.1460-2075.1992.tb05431.x; OUELLETTE M, 1990, EMBO J, V9, P1027, DOI 10.1002/j.1460-2075.1990.tb08206.x; PARRY RV, 1989, J BIOL CHEM, V264, P20025; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169; POUPON R, 1976, EUR J CLIN INVEST, V6, P279, DOI 10.1111/j.1365-2362.1976.tb00522.x; PURNELLE B, 1991, YEAST, V7, P867, DOI 10.1002/yea.320070813; RAYMOND M, 1989, P NATL ACAD SCI USA, V86, P6488, DOI 10.1073/pnas.86.17.6488; REICHEN J, 1976, AM J PHYSIOL, V231, P734, DOI 10.1152/ajplegacy.1976.231.3.734; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROST B, 1995, PROTEIN SCI, V4, P521; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; RUETZ S, 1994, J BIOL CHEM, V269, P12277; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; SILVE S, 1991, MOL CELL BIOL, V11, P1114, DOI 10.1128/MCB.11.2.1114; SIPPEL CJ, 1993, J BIOL CHEM, V268, P2083; SIPPEL CJ, 1994, J BIOL CHEM, V269, P2820; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; STIEGER B, 1992, BIOCHEM J, V284, P67, DOI 10.1042/bj2840067; STPIERRE MV, 1994, P NATL ACAD SCI USA, V91, P9476, DOI 10.1073/pnas.91.20.9476; STPIERRE MV, 1994, HEPATOLOGY, V20, pA173; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tommasini R, 1996, P NATL ACAD SCI USA, V93, P6743, DOI 10.1073/pnas.93.13.6743; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; TUTTLE DL, 1993, EUR J CELL BIOL, V60, P283; WALWORTH JC, 1987, J CELL BIOL, V105, P165	65	68	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15358	15365		10.1074/jbc.272.24.15358	http://dx.doi.org/10.1074/jbc.272.24.15358			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182565	hybrid			2022-12-27	WOS:A1997XE03400048
J	Ambrosino, C; Ruocco, MR; Chen, XN; Mallardo, M; Baudi, F; Trematerra, S; Quinto, I; Venuta, S; Scala, G				Ambrosino, C; Ruocco, MR; Chen, XN; Mallardo, M; Baudi, F; Trematerra, S; Quinto, I; Venuta, S; Scala, G			HIV-1 Tat induces the expression of the interleukin-6 (IL6) gene by binding to the IL6 leader RNA and by interacting with CAAT enhancer-binding protein beta (NF-IL6) transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; TRANS-ACTIVATOR GENE; CENTRAL NERVOUS-SYSTEM; TYPE-1 TAT; T-CELLS; MEDIATED TRANSACTIVATION; KAPOSIS-SARCOMA; HTLV-III; IN-VITRO	Human immunodeficiency virus type 1 (HIV-1) infection is associated with severe psoriasis, B cell lymphoma, and Kaposi's sarcoma, A deregulated production of interleukin-6 (IL6) has been implicated in the pathogenesis of these diseases, The molecular mechanisms underlying the abnormal IL6 secretion of HIV-1-infected cells may include transactivation of the IL6 gene by HIV-1. Here we report the molecular mechanisms of Tat activity on the expression of the IL6 gene. By using 5' deletion mutants of pIL6Pr-CAT and using IL6:HIV-1-LTR hybrid constructs where discrete regions of the IL6 promoter replaced the TAR sequence in HIV-1 LTR, we identified a short sequence of the 5'-untranslated region of the IL6 mRNA that is required for Tat to trans-activate the IL6 promoter, This sequence acquires a stem-loop structure and includes a UCU sequence that binds to Tat and is necessary for full trans-activation, In addition, we provide the evidence that Tat can function by enhancing the CAAT enhancer-binding protein (C/EBP) DNA binding activity and is able to complex with in vitro translated C/EBP beta, which is a major mediator of IL6 promoter function, By using the yeast two-hybrid system and immunoprecipitation, we observed that the interaction of Tat with C/EBP proteins also occurred in vivo. The data are consistent with the possibility that Tat may function on heterologous genes by interacting with RNA structures possibly present in a large number of cellular and viral genes. In addition, Tat may function by protein-protein interactions, leading to the generation of heterodimers with specific transcription factors.	UNIV REGGIO CALABRIA,SCH MED,DEPT CLIN & EXPT MED,I-88100 CATANZARO,ITALY; UNIV NAPLES FEDERICO II,SCH MED,DEPT BIOCHEM & BIOMED TECHNOL,I-80131 NAPLES,ITALY	Universita Mediterranea di Reggio Calabria; University of Naples Federico II			SCALA, GIUSEPPE/A-3280-2009	MALLARDO, Massimo/0000-0002-4001-3856; QUINTO, Ileana/0000-0001-8212-8515				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; BAGASRA O, 1992, J VIROL, V66, P7522, DOI 10.1128/JVI.66.12.7522-7528.1992; Baldassarre F, 1995, J BIOL CHEM, V270, P31244, DOI 10.1074/jbc.270.52.31244; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BARNETT RW, 1993, NUCLEIC ACIDS RES, V21, P151, DOI 10.1093/nar/21.1.151; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BIGGAR RJ, 1990, AIDS, V4, P1059, DOI 10.1097/00002030-199011000-00002; BOGERD HP, 1993, J VIROL, V67, P5030, DOI 10.1128/JVI.67.8.5030-5034.1993; BREEN EC, 1990, J IMMUNOL, V144, P480; BUONAGURO L, 1994, J VIROL, V68, P2677, DOI 10.1128/JVI.68.4.2677-2682.1994; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CAPUTO A, 1990, J ACQ IMMUN DEF SYND, V3, P372; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHIRMULE N, 1995, J VIROL, V69, P492, DOI 10.1128/JVI.69.1.492-498.1995; CHOWDHURY M, 1992, J VIROL, V66, P7355, DOI 10.1128/JVI.66.12.7355-7361.1992; CORALLINI A, 1993, CANCER RES, V53, P5569; CULLEN BR, 1993, CELL, V73, P417, DOI 10.1016/0092-8674(93)90126-B; DANG CV, 1989, J BIOL CHEM, V264, P18019; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; DESAI K, 1991, P NATL ACAD SCI USA, V88, P8875, DOI 10.1073/pnas.88.20.8875; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; FAUCI AS, 1984, ANN INTERN MED, V100, P92, DOI 10.7326/0003-4819-100-1-92; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GALLO P, 1989, J NEUROIMMUNOL, V23, P109, DOI 10.1016/0165-5728(89)90029-5; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOWCROFT TK, 1995, IMMUNITY, V3, P127; HOWCROFT TK, 1992, SCIENCE, V269, P1320; HUANG LM, 1994, EMBO J, V13, P2886, DOI 10.1002/j.1460-2075.1994.tb06583.x; JAKOBOVITS A, 1990, EMBO J, V9, P1165, DOI 10.1002/j.1460-2075.1990.tb08223.x; JEANG KT, 1993, J VIROL, V67, P6224, DOI 10.1128/JVI.67.10.6224-6233.1993; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; Kashanchi F, 1996, J VIROL, V70, P5503, DOI 10.1128/JVI.70.8.5503-5510.1996; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; LAPSIA MF, 1989, CELL, V59, P283; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LEONARD J, 1989, J VIROL, V63, P4919, DOI 10.1128/JVI.63.11.4919-4924.1989; LEVINE AM, 1992, BLOOD, V80, P8; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; Mavankal G, 1996, P NATL ACAD SCI USA, V93, P2089, DOI 10.1073/pnas.93.5.2089; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; NAKAJIMA K, 1989, J IMMUNOL, V142, P144; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; PAUL WE, 1995, CELL, V82, P177, DOI 10.1016/0092-8674(95)90304-6; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; RICE AP, 1988, NATURE, V332, P551, DOI 10.1038/332551a0; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; Ruocco MR, 1996, J BIOL CHEM, V271, P22479, DOI 10.1074/jbc.271.37.22479; SALK J, 1993, SCIENCE, V260, P1270, DOI 10.1126/science.8098553; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; SASTRY KJ, 1990, J BIOL CHEM, V265, P20091; SCALA G, 1993, J VIROL, V67, P2853, DOI 10.1128/JVI.67.5.2853-2861.1993; SCALA G, 1990, J EXP MED, V172, P61, DOI 10.1084/jem.172.1.61; SCALA G, 1994, J EXP MED, V179, P961, DOI 10.1084/jem.179.3.961; Schafer SL, 1996, J VIROL, V70, P6937, DOI 10.1128/JVI.70.10.6937-6946.1996; SHARP PA, 1989, CELL, V59, P229, DOI 10.1016/0092-8674(89)90279-1; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; SIOMI H, 1990, J VIROL, V64, P1803, DOI 10.1128/JVI.64.4.1803-1807.1990; SODROSKI J, 1985, SCIENCE, V229, P74, DOI 10.1126/science.2990041; TAYLOR JP, 1994, J VIROL, V68, P3971, DOI 10.1128/JVI.68.6.3971-3981.1994; TAYLOR JP, 1992, P NATL ACAD SCI USA, V89, P9617, DOI 10.1073/pnas.89.20.9617; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WESTENDORP MO, 1994, J VIROL, V68, P4177, DOI 10.1128/JVI.68.7.4177-4185.1994; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; WEY X, 1995, NATURE, V373, P117; Yang XZ, 1996, J VIROL, V70, P4576, DOI 10.1128/JVI.70.7.4576-4584.1996; YASUKAWA K, 1987, EMBO J, V6, P2939, DOI 10.1002/j.1460-2075.1987.tb02598.x; ZAULI G, 1993, CANCER RES, V53, P4481; Zhou QA, 1996, SCIENCE, V274, P605, DOI 10.1126/science.274.5287.605; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	87	96	98	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14883	14892		10.1074/jbc.272.23.14883	http://dx.doi.org/10.1074/jbc.272.23.14883			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169458	hybrid			2022-12-27	WOS:A1997XC32700055
J	Nagaich, AK; Appella, E; Harrington, RE				Nagaich, AK; Appella, E; Harrington, RE			DNA bending is essential for the site-specific recognition of DNA response elements by the DNA binding domain of the tumor suppressor protein p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE; TRANSCRIPTION INITIATION; GEL-ELECTROPHORESIS; CRYSTAL-STRUCTURE; MUTANT P53; SEQUENCE; COMPLEXES; GENE; BIREFRINGENCE; REPLICATION	We have used circular permutation assays to determine the extent and location of the DNA bend induced by the DNA binding domain of human wild type p53 (p53DBD) upon binding to several naturally occurring DNA response elements. We have found that p53DBD binding induces axial bending in all of the response elements investigated. In particular, response elements having a d(CATG) sequence at the junction of two consensus pentamers in each half-site favor highly bent complexes (bending angle is similar to 50 degrees), whereas response elements having d(CTTG) bases at this position are less bent (bending angles from similar to 37 to similar to 25 degrees). Quantitative electrophoretic mobility shift assays of different complexes show a direct correlation between the DNA bending angle and the binding affinity of the p53DBD with the response elements, i.e. the greater the stability of the complex, the more the DNA is bent by p53DBD binding. The study provides evidence that the energetics of DNA bending, as determined by the presence or absence of flexible sites in the response elements, may contribute significantly to the overall binding affinity of the p53DBD for different sequences. The results therefore suggest that both the structure and the stability of the p53-DNA complex may vary with different response elements. This variability may be correlated with variability in p53 function.	UNIV NEVADA,DEPT BIOCHEM 330,RENO,NV 89557; NCI,CELL BIOL LAB,NIH,BETHESDA,MD 20892	Nevada System of Higher Education (NSHE); University of Nevada Reno; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NCI NIH HHS [CA70274] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070274] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARBER AM, 1990, J BIOMOL STRUCT DYN, V8, P213, DOI 10.1080/07391102.1990.10507803; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BRENOWITZ M, 1990, BIOCHEMISTRY-US, V29, P3374, DOI 10.1021/bi00465a033; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; CAIRNEY KL, 1982, BIOPOLYMERS, V21, P923, DOI 10.1002/bip.360210506; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CAREY J, 1988, P NATL ACAD SCI USA, V85, P975, DOI 10.1073/pnas.85.4.975; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; GORIN AA, 1995, J MOL BIOL, V247, P34, DOI 10.1006/jmbi.1994.0120; HAGERMAN PJ, 1981, BIOPOLYMERS, V20, P1503, DOI 10.1002/bip.1981.360200710; Hagerman PJ, 1996, P NATL ACAD SCI USA, V93, P9993, DOI 10.1073/pnas.93.19.9993; HARPER JW, 1993, CELL, V75, P805; HARRINGTON RE, 1994, PROG NUCLEIC ACID RE, V47, P195, DOI 10.1016/S0079-6603(08)60253-6; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kristjuhan A, 1995, EUR J BIOCHEM, V234, P827, DOI 10.1111/j.1432-1033.1995.827_a.x; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; LEVENE SD, 1989, SCIENCE, V245, P396, DOI 10.1126/science.2756426; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; LUMPKIN OJ, 1982, BIOPOLYMERS, V21, P2315, DOI 10.1002/bip.360211116; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MCNAMARA PT, 1990, J BIOMOL STRUCT DYN, V8, P529, DOI 10.1080/07391102.1990.10507827; MIYASHITA T, 1995, CELL, V80, P293; NAGAICH AK, 1994, J BIOL CHEM, V269, P7824; Nagaich AK, 1997, J BIOL CHEM, V272, P14830, DOI 10.1074/jbc.272.23.14830; NAMBA H, 1995, CANCER RES, V55, P2075; NARDULLI AM, 1992, MOL CELL BIOL, V12, P2037, DOI 10.1128/MCB.12.5.2037; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; PRIVES C, 1994, COLD SPRING HARB SYM, V59, P207, DOI 10.1101/SQB.1994.059.01.025; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; Sambrook J., 2002, MOL CLONING LAB MANU; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SENEAR DF, 1991, J BIOL CHEM, V266, P13661; Sitlani A, 1996, P NATL ACAD SCI USA, V93, P3248, DOI 10.1073/pnas.93.8.3248; STARR DB, 1995, J MOL BIOL, V250, P434; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; VANDERVLIET PC, 1993, BIOESSAYS, V15, P25, DOI 10.1002/bies.950150105; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZHANG W, 1993, CANCER RES, V53, P4272; ZHURKIN VB, 1991, P NATL ACAD SCI USA, V88, P7046, DOI 10.1073/pnas.88.16.7046; ZINKEL SS, 1991, J MOL BIOL, V219, P201, DOI 10.1016/0022-2836(91)90562-K	64	86	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14842	14849		10.1074/jbc.272.23.14842	http://dx.doi.org/10.1074/jbc.272.23.14842			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169453	hybrid			2022-12-27	WOS:A1997XC32700050
J	Sangameswaran, L; Fish, LM; Koch, BD; Rabert, DK; Delgado, SG; Ilnicka, M; Jakeman, LB; Novakovic, S; Wong, K; Sze, P; Tzoumaka, E; Stewart, GR; Herman, RC; Chan, H; Eglen, RM; Hunter, JC				Sangameswaran, L; Fish, LM; Koch, BD; Rabert, DK; Delgado, SG; Ilnicka, M; Jakeman, LB; Novakovic, S; Wong, K; Sze, P; Tzoumaka, E; Stewart, GR; Herman, RC; Chan, H; Eglen, RM; Hunter, JC			A novel tetrodotoxin-sensitive, voltage-gated sodium channel expressed in rat and human dorsal root ganglia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SKELETAL-MUSCLE; FUNCTIONAL EXPRESSION; XENOPUS-OOCYTES; ALPHA-SUBUNIT; NA+ CHANNELS; BRAIN; CELLS; RNA; INJECTION; CLONING	Dorsal root ganglion neurons express a wide repertoire of sodium channels with different properties. Here, we report the cloning from rat, dorsal root ganglia (DRG), cellular expression, and functional analysis of a novel tetrodotoxin-sensitive peripheral sodium channel (PN), PN1. PN1 mRNA is expressed in many different tissues. Within the rat DRG, both the mRNA and PN1-like immunoreactivity are present in small and large neurons. The abundance of sodium channel mRNAs in rat DRG is rBI > PN1 greater than or equal to PN3 >>> rBIII by quantitative reverse transcription-polymerase chain reaction analysis. Data from reverse transcription-polymerase chain reaction and sequence analyses of human DRG and other human tissues suggest that rat PN1 is an ortholog of the human neuroendocrine channel. In Xenopus oocytes, PN1 exhibits kinetics that are similar to rBIIa sodium currents and is inhibited by tetrodotoxin with an IC50 of 4.3 +/- 0.92 nM. Unlike rBIIa, the inactivation kinetics of PN1 are not accelerated by the coexpression of the beta-subunits.			Sangameswaran, L (corresponding author), ROCHE BIOSCI,DEPT MOL PHARMACOL,CTR BIOL RES,NEUROBIOL UNIT,3401 HILLVIEW AVE,PALO ALTO,CA 94304, USA.			Jakeman, Lyn/0000-0002-1760-8819; Koch, Bruce/0000-0003-1713-2301				AHMED CMI, 1992, P NATL ACAD SCI USA, V89, P8220, DOI 10.1073/pnas.89.17.8220; Akopian AN, 1996, NATURE, V379, P257, DOI 10.1038/379257a0; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BELCHER SM, 1995, P NATL ACAD SCI USA, V92, P11034, DOI 10.1073/pnas.92.24.11034; Benzanilla F, 1977, J GEN PHYSIOL, V70, P549; Catterall W A, 1991, Curr Opin Neurobiol, V1, P5, DOI 10.1016/0959-4388(91)90004-Q; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CRIBBS LL, 1990, FEBS LETT, V275, P195, DOI 10.1016/0014-5793(90)81470-9; DARCANGELO G, 1993, J CELL BIOL, V122, P915, DOI 10.1083/jcb.122.4.915; ELLIOTT AA, 1993, J PHYSIOL-LONDON, V463, P39, DOI 10.1113/jphysiol.1993.sp019583; FLEIG A, 1994, PFLUG ARCH EUR J PHY, V427, P399, DOI 10.1007/BF00374253; FRANKE C, 1990, PFLUG ARCH EUR J PHY, V415, P399, DOI 10.1007/BF00373616; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; GEORGE AL, 1992, P NATL ACAD SCI USA, V89, P4893, DOI 10.1073/pnas.89.11.4893; GEORGE AL, 1992, ANN NEUROL, V31, P131, DOI 10.1002/ana.410310203; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P279; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; HUGUENARD JR, 1988, J NEUROPHYSIOL, V59, P778, DOI 10.1152/jn.1988.59.3.778; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; JOHO RH, 1990, MOL BRAIN RES, V7, P105, DOI 10.1016/0169-328X(90)90087-T; KALLEN RG, 1993, MOL NEUROBIOL, V7, P383, DOI 10.1007/BF02769184; KLUGBAUER N, 1995, EMBO J, V14, P1084, DOI 10.1002/j.1460-2075.1995.tb07091.x; Kozak CA, 1996, MAMM GENOME, V7, P787, DOI 10.1007/s003359900235; MOORMAN JR, 1990, NEURON, V4, P243, DOI 10.1016/0896-6273(90)90099-2; NILIUS B, 1988, BIOPHYS J, V53, P857, DOI 10.1016/S0006-3495(88)83166-7; PATTON DE, 1991, NEURON, V7, P637, DOI 10.1016/0896-6273(91)90376-B; PATTON DE, 1994, J BIOL CHEM, V269, P17649; RAMAKRISHNAN R, 1994, J VIROL, V68, P1864, DOI 10.1128/JVI.68.3.1864-1873.1994; Sangameswaran L, 1996, J BIOL CHEM, V271, P5953, DOI 10.1074/jbc.271.11.5953; SCHREIBMAYER W, 1994, PFLUG ARCH EUR J PHY, V426, P453, DOI 10.1007/BF00388310; SUZUKI H, 1988, FEBS LETT, V228, P195, DOI 10.1016/0014-5793(88)80615-X; TOLEDOARAL JJ, 1995, NEURON, V14, P607, DOI 10.1016/0896-6273(95)90317-8; TRIMMER JS, 1989, NEURON, V3, P233; ZHOU JY, 1991, NEURON, V7, P775, DOI 10.1016/0896-6273(91)90280-D	36	231	261	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14805	14809		10.1074/jbc.272.23.14805	http://dx.doi.org/10.1074/jbc.272.23.14805			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169448	hybrid			2022-12-27	WOS:A1997XC32700045
J	Kleeman, TA; Wei, DB; Simpson, KL; First, EA				Kleeman, TA; Wei, DB; Simpson, KL; First, EA			Human tyrosyl tRNA synthetase shares amino acid sequence homology with a putative cytokine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; SITE-DIRECTED MUTAGENESIS; SPECIES-SPECIFIC AMINOACYLATION; ACTIVATING POLYPEPTIDE-II; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; BACILLUS-STEAROTHERMOPHILUS; CRYSTAL-STRUCTURE; ANTICODON LOOP; SEARCH TOOL	To test the hypothesis that tRNA(Tyr) recognition differs between bacterial and human tyrosyl-tRNA synthetases, we sequenced several clones identified as human tyrosyl-tRNA synthetase cDNAs by the Human Genome Project, We found that human tyrosyl-tRNA synthetase is composed of three domains: 1) an aminoterminal Rossmann fold domain that is responsible for formation of the activated E.Tyr-AMP intermediate and is conserved among bacteria, archeae, and eukaryotes; 2) a tRNA anticodon recognition domain that has not been conserved between bacteria and eukaryotes; and 3) a carboxyl-terminal domain that is unique to the human tyrosyl-tRNA synthetase and whose primary structure is 49% identical to the putative human cytokine endothelial monocyte-activating protein II, 50% identical to the carboxyl-terminal domain of methionyl-tRNA synthetase from Caenorhabditis elegans, and 43% identical to the carboxyl-terminal domain of Arc1p from Saccharomyces cerevisiae, The first two domains of the human tyrosyl-tRNA synthetase are 52, 36, and 16% identical to tyrosyl-tRNA synthetases from S. cerevisiae, Methanococcus jannaschii, and Bacillus stearothermophilus, respectively, Nine of fifteen amino acids known to be involved in the formation of the tyrosyl-adenylate complex in B. stearothermophilus are conserved across all of the organisms, whereas amino acids involved in the recognition of tRNA(Tyr) are not conserved, Kinetic analyses of recombinant human and B. stearothermophilus tyrosyl-tRNA synthetases expressed in Escherichia cell indicate that human tyrosyl-tRNA synthetase ami noacylates human but not B. stearothermophilus tRNA(Tyr), and vice versa, supporting the original hypothesis, It is proposed that like endothelial monocyte-activating protein II and the carboxyl-terminal domain of Arc1p, the carboxyl-terminal domain of human tyrosyl-tRNA synthetase evolved from gene duplication of the carboxyl-terminal domain of methionyl-tRNA synthetase and may direct tRNA to the active site of the enzyme.	LOUISIANA STATE UNIV,MED CTR,DEPT BIOCHEM & MOL BIOL,SHREVEPORT,LA 71130	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053693] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53693-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AVIS JM, 1993, BIOCHEMISTRY-US, V32, P5312, DOI 10.1021/bi00071a005; BEDOUELLE H, 1995, EMBO J, V14, P2945, DOI 10.1002/j.1460-2075.1995.tb07294.x; BEDOUELLE H, 1993, BIOCHIMIE, V75, P1099, DOI 10.1016/0300-9084(93)90009-H; BEDOUELLE H, 1986, NATURE, V320, P371, DOI 10.1038/320371a0; BEDOUELLE H, 1990, BIOCHIMIE, V72, P589, DOI 10.1016/0300-9084(90)90122-W; BHAT TN, 1982, J MOL BIOL, V158, P699, DOI 10.1016/0022-2836(82)90255-8; BIRNBOIM HC, 1983, METHOD ENZYMOL, V100, P243; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; BRICK P, 1987, J MOL BIOL, V194, P287, DOI 10.1016/0022-2836(87)90376-7; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; BUECHTER DD, 1993, CRIT REV BIOCHEM MOL, V28, P309, DOI 10.3109/10409239309078438; CASSIO D, 1971, EUR J BIOCHEM, V20, P283, DOI 10.1111/j.1432-1033.1971.tb01393.x; CHOW CM, 1993, J BIOL CHEM, V268, P12855; CLARK JM, 1962, J BIOL CHEM, V237, P3698; dePouplana LR, 1996, P NATL ACAD SCI USA, V93, P166, DOI 10.1073/pnas.93.1.166; DOCTOR BP, 1963, J BIOL CHEM, V238, P3677; DORIZZI M, 1977, NUCLEIC ACIDS RES, V4, P31, DOI 10.1093/nar/4.1.31; DOUBLIE S, 1995, STRUCTURE, V3, P17, DOI 10.1016/S0969-2126(01)00132-0; Drabkin HJ, 1996, MOL CELL BIOL, V16, P907; EDWARDS H, 1991, P NATL ACAD SCI USA, V88, P1153, DOI 10.1073/pnas.88.4.1153; ERIANI G, 1995, J MOL EVOL, V40, P499; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1581, DOI 10.1021/bi00405a028; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; FIRST EA, 1993, BIOCHEMISTRY-US, V32, P13651, DOI 10.1021/bi00212a033; FIRST EA, 1993, BIOCHEMISTRY-US, V32, P13658, DOI 10.1021/bi00212a034; FRANTZ JD, 1995, J BIOL CHEM, V270, P20692, DOI 10.1074/jbc.270.35.20692; GIEGE R, 1993, PROG NUCLEIC ACID RE, V45, P129, DOI 10.1016/S0079-6603(08)60869-7; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIPPS D, 1995, P NATL ACAD SCI USA, V92, P5550, DOI 10.1073/pnas.92.12.5550; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOUNTONDJI C, 1986, BIOCHIMIE, V68, P1071, DOI 10.1016/S0300-9084(86)80181-X; KAO J, 1992, J BIOL CHEM, V267, P20239; KAO J, 1994, J BIOL CHEM, V269, P25106; KIM JS, 1993, PROTEIN SCI, V2, P348; LABOUZE E, 1989, J MOL BIOL, V205, P729, DOI 10.1016/0022-2836(89)90317-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lage H, 1996, GENE, V178, P187, DOI 10.1016/0378-1119(96)00313-7; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; MEINNEL T, 1992, NUCLEIC ACIDS RES, V20, P4741, DOI 10.1093/nar/20.18.4741; Moras D, 1992, CURR OPIN STRUC BIOL, V2, P138; NEGRUTSKI BS, 1994, P NATL ACAD SCI USA, V91, P64; Pearson W R, 1994, Methods Mol Biol, V25, P365; QUINN CL, 1995, BIOCHEMISTRY-US, V34, P12489, DOI 10.1021/bi00039a001; RADLOFF R, 1967, P NATL ACAD SCI USA, V57, P1514, DOI 10.1073/pnas.57.5.1514; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWOB E, 1993, EMBO J, V12, P5201, DOI 10.1002/j.1460-2075.1993.tb06215.x; SHIBA K, 1994, J BIOL CHEM, V269, P30049; SIMONCSITS A, 1977, NATURE, V269, P833, DOI 10.1038/269833a0; Simos G, 1996, EMBO J, V15, P5437, DOI 10.1002/j.1460-2075.1996.tb00927.x; SMITH MC, 1988, J BIOL CHEM, V263, P7211; STAPULIONIS R, 1995, P NATL ACAD SCI USA, V92, P7158, DOI 10.1073/pnas.92.16.7158; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANTOL H, 1987, EMBO J, V6, P35, DOI 10.1002/j.1460-2075.1987.tb04715.x; VIDALCROS A, 1992, J MOL BIOL, V223, P801, DOI 10.1016/0022-2836(92)90991-R; WALTER P, 1983, P NATL ACAD SCI-BIOL, V80, P2437, DOI 10.1073/pnas.80.9.2437; WARD WHJ, 1988, BIOCHEMISTRY-US, V27, P1041, DOI 10.1021/bi00403a029; WARD WHJ, 1988, BIOCHEMISTRY-US, V27, P5525, DOI 10.1021/bi00415a021; WEBSTER T, 1984, SCIENCE, V226, P1315, DOI 10.1126/science.6390679; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WOLFSON AD, 1990, J CHROMATOGR, V503, P277, DOI 10.1016/S0021-9673(01)81511-9; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173	65	100	117	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14420	14425		10.1074/jbc.272.22.14420	http://dx.doi.org/10.1074/jbc.272.22.14420			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162081	hybrid			2022-12-27	WOS:A1997XB49200068
J	Mijatovic, T; Kruys, V; Caput, D; Defrance, P; Huez, G				Mijatovic, T; Kruys, V; Caput, D; Defrance, P; Huez, G			Interleukin-4 and -13 inhibit tumor necrosis factor-alpha mRNA translational activation in lipopolysaccharide-induced mouse macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TYROSINE PHOSPHORYLATION; GENE-EXPRESSION; PROTEIN-KINASES; CELLS; PATHWAY; BIOSYNTHESIS; SUPPRESSION; CYTOKINES; ENDOTOXIN	The production of tumor necrosis factor-alpha (TNF-alpha) by lipopolysaccharide (LPS)-stimulated macrophages can be markedly inhibited by the two closely related cytokines, interleukin (IL)-4 and IL-13. To investigate the molecular mechanism of this inhibition, we analyzed the effect of the two cytokines on TNF-alpha production and TNF-alpha mRNA accumulation in the mouse macrophage cell lines RAW 264.7 and 5774 stimulated by LPS, Whereas LPS induced TNF-alpha production is strongly suppressed by both cytokines, TNF-alpha mRNA accumulation is not significantly affected, indicating that IL,-4 and IL-13 induce a translational repression of TNF-alpha mRNA, Transfection of reporter gene constructs containing different regions of the TNF-alpha gene revealed that the inhibitory action ofIL-4 and IL-13 is mediated by the UA-rich sequence present in the TNF-alpha mRNA 3'-untranslated region.	FREE UNIV BRUSSELS, DEPT BIOL MOL, CHIM BIOL LAB, B-1640 RHODE ST GENESE, BRUSSELS, BELGIUM; SANOFI ELF BIORECH, F-31676 LABEGE, FRANCE	Sanofi-Aventis			Kruys, Veronique I/N-6613-2018	Kruys, Veronique/0000-0002-3144-5403				BEUTLER B, 1988, BIOCHEMISTRY-US, V27, P7575, DOI 10.1021/bi00420a001; BEUTLER BE, 1992, TUMOR NECROSIS FACTO; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; DANDREA A, 1995, J EXP MED, V181, P537, DOI 10.1084/jem.181.2.537; DEVRIES JE, 1993, RES IMMUNOL, V144, P597, DOI 10.1016/S0923-2494(05)80009-4; DOHERTY TM, 1993, J IMMUNOL, V151, P7151; DONG ZY, 1993, J EXP MED, V177, P1071, DOI 10.1084/jem.177.4.1071; Duschl A, 1996, EUR CYTOKINE NETW, V7, P37; ESSNER R, 1989, J IMMUNOL, V142, P3857; GAUTAM S, 1992, J IMMUNOL, V148, P1725; GEPPERT TD, 1994, MOL MED, V1, P93; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gueydan C, 1996, MOL MED, V2, P479, DOI 10.1007/BF03401907; HAN J, 1991, J IMMUNOL, V146, P1843; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAN JH, 1993, J BIOL CHEM, V268, P25009; HAN JH, 1991, BIOCHIM BIOPHYS ACTA, V1090, P22, DOI 10.1016/0167-4781(91)90032-H; HART PH, 1992, IMMUNOLOGY, V76, P560; HART PH, 1989, P NATL ACAD SCI USA, V86, P3803, DOI 10.1073/pnas.86.10.3803; KRUYS V, 1993, J EXP MED, V177, P1383, DOI 10.1084/jem.177.5.1383; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MALEFYT RD, 1993, RES IMMUNOL, V144, P629, DOI 10.1016/S0923-2494(05)80016-1; MALEFYT RD, 1993, J IMMUNOL, V151, P6370; Marchant A, 1996, J INFLAMM, V46, P114; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MIRESLUIS A, 1993, TRENDS BIOTECHNOL, V11, P74, DOI 10.1016/0167-7799(93)90053-C; OGARRA A, 1993, RES IMMUNOL, V144, P567, DOI 10.1016/S0923-2494(05)80003-3; PEPPEL K, 1991, J EXP MED, V173, P349, DOI 10.1084/jem.173.2.349; PRICHETT W, 1995, J INFLAMM, V45, P97; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; SONE S, 1992, EUR RESPIR J, V5, P174; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; Willeaume V, 1996, J INFLAMM, V46, P1	36	98	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14394	14398		10.1074/jbc.272.22.14394	http://dx.doi.org/10.1074/jbc.272.22.14394			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162077	hybrid			2022-12-27	WOS:A1997XB49200064
J	Rowell, CA; Kowalczyk, JJ; Lewis, MD; Garcia, AM				Rowell, CA; Kowalczyk, JJ; Lewis, MD; Garcia, AM			Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; CELLS; PRENYLATION; MEVALONATE; INHIBITORS; P21RAS; POTENT; FARNESYLTRANSFERASE; IDENTIFICATION; TRANSFERASE	It has recently been reported that Ki-Ras protein can be modified in vitro by farnesylation or geranylgeranylation. However, a previous analysis of Ki-Bas prenylation in vivo found only farnesylated Ki-Ras. In this report it is shown that under normal conditions, Ki-Ras is farnesylated in vivo and when cells are treated with the farnesyl transferase inhibitors B956 or B957, farnesylation is inhibited and Ki-Ras becomes geranylgeranylated in a dose dependent manner. These results have strong implications in the design of anticancer drugs based on inhibition of prenylation.	EISAI RES INST,ANDOVER,MA 01810	Eisai Co Ltd								BROWN MS, 1980, J LIPID RES, V21, P505; Buss JE, 1995, CHEM BIOL, V2, P787, DOI 10.1016/1074-5521(95)90083-7; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FAUST J, 1987, J BIOL CHEM, V262, P1996; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; James G, 1996, P NATL ACAD SCI USA, V93, P4454, DOI 10.1073/pnas.93.9.4454; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; KIM CM, 1992, J BIOL CHEM, V267, P23113; KOHL NE, 1993, SCIENCE, V260, P934; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; MANNE V, 1995, DRUG DEVELOP RES, V34, P121, DOI 10.1002/ddr.430340205; NAGASU T, 1995, CANCER RES, V55, P5310; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RILLING HC, 1993, ARCH BIOCHEM BIOPHYS, V301, P210, DOI 10.1006/abbi.1993.1135; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235	21	304	312	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14093	14097		10.1074/jbc.272.22.14093	http://dx.doi.org/10.1074/jbc.272.22.14093			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162034	hybrid			2022-12-27	WOS:A1997XB49200021
J	Haribabu, B; Steeber, DA; Ali, H; Richardson, RM; Snyderman, R; Tedder, TF				Haribabu, B; Steeber, DA; Ali, H; Richardson, RM; Snyderman, R; Tedder, TF			Chemoattractant receptor-induced phosphorylation of L-selectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION MOLECULE-1; HIGH ENDOTHELIAL VENULES; PROTEIN KINASE-C; HOMING RECEPTOR; CELL-SURFACE; LYMPHOCYTE; ACTIVATION; EXPRESSION; BINDING; ANTIGEN	The selectin adhesion molecules and chemoattractant receptors synergistically regulate leukocyte migration into lymphoid tissues and sites of inflammation, but little is known about how these families of receptors modulate each other's function. In this study, L-selectin was found to be phosphorylated in lymphoblastoid cell lines, and phosphorylation was enhanced by phorbol ester (phorbol la-myristate 13-acetate (PMA)) treatment. Interactions between L selectin and chemoattractant receptors were therefore examined using transfected rat basophilic leukemia cell lines (RBL-2H3) that expressed human L-selectin along with human leukocyte chemoattractant receptors, L-selectin was rapidly phosphorylated in cells treated with chemoattractants, thrombin, IgE receptor agonists, or PMA, Pertussis toxin or the protein kinase C inhibitor, staurosporine, completely blocked chemoattractant receptor-induced phosphorylation of L-selectin, PMA-induced phosphorylation was on serine residues within the cytoplasmic tail of L selectin that have been well conserved during recent evolution, Although L-selectin phosphorylation was not essential for basal levels of adhesion through L-selectin in transformed cell lines, the rapid increase in ligand binding activity of L-selectin that occurs following leukocyte activation was blocked by staurosporine, These results demonstrate that L-selectin can be phosphorylated following engagement of chemoattractant receptors and suggest that this may be a physiologically relevant mechanism for the synergistic regulation of these receptors during leukocyte migration.	DUKE UNIV,MED CTR,DEPT IMMUNOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	Duke University; Duke University			Bodduluri, Haribabu/A-2584-2010	Bodduluri, Haribabu/0000-0002-8261-3294	NCI NIH HHS [CA-54464] Funding Source: Medline; NHLBI NIH HHS [HL-50985] Funding Source: Medline; NIAID NIH HHS [AI-26872] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA054464, R01CA054464] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL050985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026872] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALI H, 1994, J BIOL CHEM, V269, P24557; ALI H, 1993, J BIOL CHEM, V268, P24247; ALLPORT JR, 1997, IN PRESS J IMMUNOL; BARGATZE RF, 1993, J EXP MED, V178, P367, DOI 10.1084/jem.178.1.367; BENBARUCH A, 1995, J BIOL CHEM, V270, P11703, DOI 10.1074/jbc.270.20.11703; BJERKNES M, 1986, SCIENCE, V231, P402, DOI 10.1126/science.3941903; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; Brenner B, 1996, P NATL ACAD SCI USA, V93, P15376, DOI 10.1073/pnas.93.26.15376; BUTCHER EC, 1993, RES IMMUNOL, V144, P695, DOI 10.1016/S0923-2494(93)80053-2; BUTCHER EC, 1979, J IMMUNOL, V123, P1996; CHEN AJ, 1995, J EXP MED, V182, P519, DOI 10.1084/jem.182.2.519; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; GILMAN AG, 1989, JAMA-J AM MED ASSOC, V262, P1819, DOI 10.1001/jama.262.13.1819; GRIFFIN JD, 1990, J IMMUNOL, V145, P576; JUNG TM, 1990, J IMMUNOL, V144, P3130; KANSAS GS, 1993, J EXP MED, V177, P833, DOI 10.1084/jem.177.3.833; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; LEUDANNA C, 1996, SCIENCE, V271, P981; LEY K, 1995, J IMMUNOL, V155, P525; MANGER B, 1987, J IMMUNOL, V139, P2755; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Preece G, 1996, J BIOL CHEM, V271, P11634, DOI 10.1074/jbc.271.20.11634; Richardson RM, 1996, J BIOL CHEM, V271, P28717, DOI 10.1074/jbc.271.45.28717; RICHARDSON RM, 1995, BIOCHEMISTRY-US, V34, P14193, DOI 10.1021/bi00043a025; SNYDERMAN R, 1992, INFLAMMATION BASIC P, P421; SPERTINI O, 1991, NATURE, V349, P691, DOI 10.1038/349691a0; SPERTINI O, 1991, LEUKEMIA, V5, P300; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; STEEBER DA, 1997, IN PRESS J IMMUNOL; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; TEDDER TF, 1990, J IMMUNOL, V144, P532; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; TEDDER TF, 1990, EUR J IMMUNOL, V20, P1351, DOI 10.1002/eji.1830200622; WATSON SP, 1988, BIOCHEM J, V249, P345, DOI 10.1042/bj2490345; YEDNOCK TA, 1987, J CELL BIOL, V104, P725, DOI 10.1083/jcb.104.3.725	36	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13961	13965		10.1074/jbc.272.21.13961	http://dx.doi.org/10.1074/jbc.272.21.13961			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153259	Green Published, hybrid			2022-12-27	WOS:A1997XA06200074
J	Pichler, M; Cassidy, TN; Reimer, D; Haase, H; Krause, R; Ostler, D; Striessnig, J				Pichler, M; Cassidy, TN; Reimer, D; Haase, H; Krause, R; Ostler, D; Striessnig, J			beta subunit heterogeneity in neuronal L-type Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-CHANNEL; SUBCELLULAR-DISTRIBUTION; FUNCTIONAL EXPRESSION; SKELETAL-MUSCLE; CA-2+ CHANNELS; IDENTIFICATION; LOCALIZATION; BRAIN; ACTIVATION; ALPHA(1A)	Heterologous expression studies have shown that the activity of voltage-gated Ca2+ channels is regulated by their beta subunits in a beta subunit isoform-specific manner, In this study we therefore investigated if one or several beta subunit isoforms associate with L-type Ca2+ channels in different regions of mammalian brain, All four beta subunit isoforms (beta 1b, beta 2, beta 3, and beta 4) are expressed in cerebral cortex as shown in immunoblots, Immunoprecipitation of (+)-[H-3]isradipine-labeled L-type channels revealed that the majority of beta subunit-associated L-type channels was associated with beta 3 (42 +/- 8%) and beta 4 (42 +/- 7%) subunits, whereas beta 1b and beta 2 were present in a smaller fraction of channel complexes, beta 3 and beta 4 were also the major L-type channel beta subunits in hippocampus. In cerebellum beta 1b, beta 2, and beta 3 but not beta 4 subunits were expressed at lower levels than in cortex, Accordingly, beta 4 was the most prominent beta subunit in cerebellar L-type channels, This beta subunit composition was very similar to the one determined for I-125-omega-conotoxin-GVIA-labeled N-type and I-I25-omega-conotoxin-MVIIC-labeled P/Q-type channel complexes in cerebral cortex and cerebellum, Our data show that all four beta subunit isoforms associate with L-type Ca2+ channels in mammalian brain, This beta subunit heterogeneity may play an important role for the fine tuning of L-type channel function and modulation in neurons.	INST BIOCHEM PHARMAKOL, A-6020 INNSBRUCK, AUSTRIA; MAX DELBRUCK CTR MOL MED, D-13125 BERLIN, GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine			Striessnig, Joerg/S-9334-2017	Striessnig, Joerg/0000-0002-9406-7120				BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; Cens T, 1996, PFLUG ARCH EUR J PHY, V431, P771, DOI 10.1007/BF02253842; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; ELLINOR PT, 1993, NATURE, V363, P455, DOI 10.1038/363455a0; GLOSSMANN H, 1990, REV PHYSIOL BIOCH P, V114, P1; GLOSSMANN H, 1985, METHOD ENZYMOL, V109, P513; Gurnett CA, 1996, J BIOL CHEM, V271, P27975, DOI 10.1074/jbc.271.45.27975; HAASE H, 1993, FEBS LETT, V335, P217, DOI 10.1016/0014-5793(93)80733-B; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Liu HY, 1996, J BIOL CHEM, V271, P13804, DOI 10.1074/jbc.271.23.13804; MITTERDORFER J, 1994, FEBS LETT, V352, P141, DOI 10.1016/0014-5793(94)00938-4; MOEBIUS FF, 1994, J BIOL CHEM, V269, P29314; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; OLCESE R, 1994, NEURON, V13, P1433, DOI 10.1016/0896-6273(94)90428-6; PEREZREYES E, 1995, KIDNEY INT, V48, P1111, DOI 10.1038/ki.1995.395; PICHLER M, 1906, BIOCHEMISTRY-US, V35, P14659; ROCHE JP, 1995, FEBS LETT, V371, P43, DOI 10.1016/0014-5793(95)00860-C; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; Scott VES, 1996, J BIOL CHEM, V271, P3207, DOI 10.1074/jbc.271.6.3207; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; Striessnig J, 1996, BIOPHYS J, V70, pWAMB1; STRIESSNIG J, 1993, CELL PHYSIOL BIOCHEM, V3, P295, DOI 10.1159/000154695; STRIESSNIG J, 1991, METHODS NEUROSCI, V4, P210; SuhKim H, 1996, MOL PHARMACOL, V50, P1330; TANAKA O, 1995, MOL BRAIN RES, V30, P1, DOI 10.1016/0169-328X(94)00265-G; Thibault O, 1996, SCIENCE, V272, P1017, DOI 10.1126/science.272.5264.1017; WELLING A, 1995, PFLUG ARCH EUR J PHY, V429, P400, DOI 10.1007/BF00374156; WESTENBROEK RE, 1995, J NEUROSCI, V15, P6403; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; WITCHER DR, 1995, J BIOL CHEM, V270, P18088, DOI 10.1074/jbc.270.30.18088	37	96	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13877	13882		10.1074/jbc.272.21.13877	http://dx.doi.org/10.1074/jbc.272.21.13877			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153247	hybrid			2022-12-27	WOS:A1997XA06200062
J	Miranda, JD; Barnes, EM				Miranda, JD; Barnes, EM			Repression of gamma-aminobutyric acid type A receptor alpha 1-polypeptide biosynthesis requires chronic agonist exposure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA-A-RECEPTOR; CEREBRAL CORTICAL-NEURONS; SUBUNIT MESSENGER-RNAS; BENZODIAZEPINE RECEPTORS; DOWN-REGULATION; RAT-BRAIN; CHICK-EMBRYO; COMPLEX; IDENTIFICATION; EXPRESSION	Although it is well established that the number of gamma-aminobutyric acid type A (GABA(A)) receptors declines in cortical neurons exposed to GABA(A) receptor agonists, the mechanisms responsible for this use-dependent down-regulation remain unclear. Two hypotheses have been proposed: (i) agonist-evoked sequestration and degradation of surface GABA(A) receptors and (ii) repression of receptor subunit biosynthesis. We have addressed this problem using [S-35]Met/Cys pulse-chase labeling of chick cortical newtons in culture and immunoprecipitation and immunoblotting with an antibody (RP4) directed against a GABA(A) receptor alpha(1)-(331-381) fusion protein. Exposure of the cells to GABA or isoguvacine for 2 h to 4 days had no effect on the initial rate of S-35 incorporation into the GABA(A) receptor 51-kDa alpha 1 polypeptide, but this rate declined by 33% after a 7-day treatment, This is consistent with a previous report (Baumgartner, B. J., Harvey, R. J., Darlison, M. G., and Barnes, E. M. (1994) Mol. Brain Res. 26, 9-17) that a 7-day GABA treatment of this preparation produced a 45% reduction in the alpha 1 subunit mRNA level, while a 4-day exposure had no detectable effect. On the other hand, after a 4-day exposure to these agonists, a 30% reduction in the level of the alpha 1 polypeptide was observed on immunoblots, similar to that found previously for down-regulation of GABA(A) receptor ligand-binding sites, Thus, the de nova synthesis of GABA(A) receptor alpha 1 subunits is subject to a delayed use-dependent repression that was observed after, rather than before, the decline in neuronal levels of the polypeptide. Pulse-chase experiments showed a monophasic degradation of the GABA(A) receptor S-35-alpha 1 subunit With a t(1/2) = 7.7 h, a process that was unaffected by the addition of GABA to neurons during the chase period. These nascent S-35-labeled polypeptides are presumably diluted into the neuronal pool of unlabeled unassembled al subunits, which was found to exceed by a 4:1 molar ratio the amount assembled into [H-3]flunitrazepam binding sites. Thus, the data reveal an alternative scheme for degradation of GABA(A) receptor polypeptides: a pathway that may participate in the agonist-independent degradation of unassembled receptor subunits. This differs from another pathway for the agonist-dependent degradation of mature GABA(A) receptors derived from the neuronal surface (Calkin, P. A. and Barnes, E. M., Jr. (1994) J. Biol. Chem. 269, 1548-1553).	BAYLOR COLL MED, DEPT BIOCHEM, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DIV NEUROSCI, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine					NIGMS NIH HHS [GM14156] Funding Source: Medline; NINDS NIH HHS [NS11535, NS34253] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM014156] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS011535, R01NS034253, P01NS011535] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barnes EM, 1996, INT REV NEUROBIOL, V39, P53, DOI 10.1016/S0074-7742(08)60663-7; BATESON AN, 1991, MOL BRAIN RES, V9, P333, DOI 10.1016/0169-328X(91)90081-8; BAUMGARTNER BJ, 1994, MOL BRAIN RES, V26, P9, DOI 10.1016/0169-328X(94)90068-X; BENKE D, 1991, J RECEPTOR RES, V11, P407, DOI 10.3109/10799899109066418; BORDEN LA, 1984, SCIENCE, V226, P857, DOI 10.1126/science.6093257; Brown MJ, 1996, BRIT J PHARMACOL, V118, P1103, DOI 10.1111/j.1476-5381.1996.tb15512.x; BURT DR, 1994, CURR TOP MEMBR, V42, P215, DOI 10.1016/S0070-2161(08)60824-2; CALKIN PA, 1994, J BIOL CHEM, V269, P1548; CALKIN PA, 1994, MOL BRAIN RES, V26, P18, DOI 10.1016/0169-328X(94)90069-8; CELENTANO JJ, 1994, BIOPHYS J, V66, P1039, DOI 10.1016/S0006-3495(94)80885-9; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; CZAJKOWSKI C, 1989, MOL PHARMACOL, V35, P183; DARLISON MG, 1995, SEMIN NEUROSCI, V7, P115, DOI 10.1006/smns.1995.0013; DeBlas AL, 1996, MOL NEUROBIOL, V12, P55, DOI 10.1007/BF02740747; FIRESTONE GL, 1990, METHOD ENZYMOL, V182, P688; HABLITZ JJ, 1989, BRAIN RES, V501, P332, DOI 10.1016/0006-8993(89)90650-1; HIROUCHI M, 1992, MOL BRAIN RES, V15, P327, DOI 10.1016/0169-328X(92)90125-U; KANG I, 1991, BRIT J PHARMACOL, V103, P1285, DOI 10.1111/j.1476-5381.1991.tb09781.x; Katsura M, 1996, EUR J PHARMACOL, V298, P71, DOI 10.1016/0014-2999(95)00764-4; KENDRICK NC, 1994, ANAL BIOCHEM, V219, P297, DOI 10.1006/abio.1994.1269; KROLL DJ, 1993, DNA CELL BIOL, V12, P441, DOI 10.1089/dna.1993.12.441; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MAKSAY G, 1988, J NEUROCHEM, V50, P1865, DOI 10.1111/j.1471-4159.1988.tb02490.x; MALOTEAUX JM, 1987, EUR J PHARMACOL, V144, P173, DOI 10.1016/0014-2999(87)90517-6; MCKERNAN RM, 1991, FEBS LETT, V286, P44, DOI 10.1016/0014-5793(91)80936-W; MEHTA AK, 1992, MOL BRAIN RES, V16, P29, DOI 10.1016/0169-328X(92)90190-M; MHATRE MC, 1994, MOL BRAIN RES, V24, P159, DOI 10.1016/0169-328X(94)90128-7; Miranda J. D., 1995, Society for Neuroscience Abstracts, V21, P1839; Miranda JD, 1997, DEV BRAIN RES, V99, P176, DOI 10.1016/S0165-3806(97)00016-3; MONTPIED P, 1991, J BIOL CHEM, V266, P6011; NAYEEM N, 1994, J NEUROCHEM, V62, P815; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; ROCA DJ, 1990, MOL PHARMACOL, V37, P37; SIEGHART W, 1995, PHARMACOL REV, V47, P181; SKINNER MK, 1983, BIOCHEM J, V209, P281, DOI 10.1042/bj2090281; STEPHENSON FA, 1990, J BIOL CHEM, V265, P21160; TEHRANI MHJ, 1986, DEV BRAIN RES, V25, P91; TEHRANI MHJ, 1988, NEUROSCI LETT, V87, P288, DOI 10.1016/0304-3940(88)90463-6; TEHRANI MHJ, 1993, J NEUROCHEM, V60, P1755; TEHRANI MHJ, 1991, J NEUROCHEM, V57, P1307, DOI 10.1111/j.1471-4159.1991.tb08295.x; TEHRANI MHJ, 1994, MOL BRAIN RES, V24, P55; THAMPY KG, 1983, DEV BRAIN RES, V8, P101, DOI 10.1016/0165-3806(83)90161-X	43	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16288	16294		10.1074/jbc.272.26.16288	http://dx.doi.org/10.1074/jbc.272.26.16288			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195932	hybrid			2022-12-27	WOS:A1997XG01900036
J	Bessen, RA; Raymond, GJ; Caughey, B				Bessen, RA; Raymond, GJ; Caughey, B			In situ formation of protease-resistant prion protein in transmissible spongiform encephalopathy-infected brain slices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB DISEASE; FATAL FAMILIAL INSOMNIA; AMYLOID PLAQUES; MOUSE SCRAPIE; PRP; FIBRILS; CONVERSION; HAMSTERS; STRAIN; MICE	The transmissible spongiform encephalopathies (TSEs) comprise a group of fatal neurodegenerative diseases that are characterized by the conversion of the normal host cellular prion protein (PrPc), to the abnormal protease-resistant prion protein isoform (PrP-res). It has been proposed, though not proven, that the infectious TSE agent consists solely of PrP-res and that PrP-res-induced conformational conversion of PrPc to additional PrP res represents agent replication. In this study we demonstrate in situ conversion of protease-sensitive PrPc to PrP-res in TSE-infected brain slices. One step in this process is the binding of soluble PrPc to endogenous PrP-res deposits. The newly formed PrP-res associated with the slices in a pattern that correlated with the pre-existing brain distribution of PrP-res. Punctate in situ PrP conversion was observed in brain regions containing PrP-res amyloid plaques, and a more dispersed conversion product was detected in areas containing diffuse PrP-res deposits. These studies provide direct evidence that PrP-res formation involves the incorporation of soluble PrPc into both nonfibrillar and fibrillar PrP-res deposits in TSE-infected Ir,rain. Our findings suggest that the in situ PrP conversion reaction leads to additional polymerization of endogenous PrP-res aggregates and is analogous to the process of PrP-res fibril and subfibril growth in vivo.	NIAID,ROCKY MT LABS,PERSISTENT VIRAL DIS LAB,NIH,HAMILTON,MT 59840	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								BARRY RA, 1985, J IMMUNOL, V135, P603; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1992, J GEN VIROL, V73, P329, DOI 10.1099/0022-1317-73-2-329; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; BODE L, 1985, J GEN VIROL, V66, P2471, DOI 10.1099/0022-1317-66-11-2471; Bossers A, 1997, P NATL ACAD SCI USA, V94, P4931, DOI 10.1073/pnas.94.10.4931; BRUCE ME, 1989, NEUROSCI LETT, V102, P1, DOI 10.1016/0304-3940(89)90298-X; CASPAR DLD, 1980, BIOPHYS J, V32, P101; Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; CAUGHEY B, 1997, J VIROL, V71, P4701; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; DEARMOND SJ, 1985, CELL, V41, P221, DOI 10.1016/0092-8674(85)90076-5; DIRINGER H, 1983, NATURE, V306, P476, DOI 10.1038/306476a0; Edenhofer F, 1996, J VIROL, V70, P4724, DOI 10.1128/JVI.70.7.4724-4728.1996; Esler WP, 1996, BIOCHEMISTRY-US, V35, P749, DOI 10.1021/bi951685w; GAJDUSEK DC, 1988, J NEUROIMMUNOL, V20, P95; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; HECKER R, 1992, GENE DEV, V6, P1213, DOI 10.1101/gad.6.7.1213; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JEFFREY M, 1994, NEUROSCI LETT, V174, P39, DOI 10.1016/0304-3940(94)90113-9; JEFFREY M, 1992, NEUROSCI LETT, V147, P106, DOI 10.1016/0304-3940(92)90785-6; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KIMBERLIN RH, 1978, J GEN VIROL, V39, P487, DOI 10.1099/0022-1317-39-3-487; KIMBERLIN RH, 1987, J GEN VIROL, V68, P1875, DOI 10.1099/0022-1317-68-7-1875; KITAMOTO T, 1986, ANN NEUROL, V20, P204, DOI 10.1002/ana.410200205; KITAMOTO T, 1992, AM J PATHOL, V140, P1285; Kocisko DA, 1996, BIOCHEMISTRY-US, V35, P13434, DOI 10.1021/bi9610562; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; LANSBURY PT, 1994, SCIENCE, V265, P1510, DOI 10.1126/science.8079159; LIAUTARD JP, 1991, FEBS LETT, V294, P155, DOI 10.1016/0014-5793(91)80657-O; MAGGIO JE, 1992, P NATL ACAD SCI USA, V89, P5462, DOI 10.1073/pnas.89.12.5462; MEDORI R, 1992, NEW ENGL J MED, V326, P444, DOI 10.1056/NEJM199202133260704; MERZ PA, 1981, ACTA NEUROPATHOL, V54, P63, DOI 10.1007/BF00691333; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; SNOW AD, 1989, ACTA NEUROPATHOL, V77, P337, DOI 10.1007/BF00687367; SOMERVILLE RA, 1989, J GEN VIROL, V70, P25, DOI 10.1099/0022-1317-70-1-25; WELLS GAH, 1987, VET REC, V121, P419, DOI 10.1136/vr.121.18.419; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wickner RB, 1995, YEAST, V11, P1671, DOI 10.1002/yea.320111609; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	50	37	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15227	15231		10.1074/jbc.272.24.15227	http://dx.doi.org/10.1074/jbc.272.24.15227			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182546	hybrid			2022-12-27	WOS:A1997XE03400029
J	Kimura, Y; Kurzydlowski, K; Tada, M; MacLennan, DH				Kimura, Y; Kurzydlowski, K; Tada, M; MacLennan, DH			Phospholamban inhibitory function is activated by depolymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; SITE-SPECIFIC MUTAGENESIS; TRANSMEMBRANE DOMAIN; ION-CHANNEL; PHOSPHORYLATION; CA-2+-ATPASE; ASSOCIATION; CA2+-ATPASE; SEQUENCE; ALTERS	Phospholamban (PLN), a homopentameric, integral membrane protein, reversibly inhibits cardiac sarcoplasmic reticulum Ca2+-ATPase (SERCA2a) activity through intramembrane interactions, Here, alanine-scanning mutagenesis of the PLN transmembrane sequence was used to identify two functional domains on opposite faces of the transmembrane helix. Mutations in one face diminish inhibitory interactions with transmembrane sequences of SERCA2a, but have relatively little effect on the pentameric state, while mutations in the other face activate inhibitory interactions and enhance monomer formation, Double mutants are monomeric, but loss of inhibitory function is dominant over activation of inhibitory function, These observations support the proposal that the SERCA2a interaction site lies on the helical face which is not involved in pentamer formation, Four highly inhibitory mutants are effectively devoid of pentamer, suggesting that pentameric PLN represents a less active or inactive reservoir that dissociates to provide inhibitory monomeric PLN subunits, A model is presented in which the degree of PLN inhibition of SERCA2a activity is ultimately determined by the concentration of the inhibited PLN monomer SERCA2a heterodimeric complex, The concentration of this inhibited complex is determined by the dissociation constant for the PLN pentamer (which is mutation-sensitive) and by the dissociation constant for the PLN/SERCA2a heterodimer (which is likely to be mutation-sensitive).	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L6,CANADA; OSAKA UNIV,SCH MED,DEPT MED & PATHOPHYSIOL,SUITA,OSAKA 565,JAPAN	University of Toronto; Osaka University								ADAMS PD, 1995, NAT STRUCT BIOL, V2, P154, DOI 10.1038/nsb0295-154; ARKIN IT, 1995, J MOL BIOL, V248, P824, DOI 10.1006/jmbi.1995.0263; ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; FUJII J, 1988, FEBS LETT, V227, P51, DOI 10.1016/0014-5793(88)81412-1; FUJII J, 1989, J BIOL CHEM, V264, P12950; FUJII J, 1987, J CLIN INVEST, V79, P301, DOI 10.1172/JCI112799; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; JONES LR, 1985, J BIOL CHEM, V260, P7721; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; Kimura Y, 1996, J BIOL CHEM, V271, P21726, DOI 10.1074/jbc.271.36.21726; KINGSTON RE, 1990, CURRENT PROTOCOLS MO; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; Mayer EJ, 1996, J BIOL CHEM, V271, P1669, DOI 10.1074/jbc.271.3.1669; Odermatt A, 1996, NAT GENET, V14, P191, DOI 10.1038/ng1096-191; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; TADA M, 1992, ANN NY ACAD SCI, V671, P92, DOI 10.1111/j.1749-6632.1992.tb43787.x; TAYLOR WR, 1986, J THEOR BIOL, V119, P205, DOI 10.1016/S0022-5193(86)80075-3; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; TOYOFUKU T, 1994, J BIOL CHEM, V269, P22929	24	244	249	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15061	15064		10.1074/jbc.272.24.15061	http://dx.doi.org/10.1074/jbc.272.24.15061			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182523	hybrid			2022-12-27	WOS:A1997XE03400006
J	Lesecq, S; Baudin, V; Kister, J; Poyart, C; Pagnier, J				Lesecq, S; Baudin, V; Kister, J; Poyart, C; Pagnier, J			Influence of the A helix structure on the polymerization of hemoglobin S	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SICKLE-CELL HEMOGLOBIN; ESCHERICHIA-COLI; DEOXYHEMOGLOBIN-S; FIBERS	Hb S variants containing Lys-beta 132 --> Ala or Asn substitutions were engineered to evaluate the consequences of the A helix destabilization in the polymerization process. Previous studies suggested that the loss of the Glu-beta 7-Lys-beta 132 salt bridge in the recombinant Hb beta E6V/E7A could be responsible for the destabilization of the A helix. The recombinant Hb (rHb) S/beta 132 variants polymerized with an increased delay time as well as decreased maximum absorbance and Hb solubility values similar to that of Hb S. These data indicate that the strength of the donor-acceptor site interaction may be reduced due to an altered conformation of the A helix. The question arises whether this alternation leads to a true inhibition of the polymerization process or to qualitatively different polymers. The oxygen affinity of the beta 132 mutated rHbs was similar to that of Hb A and S, whereas the cooperatively and effects of organic phosphates were reduced. This could be attributed to the modifications in the central cavity due to loss of the positively charged lysine. Since Lys-beta 132 is involved in the stabilization of the alpha 1-beta 1 interface, the loss of the beta 132(H10)-beta 128(H6) salt bridge may be responsible for the marked thermal instability of the beta 132 mutated rHbs.	HOP BICETRE,INSERM U299,F-94275 LE KREMLIN BICETR,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)			BAUDIN-CREUZA, Véronique/K-7309-2017	BAUDIN-CREUZA, Véronique/0000-0003-1032-3236				ADACHI K, 1979, J BIOL CHEM, V254, P7765; ANDERSEN ME, 1971, J BIOL CHEM, V246, P4790; BENESCH RE, 1982, NATURE, V299, P231, DOI 10.1038/299231a0; BIHOREAU MT, 1992, PROTEIN SCI, V1, P145; BOOKCHIN RM, 1971, J MOL BIOL, V60, P263, DOI 10.1016/0022-2836(71)90292-0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CARRAGHER B, 1988, J MOL BIOL, V199, P315, DOI 10.1016/0022-2836(88)90316-6; DICKERSON RE, 1983, HEMOGLOBIN STRUCTURE, P118; EDELSTEIN SJ, 1981, J MOL BIOL, V150, P557, DOI 10.1016/0022-2836(81)90381-8; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; FERMI G, 1981, ATLAS MOL STRUCTURE, V2, P20; HIMANEN JP, 1995, J BIOL CHEM, V270, P13885, DOI 10.1074/jbc.270.23.13885; International Hemoglobin Information Center, 1996, HEMOGLOBIN, V20, P215; KISTER J, 1987, J BIOL CHEM, V262, P12085; LANGDOWN JV, 1989, BRIT J HAEMATOL, V71, P443; Lesecq S, 1996, J BIOL CHEM, V271, P17211, DOI 10.1074/jbc.271.29.17211; MARDEN MC, 1988, BIOCHEMISTRY-US, V27, P1659, DOI 10.1021/bi00405a041; MONTPLAISIR N, 1986, P NATL ACAD SCI USA, V83, P9363; NAGAI K, 1985, P NATL ACAD SCI USA, V82, P7252, DOI 10.1073/pnas.82.21.7252; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; NAGEL RL, 1980, NATURE, V283, P823; PADLAN EA, 1985, J BIOL CHEM, V260, P8272; PAGNIER J, 1990, BRIT J HAEMATOL, V74, P531, DOI 10.1111/j.1365-2141.1990.tb06346.x; POYART C, 1981, NOUV REV FR HEMATOL, V23, P17; Reddy LR, 1996, J BIOL CHEM, V271, P24564, DOI 10.1074/jbc.271.40.24564; RODGERS DW, 1987, P NATL ACAD SCI USA, V84, P6157, DOI 10.1073/pnas.84.17.6157; SACK JS, 1978, HEMOGLOBIN, V2, P143; WAJEMAN H, 1973, NOUV REV FR HEMATOL, V13, P89	28	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15242	15246		10.1074/jbc.272.24.15242	http://dx.doi.org/10.1074/jbc.272.24.15242			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182548	Green Published, hybrid			2022-12-27	WOS:A1997XE03400031
J	Awrey, DE; Weilbaecher, RG; Hemming, SA; Orlicky, SM; Kane, CM; Edwards, AM				Awrey, DE; Weilbaecher, RG; Hemming, SA; Orlicky, SM; Kane, CM; Edwards, AM			Transcription elongation through DNA arrest sites - A multistep process involving both RNA polymerase II subunit RPB9 and TFIIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTE READ-THROUGH; FACTOR-SII; SACCHAROMYCES-CEREVISIAE; NASCENT TRANSCRIPT; TERMINATION SITES; INTRINSIC BLOCKS; YEAST; GENE; CLEAVAGE; INITIATION	The role of yeast RNA polymerase II (pol II) subunit RPB9 in transcript elongation was investigated by examining the biochemical properties of pol II lacking RPB9 (pol II Delta 9). The maximal rate of chain elongation was nearly identical for pol II and pol II Delta 9. By contrast, pol II Delta 9 elongated more efficiently through DNA sequences that signal the elongation complex to pause or arrest. The addition of purified recombinant RPB9 to pol II Delta 9 restored the elongation properties of the mutant polymerase to those of the wild-type enzyme. Arrested pol II Delta 9 complexes were refractory to levels of TFIIS that promoted maximal read-through with pol II. However, both pol II and pol II Delta 9 complexes stimulated with TFIIS undergo transcript cleavage, confirming that transcript cleavage and read-through activities can be uncoupled. Our observations suggest that both TFIIS and RPB9 are required to stimulate the release of RNA polymerase II from the arrested state.	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	Awrey, DE (corresponding author), MCMASTER UNIV,INST MOL BIOL & BIOTECHNOL,CANC RES GRP,HAMILTON,ON L8N 3Z5,CANADA.			Orlicky, Stephen/0000-0002-8172-2042; Edwards, Aled/0000-0002-4782-6016				AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; BUILT CJ, 1996, SCIENCE, V273, P1058; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; Chen Y, 1996, J BIOL CHEM, V271, P5993, DOI 10.1074/jbc.271.11.5993; CHRISTIE KR, 1994, J BIOL CHEM, V269, P936; CIPRESPALACIN G, 1994, P NATL ACAD SCI USA, V91, P8087, DOI 10.1073/pnas.91.17.8087; CIPRESPALACIN G, 1995, BIOCHEMISTRY-US, V34, P15375, DOI 10.1021/bi00046a046; DEQUARDCHABLAT M, 1991, J BIOL CHEM, V266, P15300; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; FURTERGRAVES EM, 1994, NUCLEIC ACIDS RES, V22, P4932, DOI 10.1093/nar/22.23.4932; FURTERGRAVES EM, 1991, MOL CELL BIOL, V11, P4121, DOI 10.1128/MCB.11.8.4121; GIARDINA C, 1993, SCIENCE, V261, P759, DOI 10.1126/science.8342041; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; Gu WG, 1995, J BIOL CHEM, V270, P30441, DOI 10.1074/jbc.270.51.30441; GU WG, 1993, J BIOL CHEM, V268, P25604; GUO HL, 1993, J BIOL CHEM, V268, P18762; HAWLEY DK, 1993, CELL MOL BIOL RES, V39, P339; HEKMATPANAH DS, 1991, MOL CELL BIOL, V11, P5781, DOI 10.1128/MCB.11.11.5781; HSU LM, 1995, P NATL ACAD SCI USA, V92, P11588, DOI 10.1073/pnas.92.25.11588; HULL MW, 1995, GENE DEV, V9, P481, DOI 10.1101/gad.9.4.481; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; KAINE BP, 1994, P NATL ACAD SCI USA, V91, P3854, DOI 10.1073/pnas.91.9.3854; Kane C. M., 1994, TRANSCRIPTION MECH R, P279; KANE CM, 1996, METHOD ENZYMOL, V274, P419; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KHAZAK V, 1995, MOL BIOL CELL, V6, P759, DOI 10.1091/mbc.6.7.759; Klinger C, 1996, EMBO J, V15, P4643, DOI 10.1002/j.1460-2075.1996.tb00841.x; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LANGER D, 1995, P NATL ACAD SCI USA, V92, P5768, DOI 10.1073/pnas.92.13.5768; LUSE DS, 1987, J BIOL CHEM, V262, P14990; MAICAS E, 1990, NUCLEIC ACIDS RES, V18, P3387, DOI 10.1093/nar/18.11.3387; MCKUNE K, 1995, MOL CELL BIOL, V15, P6895; NAKANISHI T, 1995, J BIOL CHEM, V270, P8991, DOI 10.1074/jbc.270.15.8991; NOGI Y, 1993, MOL CELL BIOL, V13, P114, DOI 10.1128/MCB.13.1.114; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; ORLOVA M, 1995, P NATL ACAD SCI USA, V92, P4596, DOI 10.1073/pnas.92.10.4596; Powell W, 1996, J BIOL CHEM, V271, P6866, DOI 10.1074/jbc.271.12.6866; QIAN XQ, 1993, NATURE, V365, P277, DOI 10.1038/365277a0; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1994, TRANSCRIPTION MECHAN, P263; SADHALE PP, 1994, MOL CELL BIOL, V14, P6164, DOI 10.1128/MCB.14.9.6164; SENTENAC A, 1992, TRANSCRIPTIONAL REGU, P27; SHPAKOVSKI GV, 1995, MOL CELL BIOL, V15, P4702; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; Thuillier V, 1996, EMBO J, V15, P618, DOI 10.1002/j.1460-2075.1996.tb00394.x; Treich Isabelle, 1992, Gene Expression, V2, P31; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; WOYCHIK NA, 1991, J BIOL CHEM, V266, P19053; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313; Woychik Nancy A., 1993, Gene Expression, V3, P77; Wu JS, 1996, P NATL ACAD SCI USA, V93, P11552, DOI 10.1073/pnas.93.21.11552	58	99	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14747	14754		10.1074/jbc.272.23.14747	http://dx.doi.org/10.1074/jbc.272.23.14747			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169440	hybrid			2022-12-27	WOS:A1997XC32700037
J	Crawley, JB; Rawlinson, L; Lali, FV; Page, TH; Saklatvala, J; Foxwell, BMJ				Crawley, JB; Rawlinson, L; Lali, FV; Page, TH; Saklatvala, J; Foxwell, BMJ			T cell proliferation in response to interleukins 2 and 7 requires p38MAP kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; MICE LACKING JAK3; P70 S6 KINASE; PROTEIN-KINASE; IL-2 RECEPTOR; C-JUN; LYMPHOCYTES-T; CASCADE; PHOSPHORYLATION; ASSOCIATION	Interleukin-2 (IL-2) is a potent T cell mitogen. However, the signaling pathways by which IL-2 mediates its mitogenic effect are not fully understood. One of the members of the mitogen-activated protein kinase (MAPK) family, p42/44MAPK (ERK2/1), is known to be activated by IL-2. We have now investigated the response to IL-2 of two other members of the MAP kinase family, p54MAP kinase (stress-activated protein kinase (SAPK)/Jun-N-terminal kinase (JNK)) and p38MAP kinase (p38/Mpk2/CSBP/RK), which respond primarily to stressful and inflammatory stimuli (e.g. tumor necrosis factor-alpha, IL-1, and lipopolysaccharide). Here we show that IL-2, and another T cell growth factor, IL-7, activate both SAPK/JNK and p38MAP kinase. Furthermore, inhibition of p38MAP kinase activity with a specific pyrinidyl imidazole inhibitor SB203580 that prevents activation of its downstream effector, MAPK-activating protein kinase-2, correlated with suppression of IL-2- and IL-7-driven T cell proliferation. These data indicate that in T cells p38MAP kinase has a role in transducing the mitogenic signal.	KENNEDY INST,LONDON W6 8LH,ENGLAND	University of Oxford			Lali, Ferdinand/AAD-1946-2019; Ferdinand, Lali/AAH-4867-2020	Ferdinand, Lali/0000-0001-5890-9936; Page, Theresa/0000-0002-2664-4256				AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Crawley JB, 1996, EUR J IMMUNOL, V26, P2717, DOI 10.1002/eji.1830261125; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; CUENDA A, 1996, EMBO J, V15, P4293; Dabrowski A, 1996, J BIOL CHEM, V271, P5686, DOI 10.1074/jbc.271.10.5686; DADI H, 1994, BLOOD, V84, P1579; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUMONT FJ, 1990, J IMMUNOL, V144, P251; EVANS GA, 1995, J BIOL CHEM, V270, P28858, DOI 10.1074/jbc.270.48.28858; FAIRHURST RM, 1993, IMMUNOLOGY, V79, P112; FOXWELL BMJ, 1995, EUR J IMMUNOL, V25, P3041, DOI 10.1002/eji.1830251109; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GRAVES JD, 1992, J IMMUNOL, V148, P2417; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Higuchi M, 1996, EUR J IMMUNOL, V26, P1322, DOI 10.1002/eji.1830260622; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; MERIDA I, 1991, J IMMUNOL, V147, P2202; MINAMI Y, 1995, IMMUNITY, V2, P89, DOI 10.1016/1074-7613(95)90081-0; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MOWER DA, 1994, J IMMUNOL, V152, P4832; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; PAGE TH, 1995, EUR J IMMUNOL, V25, P2956, DOI 10.1002/eji.1830251036; PAGE TH, 1993, J IMMUNOL, V151, P4753; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PERKINS GR, 1993, J EXP MED, V178, P1429, DOI 10.1084/jem.178.4.1429; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RANGES GE, 1989, J IMMUNOL, V142, P1203; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SAKALATVALA J, 1996, J BIOL CHEM, V271, P6586; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SATOH T, 1992, J BIOL CHEM, V267, P25423; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SAWAMI H, 1992, J CELL PHYSIOL, V151, P367, DOI 10.1002/jcp.1041510218; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shapiro PS, 1996, J BIOL CHEM, V271, P5750, DOI 10.1074/jbc.271.10.5750; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Theze J, 1996, IMMUNOL TODAY, V17, P481, DOI 10.1016/0167-5699(96)10057-C; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WILLCOCKS JL, 1993, EUR J IMMUNOL, V23, P716, DOI 10.1002/eji.1830230322; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YIN TG, 1995, BLOOD, V85, P3101, DOI 10.1182/blood.V85.11.3101.bloodjournal85113101; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	65	212	216	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					15023	15027		10.1074/jbc.272.23.15023	http://dx.doi.org/10.1074/jbc.272.23.15023			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169478	hybrid			2022-12-27	WOS:A1997XC32700075
J	Rogers, ME; Sun, M; Lerner, MR; Vogt, RG				Rogers, ME; Sun, M; Lerner, MR; Vogt, RG			Snmp-1, a novel membrane protein of olfactory neurons of the silk moth Antheraea polyphemus with homology to the CD36 family of membrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEROMONE-BINDING-PROTEIN; GLYCOPROTEIN-IV CD36; TOBACCO HAWK MOTH; MANDUCA-SEXTA; SIGNAL TRANSDUCTION; RECEPTOR NEURONS; TYROSINE KINASES; NERVE GROWTH; GENE FAMILY; LIMP-II	While olfactory neurons of silk moths are well known for their exquisite sensitivity to sex pheromone odorants, molecular mechanisms underlying this sensitivity are poorly understood. In searching for proteins that might support olfactory mechanisms, we characterized the protein profile of olfactory neuron receptor membranes of the wild silk moth Antheraea polyphemus. We have purified and cloned a prominent 67-kDa protein which we have named Snmp-1 (sensory neuron membrane protein-1). Northern blot analysis suggests that Snmp-1 is uniquely expressed in antennal tissue; in situ hybridization and immunocytochemical analyses show that Snmp-1 is expressed in olfactory neurons and that the protein is localized to the cilia, dendrites, and somata but not the axons. Snmp-1 mRNA expression increases significantly 1-2 days before the end of adult development, coincident with the functional maturation of the olfactory system. Sequence analysis suggests Snmp-1 is homologous with the CD36 protein family, a phylogenetically diverse family of receptor-like membrane proteins. CD36 family proteins are characterized as having two transmembrane domains and interacting with proteinaceous ligands; Snmp-1 is the first member of this family identified in nervous tissue. These findings argue that Snmp-1 has an important role in olfaction; possible roles of Snmp-1 in odorant detection are discussed.	UNIV S CAROLINA, DEPT BIOL, COLUMBIA, SC 29208 USA; YALE UNIV, SCH MED, DEPT INTERNAL MED, NEW HAVEN, CT 06520 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Yale University					NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000588] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC-00588] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ACTON SL, 1994, J BIOL CHEM, V269, P21003; AEBERSOLD RH, 1986, J BIOL CHEM, V261, P4229; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; BARNWELL JW, 1985, J IMMUNOL, V135, P3494; BOECKH J, 1965, COLD SPRING HARB SYM, V30, P263, DOI 10.1101/SQB.1965.030.01.028; BOECKH J, 1979, J COMP PHYSIOL, V132, P235, DOI 10.1007/BF00614495; BOEKHOFF I, 1990, J COMP PHYSIOL B, V160, P99, DOI 10.1007/BF00258768; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; Buck LB, 1996, ANNU REV NEUROSCI, V19, P517, DOI 10.1146/annurev.ne.19.030196.002505; BULL HA, 1994, FEBS LETT, V351, P41, DOI 10.1016/0014-5793(94)00814-0; Byrd CA, 1996, J NEUROBIOL, V29, P445, DOI 10.1002/(SICI)1097-4695(199604)29:4<445::AID-NEU3>3.0.CO;2-8; CALVO D, 1995, GENOMICS, V25, P100, DOI 10.1016/0888-7543(95)80114-2; CALVO D, 1993, J BIOL CHEM, V268, P18929; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ERSKINE L, 1995, DEV BIOL, V171, P330, DOI 10.1006/dbio.1995.1285; FADOOL DA, 1992, NEURON, V9, P907, DOI 10.1016/0896-6273(92)90243-7; Gardner JP, 1996, P NATL ACAD SCI USA, V93, P3503, DOI 10.1073/pnas.93.8.3503; GYORGYI TK, 1988, P NATL ACAD SCI USA, V85, P9851, DOI 10.1073/pnas.85.24.9851; HART K, 1993, J MOL BIOL, V234, P249, DOI 10.1006/jmbi.1993.1580; Hildebrand J.G., 1980, RECEPTORS NEUROTRANS, P261; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; Joneckis CC, 1996, BLOOD, V87, P4862, DOI 10.1182/blood.V87.11.4862.bloodjournal87114862; KAISSLING KE, 1991, J INSECT PHYSIOL, V37, P71, DOI 10.1016/0022-1910(91)90021-Q; KAISSLING KE, 1986, ANNU REV NEUROSCI, V9, P121, DOI 10.1146/annurev.ne.09.030186.001005; KARLIN S, 1990, P NATL ACAD SCI USA, V87, P2264, DOI 10.1073/pnas.87.6.2264; KEIL TA, 1984, ZOOMORPHOLOGY, V104, P147, DOI 10.1007/BF00312133; KEIL TA, 1992, MICROSC RES TECHNIQ, V22, P351, DOI 10.1002/jemt.1070220405; KEIL TA, 1991, TISSUE CELL, V23, P821, DOI 10.1016/0040-8166(91)90034-Q; LEGENDRE N, 1988, BIOTECHNIQUES, V6, P154; LEUNG LLK, 1992, J BIOL CHEM, V267, P18244; Maniatis T., 1982, MOL CLONING; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCOBB DP, 1988, NEURON, V1, P377, DOI 10.1016/0896-6273(88)90187-0; MICHEL WC, 1992, J NEUROSCI, V12, P3979; NEUGEBAUER KM, 1991, NEURON, V6, P345, DOI 10.1016/0896-6273(91)90244-T; OCKENHOUSE CF, 1989, J CLIN INVEST, V84, P468, DOI 10.1172/JCI114188; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; PEARCE SFA, 1995, J BIOL CHEM, V270, P2981, DOI 10.1074/jbc.270.7.2981; PEARCE SFA, 1994, BLOOD, V84, P384; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Pelosi P, 1996, J NEUROBIOL, V30, P3; RAU P, 1929, T ACAD SCI ST LOUIS, V26, P80; SANES JR, 1976, DEV BIOL, V51, P282, DOI 10.1016/0012-1606(76)90144-5; SCHNEIDER D, 1968, NATURWISSENSCHAFTEN, V55, P395, DOI 10.1007/BF00593307; SCHNEIDER D, 1969, SCIENCE, V163, P1031, DOI 10.1126/science.163.3871.1031; SCHWEITZER ES, 1976, J INSECT PHYSIOL, V22, P955, DOI 10.1016/0022-1910(76)90078-0; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; SILVERSTEIN RL, 1989, J CLIN INVEST, V84, P546, DOI 10.1172/JCI114197; Steinbrecht RA, 1996, CHEM SENSES, V21, P719, DOI 10.1093/chemse/21.6.719; TANDON NN, 1989, J BIOL CHEM, V264, P7570; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TREZZINI C, 1990, IMMUNOLOGY, V71, P29; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; VANDENBERG MJ, 1991, J INSECT PHYSIOL, V37, P79, DOI 10.1016/0022-1910(91)90022-R; VEGA MA, 1991, J BIOL CHEM, V266, P16818; Vogt R.G., 1987, P385; VOGT RG, 1993, J NEUROBIOL, V24, P581, DOI 10.1002/neu.480240505; VOGT RG, 1981, NATURE, V293, P161, DOI 10.1038/293161a0; VOGT RG, 1989, J NEUROSCI, V9, P3332; VOGT RG, 1991, J NEUROBIOL, V22, P74, DOI 10.1002/neu.480220108; VOGT RG, 1985, P NATL ACAD SCI USA, V82, P8827, DOI 10.1073/pnas.82.24.8827; VOGT RG, 1991, J NEUROSCI, V11, P2972; VOGT RG, 1988, J BIOL CHEM, V263, P3952; Vogt Richard G., 1995, P341, DOI 10.1017/CBO9780511529931.014; WATERSTON R, 1995, P NATL ACAD SCI USA, V92, P10836, DOI 10.1073/pnas.92.24.10836; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	70	156	175	3	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14792	14799		10.1074/jbc.272.23.14792	http://dx.doi.org/10.1074/jbc.272.23.14792			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169446	hybrid			2022-12-27	WOS:A1997XC32700043
J	Xie, QW				Xie, QW			A novel lipopolysaccharide-response element contributes to induction of nitric oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTERFERON-GAMMA; BACTERIAL LIPOPOLYSACCHARIDE; CONFERS INDUCIBILITY; MOUSE MACROPHAGES; GENE; BINDING; CELLS; EXPRESSION; PROTEIN	The gene encoding the high output isoform of nitric oxide synthase represents a large class of alarm and defense genes transcriptionally induced in response to bacterial lipopolysaccharide (LPS). The promoters of most of these genes contain at least two LPS-response elements, one of which commonly binds transcription factors of the NF-kappa B/Rel family. Here a novel LPS-response element is identified in the inducible nitric oxide synthase promoter, termed LREAA, which contains critical adenosine residues lying 19-20 base pairs downstream of the proximal NF-kappa B binding element (NF kappa Bd). Both NF kappa Bd and LREAA are required for LPS-induced promoter activity. A protein partially recognized by antibody against transcription factor Oct-1 binds to the LREAA element constitutively in untreated macrophages while contributing to a DNA-protein complex that includes NF-kappa B p50 in macrophages treated with LPS. NF-kappa B p50 and the LREAA-binding proteins may together recruit an LPS-triggered transactivator of transcription.	CORNELL UNIV,COLL MED,DEPT MED,BEATRICE & SAMUEL A SEAVER LAB,NEW YORK,NY 10021	Cornell University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034543, R21AI034543] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34543] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARTRAIN NA, 1994, J BIOL CHEM, V269, P6765; DING AH, 1995, J LEUKOCYTE BIOL, V57, P174, DOI 10.1002/jlb.57.1.174; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Goldring CEP, 1996, NUCLEIC ACIDS RES, V24, P1682, DOI 10.1093/nar/24.9.1682; GOLUB EI, 1989, NUCLEIC ACIDS RES, V17, P4902, DOI 10.1093/nar/17.12.4902; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAVALLESE EM, 1989, MOL CELL BIOL, V9, P3184, DOI 10.1128/MCB.9.8.3184; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; Lin AW, 1996, J BIOL CHEM, V271, P11911, DOI 10.1074/jbc.271.20.11911; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; Morrison D C, 1979, Adv Immunol, V28, P293; Murphy WJ, 1996, J ENDOTOXIN RES, V3, P381, DOI 10.1177/096805199600300502; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NISHIZAWA M, 1990, MOL CELL BIOL, V10, P2002, DOI 10.1128/MCB.10.5.2002; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; VERRIJER CP, 1993, BIOCHIM BIOPHYS ACTA, V173, P1; WANG J, 1991, MOL CELL BIOL, V11, P75, DOI 10.1128/MCB.11.1.75; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1994, J LEUKOCYTE BIOL, V56, P576, DOI 10.1002/jlb.56.5.576; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; XIE QW, 1993, T ASSOC AM PHYSICIAN, V106, P1	34	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14867	14872		10.1074/jbc.272.23.14867	http://dx.doi.org/10.1074/jbc.272.23.14867			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169456	hybrid			2022-12-27	WOS:A1997XC32700053
J	Abbott, DW; Holt, JT				Abbott, DW; Holt, JT			Finkel-Biskis-Reilly mouse osteosarcoma virus v-fos inhibits the cellular response to ionizing radiation in a myristoylation-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; V(D)J RECOMBINATION; DNA-REPAIR; TRANSACTIVATION; GENE; MYRISTYLATION; CELLS; ASSOCIATION; EXPRESSION; HOMOLOG	DNA damage is recognized as a central component of carcinogenesis, DNA-damaging agents activate a number of signal transduction pathways that lead to repair of the DNA, apoptosis, or cell cycle arrest, It is reasoned that a cell deficient in DNA repair is more likely to acquire other cancer-promoting mutations, Despite the recent interest in the link between DNA damage and carcinogenesis, retroviral oncogenes have not yet been shown to affect the DNA damage-signaling pathway. In this report, we show that Finkel-Biskis-Reilly mouse osteosarcoma virus (FBR) v-fos, the retroviral homologue of the c-fos proto-oncogene, inhibits the cellular response to ionizing radiation, Cells that express FBR v-Fos show a decreased ability to repair DNA damage caused by ionizing radiation, and these cells show decreased survival in response to ionizing radiation, In addition, FBR v-Fos inhibits DNA-dependent protein kinase, a kinase specifically activated upon exposure to ionizing radiation, These effects were specific to ionizing radiation, as no effect of FBR v-Fos on the UV light signaling pathway was seen. Last, these effects were dependent on a lipid modification required for FBR v-Fos tumorigenesis, that of myristoylation of FBR v-Fos. A non-myristoylated mutant FBR v-Fos caused none of these effects, This study suggests that a retroviral oncogene can lead to an increased genomic instability, which can ultimately increase the carcinogenic potential of a cell.	VANDERBILT UNIV,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PATHOL,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,CTR CANC,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; Vanderbilt University				Abbott, Derek/0000-0003-4387-8094	NATIONAL CANCER INSTITUTE [R01CA051735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA51735] Funding Source: Medline; NIGMS NIH HHS [5T32GM07347] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON CW, 1996, MOL ANAL DNA REARRAN, P91; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; Errami A, 1996, MOL CELL BIOL, V16, P1519; FINKEL MP, 1975, FRONTIERS RADIATION, V10, P28; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Funk M, 1997, MOL CELL BIOL, V17, P537, DOI 10.1128/MCB.17.2.537; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jotte RM, 1996, J CELL BIOL, V135, P457, DOI 10.1083/jcb.135.2.457; JOTTE RM, 1994, J BIOL CHEM, V269, P16383; KAMATA N, 1992, MOL CELL BIOL, V12, P876, DOI 10.1128/MCB.12.2.876; KAMATA N, 1991, MOL CELL BIOL, V11, P765, DOI 10.1128/MCB.11.2.765; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; KHARBANDA S, 1994, P NATL ACAD SCI USA, V91, P5416, DOI 10.1073/pnas.91.12.5416; KLOCKER H, 1985, European Journal of Cell Biology, V39, P346; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LUCIBELLO FC, 1991, NEW BIOL, V3, P671; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; UCKUN FM, 1993, P NATL ACAD SCI USA, V90, P252, DOI 10.1073/pnas.90.1.252; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; YAUN ZM, 1996, NATURE, V382, P272	34	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14005	14008		10.1074/jbc.272.22.14005	http://dx.doi.org/10.1074/jbc.272.22.14005			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162016	hybrid			2022-12-27	WOS:A1997XB49200003
J	Jing, J; Peretz, T; SingerLahat, D; Chikvashvili, D; Thornhill, WB; Lotan, I				Jing, J; Peretz, T; SingerLahat, D; Chikvashvili, D; Thornhill, WB; Lotan, I			Inactivation of a voltage-dependent K+ channel by beta subunit - Modulation by a phosphorylation-dependent interaction between the distal C terminus of alpha subunit and cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; XENOPUS-OOCYTES; BRAIN; DIVERSITY	Kv1.1/Kv beta 1.1 (alpha beta) K+ channel expressed in Xenopus oocytes was shown to have a fast inactivating current component, The fraction of this component (extent of inactivation) is increased by microfilament disruption induced by cytochalasins or by phosphorylation of the alpha subunit at Ser-446, which impairs the interaction of the channel with microfilaments, The relevant sites of interaction on the channel molecules have not been identified. Using a phosphorylation-deficient mutant of alpha, S446A to ensure maximal basal interaction of the channel with the cytoskeleton, we show that one relevant site is the end of the C terminus of alpha. Truncation of the last six amino acids resulted in alpha beta channels with an extent of inactivation up to 2.5-fold larger and its further enhancement by cytochalasins being reduced 2-fold, The wild-type channels exhibited strong inactivation, which could not be markedly increased either by cytochalasins or by the C-terminal mutations, indicating that the interaction of the wild-type channels with microfilaments was minimal to begin with, presumably because of extensive basal phosphorylation. Since the C-terminal end of Kv1.1 was shown to participate in channel clustering via an interaction with members of the PSD-95 family of proteins, we propose that a similar interaction with an endogenous protein takes place, contributing to channel connection to the oocyte cytoskeleton, This is the first report to assign a modulatory role to such an interaction: together with the state of phosphorylation of the channel, it regulates the extent of inactivation conferred by the beta subunit.	TEL AVIV UNIV,SACKLER SCH MED,DEPT PHYSIOL & PHARMACOL,IL-69978 RAMAT AVIV,ISRAEL; MT SINAI HOSP,MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10029	Tel Aviv University; Sackler Faculty of Medicine; Icahn School of Medicine at Mount Sinai								BAUMANN A, 1988, EMBO J, V7, P2454; CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; Dascal N., 1992, METHODS MOL BIOL VOL, VVolume 13, P205; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Heinemann SH, 1996, J PHYSIOL-LONDON, V493, P625, DOI 10.1113/jphysiol.1996.sp021409; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; IVANINA T, 1994, BIOCHEMISTRY-US, V33, P8786, DOI 10.1021/bi00195a021; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; Kim E, 1996, NEUROPHARMACOLOGY, V35, P993, DOI 10.1016/0028-3908(96)00093-7; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Laube G, 1996, MOL BRAIN RES, V42, P51, DOI 10.1016/S0169-328X(96)00120-9; LEVIN G, 1995, J BIOL CHEM, V270, P14611, DOI 10.1074/jbc.270.24.14611; Levin G, 1996, J BIOL CHEM, V271, P29321, DOI 10.1074/jbc.271.46.29321; MORALES MJ, 1995, J BIOL CHEM, V270, P6272, DOI 10.1074/jbc.270.11.6272; PERNEY T M, 1991, Current Opinion in Cell Biology, V3, P663, DOI 10.1016/0955-0674(91)90039-2; Pongs O, 1992, PHYSL REV S, V72, pS69; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RUDY B, 1991, Molecular and Cellular Neuroscience, V2, P89, DOI 10.1016/1044-7431(91)90001-5; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; TEMPEL BL, 1988, NATURE, V332, P837, DOI 10.1038/332837a0	24	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14021	14024		10.1074/jbc.272.22.14021	http://dx.doi.org/10.1074/jbc.272.22.14021			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162020	hybrid			2022-12-27	WOS:A1997XB49200007
J	Underhill, DA; Gros, P				Underhill, DA; Gros, P			The paired-domain regulates DNA binding by the homeodomain within the intact Pax-3 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME TYPE-I; WAARDENBURG SYNDROME; ALVEOLAR RHABDOMYOSARCOMA; SEQUENCE RECOGNITION; CRYSTAL-STRUCTURE; NEURAL-TUBE; BOX GENE; MUTATION; IDENTIFICATION; DROSOPHILA	Pax-3 contains two structurally independent DNA-binding domains, a paired-domain and a homeodomain, Their functional interdependence has been suggested by the analysis of the Sp-delayed (Sp(d)) mouse mutant, in which a glycine to arginine substitution at position 9 of the paired-domain abrogates DNA binding by both domains, This glycine is located in the beta-turn portion of a beta-hairpin motif, and the requirement for this structure was investigated by mutagenesis at this and neighboring positions, At position 9, only substitution with proline increased DNA binding by the paired-domain and homeodomain above the level observed with the Sp(d) arginine mutation, suggesting that the beta-turn is necessary for the function of both DNA-binding domains, Alanine scanning mutagenesis also identified a number of flanking residues important for DNA binding by both domains, emphasizing the requirement of the beta-hairpin for the interaction of Pax-3 with DNA. Furthermore, we show that these mutations reduce binding by the homeodomain at the monomeric level and do not impair dimerization on a TAAT(N)(2)ATTA consensus motif, In contrast, the wild-type paired-domain was found to prevent dimerization on consensus motifs with 3-base pair spacing of the type TAAT(N)(3)ATTA. Importantly, both the deleterious effect of the Sp(d) mutation on homeodomain DNA binding and the loss of dimerization on TAAT(N)(3)ATTA motifs can be transferred to a heterologous homeodomain from the human phox protein. Moreover, the presence of the paired-domain affects sequence discrimination within the 3-base pair spacer in this context, These analyses establish that the beta-hairpin motif is essential for paired domain and homeodomain DNA binding, and suggest a novel mechanism by which the paired-domain can influence sequence specificity of the homeodomain within the Pax-3 polypeptide.	MCGILL UNIV, DEPT BIOCHEM, MONTREAL, PQ H3G 1Y6, CANADA	McGill University				Underhill, Darrell/0000-0003-0957-7407				BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BALDWIN CT, 1995, AM J MED GENET, V58, P115, DOI 10.1002/ajmg.1320580205; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; Bertuccioli C, 1996, DEVELOPMENT, V122, P2673; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CHALEPAKIS G, 1995, GENE, V162, P267, DOI 10.1016/0378-1119(95)00345-7; CHISHOLM AD, 1995, NATURE, V377, P52, DOI 10.1038/377052a0; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DAVIS RJ, 1994, CANCER RES, V54, P2869; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FRANZ T, 1993, ANAT EMBRYOL, V187, P153; Fujioka M, 1996, DEVELOPMENT, V122, P2697; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GOUTTE C, 1993, J MOL BIOL, V233, P359, DOI 10.1006/jmbi.1993.1517; GRUENEBERG DA, 1995, MOL CELL BIOL, V15, P3318; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; Jun S, 1996, DEVELOPMENT, V122, P2639; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; LU QA, 1995, MOL CELL BIOL, V15, P3786; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; MOASE CE, 1992, J MED GENET, V29, P145, DOI 10.1136/jmg.29.3.145; NOLL M, 1993, CURR OPIN GENET DEV, V3, P595, DOI 10.1016/0959-437X(93)90095-7; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; UNDERHILL DA, 1995, P NATL ACAD SCI USA, V92, P3692, DOI 10.1073/pnas.92.9.3692; Vogan KJ, 1996, MOL CELL BIOL, V16, P6677; VOGAN KJ, 1993, GENOMICS, V17, P364, DOI 10.1006/geno.1993.1333; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; Wilson DS, 1996, P NATL ACAD SCI USA, V93, P6886, DOI 10.1073/pnas.93.14.6886; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; ZHANG YH, 1995, NATURE, V377, P55, DOI 10.1038/377055a0	42	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14175	14182		10.1074/jbc.272.22.14175	http://dx.doi.org/10.1074/jbc.272.22.14175			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162047	hybrid			2022-12-27	WOS:A1997XB49200034
J	Bismuth, Y; Kavanaugh, MP; Kanner, BI				Bismuth, Y; Kavanaugh, MP; Kanner, BI			Tyrosine 140 of the gamma-aminobutyric acid transporter GAT-1 plays a critical role in neurotransmitter recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE-NOREPINEPHRINE TRANSPORTERS; RAT-BRAIN; GABA TRANSPORTER; BINDING-SITE; GLUTAMATE TRANSPORTER; XENOPUS OOCYTES; SODIUM; DOMAINS; EXPRESSION; SUBSTRATE	The gamma-aminobutyric acid (GABA) transporter GAT-1 is located in nerve terminals and catalyzes the electrogenic reuptake of the neurotransmitter with two sodium ions and one chloride, We now identify a single tyrosine residue that is critical for GABA recognition and transport, It is completely conserved throughout the superfamily, and even substitution to the other aromatic amino acids, phenylalanine (Y140F) and tryptophan (Y140W), results in completely inactive transporters, Electrophysiological characterization reveals that both mutant transporters exhibit the sodium-dependent transient currents associated with sodium binding as well as the chloride-dependent lithium leak currents characteristic of GAT-1. On the other hand, in both mutants GABA is neither able to induce a steady-state transport current nor to block their transient currents. The nontransportable analog SKF 100330A potently inhibits the sodium-dependent transient in the wild type GAT-1 but not in the Y140W transporter. It partly blocks the transient of Y140F. Thus, although sodium and chloride binding are unimpaired in the tyrosine mutants, they have a specific defect in the binding of GABA. The total conservation of the residue throughout the family suggests that tyrosine 140 may be involved in the liganding of the amino group, the moiety common to all of the neurotransmitters.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT BIOCHEM,IL-91120 JERUSALEM,ISRAEL; OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Hebrew University of Jerusalem; Oregon Health & Science University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048709] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS016708, R01NS016708] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48709] Funding Source: Medline; NINDS NIH HHS [NS16708] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALI FE, 1985, J MED CHEM, V28, P653, DOI 10.1021/jm50001a020; BARKER EL, 1994, MOL PHARMACOL, V46, P799; Bennett ER, 1997, J BIOL CHEM, V272, P1203, DOI 10.1074/jbc.272.2.1203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buck KJ, 1995, MOL PHARMACOL, V48, P1030; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GIROS B, 1994, J BIOL CHEM, V269, P15985; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; KANNER BI, 1994, FEBS LETT, V356, P191, DOI 10.1016/0014-5793(94)01255-5; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; KESHET GI, 1995, FEBS LETT, V371, P39, DOI 10.1016/0014-5793(95)00859-8; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; KLEINBERGERDORON N, 1994, J BIOL CHEM, V269, P3063; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MABJEESH NJ, 1992, J BIOL CHEM, V267, P2563; Mager S, 1996, J NEUROSCI, V16, P5405; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; Olivares L, 1997, J BIOL CHEM, V272, P1211, DOI 10.1074/jbc.272.2.1211; PANTANOWITZ S, 1993, J BIOL CHEM, V268, P3222; RADIAN R, 1986, J BIOL CHEM, V261, P5437; RADIAN R, 1985, J BIOL CHEM, V260, P1859; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAMURA S, 1995, J BIOL CHEM, V270, P28712, DOI 10.1074/jbc.270.48.28712; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; ZHANG YM, 1994, J BIOL CHEM, V269, P19573	34	100	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16096	16102		10.1074/jbc.272.26.16096	http://dx.doi.org/10.1074/jbc.272.26.16096			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195904	Green Published, hybrid			2022-12-27	WOS:A1997XG01900008
J	Huntley, CC; De, BP; Banerjee, AK				Huntley, CC; De, BP; Banerjee, AK			Phosphorylation of Sendai virus phosphoprotein by cellular protein kinase C zeta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; RESPIRATORY SYNCYTIAL VIRUS; P-PROTEIN; MEASLES-VIRUS; TRANSCRIPTIONAL ACTIVITY; MONOCLONAL-ANTIBODIES; NUCLEOCAPSID PROTEIN; GENE-EXPRESSION; RNA-SYNTHESIS; ACTIVATION	The phosphoproteins (P) of nonsegmented negative strand RNA viruses are viral RNA polymerase subunits involved in both transcription and replication during the virus life cycle. Phosphorylation of P proteins in several negative strand RNA viruses by specific cellular kinases was found to be required for P protein function. In the present study, using bacterially expressed unphosphorylated P protein of Sendai virus, a mouse parainfluenza virus, we have shown that the major cellular kinase that phosphorylates P protein in vitro is biochemically and immunologically indistinguishable from protein kinase C (PRC) zeta isoform. PKC zeta was packaged into the Sendai virion and remained associated with purified viral ribonucleoprotein, where it phosphorylated both the P and the nucleocapsid protein in vitro. When PHC zeta-specific inhibitory pseudosubstrate peptide was introduced into LLC-MK2 cells prior to Sendai virus infection, production of progeny virus was dramatically attenuated, and kinetic analysis revealed that primary transcription was repressed. These data indicate that phosphorylation of the Sendai virus P protein by PKC zeta plays a critical role in the virus life cycle.	CLEVELAND CLIN FDN,RES INST,DEPT MOL BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NIAID NIH HHS [AI32027] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032027] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANERJEE AK, 1991, PHARMACOL THERAPEUT, V51, P47, DOI 10.1016/0163-7258(91)90041-J; BARIK S, 1992, J VIROL, V66, P1109, DOI 10.1128/JVI.66.2.1109-1118.1992; BARIK S, 1992, P NATL ACAD SCI USA, V89, P6570, DOI 10.1073/pnas.89.14.6570; BARIK S, 1995, VIROLOGY, V213, P405, DOI 10.1006/viro.1995.0013; BELL RM, 1991, J BIOL CHEM, V266, P4661; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BYRAPPA S, 1995, VIROLOGY, V208, P408, DOI 10.1006/viro.1995.1169; Byrappa S, 1996, VIROLOGY, V216, P228, DOI 10.1006/viro.1996.0052; Canter DM, 1996, VIROLOGY, V219, P376, DOI 10.1006/viro.1996.0263; CHATTOPADHYAY D, 1988, P NATL ACAD SCI USA, V85, P7977, DOI 10.1073/pnas.85.21.7977; CURRAN J, 1991, EMBO J, V10, P3079, DOI 10.1002/j.1460-2075.1991.tb07860.x; Curran J, 1996, VIROLOGY, V221, P130, DOI 10.1006/viro.1996.0359; CURRAN J, 1994, VIROLOGY, V202, P875, DOI 10.1006/viro.1994.1409; DAS T, 1995, J BIOL CHEM, V270, P24100, DOI 10.1074/jbc.270.41.24100; DAS T, 1995, VIROLOGY, V211, P218, DOI 10.1006/viro.1995.1394; DE BP, 1995, P NATL ACAD SCI USA, V92, P5204, DOI 10.1073/pnas.92.11.5204; DESHPANDE KL, 1985, VIROLOGY, V140, P125, DOI 10.1016/0042-6822(85)90451-9; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; DYER RM, 1994, J IMMUNOL, V153, P1171; EINBERGER H, 1990, J VIROL, V64, P4274, DOI 10.1128/JVI.64.9.4274-4280.1990; FINCO TS, 1993, J BIOL CHEM, V268, P17676; Folgueira L, 1996, J VIROL, V70, P223, DOI 10.1128/JVI.70.1.223-231.1996; GALINSKI MS, 1986, VIROLOGY, V155, P46, DOI 10.1016/0042-6822(86)90167-4; GALINSKI MS, 1991, PARAMYXOVIRUSES; GAO Y, 1995, EMBO J, V14, P1240, DOI 10.1002/j.1460-2075.1995.tb07107.x; GOMBART AF, 1993, J VIROL, V67, P4133, DOI 10.1128/JVI.67.7.4133-4141.1993; GOMBART AF, 1995, VIRUS RES, V37, P63, DOI 10.1016/0168-1702(95)00020-Q; HORIKAMI SM, 1992, J VIROL, V66, P4901, DOI 10.1128/JVI.66.8.4901-4908.1992; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUNTLEY CC, 1995, VIROLOGY, V211, P561, DOI 10.1006/viro.1995.1438; KOCHS G, 1993, EUR J BIOCHEM, V216, P597, DOI 10.1111/j.1432-1033.1993.tb18179.x; MAZUMDER B, 1994, VIROLOGY, V205, P104, DOI 10.1006/viro.1994.1624; MAZUMDER B, 1994, VIROLOGY, V205, P93, DOI 10.1006/viro.1994.1623; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; RYAN KW, 1990, VIROLOGY, V174, P515, DOI 10.1016/0042-6822(90)90105-Z; RYAN KW, 1991, VIROLOGY, V180, P126, DOI 10.1016/0042-6822(91)90016-5; SANCHEZSECO MP, 1995, J GEN VIROL, V76, P425, DOI 10.1099/0022-1317-76-2-425; SAPDAFORA D, 1996, J VIROL, V70, P4538; SEGEV Y, 1995, J VIROL, V69, P2480, DOI 10.1128/JVI.69.4.2480-2485.1995; SHEN SS, 1990, DEV BIOL, V140, P272, DOI 10.1016/0012-1606(90)90077-V; SMALLWOOD S, 1994, VIROLOGY, V202, P154, DOI 10.1006/viro.1994.1331; TAKACS A, 1992, J VIROL, V30, P166; VIDAL S, 1988, J VIROL, V62, P2200, DOI 10.1128/JVI.62.6.2200-2203.1988; VILLANUEVA N, 1994, J GEN VIROL, V75, P555, DOI 10.1099/0022-1317-75-3-555	46	32	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16578	16584		10.1074/jbc.272.26.16578	http://dx.doi.org/10.1074/jbc.272.26.16578			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195969	hybrid			2022-12-27	WOS:A1997XG01900073
J	Karas, M; Danilenko, M; Fishman, D; LeRoith, D; Levy, J; Sharoni, Y				Karas, M; Danilenko, M; Fishman, D; LeRoith, D; Levy, J; Sharoni, Y			Membrane-associated insulin-like growth factor-binding protein-3 inhibits insulin-like growth factor-I-induced insulin-like growth factor-I receptor signaling in ishikawa endometrial cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGF-I; GENE-EXPRESSION; RAT; PROLIFERATION; POTENTIATION; FIBROBLASTS; MODULATION; HORMONE	The function of cell surface-associated insulin-like growth factor-binding proteins (IGFBPs) is controversial. Both inhibition and facilitation of IGF action as well as IGF-independent effects have been reported. We examined the influence of endogenous cell surface-associated IGFBPs on IGF-I receptor (IGF-IR) function in Ishikawa endometrial cancer cells by comparing the effects of IGF-I and its truncated analog des-(1-3)-IGF-I on several components of the IGF-IR signal transduction pathway in the absence of significant amounts of soluble IGFBPs. IGF-I and des-(1-3)-IGF-I are known to have similar affinities for IGF-IR, although the affinity of des(1-3)-IGF-I for IGFBPs is greatly reduced. Here we show that the two ligands were equipotent not only in IGF-IR binding but also in receptor activation in NIH 3T3 cells overexpressing IGF-IR and possessing a relatively small number of cell surface-associated IGFBPs. In contrast, des-(1-3)-IGF-I manifested a remarkably higher potency as compared with IGF-I in inducing short and middle term cellular responses in IGF-IR-transfected Ishikawa endometrial cancer cells possessing a high number of both the receptor and the cell membrane-bound IGFBP-3. Thus, this difference in the effects of IGF-I and des-(1-3)-IGF-I can be attributed to the attenuation of IGF-I-mediated IGF-IR signaling by membrane-bound IGFBP-3.	BEN GURION UNIV NEGEV, SOROKA MED CTR KUPAT HOLIM, FAC HLTH SCI, DEPT CLIN BIOCHEM, IL-84105 BEER SHEVA, ISRAEL; BEN GURION UNIV NEGEV, SOROKA MED CTR KUPAT HOLIM, FAC HLTH SCI, DEPT IMMUNOL & MICROBIOL, IL-84105 BEER SHEVA, ISRAEL; NIDDK, DIABET BRANCH, NIH, BETHESDA, MD 20892 USA	Ben Gurion University; Soroka Medical Center; Ben Gurion University; Soroka Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			SHARONI, YOAV/F-1223-2012; Danilenko, Michael/F-2283-2012	Danilenko, Michael/0000-0001-9466-6169				BACH LA, 1992, DIABETES, V41, P499, DOI 10.2337/diabetes.41.4.499; BALLARD FJ, 1987, BIOCHEM BIOPH RES CO, V149, P398, DOI 10.1016/0006-291X(87)90380-9; BASERGA R, 1995, CANCER RES, V55, P249; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN JC, 1994, J CELL PHYSIOL, V158, P69, DOI 10.1002/jcp.1041580110; Chevalier X, 1996, BRIT J RHEUMATOL, V35, P515; Conover CA, 1996, ENDOCRINOLOGY, V137, P2286, DOI 10.1210/en.137.6.2286; CONOVER CA, 1992, ENDOCRINOLOGY, V130, P3191, DOI 10.1210/en.130.6.3191; CORTIZO AM, 1995, J ENDOCRINOL, V144, P119, DOI 10.1677/joe.0.1440119; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Hatefi Y, 1974, Methods Enzymol, V31, P770; Heding A, 1996, J BIOL CHEM, V271, P13948, DOI 10.1074/jbc.271.24.13948; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Karas Michael, 1995, Progress in Growth Factor Research, V6, P513, DOI 10.1016/0955-2235(95)00033-X; KATO H, 1993, J BIOL CHEM, V268, P2655; Kelley KM, 1996, INT J BIOCHEM CELL B, V28, P619, DOI 10.1016/1357-2725(96)00005-2; Kleinman D, 1996, ENDOCRINOLOGY, V137, P1089, DOI 10.1210/en.137.3.1089; KLEINMAN D, 1995, ENDOCRINOLOGY, V136, P2531, DOI 10.1210/en.136.6.2531; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LORD APD, 1994, J ENDOCRINOL, V140, P475, DOI 10.1677/joe.0.1400475; LORENZO M, 1993, J CELL BIOL, V123, P1567, DOI 10.1083/jcb.123.6.1567; MCGRATH MF, 1991, ENDOCRINOLOGY, V129, P671, DOI 10.1210/endo-129-2-671; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OH Y, 1993, J BIOL CHEM, V268, P26045; OH YM, 1993, J BIOL CHEM, V268, P14964; OKAJIMA T, 1992, ENDOCRINOLOGY, V130, P2201, DOI 10.1210/en.130.4.2201; PARK JHY, 1992, ENDOCRINOLOGY, V131, P1359, DOI 10.1210/en.131.3.1359; RAPRAEGER AC, 1994, METHOD ENZYMOL, V245, P219; Rogers J, 1996, REGUL PEPTIDES, V61, P189, DOI 10.1016/0167-0115(95)00155-7; RUSSO VC, 1994, GROWTH FACTORS, V11, P301, DOI 10.3109/08977199409011003; SAMARAS SE, 1995, AM J PHYSIOL-ENDOC M, V268, pE1057, DOI 10.1152/ajpendo.1995.268.6.E1057; SILVERMAN LA, 1995, ENDOCRINOLOGY, V136, P720, DOI 10.1210/en.136.2.720; SUNIC D, 1995, BBA-GEN SUBJECTS, V1245, P43, DOI 10.1016/0304-4165(95)00076-N; TAMIR A, 1994, J IMMUNOL, V152, P3391; TOMINAGA T, 1994, ENDOCRINOLOGY, V135, P1212, DOI 10.1210/en.135.3.1212; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361	39	52	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16514	16520		10.1074/jbc.272.26.16514	http://dx.doi.org/10.1074/jbc.272.26.16514			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195961	hybrid			2022-12-27	WOS:A1997XG01900065
J	Qie, LX; Nagiec, MM; Baltisberger, JA; Lester, RL; Dickson, RC				Qie, LX; Nagiec, MM; Baltisberger, JA; Lester, RL; Dickson, RC			Identification of a Saccharomyces gene, LCB3, necessary for incorporation of exogenous long chain bases into sphingolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PALMITOYLTRANSFERASE; MUTANT STRAINS; CEREVISIAE; MEMBRANE; PROTEIN; BIOSYNTHESIS; YEAST; PHOSPHOLIPIDS; CERAMIDE	To identify genes necessary for sphingolipid synthesis in Saccharomyces cerevisiae we developed a procedure to enrich for mutants unable to incorporate exogenous long chain base into sphingolipids. We show here that a mutant strain, AG84-3, isolated by using the enrichment procedure, makes sphingolipids from endogenously synthesized but not from exogenously supplied long chain base. A gene termed LCB3 (YJL134W, GenBank designation X87371x21), which complements the long chain base utilization defect of strain AG84-3, was isolated from a genomic DNA library, The gene is predicted to encode a protein with multiple membrane-spanning domains and a COOH-terminal glycosylphosphatidylinositiol cleavage/attachment site, Deletion of the lcb3 gene in a wild type genetic background reduces the rate of exogenous long chain base incorporation into sphingolipids and makes the host strain more resistant to growth inhibition by long chain bases, Only one protein in current data bases, the S, cerevisiae open-reading frame YKR053C, whose function is unknown, shows homology to the Lcb3 protein, The two proteins are not, however, functional homologs because deletion of the YKR053C open reading frame does not impair long chain base utilization or enhance resistance of cells to growth inhibition by long chain bases, Based upon these data we hypothesize that the Lcb3 protein is a plasma membrane transporter capable of transporting sphingoid long chain bases into cells, It is the first candidate for such a transporter and the first member of what appears to be a new class of membrane-bound proteins.	UNIV KENTUCKY,MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40536; UNIV KENTUCKY,MED CTR,LUCILLE P MARKEY CANC CTR,LEXINGTON,KY 40536	University of Kentucky; University of Kentucky					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041302] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41302] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; DICKSON RC, 1990, MOL CELL BIOL, V10, P2176, DOI 10.1128/MCB.10.5.2176; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; GIETZ RD, 1992, NUCLEIC ACIDS RES, V8, P1425; HANSON BA, 1980, J LIPID RES, V21, P309; HANSON BA, 1980, J BACTERIOL, V142, P79, DOI 10.1128/JB.142.1.79-89.1980; JOHNSTON SA, 1982, P NATL ACAD SCI USA, V79, P6871; LESTER RL, 1993, ADV LIPID RES, V26, P253; LESTER RL, 1993, J BIOL CHEM, V268, P845; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; NAGIEC MM, 1994, P NATL ACAD SCI USA, V91, P7899, DOI 10.1073/pnas.91.17.7899; NAGIEC MM, 1993, J BIOL CHEM, V268, P22156; NAGIEC MM, 1997, J BIOL CHEM, V272, P9000; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; NUOFFER C, 1993, J BIOL CHEM, V268, P10558; PATTON JL, 1992, J BACTERIOL, V174, P7180, DOI 10.1128/jb.174.22.7180-7184.1992; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; PINTO WJ, 1992, J BACTERIOL, V174, P2575, DOI 10.1128/jb.174.8.2575-2581.1992; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH SW, 1974, J BIOL CHEM, V249, P3395; STEINER MR, 1972, BIOCHIM BIOPHYS ACTA, V260, P222, DOI 10.1016/0005-2760(72)90035-5; STEINER S, 1969, P NATL ACAD SCI USA, V64, P1042, DOI 10.1073/pnas.64.3.1042; ZWEERINK MM, 1992, J BIOL CHEM, V267, P25032	31	72	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16110	16117		10.1074/jbc.272.26.16110	http://dx.doi.org/10.1074/jbc.272.26.16110			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195906	hybrid			2022-12-27	WOS:A1997XG01900010
J	Tournamille, C; LeVanKim, C; Gane, P; Blanchard, D; Proudfoot, AE; Cartron, JP; Colin, Y				Tournamille, C; LeVanKim, C; Gane, P; Blanchard, D; Proudfoot, AE; Cartron, JP; Colin, Y			Close association of the first and fourth extracellular domains of the Duffy antigen/receptor for chemokines by a disulfide bond is required for ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-KNOWLESI MALARIA; NEGATIVE INDIVIDUALS; MOLECULAR-BASIS; A RECEPTOR; ANTIGEN; INTERLEUKIN-8; IDENTIFICATION; EXPRESSION; PARASITE; VIVAX	It has been demonstrated that the promiscuous chemokine binding profile of the Huffy antigen/reaeptor for chemokines (DARC) is given by its extracellular NH2-terminal region. However, the relationship among the Fy6, Fy(a)/(b), and Fy3 epitopes, localized in the first and fourth extracellular domains of DARC, respectively, and the chemokine binding sites remained a matter of controversy. Here, we performed cross-displacement and cross-inhibition experiments indicating that all anti-Fy6, anti-Fy(a), and anti-Fy3 monoclonal antibodies and interleukin 8 are antagonists for binding to red cells. Biopanning of phage peptide libraries with an anti-Fy6 monoclonal antibody led to the identification of the motif phe(22)-Glu(23), th, mutation of which altered the binding of both anti-Fy6 and chemokines (interleukin 8, MGSA, RANTES (regulated on activation normal T cell expressed)) to DARC transfectants. These results characterized the core of the Fy6 epitope and provided definitive proof of the tight relationship between Fy6 and the chemokine receptor site. Analysis of red cells treated by sulfhydryl group-modifying reagents suggested that the chemokine receptor function of DARC required the integrity of disulfide bond(s) but not that of free sulfhydryl group(s). Accordingly, mutation of cysteines 51 and 276 abolished chemokine binding to DARC transfectants. Altogether, our results suggested that the chemokine binding pocket of DARC included sequences located in the first and fourth extracellular domains which are brought into close vicinity by a disulfide bridge.	INST NATL TRANSFUS SANGUINE, INSERM, U76, F-75015 PARIS, FRANCE; ETAB TRANSFUS SANGUINE, F-44000 NANTES, FRANCE; GLAXO WELLCOME RES & DEV LTD, GENEVA BIOMED RES INST, CH-1228 GENEVA, SWITZERLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); GlaxoSmithKline			colin, yves/O-1910-2017; le van kim, caroline/O-7030-2017	colin, yves/0000-0001-5196-4254; le van kim, caroline/0000-0002-3251-1310				ALOUANI S, 1995, EUR J BIOCHEM, V227, P328, DOI 10.1111/j.1432-1033.1995.tb20393.x; CHAUDHURI A, 1989, J BIOL CHEM, V264, P13770; CHAUDHURI A, 1995, BLOOD, V85, P615, DOI 10.1182/blood.V85.3.615.bloodjournal853615; Chaudhuri A, 1997, BLOOD, V89, P701, DOI 10.1182/blood.V89.2.701; CHAUDHURI A, 1993, P NATL ACAD SCI USA, V90, P10793, DOI 10.1073/pnas.90.22.10793; CHAUDHURI A, 1994, J BIOL CHEM, V269, P7835; Chitnis CE, 1996, J EXP MED, V184, P1531, DOI 10.1084/jem.184.4.1531; DARBONNE WC, 1991, J CLIN INVEST, V88, P1362, DOI 10.1172/JCI115442; HADLEY TJ, 1994, J CLIN INVEST, V94, P985, DOI 10.1172/JCI117465; HADLEY TJ, 1984, SCIENCE, V223, P597, DOI 10.1126/science.6695171; Hausman E, 1996, TRANSFUSION, V36, P421, DOI 10.1046/j.1537-2995.1996.36596282585.x; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HORUK R, 1994, J BIOL CHEM, V269, P17730; Horuk R, 1996, J LEUKOCYTE BIOL, V59, P29, DOI 10.1002/jlb.59.1.29; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; Iwamoto S, 1996, BIOCHEM BIOPH RES CO, V222, P852, DOI 10.1006/bbrc.1996.0833; Iwamoto S, 1996, BLOOD, V87, P378; LEONG SR, 1994, J BIOL CHEM, V269, P19343; LU ZH, 1995, J BIOL CHEM, V270, P26239; MALLINSON G, 1995, BRIT J HAEMATOL, V90, P823, DOI 10.1111/j.1365-2141.1995.tb05202.x; MILLER LH, 1975, SCIENCE, V189, P561, DOI 10.1126/science.1145213; MILLER LH, 1976, NEW ENGL J MED, V295, P302, DOI 10.1056/NEJM197608052950602; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NEOTE K, 1994, BLOOD, V84, P44; PEIPER SC, 1995, J EXP MED, V181, P1311, DOI 10.1084/jem.181.4.1311; RIWOM S, 1994, VOX SANG, V66, P61, DOI 10.1111/j.1423-0410.1994.tb00279.x; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; RUSSO DCW, 1994, BLOOD, V84, P3518; SAMANTA AK, 1993, J BIOL CHEM, V268, P6147; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; SZABO MC, 1995, J BIOL CHEM, V270, P25348, DOI 10.1074/jbc.270.43.25348; TOURNAMILLE C, 1995, HUM GENET, V95, P407, DOI 10.1007/BF00208965; TOURNAMILLE C, 1995, NAT GENET, V10, P224, DOI 10.1038/ng0695-224; Wasniowska K, 1996, MOL IMMUNOL, V33, P917; WASNIOWSKA K, 1994, TRANSFUS MED REV, V8, P281, DOI 10.1016/S0887-7963(94)70119-X	35	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16274	16280		10.1074/jbc.272.26.16274	http://dx.doi.org/10.1074/jbc.272.26.16274			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195930	hybrid			2022-12-27	WOS:A1997XG01900034
J	vanEchtenDeckert, G; Zschoche, A; Bar, T; Schmidt, RR; Raths, A; Heinemann, T; Sandhoff, K				vanEchtenDeckert, G; Zschoche, A; Bar, T; Schmidt, RR; Raths, A; Heinemann, T; Sandhoff, K			cis-4-Methylsphingosine decreases sphingolipid biosynthesis by specifically interfering with serine palmitoyltransferase activity in primary cultured neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 FIBROBLASTS; SPHINGOSINE 1-PHOSPHATE; CELLULAR PROLIFERATION; 2ND MESSENGER; GLYCOSPHINGOLIPID BIOSYNTHESIS; INDEPENDENT PATHWAY; KINASE; SPHINGOSINE-1-PHOSPHATE; INHIBITION; BINDING	The effect of six different structurally modified sphingosine analogues on biosynthesis of sphingolipids was studied in primary cultured murine cerebellar neurons, Treatment of cells with cis-4-methylsphingosine at micromolar levels resulted in a markedly decreased sphingolipid biosynthesis, whereas the other compounds examined, trans-5-methylsphingosine, cis-5-methylsphingosine, trans-5-methylsphingosine, cis-sphingosine, and 1-deoxysphingosine, inhibited sphingolipid biosynthesis less efficiently, The inhibition of sphingolipid biosynthesis by the various compounds was paralleled by a decrease of serine palmitoyltransferase activity in situ, For cis-4-methylsphingosine the inhibitory effect on serine palmitoyltransferase activity was shown to be concentration- and time-dependent, Half-maximal reduction of enzyme activity occurred after 24 hours of treatment with 10 mu M of the compound, The activity of other enzymes of sphingolipid biosynthesis as well as phospholipid and protein biosynthesis was not affected. Analysis of the sphingoid moiety of cellular sphingolipids suggests that the sphingosine analogues listed above were subject to degradation rather than being utilized as precursors for sphingolipid biosynthesis by cultured neurons, Except of 1-deoxysphingosine, the other five sphingosine analogues were shown to be substrates for sphingosine kinase in vitro. After 24 h of treatment of primary cerebellar neurons with the various sphingosine analogues the relative percentage of the respective intracellular l-phosphate derivatives paralleled exactly the inhibitory effect on serine palmitoyltransferase activity observed when cells were treated with the unphosphorylated compounds, In contrast to the respective l-phosphate derivatives of the other methyl-l,ranched sphingosine analogues examined, cis-4-methylsphingosine l-phosphate showed an intracellular accumulation suggesting a delayed turnover rate in cultured murine neurons for this compound, These results suggest that the inhibitory effect of the sphingosine analogues on serine palmitoyltransferase is mediated by their respective l-phosphate derivatives and that the pronounced effect of cis-4-methylsphingosine is caused by a high intracellular concentration of cis-4-methylsphingosine 1-phosphate. cis-4-Methylsphingosine, in addition, caused drastic changes in cell morphology of primary cerebellar neurons, which were not observed when these cells were treated with one of the other sphingosine analogues examined.	UNIV KONSTANZ, FAK CHEM, D-78434 CONSTANCE, GERMANY	University of Konstanz	vanEchtenDeckert, G (corresponding author), UNIV BONN, INST ORGAN CHEM & BIOCHEM, GERHARD DOMAGK STR 1, D-53121 BONN, GERMANY.							BAR T, 1993, LIEBIGS ANN CHEM, P419; BIRK R, 1991, J LABELLED COMPD RAD, V29, P289, DOI 10.1002/jlcr.2580290306; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNERWEISS G, 1992, TETRAHEDRON, V48, P5855, DOI 10.1016/S0040-4020(01)90177-2; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; BUEHRER BM, 1993, ADV LIPID RES, V26, P59; GAVER RC, 1966, J AM CHEM SOC, V88, P3643, DOI 10.1021/ja00967a032; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; INOKUCHI JI, 1987, J LIPID RES, V28, P565; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; MANDON EC, 1991, EUR J BIOCHEM, V198, P667, DOI 10.1111/j.1432-1033.1991.tb16065.x; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; MESSER A, 1977, BRAIN RES, V130, P1, DOI 10.1016/0006-8993(77)90838-1; Nakamura S, 1996, J BIOL CHEM, V271, P1255, DOI 10.1074/jbc.271.3.1255; OHTA H, 1995, CANCER RES, V55, P691; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; OLIVERA A, 1994, J BIOL CHEM, V269, P17924; OLIVERA A, 1994, ANAL BIOCHEM, V223, P306, DOI 10.1006/abio.1994.1589; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; SCHWARZMANN G, 1987, METHOD ENZYMOL, V138, P318; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P169, DOI 10.1515/bchm2.1973.354.1.169; STOFFEL W, 1970, H-S Z PHYSIOL CHEM, V351, P1041, DOI 10.1515/bchm2.1970.351.2.1041; SU Y, 1994, J BIOL CHEM, V269, P16512; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; TRENKNER E, 1977, J CELL BIOL, V75, P915, DOI 10.1083/jcb.75.3.915; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; VANECHTEN G, 1989, J NEUROCHEM, V52, P207; VANECHTEN G, 1990, J BIOL CHEM, V265, P9333; VANVELDHOVEN PP, 1993, ADV LIPID RES, V26, P69; WANG E, 1991, J BIOL CHEM, V266, P14486; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; YATOMI Y, 1995, ANAL BIOCHEM, V230, P315, DOI 10.1006/abio.1995.1480; ZACHARIAS C, 1994, J BIOL CHEM, V269, P13313; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; ZIMMERMANN P, 1988, LIEBIGS ANN CHEM, P663; ZWEERINK MM, 1992, J BIOL CHEM, V267, P25032	43	68	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15825	15833		10.1074/jbc.272.25.15825	http://dx.doi.org/10.1074/jbc.272.25.15825			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188480	hybrid			2022-12-27	WOS:A1997XF32900040
J	Davey, MJ; Funnell, BE				Davey, MJ; Funnell, BE			Modulation of the P1 plasmid partition protein ParA by ATP, ADP, and P1 ParB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; BINDING; SEQUENCE; ATPASES; SYSTEM; MOTIF	ParA is an essential P1 plasmid partition protein. It represses transcription of the par genes (parA and parB) and is also required for a second, as yet undefined step in partition. ParA is a ParB-stimulated ATPase that binds to a specific DNA site in the par promoter region, ATP binding and hydrolysis by ParA affect ParA activities in vitro. ATP and ADP binding stimulate ParA DNA binding and dimerization; however, ATP hydrolysis has a negative effect on DNA binding. Our current experiments reveal that ATP binding and hydrolysis affect ParA conformation and ParA sensitivity to ParB, Nucleotide binding assays show that ParA binds ATP better than ADP (K-d values of 33 and 50 mu M, respectively), Interaction with these nucleotides as well as ATP hydrolysis by ParA alter ParA conformation as established by CD and ParA sensitivity to heat denaturation. Finally, we show that ParB stimulates ParA DNA binding, This stimulation requires ATP hydrolysis in vitro, suggesting that one role for ATP hydrolysis in vivo is to make ParA repressor sensitive to ParB, Our observations lead to the suggestion that ATP binding and hydrolysis have separable roles in ParA repressor function and perhaps in ParA partition functions as well.	UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON M5S 1A8,CANADA	University of Toronto			Davey, Megan/B-4066-2012	Funnell, Barbara/0000-0002-1828-6567				ABELES AL, 1985, J MOL BIOL, V185, P261, DOI 10.1016/0022-2836(85)90402-4; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; DAVEY MJ, 1994, J BIOL CHEM, V269, P29908; Davis MA, 1996, MOL MICROBIOL, V21, P1029, DOI 10.1046/j.1365-2958.1996.721423.x; DAVIS MA, 1992, MOL MICROBIOL, V6, P1141, DOI 10.1111/j.1365-2958.1992.tb01552.x; DAVIS MA, 1988, EMBO J, V7, P1881, DOI 10.1002/j.1460-2075.1988.tb03021.x; FRANZEN JS, 1961, J BIOL CHEM, V236, P515; FRIEDMAN SA, 1988, PLASMID, V19, P103, DOI 10.1016/0147-619X(88)90049-2; FUNNELL BE, 1991, J BIOL CHEM, V266, P14328; FUNNELL BE, 1995, J BACTERIOL, V177, P2381, DOI 10.1128/jb.177.9.2381-2386.1995; FUNNELL BE, 1988, P NATL ACAD SCI USA, V85, P6657, DOI 10.1073/pnas.85.18.6657; FUNNELL BE, 1996, ROLE BACTERIAL MEMBR, P123; HAYES F, 1994, MOL MICROBIOL, V11, P249, DOI 10.1111/j.1365-2958.1994.tb00305.x; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; IKEDA H, 1968, COLD SPRING HARB SYM, V33, P791, DOI 10.1101/SQB.1968.033.01.091; KOONIN EV, 1993, J MOL BIOL, V229, P1165, DOI 10.1006/jmbi.1993.1115; MOTALLEBIVESHAREH M, 1990, MOL MICROBIOL, V4, P1455, DOI 10.1111/j.1365-2958.1990.tb02056.x; MYLES GM, 1991, BIOCHEMISTRY-US, V30, P3824, DOI 10.1021/bi00230a004; Sambrook J., 2002, MOL CLONING LAB MANU; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHNEIDER E, 1994, J BIOL CHEM, V269, P20456; VANDERWOLK J, 1993, MOL MICROBIOL, V8, P31; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	27	55	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15286	15292		10.1074/jbc.272.24.15286	http://dx.doi.org/10.1074/jbc.272.24.15286			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182555	hybrid			2022-12-27	WOS:A1997XE03400038
J	Kobayashi, T; Kiriyama, M; Hirata, T; Hirata, M; Ushikubi, F; Narumiya, S				Kobayashi, T; Kiriyama, M; Hirata, T; Hirata, M; Ushikubi, F; Narumiya, S			Identification of domains conferring ligand binding specificity to the prostanoid receptor - Studies on chimeric prostacyclin/prostaglandin D receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-E RECEPTOR; BETA-ADRENERGIC-RECEPTOR; NORTHERN BLOT ANALYSIS; BETA-2-ADRENERGIC RECEPTORS; THROMBOXANE-A2 RECEPTOR; PROSTACYCLIN RECEPTOR; SPECIES SELECTIVITY; TERMINAL DOMAINS; MOLECULAR-BASIS; CDNA CLONING	To identify domains conferring ligand binding specificity to prostanoid receptors, we constructed a series of chimeric receptors by successively replacing the regions from the carboxyl-terminal tail of mouse prostacyclin (prostaglandin I (PGI)) receptor (mIP) with the corresponding regions of the mouse PGD receptor (mDP), The mIP receptor expressed in COS 7 cells bound [H-3]iloprost, a PGI(2) analog and [H-3]PGE(1) with K-d values of 13 and 27 nM, respectively, This receptor did not bind [H-3]PGD(2), [H-3]PGE(2), and [H-3]PGF(2 alpha). The mDP receptor bound only [H-3]PGD(2) with a K-d value of 43 nM, The chimeric IPN-VII/DPC receptor with replacement of the carboxyl tail of the mIP receptor with that of the mDP receptor showed 12-16-fold higher affinities for [H-3]iloprost and [H-3]PGE(1) than the mIP receptor, The region extending from the sixth transmembrane domain to the carboxyl terminus of the mIP receptor was next replaced with the corresponding region of the mDP receptor, This chimeric IPN-V/DPVI-C receptor acquired the ability to bind [H-3]PGD(2) and [H-3]PGE(2) without decreasing the affinities of the mIP receptor to [H-3]iloprost and [H-3]PGE(1). These binding characteristics did not change when the fourth and fifth transmembrane domains of the mIP receptor were further replaced with She corresponding regions of the mDP receptor, However, when the first extracellular to second intracellular loop of the mIP receptor containing the third transmembrane domain was further replaced with those of the mDP receptor, the affinities for [H-3]PGE(1), [H-3]PGE(2), and [3H]iloprost were markedly decreased, whereas that far [H-3]PGD(2) was increased by about 2-fold, [H-3]PGF(2 alpha) showed no affinity for the mIP, mDP, and all the chimeric receptors. These results suggest that She sixth to seventh transmembrane domain of the mIP receptor confers the specificity of this receptor to bind selectively to PGE(1) and not to PGE(2) and that the third transmembrane domain of the mDP, receptor confers the selective binding of PGD(2) to this receptor.	KYOTO UNIV,FAC MED,DEPT PHARMACOL,SAKYO KU,KYOTO 60601,JAPAN	Kyoto University				Hirata, Takako/0000-0002-1740-6168				BOIE Y, 1995, J BIOL CHEM, V270, P18910, DOI 10.1074/jbc.270.32.18910; COLEMAN RA, 1990, COMPREHENSIVE MED CH, V3, P643; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FONG TM, 1992, J BIOL CHEM, V267, P25668; FRIELLE T, 1988, P NATL ACAD SCI USA, V85, P9494, DOI 10.1073/pnas.85.24.9494; FUNK CD, 1993, MOL PHARMACOL, V44, P934; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GETHER U, 1993, P NATL ACAD SCI USA, V90, P6194, DOI 10.1073/pnas.90.13.6194; HALUSHKA PV, 1989, ANNU REV PHARMACOL, V29, P213; HIRATA M, 1994, P NATL ACAD SCI USA, V91, P11192, DOI 10.1073/pnas.91.23.11192; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HONDA A, 1993, J BIOL CHEM, V268, P7759; KATSUYAMA M, 1995, FEBS LETT, V372, P151, DOI 10.1016/0014-5793(95)00966-D; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEIGH PJ, 1984, J BIOL CHEM, V259, P2431; MONCADA S, 1985, PHARMACOL BASIS THER, P660; NAMBA T, 1992, BIOCHEM BIOPH RES CO, V184, P1197, DOI 10.1016/S0006-291X(05)80009-9; NAMBA T, 1994, J BIOL CHEM, V269, P9986; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NARUMIYA S, 1993, J LIPID MEDIATOR, V6, P155; NEGISHI M, 1993, J BIOL CHEM, V268, P9517; SACHAIS BS, 1993, J BIOL CHEM, V268, P2319; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SCHAMBYE HT, 1994, P NATL ACAD SCI USA, V91, P7046, DOI 10.1073/pnas.91.15.7046; STRADER CD, 1991, J BIOL CHEM, V266, P5; STRADER CD, 1989, J BIOL CHEM, V264, P13572; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; SUGIMOTO Y, 1994, J BIOL CHEM, V269, P1356; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; TOH H, 1995, FEBS LETT, V361, P17, DOI 10.1016/0014-5793(95)00129-W; TOWN MH, 1983, PROSTAGLANDINS, V25, P13; TSAI AL, 1989, J BIOL CHEM, V264, P61; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; USHIKUBI F, 1995, J LIPID MEDIAT CELL, V12, P343, DOI 10.1016/0929-7855(95)00022-I; WATABE A, 1993, J BIOL CHEM, V268, P20175; WONG SKF, 1994, J BIOL CHEM, V269, P18968	38	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15154	15160		10.1074/jbc.272.24.15154	http://dx.doi.org/10.1074/jbc.272.24.15154			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182536	hybrid			2022-12-27	WOS:A1997XE03400019
J	Rhee, SG; Bae, YS				Rhee, SG; Bae, YS			Regulation of phosphoinositide-specific phospholipase C isozymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							SMOOTH-MUSCLE CELLS; G-PROTEINS; C-GAMMA-1; RECEPTOR; PHOSPHORYLATION; ACTIVATION; SUBUNIT; SIGNAL; CYCLE; G(Q)				Rhee, SG (corresponding author), NHLBI,LAB CELL SIGNALING,NIH,BLDG 3,RM 122,3 CTR DR,MSC 0320,BETHESDA,MD 20892, USA.							Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; COCKCROFT S, 1992, BIOCHEM J, V288, P1; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Dippel E, 1996, P NATL ACAD SCI USA, V93, P1391, DOI 10.1073/pnas.93.4.1391; DIVECHA N, 1995, BIOCHEM J, V312, P63, DOI 10.1042/bj3120063; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DRAYER AL, 1994, EMBO J, V13, P1601, DOI 10.1002/j.1460-2075.1994.tb06423.x; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; GomezGuerrero C, 1996, J IMMUNOL, V156, P4369; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; Hwang SC, 1996, J BIOL CHEM, V271, P18342, DOI 10.1074/jbc.271.31.18342; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; Jiang HP, 1996, J BIOL CHEM, V271, P13430, DOI 10.1074/jbc.271.23.13430; JONES GA, 1993, J BIOL CHEM, V268, P20845; Keely PJ, 1996, J BIOL CHEM, V271, P26668, DOI 10.1074/jbc.271.43.26668; Kim CG, 1996, J BIOL CHEM, V271, P21187, DOI 10.1074/jbc.271.35.21187; KNANG Y, 1996, J BIOL CHEM, V271, P3975; KOZASA T, 1993, P NATL ACAD SCI USA, V90, P9176, DOI 10.1073/pnas.90.19.9176; Kuang YN, 1996, P NATL ACAD SCI USA, V93, P2964, DOI 10.1073/pnas.93.7.2964; LEE CW, 1994, J BIOL CHEM, V269, P25335; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; Lee SB, 1996, BLOOD, V88, P1684; LEE YH, 1993, BIOCHEM BIOPH RES CO, V194, P665, DOI 10.1006/bbrc.1993.1873; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; Liu MY, 1996, J BIOL CHEM, V271, P7066, DOI 10.1074/jbc.271.12.7066; Lyu MS, 1996, MAMM GENOME, V7, P501, DOI 10.1007/s003359900151; MANZOLI L, 1997, IN PRESS CANC RES; MARMIROLI S, 1994, J BIOL CHEM, V269, P13; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MISRA UK, 1995, BIOCHEM J, V309, P151, DOI 10.1042/bj3090151; NAKAMURA F, 1995, J BIOL CHEM, V270, P6246, DOI 10.1074/jbc.270.11.6246; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; RHEE SG, 1992, J BIOL CHEM, V267, P12393; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SMITH MR, 1994, P NATL ACAD SCI USA, V91, P6554, DOI 10.1073/pnas.91.14.6554; Smith MR, 1996, BIOCHEM BIOPH RES CO, V222, P186, DOI 10.1006/bbrc.1996.0719; STEHNOBITTEL L, 1995, J BIOL CHEM, V270, P30068; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; YORK JD, 1994, J BIOL CHEM, V269, P7847; Zhang SY, 1996, J BIOL CHEM, V271, P20208, DOI 10.1074/jbc.271.33.20208; Zhu X, 1996, P NATL ACAD SCI USA, V93, P2827, DOI 10.1073/pnas.93.7.2827	50	796	820	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15045	15048		10.1074/jbc.272.24.15045	http://dx.doi.org/10.1074/jbc.272.24.15045			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182519	hybrid			2022-12-27	WOS:A1997XE03400002
J	Jurutka, PW; Hsieh, JC; Remus, LS; Whitfield, GK; Thompson, PD; Haussler, CA; Blanco, JCG; Ozato, K; Haussler, MR				Jurutka, PW; Hsieh, JC; Remus, LS; Whitfield, GK; Thompson, PD; Haussler, CA; Blanco, JCG; Ozato, K; Haussler, MR			Mutations in the 1,25-dihydroxyvitamin D-3 receptor identifying C-terminal amino acids required for transcriptional activation that are functionally dissociated from hormone binding, heterodimeric DNA binding, and interaction with basal transcription factor IIB, in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D-RECEPTOR; D-RESPONSIVE ELEMENT; HUMAN ESTROGEN-RECEPTOR; RAT OSTEOCALCIN GENE; RETINOID-X-RECEPTOR; PROTEIN-KINASE-C; THYROID-HORMONE; FACTOR TFIIB; TRANSACTIVATION DOMAIN; CRYSTAL-STRUCTURE	To investigate a potential ligand-dependent transcriptional activation domain (AF-2) in the C-terminal region of the human vitamin D receptor (hVDR), two conserved residues, Leu-417 and Glu-420, were replaced with alanines by site-directed mutagenesis (L417A and E420A). Transcriptional activation in response to 1,25-dihydroxyvitamin D-3 (1,25-(OH)(2)D-3) was virtually eliminated when either point mutant was transfected into several mammalian cell lines. Furthermore, both mutants exhibited a dominant negative phenotype when expressed in COS-7 cells. Scatchard analysis at 4 degrees C and a ligand-dependent DNA binding assay at 25 degrees C revealed essentially normal 1,25-(OH)(2)D-3 binding for the mutant hVDRs, which were also equivalent to native receptor in associating with the rat osteocalcin vitamin D responsive element as a presumed heterodimer with retinoid X receptor. Glutathione S-transferase-human transcription factor IIB (TFIIB) fusion protein linked to Sepharose equally coprecipitated the wild-type hVDR and the AF-2 mutants. These data implicate amino acids Leu-417 and Glu-420, residing in a putative alpha-helical region at the extreme C terminus of hVDR, as critical in the mechanism of 1,25-(OH)(2)D-3-stimulated transcription, likely mediating an interaction with a coactivator(s) or a component of the basal transcriptional machinery distinct from TFIIB.	UNIV ARIZONA,COLL MED,DEPT BIOCHEM,TUCSON,AZ 85724; NICHHD,LAB MOL GROWTH REGULAT,NIH,BETHESDA,MD 20892	University of Arizona; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Blanco, Jorge/AAW-3752-2020	Jurutka, Peter/0000-0002-4950-9161; Blanco, Jorge/0000-0002-6173-0213; Haussler, Carol/0000-0001-8360-3066; Haussler, Mark/0000-0002-7097-1801	NIAMS NIH HHS [AR-15781] Funding Source: Medline; NIDDK NIH HHS [DK-33351, DK-49604] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR015781, R01AR015781] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049604, R37DK033351, R01DK033351] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BANIAHMAD C, 1995, MOL ENDOCRINOL, V9, P34, DOI 10.1210/me.9.1.34; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; Blanco JCG, 1996, GENES CELLS, V1, P209, DOI 10.1046/j.1365-2443.1996.d01-229.x; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BREEN EC, 1994, P NATL ACAD SCI USA, V91, P12902, DOI 10.1073/pnas.91.26.12902; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CLEMENS TL, 1988, ENDOCRINOLOGY, V122, P1224, DOI 10.1210/endo-122-4-1224; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; DOKOH S, 1984, CANCER RES, V44, P2103; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HAUSSLER MR, 1995, BONE, V17, pS33, DOI 10.1016/8756-3282(95)00205-R; HAUSSLER MR, 1997, IN PRESS J ENDOCRINO; HAUSSLER MR, 1988, PROGR ENDOCRINOLOGY, V1, P763; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; HSIEH JC, 1995, BIOCHEM BIOPH RES CO, V215, P1, DOI 10.1006/bbrc.1995.2426; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; HSIEH JC, 1993, J BIOL CHEM, V268, P15118; INCE BA, 1993, J BIOL CHEM, V268, P14026; Jin CH, 1996, MOL ENDOCRINOL, V10, P196, DOI 10.1210/me.10.2.196; JURUTKA PW, 1993, J BIOL CHEM, V268, P6791; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEHMANN JM, 1993, MOL CELL BIOL, V13, P7698, DOI 10.1128/MCB.13.12.7698; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; MACDONALD PN, 1995, J BIOL CHEM, V270, P4748, DOI 10.1074/jbc.270.9.4748; MACDONALD PN, 1991, J BIOL CHEM, V266, P18808; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MARKOSE ER, 1990, P NATL ACAD SCI USA, V87, P1701, DOI 10.1073/pnas.87.5.1701; MCDONNELL DP, 1987, SCIENCE, V235, P1214, DOI 10.1126/science.3029866; Minucci S, 1997, MOL CELL BIOL, V17, P644, DOI 10.1128/MCB.17.2.644; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAKAJIMA S, 1994, MOL ENDOCRINOL, V8, P159, DOI 10.1210/me.8.2.159; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; ONATE SA, 1995, SCIENCE, V270, P1354; OZONO K, 1990, J BIOL CHEM, V265, P21881; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; Schulman IG, 1996, MOL CELL BIOL, V16, P3807; SONE T, 1991, J BIOL CHEM, V266, P23296; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TERPENING CM, 1991, MOL ENDOCRINOL, V5, P373, DOI 10.1210/mend-5-3-373; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; TONE Y, 1994, J BIOL CHEM, V269, P31157; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; UPPALURI R, 1995, MOL CELL BIOL, V15, P1499; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; Whitfield GK, 1996, MOL ENDOCRINOL, V10, P1617, DOI 10.1210/me.10.12.1617; WHITFIELD GK, 1995, MOL ENDOCRINOL, V9, P1166, DOI 10.1210/me.9.9.1166	60	70	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14592	14599		10.1074/jbc.272.23.14592	http://dx.doi.org/10.1074/jbc.272.23.14592			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169418	Green Submitted, hybrid			2022-12-27	WOS:A1997XC32700015
J	Linse, S; Hardig, Y; Schultz, DA; Dahlback, B				Linse, S; Hardig, Y; Schultz, DA; Dahlback, B			A region of vitamin K-dependent protein S that binds to C4b binding protein (C4BP) identified using bacteriophage peptide display libraries	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN C4B-BINDING PROTEIN; FUNCTIONAL-CHARACTERIZATION; 3-DIMENSIONAL STRUCTURE; MOLECULAR-CLONING; PHAGE DISPLAY; BETA-CHAIN; MODULE; SELECTION; DOMAIN; ALPHA	Vitamin K-dependent protein S, a blood coagulation inhibitor, interacts with the C4b-binding protein (C4BP) in human plasma with high affinity (K-D = 0.1 nM). Identification of a portion of protein S that binds to C4BP has been approached using random libraries of 6- and 15-mer peptides displayed on bacteriophage surfaces. Bacteriophage binding to the beta-chain of C4BP were selected in several rounds of affinity purification with intervening amplification in E. coli. Homology searches of the affinity purified peptide sequences against protein S led to the identification of four regions in protein S that were similar to several of the selected peptides. These regions were synthesized as linear peptides and tested in inhibition experiments. Only one distinct peak (around position 450) was observed when the homology scores versus human protein S sequence were averaged over all affinity purified peptides. A synthetic peptide comprising residues 439-460 in human protein S was found to inhibit protein S binding to C4BP. The same result was found with two overlapping peptides (residues 447-468 and 435-468, respectively) in a second set of synthetic peptides. Direct binding of the peptides to C4BP was inferred from titrations monitored by recording the near UV circular dichroism spectra or the polarization of tryptophan fluorescence. The results suggest that residues 447-460 constitute a portion of protein S that is important for the interaction with C4BP. These findings may have implications for patients suffering from thrombosis, due to the lack of free protein S, by directing the design of drugs that disrupt protein S binding to C4BP.	LUND UNIV,MALMO UNIV HOSP,DEPT CLIN CHEM,S-20502 MALMO,SWEDEN; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	Lund University; Skane University Hospital; University of California System; University of California San Diego	Linse, S (corresponding author), LUND UNIV,CTR CHEM,DEPT PHYS CHEM 2,POB 124,S-22100 LUND,SWEDEN.			Dahlback, Bjorn/0000-0003-1546-0328; Linse, Sara/0000-0001-9629-7109	PHS HHS [B100120] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BARLOW PN, 1992, BIOCHEMISTRY-US, V31, P3626, DOI 10.1021/bi00129a011; BARLOW PN, 1993, J MOL BIOL, V232, P268, DOI 10.1006/jmbi.1993.1381; BARON M, 1992, PROTEIN SCI, V1, P81; BERTINA RM, 1990, BLOOD, V76, P538; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; CHANG CTG, 1994, THROMB HAEMOSTASIS, V71, P461; CHU MD, 1994, BBA-GENE STRUCT EXPR, V1217, P325, DOI 10.1016/0167-4781(94)90294-1; DAHLBACK B, 1984, J BIOL CHEM, V259, P1631; DAHLBACK B, 1986, P NATL ACAD SCI USA, V83, P4199, DOI 10.1073/pnas.83.12.4199; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; DAHLBACK B, 1983, P NATL ACAD SCI-BIOL, V80, P3461, DOI 10.1073/pnas.80.11.3461; DAHLBACK B, 1990, J BIOL CHEM, V265, P16082; DE FRUTOS PG, 1994, BLOOD, V84, P815; DOOLEY CT, 1994, SCIENCE, V266, P2019, DOI 10.1126/science.7801131; DOWNING AK, 1997, IN PRESS CELL; DUCHEMIN J, 1995, BLOOD, V86, P3436, DOI 10.1182/blood.V86.9.3436.bloodjournal8693436; FERNANDEZ JA, 1993, J BIOL CHEM, V268, P16788; FERNANDEZ JA, 1994, BIOCHEMISTRY-US, V33, P11073, DOI 10.1021/bi00203a003; GERSHAGEN S, 1987, FEBS LETT, V220, P129, DOI 10.1016/0014-5793(87)80890-6; GREENGARD JS, 1995, BIOCHEM J, V305, P397, DOI 10.1042/bj3050397; GU HD, 1995, PROTEIN SCI, V4, P1108, DOI 10.1002/pro.5560040609; HARDIG Y, 1995, BIOCHEM J, V308, P795; Hardig Y, 1996, J BIOL CHEM, V271, P20861, DOI 10.1074/jbc.271.34.20861; HARDIG Y, 1993, J BIOL CHEM, V269, P2535; He XH, 1997, BIOCHEMISTRY-US, V36, P3745, DOI 10.1021/bi962315q; HE XH, 1993, EUR J BIOCHEM, V217, P857, DOI 10.1111/j.1432-1033.1993.tb18314.x; HILLARP A, 1989, FEBS LETT, V259, P53, DOI 10.1016/0014-5793(89)81492-9; HILLARP A, 1988, J BIOL CHEM, V263, P12759; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; LUNDWALL A, 1986, P NATL ACAD SCI USA, V83, P6717; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; NELSON RM, 1991, BIOCHEMISTRY-US, V30, P2384, DOI 10.1021/bi00223a013; NELSON RM, 1992, J BIOL CHEM, V267, P8140; NISHI T, 1993, EXP MED, V11, P1759; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; Schumacher TNM, 1996, SCIENCE, V271, P1854, DOI 10.1126/science.271.5257.1854; SCHWALBE R, 1990, J BIOL CHEM, V265, P16074; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; SMITH GP, 1993, GENE, V128, P37, DOI 10.1016/0378-1119(93)90150-2; SUNNERHAGEN M, 1995, NAT STRUCT BIOL, V2, P504, DOI 10.1038/nsb0695-504; VILLOTREUX BO, 1996, PROTEIN ENG, V8, P1253; WALKER FJ, 1989, J BIOL CHEM, V264, P17645; WEINSTEIN RE, 1990, J CLIN INVEST, V86, P1928, DOI 10.1172/JCI114926; YASUDA F, 1995, J BIOCHEM-TOKYO, V117, P374, DOI 10.1093/jb/117.2.374	50	33	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14658	14665		10.1074/jbc.272.23.14658	http://dx.doi.org/10.1074/jbc.272.23.14658			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169428	hybrid			2022-12-27	WOS:A1997XC32700025
J	Chen, SY; Wang, J; Yu, GQ; Liu, WH; Pearce, D				Chen, SY; Wang, J; Yu, GQ; Liu, WH; Pearce, D			Androgen and glucocorticoid receptor heterodimer formation - A possible mechanism for mutual inhibition of transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; NONRECEPTOR FACTORS; HORMONE RECEPTORS; RESPONSE ELEMENT; SKELETAL-MUSCLE; GENE ACTIVATION; RAT; TRANSACTIVATION; RECOGNITION; REPRESSION	The androgen and glucocorticoid hormones elicit divergent and often opposing effects in cells, tissues, and animals, A wide range of physiological and molecular biological evidence suggests that the receptors that mediate these effects, the androgen and glucocorticoid re ceptors (AR and GR, respectively), influence each other's transcriptional activity. We now show that coexpressed AR and GR indeed do interact at the transcriptional level and that this interaction is correlated with their ability to form heterodimers at a common DNA site, in vitro and in vivo. Furthermore, mutants that cannot heterodimerize do not inhibit each other's activity, These observations provide the first evidence that the opposing physiological effects of the androgen and glucocorticoid hormones are due to the direct physical interaction between their receptors at the transcriptional level.	SAN FRANCISCO GEN HOSP,DEPT MED,DIV NEPHROL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM BIOMED SCI,SAN FRANCISCO,CA 94143	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK051151, R01DK051151, R56DK051151] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK51151-02] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADLER AJ, 1993, MOL CELL BIOL, V13, P6326, DOI 10.1128/MCB.13.10.6326; ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; Bubulya A, 1996, J BIOL CHEM, V271, P24583, DOI 10.1074/jbc.271.40.24583; DAHLBERG E, 1981, ENDOCRINOLOGY, V108, P1431, DOI 10.1210/endo-108-4-1431; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EISEN LP, 1985, J BIOL CHEM, V260, P1805; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FREEDMAN LP, 1988, NATURE, V334, P540; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KALLIO PJ, 1995, MOL ENDOCRINOL, V9, P1017, DOI 10.1210/me.9.8.1017; KASPAR F, 1993, MOL CELL BIOL, V13, P7850, DOI 10.1128/MCB.13.12.7850; Liu WH, 1995, P NATL ACAD SCI USA, V92, P12480, DOI 10.1073/pnas.92.26.12480; Liu WH, 1996, MOL ENDOCRINOL, V10, P1399, DOI 10.1210/me.10.11.1399; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MAYER M, 1975, AM J PHYSIOL, V229, P1381, DOI 10.1152/ajplegacy.1975.229.5.1381; MAYER M, 1976, METABOLISM, V25, P157, DOI 10.1016/0026-0495(76)90046-9; MONDER C, 1994, ENDOCRINOLOGY, V134, P1193, DOI 10.1210/en.134.3.1193; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; Pearce David, 1995, P525; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; RUNDLETT SE, 1995, MOL CELL ENDOCRINOL, V109, P1, DOI 10.1016/0303-7207(95)03477-O; RUPPRECHT R, 1993, MOL ENDOCRINOL, V7, P597, DOI 10.1210/me.7.4.597; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SJOGREN J, 1994, BBA-MOL CELL RES, V1224, P17, DOI 10.1016/0167-4889(94)90108-2; SJOGREN J, 1995, BBA-GEN SUBJECTS, V1244, P117, DOI 10.1016/0304-4165(94)00208-F; SMITH RG, 1984, J STEROID BIOCHEM, V20, P277, DOI 10.1016/0022-4731(84)90217-6; SYMS AJ, 1987, J STEROID BIOCHEM, V28, P109, DOI 10.1016/0022-4731(87)90365-7; TRAPP T, 1994, NEURON, V13, P1457, DOI 10.1016/0896-6273(94)90431-6; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; WRIGHT APH, 1991, P NATL ACAD SCI USA, V88, P8283, DOI 10.1073/pnas.88.19.8283	36	156	158	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14087	14092		10.1074/jbc.272.22.14087	http://dx.doi.org/10.1074/jbc.272.22.14087			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162033	hybrid			2022-12-27	WOS:A1997XB49200020
J	Dan, N; Lehrman, MA				Dan, N; Lehrman, MA			Oligomerization of hamster UDP-GlcNAc:Dolichol-P GlcNAc-1-P transferase, an enzyme with multiple transmembrane spans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE N-ACETYLGLUCOSAMINE-1-PHOSPHATE TRANSFERASE; CIS-ISOPRENYLTRANSFERASE ACTIVITY; N-GLYCOSYLATION; TARGET ANALYSIS; MAMMARY-GLAND; CELLS; GLYCOPROTEINS; BIOSYNTHESIS; EXPRESSION; SEQUENCE	Hamster UDP-GlcNAc:dolichol-P GlcNAc-1-P transferase (GPT), which initiates N-linked glycosylation by catalyzing the synthesis of GlcNAc-P-P-dolichol, has multiple transmembrane spans and a catalytic site that probably exists on the cytosolic face of the endoplasmic reticulum membrane (Dan, N., Middleton, R. M., and Lehrman, M. A. (1996) J. Biol. Chem. 271, 30717-30725), In this report, we demonstrate that GPT forms functional oligomers, probably dimers, Oligomers were detected by chemical cross-linking of GPT and by a dominant-negative effect caused by co-expression of enzymatically inactive (but properly folded) GPT mutants, The GPT mutants had no effect on two other dolichol-P-dependent endoplasmic reticulum enzymes, Mixing experiments indicated that mature GPT was competent for oligomerization. Oligomerization appeared to be favored in detergent extracts compared with intact microsomes. Detergent treatments were found to prevent, rather than promote, nonspecific aggregation of GPT, These results demonstrate that GPT subunits can physically interact and influence each other, The implications of oligomerization for enzyme function are discussed, From these results, we conclude that GPT is one of a very small number of multitransmembrane span enzymes that can form multimers.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM038545, R01GM038545] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38545] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1990, J BIOL CHEM, V265, P14691; CRICK DC, 1994, J BIOL CHEM, V269, P10559; CRICK DC, 1994, J NEUROCHEM, V62, P247; Dan N, 1996, J BIOL CHEM, V271, P30717, DOI 10.1074/jbc.271.48.30717; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Helenius A, 1979, Methods Enzymol, V56, P734; Hille B., 1992, IONIC CHANNELS EXCIT, P236; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; KEMPNER ES, 1993, TRENDS BIOCHEM SCI, V18, P236, DOI 10.1016/0968-0004(93)90169-N; KEMPNER ES, 1989, METHOD ENZYMOL, V172, P410; LEHRMAN M A, 1991, Glycobiology, V1, P553, DOI 10.1093/glycob/1.6.553; LEHRMAN MA, 1994, GLYCOBIOLOGY, V4, P768, DOI 10.1093/glycob/4.6.768; LEHRMAN MA, 1988, J BIOL CHEM, V263, P19796; LENNON K, 1995, GLYCOBIOLOGY, V5, P633, DOI 10.1093/glycob/5.6.633; Ma J, 1996, J BIOL CHEM, V271, P11197, DOI 10.1074/jbc.271.19.11197; MOTA OM, 1994, BIOCHEM BIOPH RES CO, V204, P284, DOI 10.1006/bbrc.1994.2457; RAJPUT B, 1994, J BIOL CHEM, V269, P16054; ROSENWALD AG, 1990, J BIOL CHEM, V265, P14544; SHAILUBHAI K, 1988, J BIOL CHEM, V263, P15964; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; WALDMAN BC, 1987, J CELL PHYSIOL, V131, P302, DOI 10.1002/jcp.1041310303; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; ZHU XY, 1990, J BIOL CHEM, V265, P14250; ZHU XY, 1992, J BIOL CHEM, V267, P8895	26	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14214	14219		10.1074/jbc.272.22.14214	http://dx.doi.org/10.1074/jbc.272.22.14214			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162053	hybrid			2022-12-27	WOS:A1997XB49200040
J	Jascur, T; Gilman, J; Mustelin, T				Jascur, T; Gilman, J; Mustelin, T			Involvement of phosphatidylinositol 3-kinase in NFAT activation in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RECEPTOR TYROSINE KINASES; PHOSPHOINOSITIDE 3-KINASE; INSULIN STIMULATION; DIRECT ASSOCIATION; ANTIGEN RECEPTOR; NUCLEAR FACTOR; SH2 DOMAINS; P85 SUBUNIT; CALCINEURIN	Phosphatidylinositol 3-kinase (PI3-K) has been implicated in the regulation of cell proliferation in many cell types, We have previously shown that in T cells the PI3-K inhibitor, wortmannin, interferes with activation of the mitogen-activated kinase, Erk2, after T cell receptor (TcR) stimulation, To further explore the involvement of PI3-K in T cell activation, we created a set of potentially dominant negative PI3-K constructs comprising individual or tandem domains of the regulatory p85 subunit and tested their effect on downstream signaling events like Erk2 activation and transcription from an NFAT (nuclear factor of activated T cells) element taken from the interleukin-2 promoter, Following TcR stimulation, activation of Erk2 was only inhibited by a previously described truncated form of p85 that cannot bind the catalytic subunit, but not by other constructs of p85, In contrast, several mutant p85 alleles had dramatic effects on NFAT activation. Most interestingly, the N-terminal SH2 domain had an inhibitory effect, whereas a mutant p85 containing only the two SH2 domains enhanced basal NFAT activity in a Ras-dependent manner, Ionomycin induced synergistic activation of NFAT in cells expressing p85 mutants that contained the C-terminal SH2 domain. Analysis of phosphotyrosine-containing proteins bound to truncated p85 constructs revealed cooperative binding of the two SH2 domains but no apparent differences between the N- and C-terminal SH2 domains, Wortmannin did not interfere with NFAT activation, although it inhibited PI3-K and Erk2 activation in the same experiment, These results suggest that PI3-K is involved in NFAT activation through a complex adaptor function of its regulatory subunit and that its lipid kinase activity is dispensable for this effect.	LA JOLLA INST ALLERGY & IMMUNOL, DIV CELL BIOL, SAN DIEGO, CA 92121 USA	La Jolla Institute for Immunology				Mustelin, Tomas/0000-0001-5912-8840	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035603] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048960] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35603] Funding Source: Medline; NIGMS NIH HHS [GM48960] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARRERA AC, 1994, J BIOL CHEM, V269, P19435; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; EXLEY M, 1994, J BIOL CHEM, V269, P15140; Fang N, 1996, J IMMUNOL, V157, P3769; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; HU P, 1994, MOL CELL BIOL, V14, P2577, DOI 10.1128/MCB.14.4.2577; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Liu YC, 1997, J BIOL CHEM, V272, P168; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NEL AE, 1990, J IMMUNOL, V144, P2683; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VICIANA PR, 1994, NATURE, V370, P527; VICIANA R, 1996, EMBO J, V15, P2442; vonWillebrand M, 1996, EUR J BIOCHEM, V235, P828; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; WARD SG, 1992, EUR J IMMUNOL, V22, P45, DOI 10.1002/eji.1830220108; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; WOODROW MA, 1993, J IMMUNOL, V150, P3853; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	44	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14483	14488		10.1074/jbc.272.22.14483	http://dx.doi.org/10.1074/jbc.272.22.14483			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162091	hybrid			2022-12-27	WOS:A1997XB49200078
J	Kwon, BS; Tan, KB; Ni, J; KwiOkOh; Lee, ZH; Kim, KK; Kim, YJ; Wang, S; Gentz, R; Yu, GL; Harrop, J; Lyn, SD; Silverman, C; Porter, TG; Truneh, A; Young, PR				Kwon, BS; Tan, KB; Ni, J; KwiOkOh; Lee, ZH; Kim, KK; Kim, YJ; Wang, S; Gentz, R; Yu, GL; Harrop, J; Lyn, SD; Silverman, C; Porter, TG; Truneh, A; Young, PR			A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; CELL ANTIGEN 4-1BB; HUMAN B-CELLS; MOLECULAR-CLONING; TNF RECEPTOR; CHROMOSOMAL LOCALIZATION; INSITU HYBRIDIZATION; HUMAN GENOME; CD40 LIGAND; EXPRESSION	The tumor necrosis factor receptor (TNFR) superfamily consists of approximately 10 characterized members of human proteins. We have identified a new member of the TNFR superfamily, TR2, from a search of an expressed sequence tag data base, cDNA cloning and Northern blot hybridization demonstrated multiple mRNA species, of which a 1.7-kilobase form was most abundant. However, TR2 is encoded by a single gene which, maps to chromosome 1p36.22-36.3, in the same region as several other members of the TNFR superfamily. The most abundant TR2 open reading frame encodes a 283-amino acid single transmembrane protein with a 36-residue signal sequence, two perfect and two imperfect TNFR-like cysteine-rich domains, and a short cytoplasmic tail with some similarity to 4-1BB and CD40. TR2 mRNA is expressed in multiple human tissues and cell lines and shows a constitutive and relatively high expression in peripheral blood T cells, B cells, and monocytes. A TR2-Fc fusion protein inhibited a mixed lymphocyte reaction-mediated proliferation suggesting that the receptor and/or its ligand play a role in T cell stimulation.	INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202; DEPT MOL IMMUNOL,KING OF PRUSSIA,PA 19406; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; GlaxoSmithKline; Human Genome Sciences Inc	Kwon, BS (corresponding author), INDIANA UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,INDIANAPOLIS,IN 46202, USA.		Kim, Kack-Kyun/C-5031-2012; Truneh, Alem/ABB-7891-2020	Kim, Kack-Kyun/0000-0002-1279-5387; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028175] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040248] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 28175] Funding Source: Medline; NIAMS NIH HHS [AR 40248] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; BAENS M, 1993, GENOMICS, V16, P214, DOI 10.1006/geno.1993.1161; BAKER E, 1991, CYTOGENET CELL GENET, V57, P117, DOI 10.1159/000133127; BANCHEREAU J, 1991, NATURE, V353, P678, DOI 10.1038/353678a0; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BAUM PR, 1994, EMBO J, V13, P3992, DOI 10.1002/j.1460-2075.1994.tb06715.x; BIRKELAND ML, 1995, EUR J IMMUNOL, V25, P926, DOI 10.1002/eji.1830250410; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; FANSLOW WC, 1992, J IMMUNOL, V149, P655; GILLETTEFERGUSO.L, 1994, EUR J IMMUNOL, V24, P1182; GOODWIN RG, 1993, EUR J IMMUNOL, V23, P2631, DOI 10.1002/eji.1830231037; GRABSTEIN KH, 1993, J IMMUNOL, V150, P3141; GRAMMER AC, 1995, J IMMUNOL, V154, P4996; GRASS HJ, 1994, BLOOD, V83, P2045; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HENG HHQ, 1994, HUM MOL GENET, V3, P61, DOI 10.1093/hmg/3.1.61; HOWARD ST, 1991, VIROLOGY, V180, P633, DOI 10.1016/0042-6822(91)90077-O; HU FQ, 1994, VIROLOGY, V204, P343, DOI 10.1006/viro.1994.1539; Hurtado JC, 1997, J IMMUNOL, V158, P2600; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KOEFFLER HP, 1980, BLOOD, V56, P265; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; KWON BS, 1994, J IMMUNOL, V152, P2256; KWON BS, 1989, P NATL ACAD SCI USA, V86, P1963, DOI 10.1073/pnas.86.6.1963; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MALLETT S, 1991, IMMUNOL TODAY, V12, P220, DOI 10.1016/0167-5699(91)90033-P; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; POLLOK KE, 1993, J IMMUNOL, V150, P771; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 2002, MOL CLONING LAB MANU; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMITH CA, 1993, CELL, V73, P1439; SMITH GL, 1993, J GEN VIROL, V74, P1725, DOI 10.1099/0022-1317-74-9-1725; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Torcia M, 1996, CELL, V85, P345, DOI 10.1016/S0092-8674(00)81113-7; TUCKER KA, 1987, BLOOD, V70, P372; VANLIER RAW, 1987, J IMMUNOL, V139, P1589	49	240	273	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14272	14276		10.1074/jbc.272.22.14272	http://dx.doi.org/10.1074/jbc.272.22.14272			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162061	hybrid			2022-12-27	WOS:A1997XB49200048
J	Doege, KJ; Coulter, SN; Meek, LM; Maslen, K; Wood, JG				Doege, KJ; Coulter, SN; Meek, LM; Maslen, K; Wood, JG			A human-specific polymorphism in the coding region of the aggrecan gene - Variable number of tandem repeats produce a range of core protein sizes in the general population	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; BOVINE CARTILAGE PROTEOGLYCAN; DEDUCED PRIMARY STRUCTURE; MOLECULAR-CLONING; HUMAN DNA; SEQUENCE; EXPRESSION; NANOMELIA; DISEASE; SEGMENT	Aggrecan, one of the major structural genes of cartilage, encodes a proteoglycan core protein composed of an extended central glycosaminoglycan bearing domain, flanked by globular domains at each end, The central region consists of long stretches of repeating amino acids that serve as attachment sites for glycosaminoglycans such as chondroitin and keratan sulfate; the terminal globular domains interact with other cartilage components, The glycosaminoglycan attachment region is encoded in several species by a single large exon, within which are several different types of repeating sequences. Several species show within this exon a similar block of conserved repeats for attachment of chondroitin sulfate, but in humans this group of repeats is particularly well conserved, Examination of genomic DNA from a population of unrelated individuals by polymerase chain reaction or Southern blot assays shows this block of repeat sequences exists in multiple allelic forms, which differ by the number of repeats at this site in each allele, Thirteen different alleles have been identified, with repeat numbers ranging from 13 to 33, This is an unusual example of an expressed variable number of tandem repeat polymorphism, This polymorphism is apparently restricted to humans, of several species examined, This polymorphism results in individuals with differing length aggrecan core proteins, bearing different numbers of potential attachment sites for chondroitin sulfate. The possibility exists for a molecular understanding of biological variation in cartilage functional properties.			Doege, KJ (corresponding author), SHRINERS HOSP CRIPPLED CHILDREN,3101 SW SAM JACKSON PK RD,PORTLAND,OR 97210, USA.							ANTONSSON P, 1989, J BIOL CHEM, V264, P16170; ASPBERG A, 1995, P NATL ACAD SCI USA, V92, P10590, DOI 10.1073/pnas.92.23.10590; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; DJIAN P, 1991, P NATL ACAD SCI USA, V88, P5321, DOI 10.1073/pnas.88.12.5321; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE K, 1990, BIOCHEM SOC T, V18, P200, DOI 10.1042/bst0180200; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; DOMOWICZ M, 1995, DEV BIOL, V171, P655, DOI 10.1006/dbio.1995.1312; FINKELSTEIN JE, 1991, AM J HUM GENET, V48, P97; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GUM JR, 1992, AM J RESP CELL MOL, V7, P557, DOI 10.1165/ajrcmb/7.6.557; HALBERG DF, 1988, J BIOL CHEM, V263, P9486; HARDINGHAM T, 1990, SEMIN ARTHRITIS RHEU, V20, P12, DOI 10.1016/0049-0172(90)90044-G; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; ITO K, 1995, J BIOL CHEM, V270, P958, DOI 10.1074/jbc.270.2.958; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; JIMENEZ SA, 1994, ANN RHEUM DIS, V53, P789, DOI 10.1136/ard.53.12.789; LI H, 1993, J BIOL CHEM, V268, P23504; NASO MF, 1994, J BIOL CHEM, V269, P32999; OLDBERG A, 1987, BIOCHEM J, V243, P255, DOI 10.1042/bj2430255; ORKIN RW, 1976, DEV BIOL, V50, P82, DOI 10.1016/0012-1606(76)90069-5; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; Sambrook J., 2002, MOL CLONING LAB MANU; SORIMACHI H, 1988, J BIOL CHEM, V263, P17678; STIRPE NS, 1989, DEVELOPMENT, V107, P22; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; Tokino T, 1996, HUM GENET, V97, P625, DOI 10.1007/s004390050106; UJITA M, 1994, J BIOL CHEM, V269, P27603; VALHMU WB, 1995, BIOCHEM J, V309, P535, DOI 10.1042/bj3090535; WALCZ E, 1994, GENOMICS, V22, P364, DOI 10.1006/geno.1994.1396; WIGHT TN, 1991, CELL BIOL EXTRACELLU, P45, DOI DOI 10.1007/978-1-4615-3770-0_3; WONG M, 1992, J BIOL CHEM, V267, P5592	34	88	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13974	13979		10.1074/jbc.272.21.13974	http://dx.doi.org/10.1074/jbc.272.21.13974			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153261	hybrid			2022-12-27	WOS:A1997XA06200076
J	Krah, R; ODea, MH; Gellert, M				Krah, R; ODea, MH; Gellert, M			Reverse gyrase from Methanopyrus kandleri - Reconstitution of an active extremozyme from its two recombinant subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I TOPOISOMERASE; ATP; SULFOLOBUS; EXPRESSION; CLEAVAGE; INVITRO; BINDING	Reverse gyrases are ATP-dependent type I 5'-topoisomerases that positively supercoil DNA. Reverse gyrase from Methanopyrus kandleri is unique as the first heterodimeric type I 5'-topoisomerase described, con sisting of a 138-kDa subunit involved in the hydrolysis of ATP (RgyB) and a 43-kDa subunit that forms the covalent complex with DNA during the topoisomerase reaction (RgyA). Here we report the reconstitution of active reverse gyrase from the two recombinant proteins overexpressed in Escherichia coli. Both proteins have been purified by column chromatography to >90% homogeneity. RgyB has a DNA-dependent ATPase activity at high temperature (80 degrees C) and is independent of the presence of RgyA RgyA alone has no detectable activity. The addition of RgyA to RgyB reconstitutes positive supercoiling activity, but the RgyB and RgyA subunits form a stable heterodimer only after being heated together. This is the first case in which it has been possible to reconstitute an active heterodimeric enzyme of a hyperthermophilic prokaryote from recombinant proteins.	NIDDK,MOL BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ADAMS MWW, 1995, BIO-TECHNOL, V13, P662, DOI 10.1038/nbt0795-662; ADAMS MWW, 1995, CHEM ENG NEWS   1218, P32; BURGESS RR, 1991, METHOD ENZYMOL, V208, P3; CONFALONIERI F, 1993, P NATL ACAD SCI USA, V90, P4753, DOI 10.1073/pnas.90.10.4753; DELATOUR CB, 1990, J BACTERIOL, V172, P6803, DOI 10.1128/jb.172.12.6803-6808.1990; DELATOUR CB, 1991, J BACTERIOL, V173, P3921, DOI 10.1128/JB.173.12.3921-3923.1991; DIRUGGIERO J, 1995, APPL ENVIRON MICROB, V61, P159, DOI 10.1128/AEM.61.1.159-164.1995; Forterre P, 1996, CELL, V85, P789, DOI 10.1016/S0092-8674(00)81262-3; FORTERRE P, 1985, EMBO J, V4, P2123, DOI 10.1002/j.1460-2075.1985.tb03902.x; HUBER R, 1995, NATURE, V376, P57, DOI 10.1038/376057a0; JAXEL C, 1989, EMBO J, V8, P3135, DOI 10.1002/j.1460-2075.1989.tb08466.x; KOVALSKY OI, 1990, NUCLEIC ACIDS RES, V18, P2801, DOI 10.1093/nar/18.9.2801; KOZYAVKIN SA, 1994, J BIOL CHEM, V269, P11081; Krah R, 1996, P NATL ACAD SCI USA, V93, P106, DOI 10.1073/pnas.93.1.106; NAKASU S, 1985, EMBO J, V4, P2705, DOI 10.1002/j.1460-2075.1985.tb03990.x; Rivera MC, 1996, INT J SYST BACTERIOL, V46, P348, DOI 10.1099/00207713-46-1-348; ROBB FT, 1995, ARCHAEA LAB MANUAL T, V3; SHIBATA T, 1987, J BIOL CHEM, V262, P10419; SLESAREV AI, 1988, EUR J BIOCHEM, V173, P395, DOI 10.1111/j.1432-1033.1988.tb14012.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223	21	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13986	13990		10.1074/jbc.272.21.13986	http://dx.doi.org/10.1074/jbc.272.21.13986			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153263	hybrid			2022-12-27	WOS:A1997XA06200078
J	Djie, MZ; Stone, SR; LeBonniec, BF				Djie, MZ; Stone, SR; LeBonniec, BF			Intrinsic specificity of the reactive site loop of alpha(1)-antitrypsin, alpha(1)-antichymotrypsin, antithrombin III, and protease nexin I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; NEURITE-PROMOTING FACTOR; HEPARIN COFACTOR-II; PROTEINASE-INHIBITORS; DIRECTED MUTAGENESIS; HUMAN ALPHA-1-ANTICHYMOTRYPSIN; CRYSTAL-STRUCTURE; ANTI-THROMBIN; EGLIN-C; ALPHA-1-ANTITRYPSIN	Members of the serpin (serine protease inhibitor) family share a similar backbone structure but expose a variable reactive-site loop, which binds to the catalytic groove of the target protease. Specificity originates in part from the sequence of this loop and also from secondary binding sites that contribute to the inhibitor function. To clarify the intrinsic contribution of the reactive-site loop, alpha(1)-antichymotrypsin has been utilized as a scaffold to construct chimeras carrying the loop of antithrombin III, protease nexin 1, or alpha(1)-antitrypsin. Reactive-site loops not only vary in sequence but also in length; therefore, the length of the reactive-site loop was also varied in the chimeras. The efficacy of the specificity transfer was evaluated by measuring the stoichiometry of the reaction, the ability to form an SDS-stable complex, and the association rate constant with a number of potential targets (chymotrypsin, neutrophil elastase, trypsin, thrombin, factor Xa, activated protein C, and urokinase). Overall, substitution of a reactive-site loop was not sufficient to transfer the specificity of a given serpin to alpha(1)-antichymotrypsin. Specificity of the chimera partly matched that of the loop donor and partly that of the acceptor, whereas the behavior as an inhibitor or a substrate depended upon the targeted protease. Results suggest that, aside from the contributions of the loop sequence and the framework-specific secondary binding sites, an intramolecular control may be essential for productive interaction.	UNIV CAMBRIDGE,MRC CTR,DEPT HAEMATOL,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology; University of Cambridge			Le Bonniec, Bernard/S-5756-2016; Le Bonniec, Bernard/ABA-1366-2020	Le Bonniec, Bernard/0000-0002-8432-7363; Le Bonniec, Bernard/0000-0002-8432-7363				AVRON A, 1991, FEBS LETT, V280, P41, DOI 10.1016/0014-5793(91)80199-D; BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BJORK I, 1992, J BIOL CHEM, V267, P1976; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; CHANDRA T, 1983, BIOCHEMISTRY-US, V22, P5055, DOI 10.1021/bi00291a001; CHEN ZG, 1983, J MOL BIOL, V164, P283, DOI 10.1016/0022-2836(83)90078-5; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23616; DENNIS MS, 1995, J BIOL CHEM, V270, P25411, DOI 10.1074/jbc.270.43.25411; DERECHIN VM, 1990, J BIOL CHEM, V265, P5623; Djie MZ, 1996, BIOCHEMISTRY-US, V35, P11461, DOI 10.1021/bi952717i; DONOVAN FM, 1994, J BIOL CHEM, V269, P17199; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; ELDERING E, 1992, J BIOL CHEM, V267, P7013; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; Engh RA, 1995, TRENDS BIOTECHNOL, V13, P503, DOI 10.1016/S0167-7799(00)89013-7; FRIGERIO F, 1992, J MOL BIOL, V225, P107, DOI 10.1016/0022-2836(92)91029-O; GLOOR S, 1986, CELL, V47, P687; HEINZ DW, 1992, BIOCHEMISTRY-US, V31, P8755, DOI 10.1021/bi00152a011; HERMANS JM, 1993, BIOCHEM J, V295, P239, DOI 10.1042/bj2950239; HOPKINS PCR, 1995, J BIOL CHEM, V270, P11866, DOI 10.1074/jbc.270.20.11866; HOPKINS PCR, 1995, BIOCHEMISTRY-US, V34, P15872, DOI 10.1021/bi00048a033; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JIANG HB, 1994, J BIOL CHEM, V269, P55; Jiang HB, 1996, J BIOL CHEM, V271, P28017, DOI 10.1074/jbc.271.45.28017; KEIJER J, 1991, J BIOL CHEM, V266, P10700; KILPATRICK L, 1991, J IMMUNOL, V146, P2388; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P6970; LEBONNIEC BF, 1995, BIOCHEMISTRY-US, V34, P12241, DOI 10.1021/bi00038a019; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P539, DOI 10.1016/0167-4838(83)90272-8; MADISON EL, 1990, J BIOL CHEM, V265, P21423; NAIDOO N, 1995, J BIOL CHEM, V270, P14548, DOI 10.1074/jbc.270.24.14548; OLSON ST, 1995, J BIOL CHEM, V270, P9717, DOI 10.1074/jbc.270.17.9717; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; OWEN MC, 1991, FEBS LETT, V280, P216, DOI 10.1016/0014-5793(91)80296-F; PATSTON PA, 1990, J BIOL CHEM, V265, P10786; PHILLIPS JE, 1994, J BIOL CHEM, V269, P16696; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; PRATT CW, 1992, J BIOL CHEM, V267, P8795; ROBERTS BL, 1992, P NATL ACAD SCI USA, V89, P2429, DOI 10.1073/pnas.89.6.2429; ROGERS SJ, 1992, J BIOL CHEM, V267, P3613; RUBIN H, 1994, BIOCHEMISTRY-US, V33, P7627, DOI 10.1021/bi00190a016; RUBIN H, 1990, J BIOL CHEM, V265, P1199; Sambrook J., 2002, MOL CLONING LAB MANU; SCHECHTER NM, 1993, J BIOL CHEM, V268, P23626; SHEFFIELD WP, 1994, FEBS LETT, V339, P147, DOI 10.1016/0014-5793(94)80403-6; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; Song HK, 1995, FEBS LETT, V377, P150; Stavridi ES, 1996, BIOCHEMISTRY-US, V35, P10608, DOI 10.1021/bi9605806; STEPHENS AW, 1988, J BIOL CHEM, V263, P15849; STONE SR, 1995, BIOCHEMISTRY-US, V34, P5164, DOI 10.1021/bi00015a030; STONE SR, 1994, BIOCHEMISTRY-US, V33, P7731, DOI 10.1021/bi00190a028; STONE SR, 1987, ARCH BIOCHEM BIOPHYS, V252, P237, DOI 10.1016/0003-9861(87)90028-2; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; TRAVIS J, 1981, METHOD ENZYMOL, V80, P765; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; VIDAUD D, 1992, J CLIN INVEST, V89, P1537, DOI 10.1172/JCI115746; WALEY SG, 1985, BIOCHEM J, V227, P843, DOI 10.1042/bj2270843; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; YORK JD, 1991, J BIOL CHEM, V266, P8495	62	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16268	16273		10.1074/jbc.272.26.16268	http://dx.doi.org/10.1074/jbc.272.26.16268			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195929	hybrid			2022-12-27	WOS:A1997XG01900033
J	Jones, SA; Dewald, B; ClarkLewis, I; Baggiolini, M				Jones, SA; Dewald, B; ClarkLewis, I; Baggiolini, M			Chemokine antagonists that discriminate between interleukin-8 receptors - Selective blockers of CXCR2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL-ACTIVATING PEPTIDE-2; HIGH-AFFINITY; GRO-ALPHA; CHEMOTACTIC CYTOKINES; SIGNAL-TRANSDUCTION; BINDING; RESIDUES; IL-8R1; NAP-2	Human neutrophils express two interleukin (IL)-8 receptors, CXC chemokine receptor (CXCR) 1 and CXCR2. IL-8 with changes to the NH2-terminal ELR motif can block IL-8-induced neutrophil functions (Moser, B., Dewald, B., Barella, L., Schumacher, C., Baggiolini, Ri., and Clark-Lewis, I. (1993) J. Biol. Chem. 268, 7125-7128). We have now examined the effect of NH2-terminally modified analogs of IL-8, GRO alpha, and PF4 on CXCR1 and CXCR2 independently. Using stable Jurkat transfectants expressing either CXCR1 or CXCR2, it was shown that analogs derived from IL-8 bound both IL-8 receptors with similar affinity and could block IL-8-induced Ca2+ mobilization. By contrast, analogs of GRO alpha and PF4, (R)GRO alpha and (R)PF4, bound only CXCR2 with high affinity and blocked Ca2+ mobilization induced only via CXCR2. The differential effect on CXCR1 and CXCR2 was also demonstrated in studies with isolated neutrophils. Thus (R)GRO alpha and (R)PF4 inhibited only the GRO alpha but not the IL-8-stimulated elastase release, and these two analogs had no effect on IL-8-elicited superoxide generation, a response that is mediated by CXCR1 but not by CXCR2. These results show that CXCR2 selective receptor antagonists can be generated based upon the secondary binding determinants of GRO alpha and PF4. They also highlight the primary importance of CXCR1 in chemokine-mediated release of granule enzymes and superoxide generation. The selective antagonists described may be used in future studies on IL-8 receptor signaling to define distinct steps leading to various functional responses induced in neutrophils via CXCR1 and CXCR2.	UNIV BERN,THEODOR KOCHER INST,CH-3000 BERN,SWITZERLAND; UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER,BC V6T 1W5,CANADA; UNIV BRITISH COLUMBIA,DEPT BIOCHEM,VANCOUVER,BC V6T 1W5,CANADA	University of Bern; University of British Columbia; University of British Columbia			Jones, Simon Arnett/Q-7017-2018	Jones, Simon Arnett/0000-0001-7297-9711	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050969] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 50969] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; GEISER T, 1993, J BIOL CHEM, V268, P15419; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; JONES OTG, 1994, METHOD ENZYMOL, V233, P222; Jones SA, 1996, P NATL ACAD SCI USA, V93, P6682, DOI 10.1073/pnas.93.13.6682; JONES SA, 1995, FEBS LETT, V364, P211, DOI 10.1016/0014-5793(95)00397-R; LEE J, 1992, J BIOL CHEM, V267, P16283; LOETSCHER P, 1994, FEBS LETT, V341, P187, DOI 10.1016/0014-5793(94)80454-0; Lowman HB, 1996, J BIOL CHEM, V271, P14344, DOI 10.1074/jbc.271.24.14344; MOSER B, 1991, J BIOL CHEM, V266, P10666; MOSER B, 1993, J BIOL CHEM, V268, P7125; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; SCHRAUFSTATTER IU, 1995, J BIOL CHEM, V270, P10428, DOI 10.1074/jbc.270.18.10428; SCHUMACHER C, 1992, P NATL ACAD SCI USA, V89, P10542, DOI 10.1073/pnas.89.21.10542; SCHUMACHER C, 1994, ANAL BIOCHEM, V222, P262, DOI 10.1006/abio.1994.1483; THELEN M, 1988, FASEB J, V2, P2702, DOI 10.1096/fasebj.2.11.2840318; THELEN M, 1993, PHYSIOL REV, V73, P797, DOI 10.1152/physrev.1993.73.4.797; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; WALZ A, 1989, J EXP MED, V170, P1745, DOI 10.1084/jem.170.5.1745	26	108	115	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16166	16169		10.1074/jbc.272.26.16166	http://dx.doi.org/10.1074/jbc.272.26.16166			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195914	hybrid			2022-12-27	WOS:A1997XG01900018
J	Kobayashi, S; Okumura, N; Nakamoto, T; Okada, M; Hirai, H; Nagai, K				Kobayashi, S; Okumura, N; Nakamoto, T; Okada, M; Hirai, H; Nagai, K			Activation of pp60(c-src) depending on cell density in PC12h cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; GROWTH-FACTOR; SH3 DOMAINS; PHOSPHORYLATED PROTEINS; EXTRACELLULAR-MATRIX; NEURITE OUTGROWTH; V-CRK; C-SRC; ADHESION; ASSOCIATION	The Src family tyrosine kinases and their substrates are involved in cell-cell and cell-matrix interactions. We found that in PC12h cells, an increase of cell density enhanced the tyrosine phosphorylation levels of several intracellular proteins including p130(cas). Because it is a possible substrate for Src family kinases, we measured pp60(c-src) activity and found that it was higher in high density cultures than in low density cultures. This phenomenon was also observed in PC12 (the parental cell line of the PC12h subclone), Balb/c 3T3, Swiss 3T3, and Hela cells, One of the possible mechanisms regulating the kinase activity of pp60(c-src) is the phosphorylation and dephosphorylation of its negative regulatory site located at its C terminus. However, the tyrosine phosphorylation level of the regulatory site did not change depending on cell density. Subcellular fractionation showed that in high density culture, pp60(c-src) was translocated from detergent-soluble to detergent-insoluble fractions, These results suggest that cell-cell interaction might induce the activation of pp60(c-src) without changing its tyrosine phosphorylation levels.	OSAKA UNIV,INST PROT RES,DIV PROT METAB,SUITA,OSAKA 565,JAPAN; UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN	Osaka University; University of Tokyo								BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BEGGS HE, 1994, J CELL BIOL, V127, P825, DOI 10.1083/jcb.127.3.825; BOLEN JB, 1987, ONCOGENE RES, V1, P149; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHEN YH, 1994, J BIOL CHEM, V269, P27372; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATANAKA H, 1981, BRAIN RES, V222, P225, DOI 10.1016/0006-8993(81)91029-5; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KHAN MA, 1995, FEBS LETT, V362, P201, DOI 10.1016/0014-5793(95)00250-D; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; NADA S, 1994, ONCOGENE, V9, P3571; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; ONO M, 1988, MOL CELL BIOL, V8, P4190, DOI 10.1128/MCB.8.10.4190; OTTILIE S, 1992, ONCOGENE, V7, P1625; PARSONS SJ, 1986, BIOCHEM BIOPH RES CO, V134, P736, DOI 10.1016/S0006-291X(86)80482-X; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROHRSCHNEIDER L, 1983, MOL CELL BIOL, V3, P731, DOI 10.1128/MCB.3.4.731; SAKAI R, 1994, J BIOL CHEM, V269, P32740; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WALKER F, 1993, J BIOL CHEM, V268, P19552; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264	39	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16262	16267		10.1074/jbc.272.26.16262	http://dx.doi.org/10.1074/jbc.272.26.16262			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195928	hybrid			2022-12-27	WOS:A1997XG01900032
J	Le, H; Tanguay, RL; Balasta, ML; Wei, CC; Browning, KS; Metz, AM; Goss, DJ; Gallie, DR				Le, H; Tanguay, RL; Balasta, ML; Wei, CC; Browning, KS; Metz, AM; Goss, DJ; Gallie, DR			Translation initiation factors eIF-iso4G and eIF-4B interact with the poly(A)-binding protein and increase its RNA binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; WHEAT-GERM; ISOZYME FORM; IN-VITRO; CAP; YEAST; IDENTIFICATION; TAX; DEADENYLATION; PURIFICATION	The 5'-cap and the poly(A) tail act synergistically to increase the translational efficiency of eukaryotic mRNAs, which suggests that these two mRNA elements communicate during translation, We report here that the cap-associated eukaryotic initiation factors (eLFs), i.e, the two isoforms of the cap-binding complex (eIF-4F and eLF-iso4F) and eIF-4B, bind to the poly(A)-binding protein (PABP) both in the presence and absence of poly(A) RNA, The interactions between PABP and eIF-4F, eIF-iso4F, and eIF-4B were measured in the absence of poly(A) RNA using far Western analysis and confirmed by direct fluorescence titration studies, The functional consequence of the interaction between these initiation factors and PABP was examined using RNA binding assays and RNA mobility shift analysis, eIF-4F, eIF-iso4F, and eIF-4B promoted PARR activity through a shift in its equilibrium affinity for poly(A), eIF-iso4G, the large subunit of eIF-iso4F, was the subunit responsible for the interaction between eLF-iso4F and PABP and was the subunit that promoted PABP RNA binding activity, Truncation analysis of eIF-iso4G indicated that a domain close to its N-terminal end appeared to be involved in binding PARR, These results suggest that the interaction between PABP and eIF-4B and eIF-iso4G may be involved in mediating the functional co-dependence observed between the cap and the poly(A) tail during translation.	UNIV CALIF RIVERSIDE, DEPT BIOCHEM, RIVERSIDE, CA 92521 USA; CUNY HUNTER COLL, DEPT CHEM, NEW YORK, NY 10021 USA; UNIV TEXAS, DEPT CHEM & BIOCHEM, AUSTIN, TX 78712 USA	University of California System; University of California Riverside; City University of New York (CUNY) System; Hunter College (CUNY); University of Texas System; University of Texas Austin				Wei, Chin-Chuan/0000-0001-6453-9409				ALLEN ML, 1992, J BIOL CHEM, V267, P23232; ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; BALASTA ML, 1993, J BIOL CHEM, V268, P18599; Beelman CA, 1996, NATURE, V382, P642, DOI 10.1038/382642a0; BRAUWEILER A, 1995, J BIOL CHEM, V270, P12814, DOI 10.1074/jbc.270.21.12814; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; BROWNING KS, 1992, J BIOL CHEM, V267, P10096; BROWNING KS, 1987, J BIOL CHEM, V262, P538; Browning KS, 1996, PLANT MOL BIOL, V32, P107, DOI 10.1007/BF00039380; BROWNING KS, 1985, FED PROC, V44, P1224; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; Firpo MA, 1996, J BIOL CHEM, V271, P4693; GALLIE DR, 1994, J BIOL CHEM, V269, P17166; Gallie DR, 1997, J BIOL CHEM, V272, P1046, DOI 10.1074/jbc.272.2.1046; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; GORLACH M, 1994, EXP CELL RES, V211, P400, DOI 10.1006/excr.1994.1104; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; Kuhn U, 1996, J MOL BIOL, V256, P20, DOI 10.1006/jmbi.1996.0065; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LAX SR, 1986, METHOD ENZYMOL, V118, P109; Le H, 1997, EUR J BIOCHEM, V243, P350, DOI 10.1111/j.1432-1033.1997.0350a.x; Methot N, 1996, RNA, V2, P38; Metz AM, 1996, J BIOL CHEM, V271, P31033, DOI 10.1074/jbc.271.49.31033; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; VANHEERDEN A, 1994, J BIOL CHEM, V269, P17454; WEBSTER C, 1991, J BIOL CHEM, V266, P23341; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; Yin MJ, 1996, MOL CELL BIOL, V16, P3156; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42	35	225	229	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16247	16255		10.1074/jbc.272.26.16247	http://dx.doi.org/10.1074/jbc.272.26.16247			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195926	hybrid			2022-12-27	WOS:A1997XG01900030
J	Li, JF; Schmidt, AM				Li, JF; Schmidt, AM			Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; OCTAMER-BINDING-PROTEINS; TUMOR-NECROSIS-FACTOR; CIS-ACTING ELEMENTS; ALZHEIMER-DISEASE; OXIDANT STRESS; DNA-BINDING; DIABETIC COMPLICATIONS; NEURITE OUTGROWTH; VASCULAR-DISEASE	The receptor for advanced glycation end products, RAGE, is a member of the immunoglobulin superfamily of cell surface molecules differentially expressed on a range of cell types. Ligation of RAGE perturbs homeostatic mechanisms and, potentially, provides a basis for cellular dysfunction in pathologic situations in which its ligands accumulate. To understand factors underlying RAGE expression, we cloned the 5'-flanking region of the RAGE gene and characterized putative regulatory motifs. Analysis of the putative promoter region revealed the presence of three potential NF-kappa B-like and two SP1 binding sites. Transient transfection of vascular endothelial and smooth muscle cells using chimeric 5'-deletion constructs linked to luciferase reporter revealed that the region -1543/-587 contributed importantly to both basal and stimulated expression of the RAGE gene. This region of the RAGE gene contained three putative NF-kappa B-like binding sites and was responsible for increased luciferase activity observed when endothelial or smooth muscle cells were stimulated with lipopolysaccharide. DNase I footprinting assays and electrophoretic mobility shift assay revealed that two of the three NF-kappa B-like binding sites (1 and 2) were likely functional and responsive to stimuli. Upon simultaneous mutation of NF-kappa B-like sites 1 and 2, both basal promoter expression and response to stimulation with LPS, as measured by relative luciferase activity, were significantly diminished. These results point to NF-kappa B-dependent mechanisms regulating cellular expression of RAGE and suggest a means of linking RAGE to the inflammatory response.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT SURG,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University					NIA NIH HHS [AG00602] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BRETT J, 1993, AM J PATHOL, V143, P1699; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; BUONO P, 1993, FEBS LETT, V328, P243, DOI 10.1016/0014-5793(93)80936-O; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FREDMAN J, 1994, CIRCULATION, V90, P1567; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; LOPEZCABRERA M, 1993, J BIOL CHEM, V268, P1187; Maxam A M, 1980, Methods Enzymol, V65, P499; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; Miyata T, 1996, J CLIN INVEST, V98, P1088, DOI 10.1172/JCI118889; MIYATA T, 1993, J CLIN INVEST, V92, P1243, DOI 10.1172/JCI116696; MIYATA T, 1994, J CLIN INVEST, V93, P521, DOI 10.1172/JCI117002; NEEPER M, 1992, J BIOL CHEM, V267, P14998; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; Park L, 1996, CIRCULATION, V94, P200; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; RITTHALER U, 1995, AM J PATHOL, V146, P688; RUDERMAN NB, 1992, FASEB J, V6, P2905, DOI 10.1096/fasebj.6.11.1644256; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; SCHMIDT AM, 1995, NAT MED, V1, P1002, DOI 10.1038/nm1095-1002; SCHMIDT AM, 1994, ARTERIOSCLER THROMB, V14, P1521, DOI 10.1161/01.ATV.14.10.1521; SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SCHMIDT AM, 1994, CIRCULATION, V90, P1251; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SMITH MA, 1994, P NATL ACAD SCI USA, V91, P5710, DOI 10.1073/pnas.91.12.5710; SMITH MA, 1994, AM J PATHOL, V145, P42; SUGAYA K, 1994, GENOMICS, V23, P408, DOI 10.1006/geno.1994.1517; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397; WAUTIER JL, 1994, P NATL ACAD SCI USA, V91, P7742, DOI 10.1073/pnas.91.16.7742; YAN SD, 1994, P NATL ACAD SCI USA, V91, P7787, DOI 10.1073/pnas.91.16.7787; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yan Shi Du, 1996, Neurology, V46, pA276	45	418	450	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16498	16506		10.1074/jbc.272.26.16498	http://dx.doi.org/10.1074/jbc.272.26.16498			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195959	hybrid			2022-12-27	WOS:A1997XG01900063
J	Terada, Y; Yanase, M; Takata, H; Takaha, T; Okada, S				Terada, Y; Yanase, M; Takata, H; Takaha, T; Okada, S			Cyclodextrins are not the major cyclic alpha-1,4-glucans produced by the initial action of cyclodextrin glucanotransferase on amylose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CIRCULANS STRAIN-251; X-RAY STRUCTURE; PANCREATIC ALPHA-AMYLASE; GLYCOSYLTRANSFERASE; RESOLUTION; RESIDUES; PURIFICATION	The initial acl;ion of cyclodextrin glucanotransferase (CGTase, EC 2.4.1.19) from an alkalophilic Bacillus sp. A2-5a on amylose was investigated. Synthetic amylose was incubated with purified CGTase then terminated in the very early stage of the enzyme reaction. When the reaction mixture was treated with glucoamylase and the resulting glucoamylase-resistant glucans were analyzed with high performance anion exchange chromatography, cyclic alpha-1,4-glucans, with degree of polymerization ranging from 9 to more than 60, in addition to well known alpha-, beta-, and gamma-cyclodextrin (CD), were detected. The time-course analysis revealed that larger cyclic alpha-1,4-glucans were preferentially produced in the initial stage of the cyclization reaction and were subsequently converted into smaller cyclic alpha-1,4-glucans and into the final major product, beta-CD. CGTase from Bacillus macerans also produced large cyclic alpha-1,4-glucans except that the final major product was alpha-CD. Based on these re suits, a new model for the action of CGTase on amylose was proposed, which may contradict the widely held view of the cyclization reaction of CGTase.			Terada, Y (corresponding author), EZAKI GLICO CO LTD,BIOCHEM RES LAB,NISHIYODOGAWA KU,UTAJIMA 4-6-5,OSAKA 555,JAPAN.							BUISSON G, 1987, EMBO J, V6, P3909, DOI 10.1002/j.1460-2075.1987.tb02731.x; FRENCH D, 1965, ARCH BIOCHEM BIOPHYS, V111, P153, DOI 10.1016/0003-9861(65)90334-6; KLEIN C, 1991, J MOL BIOL, V217, P737, DOI 10.1016/0022-2836(91)90530-J; KLEIN C, 1992, BIOCHEMISTRY-US, V31, P8740, DOI 10.1021/bi00152a009; Knegtel RMA, 1996, J MOL BIOL, V256, P611, DOI 10.1006/jmbi.1996.0113; KNEGTEL RMK, 1995, J BIOL CHEM, V270, P29256, DOI 10.1074/jbc.270.49.29256; KOBAYASHI S, 1973, P S AM AM RES SOC JA, V8, P29; KOBAYASHI S, 1991, DENPUN KAGAKU, V38, P314; KOMETANI T, 1994, BIOSCI BIOTECH BIOCH, V58, P517, DOI 10.1271/bbb.58.517; KUBOTA M, 1994, OYO TOSHITSU KAGAKU, V41, P245; LARSON SB, 1994, J MOL BIOL, V235, P1560, DOI 10.1006/jmbi.1994.1107; LAWSON CL, 1994, J MOL BIOL, V236, P590, DOI 10.1006/jmbi.1994.1168; MATSUURA Y, 1984, J BIOCHEM-TOKYO, V95, P697, DOI 10.1093/oxfordjournals.jbchem.a134659; MIWA I, 1972, CLIN CHIM ACTA, V37, P538, DOI 10.1016/0009-8981(72)90483-4; NAKAMURA A, 1993, BIOCHEMISTRY-US, V32, P6624, DOI 10.1021/bi00077a015; NAKAMURA A, 1994, BIOCHEMISTRY-US, V33, P9929, DOI 10.1021/bi00199a015; PENNINGA D, 1995, BIOCHEMISTRY-US, V34, P3368, DOI 10.1021/bi00010a028; PULLEY AO, 1961, BIOCHEM BIOPH RES CO, V5, P11, DOI 10.1016/0006-291X(61)90071-7; QIAN MX, 1994, BIOCHEMISTRY-US, V33, P6284, DOI 10.1021/bi00186a031; SAENGER W, 1980, ANGEW CHEM INT EDIT, V19, P344, DOI 10.1002/anie.198003441; SCHMID G, 1989, TRENDS BIOTECHNOL, V7, P244, DOI 10.1016/0167-7799(89)90015-2; Strokopytov B, 1996, BIOCHEMISTRY-US, V35, P4241, DOI 10.1021/bi952339h; STROKOPYTOV B, 1995, BIOCHEMISTRY-US, V34, P2234, DOI 10.1021/bi00007a018; TAKAHA T, 1993, J BIOL CHEM, V268, P1391; Takaha T, 1996, J BIOL CHEM, V271, P2902, DOI 10.1074/jbc.271.6.2902; Takata H, 1996, CARBOHYD RES, V295, P91, DOI 10.1016/S0008-6215(96)00217-0; Takata H, 1996, J BACTERIOL, V178, P1600, DOI 10.1128/jb.178.6.1600-1606.1996	27	119	127	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15729	15733		10.1074/jbc.272.25.15729	http://dx.doi.org/10.1074/jbc.272.25.15729			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188466	hybrid			2022-12-27	WOS:A1997XF32900026
J	Frohm, M; Agerberth, B; Ahangari, G; StahleBackdahl, M; Liden, S; Wigzell, H; Gudmundsson, GH				Frohm, M; Agerberth, B; Ahangari, G; StahleBackdahl, M; Liden, S; Wigzell, H; Gudmundsson, GH			The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL PEPTIDE; PROTEIN; ANTIBIOTICS; DEFENSINS; ANTIBODY; CLONING; FAMILY; CELLS; SKIN	The epithelia constitute a major barrier to the environment and provide the first line of defense against invading microbes. Antimicrobial peptides are emerging as participants in the defense system of epithelial barriers in general, Originally we isolated the human antimicrobial peptide LL-37 from granulocytes. The gene (CAMP or cathelicidin antimicrobial peptide) coding for this peptide belongs to the cathelicidin family, whose members contain a conserved pro-part of the cathelin type, The human genome seems to have only one gene of this family, whereas some mammalian species have several cathelicidin genes, In the present work we demonstrate up-regulation of this human cathelicidin gene in inflammatory skin disorders, whereas in normal skin no induction was found, By in situ hybridization and immunohistochemistry the transcript and the peptide were located in keratinocytes throughout the epidermis of the inflammatory regions. In addition, the peptide was detected in partially pure fractions derived from psoriatic scales by immunoblotting. These fractions also exhibited antibacterial activity. We propose a protective role for LL-37, when the integrity of the skin barrier is damaged, participating in the first Line of defense, and preventing local-infection and systemic invasion of microbes.	KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,S-17177 STOCKHOLM,SWEDEN; KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,DEPT DERMATOL,S-10401 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital			Gudmundsson, Gudmundur H/K-9178-2015	Gudmundsson, Gudmundur H/0000-0001-5793-0565				AGERBERTH B, 1995, P NATL ACAD SCI USA, V92, P195, DOI 10.1073/pnas.92.1.195; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BOS JD, 1993, IMMUNOL TODAY, V14, P75, DOI 10.1016/0167-5699(93)90062-P; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COWLAND JB, 1995, FEBS LETT, V368, P173, DOI 10.1016/0014-5793(95)00634-L; Diamond G, 1996, P NATL ACAD SCI USA, V93, P5156, DOI 10.1073/pnas.93.10.5156; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; DUJKMAN HBP, 1995, BIOCHEMICA, V2, P21; Frohm M, 1996, EUR J BIOCHEM, V237, P86, DOI 10.1111/j.1432-1033.1996.0086n.x; GROSSMAN RM, 1989, P NATL ACAD SCI USA, V86, P6367, DOI 10.1073/pnas.86.16.6367; Gudmundsson GH, 1996, EUR J BIOCHEM, V238, P325, DOI 10.1111/j.1432-1033.1996.0325z.x; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; JONES DE, 1992, J BIOL CHEM, V267, P23216; LARRICK JW, 1995, INFECT IMMUN, V63, P1291, DOI 10.1128/IAI.63.4.1291-1297.1995; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; Paquet P, 1996, INT ARCH ALLERGY IMM, V109, P308, DOI 10.1159/000237257; Russell JP, 1996, INFECT IMMUN, V64, P1565, DOI 10.1128/IAI.64.5.1565-1568.1996; Sambrook J., 2002, MOL CLONING LAB MANU; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O	24	605	630	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15258	15263		10.1074/jbc.272.24.15258	http://dx.doi.org/10.1074/jbc.272.24.15258			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182550	hybrid			2022-12-27	WOS:A1997XE03400033
J	Hatakeyama, S; Jensen, JP; Weissman, AM				Hatakeyama, S; Jensen, JP; Weissman, AM			Subcellular localization and ubiquitin-conjugating enzyme (E2) interactions of mammalian HECT family ubiquitin protein ligases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; CELL ANTIGEN RECEPTOR; IN-VIVO; NUCLEAR-LOCALIZATION; ACTIVATING ENZYME; ESCHERICHIA-COLI; CARRIER PROTEIN; ZETA-CHAIN; KAPPA-B; DEGRADATION	In most instances, the transfer of ubiquitin to target proteins is catalyzed by the action of ubiquitin protein ligases (E3s), Full-length cDNAs encoding murine E6-associated protein (mE6-AP) as well as Nedd-4, a protein that is homologous to E6-AP in its C terminus, were cloned. Nedd-4 and mouse E6-AP are both enzymatically active E3s and function with members of the UbcH5 family of E2s, Mouse E6-AP, like its human counterpart, ubiquitinates p53 in the presence of human papilloma virus E6 protein, while Nedd-4 does not, Consistent with its role in p53 ubiquitination, mE6-AP was found both in the nucleus and cytosol, while Nedd-4 was found only in the cytosol, Binding studies implicate a 150-amino acid region that is 40% identical between mE6-AP and Nedd-4 as a binding site for the C terminal portion of an E2 enzyme (UbcH5B), Nedd-4 was determined to have a second nonoverlapping E2 binding site that recognizes the first 67 amino acids of UbcH5B but not the more C-terminal portion of this E2. These findings provide the first demonstration of physical interactions between mammalian E2s and E3s and establish that these interactions occur independently of ubiquitin and an intact E3 catalytic domain, Furthermore, the presence of two E2 binding sites within Nedd-4 suggests models for ubiquitination involving multiple E2 enzymes associated with E3s.	NCI,LAB IMMUNE CELL BIOL,DIV BASIC SCI,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Hatakeyama, Shigetsugu/C-8333-2012	Hatakeyama, Shigetsugu/0000-0002-2150-9979				BLUMENFELD N, 1994, J BIOL CHEM, V269, P9574; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; Cenciarelli C, 1996, J BIOL CHEM, V271, P8709, DOI 10.1074/jbc.271.15.8709; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DOHMEN J, 1991, P NATL ACAD SCI USA, V83, P7351; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Gonen H, 1996, J BIOL CHEM, V271, P302, DOI 10.1074/jbc.271.1.302; GRENFELL SJ, 1994, BIOCHEM J, V300, P701, DOI 10.1042/bj3000701; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GWOZD CS, 1995, BIOCHEMISTRY-US, V34, P6296, DOI 10.1021/bi00019a006; HATFIELD PM, 1990, J BIOL CHEM, V265, P15813; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOFMANN K, 1995, FEBS LETT, V358, P153, DOI 10.1016/0014-5793(94)01415-W; HUIBREGTSE JM, 1994, COLD SPRING HARB SYM, V59, P237, DOI 10.1101/SQB.1994.059.01.028; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; RUTLEDGE T, 1992, EMBO J, V11, P3245, DOI 10.1002/j.1460-2075.1992.tb05402.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WANGE RL, 1993, J BIOL CHEM, V268, P19797; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILKINSON KD, 1995, ANNU REV NUTR, V15, P161, DOI 10.1146/annurev.nu.15.070195.001113; Yang M, 1997, J BIOL CHEM, V272, P1970, DOI 10.1074/jbc.272.3.1970; ZHEN M, 1993, MOL CELL BIOL, V13, P1371, DOI 10.1128/MCB.13.3.1371	54	82	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15085	15092		10.1074/jbc.272.24.15085	http://dx.doi.org/10.1074/jbc.272.24.15085			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182527	hybrid			2022-12-27	WOS:A1997XE03400010
J	Prossnitz, ER				Prossnitz, ER			Desensitization of N-formylpeptide receptor-mediated activation is dependent upon receptor phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMYL PEPTIDE RECEPTOR; LEUKOCYTE CHEMOATTRACTANT RECEPTORS; G-PROTEIN; RHODOPSIN PHOSPHORYLATION; KINASE; MECHANISM; BINDING; CELLS	The human N-formylpeptide receptor (FPR) represents one of the most thoroughly studied leukocyte chemoattractant receptors, Despite this, little is known about the molecular mechanisms involved in the activation and desensitization of this receptor. To assess the role of phosphorylation in receptor function, U937 promonocytic cells were stably transfected to express the recombinant human FPR, Three mutant forms of the FPR lacking specific serine and threonine residues in the receptor C terminus were studied with respect to activation and desensitization. Replacement of all 11 serine and threonine residues within the C terminus by alanine and glycine residues (Delta ST) resulted in a receptor capable of ligand binding and G protein activation similar to the wild-type receptor, However, whereas the wild-type FPR was phosphorylated on both serine and threonine residues upon exposure to agonist and displayed a significantly reduced ability to stimulate G protein-mediated GTP hydrolysis upon subsequent exposure to agonist, Delta ST demonstrated a complete lack of phosphorylation and displayed little alteration in its ability to stimulate G protein-mediated GTP hydrolysis upon a subsequent exposure to agonist. In addition to desensitization of G protein-mediated GTP hydrolysis, calcium mobilization was assayed to test whether desensitization occurred at a site distal to G protein activation, However, as observed with G protein activation, Delta ST underwent no desensitization of the calcium mobilization response upon a second exposure to agonist, To define more precisely the role of specific serine and threonine residues, two additional mutants were analyzed, Replacement either of Ser(328), Thr(329), Thr(331) and Ser(332) (mutant A) or of Thr(334), Thr(336), Ser(338) and Thr(339) (mutant B) resulted in functional receptors that exhibited similar to 50% the level of phosphorylation following stimulation, Whereas mutant A, like Delta ST, could not be significantly desensitized by exposure to agonist, mutant B exhibited partial desensitization. These results indicate that phosphorylation of the FPR is a necessary and sufficient step in cellular desensitization, that multiple phosphorylation sites are involved, and that redundant desensitization does not occur downstream of G protein activation in the signaling cascade.			Prossnitz, ER (corresponding author), Scripps Res Inst, DEPT IMMUNOL, IMM25, 10550 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Prossnitz, Eric R./B-4543-2008	Prossnitz, Eric/0000-0001-9190-8302	NIAID NIH HHS [AI33503, AI36357] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI036357, R56AI033503, R01AI033503, R01AI036357] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALI H, 1993, J BIOL CHEM, V268, P24247; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DETOGNI P, 1985, BIOCHIM BIOPHYS ACTA, V838, P23, DOI 10.1016/0304-4165(85)90245-4; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; INGLESE J, 1993, J BIOL CHEM, V268, P23735; Kew RR, 1997, J LEUKOCYTE BIOL, V61, P329, DOI 10.1002/jlb.61.3.329; MCLEISH KR, 1989, MOL PHARMACOL, V36, P384; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; OFLAHERTY JT, 1979, J CELL BIOL, V80, P564, DOI 10.1083/jcb.80.3.564; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; OHGURO H, 1994, BIOCHEMISTRY-US, V33, P1023, DOI 10.1021/bi00170a022; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P10686, DOI 10.1074/jbc.270.18.10686; PROSSNITZ ER, 1991, BIOCHEM BIOPH RES CO, V179, P471, DOI 10.1016/0006-291X(91)91394-R; PROSSNITZ ER, 1993, BIOCHEM J, V294, P581, DOI 10.1042/bj2940581; PROSSNITZ ER, 1993, J IMMUNOL, V151, P5704; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; PULLEN N, 1994, BIOCHEMISTRY-US, V33, P14536, DOI 10.1021/bi00252a021; RICHARDON RM, 1995, J BIOL CHEM, V270, P27829, DOI 10.1074/jbc.270.46.27829; RICHARDSON RM, 1995, BIOCHEMISTRY-US, V34, P14193, DOI 10.1021/bi00043a025; SCHREIBER RE, 1993, J LEUKOCYTE BIOL, V53, P470, DOI 10.1002/jlb.53.4.470; SWOPE SL, 1995, ANN NY ACAD SCI, V757, P197, DOI 10.1111/j.1749-6632.1995.tb17476.x; TARDIF M, 1993, J IMMUNOL, V150, P3534; TOMHAVE ED, 1994, J IMMUNOL, V153, P3267; WILDE MW, 1989, J BIOL CHEM, V264, P190; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; ZHAO XY, 1995, BIOPHYS CHEM, V56, P183, DOI 10.1016/0301-4622(95)00031-R	31	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15213	15219		10.1074/jbc.272.24.15213	http://dx.doi.org/10.1074/jbc.272.24.15213			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182544	hybrid			2022-12-27	WOS:A1997XE03400027
J	Poole, RC; Halestrap, AP				Poole, RC; Halestrap, AP			Interaction of the erythrocyte lactate transporter (monocarboxylate transporter 1) with an integral 70-kDa membrane glycoprotein of the immunoglobulin superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPHORIN-A; CDNA CLONING; XENOPUS-OOCYTES; RAT; INHIBITION; PYRUVATE; PROTEIN; CELLS; MCT1; IDENTIFICATION	Treatment of intact erythrocytes with 4,4'-diisothiocyanostilbene-2,2'-disulfonate (DIDS) causes irreversible inhibition and chemical labeling of the lactate transporter, monocarboxylate transporter 1 (MCT1) (Poole, R. C., and Halestrap, A. P. (1992) Biochem. J. 283, 855-862). In rat eythrocytes DIDS also causes cross-linking of MCT1 to another protein in the membrane to give a product of 130 kDa on SDS-polyacrylamide gel electrophoresis. Cross-linking is markedly reduced by those compounds that protect against irreversible inhibition of lactate transport by DIDS and enhanced by imposition of a pH gradient across the plasma membrane to recruit the substrate binding site of MCT1 to an exofacial conformation, These data indicate that DIDS cross-linking is via the same site on MCT1 as is responsible for inhibition of transport. Antibodies raised against the cross-linked conjugate react with proteins of approximately 40 kDa (MCT1) and 70 kDa on Western blots of erythrocyte membranes and an additional band of 130 kDa after treatment of erythrocytes with 100 mu M DIDS. The 70-kDa protein that is cross-linked to MCT1 was purified and shown to contain N-linked carbohydrate; the apparent core molecular mass is 40 kDa. Amino acid sequencing showed that the protein is the rat equivalent of the membrane-spanning mouse teratocarcinoma glycoprotein GP-70, a member of the immunoglobulin superfamily related to basigin (Ozawa, M., Huang, R. P., Furukawa, T., and Muramatsu, T. (1988) J. Biol. Chem. 263, 3059-3062). Possible implications of the specific interaction between MCT1 and this protein are discussed.	UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND	University of Bristol			Halestrap, Andrew P/G-7275-2011	Halestrap, Andrew/0000-0001-5374-2778	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Carpenter L, 1996, BBA-BIOMEMBRANES, V1279, P157, DOI 10.1016/0005-2736(95)00254-5; CARPENTER L, 1994, BIOCHEM J, V304, P751, DOI 10.1042/bj3040751; DONOVAN JA, 1985, BIOCHEMISTRY-US, V24, P561, DOI 10.1021/bi00324a003; EDLUND GL, 1988, BIOCHEM J, V249, P117, DOI 10.1042/bj2490117; FURTHMAYR H, 1976, BIOCHEMISTRY-US, V15, P1137, DOI 10.1021/bi00650a028; GARCIA CK, 1994, CELL, V76, P865, DOI 10.1016/0092-8674(94)90361-1; GARCIA CK, 1995, J BIOL CHEM, V270, P1843, DOI 10.1074/jbc.270.4.1843; GROVES JD, 1994, J MEMBRANE BIOL, V140, P81; GROVES JD, 1992, J BIOL CHEM, V267, P22163; JACKSON VN, 1995, BBA-BIOMEMBRANES, V1238, P193, DOI 10.1016/0005-2736(95)00160-5; JHUN BH, 1991, BIOCHIM BIOPHYS ACTA, V1061, P149, DOI 10.1016/0005-2736(91)90279-H; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; MONTASELL BR, 1994, P NATL ACAD SCI USA, V91, P9569; NEHME CL, 1995, BIOCHEM J, V310, P693, DOI 10.1042/bj3100693; OZAWA M, 1988, J BIOL CHEM, V263, P3059; POOLE RC, 1991, BIOCHEM J, V275, P307, DOI 10.1042/bj2750307; POOLE RC, 1992, BIOCHEM J, V283, P855, DOI 10.1042/bj2830855; POOLE RC, 1994, BIOCHEM J, V303, P755, DOI 10.1042/bj3030755; Poole RC, 1996, BIOCHEM J, V320, P817, DOI 10.1042/bj3200817; POOLE RC, 1993, AM J PHYSIOL, V264, pC761, DOI 10.1152/ajpcell.1993.264.4.C761; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schuster VL, 1996, BBA-MOL CELL RES, V1311, P13, DOI 10.1016/0167-4889(95)00186-7; SEULBERGER H, 1992, NEUROSCI LETT, V140, P93, DOI 10.1016/0304-3940(92)90690-9; TAKANAGA H, 1995, BIOCHEM BIOPH RES CO, V217, P370, DOI 10.1006/bbrc.1995.2786; Wang X, 1996, AM J PHYSIOL-HEART C, V270, pH476, DOI 10.1152/ajpheart.1996.270.2.H476; WANG XM, 1993, BIOCHEM J, V290, P249, DOI 10.1042/bj2900249; WANG XM, 1993, AM J PHYSIOL, V267, pH1759	27	62	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14624	14628		10.1074/jbc.272.23.14624	http://dx.doi.org/10.1074/jbc.272.23.14624			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169423	hybrid			2022-12-27	WOS:A1997XC32700020
J	Prado, GN; Taylor, L; Polgar, P				Prado, GN; Taylor, L; Polgar, P			Effects of intracellular tyrosine residue mutation and carboxyl terminus truncation on signal transduction and internalization of the rat bradykinin B2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; MUSCARINIC ACETYLCHOLINE; LOOP; FIBROBLASTS; EXPRESSION; KININS; MUTANT; DOMAIN	Presently, little is known of the amino acid motif(s) participating in bradykinin B2 receptor-mediated signal transduction processes. In this report we investigate the potential role of the two existing tyrosine (Tyr) residues in the intracellular regions and the carboxyl terminus in the regulatory function of this receptor. Rat-1 cells, which do not contain detectable bradykinin B2 receptor, were transfected with wild type and mutant receptor cDNAs, Tyr-131 and Tyr-321 were each mutated to corresponding alanine-, serine-, and phenylalanine-containing sequences. The last 34 amino acid residues of the carboxyl terminus were truncated, Rat-1 cells transfected with the mutant forms of the receptor cDNA including the truncated COOH-terminal cDNA all bound [H-3]bradykinin with essentially the same K-d of approximately 2.2 nM as cells transfected with the wild type bradykinin B2 receptor, However, mutating Tyr-131 resulted in important changes in bradykinin-stimulated phosphoinositide turnover and arachidonate release. For example, exchanging Tyr-131 for alanine led to an 80% decreased arachidonate release (p < 0.005), 90% decrease in inositol phosphate (IP) accumulation (p < 0.001), with receptor uptake at 15 min remaining essentially unchanged, Mutating the same Tyr to phenylalanine resulted in unchanged bradykinin-stimulated TP accumulation, only a slightly lowered arachidonate release, and unchanged receptor uptake at 15 min, Mutating Tyr-321 to alanine resulted in a very different pattern, There was a small but significant reduction in arachidonate release (p < 0.03) and IP accumulation (p < 0.008) with a large, 30%, increase in receptor uptake at 15 min (p < 0.010), Truncation of a portion of the carboxyl tail also proved meaningful, with a 60% decrease in arachidonate release and an 80% decrease in IP accumulation, The truncation also resulted in a large, 130%, decrease in receptor uptake at 15 min (p < 0.023), Taken together, these results point to Tyr-131 as an important element in determining bradykinin-stimulated arachidonate release and IP accumulation. Tyrosine phosphorylation at this site apparently does not play a major role, Tyr-131, Tyr-321, and the carboxyl tail appear to be important in determining receptor uptake.			Prado, GN (corresponding author), BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118, USA.			Polgar, Peter/0000-0002-9112-1101	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025776] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL25776] Funding Source: Medline; PHS HHS [A600115] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARORA KK, 1995, J BIOL CHEM, V270, P22820, DOI 10.1074/jbc.270.39.22820; Blaukat A, 1996, J BIOL CHEM, V271, P32366, DOI 10.1074/jbc.271.50.32366; BLOUNT P, 1993, J BIOL CHEM, V268, P16388; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; Franci C, 1996, J IMMUNOL, V157, P5606; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huang CF, 1996, ARCH BIOCHEM BIOPHYS, V327, P161, DOI 10.1006/abbi.1996.0104; JONG YJI, 1993, P NATL ACAD SCI USA, V90, P10994, DOI 10.1073/pnas.90.23.10994; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LEE NH, 1993, J BIOL CHEM, V268, P7949; MARGOLIUS HS, 1989, ANNU REV PHARMACOL, V29, P343; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, pA772; MCINTYRE P, 1993, MOL PHARMACOL, V44, P346; MORO O, 1993, J BIOL CHEM, V268, P6862; REGOLI D, 1980, PHARMACOL REV, V32, P1; Ricupero D, 1992, Mediators Inflamm, V1, P133, DOI 10.1155/S096293519200022X; ROBERTS RA, 1989, J CELL SCI, V94, P527; TAYLOR L, 1992, BIOCHEM BIOPH RES CO, V188, P786, DOI 10.1016/0006-291X(92)91125-A; THOMAS WG, 1995, J BIOL CHEM, V270, P22153, DOI 10.1074/jbc.270.38.22153; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; TSUGA H, 1994, J BIOL CHEM, V269, P32522	24	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14638	14642		10.1074/jbc.272.23.14638	http://dx.doi.org/10.1074/jbc.272.23.14638			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169425	hybrid			2022-12-27	WOS:A1997XC32700022
J	Marsters, SA; Ayres, TM; Skubatch, M; Gray, CL; Rothe, M; Ashkenazi, A				Marsters, SA; Ayres, TM; Skubatch, M; Gray, CL; Rothe, M; Ashkenazi, A			Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappa B and AP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; CD40; SUPERFAMILY; INVOLVEMENT; PROTEINS	The mammalian tumor necrosis factor receptor (TNFR) family consists of 10 cell-surface proteins that regulate development and homeostasis of the immune system. Based on an expressed sequence tag, we have cloned a cDNA encoding a novel member of the human TNFR family, A closely related protein, designated HVEM (for herpesvirus entry mediator), was identified independently by another group as a mediator of herpesvirus entry into mammalian cells (Montgomery, R., Warner, M., Lum, B., and Spear, P. (1996) Cell 87, 427-436). HVEM differed from our clone by two amino acid residues, suggesting that the two proteins represent polymorphism of a single HVEM gene. We detected HVEM mRNA expression in several human fetal and adult tissues, although the predominant sites of expression were lymphocyte-rich tissues such as adult spleen and peripheral blood leukocytes. The cytoplasmic region of HVEM bound to several members of the TNFR-associated factor (TRAF) family, namely TRAF1, TRAF2, TRAF3, and TRAF5, but not to TRAF6. Transient transfection of HVEM into human 293 cells caused marked activation of nuclear factor-kappa B (NF-kappa B), a transcriptional regulator of multiple immunomodulatory and inflammatory genes. HVEM transfection induced also marked activation of Jun N terminal kinase, and of the Jun-containing transcription factor AP-1, a regulator of cellular stress-response genes. These results suggest that HVEM is linked via TRAFs to signal transduction pathways that activate the immune response.	GENENTECH INC,DEPT MOL ONCOL,S SAN FRANCISCO,CA 94080; TULARIK INC,DEPT MOL BIOL,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech			Ashkenazi, Avi/ABG-2712-2020	Ashkenazi, Avi/0000-0002-6890-4589				Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARSTERS SA, 1995, P NATL ACAD SCI USA, V92, P5401, DOI 10.1073/pnas.92.12.5401; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Tewari M, 1996, CURR OPIN GENET DEV, V6, P39, DOI 10.1016/S0959-437X(96)90008-8	28	259	280	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14029	14032		10.1074/jbc.272.22.14029	http://dx.doi.org/10.1074/jbc.272.22.14029			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162022	hybrid			2022-12-27	WOS:A1997XB49200009
J	Yannone, SM; Burgess, BK				Yannone, SM; Burgess, BK			Identification of a palindromic sequence that is responsible for the up-regulation of NAPDH-ferredoxin reductase in a ferredoxin I deletion strain of Azotobacter vinelandii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CENTER; ENDONUCLEASE-III; DNA-BINDING; RNA-BINDING; PROTEIN; CLONING; OXIDOREDUCTASE; RESOLUTION	Azotobacter vinelandii ferredoxin I (AvFdI) is one member of a class of 7Fe ferredoxins found in a variety of organisms that are all capable of aerobic growth. Disruption of the fdxA gene, which encodes AvFdI, leads to overexpression of its redox partner, NADPH-ferredoxin reductase (FPR), In this study the mechanism of FdI-mediated regulation of FPR was investigated, Northern analysis has shown that regulation is at the level of fpr transcription, the start site for transcription has been identified, and it is preceded by a canonical sigma 70-type bacterial promoter, Gel mobility shift assays show that there is a putative regulatory protein in A, vinelandii that binds specifically upstream of the -35 region, That protein is not AvFdI, A palindromic sequence was identified as a putative binding site, and randomization of that sequence completely eliminates binding of the putative regulatory protein, A luciferase reporter gene was placed under control of the A. vinelandii fpr promoter and introduced into wild type and FdI(-) strains of A, vinelandii, Luciferase activity was enhanced 7-fold in the FdI(-) mutant relative to the wild type, Alteration of the palindromic sequence reduced the luciferase levels in the FdI(-) strain to those of the wild type, demonstrating that FdI regulates FPR through the palindrome and that the reaction is an activation rather than a repression, The identified palindrome is similar to 50% identical to the SoxS binding site upstream of Escherichia coli fpr, suggesting that A, vinelandii may have a SoxS-like regulatory system and that the function of FdI might be to specifically inactivate that system.	UNIV CALIF IRVINE,DEPT MOL BIOL & BIOCHEM,IRVINE,CA 92697	University of California System; University of California Irvine			Yannone, Steven/ABA-3524-2021; Yannone, Steven/G-1927-2011		NIGMS NIH HHS [GM-45209] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045209] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BAGDASARIAN M, 1981, GENE, V16, P237, DOI 10.1016/0378-1119(81)90080-9; BEINERT H, 1983, ARCH BIOCHEM BIOPHYS, V222, P331; EMPTAGE MH, 1980, J BIOL CHEM, V255, P1793; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; IISMAA SE, 1991, J BIOL CHEM, V266, P21563; INNIS MA, 1990, PCR PROTOCOLS GUIDE, P177; ISAS JM, 1994, J BIOL CHEM, V269, P19404; ISAS JM, 1995, J BIOL CHEM, V270, P21258, DOI 10.1074/jbc.270.36.21258; Jair KW, 1996, MOL MICROBIOL, V19, P307, DOI 10.1046/j.1365-2958.1996.368893.x; JANSEN T, 1988, CURR GENET, V13, P517, DOI 10.1007/BF02427758; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; LAMBERT JR, 1994, P NATL ACAD SCI USA, V15, P7345; LIANG JH, 1993, J BACTERIOL, V175, P1697, DOI 10.1128/JB.175.6.1697-1704.1993; LIOCHEV SI, 1994, P NATL ACAD SCI USA, V91, P1328, DOI 10.1073/pnas.91.4.1328; MANIATIS T, 1982, MOL CLONING LABORATO, P466; MARTIN AE, 1989, J BACTERIOL, V171, P3162, DOI 10.1128/jb.171.6.3162-3167.1989; MERRITT EA, 1993, ACTA CRYSTALLOGR D, V49, P272, DOI 10.1107/S0907444992007248; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; MORGAN TV, 1988, J BIOL CHEM, V263, P1370; STEPHENS PJ, 1991, BIOCHEMISTRY-US, V30, P3200, DOI 10.1021/bi00227a007; STEPHENS PJ, 1985, P NATL ACAD SCI USA, V82, P5661, DOI 10.1073/pnas.82.17.5661; STOUT CD, 1988, J BIOL CHEM, V263, P9256; STOUT CD, 1989, J MOL BIOL, V205, P545, DOI 10.1016/0022-2836(89)90225-8; STOUT CD, 1993, J BIOL CHEM, V268, P25920; STOUT GH, 1988, P NATL ACAD SCI USA, V85, P1020, DOI 10.1073/pnas.85.4.1020; THOMSON AJ, 1991, FEBS LETT, V285, P230, DOI 10.1016/0014-5793(91)80807-F; VASQUEZ A, 1994, PROTEIN EXPRES PURIF, V5, P96	31	20	20	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14454	14458		10.1074/jbc.272.22.14454	http://dx.doi.org/10.1074/jbc.272.22.14454			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162086	hybrid			2022-12-27	WOS:A1997XB49200073
J	Hollander, MC; Zhan, QM; Bae, I; Fornace, AJ				Hollander, MC; Zhan, QM; Bae, I; Fornace, AJ			Mammalian GADD34, an apoptosis- and DNA damage-inducible gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; IMMEDIATE EARLY RESPONSE; P53-REGULATED PROTEIN; GROWTH ARREST; P53; CELLS; INDUCTION; CHECKPOINT; DIFFERENTIATION; NEUROBLASTOMA	The mammalian cellular response to genotoxic stress is a complex process involving many known and probably many as yet unknown genes. Induction of the human DNA damage- and growth arrest-inducible gene, GADD34, by ionizing radiation was only seen in certain cell lines and correlated with apoptosis following ionizing radiation. In addition, the kinetics and dose response of GADD34 to ionizing radiation closely paralleled that of the apoptosis inhibitor, BAX. However, unlike BAX, the GADD34 response was independent of cellular p53 status. The carboxyl terminus of GADD34 has homology with the carboxyl termini of two viral proteins, one of which is known to prevent apoptosis of virus infected cells. The association of GADD34 expression with certain types of apoptosis and its homology with a known apoptosis regulator suggests that GADD34 may play a role in apoptosis as well.	SAMYANG GENEX RES INST,TAEJON 305348,SOUTH KOREA		Hollander, MC (corresponding author), NCI,MOL PHARMACOL LAB,DIV BASIC SCI,NIH,BETHESDA,MD 20892, USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; APTE SS, 1995, GENOMICS, V26, P592, DOI 10.1016/0888-7543(95)80180-T; BAE IS, 1995, CANCER RES, V55, P2387; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU J, 1992, P NATL ACAD SCI USA, V89, P3266, DOI 10.1073/pnas.89.8.3266; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOLE M, 1994, CANCER RES, V54, P3253; FAN SJ, 1994, CANCER RES, V54, P5824; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FORNACE AJ, 1986, NUCLEIC ACIDS RES, V14, P5793, DOI 10.1093/nar/14.14.5793; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORNACE AJ, 1980, MUTAT RES, V70, P323, DOI 10.1016/0027-5107(80)90022-6; He B, 1996, J VIROL, V70, P84, DOI 10.1128/JVI.70.1.84-90.1996; Hollander M. C., 1995, DNA REPAIR MECH IMPA, P221; HOLLANDER MC, 1990, BIOTECHNIQUES, V9, P174; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEVINE B, 1993, NATURE, V361, P739, DOI 10.1038/361739a0; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MELLENTIN JD, 1989, SCIENCE, V246, P379, DOI 10.1126/science.2799390; OCONNOR PM, 1993, CANCER RES, V53, P4776; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RUBIO MP, 1994, CANCER RES, V54, P4760; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEWART N, 1995, ONCOGENE, V10, P109; SYLVESTER SL, 1994, J BIOL CHEM, V269, P20119; VONDEIMLING A, 1992, CANCER RES, V52, P4277; WALTON MI, 1993, CANCER RES, V53, P1853; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHAN QM, 1994, ONCOGENE, V9, P3743; ZHAN QM, 1995, INT J ONCOL, V6, P937	44	144	150	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13731	13737		10.1074/jbc.272.21.13731	http://dx.doi.org/10.1074/jbc.272.21.13731			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153226	hybrid			2022-12-27	WOS:A1997XA06200041
J	Wright, MB; Ramos, J; Gomez, MJ; Moulder, K; Scherrer, M; Munson, G; Gaber, RF				Wright, MB; Ramos, J; Gomez, MJ; Moulder, K; Scherrer, M; Munson, G; Gaber, RF			Potassium transport by amino acid permeases in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ION-TRANSPORT; ARABIDOPSIS-THALIANA; PLASMA-MEMBRANE; K+ TRANSPORTERS; SHUTTLE VECTORS; YEAST; GENE; EXPRESSION; SEQUENCE	Deletion of the potassium transporter genes TRK1 and TRK2 impairs potassium uptake in Saccharomyces cerevisiae, resulting in a greatly increased requirement for the ion and the inability to grow on low pH medium. Selection for mutations that restored growth of trk1 Delta trk2 Delta cells on low pH (3.0) medium led to the isolation of a dominant suppressor that also partially suppressed the increased K+ requirement of these cells. Molecular analysis revealed the suppressor to be an allele of BAP2 that encodes a permease for branched chain amino acids. The suppressor mutation (BAP2-1) converts a phenylalanine codon, highly conserved among the amino acid permease genes, to a serine codon in a region predicted to lie within the sixth membrane-spanning domain. Generation of the analogous mutation in the histidine permease produced an allele, HIP1-293, that similarly suppressed the low pH sensitivity of trk1 Delta trk2 Delta cells. Suppression of trk1 Delta trk2 Delta phenotypes by BAP2-1 or HIP1-293 was correlated with increased Rb+ uptake. The presence of the substrate amino acids enhanced but was not essential for suppression of trk1 Delta trk2 Delta phenotypes and increased Rb+ uptake. The conserved site altered by the suppressor mutations appears to be important; his4 HIP1-293 cells show an increased requirement for histidine compared with his4 HIP1 cells.	NORTHWESTERN UNIV, DEPT BIOCHEM, EVANSTON, IL 60208 USA; NORTHWESTERN UNIV, DEPT MOL BIOL, EVANSTON, IL 60208 USA; NORTHWESTERN UNIV, DEPT CELL BIOL, EVANSTON, IL 60208 USA; ESCUELA TECN SUPER INGN AGRON & MONTES, DEPT MICROBIOL, CORDOBA 14071, SPAIN	Northwestern University; Northwestern University; Northwestern University				Munson, George/0000-0002-3692-8199; Wright, matthewwright/0000-0002-0532-3381				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; ANDERSON JA, 1991, GENE, V99, P39, DOI 10.1016/0378-1119(91)90031-6; BALLARINDENTI A, 1984, BIOCHIM BIOPHYS ACTA, V778, P1, DOI 10.1016/0005-2736(84)90442-5; BANUELOS MA, 1995, EMBO J, V14, P3021, DOI 10.1002/j.1460-2075.1995.tb07304.x; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BERTL A, 1995, P NATL ACAD SCI USA, V92, P2701, DOI 10.1073/pnas.92.7.2701; BORSTPAUWELS GWFH, 1981, BIOCHIM BIOPHYS ACTA, V650, P88, DOI 10.1016/0304-4157(81)90002-2; CALAHORRA M, 1987, BIOCHIM BIOPHYS ACTA, V899, P229, DOI 10.1016/0005-2736(87)90404-4; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Didion T, 1996, J BACTERIOL, V178, P2025, DOI 10.1128/jb.178.7.2025-2029.1996; DOSCH DC, 1984, J BACTERIOL, V160, P1188, DOI 10.1128/JB.160.3.1188-1190.1984; EDDY AA, 1971, BIOCHEM J, V122, P701, DOI 10.1042/bj1220701; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; GABER RF, 1990, MOL CELL BIOL, V10, P643, DOI 10.1128/MCB.10.2.643; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; GRAUSLUND M, 1995, BBA-MOL CELL RES, V1269, P275, DOI 10.1016/0167-4889(95)00138-8; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; GUFFANTI AA, 1995, J BACTERIOL, V177, P4557, DOI 10.1128/jb.177.15.4557-4561.1995; IVEY DM, 1993, J BIOL CHEM, V268, P11296; KO CH, 1993, MOL CELL BIOL, V13, P638, DOI 10.1128/MCB.13.1.638; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; KO CH, 1990, GENETICS, V125, P305; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; MAI B, 1994, GENE, V143, P129, DOI 10.1016/0378-1119(94)90617-3; RAMOS J, 1985, ARCH MICROBIOL, V143, P88, DOI 10.1007/BF00414774; RAMOS J, 1994, J BACTERIOL, V176, P249, DOI 10.1128/JB.176.1.249-252.1994; RODRIGUEZNAVARRO A, 1984, J BACTERIOL, V159, P940; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHACHTMAN DP, 1992, SCIENCE, V258, P1654, DOI 10.1126/science.8966547; SCHACHTMAN DP, 1994, NATURE, V370, P655, DOI 10.1038/370655a0; SEASTON A, 1976, BIOCHEM J, V154, P669, DOI 10.1042/bj1540669; SEASTON A, 1973, BIOCHEM J, V134, P1031, DOI 10.1042/bj1341031; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; SHERMAN F, 1988, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SOLDATENKOV VA, 1995, GENE, V161, P97, DOI 10.1016/0378-1119(95)00274-A; TANAKA J, 1985, GENE, V38, P205, DOI 10.1016/0378-1119(85)90219-7; VANDENBOL M, 1989, GENE, V83, P153, DOI 10.1016/0378-1119(89)90413-7; VIDAL M, 1990, GENETICS, V125, P313; VIDAL M, 1994, YEAST, V10, P141, DOI 10.1002/yea.320100202; VIDAL M, 1995, P NATL ACAD SCI USA, V92, P2370, DOI 10.1073/pnas.92.6.2370	44	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13647	13652		10.1074/jbc.272.21.13647	http://dx.doi.org/10.1074/jbc.272.21.13647			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153214	hybrid			2022-12-27	WOS:A1997XA06200029
J	Leslie, CC				Leslie, CC			Properties and regulation of cytosolic phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ARACHIDONOYL-HYDROLYZING PHOSPHOLIPASE-A2; MOUSE PERITONEAL-MACROPHAGES; ACTIVATED PROTEIN-KINASES; TUMOR-NECROSIS-FACTOR; HUMAN PLATELETS; LYSOPHOSPHOLIPASE ACTIVITY; HUMAN NEUTROPHILS; FACTOR-ALPHA; MAP KINASE; PHOSPHORYLATION		UNIV COLORADO, SCH MED, DEPT PATHOL, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Leslie, CC (corresponding author), NATL JEWISH MED & RES CTR, DEPT PEDIAT, DIV BASIC SCI, 1400 JACKSON ST, DENVER, CO 80206 USA.				NHLBI NIH HHS [HL 34303, P01 HL034303] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDULLAH K, 1995, BBA-GEN SUBJECTS, V1244, P157, DOI 10.1016/0304-4165(94)00218-M; ACKERMANN EJ, 1995, BBA-LIPID LIPID MET, V1259, P125, DOI 10.1016/0005-2760(95)00143-Z; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; Chen X, 1996, BBA-LIPID LIPID MET, V1299, P23, DOI 10.1016/0005-2760(95)00166-2; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; DAMRON DS, 1993, J BIOL CHEM, V268, P27335; DECARVALHO MGS, 1995, J BIOL CHEM, V270, P20439, DOI 10.1074/jbc.270.35.20439; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DEREWENDA ZS, 1993, TRENDS BIOCHEM SCI, V18, P20, DOI 10.1016/0968-0004(93)90082-X; DOERFLER ME, 1994, J CLIN INVEST, V93, P1583, DOI 10.1172/JCI117138; Enari M, 1996, EUR J BIOCHEM, V236, P533, DOI 10.1111/j.1432-1033.1996.t01-1-00533.x; Flati V, 1996, EMBO J, V15, P1566, DOI 10.1002/j.1460-2075.1996.tb00501.x; FOUDA SI, 1995, BIOCHEM J, V308, P815, DOI 10.1042/bj3080815; Gijon M, 1996, FASEB J, V10, pL19; Gilbert JJ, 1996, J IMMUNOL, V156, P2054; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Graber MN, 1996, J BIOL CHEM, V271, P883, DOI 10.1074/jbc.271.2.883; Gresham A, 1996, AM J PHYSIOL-CELL PH, V270, pC1037, DOI 10.1152/ajpcell.1996.270.4.C1037; HANEL AM, 1995, BIOCHEMISTRY-US, V34, P7807, DOI 10.1021/bi00024a004; HARRISON KA, 1995, J BIOL CHEM, V270, P17273, DOI 10.1074/jbc.270.29.17273; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; HUANG Z, 1994, ANAL BIOCHEM, V222, P110, DOI 10.1006/abio.1994.1461; Hwang SC, 1996, J BIOL CHEM, V271, P18342, DOI 10.1074/jbc.271.31.18342; KAST R, 1993, J BIOL CHEM, V268, P16795; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; KRAMER RM, 1995, J BIOL CHEM, V270, P14816, DOI 10.1074/jbc.270.24.14816; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; LESLIE CC, 1991, J BIOL CHEM, V266, P11366; LI B, 1994, BIOCHEMISTRY-US, V33, P8594, DOI 10.1021/bi00194a026; Li B, 1996, BIOCHEMISTRY-US, V35, P3156, DOI 10.1021/bi952141x; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; MIYASHITA A, 1995, NUCLEIC ACIDS RES, V23, P293, DOI 10.1093/nar/23.2.293; MURPHY RC, 1997, PLATELET ACTIVATING, P51; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; OBEID LM, 1995, J CELL BIOCHEM, V58, P191, DOI 10.1002/jcb.240580208; Pete MJ, 1996, J BIOL CHEM, V271, P18114, DOI 10.1074/jbc.271.30.18114; PetersGolden M, 1996, BIOCHEM J, V318, P797, DOI 10.1042/bj3180797; Pickard RT, 1996, J BIOL CHEM, V271, P19225, DOI 10.1074/jbc.271.32.19225; QIU Z, 1996, FASEB J, V10, P985; QIU ZH, 1993, J BIOL CHEM, V268, P24506; QIU ZH, 1994, J BIOL CHEM, V269, P19480; RAO GN, 1995, BBA-MOL CELL RES, V1265, P67, DOI 10.1016/0167-4889(95)91997-Z; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Sapirstein A, 1996, J BIOL CHEM, V271, P21505, DOI 10.1074/jbc.271.35.21505; Schalkwijk CG, 1996, BIOCHEM J, V313, P91, DOI 10.1042/bj3130091; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; SHARP JD, 1993, J LIPID MEDIATOR, V8, P183; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHARP JD, 1994, J BIOL CHEM, V269, P23250; Shuttleworth TJ, 1996, J BIOL CHEM, V271, P21720, DOI 10.1074/jbc.271.36.21720; SierraHonigmann R, 1996, LAB INVEST, V74, P684; SMITH W, 1996, ADV IMMUNOL, V62, P166; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; TAY A, 1994, BBA-GENE STRUCT EXPR, V1217, P345, DOI 10.1016/0167-4781(94)90299-2; TAY A, 1994, BIOCHEM J, V304, P417, DOI 10.1042/bj3040417; TAY A, 1995, GENOMICS, V26, P138, DOI 10.1016/0888-7543(95)80093-2; TAY A, 1994, GENOMICS, V23, P718, DOI 10.1006/geno.1994.1569; TRIMBLE LA, 1993, BIOCHEMISTRY-US, V32, P12560, DOI 10.1021/bi00210a002; VoelkelJohnson C, 1996, J IMMUNOL, V156, P201; WATERMAN WH, 1995, BIOCHEM BIOPH RES CO, V209, P271, DOI 10.1006/bbrc.1995.1499; Waterman WH, 1996, BIOCHEM J, V319, P17, DOI 10.1042/bj3190017; WU T, 1994, J CLIN INVEST, V93, P571, DOI 10.1172/JCI117009; WU T, 1994, NUCLEIC ACIDS RES, V22, P5093, DOI 10.1093/nar/22.23.5093; XU XX, 1994, J BIOL CHEM, V269, P31693	77	716	724	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	1997	272	27					16709	16712		10.1074/jbc.272.27.16709	http://dx.doi.org/10.1074/jbc.272.27.16709			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XH446	9201969	hybrid			2022-12-27	WOS:A1997XH44600001
J	Balsinde, J; Dennis, EA				Balsinde, J; Dennis, EA			Function and inhibition of intracellular calcium-independent phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ARACHIDONIC-ACID RELEASE; PROTEIN-KINASE-C; CELL-LINE; CYTOSOLIC PHOSPHOLIPASE-A(2); MEDIATED PHAGOCYTOSIS; P388D(1) MACROPHAGES; PANCREATIC-ISLETS; INSULIN-SECRETION; MOBILIZATION; ACTIVATION		UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093	University of California System; University of California San Diego			Balsinde, Jesús/C-7833-2018; Dennis, Edward A./M-5554-2019	Balsinde, Jesús/0000-0002-4157-6714; Dennis, Edward A./0000-0003-3738-3140	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026171] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 26171] Funding Source: Medline; NIGMS NIH HHS [GM 51606, GM 20501] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; ACKERMANN EJ, 1959, BIOCHIM BIOPHYS ACTA, P125; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 1996, EUR J BIOCHEM, V235, P480, DOI 10.1111/j.1432-1033.1996.00480.x; BALSINDE J, 1991, J BIOL CHEM, V266, P15638; Balsinde J, 1997, BIOCHEM J, V321, P805, DOI 10.1042/bj3210805; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; BALSINDE J, 1994, EUR J BIOCHEM, V221, P1013, DOI 10.1111/j.1432-1033.1994.tb18818.x; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Chilton FH, 1996, BBA-LIPID LIPID MET, V1299, P1, DOI 10.1016/0005-2760(95)00169-7; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CondeFrieboes K, 1996, J AM CHEM SOC, V118, P5519, DOI 10.1021/ja953553w; DANIELS SB, 1986, BIOCHEMISTRY-US, V25, P1436, DOI 10.1021/bi00354a037; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Farooqui AA, 1995, BRAIN RES REV, V21, P152, DOI 10.1016/0165-0173(95)00008-9; FONTEH AN, 1993, J IMMUNOL, V150, P563; GROSS RW, 1995, J BIOL CHEM, V270, P14855, DOI 10.1074/jbc.270.25.14855; HATTORI M, 1994, J BIOL CHEM, V269, P23150; HAUNG Z, 1996, BIOCHEMISTRY-US, V35, P3712; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HAZEN SL, 1993, J BIOL CHEM, V268, P9892; KARIMI K, 1995, J IMMUNOL, V155, P5786; KONRAD RJ, 1994, BIOCHEMISTRY-US, V33, P13284, DOI 10.1021/bi00249a015; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LEHMAN JJ, 1993, J BIOL CHEM, V268, P20713; LENNARTZ MR, 1993, J LEUKOCYTE BIOL, V54, P389, DOI 10.1002/jlb.54.5.389; Lio YC, 1996, BBA-LIPID LIPID MET, V1302, P55, DOI 10.1016/0005-2760(96)00002-1; MARTIN A, 1994, SIGNAL ACTIVATED PHO, P139; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Pickard RT, 1996, J BIOL CHEM, V271, P19225, DOI 10.1074/jbc.271.32.19225; Portilla D, 1996, J BIOL CHEM, V271, P15451, DOI 10.1074/jbc.271.26.15451; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; Ramanadham S, 1996, BIOCHEMISTRY-US, V35, P5464, DOI 10.1021/bi952652j; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; ROSS MI, 1985, ARCH BIOCHEM BIOPHYS, V238, P247, DOI 10.1016/0003-9861(85)90162-6; SHARP JD, 1994, J BIOL CHEM, V269, P23250; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; THOMSON FJ, 1995, BIOCHEM J, V306, P305, DOI 10.1042/bj3060305; Wolf MJ, 1996, J BIOL CHEM, V271, P20989, DOI 10.1074/jbc.271.35.20989	44	277	282	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16069	16072		10.1074/jbc.272.26.16069	http://dx.doi.org/10.1074/jbc.272.26.16069			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195897	Green Published, hybrid			2022-12-27	WOS:A1997XG01900001
J	Goyal, J; Wang, KW; Liu, M; Subbaiah, PV				Goyal, J; Wang, KW; Liu, M; Subbaiah, PV			Novel function of lecithin-cholesterol acyltransferase - Hydrolysis of oxidized polar phospholipids generated during lipoprotein oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; LOW-DENSITY-LIPOPROTEIN; HUMAN-PLASMA; FACTOR-ACETYLHYDROLASE; ENDOTHELIAL-CELLS; LIPID-PEROXIDATION; LYSOLECITHIN ACYLTRANSFERASE; PAF-ACETYLHYDROLASE; SMOOTH-MUSCLE; LDL	Although the major function of lecithin-cholesterol acyltransferase (LCAT) is cholesterol esterification, our previous studies showed that it can also hydrolyze platelet-activating factor (PAF), Because of the structural similarities between PAF and the truncated phosphatidylcholines (polar PCs) generated during lipoprotein oxidation, we investigated the possibility that LCAT may also hydrolyze polar PCs to lyso-PC during the oxidation of plasma. PAF acetylhydrolase (PAF=AH), which is known to hydrolyze polar PCs in human plasma, was completely inhibited by 0.2 mM p-amino-ethyl benzenesulfonyl fluoride (Pefabloc), a new serine esterase inhibitor, which had no effect on LCAT at this concentration. On the other hand, 1 mM diisopropylfluorophosphate (DFP) completely inhibited LCAT but had no effect on PAF-AH, Polar PC accumulation during the oxidation of plasma increased by 44% in the presence of 0.2 mM Pefabloc and by 30% in the presence of 1 mM DFP, The formation of lyso-PC was concomitantly inhibited by both of the inhibitors. The combination of the two inhibitors resulted in the maximum accumulation of polar PCs, suggesting that both PAF-AH and LCAT are involved in their breakdown, Oxidation of chicken plasma, which has no PAF-AH activity, also resulted in the formation of lyse-PC from the hydrolysis of polar PC, which was inhibited by DFP, Polar PCs, either isolated from oxidized plasma or by oxidation of labeled synthetic PCs, were hydrolyzed by purified LCAT, which had no detectable PAF-AH activity. These results demonstrate a novel function for LCAT in the detoxification of polar PCs generated during lipoprotein oxidation, especially when the PAF-AH is absent or inactivated.	RUSH MED COLL,SECT ENDOCRINOL & METAB,DEPT MED,CHICAGO,IL 60612; RUSH MED COLL,DEPT BIOCHEM,CHICAGO,IL 60612	Rush University; Rush University			Subbaiah, Papasani/U-1104-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052597] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 52597] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMBROSIO G, 1994, J CLIN INVEST, V93, P2408, DOI 10.1172/JCI117248; ARON L, 1978, J BIOL CHEM, V253, P7220; BIELICKI JK, 1995, BBA-LIPID LIPID MET, V1258, P35, DOI 10.1016/0005-2760(95)00092-Q; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONELLI FS, 1989, J BIOL CHEM, V264, P14723; CABOT MC, 1984, COMP BIOCHEM PHYS B, V78, P37, DOI 10.1016/0305-0491(84)90141-X; CHEN CH, 1982, J LIPID RES, V23, P680; DENTAN C, 1994, ARTERIOSCLER THROMB, V14, P353, DOI 10.1161/01.ATV.14.3.353; Dentan C, 1996, BBA-LIPID LIPID MET, V1299, P353, DOI 10.1016/0005-2760(95)00226-X; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; FRANCONE OL, 1991, P NATL ACAD SCI USA, V88, P1716, DOI 10.1073/pnas.88.5.1716; Glomset J A, 1979, Prog Biochem Pharmacol, V15, P41; GLOMSET JA, 1968, J LIPID RES, V9, P155; HABERLAND ME, 1992, MONOGR HUM GENET, V14, P35; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HENGSTSCHLAGEROTTNAD E, 1995, J BIOL CHEM, V270, P26139, DOI 10.1074/jbc.270.44.26139; HESSLER JR, 1979, ATHEROSCLEROSIS, V32, P213, DOI 10.1016/0021-9150(79)90166-7; ITABE H, 1994, J BIOL CHEM, V269, P15274; ITABE H, 1988, BIOCHIM BIOPHYS ACTA, V962, P8; JONAS A, 1991, BIOCHIM BIOPHYS ACTA, V1084, P205, DOI 10.1016/0005-2760(91)90062-M; KAMIDO H, 1995, J LIPID RES, V36, P1876; KAPLANHARRIS L, 1980, J LIPID RES, V21, P617; KHAN BV, 1995, J CLIN INVEST, V95, P1262, DOI 10.1172/JCI117776; KLIMOV A N, 1989, Biokhimiya, V54, P118; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; LEHR HA, 1993, ARTERIOSCLER THROMB, V13, P1013, DOI 10.1161/01.ATV.13.7.1013; LIAPIKOS TA, 1994, BBA-LIPID LIPID MET, V1212, P353, DOI 10.1016/0005-2760(94)90210-0; LIU M, 1993, BIOCHIM BIOPHYS ACTA, V1168, P144, DOI 10.1016/0005-2760(93)90118-S; LIU M, 1994, P NATL ACAD SCI USA, V91, P6035, DOI 10.1073/pnas.91.13.6035; LODGE JK, 1995, BBA-LIPID LIPID MET, V1256, P130, DOI 10.1016/0005-2760(94)00253-U; MACKNESS MI, 1989, BIOCHEM PHARMACOL, V38, P385, DOI 10.1016/0006-2952(89)90376-6; MACKNESS MI, 1995, ATHEROSCLEROSIS, V115, P243, DOI 10.1016/0021-9150(94)05524-M; MARINETTI GV, 1962, J LIPID RES, V3, P1; MIWA M, 1988, J CLIN INVEST, V82, P1983, DOI 10.1172/JCI113818; MIWA M, 1984, J BIOCHEM-TOKYO, V96, P761, DOI 10.1093/oxfordjournals.jbchem.a134894; MUROHARA T, 1994, AM J PHYSIOL-HEART C, V267, pH2441, DOI 10.1152/ajpheart.1994.267.6.H2441; NEVILLE TA, 1996, CIRCULATION, V94, P222; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; PARTHASARATHY S, 1990, P NATL ACAD SCI USA, V87, P9741, DOI 10.1073/pnas.87.24.9741; PIRAN U, 1976, J BIOCHEM-TOKYO, V80, P887, DOI 10.1093/oxfordjournals.jbchem.a131352; Puettmann Michael, 1993, Clinical Chemistry, V39, P782; QU SJ, 1993, BIOCHEMISTRY-US, V32, P3089, DOI 10.1021/bi00063a021; QUINN MT, 1991, BIOCHIM BIOPHYS ACTA, V1082, P293, DOI 10.1016/0005-2760(91)90205-V; Schlame M, 1996, J LIPID RES, V37, P2608; SCHMITT A, 1995, BBA-LIPID LIPID MET, V1256, P284, DOI 10.1016/0005-2760(95)00032-8; SMILEY PL, 1991, J BIOL CHEM, V266, P11104; Stafforini DM, 1996, J CLIN INVEST, V97, P2784, DOI 10.1172/JCI118733; Stafforini DM, 1996, BBA-LIPID LIPID MET, V1301, P161, DOI 10.1016/0005-2760(96)00040-9; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1989, J LIPID RES, V30, P305; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; SUBBAIAH PV, 1980, J BIOL CHEM, V255, P9275; SUBBAIAH PV, 1992, BIOCHIM BIOPHYS ACTA, V1128, P83, DOI 10.1016/0005-2760(92)90261-S; Subbaiah PV, 1996, BBA-LIPID LIPID MET, V1301, P115, DOI 10.1016/0005-2760(96)00028-8; SUGIYAMA S, 1994, CIRC RES, V74, P565, DOI 10.1161/01.RES.74.4.565; TANAKA T, 1993, BIOCHIM BIOPHYS ACTA, V1166, P264, DOI 10.1016/0005-2760(93)90107-K; TETTA C, 1990, INT ARCH ALLER A IMM, V91, P244, DOI 10.1159/000235124; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; TJOELKER LW, 1995, J BIOL CHEM, V270, P25481, DOI 10.1074/jbc.270.43.25481; Tokumura A, 1996, LIPIDS, V31, P1251, DOI 10.1007/BF02587909; WATSON AD, 1995, J CLIN INVEST, V95, P774, DOI 10.1172/JCI117726; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359; YAMADA Y, 1994, P NATL ACAD SCI USA, V91, P10320, DOI 10.1073/pnas.91.22.10320	64	99	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16231	16239		10.1074/jbc.272.26.16231	http://dx.doi.org/10.1074/jbc.272.26.16231			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195924	hybrid			2022-12-27	WOS:A1997XG01900028
J	Tomashek, JJ; Garrison, BS; Klionsky, DJ				Tomashek, JJ; Garrison, BS; Klionsky, DJ			Reconstitution in vitro of the V-1 complex from the yeast vacuolar proton-translocating ATPase - Assembly recapitulates mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASE; SACCHAROMYCES-CEREVISIAE; ADENOSINE-TRIPHOSPHATASE; 14-KDA SUBUNIT; ENCODES; PUMP; MEMBRANE; BINDING; ENZYME	Oligomeric assembly is a fundamental aspect of many complex enzymes, Using our native gel technique for examining subcomplexes of the V-ATPase V-1 sector, we have developed an in vitro reconstitution assay for assembly of this complex. Assembly of complex II, the soluble V-1 complex observed in native gels, is dependent upon the presence of divalent cations and physiological temperatures. Assembly of soluble V-1 can occur in a stepwise fashion from smaller subcomplexes found in some strains deleted for V-ATPase subunits. Specifically, V-1 can be assembled directly from complex III (subunits E and G) with complex IV (subunits A, B, D, and F) without prior disassembly of complex IV. The formation of complex III in vivo is also shown to be essential and could not be achieved in vitro. Assembly from simpler precursors is possible and is enhanced by added ATP. Assembly can be blocked by N-ethylmaleimide in a Vma1p (subunit A)-specific manner. From these data, we extend our previous model to consider an assembly pathway whose steps reflect the catalytic mechanism of the Boyer binding-change model.	UNIV CALIF DAVIS,MICROBIOL SECT,DAVIS,CA 95616	University of California System; University of California Davis					NIGMS NIH HHS [GM53396] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053396] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; DSCHIDA WJA, 1995, J BIOL CHEM, V270, P1557, DOI 10.1074/jbc.270.4.1557; FENG Y, 1992, J BIOL CHEM, V267, P5817; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; HARVEY WR, 1992, J EXP BIOL, V172, P1; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HO MN, 1993, J BIOL CHEM, V268, P18286; HO MN, 1993, J BIOL CHEM, V268, P221; KAKINUMA Y, 1981, J BIOL CHEM, V256, P859; KANE PM, 1995, J BIOL CHEM, V270, P17025; KASHO VN, 1989, P NATL ACAD SCI USA, V86, P8708, DOI 10.1073/pnas.86.22.8708; MORANO KA, 1994, J CELL SCI, V107, P2813; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; NELSON H, 1994, J BIOL CHEM, V269, P24150; Okamoto M, 1996, J BIOCHEM-TOKYO, V120, P608; Parra KJ, 1996, J BIOL CHEM, V271, P19592, DOI 10.1074/jbc.271.32.19592; PUOPOLO K, 1990, J BIOL CHEM, V265, P14836; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; TOGNOLI L, 1985, EUR J BIOCHEM, V146, P581, DOI 10.1111/j.1432-1033.1985.tb08691.x; Tomashek JJ, 1996, J BIOL CHEM, V271, P10397, DOI 10.1074/jbc.271.17.10397; WANG ZQ, 1990, J BIOL CHEM, V265, P21957; Ward JM, 1995, METHOD CELL BIOL, V50, P149, DOI 10.1016/S0091-679X(08)61028-6; Xie XS, 1996, J BIOL CHEM, V271, P30980	23	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16618	16623		10.1074/jbc.272.26.16618	http://dx.doi.org/10.1074/jbc.272.26.16618			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195975	hybrid			2022-12-27	WOS:A1997XG01900079
J	Auguste, P; Guillet, C; Fourcin, M; Olivier, C; Veziers, J; PouplardBarthelaix, A; Gascan, H				Auguste, P; Guillet, C; Fourcin, M; Olivier, C; Veziers, J; PouplardBarthelaix, A; Gascan, H			Signaling of type II oncostatin M receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-INHIBITORY FACTOR; CYTOKINE RECEPTORS; GROWTH-FACTOR; CELLS; GP130; INTERLEUKIN-6; ACTIVATION; KINASE; ASSOCIATION; TRANSDUCER	Oncostatin M (OSM), mediates its bioactivities through two different heterodimer receptors. They both involve the gp130-transducing receptor, which dimerizes with either leukemia inhibitor receptor beta or with OSM receptor beta (OSMR beta) to generate, respectively, type I and type II OSM receptors. Co-precipitation of gp130-associated proteins, flow cytometry, polymerase chain reaction, and tyrosine phosphorylation analyses allowed the characterization of both types of OSM receptors expressed on the surface of different cell lines, It also allowed the detection of a large size protein, p250, that specifically associates to the type II OSM receptor components anti that is tyrosine-phosphorylated after the activation peak of the gp130.OSMR beta heterocomplex, The restricted expression of type I OSM receptor by the SAR choriocarcinoma cell line, and type II receptor by the A375 melanoma cell line, permitted the characterization of their signaling machineries. Both type I and type II OSM receptors activated Jak1, Jak2, and Tyk2 receptor-associated tyrosine kinases, The information is nest relayed to the nucleus by the STAT3 transcriptional activator, which is recruited by both types of OSM receptors, In addition, STAT5b was specifically activated through the gp120.OSMR beta type II heterocomplex. The signaling pathway differences observed between the common type I LIF/OSM receptor and the specific type II OSM receptor might explain some of the bioactivities specifically displayed by OSM.	CHU ANGERS, BIOL CELLULAIRE LAB, F-49033 ANGERS, FRANCE	Universite d'Angers; Centre Hospitalier Universitaire d'Angers			OLIVIER, Christophe/L-1598-2015; Veziers, Joelle/P-6232-2014	Auguste, Patrick/0000-0003-1485-0295				BAUMANN H, 1993, J BIOL CHEM, V268, P8414; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; Bruce A. Gregory, 1992, Progress in Growth Factor Research, V4, P157, DOI 10.1016/0955-2235(92)90029-H; BRUCE AG, 1992, J IMMUNOL, V149, P1271; Chevalier S, 1996, J BIOL CHEM, V271, P14764, DOI 10.1074/jbc.271.25.14764; Clegg CH, 1996, NATURE, V384, P261, DOI 10.1038/384261a0; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Fourcin M, 1996, J BIOL CHEM, V271, P11756, DOI 10.1074/jbc.271.20.11756; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; LIU JW, 1992, J BIOL CHEM, V267, P16763; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; PETRICOIN E, 1996, 1 JOINT M ICS ISICR; RICHARDS CD, 1992, J IMMUNOL, V148, P1731; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; Robledo O, 1997, J BIOL CHEM, V272, P4855, DOI 10.1074/jbc.272.8.4855; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHIEVEN GL, 1992, J IMMUNOL, V149, P1676; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; THOMA B, 1994, J BIOL CHEM, V269, P6215; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739	29	97	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15760	15764		10.1074/jbc.272.25.15760	http://dx.doi.org/10.1074/jbc.272.25.15760			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188471	hybrid			2022-12-27	WOS:A1997XF32900031
J	Autry, JM; Jones, LR				Autry, JM; Jones, LR			Functional co-expression of the canine cardiac Ca2+ pump and phospholamban in Spodoptera frugiperda (Sf21) cells reveals new insights on ATPase regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; CA-2+ TRANSPORT; PHOSPHORYLATION; CA-2+-ATPASE; VESICLES; RECONSTITUTION; STIMULATION; MODULATION; MECHANISM; GLUTAMINE	The utility of the baculovirus cell expression system for investigating Ca2+-ATPase and phospholamban regulatory interactions was examined, cDNA encoding the canine cardiac sarco(endo)plasmic Ca2+-ATPase primp (SERCA2a) was cloned for the first time and expressed in the presence and absence of phospholamban in Spodoptera frugiperda (Sf21) insect cells, The recombinant Ca2+ pump was produced in high yield, contributing 20% of the total membrane protein in Sf21 microsomes. At least 70% of the expressed pumps were active, Coexpression of wild-type, pentameric phospholamban with the Ca2+-ATPase decreased the apparent affinity of the ATPase for Ca2+, but had no effect on the maximum velocity of the enzyme, similar to phospholamban's action in cardiac sarcoplasmic reticulum vesicles, To investigate the importance of the oligomeric structure of phospholamban in ATPase regulation, SERCA2a was coexpressed with a monomeric mutant of phospholamban, in which leucine residue 37 was changed to alanine. Surprisingly, monomeric phospholamban suppressed SERCA2a Ca2+ affinity more strongly than did wild-type phospholamban, demonstrating that the pentamer is not essential for Ca2+ pump inhibition and that the monomer is the more active species, To test if phospholamban functions as a Ca2+ channel, Sf21 microsomes expressing either SEBCA2a or SERCA2a plus phospholamban were actively loaded with Ca2+ and then assayed for unidirectional Ca-45(2+) efflux. No evidence for a Ca2+ channel activity of phospholamban was obtained, We conclude that the phospholamban monomer is an important regulatory component inhibiting SERCA2a in cardiac sarcoplasmic reticulum membranes, and that the channel activity of phospholamban previously observed in planar bilayers is not involved in the mechanism of ATPase regulation.	INDIANA UNIV,SCH MED,KRANNERT INST CARDIOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MED,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis			Autry, Joseph M./X-6839-2019	Autry, Joseph M./0000-0002-1144-725X	NHLBI NIH HHS [HL49428, HL06308] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049428, R37HL049428] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antipenko AY, 1997, J BIOL CHEM, V272, P2852, DOI 10.1074/jbc.272.5.2852; ARKIN IT, 1995, J MOL BIOL, V248, P824, DOI 10.1006/jmbi.1995.0263; BRIGGS FN, 1992, J BIOL CHEM, V267, P26056; CAMPBELL AM, 1991, J BIOL CHEM, V266, P16050; CANTILINA T, 1993, J BIOL CHEM, V268, P17018; CENTENO F, 1994, FEBS LETT, V354, P117, DOI 10.1016/0014-5793(94)01104-4; CHAMBERLAIN BK, 1984, J BIOL CHEM, V259, P7540; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; Cornea RL, 1997, BIOCHEMISTRY-US, V36, P2960, DOI 10.1021/bi961955q; EGGERMONT JA, 1989, BIOCHEM J, V260, P757, DOI 10.1042/bj2600757; FUJII J, 1990, FEBS LETT, V273, P232, DOI 10.1016/0014-5793(90)81092-3; GAMBEL AM, 1992, BIOCHIM BIOPHYS ACTA, V1131, P203, DOI 10.1016/0167-4781(92)90078-E; GUTENSKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HARRER JM, 1995, MOL CELL BIOCHEM, V146, P13, DOI 10.1007/BF00926876; INUI M, 1986, J BIOL CHEM, V261, P1794; JONES LR, 1977, J BIOL CHEM, V252, P3315; JONES LR, 1993, J BIOL CHEM, V268, P11486; JONES LR, 1979, J BIOL CHEM, V254, P530; Kimura Y, 1996, J BIOL CHEM, V271, P21726, DOI 10.1074/jbc.271.36.21726; Kimura Y., 1997, Biophysical Journal, V72, pA332; KOVACS RJ, 1988, J BIOL CHEM, V263, P18364; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1988, J BIOL CHEM, V263, P15024; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MORRIS GL, 1991, J BIOL CHEM, V266, P11270; MOVSESIAN MA, 1994, CIRCULATION, V90, P653, DOI 10.1161/01.CIR.90.2.653; Odermatt A, 1996, J BIOL CHEM, V271, P14206, DOI 10.1074/jbc.271.24.14206; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; REDDY LG, 1995, J BIOL CHEM, V270, P9390, DOI 10.1074/jbc.270.16.9390; Reddy LG, 1996, J BIOL CHEM, V271, P14964, DOI 10.1074/jbc.271.25.14964; SCOTT BT, 1988, J BIOL CHEM, V263, P8958; SHAM JSK, 1991, AM J PHYSIOL, V261, pH1344, DOI 10.1152/ajpheart.1991.261.4.H1344; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; SKERJANC IS, 1993, J BIOL CHEM, V268, P15944; TADA M, 1989, BIOESSAYS, V10, P157, DOI 10.1002/bies.950100505; TADA M, 1982, MOL CELL BIOCHEM, V46, P73; TATULIAN SA, 1995, BIOCHEMISTRY-US, V34, P4448, DOI 10.1021/bi00013a038; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; VERBOOMEN H, 1992, BIOCHEM J, V286, P591, DOI 10.1042/bj2860591; VOSS J, 1994, BIOPHYS J, V67, P190, DOI 10.1016/S0006-3495(94)80469-2; VOSS JC, 1995, BIOPHYS J, V68, P1787, DOI 10.1016/S0006-3495(95)80355-3; WEGENER AD, 1984, J BIOL CHEM, V259, P1834	47	133	134	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15872	15880		10.1074/jbc.272.25.15872	http://dx.doi.org/10.1074/jbc.272.25.15872			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188486	hybrid			2022-12-27	WOS:A1997XF32900046
J	Ishiguro, N; Brown, GD; Meruelo, D				Ishiguro, N; Brown, GD; Meruelo, D			Activation transcription factor 1 involvement in the regulation of murine H-2D(d) expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I GENES; MAJOR HISTOCOMPATIBILITY COMPLEX; COMPLETE NUCLEOTIDE-SEQUENCE; RADIATION LEUKEMIA-VIRUS; MOUSE TRANSPLANTATION ANTIGENS; DNA-BINDING ACTIVITY; GRC-G/C REGION; NF-KAPPA-B; HLA GENE; ALLELIC VARIATION	Resistance to radiation leukemia virus-induced leukemia is correlated with an increase in H-2D expression on the thymocyte surface, Recently, it has been shown that elevated H-2D(d) expression on the infected thymocyte is a result of elevated mRNA transcription and that the transcriptional increase is correlated with elevated levels of a DNA binding activity, H-2 binding factor 1 (H-2 BF1), which recognizes the 5'-flanking sequences (5'-TGACGCG-3') of the H-2D(d) gene, This target for transcription factor binding has been found to be identical in the 5'-regulatory region of 12 rodent class I genes, nine of which have been shown to be functional genes, Furthermore, tills cis-element is found 5' of 20 primate class I genes (15 human genes), seven of which are known to be functional, Here, we demonstrate that activation transcription factor 1 (ATF-1) is one component of H-2 BF1, In addition, the levels of ATF-1 mRNA in uninfected and radiation leukemia virus-infected thymocytes parallel those of H-2D(d) mRNA, and therefore, it is suggested that ATF-1 up-regulates the transcription of the H-2D(d) gene after radiation leukemia virus infection of thymocytes. Transfection experiments also demonstrate that ATF-1 activates a reporter plasmid that contains the H-2 BF1 motif, but not a reporter lacking this motif, This is the first demonstration of the interaction of ATF-1 with 5'-regulatory sequences of major histocompatibility complex class I genes.	NYU,MED CTR,DEPT PATHOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University			Ishiguro, Nobuhisa/A-5199-2012		NATIONAL CANCER INSTITUTE [R37CA022247, R01CA022247] Funding Source: NIH RePORTER; NCI NIH HHS [CA22247] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRISANI OM, 1988, MOL CELL BIOL, V8, P1947, DOI 10.1128/MCB.8.5.1947; ARNOLD B, 1984, NUCLEIC ACIDS RES, V12, P9473, DOI 10.1093/nar/12.24.9473; BACH RG, 1984, J EXP MED, V160, P270, DOI 10.1084/jem.160.1.270; BALAS A, 1994, IMMUNOGENETICS, V39, P452; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; Brown G. D., 1991, Immunogenetics of the major histocompatibility complex., P268; BROWN GD, 1989, J IMMUNOGENET, V16, P351; BROWN GD, 1988, IMMUNOGENETICS, V27, P239, DOI 10.1007/BF00376118; BROWN GD, 1991, RES IMMUNOL, V142, P431, DOI 10.1016/0923-2494(91)90043-I; BROWN GD, 1994, ALLERG IMMUNOL PARIS, V13, P59; CEREB N, 1994, J IMMUNOL, V152, P3873; CHANDRA G, 1995, J IMMUNOL, V155, P4535; CHERTKOFF LP, 1991, HUM IMMUNOL, V31, P153, DOI 10.1016/0198-8859(91)90020-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHORNEY MJ, 1990, MOL CELL BIOL, V10, P243, DOI 10.1128/MCB.10.1.243; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DEY A, 1992, MOL CELL BIOL, V12, P3590, DOI 10.1128/MCB.12.8.3590; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURAN LW, 1989, J IMMUNOL, V142, P288; FEUERSTEIN N, 1995, J IMMUNOL, V154, P68; FISHER DA, 1989, J MOL EVOL, V28, P306, DOI 10.1007/BF02103426; FRELS W I, 1990, New Biologist, V2, P1024; GERAGHTY DE, 1987, P NATL ACAD SCI USA, V84, P9145, DOI 10.1073/pnas.84.24.9145; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUSSOW D, 1987, IMMUNOGENETICS, V25, P313, DOI 10.1007/BF00404424; GUTSCH DE, 1994, MOL CELL BIOL, V14, P1939, DOI 10.1128/MCB.14.3.1939; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOOD L, 1983, ANNU REV IMMUNOL, V1, P529, DOI 10.1146/annurev.iy.01.040183.002525; HOWARD P, 1991, J BIOL CHEM, V266, P10189; ISAMAT M, 1990, NUCLEIC ACIDS RES, V18, P6702; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KIRISITS MJ, 1994, IMMUNOGENETICS, V39, P301, DOI 10.1007/BF00189226; KIRISITS MJ, 1992, IMMUNOGENETICS, V35, P365; KLEIN J, 1983, ANNU REV IMMUNOL, V1, P119, DOI 10.1146/annurev.iy.01.040183.001003; KOBAYASHI M, 1995, NUCLEIC ACIDS RES, V23, P2848, DOI 10.1093/nar/23.15.2848; KOLLER BH, 1988, J IMMUNOL, V141, P897; KORBER B, 1987, P NATL ACAD SCI USA, V84, P3380, DOI 10.1073/pnas.84.10.3380; KRYSPINSORENSEN I, 1991, IMMUNOGENETICS, V33, P213, DOI 10.1007/BF01719245; LAMBRACHT D, 1995, IMMUNOGENETICS, V41, P375, DOI 10.1007/BF00163995; LEE DR, 1988, J EXP MED, V168, P1719, DOI 10.1084/jem.168.5.1719; LEE MR, 1992, J IMMUNOL, V148, P1906; LEMONNIER FA, 1983, IMMUNOGENETICS, V18, P65, DOI 10.1007/BF00401357; LIEBERMAN M, 1979, INT J CANCER, V24, P168, DOI 10.1002/ijc.2910240208; MALISSEN M, 1982, P NATL ACAD SCI-BIOL, V79, P893, DOI 10.1073/pnas.79.3.893; MERUELO D, 1977, J EXP MED, V146, P1079, DOI 10.1084/jem.146.4.1079; MERUELO D, 1979, J EXP MED, V149, P898, DOI 10.1084/jem.149.4.898; MERUELO D, 1978, J EXP MED, V147, P470, DOI 10.1084/jem.147.2.470; MESSER G, 1992, J IMMUNOL, V148, P4043; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MORITA T, 1985, IMMUNOGENETICS, V21, P367, DOI 10.1007/BF00430802; NGUYEN C, 1985, IMMUNOGENETICS, V21, P479, DOI 10.1007/BF00430931; NOBUNAGA T, 1992, J IMMUNOL, V149, P871; POHLA H, 1989, IMMUNOGENETICS, V29, P297, DOI 10.1007/BF00352839; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; SAJI M, 1992, P NATL ACAD SCI USA, V89, P1944, DOI 10.1073/pnas.89.5.1944; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEPART BS, 1986, J IMMUNOL, V136, P3489; SCHMIDT H, 1990, IMMUNOGENETICS, V31, P245; SHER BT, 1985, P NATL ACAD SCI USA, V82, P1175, DOI 10.1073/pnas.82.4.1175; SIMONSEN CC, 1983, MOL CELL BIOL, V3, P2250, DOI 10.1128/MCB.3.12.2250; SINGER DS, 1988, CURR TOP MICROBIOL, V137, P148; SINGER DS, 1988, IMMUNOGENETICS, V28, P13, DOI 10.1007/BF00372524; SODOYER R, 1984, EMBO J, V3, P879, DOI 10.1002/j.1460-2075.1984.tb01900.x; SRIVASTAVA R, 1991, IMMUNOGENETICS MAJOR, P100; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STEINMETZ M, 1981, CELL, V24, P125, DOI 10.1016/0092-8674(81)90508-0; STEINMETZ M, 1981, CELL, V25, P683, DOI 10.1016/0092-8674(81)90175-6; STRACHAN T, 1984, EMBO J, V3, P887, DOI 10.1002/j.1460-2075.1984.tb01901.x; TIBENSKY D, 1990, IMMUNOGENETICS, V32, P210, DOI 10.1007/BF02114976; TRECO DA, 1990, CURRENT PROTOCOLS MO; VALLEJO AN, 1995, J IMMUNOL, V154, P3912; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; WATTS S, 1987, J IMMUNOL, V139, P3878; WATTS S, 1989, EMBO J, V8, P1749, DOI 10.1002/j.1460-2075.1989.tb03568.x; WEISS E, 1983, EMBO J, V2, P453, DOI 10.1002/j.1460-2075.1983.tb01444.x; WEISS EH, 1985, IMMUNOBIOLOGY, V170, P367, DOI 10.1016/S0171-2985(85)80061-9	81	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15993	16001		10.1074/jbc.272.25.15993	http://dx.doi.org/10.1074/jbc.272.25.15993			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188502	hybrid			2022-12-27	WOS:A1997XF32900062
J	Sekiguchi, J; Cheng, CH; Shuman, S				Sekiguchi, J; Cheng, CH; Shuman, S			Kinetic analysis of DNA and RNA strand transfer reactions catalyzed by vaccinia topoisomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC INTERACTION; DUPLEX DNA; ESCHERICHIA-COLI; CLEAVAGE; SEQUENCE; BINDING	Vaccinia topoisomerase binds duplex DNA and forms a covalent DNA-(3'-phosphotyrosyl) protein adduct at the sequence 5'-CCCTT down arrow. The enzyme reacts readily with a 36-mer CCCTT strand (DNA-p-RNA) composed of DNA 5' and RNA 3' of the scissile bond. However, a 36-mer composed of RNA 5' and DNA 3' of the scissile phosphate (RNA-p-DNA) is a poor substrate for covalent adduct formation, Vaccinia topoisomerase efficiently transfers covalently held CCCTT-containing DNA to 5'-OH-terminated RNA accepters; the topoisomerase can therefore be used to tag the 5' end of RNA in vitro. Religation of the covalently bound CCCTT-containing DNA strand to a 5'-OH-terminated DNA acceptor is efficient and rapid (k(rel) > 0.5 s(-1)), provided that the acceptor DNA is callable of base pairing to the noncleaved DNA strand of the topoisomerase-DNA donor complex, The rate of strand transfer to DNA is not detectably affected by base mismatches at the 5' nucleotide of the acceptor strand, Nucleotide deletions and insertions at the 5' end of the acceptor slow the rate of religation; the observed hierarchy of reaction rates is as follows: +1 insertion > -1 deletion > +2 insertion >> -2 deletion, These findings underscore the importance of a properly positioned 5'-OH terminus in transesterification reaction chemistry, but they also raise the possibility that topoisomerase may generate mutations by sealing DNA molecules with mispaired or unpaired ends.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center				Sekiguchi, JoAnn/0000-0002-7178-4258	NIGMS NIH HHS [GM46330] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046330, R37GM046330] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOTT S, 1986, J MOL BIOL, V188, P631, DOI 10.1016/S0022-2836(86)80011-0; Cheng CH, 1997, J BIOL CHEM, V272, P8263, DOI 10.1074/jbc.272.13.8263; HENNINGFELD KA, 1995, BIOCHEMISTRY-US, V34, P6120, DOI 10.1021/bi00018a015; MORHAM SG, 1992, J BIOL CHEM, V267, P15984; Petersen BO, 1996, J MOL BIOL, V263, P181, DOI 10.1006/jmbi.1996.0568; Petersen BO, 1997, J BIOL CHEM, V272, P3891, DOI 10.1074/jbc.272.7.3891; Petersen BO, 1997, NUCLEIC ACIDS RES, V25, P2091, DOI 10.1093/nar/25.11.2091; SALAZAR M, 1993, BIOCHEMISTRY-US, V32, P4207, DOI 10.1021/bi00067a007; Sekiguchi J, 1997, NUCLEIC ACIDS RES, V25, P727, DOI 10.1093/nar/25.4.727; Sekiguchi J, 1996, EMBO J, V15, P3448, DOI 10.1002/j.1460-2075.1996.tb00711.x; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P31731; Sekiguchi JA, 1996, P NATL ACAD SCI USA, V93, P785, DOI 10.1073/pnas.93.2.785; SHUMAN S, 1991, J BIOL CHEM, V266, P1796; Shuman S, 1995, BIOCHEMISTRY-US, V34, P16138, DOI 10.1021/bi00049a029; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1992, J BIOL CHEM, V267, P16755; SHUMAN S, 1992, J BIOL CHEM, V267, P8620; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1993, J BIOL CHEM, V268, P18943; SHUMAN S, 1991, P NATL ACAD SCI USA, V88, P10104, DOI 10.1073/pnas.88.22.10104; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; SHUMAN S, 1994, J BIOL CHEM, V269, P23678; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; Yang SW, 1996, P NATL ACAD SCI USA, V93, P11534, DOI 10.1073/pnas.93.21.11534	25	23	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15721	15728		10.1074/jbc.272.25.15721	http://dx.doi.org/10.1074/jbc.272.25.15721			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188465	hybrid			2022-12-27	WOS:A1997XF32900025
J	David, NE; Gee, M; Andersen, B; Naider, F; Thorner, J; Stevens, RC				David, NE; Gee, M; Andersen, B; Naider, F; Thorner, J; Stevens, RC			Expression and purification of the Saccharomyces cerevisiae alpha-factor receptor (Ste2p), a 7-transmembrane-segment G protein-coupled receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTED INSECT CELLS; PHEROMONE RESPONSE PATHWAY; DOPAMINE D-2 RECEPTOR; ESCHERICHIA-COLI; BINDING PROTEIN; GENE-EXPRESSION; YEAST; SUBUNIT; ACETYLCHOLINE; MUTANTS	A plasmid vector was developed that permitted high-level expression of a functional form of the Saccharomyces cerevisiae alpha-factor receptor (the STE2 gene product) tagged at its C-terminal end with an epitope (FLAG) and a His(6) tract. When expressed in yeast from this plasmid, Ste2p was produced at a level at least S-fold higher than that reported previously for any other 7-transmembrane-segment receptor expressed in the same cells. For purification, isolated cell membranes containing the overexpressed receptor were solubilized with detergent under specific conditions and subjected to immobilized metal affinity chromatography. Yields as high as 1 mg of nearly homogeneous (95%) receptor were routinely obtained even from relatively small scale preparations (60 g of frozen cell paste). The purified receptor was :reconstituted into artificial phospholipid vesicles. Radioligand binding studies demonstrated that the purified receptor, in the reconstituted vesicles, bound its tridecapeptide ligand (alpha-factor) with a K-D (155 nM) consistent with the affinity expected for this receptor in the absence of its associated G protein. Efficient restoration of ligand binding activity upon reconstitution required the addition of solubilized membranes prepared from a yeast strain lacking the receptor. Sufficient amounts of active material can be obtained by this procedure to allow physical studies of this receptor and other 7-transmembrane-segment receptors expressed in this system.	UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, DEPT CELL & MOL BIOL, BERKELEY, CA 94720 USA; ROYAL VET & AGR UNIV, DEPT PLANT BIOL, DK-1871 FREDERIKSBERG C, DENMARK; UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DONNER LAB, DIV LIFE SCI, BERKELEY, CA 94720 USA; CUNY COLL STATEN ISL, DEPT CHEM, STATEN ISL, NY 10314 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of Copenhagen; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; City University of New York (CUNY) System; College of Staten Island (CUNY)			THORNER, Jeremy/O-6132-2019; Stevens, Raymond/K-7272-2015	THORNER, Jeremy/0000-0002-2583-500X; Stevens, Raymond/0000-0002-4522-8725	NIGMS NIH HHS [GM07232, GM22087, GM22086] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022086, R56GM022087, T32GM007232, R56GM022086, R01GM022087] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; BLUMER KJ, 1988, J BIOL CHEM, V263, P10836; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAN RK, 1983, J BACTERIOL, V155, P903, DOI 10.1128/JB.155.2.903-906.1983; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; CHAPOT MP, 1990, EUR J BIOCHEM, V187, P137, DOI 10.1111/j.1432-1033.1990.tb15287.x; CLARK CD, 1994, J BIOL CHEM, V269, P8831; COUGHLIN SR, 1994, CURR OPIN CELL BIOL, V6, P191, DOI 10.1016/0955-0674(94)90135-X; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DOHLMAN HG, 1993, P NATL ACAD SCI USA, V90, P9688, DOI 10.1073/pnas.90.20.9688; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FRASER CM, 1994, PROG NUCLEIC ACID RE, V49, P113; GRISSHAMMER R, 1993, BIOCHEM J, V295, P571, DOI 10.1042/bj2950571; Harlow E., 1988, ANTIBODIES LAB MANUA; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; HUANG HJ, 1992, BIOCHEM BIOPH RES CO, V182, P1180, DOI 10.1016/0006-291X(92)91856-L; JAVITCH JA, 1994, J RECEPTOR RES, V14, P99, DOI 10.3109/10799899409066999; JENNESS DD, 1986, MOL CELL BIOL, V6, P318, DOI 10.1128/MCB.6.1.318; JONES EW, 1991, METHOD ENZYMOL, V194, P428; JULIUS D, 1983, CELL, V32, P839, DOI 10.1016/0092-8674(83)90070-3; KING K, 1990, SCIENCE, V250, P121, DOI 10.1126/science.2171146; KONIG B, 1994, BBA-MOL CELL RES, V1223, P261, DOI 10.1016/0167-4889(94)90235-6; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; KURJAN J, 1993, ANNU REV GENET, V27, P147; Kwatra MM, 1995, PROTEIN EXPRES PURIF, V6, P717, DOI 10.1006/prep.1995.0001; LEVY D, 1992, BIOCHIM BIOPHYS ACTA, V1107, P283, DOI 10.1016/0005-2736(92)90415-I; MILLS A, 1993, FEBS LETT, V320, P130, DOI 10.1016/0014-5793(93)80077-8; PARKER EM, 1991, J BIOL CHEM, V266, P519; PRICE LA, 1995, MOL CELL BIOL, V15, P6188; RATHS SK, 1988, J BIOL CHEM, V263, P17333; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; ROMANOS MA, 1992, YEAST, V8, P423, DOI 10.1002/yea.320080602; SANDER P, 1994, BBA-BIOMEMBRANES, V1193, P255, DOI 10.1016/0005-2736(94)90161-9; SANDER P, 1994, FEBS LETT, V344, P41, DOI 10.1016/0014-5793(94)00335-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SCHERTLER GFX, 1995, P NATL ACAD SCI USA, V92, P11578, DOI 10.1073/pnas.92.25.11578; Sherman F, 1979, METHODS YEAST GENETI; TEETER MM, 1994, J MED CHEM, V37, P2874, DOI 10.1021/jm00044a008; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002	42	77	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15553	15561		10.1074/jbc.272.24.15553	http://dx.doi.org/10.1074/jbc.272.24.15553			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182592	hybrid			2022-12-27	WOS:A1997XE03400075
J	Jutras, I; Seidah, NG; Reudelhuber, TL; Brechler, V				Jutras, I; Seidah, NG; Reudelhuber, TL; Brechler, V			Two activation states of the prohormone convertase PC1 in the secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPROTEIN CONVERTASES; ATT-20 CELLS; HUMAN PRORENIN; PROOPIOMELANOCORTIN; BIOSYNTHESIS; PROTEIN; IDENTIFICATION; CONVERSION; SEQUENCE; ENZYMES	PC1, a neuroendocrine member of the prohormone convertase family of serine proteinases, is implicated in the processing of proproteins in the secretory pathway. PC1 is synthesized as a zymogen and cleaves not only its own profragment in the endoplasmic reticulum, but a subset of protein substrates in the Golgi apparatus and in the Golgi-distal compartments of the regulated secretory pathway. Likewise, mouse PC1 (mPC1) has previously been shown to cleave human prorenin in GH4 cells (that contain secretory granules) while being unable to cleave prorenin in cells, such as Chinese hamster ovary (CHO) or BSC-40, which are devoid of secretory granules. In the current study, we show that removal of a C-terminal tail of mPC1 allows the efficient cleavage of prorenin in the constitutive secretory pathway of CHO cells. The C-terminal tail thus appears to act as an inhibitor of PCI activity against certain substrates in the endoplasmic reticulum and Golgi apparatus, and its removal, which occurs naturally in secretory granules, may explain the observed granule-specific processing of certain proproteins. These results also demonstrate that PC1 is present in a partially active state prior to the secretory granules where it is processed to a maximally active state.	INST RECH CLIN MONTREAL, LAB MOL BIOCHEM HYPERTENS, MONTREAL, PQ H2W 1R7, CANADA; INST RECH CLIN MONTREAL, BIOCHEM NEUROENDOCRINOL LAB, MONTREAL, PQ H2W 1R7, CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal			Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342				BENJANNET S, 1995, J NEUROCHEM, V64, P2303; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BRAKS JAM, 1994, CELL, V78, P263, DOI 10.1016/0092-8674(94)90296-8; Brechler V, 1996, J BIOL CHEM, V271, P20636, DOI 10.1074/jbc.271.34.20636; CHU WN, 1990, MOL ENDOCRINOL, V4, P1905, DOI 10.1210/mend-4-12-1905; CHU WN, 1992, HYPERTENSION, V20, P782, DOI 10.1161/01.HYP.20.6.782; DeBie I, 1996, J CELL BIOL, V135, P1261, DOI 10.1083/jcb.135.5.1261; FRITZ LC, 1987, J BIOL CHEM, V262, P12409; GOODMAN LJ, 1994, BIOCHEM BIOPH RES CO, V201, P795, DOI 10.1006/bbrc.1994.1771; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Mercure C, 1996, HYPERTENSION, V28, P840, DOI 10.1161/01.HYP.28.5.840; Reudelhuber Timothy L., 1995, P1621; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; SCHMIDT WK, 1995, MOL BIOL CELL, V6, P1271, DOI 10.1091/mbc.6.10.1271; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; YI Z, 1993, J BIOL CHEM, V268, P5615; ZHOU A, 1994, J BIOL CHEM, V269, P17440; ZHOU A, 1995, J BIOL CHEM, V270, P21509, DOI 10.1074/jbc.270.37.21509; ZHOU Y, 1994, J BIOL CHEM, V269, P18408; ZHOU Y, 1995, J BIOL CHEM, V270, P24702, DOI 10.1074/jbc.270.42.24702; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641	29	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15184	15188		10.1074/jbc.272.24.15184	http://dx.doi.org/10.1074/jbc.272.24.15184			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182540	hybrid			2022-12-27	WOS:A1997XE03400023
J	Milev, P; Fischer, D; Haring, M; Schulthess, T; Margolis, RK; ChiquetEhrismann, R; Margolis, RU				Milev, P; Fischer, D; Haring, M; Schulthess, T; Margolis, RK; ChiquetEhrismann, R; Margolis, RU			The fibrinogen-like globe of tenascin-C mediates its interactions with neurocan and phosphacan/protein-tyrosine phosphatase-zeta/beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; CELL-ADHESION MOLECULES; LINKED OLIGOSACCHARIDES; PROTEIN; BINDING; BRAIN; DOMAIN; EXPRESSION; CYTOTACTIN; VARIANTS	Two nervous tissue-specific chondroitin sulfate proteoglycans, neurocan and phosphacan (the extracellular domain of protein-tyrosine phosphatase zeta/P), are high-affinity ligands of tenascin-C. Using portions of tenascin-C expressed as recombinant proteins in human fibrosarcoma cells, we have demonstrated both by direct radioligand binding assays and inhibition studies that phosphacan binding is retained in all deletion variants except those lacking the fibrinogen-like globe and that phosphacan binds to this single domain with nearly the same affinity (K-d similar to 12 nM) as to native or recombinant tenascin-C. However, maximum binding of neurocan requires both the fibrinogen globe and some of the adjacent fibronectin type III repeats. Binding of phosphacan and neurocan to intact tenascin-C, and of phosphacan to the fibrinogen globe, is significantly increased in the presence of calcium. Chondroitinase treatment of the proteoglycans did not affect their binding to either native tenascin-C or to any of the recombinant proteins, demonstrating that these interactions are: mediated by the proteoglycan core proteins rather than through the glycosaminoglycan chains. These results are also consistent with rotary shadowing electron micrographs that show phosphacan as a rod terminated at one end by a globular domain that is frequently seen apposed to the fibrinogen globe in mixtures of phosphacan and tenascin-C, C6 glioma cells adhere to and spread on deletion variants of tenascin-C containing only the epidermal growth factor-like domains or the fibronectin type III repeats and the fibrinogen globe, In both cases cell adhesion was inhibited by similar concentrations of phosphacan, demonstrating that the fibrinogen globe is not necessary for this effect, which is apparently mediated by a direct action of phosphacan on the cells rather than by its interaction with the proteoglycan binding site on tenascin-C.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND; UNIV BASEL,BIOCTR,CH-4056 BASEL,SWITZERLAND; SUNY HLTH SCI CTR,DEPT PHARMACOL,BROOKLYN,NY 11203	New York University; Friedrich Miescher Institute for Biomedical Research; University of Basel; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013876, R01NS009348] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-00129] Funding Source: Medline; NINDS NIH HHS [NS-13876, NS-09348] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AUKHIL I, 1993, J BIOL CHEM, V268, P2542; BAOMBAGULEY T, 1987, J BIOL CHEM, V262, P1927; CHIQUETEHRISMANN R, 1988, CELL, V53, P383, DOI 10.1016/0092-8674(88)90158-4; DANG CV, 1985, J BIOL CHEM, V260, P9713; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FISCHER D, 1995, J BIOL CHEM, V270, P3378, DOI 10.1074/jbc.270.7.3378; FISCHER D, 1997, IN PRESS J CELL SCI; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; GRUMET M, 1994, J BIOL CHEM, V269, P12142; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; Hansen JE, 1996, NUCLEIC ACIDS RES, V24, P248, DOI 10.1093/nar/24.1.248; HOFFMAN S, 1988, J CELL BIOL, V106, P519, DOI 10.1083/jcb.106.2.519; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JONES FS, 1989, P NATL ACAD SCI USA, V86, P1905, DOI 10.1073/pnas.86.6.1905; JONES FS, 1996, TENASCIN COUNTERADHE, P1; JOSHI P, 1993, J CELL SCI, V106, P389; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; KRUSIUS T, 1986, J BIOL CHEM, V261, P8237; KRUSIUS T, 1987, BIOCHEM J, V245, P229, DOI 10.1042/bj2450229; LEVY JB, 1993, J BIOL CHEM, V268, P10573; Maeda N, 1996, DEVELOPMENT, V122, P647; Margolis RK, 1996, PERSPECT DEV NEUROBI, V3, P273; Matsushita M, 1996, J BIOL CHEM, V271, P2448, DOI 10.1074/jbc.271.5.2448; MAUREL P, 1995, DNA SEQUENCE, V5, P323, DOI 10.3109/10425179509030989; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; MILEV P, 1995, J BIOL CHEM, V270, P24650, DOI 10.1074/jbc.270.42.24650; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; Milev P, 1996, J BIOL CHEM, V271, P15716, DOI 10.1074/jbc.271.26.15716; MORGELIN M, 1995, BIOCHEM J, V307, P595; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PAULSSON M, 1987, BIOCHEM J, V245, P763, DOI 10.1042/bj2450763; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; PRIETO AL, 1992, J CELL BIOL, V119, P663, DOI 10.1083/jcb.119.3.663; RAUCH U, 1992, J BIOL CHEM, V267, P19536; RAUCH U, 1991, J BIOL CHEM, V266, P14785; Sakurai T, 1996, J NEUROSCI RES, V43, P694, DOI 10.1002/(SICI)1097-4547(19960315)43:6<694::AID-JNR6>3.3.CO;2-9; SCHENK S, 1994, METHOD ENZYMOL, V245, P52; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; TUCKER RP, 1994, DEVELOPMENT, V120, P637; WRIGHT DW, 1988, J ULTRA MOL STRUCT R, V100, P224, DOI 10.1016/0889-1605(88)90039-0	41	82	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15501	15509		10.1074/jbc.272.24.15501	http://dx.doi.org/10.1074/jbc.272.24.15501			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182584	hybrid			2022-12-27	WOS:A1997XE03400067
J	Yan, Y; Shay, JW; Wright, WE; Mumby, MC				Yan, Y; Shay, JW; Wright, WE; Mumby, MC			Inhibition of protein phosphatase activity induces p53-dependent apoptosis in the absence of p53 transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; CASEIN KINASE-II; WILD-TYPE P53; DNA-BINDING FUNCTION; LARGE-T-ANTIGEN; OKADAIC ACID; TRANSCRIPTIONAL ACTIVATION; IN-VITRO; MAMMALIAN-CELLS; CYCLIN-G	Inhibitors of type 1 and type 2A protein phosphatases were used to examine the involvement of protein phosphorylation in regulating the functions of endogenous p53. Exposure of Balb/c 3T3 cells to okadaic acid, tin inhibitor of protein phosphatases 1 and 2A, increased the phosphorylation of p53 without changing p53 levels, Okadaic acid treatment enhanced the binding of p53 to a consensus DNA target sequence and caused a 5-8-fold increase in p53 transcriptional activity. Transient expression of SV40 small tumor antigen, a specific inhibitor of protein phosphatase 2A, caused a 4-fold increase in p53 transcriptional activity. Incubation of Balb/c 3T3 cells with okadaic acid also induced programmed cell death in a dose-and time-dependent manner. Decreases in viability, morphological changes, and the appearance of DNA fragmentation were dependent on p53 since cells lacking functional p53 were resistant to okadaic acid-induced apoptosis. The p53-dependent apoptosis induced by okadaic acid was rapid and did not require p53 transcriptional activity. The fact that SV40 small tumor antigen did not induce apoptosis provides additional evidence that p53 transcriptional activity is not sufficient for p53-mediated apoptosis. These results indicate that signaling pathways involving protein phosphorylation play critical roles in controlling the apoptotic activity of p53. Furthermore, a basal level of protein phosphatase 1 or 2A activity is necessary to prevent p53-dependent apoptosis.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Shay, Jerry W/F-7878-2011		NHLBI NIH HHS [HL31107] Funding Source: Medline; NIGMS NIH HHS [GM49505] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031107] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049505] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDISON C, 1990, ONCOGENE, V5, P423; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUCHS B, 1995, EUR J BIOCHEM, V228, P625, DOI 10.1111/j.1432-1033.1995.0625m.x; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GJERTSEN BT, 1995, BBA-MOL CELL RES, V1269, P187, DOI 10.1016/0167-4889(95)00117-B; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Hansen RS, 1996, ONCOGENE, V13, P995; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hecker D, 1996, ONCOGENE, V12, P953; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAMAL S, 1995, ONCOGENE, V10, P2095; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KIGUCHI K, 1994, CELL GROWTH DIFFER, V5, P995; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1994, J LAB CLIN MED, V123, P817; LI YC, 1991, MOL CELL BIOL, V11, P1883, DOI 10.1128/MCB.11.4.1883; MAYR GA, 1995, CANCER RES, V55, P2410; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MIYASHITA T, 1995, CELL, V80, P293; MULLER E, 1995, ONCOGENE, V10, P1175; MULLER E, 1993, ONCOGENE, V8, P2193; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PRICE BD, 1995, ONCOGENE, V11, P73; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sambrook J., 2002, MOL CLONING LAB MANU; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; STEPHEN CW, 1992, J MOL BIOL, V225, P1; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YATSUNAMI J, 1993, CANCER RES, V53, P239; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZHANG W, 1994, CANCER RES, V54, P4448	68	114	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15220	15226		10.1074/jbc.272.24.15220	http://dx.doi.org/10.1074/jbc.272.24.15220			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182545	hybrid			2022-12-27	WOS:A1997XE03400028
J	Eid, JE; SollnerWebb, B				Eid, JE; SollnerWebb, B			ST-2, a telomere and subtelomere duplex and g-strand binding protein activity in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ARABIDOPSIS-THALIANA; PLASMODIUM-BERGHEI; DNA QUADRUPLEXES; RICH STRAND; YEAST; SEQUENCE; RAP1; REPEAT; IDENTIFICATION	From Trypanosoma brucei, we identified ST-2, a protein complex that interacts with telomeric DNA and exhibits novel features. It binds specifically to the double-stranded telomere repeats (TTAGGG) and more tightly to the subtelomere 29-base pair elements that separate the telomere repeats from their proximal telomere-associated sequences, Interestingly, ST-2 showed still greater affinity for the G-rich strand of the telomere present either as an overhang or in a single-stranded form, but it exhibited the highest affinity for the G-rich strand of the subtelomere repeats. The binding characteristics of ST-2 are complementary to those of ST-1, a 39-kDa polypeptide we previously identified in T. brucei (Eid, J., and Sollner-Webb, B. (1995) Mol. Cell. Biol. 15, 389-397) that binds preferentially to the C-rich strands of the subtelomere and telomere repeats, UV cross-linking revealed five polypeptides of ST-2 that bind directly to the G-rich strand of the DNA, one of which is phosphorylated, Furthermore, the presence of ST-1 is critical for ST-2 complex binding both to the G-rich strand and to the duplex DNA, evidently as part of the ST-2 complex, This indicates that when binding to the duplex subtelomere and telomere repeats, ST-2 may act as a protein bridge with its ST-1 subunit binding to the C-rich strand and its five other cross-linkable polypeptides binding to the G-rich strand. Such an association could serve to hold the genomic subtelomeric and telomeric sequences in a partially single-stranded configuration to facilitate the recombinational events in this region that are crucial to the parasite.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034231] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34231] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACKBURN EH, 1981, P NATL ACAD SCI-BIOL, V78, P2263, DOI 10.1073/pnas.78.4.2263; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BORST P, 1991, IMMUNOL TODAY, V12, pA29; BRIGATI C, 1993, MOL CELL BIOL, V13, P1306, DOI 10.1128/MCB.13.2.1306; CARDENAS ME, 1993, GENE DEV, V7, P883, DOI 10.1101/gad.7.5.883; CHENG JF, 1991, NUCLEIC ACIDS RES, V19, P149, DOI 10.1093/nar/19.1.149; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COREN JS, 1991, MOL CELL BIOL, V11, P2282, DOI 10.1128/MCB.11.4.2282; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; CROSS S, 1990, NUCLEIC ACIDS RES, V18, P6649, DOI 10.1093/nar/18.22.6649; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; EID JE, 1995, MOL CELL BIOL, V15, P389, DOI 10.1128/MCB.15.1.389; ENOMOTO S, 1994, GENETICS, V136, P757; FANG GW, 1991, NUCLEIC ACIDS RES, V19, P5515, DOI 10.1093/nar/19.20.5515; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; Field H, 1996, EXP PARASITOL, V83, P155, DOI 10.1006/expr.1996.0060; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; GILSON E, 1994, NUCLEIC ACIDS RES, V22, P5310, DOI 10.1093/nar/22.24.5310; GIRALDO R, 1994, P NATL ACAD SCI USA, V91, P7658, DOI 10.1073/pnas.91.16.7658; GIRALDO R, 1994, EMBO J, V13, P2411, DOI 10.1002/j.1460-2075.1994.tb06526.x; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GREIDER CW, 1994, CURR OPIN GENET DEV, V4, P203, DOI 10.1016/S0959-437X(05)80046-2; GUZMAN PA, 1994, MICROBIOL-UK, V140, P551, DOI 10.1099/00221287-140-3-551; HORN D, 1995, CELL, V83, P555, DOI 10.1016/0092-8674(95)90095-0; KONKEL LMC, 1995, P NATL ACAD SCI USA, V92, P5558, DOI 10.1073/pnas.92.12.5558; KYRION G, 1993, GENE DEV, V7, P1146, DOI 10.1101/gad.7.7a.1146; LEJNINE S, 1995, P NATL ACAD SCI USA, V92, P2393, DOI 10.1073/pnas.92.6.2393; LEROY JL, 1994, NUCLEIC ACIDS RES, V22, P1600, DOI 10.1093/nar/22.9.1600; LIU ZP, 1995, P NATL ACAD SCI USA, V92, P6002, DOI 10.1073/pnas.92.13.6002; LIU ZP, 1991, GENE DEV, V5, P49, DOI 10.1101/gad.5.1.49; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; PETRACEK ME, 1994, EMBO J, V13, P3648, DOI 10.1002/j.1460-2075.1994.tb06672.x; PONZI M, 1992, NUCLEIC ACIDS RES, V20, P4491, DOI 10.1093/nar/20.17.4491; PONZI M, 1990, MOL BIOCHEM PARASIT, V41, P73, DOI 10.1016/0166-6851(90)90098-7; RHODES D, 1995, CURR OPIN STRUC BIOL, V5, P311, DOI 10.1016/0959-440X(95)80092-1; RICHARDS EJ, 1992, NUCLEIC ACIDS RES, V20, P4039, DOI 10.1093/nar/20.15.4039; ROUYER F, 1990, EMBO J, V9, P505, DOI 10.1002/j.1460-2075.1990.tb08137.x; RUDENKO G, 1995, CELL, V83, P547, DOI 10.1016/0092-8674(95)90094-2; SANTORI F, 1994, RES MICROBIOL, V145, P519, DOI 10.1016/0923-2508(94)90029-9; SHENG H, 1995, MOL CELL BIOL, V15, P1144; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; TUMMERUP H, 1994, MOL CELL BIOL, V14, P5777; VIGNAIS ML, 1989, J BIOL CHEM, V264, P8463; WANG WL, 1992, NUCLEIC ACIDS RES, V20, P6621, DOI 10.1093/nar/20.24.6621; WEIDEN M, 1991, MOL CELL BIOL, V11, P3823, DOI 10.1128/MCB.11.8.3823; WILKIE AOM, 1991, CELL, V64, P595, DOI 10.1016/0092-8674(91)90243-R; WRIGHT JH, 1992, GENE DEV, V6, P197, DOI 10.1101/gad.6.2.197; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; ZENTGRAF U, 1995, PLANT MOL BIOL, V27, P467, DOI 10.1007/BF00019314	52	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14927	14936		10.1074/jbc.272.23.14927	http://dx.doi.org/10.1074/jbc.272.23.14927			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169464	hybrid			2022-12-27	WOS:A1997XC32700061
J	Hara, S; Swigart, P; Jones, D; Cockcroft, S				Hara, S; Swigart, P; Jones, D; Cockcroft, S			The first 5 amino acids of the carboxyl terminus of phosphatidylinositol transfer protein (PITP) alpha play a critical role in inositol lipid signaling - Transfer activity of PITP is essential but not sufficient for restoration of phospholipase C signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN; CA2+-ACTIVATED SECRETION; SPECIFICITY; BINDING	Phosphatidylinositol transfer protein (PITP) is essential for phospholipase C signaling and for constitutive and regulated vesicular traffic. PITP has a single lipid-binding site that can reversibly bind phosphatidylinositol (PI) and phosphatidylcholine (PC) and transfer these lipids between membrane compartments in vitro. The role of the carboxyl terminus was examined by comparing wild-type PITP alpha with PITP alpha in which 5, 10, and 20 amino acids were deleted from the C terminus. Delta 5- and Delta 10-PITP had reduced PI and PC transfer activities compared with wild-type PITP, with the effect on PI transfer being more marked than that on PC transfer. Delta 20-PITP was inactive at all concentrations tested. All three truncated mutants were unable to restore G-protein-mediated phospholipase C beta stimulation in HL-60 cells. Delta 5- and Delta 10-PITP, but not Delta 20-PITP, inhibited the signaling function of wild-type protein without any effect on lipid transfer in vitro. We conclude that (a) the carboxyl terminus of PITP plays a critical role in phospholipase C signaling; (b) the transfer activity is not the only determining factor that dictates the restorative function of PITP in inositol lipid signaling; and (c) the dominant inhibitory effects of Delta 5- and Delta 10-PITP on wild-type PITP in phospholipase C signaling suggest the existence of a receptor for PITP.	UNIV LONDON UNIV COLL, DEPT PHYSIOL, LONDON WC1E 6JJ, ENGLAND	University of London; University College London			Cockcroft, Shamshad/F-9480-2011	Cockcroft, Shamshad/0000-0002-5731-476X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALB JG, 1995, P NATL ACAD SCI USA, V92, P8826, DOI 10.1073/pnas.92.19.8826; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; Cunningham E, 1996, P NATL ACAD SCI USA, V93, P6589, DOI 10.1073/pnas.93.13.6589; CUNNINGHAM E, 1995, CURR BIOL, V5, P775, DOI 10.1016/S0960-9822(95)00154-0; Fensome A, 1996, CURR BIOL, V6, P730, DOI 10.1016/S0960-9822(09)00454-0; Fukami K, 1996, J BIOL CHEM, V271, P2646, DOI 10.1074/jbc.271.5.2646; GEIJTENBEEK TBH, 1994, BBA-LIPID LIPID MET, V1213, P309, DOI 10.1016/0005-2760(94)00063-8; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HELMKAMP GM, 1990, SUBCELLULAR BIOCH, P129; KAUFFMANNZEH A, 1995, SCIENCE, V268, P1188, DOI 10.1126/science.7761838; LOPEZ MC, 1994, J CELL BIOL, V125, P113, DOI 10.1083/jcb.125.1.113; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; SKINNER HB, 1993, EMBO J, V12, P4775, DOI 10.1002/j.1460-2075.1993.tb06166.x; SOMERHARJU P, 1983, BIOCHIM BIOPHYS ACTA, V731, P186, DOI 10.1016/0005-2736(83)90008-1; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; TIMMERMANSHEREIJGERS JLPM, 1995, J BIOL CHEM, V270, P14263, DOI 10.1074/jbc.270.24.14263; Tremblay JM, 1996, J BIOL CHEM, V271, P21075, DOI 10.1074/jbc.271.35.21075; VANPARIDON PA, 1987, BIOCHIM BIOPHYS ACTA, V903, P68, DOI 10.1016/0005-2736(87)90156-8; VANPARIDON PA, 1987, BIOCHIM BIOPHYS ACTA, V898, P172, DOI 10.1016/0005-2736(87)90035-6; VIHTELIC TS, 1993, J CELL BIOL, V122, P1013, DOI 10.1083/jcb.122.5.1013; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73	23	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14908	14913		10.1074/jbc.272.23.14908	http://dx.doi.org/10.1074/jbc.272.23.14908			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169461	hybrid			2022-12-27	WOS:A1997XC32700058
J	Honkakoski, P; Negishi, M				Honkakoski, P; Negishi, M			Characterization of a phenobarbital-responsive enhancer module in mouse P450 Cyp2b10 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATION; GLYCOPROTEIN GENE; RAT-LIVER; INVITRO TRANSCRIPTION; TRANSGENIC MICE; CYTOCHROME-P-450; EXPRESSION; ELEMENTS; INDUCTION; PROMOTER	Induction of drug- and carcinogen-metabolizing cytochrome P450s by xenobiotic chemicals is a common cellular defense mechanism, usually leading to increased detoxification of xenobiotics but sometimes, paradoxically, to formation of more toxic and carcinogenic metabolites. Phenobarbital (PB) is an archetypal representative for chemicals including industrial solvents, pesticides, plant products, and clinically used drugs that induce several genes within CYP subfamilies 2B, 2A, 2C, and 3A in rodents and humans, Although the transcription of these CYP genes is activated by PB, the associated molecular mechanisms have not yet been elucidated. Here we have analyzed, in detail, enhancer activity of a far upstream region of mouse Cyp2b10 gene and report a 132-base pair PB-responsive enhancer module (PBREM) with a 33-base pair core element containing binding sites for nuclear factor I- and nuclear receptor-like factors. Mutations of these binding sites abolish the ability of PBREM to respond to inducers in mouse primary hepatocyte.	NIEHS,REPROD & DEV TOXICOL LAB,PHARMACOGENET SECT,NIH,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Honkakoski, Paavo/AAJ-1278-2020; Negishi, Masahiko/F-7805-2019	Honkakoski, Paavo/0000-0002-4332-3577; Negishi, Masahiko/0000-0002-2076-8928				ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONNEY AH, 1967, PHARMACOL REV, V19, P317; ESCALANTE B, 1991, SCIENCE, V251, P799, DOI 10.1126/science.1846705; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FOURNIER T, 1994, J BIOL CHEM, V269, P27175; GED C, 1991, BIOCHIM BIOPHYS ACTA, V1088, P433, DOI 10.1016/0167-4781(91)90138-C; GUENGERICH FP, 1988, CANCER RES, V48, P2946; HATTORI M, 1990, DNA CELL BIOL, V9, P777, DOI 10.1089/dna.1990.9.777; HE JS, 1991, J BIOL CHEM, V266, P7864; HONKAKOSKI P, 1992, BIOCHEM J, V285, P979, DOI 10.1042/bj2850979; Honkakoski P, 1996, J BIOL CHEM, V271, P9746, DOI 10.1074/jbc.271.16.9746; HONKAKOSKI P, 1992, BIOCHEM PHARMACOL, V42, P2121; Huss JM, 1996, P NATL ACAD SCI USA, V93, P4666, DOI 10.1073/pnas.93.10.4666; IZBAN MG, 1989, J BIOL CHEM, V264, P9171; KENDE AS, 1985, MOL PHARMACOL, V28, P445; KIM J, 1991, BIOCHEMISTRY-US, V30, P10287, DOI 10.1021/bi00106a029; KOCAREK TA, 1990, MOL PHARMACOL, V38, P440; LAKSO M, 1991, EUR J BIOCHEM, V195, P477, DOI 10.1111/j.1432-1033.1991.tb15728.x; LECAM A, 1994, J BIOL CHEM, V269, P21532; LEE YM, 1993, MOL CELL BIOL, V13, P432, DOI 10.1128/MCB.13.1.432; LIANG QW, 1995, J BIOL CHEM, V270, P18606, DOI 10.1074/jbc.270.31.18606; Luc PV, 1996, BIOCHEM PHARMACOL, V51, P345, DOI 10.1016/0006-2952(95)02190-6; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MATSUNAGA T, 1990, BIOCHEMISTRY-US, V29, P1329, DOI 10.1021/bi00457a032; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; ODDOS J, 1989, NUCLEIC ACIDS RES, V17, P8877, DOI 10.1093/nar/17.21.8877; PALMER CNA, 1994, J BIOL CHEM, V269, P18083; Park Y, 1996, DNA CELL BIOL, V15, P693, DOI 10.1089/dna.1996.15.693; Park YK, 1996, J BIOL CHEM, V271, P23725, DOI 10.1074/jbc.271.39.23725; PORTER TD, 1991, J BIOL CHEM, V266, P13469; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; PRABHU L, 1995, P NATL ACAD SCI USA, V92, P9628, DOI 10.1073/pnas.92.21.9628; RAMSDEN R, 1993, J BIOL CHEM, V268, P21722; RATAJCZAK T, 1992, J BIOL CHEM, V267, P11111; SHEPHARD EA, 1994, DNA CELL BIOL, V13, P793, DOI 10.1089/dna.1994.13.793; SIDHU JS, 1995, J BIOL CHEM, V270, P12762, DOI 10.1074/jbc.270.21.12762; SNYDER R, 1979, PHARMACOL THERAPEUT, V7, P203, DOI 10.1016/0163-7258(79)90030-5; TELHADA MB, 1992, ARCH BIOCHEM BIOPHYS, V298, P715, DOI 10.1016/0003-9861(92)90471-8; TROTTIER E, 1995, GENE, V158, P263, DOI 10.1016/0378-1119(94)00916-G; UPADHYA P, 1992, NUCLEIC ACIDS RES, V20, P557, DOI 10.1093/nar/20.3.557; Waterman MR, 1986, CYTOCHROME P450 STRU, P345; WAXMAN DJ, 1992, BIOCHEM J, V281, P577, DOI 10.1042/bj2810577; WHITLOCK JP, 1986, ANNU REV PHARMACOL, V26, P333; WONG G, 1989, J BIOL CHEM, V264, P2920; YOSHIOKA H, 1990, J BIOL CHEM, V265, P14612	46	131	139	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14943	14949		10.1074/jbc.272.23.14943	http://dx.doi.org/10.1074/jbc.272.23.14943			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169466	hybrid			2022-12-27	WOS:A1997XC32700063
J	Krupnick, JG; Goodman, OB; Keen, JH; Benovic, JL				Krupnick, JG; Goodman, OB; Keen, JH; Benovic, JL			Arrestin/clathrin interaction - Localization of the clathrin binding domain of nonvisual arrestins to the carboxyl terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; VISUAL ARRESTIN; SUBCELLULAR-DISTRIBUTION; RHODOPSIN INTERACTION; 48-KDA PROTEIN; SEQUESTRATION; PHOSPHORYLATION; INTERNALIZATION; EXPRESSION; FAMILY	We have recently demonstrated that the nonvisual arrestins, beta-arrestin and arrestin3, interact with high affinity and stoichiometrically with clathrin, and we postulated that this interaction mediates internalization of G protein-coupled receptors (Goodman, O.B., Jr., Krupnick, J. G., Santini, F., Gurevich, V. V., Penn, R. B., Gagnon, A. W., Keen, J. H., and Benovic, J. L. (1996) Nature 383, 447-450). In this study, we localized the clathrin binding domain of arrestin3 using a variety of approaches. Truncation mutagenesis demonstrated that the COOH-terminal half of arrestin3 is required for clathrin interaction. Assessment of the clathrin binding properties of various glutathione S-transferase-arrestin3 fusion proteins indicated that the predominant clathrin binding domain is contained within residues 367-385. Alanine scanning mutagenesis further localized this domain to residues 371-379, and site-directed mutagenesis demonstrated the critical importance of both hydrophobic (Leu-373, Ile-374, and Phe-376) and acidic (Glu-375 and Glu-377) residues in the arrestin3/clathrin interaction. These results are complementary to the observation that hydrophobic and basic residues in clathrin are critical for its interaction with nonvisual arrestins (Goodman, O. B., Jr., Krupnick, J. G., Gurevich, V.V., Benovic, J. L., and Keen, J. H. (1997) J. Biol. Chem 272, 15017-15022). Lastly, an arrestin3;mutant in which Leu-378, Ile-374, and Phe-376 were mutated to Ala was significantly defective in its ability to promote beta(2)-adrenergic receptor internalization in COS-1 cells when compared with wild-type arrestin3. Taken together, these results implicate a discrete region of arrestin3 in high affinity binding to clathrin, an interaction critical for agonist-promoted internalization of the beta(2)-adrenergic receptor.	THOMAS JEFFERSON UNIV,KIMMEL CANC INST,DEPT MOL PHARMACOL & BIOCHEM,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,KIMMEL CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University				Goodman, Oscar/0000-0002-0882-3621	NIGMS NIH HHS [GM44944, GM47417, GM28526] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM047417, R01GM044944, R01GM047417, R01GM028526] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Berry SA, 1996, MOL PHARMACOL, V50, P306; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; CRAFT CM, 1994, J BIOL CHEM, V269, P4613; DUA HS, 1992, CURR EYE RES, V11, P107, DOI 10.3109/02713689208999519; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; FONSECA MI, 1995, J BIOL CHEM, V270, P8902, DOI 10.1074/jbc.270.15.8902; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; GOODMAN OB, 1995, J BIOL CHEM, V270, P23768, DOI 10.1074/jbc.270.40.23768; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Krueger KM, 1997, J BIOL CHEM, V272, P5; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MALOTEAUX JM, 1994, BIOCHEM PHARMACOL, V47, P77, DOI 10.1016/0006-2952(94)90439-1; Menard L, 1996, BIOCHEMISTRY-US, V35, P4155, DOI 10.1021/bi952961+; MULLER S, 1995, BIOCHEM SOC T, V23, P141; MURAKAMI A, 1993, FEBS LETT, V334, P203, DOI 10.1016/0014-5793(93)81712-9; Pak Y, 1996, MOL PHARMACOL, V50, P1214; PENN RB, 1997, HDB PHYSL; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; RAPOPORT B, 1992, MOL CELL ENDOCRINOL, V84, pR39, DOI 10.1016/0303-7207(92)90038-8; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; Slowiejko DM, 1996, J NEUROCHEM, V66, P186; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; Tolbert LM, 1996, J BIOL CHEM, V271, P17335, DOI 10.1074/jbc.271.29.17335; TSUGA H, 1994, J BIOL CHEM, V269, P32522; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; YANG J, 1995, MOL PHARMACOL, V48, P477; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302; ZOZULYA SA, 1990, PROTEIN ENG, V3, P453, DOI 10.1093/protein/3.5.453	46	235	240	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					15011	15016		10.1074/jbc.272.23.15011	http://dx.doi.org/10.1074/jbc.272.23.15011			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169476	hybrid			2022-12-27	WOS:A1997XC32700073
J	Pirozzi, G; McConnell, SJ; Uveges, AJ; Carter, JM; Sparks, AB; Kay, BK; Fowlkes, DM				Pirozzi, G; McConnell, SJ; Uveges, AJ; Carter, JM; Sparks, AB; Kay, BK; Fowlkes, DM			Identification of novel human WW domain-containing proteins by cloning of ligand targets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-CHANNEL; LIDDLES SYNDROME; BETA-SUBUNIT; BINDING; EXPRESSION; BRAIN; GENE; SYNAPTOTAGMIN; HYPERTENSION; DYSTROPHIN	A recently described protein module consisting of 35-40 semiconserved residues, termed the WW domain, has been identified in a number of diverse proteins in eluding dystrophin and Yes-associated protein (YAP). Two putative ligands of YAP, termed WBP-1 and WBP-2, have been found previously to contain several short peptide regions consisting of PPPPY residues (PY motif) that mediate binding to the WW domain of YAP. Although the function(s) of the WW domain remain to be elucidated, these observations strongly support a role for the WW domain in protein-protein interactions. Here we report the isolation of three novel human cDNAs encoding a total of nine WW domains, using a newly developed approach termed COLT (cloning of ligand targets), in which the rapid cloning of modular protein domains is accomplished by screening cDNA expression libraries with specific peptide ligands. Two of the new genes identified appear to be members of a family of proteins, including Rsp5 and Nedd-4, which have ubiquitin-protein ligase activity. In addition, we demonstrate that peptides corresponding to PY and PY-like motifs present in several known signaling or regulatory proteins, including RasGAP, AP-2, p53BP-2 (p53-binding protein-2), interleukin-6 receptor-alpha, chloride channel CLCN5, and epithelial sodium channel ENaC, can selectively bind to certain of these novel WW domains.	UNIV N CAROLINA, DEPT BIOL, CURRICULUM GENET & MOL BIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Pirozzi, G (corresponding author), CYTOGEN CORP, 201 COLL RD E CN 5309, PRINCETON, NJ 08540 USA.		Carter, John Mark/P-9919-2019; Carter, John Mark/K-2485-2015	Carter, John Mark/0000-0001-8251-4168; Carter, John Mark/0000-0001-8251-4168				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDRE B, 1994, BIOCHEM BIOPH RES CO, V205, P1201, DOI 10.1006/bbrc.1994.2793; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; CHEN JK, 1993, J AM CHEM SOC, V115, P12591, DOI 10.1021/ja00079a051; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DUILIO A, 1991, NUCLEIC ACIDS RES, V19, P5269, DOI 10.1093/nar/19.19.5269; Einbond A, 1996, FEBS LETT, V384, P1, DOI 10.1016/0014-5793(96)00263-3; Gamier L, 1996, NATURE, V381, P744, DOI 10.1038/381744a0; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; Helps NR, 1995, FEBS LETT, V377, P295, DOI 10.1016/0014-5793(95)01347-4; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; HOFMANN K, 1995, FEBS LETT, V358, P153, DOI 10.1016/0014-5793(94)01415-W; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; Lu KP, 1996, NATURE, V380, P544; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; MORI S, 1992, J BIOL CHEM, V267, P6429; PARENT LJ, 1995, J VIROL, V69, P5455, DOI 10.1128/JVI.69.9.5455-5460.1995; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Sudol M, 1996, TRENDS BIOCHEM SCI, V21, P161, DOI 10.1016/0968-0004(96)30018-2; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; SUGITA T, 1990, J EXP MED, V171, P2001, DOI 10.1084/jem.171.6.2001; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WOYCHIK RP, 1985, NATURE, V318, P36, DOI 10.1038/318036a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	49	144	157	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14611	14616		10.1074/jbc.272.23.14611	http://dx.doi.org/10.1074/jbc.272.23.14611			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169421	Green Published, hybrid			2022-12-27	WOS:A1997XC32700018
J	Deacon, K; Blank, JL				Deacon, K; Blank, JL			Characterization of the mitogen-activated protein kinase kinase 4 (MKK4)/c-Jun NH2-terminal kinase 1 and MKK3/p38 pathways regulated by MEK kinases 2 and 3 - MEK kinase 3 activates MKK3 but does not cause activation of p38 kinase in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; C-JUN; B-RAF; POTENTIAL MEDIATOR; MAMMALIAN-CELLS; GROWTH-FACTOR; BOVINE BRAIN; MAP KINASES; STRESS; PHOSPHORYLATION	We previously reported the isolation of cDNAs encoding two mammalian mitogen-activated protein kinase (MAPK)/extracellular-regulated kinase (ERK) kinase kinases, designated MEKK2 and MEKK3 (Blank, J.L., Gerwins, P., Elliott, E.M., Sather, S. and Johnson, G.L. (1996) J. Biol. Chem. 271, 5361-5368). Tn the present study, cotransfection experiments were used to examine the regulation by MEKK2 and MEKK3 of the dual specificity MAP kinase kinases, MKK3 and MKK4. MKK3 specifically phosphorylates and activates p38, whereas MKK4 phosphorylates and activates both p38 and JNK. Coexpression of MEKK2 or MEKK3 with MKK4 in COS-7 cells resulted in activation of MKK4, as assessed by enhanced autophosphorylation and by its ability to phosphorylate and activate recombinant JNK1 or p38 in vitro. MKK3 autophosphorylation and activation of p38 was also observed following coexpression of MKKS with MEKK3, but not with MEKK2. Consistent with these observations, immunoprecipitated MEKK2 directly activated recombinant MKK4 in vitro but failed to activate MKK3. The sites of activating phosphorylation in MKK3 and MKK4 were identified within kinase subdomains VIT and VIII. Replacement of Ser(189) or Thr(193) in MKK3 with Ala abolished autophosphorylation and activation of MKK3 by MEKK3. Analogous mutations in MKK4 indicated that Ser(221) and, to a lesser extent, Thr(225) were necessary for MKK4 activation by MEKK2 and MEKK3. These data indicate that MKK3 is preferentially activated by MEKK3, whereas MKK4 is activated both by MEKK2 and MEKK3. Consistent with these observations, MEKK2 and MEKK3 also activated JNK1 in vivo. However, MEKK3 failed to activate p38 when coexpressed in either the absence or presence of MKK3, indicating that MEKK3 is not coupled to p38 activation in vivo. These observations suggest that regulation of p38 and JNK1 pathways by MEKK3 may involve distinct mechanisms to prevent p38 activation but to allow JNK1 activation.	UNIV LEICESTER,SCH MED,DEPT CELL PHYSIOL & PHARMACOL,LEICESTER LE1 9HN,LEICS,ENGLAND	University of Leicester								Adler V, 1996, J BIOL CHEM, V271, P23304, DOI 10.1074/jbc.271.38.23304; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P26303, DOI 10.1074/jbc.270.44.26303; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; CATLING AD, 1994, J BIOL CHEM, V269, P30014; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coso OA, 1996, J BIOL CHEM, V271, P3963; Crespo P, 1996, ONCOGENE, V13, P455; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DUAM G, 1994, TRENDS BIOCHEM SCI, V19, P474; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hirai S, 1996, ONCOGENE, V12, P641; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Ishizuka T, 1996, J BIOL CHEM, V271, P12762, DOI 10.1074/jbc.271.22.12762; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MITCHELL FM, 1995, BIOCHEM J, V309, P381, DOI 10.1042/bj3090381; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROSSETTE C, 1996, SCIENCE, V274, P1194; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STORM SM, 1990, ONCOGENE, V5, P345; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; YAN MH, 1994, NATURE, V372, P798; YAN MH, 1994, J BIOL CHEM, V269, P19067; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	79	99	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14489	14496		10.1074/jbc.272.22.14489	http://dx.doi.org/10.1074/jbc.272.22.14489			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162092	hybrid			2022-12-27	WOS:A1997XB49200079
J	Martin, TFJ; Kowalchyk, JA				Martin, TFJ; Kowalchyk, JA			Docked secretory vesicles undergo Ca2+-activated exocytosis in a cell-free system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSTRIDIAL NEUROTOXINS; PROTEIN; FUSION; MEMBRANE; DOCKING; COMPLEX	The Ca2+-activated fusion of secretory vesicles with the plasma membrane responsible for regulated neurotransmitter and hormone secretion has previously been studied in permeable neuroendocrine cells, where requirements for ATP and cytosolic proteins were identified, As reported here, Ca2+-activated fusion mechanisms are also preserved following cell homogenization. The release of norepinephrine (NE) and other vesicle constituents from a PC12 cell membrane fraction was activated by micromolar Ca2+ (EC50 similar to 3 mu M) and exhibited a dependence upon MgATP and cytosol, Ca2+-dependent NE release was inhibited by botulinum neurotoxins and by CAPS (Ca2+-dependent activator protein for secretion) antibody implying that syntaxin, synaptobrevin, SNAP-25 (synaptosomal-associated protein of 25 kDa), and CAPS are required for regulated exocytosis in this system, The exocytosis-competent membrane fraction consisted of rapidly sedimenting dense core vesicles associated with plasma membrane fragments. Free vesicles did not release NE either in the absence or presence of plasma membranes, indicating that only docked vesicles were competent for exocytosis under the reconstitution conditions used, A cell-free system for Ca2+-activated fusion will facilitate studies on the roles of essential proteins such as syntaxin, synaptobrevin, SNAP-25, and CAPS that act at post-docking steps in the regulated exocytotic pathway.			Martin, TFJ (corresponding author), UNIV WISCONSIN, DEPT BIOCHEM, 420 HENRY MALL, MADISON, WI 53706 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK025861, R01DK040428, R01DK025861] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40428, DK25861] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Augustine GJ, 1996, ANNU REV PHARMACOL, V36, P659, DOI 10.1146/annurev.pa.36.040196.003303; Banerjee A, 1996, J BIOL CHEM, V271, P20227, DOI 10.1074/jbc.271.34.20227; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BROADIE K, 1995, NEURON, V15, P663, DOI 10.1016/0896-6273(95)90154-X; CHERNOMORDIK LV, 1995, CURR OPIN STRUC BIOL, V5, P541, DOI 10.1016/0959-440X(95)80041-7; CRABB JH, 1985, J CELL BIOL, V101, P2263, DOI 10.1083/jcb.101.6.2263; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Henkel AW, 1996, CURR OPIN NEUROBIOL, V6, P350, DOI 10.1016/S0959-4388(96)80119-X; LLINAS R, 1995, J PHYSIOL-PARIS, V89, P77, DOI 10.1016/0928-4257(96)80554-7; LOMNETH R, 1991, J NEUROCHEM, V57, P1413, DOI 10.1111/j.1471-4159.1991.tb08308.x; MACLEAN CM, 1992, BIOCHEM J, V286, P747, DOI 10.1042/bj2860747; MARTIN TFJ, 1997, IN PRESS TRENDS CELL; MARTIN TFJ, 1989, METHOD ENZYMOL, V168, P225; Niemann Heiner, 1994, Trends in Cell Biology, V4, P179, DOI 10.1016/0962-8924(94)90203-8; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Schiavo G, 1996, P NATL ACAD SCI USA, V93, P13327, DOI 10.1073/pnas.93.23.13327; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; WAGNER JA, 1985, J NEUROCHEM, V45, P1244, DOI 10.1111/j.1471-4159.1985.tb05549.x; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9	26	64	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14447	14453		10.1074/jbc.272.22.14447	http://dx.doi.org/10.1074/jbc.272.22.14447			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162085	hybrid			2022-12-27	WOS:A1997XB49200072
J	Shigematsu, H; Iwasaki, H; Otsuka, T; Ohno, Y; Arima, F; Niho, Y				Shigematsu, H; Iwasaki, H; Otsuka, T; Ohno, Y; Arima, F; Niho, Y			Role of the vav proto-oncogene product (Vav) in erythropoietin-mediated cell proliferation and phosphatidylinositol 3-kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; ERYTHROID-DIFFERENTIATION; HEMATOPOIETIC-CELLS; EXCHANGE FACTOR; KINASE PATHWAY; STEEL FACTOR; SH2 DOMAINS; RECEPTOR; ACTIVATION	The vav proto-oncogene product (Vav), which is specifically expressed in hematopoietic cells, contains multiple structural motifs commonly used by intracellular signaling molecules, Although a variety of stimuli including erythropoietin (Epo) have been shown to tyrosine phosphorylate Vav, little is known about the Vav signal transduction pathway. Here, we have investigated the role of Vav in the Epo signaling pathway by characterizing its interaction with other proteins, using the human Epo-responsive cell line, F-36P, Immunoprecipitation and immunoblot analyses have demonstrated that Vav was associated with the Epo receptor (EpoR) in an Epo-independent manner and was tyrosine-phospho rylated after Epo stimulation, Furthermore, two phosphotyrosine proteins (pp70 and pp100) co-immunoprecipitated with the regulatory subunit of phosphatidylinositol 3-kinase (PI3-kinase) (p85) were identified as EpoR and Vav, respectively. The interaction between Vav and p85 was shown to be mediated through the SH2 domains of p85 by an in vitro binding assay and confirmed by the presence of in vitro PI3-kinase activity associated with Vav, Treatment of the cells with antisense-vav and -p85 abrogated Epo induced cell proliferation and PI3-kinase activity, Finally, we found that JAK2 was associated with Vav in vivo and that Vav could be tyrosine-phosphorylated by activated JAK2 in vitro, These results suggest the possible role of JAK2 for tyro sine phosphorylation of Vav and involvement of Vav and PI3-kinase in Epo-induced proliferative signals.	KYUSHU UNIV, FAC MED, DEPT INTERNAL MED 1, FUKUOKA 812, JAPAN	Kyushu University	Shigematsu, H (corresponding author), KYUSHU UNIV, FAC MED, CTR CANC, HIGASHI KU, 3-1-1 MAIDASHI, FUKUOKA 812, JAPAN.							ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CHIBA S, 1991, BLOOD, V78, P2261; CLEVENGER CV, 1995, J BIOL CHEM, V270, P13246, DOI 10.1074/jbc.270.22.13246; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DAMEN JE, 1993, BLOOD, V81, P3204; DAMEN JE, 1993, BLOOD, V82, P2296; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; GOBERT S, 1995, BLOOD, V86, P598, DOI 10.1182/blood.V86.2.598.bloodjournal862598; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HOBERT O, 1994, J BIOL CHEM, V269, P20225; IHRE JN, 1995, NATURE, V377, P591; JONES SS, 1990, BLOOD, V76, P31; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KRANTZ SB, 1991, BLOOD, V77, P419; MACHIDE M, 1995, ONCOGENE, V11, P619; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARUYAMA K, 1994, J BIOL CHEM, V269, P5976; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1994, BLOOD, V84, P1501; MIURA O, 1994, J BIOL CHEM, V269, P614; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; MIURA Y, 1994, J BIOL CHEM, V269, P29962; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; REN HY, 1994, J BIOL CHEM, V269, P19633; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TORTI M, 1992, J BIOL CHEM, V267, P8293; WENG WK, 1994, J BIOL CHEM, V269, P32514; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	53	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14334	14340		10.1074/jbc.272.22.14334	http://dx.doi.org/10.1074/jbc.272.22.14334			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162069	hybrid			2022-12-27	WOS:A1997XB49200056
J	Shibutani, S; Takeshita, M; Grollman, AP				Shibutani, S; Takeshita, M; Grollman, AP			Translesional synthesis on DNA templates containing a single abasic site - A mechanistic study of the ''A rule''	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE INSERTION FIDELITY; APURINIC APYRIMIDINIC SITES; MISPAIR EXTENSION KINETICS; SIMIAN KIDNEY-CELLS; MAMMALIAN-CELLS; DEOXYRIBONUCLEIC-ACID; REVERSE-TRANSCRIPTASE; MUTAGENIC PROPERTIES; ESCHERICHIA-COLI; INVITRO	Site-specifically modified oligodeoxynucleotides containing a single natural abasic site or a chemically synthesized (tetrahydrofuran or deoxyribitol) model abasic site were used as templates for primer extension reactions catalyzed by the Klenow fragment of Escherichia coli DNA polymerase I or by calf thymus DNA polymerase alpha. Analysis of the fully extended products of these reactions indicated that both polymerases preferentially incorporate dAMP opposite the natural abasic site and tetrahydrofuran, while DNA templates containing the ring-opened deoxyribitol moiety block translesional synthesis, promoting sequence context-dependent deletions. The frequency of nucleotide insertion opposite the three types of abasic sites follows the order dAMP > dGMP > dCMP > dTMP. The frequency of chain extension was highest when dAMP was positioned opposite a natural abasic site. The frequency of translesional synthesis past abasic sites follows the order tetrahydrofuran > deoxyribose > deoxyribitol. The Klenow fragment promotes blunt end addition of dAMP; this reaction was much less efficient than insertion of dAMP opposite an abasic site. We conclude that the miscoding potential of a natural abasic site in vitro closely resembles that of its tetrahydrofuran analog. Ring-opened abasic sites favor deletions. Studies with polymerase alpha in vitro predict preferential incorporation of dAMP at abasic sites in mammalian cells.			Shibutani, S (corresponding author), SUNY STONY BROOK, DEPT PHARMACOL SCI, STONY BROOK, NY 11794 USA.			Shibutani, Shinya/0000-0003-4190-9512	NCI NIH HHS [CA17395] Funding Source: Medline; NIEHS NIH HHS [ES04068] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA017395, R37CA017395] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES004068] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAILLY V, 1989, BIOCHEM J, V262, P681; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; CLARK JM, 1987, J MOL BIOL, V198, P123, DOI 10.1016/0022-2836(87)90462-1; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; CREIGHTON S, 1995, J BIOL CHEM, V270, P4759, DOI 10.1074/jbc.270.9.4759; DOSANJH MK, 1991, BIOCHEMISTRY-US, V30, P11595, DOI 10.1021/bi00113a015; GENTIL A, 1990, BIOCHEM BIOPH RES CO, V173, P704, DOI 10.1016/S0006-291X(05)80092-0; GENTIL A, 1992, J MOL BIOL, V227, P981, DOI 10.1016/0022-2836(92)90513-J; GIBBS PEM, 1995, J MOL BIOL, V251, P229, DOI 10.1006/jmbi.1995.0430; HEVRONI D, 1988, P NATL ACAD SCI USA, V85, P5046, DOI 10.1073/pnas.85.14.5046; IDE H, 1995, NUCLEIC ACIDS RES, V23, P123, DOI 10.1093/nar/23.1.123; JONES AS, 1968, J CHEM SOC C, P2042, DOI 10.1039/j39680002042; KLINEDINST DK, 1992, MOL CARCINOGEN, V6, P32, DOI 10.1002/mc.2940060107; KUNKEL TA, 1984, P NATL ACAD SCI-BIOL, V81, P1494, DOI 10.1073/pnas.81.5.1494; KUNKEL TA, 1983, BIOCHEMISTRY-US, V22, P2378, DOI 10.1021/bi00279a012; KUNZ BA, 1994, P NATL ACAD SCI USA, V91, P8165, DOI 10.1073/pnas.91.17.8165; LAWRENCE CW, 1990, NUCLEIC ACIDS RES, V18, P2153, DOI 10.1093/nar/18.8.2153; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; MANIATIS F, 1972, MOL CLONING LAB MANU, P122; Maxam A M, 1980, Methods Enzymol, V65, P499; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; MILLICAN TA, 1984, NUCLEIC ACIDS RES, V12, P7435, DOI 10.1093/nar/12.19.7435; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; MORIYA M, 1994, P NATL ACAD SCI USA, V91, P11899, DOI 10.1073/pnas.91.25.11899; MOZZHERIN DJ, 1997, IN PRESS P NATL ACAD; NETO JBC, 1992, J BIOL CHEM, V267, P19718; NETO JBC, 1994, J MOL BIOL, V240, P416, DOI 10.1006/jmbi.1994.1457; PIERRE J, 1981, J BIOL CHEM, V256, P217; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; SAGHER D, 1985, NUCLEIC ACIDS RES, V13, P4285, DOI 10.1093/nar/13.12.4285; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; SCHAAPER RM, 1983, P NATL ACAD SCI-BIOL, V80, P487, DOI 10.1073/pnas.80.2.487; SHIBUTANI S, 1991, CARCINOGENESIS, V12, P813, DOI 10.1093/carcin/12.5.813; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHIBUTANI S, 1993, J BIOL CHEM, V268, P11703; SHIBUTANI S, 1993, CHEM RES TOXICOL, V6, P625, DOI 10.1021/tx00035a006; SHIBUTANI S, 1993, BIOCHEMISTRY-US, V32, P7531, DOI 10.1021/bi00080a027; SHIBUTANI S, 1993, BIOCHEMISTRY-US, V32, P4615, DOI 10.1021/bi00068a019; STRAUSS BS, 1991, BIOESSAYS, V13, P79, DOI 10.1002/bies.950130206; TAKESHITA M, 1994, NUCLEIC ACIDS RES, V22, P1897, DOI 10.1093/nar/22.10.1897; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; WEISS B, 1987, ADV ENZYMOL RAMB, V60, P1	45	142	146	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13916	13922		10.1074/jbc.272.21.13916	http://dx.doi.org/10.1074/jbc.272.21.13916			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153253	hybrid			2022-12-27	WOS:A1997XA06200068
J	Gamard, CJ; Dbaibo, GS; Liu, B; Obeid, LM; Hannun, YA				Gamard, CJ; Dbaibo, GS; Liu, B; Obeid, LM; Hannun, YA			Selective involvement of ceramide in cytokine-induced apoptosis - Ceramide inhibits phorbol ester activation of nuclear factor kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HL-60 CELL-DIFFERENTIATION; SIGNAL-TRANSDUCTION; FACTOR-ALPHA; SPHINGOMYELIN TURNOVER; ACID SPHINGOMYELINASE; CYCLE ARREST; FREE SYSTEM; TNF-ALPHA; PATHWAY	Among its diverse biologic effects, the cytokine tumor necrosis factor cu causes the rapid nuclear translocation of the transcription factor, nuclear factor kappa B (NF-kappa B). The p55 tumor necrosis factor (TNF) receptor shares with the related APO-1/Fas antigen the ability to initiate apoptosis. We investigated the role of the sphingolipid mediator ceramide in the cytokine-induced signaling mechanisms leading to NF-kappa B activation and cell death. Several lines of evidence presented here suggest that ceramide generated in response to TNF alpha or Fas activation is not involved in NF-kappa B activation. (i) Cell-permeable ceramides and exogenous sphingomyelinase failed to induce either nuclear translocation of NF-kappa B or degradation of its cytosolic inhibitor, I-kappa B, in Jurkat T cells. (ii) Ceramide treatment of cells inhibited phorbol ester-induced activation of NF-kappa B. (iii) TNF alpha potently activated NF-kappa B in a cell. line deficient in acid sphingomyelinase. (iv) TNF alpha activated NF-kappa B within minutes without altering ceramide levels. (v) Treatment of Jurkat cells with cross-linking antibodies to APO-1/Fas induced large scale increases in ceramide and apoptosis without affecting NF-kappa B. (vi) Ceramide generation in response to pas activation was inhibited by N-acetyltyrosinylvalinylalanylaspartyl chloromethyl ketone, a peptide inhibitor of interleukin-lp-converting enzymelike proteases, whereas TNF alpha-induced NF-kappa B activation was unaffected by the inhibitor. These results show that ceramide accumulation belongs selectively to the apoptotic pathway(s) induced by cytokines, and, if anything, ceramide may participate in negative feedback regulation of NF-kappa B.	DUKE UNIV,MED CTR,DEPT MED & CELL BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PEDIAT,DURHAM,NC 27710	Duke University; Duke University			Dbaibo, Ghassan S./X-2978-2019	obeid, lina/0000-0002-0734-0847	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG012467, R55AG012467] Funding Source: NIH RePORTER; NIA NIH HHS [AG12467] Funding Source: Medline; NIGMS NIH HHS [GM-43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BETTS JC, 1994, J BIOL CHEM, V269, P8455; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cain K, 1996, BIOCHEM J, V314, P27, DOI 10.1042/bj3140027; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FERLINZ K, 1991, BIOCHEM BIOPH RES CO, V179, P1187, DOI 10.1016/0006-291X(91)91697-B; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GRILLI M, 1993, INT REV CYTOL, V143, P1; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Higuchi M, 1996, J IMMUNOL, V157, P297; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JI L, 1995, FEBS LETT, V358, P211, DOI 10.1016/0014-5793(94)01428-4; JOHNS LD, 1994, J IMMUNOL, V152, P5877; KIM MY, 1991, J BIOL CHEM, V266, P484; KRONKE M, 1990, CELL SIGNAL, V2, P1, DOI 10.1016/0898-6568(90)90027-8; KUNO K, 1994, INT IMMUNOL, V6, P1269, DOI 10.1093/intimm/6.8.1269; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; LOWENTHAL JW, 1989, J IMMUNOL, V142, P3121; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; PREISS J, 1986, J BIOL CHEM, V261, P8597; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; RENSINGEHL A, 1995, J INFLAMM, V45, P161; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; Schuchman EHDR, 1995, METABOLIC MOL BASIS, V7th, P2601; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Totpal K, 1996, J INTERF CYTOK RES, V16, P259, DOI 10.1089/jir.1996.16.259; VANVELDHOVEN PP, 1989, ANAL BIOCHEM, V183, P177, DOI 10.1016/0003-2697(89)90186-3; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; YANG ZH, 1993, J BIOL CHEM, V268, P20520	55	94	96	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16474	16481		10.1074/jbc.272.26.16474	http://dx.doi.org/10.1074/jbc.272.26.16474			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195956	hybrid			2022-12-27	WOS:A1997XG01900060
J	Kumar, CS; James, IE; Wong, A; Mwangi, V; Feild, JA; Nuthulaganti, P; Connor, JR; Eichman, C; Ali, F; Hwang, SM; Rieman, DJ; Drake, FH; Gowen, M				Kumar, CS; James, IE; Wong, A; Mwangi, V; Feild, JA; Nuthulaganti, P; Connor, JR; Eichman, C; Ali, F; Hwang, SM; Rieman, DJ; Drake, FH; Gowen, M			Cloning and characterization of a novel integrin beta(3) subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET GLYCOPROTEIN-IIIA; VITRONECTIN RECEPTOR; BONE-RESORPTION; CELL-ADHESION; CYTOPLASMIC DOMAIN; EXTRACELLULAR-MATRIX; OSTEOCLASTS; EXPRESSION; INHIBITION; APOPTOSIS	We have identified a novel integrin beta(3) subunit, termed beta(3C), from a human osteoclast cDNA library. The COOH-terminal sequence and 5'-untranslated region of the beta(3C) subunit differs from the previously reported beta(3A) (platelet) and beta(3B) (placenta) sequences, while the regions coding for the transmembrane and extracellular domains are identical. The beta(3C) cytoplasmic domain contains 37 amino acids, the last 17 of which are encoded by a novel exon located about 6 kilobase pairs downstream of exon 14 of the beta(3A) gene. HEK 293 cells were stably co-transfected with alpha(V) and either beta(3C) (HEK beta(3C)) or beta(3A) (HEK beta(3A). The viability of HER beta(3C) cells was lower than that of HER beta(3A) cells, and HEH beta(3C) cells in culture grew as clusters rather than as a monolayer. The novel cytoplasmic domain did not affect receptor binding affinity; both alpha(V) beta(3A) and alpha(V) beta(3C) isoforms exhibited high affinity binding to I-125-echistatin and cyclic and linear RGD peptides. However, in contrast to HEK beta(3A) HEK beta(3C) cells failed to adhere to osteopontin, an alpha(V) beta(3) matrix protein. The data provide further support for the key role of the cytoplasmic domain of the beta(3) integrin in cell adhesion and suggest a potential role for the beta(3C) integrin subunit in modulating cell-matrix interactions.	SMITHKLINE BEECHAM PHARMACEUT,DEPT CELLULAR BIOCHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT MOL IMMUNOL,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT MED CHEM,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Kumar, CS (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,RES & DEV,DEPT MOL GENET,709 SWEDELAND RD,POB 1539,KING OF PRUSSIA,PA 19406, USA.		Kumar, Dr Suresh/HHZ-2615-2022; chitta, suresh kumar/N-1569-2016; KUMAR, P. SURESH/AAT-8951-2020	Kumar, Dr Suresh/0000-0002-2539-6553; KUMAR, P. SURESH/0000-0003-3222-2604				AIYAR N, 1994, MOL CELL BIOCHEM, V131, P75, DOI 10.1007/BF01075727; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALTRUDA F, 1990, GENE, V95, P261, DOI 10.1016/0378-1119(90)90369-3; BALZAC F, 1993, J CELL BIOL, V121, P171, DOI 10.1083/jcb.121.1.171; Belkin A. M., 1995, Molecular Biology of the Cell, V6, p284A; BERGSMA DJ, 1992, BIOCHEM BIOPH RES CO, V183, P989, DOI 10.1016/S0006-291X(05)80288-8; BOSSY B, 1990, BIOCHEMISTRY-US, V29, P10191, DOI 10.1021/bi00496a006; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHERESH DA, 1987, J BIOL CHEM, V262, P1434; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CHUNTHARAPAI A, 1993, EXP CELL RES, V205, P345, DOI 10.1006/excr.1993.1096; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DALTON SL, 1995, MOL BIOL CELL, V6, P1781, DOI 10.1091/mbc.6.12.1781; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511; FILDARO EJ, 1995, J CELL BIOL, V130, P441; FISHER JE, 1993, ENDOCRINOLOGY, V132, P1411, DOI 10.1210/en.132.3.1411; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; HENSLEY P, 1994, J BIOL CHEM, V269, P23949; HORTON M, 1990, INT J EXP PATHOL, V71, P741; HORTON MA, 1991, EXP CELL RES, V195, P368, DOI 10.1016/0014-4827(91)90386-9; HUGHES DE, 1995, J BONE MINER RES, V10, P1478; HUGHES DE, 1995, J BONE MINER RES, V10, pS326; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JAMES IE, 1991, J HISTOCHEM CYTOCHEM, V39, P905, DOI 10.1177/39.7.1865107; JOHNSON GD, 1981, TECHNIQUES CLIN IMMU, P106; LANGUINO LR, 1992, J BIOL CHEM, V267, P7116; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LOUTIT JF, 1982, IMMUNOBIOLOGY, V161, P193, DOI 10.1016/S0171-2985(82)80074-0; MEREDITH J, 1995, SCIENCE, V269, P1570, DOI 10.1126/science.7545312; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; NIJWEIDE PJ, 1986, PHYSIOL REV, V66, P855, DOI 10.1152/physrev.1986.66.4.855; Parfitt AM, 1996, J BONE MINER RES, V11, P150; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; ROSA JP, 1988, BLOOD, V72, P593; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SAMBROOK J, 1989, CLONING LAB MANUAL, V2; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SATO M, 1990, J CELL BIOL, V111, P1713, DOI 10.1083/jcb.111.4.1713; SATO M, 1994, J BONE MINER RES, V9, P1441; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; TOIN HM, 1989, P NATL ACAD SCI USA, V86, P5415; Wong A, 1996, MOL PHARMACOL, V50, P529; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; ZIMRIN AB, 1988, J CLIN INVEST, V81, P1470, DOI 10.1172/JCI113478; ZIMRIN AB, 1990, J BIOL CHEM, V265, P8590	47	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16390	16397		10.1074/jbc.272.26.16390	http://dx.doi.org/10.1074/jbc.272.26.16390			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195946	hybrid			2022-12-27	WOS:A1997XG01900050
J	Ossina, NK; Cannas, A; Powers, VC; Fitzpatrick, PA; Knight, JD; Gilbert, JR; Shekhtman, EM; Tomei, LD; Umansky, SR; Kiefer, MC				Ossina, NK; Cannas, A; Powers, VC; Fitzpatrick, PA; Knight, JD; Gilbert, JR; Shekhtman, EM; Tomei, LD; Umansky, SR; Kiefer, MC			Interferon-gamma modulates a p53-independent apoptotic pathway and apoptosis-related gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; TUMOR-NECROSIS-FACTOR; IN-VIVO; MOLECULAR-CLONING; BCL-2 HOMOLOG; DNA-DAMAGE; PROTEIN; FAMILY; FAS; REGULATORS	Interferon (IFN)-gamma increases the sensitivity of tumor cell lines, many of which are p53 mutants, to tumor necrosis factor-alpha-mediated and anti Fas antibody-mediated cell death. To better understand the mechanism of IFN-gamma action in modulating the cell death response independently of p53 function, we analyzed the death of the human colon adenocarcinoma cell line, HT-29, following treatment with IFN-gamma and various cytotoxic agents. Here we show that IFN-gamma modulates cell death by sensitizing the cells to killing by numerous pro-apoptotic stimuli but not pro-necrotic stimuli. Furthermore, we show that select genes from several important apoptosis-related gene families are induced by IFN-gamma, including the apoptosis-signaling receptors CD95 (Fas/APO-1) and TNFR 1 and interleukin-1 beta-converting enzyme (Ice) family members Ice, CPP32 (Yama, apopain), ICErel-II (TX, Ich-2), Mch-3 (ICE-LAP3, CMH-1), Mch-4, and Mch-5 (MACH, FLICE). Of the bcl-2 family members, IFN-gamma directly induced bah but notably not bar, which is activated by p53. The IFN-responsive transcriptional activator interferon regulatory factor-1 was also strongly induced and translocated into the nucleus following IFN-gamma treatment. We propose that IFN-gamma modulates a p53-independent apoptotic pathway by both directly and indirectly inducing select apoptosis-related genes.	LXR BIOTECHNOL INC,RICHMOND,CA 94804					Ossina, Natalya/0000-0002-0444-8174				BARR PJ, 1994, BIO-TECHNOL, V12, P487, DOI 10.1038/nbt0594-487; BODRUG SE, 1995, CELL DEATH DIFFER, V2, P173; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALABRESI P, 1990, PHARMACOL BASIS THER, P1202; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FRANSEN L, 1986, EUR J CANCER CLIN ON, V22, P419, DOI 10.1016/0277-5379(86)90107-0; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Krajewska M, 1996, CANCER RES, V56, P2422; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; KRAJEWSKI S, 1995, AM J PATHOL, V146, P1309; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Lomo J, 1996, CANCER RES, V56, P40; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARUYAMA M, 1989, NUCLEIC ACIDS RES, V17, P3292, DOI 10.1093/nar/17.8.3292; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Sambrook J., 2002, MOL CLONING LAB MANU; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; Schulze-Osthoff Klaus, 1994, Trends in Cell Biology, V4, P421, DOI 10.1016/0962-8924(94)90102-3; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANIGUCHI T, 1995, J CANCER RES CLIN, V121, P516, DOI 10.1007/BF01197763; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TOMEI LD, 1991, APOPTOSIS MOL BASIS, P1; TSUJIMOTO M, 1986, J IMMUNOL, V136, P2441; UMANSKY SR, 1982, J THEOR BIOL, V97, P591, DOI 10.1016/0022-5193(82)90360-5; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7	58	249	257	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16351	16357		10.1074/jbc.272.26.16351	http://dx.doi.org/10.1074/jbc.272.26.16351			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195941	hybrid			2022-12-27	WOS:A1997XG01900045
J	Dhoest, A; Zhao, ZA; DeGeest, B; Deridder, E; Sillen, A; Engelborghs, Y; Collen, D; Holvoet, P				Dhoest, A; Zhao, ZA; DeGeest, B; Deridder, E; Sillen, A; Engelborghs, Y; Collen, D; Holvoet, P			Role of the Arg(123)-Tyr(166) paired helix of apolipoprotein A-I in lecithin:cholesterol acyltransferase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEINS; SYNTHETIC PEPTIDE ANALOGS; AMPHIPATHIC HELIX; PHOSPHOLIPID-BINDING; DISCOIDAL COMPLEXES; CNBR FRAGMENTS; APOA-I; PROTEINS; DOMAINS; MODEL	The Arg(123)-Tyr(166) central and Ala(190)-Gln(243) carboxy-terminal pairs of helices of apoA-I were substituted with the pair of helices of apoA-II, resulting in the apoA-I(Delta(Arg(123)-Tyr(166)),del A-II(Ser(12)-Ala(75))) and apoA-I(Delta(Ala(190)-Gln(243)),del A-II(Ser(12)-Gln(77))) chimeras, respectively, The structures of these chimeras in aqueous solution and in reconstituted high density lipoproteins (rHDL) and the lecithin:cholesterol acyltransferase (LCAT) activation properties of the rHDL were studied, Recombinant human apoA-I and the chimeras were expressed in Escherichia coli and purified from the periplasmic space, Binding of the apolipoproteins with palmitoyloleoylphosphatidylcholine was associated with a similar shift of Trp fluorescence maxima from 337 to 332 nm, from 339 to 334 nm, and from 337 to 333 nm, respectively, All rHDL had a Stokes radius of 4.8 nm and contained 2 apolipoprotein molecules/particle. Circular dichroism measurements revealed eight a-helices per apoA-I and per chimera molecule, The catalytic efficiencies of LCAT activation were 1.5 +/- 0.33 (mean +/- S.D.; n = 3), 0.054 +/- 0.009 (p < 0.001 versus apoA-I), and 1.3 +/- 0.32 (p = not significant versus apoA-I) nmol of cholesteryl ester/h/mu M, respectively. The lower LCAT activity of the central domain chimera was due to a 27-fold reduced V-max with unaltered K-m, Binding of radiolabeled LCAT to rHDL of apoA-I and apoA-I(Delta(Arg(123)-Tyr(166)),del A-II(Ser(12)-Ala(75))) was very similar. In conclusion, although substitution of the Arg(123)-Tyr(166) central or Ala(190)-Gln(243) carboxyl-terminal pair of helices of apoA-I with the pair of helices of apoA-II yields chimeras with structure similar to that of native apoA-I, exchange of the central domain (but not the carboxyl-terminal domain) of apoA-I reduces the rate of LCAT activity that is independent of binding to rHDL.	CATHOLIC UNIV LEUVEN,CTR MOL & VASC BIOL,B-3000 LOUVAIN,BELGIUM; CATHOLIC UNIV LEUVEN,LAB CHEM & BIOL DYNAM,B-3000 LOUVAIN,BELGIUM	KU Leuven; KU Leuven			De Geest, Bart/AHB-0394-2022; HOLVOET, PAUL/T-8434-2017	HOLVOET, PAUL/0000-0001-9201-0772; De Geest, Bart/0000-0001-5580-686X				ANANTHARAMAIAH GM, 1990, ARTERIOSCLEROSIS, V10, P95, DOI 10.1161/01.ATV.10.1.95; ANANTHARAMAIAH GM, 1985, J BIOL CHEM, V260, P248; BANKA CL, 1991, J BIOL CHEM, V266, P23886; BOLIN DJ, 1994, J BIOL CHEM, V269, P7429; BONELLI FS, 1989, J BIOL CHEM, V264, P14723; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1043, P245, DOI 10.1016/0005-2760(90)90023-Q; BRASSEUR R, 1991, J BIOL CHEM, V266, P16120; BREWER HB, 1978, BIOCHEM BIOPH RES CO, V80, P623, DOI 10.1016/0006-291X(78)91614-5; CHEN CH, 1986, EUR J BIOCHEM, V155, P589, DOI 10.1111/j.1432-1033.1986.tb09529.x; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CHEUNG P, 1983, NUCLEIC ACIDS RES, V11, P3703, DOI 10.1093/nar/11.11.3703; FUKUSHIMA D, 1980, J BIOL CHEM, V255, P651; HOLVOET P, 1995, BIOCHEMISTRY-US, V34, P13334, DOI 10.1021/bi00041a009; Holvoet P, 1996, J BIOL CHEM, V271, P19395, DOI 10.1074/jbc.271.32.19395; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1993, J BIOL CHEM, V268, P1596; JONAS A, 1989, J BIOL CHEM, V264, P4818; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; KROON DJ, 1978, J AM CHEM SOC, V100, P5975, DOI 10.1021/ja00486a078; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; MANIATIS T, 1982, MOL CLONING LABORATO, P200; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MENG QH, 1993, J BIOL CHEM, V268, P16966; MINNICH A, 1992, J BIOL CHEM, V267, P16553; NAKAGAWA SH, 1985, J AM CHEM SOC, V107, P7087, DOI 10.1021/ja00310a055; ROBERTS GCK, 1981, STANDARDS FLUORESCEN, P49; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SEGREST JP, 1991, PROTEINS, V9, P79; SEGREST JP, 1992, J LIPID RES, V33, P141; SORCITHOMAS M, 1993, J BIOL CHEM, V268, P21403; SPARKS DL, 1995, J BIOL CHEM, V270, P5151, DOI 10.1074/jbc.270.10.5151; Sparrow J T, 1980, Ann N Y Acad Sci, V348, P187, DOI 10.1111/j.1749-6632.1980.tb21300.x; SRINIVAS RV, 1991, J CELL BIOCHEM, V45, P224, DOI 10.1002/jcb.240450214; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; SWANEY JB, 1986, METHOD ENZYMOL, V128, P613; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANLOO B, 1992, BIOCHIM BIOPHYS ACTA, V1128, P258, DOI 10.1016/0005-2760(92)90316-N; VANLOO B, 1991, J LIPID RES, V32, P1253; VERCAEMST R, 1989, ATHEROSCLEROSIS, V78, P245, DOI 10.1016/0021-9150(89)90230-X; WALD JH, 1990, J BIOL CHEM, V265, P20044; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHOU C, 1990, BIOTECHNIQUES, V8, P172	45	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15967	15972		10.1074/jbc.272.25.15967	http://dx.doi.org/10.1074/jbc.272.25.15967			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188498	hybrid			2022-12-27	WOS:A1997XF32900058
J	Lebowitz, PF; Casey, PJ; Prendergast, GC; Thissen, JA				Lebowitz, PF; Casey, PJ; Prendergast, GC; Thissen, JA			Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS TRANSFORMATION; FARNESYL; GERANYLGERANYL; MECHANISM	Protein farnesyltransferase inhibitors (FTIs) inhibit Pas transformation and has-dependent tumor cell growth, but the biological mechanisms underlying these activities is unclear, In previous work, we presented support for the hypothesis that the anti-transforming effects of FTIs depend upon alterations in the function of RhoB, a member of the Rho family of proteins that regulate cytoskeletal actin, cell adhesion, and cell growth. A significant question that needed to be addressed was whether FTIs could directly alter the prenylation as well as the function of RhoB in cells, This issue is complex because farnesylated and geranylgeranylated forms of RhoB (RhoB-F and RhoE-GG) both exist in cells, Here, we show that RhoB farnesylation in vitro can be catalyzed by protein farnesyltransferase and that the peptidomimetic FTI L-739,749 inhibits the farnesylation of RhoB both in vitro and in intact cells, In drug-treated cells, the level of RhoB-GG increased in parallel with the decrease in RhoB-F, In addition to altering RhoB prenylation, L-739,749 suppressed RhoB-dependent cell growth, Taken together, the results suggest that the inhibitory effects of FTIs on RhoB function can be mediated by a relative loss of RhoB-F, a gain of RhoB-GG, or both, Our findings strengthen the causal link between RhoB inhibition and the anti-transforming effects of FTIs and indicate that differently prenylated forms of RhoB may have unique functions.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,CELL & MOL BIOL GRAD GRP,PHILADELPHIA,PA 19104; DUKE UNIV,MED CTR,DEPT MOL CANC BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	The Wistar Institute; University of Pennsylvania; Duke University; Duke University				Casey, Patrick/0000-0002-7366-9309	NATIONAL CANCER INSTITUTE [R29CA065892] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046372] Funding Source: NIH RePORTER; NCI NIH HHS [CA65892] Funding Source: Medline; NIGMS NIH HHS [GM 46372] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON P, 1992, J BIOL CHEM, V267, P20033; ARMSTRONG SA, 1995, J BIOL CHEM, V270, P7864, DOI 10.1074/jbc.270.14.7864; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; FARNSWORTH C C, 1990, Methods (Orlando), V1, P231, DOI 10.1016/S1046-2023(05)80322-6; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; Lebowitz PF, 1997, CANCER RES, V57, P708; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; SYMONS M, 1995, CURR OPIN BIOTECH, V6, P668, DOI 10.1016/0958-1669(95)80110-3; Thissen JA, 1996, ANAL BIOCHEM, V243, P80, DOI 10.1006/abio.1996.0484; Yokoyama K, 1997, J BIOL CHEM, V272, P3944, DOI 10.1074/jbc.272.7.3944; ZHANG FL, 1994, J BIOL CHEM, V269, P23465	24	196	204	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15591	15594		10.1074/jbc.272.25.15591	http://dx.doi.org/10.1074/jbc.272.25.15591			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188444	hybrid			2022-12-27	WOS:A1997XF32900004
J	Smith, MA; Fanger, GR; OConnor, LT; Bridle, P; Maue, RA				Smith, MA; Fanger, GR; OConnor, LT; Bridle, P; Maue, RA			Selective regulation of agrin mRNA induction and alternative splicing in PC12 cells by ras-dependent actions of nerve growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPING NEUROMUSCULAR SYNAPSES; SODIUM-CHANNEL EXPRESSION; MESSENGER-RNA EXPRESSION; GENE-EXPRESSION; NEURONAL DIFFERENTIATION; ACETYLCHOLINE-RECEPTORS; SIGNAL-TRANSDUCTION; CULTURED MYOTUBES; CILIARY GANGLION; BASAL LAMINA	The extracellular matrix protein agrin plays an important role in the formation and maintenance of the neuromuscular junction, However, regulation of agrin gene expression and pre-mRNA splicing, important in determining the biological actions of agrin, is not well understood, To begin to identify mechanisms controlling agrin expression, quantitative polymerase chain reaction techniques were used to analyze the effect of growth factors on the expression of agrin mRNA isoforms in rat pheochromocytoma (PC12) cells. Agrin transcripts in untreated cells lacked inserts in the Y and Z sites (agrin(y0z0)), encoding agrin isoforms with low acetylcholine receptor aggregating activity and a primarily non-neuronal tissue distribution, Transcripts encoding isoforms with high aggregating activity and neuronal tissue distribution (agrin(y4z8) agrin(y4z11), and agrin(y4z19)) were not detected, Treatment of PC12 cells with nerve growth factor (NGF) caused a significant increase in total agrin mRNA, In contrast, exposure to epidermal growth factor had no effect, Analysis of alternative splicing of agrin mRNA revealed that NGF elicited a specific increase in agrin(y4) and agrin(z8) mRNAs that did not occur in the presence of epidermal growth factor, insulin, dexamethasone, or retinoic acid. Analysis of PC12 sublines stably overexpressing a dominant inhibitory form of p21 Ras indicated that NGF induced changes in levels of agrin mRNA and alternative splicing required Ras activity, The results show that NGF can influence important aspects of neuronal differentiation by regulating alternative splicing, Furthermore, these data provide insight into the mechanisms governing agrin gene expression and suggest that neurotrophic factors may play a role in regulating agrin expression in vivo.	DARTMOUTH COLL, SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA; DARTMOUTH COLL, SCH MED, DEPT PHYSIOL, HANOVER, NH 03755 USA	Dartmouth College; Dartmouth College	Smith, MA (corresponding author), UNIV CALIF IRVINE, DEPT ANAT & NEUROBIOL, IRVINE, CA 92697 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007351, R01NS028767, R01NS033213, R29NS028767] Funding Source: NIH RePORTER; NINDS NIH HHS [NS33213, NS28767, NS07351] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARKER PA, 1993, J BIOL CHEM, V268, P15150; BIROC SL, 1993, DEV BRAIN RES, V75, P119, DOI 10.1016/0165-3806(93)90071-H; BORSI L, 1990, FEBS LETT, V261, P175, DOI 10.1016/0014-5793(90)80664-5; BOWE MA, 1995, ANNU REV NEUROSCI, V18, P443; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; Campagna JA, 1995, NEURON, V15, P1365, DOI 10.1016/0896-6273(95)90014-4; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FANGER GR, 1993, J NEUROCHEM, V61, P1977, DOI 10.1111/j.1471-4159.1993.tb09844.x; FANGER GR, 1995, J NEUROSCI, V15, P202; FERNS M, 1992, NEURON, V8, P1079, DOI 10.1016/0896-6273(92)90129-2; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GODFREY EW, 1988, J CELL BIOL, V106, P1263, DOI 10.1083/jcb.106.4.1263; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; Guroff G., 1985, CELL CULTURE NEUROSC, P245, DOI 10.1007/978-1-4613-2473-7_8; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; HAMMES A, 1994, FASEB J, V8, P428, DOI 10.1096/fasebj.8.6.8168693; Henderson CE, 1996, CURR OPIN NEUROBIOL, V6, P64, DOI 10.1016/S0959-4388(96)80010-9; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOCH W, 1993, NEURON, V11, P479, DOI 10.1016/0896-6273(93)90152-H; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KIM HG, 1994, P NATL ACAD SCI USA, V91, P12341, DOI 10.1073/pnas.91.25.12341; LATCHMAN D S, 1990, New Biologist, V2, P297; LAUTERBORN JC, 1994, EXP NEUROL, V125, P22, DOI 10.1006/exnr.1994.1003; LI Z, 1997, IN PRESS NEUROSCIENC; LIETH E, 1992, DEV BIOL, V149, P41, DOI 10.1016/0012-1606(92)90262-F; LINDENBAUM MH, 1988, J BIOL CHEM, V263, P5662; LO DC, 1995, NEURON, V15, P979, DOI 10.1016/0896-6273(95)90085-3; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; MA E, 1994, J NEUROSCI, V14, P2943; MA EB, 1995, J NEUROBIOL, V26, P585, DOI 10.1002/neu.480260411; MAGNUSON VL, 1991, J BIOL CHEM, V266, P14654; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MENDELL LM, 1994, NEUROSCIENTIST, V1, P21; MINTHWORBY CA, 1994, J BIOL CHEM, V269, P15460; OCONNOR LT, 1995, MOL BRAIN RES, V33, P277, DOI 10.1016/0169-328X(95)00147-K; OCONNOR LT, 1994, J NEUROSCI, V14, P1141, DOI 10.1523/JNEUROSCI.14-03-01141.1994; PERRONEBIZZOZERO NI, 1993, J CELL BIOL, V120, P1263, DOI 10.1083/jcb.120.5.1263; REIST NE, 1992, NEURON, V8, P865, DOI 10.1016/0896-6273(92)90200-W; REYES AA, 1993, MOL BRAIN RES, V17, P201, DOI 10.1016/0169-328X(93)90003-8; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; SALTIEL AR, 1994, BIOESSAYS, V16, P405, DOI 10.1002/bies.950160608; SALTIEL AR, 1991, MOL CELL ENDOCRINOL, V81, pC197, DOI 10.1016/0303-7207(91)90198-2; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P2579, DOI 10.1073/pnas.74.6.2579; SHIFRIN VI, 1993, J BIOL CHEM, V268, P25376; SMITH MA, 1994, NEURON, V12, P795, DOI 10.1016/0896-6273(94)90332-8; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; STONE DM, 1995, J NEUROSCI, V15, P6767; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TAKAGI T, 1990, SCIENCE, V249, P1580; Tansey MG, 1996, J CELL BIOL, V134, P465, DOI 10.1083/jcb.134.2.465; THOMAS WS, 1995, DEV BIOL, V168, P662, DOI 10.1006/dbio.1995.1110; THOMAS WS, 1993, DEV BIOL, V158, P523, DOI 10.1006/dbio.1993.1210; TSEN G, 1995, J BIOL CHEM, V270, P3392, DOI 10.1074/jbc.270.7.3392; WANG T, 1995, J NEUROSCI, V15, P4796; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; ZHAO Y, 1995, AM J PHYSIOL-LUNG C, V268, pL173, DOI 10.1152/ajplung.1995.268.2.L173	68	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15675	15681		10.1074/jbc.272.25.15675	http://dx.doi.org/10.1074/jbc.272.25.15675			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188458	hybrid			2022-12-27	WOS:A1997XF32900018
J	Dean, WL; Chen, D; Brandt, PC; Vanaman, TC				Dean, WL; Chen, D; Brandt, PC; Vanaman, TC			Regulation of platelet plasma membrane Ca2+-ATPase by cAMP-dependent and tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-PUMPING ATPASE; ERYTHROCYTE-MEMBRANE; PROTEIN-KINASES; CALCIUM-PUMP; ASSOCIATION; PP125(FAK); CALMODULIN; INTEGRIN; RECEPTOR; CELLS	As a consequence of its central role in the regulation of calcium metabolism in the platelet, the plasma membrane Ca2+-ATPase (PMCA) was assessed for cAMP dependent and tyrosine phosphorylation, Addition of forskolin or prostaglandin El, agents known to elevate platelet cAMP and calcium efflux, to platelets pre-labeled with [P-32]PO4 resulted in the direct phosphorylation of platelet PMCA. Similarly, addition of the catalytic subunit of protein kinase A to platelet plasma membranes resulted in a 1.4-fold stimulation of activity, Thus, the previously reported inhibition of platelet activation by elevated intracellular cAMP may be accomplished in part by stimulation of PMCA, likely resulting in a decrease in intracellular calcium. Treatment with thrombin evoked tyrosine phosphorylation of platelet PMCA, while PMCA from resting platelets exhibited little tyrosine phosphorylation. Phosphorylation of platelet plasma membranes by pp60(src) resulted in 75% inhibition of PMCA activity within 15 min, Similarly, membranes isolated from thrombin treated platelets exhibited 40% lower PMCA activity than those from resting platelets, Phosphorylation of erythrocyte ghosts and purified PMCA by pp60(src) also resulted in up to 75% inhibition of Ca2+-ATPase activity, and inhibition was correlated with tyrosine phosphorylation, Sequencing of a peptide obtained after P-32 labeling of purified erythrocyte PMCA in vitro showed that tyrosine 1176 of PMCA4b is phosphorylated by pp60(src). These results indicate that tyrosine phosphorylation of platelet PMCA may serve as positive feedback to inhibit PMCA and increase intracellular calcium during platelet activation.	UNIV KENTUCKY, MED CTR, DEPT BIOCHEM, LEXINGTON, KY 40536 USA; UNIV LOUISVILLE, SCH MED, DEPT BIOCHEM, LOUISVILLE, KY 40292 USA	University of Kentucky; University of Louisville					NINDS NIH HHS [NS21868] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021868] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BORKE JL, 1989, AM J PHYSIOL, V257, pF842, DOI 10.1152/ajprenal.1989.257.5.F842; BRANDT P, 1992, J BIOL CHEM, V267, P4376; BRANDT P, 1988, P NATL ACAD SCI USA, V85, P2914, DOI 10.1073/pnas.85.9.2914; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DASH D, 1995, FEBS LETT, V363, P231, DOI 10.1016/0014-5793(95)00320-9; DEAN WL, 1994, HYPERTENSION, V23, P31, DOI 10.1161/01.HYP.23.1.31; DEAN WL, 1995, CELL CALCIUM, V17, P65, DOI 10.1016/0143-4160(95)90103-5; DEAN WL, 1988, METHOD ENZYMOL, V157, P351; Fleming I, 1996, J BIOL CHEM, V271, P11009, DOI 10.1074/jbc.271.18.11009; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; HARMON JT, 1992, METHOD ENZYMOL, V215, P32; HAYNES DH, 1993, PLATELETS, V4, P231, DOI 10.3109/09537109309013223; HEEMSKERK JWM, 1994, PLATELETS, V5, P295, DOI 10.3109/09537109409006439; Jayaraman T, 1996, SCIENCE, V272, P1492, DOI 10.1126/science.272.5267.1492; JOHNSON JS, 1988, J MEMBRANE BIOL, V104, P147; JOHNSON JS, 1992, BIOCHIM BIOPHYS ACTA, V1105, P19; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NEGRESCU EV, 1995, J BIOL CHEM, V270, P1057, DOI 10.1074/jbc.270.3.1057; NEYSES L, 1985, J BIOL CHEM, V260, P283; NIGGLI V, 1981, J BIOL CHEM, V256, P395; ODA A, 1992, J BIOL CHEM, V267, P20075; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; STAUFFER TP, 1995, J BIOL CHEM, V270, P12184, DOI 10.1074/jbc.270.20.12184; Steck T L, 1974, Methods Enzymol, V31, P172; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; WEST MHP, 1984, ELECTROPHORESIS, V5, P133, DOI 10.1002/elps.1150050302	28	99	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15113	15119		10.1074/jbc.272.24.15113	http://dx.doi.org/10.1074/jbc.272.24.15113			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182531	hybrid			2022-12-27	WOS:A1997XE03400014
J	Sonoda, Y; Kasahara, T; Yamaguchi, Y; Kuno, K; Matsushima, K; Mukaida, N				Sonoda, Y; Kasahara, T; Yamaguchi, Y; Kuno, K; Matsushima, K; Mukaida, N			Stimulation of interleukin-8 production by okadaic acid and vanadate in a human promyelocyte cell line, an HL-60 subline - Possible role of mitogen-activated protein kinase on the okadaic acid-induced NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NEUTROPHIL CHEMOTACTIC FACTOR; MESSENGER-RNA EXPRESSION; FACTOR-ALPHA; MAP KINASE; TNF-ALPHA; GENE-EXPRESSION; FACTOR BINDING; FACTOR MCAF; PHOSPHORYLATION	Most types of cells can produce interleukin (IL)-8 in response to various inflammatory stimuli, To study the role of protein phosphatases in the signal transduction leading to IL-8 production, a subline of HL-60 (C-15)was treated with okadaic acid (OA) and sodium orthovanadate (VA), inhibitors of phosphoserine/phosphothreonine phosphatase and phosphotyrosine phosphatase, respectively, Both OA and VA dramatically increased IL-8 secretion up to 200-fold in the HL-60 cells, OA and VA stimulation was accompanied by a marked increase in IL-8 mRNA expression and also by activation of a transcription factor, NP-KB. In addition, an essential role of the NF-KB site in the IL-8 gene activation was confirmed by the chloramphenicol acetyltransferase assay,IL-8 production by OA or VA was inhibited by protein kinase inhibitors, including staurosporine, H-7, R252a, herbimycin A, and genistein, Both OA and VA induced significant tyrosine phosphorylation of p44, which was presumed to be Erk1, a member of the mitogen-activated protein kinase family, with concomitant activation of the mitogen-activated protein kinase activity, In parallel, rapid degradation of I kappa B-alpha, an inhibitory component. of NF-kappa B, was observed. Since OA-activated Erk1 phosphorylated recombinant I kappa B-alpha in vitro, we assumed that Erk1 is involved in the phosphorylation and subsequent degradation of I kappa B-alpha, thus leading to the activation of IL-8 gene transcription.	KYORITSU COLL PHARMACEUT SCI,DEPT BIOCHEM,MINATO KU,TOKYO 105,JAPAN; KUMAMOTO UNIV,SCH MED,DIV CELL DIFFERENTIAT,KUMAMOTO 860,JAPAN; KANAZAWA UNIV,CANC RES INST,DEPT PHARMACOL,ISHIKAWA 960,JAPAN	Kumamoto University; Kanazawa University			KUNO, Kouji/D-8439-2015; Mukaida, Naofumi/D-7623-2011	Mukaida, Naofumi/0000-0002-4193-1851				ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; CAVAILLON J-M, 1990, Cytokine, V2, P313, DOI 10.1016/1043-4666(90)90061-W; CHEN JZ, 1996, CELL, V84, P853; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; FISCHKOFF SA, 1986, BLOOD, V68, P185; FURUTANI Y, 1989, BIOCHEM BIOPH RES CO, V159, P249, DOI 10.1016/0006-291X(89)92430-3; GOMOLIN HI, 1993, BLOOD, V82, P1868; GUY GR, 1992, J BIOL CHEM, V267, P1846; ISHIKAWA Y, 1995, J BIOL CHEM, V270, P4158, DOI 10.1074/jbc.270.8.4158; KASAHARA T, 1990, BIOCHEM BIOPH RES CO, V167, P1242, DOI 10.1016/0006-291X(90)90657-9; KASAHARA T, 1991, IMMUNOLOGY, V74, P60; KO YC, 1992, J IMMUNOL METHODS, V149, P227, DOI 10.1016/0022-1759(92)90254-Q; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P9288; KUNO K, 1995, J BIOL CHEM, V270, P27914, DOI 10.1074/jbc.270.46.27914; LARSEN CG, 1989, IMMUNOLOGY, V68, P31; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; Leonardo MJ, 1998, CELL, V58, P227; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MATSUSHIMA K, 1989, J EXP MED, V169, P1185; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; SUNG SSJ, 1993, J BIOL CHEM, V268, P5802; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TORRES M, 1993, J IMMUNOL, V150, P1563; TRIESMAN R, 1994, CURR OPIN GENET DEV, V4, P96; WHITE MV, 1989, IMMUNOL LETT, V22, P151, DOI 10.1016/0165-2478(89)90182-X; XIA HZ, 1993, BLOOD, V82, P2806; YAN MH, 1994, NATURE, V372, P798; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818	42	89	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15366	15372		10.1074/jbc.272.24.15366	http://dx.doi.org/10.1074/jbc.272.24.15366			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182566	hybrid			2022-12-27	WOS:A1997XE03400049
J	Waite, KA; Wallin, R; QualliotineMann, D; McPhail, LC				Waite, KA; Wallin, R; QualliotineMann, D; McPhail, LC			Phosphatidic acid-mediated phosphorylation of the NADPH oxidase component p47-phox - Evidence that phosphatidic acid may activate a novel protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; RESPIRATORY BURST ENZYME; ZIPPER-LIKE SEQUENCES; GTP-BINDING PROTEIN; CELL-FREE SYSTEM; HUMAN-NEUTROPHILS; PHOSPHOLIPASE-D; SUPEROXIDE PRODUCTION; LEUCYL-PHENYLALANINE	Phosphatidic acid (PA), generated by phospholipase D activation, has been linked to the activation of the neutrophil respiratory burst enzyme, NADPH oxidase; however, the intracellular enzyme targets for PA remain unclear. We have recently shown (McPhail, L, C,, Qualliotine-Mann, D,, and Waite, K, A, (1995) Proc. Natl, Acad, Sci, U. S, A. 92, 7931-7935) that a PA-activated protein kinase is involved in the activation of NADPH oxidase in a cell-free system. This protein kinase phosphorylates numerous endogenous proteins, including p47-phox, a component of the NADPH oxidase complex. Phospholipids other than PA were less effective at inducing endogenous protein phosphorylation, Several of these endogenous substrates were also phosphorylated during stimulation of intact cells by opsonized zymosan, an agonist that induces phospholipase D activation, We sought to identify the PA-activated protein kinase that phosphorylates p47-phox, The PA dependent protein kinase was shown to be cytosolic. cis-Unsaturated fatty acids were poor inducers of protein kinase activity, suggesting that the PA-activated protein kinase is not a fatty acid-regulated protein kinase (e.g. protein kinase N), Chromatographic techniques separated the PA activated protein kinase from a number of other protein kinases known to be activated by PA or to phosphorylate p47-phox. These included isoforms of protein kinase C, p21 (Cdc42/Rac)-activated protein kinase, and mitogen-activated protein kinase. Gel filtration chromatography indicated that the protein kinase has an apparent molecular size of 125 kDa, Screening of cytosolic fractions from several cell types and rat brain suggested the enzyme has widespread cell and tissue distribution. The partially purified protein kinase was sensitive to the same protein kinase inhibitors that diminished NADPH oxidase activation and was independent of guanosine 5'-3-O-(thio)triphosphate and Ca2+. Phosphoamino acid analysis showed that serine and tyrosine residues were phosphorylated on p47-phox by this kinase(s). These data indicate that one or more potentially novel protein kinases are targets for PA in neutrophils and other cell types. Furthermore, a PA-activated protein kinase is likely to be an important regulator of the neutrophil respiratory burst by phosphorylation of the NADPH oxidase component p47-phox.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT BIOCHEM, MED CTR, WINSTON SALEM, NC 27157 USA; WAKE FOREST UNIV, MED CTR, DEPT MED, WINSTON SALEM, NC 27157 USA; WAKE FOREST UNIV, MED CTR, DIV INFECT DIS, WINSTON SALEM, NC 27157 USA; WAKE FOREST UNIV, MED CTR, DIV RHEUMATOL, WINSTON SALEM, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest University; Wake Forest University			McPhail, Linda C/D-9505-2013	McPhail, Linda C/0000-0002-8670-306X	NATIONAL CANCER INSTITUTE [T32CA009422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022564] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA9422] Funding Source: Medline; NIAID NIH HHS [2RO1AI-22564, R01 AI022564] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; AGWU DE, 1989, J BIOL CHEM, V264, P1405; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; AMREIN PC, 1980, BLOOD, V56, P442; ARIS JP, 1993, BIOCHIM BIOPHYS ACTA, V1174, P171, DOI 10.1016/0167-4781(93)90111-P; BELLAVITE P, 1988, J BIOL CHEM, V263, P8210; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALDWELL SE, 1988, J CLIN INVEST, V81, P1485, DOI 10.1172/JCI113480; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; DANG PMC, 1994, FEBS LETT, V349, P338, DOI 10.1016/0014-5793(94)00700-4; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DELLABIANCA V, 1991, BIOCHEM BIOPH RES CO, V177, P948, DOI 10.1016/0006-291X(91)90630-P; Dieterich S, 1996, FEBS LETT, V381, P183, DOI 10.1016/0014-5793(96)00116-0; DING J, 1996, FASEB J, V10, pA1268; DING JB, 1994, FEBS LETT, V348, P149, DOI 10.1016/0014-5793(94)00593-1; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; GABIG TG, 1990, J IMMUNOL, V145, P945; GERARD C, 1986, J CLIN INVEST, V77, P61, DOI 10.1172/JCI112302; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GRINSTEIN S, 1993, J BIOL CHEM, V268, P20223; HEYWORTH PG, 1990, J BIOENERG BIOMEMBR, V22, P1, DOI 10.1007/BF00762842; HUNTER T, 1988, COLD SPRING HARB SYM, V53, P131, DOI 10.1101/SQB.1988.053.01.019; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; Kent JD, 1996, J IMMUNOL, V157, P4641; KHAN WA, 1994, J BIOL CHEM, V269, P9729; KIM HD, 1986, J PHARMACOL EXP THER, V236, P585; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KRAMER IM, 1988, J BIOL CHEM, V263, P2352; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETO TL, 1991, J BIOL CHEM, V266, P19812; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MCPHAIL LC, 1993, EUR J HAEMATOL, V51, P294; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; MCPHAIL LC, 1983, J CLIN INVEST, V72, P192, DOI 10.1172/JCI110957; MCPHAIL LC, 1995, P NATL ACAD SCI USA, V92, P7931, DOI 10.1073/pnas.92.17.7931; MORRICE NA, 1994, FEBS LETT, V351, P171, DOI 10.1016/0014-5793(94)00854-X; MORRICE NA, 1994, J BIOL CHEM, V269, P20040; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V204, P348, DOI 10.1006/bbrc.1994.2466; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; PALMER RH, 1994, FEBS LETT, V356, P5, DOI 10.1016/0014-5793(94)01202-4; PALMER RH, 1995, BIOCHEM J, V309, P315, DOI 10.1042/bj3090315; Peng B, 1996, J BIOL CHEM, V271, P32233, DOI 10.1074/jbc.271.50.32233; PONTREMOLI S, 1990, J BIOL CHEM, V265, P706; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; QUALLIOTINEMANN D, 1993, J BIOL CHEM, V268, P23843; RAVICHANDRAN V, 1994, J BIOL CHEM, V269, P25010; ROOS D, 1981, J IMMUNOL, V126, P433; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; SENISTERRA GA, 1993, BIOCHEM BIOPH RES CO, V190, P33, DOI 10.1006/bbrc.1993.1006; SMALLWOOD JI, 1992, J LEUKOCYTE BIOL, V51, P84, DOI 10.1002/jlb.51.1.84; SOZZANI S, 1992, J BIOL CHEM, V267, P20481; STASEK JE, 1993, BIOCHEM BIOPH RES CO, V191, P134, DOI 10.1006/bbrc.1993.1194; STASIA MJ, 1990, FEBS LETT, V274, P61, DOI 10.1016/0014-5793(90)81329-M; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; THOMPSON HL, 1994, J BIOL CHEM, V269, P9486; THOMPSON NT, 1991, TRENDS PHARMACOL SCI, V12, P404, DOI 10.1016/0165-6147(91)90617-2; TORRES M, 1993, J IMMUNOL, V150, P1563; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UHLINGER DJ, 1992, BIOCHEM BIOPH RES CO, V187, P940, DOI 10.1016/0006-291X(92)91288-2; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WITT JJ, 1975, ANAL BIOCHEM, V66, P253, DOI 10.1016/0003-2697(75)90743-5; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	84	127	130	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15569	15578		10.1074/jbc.272.24.15569	http://dx.doi.org/10.1074/jbc.272.24.15569			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182594	hybrid			2022-12-27	WOS:A1997XE03400077
J	Zhang, LR; Sports, CD; Osawa, S; Weiss, ER				Zhang, LR; Sports, CD; Osawa, S; Weiss, ER			Rhodopsin phosphorylation sites and their role in arrestin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LIGHT-DEPENDENT PHOSPHORYLATION; COUPLED RECEPTOR KINASES; ROD OUTER SEGMENTS; BOVINE RHODOPSIN; CARBOXYL-TERMINUS; VISUAL ARRESTIN; IN-VIVO; ANTIPEPTIDE ANTIBODIES; SEQUENCE-ANALYSIS	Rhodopsin, the rod cell photoreceptor, undergoes rapid desensitization upon exposure to light, resulting in uncoupling of the receptor from its G protein, transducin (G(t)). Phosphorylation of serine and threonine residues located in the COOH terminus of rhodopsin is the first step in this process, followed by the binding of arrestin. In this study, a series of mutants was generated in which these COOH-terminal phosphorylation substrate sites were substituted with alanines. These mutants were expressed in HEK-293 cells and analyzed for their ability to be phosphorylated by rhodopsin kinase and to bind arrestin. The results demonstrate that rhodopsin kinase can efficiently phosphorylate other serine and threonine residues in the absence of the sites reported to be the preferred substrates for rhodopsin kinase. A correlation was observed between the level of rhodopsin phosphorylation and the amount of arrestin binding to these mutants. However, mutants T340A and S343A. demonstrated a significant reduction in arrestin binding even though the level of phosphorylation was similar to that of wild-type rhodopsin. Substitution of Thr-340 and Ser-343 with glutamic acid residues (T340E and S343E, respectively) was not sufficient to promote the binding of arrestin in the absence of phosphorylation by rhodopsin kinase. When S343E was phosphorylated, its ability to bind arrestin was similar to that of wild-type rhodopsin. Surprisingly, arrestin binding to phosphorylated T340E did not increase to the level observed for wild-type rhodopsin. These results suggest that 2 amino acids, Thr-340 and Ser-343, play important but distinct roles in promoting the binding of arrestin to rhodopsin.	UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Weiss, Ellen/AAK-9868-2020		NIGMS NIH HHS [GM43582, GM47438] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047438, R01GM043582, R29GM043582, R55GM047438] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMUS G, 1991, VISION RES, V31, P17, DOI 10.1016/0042-6989(91)90069-H; ADAMUS G, 1993, ARCH BIOCHEM BIOPHYS, V304, P443, DOI 10.1006/abbi.1993.1373; ATON B, 1984, EXP EYE RES, V38, P547, DOI 10.1016/0014-4835(84)90173-8; ATON BR, 1984, BIOCHEMISTRY-US, V23, P1737, DOI 10.1021/bi00303a024; BOLLUM FJ, 1968, METHODS ENZYMOLOGY B, V12, P169; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN NG, 1992, EUR J BIOCHEM, V208, P659, DOI 10.1111/j.1432-1033.1992.tb17232.x; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; GREENE NM, 1995, J BIOL CHEM, V270, P6710, DOI 10.1074/jbc.270.12.6710; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KELLEHER DJ, 1990, J BIOL CHEM, V265, P2632; KELLEHER DJ, 1985, J CYCLIC NUCL PROT, V10, P579; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KLAPPER MH, 1977, BIOCHEM BIOPH RES CO, V78, P1018, DOI 10.1016/0006-291X(77)90523-X; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIMBIRD LE, 1996, CELL SURFACE RECEPTO; McCall R. B., 1975, FUNDAMENTAL STAT PSY; MCDOWELL JH, 1993, BIOCHEMISTRY-US, V32, P4968, DOI 10.1021/bi00069a036; MILLER JL, 1984, VISION RES, V24, P1509, DOI 10.1016/0042-6989(84)90313-4; MORRISON P, 1993, J BIOL CHEM, V268, P15536; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P937, DOI 10.1021/bi00456a013; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; OHGURO H, 1994, BIOCHEMISTRY-US, V33, P1023, DOI 10.1021/bi00170a022; Ohguro H, 1996, J BIOL CHEM, V271, P5215; OSAWA S, 1994, MOL PHARMACOL, V46, P1036; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PAPAC DI, 1993, BIOCHEMISTRY-US, V32, P5930, DOI 10.1021/bi00074a002; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; PUIG J, 1995, FEBS LETT, V362, P185, DOI 10.1016/0014-5793(95)00225-X; PULLEN N, 1994, BIOCHEMISTRY-US, V33, P14536, DOI 10.1021/bi00252a021; PULLEN N, 1993, BIOCHEMISTRY-US, V32, P3958, DOI 10.1021/bi00066a016; RANGANATHAN R, 1995, CELL, V81, P841, DOI 10.1016/0092-8674(95)90004-7; Robinson Phyllis, 1996, Investigative Ophthalmology and Visual Science, V37, pS809; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; SHI W, 1995, J BIOL CHEM, V270, P2112, DOI 10.1074/jbc.270.5.2112; WEISS ER, 1987, J BIOL CHEM, V262, P4319; WEISS ER, 1988, J BIOL CHEM, V263, P6150; WEISS ER, 1994, BIOCHEMISTRY-US, V33, P7587, DOI 10.1021/bi00190a011; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; WISTOW GJ, 1986, FEBS LETT, V196, P23, DOI 10.1016/0014-5793(86)80207-1; WITTEKIND M, 1989, BIOCHEMISTRY-US, V28, P9908, DOI 10.1021/bi00452a005; Yamamura H.L., 1985, NEUROTRANSMITTER REC; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	56	57	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14762	14768		10.1074/jbc.272.23.14762	http://dx.doi.org/10.1074/jbc.272.23.14762			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169442	Green Published, hybrid			2022-12-27	WOS:A1997XC32700039
J	Mashkevich, G; Repetto, B; Glerum, DM; Jin, C; Tzagoloff, A				Mashkevich, G; Repetto, B; Glerum, DM; Jin, C; Tzagoloff, A			SHY1, the yeast homolog of the mammalian SURF-1 gene encodes a mitochondrial protein required for respiration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; NUCLEAR MUTANTS; EXPRESSION; MEMBRANE; SITES; IDENTIFICATION; ORGANIZATION; OXIDASE; VECTORS	C173 and W125 are pet mutants of Saccharomyces cerevisiae, partially deficient in cytochrome oxidase but with elevated concentrations of cytochrome c. Assays of electron transport chain enzymes indicate that the mutations exert different effects on the terminal respiratory pathway, including an inefficient transfer of electrons between the bc(1) and the cytochrome oxidase complexes, A cloned gene capable of restoring respiration in C173/U1 and W125 is identical to reading frame YGR112w of yeast chromosome VII (GenBank Z72897), The encoded protein is homologous to the product of the mammalian SURF-I gene, In view of the homology, the yeast gene has been designated SHY1 (Surf Homolog of Yeast), An antibody against the carboxyl-terminal half of Shy1p has been used to localize the protein in the inner mitochondrial membrane. Deletion of part of SHY1 produces a phenotype similar to that of G91 mutants, Disruption of SHY1 at a BamHI site, located approximately 2/3 of the way into the gene, has no obvious phenotypic consequence, This evidence, together with the ability of a carboxyl-terminal coding sequence starting from the BamHI site to complement a shy1 mutant, suggests that the Shy1p contains two domains that can be separately expressed to form a functional protein.			Mashkevich, G (corresponding author), COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA.		Glerum, Moira/AHD-3271-2022		NHLBI NIH HHS [HL22174] Funding Source: Medline; NIGMS NIH HHS [R01 GM050187] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022174, R37HL022174, R56HL022174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050187] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON DS, 1986, P NATL ACAD SCI USA, V83, P9011, DOI 10.1073/pnas.83.23.9011; ARMES N, 1995, MOL CELL BIOL, V15, P2367; BEGGS JD, 1978, NATURE, V275, P104, DOI 10.1038/275104a0; BOTSTEIN D, 1982, MOL BIOL YEAST SACCH, P607; BUCHWALD P, 1991, MOL GEN GENET, V229, P413, DOI 10.1007/BF00267464; COLOMBO P, 1992, P NATL ACAD SCI USA, V89, P6358, DOI 10.1073/pnas.89.14.6358; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Glick BS, 1995, METHOD ENZYMOL, V260, P224, DOI 10.1016/0076-6879(95)60140-6; GRIVELL LA, 1995, CRIT REV BIOCHEM MOL, V30, P121, DOI 10.3109/10409239509085141; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; King EJ, 1932, BIOCHEM J, V26, P292, DOI 10.1042/bj0260292; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KOERNER TJ, 1985, J BIOL CHEM, V260, P5871; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENNARD A, 1994, DNA CELL BIOL, V13, P1117, DOI 10.1089/dna.1994.13.1117; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; PEL HJ, 1992, CURR GENET, V21, P139, DOI 10.1007/BF00318473; PON L, 1989, J CELL BIOL, V109, P2603, DOI 10.1083/jcb.109.6.2603; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHMIDT RJ, 1984, MOL BIOL EVOL, V1, P317; SHERMAN F, 1963, GENETICS, V48, P375; TAKEDA M, 1986, J BIOL CHEM, V261, P5126; ten Berge A M, 1974, Mol Gen Genet, V131, P113; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228	32	110	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14356	14364		10.1074/jbc.272.22.14356	http://dx.doi.org/10.1074/jbc.272.22.14356			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162072	hybrid			2022-12-27	WOS:A1997XB49200059
J	Whyte, DB; Kirschmeier, P; Hockenberry, TN; NunezOliva, I; James, L; Catino, JJ; Bishop, WR; Pai, JK				Whyte, DB; Kirschmeier, P; Hockenberry, TN; NunezOliva, I; James, L; Catino, JJ; Bishop, WR; Pai, JK			K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSLATIONAL MODIFICATION; PRENYLATION; FARNESYLTRANSFERASE; P21RAS; GROWTH; LINES; ISOPRENOIDS; MEVALONATE	The association of mutant forms of Ras protein with a variety of human cancers has stimulated intense interest in therapies based on inhibiting oncogenic Ras signaling, Attachment of Ras proteins to the plasma membrane is required for effective Ras signaling and is initiated by the enzyme farnesyl protein transferase. We found that in the presence of potent farnesyl protein transferase inhibitors, Ras proteins in the human colon carcinoma cell line DLD-1 were alternatively prenylated by geranylgeranyl transferase-1, When H-Ras, N-Ras, K-Ras4A, and K-Ras4B were expressed individually in COS cells, H-Ras prenylation and membrane association were found to be uniquely sensitive to farnesyl transferase inhibitors; N- and K-Ras proteins incorporated the geranylgeranyl isoprene group and remained associated with the membrane fraction, The alternative prenylation of N- and K-Ras has significant implications for our understanding of the mechanism of action of farnesyl protein transferase inhibitors as anti-cancer chemotherapeutics.			Whyte, DB (corresponding author), SCHERING PLOUGH CORP,RES INST,DEPT TUMOR BIOL,BLDG K15-4-4600,2015 GALLOPING HILL RD,KENILWORTH,NJ 07033, USA.							BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bishop WR, 1995, J BIOL CHEM, V270, P30611, DOI 10.1074/jbc.270.51.30611; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1992, J LIPID RES, V33, P1731; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; James G, 1996, P NATL ACAD SCI USA, V93, P4454, DOI 10.1073/pnas.93.9.4454; JAMES GL, 1994, J BIOL CHEM, V269, P27705; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KIM CM, 1992, J BIOL CHEM, V267, P23113; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Miyake M, 1996, FEBS LETT, V378, P15, DOI 10.1016/0014-5793(95)01416-0; REESE JH, 1991, MOL CELL BIOCHEM, V104, P109; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; RILLING HC, 1993, ARCH BIOCHEM BIOPHYS, V301, P210, DOI 10.1006/abbi.1993.1135; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; SINENSKY M, 1992, BIOESSAYS, V14, P25, DOI 10.1002/bies.950140106; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	25	696	716	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14459	14464		10.1074/jbc.272.22.14459	http://dx.doi.org/10.1074/jbc.272.22.14459			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162087	hybrid			2022-12-27	WOS:A1997XB49200074
J	CordeiroStone, M; Zaritskaya, LS; Price, LK; Kaufmann, WK				CordeiroStone, M; Zaritskaya, LS; Price, LK; Kaufmann, WK			Replication fork bypass of a pyrimidine dimer blocking leading strand DNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XERODERMA-PIGMENTOSUM VARIANT; IRRADIATED HUMAN-CELLS; ULTRAVIOLET-LIGHT; HUMAN-FIBROBLASTS; POSTREPLICATION REPAIR; EXCISION REPAIR; N-2-ACETYLAMINOFLUORENE ADDUCTS; ANCHORAGE INDEPENDENCE; INDUCED MUTATIONS; THYMINE DIMERS	We constructed a double-stranded plasmid containing a single cis,syn-cyclobutane thymine dimer (T[c,s]T) 385 base pairs from the center of the SV40 origin of replication. This circular DNA was replicated in vitro by extracts from several types of human cells. The dimer was placed on the leading strand template of the first replication fork to encounter the lesion, Two-dimensional gel electrophoresis of replication intermediates documented the transient arrest of the replication fork by the dimer. Movement of the replication fork beyond the dimer was recognized by the appearance of a single fork are in DNA sequences located between the T[c,s]T and the half-way point around the circular template (180 degrees from the origin). Upon completion of plasmid replication, the T[c,s]T was detected by T4 endonuclease V in about one-half (46 +/- 9%) of the closed circular daughter molecules. Our results demonstrate that extracts prepared from HeLa cells and SV40-transformed human fibroblasts (SV80, IDH4), including a cell line defective in nucleotide-excision repair (XPA), were competent for leading strand DNA synthesis opposite the pyrimidine dimer and replication fork bypass. In contrast, dimer bypass was severely impaired in otherwise replication-competent extracts from two different xeroderma pigmentosum variant cell lines.			CordeiroStone, M (corresponding author), UNIV N CAROLINA, SCH MED, DEPT PATHOL & LAB MED, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA.				NCI NIH HHS [CA55065, CA42765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055065, R55CA055065, P01CA042765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANANTHASWAMY HN, 1990, PHOTOCHEM PHOTOBIOL, V52, P1119, DOI 10.1111/j.1751-1097.1990.tb08452.x; BOYER JC, 1991, CANCER RES, V51, P2960; BOYER JC, 1990, CANCER RES, V50, P2593; BRASH DE, 1987, P NATL ACAD SCI USA, V84, P3782, DOI 10.1073/pnas.84.11.3782; BREDBERG A, 1986, P NATL ACAD SCI USA, V83, P8273, DOI 10.1073/pnas.83.21.8273; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CANCER CELL, V6, P229; BURK PG, 1971, J LAB CLIN MED, V77, P759; CARTY MP, 1993, MOL CELL BIOL, V13, P533, DOI 10.1128/MCB.13.1.533; Carty MP, 1996, J BIOL CHEM, V271, P9637, DOI 10.1074/jbc.271.16.9637; CHOI KH, 1983, CYTOGENET CELL GENET, V36, P633, DOI 10.1159/000131987; CLEAVER JE, 1980, CARCINOGENESIS, V1, P647, DOI 10.1093/carcin/1.8.647; CLEAVER JE, 1979, BIOCHIM BIOPHYS ACTA, V564, P122, DOI 10.1016/0005-2787(79)90193-X; CLEAVER JE, 1972, J INVEST DERMATOL, V58, P124, DOI 10.1111/1523-1747.ep12538913; Cleaver JE, 1995, METABOLIC MOL BASES, VIII, P4393; CLINGEN PH, 1995, CANCER RES, V55, P2245; CORDEIROSTONE M, 1979, BIOPHYS J, V27, P287, DOI 10.1016/S0006-3495(79)85218-2; DIJKWEL PA, 1994, NUCLEIC ACIDS RES, V22, P4989, DOI 10.1093/nar/22.23.4989; DUMAZ N, 1994, MUTAT RES, V307, P375, DOI 10.1016/0027-5107(94)90311-5; EDENBERG HJ, 1976, BIOPHYS J, V16, P849, DOI 10.1016/S0006-3495(76)85735-9; FUGIWARA Y, 1976, MUTAT RES, V37, P91; HESSEL A, 1992, ARCH DERMATOL, V128, P1233, DOI 10.1001/archderm.128.9.1233; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; Hoffmann JS, 1996, P NATL ACAD SCI USA, V93, P13766, DOI 10.1073/pnas.93.24.13766; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; *INT AG RES CANC W, 1992, IARC MONOGR EVAL CAR, V55, P43; JUNG EG, 1970, NATURE, V228, P361, DOI 10.1038/228361a0; KAUFMANN WK, 1981, J MOL BIOL, V149, P171, DOI 10.1016/0022-2836(81)90297-7; KAUFMANN WK, 1994, MUTAT RES, V314, P67, DOI 10.1016/0921-8777(94)90062-0; KAUFMANN WK, 1989, CARCINOGENESIS, V10, P1, DOI 10.1093/carcin/10.1.1; KING SA, 1995, EXP CELL RES, V217, P100, DOI 10.1006/excr.1995.1068; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LEBKOWSKI JS, 1985, P NATL ACAD SCI USA, V82, P8606, DOI 10.1073/pnas.82.24.8606; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; LEHMANN AR, 1972, J MOL BIOL, V66, P319, DOI 10.1016/0022-2836(72)90418-4; LI JJ, 1985, MOL CELL BIOL, V5, P1238, DOI 10.1128/MCB.5.6.1238; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; MAHER VM, 1976, NATURE, V261, P593, DOI 10.1038/261593a0; MCCORMICK JJ, 1986, CANCER RES, V46, P489; MCGREGOR WG, 1991, MOL CELL BIOL, V11, P1927, DOI 10.1128/MCB.11.4.1927; MENEGHINI R, 1976, BIOCHIM BIOPHYS ACTA, V425, P419, DOI 10.1016/0005-2787(76)90006-X; MENEGHINI R, 1981, BIOPHYS J, V33, P81, DOI 10.1016/S0006-3495(81)84873-4; MENEGHINI R, 1976, BIOCHIM BIOPHYS ACTA, V425, P428, DOI 10.1016/0005-2787(76)90007-1; MOORE P, 1979, NATURE, V278, P664, DOI 10.1038/278664a0; MOORE PD, 1981, P NATL ACAD SCI-BIOL, V78, P110, DOI 10.1073/pnas.78.1.110; MYHR BC, 1979, MUTAT RES, V62, P341, DOI 10.1016/0027-5107(79)90089-7; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; ODAY CL, 1992, NUCLEIC ACIDS RES, V20, P5403, DOI 10.1093/nar/20.20.5403; Raha M, 1996, P NATL ACAD SCI USA, V93, P2941, DOI 10.1073/pnas.93.7.2941; ROBERTS JD, 1988, P NATL ACAD SCI USA, V85, P7064, DOI 10.1073/pnas.85.19.7064; ROBERTS JD, 1993, METHODS MOL GENET, V2, P295; SCOTTO J, 1983, NIH832433 US DEP HLT, P1; SETLOW RB, 1965, P NATL ACAD SCI USA, V53, P1111, DOI 10.1073/pnas.53.5.1111; SHAY JW, 1992, EXP GERONTOL, V27, P477, DOI 10.1016/0531-5565(92)90003-I; Svoboda DL, 1995, P NATL ACAD SCI USA, V92, P11975, DOI 10.1073/pnas.92.26.11975; TESSMAN I, 1992, P NATL ACAD SCI USA, V89, P1159, DOI 10.1073/pnas.89.4.1159; THIELMANN HW, 1991, CANCER RES, V51, P3456; THOMAS DC, 1995, J BIOL CHEM, V270, P21226, DOI 10.1074/jbc.270.36.21226; THOMAS DC, 1994, P NATL ACAD SCI USA, V91, P7752, DOI 10.1073/pnas.91.16.7752; THOMAS DC, 1993, P NATL ACAD SCI USA, V90, P7744, DOI 10.1073/pnas.90.16.7744; TorresRamos CA, 1996, P NATL ACAD SCI USA, V93, P9676, DOI 10.1073/pnas.93.18.9676; VANZEELAND AA, 1982, PROG MUTAT RES, V4, P375; VOLPE JPG, 1995, MUTAT RES-DNA REPAIR, V337, P111, DOI 10.1016/0921-8777(95)00015-C; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WANG YC, 1993, MOL CELL BIOL, V13, P4276, DOI 10.1128/MCB.13.7.4276; WATANABE M, 1985, MUTAT RES, V146, P285, DOI 10.1016/0167-8817(85)90070-7; WATERS HL, 1993, J INVEST DERMATOL, V101, P744, DOI 10.1111/1523-1747.ep12371686; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	70	116	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13945	13954		10.1074/jbc.272.21.13945	http://dx.doi.org/10.1074/jbc.272.21.13945			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153257	hybrid, Green Published			2022-12-27	WOS:A1997XA06200072
J	Yoshida, R; Imai, T; Hieshima, K; Kusuda, J; Baba, M; Kitaura, M; Nishimura, M; Kakizaki, M; Nomiyama, H; Yoshie, O				Yoshida, R; Imai, T; Hieshima, K; Kusuda, J; Baba, M; Kitaura, M; Nishimura, M; Kakizaki, M; Nomiyama, H; Yoshie, O			Molecular cloning of a novel human CC chemokine EBI1-ligand chemokine that is a specific functional ligand for EBI1, CCR7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; MONOCYTE CHEMOATTRACTANT PROTEIN-3; HUMAN INTERLEUKIN-8 RECEPTOR; CHEMOTACTIC CYTOKINES; INDUCIBLE PROTEIN-10; HUMAN HERPESVIRUS-6; MESSENGER-RNA; GRO-ALPHA; T-CELLS; EXPRESSION	By searching the expressed sequence tag (EST) data base, we identified partial cDNA sequences encoding a novel human CC chemokine. We determined the complete cDNA sequence that encodes a highly basic polypeptide of a total 98 amino acids with 20 to 30% identity to other human CC chemokines. We termed this novel chemokine from EBI1-Ligand Chemokine as ELC (see below). The ELC mRNA was most strongly expressed in the thymus and lymph nodes. Recombinant ELC protein was expressed as a fusion protein with the Flag tag (ELC-Flag). For receptor-binding assays, recombinant ELC protein fused with the secreted form of alkaline phosphatase (SEAP) was used. By stably expressing five CC chemokine receptors (CCR1 to 5) and five orphan receptors, ELC-SEAP was found to bind specifically to an orphan receptor EBI1. Only ELC-Flag, but not MCP-1, MCP-2, MCP-3, eotaxin, MIP-1 alpha, MIP-1 beta, RANTES (regulated on activation normal T cell expressed and secreted), thymus and activation-regulated chemokine (TARC), or liver and activation-regulated chemokine (LARC), competed with ELC-SEAP for EBI1. ELC-Flag-induced transient calcium mobilization and chemotactic responses in EBI1-transfected cells. ELC-Flag also induced chemotaxis in HUT78 cells expressing endogenous EBI1 at high levels. By somatic hybrid and radiation hybrid analyses, the gene for ELC (SCYA19) was mapped to chromosome 9p13 instead of chromosome 17q11.2 where the genes for CC chemokines are clustered. Taken together, ELC is a highly specific ligand for EBI1, which is known to be expressed in activated B and T lymphocytes and strongly up-regulated in B cells infected with Epstein-Barr virus and T cells infected with herpesvirus 6 or 7. ELC and EBI1 may thus play roles in migration and homing of normal lymphocytes, as well. as in pathophysiology of lymphocytes infected with these herpesviruses. We propose EBI1 to be designated as CCR7.	SHIONOGI INST MED SCI,SETTSU,OSAKA 566,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT BIOCHEM,KUMAMOTO 860,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT INTERNAL MED,KUMAMOTO 860,JAPAN; NATL INST HLTH,LAB GENET RESOURCES,SHINJUKU KU,TOKYO 16,JAPAN	Shionogi & Company Limited; Kumamoto University; Kumamoto University			Nomiyama, Hisayuki/F-2840-2013; Hieshima, Kunio/AAF-7040-2019	Nomiyama, Hisayuki/0000-0002-2716-4043; Hieshima, Kunio/0000-0002-7786-4646; Yoshie, Osamu/0000-0003-4353-5809				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; BABA M, 1997, IN PRESS J BIOL CHEM; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BENBARUCH A, 1995, J BIOL CHEM, V270, P11703, DOI 10.1074/jbc.270.20.11703; BENBARUCH A, 1995, J BIOL CHEM, V270, P22123, DOI 10.1074/jbc.270.38.22123; BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; BROXMEYER HE, 1990, BLOOD, V76, P1110; BURGSTAHLER R, 1995, BIOCHEM BIOPH RES CO, V215, P737, DOI 10.1006/bbrc.1995.2525; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; Chang H C, 1989, Int Immunol, V1, P388, DOI 10.1093/intimm/1.4.388; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHEE MS, 1990, NATURE, V344, P774, DOI 10.1038/344774a0; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COMBADIERE C, 1995, DNA CELL BIOL, V14, P673, DOI 10.1089/dna.1995.14.673; COMBADIERE C, 1995, J BIOL CHEM, V270, P29671; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; DavisPoynter NJ, 1997, J VIROL, V71, P1521, DOI 10.1128/JVI.71.2.1521-1529.1997; DOBNER T, 1992, EUR J IMMUNOL, V22, P2795, DOI 10.1002/eji.1830221107; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; FRANCI C, 1995, J IMMUNOL, V154, P6511; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; FURUTANI Y, 1989, BIOCHEM BIOPH RES CO, V159, P249, DOI 10.1016/0006-291X(89)92430-3; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GEISER T, 1993, J BIOL CHEM, V268, P15419; GOMPELS UA, 1995, VIROLOGY, V209, P29, DOI 10.1006/viro.1995.1228; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; HASEGAWA H, 1994, J VIROL, V68, P5326, DOI 10.1128/JVI.68.8.5326-5329.1994; Hieshima K, 1997, J BIOL CHEM, V272, P5846, DOI 10.1074/jbc.272.9.5846; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; Imai T, 1996, J BIOL CHEM, V271, P21514, DOI 10.1074/jbc.271.35.21514; IMAI T, 1997, IN PRESS J BIOL CHEM; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LEE J, 1992, J BIOL CHEM, V267, P16283; LIPES MA, 1988, P NATL ACAD SCI USA, V85, P9704, DOI 10.1073/pnas.85.24.9704; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; MILLER MD, 1989, J IMMUNOL, V143, P2907; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Naruse K, 1996, GENOMICS, V34, P236, DOI 10.1006/geno.1996.0274; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NICHOLAS J, 1992, NATURE, V355, P362, DOI 10.1038/355362a0; Nicholas J, 1996, J VIROL, V70, P5975, DOI 10.1128/JVI.70.9.5975-5989.1996; Nomiyama H, 1997, GENOMICS, V40, P211, DOI 10.1006/geno.1996.4552; OBARU K, 1986, J BIOCHEM-TOKYO, V99, P885, DOI 10.1093/oxfordjournals.jbchem.a135549; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; OPDENAKKER G, 1993, BIOCHEM BIOPH RES CO, V191, P535, DOI 10.1006/bbrc.1993.1251; PERICAKVANCE MA, 1995, ANN HUM GENET, V59, P347, DOI 10.1111/j.1469-1809.1995.tb00756.x; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; RAPORT CJ, 1995, GENE, V163, P295, DOI 10.1016/0378-1119(95)00336-5; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SARRIS AH, 1993, J EXP MED, V178, P1127, DOI 10.1084/jem.178.3.1127; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; SCHWEICKART VL, 1994, GENOMICS, V23, P643, DOI 10.1006/geno.1994.1553; Smith RF, 1996, GENOME RES, V6, P454, DOI 10.1101/gr.6.5.454; STRIETER RM, 1995, BIOCHEM BIOPH RES CO, V210, P51, DOI 10.1006/bbrc.1995.1626; Uguccioni M, 1996, J EXP MED, V183, P2379, DOI 10.1084/jem.183.5.2379; VanSnick J, 1996, J IMMUNOL, V157, P2570; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YOSHIDA T, 1995, FEBS LETT, V360, P155, DOI 10.1016/0014-5793(95)00093-O; YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3; Zaballos A, 1996, BIOCHEM BIOPH RES CO, V227, P846, DOI 10.1006/bbrc.1996.1595	76	336	365	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13803	13809		10.1074/jbc.272.21.13803	http://dx.doi.org/10.1074/jbc.272.21.13803			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153236	hybrid			2022-12-27	WOS:A1997XA06200051
J	HerreraVelit, P; Knutson, KL; Reiner, NE				HerreraVelit, P; Knutson, KL; Reiner, NE			Phosphatidylinositol 3-kinase-dependent activation of protein kinase C-zeta in bacterial lipopolysaccharide-treated human monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; CELLS; ISOFORM; 3-KINASE; ENDOTOXIN; RESPONSES; INHIBITOR; RECEPTOR; ISOZYME; ALPHA	The isoform identity of activated protein kinase C (PRC) and its regulation were investigated in bacterial lipopolysaccharide (LPS)-treated human monocytes. Resolution of detergent-soluble lysates prepared from LPS-treated, peripheral blood monocytes using Mono Q anion-exchange chromatography revealed two principal peaks of myelin basic protein kinase activity. Immunoblotting and immunoprecipitation with isoform-specific anti-PKC antibodies showed that the major and latest eluting peak is accounted for by PKC-zeta. In addition to primary monocytes, activation of PKC-zeta in response to LPS was also observed in the human promonocytic cell lines, U937 and THP-1. Consistent with its identity as PKC-zeta, the kinase did not depend upon the presence of lipids, Ca2+, or diacylglycerol for activity. In addition, the kinase phosphorylates peptide a and myelin basic protein with equal efficiency but phosphorylates Kemptide and protamine sulfate poorly. Translocation of PKC-zeta from the cytosolic to the particulate membrane fraction upon exposure of monocytes to LPS provided further evidence for activation of the kinase. Preincubation of monocytes with the phosphatidylinositol 3-kinase (PI 3-kinase) inhibitors, wortmannin or LY294002, abrogated LPS-induced activation of PKC-zeta. Furthermore, activation of PKC-zeta failed to occur in U937 cells transfected with a dominant negative mutant Of the p85 subunit of PI 3-kinase, PKC-zeta activity was also observed to be enhanced in vitro by the addition of phosphatidylinositol 3,4,5P(3). These findings are consistent with a model in which PKC-zeta is activated downstream of PI 3-kinase in monocytes in response to LPS.	UNIV BRITISH COLUMBIA,FAC MED,DEPT MED,DIV INFECT DIS,VANCOUVER,BC V5Z 3J5,CANADA; UNIV BRITISH COLUMBIA,FAC MED,DEPT MICROBIOL & IMMUNOL,VANCOUVER,BC V5Z 3J5,CANADA; UNIV BRITISH COLUMBIA,FAC SCI,VANCOUVER,BC V5Z 3J5,CANADA; VANCOUVER HOSP & HLTH SCI CTR,RES INST,VANCOUVER,BC V5Z 3J5,CANADA	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia				Herrera, Patricia/0000-0001-8754-9335				BAIER G, 1993, J BIOL CHEM, V268, P4997; BATLLE E, 1994, FEBS LETT, V344, P161, DOI 10.1016/0014-5793(94)00379-3; Boutin JA, 1996, J CHROMATOGR B, V684, P179, DOI 10.1016/0378-4347(95)00563-3; CHANG ZL, 1993, IMMUNOLOGY, V80, P360; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; Gomez J, 1997, J IMMUNOL, V158, P1516; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HerreraVelit P, 1996, J IMMUNOL, V156, P1157; KILEY SC, 1995, J CELL SCI, V108, P1003; KNUTSON KL, 1994, ENDOCRINOLOGY, V135, P881, DOI 10.1210/en.135.3.881; KOCHS G, 1993, EUR J BIOCHEM, V216, P597, DOI 10.1111/j.1432-1033.1993.tb18179.x; KONNO Y, 1989, J BIOCHEM-TOKYO, V106, P673, DOI 10.1093/oxfordjournals.jbchem.a122915; LIU MK, 1994, J IMMUNOL, V153, P2642; LOZANO J, 1994, J BIOL CHEM, V269, P19200; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; SACKTOR TC, 1993, P NATL ACAD SCI USA, V90, P8342, DOI 10.1073/pnas.90.18.8342; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; SHAPIRA L, 1994, J IMMUNOL, V153, P1818; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; TOKER A, 1994, J BIOL CHEM, V269, P32358; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wang DS, 1996, J ORG CHEM, V61, P5905, DOI 10.1021/jo960602u; WATSON RWG, 1994, J LEUKOCYTE BIOL, V56, P95, DOI 10.1002/jlb.56.1.95; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; ZHOU GS, 1994, EXP CELL RES, V214, P1, DOI 10.1006/excr.1994.1227	32	120	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16445	16452		10.1074/jbc.272.26.16445	http://dx.doi.org/10.1074/jbc.272.26.16445			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195953	hybrid			2022-12-27	WOS:A1997XG01900057
J	Wang, YP; Kuropatwinski, KK; White, DW; Hawley, TS; Hawley, RG; Tartaglia, LA; Baumann, H				Wang, YP; Kuropatwinski, KK; White, DW; Hawley, TS; Hawley, RG; Tartaglia, LA; Baumann, H			Leptin receptor action in hepatic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE PLASMA-PROTEINS; RESPONSE ELEMENTS; INSULIN-RECEPTOR; CYTOKINE-RESPONSE; GROWTH-HORMONE; GENES; VIRUS; PHOSPHORYLATION; INTERLEUKIN-6; SUBSTRATE-1	Leptin, an adipocyte-secreted hormone, is one of the central regulators of body weight homeostasis. In humans and rodents, two major forms of leptin receptors (OB-R) are expressed. The short form (OB-R-S), considered to lack signaling capability, is detected in many organs. In contrast, OB-R long form (OB-R-L) predominates in the hypothalamus, but is also present at low levels in peripheral tissues. Transient transfection experiments have demonstrated that OB-R-L transduces an intracellular signaling similar to interleukin (IL)-6 type-cytokine receptors. To define the specificity by which OB-R induces genes and cooperates with signal transduction pathways utilized by other hormones and cytokines, rat and human hepatoma cell lines were generated which stably express human OB-R-L. Hepatoma cell lines selected for appreciable levels of OB-R-L mRNA display enhanced leptin binding and responded to leptin with an IL-6 receptor-like signaling that includes the activation of STAT proteins, induction of acute-phase plasma proteins, and synergism with IL-1 and tumor necrosis factor-alpha. A leptin-mediated recruitment of phosphatidylinositol 3-kinase to insulin receptor substrate-2 was also detected. However, no significant tyrosine phosphorylation of insulin receptor substrate-2 and modulation of the immediate cell response to insulin were observed. The data suggest that OB-R-L action in hepatic cells is equivalent to that of IL-6 receptor. However, leptin does not play a specific role in muting insulin action on hepatoma cells and therefore may not contribute to the diabetic symptoms associated with obesity.	ROSWELL PK CANC INST, DEPT MOL & CELLULAR BIOL, BUFFALO, NY 14263 USA; MILLENNIUM PHARMACEUT INC, CAMBRIDGE, MA 02139 USA; TORONTO HOSP, ONCOL GEN THERAPY PROGRAM, TORONTO, ON M5G 2M1, CANADA	Roswell Park Cancer Institute; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; University of Toronto; University Toronto Affiliates; University Health Network Toronto				Hawley, Robert/0000-0003-3512-5818	NCI NIH HHS [CA26122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; Argetsinger LS, 1996, J BIOL CHEM, V271, P29415, DOI 10.1074/jbc.271.46.29415; Bai YL, 1996, J BIOL CHEM, V271, P13939, DOI 10.1074/jbc.271.24.13939; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BAUMANN H, 1988, METHOD ENZYMOL, V163, P566; BAUMANN H, 1986, J CELL BIOL, V102, P370, DOI 10.1083/jcb.102.2.370; BAUMANN H, 1990, J BIOL CHEM, V265, P22275; BAUMANN H, 1988, J BIOL CHEM, V263, P17390; BAUMANN H, 1993, J IMMUNOL, V151, P4248; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; BRECHNER T, 1991, MOL BIOL MED, V8, P267; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Campos SP, 1996, J BIOL CHEM, V271, P24418, DOI 10.1074/jbc.271.40.24418; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; Hawley RG, 1996, ANN NY ACAD SCI, V795, P341, DOI 10.1111/j.1749-6632.1996.tb52687.x; HAWLEY RG, 1994, GENE THER, V1, P136; Hawley RG, 1996, P NATL ACAD SCI USA, V93, P10297, DOI 10.1073/pnas.93.19.10297; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; Klein S, 1996, DIABETES, V45, P984, DOI 10.2337/diabetes.45.7.984; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; Kordula T, 1996, J BIOL CHEM, V271, P6752, DOI 10.1074/jbc.271.12.6752; Lai CF, 1996, J BIOL CHEM, V271, P13968, DOI 10.1074/jbc.271.24.13968; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Mercer JG, 1996, FEBS LETT, V387, P113, DOI 10.1016/0014-5793(96)00473-5; MILLER AD, 1991, J VIROL, V65, P2220, DOI 10.1128/JVI.65.5.2220-2224.1991; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; White DW, 1997, J BIOL CHEM, V272, P4065, DOI 10.1074/jbc.272.7.4065; WHITE MF, 1994, J BIOL CHEM, V269, P1; Won K., 1993, ACUTE PHASE PROTEINS, P255; Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	48	183	187	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16216	16223		10.1074/jbc.272.26.16216	http://dx.doi.org/10.1074/jbc.272.26.16216			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195922	hybrid			2022-12-27	WOS:A1997XG01900026
J	White, KA; Kaltashov, IA; Cotter, RJ; Raetz, CRH				White, KA; Kaltashov, IA; Cotter, RJ; Raetz, CRH			A mono-functional 3-deoxy-D-manno-octulosonic acid (Kdo) transferase and a Kdo kinase in extracts of Haemophilus influenzae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-A MUTANTS; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; 3-DEOXY-D-MANNOOCTULOSONATE-8-PHOSPHATE SYNTHETASE; LIPOPOLYSACCHARIDE BIOSYNTHESIS; BORDETELLA-PERTUSSIS; IDENTIFICATION; ENDOTOXINS; STRAIN; OLIGOSACCHARIDE	Lipopolysaccharide of Haemophilus influenzae contains a single 3-deoxy-D-manno-octulosonic acid (Kdo) residue, linked to the 6' position of lipid A. In Escherichia coli and related organisms, a Kdo disaccharide is attached to lipid A. In previous studies, we cloned the gene (kdtA) encoding the E. coli Kdo transferase and demonstrated that homogeneous preparations of KdtA polypeptide catalyzed the attachment of both Kdo groups to the precursor, lipid IVA. E. coli KdtA produced only traces of mono-glycosylated product. We now show that a single Kdo is transferred to lipid IVA in extracts of H. influenzae. The mono-functional Kdo transferase of H. influenzae is membrane-bound, and the reaction is dependent upon a CMP-Kdo-generating system, as in E. coli. The specific activity of Kdo transfer to lipid IVA is 0.5-1 nmol/min/mg in H. influenzae membranes. Utilizing solubilized H. influenzae membranes, milligram quantities of Kdo-lipid IVA were prepared for analysis. Matrix-assisted laser desorption/ionization mass spectrometry revealed a parent ion (M - H)(-) at m/z 1626.0, consistent with the addition of a single Kdo moiety. Like lipid IVA, Kdo-lipid IVA was an excellent substrate for the bi-functional Kdo transferase of E. coli. In membranes of H. influenzae, but not E. coli, Kdo-lipid IVA was further phosphorylated in the presence of ATP, yielding a mono-phosphorylated Kdo-lipid IVA with a parent ion (M - H)(-) at m/z 1703.9. The identification of the monofunctional H. influenzae Kdo transferase, which is encoded by a KdtA homologue that displays 50% identity to its E. coli counterpart, should facilitate the mechanistic dissection of more complex multi-functional Kdo transferases, like those of E. coli and Chlamydia trachomatis.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; JOHNS HOPKINS UNIV, DEPT PHARMACOL, MIDDLE ATLANTIC MASS SPECTROMETRY LAB, BALTIMORE, MD 21205 USA	Duke University; Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033967, R01GM051310] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33967, GM-51310] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELUNIS CJ, 1995, J BIOL CHEM, V270, P27646, DOI 10.1074/jbc.270.46.27646; BELUNIS CJ, 1992, J BIOL CHEM, V267, P18702; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BOCK K, 1994, EUR J BIOCHEM, V225, P1029, DOI 10.1111/j.1432-1033.1994.1029b.x; BRADE H, 1985, J BACTERIOL, V161, P795, DOI 10.1128/JB.161.2.795-798.1985; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; CAROFF M, 1987, CARBOHYD RES, V161, P4; CHABY R, 1975, EUR J BIOCHEM, V59, P277, DOI 10.1111/j.1432-1033.1975.tb02452.x; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; COSTELLO CE, 1990, METHOD ENZYMOL, V193, P738, DOI 10.1016/0076-6879(90)93448-T; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; GOLDMAN R, 1987, NATURE, V329, P162, DOI 10.1038/329162a0; HAMMOND SM, 1987, NATURE, V327, P730, DOI 10.1038/327730a0; HAMPTON RY, 1988, J BIOL CHEM, V263, P14802; HELANDER IM, 1988, EUR J BIOCHEM, V177, P483, DOI 10.1111/j.1432-1033.1988.tb14398.x; Hood DW, 1996, MOL MICROBIOL, V22, P951, DOI 10.1046/j.1365-2958.1996.01545.x; KUMADA H, 1995, J BACTERIOL, V177, P2098, DOI 10.1128/jb.177.8.2098-2106.1995; KUMADA H, 1993, CURR MICROBIOL, V26, P239, DOI 10.1007/BF01577383; LEDUR A, 1978, EUR J BIOCHEM, V84, P579, DOI 10.1111/j.1432-1033.1978.tb12201.x; LEE NG, 1995, J BIOL CHEM, V270, P27151, DOI 10.1074/jbc.270.45.27151; Masoud H, 1997, BIOCHEMISTRY-US, V36, P2091, DOI 10.1021/bi961989y; Miller J.H., 1972, EXPT MOL GENETICS; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, V1, P7; NISHIJIMA M, 1979, J BIOL CHEM, V254, P7837; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; PHILLIPS NJ, 1992, BIOCHEMISTRY-US, V31, P4515, DOI 10.1021/bi00133a019; PRICE NPJ, 1994, J BACTERIOL, V176, P4646, DOI 10.1128/JB.176.15.4646-4655.1994; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RICK PD, 1977, J BIOL CHEM, V252, P4904; RICK PD, 1977, J BIOL CHEM, V252, P4895; RUAN M, 1990, J IMMUNOL, V145, P3379; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; ZAMZE SE, 1987, BIOCHEM J, V245, P583, DOI 10.1042/bj2450583; [No title captured]	40	50	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16555	16563		10.1074/jbc.272.26.16555	http://dx.doi.org/10.1074/jbc.272.26.16555			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195966	hybrid			2022-12-27	WOS:A1997XG01900070
J	Petrescu, SM; Petrescu, AJ; Titu, HN; Dwek, RA; Platt, FM				Petrescu, SM; Petrescu, AJ; Titu, HN; Dwek, RA; Platt, FM			Inhibition of N-glycan processing in B16 melanoma cells results in inactivation of tyrosinase but does not prevent its transport to the melanosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; LINKED OLIGOSACCHARIDES; MAMMALIAN TYROSINASE; MOUSE MELANOMA; SUGAR CHAINS; GLYCOPROTEINS; GLYCOSYLATION; GOLGI; BUTYLDEOXYNOJIRIMYCIN; BIOSYNTHESIS	Tyrosinase is the key enzyme in melanin biosynthesis, catalyzing multiple steps ill this pathway, The mature glycoprotein is transported from the Golgi to the melanosome where melanin biosynthesis occurs, In this study, we have investigated the effects of inhibitors of N-glycan processing on the synthesis, transport, and catalytic activity of tyrosinase. When B16 mouse melanoma cells were cultured ill the presence of N-butyldeoxynojirimycin , an inhibitor of the endoplasmic reticulum-processing enzymes alpha-glucosidases I and II, the enzyme was synthesized and transported to the melanosome but almost completely lacked catalytic activity, The cells contained only 2% of the melanin found in untreated cells, Structural analysis of the N-glycans from N-butyldeoxgngirimycin-treated B16 cells demonstrated that three oligosaccharide structures (Glc(3)Man(7-9)) predominated, Removal of the glucose residues with alpha-glucosidases I and II failed to restore enzymatic activity, suggesting that the glucosylated N-glycans do not sterically interfere with the enzyme's active sites, The mannosidase inhibitor deoxymannojirimycin had no effect. on catalytic activity suggesting that the retention of glucosylated N-glycans results in the inactivation of this enzyme, The retention of glucosylated N-glycans does not therefore result in misfolding and degradation of the glycoprotein, as the enzyme is transported to the melanosome, but may cause conformational changes in its catalytic domains.	UNIV OXFORD, GLYCOBIOL INST, OXFORD OX1 3QU, ENGLAND; INST BIOCHEM, BUCHAREST 77700 17, ROMANIA	University of Oxford; Romanian Academy of Sciences; Institute of Biochemistry, Bucharest			Petrescu, Stefana M/I-9240-2012; Petrescu, Stefana/AAJ-9505-2021; Platt, Frances/G-1004-2010; Petrescu, Andrei-Jose J/G-4576-2016	Petrescu, Stefana M/0000-0002-4047-0811; Petrescu, Stefana/0000-0002-4047-0811; Petrescu, Andrei-Jose J/0000-0002-4478-3946; Platt, Frances/0000-0001-7614-0403	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AROCA P, 1993, J BIOL CHEM, V268, P25650; DWEK RA, 1995, SCIENCE, V269, P1234, DOI 10.1126/science.7652569; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; Fischer PB, 1996, J VIROL, V70, P7143, DOI 10.1128/JVI.70.10.7143-7152.1996; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEARING VJ, 1981, INT J BIOCHEM, V13, P99, DOI 10.1016/0020-711X(81)90141-5; HEARING VJ, 1976, BIOCHEM J, V157, P549, DOI 10.1042/bj1570549; IMOKAWA G, 1990, J INVEST DERMATOL, V95, P39, DOI 10.1111/1523-1747.ep12873289; IMOKAWA G, 1982, CANCER RES, V42, P1994; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; JIMENEZCERVANTES C, 1993, EUR J BIOCHEM, V217, P549, DOI 10.1111/j.1432-1033.1993.tb18276.x; JOLLEY RL, 1974, J BIOL CHEM, V249, P335; KARLSSON GB, 1993, J BIOL CHEM, V268, P570; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKIN JD, 1986, J BIOL CHEM, V261, P6626; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; MULLER G, 1988, EMBO J, V7, P2723, DOI 10.1002/j.1460-2075.1988.tb03126.x; OHKURA T, 1984, ARCH BIOCHEM BIOPHYS, V235, P63, DOI 10.1016/0003-9861(84)90255-8; OLAFSON RW, 1990, J BIOL CHEM, V265, P12240; Parodi AJ, 1996, TRENDS GLYCOSCI GLYC, V8, P1, DOI 10.4052/tigg.8.1; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; PLATT FM, 1992, EUR J BIOCHEM, V208, P187, DOI 10.1111/j.1432-1033.1992.tb17173.x; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; TAKAHASHI H, 1992, J INVEST DERMATOL, V98, P481, DOI 10.1111/1523-1747.ep12499862; VALVERDE P, 1992, ARCH BIOCHEM BIOPHYS, V297, P221, DOI 10.1016/0003-9861(92)90665-J; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WADA I, 1995, J BIOL CHEM, V270, P20298, DOI 10.1074/jbc.270.35.20298; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WINCHESTER B, 1992, GLYCOBIOLOGY, V2, P199, DOI 10.1093/glycob/2.3.199	32	69	72	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15796	15803		10.1074/jbc.272.25.15796	http://dx.doi.org/10.1074/jbc.272.25.15796			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188477	hybrid			2022-12-27	WOS:A1997XF32900037
J	Ruckdeschel, K; Machold, J; Roggenkamp, A; Schubert, S; Pierre, J; Zumbihl, R; Liautard, JP; Heesemann, J; Rouot, B				Ruckdeschel, K; Machold, J; Roggenkamp, A; Schubert, S; Pierre, J; Zumbihl, R; Liautard, JP; Heesemann, J; Rouot, B			Yersinia enterocolitica promotes deactivation of macrophage mitogen-activated protein kinases extracellular signal-regulated kinase-1/2, p38, and c-jun NH2-terminal kinase - Correlation with its inhibitory effect on tumor necrosis factor-alpha production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CYCLIC-AMP; VIRULENCE DETERMINANT; TYROSINE-PHOSPHATASE; MAMMALIAN-CELLS; BACTERIAL LIPOPOLYSACCHARIDE; RESPIRATORY BURST; YOPE CYTOTOXIN; TARGET-CELL; PSEUDOTUBERCULOSIS; PHOSPHORYLATION	The enteropathogenic bacterium Yersinia enterocolitica counteracts host defense mechanisms by interfering with eukaryotic signal transduction pathways. In this study, we investigated the mechanism by which Y. enterocolitica prevents macrophage tumor necrosis factor-alpha (TNF alpha) production, Murine J774A.1 macrophages responded to Y. enterocolitica infection by rapid activation of mitogen activated protein kinases (MAPK) extracellular signal-regulated kinase (ERK), p38, and c-Jun NH2-terminal kinase (JNK), However, after initial activation, the virulent Y. enterocolitica strain harboring the Y. enterocolitica virulence plasmid caused a substantial decrease in ERK1/2 and p38 tyrosine phosphorylation, Simultaneously, the virulent Y. enterocolitica strain gradually suppressed phosphorylation of the transcription factors EIk-1, activating transcription factor 2 (ATF2), and c-Jun, indicating time-dependent inhibition of ERK1/2, p38, and JNK kinase activities, respectively, Analysis of different Y. enterocolitica mutants revealed that (i) MAPK inactivation parallels the inhibition of TNF alpha release, (ii) the suppressor effect on TNF alpha production, which originates from the lack of TNF alpha mRNA, is distinct from the ability of Y. enterocolitica to resist phagocytosis and to prevent the oxidative burst, (iii) the tyrosine phosphatase YopH, encoded by the Y. enterocolitica virulence plasmid, is not involved in the decrease of ERK1/2 and p38 tyrosine phosphorylation or in the cytokine suppressive effect. Altogether, these results indicate that Y. enterocolitica possesses one or more virulence proteins that suppress TNF alpha production by inhibiting ERK1/2, p38, and JNK kinase activities.	FAC PHARM CHATENAY MALABRY,INSERM U461,F-92296 CHATENAY MALABR,FRANCE; UNIV MONTPELLIER 2,INSERM U431,F-34095 MONTPELLIER 5,FRANCE; MAX VON PETTENKOFER INST HYG & MIKROBIOL,D-80336 MUNICH,GERMANY	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; University of Munich								AUTENRIETH IB, 1995, J INFECT DIS, V172, P490, DOI 10.1093/infdis/172.2.490; AUTENRIETH IB, 1992, MED MICROBIOL IMMUN, V181, P333; BEUSCHER HU, 1995, INFECT IMMUN, V63, P1270, DOI 10.1128/IAI.63.4.1270-1277.1995; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BLISKA JB, 1995, INFECT IMMUN, V63, P681, DOI 10.1128/IAI.63.2.681-685.1995; BLISKA JB, 1992, J EXP MED, V176, P1625, DOI 10.1084/jem.176.6.1625; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; Boland A, 1996, EMBO J, V15, P5191, DOI 10.1002/j.1460-2075.1996.tb00904.x; Caron E, 1996, J IMMUNOL, V156, P2885; CARON E, 1994, INFECT IMMUN, V62, P5267, DOI 10.1128/IAI.62.12.5267-5274.1994; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DESCOTEAUX A, 1989, MOL CELL BIOL, V9, P5523; Dziarski R, 1996, J INFECT DIS, V174, P777, DOI 10.1093/infdis/174.4.777; FALLMAN M, 1995, INFECT IMMUN, V63, P3117; FISCHER T, 1995, BIOCHEM J, V311, P995, DOI 10.1042/bj3110995; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GAEDE KI, 1995, INFECT IMMUN, V63, P714, DOI 10.1128/IAI.63.2.714-719.1995; GALYOV EE, 1993, NATURE, V361, P730, DOI 10.1038/361730a0; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; GREEN SP, 1995, J LEUKOCYTE BIOL, V57, P972, DOI 10.1002/jlb.57.6.972; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hakansson S, 1996, MOL MICROBIOL, V20, P593, DOI 10.1046/j.1365-2958.1996.5251051.x; HAMBLETON J, 1995, J EXP MED, V182, P147, DOI 10.1084/jem.182.1.147; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAN JH, 1993, J BIOL CHEM, V268, P25009; HARTLAND EL, 1994, INFECT IMMUN, V62, P4445, DOI 10.1128/IAI.62.10.4445-4453.1994; HEESEMANN J, 1987, FEMS MICROBIOL LETT, V48, P229, DOI 10.1016/0378-1097(87)90167-4; HEESEMANN J, 1985, J CLIN MICROBIOL, V22, P168, DOI 10.1128/JCM.22.2.168-175.1985; HEESEMANN J, 1986, INFECT IMMUN, V54, P561, DOI 10.1128/IAI.54.2.561-567.1986; HOLMSTROM A, 1995, INFECT IMMUN, V63, P2269; HOOVER DL, 1994, INFECT IMMUN, V62, P4432, DOI 10.1128/IAI.62.10.4432-4439.1994; Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959; JOSEPH CK, 1994, J BIOL CHEM, V269, P17606; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIU MK, 1994, J IMMUNOL, V153, P2642; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; NAKAJIMA R, 1995, INFECT IMMUN, V63, P3021, DOI 10.1128/IAI.63.8.3021-3029.1995; NAKAJIMA R, 1993, INFECT IMMUN, V61, P23, DOI 10.1128/IAI.61.1.23-31.1993; PERSSON C, 1995, MOL MICROBIOL, V18, P135, DOI 10.1111/j.1365-2958.1995.mmi_18010135.x; Pettersson J, 1996, SCIENCE, V273, P1231, DOI 10.1126/science.273.5279.1231; REIMANN T, 1994, J IMMUNOL, V153, P5740; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; ROGGENKAMP A, 1996, FEMS MICROBIOL LETT, V134, P69; ROSQVIST R, 1991, INFECT IMMUN, V59, P4562, DOI 10.1128/IAI.59.12.4562-4569.1991; ROSQVIST R, 1994, EMBO J, V13, P964, DOI 10.1002/j.1460-2075.1994.tb06341.x; ROSQVIST R, 1988, INFECT IMMUN, V56, P2139, DOI 10.1128/IAI.56.8.2139-2143.1988; ROSQVIST R, 1990, MOL MICROBIOL, V4, P657, DOI 10.1111/j.1365-2958.1990.tb00635.x; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Ruckdeschel K, 1996, INFECT IMMUN, V64, P724, DOI 10.1128/IAI.64.3.724-733.1996; Sanghera JS, 1996, J IMMUNOL, V156, P4457; Schulte R, 1996, INFECT IMMUN, V64, P2106, DOI 10.1128/IAI.64.6.2106-2113.1996; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; Sory MP, 1995, P NATL ACAD SCI USA, V92, P11998, DOI 10.1073/pnas.92.26.11998; SORY MP, 1994, MOL MICROBIOL, V14, P583, DOI 10.1111/j.1365-2958.1994.tb02191.x; STRALEY SC, 1993, INFECT IMMUN, V61, P3105, DOI 10.1128/IAI.61.8.3105-3110.1993; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Trotta R, 1996, J EXP MED, V184, P1027, DOI 10.1084/jem.184.3.1027; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WRIGHT SD, 1995, IMMUNOL TODAY, V16, P297, DOI 10.1016/0167-5699(95)80185-5; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; Zheng ZM, 1996, IMMUNOLOGY, V87, P544, DOI 10.1046/j.1365-2567.1996.513591.x; ZUMBIHL R, 1994, EUR J PHARM-MOLEC PH, V288, P9, DOI 10.1016/0922-4106(94)90004-3	68	121	127	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15920	15927		10.1074/jbc.272.25.15920	http://dx.doi.org/10.1074/jbc.272.25.15920			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188492	hybrid			2022-12-27	WOS:A1997XF32900052
J	Cunillera, N; Boronat, A; Ferrer, A				Cunillera, N; Boronat, A; Ferrer, A			The Arabidopsis thaliana FPS1 gene generates a novel mRNA that encodes a mitochondrial farnesyl-diphosphate synthase isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; SITE-DIRECTED MUTAGENESIS; ISOPRENOID BIOSYNTHESIS; PYROPHOSPHATE SYNTHASE; COORDINATE REGULATION; CONSERVED ASPARTATE; MOLECULAR-CLONING; YEAST; PLANT; PRENYLTRANSFERASE	The enzyme farnesyl-diphosphate synthase (FPS; EC 2,5,1.1,/EC 2.5.1.10) catalyzes the synthesis of farnesyl diphosphate from isopentenyl diphosphate and di methylallyl diphosphate, FPS is considered to play a key role in isoprenoid biosynthesis, We have reported previously that Arabidopsis thaliana contains two differentially expressed genes, FPS1 and FPS2, encoding two highly similar FPS isoforms, FPS1 and FPS2, (Cunillera, N., Arro, M., Delourme, D., Karst, F., Boronat, A., and Ferrer, A, (1996) J, Biol, Chem, 271, 7774-7780), In this paper we report the characterization of a novel Arabidopsis FPS mRNA (FPS1L mRNA) derived from the FPS1 gene, A cDNA corresponding to the FPS1L mRNA was cloned using a reverse transcription-polymerase chain reaction strategy, Northern blot analysis showed that the two FPS1-derived mRNAs are differentially expressed, The FPS1L mRNA accumulates preferentially in inflorescences, whereas the previously reported FPS1 mRNA (FPS1S mRNA) is predominantly expressed in roots and inflorescences, FPS1L mRNA contains an inframe AUG start codon located 123 nucleotides upstream of the AUG codon used in the translation of the FPS1S isoform, Translation of the FPS1L mRNA from the upstream AUG codon generates a novel FPS1 isoform (FPS1L) with an NH2-terminal extension of 41 amino acid residues, which has all the characteristics of a mitochondrial transit peptide, The functionality of the FPS1L NH2-terminal extension as a mitochondrial transit peptide was demonstrated by its ability to direct a passenger protein to yeast mitochondria in vivo and by in vitro import experiments using purified plant mitochondria, The Arabidopsis FPS1L isoform is the first FPS reported to contain a mitochondrial transit peptide.	UNIV BARCELONA,FAC FARM,UNITAT BIOQUIM,E-08028 BARCELONA,SPAIN; UNIV BARCELONA,FAC QUIM,DEPT BIOQUIM & BIOL MOL,BARCELONA 08028,SPAIN	University of Barcelona; University of Barcelona			Ferrer, Albert/AAI-4595-2021	Ferrer, Albert/0000-0002-0741-2388				Adiwilaga K, 1996, PLANT MOL BIOL, V30, P935, DOI 10.1007/BF00020805; ATTUCCI S, 1995, ARCH BIOCHEM BIOPHYS, V321, P493, DOI 10.1006/abbi.1995.1422; BARTLEY GE, 1995, PLANT CELL, V7, P1027, DOI 10.1105/tpc.7.7.1027; BOWLER C, 1989, P NATL ACAD SCI USA, V86, P3237, DOI 10.1073/pnas.86.9.3237; CAELLES C, 1989, PLANT MOL BIOL, V13, P627, DOI 10.1007/BF00016018; Campos N, 1995, PLANT CELL, V7, P2163, DOI 10.1105/tpc.7.12.2163; CHAPPELL J, 1995, ANNU REV PLANT PHYS, V46, P521, DOI 10.1146/annurev.pp.46.060195.002513; CHAUMONT F, 1990, J BIOL CHEM, V265, P16856; CHEN AJ, 1994, PROTEIN SCI, V3, P600; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; CRISSEN G, 1995, PLANT J, V8, P167; CUNILLERA C, 1996, J BIOL CHEM, V271, P7774; DANPURE CJ, 1995, TRENDS CELL BIOL, V5, P238; DEAN C, 1985, EMBO J, V4, P3055, DOI 10.1002/j.1460-2075.1985.tb04045.x; DELOURME D, 1994, PLANT MOL BIOL, V26, P1867, DOI 10.1007/BF00019499; ENJUTO M, 1994, P NATL ACAD SCI USA, V91, P927, DOI 10.1073/pnas.91.3.927; GERLACH WL, 1979, NUCLEIC ACIDS RES, V7, P1869, DOI 10.1093/nar/7.7.1869; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GRAY JC, 1987, ADV BOT RES, V14, P25; HINNEBUSCH AG, 1991, MOL CELLULAR BIOL YE, P627; Homann V, 1996, CURR GENET, V30, P232, DOI 10.1007/s002940050126; HUANG JT, 1990, PLANT CELL, V2, P1249, DOI 10.1105/tpc.2.12.1249; HUGUENEY P, 1990, FEBS LETT, V273, P235, DOI 10.1016/0014-5793(90)81093-4; JOLY A, 1993, J BIOL CHEM, V268, P26983; KINGSTON RE, 1997, CURRENT PROTOCOLS MO; KLEINIG H, 1989, ANNU REV PLANT PHYS, V40, P39, DOI 10.1146/annurev.pp.40.060189.000351; KRISANS SK, 1994, J BIOL CHEM, V269, P14165; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LUMBRERAS V, 1995, PLANT J, V8, P541, DOI 10.1046/j.1365-313X.1995.8040541.x; MARRERO PF, 1992, J BIOL CHEM, V267, P21873; Matsushita Y, 1996, GENE, V172, P207, DOI 10.1016/0378-1119(96)00054-6; MCGARVEY DJ, 1995, PLANT CELL, V7, P1015, DOI 10.1105/tpc.7.7.1015; Mireau H, 1996, PLANT CELL, V8, P1027, DOI 10.1105/tpc.8.6.1027; Pan ZQ, 1996, ARCH BIOCHEM BIOPHYS, V332, P196, DOI 10.1006/abbi.1996.0333; PING LC, 1996, GENE AMST, V171, P193; POULTER CD, 1981, BIOSYNTHESIS ISOPREN, P161; ROSSER DSE, 1989, J BIOL CHEM, V264, P12653; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; RUNQUIST M, 1994, J BIOL CHEM, V269, P5804; Sanchez H, 1996, EMBO J, V15, P2138, DOI 10.1002/j.1460-2075.1996.tb00567.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMITZ UK, 1989, PLANT CELL, V1, P783, DOI 10.1105/tpc.1.8.783; SPEAR DH, 1992, J BIOL CHEM, V267, P1462; STERMER BA, 1994, J LIPID RES, V35, P1133; von Heijne G, 1992, Genet Eng (N Y), V14, P1; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WILKIN DJ, 1990, J BIOL CHEM, V265, P4607	47	134	147	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15381	15388		10.1074/jbc.272.24.15381	http://dx.doi.org/10.1074/jbc.272.24.15381			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182568	hybrid			2022-12-27	WOS:A1997XE03400051
J	Zilberberg, N; Froy, O; Loret, E; Cestele, S; Arad, D; Gordon, D; Gurevitz, M				Zilberberg, N; Froy, O; Loret, E; Cestele, S; Arad, D; Gordon, D; Gurevitz, M			Identification of structural elements of a scorpion alpha-neurotoxin important for receptor site recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROCTONUS-AUSTRALIS-HECTOR; INSECT SODIUM-CHANNELS; TOXIN-II; 3-DIMENSIONAL STRUCTURE; DIRECTED MUTAGENESIS; CIRCULAR-DICHROISM; BINDING-SITES; K+ CHANNEL; CHARYBDOTOXIN; PURIFICATION	alpha-Neurotoxins from scorpion venoms constitute the most studied group of modifiers of the voltage-sensitive sodium channels, and yet, their toxic site has not been characterized. We used an efficient bacterial expression system for modifying specific amino acid residues of the highly insecticidal alpha-neurotoxin Lqh alpha IT from the scorpion Leiurus quinquestriatus hebraeus. Toxin variants modified at tight turns, the C-terminal region, and other structurally related regions were subjected to neuropharmacological and structural analyses. This approach highlighted both aromatic (Tyr(10) and Phe(17)) and positively charged (Lys(8), Arg(18), Lys(62), and Arg(64)) residues that (i) may interact directly with putative recognition points at the receptor site on the sodium channel; (ii) are important for the spatial arrangement of the toxin polypeptide; and (iii) contribute to the formation of an electrostatic potential that may be involved in biorecognition of the receptor site. The latter was supported by a suppressor mutation (E15A) that restored a detrimental effect caused by a K8D substitution. The feasibility of producing anti-insect scorpion neurotoxins with augmented toxicity was demonstrated by the substitution of the C-terminal arginine with histidine. Altogether, the present study provides for the first time an insight into the putative toxic surface of a scorpion neurotoxin affecting sodium channel gating.	TEL AVIV UNIV, FAC LIFE SCI, DEPT PLANT SCI, IL-69978 RAMAT AVIV, ISRAEL; TEL AVIV UNIV, FAC LIFE SCI, DEPT MOL MICROBIOL & BIOTECHNOL, IL-69978 RAMAT AVIV, ISRAEL; IBSM, LIDSM, CNRS, UPR 9027, F-13402 MARSEILLE 20, FRANCE; FAC MED, SECTOR NORD, LAB BIOCHIM, CNRS, URA 1455, F-13916 MARSEILLE 20, FRANCE	Tel Aviv University; Tel Aviv University; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)			Froy, Oren/C-3550-2009; Zilberberg, Noam/F-2005-2012; Cestèle, Sandrine/O-7657-2016	Cestèle, Sandrine/0000-0002-5982-1562; Zilberberg, Noam/0000-0002-7848-2391				ARONHEIM A, 1988, J BIOL CHEM, V263, P9933; BOUGIS PE, 1989, J BIOL CHEM, V264, P19259; CATTERALL WA, 1980, ANNU REV PHARMACOL, V20, P15, DOI 10.1146/annurev.pa.20.040180.000311; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; CESTELE S, 1995, J BIOL CHEM, V270, P15153, DOI 10.1074/jbc.270.25.15153; DARBON H, 1983, INT J PEPT PROT RES, V22, P179; DARBON H, 1982, INTJ PEPT PROTEIN RE, V20, P30; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DUFTON MJ, 1984, J MOL EVOL, V20, P120, DOI 10.1007/BF02257372; EITAN M, 1990, BIOCHEMISTRY-US, V29, P5941, DOI 10.1021/bi00477a009; ELAYEB M, 1986, EUR J BIOCHEM, V155, P289; ELAYEB M, 1986, BIOCHEMISTRY-US, V25, P6671, DOI 10.1021/bi00369a052; ESCOBAR L, 1993, BIOCHEMISTRY-US, V32, P6982, DOI 10.1021/bi00078a024; FONTECILLACAMPS JC, 1988, P NATL ACAD SCI USA, V85, P7443, DOI 10.1073/pnas.85.20.7443; FONTECILLACAMPS JC, 1982, TOXICON, V20, P1, DOI 10.1016/0041-0101(82)90137-4; FONTECILLACAMPS JC, 1989, J MOL EVOL, V29, P63, DOI 10.1007/BF02106182; Fraenkel Y, 1996, CRIT REV BIOCHEM MOL, V31, P273, DOI 10.3109/10409239609106586; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; GORDON D, 1992, BIOCHEMISTRY-US, V31, P7622, DOI 10.1021/bi00148a025; GORDON D, 1993, FEBS LETT, V315, P125, DOI 10.1016/0014-5793(93)81147-R; Gordon D, 1996, J BIOL CHEM, V271, P8034, DOI 10.1074/jbc.271.14.8034; Gordon D, 1990, CURR OPIN CELL BIOL, V2, P695, DOI 10.1016/0955-0674(90)90113-S; GRANIER C, 1989, MOL IMMUNOL, V26, P503, DOI 10.1016/0161-5890(89)90001-1; GUREVITZ M, 1991, TOXICON, V29, P1270, DOI 10.1016/0041-0101(91)90200-B; HOUSSET D, 1994, J MOL BIOL, V238, P88, DOI 10.1006/jmbi.1994.1270; INISAN AG, 1995, INT J PEPT PROT RES, V45, P441; KHARRAT R, 1989, EUR J BIOCHEM, V181, P381, DOI 10.1111/j.1432-1033.1989.tb14735.x; Landon C, 1996, EUR J BIOCHEM, V236, P395, DOI 10.1111/j.1432-1033.1996.00395.x; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; Martin-Eauclaire M. F., 1995, Handbook of neurotoxicology., P683; MARTINEAUCLAIRE MF, 1994, EUR J BIOCHEM, V223, P637, DOI 10.1111/j.1432-1033.1994.tb19036.x; MIRANDA F, 1970, EUR J BIOCHEM, V16, P514, DOI 10.1111/j.1432-1033.1970.tb01111.x; MOSKOWITZ H, 1994, INSECT BIOCHEM MOLEC, V24, P13, DOI 10.1016/0965-1748(94)90118-X; OHANA B, 1990, BIOCHEMISTRY-US, V29, P6409, DOI 10.1021/bi00479a011; PARK CS, 1992, BIOCHEMISTRY-US, V31, P7749, DOI 10.1021/bi00149a002; PASHKOV VS, 1988, BIOPHYS CHEM, V31, P121, DOI 10.1016/0301-4622(88)80016-4; PERCZEL A, 1993, INT J PEPT PROT RES, V41, P223; REED L. J., 1938, AMER JOUR HYG, V27, P493; Rogers JC, 1996, BIOPHYS J, V70, pTU327; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAMPIERI F, 1978, BIOCHIM BIOPHYS ACTA, V535, P100, DOI 10.1016/0005-2795(78)90037-5; STAMPE P, 1994, BIOCHEMISTRY-US, V33, P443, DOI 10.1021/bi00168a008; STRICHARTZ GR, 1986, NATURAL TOXINS ANIMA, P265; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; Tugarinov V, 1997, BIOCHEMISTRY-US, V36, P2414, DOI 10.1021/bi961497l; ZILBERBERG N, 1993, ANAL BIOCHEM, V209, P203, DOI 10.1006/abio.1993.1105; Zilberberg N, 1996, BIOCHEMISTRY-US, V35, P10215, DOI 10.1021/bi9528309; Zlotkin E., 1978, ARTHROPOD VENOMS, P317	49	108	113	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14810	14816		10.1074/jbc.272.23.14810	http://dx.doi.org/10.1074/jbc.272.23.14810			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169449	hybrid			2022-12-27	WOS:A1997XC32700046
J	deSilva, D; DavisKaplan, S; Fergestad, J; Kaplan, J				deSilva, D; DavisKaplan, S; Fergestad, J; Kaplan, J			Purification and characterization of Fet3 protein, a yeast homologue of ceruloplasmin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; IRON UPTAKE; MOLECULAR CHARACTERIZATION; TRANSPORT PROTEIN; GENE; OXIDASE; APOFERRITIN; ENCODES; COPPER	The FET3 gene product of Saccharomyces cerevisiae is an essential component of the high affinity iron transport system, Based on FET3 sequence homology to the multicopper oxidase family and iron oxidation studies in spheroplasts (De Silva, D. M., Askwith, C. C., Eide, D., and Kaplan, J. (1995) J. Biol. Chem. 270, 1098-1101), it was hypothesized that the Fet3 protein (Fet3p) was a cell surface ferroxidase, To further characterize the protein, we have isolated Fet3p from yeast membranes and purified the protein to apparent homogeneity, Consistent with its localization at the plasma membrane, Fet3p is a glycosylated protein, SDS-polyacrylamide gel electrophoresis analysis showed that the protein was present in two differentially glycosylated forms of approximately 120 and 100 kDa, Purified Fet3p is a copper containing protein that is able to catalyze the oxidation of a variety of organic compounds in addition to ferrous iron, Azide and metal chelators strongly inhibited enzyme activity, Iron appeared to be the best substrate for the enzyme, and the apparent K-m for ferrous oxidation was 2 mu M. Interestingly, Fet3p was able to effectively catalyze the incorporation of iron onto apotransferrin, We conclude that Fet3p is a ferro-O-2-oxidoreductase in yeast, homologous to the human plasma protein ceruloplasmin.	UNIV UTAH,COLL MED,DEPT PATHOL,SCH MED,DIV CELL BIOL & IMMUNOL,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah					NIDDK NIH HHS [NIDDK-5-30534, NIDDK-T32 DK07115] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007115] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Askwith C, 1997, J BIOL CHEM, V272, P401; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BOYER RF, 1983, BIOCHEM BIOPH RES CO, V116, P244, DOI 10.1016/0006-291X(83)90407-2; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; DESILVA D, 1992, ARCH BIOCHEM BIOPHYS, V293, P409, DOI 10.1016/0003-9861(92)90413-Q; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; DIX DR, 1994, J BIOL CHEM, V269, P26092; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; Lesuisse E, 1996, J BIOL CHEM, V271, P13578, DOI 10.1074/jbc.271.23.13578; LOVSTAD RA, 1979, GEN PHARMACOL, V10, P147; MESSERSCHMIDT A, 1990, EUR J BIOCHEM, V187, P341, DOI 10.1111/j.1432-1033.1990.tb15311.x; Musci G, 1996, J BIOL CHEM, V271, P1972, DOI 10.1074/jbc.271.4.1972; OSAKI S, 1966, J BIOL CHEM, V241, P2746; Ryde U, 1996, J MOL BIOL, V261, P586, DOI 10.1006/jmbi.1996.0484; Ryden L., 1984, COPP PROTEINS COPP E, V3, P37; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; YOSHIDA K, 1995, NAT GENET, V9, P267, DOI 10.1038/ng0395-267; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	19	94	95	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14208	14213		10.1074/jbc.272.22.14208	http://dx.doi.org/10.1074/jbc.272.22.14208			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162052	hybrid			2022-12-27	WOS:A1997XB49200039
J	vonPoser, C; Ichtchenko, K; Shao, XG; Rizo, J; Sudhof, TC				vonPoser, C; Ichtchenko, K; Shao, XG; Rizo, J; Sudhof, TC			The evolutionary pressure to inactivate - A subclass of synaptotagmins with an amino acid substitution that abolishes Ca2+ binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOFORM; BRAIN; PROTEINS; RELEASE; SENSOR; DOMAIN; CELLS	Synaptotagmin I is a Ca2+-binding protein of synaptic vesicles that serves as a Ca2+ sensor for neurotransmitter release and was the first member found of a large family of trafficking proteins. We have now identified a novel synaptotagmin, synaptotagmin XI, that is highly expressed in brain and at lower levels in other tissues. Like other synaptotagmins, synaptotagmin XI has a single transmembrane region and two cytoplasmic C-2-domains but is most closely related to synaptotagmin TV with which it forms a new subclass of synaptotagmins. The first C-2-domain of synaptotagmin I (the C(2)A-domain) binds phospholipids as a function of Ca2+ and contains a Ca2+-binding site, the C-2-motif, that binds at least two Ca2+ ions via five aspartate residues and is conserved in most C-2-domains (Shao, X., Davletov, B., Sutton, B., Sudhof, T. C., Rizo, J. R. (1996) Science 273, 248-253). In the C(2)A-domains of synaptotagmins IV and XI, however, one of the five Ca2+-binding aspartates in the C-2-motif is substituted for a serine, suggesting that these C-2-domains do not bind Ca2+. To test this, we produced recombinant C(2)A-domains from synaptotagmins IV and XI with either wild type serine or mutant aspartate in the C-2-motif. Circular dichroism showed that Ca2+ stabilizes both mutant but not wild type C-2-domains against temperature-induced denaturation, indicating that the mutations restore Ca2+-binding to the wild type C-2-domains. Furthermore, wild type C(2)A-domains of synaptotagmins IV and XI exhibited no Ca2+-dependent phospholipid binding, whereas mutant C(2)A-domains bound phospholipids as a function of Ca2+ similarly to wild type synaptotagmin I. These experiments suggest that a class of synaptotagmins was selected during evolution in which the Ca2+-binding site of the C(2)A-domain was inactivated by a single point mutation. Thus, synaptotagmins must have Ca2+-independent functions as well as Ca2+-dependent functions that are selectively maintained in distinct members of this gene family.	UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL & BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NINDS NIH HHS [R29-NS33731] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS033731] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BABITY JM, 1996, SOC NEUR ABSTR; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; CRAXTON M, 1995, FEBS LETT, V361, P196, DOI 10.1016/0014-5793(95)00176-A; DAVLETOV BA, 1994, J BIOL CHEM, V269, P28547; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Fukuda M, 1996, J BIOL CHEM, V271, P8430, DOI 10.1074/jbc.271.14.8430; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HILBUSH BS, 1994, P NATL ACAD SCI USA, V91, P8195, DOI 10.1073/pnas.91.17.8195; HUDSON AW, 1995, P NATL ACAD SCI USA, V92, P5895, DOI 10.1073/pnas.92.13.5895; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LI C, 1995, J BIOL CHEM, V270, P24898, DOI 10.1074/jbc.270.42.24898; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Shao XG, 1997, NEURON, V18, P133, DOI 10.1016/S0896-6273(01)80052-0; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; ULLRICH B, 1994, NEURON, V13, P1281, DOI 10.1016/0896-6273(94)90415-4; VICIAN L, 1995, P NATL ACAD SCI USA, V92, P2164, DOI 10.1073/pnas.92.6.2164; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	26	143	145	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14314	14319		10.1074/jbc.272.22.14314	http://dx.doi.org/10.1074/jbc.272.22.14314			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162066	hybrid			2022-12-27	WOS:A1997XB49200053
J	Seiffert, D; Smith, JW				Seiffert, D; Smith, JW			The cell adhesion domain in plasma vitronectin is cryptic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; RECEPTOR-MEDIATED ENDOCYTOSIS; HEPARIN-BINDING PROPERTIES; THROMBIN-ANTITHROMBIN-III; SERUM SPREADING FACTOR; S-PROTEIN VITRONECTIN; PLATELET-AGGREGATION; ENDOTHELIAL-CELLS; STRUCTURAL REQUIREMENTS; SUBSTRATE ADHESION	Vitronectin (Vn) is a major adhesive glycoprotein in blood. However, many of the functions of Vn are regulated by its conformational state and degree of multimerization. Here, the ability of native and denatured Vn to bind to integrin adhesion receptors was compared. Three lines of evidence suggest that the native, plasma form of Vn is not an adhesive glycoprotein. (i) Antibodies that bind in close proximity to the cell adhesion domain of Vn fail to bind to native Vn present in unfractionated plasma. (ii) Denatured Vn binds to both glycoprotein IIb/IIIa and alpha(v) beta(3), in a dose-dependent manner. In contrast, native Vn is unable to bind either integrin. (iii) Thermal denaturation of native Vn, or its complexation with type 1 plasminogen activator inhibitor, exposed the cell adhesion domain of Vn. Thus, while plasma Vn is unable to bind integrins and is not an adhesive glycoprotein, the conformationally altered from of the protein binds avidly to both alpha(v) beta(3), and glycoprotein IIb/IIIa. The data presented here indicate that such conformational changes in Vn are likely to occur in areas of tissue injury and thrombosis.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; BURNHAM INST, LA JOLLA, CA 92037 USA	Scripps Research Institute; Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [R01CA056483] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL050704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042750] Funding Source: NIH RePORTER; NCI NIH HHS [CA56483] Funding Source: Medline; NHLBI NIH HHS [HL50704] Funding Source: Medline; NIAMS NIH HHS [AR42750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ASCH E, 1990, J CLIN INVEST, V85, P1372, DOI 10.1172/JCI114581; BARNES DW, 1985, J BIOL CHEM, V260, P9117; BHATTACHARYA S, 1995, J BIOL CHEM, V270, P16781, DOI 10.1074/jbc.270.28.16781; BOOTH NA, 1992, ANN NY ACAD SCI, V667, P70, DOI 10.1111/j.1749-6632.1992.tb51599.x; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; CHERNY RC, 1993, J BIOL CHEM, V268, P9725; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DEBOER HC, 1992, J BIOL CHEM, V267, P2264; DIFAZIO LT, 1994, J SURG RES, V57, P133, DOI 10.1006/jsre.1994.1120; EIKELENBOOM P, 1994, VIRCHOWS ARCH, V424, P421, DOI 10.1007/BF00190565; GEBB C, 1986, J BIOL CHEM, V261, P6698; HAYASHI M, 1985, J BIOCHEM-TOKYO, V98, P1135, DOI 10.1093/oxfordjournals.jbchem.a135363; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HILDEBRAND A, 1989, J BIOL CHEM, V264, P15429; HOGASEN K, 1992, J BIOL CHEM, V267, P23076; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IZUMI M, 1989, BIOCHIM BIOPHYS ACTA, V990, P101, DOI 10.1016/S0304-4165(89)80019-4; JENNE D, 1985, EMBO J, V4, P3153, DOI 10.1002/j.1460-2075.1985.tb04058.x; KRUITHOF EKO, 1987, BLOOD, V70, P1645; KVASSMAN JO, 1995, FIBRINOLYSIS, V9, P215, DOI 10.1016/S0268-9499(08)80062-8; LANE DA, 1987, J BIOL CHEM, V262, P16343; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; LOSKUTOFF DJ, 1991, FIBRINOLYSIS, V5, P197, DOI 10.1016/0268-9499(91)90001-K; MOHRI H, 1991, AM J CLIN PATHOL, V96, P605, DOI 10.1093/ajcp/96.5.605; NASKI MC, 1993, J BIOL CHEM, V268, P12367; PANETTI TS, 1993, J BIOL CHEM, V268, P11492; PANETTI TS, 1993, J BIOL CHEM, V268, P11988; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; PREISSNER KT, 1989, BLOOD, V74, P1989; PREISSNER KT, 1987, J BIOL CHEM, V262, P12247; ROGER M, 1992, NOUV REV FR HEMATOL, V34, P47; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHLEEF RR, 1985, J LAB CLIN MED, V106, P408; Seiffert D, 1996, J BIOL CHEM, V271, P5474, DOI 10.1074/jbc.271.10.5474; Seiffert D, 1996, BLOOD, V88, P552, DOI 10.1182/blood.V88.2.552.bloodjournal882552; SEIFFERT D, 1995, FEBS LETT, V368, P155, DOI 10.1016/0014-5793(95)00630-R; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; Seiffert D, 1996, J BIOL CHEM, V271, P29644, DOI 10.1074/jbc.271.47.29644; SMITH JW, 1990, J BIOL CHEM, V265, P2168; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SMITH JW, 1994, J BIOL CHEM, V269, P960; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; THIAGARAJAN P, 1988, THROMB HAEMOSTASIS, V60, P514; THIAGARAJAN P, 1988, J BIOL CHEM, V263, P3035; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; TOMASINI BR, 1988, BLOOD, V72, P903; VANMEIJER M, 1995, FIBRINOLYSIS, V9, P263, DOI 10.1016/S0268-9499(95)80015-8; WALTZ DA, 1994, J BIOL CHEM, V269, P14746; WEI Y, 1994, J BIOL CHEM, V269, P32380; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; ZHAO Y, 1993, BIOCHEM BIOPH RES CO, V192, P575, DOI 10.1006/bbrc.1993.1454	52	106	110	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13705	13710		10.1074/jbc.272.21.13705	http://dx.doi.org/10.1074/jbc.272.21.13705			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153222	hybrid			2022-12-27	WOS:A1997XA06200037
J	Bailly, S; Brand, C; Chambaz, EM; Feige, JJ				Bailly, S; Brand, C; Chambaz, EM; Feige, JJ			Analysis of small latent transforming growth factor-beta complex formation and dissociation by surface plasmon resonance - Absence of direct interaction with thrombospondins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE; CONDITIONED MEDIUM; ENDOTHELIAL-CELLS; FACTOR-BETA-1; ACTIVATION; BINDING; IDENTIFICATION; REQUIREMENT; MECHANISM; RECEPTOR	Transforming growth factor-beta (TGF beta) is a pluripotent regulator of cell growth and differentiation. The growth factor is expressed as a latent complex that must be converted to an active form before interacting with its ubiquitous high affinity receptors. This conversion involves the release of the mature TGF beta through disruption of the noncovalent interactions with its propeptide or latency associated protein (LAP). Complex formation or dissociation between LAP and TGF beta plays a very important role in TGF beta biological activity at different steps. To further characterize the kinetic parameters of this interaction, we have employed surface plasmon resonance biosensor methodology. Using this technique, we observed real time association of LAP with mature TGF beta 1. The complex formation showed an equilibrium K-d around 3-7 nM. Furthermore, we observed dissociation of the complex in the presence of extreme pH, chaotropic agents, or plasmin, confirming their effects on TGF beta activation, The same approach was used to examine whether latent TGF beta 1 could interact with thrombospondins, previously described as activators of latent TGF beta. Using this method, we could not detect any direct interaction of thrombospondins with either LAP alone, TGF beta 1 alone, or the small latent TGF beta 1 complex. This suggests that activation of latent TGF beta 1 complex by thrombospondins is through an indirect mechanism.			Bailly, S (corresponding author), CEA GRENOBLE,DBMS,BRCE,INSERM,U244,17 RUE MARTYRS,F-38054 GRENOBLE 9,FRANCE.		bailly, sabine/G-3540-2013; Feige, Jean-Jacques/M-8905-2017	bailly, sabine/0000-0003-1043-7030; Feige, Jean-Jacques/0000-0002-1354-7692				ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; Bottinger EP, 1996, P NATL ACAD SCI USA, V93, P5877, DOI 10.1073/pnas.93.12.5877; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; Flaumenhaft R, 1993, Adv Pharmacol, V24, P51, DOI 10.1016/S1054-3589(08)60933-3; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GENTRY LE, 1990, BIOCHEMISTRY-US, V29, P6851, DOI 10.1021/bi00481a014; GENTRY LE, 1988, MOL CELL BIOL, V8, P4162, DOI 10.1128/MCB.8.10.4162; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; KOJIMA S, 1993, J CELL BIOL, V121, P439, DOI 10.1083/jcb.121.2.439; LAWLER J, 1982, J BIOL CHEM, V257, P2257; Lawrence DA, 1996, EUR CYTOKINE NETW, V7, P363; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MILLER DM, 1992, MOL ENDOCRINOL, V6, P694, DOI 10.1210/me.6.5.694; PELLERIN S, 1993, J BIOL CHEM, V268, P18810; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; Saharinen J, 1996, EMBO J, V15, P245, DOI 10.1002/j.1460-2075.1996.tb00355.x; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; SHA X, 1989, MOL ENDOCRINOL, V3, P1090, DOI 10.1210/mend-3-7-1090; SHA X, 1991, J CELL BIOL, V114, P827, DOI 10.1083/jcb.114.4.827; SOUCHELNITSKIY S, 1995, ENDOCRINOLOGY, V136, P5118, DOI 10.1210/en.136.11.5118; TUCKER RF, 1984, P NATL ACAD SCI-BIOL, V81, P6757, DOI 10.1073/pnas.81.21.6757; Wakefield LM, 1989, GROWTH FACTORS, V1, P203, DOI 10.3109/08977198908997997; WAKEFIELD LM, 1990, J CLIN INVEST, V86, P1976, DOI 10.1172/JCI114932	27	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16329	16334		10.1074/jbc.272.26.16329	http://dx.doi.org/10.1074/jbc.272.26.16329			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195938	hybrid			2022-12-27	WOS:A1997XG01900042
J	Nakagawa, H; Inomoto, T; Rustgi, AK				Nakagawa, H; Inomoto, T; Rustgi, AK			A CACCC box-like cis-regulatory element of the Epstein-Barr virus ED-LS promoter interacts with a novel transcriptional factor in tissue-specific squamous epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KERATINOCYTE-SPECIFIC TRANSCRIPTION; BETA-GLOBIN PROMOTER; BINDING-PROTEINS; NUCLEAR PROTEINS; TRANSGENIC MICE; GENE-EXPRESSION; SV40 ENHANCER; CELLS; DIFFERENTIATION; DNA	The Epstein-Barr (EBV) virus induces a lytic state after infecting epithelial cells. Subsequently, there is infection of B lymphocytes with two types of cycles, latent and lytic. Apart from linkage of the EBV latent membrane protein-1 (LMP-1) with benign and malignant conditions of squamous epithelial cells, little is known about other EBV gene products that may be important in these processes as well as cellular transcriptional factors that regulate EBV gene expression in these epithelial cells. The EBV ED-L2 promoter, an early lytic cycle promoter, is located upstream of a transcription start site for a short open reading frame designated BNLF2 and just downstream of the BNLF1 (LMP-1) open reading frame. We have previously used the EBV ED-L2 promoter to target oncogenes in transgenic mice, resulting in tissue-specific expression in the tongue, esophagus, forestomach, and skin, all sharing stratifying squamous epithelia, alternatively called keratinocytes. In the present study, we have functionally dissected the ED-L2 promoter by making deletion constructs fused to the luciferase reporter gene with transient transfections into squamous and nonsquamous epithelial cell lines as well as B lymphocytes. A CACCC box-like cis-regulatory element has been identified that is located between -218 and -187 base pairs of the ED-L2 promoter that confers significant promoter activity only in squamous epithelial cells. This cis-regulatory element is active in a heterologous minimal herpes simplex virus thymidine kinase promoter reporter gene construct when transfected into squamous epithelial cells but not in nonsquamous epithelial cells. DNA gel mobility shift assays have led to the identification of DNA-protein complexes that bind the CACCC box-like element. One of these proteins is a novel transcriptional factor that is uniquely active in stratified squamous epithelial cells, designated as keratinocyte specific factor (KSF). KSF may be related to Sp1 but appears to be distinct from Sp1. In addition, KSF may interact with related or identical cis-regulatory elements found in human papillomavirus-11 E6 and cytokeratin K3 promoters that are active in keratinocytes. In aggregate, KSF may be important in the transcriptional regulation of viral and eukaryotic genes in keratinocytes.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,GASTROINTESTINAL UNIT,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HEMATOL ONCOL UNIT,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital					NIDDK NIH HHS [DK40561, DK43351] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351, P30DK040561] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BLESSING M, 1987, EMBO J, V6, P567, DOI 10.1002/j.1460-2075.1987.tb04792.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYRNE C, 1993, MOL CELL BIOL, V13, P3176, DOI 10.1128/MCB.13.6.3176; CHUNG DC, 1995, J BIOL CHEM, V270, P8829, DOI 10.1074/jbc.270.15.8829; COHEN JI, 1993, ANN INTERN MED, V118, P45; COWIE A, 1988, MOL CELL BIOL, V8, P3122, DOI 10.1128/MCB.8.8.3122; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DLUGOSZ AA, 1994, CANCER RES, V54, P6413; DONG G, 1994, J VIROL, V68, P1115, DOI 10.1128/JVI.68.2.1115-1127.1994; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HUDSON GS, 1985, J VIROL, V53, P528, DOI 10.1128/JVI.53.2.528-535.1985; Jenkins TD, 1996, ONCOGENE, V13, P1809; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kieff E, 1996, VIROLOGY, P2343; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; MACK DH, 1991, P NATL ACAD SCI USA, V88, P9102, DOI 10.1073/pnas.88.20.9102; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MISSEYANNI A, 1991, NUCLEIC ACIDS RES, V19, P2849, DOI 10.1093/nar/19.11.2849; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; Nakagawa H, 1997, ONCOGENE, V14, P1185, DOI 10.1038/sj.onc.1200937; NAKAGAWA H, 1995, CANCER-AM CANCER SOC, V76, P541, DOI 10.1002/1097-0142(19950815)76:4<541::AID-CNCR2820760402>3.0.CO;2-I; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; RAABTRAUB N, 1983, J VIROL, V48, P580, DOI 10.1128/JVI.48.3.580-590.1983; RHEINWALD JG, 1981, CANCER RES, V41, P1657; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; TSENG H, 1992, P NATL ACAD SCI USA, V89, P10311, DOI 10.1073/pnas.89.21.10311; URIER G, 1989, EMBO J, V8, P1447, DOI 10.1002/j.1460-2075.1989.tb03527.x; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; WU RL, 1994, J BIOL CHEM, V269, P28450; WU RL, 1993, J CELL SCI, V105, P303; XIAO JH, 1987, GENE DEV, V1, P794, DOI 10.1101/gad.1.8.794	40	26	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16688	16699		10.1074/jbc.272.26.16688	http://dx.doi.org/10.1074/jbc.272.26.16688			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195985	hybrid			2022-12-27	WOS:A1997XG01900089
J	Szaszi, K; Buday, L; Kapus, A				Szaszi, K; Buday, L; Kapus, A			Shrinkage-induced protein tyrosine phosphorylation in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE; C-JUN; TRANSPORT PATHWAYS; VOLUME REGULATION; ACTIVATION; EXCHANGE; STRESS; YEAST; GRB2	To investigate the signal transduction of osmotic stress, we examined hypertonicity-induced tyrosine phosphorylations in Chinese hamster ovary cells. Hyperosmosis elicited characteristic phosphotyrosine accumulation in at least 3 proteins (approximate to 42, approximate to 85, and approximate to 120 kDa). The most prominent response occurred in the 85-kDa band (p85) whose phosphorylation was rapid, sustained, apparent already at mild hypertonicity (350 mosM), proportional to the extracellular osmotic concentration, and reversible. Hyperosmotic environment could not induce tyrosine phosphorylation if cell shrinkage was prevented by nystatin and appropriately composed media. Conversely, isotonic shrinkage caused strong tyrosine phosphorylation. Thus, the initial signal is a decrease in cell volume and not an increase in the intra- or extracellular osmotic concentration, or a rise in cytosolic K+ and Cl- levels. Tyrosine phosphorylation of p85 was not due to the hypertonicity-induced protein kinase C-dependent stimulation of the extracellular signal-regulated protein kinase, nor to the activation of stress-activated protein kinases. Tonicity-responsive proteins interacted with Grb2-glutathione S-transferase fusion proteins: the 120-kDa protein complexed with the SH2 and both SH3 domains, whereas p85 associated with the SH2 and the N-terminal SH3 domains of the adapter. Tyrosine phosphorylation of p85 is a sensitive indicator of reduced intracellular hydration and might signify a hitherto unrecognized, early volume-dependent signaling event.	SEMMELWEIS UNIV MED,DEPT PHYSIOL,H-1444 BUDAPEST 8,HUNGARY; SEMMELWEIS UNIV MED,LAB CELLULAR & MOL PHYSIOL,H-1444 BUDAPEST 8,HUNGARY; SEMMELWEIS UNIV MED,DEPT MED CHEM MOL BIOL & PATHOBIOCHEM,H-1444 BUDAPEST 8,HUNGARY	Semmelweis University; Semmelweis University; Semmelweis University			Szaszi, Katalin/J-7522-2012	Szaszi, Katalin/0000-0002-2490-8422				Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; Aharonovitz O, 1996, J BIOL CHEM, V271, P16494, DOI 10.1074/jbc.271.28.16494; ALLESSI DR, 1995, J BIOL CHEM, V270, P27489; BIANCHINI L, 1995, AM J PHYSIOL-CELL PH, V269, pC998, DOI 10.1152/ajpcell.1995.269.4.C998; Bianchini L, 1997, J BIOL CHEM, V272, P271; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; BOOKSTEIN C, 1994, J BIOL CHEM, V269, P29704; BREITWIESER GE, 1990, AM J PHYSIOL, V258, pC749, DOI 10.1152/ajpcell.1990.258.4.C749; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; BURG MB, 1995, AM J PHYSIOL-RENAL, V268, pF983, DOI 10.1152/ajprenal.1995.268.6.F983; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GARGOVA GZ, 1994, SCIENCE, V265, P806; GARNER MM, 1994, AM J PHYSIOL, V266, pC877, DOI 10.1152/ajpcell.1994.266.4.C877; GOOD DW, 1995, J BIOL CHEM, V270, P9883, DOI 10.1074/jbc.270.17.9883; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; HAAS M, 1995, J BIOL CHEM, V270, P28955, DOI 10.1074/jbc.270.48.28955; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANDLER JS, 1993, AM J PHYSIOL, V265, pC1449, DOI 10.1152/ajpcell.1993.265.6.C1449; Haussinger D, 1996, BIOCHEM J, V313, P697; Hoffmann EK, 1995, INT REV CYTOL, V161, P173; IKEHARA T, 1986, J MEMBRANE BIOL, V90, P231; ITOH T, 1994, J CLIN INVEST, V93, P2387, DOI 10.1172/JCI117245; KAPUS A, 1994, J BIOL CHEM, V269, P23544; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LANIUS RA, 1993, MOL BRAIN RES, V20, P192, DOI 10.1016/0169-328X(93)90041-M; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; Lytle C, 1996, AM J PHYSIOL-CELL PH, V270, pC437, DOI 10.1152/ajpcell.1996.270.2.C437; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MEIJER AJ, 1992, J BIOL CHEM, V267, P5823; Nath SK, 1996, AM J PHYSIOL-GASTR L, V270, pG431, DOI 10.1152/ajpgi.1996.270.3.G431; OCONNELL ME, 1995, AM J PHYSIOL, V269, pC1513; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAJENDRAN VM, 1995, J BIOL CHEM, V270, P11051, DOI 10.1074/jbc.270.19.11051; ROBERTSON MA, 1994, AM J PHYSIOL, V267, pC146, DOI 10.1152/ajpcell.1994.267.1.C146; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; Rottenberg H, 1979, Methods Enzymol, V55, P547; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SARKADI B, 1991, BIOCHIM BIOPHYS ACTA, V1071, P407, DOI 10.1016/0304-4157(91)90005-H; Satoh T, 1996, FEBS LETT, V386, P230, DOI 10.1016/0014-5793(96)00449-8; SCHLIESS F, 1995, BIOCHEM J, V309, P13, DOI 10.1042/bj3090013; SOLEIMANI M, 1994, J BIOL CHEM, V269, P15613; TERADA Y, 1994, J BIOL CHEM, V269, P31296; TILLY BC, 1993, J BIOL CHEM, V268, P19919; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; TREHARNE KJ, 1994, AM J PHYSIOL-LUNG C, V267, pL592, DOI 10.1152/ajplung.1994.267.5.L592; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	57	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16670	16678		10.1074/jbc.272.26.16670	http://dx.doi.org/10.1074/jbc.272.26.16670			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195983	hybrid			2022-12-27	WOS:A1997XG01900087
J	Ng, DS; Francone, OL; Forte, TM; Zhang, JL; Haghpassand, M; Rubin, EM				Ng, DS; Francone, OL; Forte, TM; Zhang, JL; Haghpassand, M; Rubin, EM			Disruption of the murine lecithin:cholesterol acyltransferase gene causes impairment of adrenal lipid delivery and up-regulation of scavenger receptor class B type I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY LIPOPROTEIN; APOPROTEIN-A-I; RAT; METABOLISM; DEFICIENCY; ESTERS; MICE	Lecithin:cholesterol acyltransferase (LCAT) is the major determinant of the cholesteryl ester (CE) content of high density lipoprotein (HDL) in plasma, The selective uptake of HDL-CE is postulated to participate in delivery of tissue-derived cholesterol both to the liver and steroidogenic tissues. Recent studies comparing mice with similarly low levels of HDL, due to the absence of either of the two major HDL-associated apolipoproteins apoA-I and apoA-II, suggest that apoA-I is crucial in modulating this process, possibly through interaction with scavenger receptor class B type I (SR-BI), Because of the central role of LCAT in determining the size, lipid composition, and plasma concentration of HDL, we have created LCAT-deficient mice by gene targeting to examine the effect of:LCAT deficiency on HDL structure and composition and adrenal cholesterol delivery, The HDL in the LCAT-deficient mice was reduced in its plasma concentration (92%) and CE content (96%), The HDL particles were heterogeneous in size and morphology and included numerous discoidal particles, mimicking those observed in LCAT-deficient humans. The adrenals of the male Lcat (-/-) mice were severely depleted of lipid stores, which was associated with a 2-fold up-regulation of the adrenal SR-BI mRNA. These studies demonstrate that LCAT deficiency, similar to apoA-I deficiency, is associated with a. marked decrease in adrenal cholesterol delivery and supports the hypothesis that adrenal SR-BI expression is regulated by the adrenal cholesterol.	UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,CTR HUMAN GENOME,DIV LIFE SCI,BERKELEY,CA 94720; DEPT CARDIOVASC & METAB DIS,DIV CENT RES,GROTON,CT 06340; UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,MOL MED RES PROGRAM,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DONNER LAB,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018574] Funding Source: NIH RePORTER; NHLBI NIH HHS [PPG HL 18574] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHAO Y, 1979, J BIOL CHEM, V254, P1360; COALSON RE, 1981, STAINING PROCEDURES, P228; DREVON CA, 1981, J LIPID RES, V22, P37; FORTE T, 1974, SCAND J CLIN LAB INV, V33, P121, DOI 10.3109/00365517409100640; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; FRANCONE OL, 1995, J CLIN INVEST, V96, P1440, DOI 10.1172/JCI118180; Francone OL, 1996, J LIPID RES, V37, P1268; FRANCONE OL, 1996, J LIPID RES, V38, P813; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; GLOMSET JA, 1968, J LIPID RES, V9, P155; HOVIG T, 1974, Scandinavian Journal of Clinical and Laboratory Investigation Supplement, V33, P135, DOI 10.3109/00365517409100642; JAIN SK, 1982, J LAB CLIN MED, V99, P816; MITCHELL CD, 1980, J LIPID RES, V21, P625; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; PASZTY C, 1995, NAT GENET, V11, P33, DOI 10.1038/ng0995-33; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; Plump AS, 1996, J CLIN INVEST, V97, P2660, DOI 10.1172/JCI118716; SALE FO, 1984, ANAL BIOCHEM, V142, P347, DOI 10.1016/0003-2697(84)90475-5; SCHUMAKER VN, 1970, J THEOR BIOL, V26, P89, DOI 10.1016/S0022-5193(70)80034-0; VONACKERSTEIN A, 1995, ARTERIOSCLER THROMB, V15, P691; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001	24	124	129	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15777	15781		10.1074/jbc.272.25.15777	http://dx.doi.org/10.1074/jbc.272.25.15777			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188474	hybrid			2022-12-27	WOS:A1997XF32900034
J	Richarme, G; Caldas, TD				Richarme, G; Caldas, TD			Chaperone properties of the bacterial periplasmic substrate-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT TRANSPORT-SYSTEMS; ESCHERICHIA-COLI; STREPTOCOCCUS-PNEUMONIAE; SALMONELLA-TYPHIMURIUM; MOLECULAR CHAPERONES; NUCLEOTIDE-SEQUENCE; MEMBRANE-COMPONENTS; REPLICATION PROTEIN; BACILLUS-SUBTILIS; PEPTIDE PERMEASES	Bacterial periplasmic substrate-binding proteins are initial receptors in the process of active transport across cell membranes and/or chemotaxis. Each of them binds a specific substrate (e.g. sugar, amino acid, or ion) with high affinity, For transport, each binding protein interacts with a cognate membrane complex consisting of two hydrophobic proteins and two subunits of a hydrophilic ATPase. For chemotaxis, binding proteins interact with specific membrane chemotaxis receptors, We report, herewith, that the oligopeptide-binding protein OppA of Escherichia coli, the maltose-binding protein MalE of E. coli, and the galactose-binding protein MglB of Salmonella typhimurium interact with unfolded and denatured proteins, such as the molecular chaperones that are involved in protein folding and protein renaturation after stress. These periplasmic substrate-binding proteins promote the functional folding of citrate synthase and alpha-glucosidase after urea denaturation. They prevent the aggregation of citrate synthase under heat shock conditions, and they form stable complexes with several unfolded proteins, such as reduced carboxymethyl alpha-lactalbumin and unfolded bovine pancreatic trypsin inhibitor. These chaperone-like functions are displayed by both the liganded and ligand-free forms of binding proteins, and they occur at binding protein concentrations that are 10-100-fold lower than their periplasmic concentration. These results suggest that bacterial periplasmic substrate-binding proteins, in addition to their function in transport and chemotaxis, might be implicated in protein folding and protection from stress in the periplasm.			Richarme, G (corresponding author), UNIV PARIS 07, INST JACQUES MONOD, 2 PL JUSSIEU, F-75005 PARIS, FRANCE.							AMES GF, 1989, J BIOL CHEM, V264, P3998; AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; Ames GFL, 1996, J BIOL CHEM, V271, P14264, DOI 10.1074/jbc.271.24.14264; BENSON SA, 1985, ANNU REV BIOCHEM, V54, P101; BOOS W, 1995, E COLI SALMONELLA TY, P1175; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CLARKE S, 1979, J BIOL CHEM, V254, P9695; CUNDELL DR, 1995, INFECT IMMUN, V63, P2493, DOI 10.1128/IAI.63.7.2493-2498.1995; DASSA E, 1985, EMBO J, V4, P2287, DOI 10.1002/j.1460-2075.1985.tb03928.x; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; EMR SD, 1982, J BIOL CHEM, V257, P5852; FERENCI T, 1980, J SUPRAMOL STR CELL, V13, P101, DOI 10.1002/jss.400130110; GILSON E, 1982, NUCLEIC ACIDS RES, V10, P7449, DOI 10.1093/nar/10.22.7449; GILSON E, 1988, EMBO J, V7, P3971, DOI 10.1002/j.1460-2075.1988.tb03284.x; GUYER CA, 1986, J BACTERIOL, V168, P775, DOI 10.1128/jb.168.2.775-779.1986; HARAYAMA S, 1983, J BACTERIOL, V153, P408, DOI 10.1128/JB.153.1.408-415.1983; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HIGGINS CF, 1982, NATURE, V298, P723, DOI 10.1038/298723a0; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; HIGGINS CF, 1986, J BACTERIOL, V168, P775; HILES ID, 1986, EUR J BIOCHEM, V158, P561, DOI 10.1111/j.1432-1033.1986.tb09791.x; HOGG RW, 1991, MOL GEN GENET, V229, P453, DOI 10.1007/BF00267469; HULTGREN SJ, 1991, ANNU REV MICROBIOL, V46, P363; ITO K, 1981, CELL, V24, P707, DOI 10.1016/0092-8674(81)90097-0; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KASHIWAGI K, 1990, J BIOL CHEM, V265, P8387; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LANGER T, 1992, NATURE, V356, P383; Lazar SW, 1996, J BACTERIOL, V178, P1770, DOI 10.1128/jb.178.6.1770-1773.1996; LEMAUX PG, 1978, CELL, V13, P427, DOI 10.1016/0092-8674(78)90317-3; LIBEREK K, 1991, P NATL ACAD SCI USA, V22, P14491; LILIE H, 1993, PROTEIN SCI, V2, P1490, DOI 10.1002/pro.5560020913; MAGNUSON R, 1994, CELL, V77, P207, DOI 10.1016/0092-8674(94)90313-1; MARTINEAU P, 1990, BIOCHIMIE, V72, P397, DOI 10.1016/0300-9084(90)90063-M; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MISSIAKAS D, 1993, J BACTERIOL, V175, P2616; PEARCE BJ, 1994, MOL MICROBIOL, V12, P881, DOI 10.1111/j.1365-2958.1994.tb01076.x; PEREGO M, 1991, MOL MICROBIOL, V5, P173, DOI 10.1111/j.1365-2958.1991.tb01838.x; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; RICHARME G, 1993, J BIOL CHEM, V268, P9473; RICHARME G, 1993, J BIOL CHEM, V268, P24074; RICHARME G, 1983, BIOCHIM BIOPHYS ACTA, V748, P99, DOI 10.1016/0167-4838(83)90032-8; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; Shilton BH, 1996, J MOL BIOL, V264, P364, DOI 10.1006/jmbi.1996.0646; SHUMAN HA, 1981, J BIOL CHEM, V256, P560; SPRINGER MS, 1977, P NATL ACAD SCI USA, V74, P3312, DOI 10.1073/pnas.74.8.3312; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; ZHANG YH, 1992, J BIOL CHEM, V267, P22813; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591; [No title captured]	54	109	116	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15607	15612		10.1074/jbc.272.25.15607	http://dx.doi.org/10.1074/jbc.272.25.15607			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188448	hybrid			2022-12-27	WOS:A1997XF32900008
J	Ahn, CY; Byun, J; Yim, JB				Ahn, CY; Byun, J; Yim, JB			Purification, cloning, and functional expression of dihydroneopterin triphosphate 2'-epimerase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER; CYCLOHYDROLASE-I; BIOSYNTHESIS; PTERIDINES; MONAPTERIN; EXCRETION; NEOPTERIN; SYNTHASE; BINDING; RAT	Dihydroneopterin triphosphate (H2NTP) 2'-epimerase from Escherichia coli catalyzes the epimerization of H,NTP to dihydromonapterin triphosphate (H,MTP). The enzyme was purified 954-fold to apparent]homogeneity by a combination of ammonium sulfate fractionation and column chromatography of Cibacron blue 3GA dye ligand, phenyl-Sepharose CL-4B, methotrexate-agarose, and Superdex 200 HR 10/30 FPLC column. The molecular mass of the epimerase determined on a Superdex column was 82.6 kDa, while the subunit molecular mass determined on SDS-polyacrylamide gel electrophoresis was 13.7 kDa, This implies that the epimerase most probably exists as homohexamer, The 20-amino acid sequence from the N terminus was determined (AQPAAIIRIKNLRLRTFIGI). Based on this sequence, the gene encoding the epimerase was cloned using a simple polymerase chain reaction approach, Translation of the nucleotide sequence of the cloned gene revealed the presence of an open reading frame containing 120 amino acids with a predicted molecular mass of 13,993 Da, The epimerase gene located in a 2.3-kilobase BamHI-EcoRI fragment from Kohara's clone 406 was overexpressed 300 fold, which was confirmed by the prominent increase in the 14-kDa protein band on SDS-polyacrylamide electrophoresis gels, It showed no homology with the sequences of isomerases or other enzymes in GenBanK/EMBL data bases.	SEOUL NATL UNIV,DEPT MICROBIOL,COLL NAT SCI,KWANAK GU,SEOUL 151742,SOUTH KOREA	Seoul National University (SNU)								BLAU N, 1987, UNCONJUGATED PTERINS, P105; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHA KW, 1991, J BIOL CHEM, V266, P12294; CREMERBARTELS G, 1987, BIOCH CLIN ASPECTS P, V5, P359; DORSETT DL, 1979, BIOCHEMISTRY-US, V12, P2596; GERDING H, 1989, BIOL CHEM H-S, V370, P383; GUROFF G, 1969, J BIOL CHEM, V244, P142; HAMES BD., 1981, GEL ELECTROPHORESIS, P1; HANNEKEN L, 1989, BIOL CHEM H-S, V370, P384; HEINE MC, 1975, BIOCHIM BIOPHYS ACTA, V411, P236, DOI 10.1016/0304-4165(75)90304-9; JENNINGS IG, 1991, P NATL ACAD SCI USA, V88, P5734, DOI 10.1073/pnas.88.13.5734; JONES THD, 1967, J BIOL CHEM, V242, P3989; JONES THD, 1964, BIOCHEM BIOPH RES CO, V17, P486, DOI 10.1016/0006-291X(64)90051-8; KANG DM, 1995, PTERIDINES, V6, P93; KLEIN R, 1992, ANAL BIOCHEM, V203, P134, DOI 10.1016/0003-2697(92)90053-A; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; MATHIS JB, 1970, J BIOL CHEM, V245, P3015; Matsudaira PT., 1993, PRACTICAL GUIDE PROT; NAR H, 1994, EMBO J, V13, P1255, DOI 10.1002/j.1460-2075.1994.tb06377.x; OGIWARA S, 1992, TETRAHEDRON LETT, V33, P1341, DOI 10.1016/S0040-4039(00)91617-4; PARK YS, 1990, BIOCHIM BIOPHYS ACTA, V1038, P186, DOI 10.1016/0167-4838(90)90203-R; REMBOLD H, 1971, HOPPESEYLERS Z PHYSL, V342, P1271; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TILLINGHAST HS, 1987, J CELL SCI, V87, P45; URUSHIBARA T, 1971, BIOCHEM J, V125, P141, DOI 10.1042/bj1250141; WACHTER H, 1980, NATURWISSENSCHAFTEN, V67, P610, DOI 10.1007/BF00396550; WACHTER H, 1979, H-S Z PHYSIOL CHEM, V360, P1957; YIM JB, 1993, HELV CHIM ACTA, V76, P1970, DOI 10.1002/hlca.19930760516; YIM JJ, 1976, J BIOL CHEM, V251, P5087; YOON KH, 1993, PTERIDINES, V4, P43; ZHAO GS, 1994, P NATL ACAD SCI USA, V91, P1366, DOI 10.1073/pnas.91.4.1366	33	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15323	15328		10.1074/jbc.272.24.15323	http://dx.doi.org/10.1074/jbc.272.24.15323			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182560	hybrid			2022-12-27	WOS:A1997XE03400043
J	Ghosh, A; Desai, SY; Sarkar, SN; Ramaraj, P; Ghosh, SK; Bandyopadhyay, S; Sen, GC				Ghosh, A; Desai, SY; Sarkar, SN; Ramaraj, P; Ghosh, SK; Bandyopadhyay, S; Sen, GC			Effects of mutating specific residues present near the amino terminus of 2'-5'-oligoadenylate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RNA-BINDING DOMAIN; 2-5A SYNTHETASE; HUMAN-CELLS; INTERFERON; EXPRESSION; IDENTIFICATION; ENZYMES; 69-KDA; FORMS	In this study, we investigated the role of specific amino acid residues present near the amino terminus of the 9-2 isozyme of 2'5'-oligoadenylate synthetase. In vitro expression of deletion mutants showed that residues 1-9 are required for enzyme activity. Within this region, residues 3, 7, and 8 were found to be conserved among all known isozymes of 2'5'-oligoadenylate synthetase. Mutation of these residues singly or in combination resulted in partial or total loss of enzyme activity. Substitution of the proline residue at position 7 by different residues caused a partial or complete loss of activity. The properties of the inactive P7Q mutant were further explored by expressing the protein in bacteria. The bacterially expressed protein was also enzymatically inactive, The mutant protein could bind the substrate ATP and the activator double-stranded RNA normally, Oligomerization properties of the protein were examined by an affinity-based interaction assay and by glycerol gradient centrifugation; there was no detectable difference between the wild type and the P7Q mutant. These results demonstrated the importance of the proline residue at position 7 in conferring enzyme activity to the protein without affecting its other properties.	CLEVELAND CLIN FDN,DEPT MOL BIOL,RES INST,CLEVELAND,OH 44195	Cleveland Clinic Foundation			Sarkar, Saumendra N/B-5038-2011	Sarkar, Saumendra N/0000-0002-2850-6121	NATIONAL CANCER INSTITUTE [P01CA062220, R01CA068782] Funding Source: NIH RePORTER; NCI NIH HHS [CA-62220, CA-68782] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHEBATH J, 1987, J BIOL CHEM, V262, P3852; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; DESAI SY, 1995, J BIOL CHEM, V270, P3454, DOI 10.1074/jbc.270.7.3454; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; GHOSH SK, 1991, J BIOL CHEM, V266, P15293; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; HAYSTEAD CMM, 1993, EUR J BIOCHEM, V214, P459, DOI 10.1111/j.1432-1033.1993.tb17942.x; HOVANESSIAN AG, 1991, J INTERFERON RES, V11, P199, DOI 10.1089/jir.1991.11.199; ICHII Y, 1986, NUCLEIC ACIDS RES, V14, P10117, DOI 10.1093/nar/14.24.10117; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; Kon N, 1996, J BIOL CHEM, V271, P19983, DOI 10.1074/jbc.271.33.19983; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MARIE I, 1990, J BIOL CHEM, V265, P18601; MARIE I, 1992, J BIOL CHEM, V267, P9933; MCCORMACK SJ, 1992, VIROLOGY, V188, P47, DOI 10.1016/0042-6822(92)90733-6; MORY Y, 1989, J INTERFERON RES, V9, P295, DOI 10.1089/jir.1989.9.295; PATEL RC, 1992, J BIOL CHEM, V267, P7671; PATEL RC, 1995, P NATL ACAD SCI USA, V92, P8283, DOI 10.1073/pnas.92.18.8283; PATEL RC, 1995, CELL MOL BIOL RES, V40, P671; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; VILCEK J, 1996, FIELDS VIROLOGY, P375	22	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15452	15458		10.1074/jbc.272.24.15452	http://dx.doi.org/10.1074/jbc.272.24.15452			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182577	hybrid			2022-12-27	WOS:A1997XE03400060
J	Kato, A; Sugiura, N; Saruta, Y; Hosoiri, T; Yasue, H; Hirose, S				Kato, A; Sugiura, N; Saruta, Y; Hosoiri, T; Yasue, H; Hirose, S			Targeting of endopeptidase 24.16 to different subcellular compartments by alternative promoter usage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-BINDING PROTEIN; BRAIN SYNAPTIC-MEMBRANES; THIOL-DEPENDENT METALLOENDOPEPTIDASE; MITOCHONDRIAL INTERMEDIATE PEPTIDASE; TRANSFER-RNA-SYNTHETASES; AMINO-ACID-SEQUENCE; THIMET OLIGOPEPTIDASE; RAT-BRAIN; TRANSCRIPTION FACTOR; MOLECULAR-CLONING	Endopeptidase 24.16 or mitochondrial oligopeptidase, abbreviated here as EP 24.16 (MOP), is a thiol- and metal-dependent oligopeptidase that is found in multiple intracellular compartments in mammalian cells, From an analysis of the corresponding gene, we found that the distribution of the enzyme to appropriate subcellular locations is achieved by the use of alternative sites for the initiation of transcription. The pig EP 24.16 (MOP) gene spans over 100 kilobases and is organized into 16 exons, The core protein sequence is encoded by exons 5-16 which match perfectly with exons 2-13 of the gene for endopeptidase 24.15, another member of the thimet oligopeptidase family, These two sets of 11 exons share the same splice sites, suggesting a common ancestor. Multiple species of mRNA for EP 24.16 (MOP) were detected by the 5'-rapid amplification of cDNA ends and they were shown to have been generated from a single gene by alternative choices of sites for the initiation of transcription and splicing, Two types of transcript were prepared, corresponding to transcription from distal and proximal sites, Their expression in vit ro in COS-l cells indicated that they encoded two isoforms (long and short) which differed only at their amino termini: the long form contained a cleavable mitochondrial targeting sequence and was directed to mitochondria; the short form, lacking such a signal sequence, remained in the cytosol. The complex structure of the EP 24.16 (MOP) gene thus allows, by alternative promoter usage, a fine transcriptional regulation of coordinate expression, in the different subcellular compartments, of the two isoforms arising from a single gene.	TOKYO INST TECHNOL,DEPT SCI BIOL,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN; NATL DEF MED COLL,DEPT BIOCHEM 1,TOKOROZAWA,SAITAMA 359,JAPAN; NATL INST ANIM IND,ANIM GENOME RES GRP,IBARAKI,OSAKA 305,JAPAN	Tokyo Institute of Technology; National Defense Medical College - Japan; National Agriculture & Food Research Organization - Japan			Kato, Akira/E-6328-2010	Kato, Akira/0000-0002-9083-1443				BARRETT AJ, 1990, BIOCHEM J, V271, P701, DOI 10.1042/bj2710701; BARRETT AJ, 1995, METHOD ENZYMOL, V248, P529; BOND JS, 1985, INT J BIOCHEM, V17, P565, DOI 10.1016/0020-711X(85)90287-3; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUCHLER M, 1994, EUR J BIOCHEM, V219, P627, DOI 10.1111/j.1432-1033.1994.tb19978.x; CAMARGO ACM, 1972, J NEUROCHEM, V19, P37, DOI 10.1111/j.1471-4159.1972.tb01251.x; CHATTON B, 1988, J BIOL CHEM, V263, P52; CHECLER F, 1986, J BIOL CHEM, V261, P1274; CHECLER F, 1983, J NEUROCHEM, V41, P375, DOI 10.1111/j.1471-4159.1983.tb04753.x; CHECLER F, 1984, J NEUROCHEM, V43, P1295, DOI 10.1111/j.1471-4159.1984.tb05386.x; CONLIN CA, 1995, METHOD ENZYMOL, V248, P567; CONLIN CA, 1992, J BACTERIOL, V174, P5881, DOI 10.1128/jb.174.18.5881-5887.1992; DANPURE CJ, 1995, TRENDS CELL BIOL, V5, P230, DOI 10.1016/S0962-8924(00)89016-9; DAUCH P, 1995, J BIOL CHEM, V270, P27266, DOI 10.1074/jbc.270.45.27266; DAVIES MS, 1986, GENE, V45, P183, DOI 10.1016/0378-1119(86)90253-2; HAGIWARA H, 1989, EUR J BIOCHEM, V185, P405, DOI 10.1111/j.1432-1033.1989.tb15129.x; HARPER E, 1970, BIOCHIM BIOPHYS ACTA, V198, P286; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HEIDRICH HG, 1969, H-S Z PHYSIOL CHEM, V350, P1430, DOI 10.1515/bchm2.1969.350.2.1430; HENRICH B, 1993, J BACTERIOL, V175, P7290, DOI 10.1128/JB.175.22.7290-7300.1993; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISAYA G, 1994, MOL CELL BIOL, V14, P5603, DOI 10.1128/MCB.14.8.5603; ISAYA G, 1992, P NATL ACAD SCI USA, V89, P8317, DOI 10.1073/pnas.89.17.8317; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KATO A, 1994, EUR J BIOCHEM, V221, P159, DOI 10.1111/j.1432-1033.1994.tb18725.x; KAWABATA S, 1992, J BIOL CHEM, V267, P10331; KAWABATA S, 1993, J BIOL CHEM, V268, P12498; KIRON MAR, 1989, J BIOL CHEM, V264, P4138; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MCKIE N, 1993, BIOCHEM J, V295, P57, DOI 10.1042/bj2950057; MIZUGUCHI G, 1995, J BIOL CHEM, V270, P9384, DOI 10.1074/jbc.270.16.9384; MONNET V, 1995, METHOD ENZYMOL, V248, P579; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; ORLOWSKI M, 1989, BIOCHEM J, V261, P951, DOI 10.1042/bj2610951; PIEROTTI A, 1990, BIOCHEMISTRY-US, V29, P10323, DOI 10.1021/bi00497a006; PIEROTTI A, 1994, BIOCHEMISTRY-US, V33, P622, DOI 10.1021/bi00168a600; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; ROSENBERG E, 1988, BIOCHEM BIOPH RES CO, V156, P1230, DOI 10.1016/S0006-291X(88)80764-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERIZAWA A, 1995, J BIOL CHEM, V270, P2092, DOI 10.1074/jbc.270.5.2092; SERIZAWA A, 1997, IN PRESS PROTEOLYSIS; SUGIURA N, 1992, J BIOL CHEM, V267, P18067; SUGIURA N, 1991, PEPTIDE REGULATION C, P157; THOMPSON A, 1995, BIOCHEM BIOPH RES CO, V213, P66, DOI 10.1006/bbrc.1995.2099; TISLJAR U, 1993, BIOL CHEM H-S, V374, P91; TISLJAR U, 1990, FEBS LETT, V264, P84, DOI 10.1016/0014-5793(90)80771-A; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WUNSCH E, 1963, H-S Z PHYSIOL CHEM, V333, P149, DOI 10.1515/bchm2.1963.333.1.149	54	38	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15313	15322		10.1074/jbc.272.24.15313	http://dx.doi.org/10.1074/jbc.272.24.15313			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182559	hybrid			2022-12-27	WOS:A1997XE03400042
J	Komissarova, N; Kashlev, M				Komissarova, N; Kashlev, M			RNA polymerase switches between inactivated and activated states by translocating back and forth along the DNA and the RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACILITATED TRANSCRIPT CLEAVAGE; ESCHERICHIA-COLI; TERNARY COMPLEXES; ELONGATION COMPLEXES; STRUCTURAL-ANALYSIS; CHAIN ELONGATION; TERMINATION; MECHANISM	Important regulatory events in both prokaryotic and eukaryotic transcription are currently explained in terms of an inchworming model of elongation, In this model, RNA extension is carried out by a mobile catalytic center that, at certain DNA sites, advances within stationary RNA polymerase. This idea emerged from the observation that footprints of individual elongation complexes, halted in vitro at consecutive DNA positions, can remain fixed on the template for several contiguous nucleotide additions. Here, we examine in detail the structural transitions that occur immediately after the enzyme stops at sites where discontinuous advancement of RNA polymerase is observed, We demonstrate that halting at such special sites does not ''freeze'' RNA polymerase at one location but induces it to leave its initial position and to slide backward along the DNA and the RNA without degrading the transcript. The resulting loss of contact between the RNA S'-hydroxyl and the enzyme's catalytic center leads to temporary loss of the catalytic activity, This process is equilibrated with enzyme return to the original location, so that]RNA polymerase is envisaged as an oscillating object switching between catalytically active and inactive states. The retreated isoform constitutes a principal intermediate in factor-induced endonucleolytic RNA cleavage. These oscillations of RNA polymerase can explain its apparent discontinuous advancement, which had been interpreted as indicating flexibility within the enzyme.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702; PUBL HLTH RES INST CITY NEW YORK INC,NEW YORK,NY 10016	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NIGMS NIH HHS [GM49242] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; Chan Cathleen L., 1994, V3, P297; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; GU WG, 1993, J BIOL CHEM, V268, P25604; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; KASHLEV M, 1993, CELL, V75, P147, DOI 10.1016/S0092-8674(05)80091-1; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; KERPPOLA T, 1992, FED AM SOC EXP BIOL, V5, P2833; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; MUSTAEV A, 1993, J BIOL CHEM, V268, P19185; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; ORLOVA M, 1995, P NATL ACAD SCI USA, V92, P4596, DOI 10.1073/pnas.92.10.4596; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1993, TRANSCRIPTION, P263; Rogers S G, 1980, Methods Enzymol, V65, P201; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P805; SPENCER CA, 1990, ONCOGENE, V5, P777; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; WIEST DK, 1992, J BIOL CHEM, V267, P7733; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; ZAYCHIKOV E, 1995, P NATL ACAD SCI USA, V92, P1739, DOI 10.1073/pnas.92.5.1739	32	208	216	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15329	15338		10.1074/jbc.272.24.15329	http://dx.doi.org/10.1074/jbc.272.24.15329			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182561	hybrid			2022-12-27	WOS:A1997XE03400044
J	Lee, Y; Nazar, RN				Lee, Y; Nazar, RN			Ribosomal 5 S rRNA maturation in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-BINDING-SITE; 5-S RNA; DROSOPHILA-MELANOGASTER; INVITRO SYNTHESIS; PROCESSING SITE; 3' END; PRECURSOR; YEAST; COMPLEX; MUTANT	The maturation of the ribosomal 5 S RNA in Saccharomyces cerevisiae is examined based on the expression of mutant 5 S rRNA genes, in vivo, and a parallel analysis of RNA processing, in, vitro. Both types of analysis indicate that 5 S rRNA processing is not dependent on the nucleotide sequence of either the external transcribed spacer or the mature 5 S rRNA. The results further indicate the RNA is processed by an exonuclease activity which is limited primarily or entirely by helix I, the secondary structure formed between the mature and interacting termini. The 5 S RNA binding protein (YL3) also appears not to influence directly the maturation process, but rather to play a role in protecting the rRNA from further degradation by ''housekeeping'' nucleases. Taken together, the results continue to support a ''quality control'' function which helps to ensure that during maturation only normal precursors are processed and assembled into active ribosomes.	UNIV GUELPH,DEPT GENET & MOL BIOL,GUELPH,ON N1G 2W1,CANADA	University of Guelph								ARIES JP, 1991, METHOD ENZYMOL, V194, P735; DENIS H, 1973, BIOCHIMIE, V55, P1137, DOI 10.1016/S0300-9084(73)80453-5; DESHMUKH M, 1993, MOL CELL BIOL, V13, P2835, DOI 10.1128/MCB.13.5.2835; FRENDEWEY D, 1985, J BIOL CHEM, V260, P449; GOOD L, 1992, NUCLEIC ACIDS RES, V20, P4934, DOI 10.1093/nar/20.18.4934; HAMADA H, 1979, CELL, V17, P163, DOI 10.1016/0092-8674(79)90304-0; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; JACQ B, 1977, J MOL BIOL, V117, P785, DOI 10.1016/0022-2836(77)90069-9; LEE Y, 1995, NUCLEIC ACIDS RES, V23, P634, DOI 10.1093/nar/23.4.634; LEE Y, 1995, J BIOL CHEM, V270, P28003; LEVINGER L, 1992, J BIOL CHEM, V267, P23683; MAXAM AM, 1977, NATURE, V267, P643, DOI 10.1038/267643a0; MCDOUGALL J, 1983, J BIOL CHEM, V258, P5256; MCDOUGALL J, 1987, NUCLEIC ACIDS RES, V15, P161, DOI 10.1093/nar/15.1.161; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NAZAR RN, 1979, EUR J BIOCHEM, V102, P573, DOI 10.1111/j.1432-1033.1979.tb04274.x; NAZAR RN, 1979, J BIOL CHEM, V254, P7724; NAZAR RN, 1983, NUCLEIC ACIDS RES, V11, P3155, DOI 10.1093/nar/11.10.3155; NAZAR RN, 1982, CELL NUCLEUS, V10, P1; PEACOCK AC, 1967, BIOCHEMISTRY-US, V6, P1818, DOI 10.1021/bi00858a033; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PERCIVALSMITH A, 1987, MOL CELL BIOL, V7, P2484, DOI 10.1128/MCB.7.7.2484; PICARD B, 1979, P NATL ACAD SCI USA, V76, P241, DOI 10.1073/pnas.76.1.241; PIPER PW, 1983, EMBO J, V2, P353, DOI 10.1002/j.1460-2075.1983.tb01430.x; PREISER PR, 1991, J BIOL CHEM, V266, P7509; PREISER PR, 1991, J BIOL CHEM, V266, P23602; PRISER P, 1993, J BIOL CHEM, V268, P11553; RINKE J, 1982, CELL, V29, P149, DOI 10.1016/0092-8674(82)90099-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEITZ JA, 1988, J CELL BIOL, V106, P545, DOI 10.1083/jcb.106.3.545; SZOSTAK JW, 1979, PLASMID, V2, P536, DOI 10.1016/0147-619X(79)90053-2; TANG BZ, 1992, J BIOL CHEM, V267, P17738; TEKAMP PA, 1980, J BIOL CHEM, V255, P9501; VANRYK DI, 1990, J BIOL CHEM, V265, P8377; VANRYK DI, 1992, J BIOL CHEM, V267, P16177; VASISHT V, 1994, J BIOL CHEM, V269, P18468; XING YY, 1989, GENE DEV, V3, P1008, DOI 10.1101/gad.3.7.1008	38	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15206	15212		10.1074/jbc.272.24.15206	http://dx.doi.org/10.1074/jbc.272.24.15206			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182543	hybrid			2022-12-27	WOS:A1997XE03400026
J	Watts, SD; Capaldi, RA				Watts, SD; Capaldi, RA			Interactions between the F-1 and F-0 parts in the Escherichia coli ATP synthase - Associations involving the loop region of C subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; EPSILON-SUBUNIT; GAMMA-SUBUNIT; H+ TRANSPORT; POLAR LOOP; MECHANISM; BINDING; F1; F1-ATPASE; CLEAVAGE	The N-ethylmaleimide reactivity of c subunits in Escherichia coli F1F0 ATP synthase (ECF1F0) isolated from five mutants, each with a cysteine at a different position in the polar loop region (positions 39, 40, 42, 43, and 44), has been investigated. The maleimide was found to react with Cys placed at positions 42, 43, and 44 but not at 39 or 40, All copies of the c subunit reacted similarly when the Cys was at position 43 or 44, In contrast, the Cys in the mutant cQ42C reacted as two classes, with 60% reacting relatively rapidly and 40% reacting at a rate 40-fold slower. After removing F-1, all copies of the c subunit in this mutant reacted equally fast. Therefore, the slow class in the cQ42C mutant represents c subunits shielded by, and probably involved directly in, the interaction of the F-0 with gamma and epsilon subunits of the F-1 part, Based on the estimated stoichiometry of c subunits in the ECF1F0 complex, 4 or 5 c subunits are involved in this F-1 interaction. N-Ethylmaleimide modification of all of the c subunits reduced ATPase activity by only 30% in ECF1F0 from mutant cQ42C. Modification of the more rapidly reacting class had little effect on ATP hydrolysis-driven proton translocation, and did not alter the DCCD inhibition of ATPase activity. However, as those c subunits involved in the F-1 interaction became modified, DCCD inhibition was progressively lost, as was coupling between ATP hydrolysis and proton translocation.	UNIV OREGON,INST MOL BIOL,EUGENE,OR 97403	University of Oregon					NHLBI NIH HHS [HL24526, HL22450] Funding Source: Medline; NIGMS NIH HHS [GM07759] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007759] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; AGGELER R, 1995, BBA-BIOENERGETICS, V1230, P62, DOI 10.1016/0005-2728(95)00040-P; AGGELER R, 1987, BIOCHEMISTRY-US, V26, P7107, DOI 10.1021/bi00396a036; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Capaldi RA, 1996, J BIOENERG BIOMEMBR, V28, P397, DOI 10.1007/BF02113980; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; DOWNER NW, 1976, BIOCHEMISTRY-US, V15, P2930, DOI 10.1021/bi00658a036; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Fillingame RH, 1996, CURR OPIN STRUC BIOL, V6, P491, DOI 10.1016/S0959-440X(96)80114-X; FILLINGAME RH, 1992, J BIOENERG BIOMEMBR, V24, P485, DOI 10.1007/BF00762366; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FRAGA D, 1989, J BIOL CHEM, V264, P6797; GIRVIN ME, 1993, BIOCHEMISTRY-US, V32, P12167, DOI 10.1021/bi00096a029; GIRVIN ME, 1995, BIOCHEMISTRY-US, V34, P1635, DOI 10.1021/bi00005a020; GIRVIN ME, 1994, BIOCHEMISTRY-US, V33, P665, DOI 10.1021/bi00169a006; HOPPE J, 1984, BIOCHIM BIOPHYS ACTA, V768, P1, DOI 10.1016/0304-4173(84)90005-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lill H, 1996, J BIOL CHEM, V271, P32737, DOI 10.1074/jbc.271.51.32737; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4134, DOI 10.1021/bi00313a019; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; Singh S, 1996, FEBS LETT, V397, P30, DOI 10.1016/S0014-5793(96)01127-1; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; TURINA P, 1994, BIOCHEMISTRY-US, V33, P14275, DOI 10.1021/bi00251a040; WALKER JE, 1994, FEBS LETT, V346, P39, DOI 10.1016/0014-5793(94)00368-8; WATTS SD, 1995, FEBS LETT, V368, P235, DOI 10.1016/0014-5793(95)00658-V; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; WILKENS S, 1994, BIOL CHEM H-S, V375, P43; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609	34	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15065	15068		10.1074/jbc.272.24.15065	http://dx.doi.org/10.1074/jbc.272.24.15065			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182524	hybrid			2022-12-27	WOS:A1997XE03400007
J	Wong, PW; Brackney, WR; Pessah, IN				Wong, PW; Brackney, WR; Pessah, IN			ortho-substituted polychlorinated biphenyls alter microsomal calcium transport by direct interaction with ryanodine receptors of mammalian brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; CA-2+ RELEASE CHANNEL; II-III-LOOP; SKELETAL-MUSCLE; DIHYDROPYRIDINE RECEPTOR; H-3 RYANODINE; RAT-BRAIN; SARCOPLASMIC-RETICULUM; SYMPATHETIC NEURONS; CA2+ RELEASE	A stringent structure-activity relationship among polychlorinated biphenyls (PCBs) possessing two or more ortho-chlorine substituents is observed for activation of ryanodine receptors in mammalian brain, revealing an arylhydrocarbon receptor-independent mechanism through which non-coplanar PCBs disrupt neuronal Ca2+ signaling. Of the congeners assayed, noncoplanar PCB 95 exhibits the highest potency (EC50 = 12-24 mu M) toward activating high affinity [H-3]ryanodine-binding in rat hippocampus, cerebellum, and cerebral cortex, Coplanar PCB 66 and PCB 126 have no ryanodine receptor activity in all brain regions examined, PCB 95 enhances [H-3]ryanodine-binding affinity and capacity by significantly altering modulation by Ca2+ and Mg2+, thereby stabilizing a high affinity conformation of the ryanodine receptor, Ca2+ transport measurements using cortical microsomes reveal that PCB 95 discriminates between inositol 1,4,5-trisphosphate- and ryanodine-sensitive stores, PCB 95 selectively mobilizes Ca2+ from ryanodine-sensitive stores in a dose-dependent manner (EC50 = 3.5 mu M) and is completely inhibited by ryanodine receptor blockers, whereas coplanar PCBs are inactive, These data demonstrate that ortho-substituted PCBs disrupt Ca2+ transport in central neurons by direct interaction with ryanodine receptors, showing high selectivity and specificity, Alteration of Ca2+ signaling mediated by ryanodine receptors in specific regions of the central nervous system may account, at least in part, for the significant impact of these agents toward neurodevelopment and neuroplasticity in mammals.	UNIV CALIF DAVIS, SCH VET MED, DEPT MOL BIOSCI, DAVIS, CA 95616 USA	University of California System; University of California Davis			Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007059, R01ES005002] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES07059, ES05707, 1RO1 ES05002] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AIREY JA, 1991, DEV BIOL, V148, P365, DOI 10.1016/0012-1606(91)90344-3; ASHLEY RH, 1989, J MEMBRANE BIOL, V111, P179, DOI 10.1007/BF01871781; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Chavis P, 1996, NATURE, V382, P719, DOI 10.1038/382719a0; CHEN YCJ, 1994, AM J PUBLIC HEALTH, V84, P415, DOI 10.2105/AJPH.84.3.415; CHEN YJ, 1994, DEV MED CHILD NEUROL, V36, P312, DOI 10.1111/j.1469-8749.1994.tb11851.x; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; de Voogt P., 1989, HALOGENATED BIPHENYL, V3 -45; ELHAYEK R, 1995, J BIOL CHEM, V270, P22116, DOI 10.1074/jbc.270.38.22116; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FURUICHI T, 1994, J NEUROSCI, V14, P4794; FUTATSUGI A, 1995, BIOCHEM J, V305, P373, DOI 10.1042/bj3050373; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; GOMEZ TM, 1995, NEURON, V14, P1233, DOI 10.1016/0896-6273(95)90270-8; JACOBSON JL, 1990, J PEDIATR-US, V116, P38, DOI 10.1016/S0022-3476(05)81642-7; Jacobson JL, 1996, NEW ENGL J MED, V335, P783, DOI 10.1056/NEJM199609123351104; KODAVANTI PRS, 1993, TOXICOL APPL PHARM, V123, P97, DOI 10.1006/taap.1993.1226; KODAVANTI PRS, 1995, TOXICOL APPL PHARM, V130, P140, DOI 10.1006/taap.1995.1018; KOOPMANESSEBOOM C, 1994, CHEMOSPHERE, V29, P2327, DOI 10.1016/0045-6535(94)90401-4; LAI FA, 1992, BIOCHEM J, V288, P553, DOI 10.1042/bj2880553; LEDBETTER MW, 1994, J BIOL CHEM, V269, P31544; LIPSCOMBE D, 1988, NEURON, V1, P355, DOI 10.1016/0896-6273(88)90185-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU XY, 1995, J BIOL CHEM, V270, P18459, DOI 10.1074/jbc.270.31.18459; MARKS AR, 1991, J CELL BIOL, V114, P303, DOI 10.1083/jcb.114.2.303; MARTINEZSERRANO A, 1989, BIOCHEM BIOPH RES CO, V161, P965, DOI 10.1016/0006-291X(89)91337-5; MARTY I, 1994, P NATL ACAD SCI USA, V91, P2270, DOI 10.1073/pnas.91.6.2270; MCPHERSON PS, 1990, J BIOL CHEM, V265, P18454; MINTA A, 1989, J BIOL CHEM, V264, P8171; MULLIN MD, 1984, ENVIRON SCI TECHNOL, V18, P468, DOI 10.1021/es00124a014; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; PADUA RA, 1994, J NEUROCHEM, V62, P2340; PALADE P, 1987, J BIOL CHEM, V262, P6135; PESSAH IN, 1991, MOL PHARMACOL, V39, P679; SAFE S, 1993, ENVIRON HEALTH PERSP, V100, P259, DOI 10.2307/3431532; SAFE S, 1987, POLYCHLORINATED BIPH, P1; SCHANTZ SL, 1995, FUND APPL TOXICOL, V26, P117, DOI 10.1006/faat.1995.1081; SCHANTZ SL, 1997, IN PRESS NEUROTOXICO; SCHANTZ SL, 1997, IN PRESS BEHAV TOXIC; SEEGAL RF, 1991, NEUROTOXICOLOGY, V12, P55; SEEGAL RF, 1990, TOXICOL APPL PHARM, V106, P136, DOI 10.1016/0041-008X(90)90113-9; SEEGAL RF, 1991, TOXICOLOGY, V66, P145, DOI 10.1016/0300-483X(91)90215-M; SHAIN W, 1991, TOXICOL APPL PHARM, V111, P33, DOI 10.1016/0041-008X(91)90131-W; THAYER SA, 1988, MOL PHARMACOL, V34, P664; VERMA A, 1992, MOL BIOL CELL, V3, P621, DOI 10.1091/mbc.3.6.621; WHITE AM, 1993, FEBS LETT, V318, P259, DOI 10.1016/0014-5793(93)80524-X; Wong PW, 1996, MOL PHARMACOL, V49, P740; WONG PW, 1997, IN PRESS NEUROTOXICO; ZIMANYI I, 1991, BRAIN RES, V561, P181, DOI 10.1016/0006-8993(91)91594-Q	50	98	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15145	15153		10.1074/jbc.272.24.15145	http://dx.doi.org/10.1074/jbc.272.24.15145			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182535	hybrid			2022-12-27	WOS:A1997XE03400018
J	Yang, Q; McDermott, PJ; Duzic, E; Pleij, CWA; Sherlock, JD; Lanier, SM				Yang, Q; McDermott, PJ; Duzic, E; Pleij, CWA; Sherlock, JD; Lanier, SM			The 3'-untranslated region of the alpha(2C)-adrenergic receptor mRNA impedes translation of the receptor message	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; NUCLEOTIDE-BINDING PROTEIN; MESSENGER-RNA TRANSLATION; ALPHA-2-ADRENERGIC RECEPTOR; SIGNAL TRANSDUCTION; ALPHA-ADRENOCEPTORS; BETA-ADRENOCEPTORS; GENE-EXPRESSION; RAT-BRAIN; SUBTYPES	We report that tyro subtypes of alpha(2)-adrenergic receptors (alpha(2A/D)- and alpha(2C)-AR) are ectopically expressed with dramatically different efficiencies and that this difference is due to a 288-nucleotide (nt) segment in the 3'-untranslated region (3'-UTR) of the alpha(2C)-AR mRNA that impairs translational processing, NIH-3T3 fibroblasts mere transfected with receptor constructs (coding region plus 552 nt, alpha(2C)-AR; coding region plus 1140 nt, alpha(2A/D)-AR) and a vector conferring G418 resistance, Transcription was driven by the murine sarcoma virus promoter element, and the receptor gene segment was upstream of an SV40 polyadenylation cassette, Drug-resistant transfectants were evaluated for expression of receptor mRNA and protein, 90% of the NIH-3T3 alpha(2C)-AR transfectants expressed receptor mRNA, but only 14% of the clonal cell Lines expressed receptor protein, In contrast, 90% of the NIH-3T3 alpha(2A/D)-AR transfectants expressed receptor protein (200-5000 fmol/mg), Similar results were obtained following transfection of DDT1MF-2 cells with the two receptor constructs. The role of the 3'-UTR of the alpha(2C)-AR in mRNA processing was determined by generating new constructs in which the 3'-UTR. was progressively truncated from 552 to 470, 182, 143, or 74 nt 3' to the stop codon. Truncation of the 3'-UTR resulted in the expression of receptor protein in the G418-resistant transfectants (nt 74, 100%; nt 143, 80%; nt 182, 50%), The level of mRNA in the transfectants expressing the receptor protein was not greater than that in nonexpressing clones, and the differences in protein expression did not reflect altered mRNA stability in the truncated construct. The alpha(2C)-AR mRNA with the longer 3'-UTR underwent translational initiation as it was found in the polysome fraction, indicating that the lack of receptor protein was due to impaired translational elongation or termination. These data suggest that translational efficiency is a hey mechanism for regulating alpha(2C)-AR expression and associated signaling events.	MED UNIV S CAROLINA,DEPT PHARMACOL,CHARLESTON,SC 29425; MED UNIV S CAROLINA,DEPT MED,DIV CARDIOL,CHARLESTON,SC 29425; LEIDEN UNIV,LEIDEN INST CHEM,NL-2300 RA LEIDEN,NETHERLANDS	Medical University of South Carolina; Medical University of South Carolina; Leiden University; Leiden University - Excl LUMC			Yang, Qing/H-5342-2012	Yang, Qing/0000-0002-5068-6085; Lanier, Stephen/0000-0002-2740-7607	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048788] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024821, R29NS024821] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48788] Funding Source: Medline; NINDS NIH HHS [NS24821] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BYLUND DB, 1989, J PHARMACOL EXP THER, V251, P640; COUPRY I, 1992, J BIOL CHEM, V267, P9852; CRAIG N, 1973, J CELL PHYSIOL, V82, P133, DOI 10.1002/jcp.1040820202; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; DUZIC E, 1992, J BIOL CHEM, V267, P9844; DUZIC E, 1992, J BIOL CHEM, V267, P24045; ELIZABETH RG, 1994, NATURE, V369, P315; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; GOLDSPINK PH, 1996, AM J PHYSIOL, V40, pH2584; GULTYAEV AP, 1995, J MOL BIOL, V250, P37, DOI 10.1006/jmbi.1995.0356; HAMAMDZIC D, 1995, AM J PHYSIOL-ENDOC M, V269, pE162, DOI 10.1152/ajpendo.1995.269.1.E162; Hannan AJ, 1996, NEUROSCIENCE, V72, P889, DOI 10.1016/0306-4522(95)00593-5; HIEBLE JP, 1995, J MED CHEM, V38, P3415, DOI 10.1021/jm00018a001; Hovland R, 1996, INT J BIOCHEM CELL B, V28, P1089, DOI 10.1016/1357-2725(96)00059-3; HU G, 1993, J BIOL CHEM, V268, P23441; IVESTER CT, 1995, J BIOL CHEM, V270, P21950, DOI 10.1074/jbc.270.37.21950; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; JewellMotz EA, 1996, J BIOL CHEM, V271, P18082, DOI 10.1074/jbc.271.30.18082; KIMHA J, 1995, CELL, V81, P403, DOI 10.1016/0092-8674(95)90393-3; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; LANIER SM, 1991, J BIOL CHEM, V266, P10470; LORENZ W, 1990, MOL PHARMACOL, V38, P599; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; NICHOLAS AP, 1993, J COMP NEUROL, V328, P575, DOI 10.1002/cne.903280409; Rosin DL, 1996, J COMP NEUROL, V372, P135; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; RUFFOLO RR, 1995, J MED CHEM, V38, P3681, DOI 10.1021/jm00019a001; SaulnierBlache JS, 1996, MOL PHARMACOL, V50, P1432; SCHEININ M, 1994, MOL BRAIN RES, V21, P133, DOI 10.1016/0169-328X(94)90386-7; Sommerville J, 1996, FASEB J, V10, P435, DOI 10.1096/fasebj.10.4.8647342; SONENBERG N, 1994, CURR OPIN GENET DEV, V4, P310, DOI 10.1016/S0959-437X(05)80059-0; Talley EM, 1996, J COMP NEUROL, V372, P111, DOI 10.1002/(SICI)1096-9861(19960812)372:1<111::AID-CNE8>3.0.CO;2-6; THEODORAKIS NG, 1988, J BIOL CHEM, V263, P14579; THOLANIKUNNEL BG, 1995, J BIOL CHEM, V270, P12787, DOI 10.1074/jbc.270.21.12787; VANBATENBURG E, 1994, J THEOR BIOL, V174, P269; VOIGT MM, 1991, FEBS LETT, V278, P45, DOI 10.1016/0014-5793(91)80080-M; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; WILSON AL, 1991, MOL PHARMACOL, V39, P481; Wormington M, 1993, CURR OPIN CELL BIOL, V5, P950, DOI 10.1016/0955-0674(93)90075-2; Wozniak M, 1996, J BIOL CHEM, V271, P5017	40	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15466	15473		10.1074/jbc.272.24.15466	http://dx.doi.org/10.1074/jbc.272.24.15466			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182579	hybrid			2022-12-27	WOS:A1997XE03400062
J	Heasley, LE; Thaler, S; Nicks, M; Price, B; Skorecki, K; Nemenoff, RA				Heasley, LE; Thaler, S; Nicks, M; Price, B; Skorecki, K; Nemenoff, RA			Induction of cytosolic phospholipase A(2) by oncogenic Ras in human non-small cell lung cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; MESANGIAL CELLS; COLON-CANCER; MAP KINASE; EXPRESSION; ACTIVATION; MUTATIONS; PROTEIN; GENE; BIOSYNTHESIS	Mutations in Ras family members that confer oncogenic potential are frequently observed in specific human cancers. We report that human non-small cell lung cancer (NSCLC) lines that harbor oncogenic mutations in Ki-Ras (H460, A549, H2122) synthesized high levels of prostaglandin E-2 (PGE(2)) compared with NSCLC lacking Ras mutations or non-transformed lung epithelial cells (BEAS-2B). This increased PGE(2) production was mediated by constitutively high expression of 85-kDa cytosolic phospholipase A(2) (cPLA(2)) and cyclooxygenase 2 (COX-2). The increased expression of cPLA(2) protein was mediated through elevated mRNA levels and activation of the cPLA(2) promoter. Induction of cPLA(2) promoter activity was blocked by expression of dominant-negative forms of Ras. Inhibition of Ras by the farnesyltransferase inhibitor BZA-5B inhibited prostaglandin synthesis in H2122 cells by decreasing expression of both cPLA(2) and COX-2. Finally, inhibitors of eicosanoid synthesis blocked anchorage-independent growth of NSCLC lines exhibiting Ki-Ras mutations. These results identify cPLA(2) as a novel Ras-inducible regulator of eicosanoid synthesis that participates in cellular transformation.	UNIV COLORADO, HLTH SCI CTR, DIV RENAL DIS & HYPERTENS, DEPT MED, DENVER, CO 80262 USA; TECHNION ISRAEL INST TECHNOL, DEPT NEPHROL & MOL MED, IL-31096 HAIFA, ISRAEL	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Technion Israel Institute of Technology					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK019928, R01DK029902, R56DK029902, R37DK029902] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58157] Funding Source: Medline; NIDDK NIH HHS [DK 19928, DK 29902] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARKER K, 1989, J VIROL, V63, P2929, DOI 10.1128/JVI.63.7.2929-2935.1989; BOS JL, 1989, CANCER RES, V49, P4682; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHO H, 1991, J MED CHEM, V34, P1503, DOI 10.1021/jm00108a039; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; GOETZL EJ, 1995, FASEB J, V9, P1051, DOI 10.1096/fasebj.9.11.7649404; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; Guthridge CJ, 1995, ANTICANCER RES, V15, P1957; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; HUBBARD WC, 1989, CANCER RES, V49, P826; HULKOWER KI, 1992, BIOCHEM BIOPH RES CO, V184, P712, DOI 10.1016/0006-291X(92)90648-5; JAMES GL, 1994, J BIOL CHEM, V269, P27705; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MARNETT LJ, 1992, CANCER RES, V52, P5575; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MAXWELL AP, 1993, BIOCHEM J, V295, P763, DOI 10.1042/bj2950763; MCLEMORE TL, 1988, CANCER RES, V48, P3140; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MILLS NE, 1995, CANCER RES, V55, P1444; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; MITSUDOMI T, 1991, CANCER RES, V51, P4999; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; Phelps RM, 1996, J CELL BIOCHEM, P32; RAO CV, 1995, CANCER RES, V55, P1464; RAO GN, 1994, J BIOL CHEM, V269, P32586; SALARI H, 1984, PROSTA LEUKOTR MED, V13, P53, DOI 10.1016/0262-1746(84)90102-1; SUN JZ, 1995, CANCER RES, V55, P4243; Tang DG, 1996, P NATL ACAD SCI USA, V93, P5241, DOI 10.1073/pnas.93.11.5241; TAY A, 1994, BBA-GENE STRUCT EXPR, V1217, P345, DOI 10.1016/0167-4781(94)90299-2; VALITUTTI S, 1991, CELL SIGNAL, V3, P321, DOI 10.1016/0898-6568(91)90061-X; WU T, 1994, NUCLEIC ACIDS RES, V22, P5093, DOI 10.1093/nar/22.23.5093	33	151	158	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14501	14504		10.1074/jbc.272.23.14501	http://dx.doi.org/10.1074/jbc.272.23.14501			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169405	hybrid			2022-12-27	WOS:A1997XC32700002
J	Sugumaran, G; Katsman, M; Sunthankar, P; Drake, RR				Sugumaran, G; Katsman, M; Sunthankar, P; Drake, RR			Biosynthesis of chondroitin sulfate - Purification of glucuronosyl transferase II and use of photoaffinity labeling for characterization of the enzyme as an 80-kDa protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSAMINYLTRANSFERASE REACTIONS; EMBRYO EPIPHYSEAL CARTILAGE; MOUSE MASTOCYTOMA-CELLS; HEPARAN-SULFATE; PROTEOCHONDROITIN SULFATE; ENDOPLASMIC-RETICULUM; D-XYLOSE; GOLGI; SULFOTRANSFERASE; LIVER	A photoaffinity analogue, [beta-P-32]5-azido-UDP-GlcA, was used to photolabel the enzymes that utilize UDP-GlcA in cartilage microsomes and rat liver microsomes, SDS-polyacrylamide gel electrophoresis analysis of photolabeled cartilage microsomes, which are specialized in chondroitin sulfate synthesis, showed a major radiolabeled band at 80 kDa and other minor radiolabeled bands near 40 and 60 kDa, Rat liver microsomes, which are enriched for enzymes of detoxification by glucuronidation, had a different pattern with multiple major labeled bands near 50-60 and 35 kDa, To determine that the photolabeled 80-kDa protein is the GlcA transferase II, we have purified the enzyme from cartilage microsomes, This membrane-bound enzyme, involved in the transfer of GlcA residues to non-reducing terminal GalNAc residues of the chondroitin polymer, has now been solubilized, stabilized, and then purified greater than 1350-fold by sequential chromatography on Q-Sepharose, heparin-Sepharose, and WGA-agarose. The purified enzyme exhibited a conspicuous silver-stained protein band on SDS-polyacrylamide gel electrophoresis that coincided with the major radiolabeled band of 80 kDa, SDS-polyacrylamide gel analysis of photoaffinity-labeled active fractions from the Q-Sepharose, heparin-Sepharose, and WGA-agarose also indicated only the single radiolabeled band at 80 kDa, Intensity of photolabeling in each of the fractions examined coincided with enzyme activity, The photolabeling of this 80-kDa protein was saturable with the photoprobe and could be inhibited by the addition of UDP-GlcA prior to the addition of the photoprobe. Thus, the photolabeling with [beta-P-32]5-azido-UDP-GlcA has identified the GlcA transferase II as an 80-kDa protein, The purified enzyme was capable of transferring good amounts of GlcA residues to chondroitin-derived pentasaccharide with negligible transfer to pentasaccharides derived from hyaluronan or heparan.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02114; BRIGHAM & WOMENS HOSP,DIV RHEUMATOL & IMMUNOL,BOSTON,MA 02114; UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOL BIOL,LITTLE ROCK,AR 72205	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of Arkansas System; University of Arkansas Medical Sciences	Sugumaran, G (corresponding author), EDITH NOURSE ROGERS MEM VET ADM HOSP,BLDG 70,200 SPRINGS RD,BEDFORD,MA 01730, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041649] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-41649] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BLANKEN WM, 1985, J BIOL CHEM, V260, P2927; BRANDAN E, 1988, J BIOL CHEM, V263, P2417; BRANDT AE, 1969, P NATL ACAD SCI USA, V64, P374, DOI 10.1073/pnas.64.1.374; CAMPBELL P, 1994, J BIOL CHEM, V269, P26953; DRAKE R, 1990, BIOSCIENCE REP, V10, P61, DOI 10.1007/BF01116852; DRAKE RR, 1991, J BIOL CHEM, V266, P23257; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; GHOSH S, 1995, GLYCOCONJUGATE J, V12, P838, DOI 10.1007/BF00731246; GUNDLACH MW, 1985, BIOCHEM J, V226, P705, DOI 10.1042/bj2260705; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; HELTING T, 1969, J BIOL CHEM, V244, P2799; HOFFMANN HP, 1984, CONNECT TISSUE RES, V12, P151, DOI 10.3109/03008208408992780; Kitagawa H, 1996, J BIOL CHEM, V271, P6583, DOI 10.1074/jbc.271.12.6583; Kobayashi M, 1996, J BIOL CHEM, V271, P7645, DOI 10.1074/jbc.271.13.7645; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; LIND T, 1993, J BIOL CHEM, V268, P20705; LUDWIGS U, 1987, BIOCHEM J, V245, P795, DOI 10.1042/bj2450795; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; RADOMINSKA A, 1994, METHOD ENZYMOL, V230, P330; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; SCHWARTZ NB, 1974, CARBOHYD RES, V37, P167, DOI 10.1016/S0008-6215(00)87072-X; SCHWARTZ NB, 1975, J BIOL CHEM, V250, P5200; SHAILUBHAI K, 1990, J BIOL CHEM, V265, P14105; SHOREIBAH MG, 1992, J BIOL CHEM, V267, P2920; SILBERT JE, 1980, BIOCHEM J, V190, P307, DOI 10.1042/bj1900307; SILBERT JE, 1976, J BIOL CHEM, V251, P3942; Silbert JE, 1995, BBA-REV BIOMEMBRANES, V1241, P371, DOI 10.1016/0304-4157(95)00011-9; SILBERT JE, 1969, J BIOL CHEM, V244, P876; SUGUMARAN G, 1986, CARBOHYD RES, V151, P185, DOI 10.1016/S0008-6215(00)90339-2; SUGUMARAN G, 1995, J BIOL CHEM, V270, P22483, DOI 10.1074/jbc.270.38.22483; SUGUMARAN G, 1992, J BIOL CHEM, V267, P8802; SUGUMARAN G, 1991, J BIOL CHEM, V266, P9565; SUGUMARAN G, 1990, J BIOL CHEM, V265, P18284; SUGUMARAN G, 1989, METHOD ENZYMOL, V169, P382; VERTEL BM, 1993, J BIOL CHEM, V268, P11105; WIGHT TN, 1991, CELL BIOL EXTRACELLU, P45, DOI DOI 10.1007/978-1-4615-3770-0_3; WLAD H, 1994, J BIOL CHEM, V269, P24538	39	20	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14399	14403		10.1074/jbc.272.22.14399	http://dx.doi.org/10.1074/jbc.272.22.14399			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162078	hybrid			2022-12-27	WOS:A1997XB49200065
J	Hackam, AS; Wang, TL; Guggino, WB; Cutting, GR				Hackam, AS; Wang, TL; Guggino, WB; Cutting, GR			The N-terminal domain of human GABA receptor rho 1 subunits contains signals for homooligomeric and heterooligomeric interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOBUTYRIC-ACID RECEPTORS; RETINAL BIPOLAR CELLS; ACETYLCHOLINE-RECEPTOR; XENOPUS OOCYTES; ENDOPLASMIC-RETICULUM; A RECEPTORS; C-RECEPTOR; CHANNEL; RAT; PHARMACOLOGY	gamma-aminobutyric acid type C (GABA(C)) receptors identified in retina appear to be composed of GABA rho subunits. The purpose of this study was to localize signals for homooligomeric assembly of rho 1 subunits and to investigate whether the same region contained signals for heterooligomeric interaction with rho 2 subunits. In vitro translated human rho 1 was shown to be membrane-associated, and proteinase K susceptibility studies indicated that the N terminus was oriented in the lumen of ER-derived microsomal vesicles. This orientation suggested the involvement of the N terminus of rho 1 in the initial steps of subunit assembly. To test this hypothesis, mutants were created containing only N-terminal sequences (N-rho 1) or C-terminal sequences (C-rho 1) of rho 1. Co-immunoprecipitation studies revealed that N-rho 1, but not C-rho 1, interacted with rho 1 in vitro. When coexpressed in Xenopus oocytes, N-rho 1 interfered with rho 1 receptor formation. Together, these data suggested that signals for rho 1 homooligomeric assembly reside in the N-terminal half of the subunit. Sequential immunoprecipitations were then performed upon cotranslated rho 1 and rho 2 subunits which demonstrated that rho 1 and rho 2 interacted in vitro. Co-immunoprecipitation indicated that N-rho 1 specifically associated with rho 2. Therefore, the N-terminal regions of rho subunits contain the initial signals for both homooligomeric and heterooligomeric assembly into receptors with GABA(C) properties.	JOHNS HOPKINS UNIV,SCH MED,CTR GENET MED,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21287	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NEI NIH HHS [EY 09531] Funding Source: Medline; NHLBI NIH HHS [HL 47122] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009531] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047122] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMIN J, 1994, RECEPTOR CHANNEL, V2, P227; ANDERSON DJ, 1981, P NATL ACAD SCI-BIOL, V78, P5598, DOI 10.1073/pnas.78.9.5598; ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P367; BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; BORMANN J, 1995, TRENDS NEUROSCI, V18, P515, DOI 10.1016/0166-2236(95)98370-E; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Cutting G. R., 1996, Investigative Ophthalmology and Visual Science, V37, pS138; CUTTING GR, 1992, GENOMICS, V12, P801, DOI 10.1016/0888-7543(92)90312-G; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; Enz R, 1996, J NEUROSCI, V16, P4479; ENZ R, 1995, EUR J NEUROSCI, V7, P1495, DOI 10.1111/j.1460-9568.1995.tb01144.x; FEIGENSPAN A, 1994, EUR J PHARM-MOLEC PH, V288, P97, DOI 10.1016/0922-4106(94)90014-0; FEIGENSPAN A, 1993, NATURE, V361, P159, DOI 10.1038/361159a0; FFRENCHCONSTANT RH, 1991, P NATL ACAD SCI USA, V88, P7209, DOI 10.1073/pnas.88.16.7209; GELMAN MS, 1995, J BIOL CHEM, V270, P15085, DOI 10.1074/jbc.270.25.15085; GU Y, 1991, NEURON, V6, P879, DOI 10.1016/0896-6273(91)90228-R; HACKAM AS, 1995, INVEST OPHTH VIS SCI, V36, pS285; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KUHSE J, 1993, NEURON, V11, P1049, DOI 10.1016/0896-6273(93)90218-G; LUKASIEWICZ PD, 1994, J NEUROSCI, V14, P1202, DOI 10.1523/JNEUROSCI.14-03-01202.1994; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Ogurusu T, 1996, BBA-GENE STRUCT EXPR, V1305, P15, DOI 10.1016/0167-4781(95)00205-7; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; POLENZANI L, 1991, P NATL ACAD SCI USA, V88, P4318, DOI 10.1073/pnas.88.10.4318; QIAN H, 1995, INVEST OPHTH VIS SCI, V36, pS214; QIAN HH, 1994, J NEUROSCI, V14, P4299; QIAN HH, 1995, J NEUROPHYSIOL, V74, P1920, DOI 10.1152/jn.1995.74.5.1920; QIAN HH, 1993, NATURE, V361, P162, DOI 10.1038/361162a0; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; SHEN NV, 1993, NEURON, V11, P67; SHIMADA S, 1992, MOL PHARMACOL, V41, P683; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; SIVILOTTI L, 1991, PROG NEUROBIOL, V36, P35, DOI 10.1016/0301-0082(91)90036-Z; SMITH BL, 1991, J BIOL CHEM, V266, P6407; TAKAHASHI KI, 1994, JPN J PHYSL, V44, P141; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; WANG TL, 1995, J NEUROSCI, V15, P7684; WANG TL, 1994, J NEUROSCI, V14, P6524; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WOODWARD RM, 1992, MOL PHARMACOL, V42, P165; WOODWARD RM, 1993, MOL PHARMACOL, V43, P609; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8; YU XM, 1994, MOL PHARMACOL, V46, P964; ZHANG DX, 1995, P NATL ACAD SCI USA, V92, P11756, DOI 10.1073/pnas.92.25.11756	48	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13750	13757		10.1074/jbc.272.21.13750	http://dx.doi.org/10.1074/jbc.272.21.13750			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153229	hybrid			2022-12-27	WOS:A1997XA06200044
J	Heitmeier, MR; Scarim, AL; Corbett, JA				Heitmeier, MR; Scarim, AL; Corbett, JA			Interferon-gamma increases the sensitivity of islets of Langerhans for inducible nitric-oxide synthase expression induced by interleukin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REQUIRES GENE-TRANSCRIPTION; DEPENDENT DIABETES-MELLITUS; RAT PANCREATIC-ISLETS; FATTY-ACID DEFICIENCY; INSULIN-SECRETION; INDUCED INHIBITION; CELLS; MICE; DESTRUCTION; DYSFUNCTION	The purpose of this study was to evaluate the effects of interferon-gamma (IFN-gamma) alone and in combination with interleukin 1 beta (IL-1 beta) on inducible nitric-oxide synthase (iNOS) mRNA and protein expression, nitrite production, and insulin secretion by islets of Langerhans. Treatment of rat islets with IL-1 beta results in a concentration-dependent increase in the production of nitrite that is maximal at 5 units/ml. Individually, 0.1 unit/ml IL-1 beta or 150 units/ml rat IFN-gamma do not stimulate iNOS expression or nitrite production by rat islets; however, in combination, these cytokines induce the expression of iNOS and the production of nitrite to levels similar in magnitude to the individual effects of 5 units/ml IL-1 beta. The islet beta-cell, selectively destroyed during insulin-dependent diabetes mellitus, appears to be one islet cellular source of iNOS as 150 units/ml rat IFN-gamma and 0.1 unit/ml IL-1 beta induced similar effects in primary beta-cells purified by fluorescence-activated cell sorting and in the rat insulinoma cell line, RINm5F. iNOS expression and nitrite production by rat islets in response to 150 units/ml rat IFN-gamma and 0.1 unit/ml IL-1 beta are correlated with an inhibition of insulin secretion and islet degeneration that are prevented by the iNOS inhibitor aminoguanidine. The mechanism by which IFN-gamma increases the sensitivity of beta-cells for IL-1-induced iNOS expression appears to be associated with an increase in the stability of iNOS mRNA. Last, cellular damage during physical dispersion of islets results in the release of sufficient amounts of IL-1 beta to induce iNOS expression and nitrite production in the presence of exogenously added rat IFN-gamma. The cellular source of IL-1 beta under these conditions is believed to be resident islet macrophages as depletion of macrophages prior to dispersion prevents IFN-gamma-induced iNOS expression and nitrite formation by dispersed islet cells, These studies show that the T lymphocyte cytokine, IFN-1 beta increases the sensitivity of rat islets to the effects of IL-<1beta> on iNOS expression and nitrite production by 10-fold, in part, through the stabilization of iNOS mRNA. Our studies also support an effector role for IFN-gamma, in concert with resident islet macrophage release of IL-1 beta, in mediating beta-cell destruction during the development of autoimmune diabetes.	ST LOUIS UNIV, SCH MED, EDWARD A DOISY DEPT BIOCHEM & MOL BIOL, ST LOUIS, MO 63104 USA	Saint Louis University								AREND WP, 1991, J CLIN INVEST, V88, P1445, DOI 10.1172/JCI115453; BENDTZEN K, 1986, SCIENCE, V232, P1545, DOI 10.1126/science.3086977; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; CAMPBELL IL, 1991, J CLIN INVEST, V87, P739, DOI 10.1172/JCI115055; CORBETT JA, 1993, AUTOIMMUNITY, V15, P145, DOI 10.3109/08916939309043889; CORBETT JA, 1992, DIABETES, V41, P552, DOI 10.2337/diabetes.41.4.552; CORBETT JA, 1992, BIOCHEM J, V287, P229, DOI 10.1042/bj2870229; CORBETT JA, 1991, J BIOL CHEM, V266, P21351; CORBETT JA, 1993, P NATL ACAD SCI USA, V90, P1731, DOI 10.1073/pnas.90.5.1731; CORBETT JA, 1992, J CLIN INVEST, V90, P2384, DOI 10.1172/JCI116129; CORBETT JA, 1995, J EXP MED, V181, P559, DOI 10.1084/jem.181.2.559; Corbett JA, 1996, AM J PHYSIOL-CELL PH, V270, pC1581, DOI 10.1152/ajpcell.1996.270.6.C1581; CORBETT JA, 1994, AM J PHYSIOL, V267, pC48, DOI 10.1152/ajpcell.1994.267.1.C48; CORBETT JA, 1993, BIOCHEMISTRY-US, V32, P13767, DOI 10.1021/bi00213a002; CORBETT JA, 1994, BIOCHEM J, V299, P719, DOI 10.1042/bj2990719; CORBETT JA, 1995, DIABET ANN, V9, P265; DEBRAYSACHS M, 1991, J AUTOIMMUN, V4, P237, DOI 10.1016/0896-8411(91)90021-4; EIZIRIK DL, 1992, FEBS LETT, V308, P249, DOI 10.1016/0014-5793(92)81285-T; EIZIRIK DL, 1994, J CLIN INVEST, V93, P1968, DOI 10.1172/JCI117188; Eizirik DL, 1996, DIABETOLOGIA, V39, P875; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; HUGHES JH, 1990, J CLIN INVEST, V86, P856, DOI 10.1172/JCI114785; LACY PE, 1991, AM J PATHOL, V138, P1183; LACY PE, 1994, MT SINAI J MED, V61, P170; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFKOWITH J, 1990, J EXP MED, V171, P729, DOI 10.1084/jem.171.3.729; MANDRUPPOULSEN T, 1985, ALLERGY, V40, P424, DOI 10.1111/j.1398-9995.1985.tb02681.x; MCDANIEL ML, 1983, METHOD ENZYMOL, V98, P182; NERUP J, 1981, AM J MED, V70, P135, DOI 10.1016/0002-9343(81)90420-4; ONO J, 1977, ENDOCRINOL JAPON, V24, P265; OSCHILEWSKI U, 1985, DIABETES, V34, P197, DOI 10.2337/diabetes.34.2.197; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; Rabinovitch A, 1996, ENDOCRINOLOGY, V137, P2093, DOI 10.1210/en.137.5.2093; RABINOVITCH A, 1993, DIABETES REV, V1, P215; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; SELDEN RF, 1991, CURRENT PROTOCOLS MO, V1; SOUTHERN C, 1990, FEBS LETT, V276, P42, DOI 10.1016/0014-5793(90)80502-A; WELSH N, 1991, ENDOCRINOLOGY, V129, P3167, DOI 10.1210/endo-129-6-3167; WRIGHT JR, 1988, P NATL ACAD SCI USA, V85, P6137, DOI 10.1073/pnas.85.16.6137; WRIGHT PH, 1971, DIABETES, V20, P33, DOI 10.2337/diab.20.1.33; ZYCHLINSKY A, 1994, J CLIN INVEST, V94, P1328, DOI 10.1172/JCI117452	42	140	141	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13697	13704		10.1074/jbc.272.21.13697	http://dx.doi.org/10.1074/jbc.272.21.13697			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153221	hybrid			2022-12-27	WOS:A1997XA06200036
J	AsanteAppiah, E; Skalka, AM				AsanteAppiah, E; Skalka, AM			A metal-induced conformational change and activation of HIV-1 integrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 INTEGRASE; DNA-BINDING DOMAIN; MONOCLONAL-ANTIBODIES; CATALYTIC DOMAIN; RETROVIRAL INTEGRATION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; VIRAL-DNA; C-TERMINUS; IN-VITRO	Retroviral integrases are composed of three independently folding domains whose organization relevant to one another is largely unknown. As an approach to understanding its structure, we have investigated the effect of the required metal cofactor(s), Mn2+ or Mg2+, on the conformation of human immunodeficiency virus type 1 (HIV-1) integrase (IN) using monoclonal antibodies (mAbs) that are specific for each of these three domains, Upon the addition of increasing concentrations of the divalent cations to immobilized HIV-1 IN in ELISA assays, binding of mAbs specific for either the C-terminal domain or for an epitope in the catalytic core domain was lost, whereas binding of an N terminus-specific mAb was unaffected. Size exclusion chromatography of a nonaggregating derivative of HIV-1 IN showed that the oligomeric state of the protein did not change under conditions in which recognition of the core and C terminus-specific mAbs was lost. Preincubation with Mn2+ increased the resistance of HIV-1 IN to proteolytic digestion and produced a digestion pattern that was significantly different from that observed with the apoprotein. A derivative that lacked the N-terminal domain, IN(50-288), exhibited the same metal-dependent changes observed with the full-length protein, whereas the isolated catalytic core domain IN(50-212) did not. From this we conclude that the metal-induced conformational change comprises a reorganization of the core and C-terminal domains. Preincubation with Mn2+ increased the specific activity of HIV-1 IN 5-fold. Enzymatic activity was inhibited by the conformation-sensitive C terminus-specific mAb, but this inhibition was reduced greatly if the enzyme was first preincubated with metal ions. Thus, it appears that apo-HIV-1 IN exists predominantly in an inactive conformation that is converted into a catalytically competent form upon the addition of metal ions.	FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111	Fox Chase Cancer Center					NATIONAL CANCER INSTITUTE [P30CA006927, R35CA047486] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47486, CA-06927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRAKE MD, 1995, J BIOL CHEM, V270, P29299, DOI 10.1074/jbc.270.49.29299; Andrake MD, 1996, J BIOL CHEM, V271, P19633, DOI 10.1074/jbc.271.33.19633; ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BIZUBBENDER D, 1994, AIDS RES HUM RETROV, V10, P1105, DOI 10.1089/aid.1994.10.1105; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; Bujacz G, 1996, STRUCTURE, V4, P89, DOI 10.1016/S0969-2126(96)00012-3; BURKE CJ, 1992, J BIOL CHEM, V267, P9639; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; BUSHMAN FD, 1994, J VIROL, V68, P2215, DOI 10.1128/JVI.68.4.2215-2223.1994; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DIXIT VM, 1986, J BIOL CHEM, V261, P1962; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; EBELING W, 1974, EUR J BIOCHEM, V47, P91, DOI 10.1111/j.1432-1033.1974.tb03671.x; EIJKELENBOOM APAM, 1995, NAT STRUCT BIOL, V2, P807, DOI 10.1038/nsb0995-807; ELLISON V, 1995, J BIOL CHEM, V270, P3320, DOI 10.1074/jbc.270.7.3320; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELMAN A, 1995, J VIROL, V69, P5908, DOI 10.1128/JVI.69.9.5908-5911.1995; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; GOFF SP, 1992, ANNU REV GENET, V26, P527, DOI 10.1146/annurev.ge.26.120192.002523; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HAINAUT P, 1993, CANCER RES, V53, P1739; HICKMAN AB, 1994, J BIOL CHEM, V269, P29279; HOLLER TP, 1993, GENE AMST, V126, P323; JENKINS TM, 1995, P NATL ACAD SCI USA, V92, P6057, DOI 10.1073/pnas.92.13.6057; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; JONES KS, 1992, J BIOL CHEM, V267, P16037; KATAYANAGI K, 1993, PROTEINS, V17, P337, DOI 10.1002/prot.340170402; Katz RA, 1996, VIROLOGY, V217, P178, DOI 10.1006/viro.1996.0105; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; KHAN E, 1991, NUCLEIC ACIDS RES, V19, P851, DOI 10.1093/nar/19.4.851; KHAN E, 1991, NUCLEIC ACIDS RES, V19, P1358, DOI 10.1093/nar/19.6.1358; KULKOSKY J, 1995, VIROLOGY, V206, P448, DOI 10.1016/S0042-6822(95)80060-3; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LEE SP, 1995, BIOCHEMISTRY-US, V34, P10215, DOI 10.1021/bi00032a015; LevyMintz P, 1996, J VIROL, V70, P8821, DOI 10.1128/JVI.70.12.8821-8832.1996; LODI PJ, 1995, BIOCHEMISTRY-US, V34, P9826, DOI 10.1021/bi00031a002; MUMM SR, 1991, J VIROL, V65, P1160, DOI 10.1128/JVI.65.3.1160-1167.1991; MURRYBRELIER A, 1990, J BIOL CHEM, V265, P7987; PETERSON CB, 1987, J BIOL CHEM, V262, P7552; PURASLUTZKE RA, 1994, NUCLEIC ACIDS RES, V22, P4125; RAMPRASAD S, 1993, CANCER RES, V53, P5361; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; SOLOMON B, 1989, BIOCHEMISTRY-US, V28, P1235, DOI 10.1021/bi00429a042; VANGENT DC, 1993, EMBO J, V12, P3261, DOI 10.1002/j.1460-2075.1993.tb05995.x; VINK C, 1994, NUCLEIC ACIDS RES, V22, P4103, DOI 10.1093/nar/22.20.4103; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419; VORA AC, 1994, NUCLEIC ACIDS RES, V22, P4454, DOI 10.1093/nar/22.21.4454; WOERNER AM, 1993, NUCLEIC ACIDS RES, V21, P3507, DOI 10.1093/nar/21.15.3507; Wolfe AL, 1996, J VIROL, V70, P1424, DOI 10.1128/JVI.70.3.1424-1432.1996; Zheng RL, 1996, P NATL ACAD SCI USA, V93, P13659, DOI 10.1073/pnas.93.24.13659	55	73	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16196	16205		10.1074/jbc.272.26.16196	http://dx.doi.org/10.1074/jbc.272.26.16196			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195919	hybrid			2022-12-27	WOS:A1997XG01900023
J	Han, P; Zhu, XY; Michaeli, T				Han, P; Zhu, XY; Michaeli, T			Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; CALMODULIN-DEPENDENT PHOSPHODIESTERASE; PROTEIN-KINASE-A; MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; ANCHORING PROTEINS; EXPRESSION; PHOSPHORYLATION; LOCALIZATION; MYOBLASTS	To further our understanding of the structure and function of phosphodiesterases of the newly identified family of high affinity cAMP-specific phosphodiesterases (PDE7), we identified and characterized the isozyme expressed in human skeletal muscle and the protein product of the previously isolated isozyme HCP1 (designated HSPDE7A1). We report the isolation of a cDNA encoding the full-length skeletal muscle isoform of human PDE7A (HSPDE7A2). The DNA sequence of this skeletal muscle cDNA indicates that PDE7A2 is a novel 5' splice variant of PDE7A encoding an isoform with a novel, hydrophobic N terminus. The 456-amino acid PDE7A2 protein is detected on Western blots as a band with an apparent mobility of 50 kDa. PDE7A2 is a high affinity cAMP-specific PDE (K-m = 0.1 mu M), which is localized to particulate cellular fractions. The PDE7A1 (HCP1) isozyme is detected on Western blots as a band with an apparent mobility of 57 kDa, demonstrating that the previously isolated HCP1 cDNA encodes the full-length PDE7A1 protein. The even distribution of PDE7A mRNA among fetal tissues and the relative abundance of its two mRNAs strongly suggest that the expression of PDE7A is regulated throughout development.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT DEV & MOL BIOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine								[Anonymous], MOL CLONING LAB MANU; BALL EH, 1980, J BIOL CHEM, V255, P2962; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BELTMAN J, 1993, MOL CELL BIOCHEM, V128, P239, DOI 10.1007/BF01076775; BENTLEY JK, 1992, J BIOL CHEM, V267, P18676; BOLGER GB, 1994, CELL SIGNAL, V6, P851, DOI 10.1016/0898-6568(94)90018-3; Bolger GB, 1996, J BIOL CHEM, V271, P1065, DOI 10.1074/jbc.271.2.1065; Charbonneau H., 1990, CYCLIC NUCLEOTIDE PH, P267; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; CONTI M, 1991, ENDOCR REV, V12, P218, DOI 10.1210/edrv-12-3-218; FLORIO VA, 1994, BIOCHEMISTRY-US, V33, P8948, DOI 10.1021/bi00196a012; FRANCIS SH, 1990, CYCLIC NUCLEOTIDE PH, P117; HANSEN RS, 1986, J BIOL CHEM, V261, P4636; HIDAKA H, 1977, BIOCHIM BIOPHYS ACTA, V484, P398, DOI 10.1016/0005-2744(77)90095-X; ICHIMURA M, 1993, BIOCHEM BIOPH RES CO, V193, P985, DOI 10.1006/bbrc.1993.1722; KEMP RG, 1996, METHOD ENZYMOL, V38, P240; KOVALA T, 1994, J BIOL CHEM, V269, P8680; Loughney K, 1996, J BIOL CHEM, V271, P796, DOI 10.1074/jbc.271.2.796; MANGANIELLO VC, 1995, CELL SIGNAL, V7, P445, DOI 10.1016/0898-6568(95)00017-J; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; MEACCI E, 1992, P NATL ACAD SCI USA, V89, P3721, DOI 10.1073/pnas.89.9.3721; MICHAELI T, 1989, EMBO J, V8, P3039, DOI 10.1002/j.1460-2075.1989.tb08454.x; MICHAELI T, 1993, J BIOL CHEM, V268, P12925; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NARINDRASORASAK S, 1982, J BIOL CHEM, V257, P4618; REPASKE DR, 1992, J BIOL CHEM, V267, P18683; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SETH PK, 1983, J CELL PHYSIOL, V116, P336, DOI 10.1002/jcp.1041160311; SETTE C, 1994, J BIOL CHEM, V269, P18271; SHARMA RK, 1991, BIOCHEMISTRY-US, V30, P5963, DOI 10.1021/bi00238a021; SONNENBURG WK, 1993, J BIOL CHEM, V268, P645; TAIRA M, 1993, J BIOL CHEM, V268, P18573	35	91	103	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16152	16157		10.1074/jbc.272.26.16152	http://dx.doi.org/10.1074/jbc.272.26.16152			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195912	hybrid			2022-12-27	WOS:A1997XG01900016
J	Hashimoto, H; Sakakibara, A; Yamasaki, M; Yoda, K				Hashimoto, H; Sakakibara, A; Yamasaki, M; Yoda, K			Saccharomyces cerevisiae VIG9 encodes GDP-mannose pyrophosphorylase, which is essential for protein glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST MUTANTS DEFICIENT; ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; GENE-CLUSTER; SEQUENCE; BIOSYNTHESIS; DEFECTS; PATHWAY; FAMILY; DNA	A genomic DNA fragment that complements a newly identified protein glycosylation-defective mutation, vig9, of Saccharomyces cerevisiae was cloned. Chromosomal integration of this fragment by homologous recombination indicated that it contains the wild type VIG9 gene. The nucleotide sequence was determined. A predicted gene product showed significant amino acid sequence homology with several bacterial enzymes that catalyze the synthesis of (deoxy)ribonucleotide diphosphate sugars from sugar phosphates and (deoxy)ribonucleotide triphosphate. We examined the enzyme activity to synthesize GDP-mannose in the cell extracts of the wild type, vig9-1 mutant, and VIG9 transformant yeasts. Reduction of the activity in the mutant cell and its restoration by VIG9 suggested that the VIG9 gene is the structural gene for GDP-mannose pyrophosphorylase of S. cerevisiae which catalyzes the production of GDP-mannose. We demonstrated the enzyme activity of Vig9 protein using a recombinant fusion protein produced in Escherichia coli.	UNIV TOKYO,DEPT BIOTECHNOL,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; BALLOU L, 1991, P NATL ACAD SCI USA, V88, P3209, DOI 10.1073/pnas.88.8.3209; Benton BK, 1996, CURR GENET, V29, P106, DOI 10.1007/BF02221573; BERNSTEIN M, 1985, J CELL BIOL, V101, P2374, DOI 10.1083/jcb.101.6.2374; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYRD JC, 1982, J BIOL CHEM, V257, P4657; CHAPMAN RE, 1994, EMBO J, V13, P4896, DOI 10.1002/j.1460-2075.1994.tb06817.x; DARAN JM, 1995, EUR J BIOCHEM, V233, P520, DOI 10.1111/j.1432-1033.1995.520_2.x; DEAN N, 1995, P NATL ACAD SCI USA, V92, P1287, DOI 10.1073/pnas.92.5.1287; DISTLER J, 1987, NUCLEIC ACIDS RES, V15, P8041, DOI 10.1093/nar/15.19.8041; FERRONOVICK S, 1984, J CELL BIOL, V98, P35, DOI 10.1083/jcb.98.1.35; GABRIEL O, 1969, ANAL BIOCHEM, V27, P545, DOI 10.1016/0003-2697(69)90068-2; Guthrie C, 1991, GUIDE YEAST GENETICS; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HILL K, 1992, GENETICS, V130, P273; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HUFFAKER TC, 1982, J BIOL CHEM, V257, P3203; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JIANG XM, 1991, MOL MICROBIOL, V5, P695, DOI 10.1111/j.1365-2958.1991.tb00741.x; KANIKENNULAT C, 1995, GENETICS, V140, P933; KEPES F, 1988, J BIOL CHEM, V263, P9155; KESSLER AC, 1993, J BACTERIOL, V175, P1412, DOI 10.1128/JB.175.5.1412-1422.1993; KLIS FM, 1994, YEAST, V10, P851, DOI 10.1002/yea.320100702; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEHLE L, 1995, GLYCOPROTEINS, P475; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; PAYTON MA, 1991, J BACTERIOL, V173, P2006, DOI 10.1128/jb.173.6.2006-2010.1991; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Poster JB, 1996, J BIOL CHEM, V271, P3837; RAM AFJ, 1994, YEAST, V10, P1019, DOI 10.1002/yea.320100804; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DJ, 1992, MOL CELL BIOL, V12, P2924, DOI 10.1128/MCB.12.7.2924; Tajima M, 1985, Yeast, V1, P67, DOI 10.1002/yea.320010108; TSAI PK, 1984, J BIOL CHEM, V259, P3805; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328	42	74	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16308	16314		10.1074/jbc.272.26.16308	http://dx.doi.org/10.1074/jbc.272.26.16308			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195935	hybrid			2022-12-27	WOS:A1997XG01900039
J	Schiemann, WP; Bartoe, JL; Nathanson, NM				Schiemann, WP; Bartoe, JL; Nathanson, NM			Box 3-independent signaling mechanisms are involved in leukemia inhibitory factor receptor alpha- and gp130-mediated stimulation of mitogen-activated protein kinase - Evidence for participation of multiple signaling pathways which converge at Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; ONCOSTATIN-M; HEMATOPOIETIN RECEPTORS; SERINE PHOSPHORYLATION; INTERLEUKIN-6 FAMILY; GENE-EXPRESSION; NEURONAL CELLS; GROWTH-HORMONE; STAT PROTEINS; LIF RECEPTOR	Chimeric receptors containing the entire or various cytoplasmic domains of either gp130 or leukemia inhibitory factor receptor alpha (LIFR) were used to identify signaling molecules and regions of these polypeptides required for the stimulation of mitogen-activated protein kinase (MAPK). Coexpression of dominant-negative Jak2 inhibited chimeric receptor-stimulated MAPK activity by similar to 70%, while expression of dominant-negative Ras completely blocked MAPK activation by either receptor polypeptide. Deletion analysis identified a 24-amino acid region of gp130 that was necessary for maximal stimulation of MAPK, and contained box 3 (positions 120-129) and a consensus tyrosine binding motif (Tyr-118) for the protein-tyrosine phosphatase, SHP2. Expression of receptors lacking: this region or of chimeric gp130(Y118F) point mutants inhibited MAPK activity by similar to 55%, suggesting that Tyr-118, but not box 3, was required during activation of MAPK by gp130. Similarly, expression of chimeric LIFR constructs lacking box 3 maximally stimulated MAPK activity, while those lacking Tyr-115, a putative SHP2 binding site, inhibited stimulation of MAPK by this polypeptide. Our results demonstrate that gp130 and LIFR stimulate MAPK activity through box 3-independent mechanisms involving: (i) effects at Tyr-118 and Tyr-115, respectively, for maximal stimulation of MAPK activity and (ii) a Jak/Tyk-dependent pathway that, together with Tyr-118- or Tyr-115-generated signals, converges at the level of Ras during activation of MAPK by cytokine.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NIGMS NIH HHS [GM07018, GM07750] Funding Source: Medline; NINDS NIH HHS [NS30410] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BARTOE JL, 1996, SOC NEUR ABSTR, V22; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMANN H, 1994, J BIOL CHEM, V269, P16297; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JOHNSON JA, 1994, J BIOL CHEM, V269, P18856; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; Matozaki T, 1996, CELL SIGNAL, V8, P13, DOI 10.1016/0898-6568(95)02015-2; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; SCHIEMANN WP, 1994, J BIOL CHEM, V269, P6376; SCHIEMANN WP, 1995, P NATL ACAD SCI USA, V92, P5361, DOI 10.1073/pnas.92.12.5361; SCHIEVEN GL, 1992, J IMMUNOL, V149, P1676; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; SYMES A, 1994, MOL ENDOCRINOL, V8, P1750, DOI 10.1210/me.8.12.1750; Taga T, 1996, J NEUROCHEM, V67, P1; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; THOMA B, 1994, J BIOL CHEM, V269, P6215; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; WANG XY, 1995, J BIOL CHEM, V270, P27999; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YIN TG, 1994, J BIOL CHEM, V269, P3731; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	40	73	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16631	16636		10.1074/jbc.272.26.16631	http://dx.doi.org/10.1074/jbc.272.26.16631			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195977	hybrid			2022-12-27	WOS:A1997XG01900081
J	Thoenges, D; Schoner, W				Thoenges, D; Schoner, W			2'-O-dansyl analogs of ATP bind with high affinity to the low affinity ATP site of Na+/K+-ATPase and reveal the interaction of two ATP sites during catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT ADENOSINE-TRIPHOSPHATASE; (NA+ + K+)-ATPASE; PHOSPHORYLATION; NA,K-ATPASE; NA+,K+-ATPASE; COMPLEX; SODIUM; PHOSPHATE; TURNOVER; ENZYME	Na+/H+-transport through mammalian cell membranes by Na+/R+-ATPase (EC 3.6.1.37) needs the interaction of ATP sites with different binding affinities during catalysis: one with catalytic (high affinity site) and one with regulatory properties (low affinity site). To find affinity labels for the latter one, the effects of 2'-O-dansylated ATP analogs on Na+/K+-ATPase and its partial activities were analyzed. DANS-ATP (2'-O-(6-dimethylaminonaphthalenesulfonyl)adenosine 5'-triphosphate) inhibited noncompetitively at low ATP concentrations and competitively at high ATP concentrations the Na+/K+-activated hydrolysis of ATP under turnover conditions. It interacted preferentially with the low affinity ATP site as shown by its protective effect against the inactivation of Na+/K+-ATPase by Co(NH3)(4)ATP and Cr(H2O)(4)ATP. DANS-N-3-ATP, however, inactivated Na+/K+-ATPase, The initial velocity of inactivation shows a sigmoid concentration dependence that was converted to a hyperbola in the presence of ATP, DANS-N-3-ATP inhibited competitively the K+-activated hydrolysis of p-nitrophenyl phosphate in a fluorescein isothiocyanate-blocked enzyme but did not effect Na+-dependent phosphoenzyme formation from [gamma-P-32]ATP in a Co(NH3)(4)PO4-blocked enzyme, These effects could be described by a Koshland-Nemethy-Filmer model assuming two nucleotide binding sites in strong cooperation, Fitting all data to this model revealed that ATP was bound in a negative cooperative way with a K-d = 0.3-1 mu M to the first site and a K-d = 100-120 mu M to the second site of the enzyme containing already one ATP bound, The hydrolysis of ATP through a pathway with two ATP bound was 30 times faster than hydrolysis with one ATP bound. DANS-N-3-ATP bound in a positive cooperative way with a K-d = 500 +/- 100 mu M to the first site and a K-d = 2.5 +/- 0.5 mu M to the second site containing already one DANS-N-3-ATP bound, Therefore, DANS-N-3-ATP may be an useful affinity marker of the low affinity, regulatory ATP site.	UNIV GIESSEN,FACHBEREICH VET MED,INST BIOCHEM & ENDOKRINOL,D-35392 GIESSEN,GERMANY	Justus Liebig University Giessen								BOLDYREV AA, 1994, INT J BIOCHEM, V26, P1323, DOI 10.1016/0020-711X(94)90174-0; BUXBAUM E, 1991, EUR J BIOCHEM, V195, P407, DOI 10.1111/j.1432-1033.1991.tb15720.x; CAMPOS M, 1994, J BIOL CHEM, V269, P18028; CHUAN H, 1989, J BIOL CHEM, V264, P7981; CORNELIUS RD, 1977, INORG CHEM, V16, P2799, DOI 10.1021/ic50177a025; DUMAWAYMARIANO D, 1980, BIOCHEMISTRY-US, V19, P1496; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; HAMER E, 1993, EUR J BIOCHEM, V213, P743, DOI 10.1111/j.1432-1033.1993.tb17815.x; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; LINNERTZ H, 1995, EUR J BIOCHEM, V232, P420, DOI 10.1111/j.1432-1033.1995.tb20827.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOCZYDLOWSKI EG, 1981, J BIOL CHEM, V256, P2346; PAULS H, 1980, EUR J BIOCHEM, V109, P523, DOI 10.1111/j.1432-1033.1980.tb04824.x; PELUFFO RD, 1992, J BIOL CHEM, V267, P6596; PELUFFO RD, 1994, J BIOL CHEM, V269, P1051; PISZKIEWICZ D, 1971, BIOCHEMISTRY-US, V10, P4544, DOI 10.1021/bi00800a031; PLESNER IW, 1987, BIOPHYS J, V51, P69, DOI 10.1016/S0006-3495(87)83312-X; POST RL, 1972, J BIOL CHEM, V247, P6530; REPKE KRH, 1973, ACTA BIOL MED GER, V31, pK19; ROBERTS G, 1995, PLANT PHYSIOL, V108, P813, DOI 10.1104/pp.108.2.813; SCHEINERBOBIS G, 1993, BIOCHEMISTRY-US, V32, P9592, DOI 10.1021/bi00088a011; SCHEINERBOBIS G, 1987, EUR J BIOCHEM, V168, P123, DOI 10.1111/j.1432-1033.1987.tb13396.x; SCHONER W, 1967, EUR J BIOCHEM, V1, P334, DOI 10.1111/j.1432-1033.1967.tb00078.x; SCHONER W, 1994, SODIUM PUMP, P332; SCHWARZBAUM PJ, 1995, BBA-BIOMEMBRANES, V1233, P33, DOI 10.1016/0005-2736(94)00229-I; Segel I.H., 1975, ENZYME KINETICS; SERPERSU EH, 1990, EUR J BIOCHEM, V191, P397, DOI 10.1111/j.1432-1033.1990.tb19135.x; SIEBERT H, 1958, Z ANORG ALLG CHEM, V296, P280, DOI 10.1002/zaac.19582960129; THOENGES D, 1994, SODIUM PUMP STRUCTUR, P421; WARD DG, 1993, P NATL ACAD SCI USA, V90, P5332, DOI 10.1073/pnas.90.11.5332; YAMAZAKI A, 1994, J BIOCHEM, V116, P1360, DOI 10.1093/oxfordjournals.jbchem.a124688; ZOLOTARJOVA N, 1995, J BIOL CHEM, V270, P3989, DOI 10.1074/jbc.270.8.3989	34	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16315	16321		10.1074/jbc.272.26.16315	http://dx.doi.org/10.1074/jbc.272.26.16315			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195936	hybrid			2022-12-27	WOS:A1997XG01900040
J	Michel, JB; Feron, O; Sacks, D; Michel, T				Michel, JB; Feron, O; Sacks, D; Michel, T			Reciprocal regulation of endothelial nitric-oxide synthase by Ca2+-calmodulin and caveolin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLONING	The endothelial nitric-oxide synthase (eNOS) is a key determinant of vascular homeostasis. Like all known nitric-oxide synthases, eNOS enzyme activity is diependent on Ca2+-calmodulin. eNOS is dynamically targeted to specialized cell surface signal transducing domains termed plasmalemmal caveolae and interacts with caveolin, an integral membrane protein that comprises a key structural component of caveolae, We have previously reported that the association between eNOS and caveolin is quantitative and tissue-specific (Feron, O., Belhassen, L., Kobzick, L., Smith, T. W., Kelly, R. A., and Michel, T. (1996) J. Biol. Chem. 271, 22810-22814), We now report that in endothelial cells the interaction between eNOS and caveolin is importantly regulated by Ca2+-calmodulin, Addition of calmodulin disrupts the heteromeric complex formed between eNOS and caveolin in a Ca2+-dependent fashion. In addition, overexpression of caveolin markedly attenuates eNOS enzyme activity, but this inhibition is reversed by purified calmodulin, Caveolin overexpression does not affect the activity of the other NOS isoforms, suggesting eNOS-specific inhibition of NO synthase by caveolin, We propose a model of reciprocal regulation of eNOS in endothelial cells wherein the inhibitory eNOS-caveolin complex is disrupted by binding of Ca2+-calmodulin to eNOS, leading to enzyme activation, These findings may have broad implications for the regulation of Ca2+-dependent signal transduction in plasmalemmal caveolae.	HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Michel, JB (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,CARDIOVASC DIV, DEPT MED, 75 FRANCIS ST, BOSTON, MA 02115 USA.		FERON, Olivier/AAM-6395-2020	FERON, Olivier/0000-0001-5360-0286; Sacks, David/0000-0003-3100-0735				ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LEE CM, 1995, J BIOL CHEM, V270, P27403, DOI 10.1074/jbc.270.46.27403; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; NATHAN C, 1994, J BIOL CHEM, V269, P13725; SACKS DB, 1991, ANAL BIOCHEM, V194, P369, DOI 10.1016/0003-2697(91)90243-M; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Sase K, 1997, TRENDS CARDIOVAS MED, V7, P28, DOI 10.1016/S1050-1738(96)00121-1; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	17	460	471	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15583	15586		10.1074/jbc.272.25.15583	http://dx.doi.org/10.1074/jbc.272.25.15583			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188442	hybrid			2022-12-27	WOS:A1997XF32900002
J	Vives, E; Brodin, P; Lebleu, B				Vives, E; Brodin, P; Lebleu, B			A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-TRANSFER; OKADAIC ACID; TRANSPORT; PEPTIDES; CAVEOLAE	Tat is an 86-amino acid protein involved in the replication of human immunodeficiency virus type 1 (HIV-1). Several studies have shows that exogenous Tat protein was able to translocate through the plasma membrane and to reach the nucleus to transactivate the viral genome, A region of the Tat protein centered on a cluster of basic amino acids has been assigned to this translocation activity, Recent data have demonstrated that chemical coupling of a Tat-derived peptide (extending from residues 37 to 72) to several proteins allowed their functional internalization into several cell lines or tissues, A part of this same domain can be folded in an alpha-helix structure with amphipathic characteristics. Such helical structures have been considered as key determinants for the uptake of several enveloped viruses by fusion or endocytosis. In the present study, we have delineated the main determinants required for Tat translocation within this sequence by synthesizing several peptides covering the Tar domain from residues 37 to 60. Unexpectedly, the domain extending from amino acid 37 to 47, which corresponds to the alpha-helix structure, is not required for cellular uptake and for nuclear translocation. Peptide internalization was assessed by direct labeling with fluorescein or by indirect immunofluorescence using a monoclonal antibody directed against the Tat basic cluster. Both approaches established that all peptides containing the basic domain are taken up by cells within less than 5 min at concentrations as low as 100 nM. In contrast, a peptide with a full alpha-helix but with a truncated basic amino acid cluster is not taken up by cells, The internalization process does not involve an endocytic pathway, as no inhibition of the uptake was observed at 4 degrees C. Similar observations have been reported for a basic amino acid-rich peptide derived from the Antennapedia homeodomain (1), Short peptides allowing efficient translocation through the plasma membrane could be useful vectors for the intracellular delivery of various non-permeant drugs including antisense oligonucleotides and peptides of pharmacological interest.	CNRS,INST GENET MOL MONTPELLIER,UMR 5535,F-34033 MONTPELLIER 1,FRANCE	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier			Brodin, Priscille/E-5802-2014; VIVES, Eric/AAG-6569-2020; Brodin, Priscille/N-6979-2019	Brodin, Priscille/0000-0003-0991-7344; Brodin, Priscille/0000-0003-0991-7344; VIVES, Eric/0000-0001-5391-9641				ALLINQUANT B, 1995, J CELL BIOL, V128, P919, DOI 10.1083/jcb.128.5.919; ANDERSON DC, 1993, BIOCHEM BIOPH RES CO, V194, P876, DOI 10.1006/bbrc.1993.1903; ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; BONGARTZ JP, 1994, NUCLEIC ACIDS RES, V22, P4681, DOI 10.1093/nar/22.22.4681; CHEN LL, 1995, ANAL BIOCHEM, V227, P168, DOI 10.1006/abio.1995.1267; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; GAUDIN Y, 1995, J GEN VIROL, V76, P1541, DOI 10.1099/0022-1317-76-7-1541; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; LCRET EP, 1991, BIOCHEMISTRY-US, V30, P6013; Lebleu B, 1996, TRENDS BIOTECHNOL, V14, P109, DOI 10.1016/0167-7799(96)30005-X; LUCOCQ J, 1991, J CELL SCI, V100, P753; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; PLANK C, 1994, J BIOL CHEM, V269, P12918; RUBEN S, 1989, J VIROL, V63, P1; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; VIVES E, 1994, J VIROL, V68, P3343, DOI 10.1128/JVI.68.5.3343-3353.1994; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P7934, DOI 10.1073/pnas.89.17.7934; Wei ZP, 1996, NUCLEIC ACIDS RES, V24, P655, DOI 10.1093/nar/24.4.655	21	1953	2275	5	211	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					16010	16017		10.1074/jbc.272.25.16010	http://dx.doi.org/10.1074/jbc.272.25.16010			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188504	Green Published, hybrid			2022-12-27	WOS:A1997XF32900064
J	Tebar, F; Confalonieri, S; Carter, RE; DiFiore, PP; Sorkin, A				Tebar, F; Confalonieri, S; Carter, RE; DiFiore, PP; Sorkin, A			Eps15 is constitutively oligomerized due to homophilic interaction of its coiled-coil region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE SUBSTRATE; GROWTH-FACTOR RECEPTOR; CLATHRIN; PROTEINS; ENDOCYTOSIS; DOMAIN	Eps15 is a member of an emerging family of proteins containing a novel protein/protein interaction domain, the EH domain, of as yet unknown function, Recent findings of Eps15 association with clathrin adaptor com plex AP2 and its localization in clathrin-coated pits have implicated Eps15 in the regulation of vesicle trafficking, Here we show that Eps15 exists in several multimeric states in, vivo, When purified recombinant Eps15 or lysates of NIH 3T3 cells were treated with cross-linking reagents, covalent dimers of Eps15 and larger covalent multimers were detected in high yield, Large Eps15 oligomers co-immunoprecipitated with AP-2 at an efficiency higher than that of Eps15 dimers, Furthermore, cross-linking of the membrane-bound fraction of Eps15 in mildly permeabilized cells was as efficient as that of the cytosolic fraction, Size-exclusion column chromatography of recombinantly produced Eps15 and of total cell lysates was performed to examine the equilibrium ratio of the monomers versus the aggregated forms of Eps15. These experiments showed that essentially all the Eps15 was aggregated, whereas monomers of Eps15 could be obtained only under strong denaturing conditions. To map the region of Eps15 responsible for dimerization, fusion proteins corresponding to the three structural domains of Eps15 were prepared, Cross linking analysis revealed that the central portion of Eps15, which possesses a coiled-coil region (residues 321-520), serves as the interacting interface, The possibility that hetero-oligomeric complexes of Eps15 dimers and AP-2 function during the recruitment of proteins into coated pits is discussed.	UNIV COLORADO, HLTH SCI CTR, DEPT PHARMACOL, DENVER, CO 80262 USA; EUROPEAN INST ONCOL, I-20141 MILAN, ITALY; UNIV BARI, IST MICROBIOL, I-70124 BARI, ITALY	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; IRCCS European Institute of Oncology (IEO); Universita degli Studi di Bari Aldo Moro			Confalonieri, Stefano/AAQ-6786-2020; Di Fiore, Pier Paolo/K-2130-2012; Tebar, Francesc/H-1498-2015	Confalonieri, Stefano/0000-0001-6886-9851; Di Fiore, Pier Paolo/0000-0002-2252-0950; Tebar, Francesc/0000-0002-9522-9726; Sorkin, Alexander/0000-0002-4446-1920	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046817] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46817] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Iannolo G, 1997, CANCER RES, V57, P240; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; PARTRIDGE CA, 1995, INT J BIOCHEM, V17, P331; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; Robinson MS, 1996, MOL BIOL CELL, V7, P977; SCHMID SL, 1992, BIOESSAYS, V14, P589, DOI 10.1002/bies.950140903; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; STAROS JV, 1988, ACCOUNTS CHEM RES, V21, P435, DOI 10.1021/ar00156a001; TEBAR F, 1996, J BIOL CHEM, V271, P25727; VELU TJ, 1989, J CELL BIOCHEM, V39, P153, DOI 10.1002/jcb.240390207; VIRSHUP DM, 1988, J CELL BIOL, V106, P39, DOI 10.1083/jcb.106.1.39; Wendland B, 1996, J CELL BIOL, V135, P1485, DOI 10.1083/jcb.135.6.1485; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530	18	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15413	15418		10.1074/jbc.272.24.15413	http://dx.doi.org/10.1074/jbc.272.24.15413			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182572	hybrid			2022-12-27	WOS:A1997XE03400055
J	Tachias, K; Madison, EL				Tachias, K; Madison, EL			Variants of tissue-type plasminogen activator that display extraordinary resistance to inhibition by the serpin plasminogen activator inhibitor type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYOCARDIAL-INFARCTION; SITE-SPECIFIC MUTAGENESIS; T-PA T103N; DIRECTED MUTAGENESIS; CORONARY THROMBOLYSIS; KHRR-296-299 AAAA; IN-VITRO; FIBRIN; STRATEGIES; EFFICACY	Fibrinolysis is regulated in part by the interaction of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1). Previous investigations suggest that three specific arginine residues, Arg-298, Arg-299, and Arg-304 of t-PA, play a critical role in this important regulatory interaction. Our earlier studies have demonstrated that conversion of any of these three residues to a glutamic acid residue reduced the rate of inhibition of t-PA by PAI-1 by factors varying from 58-64. In addition, we have reported that the second order rate constant for inhibition by PAI-1 of the variant t-PA/K296E,R298E,R299E is reduced by a factor of approximately 2800 compared with that of wild type t-PA. In this study, we have significantly extended our earlier observations by identifying t-PA variants that are substantially more resistant to inhibition by PAI-1 than any previously reported variants of t-PA or urokinase-type plasminogen activator. Single-chain t-PA/ R275E,R298E,R299E,R304E, for example, is inhibited by PAI-1 approximately 120,000 times less rapidly than single-chain, wild type t-PA. We also report the first direct comparison of the effects of charge reversal mutations of Arg-298, Arg-299, and/or Arg-304 on the properties of the single- and two-chain forms of t-PA. While these mutations confer extraordinary resistance to inhibition by PAI-I to both forms of the enzyme, our observations reveal that the single-chain enzyme is affected to a greater extent than the two-chain enzyme. Two-chain, wild type t-PA is inhibited by PAI-1 approximately 1.4 times more rapidly than single-chain t-PA. The corresponding ratio increases to 7.6 or 6.7, respectively, for variants of t-PA containing the R298E,R299E or R298E,R299E,R304E mutations.	Scripps Res Inst, DEPT VASC BIOL VB1, LA JOLLA, CA 92037 USA	Scripps Research Institute					NHLBI NIH HHS [R01 HL52475, P01 HL31950] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950, R01HL052475] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEATTY K, 1980, J BIOL CHEM, V255, P3931; BENEDICT CR, 1995, CIRCULATION, V92, P3032, DOI 10.1161/01.CIR.92.10.3032; BENNETT WF, 1991, J BIOL CHEM, V266, P5191; BERGMANN SR, 1983, SCIENCE, V220, P1181; Castellino F. J, 1995, MOL BASIS THROMBOSIS, P495; COLLEN D, 1989, DRUGS, V38, P346, DOI 10.2165/00003495-198938030-00003; COLLEN D, 1991, BLOOD, V78, P3114; COLLEN D, 1983, CIRCULATION, V68, P462, DOI 10.1161/01.CIR.68.2.462; COLLEN D, 1994, THROMB HAEMOSTASIS, V72, P98; COLLEN D, 1992, AM J CARDIOL, V69, pA71; DING L, 1995, P NATL ACAD SCI USA, V92, P7627, DOI 10.1073/pnas.92.17.7627; EASTMAN D, 1992, BIOCHEMISTRY-US, V31, P419, DOI 10.1021/bi00117a016; FAY WP, 1994, BLOOD, V83, P351; GIBSON M, 1996, CIRCULATION S1, V94, P89; HIGH K, 1995, MOL BASIS THROMBOSIS; HOLMES WE, 1987, BIOCHEMISTRY-US, V26, P5133, DOI 10.1021/bi00390a036; HORREVOETS AJG, 1993, J BIOL CHEM, V268, P779; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; Ke SH, 1997, J BIOL CHEM, V272, P1811, DOI 10.1074/jbc.272.3.1811; KEYT BA, 1994, P NATL ACAD SCI USA, V91, P3670, DOI 10.1073/pnas.91.9.3670; Keyt Bruce A., 1996, P435; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMBA B, 1996, J MOL BIOL, V258, P117; LIJNEN HR, 1991, THROMB HAEMOSTASIS, V66, P88; LIJNEN HR, 1993, METHOD ENZYMOL, V223, P197; LUCAS MA, 1983, J BIOL CHEM, V258, P4249; MADISON EL, 1990, J BIOL CHEM, V265, P21423; MADISON EL, 1993, METHOD ENZYMOL, V223, P249; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MADISON EL, 1993, SCIENCE, V262, P419, DOI 10.1126/science.8211162; MADISON EL, 1994, FIBRINOLYSIS, V8, P221, DOI 10.1016/0268-9499(94)90720-X; MADISON EL, 1995, J BIOL CHEM, V270, P7558, DOI 10.1074/jbc.270.13.7558; MANN KG, 1993, PROTEOLYTIC ENZYMES, V223; PAONI NF, 1992, PROTEIN ENG, V5, P259, DOI 10.1093/protein/5.3.259; PAONI NF, 1993, THROMB HAEMOSTASIS, V70, P307; REFINO CJ, 1993, THROMB HAEMOSTASIS, V70, P313; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; SHOHET RV, 1994, THROMB HAEMOSTASIS, V71, P124; STRANDBERG L, 1995, J BIOL CHEM, V270, P23444, DOI 10.1074/jbc.270.40.23444; SUENSON E, 1981, BIOCHEM J, V197, P619, DOI 10.1042/bj1970619; Tachias K, 1997, J BIOL CHEM, V272, P28; TACHIAS K, 1995, J BIOL CHEM, V270, P18319, DOI 10.1074/jbc.270.31.18319; TATE KM, 1987, BIOCHEMISTRY-US, V26, P338, DOI 10.1021/bi00376a002; THORSEN S, 1981, BIOCHIM BIOPHYS ACTA, V668, P377, DOI 10.1016/0005-2795(81)90171-9; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VANDEWERF F, 1984, NEW ENGL J MED, V310, P609; VANMEIJER M, 1996, J BIOL CHEM, V271, P7426; WEENINGVERHOEFF EJD, 1990, PROTEIN ENG, V4, P191, DOI 10.1093/protein/4.2.191; WEIMAR W, 1981, LANCET, V2, P1018; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	51	15	19	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14580	14585		10.1074/jbc.272.23.14580	http://dx.doi.org/10.1074/jbc.272.23.14580			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169416	hybrid			2022-12-27	WOS:A1997XC32700013
J	Ye, QA; Callebaut, I; Pezhman, A; Courvalin, JC; Worman, HJ				Ye, QA; Callebaut, I; Pezhman, A; Courvalin, JC; Worman, HJ			Domain-specific interactions of human HP1-type chromodomain proteins and inner nuclear membrane protein LBR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPHOBIC CLUSTER-ANALYSIS; LAMIN-B-RECEPTOR; DROSOPHILA HETEROCHROMATIN PROTEIN; CHROMOSOMAL PROTEIN; INTEGRAL PROTEIN; ESCHERICHIA-COLI; ENVELOPE; BINDING; GENE; AUTOANTIBODIES	HP1-type chromodomain proteins self-associate as well as interact with the inner nuclear membrane protein LBR (lamin B receptor) and transcriptional coactivators TIF1 alpha and TIF1 beta. The domains of these proteins that mediate their various interactions have not been entirely defined. HP1-type proteins are predicted by hydrophobic cluster analysis to consist of two homologous but distinct globular domains, corresponding to the chromodomain and chrome shadow domain, separated by a hinge region. We show here that the chrome shadow domain mediates the self-associations of HP1-type proteins and is also necessary for binding to LBR both in vitro and in the yeast two-hybrid assay. Hydrophobic cluster analysis also predicts that the nucleoplasmic amino-terminal portion of LBR contains two globular domains separated by a hinge region. The interactions of the LBR domains with an HP1-type protein were also analyzed by the yeast two-hybrid and in vitro binding assays, which showed that a portion of the second globular domain is necessary for binding. The modular domain organization of HP1-type proteins and LBR can explain some of the diverse protein-protein interactions at the chromatin-lamina-membrane interface of the nuclear envelope.	COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT ANAT & CELL BIOL, NEW YORK, NY 10032 USA; UNIV PARIS 06, CNRS, URA 09, LAB MINERAL CRISTALLOG PARIS, F-75252 PARIS 05, FRANCE; UNIV PARIS 07, F-75252 PARIS 05, FRANCE; UNIV PARIS 07, INST JACQUES MONOD, DEPT BIOL CELLULAIRE, CNRS, F-75251 PARIS 05, FRANCE	Columbia University; Columbia University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite					NCI NIH HHS [CA66974] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066974] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AASLAND R, 1995, NUCLEIC ACIDS RES, V23, P3168; BLOBEL G, 1985, P NATL ACAD SCI USA, V82, P8527, DOI 10.1073/pnas.82.24.8527; Callebaut I, 1997, BIOCHEM J, V321, P125, DOI 10.1042/bj3210125; CALLEBAUT I, 1995, FEBS LETT, V374, P211, DOI 10.1016/0014-5793(95)01109-R; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHAUDHARY N, 1993, J CELL BIOL, V122, P295, DOI 10.1083/jcb.122.2.295; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Collas P, 1996, J CELL BIOL, V135, P1715, DOI 10.1083/jcb.135.6.1715; COURVALIN JC, 1992, J BIOL CHEM, V267, P19035; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; KOONIN EV, 1995, NUCLEIC ACIDS RES, V23, P4229, DOI 10.1093/nar/23.21.4229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSOUED K, 1991, EUR J IMMUNOL, V21, P1959, DOI 10.1002/eji.1830210826; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LEMESLEVARLOOT L, 1990, BIOCHIMIE, V72, P555, DOI 10.1016/0300-9084(90)90120-6; Lin F, 1996, HEPATOLOGY, V23, P57, DOI 10.1002/hep.510230109; MATHOG D, 1984, NATURE, V308, P414, DOI 10.1038/308414a0; MORIUCHI H, 1995, P NATL ACAD SCI USA, V92, P9333, DOI 10.1073/pnas.92.20.9333; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAUNDERS WS, 1993, J CELL SCI, V104, P573; SCHULER E, 1994, J BIOL CHEM, V269, P11312; SIMOS G, 1992, EMBO J, V11, P4027, DOI 10.1002/j.1460-2075.1992.tb05496.x; SINGH PB, 1991, NUCLEIC ACIDS RES, V19, P789, DOI 10.1093/nar/19.4.789; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH S, 1994, P NATL ACAD SCI USA, V91, P10124, DOI 10.1073/pnas.91.21.10124; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; WOODCOCK S, 1992, PROTEIN ENG, V5, P629, DOI 10.1093/protein/5.7.629; WORMAN HJ, 1990, J CELL BIOL, V111, P1535, DOI 10.1083/jcb.111.4.1535; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; Ye Q, 1996, J BIOL CHEM, V271, P14653, DOI 10.1074/jbc.271.25.14653; YE Q, 1994, J BIOL CHEM, V269, P11306; YE QA, 1995, EXP CELL RES, V219, P292, DOI 10.1006/excr.1995.1230	38	278	283	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14983	14989		10.1074/jbc.272.23.14983	http://dx.doi.org/10.1074/jbc.272.23.14983			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169472	hybrid			2022-12-27	WOS:A1997XC32700069
J	Bone, H; Dechert, U; Jirik, F; Schrader, JW; Welham, MJ				Bone, H; Dechert, U; Jirik, F; Schrader, JW; Welham, MJ			SHP1 and SHP2 protein-tyrosine phosphatases associate with beta c after interleukin-3-induced receptor tyrosine phosphorylation - Identification of potential binding sites and substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; GROWTH-FACTOR RECEPTOR; COLONY-STIMULATING FACTOR; HEMATOPOIETIC-CELL PHOSPHATASE; SIGNAL-TRANSDUCTION; GM-CSF; SH2 DOMAINS; SEQUENCE SIMILARITY; SYP PHOSPHATASE; MOTH-EATEN	The cytoplasmic tyrosine phosphatases, SHP1 and SHP2, are implicated in the control of cellular proliferation and survival. Here we demonstrate that both SHP1 and SHP2 associate with the beta c subunit of the human interleukin-3 (IL-3) receptor following IL-3 stimulation and that the src homology region 2 (SH2) domains of these phosphatases mediate this interaction. Sequential immunoprecipitation analyses suggest this interaction is direct. Competition studies, using phosphotyrosine-containing peptides based on sequences surrounding key tyrosine residues within beta c, suggest that phosphorylation of tyrosine 612 is the key event mediating the association of beta c with SHP1 and SHP2. However, inhibition of SHP2 binding to beta c, did not prevent tyrosine phosphorylation of SHP2. interestingly, this same phosphopeptide served as a substrate for the tyrosine phosphatase activity of both SHP1 and SHP2. Binding of these protein-tyrosine phosphatases to the IL-3 receptor may regulate IL-3 signal transduction pathways, both through their catalytic activity and through the recruitment of other molecules to the receptor complex.	UNIV BATH, SCH PHARM & PHARMACOL, BATH BA2 7AY, AVON, ENGLAND; UNIV BRITISH COLUMBIA, DEPT MED, VANCOUVER, BC V6T 1Z3, CANADA	University of Bath; University of British Columbia								ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; CASE RD, 1994, J BIOL CHEM, V269, P10467; DECHERT U, 1994, J BIOL CHEM, V269, P5602; DECHERT U, 1995, EUR J BIOCHEM, V231, P673, DOI 10.1111/j.1432-1033.1995.0673d.x; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; Durstin M, 1996, J IMMUNOL, V157, P534; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; HARDER KW, 1994, BIOCHEM J, V298, P395, DOI 10.1042/bj2980395; IHLE JN, 1992, CHEM IMMUNOL, V51, P65; INHORN RC, 1995, P NATL ACAD SCI USA, V92, P8665, DOI 10.1073/pnas.92.19.8665; Itoh T, 1996, J BIOL CHEM, V271, P7587, DOI 10.1074/jbc.271.13.7587; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VANZANT G, 1989, EXP HEMATOL, V17, P81; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	60	59	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14470	14476		10.1074/jbc.272.22.14470	http://dx.doi.org/10.1074/jbc.272.22.14470			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162089	hybrid			2022-12-27	WOS:A1997XB49200076
J	Bickel, PE; Scherer, PE; Schnitzer, JE; Oh, P; Lisanti, MP; Lodish, HF				Bickel, PE; Scherer, PE; Schnitzer, JE; Oh, P; Lisanti, MP; Lodish, HF			Flotillin and epidermal surface antigen define a new family of caveolae-associated integral membrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; MOLECULAR-CLONING; LINKED PROTEIN; CELL-SURFACE; TRANSPORT; ADIPOCYTES; SUBDOMAINS; VESICLES; RECEPTOR; DOMAINS	Caveolae are plasmalemmal microdomains that are involved in vesicular trafficking and signal transduction. We have sought to identify novel integral membrane proteins of caveolae. Here we describe the identification and molecular cloning of flotillin. By several independent methods, flotillin behaves as a resident integral membrane protein component of caveolae. Furthermore, we have identified epidermal surface antigen both as a flotillin homologue and as a resident caveolar protein. Significantly, flotillin is a marker for the Triton-insoluble, buoyant membrane fraction in brain, where to date mRNA species for known caveolin gene family members have not been detected.	WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MASSACHUSETTS GEN HOSP, DEPT MED, DIABET UNIT, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Massachusetts Institute of Technology (MIT)			Lisanti, Michael/B-6131-2018; Bickel, Perry/Q-9185-2019; Lisanti, Michael P/C-6866-2013; Scherer, Philipp E/K-7819-2012	Lisanti, Michael/0000-0003-2034-1382; Scherer, Philipp E/0000-0003-0680-3392	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL043278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK002219, R01DK047618, R37DK047618] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43278] Funding Source: Medline; NIDDK NIH HHS [DK02219, DK47618] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; Bouillot C, 1996, J BIOL CHEM, V271, P7640, DOI 10.1074/jbc.271.13.7640; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHO YJ, 1995, GENOMICS, V27, P251, DOI 10.1006/geno.1995.1039; FROST SC, 1985, J BIOL CHEM, V260, P2646; FUCHS R, 1994, COMPUT APPL BIOSCI, V10, P171; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; Henke RC, 1996, J NEUROSCI RES, V45, P617, DOI 10.1002/(SICI)1097-4547(19960901)45:5<617::AID-JNR11>3.3.CO;2-L; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Kubler E, 1996, J BIOL CHEM, V271, P32975, DOI 10.1074/jbc.271.51.32975; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lisanti Michael P., 1995, Seminars in Developmental Biology, V6, P47, DOI 10.1016/S1044-5781(06)80084-8; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; OLIVE S, 1995, J NEUROCHEM, V65, P2307; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; Schnitzer JE, 1996, SCIENCE, V274, P239, DOI 10.1126/science.274.5285.239; SCHROEDER WT, 1994, J BIOL CHEM, V269, P19983; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEVERS NJ, 1988, J CELL SCI, V90, P341; SIMIONESCU N, 1975, J CELL BIOL, V64, P586, DOI 10.1083/jcb.64.3.586; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; STAHL A, 1995, J CELL BIOL, V129, P335, DOI 10.1083/jcb.129.2.335; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; TRAVIS J, 1993, SCIENCE, V262, P1208, DOI 10.1126/science.8235646; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445	43	482	503	3	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13793	13802		10.1074/jbc.272.21.13793	http://dx.doi.org/10.1074/jbc.272.21.13793			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153235	hybrid			2022-12-27	WOS:A1997XA06200050
J	Nare, B; Hardy, LW; Beverley, SM				Nare, B; Hardy, LW; Beverley, SM			The roles of pteridine reductase 1 and dihydrofolate reductase-thymidylate synthase in pteridine metabolism in the protozoan parasite Leishmania major	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; METHOTREXATE RESISTANCE; GENE REPLACEMENT; FOLATE; MECHANISMS; DEFICIENT; DONOVANI; PROTEINS; TROPICA; AMPLIFICATION	Trypanosomatid protozoans depend upon exogenous sources of pteridines (pterins or folates) for growth. A broad spectrum pteridine reductase (PTR1) was recently identified in Leishmania major, whose sequence places it in the short chain alcohol dehydrogenase protein family although its enzymatic activities resemble dihydrofolate reductases. The properties of PTR1 suggested a role in essential pteridine salvage as well as in antifolate resistance, To prove this, we have characterized further the properties and relative roles of PTR1 and dihydrofolate reductase-thymidylate synthase in Leishmania pteridine metabolism, using purified enzymes and knockout mutants, Recombinant L. major and Leishmania tarentolae, and native L. major PTR1s, were tetramers of 30-kDa subunits and showed similar catalytic properties with pterins and folates (pH dependence, substrate inhibition with H(2)pteridines), Unlike PTR1, dihydrofolate reductase-thymidylate synthase showed weak activity with folate and no activity with pterins, Correspondingly, studies of ptr1(-) and dhfr-ts(-) mutants implicated only PTR1 in the ability of L. major to grow on a wide array of pterins, PTR1 exhibited 2000-fold less sensitivity to inhibition by methotrexate than dihydrofolate reductase-thymidylate synthase, suggesting several mechanisms by which PTR1 may compromise antifolate inhibition in wild-type Leishmania and lines bearing PTR1 amplifications, We incorporate these results into a comprehensive model of pteridine metabolism and discuss its implications in chemotherapy of this important human pathogen.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02115 USA; UNIV MASSACHUSETTS, SCH MED, DEPT PHARMACOL, WORCESTER, MA 01605 USA; UNIV MASSACHUSETTS, SCH MED, PROGRAM MOL MED, WORCESTER, MA 01605 USA	Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester				Beverley, Stephen/0000-0001-5319-0811				BECK JT, 1991, MOL BIOCHEM PARASIT, V49, P21, DOI 10.1016/0166-6851(91)90126-Q; BECK JT, 1990, MOL BIOCHEM PARASIT, V43, P221, DOI 10.1016/0166-6851(90)90147-E; BELLO AR, 1994, P NATL ACAD SCI USA, V91, P11442, DOI 10.1073/pnas.91.24.11442; BERMAN JD, 1988, REV INFECT DIS, V10, P560; BEVERLEY SM, 1991, ANNU REV MICROBIOL, V45, P417, DOI 10.1146/annurev.mi.45.100191.002221; BEVERLEY SM, 1986, P NATL ACAD SCI USA, V83, P2584, DOI 10.1073/pnas.83.8.2584; BLAKLEY R, 1985, FOLATES PTERINS CHEM, V2, P1; Blakley R.L., 1984, FOLATES PTERINS, V1, P191; BORST P, 1995, ANNU REV MICROBIOL, V49, P427, DOI 10.1146/annurev.mi.49.100195.002235; CALLAHAN HL, 1992, J BIOL CHEM, V267, P24165; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; CLELAND WW, 1979, METHOD ENZYMOL, V63, P501; CODERRE JA, 1983, P NATL ACAD SCI-BIOL, V80, P2132, DOI 10.1073/pnas.80.8.2132; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; ELLENBERGER TE, 1987, J BIOL CHEM, V262, P10053; ELON J, 1984, ANTIMICROB AGENTS CH, V31, P1575; FUTTERMAN S, 1957, J BIOL CHEM, V228, P1031; GARRETT CE, 1984, MOL BIOCHEM PARASIT, V11, P257, DOI 10.1016/0166-6851(84)90070-7; GRUMONT R, 1986, P NATL ACAD SCI USA, V83, P5387, DOI 10.1073/pnas.83.15.5387; GUROFF G, 1967, ANAL BIOCHEM, V21, P273, DOI 10.1016/0003-2697(67)90189-3; HAYMAN R, 1978, ANAL BIOCHEM, V87, P460, DOI 10.1016/0003-2697(78)90696-6; HIRAYAMA K, 1980, BIOCHIM BIOPHYS ACTA, V612, P337, DOI 10.1016/0005-2744(80)90116-3; HOWELL EE, 1988, J BACTERIOL, V170, P3040, DOI 10.1128/jb.170.7.3040-3045.1988; JARABAK J, 1971, ARCH BIOCHEM BIOPHYS, V142, P417, DOI 10.1016/0003-9861(71)90505-4; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KAUFMAN S, 1963, P NATL ACAD SCI USA, V50, P1085, DOI 10.1073/pnas.50.6.1085; KAUFMAN S, 1986, P185; KAUR K, 1988, J BIOL CHEM, V263, P7020; KNIGHTON DR, 1994, NAT STRUCT BIOL, V1, P186, DOI 10.1038/nsb0394-186; KOSARHASHEMI B, 1993, BIOL CHEM H-S, V374, P9, DOI 10.1515/bchm3.1993.374.1-6.9; KOVACS JA, 1989, J INFECT DIS, V160, P312, DOI 10.1093/infdis/160.2.312; KROZOWSKI Z, 1994, J STEROID BIOCHEM, V51, P125, DOI 10.1016/0960-0760(94)90084-1; KWON NS, 1989, J BIOL CHEM, V264, P20496; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAR G, 1993, PLANT J, V3, P657, DOI 10.1111/j.1365-313X.1993.00657.x; Ma DQ, 1996, BIOCHEM BIOPH RES CO, V227, P885, DOI 10.1006/bbrc.1996.1600; MATHEWS CK, 1963, J BIOL CHEM, V238, P3436; MATTHEWS DA, 1986, BIOCHEMISTRY-US, V25, P4194, DOI 10.1021/bi00363a005; MATTOCK NM, 1975, ANN TROP MED PARASIT, V69, P359, DOI 10.1080/00034983.1975.11687020; MCDONALD JD, 1988, PEDIATR RES, V23, P63, DOI 10.1203/00006450-198801000-00014; MCINTYRE LJ, 1977, BIOCHIM BIOPHYS ACTA, V482, P261, DOI 10.1016/0005-2744(77)90240-6; MEEK TD, 1985, BIOCHEMISTRY-US, V24, P678, DOI 10.1021/bi00324a021; MILHOUS WK, 1985, ANTIMICROB AGENTS CH, V27, P525, DOI 10.1128/AAC.27.4.525; NATHAN HA, 1956, NATURE, V178, P741, DOI 10.1038/178741a0; NEAL RA, 1984, EXP PARASITOL, V57, P269, DOI 10.1016/0014-4894(84)90100-0; OE H, 1983, AGR BIOL CHEM TOKYO, V47, P425, DOI 10.1080/00021369.1983.10865652; OE H, 1983, AGR BIOL CHEM TOKYO, V47, P251, DOI 10.1080/00021369.1983.10865624; PAPADOPOULOU B, 1992, EMBO J, V11, P3601, DOI 10.1002/j.1460-2075.1992.tb05444.x; PAPADOPOULOU B, 1994, J BIOL CHEM, V269, P7310; PETRILLOPEIXOTO MP, 1987, ANTIMICROB AGENTS CH, V31, P1575; ROTHENBERG SP, 1980, ANAL BIOCHEM, V103, P152, DOI 10.1016/0003-2697(80)90249-3; SCOTT DA, 1987, MOL BIOCHEM PARASIT, V23, P139, DOI 10.1016/0166-6851(87)90149-6; SHIMAN R, 1985, FOLATES PTERINS, V2, P179; SIRAWARAPORN W, 1988, MOL BIOCHEM PARASIT, V31, P79, DOI 10.1016/0166-6851(88)90147-8; SMITH GK, 1987, ARCH BIOCHEM BIOPHYS, V254, P416, DOI 10.1016/0003-9861(87)90119-6; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; TIETZ A, 1964, J BIOL CHEM, V239, P4081; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAGER W, 1969, J PROTOZOOL, V16, P372, DOI 10.1111/j.1550-7408.1969.tb02284.x; VASUDEVAN SG, 1992, BIOL CHEM H-S, V373, P1067, DOI 10.1515/bchm3.1992.373.2.1067; WEBBER S, 1985, ARCH BIOCHEM BIOPHYS, V236, P681, DOI 10.1016/0003-9861(85)90674-5; WHITELEY JM, 1993, ADV EXP MED BIOL, V338, P115; *WHO EXP COMM, 1984, 701 WHO, P3; ZAKRZEWSKI SF, 1960, J BIOL CHEM, V235, P2984	65	135	138	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13883	13891		10.1074/jbc.272.21.13883	http://dx.doi.org/10.1074/jbc.272.21.13883			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153248	hybrid			2022-12-27	WOS:A1997XA06200063
J	Liu, B; Hannun, YA				Liu, B; Hannun, YA			Inhibition of the neutral magnesium-dependent sphingomyelinase by glutathione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ACID SPHINGOMYELINASE; CELL-DIFFERENTIATION; HL-60 CELLS; CERAMIDE; APOPTOSIS; PURIFICATION; METABOLISM; DEPLETION; CYCLE	Sphingomyelin hydrolysis through the activation of sphingomyelinases has become a potentially important signaling pathway with the product ceramide implicated in the regulation of cell growth, differentiation, apoptosis, and inflammatory responses. However, little is known about the regulation of sphingomyelinases, In this study, we show that the magnesium-dependent, neutral pH-optimum and membrane-associated sphingomyelinase (N-SMase) is inhibited, in a dose-dependent manner, by glutathione (GSH) at physiological concentrations with a greater than 95% inhibition observed at 5 mn GSH. The inhibitory effect of GSH was reproduced by gamma-glutamyl-cysteine, but not the cysteinyl-glycine fragment of GSH, The S-modified GSH analogs were as effective as GSH in inhibiting the N-SMase. On the other hand, neither dithiothreitol nor beta-mercaptoethanol had any effect on the N-SMase, suggesting that the sulfhydryl in GSH is not required for inhibition of N-SMase, GSH had no effect on the acid pH-optimum SMase, whereas dithiothreitol inhibited the acid SMase. These results suggest that in cells the N-SMase is inactive in the presence of physiological concentrations of GSH (1-20 mM). Finally, treatment of cultured Molt-4 cells with the GSH synthesis inhibitor, L-buthionine-(SR)-sulfoximine, resulted in a time-dependent depletion of GSH, accompanied by an increased hydrolysis of sphingomyelin and production of ceramide. Since GSH depletion is observed in a variety of cells in the process of cellular injury and apoptosis, these studies suggest that depletion of GSH may be an important mechanism in activation of N-SMase. This mechanism may therefore bring together the fields of oxidative stress and signaling through products of sphingomyelin hydrolysis.	DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA	Duke University; Duke University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825, F32GM017426] Funding Source: NIH RePORTER; NIGMS NIH HHS [F32 GM017426, F32 GM017426-01A1, GM43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BANNAI S, 1980, J BIOL CHEM, V255, P2372; BEAVER JP, 1995, EUR J CELL BIOL, V68, P47; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHATTERJEE S, 1993, ADV LIPID RES, V26, P25; Chiba T, 1996, EUR J IMMUNOL, V26, P1164, DOI 10.1002/eji.1830260530; CHRISTIE NA, 1994, ARCH BIOCHEM BIOPHYS, V313, P131, DOI 10.1006/abbi.1994.1369; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; FERNANDES RS, 1994, BIOCHEM PHARMACOL, V48, P675, DOI 10.1016/0006-2952(94)90044-2; GERARDMONNIER D, 1992, BIOCHEM PHARMACOL, V43, P451, DOI 10.1016/0006-2952(92)90563-X; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KIM MY, 1991, J BIOL CHEM, V266, P484; KITAGAWA T, 1987, JPN J HUM GENET, V32, P55, DOI 10.1007/BF01893159; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; LEVINE ES, 1993, CARDIOVASC RES, V27, P1248, DOI 10.1093/cvr/27.7.1248; LU SC, 1992, J CLIN INVEST, V90, P524, DOI 10.1172/JCI115890; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MEISTER A, 1995, METHOD ENZYMOL, V251, P3, DOI 10.1016/0076-6879(95)51106-7; MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290; MUTOH H, 1991, AM J PHYSIOL, V261, pG65, DOI 10.1152/ajpgi.1991.261.1.G65; Nyberg L, 1996, BBA-LIPID LIPID MET, V1300, P42, DOI 10.1016/0005-2760(95)00245-6; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; PIERSON HF, 1985, CANCER RES, V45, P4727; QUINTERN LE, 1987, BIOCHIM BIOPHYS ACTA, V922, P323, DOI 10.1016/0005-2760(87)90055-5; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Slater AFG, 1995, TOXICOL LETT, V82-3, P149, DOI 10.1016/0378-4274(95)03474-9; SPENCE MW, 1993, ADV LIPID RES, V26, P3; SPENCE MW, 1989, J BIOL CHEM, V264, P5358; STRUM JC, 1994, J BIOL CHEM, V269, P15493; TATE SS, 1974, J BIOL CHEM, V249, P7593; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; TIEFZE F, 1969, ANAL BIOCHEM, V27, P502; Venable ME, 1996, J BIOL CHEM, V271, P24800, DOI 10.1074/jbc.271.40.24800; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; YAMANAKA T, 1982, J NEUROCHEM, V38, P1753, DOI 10.1111/j.1471-4159.1982.tb06659.x; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	52	257	274	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16281	16287		10.1074/jbc.272.26.16281	http://dx.doi.org/10.1074/jbc.272.26.16281			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195931	hybrid			2022-12-27	WOS:A1997XG01900035
J	Ludbrook, SB; Eccleston, JF; Strom, M				Ludbrook, SB; Eccleston, JF; Strom, M			Cloning and characterization of a rhoGAP homolog from Dictyostelium discoideum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; ACTIN STRESS FIBERS; NADPH OXIDASE; RAC; FAMILY; EFFECTOR; BCR; ENDOCYTOSIS; PATHWAYS; ENCODES	Small GTPases interact with a variety of proteins that affect nucleotide binding and cleavage. GTPase activating proteins (GAPs) art: one class of these proteins that act by accelerating ire intrinsic GTPase rare resulting in the formation of the biologically inactive GDP-bound farm of the GTPase, For the Rho subfamily of GTPases, there is a growing number of proteins with rhoGAP activity that are identifiable by a homologous region of about 150 amino acids, We have exploited this homology using the polymerase chain reaction to clone the first rhoGAP homolog, called DdRacGAP, from the slime mold Dictyostelium discoideum. The GAP domain of DdRacGAP (amino acids 1-212), when expressed and purified from Escherichia coli, is active on both Dictyostelium and human Rho Family GTPases but not human Ras. The full-length protein is 1356 amino acids in length and has several interesting homologies ill addition to the GAP domain, including an SH3 domain, a dbl homology domain, and a pleckstrin homology domain.	NATL INST MED RES,DEPT PHYS BIOCHEM,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research								ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUSH J, 1993, GENE, V136, P61, DOI 10.1016/0378-1119(93)90448-C; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P1217, DOI 10.1091/mbc.4.11.1217; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Larochelle DA, 1996, J CELL BIOL, V133, P1321, DOI 10.1083/jcb.133.6.1321; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHMALZING G, 1995, J CELL BIOL, V130, P1319, DOI 10.1083/jcb.130.6.1319; SELF AJ, 1993, ONCOGENE, V8, P655; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Thain A, 1996, TRENDS GENET, V12, P209, DOI 10.1016/S0168-9525(96)90022-0; Tribioli C, 1996, P NATL ACAD SCI USA, V93, P695, DOI 10.1073/pnas.93.2.695; VOGEL G, 1987, METHOD CELL BIOL, V28, P129; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; XU XM, 1994, J BIOL CHEM, V269, P23569; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	36	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15682	15686		10.1074/jbc.272.25.15682	http://dx.doi.org/10.1074/jbc.272.25.15682			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188459	hybrid			2022-12-27	WOS:A1997XF32900019
J	Hedblom, E; Kirkness, EF				Hedblom, E; Kirkness, EF			A novel class of GABA(A) receptor subunit in tissues of the reproductive system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; CHANNELS; BINDING; GENE; PROGESTERONE; INHIBITION; ACTIVATION; EXPRESSION; SECRETION; SEQUENCE	A novel subunit of the gamma-aminobutyrate, type A (GABA,) receptor family has been identified in human and rat tissues. The subunit displays 30-40% amino acid identity with known family members and represents a distinct subunit class (termed pi). Transcripts of the pi subunit were detected in several human tissues and were particularly abundant in the uterus, The pi subunit protein call assemble with known GABA(A) receptor subunits and confer unique ligand binding properties to the recombinant receptors in which it combines. Most notably, the presence of the rr subunit alters the sensitivity of recombinant receptors to the endogenous steroid, pregnanolone. identification of the pi subunit indicates a new target for pharmacological manipulation of GABA, receptors that are located outside of the central nervous system.	INST GENOM RES,ROCKVILLE,MD 20850	J. Craig Venter Institute					NINDS NIH HHS [NS34702] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS034702] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS MD, 1995, NATURE, V377, P3; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMENTA F, 1988, PHARMACOL RES, V20, P863, DOI 10.1016/0031-6989(88)90003-3; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; BORMANN J, 1985, P NATL ACAD SCI USA, V82, P2168, DOI 10.1073/pnas.82.7.2168; BORMANN J, 1995, TRENDS NEUROSCI, V18, P515, DOI 10.1016/0166-2236(95)98370-E; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CSAPO AI, 1979, AM J OBSTET GYNECOL, V134, P823, DOI 10.1016/0002-9378(79)90954-2; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0; Davies PA, 1997, BRIT J PHARMACOL, V120, P899, DOI 10.1038/sj.bjp.0700987; DEMENEIX BA, 1986, NEUROSCIENCE, V17, P1275, DOI 10.1016/0306-4522(86)90094-1; ERDO SL, 1989, BRIT J PHARMACOL, V96, P313, DOI 10.1111/j.1476-5381.1989.tb11819.x; ERDO SL, 1989, LIFE SCI, V44, P2009, DOI 10.1016/0024-3205(89)90346-9; KIRKNESS EF, 1993, J BIOL CHEM, V268, P4420; KIRKNESS EF, 1996, CDNA LIB PROTOCOLS, P261; LICHT P, 1992, ENDOCRINOLOGY, V130, P490, DOI 10.1210/en.130.1.490; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MAJEWSKA MD, 1991, J ENDOCRINOL, V131, P427, DOI 10.1677/joe.0.1310427; PUTNAM CD, 1991, BIOL REPROD, V45, P266, DOI 10.1095/biolreprod45.2.266; RORSMAN P, 1989, NATURE, V341, P233, DOI 10.1038/341233a0; SCHMIEDEN V, 1992, EMBO J, V11, P2025, DOI 10.1002/j.1460-2075.1992.tb05259.x; SLANY A, 1995, MOL PHARMACOL, V48, P385; TOKUNAGA K, 1987, CANCER RES, V47, P5616; Whiting PJ, 1995, INT REV NEUROBIOL, V38, P95, DOI 10.1016/S0074-7742(08)60525-5	26	184	194	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15346	15350		10.1074/jbc.272.24.15346	http://dx.doi.org/10.1074/jbc.272.24.15346			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182563	hybrid			2022-12-27	WOS:A1997XE03400046
J	Hirai, S; Katoh, M; Terada, M; Kyriakis, JM; Zon, LI; Rana, A; Avruch, J; Ohno, S				Hirai, S; Katoh, M; Terada, M; Kyriakis, JM; Zon, LI; Rana, A; Avruch, J; Ohno, S			MST/MLK2, a member of the mixed lineage kinase family, directly phosphorylates and activates SEK1, an activator of c-Jun N-terminal kinase/stress-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; MAMMALIAN-CELLS; IDENTIFICATION; DOMAIN; CLONING; BRAIN; TRANSFORMATION; EXPRESSION; SUBFAMILY; CASCADE	c-Jun N-terminal kinases/stress-activated protein kinases (JNKs/SAPKs) are mitogen-activated protein kinase (MAPK)-related protein kinases that are involved in several cellular events, including growth, differentiation, and apoptosis. Mixed lineage kinases (MLKs) form a family of protein kinases sharing two leucine zipper-like motifs and a kinase domain whose primary structure is similar to both the tyrosine-specific and the serine/threonine-specific kinase classes. We have reported that a member of the MLK family, MUK/DLK/ZPK, can activate JNK/SAPK in vivo, and here we show that another member of the MLK family, MST/MLK2, activates JNK/SAPK. Both MUK/DLK/ZPK and MST/MLK2 cause a slight activation of p38/Mpk2 when overexpressed in COS-1 cells, whereas MST/MLK2, but not MCK/DLK/ ZPK, activates extracellular response kinase (ERK) to a certain degree. The activity of SEK1/MKK4/JNKK, a MAPK kinase class protein kinase designated as a direct activator of JNK/SAPK, is also induced by MUK/DLK/ ZPK or MST/MLK2 overexpression. Furthermore, recombinant MST/MLK2 produced in bacteria directly phosphorylates and activates SEK1/MKK4/JNKK in vitro, showing that MST/MLK2 acts like a MAPK kinase kinase. Taken together, these results suggest that MLK family members are MAPK kinase kinases preferentially acting on the JNK/SAPK pathway.	NATL CANC CTR,RES INST,DIV GENET,CHUO KU,TOKYO 104,JAPAN; MASSACHUSETTS GEN HOSP E,DIABET UNIT,CHARLESTOWN,MA 02129; MASSACHUSETTS GEN HOSP E,MED SERV,CHARLESTOWN,MA 02129; HARVARD UNIV,SCH MED,DEPT MED,CHARLESTOWN,MA 02129; HARVARD UNIV,DANA FARBER CANC INST,SCH MED,BOSTON,MA 02115	National Cancer Center - Japan; Harvard University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Hirai, S (corresponding author), YOKOHAMA CITY UNIV,SCH MED,DEPT BIOL MOL,KANAZAWA KU,3-9 FUKUURA,YOKOHAMA,KANAGAWA 236,JAPAN.		Rana, Ajay/ABE-3739-2020; Ohno, Shigeo/B-1768-2010	Rana, Ajay/0000-0003-0951-2566; Ohno, Shigeo/0000-0002-1294-5269				Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHOI KY, 1994, CELL, V78, P499; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOROW DS, 1995, EUR J BIOCHEM, V234, P492, DOI 10.1111/j.1432-1033.1995.492_b.x; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; EZOE K, 1994, ONCOGENE, V9, P935; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GALLO KA, 1994, J BIOL CHEM, V269, P15092; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirai S, 1996, ONCOGENE, V12, P641; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; KATOH M, 1995, ONCOGENE, V10, P1447; KIEIER F, 1996, EMBO J, V15, P7013; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; ONG YL, 1994, ONCOGENE, V9, P1745; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613, DOI 10.1006/bbrc.1994.1972; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798	38	143	149	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15167	15173		10.1074/jbc.272.24.15167	http://dx.doi.org/10.1074/jbc.272.24.15167			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182538	Green Published, hybrid			2022-12-27	WOS:A1997XE03400021
J	GuilletDeniau, I; Burnol, AF; Girard, J				GuilletDeniau, I; Burnol, AF; Girard, J			Identification and localization of a skeletal muscle secrotonin 5-HT2A receptor coupled to the Jak/STAT pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR APRF; TYROSINE PHOSPHORYLATION; SEROTONIN; PROTEIN; ACTIVATION; MORPHOGENESIS; ASSOCIATION; EXPRESSION; KINASES; FAMILY	The neurotransmitter serotonin mediates a wide variety of peripheral and central physiological effects through the binding to multiple receptor subtypes (Wilkinson, L. O., and Dourish, C. T. (1991) in Serotonin Receptor Subtypes: Basic and Clinical Aspects (Peroutka, S. J., ed) Vol. 15, pp. 147-210, Wiley-Liss, New York). Among them, serotonin 5-HT2A receptors are known to activate the phospholipase C-P second messenger pathway (Peroutka, S. J. (1995) Trends Neurosci. 18, 68-69). We identified and localized in rat skeletal muscle myoblasts a functional serotonin 5-HT2A receptor. This receptor was detected on the plasma membrane, in myoblasts, and at the level of T-tubules in contracting myotubes. Binding of serotonin to its receptor increases the expression of genes involved in myogenic differentiation. Unexpectedly, the 5-HT2A, receptor is able to activate another signaling pathway; it triggers a rapid and transient tyrosine phosphorylation of Jak2 kinase in response to serotonin. Jak2 auto-phosphorylation is followed by the tyrosine phosphorylation of STAT3 (signal transducers and activators of transcription) and its translocation into the nucleus. We also find that the 5-HT2A receptor and STAT3 co-precipitate with Jak2, indicating that they are physically associated. We conclude that the serotonin 5-HT2A receptor identified in skeletal muscle myoblasts is able to activate the intracellular phosphorylation pathway used by cytokines. The presence of serotonin receptors in T-tubules suggests a role for serotonin in excitation-contraction coupling and (or) an effect in skeletal muscle fiber repairing.			GuilletDeniau, I (corresponding author), CTR RECH ENDOCRINOL MOL & DEV,CNRS,UPR 1511,9 RUE JULES HETZEL,F-92190 MEUDON,FRANCE.		Burnol, Anne-Francoise/P-2181-2017					BAXTER G, 1995, TRENDS PHARMACOL SCI, V16, P105, DOI 10.1016/S0165-6147(00)88991-9; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK EH, 1994, J NEUROCHEM, V63, P465; CORSON MA, 1992, AM J PHYSIOL, V262, pC309, DOI 10.1152/ajpcell.1992.262.2.C309; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Franzini-Armstrong C, 1986, MYOLOGY, P125; GUILLETDENIAU I, 1994, J CELL SCI, V107, P487; HUETHER G, 1992, BIOGENIC AMINES, V8, P421; JULIUS D, 1990, P NATL ACAD SCI USA, V87, P928, DOI 10.1073/pnas.87.3.928; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LAUDER JM, 1993, TRENDS NEUROSCI, V16, P233, DOI 10.1016/0166-2236(93)90162-F; Launay JM, 1996, J BIOL CHEM, V271, P3141, DOI 10.1074/jbc.271.6.3141; LORIC S, 1992, FEBS LETT, V312, P203, DOI 10.1016/0014-5793(92)80936-B; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; PEROUTKA SJ, 1995, TRENDS NEUROSCI, V18, P68; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SHUEY DL, 1992, TERATOLOGY, V46, P367, DOI 10.1002/tera.1420460407; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WILKINSON LO, 1991, SEROTONIN RECEPTOR S, V15, P147; YAVARONE MS, 1993, TERATOLOGY, V47, P573, DOI 10.1002/tera.1420470609; ZHANG Z, 1995, SCIENCE, V267, P1990	29	124	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14825	14829		10.1074/jbc.272.23.14825	http://dx.doi.org/10.1074/jbc.272.23.14825			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169451	hybrid			2022-12-27	WOS:A1997XC32700048
J	Klein, RD; Borchers, AH; Sundareshan, P; Bougelet, C; Berkman, MR; Nagle, RB; Bowden, GT				Klein, RD; Borchers, AH; Sundareshan, P; Bougelet, C; Berkman, MR; Nagle, RB; Bowden, GT			Interleukin-1 beta secreted from monocytic cells induces the expression of matrilysin in the prostatic cell line LNCaP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; COLLAGENASE MESSENGER-RNA; MATRIX METALLOPROTEINASE; GENE-EXPRESSION; ARTICULAR CHONDROCYTES; HUMAN-ENDOMETRIUM; STROMELYSIN; STIMULATION; LOCALIZATION; CARCINOMAS	Matrilysin is a matrix metalloprotease that is overexpressed in cancer cells of epithelial origin and in normal tissues during events involving matrix remodeling such as the cycling endometrium. We previously observed that inflamed ductule and acinar epithelia in the prostate also overexpress matrilysin. The presence of infiltrating macrophages in these areas prompted us to determine if factors secreted from monocytes could induce matrilysin expression in a human prostatic cell line, Conditioned media collected from the monocyte cell line THP-1 following lipopolysaccharide treatment substantially induced matrilysin protein and mRNA expression in LNCaP prostate carcinoma cells. Matrilysin expression in LNCaP cells was also induced by recombinant interleukin (IL)-1 (50 pM), but not by equimolar concentrations of recombinant tumor necrosis factor-alpha or IL-6. The matrilysin-inducing activity of THP-1 conditioned medium was completely abrogated by preincubation with a neutralizing antibody to IL-1 beta. Transient transfection analyses with a chimeric human matrilysin promoter-chloramphenicol acetyltransferase reporter construct demonstrated that IL-1 beta activates transcription through the matrilysin promoter in LNCaP cells. This is the first report of matrilysin induction by an inflammatory cytokine in a cell line of epithelial origin, and the results suggest a potential mechanism for the overexpression of matrilysin in inflamed ducts and glands of the prostate.	UNIV ARIZONA,HLTH SCI CTR,DEPT RADIAT ONCOL,TUCSON,AZ 85724; UNIV ARIZONA,HLTH SCI CTR,DEPT PATHOL,TUCSON,AZ 85724	University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona Health Sciences					NATIONAL CANCER INSTITUTE [P01CA056666] Funding Source: NIH RePORTER; NCI NIH HHS [5PO1 CA56666] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BORCHERS AH, 1994, EXP CELL RES, V213, P143, DOI 10.1006/excr.1994.1183; BOUTTEN A, 1992, EUR J IMMUNOL, V22, P2687, DOI 10.1002/eji.1830221032; BUSIEK DF, 1992, J BIOL CHEM, V267, P9087; CAMPBELL IK, 1986, J RHEUMATOL, V13, P20; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; FRUEHAUF JP, 1992, ONCOL RES, V4, P91; GOWEN M, 1984, BIOCHIM BIOPHYS ACTA, V797, P186, DOI 10.1016/0304-4165(84)90121-1; HSIEH TC, 1995, CANCER LETT, V95, P119, DOI 10.1016/0304-3835(95)03876-X; HUTCHINSON NI, 1992, ARTHRITIS RHEUM, V35, P1227, DOI 10.1002/art.1780351016; JASSER MZ, 1994, MATRIX BIOL, V14, P241; KAMAT BR, 1987, AM J PATHOL, V127, P66; KARELINA TV, 1994, J INVEST DERMATOL, V103, P482, DOI 10.1111/1523-1747.ep12395596; Knox JD, 1996, MOL CARCINOGEN, V15, P57; LIN CW, 1988, ARCH BIOCHEM BIOPHYS, V264, P351, DOI 10.1016/0003-9861(88)90605-4; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MacNaul K L, 1992, Matrix Suppl, V1, P198; MACNAUL KL, 1990, J BIOL CHEM, V265, P17238; MARTI HP, 1992, BIOCHEM J, V285, P899, DOI 10.1042/bj2850899; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; MCCACHREN SS, 1989, ARTHRITIS RHEUM, V32, P1539, DOI 10.1002/anr.1780321207; MCDONNELL J, 1992, ARTHRITIS RHEUM, V35, P799, DOI 10.1002/art.1780350714; MCDONNELL S, 1991, MOL CARCINOGEN, V4, P527, DOI 10.1002/mc.2940040617; MITCHELL PG, 1993, BIOCHEM BIOPH RES CO, V196, P1133, DOI 10.1006/bbrc.1993.2369; MIZEL SB, 1981, P NATL ACAD SCI-BIOL, V78, P2474, DOI 10.1073/pnas.78.4.2474; MULLER D, 1991, INT J CANCER, V48, P550, DOI 10.1002/ijc.2910480412; NAKANO A, 1995, J NEUROSURG, V83, P298, DOI 10.3171/jns.1995.83.2.0298; NEWELL KJ, 1994, MOL CARCINOGEN, V10, P199, DOI 10.1002/mc.2940100404; PAJOUH MS, 1991, J CANCER RES CLIN, V117, P144, DOI 10.1007/BF01613138; Powell WC, 1996, PROSTATE, V29, P159, DOI 10.1002/1097-0045(199609)29:3<159::AID-PROS2990290304>3.0.CO;2-L; QUANTIN B, 1989, BIOCHEMISTRY-US, V28, P5327, DOI 10.1021/bi00439a004; QUINONES S, 1994, BIOCHEM J, V302, P471, DOI 10.1042/bj3020471; QUINONES S, 1989, J BIOL CHEM, V264, P8339; RODGERS WH, 1993, AM J OBSTET GYNECOL, V168, P253, DOI 10.1016/S0002-9378(12)90922-9; SAARIALHOKERE UK, 1995, J INVEST DERMATOL, V105, P190, DOI 10.1111/1523-1747.ep12317104; SAUS J, 1988, J BIOL CHEM, V263, P6742; SIEGSMUND MJ, 1994, J UROLOGY, V151, P1396, DOI 10.1016/S0022-5347(17)35267-9; STEPHENSON ML, 1987, BIOCHEM BIOPH RES CO, V144, P583, DOI 10.1016/S0006-291X(87)80006-2; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; TURNER M, 1988, BIOCHEM BIOPH RES CO, V156, P830, DOI 10.1016/S0006-291X(88)80919-7; Wilson CL, 1996, INT J BIOCHEM CELL B, V28, P123, DOI 10.1016/1357-2725(95)00121-2; WOESSNER JF, 1988, J BIOL CHEM, V263, P16918	45	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14188	14192		10.1074/jbc.272.22.14188	http://dx.doi.org/10.1074/jbc.272.22.14188			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162049	hybrid			2022-12-27	WOS:A1997XB49200036
J	Miyamoto, Y; Shinki, T; Yamamoto, K; Ohyama, Y; Iwasaki, H; Hosotani, R; Kasama, T; Takayama, H; Yamada, S; Suda, T				Miyamoto, Y; Shinki, T; Yamamoto, K; Ohyama, Y; Iwasaki, H; Hosotani, R; Kasama, T; Takayama, H; Yamada, S; Suda, T			1 alpha,25-dihydroxyvitamin D-3-24-hydroxylase (CYP24) hydroxylates the carbon at the end of the side chain (C-26) of the C-24-fluorinated analog of 1 alpha,25-dihydroxyvitamin D-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-RESPONSIVE ELEMENT; BIOLOGICAL-ACTIVITY; 25-HYDROXYVITAMIN D-3; VITAMIN-D3 METABOLITE; 24-HYDROXYLASE GENE; RAT-KIDNEY; IDENTIFICATION; EXPRESSION; 1,25-DIHYDROXYVITAMIN-D3; INTESTINE	The sequential oxidation and cleavage of the side chain of 1 alpha,25-dihydroxyvitamin D-3 (1 alpha,25(OH)(2)D-3) initiated by the hydroxylation at C-24 is considered to be the major pathway of this hormone in the target cell metabolism. In this study, we examined renal metabolism of a synthetic analog of 1 alpha,25(OH)(2)D-3, 24,24-difluoro-1 alpha,25-dihydroxyvitamin D-3 (F-2-1 alpha,25(OH)(2)D-3), C-24 of which was designed to resist metabolic hydroxylation. When kidney homogenates prepared from 1 alpha,25(OH)(2)D-3-supplemented rats were incubated with F-2-1 alpha,25(OH)(2)D-3, it was mainly converted to a more polar metabolite. We isolated and unequivocally identified the metabolite as 24,24-difluoro-1 alpha,25,26-trihydroxyvitamin D-3 (F-2-1 alpha,25,26(OH)(3)D-3) by ultraviolet absorption spectrometry, frit-fast atom bombardment liquid chromatography/mass spectroscopy analysis, and direct comparison with chemically synthesized F-2-1 alpha,25,26 (OH)(3)D-3. Metabolism of F-2-1 alpha,25(OH)(3)D-3 into F-2-1 alpha,25,26(OH)(3)D-3 by kidney homogenates was induced by the prior administration of 1 alpha,25(OH)(2)D-3 into rats. The C-24 oxidation of 1 alpha,25(OH)(2)D-3 in renal homogenates was inhibited by F-2-1 alpha,25(OH)(2)D-3 in a concentration-dependent manner. Moreover, F-2-1 alpha,25,26(OH)(3)D-3 was formed in ROS17/2.8 cells transfected with a plasmid expressing 1 alpha,25(OH)(2)D-3-24-hydroxylase (CYP24) but not in the cells transfected with that expressing vitamin D-3-25-hydroxylase (CYP27) or containing inverted CYP27 cDNA. These results show that CYP24 catalyzes not only hydroxylation at C-24 and C-23 of 1 alpha,25(OH)(2)D-3 but also at C-26 of F-2-1 alpha,25(OH)(2)D-3, indicating that this enzyme has a broader substrate specificity of the hydroxylation sites than previously considered.	SHOWA UNIV, SCH DENT, DEPT BIOCHEM, SHINAGAWA KU, TOKYO 142, JAPAN; TOKYO MED & DENT UNIV, INST MED & DENT ENGN, DIV MOL BIOL, CHIYODA KU, TOKYO 101, JAPAN; NOF CORP, TSUKUBA RES LAB, TSUKUBA, IBARAKI 30021, JAPAN; HIROSHIMA UNIV, FAC SCI, GRAD DEPT GENE SCI, HIROSHIMA 724, JAPAN; TEIKYO UNIV, FAC PHARMACEUT SCI, KANAGAWA 19901, JAPAN	Showa University; Tokyo Medical & Dental University (TMDU); Hiroshima University; Teikyo University				Yamamoto, Keiko/0000-0001-6642-7961				AKIYOSHISHIBATA M, 1994, EUR J BIOCHEM, V224, P335, DOI 10.1111/j.1432-1033.1994.00335.x; ANDO K, 1992, CHEM PHARM BULL, V40, P1662; ARMBRECHT HJ, 1991, FEBS LETT, V292, P17, DOI 10.1016/0014-5793(91)80823-L; Beckman MJ, 1996, BIOCHEMISTRY-US, V35, P8465, DOI 10.1021/bi960658i; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; DILWORTH FJ, 1995, J BIOL CHEM, V270, P16766, DOI 10.1074/jbc.270.28.16766; GUO YD, 1993, P NATL ACAD SCI USA, V90, P8668, DOI 10.1073/pnas.90.18.8668; HAHN CN, 1994, NUCLEIC ACIDS RES, V22, P2410, DOI 10.1093/nar/22.12.2410; HOLICK SA, 1980, BIOCHEM BIOPH RES CO, V97, P1031, DOI 10.1016/0006-291X(80)91479-5; IKEKAWA N, 1983, P NATL ACAD SCI-BIOL, V80, P5286, DOI 10.1073/pnas.80.17.5286; ISHIZUKA S, 1985, ARCH BIOCHEM BIOPHYS, V242, P82, DOI 10.1016/0003-9861(85)90482-5; ISHIZUKA S, 1985, VITAMIN D CHEM BIOCH, P402; KABAKOFF BD, 1982, ARCH BIOCHEM BIOPHYS, V215, P582, DOI 10.1016/0003-9861(82)90119-9; MAKIN G, 1989, BIOCHEM J, V262, P173, DOI 10.1042/bj2620173; MAYER E, 1983, J BIOL CHEM, V258, P3458; MIYAMOTO Y, 1995, J BIOCHEM-TOKYO, V118, P1068, DOI 10.1093/jb/118.5.1068; NISHIMURA A, 1994, ENDOCRINOLOGY, V134, P1794, DOI 10.1210/en.134.4.1794; OHYAMA Y, 1993, BIOCHEMISTRY-US, V32, P76, DOI 10.1021/bi00052a011; OHYAMA Y, 1994, J BIOL CHEM, V269, P10545; OHYAMA Y, 1991, FEBS LETT, V278, P195, DOI 10.1016/0014-5793(91)80115-J; PARTRIDGE JJ, 1981, HELV CHIM ACTA, V64, P2138, DOI 10.1002/hlca.19810640718; PARTRIDGE JJ, 1981, J AM CHEM SOC, V103, P1253, DOI 10.1021/ja00395a061; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; REDDY GS, 1987, BIOCHEMISTRY-US, V26, P324, DOI 10.1021/bi00375a045; SHIINA Y, 1983, ARCH BIOCHEM BIOPHYS, V220, P90, DOI 10.1016/0003-9861(83)90390-9; SHINKI T, 1992, J BIOL CHEM, V267, P13757; SIUCALDERA ML, 1995, ENDOCRINOLOGY, V136, P4195, DOI 10.1210/en.136.10.4195; SUDA T, 1970, BIOCHEMISTRY-US, V9, P4776, DOI 10.1021/bi00826a022; Suda T, 1994, Curr Opin Nephrol Hypertens, V3, P59, DOI 10.1097/00041552-199401000-00008; TANAKA Y, 1981, ARCH BIOCHEM BIOPHYS, V210, P104, DOI 10.1016/0003-9861(81)90169-7; USUI E, 1990, FEBS LETT, V274, P175, DOI 10.1016/0014-5793(90)81357-T; YAMADA S, 1984, J BIOL CHEM, V259, P884; YAMADA S, 1985, P NATL ACAD SCI USA, V82, P7485, DOI 10.1073/pnas.82.22.7485; YAMADA S, 1979, CHEM PHARM BULL, V27, P3196; ZIEROLD C, 1994, P NATL ACAD SCI USA, V91, P900, DOI 10.1073/pnas.91.3.900	36	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14115	14119		10.1074/jbc.272.22.14115	http://dx.doi.org/10.1074/jbc.272.22.14115			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162038	hybrid			2022-12-27	WOS:A1997XB49200025
J	Miyoshi, E; Higashiyama, S; Nakagawa, T; Hayashi, N; Taniguchi, N				Miyoshi, E; Higashiyama, S; Nakagawa, T; Hayashi, N; Taniguchi, N			Membrane-anchored heparin-binding epidermal growth factor-like growth factor acts as a tumor survival factor in a hepatoma cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN RECEPTOR; TRANSFORMING GROWTH-FACTOR-BETA-1; TRANSMEMBRANE FORM; EGF; EXPRESSION; APOPTOSIS; INHIBITION; PROTEIN; CANCER; LIGAND	Heparin-binding epidermal growth factor (EGF)-like growth factor (HE-EGF), which belongs to the EGF family, is produced as a membrane-anchored form (pro-HB-EGF) and later processed to a soluble form (sHB-EGF), It is known that high expression of pro-HB-EGF occurs in hepatoma tissues, although its biological meaning remains unknown, We established two types of hepatoma cell lines (AH66tc), which stably produce pro HB-EGF and sHB-EGF, respectively, While sHB-EGF-producing cells (sHB-AH) showed rapid growth, pro-HB-EGF-producing cells (pHB-AH) showed markedly suppressed cell growth as compared with the parental cells, Transforming growth factor beta or serum-starved conditions induced apoptosis of mock and sHB-AH as well as the parental cells, but not of pHB-AH, The resistance to apoptosis upon serum-starved treatment was correlated with an increase in the rate of the G(1) phase in the cell cycle due to up-regulation of the cyclin-dependent kinase inhibitor p21, The mechanism underlying this resistance of pHB-AH to apoptosis was thought to be related to the prolonged half-life of the EGF receptor followed by continuous phosphorylation of the tyrosine residues, These observations demonstrate a unique function of pro-HE-EGF that is not observed for the mature form and show that pro-HB-EGF may act as a tumor survival factor in hepatoma cells.	OSAKA UNIV,SCH MED,DEPT BIOCHEM,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT MED 1,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University			Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016	Taniguchi, Naoyuki/0000-0001-5889-5968; 				ABRAHAM JA, 1993, BIOCHEM BIOPH RES CO, V190, P125, DOI 10.1006/bbrc.1993.1020; BEDI A, 1995, CANCER RES, V55, P1811; Bosenberg MW, 1993, CURR OPIN CELL BIOL, V5, P832, DOI 10.1016/0955-0674(93)90032-L; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUANG LY, 1994, ANTICANCER RES, V14, P147; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FAN Z, 1993, J BIOL CHEM, V268, P21073; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FUKUDA K, 1993, HEPATOLOGY, V18, P945, DOI 10.1002/hep.1840180428; GILL GN, 1981, NATURE, V293, P305, DOI 10.1038/293305a0; GILLIGAN A, 1992, EXP CELL RES, V200, P235, DOI 10.1016/0014-4827(92)90169-9; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; GROSS ME, 1991, CANCER RES, V51, P1452; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HIGASHIYAMA SHIGA, 1995, J CELL BIOL, V1281, P929; HOOPI K, 1994, ONCOGENE, V9, P3017; INUI Y, 1994, GASTROENTEROLOGY, V107, P1799, DOI 10.1016/0016-5085(94)90823-0; KATSUTA H, 1973, J NATL CANCER I, V51, P1841, DOI 10.1093/jnci/51.6.1841; KLIJN JGM, 1992, ENDOCR REV, V13, P3, DOI 10.1210/er.13.1.3; Kurosawa K, 1996, BLOOD, V87, P2235, DOI 10.1182/blood.V87.6.2235.bloodjournal8762235; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; MIYAGAWA J, 1995, J CLIN INVEST, V95, P404, DOI 10.1172/JCI117669; MIYAZAWA K, 1995, BLOOD, V85, P641, DOI 10.1182/blood.V85.3.641.bloodjournal853641; MIYOSHI E, 1996, INT J CANCER, V68, P21552; MURAYAMA Y, 1995, GASTROENTEROLOGY, V109, P1051, DOI 10.1016/0016-5085(95)90562-6; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; Sambrook J., 2002, MOL CLONING LAB MANU; SCAMBIA G, 1992, J CLIN ONCOL, V10, P529, DOI 10.1200/JCO.1992.10.4.529; SPORN MB, 1991, PEPTIDE GORWTH FACTO, V1, P69; THOMPSON SA, 1994, J BIOL CHEM, V269, P2541; VAUGHAN TJ, 1992, BIOCHEM J, V287, P681, DOI 10.1042/bj2870681; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	38	65	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14349	14355		10.1074/jbc.272.22.14349	http://dx.doi.org/10.1074/jbc.272.22.14349			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162071	hybrid			2022-12-27	WOS:A1997XB49200058
J	Fang, XJ; Gibson, S; Flowers, M; Furui, T; Bast, RC; Mills, GB				Fang, XJ; Gibson, S; Flowers, M; Furui, T; Bast, RC; Mills, GB			Lysophosphatidylcholine stimulates activator protein 1 and the c-Jun N-terminal kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; AORTIC ENDOTHELIAL-CELLS; SIGNAL-TRANSDUCTION PATHWAY; LYMPHOCYTE-T ACTIVATION; EPIDERMAL GROWTH-FACTOR; SMOOTH-MUSCLE CELLS; MAP KINASE; MAMMALIAN-CELLS; PHOSPHATIDYLCHOLINE HYDROLYSIS; PHOSPHOLIPASE-A2 ACTIVITY	Lysophosphatidylcholine (lyso-PC), a natural lipid generated through the action of phospholipase A(2) on membrane phosphatidylcholine, has been implicated in atherogenesis and the inflammatory process. In vitro studies have established a role for lyso-PC in modulation of gene expression and other cellular responses including differentiation and proliferation. There is also evidence that lyso-PC may act as an intracellular second messenger transducing signals elicited from membrane-associated receptors. The mechanisms behind the diverse activities of lyso-PC are poorly understood. We report, in this study, that treatment of cultured cells with exogenous lyso-PC, at nontoxic concentrations, potently induced activator protein-1 (AP-1) DNA binding and transcriptional activity independent of well known AP-I activators, protein kinase C or mitogen-activated protein kinases ERK1 and ERK2. Lyso-PC also activated the c-Jun N-terminal kinase (JNK/SAPK), a recently characterized member of the mitogen-activated protein kinase family, known to activate AP-1. The stimulated JNK and AP-1 activities probably mediate or contribute to some bioactive effects of lyso-PC.	UNIV TEXAS,MD ANDERSON CANCER CTR,DIV MED,HOUSTON,TX 77030; UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO,ON M5G 1L5,CANADA; UNIV TORONTO,TORONTO GEN HOSP,DEPT MED,TORONTO,ON M5G 1L7,CANADA	University of Texas System; UTMD Anderson Cancer Center; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital			Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462; Gibson, Spencer/0000-0003-0119-732X	NCI NIH HHS [CA 64602] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA064602] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ANDREATTAVANLEYEN S, 1993, KIDNEY INT, V44, P932, DOI 10.1038/ki.1993.334; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ASAOKA Y, 1992, P NATL ACAD SCI USA, V89, P6447, DOI 10.1073/pnas.89.14.6447; ASAOKA Y, 1993, P NATL ACAD SCI USA, V90, P716, DOI 10.1073/pnas.90.2.716; ASAOKA Y, 1993, P NATL ACAD SCI USA, V90, P4917, DOI 10.1073/pnas.90.11.4917; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Chai YC, 1996, J BIOL CHEM, V271, P17791, DOI 10.1074/jbc.271.30.17791; CHEN Y, 1995, ATHEROSCLEROSIS, V112, P69, DOI 10.1016/0021-9150(94)05400-D; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CURRIE S, 1992, J BIOL CHEM, V267, P6056; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIMITRIJEVIC SM, 1995, MOL PHARMACOL, V48, P259; DUDEK R, 1993, P SOC EXP BIOL MED, V203, P474; Flowers MA, 1995, AM J PHYSIOL-HEART C, V269, pH1988, DOI 10.1152/ajpheart.1995.269.6.H1988; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HIRATA K, 1995, CIRC RES, V76, P958, DOI 10.1161/01.RES.76.6.958; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; INOUE N, 1992, CIRC RES, V71, P1410, DOI 10.1161/01.RES.71.6.1410; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KUGIYAMA K, 1992, CIRC RES, V71, P1422, DOI 10.1161/01.RES.71.6.1422; KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; KUME N, 1994, J CLIN INVEST, V93, P907, DOI 10.1172/JCI117047; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LOKUTA AJ, 1994, J BIOL CHEM, V269, P4832; MCHOWAT J, 1993, J BIOL CHEM, V268, P15605; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; NAKANO T, 1994, P NATL ACAD SCI USA, V91, P1069, DOI 10.1073/pnas.91.3.1069; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; NISHIJIMA J, 1989, BIOCHEMISTRY-US, V28, P2902, DOI 10.1021/bi00433a023; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHARA Y, 1994, ARTERIOSCLER THROMB, V14, P1007, DOI 10.1161/01.ATV.14.6.1007; PARK TH, 1994, CARDIOVASC RES, V28, P1263, DOI 10.1093/cvr/28.8.1263; PARTHASARATHY S, 1985, P NATL ACAD SCI USA, V82, P3000, DOI 10.1073/pnas.82.9.3000; PHILLIPSON DW, 1993, J LIPID MEDIATOR, V7, P155; PONZONI M, 1992, FEBS LETT, V310, P17, DOI 10.1016/0014-5793(92)81136-A; PORTMAN OW, 1969, J LIPID RES, V10, P158; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; QUINN MT, 1991, BIOCHIM BIOPHYS ACTA, P293; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SAITO T, 1992, JPN J PHARMACOL, V58, P340; SAKAI M, 1994, J BIOL CHEM, V269, P31430; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SU Z, 1995, CARDIOSCIENCE, V6, P31; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VADAS P, 1986, LAB INVEST, V55, P391; VIDAVER GA, 1985, J THEOR BIOL, V115, P27, DOI 10.1016/S0022-5193(85)80005-9; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YOSHIMASA T, 1992, FEBS LETT, V311, P195, DOI 10.1016/0014-5793(92)81100-Z; ZEMBOWICZ A, 1995, J CLIN INVEST, V96, P1688, DOI 10.1172/JCI118211; ZEMBOWICZ A, 1995, J BIOL CHEM, V270, P17006, DOI 10.1074/jbc.270.28.17006; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	68	70	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13683	13689		10.1074/jbc.272.21.13683	http://dx.doi.org/10.1074/jbc.272.21.13683			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153219	hybrid			2022-12-27	WOS:A1997XA06200034
J	Favre, B; Turowski, P; Hemmings, BA				Favre, B; Turowski, P; Hemmings, BA			Differential inhibition and posttranslational modification of protein phosphatase 1 and 2A in MCF7 cells treated with calyculin-A, okadaic acid, and tautomycine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; CATALYTIC SUBUNIT; SMOOTH-MUSCLE; CARBOXYL-TERMINUS; MICROCYSTIN-LR; BOVINE BRAIN; PHOSPHORYLATION; SERINE; IDENTIFICATION; EXPRESSION	Calyculin-A (CA), okadaic acid (OA), and tautomycin (TAU) are potent inhibitors of protein phosphatases 1 (PP1) and 2A (PP2A) and are widely used on cells in culture. Despite their well characterized selectivity in vitro, their exact intracellular effects on PP1 and PP2A cannot be directly deduced from their extracellular concentration because their cell permeation properties are not known. Here we demonstrate that, due to the tight binding of the inhibitors to PP1 and/or PP2A, their cell penetration could be monitored by measuring PP1 and PP2A activities in cell-free extracts. Treatment of MCF7 cells with 10 nM CA for 2 h simultaneously inhibited PP1 and PP2A activities by more than 50%. A concentration of 1 mu M OA was required to obtain a similar time course of PP2A inhibition in MCF7 cells to that observed with 10 nM CA, whereas PP1 activity was unaffected. PP1 was predominantly inhibited in MCF7 cells treated with TAU but even at 10 mu M TAU PP1 inhibition was much slower than that observed with 10 nM CA. Furthermore, binding of inhibitors to PP2Ac and/or PP1c in MCF7 cells led to differential posttranslational modifications of the carboxyl termini of the proteins as demonstrated by Western blotting. OA and CA, in contrast to TAU, induced demethylation of the carboxyl-terminal Leu(309) residue of PP2Ac. On the other hand, CA and TAU, in contrast to OA, elicited a marked decrease in immunoreactivity of the carboxyl terminus of the cu-isoform of PP1c, probably reflecting proteolysis of the protein. These results suggest that in MCF7 cells OA selectively inhibits PP2A and TAU predominantly affects PP1, a conclusion supported by their differential effects on cytokeratins in this cell line.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research								ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; BECKER W, 1994, J BIOL CHEM, V269, P22586; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; CHEN J, 1994, J BIOL CHEM, V269, P7957; COHEN P, 1988, METHOD ENZYMOL, V159, P427; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN P, 1988, METHOD ENZYMOL, V159, P390; COHEN PTW, 1993, BIOCHEM SOC T, V21, P884, DOI 10.1042/bst0210884; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; ERIKSSON JE, 1992, P NATL ACAD SCI USA, V89, P11093, DOI 10.1073/pnas.89.22.11093; ETO M, 1995, J BIOCHEM, V118, P1104, DOI 10.1093/oxfordjournals.jbchem.a124993; FAVRE B, 1994, J BIOL CHEM, V269, P16311; FUJIKI H, 1993, ADV CANCER RES, V61, P143, DOI 10.1016/S0065-230X(08)60958-6; Fukuda H, 1996, BIOCHEM BIOPH RES CO, V220, P160, DOI 10.1006/bbrc.1996.0374; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GONG MC, 1992, J BIOL CHEM, V267, P14662; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; GUY GR, 1993, J BIOL CHEM, V268, P2141; Ho DT, 1996, CARCINOGENESIS, V17, P967, DOI 10.1093/carcin/17.5.967; HONKANEN RE, 1991, J BIOL CHEM, V266, P6614; HORI M, 1991, FEBS LETT, V285, P145, DOI 10.1016/0014-5793(91)80745-O; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; KASAHARA K, 1993, J BIOL CHEM, V268, P23531; KHEWGOODALL Y, 1988, FEBS LETT, V238, P265, DOI 10.1016/0014-5793(88)80493-9; Kowluru A, 1996, ENDOCRINOLOGY, V137, P2315, DOI 10.1210/en.137.6.2315; LEE J, 1993, J BIOL CHEM, V268, P19192; Lee J, 1996, P NATL ACAD SCI USA, V93, P6043, DOI 10.1073/pnas.93.12.6043; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; LI M, 1994, BIOCHEM BIOPH RES CO, V202, P1023, DOI 10.1006/bbrc.1994.2031; LI YM, 1992, P NATL ACAD SCI USA, V89, P11867, DOI 10.1073/pnas.89.24.11867; Liu Y, 1996, J BIOCHEM-TOKYO, V119, P1004, DOI 10.1093/oxfordjournals.jbchem.a021315; MARTIN BL, 1991, FEBS LETT, V285, P6, DOI 10.1016/0014-5793(91)80712-C; MATSUZAWA S, 1994, FEBS LETT, V356, P272, DOI 10.1016/0014-5793(94)01281-4; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NAM KY, 1990, CARCINOGENESIS, V11, P1171, DOI 10.1093/carcin/11.7.1171; NAMBOODIRIPAD AN, 1996, AM J PHYSIOL, V39, pC449; OLIVIER AR, 1990, J BIOL CHEM, V265, P22460; PUNTONI F, 1995, BIOCHEM BIOPH RES CO, V207, P732, DOI 10.1006/bbrc.1995.1248; SACHER MG, 1994, J BIOL CHEM, V269, P18480; SAITO T, 1995, BIOCHEMISTRY-US, V34, P7376, DOI 10.1021/bi00022a010; SASAKI K, 1990, JPN J CANCER RES, V81, P1272, DOI 10.1111/j.1349-7006.1990.tb02690.x; Shin HJ, 1996, TETRAHEDRON, V52, P8159, DOI 10.1016/0040-4020(96)00377-8; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; TAKAI A, 1995, BIOCHEM J, V306, P657, DOI 10.1042/bj3060657; TAKIZAWA N, 1994, J BIOCHEM-TOKYO, V116, P411, DOI 10.1093/oxfordjournals.jbchem.a124540; Tanabe O, 1996, FEBS LETT, V379, P107, DOI 10.1016/0014-5793(95)01500-0; Tehrani MA, 1996, J BIOL CHEM, V271, P5164; TOVIOLA DM, 1997, J CELL SCI, V110, P23; TULLOCH AG, 1991, J BIOL CHEM, V266, P20168; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; VANDOLAH FM, 1992, J CELL PHYSIOL, V152, P190, DOI 10.1002/jcp.1041520124; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; XIE HY, 1994, BIOCHEM BIOPH RES CO, V203, P1710, DOI 10.1006/bbrc.1994.2383; XIE HY, 1994, J BIOL CHEM, V269, P1981; YAMANO H, 1994, EMBO J, V13, P5310, DOI 10.1002/j.1460-2075.1994.tb06865.x; YATSUNAMI J, 1993, CANCER RES, V53, P992; ZHANG ZJ, 1994, J BIOL CHEM, V269, P13766; Zolnierowicz S, 1996, BIOCHEM J, V317, P187, DOI 10.1042/bj3170187	63	268	278	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13856	13863		10.1074/jbc.272.21.13856	http://dx.doi.org/10.1074/jbc.272.21.13856			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153244	hybrid			2022-12-27	WOS:A1997XA06200059
J	Rossi, V; Motto, M; Pellegrini, L				Rossi, V; Motto, M; Pellegrini, L			Analysis of the methylation pattern of the maize opaque-2 (O2) promoter and in vitro binding studies indicate that the O2 b-Zip protein and other endosperm factors can bind to methylated target sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY LOCUS OPAQUE-2; MOLECULAR ANALYSIS; TRANSCRIPTIONAL ACTIVATOR; TRANSPOSABLE ELEMENT; GENE-EXPRESSION; DNA METHYLATION; ENCODES; PHOSPHORYLATION; RECOGNIZES; MUTATION	The maize opaque-2 locus (o2) has an endosperm-specific expression and is positively autoregulated by its gene product, a b-Zip protein, to a TGACGTTG motif. The genomic sequencing method was used here to describe, in leaf and endosperm, the methylation pattern of a 390-base pair region of the o2 promoter. In leaf, 96% of the C residues are methylated, whereas in endosperm the 5-methylcytosine content is 84%. Comparison of these methylation patterns indicates that the o2 tissue-specific expression does not result from the demethylation of any specific C residue and that, in vivo, O2 interacts with a methylated target sequence. Consistently, gel-shift experiments using a CpG-methylated, partially methylated, and hemimethylated o2 promoter fragments showed that, in vitro, the O2 protein binds to the major groove of a methylated target sequence, although its binding activity decreases at increasing levels of C-methylation and is more effectively reduced by methylation of the lower strand than of the upper strand of the DNA. Using partially purified endosperm cell extracts, we also show that, besides the O2 protein, other proteins specifically bind to a partially methylated o2 promoter fragment, therefore indicating that in plants a subset of different proteins may mediate the expression of a naturally occurring methylated o2 promoter.	IST SPERIMENTALE CEREALICOLTURA,I-24123 BERGAMO,ITALY	Consiglio per la Ricerca in Agricoltura e L'analisi Dell'economia Agraria (CREA)			Rossi, Vincenzo/ABC-9786-2020	Pellegrini, Luca/0000-0002-4235-7708				ANTEQUERA F, 1988, EMBO J, V7, P2295, DOI 10.1002/j.1460-2075.1988.tb03072.x; AUKERMAN MJ, 1993, PLANT MOL BIOL, V21, P355, DOI 10.1007/BF00019950; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Ciceri P, 1997, PLANT CELL, V9, P97, DOI 10.1105/tpc.9.1.97; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; DEPATER S, 1994, PLANT J, V6, P133, DOI 10.1046/j.1365-313X.1994.6020133.x; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; Fedoroff N. V., 1994, Homologous recombination and gene silencing in plants., P349; FLAVELL RB, 1994, P NATL ACAD SCI USA, V91, P3490, DOI 10.1073/pnas.91.9.3490; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; HARTINGS H, 1989, EMBO J, V8, P2795, DOI 10.1002/j.1460-2075.1989.tb08425.x; HARTINGS H, 1995, GENET RES, V65, P11, DOI 10.1017/S0016672300032961; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; INAMDAR NM, 1991, PLANT MOL BIOL, V17, P111, DOI 10.1007/BF00036811; IZAWA T, 1993, J MOL BIOL, V230, P1131, DOI 10.1006/jmbi.1993.1230; KLIMCZAK LJ, 1992, PLANT CELL, V4, P87, DOI 10.1105/tpc.4.1.87; KUNZE R, 1989, EMBO J, V8, P3177, DOI 10.1002/j.1460-2075.1989.tb08476.x; LOHMER S, 1991, EMBO J, V10, P617, DOI 10.1002/j.1460-2075.1991.tb07989.x; LOHMER S, 1993, PLANT CELL, V10, P617; MARTIENSSEN RA, 1995, CURR OPIN GENET DEV, V5, P234, DOI 10.1016/0959-437X(95)80014-X; MATZKE M, 1993, ANNU REV PLANT PHYS, V44, P53, DOI 10.1146/annurev.pp.44.060193.000413; MATZKE MA, 1995, PLANT PHYSIOL, V107, P679, DOI 10.1104/pp.107.3.679; MEYER P, 1994, EMBO J, V13, P2084, DOI 10.1002/j.1460-2075.1994.tb06483.x; MOTTO M, 1988, MOL GEN GENET, V212, P488, DOI 10.1007/BF00330854; MOTTO M, 1997, CELLULAR MOL BIOL PL; Nantel A, 1996, J BIOL CHEM, V271, P31296, DOI 10.1074/jbc.271.49.31296; NIGHTINGALE K, 1995, J BIOL CHEM, V270, P4197, DOI 10.1074/jbc.270.9.4197; Park YD, 1996, PLANT J, V9, P183, DOI 10.1046/j.1365-313X.1996.09020183.x; PELLEGRINI L, 1994, PLANT PHYSIOL, V106, P877, DOI 10.1104/pp.106.3.877; RAMACHANDRAN S, 1994, CURR OPIN GENET DEV, V4, P642, DOI 10.1016/0959-437X(94)90129-Q; ROMEMUS MJ, 1996, SCIENCE, V273, P654; RONCHI A, 1995, EMBO J, V14, P5318, DOI 10.1002/j.1460-2075.1995.tb00216.x; SCHENA M, 1993, GENE DEV, V7, P367, DOI 10.1101/gad.7.3.367; SCHLAPPI M, 1994, CELL, V77, P427, DOI 10.1016/0092-8674(94)90157-0; SCHMIDT RJ, 1987, SCIENCE, V238, P960, DOI 10.1126/science.2823388; SCHMIDT RJ, 1990, P NATL ACAD SCI USA, V87, P46, DOI 10.1073/pnas.87.1.46; SCHMIDT RJ, 1992, PLANT CELL, V4, P689, DOI 10.1105/tpc.4.6.689; SELKER EU, 1993, SCIENCE, V262, P1724, DOI 10.1126/science.8259516; STAIGER D, 1989, P NATL ACAD SCI USA, V86, P6930, DOI 10.1073/pnas.86.18.6930; TAYLOR JD, 1994, DNA PROTEIN INTERACT, P263; tenLohuis M, 1995, PLANT J, V8, P919, DOI 10.1046/j.1365-313X.1995.8060919.x; TONELLI C, 1991, MOL GEN GENET, V225, P401, DOI 10.1007/BF00261680; UEDA T, 1992, PLANT CELL, V4, P701, DOI 10.1105/tpc.4.6.701; Wang LH, 1996, PLANT CELL, V8, P747, DOI 10.1105/tpc.8.4.747; YUNES JA, 1994, PLANT CELL, V6, P237, DOI 10.1105/tpc.6.2.237	45	42	59	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13758	13765		10.1074/jbc.272.21.13758	http://dx.doi.org/10.1074/jbc.272.21.13758			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153230	hybrid			2022-12-27	WOS:A1997XA06200045
J	Wayman, GA; Tokumitsu, H; Soderling, TR				Wayman, GA; Tokumitsu, H; Soderling, TR			Inhibitory cross-talk by cAMP kinase on the calmodulin-dependent protein kinase cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; BRAIN CALMODULIN; IV KINASE; PHOSPHORYLATION; REQUIREMENT; ACTIVATION; EXPRESSION	The calmodulin-dependent kinase (CaM-K) cascade, a Ca2+-triggered system involving phosphorylation and activation of CaM-KI and CaM-KIV by CaM kinase kinase (CaM-KK), regulates transcription through direct phosphorylation of transcription factors such as cAMP response element-binding protein, We have shown previously that activated CaM-KIV can activate the mitogen-activated protein kinases (Enslen, H., Tokumitsu, H., Stork, P. J. S., Davis, R. J., and Soderling, T. R. (1996) Proc. Natl., Acad. Sci. U. S. A. 93, 10803-10808), and the present paper describes a novel regulatory cross-talk between cAMP kinase (PKA) and CaM-KK. PKA gave rapid phosphorylation in vitro and in cells of recombinant CaM-KK, resulting in 50-75% inhibition of CaM-KK activity, part of which was due to suppression of CaM-binding by phosphorylation of Ser(458) in the CaM-binding domain, However, the Ser(458) --> Ala mutant, or a truncation mutant in which the CaM-binding and autoinhibitory domains were deleted, was still partially suppressed by PKA-mediated phosphorylation, The second inhibitory site was identified as Thr(108) by site-specific mutagenesis, Treatments of COS-7, PC12, hippocampal, or Jurkat cells with the PKA activators forskolin or isoproterenol gave 30-90% inhibition of either endogenous or transfected CaM-KK and/or CaM-KIV activities. These results demonstrate that the CaM kinase cascade is negatively regulated in cells by the cAMP/PKA pathway.	OREGON HLTH SCI UNIV,VOLLUM INST L 474,PORTLAND,OR 97201	Oregon Health & Science University			Tokumitsu, Hiroshi/M-3978-2015	Tokumitsu, Hiroshi/0000-0002-2193-6794	NIDDK NIH HHS [DK07674] Funding Source: Medline; NIGMS NIH HHS [GM41292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007674] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aletta JM, 1996, J BIOL CHEM, V271, P20930, DOI 10.1074/jbc.271.34.20930; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; CHENG HC, 1986, J BIOL CHEM, V261, P989; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; CONTI MA, 1981, J BIOL CHEM, V256, P3178; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; ENSLEN H, 1995, BIOCHEM BIOPH RES CO, V207, P1038, DOI 10.1006/bbrc.1995.1289; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HASHIMOTO Y, 1989, J BIOL CHEM, V264, P10884; KAMESHITA I, 1991, BIOCHEM BIOPH RES CO, V180, P191, DOI 10.1016/S0006-291X(05)81275-6; KAMESHITA I, 1993, J BIOCHEM-TOKYO, V113, P583, DOI 10.1093/oxfordjournals.jbchem.a124087; LEE JSC, 1994, J BIOL CHEM, V269, P2158; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SHARMA RK, 1985, P NATL ACAD SCI USA, V82, P2603, DOI 10.1073/pnas.82.9.2603; Soderling TR, 1996, BBA-PROTEIN STRUCT M, V1297, P131, DOI 10.1016/S0167-4838(96)00105-7; TAN SE, 1994, J NEUROSCI, V14, P1123, DOI 10.1523/JNEUROSCI.14-03-01123.1994; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; WAYMAN GA, 1995, J BIOL CHEM, V270, P21480, DOI 10.1074/jbc.270.37.21480; Wayman GA, 1996, MOL CELL BIOL, V16, P6075	28	80	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16073	16076		10.1074/jbc.272.26.16073	http://dx.doi.org/10.1074/jbc.272.26.16073			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195898	hybrid			2022-12-27	WOS:A1997XG01900002
J	Kemper, MA; Stout, CD; Lloyd, SEJ; Prasad, GS; Fawcett, S; Armstrong, FA; Shen, BH; Burgess, BK				Kemper, MA; Stout, CD; Lloyd, SEJ; Prasad, GS; Fawcett, S; Armstrong, FA; Shen, BH; Burgess, BK			Y13C Azotobacter vinelandii Ferredoxin I - A designed [Fe-S] ligand motif contains a cysteine persulfide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; IRON-SULFUR PROTEINS; 3FE-4S CLUSTER; 4FE-4S CLUSTER; RESOLUTION; REARRANGEMENT; PURIFICATION; NITROGENASE; REFINEMENT; REACTIVITY	Ferredoxins that contain [4Fe-4S](2+/+) clusters often obtain three of their four cysteine ligands from a highly conserved CysXXCysXXCys sequence motif. Little is known about the in vitro assembly of these clusters and the role that this sequence motif plays in that process, In this study, we have used structure as a guide in attempts to direct the formation of a [4Fe-4S](2+/+) in the [3Fe-4S](+/0) location of native (7Fe) Azotobacter vinelandii ferredoxin I (AvFdI) by providing the correct three-dimensional orientation of cysteine ligands without introducing a CysXXCysXXCys motif. Tyr(13) of AvFdr occupies the position of the fourth ligating cysteine in the homologous and structurally characterized 8Fe ferredoxin from Peptococcus aerogenes and a Y13C variant of AvFdI could be easily modeled as an 8Fe protein, However, characterization of purified Y13C FdI by UV-visible spectra, circular dichroism, electron paramagnetic resonance spectroscopies, and by x-fay crystallography revealed that the protein failed to use the introduced cysteine as a ligand and retained its [3Fe-4S](+/0) cluster. Further, electrochemical characterization showed that the redox potential and pH behavior of the cluster were unaffected by the substitution of Tyr by Cys, Although Y13C FdI is functional in vivo it does differ significantly from native FdI in that it is extremely unstable in the reduced state possibly due to increased solvent exposure of the [3Fe-4S](0) cluster. Surprisingly, the rr-ray structure showed that the introduced cysteine was modified to become a persulfide, This modification may have occurred in vivo via the action of NifS, which is known to be expressed under the growth conditions used. It is interesting to note that neither of the two free cysteines present in FdI was modified, Thus, if NiFS is involved in modifying the introduced cysteine there must be specificity to the reaction.	UNIV CALIF IRVINE, DEPT BIOCHEM & MOL BIOL, IRVINE, CA 92697 USA; SCRIPPS RES INST, DEPT BIOL MOL, LA JOLLA, CA 92037 USA; UNIV OXFORD, DEPT CHEM, OXFORD, ENGLAND	University of California System; University of California Irvine; Scripps Research Institute; University of Oxford				Shen, Binghui/0000-0002-4408-407X	NIGMS NIH HHS [GM48495, GM-45209, GM-36325] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048495, R01GM036325, R01GM045209] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADMAN ET, 1976, J BIOL CHEM, V251, P3801; ADMAN ET, 1973, J BIOL CHEM, V248, P3987; ARMSTRONG FA, 1992, ADV INORG CHEM, V38, P117, DOI 10.1016/S0898-8838(08)60063-X; BACKES G, 1991, J AM CHEM SOC, V113, P2055, DOI 10.1021/ja00006a027; BEINERT H, 1990, FASEB J, V4, P2483, DOI 10.1096/fasebj.4.8.2185975; BRIGGS RG, 1978, BIOCHIM BIOPHYS ACTA, V537, P100, DOI 10.1016/0005-2795(78)90606-2; BRUSCHI M, 1988, FEMS MICROBIOL LETT, V54, P155, DOI 10.1111/j.1574-6968.1988.tb02741.x; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BUTT JN, 1991, J AM CHEM SOC, V113, P6663, DOI 10.1021/ja00017a045; BUTT JN, 1993, J AM CHEM SOC, V115, P12587, DOI 10.1021/ja00079a049; Duff JLC, 1996, J AM CHEM SOC, V118, P8593, DOI 10.1021/ja961465l; HONG JS, 1970, J BIOL CHEM, V245, P4982; HONG JS, 1967, BIOCHEM BIOPH RES CO, V29, P246, DOI 10.1016/0006-291X(67)90595-5; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HOWARD JB, 1991, ADV PROTEIN CHEM, V42, P199; HU ZG, 1994, BIOCHEMISTRY-US, V33, P14475, DOI 10.1021/bi00252a014; IISMAA SE, 1991, J BIOL CHEM, V266, P21563; ISAS JM, 1994, J BIOL CHEM, V269, P19404; ISAS JM, 1995, J BIOL CHEM, V270, P21258, DOI 10.1074/jbc.270.36.21258; JOHNSON MK, 1994, ENCY INORGANIC CHEM, V4, P1896; KARPLUS AT, 1989, ACTA CRYSTALLOGR A, V45, P50; KISSINGER CR, 1991, J MOL BIOL, V219, P693, DOI 10.1016/0022-2836(91)90665-S; LINDAHL PA, 1990, J CLUST SCI, V1, P29; MARTIN AE, 1989, J BACTERIOL, V171, P3162, DOI 10.1128/jb.171.6.3162-3167.1989; MARTIN AE, 1990, P NATL ACAD SCI USA, V87, P598, DOI 10.1073/pnas.87.2.598; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MERRITT EA, 1993, ACTA CRYSTALLOGR D, V49, P272, DOI 10.1107/S0907444992007248; MORGAN TV, 1988, J BIOL CHEM, V263, P1370; Moulis JM, 1996, J BIOL INORG CHEM, V1, P2, DOI 10.1007/s007750050017; PANTOLIANO MW, 1989, BIOCHEMISTRY-US, V28, P7205, DOI 10.1021/bi00444a012; PLOEGMAN JH, 1979, J MOL BIOL, V127, P149, DOI 10.1016/0022-2836(79)90236-5; SHEN B, 1995, P NATL ACAD SCI USA, V92, P10064, DOI 10.1073/pnas.92.22.10064; SHEN BH, 1994, J BIOL CHEM, V269, P8564; SHEN BH, 1993, J BIOL CHEM, V268, P25928; STEPHENS PJ, 1991, BIOCHEMISTRY-US, V30, P3200, DOI 10.1021/bi00227a007; STOUT CD, 1988, J BIOL CHEM, V263, P9256; STOUT CD, 1989, J MOL BIOL, V205, P545, DOI 10.1016/0022-2836(89)90225-8; STOUT GH, 1988, P NATL ACAD SCI USA, V85, P1020, DOI 10.1073/pnas.85.4.1020; STURA EA, 1994, ACTA CRYSTALLOGR D, V50, P448, DOI 10.1107/S0907444994001794; VASQUEZ A, 1994, PROTEIN EXPRES PURIF, V5, P96; ZHENG LM, 1994, J BIOL CHEM, V269, P18723; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031	42	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15620	15627		10.1074/jbc.272.25.15620	http://dx.doi.org/10.1074/jbc.272.25.15620			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188450	hybrid			2022-12-27	WOS:A1997XF32900010
J	Inoue, K; Ito, S; Takai, D; Soejima, A; Shisa, H; LePecq, JB; SegalBendirdjian, E; Kagawa, Y; Hayashi, JI				Inoue, K; Ito, S; Takai, D; Soejima, A; Shisa, H; LePecq, JB; SegalBendirdjian, E; Kagawa, Y; Hayashi, JI			Isolation of mitochondrial DNA-less mouse cell lines and their application for trapping mouse synaptosomal mitochondrial DNA with deletion mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOME INVOLVEMENT; PROTEIN-SYNTHESIS; HYBRID-CELLS; HELA-CELLS; TUMORIGENICITY; EXPRESSION; INCREASE; NUCLEAR; SEGREGATION; DYSFUNCTION	For isolation of mouse mtDNA-less (rho(0)) cell lines, we searched for various antimitochondrial drugs that were expected to decrease the mtDNA content and found that treatment with ditercalinium, an antitumor bis-intercalating agent, was extremely effective for completely excluding mtDNA in all the mouse cell lines we tested. The resulting rho(0) mouse cells were successfully used for trapping the mtDNA of living nerve cells into dividing cultured cells by fusion of the rho(0) cells with mouse brain synaptosomes, which represent synaptic endings isolated from nerve cells, With neuronal mtDNA obtained, all of the cybrid clones restored mitochondrial translation activity similarly regardless of whether the mtDNA was derived from young or aged mice, thus at least suggesting that defects in mitochondrial genomes are not involved in the age-associated mitochondrial dysfunction observed in the brain of aged mice, Furthermore, we could trap a very small amount of a common 5823-base pair deletion mutant mtDNA (Delta mtDNA(5823)) that was detectable by polymerase chain reaction in the cybrid clones. As the amount of mutant mtDNA with large scale deletions was expected to increase during prolonged cultivation of the cybrids, these cells should be available for establishment of mice containing the deletion mutant mtDNA.	UNIV TSUKUBA,INST BIOL SCI,TSUKUBA,IBARAKI 305,JAPAN; SAITAMA CANC CTR,RES INST,DEPT PATHOL,INA,SAITAMA 362,JAPAN; INST GUSTAVE ROUSSY,F-94805 VILLEJUIF,FRANCE; RHONE POULENC RORER,CTR RECH VITRY ALFORTVILLE,F-94403 VITRY SUR SEINE,FRANCE; JICHI MED SCH,DEPT BIOCHEM,MINAMI KAWACHI,TOCHIGI 32904,JAPAN	University of Tsukuba; UNICANCER; Gustave Roussy; Sanofi-Aventis; Sanofi France; Jichi Medical University				Segal-Bendirdjian, Evelyne/0000-0001-9813-4880				ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; CHEN CH, 1989, J BIOL CHEM, V264, P11934; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CLARK MA, 1982, P NATL ACAD SCI-BIOL, V79, P1144, DOI 10.1073/pnas.79.4.1144; CLAYTON DA, 1984, ANNU REV BIOCHEM, V53, P573; CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324; CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927; DESJARDINS P, 1986, SOMAT CELL MOLEC GEN, V12, P133, DOI 10.1007/BF01560660; EIZIRIK DL, 1991, BIOCHEM PHARMACOL, V42, P2275, DOI 10.1016/0006-2952(91)90230-3; HAYASHI J, 1990, BIOCHEM BIOPH RES CO, V167, P216, DOI 10.1016/0006-291X(90)91753-F; HAYASHI JI, 1986, CANCER RES, V46, P4001; HAYASHI JI, 1989, CANCER RES, V49, P4715; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HAYASHI JI, 1982, SOMAT CELL GENET, V8, P67, DOI 10.1007/BF01538651; HAYASHI JI, 1994, J BIOL CHEM, V269, P19060; HAYASHI JI, 1983, EXP CELL RES, V147, P51, DOI 10.1016/0014-4827(83)90270-7; HAYASHI JI, 1994, J BIOL CHEM, V269, P6878; HAYASHI JI, 1992, SOMAT CELL MOLEC GEN, V18, P123, DOI 10.1007/BF01233159; HAYASHI JI, 1994, J CELL BIOL, V125, P43, DOI 10.1083/jcb.125.1.43; IKEBE S, 1990, BIOCHEM BIOPH RES CO, V170, P1044, DOI 10.1016/0006-291X(90)90497-B; Inoue K, 1996, BIOCHEM BIOPH RES CO, V223, P496, DOI 10.1006/bbrc.1996.0923; IWAKURA Y, 1985, CELL, V43, P777, DOI 10.1016/0092-8674(85)90251-X; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055; LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; MIQUEL J, 1991, ARCH GERONTOL GERIAT, V12, P99, DOI 10.1016/0167-4943(91)90022-I; OLIVER NA, 1982, MOL CELL BIOL, V2, P30, DOI 10.1128/MCB.2.1.30; SEGALBENDIRDJIAN E, 1988, CANCER RES, V48, P4982; SHAY JW, 1987, MUTAT RES, V186, P149, DOI 10.1016/0165-1110(87)90028-5; SHAY JW, 1977, P NATL ACAD SCI USA, V74, P2461, DOI 10.1073/pnas.74.6.2461; Soejima A, 1996, J BIOL CHEM, V271, P26194, DOI 10.1074/jbc.271.42.26194; Takai D, 1997, J BIOL CHEM, V272, P6028, DOI 10.1074/jbc.272.9.6028; Takai D, 1995, BIOCHEM BIOPH RES CO, V217, P668, DOI 10.1006/bbrc.1995.2826; TROUNCE I, 1994, P NATL ACAD SCI USA, V91, P8334, DOI 10.1073/pnas.91.18.8334; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE DC, 1975, J CELL BIOL, V67, P174, DOI 10.1083/jcb.67.1.174; ZHANG CF, 1993, BIOCHEM BIOPH RES CO, V195, P1104, DOI 10.1006/bbrc.1993.2158; ZIEGLER ML, 1981, SOMAT CELL GENET, V7, P73, DOI 10.1007/BF01544749	40	62	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15510	15515		10.1074/jbc.272.24.15510	http://dx.doi.org/10.1074/jbc.272.24.15510			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182585	hybrid			2022-12-27	WOS:A1997XE03400068
J	Tanabe, M; Nakai, A; Kawazoe, Y; Nagata, K				Tanabe, M; Nakai, A; Kawazoe, Y; Nagata, K			Different thresholds in the responses of two heat shock transcription factors, HSF1 and HSF3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; HSP70 GENE-TRANSCRIPTION; FULL-LENGTH CDNA; ESCHERICHIA-COLI; SIGMA-FACTOR; NUCLEOTIDE-SEQUENCE; MOLECULAR CHAPERONES; RNA-POLYMERASE; HELA-CELLS; IN-VIVO	Avian cells express three HSF genes encoding a unique factor, HSF3, as well as homologues of mammalian HSF1 and HSF2. HSF1 is the major factor that mediates the heat shock signal in mammalian cells, We reported previously that cHSF3, as well as cHSF1, is activated by heat shock in chicken cells. In this study, we examined the functional differences between cHSF1 and cHSF3, Comparison of the heat-inducible DNA binding activity of cHSF1 with cHSF3 at various temperatures revealed that the latter was activated at higher temperatures than the former, At a mild heat shock, such as 41 degrees C, only cHSF1 was activated, whereas both cHSF1 and cHSF3 were activated following a severe heat shock at 45 degrees C, Heat-inducible nuclear translocation and trimerization were accompanied by DNA binding activity. We also observed that cHSF3 was activated by treating cells with higher concentrations of sodium arsenite compared to cHSF1. The DNA binding activity of cHSF3 by severe heat shock lasted for a longer period than that of cHSF1, Interestingly, the total amount of cHSF3 increased only upon severe heat shock, whereas that of HSF1 decreased. Substantial amounts of cHSF3 remained in the soluble fraction under severe heat shock, whereas cHSF1 rapidly moved to the insoluble fractions in that conditions, Comparison of transcriptional activity of the activation domains of cHSF1 and cHSF3 revealed that the activity of cHSF3 was as strong as that of cHSF1, These findings indicate that there are different thresholds for cHSF1 and cHSF3 and that cHSF3 is involved in the persistent and burst activation of stress genes upon severe stress in chicken cells, Pretreatment of cycloheximide elevated the threshold concentrations of arsenite of both factors, This suggests that denaturation of nascent polypeptides could be the first trigger for the activation of both factors, and the pathways for activation of cHSF1 and cHSF3 may be identical, or at least share some common mechanisms.	KYOTO UNIV, CHEST DIS RES INST, DEPT CELL BIOL, SAKYO KU, KYOTO 60601, JAPAN	Kyoto University								ABRAVAYA K, 1991, GENE DEV, V5, P2117, DOI 10.1101/gad.5.11.2117; ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; BECKMANN RP, 1992, J CELL BIOL, V117, P1137, DOI 10.1083/jcb.117.6.1137; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAIG EA, 1994, CELL, V78, P365, DOI 10.1016/0092-8674(94)90416-2; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERICKSON JW, 1989, GENE DEV, V3, P1462, DOI 10.1101/gad.3.9.1462; FAWCETT TW, 1994, J BIOL CHEM, V269, P32272; GALLO GJ, 1991, MOL CELL BIOL, V11, P281, DOI 10.1128/MCB.11.1.281; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GIARDINA C, 1995, MOL CELL BIOL, V15, P2737; GROSSMAN AD, 1984, CELL, V38, P383, DOI 10.1016/0092-8674(84)90493-8; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HICKEY E, 1986, GENE, V43, P147, DOI 10.1016/0378-1119(86)90018-1; JACQUIERSARLIN MR, 1995, J BIOL CHEM, V270, P14094, DOI 10.1074/jbc.270.23.14094; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; LANDICK R, 1984, CELL, V38, P175, DOI 10.1016/0092-8674(84)90538-5; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; MORIMOTO RI, 1986, J BIOL CHEM, V261, P2692; MOSSER DD, 1993, MOL CELL BIOL, V13, P5427, DOI 10.1128/MCB.13.9.5427; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; MURPHY SP, 1994, MOL CELL BIOL, V14, P5309, DOI 10.1128/MCB.14.8.5309; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; NAKAI A, 1995, MOL CELL BIOL, V15, P5268; Newton EM, 1996, MOL CELL BIOL, V16, P839; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; RABINDRAN SK, 1994, MOL CELL BIOL, V14, P6552, DOI 10.1128/MCB.14.10.6552; RAINA S, 1995, EMBO J, V14, P1043, DOI 10.1002/j.1460-2075.1995.tb07085.x; ROUVIERE PE, 1995, EMBO J, V14, P1032, DOI 10.1002/j.1460-2075.1995.tb07084.x; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SHI YH, 1995, MOL CELL BIOL, V15, P4309; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; WANG QP, 1989, J BACTERIOL, V171, P4248, DOI 10.1128/JB.171.8.4248-4253.1989; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; YAMAZAKI M, 1989, NUCLEIC ACIDS RES, V17, P7108, DOI 10.1093/nar/17.17.7108; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	54	67	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15389	15395		10.1074/jbc.272.24.15389	http://dx.doi.org/10.1074/jbc.272.24.15389			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182569	hybrid			2022-12-27	WOS:A1997XE03400052
J	Cao, ZM; Petroulakis, E; Salo, T; TriggsRaine, B				Cao, ZM; Petroulakis, E; Salo, T; TriggsRaine, B			Benign HEXA mutations, C739T(R247W) and C745T(R249W), cause beta-hexosaminidase A pseudodeficiency by reducing the alpha-subunit protein levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAY-SACHS-DISEASE; SITE-DIRECTED MUTAGENESIS; ADULT GM2 GANGLIOSIDOSIS; MOLECULAR-BASIS; LYSOSOMAL-ENZYMES; ASHKENAZI-JEWISH; A DEFICIENCY; GEL SYSTEM; COMMON; BIOSYNTHESIS	Two benign mutations, C739T(R247W) and C745T(R249W), in the alpha-subunit of beta-hexosaminidase A (Hex A) have been found in all but one of the currently identified Hex A-pseudodeficient subjects. To confirm the relationship of the benign mutations and Hex A pseudodeficiency and to determine how the benign mutations reduce Hex A activity, we transiently expressed each of the benign mutations, and other mutations associated with infantile, juvenile, and adult onset forms of G(M2) gangliosidosis, as Hex S (alpha alpha) and Hex A (alpha beta) in COS-7 cells. The benign mutations decreased the expressed Hex A and Hex S activity toward the synthetic substrate 4-methylumbelliferyl-6-sulfo-beta-N-acetylglucosaminide (4-MUGS) by 60-80%, indicating that they are the primary cause of Hex A pseudodeficiency. Western blot analysis showed that the benign mutations decreased the enzymatic activity by reducing the alpha-subunit protein level. No change in heat sensitivity, catalytic activity, or the substrate specificity to the synthetic substrates, 4-methylumbelliferyl-beta-N-acetylglucosaminide or 4-methylumbelliferyl-6-sulfo-beta-N-acetylglucosaminide, was detected. The effects of the benign mutations on Hex A were further analyzed in fibroblasts, and during transient expression, using pulse chase metabolic labeling. These studies showed that the benign mutations reduced the alpha-subunit protein by affecting its stability in vivo, not by affecting the processing of the alpha-subunit, i.e. phosphorylation, targeting, or secretion. Our studies also demonstrated that these benign mutations could be readily differentiated from disease-causing mutations using a transient expression system.	UNIV MANITOBA, DEPT BIOCHEM & MOL BIOL, WINNIPEG, MB R3E 0W3, CANADA	University of Manitoba			Triggs-Raine, Barbara/AAF-6209-2021	Triggs-Raine, Barbara/0000-0003-4719-6779				Akerman B. R., 1992, Human Mutation, V1, P303, DOI 10.1002/humu.1380010407; Andermann E, 1977, Prog Clin Biol Res, V18, P161; BEBENEK K, 1989, NUCLEIC ACIDS RES, V17, P5408, DOI 10.1093/nar/17.13.5408; BOLES DJ, 1995, AM J HUM GENET, V56, P716; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN CA, 1989, J BIOL CHEM, V264, P21705; BROWN CA, 1993, AM J HUM GENET, V53, P497; CAO Z, 1993, AM J HUM GENET, V53, P1198; CHANG DC, 1991, BIOCHIM BIOPHYS ACTA, V1092, P153, DOI 10.1016/0167-4889(91)90149-R; CONZELMANN E, 1979, H-S Z PHYSIOL CHEM, V360, P1837, DOI 10.1515/bchm2.1979.360.2.1837; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DOUCET JP, 1990, ANAL BIOCHEM, V190, P209, DOI 10.1016/0003-2697(90)90182-9; DOUCET JP, 1988, ANAL BIOCHEM, V168, P265, DOI 10.1016/0003-2697(88)90317-X; EMILIANI C, 1990, BIOCHEM J, V272, P211, DOI 10.1042/bj2720211; Fernandes Maria, 1992, Human Molecular Genetics, V1, P759, DOI 10.1093/hmg/1.9.759; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; GRAVEL RA, 1995, GM2 GANGLIOSIDOSIS M; GREBNER EE, 1986, AM J HUM GENET, V38, P505; HASILIK A, 1980, J BIOL CHEM, V255, P4946; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HECHTMAN P, 1989, CLIN GENET, V35, P364; Henderson Peter J.F., 1993, P277; KABACK M, 1993, JAMA-J AM MED ASSOC, V270, P2307, DOI 10.1001/jama.270.19.2307; Kaback M M, 1977, Prog Clin Biol Res, V18, P267; KABACK MM, 1972, METHOD ENZYMOL, V28, P862; KELLY TE, 1976, CLIN GENET, V9, P540; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Macgregor G R, 1991, Methods Mol Biol, V7, P217, DOI 10.1385/0-89603-178-0:217; MAHURAN D, 1985, ISOZYMES-CURR T BIOL, V12, P229; Mules Emilie H., 1992, Human Mutation, V1, P298, DOI 10.1002/humu.1380010406; MYEROWITZ R, 1988, J BIOL CHEM, V263, P18587; MYEROWITZ R, 1985, P NATL ACAD SCI USA, V82, P7830, DOI 10.1073/pnas.82.23.7830; NAVON R, 1986, AM J MED GENET, V24, P179, DOI 10.1002/ajmg.1320240123; NAVON R, 1990, AM J HUM GENET, V46, P817; NAVON R, 1989, SCIENCE, V243, P1471, DOI 10.1126/science.2522679; OBRIEN JS, 1978, AM J HUM GENET, V30, P602; ODOWD BF, 1985, P NATL ACAD SCI USA, V82, P1184, DOI 10.1073/pnas.82.4.1184; PAW BH, 1989, P NATL ACAD SCI USA, V86, P2413, DOI 10.1073/pnas.86.7.2413; PETERSEN GM, 1983, AM J HUM GENET, V35, P1258; PROIA RL, 1984, J BIOL CHEM, V259, P3350; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SEGLEN PO, 1983, METHOD ENZYMOL, V96, P737; Tews I, 1996, NAT STRUCT BIOL, V3, P638, DOI 10.1038/nsb0796-638; THOMAS GH, 1994, AM J HUM GENET, V54, P934; THOMAS GH, 1982, PEDIATR RES, V16, P232, DOI 10.1203/00006450-198203000-00014; TRIGGSRAINE BL, 1992, AM J HUM GENET, V51, P793; Trop Isabelle, 1992, Human Mutation, V1, P35, DOI 10.1002/humu.1380010106; VIDGOFF J, 1973, AM J HUM GENET, V25, P372; VONFIGURA K, 1983, P NATL ACAD SCI-BIOL, V80, P6066	49	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14975	14982		10.1074/jbc.272.23.14975	http://dx.doi.org/10.1074/jbc.272.23.14975			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169471	hybrid			2022-12-27	WOS:A1997XC32700068
J	Chen, M; Marinkovich, MP; Veis, A; Cai, XY; Rao, CN; OToole, EA; Woodley, DT				Chen, M; Marinkovich, MP; Veis, A; Cai, XY; Rao, CN; OToole, EA; Woodley, DT			Interactions of the amino-terminal noncollagenous (NC1) domain of type VII collagen with extracellular matrix components - A potential role in epidermal-dermal adherence in human skin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMOLYSIS BULLOSA-ACQUISITA; ANCHORING FIBRILS; BASEMENT-MEMBRANE; TISSUE FORM; PROCOLLAGEN; CHAIN; IDENTIFICATION; ANTIGEN; IV; BIOSYNTHESIS	Type VII collagen, the major component of anchoring fibrils, consists of a central collagenous triple-helical domain flanked by two noncollagenous domains, NC1 and NC2. The NC1 domain contains multiple submodules with homology to known adhesive molecules including fibronectin type III-like repeats and the A domain of von Willebrand factor. In this study, we produced the entire NC1 domain of human type VII collagen in the stably transfected human kidney 293 cell clones and purified large quantities of the recombinant NC1 protein from serum-free culture media. The recombinant NC1 formed interchain disulfide-bonded dimers and trimers and was N-linked glycosylated. Tunicamycin inhibited the cellular secretion of NC1, suggesting that N-linked glycosylation may play a role in NC1 secretion, The recombinant NC1 was indistinguishable from the authentic NCI obtained from human amnions or WISH cells with respect to N-linked sugar content, electrophoretic mobility, rotary shadow imaging, and binding affinity to type IV collagen. Purified recombinant NC1, like authentic NC1, also bound specifically to fibronectin, collagen type I, and a laminin 5/6 complex. Both monomeric and trimeric forms of NC1 exhibited equal affinity for these extracellular matrix components, suggesting that the individual arms of NC1 can function independently. The multiple interactions of NC1 with other extracellular matrix components may support epidermal-dermal adhesion.	NORTHWESTERN UNIV,SCH MED,DEPT DERMATOL,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT DENT ORAL BIOL,CHICAGO,IL 60611; STANFORD UNIV,SCH MED,PALO ALTO VET AFFAIR HLTH SYST,DIV DERMATOL,STANFORD,CA 94305	Northwestern University; Northwestern University; Stanford University				O'Toole, Edel/0000-0002-4084-4836	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041045] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01 AR 41045] Funding Source: Medline; PHS HHS [R01 A33625] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BACHINGER HP, 1981, J BIOL CHEM, V256, P3193; BACHINGER HP, 1990, J BIOL CHEM, V265, P10095; BONALDO P, 1990, BIOCHEMISTRY-US, V29, P1245, DOI 10.1021/bi00457a021; BRUCKNERTUDERMAN L, 1987, EUR J BIOCHEM, V165, P607, DOI 10.1111/j.1432-1033.1987.tb11483.x; BRUCKNERTUDERMAN L, 1995, J CELL BIOL, V131, P551, DOI 10.1083/jcb.131.2.551; BURGESON RE, 1993, J INVEST DERMATOL, V101, P252, DOI 10.1111/1523-1747.ep12365129; BURGESON RE, 1990, ANN NY ACAD SCI, V580, P32, DOI 10.1111/j.1749-6632.1990.tb17915.x; BURGESON RE, 1987, BIOL EXTRACELLULAR M, P145; Champliaud MF, 1996, J CELL BIOL, V132, P1189, DOI 10.1083/jcb.132.6.1189; CHRISTIANO AM, 1994, J BIOL CHEM, V269, P20256; CHRISTIANO AM, 1992, HUM MOL GENET, V1, P457; COLOMBATTI A, 1991, BLOOD, V77, P2305; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; GAMMON WR, 1993, J INVEST DERMATOL, V100, P618, DOI 10.1111/1523-1747.ep12472291; HOUSLEY TJ, 1980, J BIOL CHEM, V255, P121; HOVNANIAN A, 1992, J CLIN INVEST, V90, P1032, DOI 10.1172/JCI115916; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KEENE DR, 1987, J CELL BIOL, V104, P611, DOI 10.1083/jcb.104.3.611; KEENE DR, 1988, J CELL BIOL, V107, P1995, DOI 10.1083/jcb.107.5.1995; LAPIERE JC, 1993, J CLIN INVEST, V92, P1831, DOI 10.1172/JCI116774; LAPIERE JC, 1994, J INVEST DERMATOL, V94, P637; Lapiere Jean-Christophe, 1994, Journal of Dermatological Science, V8, P145, DOI 10.1016/0923-1811(94)90009-4; Lin AN, 1992, EPIDERMOLYSIS BULLOS; LUNSTRUM GP, 1986, J BIOL CHEM, V261, P9042; LUNSTRUM GP, 1987, J BIOL CHEM, V262, P13706; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; MAZZORANA M, 1993, J BIOL CHEM, V268, P3029; MORRIS NP, 1986, J BIOL CHEM, V261, P5638; NIEBOER C, 1980, BRIT J DERMATOL, V102, P383, DOI 10.1111/j.1365-2133.1980.tb06550.x; OKEEFE EJ, 1984, J INVEST DERMATOL, V82, P150, DOI 10.1111/1523-1747.ep12259708; PARENTE MG, 1991, P NATL ACAD SCI USA, V88, P6931, DOI 10.1073/pnas.88.16.6931; RIES A, 1995, J BIOL CHEM, V270, P23790, DOI 10.1074/jbc.270.40.23790; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; TIDMAN MJ, 1985, J INVEST DERMATOL, V84, P373; TIFFT CJ, 1992, J BIOL CHEM, V267, P3268; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UITTO J, 1993, SEMIN DERMATOL, V12, P191; Uitto J, 1992, Exp Dermatol, V1, P2, DOI 10.1111/j.1600-0625.1992.tb00065.x; UITTO J, 1992, J INVEST DERMATOL, V38, P391; VERRANDO P, 1987, EXP CELL RES, V170, P116, DOI 10.1016/0014-4827(87)90121-2; VERRANDO P, 1993, J INVEST DERMATOL, V101, P738, DOI 10.1111/1523-1747.ep12371685; WANG SY, 1983, P NATL ACAD SCI-BIOL, V80, P5880, DOI 10.1073/pnas.80.19.5880; WASANO K, 1985, CELL TISSUE RES, V239, P485; WOODLEY DT, 1983, BIOCHIM BIOPHYS ACTA, V761, P278, DOI 10.1016/0304-4165(83)90077-6; WOODLEY DT, 1986, J INVEST DERMATOL, V86, P668, DOI 10.1111/1523-1747.ep12275978; WOODLEY DT, 1984, NEW ENGL J MED, V310, P1007, DOI 10.1056/NEJM198404193101602; WOODLEY DT, 1988, J CLIN INVEST, V81, P683, DOI 10.1172/JCI113373; WOODLEY DT, 1987, J CLIN INVEST, V179, P1826	48	150	153	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14516	14522		10.1074/jbc.272.23.14516	http://dx.doi.org/10.1074/jbc.272.23.14516			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169408	hybrid			2022-12-27	WOS:A1997XC32700005
J	Chu, WM; Wang, ZX; Roeder, RG; Schmid, CW				Chu, WM; Wang, ZX; Roeder, RG; Schmid, CW			RNA polymerase III transcription repressed by Rb through its interactions with TFIIIB and TFIIIC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; TATA-BINDING PROTEIN; CELL-CYCLE; PHOSPHORYLATION; EXPRESSION; SEQUENCE; PROMOTER; COMPONENTS; INVITRO; ELEMENT	The retinoblastoma susceptibility gene product (Rb) generally represses RNA polymerase III (Pol III)-directed transcription. This implies that Rb interacts with essential transcription factors. Mutations in either the A or B subdomains in the Rb pocket interfere with Rb-mediated repression of Pol III-directed transcription, which indicates that both subdomains are directly involved in this activity. Addition of either purified TFIIIB or purified TFIIIC2 partially relieves Rb-mediated repression and restores activity to nuclear extracts that had been depleted of essential factors by binding to Rb. Pull down and coimmunoprecipitation experiments as web as functional assays indicate that Rb interacts with both TFIIIB and TFIIIC2 and that the A subdomain is primarily required for binding TFIIIB and the B subdomain for binding TFIIIC2. While Rb interacts with both factors, the A subdomain is more important than the B subdomain in directing Rb-mediated repression, and TFIIIB is the principal target of that activity.	UNIV CALIF DAVIS, SECT MOL & CELLULAR BIOL, DAVIS, CA 95616 USA; ROCKEFELLER UNIV, BIOCHEM & MOL BIOL LAB, NEW YORK, NY 10021 USA; UNIV CALIF DAVIS, DEPT CHEM, DAVIS, CA 95616 USA	University of California System; University of California Davis; Rockefeller University; University of California System; University of California Davis					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021346] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 21346] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREDOW S, 1990, NUCLEIC ACIDS RES, V18, P6779, DOI 10.1093/nar/18.23.6779; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHU WM, 1995, NUCLEIC ACIDS RES, V23, P1750, DOI 10.1093/nar/23.10.1750; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FUNG YKT, 1993, ONCOGENE, V8, P2659; GOTTESFELD JM, 1994, SCIENCE, V263, P81, DOI 10.1126/science.8272869; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HICKMAN MA, 1994, HUM GENE THER, V5, P1477, DOI 10.1089/hum.1994.5.12-1477; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KOSKI RA, 1982, J BIOL CHEM, V257, P4514; KOUZARIDES T, 1995, TRENDS CELL BIOL, V5, P448, DOI 10.1016/S0962-8924(00)89109-6; KUNKEL GR, 1988, GENE DEV, V2, P196, DOI 10.1101/gad.2.2.196; LITTLE RD, 1989, GENOMICS, V4, P376, DOI 10.1016/0888-7543(89)90345-5; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; QIN XQ, 1995, MOL CELL BIOL, V15, P742; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; WANG Z, 1997, MOL CELL BIOL, V16, P6841; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WHITE RJ, 1995, MOL CELL BIOL, V15, P6653; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; White RJ, 1997, TRENDS BIOCHEM SCI, V22, P77, DOI 10.1016/S0968-0004(96)10067-0; YOON JB, 1995, MOL CELL BIOL, V15, P2019; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3585, DOI 10.1073/pnas.84.11.3585	38	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14755	14761		10.1074/jbc.272.23.14755	http://dx.doi.org/10.1074/jbc.272.23.14755			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169441	hybrid			2022-12-27	WOS:A1997XC32700038
J	Goodman, OB; Krupnick, JG; Gurevich, VV; Benovic, JL; Keen, JH				Goodman, OB; Krupnick, JG; Gurevich, VV; Benovic, JL; Keen, JH			Arrestin/clathrin interaction - Localization of the arrestin binding locus to the clathrin terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2)-ADRENERGIC RECEPTOR SEQUESTRATION; PROTEIN-COUPLED RECEPTORS; PLASMA-MEMBRANE; COATED VESICLES; MECHANISM; SUBUNIT; MUTANT; AP-2; PHOSPHORYLATION; RECOGNITION	Previously we demonstrated that nonvisual arrestins exhibit a high affinity interaction with clathrin, consistent with an adaptor function in the internalization of G protein-coupled receptors (Goodman, O.B., Jr., Krupnick, J. G., Santini, F., Gurevich, V. V., Penn, R. B., Gagnon, A. W., Keen, J. H., and Benovic, J. L. (1996) Nature 383, 447-450). In this report we show that a short sequence of highly conserved residues within the globular clathrin terminal domain is responsible for arrestin binding. Limited proteolysis of clathrin cages results in the release of terminal domains and concomitant abrogation of arrestin binding. The nonvisual arrestins, beta-arrestin and arrestin3, but not visual arrestin, bind specifically to a glutathione S-transferase-clathrin terminal domain fusion protein. Deletion analysis and alanine scanning mutagenesis localize the binding site to residues 89-100 of the clathrin heavy chain and indicate that residues 1-100 can function as an independent arrestin binding domain. Site-directed mutagenesis identifies an invariant glutamine (Glu-89) and two highly conserved lysines (Lys-96 and Lys-98) as residues critical for arrestin binding, complementing hydrophobic and acidic residues in arrestin3 which have been implicated in clathrin binding (Krupnick, J. G., Goodman, O. B., Jr., Keen, J. H., and Benovic, J. L. (1997) J. Biol. Chem. 272, 15011-15016). Despite exhibiting high affinity clathrin binding, arrestins do not induce coat assembly. The terminal domain is oriented toward the plasma membrane in coated pits, and its binding of both arrestins and AP-2 suggests that this domain is the anchor responsible for adaptor-receptor recruitment to the coated pit.	THOMAS JEFFERSON UNIV, KIMMEL CANC INST, DEPT MOL PHARMACOL & BIOCHEM, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, KIMMEL CANC INST, DEPT MICROBIOL & IMMUNOL, PHILADELPHIA, PA 19107 USA	Jefferson University; Jefferson University			Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351; Goodman, Oscar/0000-0002-0882-3621	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007705] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028526, R01GM044944] Funding Source: NIH RePORTER; NIDDK NIH HHS [5-T32-DK07705-03] Funding Source: Medline; NIGMS NIH HHS [GM-28526, GM-44944] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARAK LS, 1994, J BIOL CHEM, V269, P2790; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; CROWTHER RA, 1981, J CELL BIOL, V91, P790, DOI 10.1083/jcb.91.3.790; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GOODMAN OB, 1995, J BIOL CHEM, V270, P23768, DOI 10.1074/jbc.270.40.23768; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HEUSER J, 1985, J ULTRA MOL STRUCT R, V92, P1, DOI 10.1016/0889-1605(85)90123-5; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KEEN JH, 1991, J BIOL CHEM, V266, P7950; KIRCHHAUSEN T, 1987, P NATL ACAD SCI USA, V84, P8805, DOI 10.1073/pnas.84.24.8805; KIRCHHAUSEN T, 1981, CELL, V23, P755, DOI 10.1016/0092-8674(81)90439-6; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; LIU SH, 1995, CELL, V83, P257, DOI 10.1016/0092-8674(95)90167-1; MURPHY JE, 1992, J BIOL CHEM, V267, P10850; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PEELER JS, 1993, J CELL BIOL, V120, P47, DOI 10.1083/jcb.120.1.47; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; Santini F, 1996, J CELL BIOL, V132, P1025, DOI 10.1083/jcb.132.6.1025; SCHMID SL, 1992, BIOESSAYS, V14, P589, DOI 10.1002/bies.950140903; SCHRODER S, 1991, J BIOL CHEM, V266, P7910; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; TSUGA H, 1994, J BIOL CHEM, V269, P32522; UNGEWICKELL E, 1981, COLD SPRING HARB SYM, V46, P723, DOI 10.1101/SQB.1982.046.01.069; VIGERS GPA, 1986, EMBO J, V5, P529, DOI 10.1002/j.1460-2075.1986.tb04242.x; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; YU SS, 1993, J BIOL CHEM, V268, P337; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339	34	183	186	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					15017	15022		10.1074/jbc.272.23.15017	http://dx.doi.org/10.1074/jbc.272.23.15017			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169477	hybrid			2022-12-27	WOS:A1997XC32700074
J	Jeng, AY; Fujimoto, RA; Chou, M; Tan, J; Erion, MD				Jeng, AY; Fujimoto, RA; Chou, M; Tan, J; Erion, MD			Suppression of substance P biosynthesis in sensory neurons of dorsal root ganglion by prodrug esters of potent peptidylglycine alpha-amidating monooxygenase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE-EXTENDED PEPTIDES; DOPAMINE BETA-MONOOXYGENASE; HYDROXYLATING MONOOXYGENASE; NEUROGENIC INFLAMMATION; SECRETORY GRANULES; COPPER ATOMS; ENZYME; RAT; INACTIVATION; PITUITARY	Substance P as well as many other neuropeptides are synthesized as glycine-extended precursors and converted to the biologically active C-terminal amides by posttranslational modification. The final step of posttranslational processing is catalyzed by peptidylglycine alpha-amidating monooxygenase (PAM), In a previous study, N-substituted homocysteine analogs were found to be potent inhibitors of PAM partially purified from conditioned medium of cultured rat medullary thyroid carcinoma CA-77 cells, These compounds, however, were only modest inhibitors of substance P production in cultured dorsal root ganglion cells, possibly because of poor cell penetration, Several ester derivatives of hydrocinnamoyl-phenylalanyl-homocysteine, one of the most potent PAM inhibitors, were prepared to increase the intracellular accessibility of these compounds, Hydrocinnamoyl-phenylalanyl-(S-benzoyl-homocysteine) benzyl ester was identified as the most potent compound, inhibiting substance P biosynthesis in dorsal root ganglion cells with an IC50 of 2 mu M. Inhibition of PAM resulted in a concomitant increase in the glycine-extended substance p (substance P-Gly) precursor peptide. In the presence of 3 mu M benzyl ester derivative, the intracellular substance P-Gly level was 2.4-fold higher while the substance P level was 2.1-fold lower than the corresponding peptides in control cells. These results suggest that PAM inhibition represents an effective method for suppression of substance P biosynthesis and, therefore, may have therapeutic utility in conditions associated with elevated substance P levels. Furthermore, PAM inhibition may also prove useful in decreasing other amidated peptides.			Jeng, AY (corresponding author), NOVARTIS PHARMACEUT CORP, RES DEPT, LSB-3129, 556 MORRIS AVE, SUMMIT, NJ 07901 USA.							BRADBURY AF, 1982, NATURE, V298, P686, DOI 10.1038/298686a0; BRENNER MC, 1989, BIOCHEMISTRY-US, V28, P4664, DOI 10.1021/bi00437a023; Casara P, 1996, BIOORG MED CHEM LETT, V6, P393, DOI 10.1016/0960-894X(96)00041-8; COLOMBO G, 1987, ARCH BIOCHEM BIOPHYS, V252, P71, DOI 10.1016/0003-9861(87)90009-9; EIPPER BA, 1995, BIOCHEMISTRY-US, V34, P2857, DOI 10.1021/bi00009a016; EIPPER BA, 1988, ANNU REV PHYSIOL, V50, P333, DOI 10.1146/annurev.ph.50.030188.002001; EIPPER BA, 1983, P NATL ACAD SCI-BIOL, V80, P5144, DOI 10.1073/pnas.80.16.5144; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; EIPPER BA, 1993, PROTEIN SCI, V2, P489; EIPPER BA, 1985, ENDOCRINOLOGY, V116, P2497, DOI 10.1210/endo-116-6-2497; ERION MD, 1994, J MED CHEM, V37, P4430, DOI 10.1021/jm00052a002; Gerald C, 1996, NATURE, V382, P168, DOI 10.1038/382168a0; GILLIGAN JP, 1994, INFLAMMATION, V18, P285, DOI 10.1007/BF01534269; GLEMBOTSKI CC, 1985, ARCH BIOCHEM BIOPHYS, V241, P673, DOI 10.1016/0003-9861(85)90594-6; HELME RD, 1986, NEUROSCI LETT, V66, P333, DOI 10.1016/0304-3940(86)90041-8; HILSTED L, 1986, FEBS LETT, V196, P151, DOI 10.1016/0014-5793(86)80231-9; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; JENG AY, 1990, ANAL BIOCHEM, V185, P213, DOI 10.1016/0003-2697(90)90282-E; Kagan HM, 1995, CIBA F SYMP, V192, P100; KATOPODIS AG, 1990, BIOCHEMISTRY-US, V29, P4541, DOI 10.1021/bi00471a006; KIZER JS, 1986, ENDOCRINOLOGY, V118, P2262, DOI 10.1210/endo-118-6-2262; KLINGE M, 1994, J CHEM SOC CHEM COMM, P1379, DOI 10.1039/c39940001379; KULATHILA R, 1994, ARCH BIOCHEM BIOPHYS, V311, P191, DOI 10.1006/abbi.1994.1225; LEVINE JD, 1985, J RHEUMATOL, V12, P406; LEVINE JD, 1984, SCIENCE, V226, P547, DOI 10.1126/science.6208609; LI AC, 1988, J LIPID RES, V29, P781; LOTZ M, 1987, SCIENCE, V235, P893, DOI 10.1126/science.2433770; MAINS RE, 1987, ANN NY ACAD SCI, V493, P278, DOI 10.1111/j.1749-6632.1987.tb27213.x; MAINS RE, 1986, J BIOL CHEM, V261, P1938; MARCHAND JE, 1990, J BIOL CHEM, V265, P264; MERKLER DJ, 1995, ARCH BIOCHEM BIOPHYS, V317, P93, DOI 10.1006/abbi.1995.1140; MERKLER DJ, 1994, ENZYME MICROB TECH, V16, P450, DOI 10.1016/0141-0229(94)90014-0; MERKLER DJ, 1995, FEBS LETT, V366, P165, DOI 10.1016/0014-5793(95)00516-C; MUELLER GP, 1995, NEUROPEPTIDES, V28, P333, DOI 10.1016/0143-4179(95)90098-5; OKU R, 1987, NEUROSCI LETT, V74, P315, DOI 10.1016/0304-3940(87)90316-8; PERKINS SN, 1990, BIOCHEM BIOPH RES CO, V171, P926, DOI 10.1016/0006-291X(90)90772-F; RAYCHAUDHURI A, 1991, AGENTS ACTIONS, V34, P251, DOI 10.1007/BF01993295; RHODES CH, 1993, ANN NY ACAD SCI, V689, P663, DOI 10.1111/j.1749-6632.1993.tb55622.x; TAMBURINI PP, 1988, ARCH BIOCHEM BIOPHYS, V267, P623, DOI 10.1016/0003-9861(88)90070-7; THAYER SA, 1988, J NEUROSCI, V8, P4089; TISSOT M, 1988, INFLAMMATION, V12, P25, DOI 10.1007/BF00915889; WIESENFELDHALLIN Z, 1993, REGUL PEPTIDES, V46, P165, DOI 10.1016/0167-0115(93)90027-6; WONG M, 1994, J NEUROSCI RES, V37, P97, DOI 10.1002/jnr.490370113; ZABRISKIE TM, 1992, J AM CHEM SOC, V114, P2270, DOI 10.1021/ja00032a058	44	15	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14666	14671		10.1074/jbc.272.23.14666	http://dx.doi.org/10.1074/jbc.272.23.14666			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169429	hybrid			2022-12-27	WOS:A1997XC32700026
J	Lawler, S; Feng, XH; Chen, RH; Maruoka, EM; Turck, CW; GriswoldPrenner, I; Derynck, R				Lawler, S; Feng, XH; Chen, RH; Maruoka, EM; Turck, CW; GriswoldPrenner, I; Derynck, R			The type II transforming growth factor-beta receptor autophosphorylates not only on serine and threonine but also on tyrosine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; DUAL-SPECIFICITY KINASE; TGF-BETA; ACTIVIN RECEPTOR; HETEROOLIGOMERIC COMPLEXES; SIGNAL-TRANSDUCTION; EXPRESSION CLONING; THICK VEINS; MAP KINASE; PHOSPHORYLATION	The type I and type II receptors for transforming growth factor-beta (TGF-beta) are structurally related transmembrane serine/threonine kinases, which are able to physically interact with each other at the cell surface. To help define the initial events in TGF-beta signaling, we characterized the kinase activity of the type II TGF-beta receptor. A recombinant cytoplasmic domain of the receptor was purified from Escherichia coli and baculovirus-infected insect cells. Anti-phosphotyrosine Western blotting demonstrated that the type II receptor kinase can autophosphorylate on tyrosine. Following an in vitro kinase reaction, the autophosphorylation of the cytoplasmic domain and phosphorylation of exogenous substrate was shown by phosphoamino acid analysis to occur not only on serine and threonine but also on tyrosine. The dual kinase specificity of the receptor was also demonstrated using immunoprecipitated receptors expressed in mammalian cells and in vivo P-32 labeling showed phosphorylation of the receptor on serine and tyrosine. In addition, the kinase activity of the cytoplasmic domain was inhibited by the tyrosine kinase inhibitor tyrphostin. Tryptic mapping and amino acid sequencing of in vitro autophosphorylated type II receptor cytoplasmic domain allowed the localization of the sites of tyrosine phosphorylation to positions 259, 336, and 424. Replacement of all three tyrosines with phenylalanines strongly inhibited the kinase activity of the receptor, suggesting that tyrosine autophosphorylation may play an autoregulatory role for the kinase activity of this receptor. These results demonstrate that the type II TGF-beta receptor can function as a dual specificity kinase and suggest a role for tyrosine autophosphorylation in TGF-beta receptor signaling.	UNIV CALIF SAN FRANCISCO,DEPT GROWTH & DEV,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST CARDIOVASC RES,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco			Chen, Ruey-Hwa/G-6121-2019	Chen, Ruey-Hwa/0000-0001-8124-5832	NATIONAL CANCER INSTITUTE [R01CA063101] Funding Source: NIH RePORTER; NCI NIH HHS [CA63101] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; CHEN RH, 1995, J BIOL CHEM, V270, P12235, DOI 10.1074/jbc.270.20.12235; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; DERYNCK R, 1988, EMBO J, V7, P3737, DOI 10.1002/j.1460-2075.1988.tb03257.x; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; Derynck R, 1994, CYTOKINE HDB, P319; DUNCAN PI, 1995, J BIOL CHEM, V270, P21524, DOI 10.1074/jbc.270.37.21524; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KORNBLUTH S, 1994, MOL BIOL CELL, V5, P273, DOI 10.1091/mbc.5.3.273; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LAUZE E, 1995, EMBO J, V14, P1655, DOI 10.1002/j.1460-2075.1995.tb07154.x; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; LIU F, 1995, MOL CELL BIOL, V15, P3479; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MATHEWS LS, 1993, J BIOL CHEM, V268, P19013; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; NAKAMURA T, 1992, J BIOL CHEM, V267, P18924; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; OKADOME T, 1994, J BIOL CHEM, V269, P30753; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHUM L, 1994, J CELL BIOL, V125, P903, DOI 10.1083/jcb.125.4.903; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TENDIJKE P, 1988, P NATL ACAD SCI USA, V85, P4715; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; tenDijke P, 1996, CURR OPIN CELL BIOL, V8, P139; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; WANG QM, 1994, J BIOL CHEM, V269, P14566; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	73	91	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14850	14859		10.1074/jbc.272.23.14850	http://dx.doi.org/10.1074/jbc.272.23.14850			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169454	hybrid			2022-12-27	WOS:A1997XC32700051
J	Urlaub, H; Thiede, B; Muller, EC; Brimacombe, R; WittmannLiebold, B				Urlaub, H; Thiede, B; Muller, EC; Brimacombe, R; WittmannLiebold, B			Identification and sequence analysis of contact sites between ribosomal proteins and rRNA in Escherichia coli 30 S subunits by a new approach using matrix-assisted laser desorption ionization mass spectrometry combined with N-terminal microsequencing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED AMINO-ACIDS; RNA-BINDING-SITE; CROSS-LINKING; 16S RNA; ANGSTROM RESOLUTION; NUCLEIC-ACIDS; MODEL; 2-IMINOTHIOLANE; LOCALIZATION; PEPTIDES	Cross-linked peptide-oligoribonucleotide complexes derived from distinct regions of the rRNA and individual ribosomal proteins of the 30 S ribosomal subunits from Escherichia coli were isolated and purified. Cross-linking sites at the amino acid and nucleotide level were determined by N-terminal amino acid sequence analysis in combination with matrix assisted laser desorption/ionization mass spectrometry (MALDI-MS). MALDI-MS analysis performed subsequent to a partial alkaline hydrolysis of cross-linked peptide-oligoribonucleotide complexes allowed for the first time the cross-linked rRNA moiety to be sequenced by this technique. In this manner Lys-44 in S4 was determined to be cross-linked to the oligoribonucleotide at positions 1531-1542 on the 16 S RNA (whereby either U-1541 or A-1542 is the actual cross-link site), Lys-75 in S7 to positions 1374-1379 (C-1378 cross-linked), Met-114 in S7 to 1234-1241 (U-1240 cross-linked), Lys-55 in S8 to 651-654 (U-653 cross-linked), and Lys-29 in S17 to 629-633 (U-632 cross-linked). The novel approach applied here promises to be useful for similar studies on other known protein RNA complexes.	MAX DELBRUCK CTR MOL MED,D-13125 BERLIN,GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine								ALLEN G, 1979, J BIOL CHEM, V254, P9800; ALLMANG C, 1994, NUCLEIC ACIDS RES, V22, P3708, DOI 10.1093/nar/22.18.3708; BERGMANN U, 1993, BIOCHEMISTRY-US, V32, P2880, DOI 10.1021/bi00062a020; BRIMACOMBE R, 1995, EUR J BIOCHEM, V230, P365; BROSIUS J, 1978, P NATL ACAD SCI USA, V75, P4801, DOI 10.1073/pnas.75.10.4801; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; CHAIT BT, 1993, SCIENCE, V262, P89, DOI 10.1126/science.8211132; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; CRAIN PF, 1990, METHOD ENZYMOL, V193, P783; Davies C, 1996, STRUCTURE, V4, P55, DOI 10.1016/S0969-2126(96)00009-3; Davies C, 1996, STRUCTURE, V4, P1093, DOI 10.1016/S0969-2126(96)00115-3; DRAGON F, 1994, J MOL BIOL, V244, P74, DOI 10.1006/jmbi.1994.1705; FITZGERALD MC, 1995, ANNU REV BIOPH BIOM, V24, P117, DOI 10.1146/annurev.biophys.24.1.117; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; GOLDEN BL, 1993, EMBO J, V12, P4901, DOI 10.1002/j.1460-2075.1993.tb06184.x; GREUER B, 1987, NUCLEIC ACIDS RES, V15, P3241, DOI 10.1093/nar/15.8.3241; Heilek GM, 1996, RNA, V2, P597; HERWIG S, 1993, J BIOL CHEM, V268, P4643; Jaishree TN, 1996, BIOCHEMISTRY-US, V35, P2845, DOI 10.1021/bi951062i; JENSEN ON, 1993, RAPID COMMUN MASS SP, V7, P496, DOI 10.1002/rcm.1290070619; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; KAUFMANN R, 1995, J BIOTECHNOL, V41, P155, DOI 10.1016/0168-1656(95)00009-F; KIRPEKAR F, 1994, NUCLEIC ACIDS RES, V22, P3866, DOI 10.1093/nar/22.19.3866; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KYRIATSOULIS A, 1986, NUCLEIC ACIDS RES, V14, P1171, DOI 10.1093/nar/14.3.1171; MALHOTRA A, 1994, J MOL BIOL, V240, P308, DOI 10.1006/jmbi.1994.1448; MOLLER K, 1978, J MOL BIOL, V126, P489, DOI 10.1016/0022-2836(78)90055-4; Noller HF, 1995, BIOCHEM CELL BIOL, V73, P997, DOI 10.1139/o95-107; NORDHOFF E, 1993, NUCLEIC ACIDS RES, V21, P3347, DOI 10.1093/nar/21.15.3347; OAKES MI, 1990, RIBOSOME, P180; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Pan  T., 1993, RNA WORLD, P271; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POWERS T, 1995, RNA, V1, P194; SIUZDAK G, 1994, P NATL ACAD SCI USA, V91, P11290, DOI 10.1073/pnas.91.24.11290; SPENGLER B, 1992, RAPID COMMUN MASS SP, V6, P105, DOI 10.1002/rcm.1290060207; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; STOFFLERMEILICKE M, 1990, RIBOSOME, P123; THIEDE B, 1995, FEBS LETT, V357, P65, DOI 10.1016/0014-5793(94)01323-S; Traut R. R., 1986, STRUCTURE FUNCTION G, P286; URLAUB H, 1995, EMBO J, V14, P4578, DOI 10.1002/j.1460-2075.1995.tb00137.x; WALLECZEK J, 1988, EMBO J, V7, P3571, DOI 10.1002/j.1460-2075.1988.tb03234.x; WittmannLiebold B, 1995, BIOCHEM CELL BIOL, V73, P1187, DOI 10.1139/o95-128; WITTMANNLIEBOLD B, 1990, RIBOSOME STRUCTURE F; WOODS AS, 1995, ANAL BIOCHEM, V226, P15, DOI 10.1006/abio.1995.1185; WOWER I, 1983, NUCLEIC ACIDS RES, V11, P1419, DOI 10.1093/nar/11.5.1419; WU H, 1994, NUCLEIC ACIDS RES, V22, P1687, DOI 10.1093/nar/22.9.1687	48	62	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14547	14555		10.1074/jbc.272.23.14547	http://dx.doi.org/10.1074/jbc.272.23.14547			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169412	hybrid			2022-12-27	WOS:A1997XC32700009
J	Charrier, V; Buckley, E; Parsonage, D; Galinier, A; Darbon, E; Jaquinod, M; Forest, E; Deutscher, J; Claiborne, A				Charrier, V; Buckley, E; Parsonage, D; Galinier, A; Darbon, E; Jaquinod, M; Forest, E; Deutscher, J; Claiborne, A			Cloning and sequencing of two Enterococcal glpK genes and regulation of the encoded glycerol kinases by phosphoenolpyruvate dependent, phosphotransferase system-catalyzed phosphorylation of a single histidyl residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; ESCHERICHIA-COLI; STREPTOCOCCUS-FAECALIS; CATABOLITE REPRESSION; SALMONELLA-TYPHIMURIUM; LACTIC STREPTOCOCCI; INDUCER EXCLUSION; NADH PEROXIDASE; ENZYME-IIIGLC; PROTEIN	The glpK genes of Enterococcus casseliflavus and Enterococcus faecalis, encoding glycerol kinase, the key enzyme of glycerol uptake and metabolism in bacteria, have been cloned and sequenced, The translated amino acid sequences exhibit strong homology to the amino acid sequences of other bacterial glycerol kinases, After expression of the enterococcal glpK genes in Escherichia coli, both glycerol kinases were purified and were found to be phosphorylated by enzyme I and the histidine-containing protein of the phosphoenolpyruvate: glycose phosphotransferase system. Phosphoenolpyruvate-dependent phosphorylation caused a 9-fold increase in enzyme activity, The site of phosphorylation in glycerol kinase of E. casseliflavus was determined as His-232, Site-specific mutagenesis was used to replace His-232 in glycerol kinase of E. casseliflavus with an alanyl, glutamate, or arginyl residue. The mutant proteins could no longer be phosphorylated confirming that His-232 of E. casseliflavus glycerol kinase represents the site of phosphorylation. The His(232) --> Arg glycerol kinase exhibited an about 3-fold elevated activity compared with wild-type glycerol kinase, Fructose 1,6-bisphosphate was found to inhibit E. casseliflavus glycerol kinase activity, However, neither EIIA(Glc) from E. coli nor the EIIA(Glc) domain of Bacillus subtilis had an inhibitory effect on glycerol kinase of E. casseliflavus.	CNRS, INST BIOL & CHIM PROT, F-69367 LYON 07, FRANCE; WAKE FOREST UNIV, MED CTR, DEPT BIOCHEM, WINSTON SALEM, NC 27157 USA; CNRS, INST BIOL STRUCT, F-38027 GRENOBLE 01, FRANCE	Centre National de la Recherche Scientifique (CNRS); Wake Forest University; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)			Forest, Eric/E-9042-2012	Buckley, Ellen/0000-0003-1638-2333	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035394] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35394] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON DG, 1983, APPL ENVIRON MICROB, V46, P549, DOI 10.1128/AEM.46.3.549-552.1983; Arnaud M, 1996, J BIOL CHEM, V271, P18966, DOI 10.1074/jbc.271.31.18966; BEIJER L, 1993, J GEN MICROBIOL, V139, P349, DOI 10.1099/00221287-139-2-349; CAPARON MG, 1991, METHOD ENZYMOL, V204, P556; Charrier V, 1997, BIOCHEMISTRY-US, V36, P1163, DOI 10.1021/bi961813w; CHUNG CT, 1993, METHOD ENZYMOL, V218, P621; Claiborne A, 1995, DEV BIOL STAND, V85, P129; DEBOER M, 1986, J BACTERIOL, V167, P393, DOI 10.1128/jb.167.1.393-395.1986; DEUTSCHER J, 1985, FEMS MICROBIOL LETT, V29, P237, DOI 10.1111/j.1574-6968.1985.tb00869.x; DEUTSCHER J, 1993, J BACTERIOL, V175, P3730, DOI 10.1128/JB.175.12.3730-3733.1993; DEUTSCHER J, 1986, BIOCHEMISTRY-US, V25, P6543, DOI 10.1021/bi00369a031; DEUTSCHER J, 1995, MOL MICROBIOL, V15, P1049, DOI 10.1111/j.1365-2958.1995.tb02280.x; DEUTSCHER J, 1986, J BACTERIOL, V166, P829, DOI 10.1128/jb.166.3.829-836.1986; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DORSCHUG M, 1984, EUR J BIOCHEM, V144, P113, DOI 10.1111/j.1432-1033.1984.tb08438.x; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; FUJITA Y, 1995, MOL MICROBIOL, V17, P953, DOI 10.1111/j.1365-2958.1995.mmi_17050953.x; GAY P, 1973, MOL GEN GENET, V121, P355, DOI 10.1007/BF00433234; GONZYTREBOUL G, 1991, MOL MICROBIOL, V5, P1241, DOI 10.1111/j.1365-2958.1991.tb01898.x; HOLMBERG C, 1990, J GEN MICROBIOL, V136, P2367, DOI 10.1099/00221287-136-12-2367; HURLEY JH, 1994, ANAL BIOCHEM, V219, P9; LIN ECC, 1976, ANNU REV MICROBIOL, V30, P535, DOI 10.1146/annurev.mi.30.100176.002535; LIU WZ, 1994, BIOCHEMISTRY-US, V33, P10120, DOI 10.1021/bi00199a040; Nakamura Y, 1996, NUCLEIC ACIDS RES, V24, P214, DOI 10.1093/nar/24.1.214; PARSONAGE D, 1993, J BIOL CHEM, V268, P3161; PETTIGREW DW, 1988, J BIOL CHEM, V263, P135; Pettigrew DW, 1996, J BACTERIOL, V178, P2846, DOI 10.1128/jb.178.10.2846-2852.1996; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; REIZER J, 1992, J BIOL CHEM, V267, P9158; REIZER J, 1984, J BACTERIOL, V159, P243, DOI 10.1128/JB.159.1.243-250.1984; REIZER J, 1987, SUGAR TRANSPORT META, P333; ROE BA, 1996, STREPTOCOCCAL GENOME; ROMANO AH, 1990, J BACTERIOL, V172, P6741, DOI 10.1128/jb.172.12.6741-6748.1990; ROOSSIEN FF, 1983, BIOCHIM BIOPHYS ACTA, V760, P185, DOI 10.1016/0304-4165(83)90141-1; ROSS RP, 1992, J MOL BIOL, V227, P658, DOI 10.1016/0022-2836(92)90215-6; SAIER MH, 1989, MICROBIOL REV, V53, P109, DOI 10.1128/MMBR.53.1.109-120.1989; SAIER MH, 1976, J BIOL CHEM, V251, P6606; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; STULKE J, 1995, J BACTERIOL, V177, P6928; SWEET G, 1990, J BACTERIOL, V172, P424, DOI 10.1128/JB.172.1.424-430.1990; TERZAGHI BE, 1975, APPL MICROBIOL, V29, P807, DOI 10.1128/AEM.29.6.807-813.1975; VANDERVLAG J, 1995, MOL GEN GENET, V248, P236, DOI 10.1007/BF02190806; VANDERVLAG J, 1994, J BACTERIOL, V176, P3518, DOI 10.1128/JB.176.12.3518-3526.1994; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; WEHTJE C, 1995, MICROBIOL-SGM, V141, P1193, DOI 10.1099/13500872-141-5-1193; WEISSENBORN DL, 1992, J BIOL CHEM, V267, P6122	47	75	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14166	14174		10.1074/jbc.272.22.14166	http://dx.doi.org/10.1074/jbc.272.22.14166			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162046	hybrid			2022-12-27	WOS:A1997XB49200033
J	Zhao, HR; Nagaraj, RH; Abraham, EC				Zhao, HR; Nagaraj, RH; Abraham, EC			The role of alpha- and epsilon-amino groups in the glycation-mediated cross-linking of gamma B-crystallin - Study of three site-directed mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLATION END-PRODUCTS; AGE-DEPENDENT ACCUMULATION; MAILLARD REACTION; DIABETIC COMPLICATIONS; LENS PROTEINS; EYE LENS; N-EPSILON-(CARBOXYMETHYL)LYSINE; MUTAGENESIS; OXIDATION; GLUCOSE	In the previous report we demonstrated that gamma B-crystallin is glycated predominantly at the N-terminal alpha-amino group (Casey, E. B., Zhao, H. R., and Abraham, E. C. (1995) J. Biol. Chem. 270, 20781-20786), To investigate the possible role of alpha- and epsilon-amino groups of gamma B-crystallin in glycation-mediated cross-linking, Lys-2 or Lys-163, or both, were mutated to threonine by site-directed mutagenesis in bovine gamma B-crystallin cDNA. Wild type and mutant gamma B-crystallins were expressed in Escherichia coli cells, Cross-linking studies were performed by incubating wild type and mutant gamma B-crystallins with glyceraldehyde, ribose, and galactose followed by SDS-polyacrylamide gel electrophoresis under reducing conditions, When both of the lysines of gamma B-crystallin were mutated to threonines (gamma B-K2T/K163T), the quantity of cross-linked products was greatly reduced, indicating that, despite the fact that the alpha-amino group is a major glycated site, epsilon-amino groups play a predominant role in cross-linking, Therefore, cross-linking ability depends not only upon the level of glycation but also upon which amino group is glycated. Steric hindrance may decrease the cross-linking ability of the a-amino group. Our results also show that Lys-2 and Lys-163 play almost equal roles in cross-linking of gamma B-crystallin, By incubating carbonic anhydrase, a protein with a blocked N terminus, and our novel ''no lysine'' gamma B (gamma B-K2T/K163T) with sugar, we were able to show for the first time that significant cross-linking occurs between lysines and non-lysine sites, The fact that pentosidine and imidazolysine, formed from ribose and methylglyoxal, respectively, were present in the cross-linked gamma B-crystallins revealed the existence of Lys-Arg and Lys-Lys cross-linking.	MED COLL GEORGIA,DEPT BIOCHEM & MOL BIOL,AUGUSTA,GA 30912; CASE WESTERN RESERVE UNIV,DEPT OPHTHALMOL,CTR VIS RES,CLEVELAND,OH 44106	University System of Georgia; Augusta University; Case Western Reserve University					NATIONAL EYE INSTITUTE [R29EY009912, R01EY009912, R01EY007394, R01EY011352] Funding Source: NIH RePORTER; NEI NIH HHS [EY07394, EY09912, EY11352] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BESWICK HT, 1987, BIOCHEM J, V246, P761, DOI 10.1042/bj2460761; BLUNDELL T, 1981, NATURE, V289, P771, DOI 10.1038/289771a0; BROWNLEE M, 1994, DIABETES, V43, P836, DOI 10.2337/diab.43.6.836; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; CASEY EB, 1995, J BIOL CHEM, V270, P20781, DOI 10.1074/jbc.270.35.20781; DROFT LR, 1980, HDB PROTEIN SEQUENCE, P175; DUNN JA, 1989, BIOCHEMISTRY-US, V28, P9464, DOI 10.1021/bi00450a033; DUNN JA, 1991, BIOCHEMISTRY-US, V30, P1205, DOI 10.1021/bi00219a007; HAY RE, 1987, BIOCHEM BIOPH RES CO, V146, P332, DOI 10.1016/0006-291X(87)90729-7; HAYASE F, 1989, J BIOL CHEM, V264, P3758; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORIUCHI S, 1991, J BIOL CHEM, V266, P7329; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOK CC, 1968, EXP EYE RES, V7, P148, DOI 10.1016/S0014-4835(68)80039-9; MONNIER VM, 1989, MAILLARD REACTION AG, P1; Nagaraj RH, 1996, DIABETES, V45, P587, DOI 10.2337/diabetes.45.5.587; Nagaraj RH, 1996, J BIOL CHEM, V271, P19338, DOI 10.1074/jbc.271.32.19338; NAKAMURA K, 1993, J CHEM SOC CHEM COMM, P992; OKITANI A, 1984, AGR BIOL CHEM TOKYO, V48, P1801, DOI 10.1080/00021369.1984.10866405; OLINS PO, 1990, METHOD ENZYMOL, V185, P115; PAPACONSTANTINOU J, 1965, BIOCHIM BIOPHYS ACTA, V107, P81, DOI 10.1016/0304-4165(65)90390-9; PENNINGTON J, 1994, BBA-MOL BASIS DIS, V1226, P163, DOI 10.1016/0925-4439(94)90024-8; PRABHAKARAM M, 1994, ANAL BIOCHEM, V216, P305, DOI 10.1006/abio.1994.1046; REDDY S, 1995, BIOCHEMISTRY-US, V34, P10872, DOI 10.1021/bi00034a021; SELL DR, 1991, DIABETES METAB REV, V7, P239, DOI 10.1002/dmr.5610070404; SELL DR, 1989, J BIOL CHEM, V264, P21597; SIEZEN RJ, 1985, BIOCHEM BIOPH RES CO, V127, P153, DOI 10.1016/S0006-291X(85)80138-8; SLIGHT SH, 1990, BIOCHIM BIOPHYS ACTA, V1038, P367, DOI 10.1016/0167-4838(90)90250-J; Smith JB, 1996, ANAL BIOCHEM, V243, P186, DOI 10.1006/abio.1996.0501; SWAMY MS, 1993, EXP EYE RES, V56, P177, DOI 10.1006/exer.1993.1025; SWAMY MS, 1992, CURR EYE RES, V11, P833, DOI 10.3109/02713689209033481; VLASSARA H, 1994, J LAB CLIN MED, V124, P19; VLASSARA H, 1984, J EXP MED, V160, P197, DOI 10.1084/jem.160.1.197; WANNEMACHER CF, 1968, EXP EYE RES, V7, P623, DOI 10.1016/S0014-4835(68)80018-1; WELLSKNECHT KJ, 1995, J ORG CHEM, V60, P6246, DOI 10.1021/jo00125a001	36	17	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14465	14469		10.1074/jbc.272.22.14465	http://dx.doi.org/10.1074/jbc.272.22.14465			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162088	hybrid			2022-12-27	WOS:A1997XB49200075
J	ClaverieMartin, F; Wang, M; Cohen, SN				ClaverieMartin, F; Wang, M; Cohen, SN			ARD-1 cDNA from human cells encodes a site-specific single-strand endoribonuclease that functionally resembles Escherichia coli RNase E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5-S RIBOSOMAL-RNA; MESSENGER-RNA; AMS GENE; NUCLEOTIDE-SEQUENCE; PROTEIN; DEGRADATION; STABILITY; CLEAVES; PURIFICATION; RIBONUCLEASE	The human ARD-I (activator of RNA decay) cDNA sequence can rescue mutations in the Escherichia coli rne gene, which specifies the essential endoribonuclease RNase E, resulting in RNase E-like cleavages in vivo in me-defective bacteria and in vitro in extracts isolated from these cells (Wang, M., and Cohen, S. N. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 10591-10595). Recent studies indicate that the 13.3-kDa protein encoded by ARD-I cDNA is almost identical to the carboxyl-terminal end of the bovine protein NIPP-1, a nuclear inhibitor of protein phosphatase 1; separate transcripts formed by alternative splicing are proposed to encode the discrete ARD-1 and combined ARD-1/NIPP-1 products (Van Eynde, A., Wera, S., Beullens, M., Torrekens, S., Van Leuven, F., Stalmans, W., and Bollens, M. (1995) J. Biol. Chem. 270, 28068-28074). Here we show that affinity column-purified protein encoded by human ARD-I cDNA in E. coli is a site-specific Mg2+-dependent endoribonuclease that binds in vitro to RNase E substrates, cleaves RNA at the same sites as RNase E, and, like RNase E, generates 5' phosphate termini at sites of cleavage. Our results indicate that the ARD-I peptide can function as a ribonucleolytic analog off. coli RNase E as well as a domain of the protein phosphatase inhibitor, NIPP-1.	STANFORD UNIV, MED CTR, DEPT GENET, SCH MED, STANFORD, CA 94305 USA	Stanford University				Claverie-Martin, Felix/0000-0003-2468-3267	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027241] Funding Source: NIH RePORTER; NEI NIH HHS [EY07106] Funding Source: Medline; NIGMS NIH HHS [GM27241] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APIRION D, 1978, J BIOL CHEM, V253, P1738; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; Blackburn P, 1982, ENZYMES, VXV, P317; Brawerman G., 1993, CONTROL MESSENGER RN, P149; CANNISTRARO VJ, 1993, EUR J BIOCHEM, V213, P285, DOI 10.1111/j.1432-1033.1993.tb17761.x; Caponigro G, 1996, MICROBIOL REV, V60, P233, DOI 10.1128/MMBR.60.1.233-249.1996; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; CASAREGOLA S, 1992, J MOL BIOL, V228, P30, DOI 10.1016/0022-2836(92)90489-7; CASAREGOLA S, 1994, J MOL BIOL, V238, P867, DOI 10.1006/jmbi.1994.1344; CLAVERIEMARTIN F, 1991, J BIOL CHEM, V266, P2843; Cohen SN, 1997, MOL MICROBIOL, V23, P1099, DOI 10.1111/j.1365-2958.1997.tb02593.x; CORMACK RS, 1992, J MOL BIOL, V228, P1078, DOI 10.1016/0022-2836(92)90316-C; CORMACK RS, 1993, P NATL ACAD SCI USA, V90, P9006, DOI 10.1073/pnas.90.19.9006; Davidson JN, 1972, BIOCH NUCL ACIDS; DEUTSCHER MP, 1988, TRENDS BIOCHEM SCI, V13, P136, DOI 10.1016/0968-0004(88)90070-9; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; EHRETSMANN CP, 1992, FASEB J, V6, P3186, DOI 10.1096/fasebj.6.13.1397840; GHORA BK, 1978, CELL, V15, P1055, DOI 10.1016/0092-8674(78)90289-1; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HELMERCITTERICH M, 1988, EMBO J, V7, P557, DOI 10.1002/j.1460-2075.1988.tb02845.x; Kaberdin VR, 1996, J BIOL CHEM, V271, P13103, DOI 10.1074/jbc.271.22.13103; KUWANO M, 1977, MOL GEN GENET, V154, P279, DOI 10.1007/BF00571283; Laskowski M Sr, 1980, Methods Enzymol, V65, P263; LINCHAO S, 1994, J BIOL CHEM, V269, P10797; McClure SJ, 1996, MOL MEMBR BIOL, V13, P189, DOI 10.3109/09687689609160598; MCDOWALL KJ, 1993, J BACTERIOL, V175, P4245, DOI 10.1128/JB.175.13.4245-4249.1993; MCDOWALL KJ, 1994, J BIOL CHEM, V269, P10790; McDowall KJ, 1996, J MOL BIOL, V255, P349, DOI 10.1006/jmbi.1996.0027; MCDOWALL KJ, 1995, NATURE, V274, P487; MELEFORS O, 1993, CONTROL MESSENGER RN, P53; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; MUDD EA, 1993, MOL MICROBIOL, V9, P557, DOI 10.1111/j.1365-2958.1993.tb01716.x; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; ROBERTSON HD, 1972, J BIOL CHEM, V247, P5243; ROSENBER.M, 1974, J MOL BIOL, V89, P777, DOI 10.1016/0022-2836(74)90052-7; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; ROY MK, 1983, EUR J BIOCHEM, V131, P119, DOI 10.1111/j.1432-1033.1983.tb07238.x; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Sambrook J., 2002, MOL CLONING LAB MANU; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; SOHLBERG B, 1993, P NATL ACAD SCI USA, V90, P277, DOI 10.1073/pnas.90.1.277; STRYER L, 1995, BIOCHEMISTRY-US, P216; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TARASEVICIENE L, 1995, J BIOL CHEM, V270, P26391, DOI 10.1074/jbc.270.44.26391; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; Van Eynde A, 1995, J BIOL CHEM, V270, P28068, DOI 10.1074/jbc.270.47.28068; WANG M, 1994, P NATL ACAD SCI USA, V91, P10591, DOI 10.1073/pnas.91.22.10591; WANG M, 1996, THESIS STANFORD U ST; WENNBORG A, 1995, P NATL ACAD SCI USA, V92, P7322, DOI 10.1073/pnas.92.16.7322	49	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13823	13828		10.1074/jbc.272.21.13823	http://dx.doi.org/10.1074/jbc.272.21.13823			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153239	hybrid			2022-12-27	WOS:A1997XA06200054
J	Holmskov, U; Lawson, P; Teisner, B; Tornoe, I; Willis, AC; Morgan, C; Koch, C; Reid, KBM				Holmskov, U; Lawson, P; Teisner, B; Tornoe, I; Willis, AC; Morgan, C; Koch, C; Reid, KBM			Isolation and characterization of a new member of the scavenger receptor superfamily, glycoprotein-340 (gp-340), as a lung surfactant protein-D binding molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE LECTIN; ALVEOLAR MACROPHAGES; C1Q RECEPTOR; CELLS; COLLECTINS; CONTAINS; PURIFICATION; CARBOHYDRATE; SPECIFICITY; ANTIBODY	We have purified a previously unknown glycoprotein (designated gp-340) from human bronchioalveolar lung washings from a patient with alveolar proteinosis. gp-340 was identified by its calcium-dependent binding to lung surfactant protein D (SP-D) and by its molecular mass of 340 kDa in the reduced state on SDS-polyacrylamide gel electrophoresis (PAGE). gp-340 was purified from the 10,000 x g pellet of the lavage fluid by ion-exchange and gel permeation chromatography. On SDS-PAGE, gp-340 showed an apparent molecular mass of 290 kDa in the unreduced state. On gel chromatography under non-dissociating conditions, the apparent molecular mass of gp-340 was > 1000 kDa. The presence of N-linked glycosylation was shown by digestion with N-glycosidase F, which reduced the apparent molecular mass of gp-340 under reducing condition to about 300 kDa. Partial amino acid sequence data showed the presence of scavenger-receptor type domains. Monoclonal and polyclonal antibodies were raised against gp-340, and their specificities were confirmed by Western blotting. The antibodies were used for immunohistochemical localization of gp-340 in the lung, where it was found on the surface of and within alveolar macrophages. Direct binding between gp-340 and SP-D took place at physiological ionic strength, required the presence of calcium, and was not inhibited by maltose. The binding between SP-D and mannan also required the presence of calcium, but this interaction was completely inhibited by maltose. The same binding pattern was seen between gp-340 and recombinant human SP-D composed of the trimeric neck region and three carbohydrate recognition domains. These findings indicate that the binding between gp-340 and SP-D is a protein-protein interaction rather than a lectin-carbohydrate interaction and that the binding to gp-340 takes place via the carbohydrate recognition domain of SP-D. We conclude that gp-340 is a new member of the scavenger-receptor superfamily and likely to be a truncated form of a receptor for SP-D.	UNIV OXFORD,DEPT BIOCHEM,MRC,IMMUNOCHEM UNIT,OXFORD OX1 3QU,ENGLAND; ROYAL BROMPTON NATL HEART & LUNG HOSP,DEPT ANAESTHESIA & INTENS CARE,LONDON SW3 6NP,ENGLAND; STATENS SERUM INST,DK-2300 COPENHAGEN,DENMARK	University of Oxford; Imperial College London; Statens Serum Institut	Holmskov, U (corresponding author), ODENSE UNIV,INST MED BIOL,DEPT MED MICROBIOL,DK-5000 ODENSE,DENMARK.		Holmskov, Uffe/AAA-3056-2022; Abrams, William R/A-5782-2008	Holmskov, Uffe/0000-0002-2391-9445; 				Cheng H, 1996, ANAT REC, V244, P327; CRAWFORD C, 1990, BIOCHEM J, V265, P575, DOI 10.1042/bj2650575; CROUCH E, 1994, J BIOL CHEM, V269, P17311; CROUCH E, 1994, LUNG SURFACTANT BASI, P123; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; FISHER JH, 1995, AM J RESP CELL MOL, V12, P13, DOI 10.1165/ajrcmb.12.1.7811466; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; Goding JW, 1983, MONOCLONAL ANTIBODIE; HARTSHORN KL, 1994, J CLIN INVEST, V94, P311, DOI 10.1172/JCI117323; HOLMSKOV U, 1995, BIOCHEM J, V305, P889, DOI 10.1042/bj3050889; HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8; HOPPE HJ, 1994, FEBS LETT, V344, P191, DOI 10.1016/0014-5793(94)00383-1; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; KUAN SF, 1994, AM J RESP CELL MOL, V10, P430, DOI 10.1165/ajrcmb.10.4.8136158; KUROKI Y, 1992, BIOCHEM BIOPH RES CO, V187, P963, DOI 10.1016/0006-291X(92)91291-W; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW SKA, 1993, EUR J IMMUNOL, V23, P2320, DOI 10.1002/eji.1830230940; LI XJ, 1995, J BIOL CHEM, V270, P17674, DOI 10.1074/jbc.270.30.17674; LU JH, 1992, BIOCHEM J, V284, P795, DOI 10.1042/bj2840795; LU JH, 1993, EUR J BIOCHEM, V215, P793, DOI 10.1111/j.1432-1033.1993.tb18094.x; MALHOTRA R, 1992, EUR J IMMUNOL, V22, P1437, DOI 10.1002/eji.1830220616; MALHOTRA R, 1990, J EXP MED, V172, P955, DOI 10.1084/jem.172.3.955; MERRIL CR, 1983, METHOD ENZYMOL, V96, P230; MIYAMURA K, 1994, BIOCHEM J, V300, P237, DOI 10.1042/bj3000237; NUNES DP, 1995, BIOCHEM J, V310, P41, DOI 10.1042/bj3100041; PERSSON A, 1989, BIOCHEMISTRY-US, V28, P6361, DOI 10.1021/bi00441a031; PERSSON AV, 1992, BIOCHEMISTRY-US, V31, P12183, DOI 10.1021/bi00163a030; READING CL, 1982, J IMMUNOL METHODS, V53, P261, DOI 10.1016/0022-1759(82)90175-2; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; RUBIO S, 1995, J BIOL CHEM, V270, P12162, DOI 10.1074/jbc.270.20.12162; RUST K, 1991, ARCH BIOCHEM BIOPHYS, V290, P116, DOI 10.1016/0003-9861(91)90597-C; SCHELENZ S, 1995, INFECT IMMUN, V63, P3360, DOI 10.1128/IAI.63.9.3360-3366.1995; TENNER AJ, 1995, IMMUNITY, V3, P485, DOI 10.1016/1074-7613(95)90177-9; VAN DE VELDE H, 1991, NATURE, V351, P662; VANIWAARDEN JF, 1992, BIOCHEM J, V286, P5, DOI 10.1042/bj2860005; VOORHOUT WF, 1992, J HISTOCHEM CYTOCHEM, V40, P1589, DOI 10.1177/40.10.1527377; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0	39	177	181	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13743	13749		10.1074/jbc.272.21.13743	http://dx.doi.org/10.1074/jbc.272.21.13743			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153228	hybrid			2022-12-27	WOS:A1997XA06200043
J	Yang, YB; Yu, NJ; Tai, PC				Yang, YB; Yu, NJ; Tai, PC			SecE-depleted membranes of Escherichia coli are active - SecE is not obligatorily required for the in vitro translocation of certain protein precursors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREPROTEIN TRANSLOCASE; CYTOPLASMIC MEMBRANE; SECRETORY MACHINERY; INVERTED VESICLES; PLASMA-MEMBRANE; INNER MEMBRANE; GENE; EXPORT; ATP; RECONSTITUTION	Membrane vesicles were prepared from Escherichia coli cells in which SecE was depleted to 2% of wild-type membranes. SecE depletion had pleiotropic effects; SecD, SecF, SecG, and SecY were decreased 4-6-fold, whereas SecA was increased about 16-fold over that of wild-type membranes. These membranes were substantially active in the in vitro translocation of proOmpA, which was mediated by the SecA pathway since it was inhibited by azide. Similar substantial translocation activities were observed for proLamB and proLpp in the SecE depleted membranes. However, the translocation of proPhoA was more severely impaired. These data indicate that SecE may enhance but is not obligatorily required for the translocation of at least certain precursors, and suggest that the effects of the SecE depletion on protein translocation may be precursor-dependent.	GEORGIA STATE UNIV, DEPT BIOL, ATLANTA, GA 30303 USA	University System of Georgia; Georgia State University					NIGMS NIH HHS [GM 34766] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034766] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; ARKOWITZ RA, 1994, EMBO J, V13, P954, DOI 10.1002/j.1460-2075.1994.tb06340.x; BIEKER KL, 1990, CELL, V61, P833, DOI 10.1016/0092-8674(90)90193-I; BIEKERBRADY K, 1992, EMBO J, V11, P3165, DOI 10.1002/j.1460-2075.1992.tb05393.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRISSETTE JL, 1990, P NATL ACAD SCI USA, V87, P862, DOI 10.1073/pnas.87.3.862; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CHEN L, 1986, J BACTERIOL, V167, P389, DOI 10.1128/jb.167.1.389-392.1986; CHEN LL, 1985, P NATL ACAD SCI USA, V82, P4384, DOI 10.1073/pnas.82.13.4384; Chen XC, 1996, J BIOL CHEM, V271, P29698, DOI 10.1074/jbc.271.47.29698; DOUVILLE K, 1995, J BIOL CHEM, V270, P20106, DOI 10.1074/jbc.270.34.20106; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GARDEL C, 1987, J BACTERIOL, V169, P1286, DOI 10.1128/jb.169.3.1286-1290.1987; GELLER BL, 1986, P NATL ACAD SCI USA, V83, P4219, DOI 10.1073/pnas.83.12.4219; HANADA M, 1994, J BIOL CHEM, V269, P23625; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; KIM YJ, 1994, CELL, V78, P845; KLEEREBEZEM M, 1993, MOL MICROBIOL, V7, P947, DOI 10.1111/j.1365-2958.1993.tb01186.x; KUMAMOTO CA, 1989, P NATL ACAD SCI USA, V86, P5320, DOI 10.1073/pnas.86.14.5320; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; KUMAMOTO CA, 1993, J BACTERIOL, V175, P2184, DOI 10.1128/JB.175.8.2184-2188.1993; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MATSUYAMA S, 1992, BIOCHIM BIOPHYS ACTA, V1122, P77, DOI 10.1016/0167-4838(92)90130-6; MATSUYAMA S, 1990, FEBS LETT, V269, P96, DOI 10.1016/0014-5793(90)81128-B; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; MURPHY CK, 1994, P NATL ACAD SCI USA, V91, P2557, DOI 10.1073/pnas.91.7.2557; NISHIYAMA K, 1991, BIOCHIM BIOPHYS ACTA, V1065, P89, DOI 10.1016/0005-2736(91)90015-Z; NISHIYAMA K, 1994, EMBO J, V13, P3272, DOI 10.1002/j.1460-2075.1994.tb06628.x; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; POGLIANO JA, 1994, EMBO J, V13, P554, DOI 10.1002/j.1460-2075.1994.tb06293.x; POGLIANO KJ, 1993, GENETICS, V133, P763; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RIGGS PD, 1988, GENETICS, V118, P571; ROLLO EE, 1988, J BACTERIOL, V170, P3281, DOI 10.1128/jb.170.7.3281-3282.1988; SAGARA K, 1994, J BACTERIOL, V176, P4111, DOI 10.1128/JB.176.13.4111-4116.1994; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHATZ PJ, 1991, EMBO J, V10, P1749, DOI 10.1002/j.1460-2075.1991.tb07699.x; SCHATZ PJ, 1989, GENE DEV, V3, P1035, DOI 10.1101/gad.3.7.1035; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SHIMOIKE T, 1995, J BIOL CHEM, V270, P5519, DOI 10.1074/jbc.270.10.5519; TAI PC, 1991, METHOD CELL BIOL, V34, P167; TAURA T, 1994, MOL GEN GENET, V243, P261, DOI 10.1007/BF00301061; TOKUDA H, 1991, FEBS LETT, V279, P233, DOI 10.1016/0014-5793(91)80156-W; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; WATANABE M, 1990, P NATL ACAD SCI USA, V87, P1960, DOI 10.1073/pnas.87.5.1960; WATANABE M, 1993, P NATL ACAD SCI USA, V90, P9011, DOI 10.1073/pnas.90.19.9011; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; Zhong XT, 1996, J BIOL CHEM, V271, P28057, DOI 10.1074/jbc.271.45.28057	56	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13660	13665		10.1074/jbc.272.21.13660	http://dx.doi.org/10.1074/jbc.272.21.13660			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153216	hybrid			2022-12-27	WOS:A1997XA06200031
J	Rivers, RL; Dean, RM; Chandy, G; Hall, JE; Roberts, DM; Zeidel, ML				Rivers, RL; Dean, RM; Chandy, G; Hall, JE; Roberts, DM; Zeidel, ML			Functional analysis of nodulin 26, an aquaporin in soybean root nodule symbiosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR INTRINSIC PROTEIN; CELL CHIP28 PROTEIN; WATER CHANNEL; PERIBACTEROID MEMBRANE; LENS; PHOSPHORYLATION; PERMEABILITY; LIPOSOMES; PROTEOLIPOSOMES; RECONSTITUTION	Upon infection of soybean roots, nitrogen-fixing bacteria become enclosed in a specific organelle known as the symbiosome. The symbiosome membrane (SM) is a selectively permeable barrier that controls metabolite flux between the plant cytosol and the symbiotic bacterium inside; Nodulin 26 (NOD 26), a member of the aquaporin (AQP) water channel family, is a major protein component of the SM. Expression of NOD 26 in Xenopus oocytes gave a mercury-sensitive increase in osmotic water permeability (P-f). To define the biophysical properties of NOD 26 water channels in their native membranes, symbiosomes were isolated from soybean root nodules and the SM separated as vesicles from the bacteria. Permeabilities were measured using stopped-flow fluorimetry in SM vesicles with entrapped carboxyfluorescein. Osmotic water permeability (P-f) of SM was high, with a value of 0.05 +/- 0.003 cm/s observed at 20 degrees C (mean +/- S.E.; n = 15). Water flow exhibited a low activation energy, was inhibited by HgCl2 (0.1 mM), and exhibited a unit conductance of 3.2 +/- 1.3 x 10(-15) cm(3)/s, a value 30-fold lower than that of AQP 1, the red blood cell water channel. Diffusive water permeability (P-d) was 0.0024 +/- 0.0002 cm/s, and the resulting P-f to P-d ratio was 18.3, indicating that water crosses the SM in single file fashion via the NOD 26 water channel. In addition to high water permeability, SM vesicles also show high mercury-sensitive permeability to glycerol and formamide, but not urea, suggesting that NOD 26 also fluxes these solutes. Overall, we conclude that NOD 26 acts as a water channel with a single channel conductance that is 30-fold lower than AQP 1. Because the solutes that permeate NOD 26 are far larger than water, and water appears to cross the channel via a single file pathway, solute flux across NOD 26 appears to occur by a pathway that is distinct from that for water.	UNIV PITTSBURGH,MED CTR,LAB EPITHELIAL CELL BIOL,RENAL ELECTROLYTE DIV,PITTSBURGH,PA 15213; UNIV TENNESSEE,DEPT BIOCHEM CELLULAR & MOL BIOL,KNOXVILLE,TN 37996; UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Tennessee System; University of Tennessee Knoxville; University of California System; University of California Irvine			Hall, James E/K-6306-2012	Roberts, Daniel/0000-0002-0780-7056	NEI NIH HHS [EY05661] Funding Source: Medline; NIDDK NIH HHS [DK 43955] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043955] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRE P, 1995, CURR OPIN CELL BIOL, V7, P72; CHANDY G, 1997, IN PRESS J MEMBR BIO, V178; DAY DA, 1993, SYMBIOSIS, V14, P175; DENISON RF, 1995, PLANT PHYSIOL, V108, P235, DOI 10.1104/pp.108.1.235; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; EHRING GR, 1990, J GEN PHYSIOL, V96, P631, DOI 10.1085/jgp.96.3.631; EHRING GR, 1991, J MEMBRANE BIOL, V126, P75; FINKELSTEIN A, 1986, WATER MOVEMENT LIPID; FORTIN MG, 1987, NUCLEIC ACIDS RES, V15, P813, DOI 10.1093/nar/15.2.813; GIRSCH SJ, 1985, J MEMBRANE BIOL, V83, P217, DOI 10.1007/BF01868696; HU CAA, 1992, P NATL ACAD SCI USA, V89, P9354, DOI 10.1073/pnas.89.19.9354; HUNT S, 1993, ANNU REV PLANT PHYS, V44, P483, DOI 10.1146/annurev.pp.44.060193.002411; JUNG JS, 1994, J BIOL CHEM, V269, P14648; KUYPERS FA, 1984, J CELL BIOL, V99, P2260, DOI 10.1083/jcb.99.6.2260; LANDE MB, 1995, J GEN PHYSIOL, V106, P67, DOI 10.1085/jgp.106.1.67; LEE JW, 1995, J BIOL CHEM, V270, P27051, DOI 10.1074/jbc.270.45.27051; MAGGI CA, 1986, J AUTON PHARMACOL, V6, P133, DOI 10.1111/j.1474-8673.1986.tb00640.x; Mathai JC, 1996, J BIOL CHEM, V271, P1309, DOI 10.1074/jbc.271.3.1309; MULDERS SM, 1995, J BIOL CHEM, V270, P9010, DOI 10.1074/jbc.270.15.9010; Negrete HO, 1996, J BIOL CHEM, V271, P11627, DOI 10.1074/jbc.271.20.11627; NIKAIDO H, 1985, J MEMBRANE BIOL, V85, P87, DOI 10.1007/BF01872008; OUYANG LJ, 1991, FEBS LETT, V293, P188, DOI 10.1016/0014-5793(91)81183-9; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1994, J BIOL CHEM, V269, P1668; PURCELL LC, 1994, PLANT CELL ENVIRON, V17, P837, DOI 10.1111/j.1365-3040.1994.tb00178.x; REIZER J, 1993, CRIT REV BIOCHEM MOL, V28, P235, DOI 10.3109/10409239309086796; Roth L.E., 1988, MOL GENETICS PLANT M, P220; STEIN WD, 1990, CHANNELS CARRIERS PU, P66; Streeter JG, 1995, SYMBIOSIS, V19, P175; STREETER JG, 1992, PHYSIOL PLANTARUM, V84, P584, DOI 10.1111/j.1399-3054.1992.tb04708.x; WEAVER CD, 1991, PLANT PHYSIOL, V95, P222, DOI 10.1104/pp.95.1.222; WEAVER CD, 1994, J BIOL CHEM, V269, P17858; WEAVER CD, 1992, BIOCHEMISTRY-US, V31, P8954, DOI 10.1021/bi00152a035; Whitehead LF, 1995, SYMBIOSIS, V19, P141; YE RG, 1989, BIOCHEMISTRY-US, V28, P824, DOI 10.1021/bi00428a062; ZAMPIGHI GA, 1989, J CELL BIOL, V108, P2255, DOI 10.1083/jcb.108.6.2255; ZAMPIGHI GA, 1985, P NATL ACAD SCI USA, V82, P8468, DOI 10.1073/pnas.82.24.8468; ZAMPIGHI GA, 1995, J MEMBRANE BIOL, V148, P65; ZEIDEL ML, 1994, BIOCHEMISTRY-US, V33, P1606, DOI 10.1021/bi00172a042; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZHANG YX, 1995, MOL BIOL CELL, V6, P109, DOI 10.1091/mbc.6.1.109	41	144	156	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16256	16261		10.1074/jbc.272.26.16256	http://dx.doi.org/10.1074/jbc.272.26.16256			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195927	hybrid			2022-12-27	WOS:A1997XG01900031
J	SawkaVerhelle, D; Baron, V; Mothe, I; Filloux, C; White, MF; VanObberghen, E				SawkaVerhelle, D; Baron, V; Mothe, I; Filloux, C; White, MF; VanObberghen, E			Tyr(624) and Tyr(628) in insulin receptor substrate-2 mediate its association with the insulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-DEPENDENT INTERACTION; KINASE DOMAIN AUTOPHOSPHORYLATION; FACTOR-I RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; GROWTH-HORMONE; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; 2-HYBRID SYSTEM; NPEY MOTIF	In addition to the pleckstrin homology domain and the phosphotyrosine binding domain in insulin receptor substrate (IRS)-1 and IRS-2, a region between amino acids 591 and 786 in IRS-2 (IRS-2-(591-786)) binds to the insulin receptor. Based on peptide competition studies, this region interacts with the phosphorylated regulatory loop of the insulin receptor; we designate this region the kinase regulatory loop binding (KRLB) domain. Two tyrosine residues in the KRLB domain at positions 624 and 628 are crucial for this interaction. Phosphorylation of tyrosine residues in the KRLB domain by the insulin receptor inhibits the binding to the receptor. These results reveal a novel mechanism regulating the interaction of the insulin receptor and IRS-2 that may distinguish the signal of IRS-2 from IRS-1.	FAC MED NICE,INSERM,U145,F-06107 NICE 2,FRANCE; HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			MOTHE-SATNEY, ISABELLE/Q-6377-2016	MOTHE-SATNEY, ISABELLE/0000-0002-2693-8385	NIDDK NIH HHS [DK 38712, DK 43808] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043808, R55DK038712, R01DK038712, R29DK038712] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; ECK MJ, 1996, CELL, V85, P1; Einbond A, 1996, FEBS LETT, V384, P1, DOI 10.1016/0014-5793(96)00263-3; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HARPER JW, 1993, CELL, V75, P805; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; HOLGADOMADRUGA M, 1995, NATURE, V379, P590; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Miller J.H., 1972, EXPT MOL GENETICS; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PONS S, 1995, MOL CELL BIOL, V15, P4453; PONZIO G, 1988, EMBO J, V7, P4111, DOI 10.1002/j.1460-2075.1988.tb03305.x; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; ROCCHI S, 1995, ENDOCRINOLOGY, V136, P5291, DOI 10.1210/en.136.12.5291; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; VANOBBERGHEN E, 1981, P NATL ACAD SCI-BIOL, V78, P1052; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; WILDEN PA, 1992, J BIOL CHEM, V267, P13719	40	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16414	16420		10.1074/jbc.272.26.16414	http://dx.doi.org/10.1074/jbc.272.26.16414			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195949	hybrid, Green Submitted			2022-12-27	WOS:A1997XG01900053
J	Berger, TM; Polidori, MC; Dabbagh, A; Evans, PJ; Halliwell, B; Morrow, JD; Roberts, LJ; Frei, B				Berger, TM; Polidori, MC; Dabbagh, A; Evans, PJ; Halliwell, B; Morrow, JD; Roberts, LJ; Frei, B			Antioxidant activity of vitamin C in iron-overloaded human plasma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BLOOD-PLASMA; INDUCED LIPID-PEROXIDATION; LOW-DENSITY-LIPOPROTEIN; ASCORBIC-ACID; IDIOPATHIC HEMOCHROMATOSIS; PREMATURE-INFANTS; HYDROXYL RADICALS; HUMAN-PLACENTA; BOUND IRON; METAL-IONS	Vitamin C (ascorbic acid, AA) call act as an antioxidant or a pro-oxidant in vitro, depending on the absence or the presence, respectively, of redox-active metal ions. Some adults with iron-overload and some premature infants have potentially redox-active, bleomycin-detectable iron (BDI) in their plasma, Thus, it has been hypothesized that the combination of AA, and BDI causes oxidative damage in vivo. We found that plasma of preterm infants contains high levels of AA and F-2-isoprostanes, stable lipid peroxidation end products. However, F-2-isoprostane levels were not different between those infants with BDI (138 +/- 51 pg/ml, n = 19) and those without (126 +/- 41 pg/ml, n = 10), and the same was true for protein carbonyls, a marker of protein oxidation (0.77 +/- 0.31 and 0.68 +/- 0.13 nmol/mg protein, respectively). Incubation of BDI-containing plasma from preterm infants did not result in detectable lipid hydroperoxide formation (less than or equal to 10 nM cholesteryl ester hydroperoxides) as long as AA concentrations remained high. Furthermore, when excess iron was added to adult plasma, BDI became detectable, and endogenous AA was rapidly oxidized. Despite this apparent interaction between excess iron and endogenous AA, there was no detectable lipid peroxidation as long as AA was present at >10% of its initial concentration. Finally, when iron was added to plasma devoid of AA, lipid hydroperoxides were formed immediately, whereas endogenous and exogenous AA. delayed the onset of iron-induced lipid peroxidation in a dose-dependent manlier. These findings demonstrate that in iron-overloaded plasma, AA acts an antioxidant toward lipids. Furthermore, our data do not support the hypothesis that the combination of high plasma concentrations of AA and BDI, or EDI alone, causes oxidative damage to lipids and proteins in vivo.	BOSTON UNIV,SCH MED,WHITAKER CARDIOVASC INST,EVANS MEM DEPT MED,BOSTON,MA 02118	Boston University			Halliwell, Barry/C-8318-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056170, R29HL049954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-49954, HL-56170] Funding Source: Medline; NIDDK NIH HHS [DK-48831] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ARUOMA OI, 1989, BIOCHEM J, V258, P617, DOI 10.1042/bj2580617; ARUOMA OI, 1988, BLOOD, V72, P1416; BERGER HM, 1995, FREE RADICAL RES, V22, P555, DOI 10.3109/10715769509150327; Berger TM, 1996, REDOX REP, V2, P257, DOI 10.1080/13510002.1996.11747058; CARMINE TC, 1995, CANCER LETT, V94, P219, DOI 10.1016/0304-3835(95)03852-N; CHOI JL, 1989, AM J PHYSIOL, V257, pC110, DOI 10.1152/ajpcell.1989.257.1.C110; EVANS PJ, 1994, METHOD ENZYMOL, V233, P82; EVANS PJ, 1992, FEBS LETT, V303, P210, DOI 10.1016/0014-5793(92)80521-H; FREI B, 1991, BIOCHEM J, V277, P133, DOI 10.1042/bj2770133; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; FREI B, 1988, ANAL BIOCHEM, V175, P120, DOI 10.1016/0003-2697(88)90369-7; FREI B, 1988, P NATL ACAD SCI USA, V85, P9748, DOI 10.1073/pnas.85.24.9748; GLADSTONE IM, 1994, PEDIATRICS, V93, P764; GOPINATHAN V, 1994, FEBS LETT, V349, P197, DOI 10.1016/0014-5793(94)00666-0; GROOTVELD M, 1989, J BIOL CHEM, V264, P4417; GUTTERIDGE JMC, 1982, BIOCHEM J, V206, P605, DOI 10.1042/bj2060605; GUTTERIDGE JMC, 1981, CRC CR REV CL LAB SC, V14, P257, DOI 10.3109/10408368109105866; GUTTERIDGE JMC, 1985, CLIN SCI, V68, P463, DOI 10.1042/cs0680463; Halliwell B, 1996, FREE RADICAL RES, V25, P439, DOI 10.3109/10715769609149066; Herbert V, 1996, J NUTR, V126, pS1213, DOI 10.1093/jn/126.suppl_4.1213S; JAIN SK, 1989, SEMIN HEMATOL, V26, P286; KAUR H, 1994, ANAL BIOCHEM, V220, P11, DOI 10.1006/abio.1994.1291; LINDEMAN JHN, 1992, FREE RADICAL RES COM, V16, P285, DOI 10.3109/10715769209049181; Lyras L, 1996, FREE RADICAL RES, V24, P397, DOI 10.3109/10715769609088038; MARTIN A, 1997, IN PRESS ARTERIOSCLE; MILLER DM, 1989, ARCH BIOCHEM BIOPHYS, V271, P113, DOI 10.1016/0003-9861(89)90261-0; MINETTI M, 1992, BIOCHEM J, V282, P469; MOISON RMW, 1993, LANCET, V341, P79, DOI 10.1016/0140-6736(93)92557-A; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; PERSIJN JP, 1971, CLIN CHIM ACTA, V35, P91, DOI 10.1016/0009-8981(71)90298-1; PITKANEN OM, 1990, J PEDIATR-US, V116, P760, DOI 10.1016/S0022-3476(05)82668-X; RETSKY KL, 1993, J BIOL CHEM, V268, P1304; RETSKY KL, 1995, BBA-LIPID LIPID MET, V1257, P279, DOI 10.1016/0005-2760(95)00089-U; SAMUNI A, 1983, EUR J BIOCHEM, V137, P119, DOI 10.1111/j.1432-1033.1983.tb07804.x; SILVERS KM, 1994, ARCH DIS CHILD-FETAL, V71, pF40, DOI 10.1136/fn.71.1.F40; SOSENKO IRS, 1987, AM J PHYSIOL, V252, pR693, DOI 10.1152/ajpregu.1987.252.4.R693; STREETER ML, 1981, AM J CLIN NUTR, V34, P1706, DOI 10.1093/ajcn/34.9.1706; VARSILA E, 1994, PEDIATR RES, V36, P55, DOI 10.1203/00006450-199407001-00009; WARNER BB, 1992, SEMIN PERINATOL, V16, P47	40	167	171	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15656	15660		10.1074/jbc.272.25.15656	http://dx.doi.org/10.1074/jbc.272.25.15656			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188455	hybrid			2022-12-27	WOS:A1997XF32900015
J	Lee, MG; Xu, X; Zeng, WZ; Diaz, J; Wojcikiewicz, RJH; Kuo, TH; Wuytack, F; Racymaekers, L; Muallem, S				Lee, MG; Xu, X; Zeng, WZ; Diaz, J; Wojcikiewicz, RJH; Kuo, TH; Wuytack, F; Racymaekers, L; Muallem, S			Polarized expression of Ca2+ channels in pancreatic and salivary gland cells - Correlation with initiation and propagation of [Ca2+](i) waves	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; EXOCRINE ACINAR-CELLS; CYCLIC ADP-RIBOSE; CALCIUM RELEASE; TRISPHOSPHATE; OSCILLATIONS; LOCALIZATION; AGONISTS; ISOFORMS; SIGNALS	In polarized epithelial cells [Ca2+], waves are initiated in discrete regions and propagate through the cytosol. The structural basis for these compartmentalized and coordinated eve nts are not well understood. In the present study we used a combination of [Ca2+](i) imaging at high temporal resolution, recording of Ca2+-activated Cl- current, arid immunolocalization by confocal microscopy to study the correlation between initiation and propagation of [Ca2+](i) waves and localization of Ca2+ release channels in pancreatic acini and submandibular acinar and duct cells. In all cells Ca2+ waves are initiated in the luminal pole and propagate through the cell periphery to the basal pole. All three cell types express the three known inositol 1,4,5-trisphosphate receptors (IP(3)Rs). Expression of IP(3)Rs was confined to the area just underneath the luminal and lateral membranes, with no detectable receptors in the basal pole or other regions of the cells. In pancreatic acini and SMG ducts IP(3)Rs was also found in the nuclear envelope. Expression of ryanodine receptor was detected in submandibular salivary gland cells but not pancreatic acini, Accordingly, cyclic ADP ribose was very effective in mobilizing Ca2+ from internal stores of submandibular salivary gland but not pancreatic acinar cells, Measurement of [Ca2+](i) and localization of IP(3)Rs in the same cells suggests that only a small part of IP(3)Rs participate in the initiation of the Ca2+ wave, whereas most receptors in the cell periphery probably facilitate the propagation of the Ca2+ wave. The combined results together with our previous studies on this subject lead us to conclude that the internal Ca2+ pool is highly compartmentalized and that compartmentalization is achieved in part by polarized expression of Ca2+ channels.	UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, DALLAS, TX 75235 USA; SUNY HLTH SCI CTR, DEPT PHARMACOL, SYRACUSE, NY 13210 USA; WAYNE STATE UNIV, SCH MED, DEPT PATHOL, DETROIT, MI 48201 USA; CATHOLIC UNIV LEUVEN, PHYSIOL LAB, B-3000 LOUVAIN, BELGIUM	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Wayne State University; KU Leuven			Lee, Min Goo/AAS-4636-2020; Lee, Min Goo/D-5635-2012	Lee, Min Goo/0000-0001-7436-012X; Lee, Min Goo/0000-0001-7436-012X	NIDDK NIH HHS [DK38938, DK49194, DK46591] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938, R29DK049194, R01DK049194, R01DK046591] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIREY JA, 1990, J BIOL CHEM, V265, P14187; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1996, CELL CALCIUM, V20, P95, DOI 10.1016/S0143-4160(96)90098-6; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P17917, DOI 10.1074/jbc.270.30.17917; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; DINUDOM A, 1993, CELL CALCIUM, V14, P631, DOI 10.1016/0143-4160(93)90088-N; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KASAI H, 1990, NATURE, V346, P374; LEE HC, 1993, J BIOL CHEM, V268, P293; Lee MG, 1997, J BIOL CHEM, V272, P15771, DOI 10.1074/jbc.272.25.15771; MARANTO AR, 1994, J BIOL CHEM, V269, P1222; MUALLEM S, 1989, J BIOL CHEM, V264, P205; Muallem Shmuel, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P351; NATHANSON MH, 1994, J BIOL CHEM, V269, P4693; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; Thorn P, 1996, EMBO J, V15, P999, DOI 10.1002/j.1460-2075.1996.tb00436.x; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; TOESCU EC, 1992, J BIOL CHEM, V267, P23467; TOESCU EC, 1992, EMBO J, V11, P1623, DOI 10.1002/j.1460-2075.1992.tb05208.x; TORTORICI G, 1994, J BIOL CHEM, V269, P29621; VALDEZ IH, 1991, AM J PHYSIOL, V261, pG359, DOI 10.1152/ajpgi.1991.261.2.G359; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Xu X, 1996, J PHYSIOL-LONDON, V491, P647, DOI 10.1113/jphysiol.1996.sp021246; Xu X, 1996, J BIOL CHEM, V271, P24684, DOI 10.1074/jbc.271.40.24684; Yule DI, 1997, J BIOL CHEM, V272, P9093; Zeng WZ, 1996, J BIOL CHEM, V271, P18520, DOI 10.1074/jbc.271.31.18520; ZHANG BX, 1994, J BIOL CHEM, V269, P17132	33	245	249	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15765	15770		10.1074/jbc.272.25.15765	http://dx.doi.org/10.1074/jbc.272.25.15765			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188472	hybrid			2022-12-27	WOS:A1997XF32900032
J	Wang, KL; Khan, MT; Roufogalis, BD				Wang, KL; Khan, MT; Roufogalis, BD			Identification and characterization of a calmodulin-binding domain in Ral-A, a Ras-related GTP-binding protein purified from human erythrocyte membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING PROTEIN; SYNAPTIC VESICLES; HUMAN-PLATELETS; GENE-PRODUCTS; RECOGNITION; EFFECTOR; PEPTIDES; CELLS; EXPRESSION; SEQUENCES	A 28-kDa protein (p28) has been purified from Triton X-100 extracts of human erythrocyte plasma membrane by calmodulin affinity chromatography. Based on internal peptide sequencing and its protein amino acid composition, this protein has been shown to be highly related, if not identical to, Ral-A, a Ras-related GTP-binding protein, This protein assignment is consistent with the findings that p28 binds [P-32]GTP specifically and has low GTPase activity, In this study we describe the identification and characterization of a calmodulin-binding domain in Ral-A. The Ca2+-dependent interaction of p28 with calmodulin was first detected by a calmodulin affinity column, Gel overlay experiments of both p28 and recombinant Ral-A with biotinylated calmodulin provided strong evidence that Ral-A is a calmodulin-binding protein, A peptide of 18 residues (P18) with the sequence SKEKNGKKKRKSLAKRIR has been identified as a putative calmodulin-binding domain in Ral-A, because it comprises a basic/hydrophobic composition with the propensity to form an amphiphilic helix, P18 was synthesized, and its interaction with calmodulin by gel overlay was shown to be Ca2+-dependent, Circular dichroism analysis demonstrated that this interaction results in less alpha-helical content upon calmodulin complex formation, These results indicate that Ral-A is a calmodulin-binding protein, raising the possibility that it may be associated with Ca2+-dependent intracellular signaling pathways.	UNIV SYDNEY,DEPT PHARM,SYDNEY,NSW 2006,AUSTRALIA	University of Sydney				Roufogalis, Basil/0000-0001-9123-5478				BERTRAND B, 1994, J BIOL CHEM, V269, P13703; Bhullar RP, 1996, BBA-MOL CELL RES, V1311, P181, DOI 10.1016/0167-4889(96)00002-X; BHULLAR RP, 1987, BIOCHEM J, V245, P617, DOI 10.1042/bj2450617; BHULLAR RP, 1990, FEBS LETT, V260, P48, DOI 10.1016/0014-5793(90)80063-O; BIELINSKI DF, 1993, BIOCHIM BIOPHYS ACTA, V1151, P246, DOI 10.1016/0005-2736(93)90109-D; BILLINGSLEY ML, 1990, METHOD ENZYMOL, V184, P451; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; CARDIN P, 1986, EMBO J, V5, P2203; CARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4380; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CORVAZIER E, 1992, BIOCHEM J, V281, P325, DOI 10.1042/bj2810325; COX JA, 1985, J BIOL CHEM, V260, P2527; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; EMKEY R, 1991, J BIOL CHEM, V266, P9703; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; Fischer R, 1996, J BIOL CHEM, V271, P25067, DOI 10.1074/jbc.271.41.25067; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Hinoi T, 1996, J BIOL CHEM, V271, P19710, DOI 10.1074/jbc.271.33.19710; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; IKEDA M, 1995, FEBS LETT, V375, P37, DOI 10.1016/0014-5793(95)01169-F; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; JUMINAGA D, 1994, J BIOL CHEM, V269, P1660; Kato N, 1996, BIOCHEM BIOPH RES CO, V226, P580, DOI 10.1006/bbrc.1996.1397; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KHAN MT, 1994, J BIOL CHEM, V269, P10016; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee CHJ, 1996, J NEUROSCI, V16, P6784; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MCDOWELL L, 1985, BIOCHEMISTRY-US, V24, P2979, DOI 10.1021/bi00333a026; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; OLOFSSON B, 1988, ONCOGENE, V3, P231; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Peppelenbosch MP, 1996, J BIOL CHEM, V271, P7883, DOI 10.1074/jbc.271.14.7883; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; REESE JH, 1991, MOL CELL BIOCHEM, V104, P109; RICE RH, 1971, J BIOL CHEM, V246, P831; ROTH SM, 1991, BIOCHEMISTRY-US, V30, P10078, DOI 10.1021/bi00106a003; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P13609; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VOGEL HJ, 1995, MOL CELL BIOCHEM, V149, P3, DOI 10.1007/BF01076558; VOGEL HJ, 1994, BIOCHEM CELL BIOL, V72, P357, DOI 10.1139/o94-049; VOLKNANDT W, 1993, FEBS LETT, V317, P53, DOI 10.1016/0014-5793(93)81490-Q; WANG KKW, 1988, ARCH BIOCHEM BIOPHYS, V267, P317, DOI 10.1016/0003-9861(88)90037-9; WANG KL, 1996, P 40 AUSTR SOC BIOCH, P324; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WILDEY GM, 1993, BIOCHEM BIOPH RES CO, V194, P552, DOI 10.1006/bbrc.1993.1855; YUAN T, 1995, BIOCHEMISTRY, V34; ZHANG MJ, 1994, BIOCHEMISTRY-US, V33, P1163, DOI 10.1021/bi00171a016	58	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					16002	16009		10.1074/jbc.272.25.16002	http://dx.doi.org/10.1074/jbc.272.25.16002			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188503	hybrid			2022-12-27	WOS:A1997XF32900063
J	Akamatsu, Y; Ohno, T; Hirota, K; Kagoshima, H; Yodoi, J; Shigesada, K				Akamatsu, Y; Ohno, T; Hirota, K; Kagoshima, H; Yodoi, J; Shigesada, K			Redox regulation of the DNA binding activity in transcription factor PEBP2 - The roles of two conserved cysteine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; NF-KAPPA-B; RUNT DOMAIN; GENE; AML1; THIOREDOXIN; FAMILY; LOCALIZATION; EXPRESSION; MODULATION	Transcription factor PEBP2/CBF consists of a DNA binding subunit, alpha, and a regulatory subunit, beta. The alpha subunit has an evolutionarily conserved 128-amino acid region termed ''Runt domain'' that is responsible for both DNA binding and heterodimerization with the beta subunit. The Runt domain in all mammalian submembers of the alpha subunit contains two conserved cysteine residues, and its DNA binding activity undergoes redox regulation. To investigate the mechanism of this redox regulation, we performed site-directed mutagenesis of the two conserved cysteines in the Runt domain of the mouse PEBP2 alpha A homolog. Substitution of Cys-115 to serine resulted in a partially impaired DNA binding, which remained highly sensitive to a thiol-oxidizing reagent, diamide. Conversely, the corresponding substitution of Cys-124 caused an increased DNA binding concomitant with an increased resistance to diamide. In contrast, substitution of either cysteine to aspartate was destructive to DNA binding to marked extents. These results have revealed that both Cys-115 and Cys-124 are responsible for the redox regulation in their own ways with low and high oxidizabilities, respectively. We have also found that two cellular thiol-reactive proteins, thioredoxin and Ref-1, work effectively and synergistically for activation of the Runt domain. Interestingly, the beta subunit further enhanced the activation by these proteins and reciprocally prevented the oxidative inactivation by diamide. These findings collectively suggest the possibility that the Runt domain's function in vivo could be dynamically regulated by the redox mechanism with Trx, Ref-1, and the beta subunit as key modulators.	KYOTO UNIV,INST VIRUS RES,DEPT GENET & MOL BIOL,BIOCHEM LAB,KYOTO 60601,JAPAN; KYOTO UNIV,INST VIRUS RES,DEPT BIOL RESPONSES,LAB INFECT & PREVENT,KYOTO 60601,JAPAN	Kyoto University; Kyoto University			Hirota, Kiichi/E-9181-2010	Hirota, Kiichi/0000-0003-1110-0827				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Akamatsu Y, 1997, GENE, V185, P111, DOI 10.1016/S0378-1119(96)00644-0; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; Castagnola P, 1996, EXP CELL RES, V223, P215, DOI 10.1006/excr.1996.0075; Coffman JA, 1996, DEV BIOL, V174, P43, DOI 10.1006/dbio.1996.0050; Daga A, 1996, GENE DEV, V10, P1194, DOI 10.1101/gad.10.10.1194; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; HAINAUT P, 1993, CANCER RES, V53, P4469; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HIROTA K, 1997, IN PRESS P NATL ACAD, V94; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; Kagoshima H, 1996, J BIOL CHEM, V271, P33074, DOI 10.1074/jbc.271.51.33074; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KITAOKA Y, 1994, IMMUNOL LETT, V41, P155, DOI 10.1016/0165-2478(94)90126-0; Kurokawa M, 1996, J BIOL CHEM, V271, P16870, DOI 10.1074/jbc.271.28.16870; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LU J, 1995, MOL CELL BIOL, V15, P1651; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; SACHI Y, 1995, IMMUNOL LETT, V44, P189, DOI 10.1016/0165-2478(95)00213-O; SCHULZEOSTHOFF K, 1995, BIOCHEM PHARMACOL, V50, P735, DOI 10.1016/0006-2952(95)02011-Z; SNYDER GH, 1981, BIOCHEMISTRY-US, V20, P6509, DOI 10.1021/bi00526a001; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WASYLYK C, 1993, NUCLEIC ACIDS RES, V21, P523, DOI 10.1093/nar/21.3.523; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; YODOI J, 1992, IMMUNOL TODAY, V13, P405, DOI 10.1016/0167-5699(92)90091-K	38	122	123	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14497	14500		10.1074/jbc.272.23.14497	http://dx.doi.org/10.1074/jbc.272.23.14497			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169404	hybrid			2022-12-27	WOS:A1997XC32700001
J	Pindel, EV; Kedishvili, NY; Abraham, TL; Brzezinski, MR; Zhang, J; Dean, RA; Bosron, WF				Pindel, EV; Kedishvili, NY; Abraham, TL; Brzezinski, MR; Zhang, J; Dean, RA; Bosron, WF			Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis of cocaine and heroin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ENDOPLASMIC-RETICULUM; MICROSOMAL CARBOXYLESTERASES; GLYCOPROTEIN ESTERASE; NUCLEOTIDE-SEQUENCE; PROTEINS; HYDROLASE; CHOLINESTERASE; COCAETHYLENE; LOCALIZATION	A human liver carboxylesterase (hCE-2) that catalyzes the hydrolysis of the benzoyl group of cocaine and the acetyl groups of 4-methylumbelliferyl acetate, heroin, and 6-monoacetylmorphine was purified from human liver. The purified enzyme exhibited a single band on SDS-polyacrylamide gel electrophoresis with a subunit mass of approximately 60 kDa. The native enzyme was monomeric. The isoelectric point of hCE-2 was approximately 4.9. Treatment with endoglycosidase H caused an increase in electrophoretic mobility indicating that the liver carboxylesterase was a glycoprotein of the high mannose type. The complete cDNA nucleotide sequence was determined. The authenticity of the cDNA was confirmed by a perfect sequence match of 78 amino acids derived from the hCE-2 purified from human liver. The mature 533-amino acid enzyme encoded by this cDNA shared highest sequence identity with the rabbit liver carboxylesterase form 2 (73%) and the hamster liver carboxylesterase AT51p (67%). Carboxylesterases with high sequence identity to hCE-2 have not been reported in mouse and rat liver. hCE-2 exhibited different drug ester substrate specificity from the human liver carboxylesterase called hCE-1, which hydrolyzes the methyl ester of cocaine, hCE-2 had higher catalytic efficiencies for hydrolysis of 4-methylumbelliferyl acetate, heroin, and 6-monoacetylmorphine and greater inhibition by eserine than hCE-1. hCE-2 may play an important role in the degradation of cocaine and heroin in human tissues.	INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOL BIOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT PATHOL & LAB MED, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis				Kedishvili, Natalia/0000-0001-6917-4891	NIAAA NIH HHS [T32 AA07462] Funding Source: Medline; NIDA NIH HHS [R01 DA06836] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [T32AA007462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006836] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AIDA K, 1993, BIOCHIM BIOPHYS ACTA, V1174, P72, DOI 10.1016/0167-4781(93)90093-S; BARNETT G, 1981, J ETHNOPHARMACOL, V3, P353, DOI 10.1016/0378-8741(81)90063-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brookoff D, 1996, ANN EMERG MED, V27, P316, DOI 10.1016/S0196-0644(96)70266-4; BRZEZINSKI MR, 1994, BIOCHEM PHARMACOL, V48, P1747, DOI 10.1016/0006-2952(94)90461-8; COATES PM, 1975, ANN HUM GENET, V39, P1, DOI 10.1111/j.1469-1809.1975.tb00103.x; CYGLER M, 1993, PROTEIN SCI, V2, P366; DEAN RA, 1991, FASEB J, V5, P2735, DOI 10.1096/fasebj.5.12.1916095; FENG DF, 1990, METHOD ENZYMOL, V183, P375; GAUSTAD R, 1991, BIOCHEM J, V274, P693, DOI 10.1042/bj2740693; HARANO T, 1988, J BIOCHEM-TOKYO, V103, P149, DOI 10.1093/oxfordjournals.jbchem.a122221; HEARN WL, 1991, PHARMACOL BIOCHEM BE, V39, P531, DOI 10.1016/0091-3057(91)90222-N; KEMENDULIS LM, 1996, J PHARMACOL EXP THER, V279, P713; KORZA G, 1988, J BIOL CHEM, V263, P3486; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; LEE TD, 1990, METHOD ENZYMOL, V193, P361, DOI 10.1016/0076-6879(90)93427-M; LOCKRIDGE O, 1987, J BIOL CHEM, V262, P12945; LOMBARDO D, 1982, BIOCHIM BIOPHYS ACTA, V700, P67, DOI 10.1016/0167-4838(82)90293-X; LONG RM, 1991, LIFE SCI, V48, pPL43, DOI 10.1016/0024-3205(91)90515-D; MATSUSHIMA M, 1991, FEBS LETT, V293, P37, DOI 10.1016/0014-5793(91)81147-Z; MENTLEIN R, 1980, ARCH BIOCHEM BIOPHYS, V200, P547, DOI 10.1016/0003-9861(80)90386-0; MORGAN EW, 1994, ARCH BIOCHEM BIOPHYS, V315, P495, DOI 10.1006/abbi.1994.1531; MUNGER JS, 1991, J BIOL CHEM, V266, P18832; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; OVNIC M, 1991, GENOMICS, V11, P956, DOI 10.1016/0888-7543(91)90020-F; OVNIC M, 1991, GENOMICS, V9, P344, DOI 10.1016/0888-7543(91)90263-E; OWEN JA, 1983, CAN J PHYSIOL PHARM, V61, P870, DOI 10.1139/y83-132; OZOLS J, 1987, J BIOL CHEM, V262, P15316; OZOLS J, 1989, J BIOL CHEM, V264, P12533; PLAPP BV, 1982, METHOD ENZYMOL, V87, P469; ROBBI M, 1990, BIOCHEM J, V269, P451, DOI 10.1042/bj2690451; ROBBI M, 1991, J BIOL CHEM, V266, P20498; RONAI A, 1993, BIOCHEM GENET, V31, P279, DOI 10.1007/BF02401823; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBATA F, 1993, GENOMICS, V17, P76, DOI 10.1006/geno.1993.1285; SONE T, 1994, BBA-PROTEIN STRUCT M, V1207, P138, DOI 10.1016/0167-4838(94)90063-9; STEWART DJ, 1977, LIFE SCI, V20, P1557, DOI 10.1016/0024-3205(77)90448-9; STEWART DJ, 1979, CLIN PHARMACOL THER, V25, P464; STONE CL, 1993, ALCOHOL CLIN EXP RES, V17, P911, DOI 10.1111/j.1530-0277.1993.tb00863.x; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YAN BF, 1995, J BIOL CHEM, V270, P19128, DOI 10.1074/jbc.270.32.19128; YAN BF, 1995, ARCH BIOCHEM BIOPHYS, V317, P222, DOI 10.1006/abbi.1995.1157; YAN BF, 1995, ARCH BIOCHEM BIOPHYS, V316, P899, DOI 10.1006/abbi.1995.1121; YAN BF, 1994, J BIOL CHEM, V269, P29688	47	173	186	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14769	14775		10.1074/jbc.272.23.14769	http://dx.doi.org/10.1074/jbc.272.23.14769			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169443	hybrid			2022-12-27	WOS:A1997XC32700040
J	Wu, CF; Bishopric, NH; Pratt, RE				Wu, CF; Bishopric, NH; Pratt, RE			Atrial natriuretic peptide induces apoptosis in neonatal rat cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; SMOOTH-MUSCLE CELLS; NITRIC-OXIDE SYNTHASE; TRANSGENIC MICE; ANGIOTENSIN-II; HEART-FAILURE; DNA-SYNTHESIS; ADRENERGIC REGULATION; MYOCARDIAL-FUNCTION; INDUCED HYPERTROPHY	Early heart failure is characterized by elevated plasma atrial natriuretic peptide (ANP) levels, but little is known about the direct effects of ANP on cardiac myocytes. In neonatal rat cardiac myocytes, ANP induced apoptosis in a dose-dependent and cell type-specific manner. Maximum effects occurred at 1 mu M ANP, with a 4-5-fold increase in apoptotic cells, reaching a maximum apoptotic index of 19%. In contrast, the maximum apoptotic index of ANP-treated non-myocytes was 1.1 +/- 0.2%, equivalent to control cultures. ANP treatment also sharply reduced levels of Mcl-1 mRNA, a Bcl-2 homologue, coincident with the increase in the incidence of apoptosis. ANP induction of apoptosis was receptor-dependent and mediated by cyclic GMP: the effect was mimicked by 8-bromo-cGMP, a membrane-permeable analog, and by sodium nitroprusside, an activator of soluble guanylyl cyclase, and was potentiated by a cGMP-specific phosphodiesterase inhibitor, zaprinast. Interestingly, norepinephrine, a myocyte growth factor, inhibited ANP-induced apoptosis via activation of the beta-adrenergic receptor and elevation of cyclic AMP. These results show that ANP is a specific effector of cardiac myocyte apoptosis in culture via receptor-mediated elevation of cGMP. Furthermore, at least in this model, ANP and norepinephrine may have opposing roles in the modulation of cardiac myocyte growth and survival.	STANFORD UNIV, SCH MED, DIV CARDIOVASC MED, FALK CARDIOVASC RES CTR, STANFORD, CA 94305 USA; STANFORD RES INST INT, MOL CARDIOL LAB, STANFORD, CA 94025 USA	Stanford University; SRI International; Stanford University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007708, R01HL042663, R01HL049891] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49891, HL42663, HL07708] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANKARCRONA M, 1994, EXP CELL RES, V213, P172, DOI 10.1006/excr.1994.1187; ANTIN PB, 1988, BIOTECHNIQUES, V6, P640; BARBEE RW, 1994, CIRC RES, V74, P747, DOI 10.1161/01.RES.74.4.747; BEAUVAIS F, 1995, FEBS LETT, V361, P229, DOI 10.1016/0014-5793(95)00188-F; BING OHL, 1994, J MOL CELL CARDIOL, V26, P943, DOI 10.1006/jmcc.1994.1115; BISHOPRIC NH, 1992, J BIOL CHEM, V267, P20932; BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; BLANCO FJ, 1995, AM J PATHOL, V146, P75; Bodi I, 1995, CARDIOVASC RES, V30, P975, DOI 10.1016/S0008-6363(95)00164-6; BRALET J, 1994, J PHARMACOL EXP THER, V270, P8; CAHILL PA, 1993, J CELL PHYSIOL, V154, P28, DOI 10.1002/jcp.1041540105; CAO L, 1995, HYPERTENSION, V25, P227, DOI 10.1161/01.HYP.25.2.227; Cheng W, 1996, EXP CELL RES, V226, P316, DOI 10.1006/excr.1996.0232; CHENG W, 1995, J CLIN INVEST, V96, P2247, DOI 10.1172/JCI118280; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CLEMO HF, 1995, CIRC RES, V77, P741, DOI 10.1161/01.RES.77.4.741; COATS AJS, 1994, CARDIOVASC DRUG THER, V8, P685, DOI 10.1007/BF00877115; FRANCIS GS, 1995, CURR OPIN CARDIOL, V10, P260, DOI 10.1097/00001573-199505000-00005; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; GIBBONS GH, 1995, FASEB J, V9, pA871; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; HARE JM, 1995, PROG CARDIOVASC DIS, V38, P155, DOI 10.1016/S0033-0620(05)80004-0; ITOH H, 1990, J CLIN INVEST, V86, P1690, DOI 10.1172/JCI114893; James TN, 1996, CIRCULATION, V93, P1424, DOI 10.1161/01.CIR.93.7.1424; JAMES TN, 1994, CIRCULATION, V90, P556, DOI 10.1161/01.CIR.90.1.556; JOHN SWM, 1995, SCIENCE, V267, P679, DOI 10.1126/science.7839143; Kajstura J, 1996, LAB INVEST, V74, P86; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KIRSHENBAUM LA, 1995, J BIOL CHEM, V270, P7791, DOI 10.1074/jbc.270.14.7791; KITAJIMA I, 1994, BIOCHEM BIOPH RES CO, V204, P244, DOI 10.1006/bbrc.1994.2451; KLINGER JR, 1993, J APPL PHYSIOL, V75, P198, DOI 10.1152/jappl.1993.75.1.198; KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374; KOIBUCHI Y, 1993, HYPERTENSION, V21, P1046, DOI 10.1161/01.HYP.21.6.1046; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1995, AM J PATHOL, V146, P1309; LIN XB, 1995, CIRC RES, V77, P750, DOI 10.1161/01.RES.77.4.750; MALALT Z, 1996, NEW ENGL J MED, V335, P1190; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; MORGAN HE, 1993, CIRCULATION, V87, P4; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PARKER TG, 1993, HERZ, V18, P245; PINSKY DJ, 1995, J CLIN INVEST, V95, P677, DOI 10.1172/JCI117713; Pollman MJ, 1996, CIRC RES, V79, P748, DOI 10.1161/01.RES.79.4.748; PORTER JG, 1992, AM J PHYSIOL, V263, pC1001, DOI 10.1152/ajpcell.1992.263.5.C1001; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; REYNOLDS JE, 1994, CANCER RES, V54, P6348; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SANDVIG K, 1992, EXP CELL RES, V200, P253, DOI 10.1016/0014-4827(92)90171-4; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; TAKEI Y, 1989, BIOCHEM BIOPH RES CO, V164, P537, DOI 10.1016/0006-291X(89)91752-X; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; Teiger E, 1996, J CLIN INVEST, V97, P2891, DOI 10.1172/JCI118747; TERENZI F, 1995, J BIOL CHEM, V270, P6017, DOI 10.1074/jbc.270.11.6017; Trindade Pedro, 1995, Circulation, V92, pI696; WEI CM, 1993, CIRCULATION, V88, P1004, DOI 10.1161/01.CIR.88.3.1004; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIE KP, 1995, J EXP MED, V181, P1333, DOI 10.1084/jem.181.4.1333; YAMAZAKI T, 1995, J MOL CELL CARDIOL, V27, P133, DOI 10.1016/S0022-2828(08)80013-2	62	197	223	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14860	14866		10.1074/jbc.272.23.14860	http://dx.doi.org/10.1074/jbc.272.23.14860			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169455	hybrid			2022-12-27	WOS:A1997XC32700052
J	Hu, ZZ; Zhuang, L; Guan, XY; Meng, JP; Dufau, ML				Hu, ZZ; Zhuang, L; Guan, XY; Meng, JP; Dufau, ML			Steroidogenic factor-1 is an essential transcriptional activator for gonad-specific expression of promoter I of the rat prolactin receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR; BINDING; PROTEINS; CELLS	The expression of the prolactin receptor is under the control of two putative tissue-specific (PI, gonads; PII, liver) and one common (PIII) promoters (Hu, Z. Z., Zhuang, L., and Dufau, M. L. (1996) J. Biol. Chem, 271, 10242-10246). The three promoter regions were co-localized to the rat chromosomal locus 2q16, in the order 5'-PIII-PI-PII-3'. To investigate the mechanisms of gonad-specific utilization of PI, the promoter domain, regulatory cis-elements, and trans-factors were identified in gonadal cells. The promoter domain localized to the 152-base pair 5' of the transcriptional start site at -549 is highly active in gonadal cells but has minimal. activity in hepatoma cells. It contains a steroidogenic factor 1 (SF-1) element (-668) that binds the SF-1 protein of nuclear extracts from gonadal cells and is essential for promoter activation. A CCAAT box (-623) contributes minimally to basal activity in the absence of the SF-1 element, and two adjacent TATA-like sequences act as inhibitory elements. Thus, PI belongs to a class of TATA-less/non-initiator gene promoters, These findings demonstrate an essential role for SF-1 in transcriptional activation of promoter I of the prolactin receptor gene, which may explain the tissue-specific expression of PI in the gonads but not in the liver and the mammary gland.	NICHHD,SECT MOL ENDOCRINOL,ENDOCRINOL & REPROD RES BRANCH,NIH,BETHESDA,MD 20892; NIH,NATL HUMAN GENOME RES INST,CANC GENET LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)			/A-3639-2009; Guan, Xin-Yuan/A-3639-2009	/0000-0003-1874-9805; Guan, Xin-Yuan/0000-0002-4485-6017				ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; ALCORN JL, 1993, MOL ENDOCRINOL, V7, P1072, DOI 10.1210/me.7.8.1072; AQUILANO DR, 1984, ENDOCRINOLOGY, V114, P499, DOI 10.1210/endo-114-2-499; BARNHART KM, 1994, MOL ENDOCRINOL, V8, P878, DOI 10.1210/me.8.7.878; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DOPPLER W, 1994, REV PHYSL BIOCH PHAR, V124, P94; Duval DL, 1997, BIOL REPROD, V56, P160, DOI 10.1095/biolreprod56.1.160; GUAN XY, 1994, GENOMICS, V22, P101, DOI 10.1006/geno.1994.1350; Halvorson LM, 1996, J BIOL CHEM, V271, P6645, DOI 10.1074/jbc.271.12.6645; HONDA S, 1993, J BIOL CHEM, V268, P7494; Hu ZZ, 1996, J BIOL CHEM, V271, P10242, DOI 10.1074/jbc.271.17.10242; HU ZZ, 1991, BIOCHEM BIOPH RES CO, V181, P219, DOI 10.1016/S0006-291X(05)81405-6; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; LEVENTIS R, 1990, BIOCHIM BIOPHYS ACTA, V1023, P124, DOI 10.1016/0005-2736(90)90017-I; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; Moldrup A, 1996, MOL ENDOCRINOL, V10, P661, DOI 10.1210/me.10.6.661; MORAHASHI K, 1994, MOL ENDOCRINOL, V8, P643; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; Morohashi KI, 1996, FASEB J, V10, P1569, DOI 10.1096/fasebj.10.14.9002548; NAGANO M, 1994, J BIOL CHEM, V269, P13337; NICOLL CS, 1974, HDB PHYSIOLOGY, V4, P253; Osada S, 1996, J BIOL CHEM, V271, P3891; REBOIS RV, 1982, J CELL BIOL, V94, P70, DOI 10.1083/jcb.94.1.70; Rubtsov PM, 1996, MOL BIOL+, V30, P193; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; SIROIS J, 1992, J BIOL CHEM, V267, P11586; TSAIMORRIS CH, 1993, J BIOL CHEM, V268, P4447; WEHRENBERG U, 1994, P NATL ACAD SCI USA, V91, P1440, DOI 10.1073/pnas.91.4.1440; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794	29	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14263	14271		10.1074/jbc.272.22.14263	http://dx.doi.org/10.1074/jbc.272.22.14263			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162060	hybrid			2022-12-27	WOS:A1997XB49200047
J	Mottram, JC; Frame, MJ; Brooks, DR; Tetley, L; Hutchison, JE; Souza, AE; Coombs, GH				Mottram, JC; Frame, MJ; Brooks, DR; Tetley, L; Hutchison, JE; Souza, AE; Coombs, GH			The multiple cpb cysteine proteinase genes of Leishmania mexicana encode isoenzymes that differ in their stage regulation and substrate preferences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-BRUCEI-RHODESIENSE; C-TERMINAL EXTENSION; CHAGASI PROMASTIGOTES; EXPRESSION; CRUZI; PROTEASE; AMASTIGOTES; ENZYME; RNAS; CLONING	The cpb genes of Leishmania mexicana encode stage regulated, cathepsin L-like cysteine proteinases that are leishmanial virulence factors. Field inversion gel electrophoresis and genomic mapping indicate that there are 19 cpb genes arranged in a tandem array. Five genes from the array have been sequenced and their expression analyzed, The first two genes, cpb1 and cpb2, differ significantly from the remaining 17 copies (cpb3-cpb19) in that: 1) they are expressed predominantly in metacyclic promastigotes (the form in the insect vector which is infective to mammalian macrophages) rather than amastigotes (the form that parasitizes mammals); 2) they encode enzymes with a truncation in the COOH-terminal extension, an unusual feature of these cysteine proteinases of trypanosomatids. Transfection of cpb1 into a cpb null mutant resulted in expression of an active enzyme that was shown by immunogold labeling with anti-CPB antibodies to be targeted to large lysosomes. This demonstrates that the 100-amino acid COOH-terminal extension is not essential for the activation or activity of the enzyme or for its correct intracellular trafficking. Transfection into the cpb null mutant of different copies of cpb and analysis of the phenotype of the lines showed that individual isoenzymes differ in their substrate preferences and ability to restore the loss of virulence associated with the null mutant. Comparison of the predicted amino acid sequences of the isoenzymes implicates five residues located in the mature domain (Asn(18), Asp(60), Asn(61), Ser(64), and Tyr(84)) with differences in the activities of the encoded isoenzymes. The results suggest that the individual isoenzymes have distinct roles in the parasite's interaction with its host. This complexity reflects the adaptation of cathepsin L-like cysteine proteinases to diverse functions in parasitic protozoa.	UNIV GLASGOW,INST BIOMED & LIFE SCI,DIV INFECT & IMMUN,GLASGOW G12 8QQ,LANARK,SCOTLAND	University of Glasgow	Mottram, JC (corresponding author), UNIV GLASGOW,ANDERSON COLL,WELLCOME UNIT MOL PARASITOL,56 DUMBARTON RD,GLASGOW G11 6NU,LANARK,SCOTLAND.			Mottram, Jeremy/0000-0001-5574-3766	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; ASLUND L, 1991, MOL BIOCHEM PARASIT, V45, P345, DOI 10.1016/0166-6851(91)90103-D; BANNISTER LH, 1992, MOL PARASITOLOGY PRO, P415; BATES PA, 1994, J EUKARYOT MICROBIOL, V41, P199, DOI 10.1111/j.1550-7408.1994.tb01497.x; BATES PA, 1992, PARASITOLOGY, V105, P193, DOI 10.1017/S0031182000074102; BERTI PJ, 1995, J MOL BIOL, V246, P273, DOI 10.1006/jmbi.1994.0083; CAMPETELLA O, 1992, MOL BIOCHEM PARASIT, V50, P225, DOI 10.1016/0166-6851(92)90219-A; CARMONA C, 1996, BIOCHEMISTRY-US, V35, P8149; CAZZULO JJ, 1990, MOL BIOCHEM PARASIT, V38, P41, DOI 10.1016/0166-6851(90)90203-X; CAZZULO JJ, 1992, FEMS MICROBIOL LETT, V100, P411, DOI 10.1111/j.1574-6968.1992.tb05733.x; Coombs Graham H., 1997, P177; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; DUFFY MJ, 1992, CLIN EXP METASTAS, V10, P145, DOI 10.1007/BF00132746; EAKIN AE, 1992, J BIOL CHEM, V267, P7411; EAKIN AE, 1993, J BIOL CHEM, V268, P6115; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN; HIDE G, 1997, TRYPANOSOMIASIS LEIS; ILG T, 1994, MOL BIOCHEM PARASIT, V67, P193, DOI 10.1016/0166-6851(94)00126-X; KATEGAWA H, 1996, FEBS LETT, V321, P247; KELLY JM, 1992, NUCLEIC ACIDS RES, V20, P3963, DOI 10.1093/nar/20.15.3963; KIRSCHKE H, 1987, LYSOSOMES THEIR ROLE, P193; KOIZUMI M, 1993, GENE, V129, P175, DOI 10.1016/0378-1119(93)90266-6; LEBOWITZ JH, 1993, GENE DEV, V7, P996, DOI 10.1101/gad.7.6.996; MACH L, 1994, J BIOL CHEM, V269, P13036; MACH L, 1994, J BIOL CHEM, V269, P13030; MCGRATH ME, 1995, J MOL BIOL, V247, P251, DOI 10.1006/jmbi.1994.0137; McKerrow J. H., 1994, PERSPECT DRUG DISCOV, V2, P437; MCKERROW JH, 1993, ANNU REV MICROBIOL, V47, P821, DOI 10.1146/annurev.mi.47.100193.004133; MOTTRAM JC, 1992, MOL MICROBIOL, V6, P1925, DOI 10.1111/j.1365-2958.1992.tb01365.x; Mottram JC, 1996, P NATL ACAD SCI USA, V93, P6008, DOI 10.1073/pnas.93.12.6008; MOTTRAM JC, 1993, J BIOL CHEM, V268, P21044; MOTTRAM JC, 1985, EXP PARASITOL, V59, P151, DOI 10.1016/0014-4894(85)90067-0; MOTTRAM JC, 1989, FEBS LETT, V258, P211, DOI 10.1016/0014-5793(89)81655-2; PAMER EG, 1990, NUCLEIC ACIDS RES, V18, P6141, DOI 10.1093/nar/18.20.6141; PAMER EG, 1991, INFECT IMMUN, V59, P1074, DOI 10.1128/IAI.59.3.1074-1078.1991; PUPKIS MF, 1986, EXP PARASITOL, V62, P29, DOI 10.1016/0014-4894(86)90005-6; RAMAMOORTHY R, 1992, J BIOL CHEM, V267, P1888; RAMAMOORTHY R, 1995, J BIOL CHEM, V270, P12133, DOI 10.1074/jbc.270.20.12133; ROBERTS SC, 1995, J BIOL CHEM, V270, P8884, DOI 10.1074/jbc.270.15.8884; ROBERTSON CD, 1990, MOL BIOCHEM PARASIT, V42, P269, DOI 10.1016/0166-6851(90)90170-Q; ROBERTSON CD, 1992, FEMS MICROBIOL LETT, V94, P127, DOI 10.1111/j.1574-6968.1992.tb05301.x; ROBERTSON CD, 1994, MICROBIOL-SGM, V140, P417, DOI 10.1099/13500872-140-2-417; Robertson CD, 1996, PERSPECT DRUG DISCOV, V6, P99, DOI 10.1007/BF02174048; Sakanari JA, 1997, EXP PARASITOL, V85, P63, DOI 10.1006/expr.1996.4116; Sambrook J., 2002, MOL CLONING LAB MANU; Sogin ML, 1991, CURR OPIN GENET DEV, V1, P457, DOI 10.1016/S0959-437X(05)80192-3; SOUZA AE, 1994, MOL BIOCHEM PARASIT, V63, P213, DOI 10.1016/0166-6851(94)90057-4; SOUZA AE, 1992, FEBS LETT, V311, P124, DOI 10.1016/0014-5793(92)81382-V; Tomas AM, 1996, MOL BIOCHEM PARASIT, V76, P91, DOI 10.1016/0166-6851(95)02545-6; TRABANDT A, 1990, MATRIX, V10, P349, DOI 10.1016/S0934-8832(11)80142-3; TRAUBCSEKO YM, 1993, MOL BIOCHEM PARASIT, V57, P101, DOI 10.1016/0166-6851(93)90248-V; WATANABE H, 1991, J BIOL CHEM, V266, P16897	52	108	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14285	14293		10.1074/jbc.272.22.14285	http://dx.doi.org/10.1074/jbc.272.22.14285			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162063	hybrid			2022-12-27	WOS:A1997XB49200050
J	Potapova, O; Haghighi, A; Bost, F; Liu, CT; Birrer, MJ; Gjerset, R; Mercola, D				Potapova, O; Haghighi, A; Bost, F; Liu, CT; Birrer, MJ; Gjerset, R; Mercola, D			The Jun kinase stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; C-JUN; HA-RAS; TOPOISOMERASE GENE; POLYMERASE-BETA; PHOSPHORYLATION; DOMAIN; BINDS; TRANSFORMATION; TRANSCRIPTION	We have studied the role of Jun/stress-activated protein kinase (JNK/SAPK) pathway in DNA repair and cisplatin resistance in T98G glioblastoma cells. JUN/SAPK is activated by DNA damage and phosphorylates serines 63 and 73 in the N-terminal domain of c-Jun, which is known to increase its transactivation properties, We show that treatment of T98G glioblastoma cells with cisplatin but not the transplatin isomer activates JNK/SAPK about 10-fold, T98G cells, which are highly resistent to cisplatin (IC50 = 140 +/- 13 mu M), modified to express a nonphosphorylatable dominant negative c-Jun (termed dnJun) exhibit decreased viability following treatment with cisplatin, but not transplatin, in proportion (r(Pearson) = 0.98) to the level of dnJun expressed leading to a 7-fold decreased IC50. Similar effects are observed in U87 cells, PC-3 cells, and MCF-7 cells, as well as in T98G cells modified to express TAM-67, a known inhibitor of c-Jun function. In contrast, no sensitization effect was observed in cells modified to express wildtype c-Jun, Furthermore, through quantitative polymerase chain reaction-stop assays, we show that dnJun expressing cells were inhibited in repair of cisplatin adducts (p = 0.55), whereas repair is readily detectable (p = 0.003) in parental cells. These observations indicate that the JNK/SAPK pathway is activated by cisplatin-induced DNA damage and that this response is required for DNA repair and viability following cisplatin treatment, Regulation of DNA repair following genotoxic stress may be a normal physiological role of the JNK/SAPK pathway.	SIDNEY KIMMEL CANC CTR,SAN DIEGO,CA 92121; UNIV CALIF SAN DIEGO,CTR MOL GENET,LA JOLLA,CA 92093; NIH,DIV BIOMARKERS,ROCKVILLE,MD 20850; NIH,PREVENT RES BRANCH,ROCKVILLE,MD 20850	University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA			mercola, dan/L-4182-2013; BOST, Frederic/AAN-4691-2020	mercola, dan/0000-0002-0281-9840; BOST, Frederic/0000-0003-4509-4701	NCI NIH HHS [CA 63783] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063783] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ADLER V, 1995, CELL GROWTH DIFFER, V6, P1437; BAUMGARTNER B, 1994, BBA-GENE STRUCT EXPR, V1218, P123, DOI 10.1016/0167-4781(94)90114-7; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BROWN PH, 1994, ONCOGENE, V9, P791; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FEUERSTEIN N, 1995, J BIOL CHEM, V270, P9454, DOI 10.1074/jbc.270.16.9454; Gjerset RA, 1995, MOL CARCINOGEN, V14, P275, DOI 10.1002/mc.2940140408; GROVERBARDWICK A, 1994, CARCINOGENESIS, V15, P1667, DOI 10.1093/carcin/15.8.1667; HEILAND S, 1993, EUR J BIOCHEM, V217, P813, DOI 10.1111/j.1432-1033.1993.tb18309.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HORTON JK, 1995, NUCLEIC ACIDS RES, V23, P3810, DOI 10.1093/nar/23.19.3810; HUANG DY, 1994, MOL CELL BIOL, V14, P4233, DOI 10.1128/MCB.14.6.4233; JENNERWEIN MM, 1991, NUCLEIC ACIDS RES, V19, P6209, DOI 10.1093/nar/19.22.6209; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KEDAR PS, 1991, P NATL ACAD SCI USA, V88, P3729, DOI 10.1073/pnas.88.9.3729; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MERCOLA D, 1992, ONCOGENE, V7, P1793; Potapova O, 1996, CANCER RES, V56, P280; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SHERMAN SE, 1985, SCIENCE, V230, P412, DOI 10.1126/science.4048939; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yu R, 1996, CANCER RES, V56, P2954; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7	33	215	220	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14041	14044		10.1074/jbc.272.22.14041	http://dx.doi.org/10.1074/jbc.272.22.14041			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162025	hybrid			2022-12-27	WOS:A1997XB49200012
J	Seto, NOL; Palcic, MM; Compston, CA; Li, H; Bundle, DR; Narang, SA				Seto, NOL; Palcic, MM; Compston, CA; Li, H; Bundle, DR; Narang, SA			Sequential interchange of four amino acids from blood group B to blood group A glycosyltransferase boosts catalytic activity and progressively modifies substrate recognition in human recombinant enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-SPECIFIED GLYCOSYLTRANSFERASES; GROUP-A-GENE; ACCEPTOR ALPHA-L-FUCP-(1->2)-BETA-D-GALP-OR; ABO; ALPHA-3-N-ACETYLGALACTOSAMINYLTRANSFERASE; GLYCOPROTEINS; PURIFICATION; ANTIGENS; ANALOGS; SYSTEM	The human blood group A and B glycosyltransferase enzymes are highly homologous and the alteration of four critical amino acid residues (Arg-176 --> Gly, Gly-235 --> Ser, Leu-266 --> Met, and Gly-268 - Ala) is sufficient to change the enzyme specificity from a blood group A to a blood group B glycosyltransferase, To carry out a systematic study, a synthetic gene strategy was employed to obtain their genes and to allow facile mutagenesis. Soluble forms of a recombinant glycosyltransferase A and a set of hybrid glycosyltransferase A and B mutants were expressed in Escherichia coli in high yields, which allowed them to be kinetically characterized extensively for the first time, A functional hybrid A/B mutant enzyme was able to catalyze both A and B reactions, with the k(cat) being 5-fold higher for the A donor, Surprisingly, even a single amino acid replacement in glycosyltransferase A with the corresponding residue from glycosyltransferase B (Arg-176 --> Gly) produced enzymes with glycosyltransferase A activity only, but with very large (11-fold) increases in the k(cat) and increased specificity, The increases observed in k(cat) are among the largest obtained for a single amino acid change and are advantageous for the preparative scale synthesis of blood group antigens.	UNIV ALBERTA,DEPT CHEM,EDMONTON,AB T6G 2G2,CANADA	University of Alberta	Seto, NOL (corresponding author), NATL RES COUNCIL CANADA,INST BIOL SCI,100 SUSSEX DR,OTTAWA,ON K1A 0R6,CANADA.							DAVIDSOHN I, 1972, Haematologia, V6, P177; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FUKUDA M, 1992, MOL GLYCOBIOLOGY; GINSBERG V, 1991, BIOL CARBOHYDRATES, V3; GREENWELL P, 1986, CARBOHYD RES, V149, P149, DOI 10.1016/S0008-6215(00)90375-6; ICHIKAWA Y, 1992, ANAL BIOCHEM, V202, P215, DOI 10.1016/0003-2697(92)90099-S; KESHVARA LM, 1992, GLYCOCONJUGATE J, V9, P16, DOI 10.1007/BF00731173; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; LEMIEUX RU, 1980, CAN J CHEM, V58, P631, DOI 10.1139/v80-098; LOWARY TL, 1993, CARBOHYD RES, V249, P163, DOI 10.1016/0008-6215(93)84068-H; LOWARY TL, 1994, CARBOHYD RES, V251, P33, DOI 10.1016/0008-6215(94)84275-2; NAGAI M, 1978, J BIOL CHEM, V253, P380; NAVARATNAM N, 1990, BIOCHEM J, V271, P93, DOI 10.1042/bj2710093; OEHRLEIN R, 1993, CARBOHYD RES, V244, P149, DOI 10.1016/0008-6215(93)80011-3; PALCIC MM, 1994, METHOD ENZYMOL, V230, P300; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; RACE C, 1974, CARBOHYD RES, V37, P239, DOI 10.1016/S0008-6215(00)87077-9; Sambrook J., 2002, MOL CLONING LAB MANU; SETO NOL, 1995, EUR J BIOCHEM, V234, P323, DOI 10.1111/j.1432-1033.1995.323_c.x; SINGHAL A, 1990, BIOESSAYS, V12, P223, DOI 10.1002/bies.950120506; TAKEYA A, 1990, J BIOCHEM, V107, P360, DOI 10.1093/oxfordjournals.jbchem.a123051; Watkins W M, 1980, Adv Hum Genet, V10, P1; YAMAMOTO F, 1990, J BIOL CHEM, V265, P19257; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YAMAMOTO F, 1990, J BIOL CHEM, V265, P1146; YAMAMOTO FI, 1993, VOX SANG, V64, P120, DOI 10.1111/j.1423-0410.1993.tb02529.x; YOSHIDA A, 1980, American Journal of Human Genetics, V32, P645	27	83	95	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14133	14138		10.1074/jbc.272.22.14133	http://dx.doi.org/10.1074/jbc.272.22.14133			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162041	hybrid			2022-12-27	WOS:A1997XB49200028
J	Weaver, AM; Hussaini, IM; Mazar, A; Henkin, J; Gonias, SL				Weaver, AM; Hussaini, IM; Mazar, A; Henkin, J; Gonias, SL			Embryonic fibroblasts that are genetically deficient in low density lipoprotein receptor-related protein demonstrate increased activity of the urokinase receptor system and accelerated migration on vitronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR RECEPTOR; PSEUDOMONAS EXOTOXIN-A; AFFINITY-CHROMATOGRAPHY; BASEMENT-MEMBRANE; GENE-EXPRESSION; MOLECULAR-BASIS; CELL-MIGRATION; HUMAN-PLASMA; ADHESION; ALPHA-2-MACROGLOBULIN	Low density lipoprotein receptor-related protein (LRP) mediates the endocytosis of diverse ligands, including urokinase plasminogen activator (uPA) and its receptor, uPAR, which have been implicated in cellular migration. The purpose of this study was to determine whether LRP affects cellular migration, Murine embryonic fibroblasts (MEF) that are LRP-deficient due to targeted gene disruption and exotoxin selection (MEF-2), heterozygous fibroblasts (PEA-10), and wild-type fibroblasts (MEF-1) were compared. When cultures were denuded of cells in a 1-mm-wide strip, all three cell types migrated into the denuded area. The MEF-2 cells migrated nearly twice as rapidly as the MEF-1 cells or PEA-10 cells, The difference in migration velocity was duplicated in culture wells that were precoated with serum or vitronectin and partially duplicated in wells coated with fibronectin but not in wells coated with type I collagen or Matrigel. uPA was detected in MEF-2 conditioned medium (CM) at a concentration of 0.30 +/- 0.02 nm, which was 13-fold higher than the level detected in MEF-1 CM or PEA-10 CM, suggesting one potential mechanism for the enhanced migration of MEF-2 cells. uPAR was also increased on MEF-2 cells by 4-5-fold, as determined by PI-PLC release, and by 2.5-fold, as determined by a uPA/uPAR activity assay, Mannosamine treatment, which down-regulates cell-surface uPAR, decreased MEF-2 migration by 40% without significantly affecting MEF-1 migration, MEF-2 CRI, which is uPA-rich, increased the rate of MEF-1 migration, and MEF-1 CM did not, These studies demonstrate alterations in cellular migration and in the activity of the uPA/uPAR system which accompany complete deficiency of LRP expression in fibroblasts. We propose that uPA and uPAR form an autocrine loop for promoting fibroblast migration and that LRP counteracts the activity of this system.	UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT BIOCHEM,CHARLOTTESVILLE,VA 22908; ABBOTT LABS,ABBOTT PK,IL 60064	University of Virginia; University of Virginia; Abbott Laboratories					NCI NIH HHS [CA-53462] Funding Source: Medline; NIGMS NIH HHS [GM07267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANONICK PK, 1991, BIOCHEM J, V275, P53, DOI 10.1042/bj2750053; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; COHEN RL, 1991, BLOOD, V78, P479; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DUMLER I, 1994, FEBS LETT, V343, P103, DOI 10.1016/0014-5793(94)80298-X; ELLIS V, 1992, FIBRINOLYSIS, V6, P27; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; Glass WF, 1996, J AM SOC NEPHROL, V7, P2230; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; HARLAN JM, 1993, CLIN IMMUNOL IMMUNOP, V67, pS16, DOI 10.1006/clin.1993.1079; Hayden SM, 1996, J NEUROSCI, V16, P2307; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; Higazi AAR, 1996, BLOOD, V88, P542, DOI 10.1182/blood.V88.2.542.bloodjournal882542; Hussaini IM, 1996, J LEUKOCYTE BIOL, V59, P733, DOI 10.1002/jlb.59.5.733; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jones JI, 1996, P NATL ACAD SCI USA, V93, P2482, DOI 10.1073/pnas.93.6.2482; Kindzelskii AL, 1996, J IMMUNOL, V156, P297; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; KOLEV K, 1995, BBA-PROTEIN STRUCT M, V1247, P239, DOI 10.1016/0167-4838(94)00220-B; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; LAMARRE J, 1993, J CLIN INVEST, V91, P1219, DOI 10.1172/JCI116283; LAUFFENBURGER DA, 1991, ANNU REV BIOPHYS BIO, V20, P387, DOI 10.1146/annurev.biophys.20.1.387; LIJNEN HR, 1989, BLOOD, V73, P1864; MCNEILL H, 1990, CELL REGUL, V1, P843, DOI 10.1091/mbc.1.11.843; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; NUSRAT AR, 1991, J CLIN INVEST, V87, P1091, DOI 10.1172/JCI115070; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; OLSON D, 1992, J BIOL CHEM, V267, P9129; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; PLOUG M, 1991, J BIOL CHEM, V266, P1926; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; RAGHOW R, 1994, FASEB J, V8, P823, DOI 10.1096/fasebj.8.11.8070631; RAO NK, 1995, J CLIN INVEST, V96, P465, DOI 10.1172/JCI118057; SEVLEVER D, 1993, J BIOL CHEM, V268, P10938; Sitrin RG, 1996, J CLIN INVEST, V97, P1942, DOI 10.1172/JCI118626; Sonnenberg A, 1993, Curr Top Microbiol Immunol, V184, P7; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; TOONEY PA, 1993, IMMUNOL CELL BIOL, V71, P131, DOI 10.1038/icb.1993.14; VASSALLI JD, 1987, FEBS LETT, V214, P187, DOI 10.1016/0014-5793(87)80039-X; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360; Weaver AM, 1996, J BIOL CHEM, V271, P24894, DOI 10.1074/jbc.271.40.24894; Webb DJ, 1995, EUR J BIOCHEM, V234, P714, DOI 10.1111/j.1432-1033.1995.714_a.x; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1994, J CELL SCI, V107, P719; XUE W, 1994, J IMMUNOL, V152, P4630; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	61	87	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14372	14379		10.1074/jbc.272.22.14372	http://dx.doi.org/10.1074/jbc.272.22.14372			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162074	hybrid			2022-12-27	WOS:A1997XB49200061
J	Fukumoto, S; Nishizawa, Y; Hosoi, M; Koyama, H; Yamakawa, K; Ohno, S; Morii, H				Fukumoto, S; Nishizawa, Y; Hosoi, M; Koyama, H; Yamakawa, K; Ohno, S; Morii, H			Protein kinase C delta inhibits the proliferation of vascular smooth muscle cells by suppressing G(1) cyclin expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER; 3T3 CELLS; SIGNAL-TRANSDUCTION; D1 EXPRESSION; CALCIUM-ION; G1 PHASE; EPSILON; GROWTH; ACTIVATION; FAMILY	To elucidate the physiological role of protein kinase C (PKC) delta, a ubiquitously expressed isoform in vascular smooth muscle cells (VSMC), PKC delta was stably overexpressed in A7r5 cells, rat clonal VSMC. The [H-3]thymidine incorporation in A7r5 overexpressed with PKC delta (DVs) was suppressed to 37.1 +/- 16.3% (mean +/- S.D.) of the level in control or A7r5 transfected with vector alone (EVs). The reduction of [H-3]thymidine incorporation was strongly correlated with overexpressed PKC levels. Moreover, transient transfection of a dominant negative mutant of PKC delta restored the reduced proliferation in DVs. Flow cytometry analysis demonstrated that DVs were arrested in the G(0)/G(1), phase of the cell cycle. Expression of cyclins D1 and E and retinoblastoma protein phosphorylation were reduced, while the protein levels of p27 were elevated in DVs as compared with EVs. There were no significant differences in the expression of c-fos, c-jun, c-myc, cyclin D2, D3, cyclin dependent kinase 2, cyclin-dependent kinase 4, and p21 among the clones. We conclude that PKC delta inhibits the proliferation of VSMC by arresting cells in G(1) via mainly inhibiting the expression of cyclin D1 and cyclin E.	YOKOHAMA CITY UNIV,SCH MED,DEPT MOL BIOL,YOKOHAMA,KANAGAWA 236,JAPAN	Yokohama City University	Fukumoto, S (corresponding author), OSAKA CITY UNIV,SCH MED,DEPT INTERNAL MED 2,OSAKA 545,JAPAN.		Ohno, Shigeo/B-1768-2010; Koyama, Hidenori/AAU-2346-2020	Ohno, Shigeo/0000-0002-1294-5269; Koyama, Hidenori/0000-0001-7930-2228				ANDREA JE, 1992, HYPERTENSION, V20, P585, DOI 10.1161/01.HYP.20.5.585; BIANCHI S, 1994, BIOCHEM BIOPH RES CO, V204, P691, DOI 10.1006/bbrc.1994.2515; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; HAN EKH, 1995, CARCINOGENESIS, V16, P2423, DOI 10.1093/carcin/16.10.2423; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; HUANG CL, 1987, NATURE, V329, P849, DOI 10.1038/329849a0; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; JONES LG, 1994, J BIOL CHEM, V269, P23790; KAIBUCHI K, 1986, J BIOL CHEM, V261, P1187; KO TC, 1995, ONCOGENE, V10, P177; Koyama H, 1996, CIRC RES, V79, P757, DOI 10.1161/01.RES.79.4.757; LEE MW, 1994, AM J PHYSIOL, V267, pC659, DOI 10.1152/ajpcell.1994.267.3.C659; LEHEL C, 1994, J BIOL CHEM, V269, P4761; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; MORETON K, 1995, FEBS LETT, V372, P33, DOI 10.1016/0014-5793(95)00941-2; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OSADA S, 1990, J BIOL CHEM, V265, P22434; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sasaguri T, 1996, J BIOL CHEM, V271, P8345, DOI 10.1074/jbc.271.14.8345; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tasinato A, 1995, P NATL ACAD SCI USA, V92, P12190, DOI 10.1073/pnas.92.26.12190; TSUDA T, 1986, FEBS LETT, V208, P39, DOI 10.1016/0014-5793(86)81527-7; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159	42	159	187	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13816	13822		10.1074/jbc.272.21.13816	http://dx.doi.org/10.1074/jbc.272.21.13816			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153238	hybrid			2022-12-27	WOS:A1997XA06200053
J	Han, GR; Dohi, DF; Lee, HY; Rajah, R; Walsh, GL; Hong, WK; Cohen, P; Kurie, JM				Han, GR; Dohi, DF; Lee, HY; Rajah, R; Walsh, GL; Hong, WK; Cohen, P; Kurie, JM			All-trans-retinoic acid increases transforming growth factor-beta 2 and insulin-like growth factor binding protein-3 expression through a retinoic acid receptor-alpha-dependent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRONCHIAL EPITHELIAL-CELLS; BREAST-CARCINOMA CELLS; FACTOR-BETA; TGF-BETA; GENE-EXPRESSION; VITAMIN-A; COMPLEMENTARY-DNA; CANCER CELLS; IGF-I; DIFFERENTIATION	Retinoids, including retinol and retinoic acid derivatives, maintain the normal growth and differentiation of human bronchial epithelial cells. The signaling pathways through which retinoids mediate these effects have not been defined. Insulin-like growth factor binding protein-3 (IGFBP-3) and the transforming growth factor-beta (TGF-beta) gene family (beta 1-3) were examined as potential components of the retinoid signaling pathway in normal human bronchial epithelial cells. All-transretinoic acid (t-RA) increased the levels of TGF-beta 2 and IGFBP-3 mRNA and of secreted TGF-beta and IGFBP-3 proteins. An antagonist of retinoic acid receptor-alpha, LG100629, abrogated the increase in TGF-beta 2 and IGFBP-3 mRNA levels induced by t-RA. t-RA increased IGFBP-3 mRNA levels transiently from 1 to 6 h, and subsequently a sustained increase began at 72 h, which coincided with the appearance of active TGF-beta in the media. Treatment with TGF-beta 2 increased IGFBP-3 mRNA levels, but treatment with latency-associated peptide, which inactivates secreted TGF-beta, did not abrogate the effect of t-RA on IGFBP-3 expression. These findings provide evidence that t-RA increased TGF-beta 2 and IGFBP-3 expression through an retinoic acid receptor-alpha-dependent pathway, and the increase in IGFBP-3 expression by t-RA did not require activation of the TGF-beta pathway by autocrine or paracrine mechanisms.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT THORAC HEAD & NECK MED ONCOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT THORAC & CARDIOVASC SURG,HOUSTON,TX 77030; UNIV PENN,DEPT PEDIAT,PHILADELPHIA,PA 19104	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Pennsylvania				Lee, Ho-Young/0000-0001-7556-9312	NCI NIH HHS [R29 CA 67353] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA067353] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMO ML, 1992, ENDOCRINOLOGY, V131, P1858, DOI 10.1210/en.131.4.1858; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; BATOVA A, 1992, CELL GROWTH DIFFER, V3, P763; CHOPRA DP, 1982, J NATL CANCER I, V69, P895; COHEN P, 1991, ACTA ENDOCRINOL-COP, V124, P74; COHEN P, 1991, J CLIN ENDOCR METAB, V73, P491; COHEN PS, 1995, CANCER RES, V55, P2830; Danielpour D, 1996, J CELL PHYSIOL, V166, P231, DOI 10.1002/(SICI)1097-4652(199601)166:1<231::AID-JCP24>3.0.CO;2-G; DEMARTIN R, 1987, EMBO J, V6, P3673, DOI 10.1002/j.1460-2075.1987.tb02700.x; DERYNCK R, 1988, EMBO J, V7, P3737, DOI 10.1002/j.1460-2075.1988.tb03257.x; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DROP SLS, 1992, GROWTH REGULAT, V2, P69; FONTANA JA, 1991, ENDOCRINOLOGY, V128, P1115, DOI 10.1210/endo-128-2-1115; GLICK AB, 1991, DEVELOPMENT, V111, P1081; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; Gucev ZS, 1996, CANCER RES, V56, P1545; Hembree JR, 1996, CANCER RES, V56, P1794; Holly J M, 1994, Growth Regul, V4 Suppl 1, P20; JETTEN AM, 1986, BIOCHEM SOC T, V14, P930, DOI 10.1042/bst0140930; JETTEN AM, 1987, LAB INVEST, V56, P654; JETTEN AM, 1986, EXP CELL RES, V167, P539, DOI 10.1016/0014-4827(86)90193-X; KATZ J, 1995, J CELL PHYSIOL, V165, P223, DOI 10.1002/jcp.1041650202; KIM YH, 1995, CANCER RES, V55, P5603; KOJIMA S, 1993, J CELL PHYSIOL, V155, P323, DOI 10.1002/jcp.1041550213; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; LEYEN SAV, 1994, J CELL PHYSL, V160, P265; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MARTIN JL, 1995, ENDOCRINOLOGY, V136, P1219, DOI 10.1210/en.136.3.1219; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MILLER LA, 1993, CANCER RES, V53, P2527; NILES RM, 1994, IN VITRO CELL DEV-AN, V30A, P256; NUGENT P, 1995, EXP CELL RES, V220, P495, DOI 10.1006/excr.1995.1341; Nunes I, 1996, CANCER RES, V56, P495; OH Y, 1995, J BIOL CHEM, V270, P13589, DOI 10.1074/jbc.270.23.13589; SAUNDERS NA, 1994, J BIOL CHEM, V269, P2016; SHEIKH MS, 1993, J CELL PHYSIOL, V155, P556, DOI 10.1002/jcp.1041550314; SHEIKH MS, 1992, BIOCHEM BIOPH RES CO, V188, P1122, DOI 10.1016/0006-291X(92)91348-T; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; TURLEY JM, 1995, CELL GROWTH DIFFER, V6, P655; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; WILLEY JC, 1984, CANCER RES, V44, P5124; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753; WOOD WI, 1988, MOL ENDOCRINOL, V2, P1176, DOI 10.1210/mend-2-12-1176; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; ZHANG LX, 1995, J BIOL CHEM, V270, P6022, DOI 10.1074/jbc.270.11.6022; Zhou YH, 1996, ENDOCRINOLOGY, V137, P975, DOI 10.1210/en.137.3.975	46	84	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13711	13716		10.1074/jbc.272.21.13711	http://dx.doi.org/10.1074/jbc.272.21.13711			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153223	hybrid			2022-12-27	WOS:A1997XA06200038
J	Liu, LX; Margottin, F; LeGall, S; Schwartz, O; Selig, L; Benarous, R; Benichou, S				Liu, LX; Margottin, F; LeGall, S; Schwartz, O; Selig, L; Benarous, R; Benichou, S			Binding of HIV-1 Nef to a novel thioesterase enzyme correlates with Nef-mediated CD4 down-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 NEF; HUMAN T-CELLS; NF-KAPPA-B; CYTOPLASMIC DOMAIN; MOLECULAR-CLONING; TRANSGENIC MICE; PROTEIN-KINASE; SURFACE CD4; IN-VITRO; IMMUNODEFICIENCY	Nef is a 27-kDa myristoylated protein conserved in primate lentiviruses. In vivo, simian immunodeficiency virus Nef is required in macaques to produce a high viral load and full pathological effects. Nef has at least three major effects in vitro, induction of CD4 downregulation, alteration of T cell activation pathways, and enhancement of viral infectivity. We have used the yeast two-hybrid system to identify cellular proteins that interact with HIV-1Lai Nef and could mediate Nef function. A human cDNA was isolated that encodes a new type of thioesterase, an enzyme that cleaves thioester bonds. This novel thioesterase is unlike the animal types I and II thioesterases previously cloned but is homologous to the Escherichia coli thioesterase II. Nef and this thioesterase interact in vitro and are co-immunoprecipitated by anti-Nef antibodies in CEM cells expressing Nef. Nef alleles from human immunodeficiency virus-1 (HIV-1) isolates unable to down-regulate CD4 do not react or react poorly with thioesterase. An HIV-1 NefLai mutant selected for its lack of interaction with thioesterase was also unable to down-regulate CD4 cell-surface expression. These observations suggest that this human thioesterase is a cellular mediator of Nef-induced CD4 down-regulation.	UNIV PARIS 05, INST COCHIN GENET MOL, INSERM U332, LAB BIOL MOL INTERACT PROTE, F-75014 PARIS, FRANCE; INST PASTEUR, LAB RETROVIRUS & TRANSFERT GENET, URA CNRS 1157, F-75724 PARIS 15, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Schwartz, Olivier/AAZ-3765-2021; Margottin-Goguet, Florence/F-9272-2013	Schwartz, Olivier/0000-0002-0729-1475; Margottin-Goguet, Florence/0000-0002-3124-6690; Le Gall, Sylvie/0000-0003-0385-926X; Benichou, Serge/0000-0003-3602-3530				AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; AIKEN C, 1995, J VIROL, V69, P5048, DOI 10.1128/JVI.69.8.5048-5056.1995; Aiken C, 1996, VIROLOGY, V217, P293, DOI 10.1006/viro.1996.0116; ALVAREZ E, 1990, J BIOL CHEM, V265, P16644; BANDRES JC, 1994, J VIROL, V68, P3243, DOI 10.1128/JVI.68.5.3243-3249.1994; BARKER PA, 1994, J BIOL CHEM, V269, P30645; Barnes E M Jr, 1975, Methods Enzymol, V35, P102, DOI 10.1016/0076-6879(75)35144-6; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; BENICHOU S, 1994, J BIOL CHEM, V269, P30073; BERGE RK, 1984, EUR J BIOCHEM, V141, P637, DOI 10.1111/j.1432-1033.1984.tb08239.x; BODEUS M, 1995, J GEN VIROL, V76, P1337, DOI 10.1099/0022-1317-76-6-1337; Bouhamdan M, 1996, J VIROL, V70, P697, DOI 10.1128/JVI.70.2.697-704.1996; BRADY HJM, 1993, EMBO J, V12, P4923, DOI 10.1002/j.1460-2075.1993.tb06186.x; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CAMP LA, 1994, J BIOL CHEM, V269, P23212; CLAVEL F, 1994, J VIROL, V68, P1179, DOI 10.1128/JVI.68.2.1179-1185.1994; Collette Y, 1996, J BIOL CHEM, V271, P6333, DOI 10.1074/jbc.271.11.6333; CRISE B, 1992, J BIOL CHEM, V267, P13593; CULLEN BR, 1994, VIROLOGY, V217, P293; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; DEHOOP MJ, 1992, BIOCHEM J, V286, P657, DOI 10.1042/bj2860657; EASON MG, 1994, P NATL ACAD SCI USA, V91, P11178, DOI 10.1073/pnas.91.23.11178; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GARCIA JV, 1993, J VIROL, V67, P1511, DOI 10.1128/JVI.67.3.1511-1516.1993; GOLDSMITH MA, 1995, J VIROL, V69, P4112, DOI 10.1128/JVI.69.7.4112-4121.1995; Graziani A, 1996, J BIOL CHEM, V271, P6590, DOI 10.1074/jbc.271.12.6590; GREENWAY A, 1995, J VIROL, V69, P1842, DOI 10.1128/JVI.69.3.1842-1850.1995; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; HWANG CS, 1993, J BIOL CHEM, V268, P14278; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; Lu XB, 1996, CURR BIOL, V6, P1677, DOI 10.1016/S0960-9822(02)70792-6; Luo TC, 1996, J VIROL, V70, P6493, DOI 10.1128/JVI.70.9.6493-6496.1996; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; Myers G, 1994, HUMAN RETROVIRUSES A; NAGGERT J, 1991, J BIOL CHEM, V266, P11044; NIEDERMAN TMJ, 1992, J VIROL, V66, P6213, DOI 10.1128/JVI.66.10.6213-6219.1992; Nunn MF, 1996, J VIROL, V70, P6157, DOI 10.1128/JVI.70.9.6157-6161.1996; Pandori MW, 1996, J VIROL, V70, P4283, DOI 10.1128/JVI.70.7.4283-4290.1996; RHEE SS, 1994, J VIROL, V68, P5156, DOI 10.1128/JVI.68.8.5156-5163.1994; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; RUDNICK DA, 1993, ADV ENZYMOL RAMB, V67, P375; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; Sawai ET, 1996, CURR BIOL, V6, P1519, DOI 10.1016/S0960-9822(96)00757-9; SCHWARTZ O, 1995, J VIROL, V69, P4053, DOI 10.1128/JVI.69.7.4053-4059.1995; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; SCHWARTZ O, 1993, J VIROL, V67, P3274, DOI 10.1128/JVI.67.6.3274-3280.1993; SKOWRONSKI J, 1993, EMBO J, V12, P703, DOI 10.1002/j.1460-2075.1993.tb05704.x; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; TRONO D, 1995, CELL, V82, P189, DOI 10.1016/0092-8674(95)90306-2; Welker R, 1996, VIROLOGY, V219, P228, DOI 10.1006/viro.1996.0240; YURCHAK LK, 1995, MOL CELL BIOL, V15, P6914, DOI 10.1128/mcb.15.12.6914	54	76	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13779	13785		10.1074/jbc.272.21.13779	http://dx.doi.org/10.1074/jbc.272.21.13779			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153233	hybrid			2022-12-27	WOS:A1997XA06200048
J	Gerst, JE				Gerst, JE			Conserved alpha-helical segments on yeast homologs of the synaptobrevin/VAMP family of V-SNAREs mediate exocytic function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE PROTEINS; INTEGRAL MEMBRANE-PROTEIN; SACCHAROMYCES-CEREVISIAE; VESICULAR TRANSPORT; VAMP FAMILY; COMPLEX; FUSION; SYNAPTOPHYSIN; GENES; COMPONENT	We are studying yeast homologs of the synaptobrevin/VAMP family of vesicle-associated membrane proteins, which act as vesicular compartment-soluble N-ethylmaleimide-sensitive factor attachment protein receptors (v-SNAREs) in cells having a capacity for stimulus-coupled secretion, as well as in other cell types. The yeast homologs, Snc1 and Snc2, localize to secretory vesicles and are required for normal bulk secretion in Saccharomyces cerevisiae. Here we have used Snc deletion mutants and chimeric Snc-VAMP proteins to demonstrate that these v-SNAREs can be dissected into regions that are either indispensable or dispensable for exocytic function in vivo. We have found that a region encompassing two predicted amphipathic alpha-helices (helix 1 and helix 2) (residues 32-85), which are thought to form coiled-coil structures, is essential for conferring exocytosis in yeast. Deletions in either the helix 1 or helix 2 segments result in a complete loss in the ability of the protein to confer secretion competence to snc cells and to interact genetically with components of the proposed fusion complex: the Sec9 and Sso2 t-SNAREs and the Sec17 alpha-SNAP homolog. In contrast, deletions in either the variable (residues 2-27) or putative intravesicular (residues 115-117) regions have no deleterious effect upon v-SNARE function. This makes it unlikely that sequences in either the amino or carboxyl terminus act in an exocytic capacity. Along with additional studies utilizing chimeric Snc-VAMP proteins, we suggest that although the Snc and synaptobrevin/VAMP proteins have evolved to mediate vastly different exocytic programs, their structural requirements and actions have remained remarkably well-conserved in evolution.			Gerst, JE (corresponding author), WEIZMANN INST SCI,DEPT MOL GENET,IL-76100 REHOVOT,ISRAEL.							AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; CALAKOS N, 1994, J BIOL CHEM, V269, P24534; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CORNILLE F, 1995, J BIOL CHEM, V270, P16826, DOI 10.1074/jbc.270.28.16826; COUVE A, 1994, J BIOL CHEM, V269, P23391; COUVE A, 1995, P NATL ACAD SCI USA, V92, P5987, DOI 10.1073/pnas.92.13.5987; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; GERST JE, 1991, MOL CELL BIOL, V11, P1248, DOI 10.1128/MCB.11.3.1248; GERST JE, 1992, P NATL ACAD SCI USA, V89, P4338, DOI 10.1073/pnas.89.10.4338; Goldstein A, 1975, Methods Enzymol, V42, P504; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; INOUE A, 1992, J BIOL CHEM, V267, P10613; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; OYLER GA, 1989, J CELL BIOL, V109, P3030; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; Regazzi R, 1996, EMBO J, V15, P6951, DOI 10.1002/j.1460-2075.1996.tb01087.x; Rose MD., 1990, METHODS YEAST GENETI; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STEGMANN T, 1993, VIRAL FUSION MECHANI, P89; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; TRIMBLE WS, 1993, J PHYSIOLOGY-PARIS, V87, P107, DOI 10.1016/0928-4257(93)90004-D; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163; WALWORTH NC, 1992, MOL CELL BIOL, V12, P2017, DOI 10.1128/MCB.12.5.2017; WASHBOURNE P, 1995, BIOCHEM J, V305, P721, DOI 10.1042/bj3050721; Zelicof A, 1996, J BIOL CHEM, V271, P18243, DOI 10.1074/jbc.271.30.18243	39	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16591	16598		10.1074/jbc.272.26.16591	http://dx.doi.org/10.1074/jbc.272.26.16591			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195971	hybrid			2022-12-27	WOS:A1997XG01900075
J	Kobayashi, M; Nagata, S; Kita, Y; Nakatsu, N; Ihara, S; Kaibuchi, K; Kuroda, S; Ui, M; Iba, H; Konishi, H; Kikkawa, U; Saitoh, I; Fukui, Y				Kobayashi, M; Nagata, S; Kita, Y; Nakatsu, N; Ihara, S; Kaibuchi, K; Kuroda, S; Ui, M; Iba, H; Konishi, H; Kikkawa, U; Saitoh, I; Fukui, Y			Expression of a constitutively active phosphatidylinositol 3-kinase induces process formation in rat PC12 cells - Use of Cre/loxP recombination system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; PROTEIN-KINASE; NEURONAL DIFFERENTIATION; SIGNAL-TRANSDUCTION; NEURITE OUTGROWTH; MAP KINASE; ACTIVATION; GAP-43; WORTMANNIN; INHIBITION	It has been shown that inhibition of phosphatidylinositol (PI) S-kinase blocks neurite outgrowth of PC12 cells stimulated with nerve growth factor. To further assess the role of PI S-kinase, the active form of PI 3-kinase was expressed in PC12 cells by the adenovirus mediated introduction of a site-specific recombinase, Cre. After expression of the active PI S-kinase, elevation of the levels of PI 3,4-diphosphate and PI 3,4,5-trisphosphate as well as formation of neurite-like processes was observed. The process formation was inhibited by wortmannin, a selective inhibitor of PI 3-kinase, which suggests that a high activity of PI 3-kinase was responsible for the formation of these processes. The processes lacked accumulation of F-actin and GAP43 at the growth cone, which suggests that the processes were incomplete compared with neurites. Instead, the bundling of microtubules was enhanced, which suggests that organization of the microtubules might be driving the process of elongation in the cells expressing the active PI 3-kinase. Induction of active PI 3-kinase resulted in activation of Jun N-terminal kinase but not of mitogen-activated protein kinase or protein kinase B/Rac protein kinase/Akt. These results suggest that PI 3-kinase is involved in neurite outgrowth in PC12 cells and that activation of Jun N-terminal kinase cascade may be involved in the cell response.	UNIV TOKYO, BIOL CHEM LAB,DEPT APPL BIOL CHEM, FAC AGR & LIFE SCI,BUNKYO KU, TOKYO 113, JAPAN; NARA INST SCI & TECHNOL, DIV SIGNAL TRANSDUCT, NARA 63001, JAPAN; KOBE UNIV, BIOSIGNAL RES CTR, NADA KU, KOBE, HYOGO 657, JAPAN; UNIV TOKYO, DEPT GENE REGULAT, TOKYO 108, JAPAN; UNIV TOKYO, INST MED SCI, MOL GENET LAB, TOKYO 108, JAPAN	University of Tokyo; Nara Institute of Science & Technology; Kobe University; University of Tokyo; University of Tokyo			Fukui, Yasuhisa/E-8806-2010	Nagata, Satoshi/0000-0001-9156-5215				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BENTLEY D, 1986, NATURE, V323, P712, DOI 10.1038/323712a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FUKUI Y, 1991, ONCOGENE, V6, P407; GOSLIN K, 1988, NATURE, V336, P672, DOI 10.1038/336672a0; GOSLIN K, 1990, J NEUROSCI, V10, P588; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GUERRERO I, 1986, J CELL PHYSIOL, V129, P71, DOI 10.1002/jcp.1041290111; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; HEIDEMANN SR, 1985, J CELL BIOL, V100, P916, DOI 10.1083/jcb.100.3.916; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JOSHI HC, 1985, J CELL BIOL, V101, P697, DOI 10.1083/jcb.101.3.697; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; KONISHI M, 1997, IN PRESS P NATL ACAD; MEIRI KF, 1988, J NEUROSCI, V8, P2571; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MUROYA K, 1992, ONCOGENE, V7, P277; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OKADA T, 1994, J BIOL CHEM, V269, P3563; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; SKENE JHP, 1986, SCIENCE, V233, P783, DOI 10.1126/science.3738509; YANO H, 1993, J BIOL CHEM, V268, P25846	36	118	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16089	16092		10.1074/jbc.272.26.16089	http://dx.doi.org/10.1074/jbc.272.26.16089			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195902	hybrid			2022-12-27	WOS:A1997XG01900006
J	Bourcier, T; Sukhova, G; Libby, P				Bourcier, T; Sukhova, G; Libby, P			The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; LEUKOCYTE ADHESION MOLECULE; TRANSCRIPTION FACTOR; IN-VIVO; ACTIVATION; ALPHA; EXPRESSION; PROLIFERATION; PROTEIN; SYSTEM	In the lesions of atherosclerosis, vascular smooth muscle cells (SMC) display many functions characteristic of cytokine activation that likely contribute importantly to ongoing inflammation during human atherogenesis. The transcription factor nuclear factor kappa-B (NF kappa B) often mediates the effects of cytokines on target cells, but the identity of Rel family members important in human SMC activation remains uncertain. In vitro, human SMC express multiple Rel family members. Of these, dimers of p65 and p50, but not a putative SMC-Rel, comprise basal and inducible NF kappa B binding activities. SMC express two inhibitor proteins I kappa B beta and I kappa B alpha. Interleukin-lp stimulation caused transient loss of I kappa B alpha and a sustained decrease of I kappa B beta that correlated with increased and persistent levels of p65/p50 protein and binding activity in the nucleus. SMC cultured under serum-free conditions displayed little NF kappa B activity, but addition of serum or platelet-derived growth factor did activate NF kappa B. In situ analyses showed no evidence for basal NF kappa B activity in SMC in vivo as nonatherosclerotic arteries did not contain nuclear p65 or p50 protein. However, the nuclei of intimal SMC within human atheroma did contain both Rel proteins. We conclude that (i) dimers of p65 and p50, but not SMC-Rel, comprise NF kappa B complexes in human SMC; (ii) stimulatory compo nents in serum, activate NF kappa B and likely account for previously reported ''constitutive'' NF kappa B activity in cultured SMC; and (iii) exposure to inflammatory cytokines may produce prolonged NF kappa B activation in SMC because of sustained decreases in the inhibitory subunit I kappa B-beta.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,VASC MED & ATHEROSCLEROSIS UNIT,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School			Libby, Peter/AAY-6404-2021	Libby, Peter/0000-0002-1502-502X	NHLBI NIH HHS [HL09483-01, R37 HL34636-13] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL034636, F32HL009483] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BELLAS RE, 1995, J CLIN INVEST, V96, P2521, DOI 10.1172/JCI118313; BOURCIER T, 1995, J CELL PHYSIOL, V164, P644, DOI 10.1002/jcp.1041640323; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; Johnson DR, 1996, J BIOL CHEM, V271, P16317, DOI 10.1074/jbc.271.27.16317; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; LAWRENCE R, 1994, J BIOL CHEM, V269, P28913; LE BO, 1993, EMBO J, V12, P5043; LERNBECHER T, 1994, EMBO J, V13, P4060, DOI 10.1002/j.1460-2075.1994.tb06723.x; LI H, 1993, ARTERIOSCLER THROMB, V13, P197, DOI 10.1161/01.ATV.13.2.197; LIBBY P, 1983, J CELL PHYSIOL, V115, P217, DOI 10.1002/jcp.1041150217; LOPPNOW H, 1990, J CLIN INVEST, V85, P731, DOI 10.1172/JCI114498; NAKAJIMA T, 1994, BIOCHEM BIOPH RES CO, V204, P950, DOI 10.1006/bbrc.1994.2552; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; NILSSON J, 1993, CARDIOVASC RES, V27, P1184, DOI 10.1093/cvr/27.7.1184; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RAINES EW, 1993, BRIT HEART J, V69, pS30; READ MA, 1995, IMMUNITY, V2, P493, DOI 10.1016/1074-7613(95)90030-6; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Shin WS, 1996, J BIOL CHEM, V271, P11317, DOI 10.1074/jbc.271.19.11317; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; TANAKA H, 1993, CIRCULATION, V88, P1788, DOI 10.1161/01.CIR.88.4.1788; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	35	216	230	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15817	15824		10.1074/jbc.272.25.15817	http://dx.doi.org/10.1074/jbc.272.25.15817			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188479	hybrid			2022-12-27	WOS:A1997XF32900039
J	Erlitzki, R; Fry, M				Erlitzki, R; Fry, M			Sequence specific binding protein of single-stranded and unimolecular quadruplex telomeric DNA from rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST GENE-PRODUCT; HUMAN FIBROBLASTS; NUCLEIC-ACIDS; CALF THYMUS; QUARTET STRUCTURES; EPITHELIAL-CELLS; BETA-SUBUNIT; PURIFICATION; REPEATS; CARCINOMA	A rat liver nuclear protein, unimolecular quadruplex telomere binding protein 25, (uqTBP25) is described that binds tightly and specifically single stranded and unimolecular tetraplex forms of the vertebrate telomeric DNA sequence 5'-d(TTAGGG)(n)-3', A near homogeneous uqTBP25 was purified by ammonium sulfate precipitation, chromatographic separation from other DNA binding proteins, and three steps of column chromatography, SDS-polyacrylamide gel electrophoresis and Superdex(C) 200 gel filtration disclosed for uqTBP25 subunit and native M-r values of 25.4 +/- 0.5 and 25.0 kDa, respectively, Sequences of uqTBP25 tryptic peptides were closely homologous, but not identical, to heterogeneous nuclear ribonucleoprotein A1, heterogeneous nuclear ribonucleoprotein A2/B1, and single-stranded DNA-binding proteins UP1 and HDP-1, Complexes of uqTBP25 with single-stranded or unimolecular quadruplex 5'-d(TTAGGG)(4)-3', respectively, had dissociation constants, K-d, of 2.2 or 13.4 nM. Relative to d(TAAGGG)(4), complexes with 5'-r(UUAGGG)(4)-3', blunt ended duplex telomeric DNA, or quadruplex telomeric DNA had >10 to >250-fold higher K-d values, Single base alterations within the d(TTAGGG) repeat increased the K-d of complexes with uqTBP25 by 9-215-fold, Association with uqTBP25 protected d(TTAGGG)(4) against nuclease digestion, suggesting a potential role for the protein in telomeric DNA transactions.	TECHNION ISRAEL INST TECHNOL, BRUCE RAPPAPORT FAC MED, BIOCHEM UNIT, IL-31096 HAIFA, ISRAEL	Technion Israel Institute of Technology; Rappaport Faculty of Medicine								ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Avilion AA, 1996, CANCER RES, V56, P645; BALAGURUMOORTHY P, 1992, NUCLEIC ACIDS RES, V20, P4061, DOI 10.1093/nar/20.15.4061; BALAGURUMOORTHY P, 1994, J BIOL CHEM, V269, P21858; BENDAVID Y, 1992, MOL CELL BIOL, V12, P4449, DOI 10.1128/MCB.12.10.4449; BIAMONTI G, 1994, NUCLEIC ACIDS RES, V22, P1996, DOI 10.1093/nar/22.11.1996; BIAMONTI G, 1989, J MOL BIOL, V207, P491, DOI 10.1016/0022-2836(89)90459-2; BLACKBURN EH, 1994, CELL, V77, P621, DOI 10.1016/0092-8674(94)90046-9; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; BUVOLI M, 1988, NUCLEIC ACIDS RES, V16, P3751, DOI 10.1093/nar/16.9.3751; CARDENAS ME, 1993, GENE DEV, V7, P883, DOI 10.1101/gad.7.5.883; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COBIANCHI F, 1988, J BIOL CHEM, V263, P1063; COHIANCHI F, 1986, J BIOL CHEM, V261, P3536; COREN JS, 1991, MOL CELL BIOL, V11, P2282, DOI 10.1128/MCB.11.4.2282; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; DELANGE T, 1995, TELOMERES, P265; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FANG G, 1995, TELOMERES, P69; FANG GW, 1993, P NATL ACAD SCI USA, V90, P6056, DOI 10.1073/pnas.90.13.6056; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; FRANTZ JD, 1995, J BIOL CHEM, V270, P9413, DOI 10.1074/jbc.270.16.9413; FRANTZ JD, 1995, J BIOL CHEM, V270, P20692, DOI 10.1074/jbc.270.35.20692; FRY M, 1985, BIOCHEMISTRY-US, V24, P7549, DOI 10.1021/bi00347a007; FRY M, 1988, NUCLEIC ACIDS RES, V16, P199, DOI 10.1093/nar/16.1.199; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; GIRALDO R, 1994, P NATL ACAD SCI USA, V91, P7658, DOI 10.1073/pnas.91.16.7658; GIRALDO R, 1994, EMBO J, V13, P2411, DOI 10.1002/j.1460-2075.1994.tb06526.x; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; GUPTA G, 1993, BIOCHEMISTRY-US, V32, P7098, DOI 10.1021/bi00079a005; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1995, CURR OPIN GENET DEV, V5, P249, DOI 10.1016/0959-437X(95)80016-6; HARLEY CB, 1995, TELOMERES, P247; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HENDERSON E, 1995, TELOMERES, P11; HERRICK G, 1976, J BIOL CHEM, V251, P2142; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0; KAY BK, 1990, P NATL ACAD SCI USA, V87, P1367, DOI 10.1073/pnas.87.4.1367; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; KUMAR A, 1986, J BIOL CHEM, V261, P1266; LIU ZP, 1994, CELL, V77, P1083, DOI 10.1016/0092-8674(94)90447-2; LIU ZP, 1995, P NATL ACAD SCI USA, V92, P6002, DOI 10.1073/pnas.92.13.6002; Lundblad V, 1996, CELL, V87, P369, DOI 10.1016/S0092-8674(00)81358-6; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P1387, DOI 10.1093/nar/20.6.1387; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P6461, DOI 10.1093/nar/20.24.6461; MERRILL BM, 1986, J BIOL CHEM, V261, P878; PETRACEK ME, 1994, EMBO J, V13, P3648, DOI 10.1002/j.1460-2075.1994.tb06672.x; PLANCK SR, 1980, J BIOL CHEM, V255, P1547; PRICE CM, 1990, MOL CELL BIOL, V10, P3421, DOI 10.1128/MCB.10.7.3421; Sarig G, 1997, J BIOL CHEM, V272, P4474, DOI 10.1074/jbc.272.7.4474; SCARIA PV, 1992, P NATL ACAD SCI USA, V89, P10336, DOI 10.1073/pnas.89.21.10336; SCHENKEL J, 1988, EUR J BIOCHEM, V171, P565, DOI 10.1111/j.1432-1033.1988.tb13825.x; SCHIERER T, 1994, BIOCHEMISTRY-US, V33, P2240, DOI 10.1021/bi00174a034; SEN D, 1992, METHOD ENZYMOL, V211, P191; SHARF R, 1988, BIOCHEMISTRY-US, V27, P2990, DOI 10.1021/bi00408a049; SHAY JW, 1993, ONCOGENE, V8, P1407; SMITH FW, 1993, BIOCHEMISTRY-US, V32, P8682, DOI 10.1021/bi00084a040; SUNDQUIST WI, 1989, NATURE, V344, P410; VAZIRI H, 1993, AM J HUM GENET, V52, P661; Weighardt F, 1996, BIOESSAYS, V18, P747, DOI 10.1002/bies.950180910; WEISMANSHOMER P, 1993, J BIOL CHEM, V268, P3306; WILLIAMS KR, 1985, P NATL ACAD SCI USA, V82, P5666, DOI 10.1073/pnas.82.17.5666; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	71	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15881	15890		10.1074/jbc.272.25.15881	http://dx.doi.org/10.1074/jbc.272.25.15881			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188487	hybrid			2022-12-27	WOS:A1997XF32900047
J	Lascu, I; Schaertl, S; Wang, CQ; Sarger, C; Giartosio, A; Briand, G; Lacombe, ML; Konrad, M				Lascu, I; Schaertl, S; Wang, CQ; Sarger, C; Giartosio, A; Briand, G; Lacombe, ML; Konrad, M			A point mutation of human nucleoside diphosphate kinase A found in aggressive neuroblastoma affects protein folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; TUMOR-METASTASIS; HEXAMERIC ENZYME; DROSOPHILA; MUTAGENESIS; STABILITY; NM23-H2; KILLER; PRUNE	The point mutation serine 120 to glycine in the human nucleoside diphosphate kinase A has been identified in several aggressive neuroblastomas (Chang, C. L., Zhu, X. X., Thoraval, D. H., Ungar, D., Rawwas, J., Hora, N., Strahler, J. R., Hanash, S. M. & Radany, E. (1994) Nature 370, 335-336). We expressed in bacteria and purified wild-type and S120G mutant nucleoside diphosphate kinase A. The mutant enzyme had enzymatic and structural properties similar to the wild-type enzyme, protein lead whereas its stability to denaturation by heat and urea intermediate. was markedly reduced. More importantly, upon renaturation of the urea-denatured mutant protein, a folding intermediate accumulated, having the characteristics of a molten globule. It had no tertiary structure, as shown by near UV circular dichroism, whereas the secondary structure was substantially recovered. The hydrophobic probe 8-anilino-1-naphthalene sulfonate bound to the intermediate species with an increase in fluorescence intensity and a blue shift. The hydrodynamic size was between that expected for a folded and an unfolded monomer. Finally, electrophoresis in a transverse urea gradient displayed no renaturation curve, and the protein showed the tendency to aggregate at the lowest urea concentrations. The existence of a molten globule folding intermediates resulting from an altered folding in the mutated protein might be related to the aggressiveness of neuroblastomas.	MAX PLANCK INST BIOPHYS CHEM, DEPT MOL GENET, D-37018 GOTTINGEN, GERMANY; UNIV ROMA LA SAPIENZA, DIPARTIMENTO SCI BIOCHIM A ROSSI FANELLI, I-00185 ROME, ITALY; UNIV ROMA LA SAPIENZA, CNR, CTR BIOL MOL, I-00185 ROME, ITALY; UNIV LILLE 2, LAB APPLICAT SPECTROMETRIE MASSE, F-59045 LILLE, FRANCE; UNIV PARIS 06, FAC MED ST ANTOINE, U402 INSERM, F-75571 PARIS, FRANCE	Max Planck Society; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Universite de Lille - ISITE; Universite de Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Lascu, I (corresponding author), UNIV BORDEAUX 2, IBGC, CNRS, 1 RUE CAMILLE ST SAENS, F-33077 BORDEAUX, FRANCE.							BARBERICH SJ, 1995, ONCOGENE, V10, P2343; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BYCHKOVA VE, 1995, FEBS LETT, V359, P6, DOI 10.1016/0014-5793(95)00004-S; CHANG CL, 1994, NATURE, V370, P335, DOI 10.1038/370335a0; Chang CL, 1996, ONCOGENE, V12, P659; CRAIG S, 1985, J MOL BIOL, V185, P681, DOI 10.1016/0022-2836(85)90053-1; Creighton T. E., 1993, PROTEINS STRUCTURES; CREIGHTON TE, 1979, J MOL BIOL, V129, P235, DOI 10.1016/0022-2836(79)90279-1; DEAROLF CR, 1988, DEV BIOL, V129, P159, DOI 10.1016/0012-1606(88)90170-4; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; Giartosio A, 1996, J BIOL CHEM, V271, P17845, DOI 10.1074/jbc.271.30.17845; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GILLES AM, 1991, J BIOL CHEM, V266, P8784; JI L, 1995, J BIOL CHEM, V270, P13392, DOI 10.1074/jbc.270.22.13392; JONES BE, 1994, BIOCHEMISTRY-US, V33, P15250, DOI 10.1021/bi00255a005; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LASCU I, 1983, EUR J BIOCHEM, V135, P497, DOI 10.1111/j.1432-1033.1983.tb07679.x; LASCU I, 1993, J BIOL CHEM, V268, P20268; LASCU I, 1992, J BIOL CHEM, V267, P12775; LASCU I, 1996, TECHNIQUES PROTEIN C, V7, P209; MacDonald NJ, 1996, J BIOL CHEM, V271, P25107, DOI 10.1074/jbc.271.41.25107; Milon L, 1997, HUM GENET, V99, P550, DOI 10.1007/s004390050405; Morera S, 1995, STRUCTURE, V3, P1307, DOI 10.1016/S0969-2126(01)00268-4; NATH U, 1995, BIOCHEMISTRY-US, V34, P1702, DOI 10.1021/bi00005a027; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; PTITSYN OB, 1993, PROTEIN FOLDING, P243; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SEMISOTNOV GV, 1987, FEBS LETT, V224, P9, DOI 10.1016/0014-5793(87)80412-X; SITERS RN, 1995, NAT STRUCT BIOL, V2, P353; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; VENTURELLI D, 1995, P NATL ACAD SCI USA, V92, P7435, DOI 10.1073/pnas.92.16.7435; WEBB PA, 1995, J MOL BIOL, V251, P574, DOI 10.1006/jmbi.1995.0457	34	56	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15599	15602		10.1074/jbc.272.25.15599	http://dx.doi.org/10.1074/jbc.272.25.15599			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188446	hybrid			2022-12-27	WOS:A1997XF32900006
J	Gardiner, EE; DSouza, SE				Gardiner, EE; DSouza, SE			A mitogenic action for fibrinogen mediated through intercellular adhesion molecule-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC LESIONS; B-BETA CHAIN; CELL-ADHESION; ENDOTHELIAL-CELLS; AFFINITY-CHROMATOGRAPHY; DEGRADATION PRODUCTS; VONWILLEBRAND-FACTOR; LEUKOCYTE ADHESION; HUMAN RHINOVIRUS; A-ALPHA	Intercellular adhesion molecule-1 (ICAM-1) is a cell surface ligand for alpha(L) beta(2) and alpha(M) beta(2) integrins and has a key role in leukocyte adhesion to the vascular endothelium. The plasma protein fibrinogen has also been shown to interact with ICAM-1. We have investigated the effect of fibrinogen binding to ICAM-1-expressing cells on cell proliferation. The inclusion of 200-800 nM fibrinogen but not fibronectin to the culture medium of Raji induced a 2-4-fold increase in [H-3]thymidine incorporation after 8 h. Cell proliferation in cultures containing fibrinogen was also confirmed by direct cell counting. The proliferative response in Raji was abrogated by an anti-ICAM-1 mAb 84H10 which maps to the first Ig domain of ICAM-1. A purified truncated form of ICAM-1 containing the first two Ig-Like domains and a peptide with amino acid sequence corresponding to ICAM-1 (8-22) was also able to block the proliferative action of fibrinogen on Raji. 200 nM fibrinogen induced a 3-fold increase in [H-3]thymidine incorporation by 293 cells transfected with ICAM-1 cDNA but not control nontransfected 293 cells. Comparable mitogenic effects were achieved with fibrinogen fragments X and D-100, and with a synthetic peptide with an amino acid sequence matching fibrinogen gamma chain (117-133). These results indicate that interaction between discrete sequences within ICAM-1 and fibrinogen result in cellular proliferation.	CLEVELAND CLIN FDN,JOSEPH J JACOBS CTR THROMBOSIS,CLEVELAND,OH 44195	Cleveland Clinic Foundation			Gardiner, Elizabeth/P-8716-2019; Gardiner, Elizabeth/E-7774-2011	Gardiner, Elizabeth/0000-0001-9453-9688; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL043721, R01HL043721] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 43721] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1994, FASEB J, V8, P504, DOI 10.1096/fasebj.8.8.8181668; ALTIERI DC, 1995, J BIOL CHEM, V270, P696, DOI 10.1074/jbc.270.2.696; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; BINI A, 1989, ARTERIOSCLEROSIS, V9, P109, DOI 10.1161/01.ATV.9.1.109; BUDZYNSK.AZ, 1974, J BIOL CHEM, V249, P2294; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; COBB RR, 1992, BIOCHEM BIOPH RES CO, V185, P1022, DOI 10.1016/0006-291X(92)91729-A; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DOOLITTLE RF, 1967, ARCH BIOCHEM BIOPHYS, V118, P456, DOI 10.1016/0003-9861(67)90374-8; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; DSouza SE, 1996, J BIOL CHEM, V271, P24270, DOI 10.1074/jbc.271.39.24270; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; ERBAN JK, 1992, J BIOL CHEM, V267, P2451; FAULL RJ, 1989, TRANSPLANTATION, V48, P226, DOI 10.1097/00007890-198908000-00009; FELDINGHABERMANN B, 1992, J BIOL CHEM, V267, P5070; GRAY AJ, 1993, J CELL SCI, V104, P409; GRAY AJ, 1995, J BIOL CHEM, V270, P26602, DOI 10.1074/jbc.270.44.26602; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; GRIFFITH DE, 1994, THROMB RES, V74, P207, DOI 10.1016/0049-3848(94)90109-0; HATZFELD JA, 1982, P NATL ACAD SCI-BIOL, V79, P6280, DOI 10.1073/pnas.79.20.6280; Hicks RCJ, 1996, NATURE, V379, P818, DOI 10.1038/379818a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LANGUINO LR, 1993, CELL, V73, P1423, DOI 10.1016/0092-8674(93)90367-Y; LEVESQUE JP, 1990, J BIOL CHEM, V265, P328; LEVESQUE JP, 1985, EXP CELL RES, V156, P558, DOI 10.1016/0014-4827(85)90563-4; LEVESQUE JP, 1986, P NATL ACAD SCI USA, V83, P6494, DOI 10.1073/pnas.83.17.6494; LOIKE JD, 1991, P NATL ACAD SCI USA, V88, P1044, DOI 10.1073/pnas.88.3.1044; MAKGOBA MW, 1988, NATURE, V331, P86, DOI 10.1038/331086a0; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; NAGEL T, 1994, J CLIN INVEST, V94, P885, DOI 10.1172/JCI117410; OCKENHOUSE CF, 1992, CELL, V68, P63, DOI 10.1016/0092-8674(92)90206-R; POSTIGO AA, 1991, J EXP MED, V174, P1313, DOI 10.1084/jem.174.6.1313; PRINTSEVA OY, 1992, AM J PATHOL, V140, P889; ROTHLEIN R, 1991, J IMMUNOL, V147, P3788; SCHLOSSMAN SF, 1994, LEUCOCYTE TYPING, V5; Shainoff JR, 1996, J BIOL CHEM, V271, P24129, DOI 10.1074/jbc.271.39.24129; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SMITH GE, 1985, P NATL ACAD SCI USA, V82, P8404, DOI 10.1073/pnas.82.24.8404; SPORN LA, 1995, BLOOD, V86, P1802, DOI 10.1182/blood.V86.5.1802.bloodjournal8651802; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; Suehiro K, 1997, J BIOL CHEM, V272, P5360, DOI 10.1074/jbc.272.8.5360; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; UGAROVA TP, 1993, J BIOL CHEM, V268, P21080; VALENZUELA R, 1992, AM J PATHOL, V141, P861; VANDERWAL AC, 1992, AM J PATHOL, V141, P1427; VUENTO M, 1979, BIOCHEM J, V183, P331, DOI 10.1042/bj1830331; WELDER CA, 1993, J IMMUNOL, V150, P2203; Zhang L, 1996, J BIOL CHEM, V271, P18211, DOI 10.1074/jbc.271.30.18211; ZHOU YQ, 1993, BLOOD, V82, P800	55	40	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15474	15480		10.1074/jbc.272.24.15474	http://dx.doi.org/10.1074/jbc.272.24.15474			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182580	hybrid			2022-12-27	WOS:A1997XE03400063
J	Harada, N; Iijima, S; Kobayashi, K; Yoshida, T; Brown, WR; Hibi, T; Oshima, A; Morikawa, M				Harada, N; Iijima, S; Kobayashi, K; Yoshida, T; Brown, WR; Hibi, T; Oshima, A; Morikawa, M			Human IgGFc binding protein (Fc gamma BP) in colonic epithelial cells exhibits mucin-like structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; VONWILLEBRAND-FACTOR; RECEPTOR; THIOREDOXIN; EXPRESSION; GENE; SEQUENCE; CDNA; IDENTIFICATION; LEUKEMIA	Cloning a cDNA for human IgGFc binding protein (Fc gamma BP) from human colonic epithelial cells reveals an mRNA and coding region of 17 and 16.2 kilobases, respectively. The predicted amino acid sequence contains 12 occurrences of a 400-amino acid cysteine-rich unit resembling that found in mucin. A motif (CGLCGN) in Fc gamma BP is conserved in MUC2 and prepro-von Willebrand factor. The N-terminal 450-amino acid sequences are necessary and sufficient to confer IgG Fc binding activity. Fc gamma BP mRNA is expressed only in placenta and colonic epithelial cells, These results suggest that Fc gamma BP may play an important role in immune protection and inflammation in the intestines of primates.	CHUGAI PHARMACEUT CO LTD, CENT RES LABS, TOSHIMA KU, TOKYO 171, JAPAN; TOKYO INST IMMUNOPHARMACOL INC, TOKYO, JAPAN; UNIV COLORADO, HLTH SCI CTR, DIV GASTROENTEROL, DENVER, CO 80220 USA; KEIO UNIV, SCH MED, DEPT INTERNAL MED, TOKYO 160, JAPAN; TOKYO METROPOLITAN INST MED SCI, TOKYO 113, JAPAN	Chugai Pharmaceutical Co., Ltd.; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Keio University; Tokyo Metropolitan Institute of Medical Science			Brown, William/GXN-2777-2022					AHOUSE JJ, 1993, J IMMUNOL, V151, P6076; APODACA G, 1991, J CLIN INVEST, V87, P1877, DOI 10.1172/JCI115211; BENNETT CF, 1988, NATURE, V334, P268, DOI 10.1038/334268a0; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; FRIDMAN WH, 1991, FASEB J, V5, P2684, DOI 10.1096/fasebj.5.12.1916092; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GRIPPO JF, 1985, J BIOL CHEM, V260, P93; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1994, J BIOL CHEM, V269, P2440; HARRISON L, 1995, J BIOL CHEM, V270, P5556, DOI 10.1074/jbc.270.10.5556; HILKENS J, 1988, Cancer Reviews, V11-12, P25; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; KOBAYASHI K, 1994, DIGEST DIS SCI, V39, P526, DOI 10.1007/BF02088337; KOBAYASHI K, 1989, J IMMUNOL, V143, P2567; KOBAYASHI K, 1991, J IMMUNOL, V146, P68; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYLE JW, 1988, J BIOL CHEM, V263, P16230; LAN MS, 1990, J BIOL CHEM, V265, P15294; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; MAYADAS TN, 1992, P NATL ACAD SCI USA, V89, P3531, DOI 10.1073/pnas.89.8.3531; MAYADAS TN, 1989, J BIOL CHEM, V264, P13497; MOSTOV KE, 1985, CELL, V43, P389, DOI 10.1016/0092-8674(85)90166-7; MOSTOV KE, 1984, NATURE, V308, P37, DOI 10.1038/308037a0; NAKAMURA H, 1994, IMMUNOL LETT, V42, P75, DOI 10.1016/0165-2478(94)90038-8; NEAUPORTSAUTES C, 1975, EUR J IMMUNOL, V5, P849, DOI 10.1002/eji.1830051210; NELSON JE, 1992, ANAL BIOCHEM, V207, P197, DOI 10.1016/0003-2697(92)90523-A; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PHILLIPS TE, 1988, GASTROENTEROLOGY, V94, P1390, DOI 10.1016/0016-5085(88)90678-6; PORCHET N, 1991, ARCH BIOCHEM BIOPHYS, V258, P452; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; RODEWALD R, 1984, J CELL BIOL, V99, pS159, DOI 10.1083/jcb.99.1.159s; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0; STORY CM, 1994, J EXP MED, V180, P2377, DOI 10.1084/jem.180.6.2377; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; UNKELESS JC, 1988, ANNU REV IMMUNOL, V6, P251, DOI 10.1146/annurev.iy.06.040188.001343; YODOI J, 1991, ADV CANCER RES, V57, P381	42	92	94	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15232	15241		10.1074/jbc.272.24.15232	http://dx.doi.org/10.1074/jbc.272.24.15232			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182547	hybrid			2022-12-27	WOS:A1997XE03400030
J	Kim, HK; Baumann, H				Kim, HK; Baumann, H			The carboxyl-terminal region of STAT3 controls gene induction by the mouse haptoglobin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-6 RESPONSE ELEMENTS; ACUTE-PHASE RESPONSE; HEPATOMA-CELLS; HEMATOPOIETIN RECEPTORS; SIGNAL-TRANSDUCTION; CYTOKINE RECEPTORS; STIMULATING FACTOR; MOLECULAR-CLONING; PLASMA-PROTEINS; GROWTH-FACTOR	Haptoglobin (HP) is one of the major acute phase plasma proteins in the mouse, and its synthesis is additively induced by interleukin (IL)-6 and glucocorticoids. STAT3 serves as the mediator of the IL-6 receptor signal and appears to contribute to the transcriptional induction of acute phase protein genes, The carboxyl-terminal region of STAT3, consisting of an acidic domain and containing a serine phosphorylation site, has been proposed to contribute to the induction process. To assess the role of STAT3 in the transcriptional control of the HP promoter, we applied two mutant forms of STAT3: one with a deletion of the carboxyl-terminal 55 amino acid residues, STAT3 Delta 55C, and the other with a substitution of serine 727 to alanine, STAT3SA. Like the wildtype STAT3, both mutant STAT3 forms are activated by the signal-transducing subunit of the IL-6 receptor, gp130, or by co-transfected IL-6 receptor. Ectopic expression and activation of wild-type STAT3 or STAT3SA in HepG2 hepatoma cells similarly enhance transcription through the IL-6-response element of the HP promoter, This enhancement is specific for STAT3 and cannot be reproduced by STAT1 or STAT5. In contrast, STAT3 Delta 55C inhibits IL-6-induced transcriptional activation, Interestingly, whereas receptor-activated STAT3 also enhances stimulation of the haptoglobin promoter by dexamethasone through the glucocorticoid receptor, activated STAT3 Delta 55C reduces the regulation below the level achieved by the glucocorticoid receptor alone, This transdominant action by STAT3 Delta 55C is dependent on a functional IL-6-responsive element. The data suggest that the carboxyl-terminal domain, but not its serine phosphorylation site of STAT3, is required for transcription as part of the hematopoietin receptor signaling as well as for cooperation with other transcription factors such as the glucocorticoid receptor.	ROSWELL PK CANC INST,DEPT MOL & CELLULAR BIOL,BUFFALO,NY 14263	Roswell Park Cancer Institute				Kim, Hongkyun/0000-0002-4879-7122	NIDDK NIH HHS [DK33886] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033886] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BAUMANN H, 1990, MOL CELL BIOL, V10, P5967, DOI 10.1128/MCB.10.11.5967; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMANN H, 1988, J BIOL CHEM, V263, P17390; BAUMANN H, 1983, J CELL BIOL, V97, P728, DOI 10.1083/jcb.97.3.728; BERNHARD HP, 1973, DEV BIOL, V35, P83, DOI 10.1016/0012-1606(73)90008-0; BOWMAN BH, 1982, ADV HUM GENET, V12, P189; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Campos SP, 1996, J BIOL CHEM, V271, P24418, DOI 10.1074/jbc.271.40.24418; Ceresa BP, 1996, J BIOL CHEM, V271, P12121, DOI 10.1074/jbc.271.21.12121; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Kushner I, 1993, ACUTE PHASE PROTEINS, P4; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MORELLA KK, 1995, J BIOL CHEM, V270, P8298, DOI 10.1074/jbc.270.14.8298; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; OMAHONEY JV, 1994, DNA CELL BIOL, V13, P1227, DOI 10.1089/dna.1994.13.1227; PAJOVIC S, 1994, J BIOL CHEM, V269, P2215; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; PROWSE KR, 1988, MOL CELL BIOL, V8, P42, DOI 10.1128/MCB.8.1.42; RAMJI DP, 1993, NUCLEIC ACIDS RES, V21, P289, DOI 10.1093/nar/21.2.289; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; WARD LD, 1994, J BIOL CHEM, V269, P23286; WEGENKA UM, 1993, MOL CELL BIOL, V13, P267; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yang CH, 1996, J BIOL CHEM, V271, P8057, DOI 10.1074/jbc.271.14.8057; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	47	62	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14571	14579		10.1074/jbc.272.23.14571	http://dx.doi.org/10.1074/jbc.272.23.14571			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169415	hybrid			2022-12-27	WOS:A1997XC32700012
J	Oren, Z; Hong, J; Shai, Y				Oren, Z; Hong, J; Shai, Y			A repertoire of novel antibacterial diastereomeric peptides with selective cytolytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA MOSES SOLE; ANTIMICROBIAL ACTIVITY; PHOSPHOLIPID-MEMBRANES; CHANNEL FORMATION; MODEL PEPTIDES; ANALOGS; DERMASEPTIN; SEQUENCE; PARDAXIN; POLYPEPTIDES	The increase in infectious diseases and bacterial resistance to antibiotics has resulted in intensive studies focusing on the use of linear, alpha-helical, cytolytic peptides from insects and mammals as potential drugs for new target sites in bacteria. Recent studies with diastereomers of the highly potent cytolytic peptides, pardaxin and melittin, indicate that alpha-helical structure is required for mammalian cells lysis but is not necessary for antibacterial activity, Thus, hydrophobicity and net positive charge of the polypeptide might confer selective antibacterial lytic activity. To test this hypothesis, a series of diastereomeric model peptides (12 amino acids long) composed of varying ratios of leucine and lysine were synthesized, and their structure and biological function were investigated, Peptide length and the position of D-amino acids were such that short peptides with stretches of only 1-3 consecutive L-amino acids that cannot form an alpha-helical structure were constructed, Circular dichroism spectroscopy showed that the peptides do not retain any detectable secondary structure in a hydrophobic environment, This enabled examination of the sole effect of hydrophobicity and positive charge on activity, The data reveal that modulating hydrophobicity and positive charge is sufficient to confer antibacterial activity and cell selectivity, A highly hydrophobic diastereomer that permeated both zwitterionic and negatively charged phospholipid vesicles, lysed eukaryotic and prokaryotic cells, In contrast, a highly positively charged diastereomer that only permeated slightly negatively charged phospholipid vesicles had low antibacterial activity and could not lyse eukaryotic cells, In the boundary between high hydrophobicity and high positive charge, the diastereomers acquired selective and potent antibacterial activity, Furthermore, they were completely resistant to human serum inactivation, which dramatically reduces the activity of native antibacterial peptides, In addition, a strong synergistic effect was observed at nonlethal concentrations of the peptides with the antibiotic tetracycline on resistant bacteria, The results are discussed in terms of proposed mechanisms of antibacterial activity, as well as a new strategy for the design of a repertoire of short, simple, and easily manipulated antibacterial peptides as potential drugs in the treatment of infectious diseases.	WEIZMANN INST SCI, DEPT MEMBRANE RES & BIOPHYS, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science				Hong, Jiang/0000-0003-4068-0779				AGAWA Y, 1991, J BIOL CHEM, V266, P20218; AGERBERTH B, 1995, P NATL ACAD SCI USA, V92, P195, DOI 10.1073/pnas.92.1.195; ANDREU D, 1985, BIOCHEMISTRY-US, V24, P1683, DOI 10.1021/bi00328a017; ANZAI K, 1991, BIOCHIM BIOPHYS ACTA, V1064, P256, DOI 10.1016/0005-2736(91)90310-5; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BENKIRANE N, 1993, J BIOL CHEM, V268, P26279; BLONDELLE SE, 1992, BIOCHEMISTRY-US, V31, P12688, DOI 10.1021/bi00165a020; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BOMAN HG, 1989, FEBS LETT, V259, P103, DOI 10.1016/0014-5793(89)81505-4; CHEN HC, 1988, FEBS LETT, V236, P462, DOI 10.1016/0014-5793(88)80077-2; CORNUT I, 1994, FEBS LETT, V349, P29, DOI 10.1016/0014-5793(94)00621-0; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FISHER PJ, 1994, NATURE, V368, P651, DOI 10.1038/368651a0; GAZIT E, 1994, BIOCHEMISTRY-US, V33, P10681, DOI 10.1021/bi00201a016; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HABERMANN E, 1967, H-S Z PHYSIOL CHEM, V348, P37, DOI 10.1515/bchm2.1967.348.1.37; Kiyota T, 1996, BIOCHEMISTRY-US, V35, P13196, DOI 10.1021/bi961289t; LAZAROVICI P, 1986, J BIOL CHEM, V261, P6704; LEE S, 1986, BIOCHIM BIOPHYS ACTA, V862, P211, DOI 10.1016/0005-2736(86)90485-2; LOEW LM, 1983, BIOCHEMISTRY-US, V22, P837, DOI 10.1021/bi00273a020; MCHAOURAB HS, 1994, BIOCHEMISTRY-US, V33, P6691, DOI 10.1021/bi00187a040; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; MOR A, 1991, BIOCHEMISTRY-US, V30, P8824, DOI 10.1021/bi00100a014; NICOLAS P, 1995, ANNU REV MICROBIOL, V49, P277, DOI 10.1146/annurev.mi.49.100195.001425; Oren Z, 1996, EUR J BIOCHEM, V237, P303, DOI 10.1111/j.1432-1033.1996.0303n.x; Oren Z, 1997, BIOCHEMISTRY-US, V36, P1826, DOI 10.1021/bi962507l; PAPAHADJ.D, 1967, BIOCHIM BIOPHYS ACTA, V135, P624, DOI 10.1016/0005-2736(67)90094-6; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017; RUSSELL PE, 1995, 50 YEARS ANTIMICROBI, P67; SABERWAL G, 1994, BBA-REV BIOMEMBRANES, V1197, P109, DOI 10.1016/0304-4157(94)90002-7; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SHAI Y, 1990, J BIOL CHEM, V265, P20202; SHAI Y, 1991, J BIOL CHEM, V266, P22346; Shai Y, 1996, J BIOL CHEM, V271, P7305, DOI 10.1074/jbc.271.13.7305; SHAI Y, 1988, FEBS LETT, V242, P161, DOI 10.1016/0014-5793(88)81007-X; Shaw N, 1974, Adv Appl Microbiol, V17, P63, DOI 10.1016/S0065-2164(08)70555-0; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; STRAHILEVITZ J, 1994, BIOCHEMISTRY-US, V33, P10951, DOI 10.1021/bi00202a014; VERKLEIJ AJ, 1973, BIOCHIM BIOPHYS ACTA, V323, P178, DOI 10.1016/0005-2736(73)90143-0; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; WU CSC, 1981, BIOCHEMISTRY-US, V20, P566, DOI 10.1021/bi00506a019; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	43	179	189	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14643	14649		10.1074/jbc.272.23.14643	http://dx.doi.org/10.1074/jbc.272.23.14643			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169426	hybrid			2022-12-27	WOS:A1997XC32700023
J	Ciaccia, AV; Monroe, DM; Church, FC				Ciaccia, AV; Monroe, DM; Church, FC			Arginine 200 of heparin cofactor II promotes intramolecular interactions of the acidic domain - Implication for thrombin inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-THROMBIN; REACTIVE SITE; PROTEINASE-INHIBITORS; DEPENDENT INHIBITOR; DERMATAN SULFATE; HUMAN-PLASMA; BINDING; SEQUENCE; GLYCOSAMINOGLYCANS; IDENTIFICATION	Heparin cofactor II (HCII) is presumed to be a physiological inhibitor of the serine proteinase thrombin, The reaction between HCII and thrombin is quite unique, because it involves an unusual HCII-reactive site loop sequence of Leu(444)-Ser(445), requires the presence of glycosaminoglycans for optimal activity and involves a protein-protein interaction besides the reactive site loop-active site interaction characteristic of serine proteinase inhibitor-serine proteinase pairs, Two mutations at a unique HCII residue, Arg(200) --> Als or Glu, were generated by site-directed mutagenesis, The mutations did not alter either HCII binding to heparin-Sepharose or HCII inhibition of thrombin in the presence of heparin or dermatan sulfate, suggesting that Arg(200) is not part of the glycosaminoglycan binding site of HCII. In the absence of glycosaminoglycan, there was a significant increase in alpha-thrombin inhibition by the Arg(200) mutants as compared with wild type recombinant HCII (wt-rHCII), whereas inhibition rates with chymotrypsin were identical, Inhibition of gamma(T)-thrombin, which lacks anion-binding exosite 1 ((ABE-1), the region of alpha-thrombin that interacts with the acidic domain of HCII), was significantly reduced compared with alpha-thrombin, but the reduction was more dramatic for the Arg(200)-rHCII mutants. Hirugen, which binds to ABE-1 of alpha-thrombin, also diminished inhibition of alpha-thrombin by the Arg(200)-rHCII mutants to nearly wt-rHCII levels. Both Arg(200)-rHCII mutants had significantly increased k(d) values as compared with wt-rHCII, whereas the k(d) rates were unchanged. Collectively, these results suggest that the improved inhibitory activity of the Arg(200)-rHCII mutants is mediated by enhanced interactions between the acidic domain and ABE-1, resulting in an increased HCII-thrombin association rate.	UNIV N CAROLINA,DIV HEMATOL ONCOL MED,DEPT MED,SCH MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CTR THROMBOSIS & HEMOSTASIS,SCH MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PHARMACOL,SCH MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PATHOL & LAB MED,SCH MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT MED,SCH MED,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine				Sontag, Angelina/0000-0003-4012-4537; Monroe, Dougald/0000-0002-0493-2943	NHLBI NIH HHS [HL-32656] Funding Source: Medline; NIGMS NIH HHS [5T32-GM-07040-19] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032656] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007040] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARSHAVIT R, 1986, P NATL ACAD SCI USA, V83, P976, DOI 10.1073/pnas.83.4.976; BARSHAVIT R, 1983, SCIENCE, V220, P728, DOI 10.1126/science.6836310; BLINDER MA, 1989, J BIOL CHEM, V264, P5128; BLINDER MA, 1988, BIOCHEMISTRY-US, V27, P752, DOI 10.1021/bi00402a039; BLINDER MA, 1990, J BIOL CHEM, V265, P286; BODE W, 1992, PROTEIN SCI, V1, P426; BRUAN PJ, 1988, THROMB RES, V50; CHURCH FC, 1986, ANAL BIOCHEM, V157, P77, DOI 10.1016/0003-2697(86)90198-3; CHURCH FC, 1994, TRENDS CARDIOVAS MED, V4, P140, DOI 10.1016/1050-1738(94)90066-3; CHURCH FC, 1985, P NATL ACAD SCI USA, V82, P6431, DOI 10.1073/pnas.82.19.6431; CHURCH FC, 1995, HEPARIN COFACTOR, V2, P379; Ciaccia AV, 1997, J BIOL CHEM, V272, P888, DOI 10.1074/jbc.272.2.888; Ciaccia AV, 1995, PROTEIN EXPRES PURIF, V6, P806, DOI 10.1006/prep.1995.0012; DERECHIN VM, 1990, J BIOL CHEM, V265, P5623; DODT J, 1984, FEBS LETT, V165, P180, DOI 10.1016/0014-5793(84)80165-9; GRIFFITH MJ, 1985, J BIOL CHEM, V260, P2218; GRIFFITH MJ, 1985, BIOCHEMISTRY-US, V24, P6777, DOI 10.1021/bi00345a008; HERMANS JM, 1993, BIOCHEM J, V295, P239, DOI 10.1042/bj2950239; HOFFMAN M, 1995, BLOOD CELL MOL DIS, V21, P156, DOI 10.1006/bcmd.1995.0018; HORTIN G, 1986, J BIOL CHEM, V261, P5827; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; HUNT LT, 1980, BIOCHEM BIOPH RES CO, V95, P864, DOI 10.1016/0006-291X(80)90867-0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MARCUM JA, 1984, BIOCHEMISTRY-US, V23, P1730, DOI 10.1021/bi00303a023; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; PRATT CW, 1992, J BIOL CHEM, V267, P8795; RAGG H, 1990, J BIOL CHEM, V265, P5211; RAGG H, 1990, J BIOL CHEM, V265, P22386; ROGERS SJ, 1992, J BIOL CHEM, V267, P3613; Shirk RA, 1996, ARTERIOSCL THROM VAS, V16, P1138, DOI 10.1161/01.ATV.16.9.1138; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; TOLLEFSEN DM, 1982, J BIOL CHEM, V257, P2162; TOLLEFSEN DM, 1981, J CLIN INVEST, V68, P589, DOI 10.1172/JCI110292; TOLLEFSEN DM, 1995, THROMB HAEMOSTASIS, V74, P1209; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; WHINNA HC, 1993, J BIOL CHEM, V268, P3920; WHINNA HC, 1991, J BIOL CHEM, V266, P8129; WHINNA HC, 1993, J PROTEIN CHEM, V12, P677, DOI 10.1007/BF01024926	41	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14074	14079		10.1074/jbc.272.22.14074	http://dx.doi.org/10.1074/jbc.272.22.14074			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162031	hybrid			2022-12-27	WOS:A1997XB49200018
J	Mandal, M; Kumar, R				Mandal, M; Kumar, R			Bcl-2 modulates telomerase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DAUDI CELLS; APOPTOSIS; GENE; EXPRESSION; LYMPHOMA; DISEASE; CANCER; DEATH	Apoptosis is a physiological mechanism of cell death that plays an important role in the regulation of tissue homeostasis, The regulation of apoptosis is a complex process and involves a number of gene products including the survival factor Bcl-2, which has been found to be frequently deregulated in human cancers, In addition to deregulation of apoptosis, the process of neoplasia is also believed to be driven by the activation of telomerase, a ribonucleoprotein complex that adds telomeric repeats (hexanucleotide 5'-TTAGGG-3') to the ends of replicating chromosomes, Activation of telomerase has been detected in a vast majority of human cancer cells, Although recent studies have demonstrated the wide occurrence of telomerase activation and Bcl-2 deregulation in human cancer cells, it remains unclear whether there is any linkage between the deregulation of Bcl-2 and telomerase activity in cancer cells, In the studies presented here, we report that the stable overexpression of Bcl-2 in human cancer cells with low Bcl-2 expression was accompanied by increased levels of telomerase activity, In addition, using an IL-2-dependent cytotoxic T-cell line, CTLL-8, we demonstrated that IL-2 deprivation (8 h), which is known to down-regulate Bcl-2 expression, also resulted in concurrent inhibition of telomerase activity in the absence of any detectable apoptosis and accumulation of cells in the G(0)/G(1) phase of the cell cycle. Re-exposure of IL-2-deprived CTLL-2 cells to the recombinant IL-2 led to the up-regulation of both Bcl-2 expression and telomerase activity, Taken together, these findings establish a close linkage between the modulation of telomerase activity by survival factor Bcl-2, and provide a model to study regulation of telomerase activity by an anti-apoptotic pathway that is widely deregulated in cancer cells.	UNIV TEXAS,MD ANDERSON CANCER CTR,CELL GROWTH REGULAT SECT,CELL GROWTH REGULAT LAB,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Mandal, Mahitosh/GMW-6195-2022	Mandal, Mahitosh/0000-0003-3861-3323				Avilion AA, 1996, CANCER RES, V56, P645; BACCHETTI S, 1995, INT J ONCOL, V7, P423; Bestilny LJ, 1996, CANCER RES, V56, P3796; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; BRYAN TM, 1995, EMBO J, V14, P2140; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; ENGELHARDT M, 1997, IN PRESS BLOOD; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; JENNINGS SR, 1991, CELL IMMUNOL, V133, P234, DOI 10.1016/0008-8749(91)90194-G; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KUMAR R, 1994, J BIOL CHEM, V269, P25437; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; KUMAR R, 1996, CLIN CANCER RES, V2, P115; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; Mandal M, 1996, CELL GROWTH DIFFER, V7, P311; Mandal M, 1997, CARCINOGENESIS, V18, P229, DOI 10.1093/carcin/18.1.229; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Olson DJ, 1997, CELL GROWTH DIFFER, V8, P417; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Shay Jerry W., 1996, Current Opinion in Oncology, V8, P66, DOI 10.1097/00001622-199601000-00012; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WRIGHT WE, 1995, TRENDS CELL BIOL, V5, P293, DOI 10.1016/S0962-8924(00)89044-3; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871	29	146	174	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14183	14187		10.1074/jbc.272.22.14183	http://dx.doi.org/10.1074/jbc.272.22.14183			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162048	hybrid			2022-12-27	WOS:A1997XB49200035
J	Yu, CL; Burakoff, SJ				Yu, CL; Burakoff, SJ			Involvement of proteasomes in regulating Jak-STAT pathways upon interleukin-2 stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; PROTEIN-TYROSINE KINASES; RECEPTOR-BETA CHAIN; CYTOKINE RECEPTORS; IN-VIVO; KAPPA-B; C-FOS; PHOSPHORYLATION; ACTIVATION; GENE	Interleukin-2 (IL-2) activates the receptor-associated Janus family tyrosine kinases, Jak1 and Jak3, which in turn phosphorylate and activate specific STAT proteins (signal transducers and activators of transcription), such as STATE. Activation of Jak and STAT proteins by IL-2 is transient and the mechanism for the subsequent down-regulation of their activity is largely unknown. We report here that IL-2-induced DNA-binding activity and tyrosine phosphorylation of STATE are stabilized by a proteasome inhibitor MG132; however, no detectable ubiquitination of the STAT proteins is observed. This sustained STATE activation can be blocked by protein kinase inhibitors, which is consistent with the ability of the proteasome inhibitor to stabilize IL-2-induced tyrosine phosphorylation of Jak1 and Jak3. These results suggest that proteasome-mediated protein degradation modulates protein-tyrosine phosphatase activity that negatively regulates the Jak-STAT signaling pathways.	DANA FARBER CANC INST,DEPT PEDIAT ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School			Yu, Chao-Lan/D-1834-2011	Yu, Chao-Lan/0000-0002-9381-6011	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017258] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-17258] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BHAT GJ, 1994, J BIOL CHEM, V269, P31443; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1993, MOL CELL BIOL, V13, P7515, DOI 10.1128/MCB.13.12.7515; DAVID M, 1995, MOL CELL BIOL, V15, P7050; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; HAQUE SJ, 1995, J BIOL CHEM, V270, P25709, DOI 10.1074/jbc.270.43.25709; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; JOHNSTON JA, 1995, P NATL ACAD SCI USA, V92, P8705, DOI 10.1073/pnas.92.19.8705; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; Leonard WJ, 1996, NAT MED, V2, P968, DOI 10.1038/nm0996-968; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PERNIS A, 1995, J BIOL CHEM, V270, P14517, DOI 10.1074/jbc.270.24.14517; Ravichandran KS, 1996, P NATL ACAD SCI USA, V93, P5275, DOI 10.1073/pnas.93.11.5275; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TRIER M, 1994, CELL, V78, P787; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	35	104	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14017	14020		10.1074/jbc.272.22.14017	http://dx.doi.org/10.1074/jbc.272.22.14017			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162019	hybrid			2022-12-27	WOS:A1997XB49200006
J	Hagen, FK; TenHagen, KG; Beres, TM; Balys, MM; VanWuyckhuyse, BC; Tabak, LA				Hagen, FK; TenHagen, KG; Beres, TM; Balys, MM; VanWuyckhuyse, BC; Tabak, LA			cDNA cloning and expression of a novel UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; INTESTINAL MUCIN; GALNAC; IDENTIFICATION; SELECTIN; BINDING	The cDNA for a fourth member of the mammalian UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase family, termed ppGaNTase-T4, has been cloned from a murine spleen cDNA library and expressed transiently in COS7 cells as a secreted functional enzyme. Degenerate primers, based upon regions that are conserved among the known mammalian members of the enzyme family (ppGaNTase-T1, -T2, and -T3) and three Caenorhabditis elegans homologues (ppGaNTase-TA, -TB, and -TC), were used in polymerase chain reactions to identify and clone this new isoform. Substrate preferences for recombinant murine ppGaNTase-T1 and ppGaNTase-T4 isozymes were readily distinguished. ppGaNTase-T1 glycosylated a broader range of synthetic peptide substrates; in contrast, the ppGaNTase-T4 preferentially glycosylated a single substrate among the panel of II peptides tested, Using Northern blot analysis, a ppGaNTase-T4 message of 5.5 kilobases was detectable in murine embryonic tissues, as well as the adult sublingual gland, stomach, colon, small intestine, lung, cervix, and uterus with lower levels detected in kidney, liver, heart, brain, spleen, and ovary. Thus, the pattern of expression for ppGaNTase-T4 is more restricted than for the three previously reported isoforms of the enzyme. The variation in expression patterns and substrate specificities of the ppGaNTase enzyme family suggests that differential expression of these isoenzymes may be responsible for the cell-specific repertoire of mucin-type oligosaccharides on cell-surface and secreted O-linked glycoproteins.	UNIV ROCHESTER,SCH MED & DENT,DEPT DENT RES,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM & BIOPHYS,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008108, R37DE008108] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-08108] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALBONE EF, 1994, J BIOL CHEM, V269, P16845; BEDNARCZUK TA, 1991, BIOTECHNIQUES, V10, P478; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; DOWBENKO D, 1993, J BIOL CHEM, V268, P4525; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GUM JR, 1991, J BIOL CHEM, V266, P22733; GUM JR, 1994, J BIOL CHEM, V269, P2440; HAGEN FK, 1995, GLYCOCONJUGATE J, V12, P901, DOI 10.1007/BF00731252; HAGEN FK, 1993, J BIOL CHEM, V268, P18960; HOMA FL, 1993, J BIOL CHEM, V268, P12609; KINLOCH RA, 1995, P NATL ACAD SCI USA, V92, P263, DOI 10.1073/pnas.92.1.263; LISZEWSKI MK, 1991, ANNU REV IMMUNOL, V9, P431, DOI 10.1146/annurev.iy.09.040191.002243; OHMORI H, 1994, J BIOL CHEM, V269, P17833; Sambrook J., 2002, MOL CLONING LAB MANU; SANZ L, 1992, FEBS LETT, V300, P213, DOI 10.1016/0014-5793(92)80848-B; SAWADA T, 1994, INT J CANCER, V57, P901, DOI 10.1002/ijc.2910570621; SORENSEN T, 1995, J BIOL CHEM, V270, P24166, DOI 10.1074/jbc.270.41.24166; TABAK LA, 1995, ANNU REV PHYSIOL, V57, P547, DOI 10.1146/annurev.ph.57.030195.002555; WRAGG S, 1995, J BIOL CHEM, V270, P16947, DOI 10.1074/jbc.270.28.16947; Zara J, 1996, BIOCHEM BIOPH RES CO, V228, P38, DOI 10.1006/bbrc.1996.1613	20	103	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13843	13848		10.1074/jbc.272.21.13843	http://dx.doi.org/10.1074/jbc.272.21.13843			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153242	hybrid			2022-12-27	WOS:A1997XA06200057
J	Zhang, LX; Wang, HN; Liu, D; Liddington, R; Fu, HA				Zhang, LX; Wang, HN; Liu, D; Liddington, R; Fu, HA			Raf-1 kinase and exoenzyme S interact with 14-3-3 zeta through a common site involving lysine 49	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; PSEUDOMONAS-AERUGINOSA; IN-VITRO; 14-3-3-PROTEINS; ACTIVATION; ASSOCIATION; BRAIN; IDENTIFICATION; PURIFICATION	14-3-3 proteins are a family of conserved dimeric molecules that bind to a range of cellular proteins involved in signal transduction and oncogenesis. Our solution of the crystal structure of 14-3-3 zeta revealed a conserved amphipathic groove that may allow the association of 14-3-3 with diverse ligands (Liu, D., Bienkowska, J., Petosa, C., Collier, R. J., Fu, H., and Liddington, R. (1995) Nature 376, 191-194). Here, the contributions of three positively charged residues (Lys-49, Arg-56, and Arg-60) that lie in this Raf-binding groove were investigated. Two of the charge-reversal mutations greatly (K49E) or partially (R56E) decreased the interaction of 14-3-3 zeta with Raf-1 kinase, whereas R60E showed only subtle effects on the binding. Interestingly, these mutations exhibited similar effects on the functional interaction of 14-3-3 zeta with another target protein, exoenzyme S (ExoS), an ADP-ribosyltransferase from Pseudomonas aeruginosa. The EC50 values of 14-3-3 zeta required for ExoS activation increased by similar to 110-, 5-, and 2-fold for the K49E, R56E, and R60E mutants, respectively. The drastic reduction of 14-3-3 zeta ligand affinity by the K49E mutation is due to a local electrostatic effect, rather than the result of a gross structural alteration, as evidenced by partial proteoIysis and circular dichroism analysis. This work identifies the first point mutation (K49E) that dramatically disrupts 14-3-5 zeta ligand interactions. The parallel effects of this single point mutation on both Raf-1 binding and ExoS activation strongly suggest that diverse associated proteins share a common structural binding determinant on 14-3-3 zeta.	EMORY UNIV, SCH MED, DEPT PHARMACOL, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED, GRAD PROGRAM CELL & DEV BIOL, ATLANTA, GA 30322 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; UNIV LEICESTER, DEPT BIOCHEM, LEICESTER LE1 7RH, LEICS, ENGLAND	Emory University; Emory University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Leicester				Zhang, Lixin/0000-0003-0894-9520	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053165, R01GM053165] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53165] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Bachmann M, 1996, FEBS LETT, V387, P127, DOI 10.1016/0014-5793(96)00478-4; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BOSTON PF, 1982, J NEUROCHEM, V38, P1466, DOI 10.1111/j.1471-4159.1982.tb07927.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COBURN J, 1992, CURR TOP MICROBIOL, V175, P133; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINN BE, 1995, STRUCTURE, V3, P7, DOI 10.1016/S0969-2126(01)00130-7; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; GELPERIN D, 1995, P NATL ACAD SCI USA, V92, P11539, DOI 10.1073/pnas.92.25.11539; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; ICHIMURA T, 1987, FEBS LETT, V219, P79, DOI 10.1016/0014-5793(87)81194-8; ICHIMURA T, 1995, J BIOL CHEM, V270, P28515, DOI 10.1074/jbc.270.48.28515; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; ISOBE T, 1992, FEBS LETT, V308, P121, DOI 10.1016/0014-5793(92)81257-M; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; JONES DHA, 1995, J MOL BIOL, V245, P375, DOI 10.1006/jmbi.1994.0031; KULICH SM, 1993, INFECT IMMUN, V61, P307, DOI 10.1128/IAI.61.1.307-313.1993; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Meller N, 1996, MOL CELL BIOL, V16, P5782; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Moore BE, 1967, PHYSL BIOCH ASPECTS, P343; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; ROBINSON K, 1994, BIOCHEM J, V299, P853, DOI 10.1042/bj2990853; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUEN KL, 1995, ONCOGENE, V11, P825; TOKER A, 1990, EUR J BIOCHEM, V191, P421, DOI 10.1111/j.1432-1033.1990.tb19138.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANHEUSDEN GPH, 1995, EUR J BIOCHEM, V229, P45; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	53	128	132	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13717	13724		10.1074/jbc.272.21.13717	http://dx.doi.org/10.1074/jbc.272.21.13717			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153224	hybrid			2022-12-27	WOS:A1997XA06200039
J	Lebowitz, PF; Du, W; Prendergast, GC				Lebowitz, PF; Du, W; Prendergast, GC			Prenylation of RhoB is required for its cell transforming function but not its ability to activate serum response element-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS TRANSFORMATION; GROWTH-FACTOR; FARNESYLTRANSFERASE INHIBITORS; PROTEIN; MORPHOLOGY; MEMBRANE; RAC1; P21; GDI	Rho regulates cytoskeletal actin structure and integrin-mediated cell adhesion. Rho also has a role in cell growth regulation and is required for cell transformation by oncogenic Ras. Recently, it has been demonstrated that Rho can activate transcription from the c-fos serum response element (SRE). This raised the possibility that functions required for Rho-mediated cell transformation might overlap with those involved in transcriptional regulation. Here we show that RhoB can activate the SRE and can synergize in cell transformation with constitutively activated Raf-CAAX. Significantly, unprenylated forms of RhoB that are biologically inert and unable to transform cells can still activate SRE-dependent transcription. This finding suggests that transcriptional activation by Rho may be separable from its cell transforming functions.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; UNIV PENN,CELL & MOL BIOL GRAD GRP,PHILADELPHIA,PA 19104	The Wistar Institute; University of Pennsylvania					NCI NIH HHS [CA65892] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA065892] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; Harlow E., 1988, ANTIBODIES LAB MANUA; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; Lebowitz PF, 1997, CANCER RES, V57, P708; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MIURA Y, 1993, J BIOL CHEM, V268, P510; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SYMONS M, 1995, CURR OPIN BIOTECH, V6, P668, DOI 10.1016/0958-1669(95)80110-3; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; ZALCMAN G, 1995, ONCOGENE, V1085, P1935	27	76	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16093	16095		10.1074/jbc.272.26.16093	http://dx.doi.org/10.1074/jbc.272.26.16093			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195903	hybrid			2022-12-27	WOS:A1997XG01900007
J	Cupillard, L; Koumanov, K; Mattei, MG; Lazdunski, M; Lambeau, G				Cupillard, L; Koumanov, K; Mattei, MG; Lazdunski, M; Lambeau, G			Cloning, chromosomal mapping, and expression of a novel human secretory phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-II PHOSPHOLIPASE-A2; AMINO-ACID-SEQUENCE; PANCREATIC GROUP-I; MEMBRANE-RECEPTOR; RECOMBINANT EXPRESSION; MOLECULAR-CLONING; BINDING-SITES; HUMAN-TISSUES; SNAKE-VENOM; MOM1 LOCUS	Secretory phospholipases A(2) (sPLA(2)s) represent a rapidly expanding family of structurally related enzymes found in mammals as well as in insect and snake venoms. In this report, a cDNA coding for a novel sPLA(2) has been isolated from human fetal lung, and its gene has been mapped to chromosome 16p13.1-p12. The mature sPLA(2) protein has a molecular mass of 13.6 kDa, is acidic (pI 5.3), and made up of 123 amino acids. Key structural features of the sPLA(2) include: (i) a long prepropeptide ending with an arginine doublet, (ii) 16 cysteines located at positions that are characteristic of both group I and group II sPLA(2)s, (iii) a C-terminal extension typical of group II sPLA(2)s, (iv) and the absence of elapid and pancreatic loops that are characteristic of group I sPLA(2)s. Based on these structural properties, this sPLA(2) appears as a first member of a new group of sPLA(2)s, called group X. A 1.5-kilobase transcript coding for the human group X (hGX) sPLA(2) was found in spleen, thymus, and peripheral blood leukocytes, while a less abundant 0.8-kilobase transcript was detected in the pancreas, lung, and colon. When the hGX sPLA(2), cDNA was expressed in COS cells, sPLA(2), activity preferentially accumulated in the culture medium, indicating that hGX, sPLA(2) is an actively secreted enzyme. It is maximally active at physiological pH and with 10 mM Ca2+. hGX sPLA(2) prefers phosphatidylethanolamine and phosphatidylcholine liposomes to those of phosphatidylserine.	CNRS,INST PHARMACOL MOL & CELLULAIRE,UPR 411,F-06560 VALBONNE,FRANCE; FAC MED MARSEILLE,U406 INSERM GENET MED & DEV,F-13385 MARSEILLE 05,FRANCE; CHU ST ANTOINE,URA 1283 CNRS,F-75012 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite			Dennis, Edward A./M-5554-2019; Lambeau, Gerard/GRJ-5624-2022	Dennis, Edward A./0000-0003-3738-3140; Lambeau, Gerard/0000-0002-9239-518X				AGARWAL ML, 1993, CANCER RES, V53, P5897; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANCIAN P, 1995, BIOCHEMISTRY-US, V34, P13146, DOI 10.1021/bi00040a028; ANCIAN P, 1995, J BIOL CHEM, V270, P8963, DOI 10.1074/jbc.270.15.8963; ARITA H, 1991, J BIOL CHEM, V266, P19139; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Bonventre JV, 1996, J LIPID MEDIAT CELL, V14, P15, DOI 10.1016/0929-7855(96)00503-2; BUHL WJ, 1995, BIOCHEM J, V311, P147, DOI 10.1042/bj3110147; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, J BIOL CHEM, V269, P23018; CHEN J, 1994, BBA-LIPID LIPID MET, V1215, P115, DOI 10.1016/0005-2760(94)90099-X; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DEGEUS P, 1987, NUCLEIC ACIDS RES, V15, P3743, DOI 10.1093/nar/15.9.3743; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Doggett N A, 1996, Cytogenet Cell Genet, V72, P271; EVENBERG A, 1977, J BIOL CHEM, V252, P1189; FEUCHTERMURTHY AE, 1993, NUCLEIC ACIDS RES, V21, P135, DOI 10.1093/nar/21.1.135; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Frossard PM, 1995, CLIN GENET, V48, P284; Gandolfo G, 1996, PHARMACOL TOXICOL, V78, P341, DOI 10.1111/j.1600-0773.1996.tb01386.x; GASSAMADIAGNE A, 1989, J BIOL CHEM, V264, P9470; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; GOPPELTSTRUEBE M, 1986, FEBS LETT, V202, P45, DOI 10.1016/0014-5793(86)80646-9; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAY NCC, 1982, CAN J BIOCHEM CELL B, V60, P108, DOI 10.1139/o82-015; GUTIERREZ JM, 1995, TOXICON, V33, P1405, DOI 10.1016/0041-0101(95)00085-Z; HALBAN PA, 1994, BIOCHEM J, V299, P1; Hawgood B., 1991, HDB NATURAL TOXINS R, V5, P3; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P4913; HIGASHINO K, 1994, EUR J BIOCHEM, V225, P375, DOI 10.1111/j.1432-1033.1994.00375.x; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; KANDA A, 1989, BIOCHEM BIOPH RES CO, V163, P42, DOI 10.1016/0006-291X(89)92096-2; Kerfelec B, 1986, Pancreas, V1, P430, DOI 10.1097/00006676-198609000-00007; KINI RM, 1989, TOXICON, V27, P613, DOI 10.1016/0041-0101(89)90013-5; KOMADA M, 1989, J BIOCHEM-TOKYO, V106, P545, DOI 10.1093/oxfordjournals.jbchem.a122890; KORYSTOV YN, 1993, RADIAT RES, V134, P301, DOI 10.2307/3578189; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1993, ADV SEC MESS PHOSPH, V28, P81; KRAMER RM, 1995, AGENT ACTION SUPPL, V46, P65; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; KUMAR VB, 1993, BIOCHEM BIOPH RES CO, V192, P683, DOI 10.1006/bbrc.1993.1469; LAMBEAU G, 1990, J BIOL CHEM, V265, P9526; LAMBEAU G, 1989, J BIOL CHEM, V264, P11503; LAMBEAU G, 1995, J BIOL CHEM, V270, P5534, DOI 10.1074/jbc.270.10.5534; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; Lambeau G, 1997, VENOM PHOSPHOLIPASE, P389; LANGLAIS J, 1992, BIOCHEM BIOPH RES CO, V182, P208, DOI 10.1016/S0006-291X(05)80132-9; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LILJA I, 1995, GUT, V37, P380, DOI 10.1136/gut.37.3.380; LIU PS, 1995, BIOCHEM J, V308, P399, DOI 10.1042/bj3080399; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MATSUDA Y, 1987, RES COMMUN CHEM PATH, V58, P281; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; MULHERKAR R, 1993, BIOCHEM BIOPH RES CO, V195, P1254, DOI 10.1006/bbrc.1993.2179; MURAKAMI M, 1995, J LIPID MEDIAT CELL, V12, P119, DOI 10.1016/0929-7855(95)00013-G; NAKAJIMA M, 1992, FEBS LETT, V309, P261, DOI 10.1016/0014-5793(92)80785-F; NAKANO T, 1990, FEBS LETT, V273, P23, DOI 10.1016/0014-5793(90)81042-M; NEVALAINEN TJ, 1993, INFLAMMATION, V17, P453, DOI 10.1007/BF00916585; NEVALAINEN TJ, 1993, CLIN CHEM, V39, P2453; NICOLAS JP, 1995, J BIOL CHEM, V270, P28869, DOI 10.1074/jbc.270.48.28869; Nicolas JP, 1997, J BIOL CHEM, V272, P7173, DOI 10.1074/jbc.272.11.7173; OGAWA M, 1991, RES COMMUN CHEM PATH, V74, P241; OHARA O, 1986, J BIOCHEM-TOKYO, V99, P733, DOI 10.1093/oxfordjournals.jbchem.a135532; OHARA O, 1995, PROG LIPID RES, V34, P117, DOI 10.1016/0163-7827(94)00009-B; OHMACHI M, 1996, INT J ONCOL, V9, P511; PRAML C, 1995, CANCER RES, V55, P5504; PRUZANSKI W, 1993, J LIPID MEDIATOR, V8, P161; RAE D, 1995, CLIN BIOCHEM, V28, P71, DOI 10.1016/0009-9120(94)00068-7; ROSS BM, 1995, J NEUROCHEM, V64, P2213; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SEILHAMER JJ, 1986, DNA-J MOLEC CELL BIO, V5, P519, DOI 10.1089/dna.1.1986.5.519; SHAPOSHNIKOVA VV, 1994, FEBS LETT, V348, P317, DOI 10.1016/0014-5793(94)00616-4; SHARP JD, 1994, J BIOL CHEM, V269, P23250; SOMMER CD, 1992, EUR J PHAR, V26, P87; STECK TL, 1970, SCIENCE, V168, P255, DOI 10.1126/science.168.3928.255; TANAKA T, 1987, NUCLEIC ACIDS RES, V15, P3178, DOI 10.1093/nar/15.7.3178; THOMSON FH, 1995, BIOCHEM J, V3065, P305; Tischfield JA, 1996, GENOMICS, V32, P328, DOI 10.1006/geno.1996.0126; TOJO H, 1988, J BIOL CHEM, V263, P5724; TSUJISHITA Y, 1994, P NATL ACAD SCI USA, V91, P6274, DOI 10.1073/pnas.91.14.6274; VADAS P, 1993, J LIPID MEDIATOR, V8, P1; VIAL D, 1995, J BIOL CHEM, V270, P17327, DOI 10.1074/jbc.270.29.17327; VOLWERK JJ, 1974, BIOCHEMISTRY-US, V13, P1446, DOI 10.1021/bi00704a020; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WANG R, 1994, BIOCHEM J, V304, P131, DOI 10.1042/bj3040131; WOJTASZEK PA, 1995, FEBS LETT, V367, P228, DOI 10.1016/0014-5793(95)00556-O; Wolf MJ, 1996, J BIOL CHEM, V271, P30879, DOI 10.1074/jbc.271.48.30879; YING Z, 1993, EUR J BIOCHEM, V215, P91, DOI 10.1111/j.1432-1033.1993.tb18010.x; Zvaritch E, 1996, J BIOL CHEM, V271, P250, DOI 10.1074/jbc.271.1.250	95	232	245	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15745	15752		10.1074/jbc.272.25.15745	http://dx.doi.org/10.1074/jbc.272.25.15745			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188469	hybrid			2022-12-27	WOS:A1997XF32900029
J	Ford, E; Hernandez, N				Ford, E; Hernandez, N			Characterization of a trimeric complex containing Oct-1, SNAP(c), and DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; PROXIMAL SEQUENCE ELEMENT; POU DOMAIN; BINDING DOMAIN; TRANSCRIPTION FACTOR; ACTIVATION DOMAINS; POSITIVE CONTROL; PROTEIN; PROMOTER; GENES	The human small nuclear (su) RNA promoters contain a proximal sequence element (PSE), which recruits the basal transcription factor SNAP(c), and a distal sequence element characterized by an octamer sequence, which recruits the POU domain transcription factor Oct-1, The Oct-1 POU domain and SNAP(c) bind cooperatively to probes containing a PSE and an octamer sequence, and this effect contributes to efficient transcription in vitro. In vivo, however, Oct-1 regions outside of the POU domain can activate snRNA gene transcription. Here, we have examined whether the role of these regions is to contribute to cooperative binding with SNAP(c). We find that they indeed improve cooperative binding, but most of the effect is nevertheless mediated by just the POU domain, This suggests that Oct-1 activates transcription of snRNA genes In at least two steps, recruitment of SNAP(c) mediated primarily by the POU domain, and a later step mediated by regions outside of the POU domain, We also show that a PSE-binding complex observed in nuclear extracts consists of Oct-1 and SNAP(c). Although Oct-1 cannot bind effectively to the PSE probe on its own, in the complex it contacts DNA, Thus, in a nuclear extract, SNAP(c) can recruit Oct-1 to a probe to which Oct-1 cannot bind on its own.	SUNY STONY BROOK,GENET PROGRAM,STONY BROOK,NY 11794; COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute	Ford, E (corresponding author), COLD SPRING HARBOR LAB,POB 100,COLD SPRING HARBOR,NY 11724, USA.			Hernandez, Nouria/0000-0003-1465-4585	NIGMS NIH HHS [GM38810] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038810] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASSAMUNT N, 1993, CELL, V73, P193, DOI 10.1016/0092-8674(93)90171-L; AURORA R, 1992, MOL CELL BIOL, V12, P455, DOI 10.1128/MCB.12.2.455; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CLEARY MA, 1995, MOL CELL BIOL, V15, P2090; CLEARY MA, 1993, GENE DEV, V7, P72, DOI 10.1101/gad.7.1.72; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; DEKKER N, 1993, NATURE, V362, P852, DOI 10.1038/362852a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; HENRY RW, 1995, NATURE, V374, P653, DOI 10.1038/374653a0; Hernandez Nouria, 1992, V22 PART 1-2, P281; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; Mittal V, 1996, MOL CELL BIOL, V16, P1955; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Ranish JA, 1996, CURR OPIN GENET DEV, V6, P151, DOI 10.1016/S0959-437X(96)80044-X; Sadowski CL, 1996, P NATL ACAD SCI USA, V93, P4289, DOI 10.1073/pnas.93.9.4289; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; YOON JB, 1995, MOL CELL BIOL, V15, P2019	34	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					16048	16055		10.1074/jbc.272.25.16048	http://dx.doi.org/10.1074/jbc.272.25.16048			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188510	hybrid			2022-12-27	WOS:A1997XF32900070
J	Lee, CH; Kang, HS; Chung, JK; Sekiya, F; Kim, JR; Han, JS; Kim, SR; Bae, YS; Morris, AJ; Rhee, SG				Lee, CH; Kang, HS; Chung, JK; Sekiya, F; Kim, JR; Han, JS; Kim, SR; Bae, YS; Morris, AJ; Rhee, SG			Inhibition of phospholipase D by clathrin assembly protein 3 (AP3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPSE-SPECIFIC PROTEIN; COATED VESICLES; F1-20 PROTEIN; AP-3; BINDING; DOMAIN; NP185; PURIFICATION; BRAIN; CYCLE	In the accompanying paper (Chung, J,-K., Sekiya, F., Kang, H.-S., Lee, C., Han, J.-S., Kim, S. R., Bae, Y, S., Morris, A, J,, and Rhee, S. G. (1997) J. Biol. Chem, 272, 15980-15985), synaptojanin is identified as a protein that inhibits phospholipase D (PLD) activity stimulated by ADP-ribosylation factor and phosphatidylinositol 4,5-bisphosphate (PI(4,5)P-2). Here, the purification from rat brain cytosol of another PLD-inhibitory protein that is immunologically distinct horn synaptojanin is described, and this protein is identified as clathrin assembly protein 3 (AP3) by peptide sequencing and immunoblot analysis. AP3 binds both inositol hexakisphosphate and preassembled clathrin cages with high affinity, However, neither inositol hexakisphosphate binding nor clathrin in cage binding affected the ability of AP3 to inhibit PLD. AP3 also binds to PT(4,5)P-2 with low affinity, But the PI(4,5)P-2 binding was not responsible for PLD inhibition, because the potency and efficacy of AP3 as an inhibitor of PLD were similar in the absence and presence of PI(4,5)P-2. A bacterially expressed fusion protein, glutathione S-transferase-AP3 (GST-AP3), also inhibited PLD with a potency equal to that of brain AP3. The inhibitory effect of AP3 appeared to be the result of direct interaction between AP3 and PLD because PLD bound GST-AP3 in an in vitro binding assay. Using GST fusion proteins containing various AP3 sequences, we found that the sequence extending from residues Pro-290 to Lys-320 of AP3 is critical far both inhibition of and binding to PLD. The fact that AP3 is a synapse-specific protein indicates that the AP3-dependent inhibition of PLD might play a regulatory role that is restricted to the rapid cycling of synaptic vesicles.	NHLBI,LAB CELL SIGNALING,NIH,BETHESDA,MD 20892; SUNY STONY BROOK,DEPT PHARMACOL SCI,STONY BROOK,NY 11794	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Morris, Andrew/B-7869-2010; Han, Joong-Soo/P-2072-2015	Han, Joong-Soo/0000-0002-0875-6158				AHLE S, 1990, J CELL BIOL, V111, P19, DOI 10.1083/jcb.111.1.19; AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; BECK KA, 1991, J BIOL CHEM, V266, P4442; Chung JK, 1997, J BIOL CHEM, V272, P15980, DOI 10.1074/jbc.272.25.15980; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Han JS, 1996, J BIOL CHEM, V271, P11163, DOI 10.1074/jbc.271.19.11163; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KOHTZ DS, 1988, J BIOL CHEM, V263, P7418; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; MURPHY JE, 1994, J BIOL CHEM, V269, P21346; MURPHY JE, 1991, J BIOL CHEM, V266, P4401; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; OLIVOSGLANDER IM, 1995, AM J HUM GENET, V57, P817; PERRY DG, 1992, J NEUROSCI RES, V33, P408, DOI 10.1002/jnr.490330307; PRASAD K, 1988, BIOCHEMISTRY-US, V27, P6098, DOI 10.1021/bi00416a040; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SOUSA R, 1992, J NEUROSCI, V12, P2130; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TIMERMAN AP, 1992, P NATL ACAD SCI USA, V89, P8976, DOI 10.1073/pnas.89.19.8976; UNGOWICKELL E, 1989, ANAL BIOCHEM, V179, P352; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; VONGERSDORFF H, 1994, NATURE, V370, P652, DOI 10.1038/370652a0; YE W, 1995, J NEUROSCI RES, V41, P15, DOI 10.1002/jnr.490410104; YE WL, 1995, J BIOL CHEM, V270, P10933, DOI 10.1074/jbc.270.18.10933; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; ZHOU SB, 1992, J NEUROSCI, V12, P2144; ZHOU SB, 1993, J BIOL CHEM, V268, P12655	33	47	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15986	15992		10.1074/jbc.272.25.15986	http://dx.doi.org/10.1074/jbc.272.25.15986			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188501	hybrid			2022-12-27	WOS:A1997XF32900061
J	Lee, MG; Xu, X; Zeng, WZ; Diaz, J; Kuo, TH; Wuytack, F; Racymaekers, L; Muallem, S				Lee, MG; Xu, X; Zeng, WZ; Diaz, J; Kuo, TH; Wuytack, F; Racymaekers, L; Muallem, S			Polarized expression of Ca2+ pumps in pancreatic and salivary gland cells - Role in initiation and propagation of [Ca2+](i) waves	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM POOL; ENDOPLASMIC-RETICULUM; ACINAR-CELLS; PLASMA-MEMBRANE; INTRACELLULAR STORES; RELEASE; OSCILLATIONS; PHOSPHOLAMBAN; ACTIVATION; ANTIBODIES	The present study was aimed at localization of plasma membrane (PMCA) and intracellular (SERCA) Ca2+ pumps and characterizing their role in initiation and propagation of Ca2+ waves, Specific and polarized expression of Ca2+ pumps was observed in all epithelial cells examined. Immunolocalization revealed expression of PMCA ill both the basolateral and luminal membranes of all cell types. SERCA2a appeared to be ex pressed in the luminal pole, whereas SERCA2b was expressed in the basal pole and the nuclear envelope of pancreatic acini. Interestingly, SERCA2b was found in the luminal pole of submandibular salivary gland acinar and duct cells, These cells expressed SERCA3 in the basal pole, To examine the significance of the polarized expression of SERCA and perhaps PMCA pumps in secretory cells, we compared the effect of inhibition of SERCA pumps with thapsigargine and partial Ca2+ release with ionomycin on Ca2+ release evoked by agonists and Ca2+ uptake induced by antagonists, Despite their polarized expression, Ca2+ uptake by SERCA pumps and Ca2+ efflux by PMCA resulted in uniform reduction in [Ca2+](i), Surprisingly, inhibition of the SERCA pumps, but not Ca2+ release by ionomycin, eliminated the distinct initiation sites and propagated Ca2+ waves, leading to a uniform increase in [Ca2+](i), In addition, inhibition of SERCA pumps reduced the rate of Ca2+ release from internal stores, The implication of these findings to rates of Ca2+ diffusion in the cytosol, compartmentalization of Ca2+ signaling complexes, and mechanism of Ca2+ wave propagation are discussed.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235; WAYNE STATE UNIV,SCH MED,DEPT PATHOL,DETROIT,MI 48201; CATHOLIC UNIV LEUVEN,PHYSIOL LAB,B-3000 LOUVAIN,BELGIUM	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Wayne State University; KU Leuven			Lee, Min Goo/AAS-4636-2020; Lee, Min Goo/D-5635-2012	Lee, Min Goo/0000-0001-7436-012X; Lee, Min Goo/0000-0001-7436-012X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046591, R01DK038938] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38938, DK46591] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMO HP, 1992, J BIOL CHEM, V267, P14244; ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; AMBUDKAR IS, 1989, ARCH BIOCHEM BIOPHYS, V268, P576, DOI 10.1016/0003-9861(89)90325-1; Belan PV, 1996, J BIOL CHEM, V271, P7615, DOI 10.1074/jbc.271.13.7615; BERRIDGE MJ, 1996, CELL CALCIUM, V20; CAMPBELL AM, 1993, BRAIN RES, V605, P67; DORMER RL, 1993, BIOCHIM BIOPHYS ACTA, V1152, P225, DOI 10.1016/0005-2736(93)90253-V; EGGERMONT JA, 1990, BIOCHEM J, V271, P649, DOI 10.1042/bj2710649; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; Missiaen L, 1996, Subcell Biochem, V26, P59; MUALLEM S, 1988, BIOCHEM J, V255, P301; MUALLEM S, 1988, AM J PHYSIOL, V255, pG229, DOI 10.1152/ajpgi.1988.255.2.G229; MUALLEM S, 1990, J BIOL CHEM, V265, P2011; MUALLEM S, 1989, J BIOL CHEM, V264, P205; MUALLEM S, 1989, ANNU REV PHYSIOL, V51, P83; Muallem Shmuel, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P351; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; TEPIKIN AV, 1992, J BIOL CHEM, V267, P3569; Thorn P, 1996, EMBO J, V15, P999, DOI 10.1002/j.1460-2075.1996.tb00436.x; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; TORTORICI G, 1994, J BIOL CHEM, V269, P29621; VERBOOMEN H, 1992, BIOCHEM J, V286, P591, DOI 10.1042/bj2860591; WUYTACK F, 1989, BIOCHEM J, V264, P765, DOI 10.1042/bj2640765; WUYTACK F, 1994, J BIOL CHEM, V269, P1410; Xu X, 1996, J PHYSIOL-LONDON, V491, P647, DOI 10.1113/jphysiol.1996.sp021246; Xu X, 1996, J BIOL CHEM, V271, P24684, DOI 10.1074/jbc.271.40.24684; ZHANG BX, 1992, J BIOL CHEM, V267, P24387; ZHANG BX, 1992, J BIOL CHEM, V267, P15419	30	167	169	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15771	15776		10.1074/jbc.272.25.15771	http://dx.doi.org/10.1074/jbc.272.25.15771			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188473	hybrid			2022-12-27	WOS:A1997XF32900033
J	Tanaka, T; Urade, Y; Kimura, H; Eguchi, N; Nishikawa, A; Hayaishi, O				Tanaka, T; Urade, Y; Kimura, H; Eguchi, N; Nishikawa, A; Hayaishi, O			Lipocalin-type prostaglandin D synthase (beta-trace) is a newly recognized type of retinoid transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CEREBROSPINAL-FLUID; BINDING-PROTEIN; RAT-BRAIN; ACID-BINDING; CRYSTAL-STRUCTURE; D SYNTHETASE; TERMINAL SEQUENCE; ESCHERICHIA-COLI; CHOROID-PLEXUS; LACTOGLOBULIN	Lipocalin-type prostaglandin D synthase is responsible for the biosymthesis of prostaglandin D-2, in the central nervous system and the genital organs and is secreted into the cerebrospinal fluid and the seminal plasma as beta-trace. Here we analyzed retinoids binding of the enzyme by monitoring the fluorescence quenching of an intrinsic tryptophan residue, and appearance of circular dichroism around 330 nm, and a red shift of the UV absorption spectra of retinoids. We found that the enzyme binds all-trans- or 9-cis-retinoic acid and all-trans- or 13-cis-retinal, but not all-trans-retinol, with affinities (K-d of 70-80 nM) sufficient for function as a retinoid transporter. All-trans-retinoic acid inhibited the enzyme activity in a noncompetitive manner, suggesting that it binds to the same hydrophobic pocket as prostaglandin H-2, the substrate for prostaglandin D synthase, but at a different site in this pocket. It is likely that this enzyme is a bifunctional protein that acts as both retinoid transporter and prostaglandin D-2-producing enzyme.	BIOMOL ENGN RES INST,SUITA,OSAKA 565,JAPAN; OSAKA BIOSCI INST,SUITA,OSAKA 565,JAPAN; JAPAN SCI & TECHNOL CORP,PRESTO,SUITA,OSAKA 565,JAPAN	Japan Science & Technology Agency (JST)	Tanaka, T (corresponding author), PROT ENGN RES INST,6-2-3 FURUEDAI,SUITA,OSAKA 565,JAPAN.							BAILEY JS, 1988, J BIOL CHEM, V263, P9326; Beuckmann CT, 1996, J NEUROSCI, V16, P6119; Blodorn B, 1996, NEUROSCI LETT, V209, P117, DOI 10.1016/0304-3940(96)12614-8; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CHAN P, 1994, GENOMICS, V23, P145, DOI 10.1006/geno.1994.1470; CHO YJ, 1994, J BIOL CHEM, V269, P11102; CLAUSEN J, 1961, P SOC EXP BIOL MED, V107, P170; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; DICKSON PW, 1987, J BIOL CHEM, V262, P13907; DUFOUR E, 1993, BIOPOLYMERS, V33, P589, DOI 10.1002/bip.360330408; FIORELLA PD, 1993, J BIOL CHEM, V268, P21545; Flower DR, 1996, BIOCHEM J, V318, P1; FUGATE RD, 1980, BIOCHIM BIOPHYS ACTA, V625, P28, DOI 10.1016/0005-2795(80)90105-1; HAYAISHI O, 1991, FASEB J, V5, P2575, DOI 10.1096/fasebj.5.11.1907936; HOFFMANN A, 1993, J NEUROCHEM, V61, P451; HORWITZ J, 1974, J BIOL CHEM, V249, P4712; IGARASHI M, 1992, P NATL ACAD SCI USA, V89, P5376, DOI 10.1073/pnas.89.12.5376; ITO S, 1989, PROSTAG LEUKOTR ESS, V37, P219, DOI 10.1016/0952-3278(89)90033-1; KATO M, 1985, J BIOL CHEM, V260, P4832; KURUVILLA AP, 1991, BRAIN RES, V565, P337, DOI 10.1016/0006-8993(91)91666-O; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEVIN MS, 1988, J BIOL CHEM, V263, P17715; MACDONALD PN, 1987, J BIOL CHEM, V262, P10550; MONACO HL, 1987, J MOL BIOL, V197, P695, DOI 10.1016/0022-2836(87)90476-1; NAGATA A, 1991, P NATL ACAD SCI USA, V88, P4020, DOI 10.1073/pnas.88.9.4020; NEWCOMER ME, 1995, FASEB J, V9, P229, DOI 10.1096/fasebj.9.2.7781925; NEWCOMER ME, 1993, P NATL ACAD SCI USA, V90, P9223, DOI 10.1073/pnas.90.19.9223; ONG DE, 1982, J BIOL CHEM, V257, P13385; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; PEITSCH MC, 1991, TRENDS BIOCHEM SCI, V16, P363, DOI 10.1016/0968-0004(91)90149-P; PERVAIZ S, 1987, FASEB J, V1, P209, DOI 10.1096/fasebj.1.3.3622999; ROBERT SH, 1982, METHOD ENZYMOL, V88, P506; SKERRA A, 1993, J MOL BIOL, V230, P725; SUNDEEP D, 1993, BRAIN RES, V632, P325; Toh H, 1992, Mediators Inflamm, V1, P223, DOI 10.1155/S0962935192000346; Toh H, 1996, PROTEIN ENG, V9, P1067, DOI 10.1093/protein/9.12.1067; Urade Y, 1996, J LIPID MEDIAT CELL, V14, P71, DOI 10.1016/0929-7855(96)01511-8; URADE Y, 1989, J BIOL CHEM, V264, P1041; URADE Y, 1987, J BIOL CHEM, V262, P15132; URADE Y, 1993, P NATL ACAD SCI USA, V90, P9070, DOI 10.1073/pnas.90.19.9070; URADE Y, 1995, J LIPID MEDIAT CELL, V12, P257, DOI 10.1016/0929-7855(95)00032-L; URADE Y, 1985, J BIOL CHEM, V260, P2410; URADE Y, 1995, J BIOL CHEM, V270, P1422, DOI 10.1074/jbc.270.3.1422; WATANABE K, 1994, BIOCHEM BIOPH RES CO, V203, P1110, DOI 10.1006/bbrc.1994.2297; WHITE DM, 1992, J BIOL CHEM, V267, P23202; Yamashima T, 1997, J NEUROSCI, V17, P2376; ZAHN M, 1993, NEUROSCI LETT, V154, P93, DOI 10.1016/0304-3940(93)90179-O; ZANOTTI G, 1993, J BIOL CHEM, V268, P24873; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG JH, 1992, PROTEINS, V13, P87, DOI 10.1002/prot.340130202	51	169	178	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15789	15795		10.1074/jbc.272.25.15789	http://dx.doi.org/10.1074/jbc.272.25.15789			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188476	hybrid			2022-12-27	WOS:A1997XF32900036
J	Johnson, W; Albanese, C; Handwerger, S; Williams, T; Pestell, RG; Jameson, JL				Johnson, W; Albanese, C; Handwerger, S; Williams, T; Pestell, RG; Jameson, JL			Regulation of the human chorionic gonadotropin alpha- and beta-subunit promoters by AP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-2; AMP RESPONSE ELEMENT; GENE-EXPRESSION; CYCLIC-AMP; BINDING-PROTEINS; MESSENGER-RNAS; DNA-BINDING; GLYCOPROTEIN HORMONES; PLACENTAL-LACTOGEN; ENHANCER	Production of the placental hormone, chorionic gonadotropin (CG), increases dramatically as cytotrophoblasts fuse to form syncytiotrophoblasts. The CG alpha- and beta-promoters are both responsive to cAMP, although the kinetics of cAMP stimulation are different, In an effort to understand the kinetics of cAMP stimulation are different, In an effort to understand the mechanisms of coordinate induction of these genes, AP-2 binding sites were identified in the promoter regions of the alpha and CG beta genes, AP-2 bound to the upstream regulatory element (-186 to -156 base pairs (bp)) in the alpha-promoter and to several different regions of the CG beta promoter, including footprints 2 and 4B (FP2, -311 to -279 bp; FP4B, 221 to -200 bp). AP-2 antibodies induced supershifts of these complexes, confirming the identity of the protein-DNA complex. In JEG-3 cells, which contain abundant AP-2, mutations in these CG beta AP-2 sites reduced basal activity and decreased cAMP stimulation. In AP-2-deficient Hep-G2 cells, co-transfection of AP-2 stimulated expression of the CG beta promoter 10-20-fold, and the alpha-promoter was induced by 3-6-fold. Mutations that eliminate AP-2 binding to CG beta FP4B reduced AP-2 stimulation by more than 80%, whereas mutations in FP2 reduced AP-2 stimulation by less than 50%, Analyses of AP-2 mutants revealed a requirement for the DNA binding/dimerization do main and the amino terminal proline-rich and acid-rich transactivation domains for stimulation of the CGP promoter. Primary cultures of placental cytotrophoblasts were differentiated into syncytiotrophoblasts in vitro to examine AP-2 expression by reverse transcriptase-polymerase chain reaction. AP-2 mRNA levels increased by day 2 and continued to rise in parallel with a marked increase in alpha and CG beta gene expression. We conclude that both the alpha and CG beta promoters contain binding sites for AP-2 and suggest that this transcription factor provides a mechanism for coordinating the induction of these genes during placental cell differentiation.	NORTHWESTERN UNIV,SCH MED,DIV METAB ENDOCRINOL & MOL MED,CHICAGO,IL 60611; UNIV CINCINNATI,COLL MED,CHILDRENS HOSP,DEPT ENDOCRINOL,MED CTR,CINCINNATI,OH 45229; YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520	Northwestern University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Yale University				Jameson, James/0000-0001-9538-4059	NCI NIH HHS [KO8 CA620008] Funding Source: Medline; NICHD NIH HHS [HD07447, HD23519] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R56HD007447, R01HD007447, R01HD023519] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBANESE C, 1991, MOL ENDOCRINOL, V5, P693, DOI 10.1210/mend-5-5-693; Albanese C, 1996, RECENT PROG HORM RES, V51, P23; BOKAR JA, 1989, MOL CELL BIOL, V9, P5113, DOI 10.1128/MCB.9.11.5113; BURNSIDE J, 1985, J BIOL CHEM, V260, P2705; BYRNE C, 1994, DEVELOPMENT, V120, P2369; CAMPBELL MJ, 1995, BIOTECHNIQUES, V18, P1027; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUAN CM, 1995, J BIOL CHEM, V270, P24844, DOI 10.1074/jbc.270.42.24844; FENSTERMAKER RA, 1990, MOL ENDOCRINOL, V4, P1480, DOI 10.1210/mend-4-10-1480; FIDDES JC, 1984, RECENT PROG HORM RES, V40, P43; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOLLENBERG AN, 1994, MOL CELL ENDOCRINOL, V106, P111, DOI 10.1016/0303-7207(94)90192-9; HOSHINA M, 1982, J CELL BIOL, V93, P190, DOI 10.1083/jcb.93.1.190; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JAMESON JL, 1989, J BIOL CHEM, V264, P16190; JAMESON JL, 1986, ENDOCRINOLOGY, V119, P2560; JAMESON JL, 1993, ENDOCR REV, V14, P203, DOI 10.1210/er.14.2.203; JAMESON JL, 1989, MOL ENDOCRINOL, V3, P763, DOI 10.1210/mend-3-5-763; KLIMAN HJ, 1986, ENDOCRINOLOGY, V118, P1567, DOI 10.1210/endo-118-4-1567; KURTEN RC, 1992, MOL ENDOCRINOL, V6, P536, DOI 10.1210/me.6.4.536; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; Magnaldo Thierry, 1993, Gene Expression, V3, P307; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOSER M, 1995, DEVELOPMENT, V121, P2779; NAGAYA T, 1994, PITUITARY GLAND, P63; PARK K, 1993, J BIOL CHEM, V268, P17811; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; PESTELL RG, 1994, MOL ENDOCRINOLOGY BA, P59; PHILIPP J, 1994, DEV BIOL, V165, P602, DOI 10.1006/dbio.1994.1279; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; PITTMAN RH, 1994, J BIOL CHEM, V269, P19360; RICHARDS RG, 1994, ENDOCRINOLOGY, V135, P321, DOI 10.1210/en.135.1.321; RINGLER GE, 1989, MOL CELL ENDOCRINOL, V61, P13, DOI 10.1016/0303-7207(89)90185-8; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; SNAPE AM, 1991, DEVELOPMENT, V113, P283; STEGER DJ, 1993, MOL ENDOCRINOL, V7, P1579, DOI 10.1210/me.7.12.1579; STEGER DJ, 1994, MOL CELL BIOL, V14, P5592, DOI 10.1128/MCB.14.8.5592; STEGER DJ, 1991, MOL ENDOCRINOL, V5, P243, DOI 10.1210/mend-5-2-243; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Williamson JA, 1996, GENOMICS, V35, P262, DOI 10.1006/geno.1996.0351; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	52	72	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15405	15412		10.1074/jbc.272.24.15405	http://dx.doi.org/10.1074/jbc.272.24.15405			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182571	hybrid			2022-12-27	WOS:A1997XE03400054
J	Kassam, G; Manro, A; Braat, CE; Louie, P; Fitzpatrick, SL; Waisman, DM				Kassam, G; Manro, A; Braat, CE; Louie, P; Fitzpatrick, SL; Waisman, DM			Characterization of the heparin binding properties of annexin II tetramer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; TISSUE-PLASMINOGEN ACTIVATOR; ENDOTHELIAL-CELL RECEPTOR; LIPOPROTEIN-LIPASE; LYMPHOMA-CELLS; ADHESION; PROTEINS; DOMAIN; PEPTIDES; SULFATE	In this report, we have characterized the interaction of heparin with the Ca2+- and phospholipid-binding protein annexin II tetramer (AIIt), Analysis of the circular dichroism spectra demonstrated that the Ca2+-dependent binding of AIIt to heparin caused a large decrease in the a-helical content of AIIt from similar to 44 to 31%, a small decrease in the P-sheet content from similar to 27 to 24%, and an increase in the unordered structure from 20 to 29%, The binding of heparin also decreased the Ca2+ concentration required for a half-maximal conformational change in AIIt from 360 to 84 mu M. AIIt bound to heparin with an apparent K-d of 32 +/- 6 nM (mean +/- S.D., n = 3) and a stoichiometry of 11 +/- 0.9 mol of AIIt/mol of heparin (mean +/- S.D., n = 3), The binding of heparin to AIIt was specific as other sulfated polysaccharides did not elicit a conformational change in AIIt, A region of the p36 subunit of AIIt (Phe(306)-Ser(313)) was found to contain a Cardin-Weintraub consensus sequence for glycosaminoglycan recognition, A peptide to this region underwent a conformational change upon heparin binding, Other annexins contained the Cardin-Weintraub consensus sequence, but did not undergo a substantial conformational change upon heparin binding.	UNIV CALGARY, FAC MED, DEPT MED BIOCHEM, CELL REGULAT RES GRP, CALGARY, AB T2N 4N1, CANADA	University of Calgary				Waisman, David/0000-0002-5097-9662				Agnelli G, 1996, HAEMOSTASIS, V26, P2; BAE JH, 1994, BIOCHEM J, V301, P121, DOI 10.1042/bj3010121; BARKALOW FJ, 1994, J BIOL CHEM, V269, P3957; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BOOTH BA, 1995, GROWTH REGULAT, V5, P1; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CARDIN AD, 1991, METHOD ENZYMOL, V203, P556; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; Chung CY, 1996, MOL BIOL CELL, V7, P883, DOI 10.1091/mbc.7.6.883; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; FavierPerron B, 1996, BIOCHEMISTRY-US, V35, P1740, DOI 10.1021/bi952092o; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GLEIZES PE, 1995, EUR J CELL BIOL, V66, P47; GUO NH, 1992, J BIOL CHEM, V267, P19349; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; HUBAISHY I, 1995, BIOCHEMISTRY-US, V34, P14527, DOI 10.1021/bi00044a031; JONES PG, 1994, BIOCHEMISTRY-US, V33, P13751, DOI 10.1021/bi00250a028; JONES PG, 1992, J BIOL CHEM, V267, P13993; KAETZEL MA, 1995, NEWS PHYSIOL SCI, V10, P171; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KHANNA NC, 1990, BIOCHEMISTRY-US, V29, P4852, DOI 10.1021/bi00472a015; Kojima K, 1996, J BIOL CHEM, V271, P7679, DOI 10.1074/jbc.271.13.7679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LINDBLOM A, 1991, BIOCHEM J, V279, P821, DOI 10.1042/bj2790821; LUECKE H, 1995, NATURE, V378, P512, DOI 10.1038/378512a0; MA YH, 1994, J LIPID RES, V35, P2049; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; MURPHYULLRICH JE, 1993, J BIOL CHEM, V268, P26784; PERSSON B, 1989, EUR J BIOCHEM, V179, P39, DOI 10.1111/j.1432-1033.1989.tb14518.x; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; REED KC, 1975, ANAL BIOCHEM, V67, P44, DOI 10.1016/0003-2697(75)90270-5; ROTH D, 1993, FEBS LETT, V320, P207, DOI 10.1016/0014-5793(93)80587-K; Sasisekharan R, 1996, J BIOL CHEM, V271, P3124, DOI 10.1074/jbc.271.6.3124; SHADLE PJ, 1985, J BIOL CHEM, V260, P6354; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; SWAIRJO MA, 1994, ANNU REV BIOPH BIOM, V23, P193, DOI 10.1146/annurev.bb.23.060194.001205; TRESSLER RJ, 1993, J CELL BIOCHEM, V53, P265, DOI 10.1002/jcb.240530311; TRESSLER RJ, 1992, J CELL BIOCHEM, V48, P162, DOI 10.1002/jcb.240480208; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; WONG P, 1995, J BIOL CHEM, V270, P25805, DOI 10.1074/jbc.270.43.25805; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605	47	74	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15093	15100		10.1074/jbc.272.24.15093	http://dx.doi.org/10.1074/jbc.272.24.15093			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182528	hybrid			2022-12-27	WOS:A1997XE03400011
J	Sekimoto, H; Seo, M; Dohmae, N; Takio, K; Kamiya, Y; Koshiba, T				Sekimoto, H; Seo, M; Dohmae, N; Takio, K; Kamiya, Y; Koshiba, T			Cloning and molecular characterization of plant aldehyde oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XANTHINE-OXIDASE; RABBIT LIVER; PURIFICATION; BIOSYNTHESIS; REDUCTASE; MAIZE; TRYPTOPHAN; FERREDOXIN; MUTANT; GENE	Primary structural information of a plant aldehyde oxidase (AO), which was purified from maize coleoptiles using indole-3-acetaldehyde as a substrate, was obtained by sequencing a series of cleavage peptides, permitting the cloning of the corresponding cDNA (zmAO-1), The complete nucleotide sequence was determined; the deduced amino acid sequence encodes a protein of 1358 amino acid residues of M-r 146,681, which is consistent with the size of the AO monomeric subunit, There is a significant similarity with AO from mammals and xanthine dehydrogenases from various sources, The maize AO polypeptide contains consensus sequences for iron-sulfur centers and a putative molybdopterin cofactor-binding domain, In addition, another cDNA (zmAO-2), highly homologous to zmAO-1 at both the nucleotide and amino acid sequence levels, was cloned, zmAO-2 would encode a protein of 1349 amino acid residues of M-r 145,173 and has molecular characteristics similar to those of zmAO-1. zmAO-1 was expressed at a high level in roots, which was closely correlated with immunoblotting results using antiserum raised against the purified maize AO protein, whereas zmAO-2 was expressed at a higher Level in coleoptiles than in roots, We propose each zmAO may have a unique function duping plant development.	TOKYO METROPOLITAN UNIV, DEPT BIOL, HACHIOJI, TOKYO 19203, JAPAN; INST PHYS & CHEM RES, FRONTIER RES PROGRAM, WAKO, SAITAMA 35101, JAPAN; INST PHYS & CHEM RES, DIV BIOMOL CHARACTERIZAT, WAKO, SAITAMA 35101, JAPAN	Tokyo Metropolitan University; RIKEN; RIKEN			Kamiya, Yuji/F-9420-2010; Seo, Mitsunori/N-9603-2015; Dohmae, Naoshi/C-2040-2011	Kamiya, Yuji/0000-0003-4415-520X; Dohmae, Naoshi/0000-0002-5242-9410; Koshiba, Tomokazu/0000-0001-9264-4775; Seo, Mitsunori/0000-0001-8325-7984				BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; Bandurski Robert S., 1995, P39; BARBER MJ, 1982, BIOCHEMISTRY-US, V21, P3561, DOI 10.1021/bi00258a006; BOERJAN W, 1995, PLANT CELL, V7, P1405, DOI 10.1105/tpc.7.9.1405; BOWER PJ, 1978, PLANT PHYSIOL, V61, P107, DOI 10.1104/pp.61.1.107; CALZI L, 1995, J BIOL CHEM, V270, P31037; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; GLATIGNY A, 1995, J BIOL CHEM, V270, P3534, DOI 10.1074/jbc.270.8.3534; HALL WW, 1986, ARCH BIOCHEM BIOPHYS, V251, P36, DOI 10.1016/0003-9861(86)90048-2; Hille R., 1985, Metal Ions in Biology, V7, P443; HUANG DT, 1994, BIOCHEM BIOPH RES CO, V250, P1278; ICHIDA K, 1993, GENE, V133, P279; Koshiba T, 1995, PLANT CELL PHYSIOL, V36, P1503; Koshiba T, 1996, PLANT PHYSIOL, V110, P781, DOI 10.1104/pp.110.3.781; KOSHIBA T, 1993, PLANT PHYSIOL, V102, P1319, DOI 10.1104/pp.102.4.1319; KRENITSKY TA, 1986, ARCH BIOCHEM BIOPHYS, V247, P108, DOI 10.1016/0003-9861(86)90539-4; KRENITSKY TA, 1974, COMP BIOCHEM PHYSIOL, V49, P687, DOI 10.1016/0305-0491(74)90256-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEYDECKER MT, 1995, PLANT PHYSIOL, V107, P1427, DOI 10.1104/pp.107.4.1427; Maniatis T, 1989, MOL CLONING; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P44, DOI 10.1016/0005-2744(81)90106-6; MIYATA S, 1981, PHYSIOL PLANTARUM, V51, P402, DOI 10.1111/j.1399-3054.1981.tb05577.x; NORMANLY J, 1995, PLANT PHYSIOL, V107, P323, DOI 10.1104/pp.107.2.323; RAJAGOPAL R, 1971, PHYSIOL PLANTARUM, V24, P272, DOI 10.1111/j.1399-3054.1971.tb03491.x; RAJAGOPALAN KV, 1966, METHOD ENZYMOL, V9, P364; RILEY MA, 1989, MOL BIOL EVOL, V6, P33; RYPNIEWSKI WR, 1991, BIOCHEMISTRY-US, V30, P4126, DOI 10.1021/bi00231a003; SHURE M, 1983, CELL, V35, P225, DOI 10.1016/0092-8674(83)90225-8; TOMITA S, 1993, FEBS LETT, V336, P272, DOI 10.1016/0014-5793(93)80818-F; WALKERSIMMONS M, 1989, PLANT PHYSIOL, V90, P728, DOI 10.1104/pp.90.2.728; WRIGHT AD, 1991, SCIENCE, V254, P998, DOI 10.1126/science.254.5034.998; WRIGHT RM, 1993, P NATL ACAD SCI USA, V90, P10690, DOI 10.1073/pnas.90.22.10690; YOSHIHARA S, 1985, ARCH BIOCHEM BIOPHYS, V242, P213, DOI 10.1016/0003-9861(85)90495-3	33	78	97	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15280	15285		10.1074/jbc.272.24.15280	http://dx.doi.org/10.1074/jbc.272.24.15280			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182554	hybrid			2022-12-27	WOS:A1997XE03400037
J	Shimoni, Y; Blechl, AE; Anderson, OD; Galili, G				Shimoni, Y; Blechl, AE; Anderson, OD; Galili, G			A recombinant protein of two high molecular weight glutenins alters gluten polymer formation in transgenic wheat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GEL-ELECTROPHORESIS; STORAGE PROTEINS; SUBUNITS; ENDOSPERM; REVEALS; ELASTIN; GENES	Wheat high molecular weight glutenin subunits (HMW-GS) are the most important determinants of its superiority for making leavened bread, Following synthesis, these proteins are sequestered into the endoplasmic reticulum and assemble into extremely large elastic polymers, linked by noncovalent and intermolecular disulfide bonds. To study the structural requirements for the assembly of HMW-GS, we have expressed in transgenic wheat a recombinant protein between two cognate x- and y-type subunits, In contrast to the natural polymerized x- and y-type HMW-GS, a significant amount of the recombinant subunit remained monomeric, Nonreducing SDS-polyacrylamide gel electrophoresis, coupled with limited proteolysis, showed that the monomeric form of the recombinant subunit contained an unusual intramolecular disulfide bond, linking an N-terminal cysteine to the single C-terminal cysteine residue, In addition, sucrose gradient analysis revealed that this intramolecular disulfide bond impeded the ability of the recombinant subunit to assemble into polymers. Despite of its altered assembly, a notable amount of the overexpressed recombinant subunit was also present in glutenin polymers, Moreover, its presence significantly altered the subunit composition of the polymer, Our results show that it is possible to modify gluten assembly and properties by expressing recombinant HMW-GS in transgenic wheat, and have a major implication for the improvement of wheat breadmaking quality.	WEIZMANN INST SCI,DEPT PLANT GENET,IL-76100 REHOVOT,ISRAEL; USDA ARS,WESTERN REG RES CTR,ALBANY,CA 94710	Weizmann Institute of Science; United States Department of Agriculture (USDA)								ANDERSON OD, 1989, NUCLEIC ACIDS RES, V17, P461, DOI 10.1093/nar/17.1.461; BELTON PS, 1994, J CEREAL SCI, V19, P115, DOI 10.1006/jcrs.1994.1016; Blechl AE, 1996, NAT BIOTECHNOL, V14, P875, DOI 10.1038/nbt0796-875; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; EWART JAD, 1987, J SCI FOOD AGR, V38, P277, DOI 10.1002/jsfa.2740380312; GALILI G, 1983, THEOR APPL GENET, V64, P97, DOI 10.1007/BF00272711; GRAVELAND A, 1985, J CEREAL SCI, V3, P1, DOI 10.1016/S0733-5210(85)80029-1; GREENE FC, 1988, 7TH P INT WHEAT GEN, P735; Kasarda D.D., 1989, WHEAT UNIQUE, V277, P302; KASARDA DD, 1994, ACS SYM SER, V576, P209; KREIS M, 1985, OXFORD SURVEYS PLANT, P253; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE GJ, 1983, J EXP BOT, V34, P254, DOI 10.1093/jxb/34.3.254; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATSUSHIMA N, 1992, BIOCHEM BIOPH RES CO, V186, P1057, DOI 10.1016/0006-291X(92)90854-E; MILES MJ, 1991, P NATL ACAD SCI USA, V88, P68, DOI 10.1073/pnas.88.1.68; PAYNE PI, 1987, ANNU REV PLANT PHYS, V38, P141, DOI 10.1146/annurev.pp.38.060187.001041; SHANI N, 1992, PLANT PHYSIOL, V98, P433, DOI 10.1104/pp.98.2.433; SHANI N, 1994, J BIOL CHEM, V269, P8924; SHEWRY PR, 1995, PLANT CELL, V7, P945, DOI 10.1105/tpc.7.7.945; SHEWRY PR, 1989, OXFORD SURVEYS PLANT, P163; SHEWRY PR, 1995, SEED DEV GERMINATION, P45; TAO HP, 1992, BIOCHIM BIOPHYS ACTA, V1159, P13; TATHAM AS, 1984, FEBS LETT, V177, P205, DOI 10.1016/0014-5793(84)81284-3; WERNER WE, 1992, CEREAL CHEM, V69, P535; WRIGLEY CW, 1996, NATURE, V371, P738	26	44	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15488	15495		10.1074/jbc.272.24.15488	http://dx.doi.org/10.1074/jbc.272.24.15488			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182582	hybrid			2022-12-27	WOS:A1997XE03400065
J	Du, Q; Tomkinson, AE; Gardner, PD				Du, Q; Tomkinson, AE; Gardner, PD			Transcriptional regulation of neuronal nicotinic acetylcholine receptor genes - A possible role for the DNA-binding protein Pur alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVOUS-SYSTEM; SUBUNIT GENE; PROMOTER; BRAIN; FAMILY; EXPRESSION; INTERACTS; SEQUENCE; ELEMENT; BETA-4	Nicotinic acetylcholine receptors constitute a multigene family (alpha 2-alpha 9, beta 2-beta 4) expressed in discrete temporal and spatial patterns within the nervous system. The receptors are critical for proper signal transmission between neurons and their targets. The molecular mechanisms underlying receptor gene expression have not been completely elucidated but clearly involve regulation at the level of transcription. We previously identified a novel 19-base pair (bp) transcriptional regulatory element in the promoter region of the rat beta 4 subunit gene. This 19-bp element interacts specifically with DNA-binding proteins enriched in nuclear extracts prepared from adult rat brain. Using a combination of cellulose-phosphate, DNA-cellulose, and DNA sequence-specific affinity chromatographies, we purified the 19-bp element binding activity approximately 19,000-fold. Analysis by denaturing gel electrophoresis reyealed the presence of four polypeptides in the most purified fraction, ranging in molecular masses between 31 and 114 kDa. Peptide sequence analysis revealed that one of the polypeptides is the bovine homologue of the transcriptional regulatory factor, Pur alpha. Electrophoretic mobility shift assays indicated that Pur alpha interacts directly and specifically with the 19-bp element. In addition, mobility shift assays using an anti-Pur alpha monoclonal antibody revealed the presence of Pur alpha, or an immunologically related protein, in nuclear extracts prepared from brain tissue. We hypothesize that the interaction between Pur alpha and the 19-bp element is critical for proper expression of the beta 4 subunit gene.	UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,DEPT MOL MED,SAN ANTONIO,TX 78245	University of Texas System; University of Texas Health San Antonio					NINDS NIH HHS [NS30243, R01 NS030243] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030243] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5672; BESSIS A, 1993, NUCLEIC ACIDS RES, V21, P2185, DOI 10.1093/nar/21.9.2185; Bigger CB, 1996, J BIOL CHEM, V271, P32842, DOI 10.1074/jbc.271.51.32842; BOULTER J, 1990, J BIOL CHEM, V265, P4472; BOYD RT, 1994, J NEUROBIOL, V25, P960, DOI 10.1002/neu.480250806; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CONROY WG, 1995, J BIOL CHEM, V270, P4424, DOI 10.1074/jbc.270.9.4424; DAUBAS P, 1993, P NATL ACAD SCI USA, V90, P2237, DOI 10.1073/pnas.90.6.2237; Fyodorov D, 1996, MOL CELL BIOL, V16, P5004; HAAS S, 1995, J CELL BIOL, V130, P1171, DOI 10.1083/jcb.130.5.1171; HEINEMANN S, 1990, PROG BRAIN RES, V86, P195; HERNANDEZ MC, 1995, J BIOL CHEM, V270, P3224, DOI 10.1074/jbc.270.7.3224; HU M, 1994, J NEUROCHEM, V62, P302; HU MJ, 1995, J BIOL CHEM, V270, P4497, DOI 10.1074/jbc.270.19.11619; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; MATTERSADZINSKI L, 1992, EMBO J, V11, P4529, DOI 10.1002/j.1460-2075.1992.tb05554.x; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; MILTON NGN, 1995, J BIOL CHEM, V270, P15143, DOI 10.1074/jbc.270.25.15143; PAPKE RL, 1989, NEURON, V3, P589, DOI 10.1016/0896-6273(89)90269-9; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; YANG XD, 1995, J BIOL CHEM, V270, P8514, DOI 10.1074/jbc.270.15.8514	26	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14990	14995		10.1074/jbc.272.23.14990	http://dx.doi.org/10.1074/jbc.272.23.14990			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169473	hybrid			2022-12-27	WOS:A1997XC32700070
J	Lu, YN; Planelles, V; Li, XQ; Palaniappan, C; Day, B; ChallitaEid, P; Amado, R; Stephens, D; Kohn, DB; Bakker, A; Fay, P; Bambara, RA; Rosenblatt, JD				Lu, YN; Planelles, V; Li, XQ; Palaniappan, C; Day, B; ChallitaEid, P; Amado, R; Stephens, D; Kohn, DB; Bakker, A; Fay, P; Bambara, RA; Rosenblatt, JD			Inhibition of HIV-1 replication using a mutated tRNA(Lys-3) primer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 REVERSE-TRANSCRIPTASE; RED FIBERS MERRF; TRANSFER-RNA; CLEAVAGE SPECIFICITY; TRANSFER RNA(LYS-3); MYOCLONIC EPILEPSY; BINDING-SITE; WILD-TYPE; DNA	Cellular tRNA(Lys-3) serves as the primer for reverse transcription of human immunodeficiency virus, type 1 (HIV-1). tRNA(Lys-3) interacts directly with HIV-1 reverse transcriptase, is packaged into viral particles and anneals to the primer-binding site (PBS) of the HIV-1 genome to initiate reverse transcription. Therefore, the priming step of reverse transcription is a potential target for antiviral strategies. We have developed a mutant tRNA(Lys-3) derivative with mutations in the PBS-binding region such that priming specificity was re-directed to the highly conserved TAR stem-loop region. This mutant tRNA retains high-affinity binding to HIV-1 reverse transcriptase, viral encapsidation, and is able to prime at both the targeted TAR sequence and at the viral PBS. Constitutive expression of mutant tRNA in T-cells results in marked inhibition of HIV-1 replication, as determined by measurements of viral infectivity, syncytium formation, and p24 production. Inhibition of retroviral replication through interference with the normal process of priming constitutes a new anti-retroviral approach and also provides a novel tool for dissecting molecular aspects of priming.	UNIV ROCHESTER,CTR CANC,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT MED,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT MICROBIOL,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT IMMUNOL,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV CALIF LOS ANGELES,AIDS INST,DEPT MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90095; UNIV SO CALIF,CHILDRENS HOSP LOS ANGELES,SCH MED,LOS ANGELES,CA 90027	University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of California System; University of California Los Angeles; Children's Hospital Los Angeles; University of Southern California			Bakker, Arnold B./F-8494-2010; Kohn, Donald/N-5085-2016	Bakker, Arnold B./0000-0003-1489-1847; Kohn, Donald/0000-0003-1840-6087	NIAID NIH HHS [R01 AI3655] Funding Source: Medline; NIGMS NIH HHS [R01 GM49573] Funding Source: Medline; NIMH NIH HHS [MH-199200] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ALTMAN S, 1981, CELL, V23, P1; Arts EJ, 1996, J BIOL CHEM, V271, P9054, DOI 10.1074/jbc.271.15.9054; ARTS EJ, 1994, J BIOL CHEM, V269, P14672; BARAT C, 1993, J MOL BIOL, V231, P185, DOI 10.1006/jmbi.1993.1273; BARAT C, 1991, NUCLEIC ACIDS RES, V19, P751, DOI 10.1093/nar/19.4.751; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BEHLEN LS, 1990, BIOCHEMISTRY-US, V29, P2515, DOI 10.1021/bi00462a013; Biasolo MA, 1996, J VIROL, V70, P2154, DOI 10.1128/JVI.70.4.2154-2161.1996; BORDIER B, 1990, NUCLEIC ACIDS RES, V18, P429, DOI 10.1093/nar/18.3.429; CHATTERJEE S, 1992, SCIENCE, V258, P1485, DOI 10.1126/science.1359646; Chromczynski P, 1987, ANAL BIOCHEM, V162, P156; DEVICO AL, 1991, J BIOL CHEM, V266, P6774; DORAN JL, 1988, GENE, V65, P329, DOI 10.1016/0378-1119(88)90471-4; ESSINK BBO, 1995, J BIOL CHEM, V270, P23867, DOI 10.1074/jbc.270.40.23867; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GOTO YI, 1994, BIOCHEM BIOPH RES CO, V202, P1624, DOI 10.1006/bbrc.1994.2119; HAMMANS SR, 1993, BRAIN, V116, P617, DOI 10.1093/brain/116.3.617; Harrich D, 1996, J VIROL, V70, P4017, DOI 10.1128/JVI.70.6.4017-4027.1996; HUANG Y, 1994, J VIROL, V68, P7676, DOI 10.1128/JVI.68.12.7676-7683.1994; ISEL C, 1993, J BIOL CHEM, V268, P25269; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; Isel C, 1996, EMBO J, V15, P917, DOI 10.1002/j.1460-2075.1996.tb00426.x; JACQUES PS, 1994, J BIOL CHEM, V269, P1388; JIANG M, 1993, J VIROL, V67, P3246, DOI 10.1128/JVI.67.6.3246-3253.1993; KOHLSTAEDT LA, 1992, P NATL ACAD SCI USA, V89, P9652, DOI 10.1073/pnas.89.20.9652; LEBKOWSKI JS, 1988, MOL CELL BIOL, V8, P3988, DOI 10.1128/MCB.8.10.3988; Leis J, 1993, REVERSE TRANSCRIPTAS, P33; MAK J, 1994, J VIROL, V68, P2065, DOI 10.1128/JVI.68.4.2065-2072.1994; OOMMEN A, 1992, MOL CELL BIOL, V12, P865, DOI 10.1128/MCB.12.2.865; PALANIAPPAN C, 1995, J BIOL CHEM, V270, P4861, DOI 10.1074/jbc.270.9.4861; Reed L.J., 1983, AM J HYG, V27, P493; RHIM H, 1991, J VIROL, V65, P4555, DOI 10.1128/JVI.65.9.4555-4564.1991; RICHTERCOOK NJ, 1992, J BIOL CHEM, V267, P15952; ROY KL, 1982, NUCLEIC ACIDS RES, V10, P7313, DOI 10.1093/nar/10.22.7313; SAMPSON JR, 1990, BIOCHEMISTRY-US, V29, P2523, DOI 10.1021/bi00462a014; SARIHCOTTIN L, 1992, J MOL BIOL, V226, P1, DOI 10.1016/0022-2836(92)90117-3; SILVESTRI G, 1992, AM J HUM GENET, V51, P1213; SULLENGER BA, 1990, MOL CELL BIOL, V10, P6512, DOI 10.1128/MCB.10.12.6512; TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988, DOI 10.1073/pnas.89.15.6988; WAKEFIELD JK, 1994, J VIROL, V68, P1605, DOI 10.1128/JVI.68.3.1605-1614.1994; Wakefield JK, 1996, J VIROL, V70, P966, DOI 10.1128/JVI.70.2.966-975.1996; WEISS R, 1982, RNA TUMOR VIRUSES, P209; Westaway S K, 1995, Nucleic Acids Symp Ser, P194; WOHRL BM, 1993, J BIOL CHEM, V268, P13617; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; ZAKHAROVA OD, 1995, EUR J BIOCHEM, V233, P856, DOI 10.1111/j.1432-1033.1995.856_3.x; ZAKHAROVA OD, 1995, FEBS LETT, V361, P287, DOI 10.1016/0014-5793(95)00200-S	48	17	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14523	14531		10.1074/jbc.272.23.14523	http://dx.doi.org/10.1074/jbc.272.23.14523			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169409	hybrid			2022-12-27	WOS:A1997XC32700006
J	Sattler, M; Salgia, R; Shrikhande, G; Verma, S; Uemura, P; Law, SF; Golemis, EA; Griffin, JD				Sattler, M; Salgia, R; Shrikhande, G; Verma, S; Uemura, P; Law, SF; Golemis, EA; Griffin, JD			Differential signaling after beta 1 integrin ligation is mediated through binding of CRKL to p120(CBL) and p110(HEF1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-CBL PROTOONCOGENE; ABL TYROSINE KINASE; PROTEIN PRODUCT; SH3 DOMAIN; JURKAT CELLS; FACTOR C3G; V-CBL; RECEPTOR; PHOSPHORYLATION; IDENTIFICATION	CRKL is an SH2-SH3-SH3 adapter protein that is a major substrate of the BCR/ABL oncogene, The function of CRKL in normal cells is unknown, In cells transformed by BCR/ABL we have previously shown that CRKL is associated with two focal adhesion proteins, tensin and paxillin, suggesting that CRKL, could be involved in integrin signaling, In two hematopoietic cell lines, MO7e and H9, we found that CRKL rapidly associates with tyrosine-phosphorylated proteins after cross-linking of beta 1 integrins with fibronectin or anti-beta 1 integrin monoclonal antibodies, The major tyrosine-phosphorylated CRKL-binding protein in the megakaryocytic MO7e cells was identified as p120(CBL), the cellular homolog of the v-Cbl oncoprotein, However in the lymphoid He cell line, the major tyrosine-phosphorylated CRKL-binding protein was p110(HEF1), In both cases, this binding was mediated by the CRKL SH2 domain, Interestingly, although both MO7e and H9 cells express p120(CBL) and p110(HEF1), beta 1 integrin cross-linking induces tyrosine phosphorylation of p120(CBL) (but not p110(HEF1)) in MO7e cells and of p110(HEF1) (but not p120(CBL)) in H9 cells, In both cell types, CRKL is constitutively complexed to C3G, SOS, and c-ABL through its SH3 domains, and the stoichiometry of these complexes does not change upon integrin ligation, Thus, in different cell types CRKL and its SH3-associated proteins may form different multimeric complexes depending on whether p120(CBL) or p110(HEF1) is tyrosine-phosphorylated after integrin ligation, The shift in association of CRKL and its SH3-associated proteins from p120(CBL) to p110(HEF1) could contribute to different functional outcomes of ''outside-in'' integrin signaling in different cells.	DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,BOSTON,MA 02115; FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111	Harvard University; Dana-Farber Cancer Institute; Fox Chase Cancer Center				Golemis, Erica/0000-0003-3618-3673	NCI NIH HHS [R29-CA63366, CA60821] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA060821, R29CA063366] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Andoniou CE, 1996, ONCOGENE, V12, P1981; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BALZAC F, 1993, J CELL BIOL, V121, P171, DOI 10.1083/jcb.121.1.171; BALZAC F, 1994, J CELL BIOL, V127, P557, DOI 10.1083/jcb.127.2.557; Bazzoni G, 1996, J CLIN INVEST, V98, P521, DOI 10.1172/JCI118820; Belkin AM, 1996, J CELL BIOL, V132, P211, DOI 10.1083/jcb.132.1.211; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLAKE TJ, 1991, ONCOGENE, V6, P653; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; FREDRICKSON TN, 1984, J NATL CANCER I, V72, P447; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Ishino M, 1995, ONCOGENE, V11, P2331; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Law SF, 1996, MOL CELL BIOL, V16, P3327; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Manie SN, 1997, EXP HEMATOL, V25, P45; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MEREDITH J, 1995, SCIENCE, V269, P1570, DOI 10.1126/science.7545312; NOJIMA Y, 1995, CELL IMMUNOL, V161, P8, DOI 10.1006/cimm.1995.1002; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; Sattler M, 1996, ONCOGENE, V12, P839; SATTLER M, 1995, EXP HEMATOL, V23, P1040; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Uemura N, 1997, LEUKEMIA, V11, P376, DOI 10.1038/sj.leu.2400590; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	52	77	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14320	14326		10.1074/jbc.272.22.14320	http://dx.doi.org/10.1074/jbc.272.22.14320			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162067	hybrid			2022-12-27	WOS:A1997XB49200054
J	Stutts, MJ; Rossier, BC; Boucher, RC				Stutts, MJ; Rossier, BC; Boucher, RC			Cystic fibrosis transmembrane conductance regulator inverts protein kinase A-mediated regulation of epithelial sodium channel single channel kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITOR PROTEIN; NA+ CHANNELS; MECHANISM; CELLS; CAMP; MEMBRANE; CFTR; ATP	Abnormal regulation of ion channels by members of the ABC transport protein superfamily has been implicated in hyperinsulinemic hypoglycemia and in excessive Na+ absorption by airway epithelia in cystic fibrosis (CF). How ABC proteins regulate ion conductances is unknown, but must generally involve either the number or activity of specific ion channels. Here we report that the cystic fibrosis transmembrane conductance regulator (CFTR), which is defective in CF, reverses the regulation of the activity of single epithelial sodium channels (ENaC) by cAMP. ENaC expressed alone in fibroblasts responded to activation of cAMP-dependent protein kinase with increased open probability (P-o) and mean open time, whereas ENaC co-expressed with CFTR exhibited decreased P-o and mean open time under conditions optimal for PKA-mediated protein phosphorylation. Thus, CFTR regulates ENaC at the level of single channel gating, by switching the response of single channel P-o to cAMP from an increase to a decrease.	UNIV LAUSANNE, INST PHARMACOL & TOXICOL, CH-1005 LAUSANNE, SWITZERLAND	University of Lausanne	Stutts, MJ (corresponding author), UNIV N CAROLINA, DEPT MED, CYST FIBROSIS PULM RES & TREATMENT CTR, 6023 THURSTON BOWLES BLDG, CHAPEL HILL, NC 27599 USA.							Berdiev BK, 1996, J BIOL CHEM, V271, P17704, DOI 10.1074/jbc.271.30.17704; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; BURCH LH, 1995, AM J PHYSIOL-CELL PH, V269, pC511, DOI 10.1152/ajpcell.1995.269.2.C511; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CANTIELLO HF, 1994, J BIOL CHEM, V269, P11224; CHINET TC, 1993, AM J PHYSIOL, V265, pC1050, DOI 10.1152/ajpcell.1993.265.4.C1050; CHINET TC, 1994, AM J PHYSIOL, V266, pC1061, DOI 10.1152/ajpcell.1994.266.4.C1061; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DUSZYK M, 1991, BIOMED RES-TOKYO, V12, P17; GLASS DB, 1989, J BIOL CHEM, V264, P8802; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HASSON JH, 1995, P NATL ACAD SCI USA, V92, P11495; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325; Ismailov II, 1996, J BIOL CHEM, V271, P4725; ISMAILOV II, 1994, J BIOL CHEM, V269, P10235; Mall M, 1996, FEBS LETT, V381, P47, DOI 10.1016/0014-5793(96)00079-8; MARUNAKA Y, 1991, AM J PHYSIOL, V260, pC1071, DOI 10.1152/ajpcell.1991.260.5.C1071; PACHA J, 1993, J GEN PHYSIOL, V102, P25, DOI 10.1085/jgp.102.1.25; SCHAFER JA, 1992, KIDNEY INT, V41, P255, DOI 10.1038/ki.1992.37; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SENYK O, 1995, AM J PHYSIOL-CELL PH, V268, pC1148, DOI 10.1152/ajpcell.1995.268.5.C1148; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; STUTTS MJ, 1993, J BIOL CHEM, V268, P20653; WALSH DA, 1991, METHOD ENZYMOL, V201, P304	27	157	159	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14037	14040		10.1074/jbc.272.22.14037	http://dx.doi.org/10.1074/jbc.272.22.14037			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162024	Green Published, hybrid			2022-12-27	WOS:A1997XB49200011
J	TomHon, C; Zhu, W; Millinoff, D; Hayasaka, K; Slightom, JL; Goodman, M; Gumucio, DL				TomHon, C; Zhu, W; Millinoff, D; Hayasaka, K; Slightom, JL; Goodman, M; Gumucio, DL			Evolution of a fetal expression pattern via cis changes near the gamma globin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; CORRECT DEVELOPMENTAL EXPRESSION; DOMINANT CONTROL REGION; TRANSGENIC MICE; HYPERSENSITIVE SITE; ELEMENT; SEQUENCES; NUCLEOTIDE; PRIMATES; ENHANCER	One basis for the evolution of organisms is the acquisition of new temporal and spatial domains of gene expression. Such novel expression domains could be generated either by cis sequence changes that alter the complement of trans-acting regulators binding to control elements or by changes in the expression patterns of one or more of the regulatory (trans) factors themselves. The gamma globin gene is a prime example of a gene that has undergone a distinct change in temporal expression at a defined time in evolution. Approximately 35-55 million years ago, the previously embryonic gamma gene acquired a fetal expression pattern, This change occurred in a simian primate ancestor after the separation of simian and prosimian primates but before the further separation of the major simian lineages; thus, the (prosimian) galago gamma gene retains the ancestral embryonic expression pattern, whereas the (simian) human gamma gene is fetal, This analysis of galago and human gamma genes in transgenic mice demonstrates that cis changes in sequences within a 4.0-kilobase region surrounding the gamma gene were responsible for the evolution of a novel fetal expression pattern in the gamma globin genes of simian primates.	UNIV MICHIGAN,DEPT ANAT & CELL BIOL,ANN ARBOR,MI 48109; PHARMACIA & UPJOHN CO,MOL BIOL UNIT 7242,KALAMAZOO,MI 49007; WAYNE STATE UNIV,SCH MED,DEPT ANAT,DETROIT,MI 48201	University of Michigan System; University of Michigan; Pfizer; Wayne State University					NCRR NIH HHS [M01RR00042] Funding Source: Medline; NHLBI NIH HHS [HL48802, HL 33940] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033940, R01HL048802] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BODINE DM, 1987, EMBO J, V6, P2997, DOI 10.1002/j.1460-2075.1987.tb02605.x; COOPER SJB, 1993, P NATL ACAD SCI USA, V90, P11777, DOI 10.1073/pnas.90.24.11777; CZELUSNIAK J, 1982, NATURE, V298, P297, DOI 10.1038/298297a0; DILLON N, 1991, NUCLEIC ACIDS RES, V19, P6227, DOI 10.1093/nar/19.22.6227; DILLON N, 1991, NATURE, V350, P252, DOI 10.1038/350252a0; DZIERZAK E, 1995, TRENDS GENET, V11, P359, DOI 10.1016/S0168-9525(00)89107-6; Ellis J, 1996, EMBO J, V15, P562, DOI 10.1002/j.1460-2075.1996.tb00388.x; FITCH DHA, 1991, P NATL ACAD SCI USA, V88, P7396, DOI 10.1073/pnas.88.16.7396; FRASER P, 1990, NUCLEIC ACIDS RES, V18, P3503, DOI 10.1093/nar/18.12.3503; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; GOODMAN M, 1987, COLD SPRING HARB SYM, V52, P875, DOI 10.1101/SQB.1987.052.01.096; GOODMAN M, 1984, J MOL BIOL, V180, P803, DOI 10.1016/0022-2836(84)90258-4; GOODMAN M, 1996, GENE FAMILIES STRUCT, P43; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GUMUCIO DL, 1994, J BIOL CHEM, V269, P15371; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; HARDISON RC, 1984, MOL BIOL EVOL, V1, P390; HAYASAKA K, 1993, GENOMICS, V18, P20, DOI 10.1006/geno.1993.1422; HILL A, 1984, J BIOL CHEM, V259, P3739; JANE SM, 1992, EMBO J, V11, P2961, DOI 10.1002/j.1460-2075.1992.tb05366.x; KOOP BF, 1988, P NATL ACAD SCI USA, V85, P3893, DOI 10.1073/pnas.85.11.3893; LEY TJ, 1989, J CLIN INVEST, V83, P1032, DOI 10.1172/JCI113944; LI QL, 1994, MOL CELL BIOL, V14, P6087, DOI 10.1128/MCB.14.9.6087; MASON MM, 1995, MOL CELL BIOL, V15, P407, DOI 10.1128/MCB.15.1.407; MORLEY BJ, 1992, MOL CELL BIOL, V12, P2057, DOI 10.1128/MCB.12.5.2057; PETERSON KR, 1993, P NATL ACAD SCI USA, V90, P7593, DOI 10.1073/pnas.90.16.7593; PETERSON KR, 1993, MOL CELL BIOL, V13, P4836, DOI 10.1128/MCB.13.8.4836; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; RAICH N, 1990, SCIENCE, V250, P1147, DOI 10.1126/science.2251502; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; SHIH DM, 1990, NUCLEIC ACIDS RES, V18, P5465, DOI 10.1093/nar/18.18.5465; STARCK J, 1994, BLOOD, V84, P1656; STROUBOULIS J, 1992, GENE DEV, V6, P1857, DOI 10.1101/gad.6.10.1857; TAGLE DA, 1988, J MOL BIOL, V203, P439, DOI 10.1016/0022-2836(88)90011-3; ULRICH MJ, 1990, BLOOD, V75, P990; [No title captured]	36	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14062	14066		10.1074/jbc.272.22.14062	http://dx.doi.org/10.1074/jbc.272.22.14062			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162029	hybrid			2022-12-27	WOS:A1997XB49200016
J	McQueney, MS; Amegadzie, BY; DAlessio, K; Hanning, CR; McLaughlin, MM; McNulty, D; Carr, SA; Ijames, C; Kurdyla, J; Jones, CS				McQueney, MS; Amegadzie, BY; DAlessio, K; Hanning, CR; McLaughlin, MM; McNulty, D; Carr, SA; Ijames, C; Kurdyla, J; Jones, CS			Autocatalytic activation of human cathepsin K	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-RESORPTION; MOLECULAR-CLONING; CYSTEINE-PROTEINASES; PAPAIN PRECURSOR; INHIBITION; INVITRO; PURIFICATION; OSTEOCLASTS	The in vitro activation of the recombinant purified human cathepsin K (EC 3.4.22.38) was examined by mutagenesis, Cathepsin K was expressed as a secreted proenzyme using baculovirus-infected Sf21 insect cells, Spontaneous in vitro activation of procathepsin K occurred at pH 4 and was catalyzed by exogenous mature cathepsin K, Three intermediates were identified as resulting from cleavages after Glu(19), Ser(98), and Glu(110), The mature enzyme was composed of mixture of enzymes with N termini of Gly(113), Arg(114), and Ala(115) with varying ratios depending on the preparation, Molecular weight determinations were consistent with the absence of carbohydrate in the mature protein, while electrospray mass spectroscopy indicated that six of the eight cysteine residues were in disulfide linkage, and that the protein had Met(329) as the C-terminal residue. A mutant was constructed in which the active site Cys(139) was changed to Ser. [Ser(139),Ala(163)]Procathepsin K (containing mutation C139S,S163A) failed to spontaneously process and was only partially processed in the presence of 1% exogenous wild-type mature cathepsin K forming intermediates, which were identical to those observed in the activation of wild-type, [Ser(139),Ala(163)]Procathepsin K could be fully processed to mature enzyme by including one equivalent of wild-type procathepsin K in the activation mixture, These results indicated that in vitro activation of the procathepsin K was an autocatalytic process.	SMITHKLINE BEECHAM PHARMACEUT,DEPT GENE EXPRESS SCI,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT PHYS & STRUCT CHEM,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline	McQueney, MS (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,DEPT PROT BIOCHEM,MAIL CODE UE0431,POB 1539,KING OF PRUSSIA,PA 19406, USA.		Carr, Steven A./AAH-8366-2019					BARON R, 1989, ANAT RECORD, V224, P317, DOI 10.1002/ar.1092240220; Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517; BROMME D, 1993, J BIOL CHEM, V268, P4832; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; BROMME D, 1995, BIOL CHEM H-S, V376, P379, DOI 10.1515/bchm3.1995.376.6.379; Carmona E, 1996, BIOCHEMISTRY-US, V35, P8149, DOI 10.1021/bi952736s; DELAISSE JM, 1980, BIOCHEM J, V192, P365, DOI 10.1042/bj1920365; DELAISSE JM, 1987, BONE, V8, P305, DOI 10.1016/8756-3282(87)90007-X; DELAISSE JM, 1984, BIOCHEM BIOPH RES CO, V125, P441, DOI 10.1016/0006-291X(84)90560-6; Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; HILL PA, 1994, J CELL BIOCHEM, V56, P118, DOI 10.1002/jcb.240560116; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013; LERNER UH, 1992, J BONE MINER RES, V7, P433; Li Y. P., 1994, Molecular Biology of the Cell, V5, p335A; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; SHI GP, 1995, FEBS LETT, V357, P129, DOI 10.1016/0014-5793(94)01349-6; TAYLOR MAJ, 1995, PROTEIN ENG, V8, P59, DOI 10.1093/protein/8.1.59; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; VERNET T, 1991, J BIOL CHEM, V266, P21451; VERNET T, 1995, J BIOL CHEM, V270, P10838, DOI 10.1074/jbc.270.18.10838	21	136	139	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13955	13960		10.1074/jbc.272.21.13955	http://dx.doi.org/10.1074/jbc.272.21.13955			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153258	hybrid			2022-12-27	WOS:A1997XA06200073
J	DellAcqua, ML; Scott, JD				DellAcqua, ML; Scott, JD			Protein kinase A anchoring	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							REGULATORY SUBUNIT RII; MICROTUBULE-ASSOCIATED PROTEIN-2; HIGH-AFFINITY BINDING; A-KINASE; II-BETA; BOVINE BRAIN; CLONING; LOCALIZATION; CELLS; IDENTIFICATION				DellAcqua, ML (corresponding author), OREGON HLTH SCI UNIV,VOLLUM INST,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201, USA.			Dell'Acqua, Mark/0000-0003-3798-3461	NIGMS NIH HHS [GM48231] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048231, R37GM048231] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; Amieux PS, 1997, J BIOL CHEM, V272, P3993, DOI 10.1074/jbc.272.7.3993; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1992, TRENDS BIOCHEM SCI, V17, P246, DOI 10.1016/0968-0004(92)90402-U; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; CARR DW, 1993, J BIOL CHEM, V268, P20729; Chapline C, 1996, J BIOL CHEM, V271, P6417, DOI 10.1074/jbc.271.11.6417; CHOI KY, 1994, CELL, V78, P499; COGHLAN VM, 1994, J BIOL CHEM, V269, P7658; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; CORBIN JD, 1975, J BIOL CHEM, V250, P218; DRANSFIELD DT, 1997, IN PRESS BIOCH J; DRANSFIELD DT, 1997, EMBO J, V16, P101; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; FAUX MC, 1996, CELL, V70, P8; Feliciello A, 1996, J BIOL CHEM, V271, P25350, DOI 10.1074/jbc.271.41.25350; Gamm DM, 1996, J BIOL CHEM, V271, P15736, DOI 10.1074/jbc.271.26.15736; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; GORDON T, 1992, J CLIN INVEST, V90, P992, DOI 10.1172/JCI115976; Gray PC, 1997, J BIOL CHEM, V272, P6297, DOI 10.1074/jbc.272.10.6297; Hausken ZE, 1996, J BIOL CHEM, V271, P29016, DOI 10.1074/jbc.271.46.29016; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; JOLY JC, 1989, J CELL BIOL, V109, P2289, DOI 10.1083/jcb.109.5.2289; KERYER G, 1993, P NATL ACAD SCI USA, V90, P5418, DOI 10.1073/pnas.90.12.5418; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; LEISER M, 1986, J BIOL CHEM, V261, P1904; Lester LB, 1996, J BIOL CHEM, V271, P9460, DOI 10.1074/jbc.271.16.9460; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; Li Y, 1996, J BIOL CHEM, V271, P16862, DOI 10.1074/jbc.271.28.16862; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; LIN XY, 1995, MOL CELL BIOL, V15, P2754; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; LUO ZJ, 1990, J BIOL CHEM, V265, P21804; MCCARTNEY S, 1995, J BIOL CHEM, V270, P9327, DOI 10.1074/jbc.270.16.9327; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MONS N, 1995, P NATL ACAD SCI USA, V92, P8473, DOI 10.1073/pnas.92.18.8473; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; Newton AC, 1996, CURR BIOL, V6, P806, DOI 10.1016/S0960-9822(02)00600-0; OBAR RA, 1989, NEURON, V3, P639, DOI 10.1016/0896-6273(89)90274-2; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; RUBINO HM, 1989, NEURON, V3, P631, DOI 10.1016/0896-6273(89)90273-0; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; SMITH JK, 1996, J BIOL CHEM, V271, P16703; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Subramani S, 1996, J BIOL CHEM, V271, P32483, DOI 10.1074/jbc.271.51.32483; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Vijayaraghavan S, 1997, J BIOL CHEM, V272, P4747, DOI 10.1074/jbc.272.8.4747; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2	59	227	230	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	1997	272	20					12881	12884		10.1074/jbc.272.20.12881	http://dx.doi.org/10.1074/jbc.272.20.12881			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WZ384	9190362	hybrid			2022-12-27	WOS:A1997WZ38400001
J	Burton, EA; Hunter, S; Wu, SC; Anderson, SM				Burton, EA; Hunter, S; Wu, SC; Anderson, SM			Binding of src-like kinases to the beta-subunit of the interleukin-3 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; GAMMA SIGNAL-TRANSDUCTION; PHOSPHORYLATED IG-ALPHA; GENE FAMILY; MEMBRANE-BINDING; CELL LINES; GM-CSF; CLONING; EXPRESSION; ACTIVATION	We have previously shown that stimulation of 32D c13 cells with interleukin (IL)-3 results in the activation of three src-like tyrosine kinase's, fyn, hck, and lyn. The beta subunit of the IL-3 receptor co-immunoprecipitated with hck in lysates of both unstimulated and IL-3-stimulated cells; however, the beta subunit did not precipitate with either fyn or lyn, The association of these three kinases with the beta subunit of the IL-3 receptor was further investigated using bacterial fusion proteins encoding the unique, SH3, and SH2 domains of these three kinases. Fusion proteins of both hck and fyn bound to a 150-kDa tyrosine-phosphorylated protein present in lysates of IL-3-stimulated cells. This protein was identified as the beta subunit of the IL-3 receptor by immunoblotting with an anti-beta antibody. Glutathione S-transferase (GST) fusion proteins containing the SH2 domain of hck. bound to the beta subunit although the amount of beta subunit that bound to the SH2 domain alone was only 30% of that which bound to the fusion protein containing the unique, SH3, and SH2 domains. This indicates that the SH2 domain is one of the motifs involved in binding hck. to the beta subunit, A GST fusion protein encoding a 236-amino acid region of the cytoplasmic tail of the beta subunit, which contained four tyrosine residues, bound to hck and fyn, Binding to both proteins was dramatically increased when the GST-beta fusion protein was tyrosine-phosphorylated, Far Western blot analysis was used to demonstrate the binding of the unique, SH3, and SH2 domains of hck to this 236-amino acid region of the beta subunit; tyrosine phosphorylation of this protein increased the binding of both the unique region and the SH2 domain probes, These data indicate that binding of hck to the beta subunit is mediated by both phosphotyrosine-dependent and -independent mechanisms.	UNIV COLORADO, HLTH SCI CTR, DEPT PATHOL, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								ANDERSON SM, 1995, J IMMUNOL, V155, P1660; Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; APPLEBY MW, 1995, J EXP MED, V182, P811, DOI 10.1084/jem.182.3.811; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BOULET I, 1992, ONCOGENE, V7, P703; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; BUSER CA, 1994, BIOCHEMISTRY-US, V33, P13093, DOI 10.1021/bi00248a019; CLARK MR, 1994, EMBO J, V13, P1911, DOI 10.1002/j.1460-2075.1994.tb06460.x; CLEVENGER CV, 1994, MOL ENDOCRINOL, V8, P674, DOI 10.1210/me.8.6.674; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; JOHNSON SA, 1995, J IMMUNOL, V155, P4596; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; PAZDRAK K, 1995, J EXP MED, V181, P1827, DOI 10.1084/jem.181.5.1827; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SORENSEN P, 1989, J BIOL CHEM, V264, P19253; TORIGOE T, 1992, BLOOD, V80, P617; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VENKITARAMAN AR, 1992, P NATL ACAD SCI USA, V89, P12083, DOI 10.1073/pnas.89.24.12083; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; Yajnik V, 1996, J BIOL CHEM, V271, P1813, DOI 10.1074/jbc.271.4.1813; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16189	16195		10.1074/jbc.272.26.16189	http://dx.doi.org/10.1074/jbc.272.26.16189			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195918	hybrid			2022-12-27	WOS:A1997XG01900022
J	Kirito, K; Uchida, M; Yamada, M; Miura, Y; Komatsu, N				Kirito, K; Uchida, M; Yamada, M; Miura, Y; Komatsu, N			A distinct function of STAT proteins in erythropoietin signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; DNA-BINDING ACTIVITY; LEUKEMIC-CELL LINE; TRANSCRIPTION FACTOR; SERINE PHOSPHORYLATION; INTERFERON-ALPHA; TYROSINE KINASE; INTERLEUKIN-3 IL-3; GROWTH-HORMONE; GENE FAMILY	The Janus kinase (JAK)-signal transducers and activators of transcription (STAT) pathway is an important signaling pathway of interferons and cytokines. We examined the activation of STAT proteins induced by interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM CSP), or erythropoietin (EPO) using the human leukemia cell line, UT-7, which requires these cytokines for growth. IL-3, GM-CSF, and EPO induced DNA-binding activity to the oligonucleotides corresponding to the sis-inducible elements (SIE) of c-fos, in addition to the beta-casein promoter (beta-CAP), SIE- and beta-CAP-binding proteins were identical to Stat1 alpha and Stat3 complex and to Stat5 protein, respectively. This indicates that IL-3, GM CSF, and EPO commonly activated Stat1 alpha, Stat3, and Stat5 proteins in UT-7. However, EPO hardly activated Stat1 alpha and Stat3 in UT-7/GM, which is a subline of UT-7 that grows slightly in response to EPO. Transfection studies revealed that UT7/GM cells constitutively expressing Stat1 alpha, but not Stat3, can grow as well in response to EPO as GM-CSF, suggesting that Stat1 alpha is involved in the EPO-induced proliferation of UT-7. Thus, although Stat1 alpha, Stat3, and Stat5 proteins are activated by GM-CSF, IL-3, and EPO, our data suggest that each STAT protein has a distinctive role in the actions of cytokines.	JICHI MED SCH,DEPT MED,DIV HEMATOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN	Jichi Medical University			Kirito, Keita/AEO-6802-2022					AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BRUGGEN TVD, 1995, BLOOD, V85, P1442; Cao XM, 1996, MOL CELL BIOL, V16, P1595; CHIBA S, 1991, BLOOD, V78, P2261; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1996, P NATL ACAD SCI USA, V93, P6221, DOI 10.1073/pnas.93.13.6221; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVID M, 1995, MOL CELL BIOL, V15, P7050; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; EILERS A, 1995, MOL CELL BIOL, V15, P3579; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOTHO A, 1996, BLOOD, V88, P138; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HAQUE SJ, 1995, J BIOL CHEM, V270, P25709, DOI 10.1074/jbc.270.43.25709; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Komatsu N, 1996, BLOOD, V87, P4552, DOI 10.1182/blood.V87.11.4552.bloodjournal87114552; KOMATSU N, 1993, BLOOD, V82, P456; KOMATSU N, 1991, CANCER RES, V51, P341; KOMATSU N, 1997, IN PRESS BLOOD; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; Marra F, 1996, J CLIN INVEST, V98, P1218, DOI 10.1172/JCI118905; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MIURA O, 1994, BLOOD, V84, P1501; MIURA Y, 1994, J BIOL CHEM, V269, P29962; MORELLA KK, 1995, BLOOD, V86, P557, DOI 10.1182/blood.V86.2.557.bloodjournal862557; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; OHASHI T, 1995, BLOOD, V85, P1454, DOI 10.1182/blood.V85.6.1454.bloodjournal8561454; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; Penta K, 1995, J BIOL CHEM, V270, P31282, DOI 10.1074/jbc.270.52.31282; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TORIGOE T, 1992, BLOOD, V80, P617; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	58	57	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16507	16513		10.1074/jbc.272.26.16507	http://dx.doi.org/10.1074/jbc.272.26.16507			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195960	hybrid			2022-12-27	WOS:A1997XG01900064
J	Maheo, K; AntrasFerry, J; Morel, F; Langouet, S; Guillouzo, A				Maheo, K; AntrasFerry, J; Morel, F; Langouet, S; Guillouzo, A			Modulation of glutathione S-transferase subunits A2, M1, and P1 expression by interleukin-1 beta in rat hepatocytes in primary culture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT HUMAN HEPATOCYTES; TRANSFORMING GROWTH-FACTOR-BETA-1; NUCLEOTIDE-SEQUENCE; CATALYTIC ACTIVITY; GENE-EXPRESSION; LIVER; CYTOKINES; INDUCTION; ACID; CYTOCHROME-P-450	The influence of various cytokines on the expression of glutathione S-transferases (GSTs) was investigated in rat hepatocytes in primary culture. Only treatment of hepatocytes with interleukin-1 beta (IL-1) was effective, resulting in a marked decrease in GSTs. Steady-state mRNA levels of rGSTA2 and M1 were strongly downregulated by IL-1 in a dose-dependent manner after a 24-h exposure while rGSTP1 mRNA level was increased by a 48-h treatment. Similar effects of IL-1 were observed at the protein level. The response to IL-1 appeared to be specific for each subunit within GST gene families. In addition, IL-1 strongly suppressed the induction of rGSTA2 by 3-methylcholanthrene, oltipraz (a synthetic derivative of 1,2-dithiole-3-thione), and phenobarbital and that of rGSTM1 by oltipraz and phenobarbital, whereas it was ineffective on rGSTP1 induction by these compounds. Using in vitro nuclear run-on transcription assay and Northern blot analysis of or-amanitin treated cells, IL-1-mediated rGSTM1 mRNA decrease was found to result from mRNA destabilization. These results provide the first demonstration that IL-1 regulates some major GST subunits in hepatocytes by a post-transcriptional mechanism.	UNIV RENNES 1,FAC SCI PHARMACEUT & BIOL,UNITE DETOXICAT & REPARAT TISSULAIRE,INSERM,U456,F-35043 RENNES,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes			Maheo, Karine/AAC-3259-2022; GUILLOUZO, Andre/Z-2373-2019; Langouet, Sophie A/I-2776-2015	Langouet, Sophie/0000-0002-0016-5425				ABDELRAZZAK Z, 1994, MOL PHARMACOL, V46, P1100; ABDELRAZZAK Z, 1993, MOL PHARMACOL, V44, P707; ABDELRAZZAK Z, 1995, FEBS LETT, V366, P159, DOI 10.1016/0014-5793(95)00513-9; ADAMS DJ, 1987, J BIOL CHEM, V262, P4888; ANDUS T, 1991, HEPATOLOGY, V13, P364, DOI 10.1016/0270-9139(91)92454-G; ANTRASFERRY J, 1995, EUR J BIOCHEM, V234, P390, DOI 10.1111/j.1432-1033.1995.390_b.x; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BOLLAG W, 1994, J CELL BIOCHEM, V56, P427, DOI 10.1002/jcb.240560402; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAN YL, 1984, J BIOL CHEM, V259, P224; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; DING GJF, 1985, J BIOL CHEM, V260, P3268; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GANTER G, 1989, EMBO J, V8, P3373; GUGUEN C, 1975, BIOL GASTRO-ENTEROL, V8, P223; GUILLOUZO A, 1992, COLLOQ INSE, V216, P61; Habig W H, 1981, Methods Enzymol, V77, P218; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; KAYANOKI Y, 1994, J BIOL CHEM, V269, P15488; KENSLER TW, 1987, CANCER RES, V47, P4271; KISPERT A, 1989, BIOCHEM J, V260, P789, DOI 10.1042/bj2600789; LANGOUET S, 1995, BIOCHEM BIOPH RES CO, V216, P793, DOI 10.1006/bbrc.1995.2691; Langouet S, 1996, HEPATOLOGY, V23, P881; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MEYER DJ, 1993, CARCINOGENESIS, V14, P567, DOI 10.1093/carcin/14.4.567; MORROW CS, 1992, J BIOL CHEM, V267, P10544; MOSIALOU E, 1993, BIOCHEM PHARMACOL, V45, P1645, DOI 10.1016/0006-2952(93)90305-G; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; PEMBLE SE, 1986, BIOCHEM J, V240, P885, DOI 10.1042/bj2400885; PEMBLE SE, 1992, BIOCHEM J, V287, P957, DOI 10.1042/bj2870957; PROCHASKA HJ, 1992, P NATL ACAD SCI USA, V89, P2394, DOI 10.1073/pnas.89.6.2394; RENTON KW, 1990, CAN J PHYSIOL PHARM, V68, P777, DOI 10.1139/y90-119; RENTON KW, 1983, BIOL BASIS DETOXICAT, P307; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; STENBERG G, 1992, BIOCHEM J, V284, P313, DOI 10.1042/bj2840313; TELAKOWSKIHOPKI.CA, 1985, P NATL ACAD SCI USA, V83, P9393; VANDENBERGHE Y, 1990, MOL PHARMACOL, V37, P372; VINCENTI MP, 1994, NUCLEIC ACIDS RES, V22, P4818, DOI 10.1093/nar/22.22.4818; WILLIAMS RT, 1967, FED PROC, V26, P1029; YEH FS, 1989, CANCER RES, V49, P2506	46	32	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16125	16132		10.1074/jbc.272.26.16125	http://dx.doi.org/10.1074/jbc.272.26.16125			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195908	hybrid			2022-12-27	WOS:A1997XG01900012
J	Marini, MG; Chan, K; Casula, L; Kan, YW; Cao, A; Moi, P				Marini, MG; Chan, K; Casula, L; Kan, YW; Cao, A; Moi, P			hMAF, a small human transcription factor that heterodimerizes specifically with Nrf1 and Nrf2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; BETA-GLOBIN LOCUS; DOMINANT CONTROL REGION; PORPHOBILINOGEN DEAMINASE GENE; LEUCINE ZIPPER PROTEIN; 3' UNTRANSLATED REGION; I HYPERSENSITIVE SITE; SMALL MAF PROTEINS; TRANSGENIC MICE; FACTOR NF-E2	A 1.6-kilobase pair full-length cDNA encoding a transcription factor homologous to the Maf family of proteins was isolated by screening a K562 cDNA library with the NFE2 tandem repeat probe derived from the globin locus control region. The protein, which was designated hMAF, contains a basic DNA binding domain and an extended leucine zipper but lacks any recognizable activation domain. Expressed in vitro, the hMAF protein is able to homodimerize in solution and bandshift the NFE2 tandem repeat probe. In addition to homodimers, hMAF can also form high affinity heterodimers with two members of the NFE2/CNC-bZip family (Nrf1 and Nrf2) but not with a third family member, p45-NFE2. Although hMAF/hMAF homodimers and hMAF/Nrf1 and hMAF/Nrf2 heterodimers bind to the same NFE2 site, they exert functionally opposite effects on the activity of a linked gamma-globin gene. In fact, whereas all hMAF/CNC-bZip heterodimers stimulate the activity of a gamma-promoter reporter construct in K562 cells, the association into homodimers that is induced by overexpressing hMAF inhibits the activity of the same construct. Thus variations in the expression of hMAF may account for the modulation in the activity of the genes that bear NFE2 recognition sites.	UNIV CAGLIARI,IST CLIN & BIOL ETA EVOLUT,I-09121 CAGLIARI,ITALY; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of Cagliari; Howard Hughes Medical Institute; University of California System; University of California San Francisco			Moi, Paolo/AAC-3161-2019; Marini, Maria Giuseppina/AAC-9384-2021	Marini, Maria Giuseppina/0000-0003-0371-9398; MOI, Paolo/0000-0001-7879-8057; Marini, Maria Giuseppina/0000-0002-2359-2892	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050267, R01DK016666, R37DK016666] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK16666, DK50267] Funding Source: Medline; Telethon [E.0356] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Telethon(Fondazione Telethon)		ALADJEM MI, 1995, SCIENCE, V270, P815, DOI 10.1126/science.270.5237.815; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P1006, DOI 10.1093/nar/22.6.1006; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P2383, DOI 10.1093/nar/22.12.2383; CATERINA JJ, 1991, P NATL ACAD SCI USA, V88, P1626, DOI 10.1073/pnas.88.5.1626; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHAN JY, 1995, HUM GENET, V95, P265; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; CURTIN PT, 1989, P NATL ACAD SCI USA, V86, P7082, DOI 10.1073/pnas.86.18.7082; DOMEN J, 1987, ONCOGENE RES, V1, P103; FIERING S, 1995, GENE DEV, V9, P2203, DOI 10.1101/gad.9.18.2203; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FRASER P, 1990, NUCLEIC ACIDS RES, V18, P3503, DOI 10.1093/nar/18.12.3503; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HENDRICKSON W, 1985, P NATL ACAD SCI USA, V82, P3129, DOI 10.1073/pnas.82.10.3129; HOPPE J, 1987, FEBS LETT, V223, P243, DOI 10.1016/0014-5793(87)80297-1; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; IKUTA T, 1991, P NATL ACAD SCI USA, V88, P10188, DOI 10.1073/pnas.88.22.10188; Johnsen O, 1996, NUCLEIC ACIDS RES, V24, P4289, DOI 10.1093/nar/24.21.4289; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KAWAI S, 1992, VIROLOGY, V188, P778, DOI 10.1016/0042-6822(92)90532-T; KEAVENEY M, 1989, BIOCHIM BIOPHYS ACTA, V1007, P289, DOI 10.1016/0167-4781(89)90150-4; KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0; KOTKOW KJ, 1996, P NATL ACAD SCI USA, V93, P35314; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LI QL, 1994, BLOOD, V84, P1399; LU DL, 1994, EUR J BIOCHEM, V222, P753, DOI 10.1111/j.1432-1033.1994.tb18921.x; LUNA L, 1994, GENOMICS, V22, P553, DOI 10.1006/geno.1994.1428; LUTHMAN H, 1989, EUR J BIOCHEM, V180, P259, DOI 10.1111/j.1432-1033.1989.tb14641.x; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MOI P, 1990, P NATL ACAD SCI USA, V87, P9000, DOI 10.1073/pnas.87.22.9000; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PHILIPSEN S, 1993, EMBO J, V12, P1077, DOI 10.1002/j.1460-2075.1993.tb05749.x; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PRUZINA S, 1994, BBA-GENE STRUCT EXPR, V1219, P351, DOI 10.1016/0167-4781(94)90059-0; PRUZINA S, 1991, NUCLEIC ACIDS RES, V19, P1413, DOI 10.1093/nar/19.7.1413; RAICH N, 1992, BLOOD, V79, P861; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SORRENTINO B, 1990, NUCLEIC ACIDS RES, V18, P2721, DOI 10.1093/nar/18.9.2721; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; UCHIDA K, 1987, BIOCHEM BIOPH RES CO, V148, P617, DOI 10.1016/0006-291X(87)90921-1; WADAKIYAMA Y, 1992, J BIOL CHEM, V267, P11532	61	108	111	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16490	16497		10.1074/jbc.272.26.16490	http://dx.doi.org/10.1074/jbc.272.26.16490			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195958	hybrid			2022-12-27	WOS:A1997XG01900062
J	Schneider, H; ScheinerBobis, G				Schneider, H; ScheinerBobis, G			Involvement of the M7/M8 extracellular loop of the sodium pump alpha subunit in ion transport - Structural and functional homology to P-loops of ion channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA,K-ATPASE BETA-SUBUNIT; RAT-KIDNEY NA+,K+-ATPASE; AMINO-ACID-SEQUENCE; (NA+ + K+)-ATPASE; CATALYTIC SUBUNIT; ATP-BINDING; ESSENTIAL RESIDUE; POTASSIUM-IONS; EXPRESSION; TOPOLOGY	Mutations were introduced in the motif (DDRW887)-D-884 from an extracellular peptide of the sodium pump alpha subunit localized between M7 and M8 membrane spans to investigate a possible role of this structure in ion recognition. A homologous sequence (399)QDCW(402) that occurs in the P-loops of Na+ channels was shown earlier to be important for ion gating. Mutant sodium pumps were expressed in yeast and subsequently investigated for their behavior toward ouabain, Na+, K+, and ATP. Native enzyme and D884A, D884R, D885A, D885E, or D885R mutants all bind ouabain in the presence of phosphate and Mg2+. The K-D values determined from Scatchard analysis are in the range 5-8 nM for the native enzyme and the D884A, D885E, or D885A mutants, and 15.7 +/- 2.04 and 30.1 +/- 4.32 nM for mutants D884R and D885R, respectively. This ouabain binding is reduced in the presence of K+ in a similar way for both native or mutant sodium pumps with relative affinities (K-0.5) for K+ ranging from 1.4 to 3.7 mM. Ouabain binding in the presence of 100 mu M ATP is promoted by Na+ with K-0.5 = 1.64 +/- 0.01 mM for the native enzyme and K-0.5 = 8.6 +/- 1.35 mM for the D884R mutant. The K-0.5 values of the two enzymes for ATP are 0.66 +/- 0.16 mu M and 1.1 +/- 0.12 mu M, respectively. Ouabain binding as a function of Na+ concentration, on the other hand, is very low for the D885R mutant, even at an ATP concentration of 2 mM. Phosphate or eosin, however, are recognized by this mutant enzyme, so that a major conformational change within the ATP-binding site appears unlikely. The inability of the D885R mutant to bind ouabain in the presence of Na+ and ATP could be explained by assuming that the M7/M8 connecting extracellular loop, which also contains the mutated amino acids, is invaginated within the plane of the plasma membrane and possibly involved in acceptance and/or release of Na+ ions coming from cytosolic areas of the protein. In this case, the placement of an additional positive charge might repel Na+ ions and interrupt their flow, thus not allowing the enzyme to assume the proper conformational state for ouabain binding. Such invaginated hydrophilic protein structures, such as the P-loops of Na+ and K+ channels, are already known and have been shown to participate in ion conduction.	UNIV GIESSEN,INST BIOCH & ENDOKRINOL,FACHBEREICH VET MED,D-35392 GIESSEN,GERMANY	Justus Liebig University Giessen								ARYSTARKHOVA E, 1995, J BIOL CHEM, V270, P8785, DOI 10.1074/jbc.270.15.8785; CHEN CY, 1984, NUCLEIC ACIDS RES, V12, P8951, DOI 10.1093/nar/12.23.8951; FARLEY RA, 1985, J BIOL CHEM, V260, P3899; Fiedler B, 1996, J BIOL CHEM, V271, P29312, DOI 10.1074/jbc.271.46.29312; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; GOLDSHLEGER R, 1995, BIOCHEMISTRY-US, V34, P8668, DOI 10.1021/bi00027a016; GOLDSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911, DOI 10.1073/pnas.89.15.6911; GUY HR, 1995, SOC GEN PHY, V50, P1; HAMRICK M, 1993, J BIOL CHEM, V268, P24367; HANSEN O, 1984, PHARMACOL REV, V36, P143; HEGYVARY C, 1971, J BIOL CHEM, V246, P5234; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; INAGAKI C, 1974, J BIOL CHEM, V249, P5135; JUNG JS, 1994, J BIOL CHEM, V269, P14648; KAWAKAMI K, 1986, J BIOCHEM-TOKYO, V100, P389, DOI 10.1093/oxfordjournals.jbchem.a121726; KIRSCH GE, 1995, BIOPHYS J, V68, P1804, DOI 10.1016/S0006-3495(95)80357-7; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOHRAZ M, 1994, J BIOL CHEM, V269, P2929; OVCHINNIKOV YA, 1988, FEBS LETT, V227, P230, DOI 10.1016/0014-5793(88)80904-9; Palasis M, 1996, J BIOL CHEM, V271, P14176, DOI 10.1074/jbc.271.24.14176; POST RL, 1965, J BIOL CHEM, V240, P1437; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J, 1989, MOL CLONING LAB MANU, V1-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHEINERBOBIS G, 1989, EUR J BIOCHEM, V183, P173, DOI 10.1111/j.1432-1033.1989.tb14910.x; SCHEINERBOBIS G, 1993, BIOCHEMISTRY-US, V32, P9592, DOI 10.1021/bi00088a011; SCHEINERBOBIS G, 1987, EUR J BIOCHEM, V168, P123, DOI 10.1111/j.1432-1033.1987.tb13396.x; SCHEINERBOBIS G, 1994, BBA-BIOMEMBRANES, V1193, P226, DOI 10.1016/0005-2736(94)90157-0; SCHULTHEIS PJ, 1993, J BIOL CHEM, V268, P22686; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SHYJAN AW, 1990, P NATL ACAD SCI USA, V87, P1178, DOI 10.1073/pnas.87.3.1178; SKOU JC, 1988, METHOD ENZYMOL, V156, P278; SKOU JC, 1988, METHOD ENZYMOL, V156, P1; SKOU JC, 1981, BIOCHIM BIOPHYS ACTA, V647, P232, DOI 10.1016/0005-2736(81)90251-0; SKOU JC, 1973, BIOCHIM BIOPHYS ACTA, V311, P51; TOMASELLI GF, 1995, BIOPHYS J, V68, P1814, DOI 10.1016/S0006-3495(95)80358-9; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; WANG JZ, 1992, BIOCHEM BIOPH RES CO, V182, P794, DOI 10.1016/0006-291X(92)91802-W; WANG K, 1992, J BIOL CHEM, V267, P3577; Yamagishi T., 1997, Biophysical Journal, V72, pA262; YOON KL, 1994, J BIOL CHEM, V269, P28249	46	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16158	16165		10.1074/jbc.272.26.16158	http://dx.doi.org/10.1074/jbc.272.26.16158			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195913	hybrid			2022-12-27	WOS:A1997XG01900017
J	Walker, G; Pfeilschifter, J; Kunz, D				Walker, G; Pfeilschifter, J; Kunz, D			Mechanisms of suppression of inducible nitric-oxide synthase (iNOS) expression in interferon (IFN)-gamma-stimulated RAW 264.7 cells by dexamethasone - Evidence for glucocorticoid-induced degradation of iNOS protein by calpain as a key step in post-transcriptional regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL MESANGIAL CELLS; MOLECULAR MECHANISMS; MESSENGER-RNA; INDUCTION; MACROPHAGES; INHIBIT; INTERLEUKIN-1; ACTIVATION; CALMODULIN; STEROIDS	The murine macrophage cell line RAW 264.7 expresses inducible nitric-oxide synthase (iNOS) activity upon stimulation with interferon (IFN)-gamma and/or bacterial lipopolysaccharide. We have studied the mechanisms by which the synthetic glucocorticoid dexamethasone suppresses IFN-gamma stimulated NOS expression in RAW 264.7 cells. Treatment of cells with dexamethasone reduces the formation of nitrite, one of the stable end products of NO production measured in culture supernatants with an IC50 of 9 nM. The reduction of iNOS activity is caused by decreased NOS protein levels as assessed by immunoblotting using a specific anti-iNOS antibody. Dexamethasone treatment also reduces the formation of iNOS mRNA steady state levels to about 50% in IFN-gamma-stimulated cells. This is due to decreased iNOS gene transcription and iNOS mRNA stability. More importantly, dexamethasone reduces the amount of iNOS protein by two additional mechanisms: reduction of the translation of iNOS mRNA and increased degradation of the NOS protein. Using a specific protease inhibitor for the cysteine protease calpain I, N-acetyl-Leu-Leu-norleucinal (calpain inhibitor I), the enhanced proteolysis of the iNOS protein can efficiently be blocked, whereas other protease inhibitors such as tosyl-L-lysine chloromethyl ketone have no effect. Dexamethasone does not significantly alter calpain gene expression, Northern blot analyses reveal that calpain mRNA steady state levels are virtually not affected upon incubation of the cells with IFN-gamma and dexamethasone. Immunoprecipitation using a polyclonal anti-calpain antibody reveals that calpain protein levels are also not affected by the glucocorticoid. This is the first evidence that the iNOS protein is a molecular target for the cysteine protease calpain.	UNIV FRANKFURT KLINIKUM,ZENTRUM PHARMAKOL,D-60590 FRANKFURT,GERMANY; UNIV BASEL,BIOZENTRUM,DEPT PHARMACOL,CH-4056 BASEL,SWITZERLAND	Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of Basel								BARNES PJ, 1993, TRENDS PHARMACOL SCI, V14, P436, DOI 10.1016/0165-6147(93)90184-L; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; CETKOVICCVRLJE M, 1993, ENDOCRINOLOGY, V133, P1739, DOI 10.1210/en.133.4.1739; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; DESHPANDE RV, 1995, J BIOL CHEM, V270, P2497, DOI 10.1074/jbc.270.6.2497; DIROSA M, 1990, BIOCHEM BIOPH RES CO, V172, P1246, DOI 10.1016/0006-291X(90)91583-E; ELCE JS, 1995, PROTEIN ENG, V8, P843, DOI 10.1093/protein/8.8.843; GELLER DA, 1994, ARCH SURG-CHICAGO, V129, P165; GILBERT RS, 1993, J CELL PHYSIOL, V157, P128, DOI 10.1002/jcp.1041570117; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; HONG DH, 1995, MOL CELL ENDOCRINOL, V108, P199, DOI 10.1016/0303-7207(95)03476-N; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KERN JA, 1988, J CLIN INVEST, V81, P237, DOI 10.1172/JCI113301; KLEIMERT H, 1996, MOL PHARMACOL, V19, P15; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KUNZ D, 1994, BIOCHEM J, V304, P337, DOI 10.1042/bj3040337; Kunz D, 1996, P NATL ACAD SCI USA, V93, P255, DOI 10.1073/pnas.93.1.255; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MOLINARI M, 1995, J BIOL CHEM, V270, P2032, DOI 10.1074/jbc.270.5.2032; MONCADA S, 1995, FASEB J, V9, P1319, DOI 10.1096/fasebj.9.13.7557022; MONCADA S, 1991, PHARMACOL REV, V43, P119; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; Pfeilschifter J, 1996, CELL BIOL INT, V20, P51, DOI 10.1006/cbir.1996.0008; PFEILSCHIFTER J, 1990, FEBS LETT, V273, P185, DOI 10.1016/0014-5793(90)81080-8; PFEILSCHIFTER J, 1991, EUR J PHARMACOL, V195, P179, DOI 10.1016/0014-2999(91)90399-B; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; RINGHEIM GE, 1995, BIOCHEM BIOPH RES CO, V210, P711, DOI 10.1006/bbrc.1995.1717; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; STEVENSTRUSS R, 1995, BIOCHEMISTRY-US, V34, P15638, DOI 10.1021/bi00048a006; SUZUKI K, 1995, BIOL CHEM H-S, V376, P523; TAKAKOMI SC, 1994, FASEB J, V8, P814; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; VODOVOTZ Y, 1995, J IMMUNOL, V154, P2914	38	94	96	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	1997	272	26					16679	16687		10.1074/jbc.272.26.16679	http://dx.doi.org/10.1074/jbc.272.26.16679			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XG019	9195984	hybrid			2022-12-27	WOS:A1997XG01900088
J	Kawasaki, M; Nogami, S; Satow, Y; Ohya, Y; Anraku, Y				Kawasaki, M; Nogami, S; Satow, Y; Ohya, Y; Anraku, Y			Identification of three core regions essential for protein splicing of the yeast Vma1 protozyme - A random mutagenesis study of the entire Vma1-derived endonuclease sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARCHAEA DNA-POLYMERASE; MEMBRANE H+-ATPASE; SACCHAROMYCES-CEREVISIAE; ADENOSINE-TRIPHOSPHATASE; INTERVENING SEQUENCES; BRANCHED INTERMEDIATE; CATALYTIC SUBUNIT; GENE; INTRONS	The translation product of the VMA1 gene of Saccharomyces cerevisiae undergoes protein splicing, in which the intervening region is autocatalytically excised and the franking regions are ligated. The splicing reaction is catalyzed essentially by the in-frame insert, VMA1-derived endonuclease (VDE), which is a site-specific endonuclease to mediate gene homing, Previous mutational analysis of the splicing reaction has been concentrated extensively upon the splice junctions, However, it still remains unknown which amino acid residues are crucial for the splicing reaction within the entire region of VDE and ifs neighboring elements. Tn this work, a polymerase chain reaction-based random mutagenesis strategy mas used to identify such residues throughout the overall intervening sequence of the VMA1 gene, Splicing-defective mutant proteins were initially screened using a bacterial expression system and then analyzed further in yeast cells, Mutations were mapped at the N- and C-terminal splice junctions and around the N-terminal one-third of VDE, We identified four potent mutants that yielded aberrant products with molecular masses of 200, 90, and 80 kDa. We suggest that the conserved His(362), newly identified as the essential residue for the splicing reaction, contributes to the first cleavage at. the N-terminal junction, whereas His(736) assists the second cleavage by Asn cyclization at the C-terminal junction, Mutations in these regions did not appear to destroy the endonuclease activity of VDE.	UNIV TOKYO, DEPT BIOL SCI, GRAD SCH SCI, BUNKYO KU, TOKYO 113, JAPAN; UNIV TOKYO, FAC PHARMACEUT SCI, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo; University of Tokyo			Nogami, Satoru/G-6061-2014	Nogami, Satoru/0000-0002-4517-0180				ANRAKU Y, 1994, J BIOCHEM-TOKYO, V115, P175, DOI 10.1093/oxfordjournals.jbchem.a124313; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Chong SR, 1996, J BIOL CHEM, V271, P22159, DOI 10.1074/jbc.271.36.22159; COOPER AA, 1993, EMBO J, V12, P2575, DOI 10.1002/j.1460-2075.1993.tb05913.x; DAVIS EO, 1994, EMBO J, V13, P699, DOI 10.1002/j.1460-2075.1994.tb06309.x; DAVIS EO, 1992, CELL, V71, P201, DOI 10.1016/0092-8674(92)90349-H; Fsihi H, 1996, P NATL ACAD SCI USA, V93, P3410, DOI 10.1073/pnas.93.8.3410; GIMBLE FS, 1995, J BIOL CHEM, V270, P5849, DOI 10.1074/jbc.270.11.5849; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; GIMBLE FS, 1993, J BIOL CHEM, V268, P21844; GU HH, 1993, J BIOL CHEM, V268, P7372; HIRATA R, 1992, BIOCHEM BIOPH RES CO, V188, P40, DOI 10.1016/0006-291X(92)92347-Z; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HODGES RA, 1992, NUCLEIC ACIDS RES, V20, P6153, DOI 10.1093/nar/20.23.6153; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; Kawasaki M, 1996, BIOCHEM BIOPH RES CO, V222, P827, DOI 10.1006/bbrc.1996.0826; OHYA Y, 1991, J BIOL CHEM, V266, P13971; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; PIETROKOVSKI S, 1994, PROTEIN SCI, V3, P2340, DOI 10.1002/pro.5560031218; XU MQ, 1993, CELL, V75, P1371, DOI 10.1016/0092-8674(93)90623-X; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x	21	65	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15668	15674		10.1074/jbc.272.25.15668	http://dx.doi.org/10.1074/jbc.272.25.15668			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188457	hybrid			2022-12-27	WOS:A1997XF32900017
J	Kershaw, DB; Beck, SG; Wharram, BL; Wiggins, JE; Goyal, M; Thomas, PE; Wiggins, RC				Kershaw, DB; Beck, SG; Wharram, BL; Wiggins, JE; Goyal, M; Thomas, PE; Wiggins, RC			Molecular cloning and characterization of human podocalyxin-like protein - Orthologous relationship to rabbit PCLP1 and rat podocalyxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR EPITHELIAL-CELL; BASEMENT-MEMBRANE DISEASE; GLUTATHIONE-S-TRANSFERASE; MAJOR SIALOPROTEIN; TYROSINE-PHOSPHATASE; ESCHERICHIA-COLI; MURINE HOMOLOG; MESSENGER-RNA; SIALIC-ACID; IDENTIFICATION	Human renal cortex and heart cDNA libraries were screened for a human homolog of rabbit PCLP1 using the rabbit PCLP1 cDNA as a probe, Clones spanning 5569 base pairs with an open reading frame coding for a 528-amino acid peptide a ere obtained, The putative peptide contains a potential signal peptide and a single membrane-spanning region. The extracellular domain contains multiple potential sites for N- and O-linked glycosylation and 4 cysteines for potential disulfide bonding similar to rabbit PCLP1, On Northern blot a major transcript is seen at 5.9 kilobases. Antibodies to this protein show a doublet. at 160/165 kDa on Western blots of human glomerular extract and a pattern of intense glomerular staining and vascular endothelial staining on immunofluorescence of human kidney sections. Comparison of the rabbit and human peptide sequences shows a high degree of identity in the transmembrane and intracellular domains (96%) with a lower degree of identity in the extracellular domain (36%). An antibody to the intracellular domain reacted across species (human, rabbit, and rat) and recognized both rabbit PCLP1 and rat podocalyxin. An interspecies Southern blot probed with a cDNA coding for the intracellular domain showed strong hybridization to all vertebrates tested in a pattern suggesting a single copy gene, Wa conclude that this cDNA and putative peptide represent the human homolog of rabbit PCLP1 and rat podocalyxin.	UNIV MICHIGAN,DEPT PEDIAT,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Wiggins, Roger/0000-0002-1166-2849	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039255, P01DK038149] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38149, DK02264-01A1, DK39255] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDREWS PM, 1979, KIDNEY INT, V15, P376, DOI 10.1038/ki.1979.49; BLAU EB, 1973, LAB INVEST, V28, P477; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOWNER G, 1988, J CLIN INVEST, V82, P998, DOI 10.1172/JCI113710; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; GOYAL M, 1991, J AM SOC NEPHROL, V1, P1334; GROSS JA, 1990, J IMMUNOL, V144, P3201; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HUBER S, 1988, J BIOL CHEM, V263, P752; KERJASCHKI D, 1985, AM J PATHOL, V118, P343; KERJASCHKI D, 1986, J CLIN INVEST, V78, P1142, DOI 10.1172/JCI112694; KERJASCHKI D, 1984, J CELL BIOL, V98, P1591, DOI 10.1083/jcb.98.4.1591; KERSHAW DB, 1995, J BIOL CHEM, V270, P29439, DOI 10.1074/jbc.270.49.29439; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LOGIN GR, 1987, LAB INVEST, V57, P585; MERRITT SE, 1990, LAB INVEST, V63, P762; SALANT DJ, 1980, J CLIN INVEST, V66, P71, DOI 10.1172/JCI109837; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEILER MW, 1977, LAB INVEST, V36, P48; SEILER MW, 1975, SCIENCE, V189, P390, DOI 10.1126/science.1145209; SETO D, 1990, NUCLEIC ACIDS RES, V18, P5905, DOI 10.1093/nar/18.19.5905; Shyjan AM, 1996, J IMMUNOL, V156, P2851; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THOMAS PE, 1994, J BIOL CHEM, V269, P19953; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WIGGINS RC, 1995, GENOMICS, V27, P174, DOI 10.1006/geno.1995.1021; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; WOLFE SL, 1993, MOL CELL BIOL, P708	33	118	132	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	1997	272	25					15708	15714		10.1074/jbc.272.25.15708	http://dx.doi.org/10.1074/jbc.272.25.15708			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XF329	9188463	hybrid			2022-12-27	WOS:A1997XF32900023
J	Aubert, C; Leroy, G; Bruschi, M; Wall, JD; Dolla, A				Aubert, C; Leroy, G; Bruschi, M; Wall, JD; Dolla, A			A single mutation in the heme 4 environment of Desulfovibrio desulfuricans Norway cytochrome c(3) (M-r 26,000) greatly affects the molecule reactivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE-REDUCING BACTERIA; ELECTRON-TRANSFER PROTEINS; VULGARIS HILDENBOROUGH; REDOX POTENTIALS; POLYHEMIC CYTOCHROMES; ESCHERICHIA-COLI; GENE; CLONING; RESOLUTION; LOCALIZATION	The gene encoding Desulfovibrio desulfuricans Norway cytochrome c(3) (M-r 26,000), a dimeric octaheme cytochrome belonging to the polyheme cytochrome c(3) superfamily, has been cloned and successfully expressed in another sulfate reducing bacteria, D. desulfuricans G201. The gene, named cycD, is monocistronic and encodes a cytochrome precursor of 135 amino acids with an extension at the NH2 terminus of 24 amino acids. This extension acts as a signal sequence which allows export across the cytoplasmic membrane into the periplasmic space, Tyrosine 73, which is in a close contact with the histidine sixth axial ligand to the heme 4 iron atom, has been replaced by a glutamate residue using site directed mutagenesis, The cytochrome mutant when expressed in D. desulfuricans G201, is correctly folded and matured, A global increase of the oxidoreduction potentials of about 50 mV is measured for the Y73E cytochrome. The mutation also has a strong influence on the interaction of the cytochrome with its redox partner, the hydrogenase. This suggests, like the tetraheme cytochrome c(3) (M-r 13,000), heme 4 is the interactive heme in the cytochrome-hydrogenase complex and that alteration of the heme 4 environment can greatly affect the electron transfer reaction with its redox partner.	CNRS,IFR1,UNITE BIOENERGET & INGN PROT,F-13402 MARSEILLE 20,FRANCE; UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65211	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of Missouri System; University of Missouri Columbia								AIBA H, 1981, J BIOL CHEM, V256, P1905; AKUTSU H, 1992, BIOCHIM BIOPHYS ACTA, V1140, P144, DOI 10.1016/0005-2728(92)90003-K; AMBLER RP, 1980, CYCLOTRONS CYTOCHROM; Banci L, 1996, P NATL ACAD SCI USA, V93, P14396, DOI 10.1073/pnas.93.25.14396; BRUSCHI M, 1984, BIOCHEM BIOPH RES CO, V120, P384, DOI 10.1016/0006-291X(84)91265-8; Bruschi M, 1996, BIOCHEM J, V320, P933, DOI 10.1042/bj3200933; BRUSCHI M, 1994, BBA-PROTEIN STRUCT M, V1205, P123, DOI 10.1016/0167-4838(94)90100-7; BRUSCHI M, 1994, METHOD ENZYMOL, V243, P140; CZJZEK M, 1994, J MOL BIOL, V243, P653, DOI 10.1016/0022-2836(94)90039-6; CZJZEK M, 1994, BIOCHIMIE, V76, P546, DOI 10.1016/0300-9084(94)90178-3; Czjzek M, 1996, STRUCTURE, V4, P395, DOI 10.1016/S0969-2126(96)00045-7; DAVISON J, 1987, GENE, V51, P275, DOI 10.1016/0378-1119(87)90316-7; DOLLA A, 1994, J BIOL CHEM, V269, P6340; GUERLESQUIN F, 1985, BIOCHIM BIOPHYS ACTA, V830, P296, DOI 10.1016/0167-4838(85)90286-9; GUERLESQUIN F, 1994, BIOCHIMIE, V76, P515, DOI 10.1016/0300-9084(94)90175-9; GUERLESQUIN F, 1982, BIOCHEM BIOPH RES CO, V106, P530; GUIGLIARELLI B, 1990, J MOL BIOL, V216, P161, DOI 10.1016/S0022-2836(05)80067-1; HALADJIAN J, 1991, BIOCHEM BIOPH RES CO, V179, P605, DOI 10.1016/0006-291X(91)91414-8; HIGUCHI Y, 1984, J MOL BIOL, V172, P109, DOI 10.1016/0022-2836(84)90417-0; KASSNER RJ, 1973, J AM CHEM SOC, V95, P2674, DOI 10.1021/ja00789a044; Kitamura Masaya, 1993, Protein Sequences and Data Analysis, V5, P193; LEGALL J, 1987, FEMS MICROBIOL LETT, V46, P35, DOI 10.1111/j.1574-6968.1987.tb02450.x; LEGALL J, 1994, BIOCHIMIE, V76, P655, DOI 10.1016/0300-9084(94)90142-2; Maniatis T., 1982, MOL CLONING; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MORIMOTO Y, 1991, J BIOCHEM-TOKYO, V110, P532, DOI 10.1093/oxfordjournals.jbchem.a123615; Pieulle L, 1996, BBA-BIOENERGETICS, V1273, P51, DOI 10.1016/0005-2728(95)00129-8; POLLOCK WBR, 1991, J BACTERIOL, V173, P220, DOI 10.1128/jb.173.1.220-228.1991; Postgate JR, 1984, SULPHATE REDUCING BA, V2nd; RAFFERTY SP, 1990, BIOCHEMISTRY-US, V29, P9365, DOI 10.1021/bi00492a009; REIDER R, 1984, EUR J BIOCHEM, V245, P637; ROSSI M, 1993, J BACTERIOL, V175, P4699, DOI 10.1128/JB.175.15.4699-4711.1993; SALGUEIRO CA, 1992, FEBS LETT, V314, P155, DOI 10.1016/0014-5793(92)80963-H; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VANROOIJEN GJH, 1989, J BACTERIOL, V171, P3575, DOI 10.1128/jb.171.6.3575-3578.1989; VERMA AL, 1988, J AM CHEM SOC, V110, P6617, DOI 10.1021/ja00228a004; VOORDOUW G, 1990, J BACTERIOL, V172, P6122, DOI 10.1128/jb.172.10.6122-6126.1990; VOORDOUW G, 1986, EUR J BIOCHEM, V159, P347, DOI 10.1111/j.1432-1033.1986.tb09874.x; WALKER FA, 1986, J AM CHEM SOC, V108, P5288, DOI 10.1021/ja00277a038; WEIMER PJ, 1988, APPL ENVIRON MICROB, V54, P386, DOI 10.1128/AEM.54.2.386-396.1988	40	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15128	15134		10.1074/jbc.272.24.15128	http://dx.doi.org/10.1074/jbc.272.24.15128			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182533	hybrid			2022-12-27	WOS:A1997XE03400016
J	Leprince, C; Romero, F; Cussac, D; Vayssiere, B; Berger, R; Tavitian, A; Camonis, JH				Leprince, C; Romero, F; Cussac, D; Vayssiere, B; Berger, R; Tavitian, A; Camonis, JH			A new member of the amphiphysin family connecting endocytosis and signal transduction pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH3 DOMAINS; BINDING; PROTEIN; DYNAMIN; SPECIFICITY; SEQUENCES; RECEPTORS; AFFINITY; GTPASE; GRB2	Src homology 3 (SH3) domains are conserved modules which participate in protein interaction by recognizing proline-rich motifs on target molecules, To identify new SH3-containing proteins, we performed a two-hybrid screen with a proline-rich region of human SOS-1, One of the specific SOS-1 interacting clones that were isolated from a mouse brain cDNA library defines a new protein that was named amphiphysin 2 because of its homology to the previously reported amphiphysin. Amphiphysin 2 is expressed in a number of mouse tissues through multiple RNA transcripts, Here, we report the amino acid sequence of a brain form of amphiphysin 2 (BRAMP2) encoded by a 2,5-kilobase mRNA, BRAMP2 associates in vitro with elements of the endocytosis machinery such as alpha-adaptin and dynamin, On a biosensor surface, the BRAMP2/dynamin interaction appeared to be direct and partly dependent on a proline-rich sequence of dynamin, Association with dynamin was also observed in PC12 cells after cell stimulation with nerve growth factor, suggesting that amphiphysin 2 may be connected to receptor-dependent signaling pathways, This hypothesis is strengthened by the ability of BRAMP2 to interact with the p21(ras) exchange factor SOS, in vitro, as a possible point of interconnection between the endocytic and signaling pathways.	INST COCHIN GENET MOL,INSERM U363,F-75014 PARIS,FRANCE; UNIV PARIS 05,INSERM U266,URA D1500 CNRS,PARIS,FRANCE; INST MOL GENET,INSERM U301,PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Leprince, C (corresponding author), INST CURIE,INSERM U248,26 RUE ULM,F-75231 PARIS 05,FRANCE.		Leprince, Corinne/M-7109-2018; Romero, Francisco/K-2101-2014	Leprince, Corinne/0000-0002-4462-5737; Romero, Francisco/0000-0002-9588-6881				CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERIF D, 1990, P NATL ACAD SCI USA, V87, P6639, DOI 10.1073/pnas.87.17.6639; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DECAMILLI P, 1993, J EXP MED, V178, P2219, DOI 10.1084/jem.178.6.2219; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; JANOUEIXLEROSEY I, 1995, J BIOL CHEM, V270, P14801, DOI 10.1074/jbc.270.24.14801; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; SCAIFE R, 1994, EMBO J, V13, P2574, DOI 10.1002/j.1460-2075.1994.tb06547.x; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zalcman G, 1996, J BIOL CHEM, V271, P30366, DOI 10.1074/jbc.271.48.30366	23	78	80	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	1997	272	24					15101	15105		10.1074/jbc.272.24.15101	http://dx.doi.org/10.1074/jbc.272.24.15101			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XE034	9182529	hybrid			2022-12-27	WOS:A1997XE03400012
J	Abell, AN; Segaloff, DL				Abell, AN; Segaloff, DL			Evidence for the direct involvement of transmembrane region 6 of the lutropin/choriogonadotropin receptor in activating G(S)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTEINIZING-HORMONE RECEPTOR; LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; CHORIONIC-GONADOTROPIN RECEPTOR; LIMITED PRECOCIOUS PUBERTY; BETA-ADRENERGIC-RECEPTOR; INTRACELLULAR LOOP; BETA-2-ADRENERGIC RECEPTOR; ADENYLATE-CYCLASE; BINDING; MUTATION	The luteinizing hormone/chorionic gonadotropin receptor (LHR) is a heptahelical receptor that interacts primarily with G(s). Previous studies by others have shown that some forms of familial male precocious puberty are associated with mutations of the human LHR in the sixth transmembrane region that result in constitutive activation of the receptor. This study demonstrates that a peptide corresponding to the lower portion of the sixth transmembrane region of the LHR can significantly activate adenylyl cyclase activity. Experiments with membranes derived from wild-type versus cyc(-) S49 cells demonstrate that the stimulation of cyclase by this peptide is due to an activation of G(s). As such, our data demonstrate a direct role for transmembrane region 6 of the rat LHR in activating G(s) and therefore raise the possibility that mutations in transmembrane region 6 of the LHR may directly affect the coupling of the receptor to G(s). Significantly, these data are the first to demonstrate the ability of a transmembrane portion of a G protein-coupled receptor, in the absence of any contributions from an intracellular loop region, to activate a G protein.	UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD022196] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K04HD000968, R01HD022196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-00968, HD-22196] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abell A, 1996, J BIOL CHEM, V271, P4518; BURNSTEIN ES, 1995, J BIOL CHEM, V270, P3141; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; HillEubanks D, 1996, J BIOL CHEM, V271, P3058, DOI 10.1074/jbc.271.6.3058; KOSUGI S, 1995, HUM MOL GENET, V4, P183, DOI 10.1093/hmg/4.2.183; KREMER H, 1993, HUM MOL GENET, V2, P1779, DOI 10.1093/hmg/2.11.1779; Kudo M, 1996, J BIOL CHEM, V271, P22470, DOI 10.1074/jbc.271.37.22470; LATRONICO AC, 1995, J CLIN ENDOCR METAB, V80, P2490, DOI 10.1210/jc.80.8.2490; LAUE L, 1995, P NATL ACAD SCI USA, V92, P1906, DOI 10.1073/pnas.92.6.1906; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Liu J, 1996, J BIOL CHEM, V271, P6172, DOI 10.1074/jbc.271.11.6172; LIU XB, 1993, J BIOL CHEM, V268, P1513; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; RODRIGUEZ MC, 1990, ENDOCRINOLOGY, V127, P674, DOI 10.1210/endo-127-2-674; ROSS EM, 1977, J BIOL CHEM, V252, P5761; ROZELL TG, 1995, MOL ENDOCRINOL, V9, P1727; SALOMON MR, 1981, MOL PHARMACOL, V19, P109; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; SCHREIBER RE, 1994, J BIOL CHEM, V269, P326; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; Thomas D, 1996, MOL ENDOCRINOL, V10, P760, DOI 10.1210/me.10.6.760; THOMAS DM, 1994, ENDOCRINOLOGY, V135, P1902, DOI 10.1210/en.135.5.1902; WANG HY, 1993, MOL ENDOCRINOL, V7, P1437, DOI 10.1210/me.7.11.1437; Wang Z, 1996, MOL ENDOCRINOL, V10, P748, DOI 10.1210/me.10.6.748; WANG Z, 1993, MOL ENDOCRINOL, V7, P85, DOI 10.1210/me.7.1.85; ZHU HY, 1995, MOL ENDOCRINOL, V9, P141, DOI 10.1210/me.9.2.141	34	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14586	14591		10.1074/jbc.272.23.14586	http://dx.doi.org/10.1074/jbc.272.23.14586			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169417	hybrid			2022-12-27	WOS:A1997XC32700014
J	Hundle, B; McMahon, T; Dadgar, J; Chen, CH; MochlyRosen, D; Messing, RO				Hundle, B; McMahon, T; Dadgar, J; Chen, CH; MochlyRosen, D; Messing, RO			An inhibitory fragment derived from protein kinase C epsilon prevents enhancement of nerve growth factor responses by ethanol and phorbol esters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC ALCOHOL-CONSUMPTION; NEURO-BLASTOMA CELLS; MAP KINASE; PC12 CELLS; SIGNAL-TRANSDUCTION; INDUCED DIFFERENTIATION; MOLECULAR-CLONING; SENSORY GANGLIA; ACTIVATION; OUTGROWTH	We have studied nerve growth factor (NGF)-induced differentiation of PC12 cells to identify PKC isozymes important for neuronal differentiation. Previous work showed that tumor-promoting phorbol esters and ethanol enhance NGF-induced mitogen-activated protein (MAP) kinase activation and neurite outgrowth by a PKC-dependent mechanism. Ethanol also increases expression of PKC delta and PKC epsilon, suggesting that one these isozymes regulates responses to NGF. To examine this possibility, we established PC12 cell lines that express a fragment encoding the first variable domain of PKC epsilon (amino acids 2-144), which acts as an isozyme-specific inhibitor of PKC epsilon in cardiac myocytes. Phorbol ester-stimulated translocation of PKC epsilon was markedly reduced in these PC12 cell lines. In addition, phorbol ester and ethanol did not enhance NGF-induced MAP kinase activation or neurite outgrowth in these cells. In contrast, phorbol ester and ethanol increased neurite outgrowth and MAP kinase phosphorylation in cells expressing a fragment derived from the first variable domain of PKC delta. These results demonstrate that PKC epsilon mediates enhancement of NGF-induced signaling and neurite outgrowth by phorbol esters and ethanol in PC12 cells.	UNIV CALIF SAN FRANCISCO,ERNEST GALLO CLIN & RES CTR,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94110; STANFORD UNIV,SCH MED,DEPT MOL PHARMACOL,STANFORD,CA 94305	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; Stanford University			Messing, Robert/D-3642-2015	Messing, Robert/0000-0002-5345-4431; Mochly-Rosen, Daria/0000-0002-6691-8733	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008117, R01AA010036] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 52141] Funding Source: Medline; NIAAA NIH HHS [AA 08117, AA 10036] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; BASU T, 1994, ONCOGENE, V9, P3483; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BIXBY JL, 1989, NEURON, V3, P287, DOI 10.1016/0896-6273(89)90253-5; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; CADETELEITE A, 1988, BRAIN RES, V473, P1, DOI 10.1016/0006-8993(88)90309-5; CAMPENOT RB, 1994, J NEUROCHEM, V63, P868; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GOODNIGHT J, 1994, ADV CANCER RES, V64, P159, DOI 10.1016/S0065-230X(08)60838-6; GREENE LA, 1991, CULTURING NERVE CELL, P207; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; HALL FL, 1988, J BIOL CHEM, V263, P4460; HEIDENREICH KA, 1990, J BIOL CHEM, V265, P15076; HSU L, 1984, CANCER RES, V44, P4607; HUNDLE B, 1995, J BIOL CHEM, V270, P30134; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; JAISWAL RK, 1993, J BIOL CHEM, V268, P7055; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; KILEY SC, 1995, J CELL SCI, V108, P1003; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; MACFARLANE DE, 1994, J BIOL CHEM, V269, P4327; MANCILLAS JR, 1986, SCIENCE, V231, P161, DOI 10.1126/science.2867600; MANGOURA D, 1993, J NEUROSCI RES, V35, P488, DOI 10.1002/jnr.490350505; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCNAMARA JO, 1994, J NEUROSCI, V14, P3413; MEHTA S, 1993, J NEUROCHEM, V60, P972, DOI 10.1111/j.1471-4159.1993.tb03244.x; MESSING RO, 1991, J BIOL CHEM, V266, P23428; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHMICHI M, 1993, BIOCHEM J, V295, P767, DOI 10.1042/bj2950767; OTTE AP, 1988, NATURE, V334, P618, DOI 10.1038/334618a0; OTTE AP, 1992, CELL, V68, P1021, DOI 10.1016/0092-8674(92)90074-M; PAHLMAN S, 1983, CELL DIFFER DEV, V12, P165, DOI 10.1016/0045-6039(83)90006-4; PENTNEY RJ, 1990, ALCOHOL CLIN EXP RES, V14, P878, DOI 10.1111/j.1530-0277.1990.tb01831.x; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; POWELL CT, 1992, P NATL ACAD SCI USA, V89, P147, DOI 10.1073/pnas.89.1.147; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROIVAINEN R, 1993, BRAIN RES, V624, P85, DOI 10.1016/0006-8993(93)90063-S; ROIVAINEN R, 1995, P NATL ACAD SCI USA, V92, P1891, DOI 10.1073/pnas.92.6.1891; Roivainen R, 1994, MOL BASIS ALCOHOL US, P29; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; SAITO N, 1993, BRAIN RES, V607, P241, DOI 10.1016/0006-8993(93)91512-Q; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; SOSSIN WS, 1993, TRENDS BIOCHEM SCI, V18, P207, DOI 10.1016/0968-0004(93)90189-T; SPINELLI W, 1982, CANCER RES, V42, P5067; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TAVARES MA, 1986, J SUBMICR CYTOL PATH, V18, P725; THOMAS D, 1995, J BIOL CHEM, V270, P28924, DOI 10.1074/jbc.270.48.28924; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; VOLK B, 1984, NEUROBEHAVIORAL TERA, P163; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WEST JR, 1981, SCIENCE, V211, P957; WU J, 1994, FEBS LETT, V353, P9, DOI 10.1016/0014-5793(94)01000-5; Zhang Z. H., 1996, Biophysical Journal, V70, pA391	66	87	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					15028	15035		10.1074/jbc.272.23.15028	http://dx.doi.org/10.1074/jbc.272.23.15028			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169479	hybrid			2022-12-27	WOS:A1997XC32700076
J	Rosson, D; OBrien, TG; Kampherstein, JA; Szallasi, Z; Bogi, K; Blumberg, PM; Mullin, JM				Rosson, D; OBrien, TG; Kampherstein, JA; Szallasi, Z; Bogi, K; Blumberg, PM; Mullin, JM			Protein kinase C-alpha activity modulates transepithelial permeability and cell junctions in the LLC-PK1 epithelial cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT JUNCTIONS; PHOSPHORYLATION; ACTIVATION; PROMOTERS; FAMILY; DELTA	Modulation of protein kinase C (PKC) by 12-O-tetradecanoylphorbol-13-acetate (TPA) disrupts the cell-cell junctions of the epithelial cell line LLC-PK1. To examine the role of specific PKC isoforms in this process we have created modified LLC-PK1 subclones that express wild-type and dominant negative versions of PKC-alpha under control of the tetracycline-responsive expression system. Overexpression of wild-type PKC-alpha rendered the cells more sensitive to the effects of TPA on transepithelial permeability as measured by loss of transepithelial resistance across the cell sheet. Conversely, expression of a dominant negative PKC-alpha rendered the cells more resistant to the effects of TPA as measured both by loss of transepithelial resistance as well as cell scattering. The properties of both subclones could be modulated by the addition of tetracycline, which suppressed the effect of the exogenous genes. These results indicate that the alpha isoform of PKC is at least one of the isoforms that regulate tight junctions and other cell-cell junctions of LLC-PK1 epithelia.	NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rosson, D (corresponding author), LANKENAU MED RES CTR,100 LANCASTER AVE,WYNNEWOOD,PA 19096, USA.		Mullin, James M./AAD-9348-2020	Mullin, James/0000-0001-5285-7530; Szallasi, Zoltan/0000-0001-5395-7509	NATIONAL CANCER INSTITUTE [R01CA036353, R01CA048121, R37CA036353] Funding Source: NIH RePORTER; NCI NIH HHS [CA36353, CA48121] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P51; DLUGOSZ AA, 1994, CANCER RES, V54, P6413; Dodane V, 1996, J MEMBRANE BIOL, V149, P199, DOI 10.1007/s002329900020; ELLIS B, 1992, AM J PHYSIOL, V263, pF293, DOI 10.1152/ajprenal.1992.263.2.F293; GOODE N, 1992, J BIOL CHEM, V267, P16878; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; JOVOV B, 1994, AM J PHYSIOL, V266, pF775, DOI 10.1152/ajprenal.1994.266.5.F775; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LI WQ, 1994, J BIOL CHEM, V269, P2349; LICHTFIELD DW, 1986, BIOCHEM BIOPH RES CO, V134, P1276; LUM H, 1994, AM J PHYSIOL, V267, pL223, DOI 10.1152/ajplung.1994.267.3.L223; MARANO CW, 1995, BIOCHEM BIOPH RES CO, V209, P669, DOI 10.1006/bbrc.1995.1551; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MULLIN JM, 1986, AM J PHYSIOL, V251, pC597, DOI 10.1152/ajpcell.1986.251.4.C597; Mullin JM, 1996, EXP CELL RES, V227, P12, DOI 10.1006/excr.1996.0244; Nagpala PG, 1996, J CELL PHYSIOL, V166, P249, DOI 10.1002/(SICI)1097-4652(199602)166:2<249::AID-JCP2>3.0.CO;2-P; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NIGAM SK, 1991, BIOCHEM BIOPH RES CO, V181, P548, DOI 10.1016/0006-291X(91)91224-Z; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; Owen PJ, 1996, EXP CELL RES, V225, P366, DOI 10.1006/excr.1996.0187; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	25	76	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14950	14953		10.1074/jbc.272.23.14950	http://dx.doi.org/10.1074/jbc.272.23.14950			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169467	hybrid			2022-12-27	WOS:A1997XC32700064
J	Weinkove, D; Leevers, SJ; MacDougall, LK; Waterfield, MD				Weinkove, D; Leevers, SJ; MacDougall, LK; Waterfield, MD			p60 is an adaptor for the Drosophila phosphoinositide 3-kinase, Dp110	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; PHOSPHATIDYLINOSITOL 3-KINASE; BETA-RECEPTOR; SH2 DOMAINS; PROTEIN; BINDING; ASSOCIATION; CLONING; IDENTIFICATION; EXPRESSION	The mammalian phosphoinositide 3-kinases (PI3Ks) p110 alpha, beta, and delta form heterodimers with Src homology 2 (SH2) domain-containing adaptors such as p85 alpha or p55(PIK). The two SH2 domains of these adaptors bind to phosphotyrosine residues (pY) found within the consensus sequence pYXXM. Here we show that a heterodimer of the Drosophila PI3K, Dp110, with an adaptor, p60, can be;purified from S2 cells with a pYXXM phosphopeptide affinity matrix. Using amino acid sequence from the gel-purified protein, the gene encoding p60 was cloned and mapped to the genomic region 21B8-C1, and the exon/intron structure was determined. p60 contains two SH2 domains and an inter-SH2 domain but lacks the SH3 and breakpoint cluster region homology (BH) domains found in mammalian p85 alpha and beta. Analysis of the sequence of p60 shows that the amino acids responsible fbr the SH2 domain binding specificity in mammalian p85 alpha are conserved and predicts that the inter-SH2 domain has a coiled-coil structure. The Dp110 p60 complex was immunoprecipitated with p60-specific antisera and shown to possess both lipid and protein kinase activity. The complex was found in larvae, pupae, and adults, consistent with p60 functioning as the adaptor for Dp110 throughout the Drosophila life cycle.	LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND; UCL, DEPT BIOCHEM & MOL BIOL, LONDON WC1E 6BT, ENGLAND; UCL, MRC, GRAD PROGRAMME, LONDON WC1E 6BT, ENGLAND	Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London			Weinkove, David/B-4470-2010	Weinkove, David/0000-0001-7399-1202				Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Antonetti DA, 1996, MOL CELL BIOL, V16, P2195; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Breeze AL, 1996, EMBO J, V15, P3579, DOI 10.1002/j.1460-2075.1996.tb00727.x; Chen C, 1996, ENDOCRINOLOGY, V137, P846, DOI 10.1210/en.137.3.846; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; EMORI Y, 1994, J BIOL CHEM, V269, P19474; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FERNANDEZ R, 1995, EMBO J, V14, P3373, DOI 10.1002/j.1460-2075.1995.tb07343.x; Fruman DA, 1996, GENOMICS, V37, P113, DOI 10.1006/geno.1996.0527; FRY MJ, 1992, BIOCHEM J, V288, P383, DOI 10.1042/bj2880383; HARTL DL, 1994, P NATL ACAD SCI USA, V91, P6824, DOI 10.1073/pnas.91.15.6824; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; Inukai K, 1996, J BIOL CHEM, V271, P5317, DOI 10.1074/jbc.271.10.5317; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Linassier C, 1997, BIOCHEM J, V321, P849, DOI 10.1042/bj3210849; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; Nolte RT, 1996, NAT STRUCT BIOL, V3, P364, DOI 10.1038/nsb0496-364; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PONS S, 1995, MOL CELL BIOL, V15, P4453; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; RAABE T, 1995, EMBO J, V14, P2509, DOI 10.1002/j.1460-2075.1995.tb07248.x; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; SUGAYA R, 1994, MECH DEVELOP, V45, P139, DOI 10.1016/0925-4773(94)90027-2; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vanhaesebroeck B, 1996, CANCER SURV, V27, P249; VANHAESEBROECK B, 1997, IN PRESS P NATL ACAD; VANHAESEBROECK B, 1997, IN PRESS TRENDS BIOC; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZVELEBIL MJJM, 1995, PROTEIN ENG, V8, P527, DOI 10.1093/protein/8.6.527	44	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	1997	272	23					14606	14610		10.1074/jbc.272.23.14606	http://dx.doi.org/10.1074/jbc.272.23.14606			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XC327	9169420	hybrid			2022-12-27	WOS:A1997XC32700017
J	Kirken, RA; Malabarba, MG; Xu, J; Liu, XW; Farrar, WL; Hennighausen, L; Larner, AC; Grimley, PM; Rui, H				Kirken, RA; Malabarba, MG; Xu, J; Liu, XW; Farrar, WL; Hennighausen, L; Larner, AC; Grimley, PM; Rui, H			Prolactin stimulates serine/tyrosine phosphorylation and formation of heterocomplexes of multiple Stat5 isoforms in Nb2 lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; TYROSINE PHOSPHORYLATION; SERINE PHOSPHORYLATION; GENE-EXPRESSION; HUMAN MONOCYTES; RECEPTOR; ACTIVATION; PROTEIN; KINASE; BINDING	Transcription factors of the Stat gene family are selectively activated by many hormones and cytokines. Stat5 originally was cloned as a prolactin-stimulated DNA-binding protein, but is also activated by non-lactogenic cytokines in many cell types. The recent identification of two distinct Stat5 genes, which encode a 94-kDa Stat5a and a 92-kDa Stat5b as well as several lower molecular weight isoforms, suggests additional complexity and combinatorial possibilities for transcriptional regulation. We now report a biochemical analysis of prolactin activation of Stat proteins in Nb2 lymphocytes, which was associated with: 1) rapid tyrosine phosphorylation of Stat5a, Stat5b, a COOH-terminally truncated 80-kDa Stat5 form, Stat1 alpha, and Stat3; 2) rapid and selective formation of Stat5a/b heterodimers, without involvement of Stat1 alpha or Stat3; 3) marked serine, but not threonine phosphorylation of Stat5a and Stat5b; and 4) the appearance of two qualitatively distinct Stat5 protein complexes, which discriminated between oligonucleotides corresponding to the prolactin response elements of the beta-casein and interferon regulatory factor-1 gene promoters. Collectively, our analyses showed that Stat5a and Stat5b respond similarly to prolactin receptor activation, but also suggested that the two genes have evolved unique properties that may contribute to the specificity of receptors that utilize Stat5 signaling proteins.	UNIFORMED SERV UNIV HLTH SCI,SCH MED,DEPT PATHOL,BETHESDA,MD 20814; SCI APPLICAT INT CORP,INTRAMURAL RES SUPPORT PROGRAM,FREDERICK,MD; NCI,FREDERICK CANC RES & DEV CTR,DIV BASIC SCI,MOL IMMUNOREGULAT LAB,FREDERICK,MD 21702; NIDDK,BIOCHEM & METAB LAB,NIH,BETHESDA,MD 20892; US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20814	Uniformed Services University of the Health Sciences - USA; Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); US Food & Drug Administration (FDA)			Malabarba, Maria Grazia/L-4805-2015	Malabarba, Maria Grazia/0000-0002-9457-2047; Hennighausen, Lothar/0000-0001-8319-9841				AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Ceresa BP, 1996, J BIOL CHEM, V271, P12121, DOI 10.1074/jbc.271.21.12121; DaSilva L, 1996, MOL CELL ENDOCRINOL, V117, P131, DOI 10.1016/0303-7207(95)03738-1; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; Davis E, 1996, LEUKEMIA, V10, P543; FINBLOOM DS, 1993, J IMMUNOL, V150, P2383; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GOUT PW, 1980, CANCER RES, V40, P2433; GRONER B, 1994, MOL CELL ENDOCRINOL, V100, P109, DOI 10.1016/0303-7207(94)90288-7; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KIRKEN RA, 1997, IN PRESS J BIOL CHEM, V272; Kirken Robert A., 1994, Progress in Growth Factor Research, V5, P195, DOI 10.1016/0955-2235(94)90005-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARNER AC, 1995, BBA-MOL CELL RES, V1266, P278, DOI 10.1016/0167-4889(95)00015-K; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LI S, 1995, MOL CELL BIOL, V15, P2063; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; ONEAL KD, 1993, LYMPHOKINE CYTOK RES, V12, P309; PITTIUS CW, 1988, MOL ENDOCRINOL, V2, P1027, DOI 10.1210/mend-2-11-1027; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; Rosen RL, 1996, BLOOD, V88, P1206, DOI 10.1182/blood.V88.4.1206.bloodjournal8841206; ROZAKISADCOCK M, 1993, NATURE, V363, P84; RUI H, 1994, J BIOL CHEM, V269, P5364; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V259, P1694; SIDIS Y, 1994, ENDOCRINOLOGY, V134, P1979, DOI 10.1210/en.134.4.1979; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; Wartmann M, 1996, J BIOL CHEM, V271, P31863, DOI 10.1074/jbc.271.50.31863; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	44	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14098	14103		10.1074/jbc.272.22.14098	http://dx.doi.org/10.1074/jbc.272.22.14098			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162035	hybrid			2022-12-27	WOS:A1997XB49200022
J	Liu, LQ; Askari, A				Liu, LQ; Askari, A			Evidence for the existence of two ATP-sensitive Rb+ occlusion pockets within the transmembrane domains of Na+/K+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION OCCLUSION; BETA-SUBUNIT; ALPHA-SUBUNIT; NA,K-ATPASE; NA+,K+-ATPASE; DIGESTION; SITES; K+	A trypsin digested Na+/K+-ATPase that has lost ATPase activity and about half of its protein content retains an essentially intact beta-subunit, the 10 transmembrane domains of the alpha-subunit, and the full capacity to occlude Na+ and Rb+ (a congener of K+). When this preparation was incubated at 37 degrees C in the absence of Rb+, it lost half of its Rb+ occluding capacity and two-thirds of its Na+ occluding capacity, Comparison of the Rb+ occlusion-deocclusion kinetics of the digested enzyme before and after partial inactivation indicated that (a) the affinities of the labile and the stable halves of occluded Rb+ were the same; (b) occlusion and deocclusion rates of the stable pool were lower than those of the labile pool; (c) ATP at a low affinity site (K-0.5 = 25-300 mu m) increased deocclusion rate in the stable pool and occlusion rate in the labile pool; (d) Na+ increased Rb+ deocclusion rate of the sum of the two pools but not that of the stable pool; and (e) occlusion and deocclusion rates of both pools were decreased by ouabain, These findings suggest that (a) the peptide complex of the digested enzyme contains two distinct but interacting cation occlusion pockets, one occluding two Na+ or one Rb+, and the other occluding one Na+ or one Rb+ (b) this peptide complex that is devoid of the catalytic ATP site retains an allosteric ATP site; and (c) the access channels of the two pockets are regulated differently by ATP but similarly by ouabain, Analyses of the gel electrophoretic patterns of the digested enzyme and the N termini of the appropriate bands showed that inactivation of the labile occlusion pocket was accompanied by 60-70% loss of two alpha-fragments containing H-3-H-4 and H-5-H-6 transmembrane domains, This and the previously established interactions among the transmembrane helices of alpha- and beta P-subunits suggest that one occlusion pocket is associated with H-3-H-6 domains and that the other is located within a complex of P-subunit and two alpha-fragments containing H-1-H-2 and H-7-H-10 transmembrane domains.	MED COLL OHIO, DEPT PHARMACOL, TOLEDO, OH 43699 USA						NHLBI NIH HHS [HL-36573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASKARI A, 1983, J BIOL CHEM, V258, P3453; Askari A, 1988, Prog Clin Biol Res, V268A, P149; ASKARI A, 1987, J BIOENERG BIOMEMBR, V19, P369; BLANCO G, 1994, P NATL ACAD SCI USA, V91, P8642; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; Forbush B 3rd, 1988, Prog Clin Biol Res, V268A, P229; GANJEIZADEH M, 1995, J BIOL CHEM, V270, P15707, DOI 10.1074/jbc.270.26.15707; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GOLDSHLEGER R, 1994, SODIUM PUMP, P309; HASENAUER J, 1993, J BIOL CHEM, V268, P3289; HUANG WH, 1994, SODIUM PUMP, P417; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KOSTER JC, 1995, J BIOL CHEM, V270, P14332, DOI 10.1074/jbc.270.24.14332; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; LAUGER P, 1991, SOC GEN PHY, V46, P303; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Liu GQ, 1996, FEBS LETT, V390, P323, DOI 10.1016/0014-5793(96)00687-4; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; NING G, 1993, FEBS LETT, V330, P19, DOI 10.1016/0014-5793(93)80910-M; Or E, 1996, BIOCHEMISTRY-US, V35, P6853, DOI 10.1021/bi960093q; OR E, 1993, J BIOL CHEM, V268, P16929; Palasis M, 1996, J BIOL CHEM, V271, P14176, DOI 10.1074/jbc.271.24.14176; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; Rabon EC, 1996, J BIOL CHEM, V271, P32137, DOI 10.1074/jbc.271.50.32137; ROSSI RC, 1993, J BIOL CHEM, V268, P12579; SARVAZYAN NA, 1995, J BIOL CHEM, V270, P26528, DOI 10.1074/jbc.270.44.26528; Sarvazyan NA, 1997, J BIOL CHEM, V272, P7855, DOI 10.1074/jbc.272.12.7855; SHANI M, 1987, BIOCHIM BIOPHYS ACTA, V904, P13, DOI 10.1016/0005-2736(87)90081-2; SKOU JC, 1992, J BIOENERG BIOMEMBR, V24, P249	34	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14380	14386		10.1074/jbc.272.22.14380	http://dx.doi.org/10.1074/jbc.272.22.14380			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162075	hybrid			2022-12-27	WOS:A1997XB49200062
J	Mao, SY; Metzger, H				Mao, SY; Metzger, H			Characterization of protein-tyrosine phosphatases that dephosphorylate the high affinity IgE receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN-E; FC-EPSILON; MAST-CELLS; PHOSPHORYLATION; KINASES; AGGREGATION; P53/56(LYN); EXPRESSION; COMPONENT; MECHANISM	An early event that follows aggregation of the high affinity receptor for IgE (Fc epsilon RI) is the phosphorylation of protein tyrosines, especially those on the beta- and gamma-subunits of the receptor. Disaggregation of the receptors leads to their rapid dephosphorylation, but even stably aggregated receptors undergo continual rounds of phosphorylation and dephosphorylation. We developed assays to study dephosphorylation of the receptors and other cellular proteins. Whole cell extracts dephosphorylated both subunits of the receptors rapidly and were as active against aggregated as against disaggregated Fc epsilon RI, Upon disaggregation, the in vivo dephosphorylation of the Fc epsilon RI and several other proteins followed first-order kinetics with closely similar rate constants despite substantial differences in the extent of phosphorylation. These results suggest that the level of phosphorylation of Fc epsilon RI is largely controlled by the aggregation-induced action of kinase(s) and not from changes in susceptibility to or activity of the phosphatases. Much of the total phosphatase is lost when the cells are permeabilized, but the rate of dephosphorylation of disaggregated Fc epsilon RI was comparable in intact and permeabilized cells. Thus, much of the activity utilized by the cell to dephosphorylate the Fc epsilon RI is likely to be associated with the plasma membrane.	NIAMS,ARTHRIT & RHEUMATISM BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)								ADAMCZEWSKI M, 1995, J IMMUNOL, V154, P3047; ADAMCZEWSKI M, 1992, J BIOL CHEM, V267, P18216; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; Berenstein EH, 1996, FASEB J, V10, P1245; BERGER SA, 1994, J EXP MED, V180, P471, DOI 10.1084/jem.180.2.471; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; Bolen JB, 1997, ANNU REV IMMUNOL, V15, P371, DOI 10.1146/annurev.immunol.15.1.371; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; CHADWICK D, 1989, IGE MAST CELLS ALLER, P1; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; DONELLADEANA A, 1991, EUR J BIOCHEM, V201, P501, DOI 10.1111/j.1432-1033.1991.tb16309.x; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; GRASBERGER B, 1986, P NATL ACAD SCI USA, V83, P6258, DOI 10.1073/pnas.83.17.6258; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HAMPE CS, 1994, FEBS LETT, V346, P194, DOI 10.1016/0014-5793(94)00471-4; HOLOWKA D, 1982, MOL IMMUNOL, V19, P219, DOI 10.1016/0161-5890(82)90334-0; Holowka D, 1996, ANNU REV BIOPH BIOM, V25, P79; ISERSKY C, 1974, J IMMUNOL, V112, P1909; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KENT UM, 1994, P NATL ACAD SCI USA, V91, P3087, DOI 10.1073/pnas.91.8.3087; KINET JP, 1985, BIOCHEMISTRY-US, V24, P4117, DOI 10.1021/bi00336a046; KOFFER A, 1990, J CELL BIOL, V111, P919, DOI 10.1083/jcb.111.3.919; LIU FT, 1980, J IMMUNOL, V124, P2728; MAO SY, 1995, BIOCHEMISTRY-US, V34, P1968, DOI 10.1021/bi00006a018; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; MCCONAHEY PJ, 1966, INT ARCH ALLER A IMM, V29, P185, DOI 10.1159/000229699; PAOLINI R, 1992, P NATL ACAD SCI USA, V89, P10733, DOI 10.1073/pnas.89.22.10733; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; PRIBLUDA VS, 1992, P NATL ACAD SCI USA, V89, P11446, DOI 10.1073/pnas.89.23.11446; PRIBLUDA VS, 1994, P NATL ACAD SCI USA, V91, P11246, DOI 10.1073/pnas.91.23.11246; Pribluda VS, 1997, J BIOL CHEM, V272, P11185; QUARTO R, 1986, MOL IMMUNOL, V23, P1215, DOI 10.1016/0161-5890(86)90154-9; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RIVERA J, 1988, MOL IMMUNOL, V25, P647, DOI 10.1016/0161-5890(88)90100-9; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; SWIETER M, 1995, J IMMUNOL, V155, P5330; Tamir I, 1996, BIOCHEMISTRY-US, V35, P6872, DOI 10.1021/bi952556i; Torigoe C, 1997, P NATL ACAD SCI USA, V94, P1372, DOI 10.1073/pnas.94.4.1372; WOFSY C, 1995, J BIOL CHEM, V270, P20264, DOI 10.1074/jbc.270.35.20264; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251	45	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14067	14073		10.1074/jbc.272.22.14067	http://dx.doi.org/10.1074/jbc.272.22.14067			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162030	hybrid			2022-12-27	WOS:A1997XB49200017
J	vanDelft, S; Govers, R; Strous, GJ; Verkleij, AJ; Henegouwen, PMPVE				vanDelft, S; Govers, R; Strous, GJ; Verkleij, AJ; Henegouwen, PMPVE			Epidermal growth factor induces ubiquitination of Eps15	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR; ENDOCYTOSIS; INTERNALIZATION; PURIFICATION; PROTEIN; YEAST; CELLS	Epidermal growth factor (EGF) receptor pathway substrate clone 15 (Eps15) has been described as a 142-kDa EGF receptor substrate. It has been shown to bind to the EGF receptor, adaptor protein-a, and clathrin and is present at clathrin-coated pits and vesicles. Upon stimulation of cells with EGF or transforming growth factor cu, Eps15 becomes rapidly and transiently phosphorylated on tyrosine residues. This phosphorylation coincides with an increase of 8 kDa in molecular mass. Here we show that this increase in molecular mass is not due to tyrosine phosphorylation. Instead, we found both by Western blotting and protein sequencing that this EGF-induced increase in molecular mass is the result of monoubiquitination. Eps15 ubiquitination but not tyrosine phosphorylation was inhibited under conditions that blocked EGF-induced internalization of the EGF receptor. Our results establish ubiquitination as a second form of EGF-stimulated covalent modification of Eps15.	UNIV UTRECHT,BIOMEMBRANE INST,FAC MED,DEPT CELL BIOL,NL-3584 CX UTRECHT,NETHERLANDS	Utrecht University	vanDelft, S (corresponding author), UNIV UTRECHT,BIOMEMBRANE INST,FAC BIOL,DEPT MOL CELL BIOL,PADUALAAN 8,NL-3584 CH UTRECHT,NETHERLANDS.		van Bergen en Henegouwen, Paul/B-8870-2011; Govers, Roland/O-5782-2016	van Bergen en Henegouwen, Paul/0000-0001-6050-9042; Govers, Roland/0000-0003-1359-5333				BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; DAUKAS G, 1985, J CELL BIOL, V101, P1673, DOI 10.1083/jcb.101.5.1673; DAVIE JR, 1990, BIOCHEMISTRY-US, V29, P4752, DOI 10.1021/bi00472a002; DOPHEIDE TA, 1967, J BIOL CHEM, V242, P1833; DUNN WA, 1980, J BIOL CHEM, V255, P5971; EDMAN P, 1950, ACTA CHEM SCAND, V4, P283, DOI 10.3891/acta.chem.scand.04-0283; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; HOU D, 1994, J BIOL CHEM, V269, P14244; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LOETSCHER H, 1990, J BIOL CHEM, V265, P20131; MORI S, 1992, J BIOL CHEM, V267, P6429; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; SOKOLIK CW, 1991, J BIOL CHEM, V266, P9100; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; VANDELFT S, 1997, NATO ASI SER, V101, P151; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wendland B, 1996, J CELL BIOL, V135, P1485, DOI 10.1083/jcb.135.6.1485	28	93	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	1997	272	22					14013	14016		10.1074/jbc.272.22.14013	http://dx.doi.org/10.1074/jbc.272.22.14013			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XB492	9162018	hybrid			2022-12-27	WOS:A1997XB49200005
J	Radeva, G; Petrocelli, T; Behrend, E; LeungHagesteijn, C; Filmus, J; Slingerland, J; Dedhar, S				Radeva, G; Petrocelli, T; Behrend, E; LeungHagesteijn, C; Filmus, J; Slingerland, J; Dedhar, S			Overexpression of the integrin-linked kinase promotes anchorage-independent cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; EPITHELIAL-CELLS; EXPRESSION; ADHESION; APOPTOSIS; INDUCTION; RAS	Cell adhesion to substratum has been shown to regulate cyclin A expression as well as cyclin D- and E-dependent kinases, the latter via the up-regulation of cyclin DI and the down-regulation of cyclin-Cdk inhibitors p21 and p27, respectively. This adhesion-dependent regulation of cell cycle is thought to be mediated by integrins. Here we demonstrate that stable transfection and overexpression of the integrin-linked kinase (ILK), which interacts with the beta 1 and beta 3 integrin cytoplasmic domains, induces anchorage-independent cell cycle progression but not serum independent growth of rat intestinal epithelial cells (IEC18). ILK overexpression results in increased expression of cyclin D1, activation of Cdk4 and cyclin E-associated kinases, and hyperphosphorylation of the retinoblastoma protein, In addition, ILK overexpression results in the expression of p21 and p27 Cdk inhibitors with altered electrophoretic mobilities, with the p27 from ILK-overexpressing cells having reduced inhibitory activity, The transfer of serum-exposed IEC18 cells from adherent cultures to suspension cultures results in a rapid down-regulation of expression of cyclin DI and cyclin A proteins as well as in retinoblastoma protein dephosphorylation. In marked contrast, transfer of ILK overexpressing cells from adherent to suspension cultures results in continued high levels of expression of cyclin D1 and cyclin A proteins, and a substantial proportion of the retinoblastoma protein remains in a hyperphosphorylated state, These results indicate that, when overexpressed, ILK induces signaling pathways resulting in the stimulation of G(1)/S cyclin-Cdk activities, which are normally regulated by cell adhesion and integrin engagement.	UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M4N 3M5,CANADA; UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,TORONTO,ON M4N 3M5,CANADA	University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center				Dedhar, Shoukat/0000-0003-4355-1657				AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FILMUS J, 1994, ONCOGENE, V9, P3627; FILMUS J, 1992, NUCLEIC ACIDS RES, V20, P2755, DOI 10.1093/nar/20.11.2755; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kang JS, 1996, MOL CELL BIOL, V16, P3370; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; QUARONI A, 1981, J NATL CANCER I, V67, P1353; RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schulze A, 1996, MOL CELL BIOL, V16, P4632; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	42	220	230	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	1997	272	21					13937	13944		10.1074/jbc.272.21.13937	http://dx.doi.org/10.1074/jbc.272.21.13937			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XA062	9153256	hybrid			2022-12-27	WOS:A1997XA06200071
